assay_strain,assay_subcellular_fraction,relationship_type,cell_id,assay_category,tid,assay_tax_id,assay_organism,description,src_id,assay_tissue,assay_cell_type,src_assay_id,assay_test_type,confidence_score,variant_id,doc_id,assay_type,tissue_id,curated_by,chembl_id,bao_format,assay_id
,,H,,,12052,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,1,,,,,8,,11087,B,,Autocuration,CHEMBL615117,BAO_0000019,1
,,U,,,22226,,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,1,,,,,0,,684,F,,Autocuration,CHEMBL615118,BAO_0000219,2
,,U,,,22226,,,,1,,,,,0,,15453,B,,Autocuration,CHEMBL615119,BAO_0000019,3
,,H,,,104729,9913.0,Bos taurus,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,1,,,,,4,,17841,B,,Autocuration,CHEMBL615120,BAO_0000249,4
,,N,163.0,,80001,9606.0,Homo sapiens,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),1,,143B,,,1,,17430,F,,Intermediate,CHEMBL615121,BAO_0000219,5
,,N,163.0,,80001,9606.0,Homo sapiens,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),1,,143B,,,1,,17430,F,,Intermediate,CHEMBL615122,BAO_0000219,6
,,N,163.0,,80001,10090.0,Mus musculus,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,1,,143B,,,1,,13799,F,,Intermediate,CHEMBL615123,BAO_0000219,7
,,N,163.0,,80001,9606.0,Homo sapiens,In vitro cell cytotoxicity was determined against 143B cell line,1,,143B,,,1,,17774,F,,Expert,CHEMBL615124,BAO_0000219,8
,,N,163.0,,80001,9606.0,Homo sapiens,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,1,,143B,,,1,,3801,F,,Intermediate,CHEMBL615125,BAO_0000219,9
,,N,163.0,,80001,9606.0,Homo sapiens,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,1,,143B,,,1,,17430,F,,Intermediate,CHEMBL615126,BAO_0000219,10
,,N,163.0,,80001,9606.0,Homo sapiens,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,1,,143B,,,1,,17430,F,,Intermediate,CHEMBL615127,BAO_0000219,11
,,N,163.0,,80001,9606.0,Homo sapiens,In vitro cell cytotoxicity was determined against 143B-LTK cell line,1,,143B,,,1,,17774,F,,Expert,CHEMBL615128,BAO_0000219,12
,,N,,,50185,1280.0,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,,,,,1,,11324,F,,Intermediate,CHEMBL857900,BAO_0000218,13
,,N,,,50185,1280.0,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,,,,,1,,11324,F,,Intermediate,CHEMBL615129,BAO_0000218,14
,,N,,,50185,1280.0,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,,,,,1,,11324,F,,Intermediate,CHEMBL615130,BAO_0000218,15
,,N,,,50185,1280.0,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,,,,,1,,11324,F,,Intermediate,CHEMBL615131,BAO_0000218,16
,,D,,,100122,10116.0,Rattus norvegicus,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,1,,,,,9,,11347,A,,Expert,CHEMBL884521,BAO_0000357,17
,,H,,,12054,,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),1,,,,,8,,16474,B,,Autocuration,CHEMBL615132,BAO_0000357,18
,,H,,,12054,,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,1,,,,,8,,10091,B,,Autocuration,CHEMBL615133,BAO_0000019,19
,,H,,,12054,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),1,,,,,8,,16474,B,,Autocuration,CHEMBL615134,BAO_0000357,20
,,H,,,12054,,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),1,,,,,8,,16474,B,,Autocuration,CHEMBL615135,BAO_0000357,21
,,H,,,12054,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),1,,,,,8,,16474,B,,Autocuration,CHEMBL615136,BAO_0000357,22
,,H,,,12054,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,1,,,,,8,,16474,B,,Autocuration,CHEMBL615137,BAO_0000357,23
,,H,,,12054,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,1,,,,,8,,16474,B,,Autocuration,CHEMBL615138,BAO_0000357,24
,,U,,,22226,,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",1,,,,,0,,14352,B,,Autocuration,CHEMBL836324,BAO_0000219,25
,,H,,,12054,9986.0,Oryctolagus cuniculus,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,1,,,,,8,,5646,B,,Autocuration,CHEMBL615139,BAO_0000357,26
,,H,,,12054,9986.0,Oryctolagus cuniculus,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),1,,,,,8,,5646,B,,Autocuration,CHEMBL615140,BAO_0000357,27
,,H,,,12426,,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,1,,,,,8,,10997,B,,Autocuration,CHEMBL615141,BAO_0000219,28
,,H,,,12054,3847.0,soya bean,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,1,,,,,8,,6309,B,,Autocuration,CHEMBL615142,BAO_0000357,29
,,H,,,12054,3847.0,Glycine max,Inhibitory activity against soybean 15-lipoxygenase was evaluated,1,,,,,8,,167,B,,Autocuration,CHEMBL615143,BAO_0000357,30
,,H,,,12054,3847.0,Glycine max,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,1,,,,,8,,167,B,,Autocuration,CHEMBL615144,BAO_0000357,31
,,H,,,12054,3847.0,Glycine max,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,1,,,,,8,,11087,B,,Autocuration,CHEMBL872867,BAO_0000357,32
,,H,,,12054,3847.0,Glycine max,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,1,,,,,8,,11087,B,,Autocuration,CHEMBL615145,BAO_0000357,33
,,H,,,12054,3847.0,Glycine max,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,1,,,,,8,,13622,B,,Autocuration,CHEMBL615146,BAO_0000357,34
,,H,,,12054,3847.0,Glycine max,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,1,,,,,8,,13622,B,,Autocuration,CHEMBL615147,BAO_0000357,35
,,U,,,22226,10116.0,Rattus norvegicus,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,1,,,,,0,,11347,A,,Autocuration,CHEMBL615148,BAO_0000019,36
,,U,,,22226,562.0,Escherichia coli,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,1,,,,,0,,5926,B,,Autocuration,CHEMBL615149,BAO_0000019,37
,,U,,,22226,,,Dissociation constant with dimeric 16S rRNA RNA construct B,1,,,,,0,,4567,B,,Autocuration,CHEMBL615150,BAO_0000019,38
,,M,,,22222,,,Dissociation constant towards 16S rRNA construct A,1,,,,,3,,3782,B,,Intermediate,CHEMBL615151,BAO_0000225,39
,,M,,,22222,,,Dissociation constant towards 16S rRNA construct B,1,,,,,3,,3782,B,,Intermediate,CHEMBL615152,BAO_0000225,40
,,M,,,100263,562.0,Escherichia coli,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,1,,,,,3,,4466,B,,Expert,CHEMBL615153,BAO_0000225,41
,,M,,,100263,562.0,Escherichia coli,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,1,,,,,3,,6592,B,,Expert,CHEMBL615154,BAO_0000225,42
,,H,,,13053,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),1,,,,,8,,898,B,,Autocuration,CHEMBL615155,BAO_0000019,43
,,H,,,13053,,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),1,,,,,8,,898,B,,Autocuration,CHEMBL615156,BAO_0000019,44
,,H,,,20001,9606.0,Homo sapiens,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,1,,,,,8,,13163,B,,Autocuration,CHEMBL615157,BAO_0000019,45
,,H,,,20001,9606.0,Homo sapiens,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,1,,,,,8,,13163,B,,Autocuration,CHEMBL615158,BAO_0000019,46
,,D,,,12971,10116.0,Rattus norvegicus,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",1,,,,,9,,10691,B,,Expert,CHEMBL615159,BAO_0000019,47
,,D,,,12971,10116.0,Rattus norvegicus,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",1,,,,,9,,10691,B,,Expert,CHEMBL615172,BAO_0000019,48
,,D,,,12971,10116.0,Rattus norvegicus,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",1,,,,,9,,10691,B,,Expert,CHEMBL615173,BAO_0000019,49
,,D,,,12971,10116.0,Rattus norvegicus,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",1,,,,,9,,10691,B,,Expert,CHEMBL615174,BAO_0000019,50
,,H,,,13053,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),1,,,,,8,,898,B,,Autocuration,CHEMBL884518,BAO_0000019,51
,,H,,,11512,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),1,,,,,8,,912,B,,Autocuration,CHEMBL615175,BAO_0000357,52
,,H,,,11512,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,1,,,,,8,,912,B,,Autocuration,CHEMBL615176,BAO_0000357,53
,,H,,,11512,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,1,,,,,8,,912,B,,Autocuration,CHEMBL615177,BAO_0000357,54
,Membranes,D,,,104740,10116.0,Rattus norvegicus,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,1,,,,,5,,15103,B,,Autocuration,CHEMBL615178,BAO_0000249,55
,,N,506.0,,80002,9606.0,Homo sapiens,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,1,,1A9,,,1,,5116,F,,Intermediate,CHEMBL615179,BAO_0000219,56
,,D,,,104835,10116.0,Rattus norvegicus,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,1,,Oocytes,,,7,,14578,F,,Autocuration,CHEMBL615180,BAO_0000219,57
,,D,,,104821,10116.0,Rattus norvegicus,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,1,,Oocytes,,,7,,14578,F,,Autocuration,CHEMBL615181,BAO_0000219,58
,,D,,,104848,10116.0,Rattus norvegicus,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,1,,Oocytes,,,7,,14578,F,,Autocuration,CHEMBL615182,BAO_0000219,59
,,N,506.0,,80002,9606.0,Homo sapiens,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,1,,1A9,,,1,,4787,F,,Expert,CHEMBL615183,BAO_0000219,60
,,N,506.0,,80002,9606.0,Homo sapiens,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,1,,1A9,,,1,,4787,F,,Intermediate,CHEMBL615184,BAO_0000219,61
,,N,506.0,,80002,9606.0,Homo sapiens,Cytotoxic activity against human ovarian cancer (1A9) cell line,1,,1A9,,,1,,3547,F,,Intermediate,CHEMBL615185,BAO_0000219,62
,,N,506.0,,80002,9606.0,Homo sapiens,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,1,,1A9,,,1,,3547,F,,Intermediate,CHEMBL615186,BAO_0000219,63
,,N,506.0,,80002,9606.0,Homo sapiens,Effective dose of compound against replication of 1A9 cell line was evaluated,1,,1A9,,,1,,6726,F,,Intermediate,CHEMBL615187,BAO_0000219,64
,,N,506.0,,80002,9606.0,Homo sapiens,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,1,,1A9,,,1,,3455,F,,Expert,CHEMBL885343,BAO_0000219,65
,,N,506.0,,80002,9606.0,Homo sapiens,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),1,,1A9,,,1,,5726,F,,Intermediate,CHEMBL615188,BAO_0000219,66
,,N,506.0,,80002,9606.0,Homo sapiens,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,1,,1A9,,,1,,5726,F,,Intermediate,CHEMBL615189,BAO_0000219,67
,,N,506.0,,80002,9606.0,Homo sapiens,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,1,,1A9,,,1,,5726,F,,Intermediate,CHEMBL615190,BAO_0000219,68
,,N,506.0,,80002,9606.0,Homo sapiens,Inhibitory activity against Taxol resistant 1A9 cell lines,1,,1A9,,,1,,3395,F,,Intermediate,CHEMBL615191,BAO_0000219,69
,,N,506.0,,80002,9606.0,Homo sapiens,Cytotoxicity against human ovarian cancer (1A9) cell lines.,1,,1A9,,,1,,3415,F,,Expert,CHEMBL615192,BAO_0000219,70
,,N,506.0,,80002,9606.0,Homo sapiens,Percentage inhibition of human ovarian cancer (1A9) cell lines.,1,,1A9,,,1,,3415,F,,Expert,CHEMBL827083,BAO_0000219,71
,,N,506.0,,80002,9606.0,Homo sapiens,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,1,,1A9,,,1,,17099,F,,Expert,CHEMBL615193,BAO_0000219,72
,,N,506.0,,80002,9606.0,Homo sapiens,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,1,,1A9,,,1,,17099,F,,Intermediate,CHEMBL615194,BAO_0000219,73
,,N,506.0,,80002,9606.0,Homo sapiens,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,1,,1A9,,,1,,17099,F,,Intermediate,CHEMBL615195,BAO_0000219,74
,,N,506.0,,80002,9606.0,Homo sapiens,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,1,,1A9,,,1,,17099,F,,Intermediate,CHEMBL615196,BAO_0000219,75
,,N,503.0,,81072,9606.0,Homo sapiens,Inhibitory concentration against Jurkat cells,1,,Jurkat,,,1,,17721,F,,Intermediate,CHEMBL615197,BAO_0000219,76
,,U,,,22226,,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,1,,,,,0,,1229,F,,Intermediate,CHEMBL615198,BAO_0000019,77
,,D,,,100121,10116.0,Rattus norvegicus,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,1,,,,,9,,11347,A,,Expert,CHEMBL615199,BAO_0000357,78
,,H,,,11231,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",1,,,,,8,,17117,B,,Expert,CHEMBL615200,BAO_0000357,79
,,H,,,11231,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",1,,,,,8,,17117,B,,Expert,CHEMBL615201,BAO_0000357,80
,,H,,,11231,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",1,,,,,8,,17117,B,,Expert,CHEMBL615202,BAO_0000357,81
,Microsomes,H,,,11231,5476.0,Candida albicans,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",1,,,,,8,,11375,B,,Autocuration,CHEMBL615203,BAO_0000251,82
,Microsomes,H,,,11231,5476.0,Candida albicans,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",1,,,,,8,,11375,B,,Autocuration,CHEMBL615204,BAO_0000251,83
,Microsomes,H,,,11231,4932.0,Saccharomyces cerevisiae,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",1,,,,,8,,11375,B,,Autocuration,CHEMBL615205,BAO_0000251,84
,Microsomes,H,,,11231,4932.0,Saccharomyces cerevisiae,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",1,,,,,8,,11375,B,,Autocuration,CHEMBL615206,BAO_0000251,85
,Microsomes,H,,,12083,9823.0,Sus scrofa,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",1,Liver,,,,8,,11375,B,2107.0,Autocuration,CHEMBL615207,BAO_0000251,86
,,H,,,11231,10116.0,Rattus norvegicus,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",1,,,,,8,,791,B,,Autocuration,CHEMBL827084,BAO_0000019,87
,,H,,,11231,10116.0,Rattus norvegicus,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",1,,,,,8,,791,B,,Autocuration,CHEMBL615208,BAO_0000019,88
,,H,,,11231,10116.0,Rattus norvegicus,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",1,,,,,8,,791,B,,Autocuration,CHEMBL615209,BAO_0000019,89
,Microsomes,D,,,12083,10116.0,Rattus norvegicus,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",1,Liver,,,,9,,11375,B,2107.0,Autocuration,CHEMBL615210,BAO_0000251,90
,Microsomes,D,,,12083,10116.0,Rattus norvegicus,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",1,Liver,,,,9,,11375,B,2107.0,Autocuration,CHEMBL615211,BAO_0000251,91
,Microsomes,D,,,12083,10116.0,Rattus norvegicus,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",1,Liver,,,,9,,153,B,2107.0,Autocuration,CHEMBL615212,BAO_0000251,92
,,H,,,11377,,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),1,,,,,8,,8269,B,,Expert,CHEMBL615213,BAO_0000357,93
,,H,,,11377,,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,1,,,,,8,,8269,B,,Expert,CHEMBL615273,BAO_0000357,94
,,N,726.0,,81020,9606.0,Homo sapiens,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,1,,HepG2,,,1,,17653,F,,Expert,CHEMBL615274,BAO_0000219,95
,,N,726.0,,81020,9606.0,Homo sapiens,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,1,,HepG2,,,1,,14277,F,,Intermediate,CHEMBL615275,BAO_0000219,96
,,N,726.0,,81020,9606.0,Homo sapiens,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,1,,HepG2,,,1,,1717,F,,Intermediate,CHEMBL615276,BAO_0000219,97
,,N,726.0,,81020,9606.0,Homo sapiens,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,1,,HepG2,,,1,,14091,F,,Intermediate,CHEMBL615277,BAO_0000219,98
,,N,726.0,,81020,9606.0,Homo sapiens,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,1,,HepG2,,,1,,14091,F,,Intermediate,CHEMBL615326,BAO_0000219,99
,,N,,,50606,10407.0,Hepatitis B virus,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,1,,,,,1,,17653,F,,Expert,CHEMBL883130,BAO_0000218,100
,,N,726.0,,81020,9606.0,Homo sapiens,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,1,,HepG2,,,1,,13105,F,,Intermediate,CHEMBL884519,BAO_0000219,101
,,N,726.0,,81020,9606.0,Homo sapiens,Concentration required to inhibit 50% of 2.2.15 cell line,1,,HepG2,,,1,,1717,F,,Intermediate,CHEMBL615327,BAO_0000219,102
,,N,726.0,,81020,9606.0,Homo sapiens,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,1,,HepG2,,,1,,13105,A,,Intermediate,CHEMBL615328,BAO_0000219,103
,,N,,,50587,9606.0,Homo sapiens,Cytotoxic activity of compound against uninfected 2.2.15 cells.,1,,2.2.15,,,1,,13600,F,,Intermediate,CHEMBL615329,BAO_0000218,104
,,N,,,50587,9606.0,Homo sapiens,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,1,,2.2.15,,,1,,13467,F,,Intermediate,CHEMBL615330,BAO_0000218,105
,,N,,,50606,10407.0,Hepatitis B virus,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",1,,2.2.15,,,1,,17477,F,,Expert,CHEMBL615331,BAO_0000218,106
,,N,,,50587,9606.0,Homo sapiens,In vitro anti-HBV activity in 2.2.15 cells,1,,2.2.15,,,1,,1593,F,,Intermediate,CHEMBL615332,BAO_0000218,107
,,N,,,50587,9606.0,Homo sapiens,In vitro anti-HBV activity in 2.2.15 cells; Not determined,1,,2.2.15,,,1,,1593,F,,Intermediate,CHEMBL615333,BAO_0000218,108
,,N,,,50587,9606.0,Homo sapiens,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,1,,2.2.15,,,1,,15089,F,,Intermediate,CHEMBL615334,BAO_0000218,109
,,N,,,50587,9606.0,Homo sapiens,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,1,,2.2.15,,,1,,15089,F,,Intermediate,CHEMBL615335,BAO_0000218,110
,,N,,,50587,9606.0,Homo sapiens,Cytotoxicity in 2.2.15 cells,1,,2.2.15,,,1,,1593,F,,Intermediate,CHEMBL615336,BAO_0000218,111
,,N,,,50587,9606.0,Homo sapiens,Cytotoxicity in 2.2.15 cells; Not determined,1,,2.2.15,,,1,,1593,F,,Intermediate,CHEMBL615337,BAO_0000218,112
,,N,,,50587,9606.0,Homo sapiens,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,1,,2.2.15,,,1,,13600,F,,Intermediate,CHEMBL615338,BAO_0000218,113
,,N,,,50587,9606.0,Homo sapiens,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,1,,2.2.15,,,1,,13467,F,,Intermediate,CHEMBL615339,BAO_0000218,114
,,N,,,50587,9606.0,Homo sapiens,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,1,,2.2.15,,,1,,13467,F,,Intermediate,CHEMBL615340,BAO_0000218,115
,,N,726.0,,81020,9606.0,Homo sapiens,Antiviral activity against HBV was determined in 2.215 cell line,1,,HepG2,,,1,,14764,F,,Intermediate,CHEMBL615341,BAO_0000219,116
,Microsomes,U,,,22226,9606.0,Homo sapiens,Inhibition of 20-HETE synthesis in human renal microsomes,1,,,,,0,,6531,B,,Autocuration,CHEMBL615342,BAO_0000251,117
,,U,,,22226,,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,1,,,,,0,,17322,B,,Autocuration,CHEMBL615343,BAO_0000019,118
,,N,388.0,,80612,9606.0,Homo sapiens,Inhibitory concentration against 2008 (ovarian) cells,1,,2008,,,1,,17072,F,,Intermediate,CHEMBL615344,BAO_0000219,119
,,N,388.0,,80612,9606.0,Homo sapiens,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,1,,2008,,,1,,16936,F,,Intermediate,CHEMBL615345,BAO_0000219,120
,,N,388.0,,80612,9606.0,Homo sapiens,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),1,,2008,,,1,,16936,F,,Intermediate,CHEMBL615346,BAO_0000219,121
,,N,388.0,,80612,9606.0,Homo sapiens,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,1,,2008,,,1,,17146,F,,Intermediate,CHEMBL615347,BAO_0000219,122
,,N,388.0,,80612,9606.0,Homo sapiens,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,1,,2008,,,1,,17146,F,,Intermediate,CHEMBL615348,BAO_0000219,123
,,N,561.0,,80613,9606.0,Homo sapiens,In vitro inhibition of 2008/R ovarian cancer cell line,1,,2008/R,,,1,,10797,F,,Intermediate,CHEMBL827085,BAO_0000219,124
,,N,561.0,,80613,9606.0,Homo sapiens,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,1,,2008/R,,,1,,10797,F,,Intermediate,CHEMBL615349,BAO_0000219,125
,,N,389.0,,80614,9606.0,Homo sapiens,In vitro inhibition of 2008/S ovarian cancer cell line,1,,2008/S,,,1,,10797,F,,Intermediate,CHEMBL615350,BAO_0000219,126
,,N,389.0,,80614,9606.0,Homo sapiens,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,1,,2008/S,,,1,,10797,F,,Intermediate,CHEMBL615351,BAO_0000219,127
,,S,,,100256,9606.0,Homo sapiens,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,1,,,,,2,,4823,B,,Expert,CHEMBL615352,BAO_0000220,128
,,S,,,100256,9606.0,Homo sapiens,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,1,,,,,2,,12912,B,,Intermediate,CHEMBL615353,BAO_0000220,129
,,S,,,100256,,,Inhibition of chymotrypsin-like activity of 20S proteasome,1,,,,,2,,2957,B,,Expert,CHEMBL615354,BAO_0000220,130
,,S,,,100256,,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,1,,,,,2,,2957,B,,Expert,CHEMBL615355,BAO_0000220,131
,,S,,,100256,,,Inhibitory activity against 20S proteosome,1,,,,,2,,3260,B,,Intermediate,CHEMBL615356,BAO_0000220,132
,,U,,,22226,9606.0,Homo sapiens,Compound was tested for inhibitory activity against tryptase,1,,,,,0,,3451,B,,Autocuration,CHEMBL615357,BAO_0000019,133
,,N,726.0,,81020,9606.0,Homo sapiens,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,1,,HepG2,,,1,,13885,F,,Intermediate,CHEMBL615358,BAO_0000219,134
,,N,726.0,,81020,9606.0,Homo sapiens,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,1,,HepG2,,,1,,13885,F,,Intermediate,CHEMBL827086,BAO_0000219,135
,,U,,,22226,,,Compound was tested for the inhibition of Alpha-glucosidase,1,,,,,0,,3676,B,,Autocuration,CHEMBL615359,BAO_0000019,136
,,H,,,235,,,Inhibitory concentration against human neutrophil elastase (HNE),1,,,,,8,,6043,B,,Autocuration,CHEMBL615360,BAO_0000357,137
,,U,,,22226,10116.0,Rattus norvegicus,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,1,Heart,,,,0,,11140,F,948.0,Autocuration,CHEMBL615361,BAO_0000218,138
,,H,,,19640,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,1,,,,,8,,10543,F,,Autocuration,CHEMBL615362,BAO_0000019,139
,,H,,,19640,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,1,,,,,8,,10543,F,,Expert,CHEMBL615363,BAO_0000019,140
,,H,,,19640,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,1,,,,,8,,10543,B,,Autocuration,CHEMBL615364,BAO_0000357,141
,,H,,,19640,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,1,,,,,8,,10543,F,,Expert,CHEMBL615365,BAO_0000019,142
,,N,524.0,,80360,10090.0,Mus musculus,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,1,,P338,,,1,,11365,F,,Intermediate,CHEMBL615366,BAO_0000219,143
,,N,524.0,,80360,10090.0,Mus musculus,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,1,,P338,,,1,,11365,F,,Intermediate,CHEMBL615367,BAO_0000219,144
,,N,554.0,,80384,9606.0,Homo sapiens,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,1,,PBL,,,1,,11803,F,,Intermediate,CHEMBL615368,BAO_0000219,145
,,U,,,22226,9940.0,Ovis aries,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,1,,,,,0,,11803,F,,Autocuration,CHEMBL615369,BAO_0000019,146
,,U,,,22226,9940.0,Ovis aries,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,1,,,,,0,,11803,F,,Autocuration,CHEMBL615370,BAO_0000019,147
,,H,,,191,,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),1,,,,,8,,12278,B,,Autocuration,CHEMBL615673,BAO_0000357,148
,,U,,,22226,9606.0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,1,,,,,0,,8249,F,,Autocuration,CHEMBL615674,BAO_0000019,149
,,U,,,22226,9606.0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,1,,,,,0,,8249,F,,Autocuration,CHEMBL615675,BAO_0000019,150
,,U,635.0,,22226,9606.0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,1,,CCRF-CEM,,,0,,8249,F,,Autocuration,CHEMBL615676,BAO_0000219,151
,,U,635.0,,22226,9606.0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,1,,CCRF-CEM,,,0,,8249,F,,Autocuration,CHEMBL615677,BAO_0000219,152
,,U,635.0,,22226,9606.0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,1,,CCRF-CEM,,,0,,8249,F,,Autocuration,CHEMBL615678,BAO_0000219,153
,,U,635.0,,22226,9606.0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,1,,CCRF-CEM,,,0,,8249,F,,Autocuration,CHEMBL615679,BAO_0000219,154
,,U,,,22226,9606.0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,1,,,,,0,,8249,F,,Autocuration,CHEMBL615680,BAO_0000019,155
,,U,,,22226,9606.0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,1,,,,,0,,8249,F,,Autocuration,CHEMBL615681,BAO_0000019,156
,,H,,,104290,,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,1,,,,,6,,16992,B,,Autocuration,CHEMBL857972,BAO_0000249,157
,,N,,,50264,1314.0,Streptococcus pyogenes,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,1,,,,,1,,10543,F,,Intermediate,CHEMBL857899,BAO_0000218,158
,,N,,,50527,10335.0,Human herpesvirus 3,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),1,,,,,1,,17833,F,,Intermediate,CHEMBL615371,BAO_0000218,159
,,N,468.0,,50527,10335.0,vericilla zoster virus,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,1,,HEL,,,1,,17290,F,,Expert,CHEMBL615372,BAO_0000218,160
,,N,,,50527,10335.0,vericilla zoster virus,Antiviral activity against 07/1 strain of VZV; ND: No data,1,,,,,1,,17290,F,,Intermediate,CHEMBL615373,BAO_0000218,161
,,N,,,50527,10335.0,vericilla zoster virus,Antiviral activity against 07/1 strain of VZV; ND=No data,1,,,,,1,,17290,F,,Intermediate,CHEMBL615374,BAO_0000218,162
,,N,,,50145,561.0,escherichia cloac,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",1,,,,,1,,10932,F,,Intermediate,CHEMBL615375,BAO_0000218,163
,,U,,,22226,,,Ratio of Ki at A2 to Ki at A1 receptors,1,,,,,0,,9707,B,,Autocuration,CHEMBL615376,BAO_0000019,164
,,H,,,11143,5476.0,Candida albicans,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",1,,,,,8,,2346,B,,Expert,CHEMBL615377,BAO_0000249,165
,,H,,,18077,284593.0,Candida glabrata CBS 138,"Inhibition of 1,3-beta-glucan synthase",1,,,,,8,,2205,B,,Expert,CHEMBL615378,BAO_0000357,166
,,N,832.0,,80609,9606.0,Homo sapiens,Inhibition of growth of 1-87 human tumor cell line,1,,1-87 tumor cell line,,,1,,11900,F,,Intermediate,CHEMBL615379,BAO_0000219,167
,,D,,,12166,10116.0,Rattus norvegicus,Inhibition of 1-lipoxygenase (LOX)in RBL cells,1,,,,,9,,14864,B,,Expert,CHEMBL615380,BAO_0000219,168
,,D,,,100171,3847.0,Glycine max,Inhibitory activity against soybean 1-lipoxygenase (SLO),1,,,,,9,,16474,B,,Autocuration,CHEMBL615381,BAO_0000357,169
,,D,,,100171,3847.0,Glycine max,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,1,,,,,9,,16474,B,,Autocuration,CHEMBL615382,BAO_0000357,170
,,D,,,100171,3847.0,Glycine max,% inhibition against soybean 1-lipoxygenase (SLO),1,,,,,9,,16474,B,,Autocuration,CHEMBL615383,BAO_0000357,171
,,D,,,100171,3847.0,Glycine max,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,1,,,,,9,,16474,B,,Autocuration,CHEMBL615384,BAO_0000357,172
,,D,,,100171,3847.0,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,1,,,,,9,,3094,B,,Autocuration,CHEMBL615385,BAO_0000357,173
,,D,,,100171,3847.0,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,1,,,,,9,,3094,B,,Autocuration,CHEMBL615386,BAO_0000357,174
,,D,,,100171,3847.0,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,1,,,,,9,,3094,B,,Autocuration,CHEMBL615387,BAO_0000357,175
,,D,,,100171,3847.0,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,1,,,,,9,,3094,B,,Autocuration,CHEMBL615388,BAO_0000357,176
,,D,,,100171,3847.0,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,1,,,,,9,,3094,B,,Autocuration,CHEMBL615214,BAO_0000357,177
,,D,,,100171,3847.0,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,1,,,,,9,,3094,B,,Autocuration,CHEMBL827087,BAO_0000357,178
,,D,,,100171,3847.0,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,1,,,,,9,,3094,B,,Autocuration,CHEMBL615215,BAO_0000357,179
,,D,,,100171,3847.0,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,1,,,,,9,,3094,B,,Autocuration,CHEMBL615216,BAO_0000357,180
,,D,,,100171,3847.0,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,1,,,,,9,,3094,B,,Autocuration,CHEMBL615217,BAO_0000357,181
,,D,,,100171,3847.0,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,1,,,,,9,,3094,B,,Autocuration,CHEMBL615218,BAO_0000357,182
,,D,,,100171,3847.0,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,1,,,,,9,,3094,B,,Autocuration,CHEMBL615219,BAO_0000357,183
,,U,,,22226,10090.0,Mus musculus,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,1,,,,,0,,10413,B,,Autocuration,CHEMBL615220,BAO_0000019,184
,,N,294.0,,80049,10090.0,Mus musculus,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),1,,C3H 10T1/2,,,1,,16929,F,,Intermediate,CHEMBL615221,BAO_0000219,185
,,U,,,22226,,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,1,,,,,0,,1229,F,,Intermediate,CHEMBL615222,BAO_0000019,186
,,H,,,11489,,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),1,,,,,8,,16587,B,,Autocuration,CHEMBL615223,BAO_0000357,187
,,H,,,11862,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),1,,,,,8,,16587,B,,Autocuration,CHEMBL615224,BAO_0000357,188
,,H,,,11862,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,1,,,,,8,,16587,B,,Autocuration,CHEMBL615225,BAO_0000357,189
,,H,,,11489,,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,1,,,,,8,,16587,B,,Autocuration,CHEMBL615226,BAO_0000357,190
,,H,,,11862,,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,1,,,,,8,,16587,B,,Autocuration,CHEMBL615227,BAO_0000357,191
,,D,,,12347,9913.0,Bos taurus,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,1,,,,,9,,8058,F,,Expert,CHEMBL615228,BAO_0000019,192
,,D,,,100120,10116.0,Rattus norvegicus,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,1,,,,,9,,9065,B,,Expert,CHEMBL615229,BAO_0000357,193
,,D,,,100120,10116.0,Rattus norvegicus,Inhibition of 11 beta-hydroxylase from rat adrenal gland,1,Adrenal gland,,,,9,,8865,B,2369.0,Expert,CHEMBL615230,BAO_0000357,194
,,D,,,100120,10116.0,Rattus norvegicus,Inhibition of rat adrenal 11-beta-hydroxylase,1,,,,,9,,9066,B,,Expert,CHEMBL615231,BAO_0000357,195
,,D,,,100120,10116.0,Rattus norvegicus,Inhibition of rat adrenal 11-beta-hydroxylase,1,,,,,9,,8394,B,,Expert,CHEMBL884520,BAO_0000357,196
,,D,,,100120,10116.0,Rattus norvegicus,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,1,,,,,9,,8394,B,,Expert,CHEMBL615232,BAO_0000357,197
,,H,,,10328,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,1,,,,,8,,6431,B,,Autocuration,CHEMBL615233,BAO_0000019,198
,,H,,,11490,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,1,,,,,8,,6431,B,,Autocuration,CHEMBL827088,BAO_0000357,199
,,H,,,11490,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,1,,,,,8,,6431,B,,Autocuration,CHEMBL615234,BAO_0000357,200
,,H,,,11134,,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,1,,,,,8,,9295,F,,Autocuration,CHEMBL615235,BAO_0000019,201
,,H,,,12052,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,1,,,,,8,,10193,B,,Autocuration,CHEMBL615236,BAO_0000019,202
,,H,,,11134,,,Compound was tested in vitro for inhibition of 12-LO human platelet,1,,,,,8,,13622,B,,Autocuration,CHEMBL615237,BAO_0000019,203
,,H,,,11134,,,Inhibitory concentration against human platelet 12-lipoxygenase,1,,,,,8,,12079,F,,Autocuration,CHEMBL615238,BAO_0000019,204
,,H,,,11134,,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,1,,,,,8,,13622,B,,Autocuration,CHEMBL615239,BAO_0000019,205
,,D,,,11134,9606.0,Homo sapiens,Inhibitory concentration against human platelet 12-lipoxygenase,1,,,,,9,,12079,F,,Autocuration,CHEMBL615240,BAO_0000019,206
,,H,,,11835,,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,1,,,,,8,,13500,B,,Expert,CHEMBL615241,BAO_0000019,207
,,H,,,11601,,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,1,,,,,8,,13723,B,,Expert,CHEMBL615242,BAO_0000357,208
,,H,,,11134,,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),1,,,,,8,,16474,B,,Autocuration,CHEMBL615243,BAO_0000019,209
,,H,,,11134,,,Inhibitory activity against human platelet 12-lipoxygenase,1,,,,,8,,1630,B,,Autocuration,CHEMBL615244,BAO_0000019,210
,,H,,,11134,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,1,,,,,8,,167,B,,Autocuration,CHEMBL615245,BAO_0000019,211
,,H,,,11134,,,% inhibition against human platelet 12-lipoxygenase (12-HLO),1,,,,,8,,16474,B,,Autocuration,CHEMBL615246,BAO_0000019,212
,,H,,,11134,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,1,,,,,8,,167,B,,Autocuration,CHEMBL615247,BAO_0000019,213
,,H,,,11134,,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,1,,,,,8,,16474,B,,Autocuration,CHEMBL615248,BAO_0000019,214
,,H,,,11601,,,Inhibitory activity towards porcine 12-lipoxygenase,1,,,,,8,,10091,B,,Autocuration,CHEMBL615249,BAO_0000357,215
,,H,,,11601,,,Tested for inhibition against porcine 12-LO,1,,,,,8,,11966,B,,Autocuration,CHEMBL615250,BAO_0000357,216
,,H,,,12052,,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,1,,,,,8,,951,B,,Autocuration,CHEMBL615251,BAO_0000019,217
,,H,,,12052,,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,1,,,,,8,,10997,B,,Autocuration,CHEMBL615252,BAO_0000019,218
,,H,,,12052,,,In vitro inhibition of rat platelet 12-lipoxygenase,1,,,,,8,,10193,B,,Expert,CHEMBL828340,BAO_0000019,219
,,H,,,12052,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,1,,,,,8,,10193,B,,Autocuration,CHEMBL615253,BAO_0000019,220
,,H,,,12052,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,1,,,,,8,,10193,B,,Autocuration,CHEMBL615254,BAO_0000019,221
,,H,,,12052,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,1,,,,,8,,10193,B,,Autocuration,CHEMBL615255,BAO_0000019,222
,,H,,,12052,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,1,,,,,8,,10193,B,,Autocuration,CHEMBL615256,BAO_0000019,223
,,H,,,12052,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,1,,,,,8,,10193,B,,Autocuration,CHEMBL615257,BAO_0000019,224
,,H,,,12052,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,1,,,,,8,,11087,B,,Autocuration,CHEMBL615258,BAO_0000019,225
,,N,621.0,,80007,9606.0,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,1,,41M,,,1,,15569,F,,Intermediate,CHEMBL615259,BAO_0000219,226
,,N,621.0,,80007,9606.0,Homo sapiens,In vitro antitumor activity against 41M cell line.,1,,41M,,,1,,12989,F,,Expert,CHEMBL615260,BAO_0000219,227
,,N,621.0,,80007,9606.0,Homo sapiens,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,1,,41M,,,1,,16745,F,,Intermediate,CHEMBL615261,BAO_0000219,228
,,N,621.0,,80007,9606.0,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,1,,41M,,,1,,15569,F,,Intermediate,CHEMBL615262,BAO_0000219,229
,,N,621.0,,80007,9606.0,Homo sapiens,In vitro antitumor activity against 41McisR cell line.,1,,41M,,,1,,12989,F,,Expert,CHEMBL615263,BAO_0000219,230
,,N,621.0,,80007,9606.0,Homo sapiens,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,1,,41M,,,1,,12989,F,,Expert,CHEMBL838393,BAO_0000219,231
,,N,621.0,,80007,9606.0,Homo sapiens,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,1,,41M,,,1,,16745,F,,Intermediate,CHEMBL615264,BAO_0000219,232
,,D,,,84,9606.0,Homo sapiens,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),1,,,,,9,,6210,B,,Expert,CHEMBL615265,BAO_0000357,233
,,D,,,68,9606.0,Homo sapiens,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),1,,,,,9,,6210,B,,Expert,CHEMBL615266,BAO_0000357,234
,,H,,,68,,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),1,,,,,8,,6226,B,,Expert,CHEMBL615267,BAO_0000357,235
,,H,,,10201,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,1,,,,,8,,17855,B,,Expert,CHEMBL615268,BAO_0000357,236
,,H,,,10201,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,1,,,,,8,,17855,B,,Expert,CHEMBL615269,BAO_0000357,237
,,H,,,10201,,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,1,,,,,8,,17855,B,,Expert,CHEMBL615270,BAO_0000357,238
,,H,,,12220,,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",1,,,,,8,,10413,B,,Autocuration,CHEMBL615271,BAO_0000357,239
,,H,,,11303,562.0,Escherichia coli,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",1,,,,,8,,10413,B,,Autocuration,CHEMBL615272,BAO_0000357,240
,,H,,,11303,562.0,Escherichia coli,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",1,,,,,8,,10413,B,,Autocuration,CHEMBL615103,BAO_0000357,241
,,H,,,11303,562.0,Escherichia coli,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",1,,,,,8,,10413,B,,Autocuration,CHEMBL615104,BAO_0000357,242
,,H,,,12220,,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",1,,,,,8,,10413,B,,Autocuration,CHEMBL615105,BAO_0000357,243
,,H,,,12220,,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",1,,,,,8,,10413,B,,Autocuration,CHEMBL872866,BAO_0000357,244
,,H,,,11303,9823.0,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",1,,,,,8,,7587,B,,Autocuration,CHEMBL615106,BAO_0000357,245
,,H,,,11303,9823.0,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",1,,,,,8,,7587,B,,Autocuration,CHEMBL615107,BAO_0000019,246
,,H,,,11303,9823.0,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",1,,,,,8,,7587,B,,Autocuration,CHEMBL615108,BAO_0000357,247
,,H,,,11303,9823.0,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",1,,,,,8,,7587,B,,Autocuration,CHEMBL615109,BAO_0000357,248
,,H,,,11303,9823.0,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",1,,,,,8,,7587,B,,Autocuration,CHEMBL615110,BAO_0000357,249
,,H,,,11303,9823.0,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",1,,,,,8,,7587,B,,Autocuration,CHEMBL840105,BAO_0000019,250
,,H,,,11303,9823.0,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",1,,,,,8,,7587,B,,Autocuration,CHEMBL615111,BAO_0000019,251
,,H,,,11303,9823.0,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",1,,,,,8,,7587,B,,Autocuration,CHEMBL615112,BAO_0000019,252
,,H,,,11303,9823.0,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",1,,,,,8,,7587,B,,Autocuration,CHEMBL615113,BAO_0000019,253
,,H,,,11303,9823.0,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",1,,,,,8,,7587,B,,Autocuration,CHEMBL615114,BAO_0000019,254
,,H,,,11303,9823.0,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",1,,,,,8,,7587,B,,Autocuration,CHEMBL615115,BAO_0000357,255
,,H,,,11303,9823.0,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",1,,,,,8,,7587,B,,Autocuration,CHEMBL615116,BAO_0000019,256
,,H,,,11303,,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",1,,,,,8,,7323,B,,Autocuration,CHEMBL615698,BAO_0000357,257
,,U,,,22226,9823.0,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",1,,,,,0,,7587,B,,Autocuration,CHEMBL615699,BAO_0000019,258
,,U,,,22226,9823.0,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",1,,,,,0,,7587,B,,Autocuration,CHEMBL615700,BAO_0000019,259
,,H,,,100249,4932.0,Saccharomyces cerevisiae,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,1,,,,,8,,13750,B,,Expert,CHEMBL615701,BAO_0000357,260
,,U,,,22226,10116.0,Rattus norvegicus,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,1,,,,,0,,7662,B,,Autocuration,CHEMBL615702,BAO_0000019,261
,,U,,,22226,10116.0,Rattus norvegicus,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,1,,,,,0,,7662,B,,Autocuration,CHEMBL615703,BAO_0000019,262
,,U,,,22226,10116.0,Rattus norvegicus,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",1,,,,,0,,7662,B,,Autocuration,CHEMBL615704,BAO_0000019,263
,,H,,,104698,,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",1,,,,,6,,12211,F,,Autocuration,CHEMBL615705,BAO_0000019,264
,,H,,,104698,,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",1,,,,,6,,12211,F,,Autocuration,CHEMBL615706,BAO_0000019,265
,,D,,,20033,10141.0,Cavia porcellus,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,1,Ileum,,,,9,,12211,F,2116.0,Intermediate,CHEMBL615707,BAO_0000221,266
,,H,,,10623,,,Stimulatory activity of intragastric pressure was tested in the rat,1,,,,,8,,12211,F,,Expert,CHEMBL615708,BAO_0000019,267
,,H,,,121,,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,1,,,,,8,,15453,B,,Autocuration,CHEMBL615709,BAO_0000357,268
,,U,,,22226,10116.0,Rattus norvegicus,Dose to reduce neuronal firing against 5-HT cells in rats (iv),1,,,,,0,,11884,F,,Autocuration,CHEMBL615710,BAO_0000218,269
,,H,,,12688,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,1,,,,,8,,7185,F,,Autocuration,CHEMBL615711,BAO_0000019,270
,,D,,,121,9606.0,Homo sapiens,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,1,,,,,9,,6876,B,,Expert,CHEMBL615712,BAO_0000357,271
,,D,,,121,9606.0,Homo sapiens,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,1,,,,,9,,6876,B,,Expert,CHEMBL836325,BAO_0000357,272
,,H,,,12198,,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,1,,,,,8,,11863,F,,Autocuration,CHEMBL615713,BAO_0000019,273
,,H,,,12198,,,Inhibition constant of high-affinity 5-HT uptake,1,,,,,8,,11863,B,,Autocuration,CHEMBL615714,BAO_0000357,274
,,H,,,12198,,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,1,,,,,8,,11863,F,,Autocuration,CHEMBL615715,BAO_0000019,275
,,H,,,12198,,,Maximum rate was determined for high affinity transport of 5-HT,1,,,,,8,,11863,F,,Autocuration,CHEMBL615716,BAO_0000019,276
,,H,,,104714,,,Compound was tested for agonistic activity against 5-HT uptake,1,,,,,4,,4639,F,,Autocuration,CHEMBL615717,BAO_0000019,277
,,H,,,10577,,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,1,,,,,8,,15796,B,,Expert,CHEMBL881818,BAO_0000019,278
,,H,,,105,9913.0,Bos taurus,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,1,,,,,8,,15796,B,,Expert,CHEMBL884540,BAO_0000357,279
,,D,,,104744,10116.0,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,1,,,,,5,,12801,B,,Autocuration,CHEMBL615718,BAO_0000224,280
,,H,,,104744,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,1,,,,,4,,12801,B,,Autocuration,CHEMBL615719,BAO_0000224,281
,Membranes,H,,,104744,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,1,,,,,4,,12120,B,,Autocuration,CHEMBL615720,BAO_0000249,282
,Membranes,H,,,104744,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,1,,,,,4,,12120,B,,Autocuration,CHEMBL615721,BAO_0000249,283
,,H,,,104744,,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,1,,,,,4,,11963,B,,Autocuration,CHEMBL615722,BAO_0000019,284
,,H,,,51,,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,1,,,,,8,,11701,F,,Autocuration,CHEMBL615723,BAO_0000019,285
,,H,,,51,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,Hippocampus,,,,8,,9995,B,10000000.0,Autocuration,CHEMBL615724,BAO_0000221,286
,,H,,,51,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,1,Hippocampus,,,,8,,9995,B,10000000.0,Autocuration,CHEMBL615725,BAO_0000221,287
,,H,,,51,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,Hippocampus,,,,8,,9995,B,10000000.0,Autocuration,CHEMBL615726,BAO_0000221,288
,,H,,,10576,,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),1,,,,In vivo,8,,16394,F,,Autocuration,CHEMBL615727,BAO_0000218,289
,,D,,,105570,10141.0,Cavia porcellus,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,1,,,,,9,,11574,F,,Intermediate,CHEMBL615728,BAO_0000019,290
,,H,449.0,,279,,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,1,,CHO,,,8,,15779,B,,Autocuration,CHEMBL857971,BAO_0000219,291
,,H,,,107,,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,1,,,,,8,,15363,B,,Autocuration,CHEMBL615729,BAO_0000357,292
,,D,,,12687,10116.0,Rattus norvegicus,Efficacy against 5-hydroxytryptamine 2A receptor,1,,,,,9,,15363,F,,Expert,CHEMBL615730,BAO_0000019,293
,,H,,,12687,,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,1,,,,,8,,15329,F,,Expert,CHEMBL615731,BAO_0000019,294
,,H,,,12687,,,Relative potency towards 5-HT2A receptor of rat tail artery,1,,,,,8,,15329,F,,Expert,CHEMBL615732,BAO_0000019,295
,,H,,,12687,,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,1,,,,,8,,15329,F,,Expert,CHEMBL615733,BAO_0000019,296
,,H,,,12687,,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,1,,,,,8,,15329,F,,Expert,CHEMBL615734,BAO_0000019,297
,,H,,,12687,,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,1,,,,,8,,15329,F,,Autocuration,CHEMBL615735,BAO_0000019,298
,,H,,,12687,,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,1,,,,,8,,15329,F,,Expert,CHEMBL615736,BAO_0000019,299
,,D,,,20033,10141.0,Cavia porcellus,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,1,Ileum,,,,9,,273,F,2116.0,Intermediate,CHEMBL615737,BAO_0000221,300
,,D,,,20033,10141.0,Cavia porcellus,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),1,Ileum,,,,9,,273,F,2116.0,Intermediate,CHEMBL615738,BAO_0000221,301
,,D,,,20033,10141.0,Cavia porcellus,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,1,Ileum,,,,9,,273,F,2116.0,Intermediate,CHEMBL615739,BAO_0000221,302
,,H,,,10623,,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,1,,,,,8,,12092,B,,Autocuration,CHEMBL615278,BAO_0000357,303
,,D,,,10623,10116.0,Rattus norvegicus,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,1,,,,,9,,1317,F,,Expert,CHEMBL615279,BAO_0000019,304
,,H,,,168,,,Binding affinity against 5-hydroxytryptamine 4 receptor,1,,,,,8,,12409,B,,Expert,CHEMBL615280,BAO_0000357,305
,,U,,,22226,9031.0,Gallus gallus,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,1,,,,,0,,11126,B,,Autocuration,CHEMBL615281,BAO_0000019,306
,,U,,,22226,9606.0,Homo sapiens,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,1,,,,,0,,11126,F,,Autocuration,CHEMBL615282,BAO_0000019,307
,,U,,,22226,9606.0,Homo sapiens,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,1,,,,,0,,11126,F,,Autocuration,CHEMBL615283,BAO_0000019,308
,,N,649.0,,80156,9606.0,Homo sapiens,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,1,,HL-60,,,1,,11126,B,,Autocuration,CHEMBL615284,BAO_0000219,309
,,U,,,22226,9606.0,Homo sapiens,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,1,,,,,0,,11126,B,,Autocuration,CHEMBL615285,BAO_0000019,310
,,U,,,22226,9606.0,Homo sapiens,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,1,,,,,0,,11126,B,,Autocuration,CHEMBL615286,BAO_0000019,311
,,D,,,104703,9606.0,Homo sapiens,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,1,,Oocytes,,,7,,17807,B,,Autocuration,CHEMBL615287,BAO_0000219,312
,,S,,,100256,,,Chymotryptic inhibitory activity against 26S proteasome,1,,,,,2,,16575,F,,Intermediate,CHEMBL615288,BAO_0000220,313
,,S,,,100256,,,Inhibitory activity against 26S proteasome degradation of IkB,1,,,,,2,,15407,B,,Intermediate,CHEMBL615289,BAO_0000220,314
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro inhibition of 2780/DOX ovarian cancer cell line,1,,A2780,,,1,,10797,F,,Intermediate,CHEMBL615290,BAO_0000219,315
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro inhibition of 2780/S ovarian cancer cell line,1,,A2780,,,1,,10797,F,,Intermediate,CHEMBL884522,BAO_0000219,316
,,U,,,22226,9606.0,Homo sapiens,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,1,,,,,0,,3469,F,,Autocuration,CHEMBL615291,BAO_0000019,317
,,M,,,22222,,,Association constant for binding to AATT 28-mer AATT hairpin,1,,,,,3,,16037,B,,Intermediate,CHEMBL615292,BAO_0000225,318
,,M,,,22222,,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,1,,,,,3,,16037,B,,Intermediate,CHEMBL615293,BAO_0000225,319
,,M,,,22222,,,Reaction Rate Parameter for 28-mer AATT hairpin,1,,,,,3,,16037,B,,Intermediate,CHEMBL615294,BAO_0000225,320
,,M,,,22222,,,Reaction Rate Parameter for 28-mer AATT hairpin,1,,,,,3,,16037,B,,Intermediate,CHEMBL615295,BAO_0000225,321
,,U,,,22226,9606.0,Homo sapiens,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),1,,,,,0,,16524,F,,Autocuration,CHEMBL825021,BAO_0000019,322
,,U,,,22226,9606.0,Homo sapiens,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),1,,,,,0,,16524,F,,Autocuration,CHEMBL615296,BAO_0000019,323
,,U,,,22226,9606.0,Homo sapiens,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,1,,,,,0,,16524,F,,Autocuration,CHEMBL615297,BAO_0000019,324
,,U,,,22226,10029.0,Cricetulus griseus,Cytotoxicity against cell line 2SC/20 determined by MTT test,1,,,,,0,,16758,F,,Autocuration,CHEMBL615298,BAO_0000019,325
,,U,,,22226,10029.0,Cricetulus griseus,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,1,,,,,0,,16758,F,,Autocuration,CHEMBL615299,BAO_0000019,326
,,U,,,22226,10029.0,Cricetulus griseus,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,1,,,,,0,,16758,F,,Autocuration,CHEMBL615300,BAO_0000019,327
,,H,,,241,,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,1,,,,,8,,14360,B,,Autocuration,CHEMBL615301,BAO_0000357,328
,,D,,,241,9606.0,Homo sapiens,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,1,,,,,9,,14360,B,,Expert,CHEMBL615302,BAO_0000357,329
,,U,,,22226,10116.0,Rattus norvegicus,Selectivity ratio of ID50 in liver and heart,1,,,,,0,,9964,B,,Autocuration,CHEMBL615303,BAO_0000019,330
,,H,,,12132,,,"Selectivity, ratio of relative ID50 in liver and heart",1,,,,,8,,9964,B,,Autocuration,CHEMBL615304,BAO_0000019,331
,,H,,,12132,,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,1,,,,,8,,9964,B,,Autocuration,CHEMBL615305,BAO_0000019,332
,,H,,,12132,,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",1,,,,,8,,9964,B,,Autocuration,CHEMBL615306,BAO_0000218,333
,,H,,,12132,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",1,,,,,8,,9964,B,,Autocuration,CHEMBL615307,BAO_0000218,334
,,H,,,12132,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",1,,,,In vivo,8,,9964,B,,Autocuration,CHEMBL615308,BAO_0000218,335
,,H,,,12132,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",1,,,,In vivo,8,,9964,F,,Autocuration,CHEMBL615309,BAO_0000218,336
,,U,,,22226,,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",1,,,,,0,,9964,B,,Autocuration,CHEMBL615310,BAO_0000019,337
,,H,,,12132,,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,1,,,,,8,,9964,B,,Autocuration,CHEMBL615311,BAO_0000019,338
,,U,,,22226,9606.0,Homo sapiens,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",1,,,,,0,,9964,B,,Autocuration,CHEMBL615312,BAO_0000019,339
,,H,,,12132,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,1,,,,,8,,9964,B,,Autocuration,CHEMBL615313,BAO_0000019,340
,,H,,,12132,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,1,,,,,8,,9964,F,,Autocuration,CHEMBL615314,BAO_0000019,341
,,H,,,12132,,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",1,,,,,8,,9964,B,,Autocuration,CHEMBL615315,BAO_0000019,342
,,U,,,22226,10116.0,Rattus norvegicus,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",1,,,,,0,,9964,B,,Autocuration,CHEMBL615316,BAO_0000218,343
,,H,,,12132,,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,1,,,,In vivo,8,,9964,B,,Autocuration,CHEMBL615317,BAO_0000218,344
,,H,,,12132,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",1,,,,,8,,9964,B,,Autocuration,CHEMBL615318,BAO_0000218,345
,,U,,,22226,10116.0,Rattus norvegicus,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",1,,,,,0,,9964,B,,Autocuration,CHEMBL615319,BAO_0000218,346
,,H,,,12132,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",1,,,,,8,,9964,B,,Autocuration,CHEMBL615320,BAO_0000019,347
,,H,,,12132,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",1,,,,,8,,9964,F,,Autocuration,CHEMBL615321,BAO_0000019,348
,,U,,,22226,10116.0,Rattus norvegicus,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",1,,,,,0,,3796,B,,Autocuration,CHEMBL615322,BAO_0000019,349
,,H,,,19690,562.0,Escherichia coli,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,1,,,,,8,,4251,B,,Autocuration,CHEMBL615323,BAO_0000357,350
,,H,,,19690,562.0,Escherichia coli,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,1,,,,,8,,4251,B,,Autocuration,CHEMBL615407,BAO_0000357,351
,,H,,,19690,562.0,Escherichia coli,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,1,,,,,8,,4251,B,,Autocuration,CHEMBL857267,BAO_0000357,352
,,H,,,19690,562.0,Escherichia coli,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,1,,,,,8,,4251,B,,Autocuration,CHEMBL615408,BAO_0000357,353
,,H,,,19690,,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,1,,,,,8,,166,B,,Autocuration,CHEMBL615409,BAO_0000357,354
,,H,,,19690,,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,1,,,,,8,,17861,B,,Autocuration,CHEMBL615410,BAO_0000357,355
,,H,,,19690,,,Inhibition constant against 3-dehydroquinate synthase,1,,,,,8,,166,B,,Autocuration,CHEMBL615411,BAO_0000357,356
,,H,,,19690,,,Association rate constant against 3-dehydroquinate synthase,1,,,,,8,,166,B,,Autocuration,CHEMBL615412,BAO_0000357,357
,,H,,,19690,,,Rate constant against 3-dehydroquinate synthase,1,,,,,8,,166,B,,Autocuration,CHEMBL615413,BAO_0000357,358
,,U,,,22226,,,Inhibitory activity against fuc-TVII,1,,,,,0,,3548,B,,Autocuration,CHEMBL615414,BAO_0000019,359
,Microsomes,D,,,12236,10116.0,Rattus norvegicus,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,1,Liver,,,,9,,9877,B,2107.0,Autocuration,CHEMBL615415,BAO_0000251,360
,Microsomes,D,,,12236,10116.0,Rattus norvegicus,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,1,Liver,,,,9,,9877,B,2107.0,Autocuration,CHEMBL615416,BAO_0000251,361
,Microsomes,D,,,12236,10116.0,Rattus norvegicus,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,1,Liver,,,,9,,9877,B,2107.0,Autocuration,CHEMBL615417,BAO_0000251,362
,Microsomes,D,,,12236,10116.0,Rattus norvegicus,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,1,Liver,,,,9,,9877,B,2107.0,Autocuration,CHEMBL615418,BAO_0000251,363
,Microsomes,D,,,12236,10116.0,Rattus norvegicus,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,1,Liver,,,,9,,9877,B,2107.0,Autocuration,CHEMBL615419,BAO_0000251,364
,Microsomes,D,,,12236,10116.0,Rattus norvegicus,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,1,Liver,,,,9,,9877,B,2107.0,Autocuration,CHEMBL615420,BAO_0000251,365
,Microsomes,D,,,12236,10116.0,Rattus norvegicus,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,1,Liver,,,,9,,9877,B,2107.0,Autocuration,CHEMBL615421,BAO_0000251,366
,Microsomes,D,,,12236,10116.0,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,1,Liver,,,,9,,9877,B,2107.0,Autocuration,CHEMBL615422,BAO_0000251,367
,Microsomes,D,,,12236,10116.0,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,1,Liver,,,,9,,9877,B,2107.0,Autocuration,CHEMBL615423,BAO_0000251,368
,Microsomes,D,,,12236,10116.0,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,1,Liver,,,,9,,9877,B,2107.0,Autocuration,CHEMBL872868,BAO_0000251,369
,Microsomes,D,,,12236,10116.0,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,1,Liver,,,,9,,9877,B,2107.0,Autocuration,CHEMBL615424,BAO_0000251,370
,,H,,,104832,,,Inhibitory activity against 3-phosphoglycerate kinase.,1,,,,,4,,3003,B,,Autocuration,CHEMBL825022,BAO_0000224,371
,,H,,,104832,,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,1,,,,,4,,3003,B,,Autocuration,CHEMBL615425,BAO_0000224,372
,,H,,,104832,,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",1,,,,,4,,3003,B,,Autocuration,CHEMBL615426,BAO_0000224,373
,,D,,,10612,9606.0,Homo sapiens,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,1,,,,,9,,17185,B,,Expert,CHEMBL615427,BAO_0000357,374
,,N,844.0,,80616,9606.0,Homo sapiens,Cytotoxicity on 3677 melanoma cells,1,,3677 melanoma cell line,,,1,,6072,F,,Intermediate,CHEMBL615428,BAO_0000219,375
,,N,844.0,,80616,9606.0,Homo sapiens,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,1,,3677 melanoma cell line,,,1,,6072,F,,Intermediate,CHEMBL615429,BAO_0000219,376
,,N,700.0,,80617,10090.0,Mus musculus,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,1,,MC-38,,,1,,5018,F,,Intermediate,CHEMBL615430,BAO_0000219,377
,,U,,,22226,9606.0,Homo sapiens,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,1,,,,,0,,2852,F,,Intermediate,CHEMBL615431,BAO_0000019,378
,,U,798.0,,22226,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,1,,B16,,,0,,8663,F,,Autocuration,CHEMBL615432,BAO_0000218,379
,,U,798.0,,22226,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,1,,B16,,,0,,8663,F,,Autocuration,CHEMBL615433,BAO_0000218,380
,,D,,,12464,12131.0,Human rhinovirus 14,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,1,,,,,9,,3245,F,,Expert,CHEMBL615434,BAO_0000019,381
,,N,,,50085,169066.0,Human rhinovirus sp.,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,1,,,,,1,,3245,F,,Intermediate,CHEMBL615435,BAO_0000218,382
,,N,,,50679,169066.0,human rhinovirus type 14,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,1,,,,,1,,3877,F,,Intermediate,CHEMBL615436,BAO_0000218,383
,,N,,,50679,169066.0,human rhinovirus type 14,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,1,,,,,1,,3877,F,,Intermediate,CHEMBL615437,BAO_0000218,384
,,D,,,12464,12131.0,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,1,,,,,9,,5861,F,,Expert,CHEMBL615438,BAO_0000019,385
,,D,,,12464,12131.0,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,1,,,,,9,,5861,F,,Expert,CHEMBL615439,BAO_0000019,386
,,D,,,12464,12131.0,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,1,,,,,9,,5861,F,,Expert,CHEMBL615440,BAO_0000019,387
,,D,,,12464,12131.0,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,1,,,,,9,,5861,F,,Expert,CHEMBL615441,BAO_0000019,388
,,N,,,50665,12059.0,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,1,,,,,1,,13748,F,,Intermediate,CHEMBL615641,BAO_0000218,389
,,N,,,50665,12059.0,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,1,,,,,1,,13748,F,,Intermediate,CHEMBL872065,BAO_0000218,390
,,N,,,50665,12059.0,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,1,,,,,1,,13748,F,,Intermediate,CHEMBL825023,BAO_0000218,391
,,N,,,50665,12059.0,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,1,,,,,1,,13748,F,,Intermediate,CHEMBL615642,BAO_0000218,392
,,H,,,12464,147712.0,Human rhinovirus B,Inhibition of human rhinovirus 3C protease,1,,,,,8,,13748,B,,Expert,CHEMBL615643,BAO_0000357,393
,,U,,,22226,9606.0,Homo sapiens,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,1,,,,,0,,17699,B,,Autocuration,CHEMBL615644,BAO_0000019,394
,,N,833.0,,80619,10090.0,Mus musculus,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),1,,3EM 37,,,1,,7145,F,,Intermediate,CHEMBL615645,BAO_0000218,395
,,N,833.0,,80619,10090.0,Mus musculus,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),1,,3EM 37,,,1,,7145,F,,Intermediate,CHEMBL615646,BAO_0000218,396
,,N,833.0,,80619,10090.0,Mus musculus,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),1,,3EM 37,,,1,,7145,F,,Intermediate,CHEMBL615647,BAO_0000218,397
,,N,833.0,,80619,10090.0,Mus musculus,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),1,,3EM 37,,,1,,7145,F,,Intermediate,CHEMBL615648,BAO_0000218,398
,,N,833.0,,80619,10090.0,Mus musculus,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,1,,3EM 37,,,1,,7145,F,,Intermediate,CHEMBL615649,BAO_0000218,399
,,N,833.0,,80619,10090.0,Mus musculus,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,1,,3EM 37,,,1,,7145,F,,Intermediate,CHEMBL615650,BAO_0000218,400
,,N,847.0,,80620,10090.0,Mus musculus,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,1,,3LL cell line,,,1,,5325,F,,Intermediate,CHEMBL615651,BAO_0000218,401
,,N,847.0,,80620,10090.0,Mus musculus,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,1,,3LL cell line,,,1,,5325,F,,Intermediate,CHEMBL615652,BAO_0000218,402
,,N,847.0,,80620,10090.0,Mus musculus,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,1,,3LL cell line,,,1,,5325,F,,Expert,CHEMBL615653,BAO_0000218,403
,,N,847.0,,80620,10090.0,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615654,BAO_0000219,404
,,N,847.0,,80620,10090.0,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615655,BAO_0000219,405
,,N,847.0,,80620,10090.0,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL825024,BAO_0000219,406
,,N,847.0,,80620,10090.0,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615656,BAO_0000219,407
,,N,847.0,,80620,10090.0,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615657,BAO_0000219,408
,,N,847.0,,80620,10090.0,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615658,BAO_0000219,409
,,N,847.0,,80620,10090.0,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615659,BAO_0000219,410
,,N,847.0,,80620,10090.0,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615660,BAO_0000219,411
,,N,847.0,,80620,10090.0,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615661,BAO_0000219,412
,,N,847.0,,80620,10090.0,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615662,BAO_0000219,413
,,N,847.0,,80620,10090.0,Mus musculus,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615663,BAO_0000219,414
,,N,847.0,,80620,10090.0,Mus musculus,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615664,BAO_0000219,415
,,N,847.0,,80620,10090.0,Mus musculus,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615665,BAO_0000219,416
,,N,847.0,,80620,10090.0,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615666,BAO_0000219,417
,,N,847.0,,80620,10090.0,Mus musculus,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615667,BAO_0000219,418
,,N,847.0,,80620,10090.0,Mus musculus,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615668,BAO_0000219,419
,,N,847.0,,80620,10090.0,Mus musculus,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615669,BAO_0000219,420
,,N,847.0,,80620,10090.0,Mus musculus,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615670,BAO_0000219,421
,,N,847.0,,80620,10090.0,Mus musculus,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL836739,BAO_0000219,422
,,N,847.0,,80620,10090.0,Mus musculus,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615671,BAO_0000219,423
,,N,847.0,,80620,10090.0,Mus musculus,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615672,BAO_0000219,424
,,N,847.0,,80620,10090.0,Mus musculus,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615791,BAO_0000219,425
,,N,847.0,,80620,10090.0,Mus musculus,spermine levels in 3LL cells after the treatment of 1 uM of Compound,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615792,BAO_0000219,426
,,N,847.0,,80620,10090.0,Mus musculus,spermine levels in 3LL cells after the treatment of 10 uM of Compound,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615793,BAO_0000219,427
,,N,847.0,,80620,10090.0,Mus musculus,spermine levels in 3LL cells after the treatment of 250 uM of Compound,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615794,BAO_0000219,428
,,N,847.0,,80620,10090.0,Mus musculus,spermine levels in 3LL cells after the treatment of 50 uM of Compound,1,,3LL cell line,,,1,,16169,F,,Intermediate,CHEMBL615795,BAO_0000219,429
,,N,971.0,,80621,9606.0,Homo sapiens,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,1,,3LLD122,,,1,,15547,F,,Intermediate,CHEMBL615590,BAO_0000219,430
,,U,,,22226,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,1,,,,,0,,8663,F,,Autocuration,CHEMBL615591,BAO_0000218,431
,,U,,,22226,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,1,,,,,0,,8663,F,,Autocuration,CHEMBL615592,BAO_0000218,432
,,U,,,22226,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,1,,,,,0,,8663,F,,Autocuration,CHEMBL615593,BAO_0000218,433
,,U,,,22226,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,1,,,,,0,,8663,F,,Autocuration,CHEMBL615594,BAO_0000218,434
,,N,723.0,,80951,10090.0,Mus musculus,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,1,,NIH3T3,,,1,,4504,F,,Intermediate,CHEMBL615595,BAO_0000219,435
,,N,723.0,,80951,10090.0,Mus musculus,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,1,,NIH3T3,,,1,,4504,F,,Intermediate,CHEMBL615596,BAO_0000219,436
,,H,723.0,,11169,,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,1,,NIH3T3,,,8,,12695,F,,Expert,CHEMBL615597,BAO_0000219,437
,,N,723.0,,80951,10090.0,Mus musculus,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,1,,NIH3T3,,,1,,12695,F,,Intermediate,CHEMBL615598,BAO_0000219,438
,,N,723.0,,80951,10090.0,Mus musculus,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,1,,NIH3T3,,,1,,12695,F,,Intermediate,CHEMBL615599,BAO_0000219,439
,,N,723.0,,80951,10090.0,Mus musculus,Effective dose against murine 3T3 fibroblasts cells,1,,NIH3T3,,,1,,17642,F,,Expert,CHEMBL615600,BAO_0000219,440
,,N,723.0,,80951,10090.0,Mus musculus,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,1,,NIH3T3,,,1,,17642,F,,Expert,CHEMBL615601,BAO_0000219,441
,,N,723.0,,80951,10090.0,Mus musculus,Cytotoxic effect on 3T3 cells,1,,NIH3T3,,,1,,12340,F,,Expert,CHEMBL615602,BAO_0000219,442
,,N,723.0,,80951,10090.0,Mus musculus,Cytotoxic effect on 3T3 cells,1,,NIH3T3,,,1,,12340,F,,Expert,CHEMBL615603,BAO_0000219,443
,,N,723.0,,80951,10090.0,Mus musculus,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,1,,NIH3T3,,,1,,12716,F,,Intermediate,CHEMBL615604,BAO_0000219,444
,,N,723.0,,80951,10090.0,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,1,,NIH3T3,,,1,,6277,F,,Intermediate,CHEMBL615605,BAO_0000219,445
,,N,723.0,,80951,10090.0,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,1,,NIH3T3,,,1,,6277,F,,Intermediate,CHEMBL615606,BAO_0000219,446
,,N,723.0,,80951,10090.0,Mus musculus,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,1,,NIH3T3,,,1,,6277,F,,Expert,CHEMBL884526,BAO_0000219,447
,,N,723.0,,80951,10090.0,Mus musculus,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,1,,NIH3T3,,,1,,6277,F,,Expert,CHEMBL615607,BAO_0000219,448
,,N,723.0,,80951,10090.0,Mus musculus,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,1,,NIH3T3,,,1,,6277,F,,Intermediate,CHEMBL615608,BAO_0000219,449
,,N,723.0,,80951,10090.0,Mus musculus,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,1,,NIH3T3,,,1,,6277,F,,Expert,CHEMBL615609,BAO_0000219,450
,,N,723.0,,80951,10090.0,Mus musculus,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,1,,NIH3T3,,,1,,6277,F,,Expert,CHEMBL615682,BAO_0000219,451
,,N,723.0,,80951,10090.0,Mus musculus,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,1,,NIH3T3,,,1,,6277,F,,Intermediate,CHEMBL615683,BAO_0000219,452
,,N,723.0,,80951,10090.0,Mus musculus,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,1,,NIH3T3,,,1,,17780,F,,Expert,CHEMBL615684,BAO_0000218,453
,,D,,,104860,10090.0,Mus musculus,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,1,,,,,7,,12751,F,,Autocuration,CHEMBL615685,BAO_0000219,454
,,N,723.0,,80951,10090.0,Mus musculus,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,1,,NIH3T3,,,1,,12380,F,,Expert,CHEMBL615686,BAO_0000219,455
,,N,723.0,,80951,10090.0,Mus musculus,Inhibitory activity against 3T3 cell line,1,,NIH3T3,,,1,,14892,F,,Intermediate,CHEMBL615687,BAO_0000219,456
,,N,723.0,,80951,10090.0,Mus musculus,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,1,,NIH3T3,,,1,,12695,F,,Intermediate,CHEMBL884523,BAO_0000219,457
,,H,,,11169,,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,1,,,,,8,,12695,F,,Expert,CHEMBL615688,BAO_0000019,458
,,N,723.0,,80951,10090.0,Mus musculus,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,1,,NIH3T3,,,1,,12695,F,,Intermediate,CHEMBL615689,BAO_0000219,459
,,N,723.0,,80951,10090.0,Mus musculus,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,1,,NIH3T3,,,1,,12695,F,,Intermediate,CHEMBL615690,BAO_0000219,460
,,H,,,11169,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,1,,,,,8,,12695,F,,Expert,CHEMBL615691,BAO_0000019,461
,,H,,,11169,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,1,,,,,8,,12695,F,,Expert,CHEMBL615692,BAO_0000019,462
,,N,723.0,,80951,10090.0,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,1,,NIH3T3,,,1,,6277,F,,Intermediate,CHEMBL615693,BAO_0000219,463
,,N,723.0,,80951,10090.0,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,1,,NIH3T3,,,1,,6277,F,,Expert,CHEMBL615324,BAO_0000219,464
,,D,723.0,,9,9606.0,Homo sapiens,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,1,,NIH3T3,,,9,,4959,F,,Expert,CHEMBL615325,BAO_0000219,465
,,D,723.0,,9,9606.0,Homo sapiens,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),1,,NIH3T3,,,9,,4959,F,,Expert,CHEMBL615490,BAO_0000219,466
,,D,723.0,,188,9606.0,Homo sapiens,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,1,,NIH3T3,,,9,,4959,F,,Expert,CHEMBL615491,BAO_0000219,467
,,D,723.0,,188,9606.0,Homo sapiens,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),1,,NIH3T3,,,9,,4959,F,,Expert,CHEMBL615492,BAO_0000219,468
,,N,723.0,,80951,10090.0,Mus musculus,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,1,,NIH3T3,,,1,,12082,F,,Intermediate,CHEMBL615493,BAO_0000219,469
,,N,723.0,,80951,10090.0,Mus musculus,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,1,,NIH3T3,,,1,,12082,F,,Intermediate,CHEMBL615494,BAO_0000219,470
,,N,723.0,,80951,10090.0,Mus musculus,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,1,,NIH3T3,,,1,,12082,F,,Intermediate,CHEMBL615495,BAO_0000219,471
,,N,723.0,,80951,10090.0,Mus musculus,Inhibitory concentration was calculated on 3T3 cells by using growth assay,1,,NIH3T3,,,1,,12082,F,,Intermediate,CHEMBL615496,BAO_0000219,472
,,N,723.0,,80951,10090.0,Mus musculus,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,1,,NIH3T3,,,1,,2643,F,,Intermediate,CHEMBL615497,BAO_0000219,473
,,N,723.0,,80951,10090.0,Mus musculus,Inhibition of Swiss 3T3 mouse fibroblast proliferation,1,,NIH3T3,,,1,,11926,F,,Expert,CHEMBL615498,BAO_0000219,474
,,N,723.0,,80951,10090.0,Mus musculus,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,1,,NIH3T3,,,1,,15204,A,,Intermediate,CHEMBL615499,BAO_0000219,475
,,N,723.0,,80951,10090.0,Mus musculus,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,1,,NIH3T3,,,1,,15992,F,,Expert,CHEMBL835522,BAO_0000219,476
,,N,723.0,,80951,10090.0,Mus musculus,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,1,,NIH3T3,,,1,,16279,F,,Intermediate,CHEMBL615500,BAO_0000219,477
,,N,723.0,,80951,10090.0,Mus musculus,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,,NIH3T3,,,1,,16279,F,,Intermediate,CHEMBL615501,BAO_0000219,478
,,N,723.0,,80951,10090.0,Mus musculus,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,,NIH3T3,,,1,,16279,F,,Intermediate,CHEMBL615502,BAO_0000219,479
,,N,723.0,,80951,10090.0,Mus musculus,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,,NIH3T3,,,1,,16279,F,,Intermediate,CHEMBL615503,BAO_0000219,480
,,N,723.0,,80951,10090.0,Mus musculus,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,,NIH3T3,,,1,,16279,F,,Intermediate,CHEMBL615504,BAO_0000219,481
,,N,723.0,,80951,10090.0,Mus musculus,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,,NIH3T3,,,1,,16279,F,,Intermediate,CHEMBL615505,BAO_0000219,482
,,N,723.0,,80951,10090.0,Mus musculus,Inhibition of swiss 3T3 mouse fibroblast proliferation,1,,NIH3T3,,,1,,12831,F,,Expert,CHEMBL615506,BAO_0000219,483
,,N,723.0,,80951,10090.0,Mus musculus,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,1,,NIH3T3,,,1,,13497,F,,Intermediate,CHEMBL615507,BAO_0000219,484
,,N,620.0,,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,1,,3T3-L1,,,1,,13715,F,,Intermediate,CHEMBL615508,BAO_0000218,485
,,N,620.0,,80006,10090.0,Mus musculus,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,1,,3T3-L1,,,1,,13618,F,,Intermediate,CHEMBL615509,BAO_0000219,486
,,N,620.0,,80006,10090.0,Mus musculus,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,1,,3T3-L1,,,1,,11902,F,,Intermediate,CHEMBL615510,BAO_0000219,487
,,N,620.0,,80006,10090.0,Mus musculus,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,1,,3T3-L1,,,1,,11902,F,,Intermediate,CHEMBL615511,BAO_0000219,488
,,N,620.0,,80006,10090.0,Mus musculus,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,1,,3T3-L1,,,1,,11902,F,,Intermediate,CHEMBL615512,BAO_0000219,489
,,N,620.0,,80006,10090.0,Mus musculus,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",1,,3T3-L1,,,1,,14840,F,,Intermediate,CHEMBL615513,BAO_0000218,490
,,N,620.0,,80006,10090.0,Mus musculus,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",1,,3T3-L1,,,1,,14840,F,,Intermediate,CHEMBL615514,BAO_0000218,491
,,N,620.0,,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,1,,3T3-L1,,,1,,13715,F,,Intermediate,CHEMBL615515,BAO_0000219,492
,,N,620.0,,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,1,,3T3-L1,,,1,,13715,F,,Intermediate,CHEMBL615516,BAO_0000219,493
,,N,620.0,,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,1,,3T3-L1,,,1,,13715,F,,Intermediate,CHEMBL615517,BAO_0000219,494
,,N,620.0,,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,1,,3T3-L1,,,1,,13715,F,,Intermediate,CHEMBL615518,BAO_0000219,495
,,N,620.0,,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,1,,3T3-L1,,,1,,13715,F,,Intermediate,CHEMBL615519,BAO_0000219,496
,,N,620.0,,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,1,,3T3-L1,,,1,,13715,F,,Intermediate,CHEMBL615520,BAO_0000218,497
,,N,620.0,,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,1,,3T3-L1,,,1,,13715,F,,Intermediate,CHEMBL615521,BAO_0000218,498
,,N,620.0,,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,1,,3T3-L1,,,1,,13715,F,,Intermediate,CHEMBL615522,BAO_0000218,499
,,N,620.0,,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,1,,3T3-L1,,,1,,13715,F,,Intermediate,CHEMBL615523,BAO_0000218,500
,,N,620.0,,80006,,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,1,,3T3-L1,,,1,,13715,F,,Expert,CHEMBL615524,BAO_0000218,501
,,N,620.0,,80006,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,1,,3T3-L1,,,1,,13715,F,,Expert,CHEMBL615525,BAO_0000218,502
,,N,620.0,,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,1,,3T3-L1,,,1,,13715,F,,Intermediate,CHEMBL615526,BAO_0000218,503
,,N,620.0,,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,1,,3T3-L1,,,1,,13715,F,,Intermediate,CHEMBL615527,BAO_0000218,504
,,N,620.0,,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,1,,3T3-L1,,,1,,13715,F,,Intermediate,CHEMBL615528,BAO_0000218,505
,,N,620.0,,80006,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,1,,3T3-L1,,,1,,13715,F,,Expert,CHEMBL615529,BAO_0000218,506
,,N,620.0,,80006,,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,1,,3T3-L1,,,1,,13715,F,,Expert,CHEMBL615530,BAO_0000218,507
,,N,620.0,,80006,,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,1,,3T3-L1,,,1,,13715,F,,Expert,CHEMBL615531,BAO_0000218,508
,,N,620.0,,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,1,,3T3-L1,,,1,,13715,F,,Intermediate,CHEMBL615532,BAO_0000219,509
,,N,620.0,,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,1,,3T3-L1,,,1,,13715,F,,Intermediate,CHEMBL615533,BAO_0000219,510
,,N,620.0,,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,1,,3T3-L1,,,1,,13715,F,,Intermediate,CHEMBL615534,BAO_0000219,511
,,N,620.0,,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,1,,3T3-L1,,,1,,13715,F,,Intermediate,CHEMBL615535,BAO_0000218,512
,,N,620.0,,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,1,,3T3-L1,,,1,,13715,F,,Intermediate,CHEMBL615536,BAO_0000218,513
,,N,620.0,,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,1,,3T3-L1,,,1,,13715,F,,Intermediate,CHEMBL615537,BAO_0000218,514
,,N,620.0,,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,1,,3T3-L1,,,1,,13715,F,,Intermediate,CHEMBL615538,BAO_0000218,515
,,N,620.0,,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,1,,3T3-L1,,,1,,13715,F,,Intermediate,CHEMBL836166,BAO_0000218,516
,,H,620.0,,11214,,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,1,,3T3-L1,,,8,,6411,F,,Expert,CHEMBL615539,BAO_0000219,517
,,N,620.0,,80006,10090.0,Mus musculus,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,1,,3T3-L1,,,1,,6411,F,,Intermediate,CHEMBL615540,BAO_0000219,518
,,H,620.0,,11214,,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,1,,3T3-L1,,,8,,6411,F,,Expert,CHEMBL615541,BAO_0000219,519
,,N,620.0,,80006,10090.0,Mus musculus,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,1,,3T3-L1,,,1,,3966,F,,Expert,CHEMBL615542,BAO_0000219,520
,,N,620.0,,80006,10090.0,Mus musculus,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,1,,3T3-L1,,,1,,3966,F,,Intermediate,CHEMBL615543,BAO_0000219,521
,,N,620.0,,80006,10090.0,Mus musculus,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,1,,3T3-L1,,,1,,15556,F,,Expert,CHEMBL615544,BAO_0000219,522
,,N,620.0,,80006,10090.0,Mus musculus,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,1,,3T3-L1,,,1,,5845,F,,Expert,CHEMBL615545,BAO_0000219,523
,,N,620.0,,80006,10090.0,Mus musculus,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,1,,3T3-L1,,,1,,14422,F,,Expert,CHEMBL615546,BAO_0000219,524
,,N,620.0,,80006,10090.0,Mus musculus,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,1,,3T3-L1,,,1,,5845,F,,Expert,CHEMBL615547,BAO_0000219,525
,,N,620.0,,80006,10090.0,Mus musculus,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,1,,3T3-L1,,,1,,14508,F,,Expert,CHEMBL615548,BAO_0000219,526
,,N,620.0,,80006,10090.0,Mus musculus,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,1,,3T3-L1,,,1,,14508,F,,Expert,CHEMBL615549,BAO_0000219,527
,,N,620.0,,80006,10090.0,Mus musculus,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,1,,3T3-L1,,,1,,14508,F,,Expert,CHEMBL615550,BAO_0000219,528
,,N,1118.0,,80622,10116.0,Rattus norvegicus,Inhibitory activity against rat fibroblast (3Y1) cell line,1,,3Y1 cell line,,,1,,6349,F,,Intermediate,CHEMBL615551,BAO_0000219,529
,,N,1118.0,,80622,10116.0,Rattus norvegicus,Mean concentration causing inhibition of cell growth in 3Y1 cells.,1,,3Y1 cell line,,,1,,15899,F,,Expert,CHEMBL615552,BAO_0000219,530
,,N,1118.0,,80622,10116.0,Rattus norvegicus,Cytotoxicity in 3Y1 cells.,1,,3Y1 cell line,,,1,,15899,F,,Expert,CHEMBL615553,BAO_0000219,531
,,N,1118.0,,80622,10116.0,Rattus norvegicus,Cytostatic effect in 3Y1 cells.,1,,3Y1 cell line,,,1,,15899,F,,Expert,CHEMBL615554,BAO_0000219,532
,,N,1118.0,,80622,10116.0,Rattus norvegicus,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",1,,3Y1 cell line,,,1,,15899,F,,Intermediate,CHEMBL615555,BAO_0000219,533
,,N,1118.0,,80622,10116.0,Rattus norvegicus,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,1,,3Y1 cell line,,,1,,17038,F,,Expert,CHEMBL615556,BAO_0000219,534
,,U,,,22226,,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,1,,,,,0,,12421,B,,Autocuration,CHEMBL615557,BAO_0000019,535
,,U,,,22226,,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,1,,,,,0,,12947,B,,Autocuration,CHEMBL615558,BAO_0000019,536
,,U,,,22226,,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,1,,,,,0,,12947,B,,Autocuration,CHEMBL872066,BAO_0000019,537
,,D,,,11607,9823.0,Sus scrofa,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,1,,,,,9,,4896,B,,Expert,CHEMBL615559,BAO_0000019,538
,,H,,,11607,,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,1,,,,,8,,6148,B,,Autocuration,CHEMBL615560,BAO_0000019,539
,,H,,,11607,,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,1,,,,,8,,16432,B,,Autocuration,CHEMBL615561,BAO_0000019,540
,,H,,,11607,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,1,,,,,8,,4978,B,,Expert,CHEMBL857062,BAO_0000019,541
,,H,,,11607,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),1,,,,,8,,4978,B,,Expert,CHEMBL615562,BAO_0000019,542
,,H,,,11607,,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,1,,,,,8,,3723,B,,Autocuration,CHEMBL615563,BAO_0000019,543
,,H,,,11607,,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),1,,,,,8,,3518,B,,Autocuration,CHEMBL615564,BAO_0000357,544
,,H,,,11607,,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,1,,,,,8,,4164,B,,Autocuration,CHEMBL615565,BAO_0000019,545
,,H,,,11607,,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,1,,,,,8,,3518,B,,Autocuration,CHEMBL615566,BAO_0000019,546
,,D,,,11607,9823.0,Sus scrofa,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,1,,,,,9,,4164,B,,Expert,CHEMBL615567,BAO_0000019,547
,,H,,,11607,,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,1,,,,,8,,3518,B,,Autocuration,CHEMBL615568,BAO_0000019,548
,,H,,,11607,,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),1,,,,,8,,3518,B,,Autocuration,CHEMBL615569,BAO_0000357,549
,,H,,,11607,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,1,,,,,8,,4978,B,,Autocuration,CHEMBL615570,BAO_0000019,550
,,H,,,11607,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),1,,,,,8,,4978,B,,Autocuration,CHEMBL615571,BAO_0000019,551
,,H,,,104733,,,Binding affinity against melatonin (MT1) receptor (pC1),1,,,,,4,,6455,B,,Autocuration,CHEMBL615572,BAO_0000224,552
,,U,,,22226,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,1,,,,,0,,2222,B,,Autocuration,CHEMBL615573,BAO_0000019,553
,,U,,,22226,,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,1,,,,,0,,13020,B,,Autocuration,CHEMBL615574,BAO_0000019,554
,,U,,,22226,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,1,,,,,0,,13021,B,,Autocuration,CHEMBL615575,BAO_0000019,555
,,H,,,10619,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,1,,,,,8,,14532,B,,Autocuration,CHEMBL615576,BAO_0000357,556
,,H,,,10619,,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,1,,,,,8,,14118,B,,Autocuration,CHEMBL615577,BAO_0000357,557
,,H,,,51,,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,1,Hippocampus,,,,8,,11884,B,10000000.0,Autocuration,CHEMBL615578,BAO_0000221,558
,,H,,,51,,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,1,,,,,8,,13969,B,,Expert,CHEMBL615579,BAO_0000357,559
,,H,,,51,,,Binding affinity for 5-hydroxytryptamine 1A receptor,1,,,,,8,,13392,B,,Expert,CHEMBL615580,BAO_0000357,560
,,H,,,51,,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,1,,,,,8,,14430,B,,Expert,CHEMBL615581,BAO_0000019,561
,,H,,,51,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,1,Hippocampus,,,,8,,12248,B,10000000.0,Autocuration,CHEMBL615582,BAO_0000221,562
,,H,,,51,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,1,Hippocampus,,,,8,,12249,B,10000000.0,Autocuration,CHEMBL615583,BAO_0000221,563
,,H,,,51,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,1,Hippocampus,,,,8,,9995,B,10000000.0,Autocuration,CHEMBL615584,BAO_0000221,564
,,H,,,51,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,Hippocampus,,,,8,,9995,B,10000000.0,Autocuration,CHEMBL833691,BAO_0000221,565
,,H,,,51,,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,1,Hippocampus,,,,8,,9995,B,10000000.0,Autocuration,CHEMBL615585,BAO_0000221,566
,,H,,,51,,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,1,Hippocampus,,,,8,,9995,B,10000000.0,Autocuration,CHEMBL615586,BAO_0000221,567
,,H,,,51,,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,Hippocampus,,,,8,,9995,B,10000000.0,Autocuration,CHEMBL884524,BAO_0000221,568
,,H,,,51,,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,1,Hippocampus,,,,8,,12249,B,10000000.0,Autocuration,CHEMBL615587,BAO_0000221,569
,,H,,,51,,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",1,Hippocampus,,,,8,,11799,B,10000000.0,Autocuration,CHEMBL615588,BAO_0000221,570
,Membranes,D,,,10576,10116.0,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,1,,,,,9,,14331,B,,Expert,CHEMBL615589,BAO_0000249,571
,,H,,,51,9913.0,Bos taurus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,1,Hippocampus,,,,8,,11884,B,10000000.0,Expert,CHEMBL615442,BAO_0000221,572
,,H,,,51,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,1,Hippocampus,,,,8,,14331,B,10000000.0,Autocuration,CHEMBL615443,BAO_0000221,573
,,H,,,51,,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,1,Hippocampus,,,,8,,11701,B,10000000.0,Autocuration,CHEMBL615444,BAO_0000221,574
,,H,,,51,,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,1,Hippocampus,,,,8,,11701,B,10000000.0,Expert,CHEMBL615445,BAO_0000221,575
,,H,,,51,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,1,Hippocampus,,,,8,,12248,B,10000000.0,Autocuration,CHEMBL615446,BAO_0000221,576
,,H,449.0,,51,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,1,,CHO,,,8,,12248,B,,Autocuration,CHEMBL615447,BAO_0000219,577
,,H,,,51,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,1,Hippocampus,,,,8,,12248,B,10000000.0,Expert,CHEMBL615448,BAO_0000221,578
,,H,,,51,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,1,Hippocampus,,,,8,,12249,B,10000000.0,Expert,CHEMBL615449,BAO_0000221,579
,,H,449.0,,51,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,1,,CHO,,,8,,12248,B,,Autocuration,CHEMBL615450,BAO_0000219,580
,,H,,,51,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",1,Hippocampus,,,,8,,11799,B,10000000.0,Expert,CHEMBL615451,BAO_0000221,581
,,H,,,51,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,1,,,,,8,,634,B,,Autocuration,CHEMBL615452,BAO_0000357,582
,,H,,,51,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,1,Hippocampus,,,,8,,9995,B,10000000.0,Autocuration,CHEMBL615453,BAO_0000221,583
,,H,,,51,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,Hippocampus,,,,8,,9995,B,10000000.0,Autocuration,CHEMBL615454,BAO_0000221,584
,,H,,,51,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,1,Hippocampus,,,,8,,9995,B,10000000.0,Autocuration,CHEMBL615455,BAO_0000221,585
,,H,,,51,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,Hippocampus,,,,8,,9995,B,10000000.0,Autocuration,CHEMBL615456,BAO_0000221,586
,,H,,,51,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,1,Hippocampus,,,,8,,9995,B,10000000.0,Autocuration,CHEMBL615457,BAO_0000221,587
,,H,,,51,,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,1,Hippocampus,,,,8,,12210,B,10000000.0,Expert,CHEMBL615458,BAO_0000218,588
,,H,,,51,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,Hippocampus,,,,8,,13311,B,10000000.0,Expert,CHEMBL615459,BAO_0000221,589
,,D,449.0,,51,9606.0,Homo sapiens,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",1,,CHO,,,9,,2331,B,,Expert,CHEMBL615460,BAO_0000219,590
,,H,,,51,10141.0,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,1,,,,,8,,1375,F,,Autocuration,CHEMBL615461,BAO_0000019,591
,,H,,,51,10141.0,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,1,,,,,8,,1375,F,,Autocuration,CHEMBL615462,BAO_0000019,592
,,H,,,51,10141.0,Cavia porcellus,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,1,Hippocampus,,,,8,,11574,F,10000000.0,Autocuration,CHEMBL615463,BAO_0000221,593
,,H,,,51,10141.0,Cavia porcellus,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,1,Ileum,,,,8,,12867,B,2116.0,Autocuration,CHEMBL615464,BAO_0000221,594
,,H,,,51,10141.0,Cavia porcellus,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,1,Ileum,,,,8,,12867,B,2116.0,Autocuration,CHEMBL615465,BAO_0000221,595
,,H,,,51,10141.0,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,1,Ileum,,,,8,,12867,B,2116.0,Autocuration,CHEMBL615466,BAO_0000221,596
,,H,,,51,10141.0,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,1,Ileum,,,,8,,12867,B,2116.0,Autocuration,CHEMBL615467,BAO_0000221,597
,,H,,,51,10141.0,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,1,Ileum,,,,8,,12867,B,2116.0,Autocuration,CHEMBL615468,BAO_0000221,598
,,H,,,51,10141.0,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,1,Ileum,,,,8,,12867,B,2116.0,Autocuration,CHEMBL615469,BAO_0000221,599
,,H,,,51,10141.0,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 1A receptor,1,,,,,8,,11574,B,,Autocuration,CHEMBL615470,BAO_0000357,600
,,H,,,51,10141.0,Cavia porcellus,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,1,,,,,8,,13114,B,,Autocuration,CHEMBL615471,BAO_0000357,601
,,H,,,51,10141.0,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,1,,,,,8,,13181,B,,Autocuration,CHEMBL615472,BAO_0000357,602
,,H,,,106,10141.0,Cavia porcellus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,1,Hippocampus,,,,8,,10639,B,10000000.0,Autocuration,CHEMBL883242,BAO_0000221,603
,,H,,,106,10141.0,Cavia porcellus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,1,Hippocampus,,,,8,,10639,F,10000000.0,Autocuration,CHEMBL615473,BAO_0000221,604
,,H,449.0,,11863,10029.0,Cricetulus griseus,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),1,,CHO,,,8,,11883,B,,Autocuration,CHEMBL615474,BAO_0000218,605
,,H,,,51,,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,1,,,,,8,,17785,B,,Autocuration,CHEMBL615475,BAO_0000357,606
,,H,308.0,,51,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,1,,HeLa,,,8,,1558,F,,Autocuration,CHEMBL615476,BAO_0000219,607
,,H,308.0,,51,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,1,,HeLa,,,8,,1558,F,,Autocuration,CHEMBL615477,BAO_0000219,608
,,H,,,51,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,1,,,,,8,,15740,F,,Autocuration,CHEMBL615478,BAO_0000019,609
,,H,449.0,,51,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,1,,CHO,,,8,,17624,F,,Autocuration,CHEMBL615160,BAO_0000219,610
,,H,449.0,,51,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,1,,CHO,,,8,,17624,F,,Expert,CHEMBL615161,BAO_0000219,611
,,H,449.0,,51,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,1,,CHO,,,8,,17624,F,,Autocuration,CHEMBL615162,BAO_0000219,612
,,H,449.0,,51,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,1,,CHO,,,8,,17624,F,,Autocuration,CHEMBL615163,BAO_0000219,613
,,H,449.0,,51,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,1,,CHO,,,8,,17624,B,,Expert,CHEMBL615164,BAO_0000219,614
,,H,449.0,,51,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,1,,CHO,,,8,,17624,B,,Expert,CHEMBL615165,BAO_0000219,615
,,H,449.0,,51,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,1,,CHO,,,8,,17624,B,,Autocuration,CHEMBL615166,BAO_0000219,616
,,H,,,51,,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,1,,,,,8,,14256,F,,Autocuration,CHEMBL615167,BAO_0000219,617
,,D,308.0,,51,9606.0,Homo sapiens,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,1,,HeLa,,,9,,3445,B,,Expert,CHEMBL615168,BAO_0000219,618
,,D,308.0,,51,9606.0,Homo sapiens,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,1,,HeLa,,,9,,3445,B,,Expert,CHEMBL615169,BAO_0000219,619
,,D,449.0,,51,9606.0,Homo sapiens,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,1,,CHO,,,9,,17200,B,,Expert,CHEMBL615170,BAO_0000219,620
,,D,449.0,,51,9606.0,Homo sapiens,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,1,,CHO,,,9,,17200,B,,Expert,CHEMBL615171,BAO_0000219,621
,,H,,,51,,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,1,,,,,8,,15180,F,,Autocuration,CHEMBL615694,BAO_0000019,622
,,H,,,51,,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,1,,,,,8,,15180,F,,Autocuration,CHEMBL615695,BAO_0000019,623
,,H,,,51,,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",1,,,,,8,,16026,F,,Autocuration,CHEMBL615696,BAO_0000019,624
,,H,449.0,,51,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,1,,CHO,,,8,,2759,F,,Autocuration,CHEMBL615697,BAO_0000219,625
,,D,449.0,,51,9606.0,Homo sapiens,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),1,,CHO,,,9,,2759,F,,Expert,CHEMBL859410,BAO_0000219,626
,,H,449.0,,51,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),1,,CHO,,,8,,2759,F,,Autocuration,CHEMBL615841,BAO_0000219,627
,,D,449.0,,51,9606.0,Homo sapiens,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),1,,CHO,,,9,,2759,F,,Expert,CHEMBL615842,BAO_0000219,628
,,H,449.0,,51,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,1,,CHO,,,8,,2759,F,,Autocuration,CHEMBL835003,BAO_0000219,629
,,H,449.0,,51,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),1,,CHO,,,8,,2759,F,,Autocuration,CHEMBL615843,BAO_0000219,630
,,D,449.0,,51,9606.0,Homo sapiens,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),1,,CHO,,,9,,2759,F,,Expert,CHEMBL615979,BAO_0000219,631
,,H,449.0,,51,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),1,,CHO,,,8,,2759,F,,Autocuration,CHEMBL615980,BAO_0000219,632
,,D,449.0,,51,9606.0,Homo sapiens,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),1,,CHO,,,9,,2759,F,,Expert,CHEMBL615981,BAO_0000219,633
,,D,,,51,9606.0,Homo sapiens,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,1,,,,,9,,3445,F,,Expert,CHEMBL615982,BAO_0000019,634
,,D,,,51,9606.0,Homo sapiens,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",1,,,,,9,,5272,F,,Expert,CHEMBL615983,BAO_0000019,635
,,D,,,51,9606.0,Homo sapiens,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",1,,,,,9,,5272,F,,Expert,CHEMBL615984,BAO_0000019,636
,,D,,,51,9606.0,Homo sapiens,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",1,,,,,9,,5272,F,,Expert,CHEMBL615985,BAO_0000019,637
,,H,449.0,,51,,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,1,,CHO,,,8,,17624,F,,Autocuration,CHEMBL615986,BAO_0000219,638
,,H,449.0,,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,1,,CHO,,,8,,17624,F,,Autocuration,CHEMBL615987,BAO_0000219,639
,,H,449.0,,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,1,,CHO,,,8,,17624,F,,Autocuration,CHEMBL615988,BAO_0000219,640
,,H,449.0,,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,1,,CHO,,,8,,17624,F,,Expert,CHEMBL615989,BAO_0000219,641
,,H,449.0,,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,1,,CHO,,,8,,17624,F,,Autocuration,CHEMBL615990,BAO_0000219,642
,,H,449.0,,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,1,,CHO,,,8,,17624,F,,Autocuration,CHEMBL615991,BAO_0000219,643
,,H,449.0,,51,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,1,,CHO,,,8,,17624,F,,Autocuration,CHEMBL615992,BAO_0000219,644
,,H,449.0,,51,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,1,,CHO,,,8,,17624,F,,Autocuration,CHEMBL615993,BAO_0000219,645
,,H,449.0,,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,1,,CHO,,,8,,17624,F,,Expert,CHEMBL615994,BAO_0000219,646
,,H,449.0,,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,1,,CHO,,,8,,17624,F,,Autocuration,CHEMBL615995,BAO_0000219,647
,,H,449.0,,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,1,,CHO,,,8,,17624,F,,Autocuration,CHEMBL615996,BAO_0000219,648
,,H,449.0,,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,1,,CHO,,,8,,17624,F,,Autocuration,CHEMBL615997,BAO_0000219,649
,,H,,,51,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",1,,,,,8,,6563,F,,Autocuration,CHEMBL615998,BAO_0000019,650
,,H,,,51,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",1,,,,,8,,6563,F,,Autocuration,CHEMBL615999,BAO_0000019,651
,,H,,,51,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,1,,,,,8,,6563,F,,Autocuration,CHEMBL616000,BAO_0000019,652
,,H,722.0,,51,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,1,,HEK293,,,8,,17296,F,,Autocuration,CHEMBL616001,BAO_0000219,653
,,D,,,51,9606.0,Homo sapiens,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",1,,,,,9,,6876,F,,Expert,CHEMBL616002,BAO_0000019,654
,,H,,,51,,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",1,,,,,8,,6876,F,,Expert,CHEMBL616003,BAO_0000019,655
,,D,,,51,9606.0,Homo sapiens,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,1,,,,,9,,5272,F,,Expert,CHEMBL616004,BAO_0000019,656
,,D,,,51,9606.0,Homo sapiens,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,1,,,,,9,,5272,F,,Expert,CHEMBL616005,BAO_0000019,657
,,H,,,51,,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",1,,,,,8,,5548,F,,Autocuration,CHEMBL616006,BAO_0000019,658
,,H,,,51,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",1,,,,,8,,5548,F,,Expert,CHEMBL616007,BAO_0000019,659
,,H,,,51,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",1,,,,,8,,5548,F,,Autocuration,CHEMBL616008,BAO_0000019,660
,,H,,,51,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",1,,,,,8,,5548,F,,Autocuration,CHEMBL616009,BAO_0000019,661
,,H,,,51,,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",1,,,,,8,,5929,F,,Expert,CHEMBL616010,BAO_0000019,662
,,D,,,51,9606.0,Homo sapiens,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",1,,,,,9,,5929,F,,Expert,CHEMBL616011,BAO_0000019,663
,,D,,,51,9606.0,Homo sapiens,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",1,,,,,9,,5929,F,,Expert,CHEMBL615740,BAO_0000019,664
,,H,,,51,,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",1,,,,,8,,16245,F,,Autocuration,CHEMBL615741,BAO_0000019,665
,,H,,,51,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",1,,,,,8,,5640,F,,Expert,CHEMBL615742,BAO_0000019,666
,,H,,,51,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",1,,,,,8,,5640,F,,Autocuration,CHEMBL615743,BAO_0000019,667
,,H,449.0,,51,,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,1,,CHO,,,8,,14509,F,,Autocuration,CHEMBL615744,BAO_0000219,668
,,H,449.0,,51,,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,1,,CHO,,,8,,14509,F,,Expert,CHEMBL615745,BAO_0000219,669
,,H,,,51,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,1,,,,,8,,15331,B,,Autocuration,CHEMBL615746,BAO_0000357,670
,,H,,,51,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,1,,,,,8,,15331,B,,Autocuration,CHEMBL615747,BAO_0000357,671
,,H,,,51,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",1,,,,,8,,6563,F,,Autocuration,CHEMBL615748,BAO_0000019,672
,,H,,,51,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",1,,,,,8,,6563,F,,Autocuration,CHEMBL615749,BAO_0000019,673
,,H,,,51,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,1,,,,,8,,6563,F,,Autocuration,CHEMBL615750,BAO_0000019,674
,,D,,,51,9606.0,Homo sapiens,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,1,,,,,9,,6563,F,,Expert,CHEMBL616259,BAO_0000019,675
,,H,,,51,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",1,,,,,8,,6563,F,,Autocuration,CHEMBL616260,BAO_0000019,676
,,D,,,51,9606.0,Homo sapiens,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,1,,,,,9,,5272,F,,Expert,CHEMBL616261,BAO_0000019,677
,,D,,,51,9606.0,Homo sapiens,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",1,,,,,9,,5272,F,,Expert,CHEMBL616262,BAO_0000019,678
,,D,,,51,9606.0,Homo sapiens,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",1,,,,,9,,5272,F,,Expert,CHEMBL616263,BAO_0000019,679
,,D,,,51,9606.0,Homo sapiens,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,1,,,,,9,,5272,F,,Expert,CHEMBL616264,BAO_0000019,680
,,D,,,51,9606.0,Homo sapiens,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,1,,,,,9,,5272,F,,Expert,CHEMBL616265,BAO_0000019,681
,,D,,,51,9606.0,Homo sapiens,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",1,,,,,9,,5272,F,,Expert,CHEMBL616266,BAO_0000019,682
,,D,,,51,9606.0,Homo sapiens,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",1,,,,,9,,5272,F,,Expert,CHEMBL616267,BAO_0000019,683
,,D,,,51,9606.0,Homo sapiens,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,1,,,,,9,,5272,F,,Expert,CHEMBL616268,BAO_0000019,684
,,D,,,51,9606.0,Homo sapiens,Inhibition of human 5-hydroxytryptamine 1A receptor,1,,,,,9,,16146,B,,Expert,CHEMBL616269,BAO_0000357,685
,,H,449.0,,51,,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,1,,CHO,,,8,,17624,B,,Autocuration,CHEMBL884528,BAO_0000219,686
,,D,722.0,,105,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,1,,HEK293,,,9,,13706,B,,Expert,CHEMBL616270,BAO_0000219,687
,,H,449.0,,51,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,1,,CHO,,,8,,15250,B,,Autocuration,CHEMBL616271,BAO_0000219,688
,,H,449.0,,51,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,1,,CHO,,,8,,17624,F,,Autocuration,CHEMBL616272,BAO_0000219,689
,,H,,,51,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,1,,,,,8,,6861,B,,Expert,CHEMBL616273,BAO_0000357,690
,,D,,,51,9606.0,Homo sapiens,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,1,,,,,9,,17200,B,,Expert,CHEMBL616274,BAO_0000357,691
,,H,449.0,,51,,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,1,,CHO,,,8,,17624,B,,Autocuration,CHEMBL616275,BAO_0000219,692
,,H,449.0,,51,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,1,,CHO,,,8,,17624,B,,Autocuration,CHEMBL616276,BAO_0000219,693
,,U,,,22226,10116.0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,1,,,,In vivo,0,,12058,F,,Autocuration,CHEMBL616277,BAO_0000218,694
,,U,,,22226,10116.0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,1,,,,In vivo,0,,12058,F,,Autocuration,CHEMBL616278,BAO_0000218,695
,,U,,,22226,10116.0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,1,,,,In vivo,0,,12058,F,,Autocuration,CHEMBL616279,BAO_0000218,696
,,U,,,22226,10116.0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,1,,,,In vivo,0,,12058,F,,Autocuration,CHEMBL616280,BAO_0000218,697
,,U,,,22226,10116.0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,1,,,,In vivo,0,,12058,F,,Autocuration,CHEMBL616281,BAO_0000218,698
,,U,,,22226,10116.0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,1,,,,In vivo,0,,12058,F,,Autocuration,CHEMBL616282,BAO_0000218,699
,,U,,,22226,10116.0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,1,,,,In vivo,0,,12058,F,,Autocuration,CHEMBL616283,BAO_0000218,700
,,U,,,22226,10116.0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,1,,,,In vivo,0,,12058,F,,Autocuration,CHEMBL616284,BAO_0000218,701
,,U,,,22226,10116.0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,1,,,,In vivo,0,,12058,F,,Autocuration,CHEMBL616285,BAO_0000218,702
,,U,,,22226,10116.0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,1,,,,In vivo,0,,12058,F,,Autocuration,CHEMBL616286,BAO_0000218,703
,,U,,,22226,10116.0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,1,,,,In vivo,0,,12058,F,,Autocuration,CHEMBL616287,BAO_0000218,704
,,U,,,22226,10116.0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,1,,,,In vivo,0,,12058,F,,Autocuration,CHEMBL616288,BAO_0000218,705
,,U,,,22226,10116.0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,1,,,,In vivo,0,,12058,F,,Autocuration,CHEMBL616289,BAO_0000218,706
,,U,,,22226,10116.0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,1,,,,In vivo,0,,12058,F,,Autocuration,CHEMBL615610,BAO_0000218,707
,,U,,,22226,10116.0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,1,,,,In vivo,0,,12058,F,,Autocuration,CHEMBL615611,BAO_0000218,708
,,U,,,22226,10116.0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,1,,,,In vivo,0,,12058,F,,Autocuration,CHEMBL615612,BAO_0000218,709
,,U,,,22226,10116.0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,1,,,,In vivo,0,,12058,F,,Autocuration,CHEMBL615613,BAO_0000218,710
,,U,,,22226,10116.0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,1,,,,In vivo,0,,12058,F,,Autocuration,CHEMBL615614,BAO_0000218,711
,,U,,,22226,10116.0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,1,,,,In vivo,0,,12058,F,,Autocuration,CHEMBL615615,BAO_0000218,712
,,H,,,105093,,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,1,,,,,4,,11440,B,,Autocuration,CHEMBL615616,BAO_0000019,713
,,H,,,11923,,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,1,Hypothalamus,,,,8,,6238,B,1898.0,Autocuration,CHEMBL615617,BAO_0000249,714
,,H,,,10577,,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,1,,,,,8,,10046,B,,Autocuration,CHEMBL615618,BAO_0000019,715
,,H,,,10577,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,1,,,,,8,,10046,B,,Autocuration,CHEMBL615619,BAO_0000019,716
,,H,,,10577,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,1,,,,,8,,10046,B,,Expert,CHEMBL615620,BAO_0000019,717
,,H,,,55,,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",1,,,,,8,,167,B,,Autocuration,CHEMBL615621,BAO_0000357,718
,,H,,,55,,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",1,,,,,8,,167,B,,Autocuration,CHEMBL615622,BAO_0000357,719
,,H,,,12166,,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),1,,,,,8,,11520,F,,Autocuration,CHEMBL615623,BAO_0000019,720
,,H,,,12166,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,1,,,,,8,,11520,F,,Autocuration,CHEMBL615624,BAO_0000019,721
,,H,,,12166,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,1,,,,,8,,11520,F,,Autocuration,CHEMBL615625,BAO_0000019,722
,,H,,,12166,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,1,,,,,8,,11520,F,,Autocuration,CHEMBL767045,BAO_0000019,723
,,H,,,55,10141.0,Cavia porcellus,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,1,,,,,8,,135,F,,Autocuration,CHEMBL615626,BAO_0000019,724
,,H,,,55,10141.0,Cavia porcellus,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,1,,,,,8,,135,F,,Autocuration,CHEMBL615627,BAO_0000019,725
,,H,,,55,10141.0,Cavia porcellus,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,1,,,,,8,,11311,B,,Autocuration,CHEMBL615628,BAO_0000019,726
,,H,,,55,10141.0,Cavia porcellus,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,1,,,,,8,,10193,B,,Autocuration,CHEMBL615629,BAO_0000357,727
,,D,,,55,9606.0,Homo sapiens,Inhibitory concentration against 5-lipoxygenase from human whole blood,1,,,,,9,,12281,B,,Expert,CHEMBL615630,BAO_0000357,728
,,H,,,55,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],1,,,,,8,,11311,B,,Autocuration,CHEMBL615631,BAO_0000219,729
,,H,,,17087,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,1,,,,,8,,12576,F,,Autocuration,CHEMBL615632,BAO_0000218,730
,,H,,,17087,,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,1,,,,,8,,12281,B,,Autocuration,CHEMBL615633,BAO_0000357,731
,,H,,,17087,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,1,,,,,8,,12576,F,,Autocuration,CHEMBL615634,BAO_0000218,732
,,H,,,55,9823.0,Sus scrofa,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,1,,,,,8,,11089,B,,Expert,CHEMBL615635,BAO_0000019,733
,,H,,,12166,,,In vitro inhibition of rat 5-Lipoxygenase,1,,,,,8,,11006,B,,Expert,CHEMBL615636,BAO_0000357,734
,,D,,,12166,10116.0,Rattus norvegicus,Inhibitory activity against 5-Lipoxygenase,1,,,,,9,,11481,B,,Expert,CHEMBL615637,BAO_0000357,735
,,H,702.0,,12166,,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,1,,RBL-1,,,8,,10864,B,,Expert,CHEMBL615638,BAO_0000219,736
,,H,702.0,,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),1,,RBL-1,,,8,,3595,B,,Autocuration,CHEMBL615639,BAO_0000219,737
,,H,702.0,,12166,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,1,,RBL-1,,,8,,11311,B,,Autocuration,CHEMBL615640,BAO_0000219,738
,,H,,,12166,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,1,,,,,8,,11311,B,,Autocuration,CHEMBL615796,BAO_0000019,739
,,H,,,12166,,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],1,,,,,8,,11311,B,,Autocuration,CHEMBL615845,BAO_0000219,740
,,H,,,12166,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,1,,,,,8,,11006,B,,Autocuration,CHEMBL615846,BAO_0000357,741
,,H,702.0,,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,1,,RBL-1,,,8,,3595,B,,Autocuration,CHEMBL615847,BAO_0000219,742
,,H,,,12166,,,The compound was tested for inhibition of isolated 5-Lipoxygenase,1,,,,,8,,11311,B,,Autocuration,CHEMBL615848,BAO_0000357,743
,,U,,,22226,10116.0,Rattus norvegicus,Ratio of IC50 against 5-LO and COX,1,,,,,0,,11481,B,,Autocuration,CHEMBL615849,BAO_0000019,744
,,H,,,12166,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,1,,,,,8,,11006,B,,Autocuration,CHEMBL615850,BAO_0000357,745
,,H,,,12166,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,1,,,,,8,,11006,B,,Autocuration,CHEMBL615851,BAO_0000357,746
,,H,,,12166,,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,1,,,,,8,,11311,B,,Autocuration,CHEMBL615852,BAO_0000219,747
,,H,,,12166,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,1,,,,,8,,11006,F,,Autocuration,CHEMBL615853,BAO_0000019,748
,,H,,,120,,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,1,Prostate gland,,,,8,,4288,B,2367.0,Autocuration,CHEMBL884527,BAO_0000357,749
,,U,,,22226,8932.0,Columba livia,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,1,,,,,0,,7587,B,,Autocuration,CHEMBL872871,BAO_0000019,750
,,U,,,22226,8932.0,Columba livia,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,1,,,,,0,,7587,B,,Autocuration,CHEMBL615854,BAO_0000019,751
,,U,,,22226,8932.0,Columba livia,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,1,,,,,0,,7587,B,,Autocuration,CHEMBL767046,BAO_0000019,752
,,H,,,10732,,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,1,,,,,8,,11249,B,,Autocuration,CHEMBL615855,BAO_0000357,753
,,D,,,12198,10116.0,Rattus norvegicus,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,1,,,,,9,,8003,F,,Expert,CHEMBL615856,BAO_0000019,754
,,D,,,12198,10116.0,Rattus norvegicus,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),1,,,,,9,,8003,F,,Expert,CHEMBL615857,BAO_0000019,755
,,D,,,12198,10116.0,Rattus norvegicus,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),1,,,,,9,,8003,F,,Expert,CHEMBL615858,BAO_0000019,756
,,H,,,10576,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,1,Hippocampus,,,,8,,12416,B,10000000.0,Expert,CHEMBL615859,BAO_0000221,757
,,H,,,51,,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,1,,,,,8,,16293,B,,Autocuration,CHEMBL615860,BAO_0000357,758
,,U,,,22226,9986.0,Oryctolagus cuniculus,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,1,,,,,0,,13047,B,,Autocuration,CHEMBL615861,BAO_0000019,759
,,U,,,22226,9986.0,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,1,,,,,0,,13047,B,,Autocuration,CHEMBL615862,BAO_0000019,760
,,U,,,22226,9986.0,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,1,,,,,0,,13047,B,,Autocuration,CHEMBL615863,BAO_0000019,761
,,U,,,22226,9986.0,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,1,,,,,0,,13047,B,,Autocuration,CHEMBL615864,BAO_0000019,762
,,H,,,104744,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,1,Hippocampus,,,,4,,10085,B,10000000.0,Autocuration,CHEMBL615865,BAO_0000221,763
,,H,,,104744,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,1,Hippocampus,,,,4,,10085,B,10000000.0,Autocuration,CHEMBL615866,BAO_0000221,764
,,H,,,104744,,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,1,Hippocampus,,,,4,,10085,B,10000000.0,Autocuration,CHEMBL615867,BAO_0000221,765
,Membranes,H,,,104744,,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,1,,,,,4,,9841,B,,Autocuration,CHEMBL615868,BAO_0000249,766
,,D,,,104744,10116.0,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,1,,,,,5,,8822,B,,Autocuration,CHEMBL615869,BAO_0000249,767
,,D,,,104744,10116.0,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,1,,,,,5,,9806,B,,Autocuration,CHEMBL615870,BAO_0000019,768
,,D,,,104744,10116.0,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,1,,,,,5,,9806,B,,Autocuration,CHEMBL615871,BAO_0000019,769
,,H,,,104744,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,1,,,,,4,,8868,B,,Autocuration,CHEMBL615872,BAO_0000224,770
,,H,,,104744,,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,1,Hippocampus,,,,4,,9036,B,10000000.0,Autocuration,CHEMBL833492,BAO_0000221,771
,,H,,,104744,,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,1,Hippocampus,,,,4,,11374,B,10000000.0,Autocuration,CHEMBL615873,BAO_0000221,772
,,H,,,104744,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,1,,,,,4,,10881,B,,Autocuration,CHEMBL615479,BAO_0000224,773
,,H,,,104744,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,1,,,,,4,,8822,B,,Autocuration,CHEMBL615480,BAO_0000019,774
,,D,,,104744,10116.0,Rattus norvegicus,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,1,,,,,5,,9806,B,,Autocuration,CHEMBL615481,BAO_0000249,775
,,H,,,104744,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,1,,,,,4,,15463,B,,Autocuration,CHEMBL872869,BAO_0000019,776
,,H,,,104744,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,1,,,,,4,,15463,B,,Autocuration,CHEMBL615482,BAO_0000019,777
,,H,,,104744,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,1,Brain,,,,4,,14542,B,955.0,Autocuration,CHEMBL615483,BAO_0000221,778
,,H,,,104744,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,1,Brain,,,,4,,14542,B,955.0,Autocuration,CHEMBL615484,BAO_0000221,779
,,H,,,104744,,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,1,,,,,4,,8569,B,,Autocuration,CHEMBL615485,BAO_0000019,780
,,D,,,104744,10116.0,Rattus norvegicus,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,1,,,,,5,,10062,B,,Autocuration,CHEMBL615486,BAO_0000224,781
,,H,,,104744,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,1,,,,,4,,4771,B,,Autocuration,CHEMBL615487,BAO_0000224,782
,,H,,,104744,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,1,,,,,4,,10062,B,,Autocuration,CHEMBL615488,BAO_0000224,783
,,H,,,104744,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,1,,,,,4,,10062,B,,Autocuration,CHEMBL615489,BAO_0000224,784
,,H,,,104744,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,1,,,,,4,,10062,B,,Autocuration,CHEMBL615389,BAO_0000224,785
,,H,,,104744,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,1,,,,,4,,15463,B,,Autocuration,CHEMBL615390,BAO_0000019,786
,,H,,,104744,,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,1,,,,,4,,15463,B,,Autocuration,CHEMBL615391,BAO_0000019,787
,,H,,,104744,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,1,,,,,4,,9098,B,,Autocuration,CHEMBL615392,BAO_0000224,788
,,U,,,22226,10116.0,Rattus norvegicus,Affinity for 5-hydroxytryptamine 1 receptor,1,,,,,0,,3070,B,,Autocuration,CHEMBL615393,BAO_0000019,789
,,H,,,104744,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,1,Brain,,,,4,,14542,B,955.0,Autocuration,CHEMBL615394,BAO_0000221,790
,,H,,,104744,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,1,Brain,,,,4,,14542,B,955.0,Autocuration,CHEMBL615395,BAO_0000221,791
,,H,,,104744,,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,1,,,,,4,,6398,B,,Autocuration,CHEMBL615396,BAO_0000224,792
,,H,,,104744,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,1,Brain,,,,4,,1344,B,955.0,Autocuration,CHEMBL615397,BAO_0000221,793
,,H,,,104744,,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,1,,,,,4,,11963,B,,Autocuration,CHEMBL615398,BAO_0000019,794
,,U,,,22226,10116.0,Rattus norvegicus,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,1,,,,,0,,8908,B,,Autocuration,CHEMBL615399,BAO_0000019,795
,,H,,,104744,,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,1,,,,,4,,9098,B,,Autocuration,CHEMBL615400,BAO_0000019,796
,,D,,,104744,10116.0,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,1,,,,,5,,8841,B,,Autocuration,CHEMBL615401,BAO_0000019,797
,,U,,,22226,10116.0,Rattus norvegicus,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,1,,,,,0,,8814,B,,Autocuration,CHEMBL615402,BAO_0000019,798
,,H,,,104744,,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,1,,,,,4,,11752,B,,Autocuration,CHEMBL615403,BAO_0000019,799
,,H,,,104744,,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,1,Brain,,,,4,,11642,B,955.0,Autocuration,CHEMBL615404,BAO_0000221,800
,,H,,,104744,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,1,,,,,4,,11642,B,,Autocuration,CHEMBL615781,BAO_0000019,801
,,H,,,104744,,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,1,Brain,,,,4,,9231,B,955.0,Autocuration,CHEMBL615782,BAO_0000220,802
,,H,,,104744,,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,1,Brain,,,,4,,11351,B,955.0,Autocuration,CHEMBL615783,BAO_0000221,803
,,U,,,22226,,,Compound was tested for binding affinity against 5-HT1 receptor,1,,,,,0,,4639,B,,Autocuration,CHEMBL873481,BAO_0000019,804
,,U,,,22226,,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,1,,,,,0,,1205,B,,Autocuration,CHEMBL615784,BAO_0000019,805
,,H,,,10576,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,1,,,,,8,,10025,B,,Expert,CHEMBL615785,BAO_0000357,806
,,H,,,10576,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",1,,,,,8,,13241,F,,Autocuration,CHEMBL615786,BAO_0000249,807
,,H,,,10576,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,1,,,,In vivo,8,,16245,F,,Autocuration,CHEMBL615787,BAO_0000218,808
,,H,,,10576,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,1,,,,In vivo,8,,16245,F,,Autocuration,CHEMBL615788,BAO_0000218,809
,,H,,,10576,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,1,,,,,8,,12438,F,,Autocuration,CHEMBL767044,BAO_0000019,810
,,H,,,10576,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,1,,,,In vivo,8,,16245,F,,Autocuration,CHEMBL615789,BAO_0000218,811
,,H,,,10576,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,1,,,,In vivo,8,,16245,F,,Autocuration,CHEMBL615790,BAO_0000218,812
,,H,,,10576,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,1,,,,,8,,15740,F,,Autocuration,CHEMBL615813,BAO_0000019,813
,,H,,,10576,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,1,,,,,8,,15535,F,,Autocuration,CHEMBL615814,BAO_0000219,814
,,H,,,51,,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,1,,,,,8,,15535,F,,Expert,CHEMBL615815,BAO_0000219,815
,,H,,,10576,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,1,,,,,8,,15535,F,,Autocuration,CHEMBL615816,BAO_0000219,816
,,H,,,10576,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,1,,,,,8,,9888,B,,Expert,CHEMBL615817,BAO_0000249,817
,,H,,,10576,,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,1,Hippocampus,,,,8,,10085,B,10000000.0,Autocuration,CHEMBL615818,BAO_0000221,818
,,H,,,10576,,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,1,Hippocampus,,,,8,,10085,B,10000000.0,Autocuration,CHEMBL615819,BAO_0000221,819
,Membranes,H,,,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,1,,,,,8,,17331,B,,Expert,CHEMBL615820,BAO_0000249,820
,,D,,,10576,10116.0,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,1,Hippocampus,,,,9,,10845,B,10000000.0,Expert,CHEMBL615821,BAO_0000221,821
,,D,,,10576,10116.0,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,1,Hippocampus,,,,9,,10845,B,10000000.0,Expert,CHEMBL615822,BAO_0000221,822
,,H,,,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,1,Hippocampus,,,,8,,10845,B,10000000.0,Expert,CHEMBL615823,BAO_0000221,823
,,D,,,10576,10116.0,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,1,Hippocampus,,,,9,,10845,B,10000000.0,Expert,CHEMBL615824,BAO_0000221,824
,,D,,,10576,10116.0,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,1,Hippocampus,,,,9,,10845,B,10000000.0,Expert,CHEMBL615825,BAO_0000221,825
,,H,,,10576,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,1,,,,,8,,13730,B,,Expert,CHEMBL615826,BAO_0000357,826
,,H,,,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,1,,,,,8,,13508,B,,Expert,CHEMBL615827,BAO_0000249,827
,,H,,,10576,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,1,Hippocampus,,,,8,,13508,B,10000000.0,Expert,CHEMBL615828,BAO_0000249,828
,,H,,,10576,,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,1,Hippocampus,,,,8,,12073,B,10000000.0,Expert,CHEMBL615829,BAO_0000221,829
,,H,,,10576,,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,1,Hippocampus,,,,8,,4671,B,10000000.0,Autocuration,CHEMBL615830,BAO_0000221,830
,,H,,,10576,,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,1,Hippocampus,,,,8,,13631,B,10000000.0,Expert,CHEMBL615831,BAO_0000221,831
,,H,,,10576,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,1,,,,,8,,12438,B,,Autocuration,CHEMBL615832,BAO_0000357,832
,,H,,,10576,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,1,,,,,8,,10483,B,,Autocuration,CHEMBL615833,BAO_0000019,833
,,H,,,10576,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,1,Hippocampus,,,,8,,10483,B,10000000.0,Autocuration,CHEMBL615834,BAO_0000221,834
,,H,,,10576,,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,1,,,,,8,,12352,B,,Intermediate,CHEMBL615835,BAO_0000249,835
,,H,,,10576,,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,1,Hippocampus,,,,8,,14732,B,10000000.0,Autocuration,CHEMBL615836,BAO_0000249,836
,,D,,,10576,10116.0,Rattus norvegicus,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,1,,,,,9,,11049,B,,Expert,CHEMBL615837,BAO_0000019,837
,,D,,,10576,10116.0,Rattus norvegicus,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,1,,,,,9,,11049,B,,Expert,CHEMBL615838,BAO_0000019,838
,,H,,,10576,,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",1,,,,,8,,13657,B,,Expert,CHEMBL615839,BAO_0000249,839
,,H,,,10576,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,1,,,,,8,,11473,B,,Autocuration,CHEMBL884525,BAO_0000019,840
,,H,,,10576,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,1,,,,,8,,2014,B,,Autocuration,CHEMBL615840,BAO_0000249,841
,,H,,,10576,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,1,Hippocampus,,,,8,,3086,B,10000000.0,Expert,CHEMBL615405,BAO_0000221,842
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,1,,,,,8,,15854,B,,Expert,CHEMBL615406,BAO_0000019,843
,,H,,,10576,,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,1,Hippocampus,,,,8,,10922,B,10000000.0,Expert,CHEMBL615900,BAO_0000221,844
,,H,,,10576,,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,1,Hippocampus,,,,8,,13346,B,10000000.0,Expert,CHEMBL615901,BAO_0000221,845
,,H,,,10576,,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,1,,,,,8,,15311,B,,Expert,CHEMBL615902,BAO_0000357,846
,,H,,,10576,,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,1,Hippocampus,,,,8,,10922,B,10000000.0,Autocuration,CHEMBL615903,BAO_0000221,847
,,H,,,10576,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,1,,,,,8,,10025,B,,Autocuration,CHEMBL615904,BAO_0000357,848
,,H,,,10576,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,1,,,,,8,,10025,B,,Expert,CHEMBL615905,BAO_0000357,849
,,H,,,10576,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,1,,,,,8,,9742,B,,Autocuration,CHEMBL615906,BAO_0000019,850
,,H,,,10576,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,1,,,,,8,,9742,F,,Autocuration,CHEMBL615907,BAO_0000019,851
,,H,,,10576,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,1,,,,,8,,12304,B,,Expert,CHEMBL615908,BAO_0000019,852
,,H,,,10576,,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,1,Hippocampus,,,,8,,15789,B,10000000.0,Autocuration,CHEMBL615909,BAO_0000221,853
,,H,,,10576,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",1,,,,,8,,9912,B,,Autocuration,CHEMBL615910,BAO_0000019,854
,,H,,,10576,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",1,,,,,8,,9912,B,,Autocuration,CHEMBL615911,BAO_0000019,855
,,H,,,10576,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",1,,,,,8,,9912,B,,Autocuration,CHEMBL615912,BAO_0000019,856
,,H,,,10576,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,1,,,,,8,,16693,B,,Expert,CHEMBL615913,BAO_0000019,857
,,H,,,10576,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,1,,,,,8,,13276,B,,Expert,CHEMBL615914,BAO_0000357,858
,,H,,,10576,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,1,Hippocampus,,,,8,,12678,B,10000000.0,Autocuration,CHEMBL615915,BAO_0000221,859
,,H,,,10576,,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,1,,,,,8,,11825,B,,Autocuration,CHEMBL615916,BAO_0000357,860
,,H,,,10576,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,1,,,,,8,,12443,B,,Expert,CHEMBL615917,BAO_0000357,861
,,H,,,10576,,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,1,,,,,8,,13830,B,,Expert,CHEMBL615918,BAO_0000357,862
,,H,,,10576,,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,1,Hippocampus,,,,8,,14286,B,10000000.0,Expert,CHEMBL615919,BAO_0000249,863
,,D,,,10576,10116.0,Rattus norvegicus,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,1,Hippocampus,,,,9,,14356,B,10000000.0,Expert,CHEMBL615920,BAO_0000221,864
,,H,,,10576,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,1,,,,,8,,15306,B,,Autocuration,CHEMBL615921,BAO_0000357,865
,,H,,,10576,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),1,,,,,8,,15306,B,,Expert,CHEMBL615922,BAO_0000357,866
,,D,,,10576,10116.0,Rattus norvegicus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",1,,,,,9,,16616,F,,Expert,CHEMBL881290,BAO_0000249,867
,,H,,,10576,,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",1,Hippocampus,,,,8,,3651,B,10000000.0,Autocuration,CHEMBL615923,BAO_0000221,868
,,H,,,10576,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,1,Hippocampus,,,,8,,14331,F,10000000.0,Autocuration,CHEMBL615924,BAO_0000221,869
,,H,,,10576,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,1,Hippocampus,,,,8,,14331,F,10000000.0,Autocuration,CHEMBL615925,BAO_0000221,870
,,D,,,10576,10116.0,Rattus norvegicus,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,1,,,,,9,,14178,B,,Expert,CHEMBL615926,BAO_0000357,871
,,D,,,10576,10116.0,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,1,,,,,9,,10639,B,,Expert,CHEMBL615927,BAO_0000019,872
,,H,,,10576,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,1,Hippocampus,,,,8,,12306,B,10000000.0,Autocuration,CHEMBL615928,BAO_0000221,873
,,D,,,10576,10116.0,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,1,,,,,9,,1348,B,,Expert,CHEMBL615929,BAO_0000357,874
,,H,,,10576,,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,1,Hippocampus,,,,8,,13605,B,10000000.0,Autocuration,CHEMBL615930,BAO_0000221,875
,,H,449.0,,51,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,1,,CHO,,,8,,17624,B,,Autocuration,CHEMBL615931,BAO_0000219,876
,,H,449.0,,51,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,1,,CHO,,,8,,17624,F,,Autocuration,CHEMBL615932,BAO_0000219,877
,,H,449.0,,51,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,1,,CHO,,,8,,17624,F,,Autocuration,CHEMBL615933,BAO_0000219,878
,,H,,,51,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,1,,,,,8,,15267,B,,Autocuration,CHEMBL615934,BAO_0000357,879
,,H,,,51,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,1,,,,,8,,16532,B,,Autocuration,CHEMBL615935,BAO_0000357,880
,,H,,,51,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",1,,,,,8,,6563,F,,Autocuration,CHEMBL615936,BAO_0000019,881
,,H,449.0,,51,,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,1,,CHO,,,8,,4751,B,,Autocuration,CHEMBL615937,BAO_0000219,882
,,H,,,51,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,1,,,,,8,,15463,B,,Autocuration,CHEMBL615938,BAO_0000357,883
,,H,,,51,,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),1,,,,,8,,3805,B,,Autocuration,CHEMBL615797,BAO_0000357,884
,,H,,,51,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,,,,8,,5640,B,,Autocuration,CHEMBL615798,BAO_0000357,885
,,H,,,51,,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,1,,,,,8,,6563,B,,Autocuration,CHEMBL872870,BAO_0000357,886
,,H,,,51,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,1,,,,,8,,5548,B,,Autocuration,CHEMBL615799,BAO_0000357,887
,,H,,,51,,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,1,,,,,8,,6347,B,,Autocuration,CHEMBL615800,BAO_0000357,888
,,H,722.0,,51,,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,1,,HEK293,,,8,,17296,F,,Autocuration,CHEMBL615801,BAO_0000219,889
,,H,,,51,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,1,,,,,8,,13047,B,,Autocuration,CHEMBL615802,BAO_0000019,890
,,H,,,51,,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,1,,,,,8,,15740,B,,Autocuration,CHEMBL615803,BAO_0000357,891
,,H,,,51,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",1,,,,,8,,5640,F,,Expert,CHEMBL835002,BAO_0000019,892
,,H,,,51,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",1,,,,,8,,5640,F,,Autocuration,CHEMBL615804,BAO_0000019,893
,,H,308.0,,51,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,1,,HeLa,,,8,,17211,B,,Expert,CHEMBL615805,BAO_0000219,894
,,H,449.0,,51,,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,1,,CHO,,,8,,4751,B,,Autocuration,CHEMBL615806,BAO_0000219,895
,,D,,,51,9606.0,Homo sapiens,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,1,,,,,9,,6491,B,,Expert,CHEMBL615807,BAO_0000357,896
,,H,,,51,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,1,,,,,8,,4707,B,,Autocuration,CHEMBL615808,BAO_0000357,897
,,D,,,51,9606.0,Homo sapiens,Binding affinity against 5-hydroxytryptamine 1A receptor,1,,,,,9,,13910,B,,Expert,CHEMBL615809,BAO_0000357,898
,,H,308.0,,51,,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,1,,HeLa,,,8,,16190,B,,Autocuration,CHEMBL615810,BAO_0000219,899
,,H,,,51,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,,,,8,,16633,B,,Autocuration,CHEMBL615811,BAO_0000357,900
,,H,449.0,,51,,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,1,,CHO,,,8,,11898,B,,Autocuration,CHEMBL615812,BAO_0000219,901
,,H,449.0,,51,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,1,,CHO,,,8,,11898,B,,Autocuration,CHEMBL615751,BAO_0000219,902
,,H,,,51,,,Binding affinity against human 5-hydroxytryptamine 1A receptor,1,,,,,8,,14331,B,,Autocuration,CHEMBL615752,BAO_0000357,903
,,H,449.0,,51,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,1,,CHO,,,8,,17624,B,,Expert,CHEMBL615753,BAO_0000219,904
,,H,449.0,,51,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,1,,CHO,,,8,,17624,B,,Autocuration,CHEMBL615754,BAO_0000219,905
,,H,,,51,,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,1,,,,,8,,3307,B,,Autocuration,CHEMBL615755,BAO_0000357,906
,,D,449.0,,51,9606.0,Homo sapiens,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,1,,CHO,,,9,,6563,B,,Expert,CHEMBL615756,BAO_0000219,907
,,H,,,51,,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,1,,,,,8,,14165,B,,Autocuration,CHEMBL615757,BAO_0000019,908
,,H,,,51,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,1,,,,,8,,5732,B,,Autocuration,CHEMBL615758,BAO_0000357,909
,,H,,,51,,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,1,,,,,8,,13366,B,,Expert,CHEMBL615759,BAO_0000357,910
,,H,,,51,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,1,,,,,8,,17626,B,,Autocuration,CHEMBL615760,BAO_0000357,911
,,H,308.0,,51,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,1,,HeLa,,,8,,6588,B,,Expert,CHEMBL615761,BAO_0000219,912
,,H,,,51,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,1,,,,,8,,16209,B,,Autocuration,CHEMBL872104,BAO_0000357,913
,,H,,,51,,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,1,,,,,8,,15463,B,,Autocuration,CHEMBL615762,BAO_0000357,914
,,H,,,51,,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,1,,,,,8,,15463,B,,Autocuration,CHEMBL615763,BAO_0000357,915
,,H,,,51,,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,1,,,,,8,,14770,B,,Autocuration,CHEMBL615764,BAO_0000357,916
,,H,1167.0,,51,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),1,,Cell line,,,8,,16245,B,,Autocuration,CHEMBL615765,BAO_0000219,917
,,H,,,51,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),1,,,,,8,,16245,B,,Autocuration,CHEMBL615766,BAO_0000019,918
,,H,,,51,,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,1,,,,,8,,5548,B,,Autocuration,CHEMBL615767,BAO_0000357,919
,,H,,,51,,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,,,,8,,5548,B,,Expert,CHEMBL615768,BAO_0000357,920
,,H,,,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,,,,8,,5548,B,,Autocuration,CHEMBL615769,BAO_0000357,921
,,H,,,51,,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,1,,,,,8,,6876,B,,Expert,CHEMBL615770,BAO_0000357,922
,,H,,,51,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,,,,8,,2598,B,,Autocuration,CHEMBL615771,BAO_0000357,923
,,H,,,51,,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,1,,,,,8,,17785,B,,Expert,CHEMBL615772,BAO_0000357,924
,,H,,,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,,,,,8,,6013,B,,Autocuration,CHEMBL615773,BAO_0000357,925
,,H,,,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,1,,,,,8,,5929,B,,Expert,CHEMBL615774,BAO_0000357,926
,,H,,,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,,,,8,,16633,B,,Autocuration,CHEMBL615775,BAO_0000357,927
,,H,,,51,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,1,,,,,8,,1558,B,,Autocuration,CHEMBL615776,BAO_0000357,928
,,H,,,51,,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,,,,8,,16026,B,,Expert,CHEMBL615777,BAO_0000357,929
,,H,,,51,,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,1,,,,,8,,12469,B,,Autocuration,CHEMBL615778,BAO_0000219,930
,,D,,,51,9606.0,Homo sapiens,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,1,,,,,9,,15874,B,,Expert,CHEMBL615779,BAO_0000357,931
,,H,,,51,,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,1,,,,,8,,15874,B,,Autocuration,CHEMBL615780,BAO_0000357,932
,,H,,,51,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,1,,,,,8,,3935,B,,Autocuration,CHEMBL616298,BAO_0000357,933
,,H,,,51,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,1,,,,,8,,15818,B,,Autocuration,CHEMBL616299,BAO_0000357,934
,,H,485.0,,51,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,1,,CHO-K1,,,8,,13706,B,,Autocuration,CHEMBL616300,BAO_0000219,935
,,H,485.0,,51,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,1,,CHO-K1,,,8,,13729,F,,Expert,CHEMBL616301,BAO_0000219,936
,,H,,,51,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,1,,,,,8,,15413,B,,Autocuration,CHEMBL616302,BAO_0000019,937
,,H,,,51,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),1,,,,,8,,15413,B,,Autocuration,CHEMBL616117,BAO_0000019,938
,,H,,,51,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),1,,,,,8,,15413,B,,Autocuration,CHEMBL616118,BAO_0000019,939
,,H,,,51,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,1,,,,,8,,15413,B,,Autocuration,CHEMBL616119,BAO_0000019,940
,,D,308.0,,51,9606.0,Homo sapiens,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,1,,HeLa,,,9,,3445,B,,Expert,CHEMBL616120,BAO_0000219,941
,,H,,,51,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,1,,,,,8,,15740,B,,Autocuration,CHEMBL616121,BAO_0000357,942
,,H,,,51,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,1,,,,,8,,15740,B,,Autocuration,CHEMBL616122,BAO_0000357,943
,,H,,,51,,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,1,,,,,8,,17626,B,,Autocuration,CHEMBL616123,BAO_0000357,944
,,D,,,51,9606.0,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,1,,,,,9,,4234,B,,Expert,CHEMBL616124,BAO_0000357,945
,,H,,,51,,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,1,,,,,8,,5640,B,,Expert,CHEMBL616125,BAO_0000357,946
,,H,,,51,10116.0,Rattus norvegicus,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,1,,,,,8,,5272,B,,Expert,CHEMBL616126,BAO_0000357,947
,,H,449.0,,51,,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,1,,CHO,,,8,,4622,B,,Autocuration,CHEMBL616127,BAO_0000219,948
,,H,,,51,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,1,,,,,8,,17085,B,,Expert,CHEMBL616128,BAO_0000019,949
,,H,,,51,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,1,,,,,8,,3025,B,,Autocuration,CHEMBL616129,BAO_0000357,950
,,H,,,51,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,1,,,,,8,,15315,B,,Expert,CHEMBL616130,BAO_0000357,951
,,H,,,51,,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,1,,,,,8,,15267,B,,Autocuration,CHEMBL616131,BAO_0000357,952
,,H,308.0,,51,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,1,,HeLa,,,8,,17158,B,,Autocuration,CHEMBL616132,BAO_0000219,953
,,D,308.0,,51,9606.0,Homo sapiens,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,1,,HeLa,,,9,,14214,B,,Expert,CHEMBL616133,BAO_0000219,954
,,H,,,51,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,,,,8,,17133,B,,Autocuration,CHEMBL616134,BAO_0000357,955
,,H,,,51,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,1,,,,,8,,16532,B,,Autocuration,CHEMBL616135,BAO_0000357,956
,,D,,,51,9606.0,Homo sapiens,Affinity for 5-hydroxytryptamine 1A receptor subtype,1,,,,,9,,2391,B,,Expert,CHEMBL616136,BAO_0000357,957
,,H,,,51,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,1,,,,,8,,14447,B,,Autocuration,CHEMBL616137,BAO_0000019,958
,,H,,,51,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,1,,,,,8,,14447,B,,Autocuration,CHEMBL872105,BAO_0000019,959
,,H,,,51,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,1,,,,,8,,15086,B,,Autocuration,CHEMBL616138,BAO_0000357,960
,,D,,,51,9606.0,Homo sapiens,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,1,,,,,9,,13051,B,,Expert,CHEMBL616139,BAO_0000357,961
,,H,,,51,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",1,,,,,8,,16026,F,,Autocuration,CHEMBL616140,BAO_0000019,962
,,H,,,51,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,1,,,,,8,,17085,B,,Expert,CHEMBL616141,BAO_0000019,963
,,H,,,51,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,,,,8,,17133,B,,Autocuration,CHEMBL616142,BAO_0000357,964
,,H,,,51,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,1,,,,,8,,17133,B,,Autocuration,CHEMBL616143,BAO_0000357,965
,,H,308.0,,51,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,1,,HeLa,,,8,,17211,B,,Autocuration,CHEMBL616144,BAO_0000219,966
,,H,308.0,,51,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,1,,HeLa,,,8,,17211,B,,Autocuration,CHEMBL616145,BAO_0000219,967
,,H,308.0,,51,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,1,,HeLa,,,8,,17211,B,,Autocuration,CHEMBL616012,BAO_0000219,968
,,H,308.0,,51,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,1,,HeLa,,,8,,17211,B,,Autocuration,CHEMBL616013,BAO_0000219,969
,,H,,,51,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",1,,,,,8,,16394,F,,Autocuration,CHEMBL616014,BAO_0000019,970
,,H,,,51,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",1,,,,,8,,16394,F,,Autocuration,CHEMBL616015,BAO_0000019,971
,,H,,,51,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",1,,,,,8,,16394,F,,Autocuration,CHEMBL616016,BAO_0000019,972
,,H,,,51,,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,1,,,,In vivo,8,,16394,F,,Autocuration,CHEMBL616017,BAO_0000218,973
,,H,,,51,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,1,,,,,8,,16394,B,,Autocuration,CHEMBL616018,BAO_0000019,974
,,H,,,51,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,1,,,,,8,,15740,F,,Autocuration,CHEMBL616019,BAO_0000019,975
,,H,,,51,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,1,,,,,8,,15740,F,,Autocuration,CHEMBL616020,BAO_0000019,976
,,H,,,51,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,1,,,,,8,,15740,B,,Autocuration,CHEMBL858018,BAO_0000357,977
,,H,722.0,,51,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,1,,HEK293,,,8,,17296,F,,Autocuration,CHEMBL616021,BAO_0000219,978
,,H,,,51,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",1,,,,,8,,5640,F,,Expert,CHEMBL616022,BAO_0000019,979
,,H,,,51,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",1,,,,,8,,5640,F,,Autocuration,CHEMBL616023,BAO_0000019,980
,,H,,,51,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",1,,,,,8,,5640,F,,Autocuration,CHEMBL616024,BAO_0000019,981
,,H,,,51,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",1,,,,,8,,5640,F,,Autocuration,CHEMBL616025,BAO_0000019,982
,,H,449.0,,51,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,1,,CHO,,,8,,2759,F,,Autocuration,CHEMBL616026,BAO_0000219,983
,,H,,,51,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",1,,,,,8,,16394,F,,Autocuration,CHEMBL616027,BAO_0000019,984
,,D,,,51,9606.0,Homo sapiens,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",1,,,,,9,,16394,F,,Expert,CHEMBL616028,BAO_0000019,985
,,D,,,51,9606.0,Homo sapiens,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,1,,,,,9,,3445,F,,Expert,CHEMBL616029,BAO_0000019,986
,,H,449.0,,51,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,1,,CHO,,,8,,4316,B,,Expert,CHEMBL616030,BAO_0000219,987
,,H,,,51,,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,1,,,,,8,,4316,B,,Expert,CHEMBL616031,BAO_0000019,988
,,D,,,51,9606.0,Homo sapiens,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,1,,,,,9,,15180,F,,Expert,CHEMBL616032,BAO_0000019,989
,,D,,,51,9606.0,Homo sapiens,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,1,,,,,9,,15180,F,,Expert,CHEMBL616033,BAO_0000019,990
,,H,,,51,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,1,,,,,8,,15042,F,,Autocuration,CHEMBL616034,BAO_0000019,991
,,H,,,51,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,1,,,,,8,,15042,F,,Autocuration,CHEMBL616035,BAO_0000019,992
,,H,,,51,,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,1,,,,,8,,15042,F,,Autocuration,CHEMBL616036,BAO_0000019,993
,,H,,,51,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,1,,,,,8,,15042,F,,Autocuration,CHEMBL616037,BAO_0000019,994
,,H,,,51,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,1,,,,,8,,15042,F,,Autocuration,CHEMBL616038,BAO_0000019,995
,,H,,,51,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,1,,,,,8,,15042,F,,Autocuration,CHEMBL616039,BAO_0000019,996
,,H,,,51,,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,1,,,,,8,,15042,F,,Autocuration,CHEMBL616040,BAO_0000019,997
,,D,308.0,,51,9606.0,Homo sapiens,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,1,,HeLa,,,9,,15180,F,,Expert,CHEMBL616041,BAO_0000219,998
,,D,308.0,,51,9606.0,Homo sapiens,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,1,,HeLa,,,9,,15180,F,,Expert,CHEMBL616042,BAO_0000219,999
,,D,308.0,,51,9606.0,Homo sapiens,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,1,,HeLa,,,9,,15180,F,,Expert,CHEMBL616043,BAO_0000219,1000
,,H,,,51,,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",1,,,,,8,,16245,F,,Autocuration,CHEMBL616044,BAO_0000019,1001
,,H,,,51,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",1,,,,,8,,16026,F,,Autocuration,CHEMBL616045,BAO_0000019,1002
,,H,722.0,,51,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,1,,HEK293,,,8,,17296,F,,Autocuration,CHEMBL616046,BAO_0000219,1003
,,H,449.0,,51,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),1,,CHO,,,8,,2759,F,,Autocuration,CHEMBL616047,BAO_0000219,1004
,,H,449.0,,51,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,1,,CHO,,,8,,2759,F,,Autocuration,CHEMBL616048,BAO_0000219,1005
,,D,449.0,,51,9606.0,Homo sapiens,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),1,,CHO,,,9,,2759,F,,Expert,CHEMBL616049,BAO_0000219,1006
,,H,449.0,,51,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),1,,CHO,,,8,,2759,F,,Autocuration,CHEMBL616050,BAO_0000219,1007
,,H,,,51,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,1,,,,,8,,15419,F,,Expert,CHEMBL616051,BAO_0000219,1008
,,H,,,51,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,1,,,,,8,,15419,F,,Autocuration,CHEMBL616212,BAO_0000219,1009
,,H,,,51,,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",1,,,,,8,,16026,F,,Autocuration,CHEMBL616213,BAO_0000019,1010
,,H,,,51,,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,1,,,,In vitro,8,,1414,B,,Expert,CHEMBL616214,BAO_0000219,1011
,,H,,,51,,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,1,,,,In vitro,8,,1414,B,,Expert,CHEMBL616215,BAO_0000219,1012
,,H,,,51,,,Binding activity radioligand.,1,,,,,8,,12861,B,,Autocuration,CHEMBL616216,BAO_0000357,1013
,,H,,,51,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,1,,,,,8,,12861,B,,Autocuration,CHEMBL616217,BAO_0000019,1014
,,H,,,51,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,1,,,,,8,,5104,B,,Autocuration,CHEMBL616218,BAO_0000357,1015
,,H,,,51,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,1,,,,,8,,5105,B,,Autocuration,CHEMBL616219,BAO_0000357,1016
,,H,,,51,,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,1,,,,,8,,16312,B,,Autocuration,CHEMBL616220,BAO_0000357,1017
,,D,,,51,9606.0,Homo sapiens,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,1,,,,,9,,15180,B,,Expert,CHEMBL833493,BAO_0000357,1018
,,H,,,51,,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,1,,,,,8,,5033,B,,Autocuration,CHEMBL616221,BAO_0000357,1019
,,D,449.0,,51,9606.0,Homo sapiens,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,1,,CHO,,,9,,16909,B,,Expert,CHEMBL616222,BAO_0000219,1020
,,H,,,51,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,1,,,,,8,,2590,F,,Autocuration,CHEMBL616223,BAO_0000019,1021
,,H,,,51,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,1,,,,,8,,2590,F,,Autocuration,CHEMBL616224,BAO_0000019,1022
,,H,,,51,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,1,,,,,8,,16394,B,,Expert,CHEMBL616225,BAO_0000019,1023
,,D,722.0,,51,9606.0,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,1,,HEK293,,,9,,4540,B,,Expert,CHEMBL616226,BAO_0000219,1024
,,H,722.0,,51,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,1,,HEK293,,,8,,17296,B,,Autocuration,CHEMBL616227,BAO_0000219,1025
,,H,722.0,,51,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,1,,HEK293,,,8,,17296,B,,Autocuration,CHEMBL616228,BAO_0000219,1026
,,H,722.0,,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,1,,HEK293,,,8,,15779,B,,Autocuration,CHEMBL616229,BAO_0000219,1027
,,H,722.0,,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,1,,HEK293,,,8,,15779,B,,Autocuration,CHEMBL616230,BAO_0000219,1028
,,H,722.0,,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,1,,HEK293,,,8,,15779,B,,Autocuration,CHEMBL616231,BAO_0000219,1029
,,H,,,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,1,,,,,8,,6166,B,,Autocuration,CHEMBL616232,BAO_0000357,1030
,,H,722.0,,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,1,,HEK293,,,8,,15779,B,,Autocuration,CHEMBL616233,BAO_0000219,1031
,,H,722.0,,51,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,1,,HEK293,,,8,,4199,B,,Autocuration,CHEMBL857973,BAO_0000219,1032
,,H,,,51,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,1,,,,,8,,15316,B,,Autocuration,CHEMBL616234,BAO_0000219,1033
,,H,,,51,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,1,,,,,8,,14875,B,,Autocuration,CHEMBL616235,BAO_0000357,1034
,,H,308.0,,51,,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,1,,HeLa,,,8,,14727,B,,Expert,CHEMBL616236,BAO_0000219,1035
,,H,,,51,,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,1,,,,,8,,14727,B,,Expert,CHEMBL616237,BAO_0000019,1036
,,H,722.0,,51,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,1,,HEK293,,,8,,15146,B,,Autocuration,CHEMBL616238,BAO_0000219,1037
,,H,722.0,,51,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,1,,HEK293,,,8,,5213,B,,Autocuration,CHEMBL616239,BAO_0000219,1038
,,H,,,51,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,1,,,,,8,,16429,B,,Autocuration,CHEMBL616240,BAO_0000219,1039
,,D,308.0,,51,9606.0,Homo sapiens,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,1,,HeLa,,,9,,15042,B,,Expert,CHEMBL616241,BAO_0000219,1040
,,H,722.0,,51,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,1,,HEK293,,,8,,14818,B,,Autocuration,CHEMBL616242,BAO_0000219,1041
,,H,722.0,,51,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",1,,HEK293,,,8,,4829,B,,Autocuration,CHEMBL616243,BAO_0000219,1042
,,D,,,51,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,1,,,,,9,,17200,B,,Expert,CHEMBL616244,BAO_0000357,1043
,,D,,,51,9606.0,Homo sapiens,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,1,,,,,9,,13051,B,,Autocuration,CHEMBL616245,BAO_0000357,1044
,,H,,,106,,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,1,,,,,8,,5486,B,,Autocuration,CHEMBL616246,BAO_0000357,1045
,,H,,,105,,,Binding affinity against 5-HT1D receptor,1,,,,,8,,5254,B,,Autocuration,CHEMBL616247,BAO_0000357,1046
,,H,,,105,,,Binding affinity against 5-hydroxytryptamine 1A receptor,1,,,,,8,,5254,B,,Autocuration,CHEMBL616248,BAO_0000357,1047
,,H,,,107,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,1,,,,,8,,15331,B,,Autocuration,CHEMBL616249,BAO_0000357,1048
,,H,,,10576,9606.0,Homo sapiens,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,1,,,,,8,,13506,B,,Autocuration,CHEMBL616250,BAO_0000357,1049
,,H,,,51,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,1,,,,,8,,15267,B,,Autocuration,CHEMBL616251,BAO_0000357,1050
,,H,,,11863,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,1,,,,In vivo,8,,16616,F,,Autocuration,CHEMBL616252,BAO_0000218,1051
,,H,,,11863,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,1,,,,In vivo,8,,16616,F,,Autocuration,CHEMBL616253,BAO_0000218,1052
,,H,,,11863,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,1,,,,In vivo,8,,16616,F,,Autocuration,CHEMBL616254,BAO_0000218,1053
,,D,,,11863,10090.0,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,1,,,,,9,,16616,F,,Expert,CHEMBL616255,BAO_0000218,1054
,,D,,,11863,10090.0,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,1,,,,,9,,16616,F,,Expert,CHEMBL832872,BAO_0000218,1055
,,D,,,11863,10090.0,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,1,,,,,9,,16616,F,,Expert,CHEMBL616256,BAO_0000218,1056
,,D,,,11863,10090.0,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,1,,,,,9,,16616,F,,Expert,CHEMBL616257,BAO_0000218,1057
,,D,,,11863,10090.0,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,1,,,,,9,,16616,F,,Expert,CHEMBL616258,BAO_0000218,1058
,,D,,,11863,10090.0,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,1,,,,,9,,16616,F,,Expert,CHEMBL616384,BAO_0000218,1059
,,H,,,11863,,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,1,Hippocampus,,,,8,,10297,B,10000000.0,Autocuration,CHEMBL616385,BAO_0000221,1060
,,H,,,11863,,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,1,,,,,8,,13704,B,,Expert,CHEMBL616386,BAO_0000357,1061
,,D,,,11863,10090.0,Mus musculus,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,1,Hippocampus,,,,9,,10297,B,10000000.0,Expert,CHEMBL616387,BAO_0000221,1062
,,H,,,11863,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,1,Hippocampus,,,,8,,10297,B,10000000.0,Autocuration,CHEMBL616388,BAO_0000221,1063
,,D,,,11863,10090.0,Mus musculus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,1,Hippocampus,,,,9,,10297,B,10000000.0,Expert,CHEMBL616389,BAO_0000221,1064
,,H,,,11863,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,1,Hippocampus,,,,8,,10297,B,10000000.0,Autocuration,CHEMBL616390,BAO_0000221,1065
,,H,,,11863,,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,1,,,,,8,,217,B,,Autocuration,CHEMBL616391,BAO_0000357,1066
,,D,,,11863,10090.0,Mus musculus,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,1,Hippocampus,,,,9,,10297,B,10000000.0,Expert,CHEMBL616392,BAO_0000221,1067
,,H,,,51,9823.0,Sus scrofa,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,1,,,,,8,,4921,B,,Autocuration,CHEMBL616393,BAO_0000357,1068
,,H,,,51,9823.0,Sus scrofa,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,1,,,,,8,,4921,B,,Autocuration,CHEMBL616394,BAO_0000357,1069
,,H,,,51,9823.0,Sus scrofa,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,1,,,,,8,,4996,B,,Autocuration,CHEMBL616395,BAO_0000019,1070
,,H,,,51,9823.0,Sus scrofa,Compound was evaluated for the binding affinity at 5- HT1A receptor,1,,,,,8,,12918,B,,Autocuration,CHEMBL616396,BAO_0000357,1071
,,H,,,51,9823.0,Sus scrofa,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,1,,,,,8,,5333,B,,Autocuration,CHEMBL872907,BAO_0000019,1072
,,H,,,51,9823.0,Sus scrofa,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,1,,,,,8,,4437,B,,Autocuration,CHEMBL616397,BAO_0000019,1073
,,H,,,51,9823.0,Sus scrofa,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,1,,,,,8,,1742,B,,Autocuration,CHEMBL616398,BAO_0000019,1074
,,H,,,51,9823.0,Sus scrofa,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,1,,,,,8,,16688,B,,Expert,CHEMBL616399,BAO_0000357,1075
,,H,,,51,9823.0,Sus scrofa,Binding activity radioligand.,1,,,,,8,,12861,B,,Autocuration,CHEMBL857065,BAO_0000357,1076
,,H,,,51,9823.0,Sus scrofa,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,1,,,,,8,,12861,B,,Expert,CHEMBL616400,BAO_0000019,1077
,,H,,,51,9823.0,Sus scrofa,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,1,,,,,8,,12861,B,,Autocuration,CHEMBL616401,BAO_0000019,1078
,,H,,,10624,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,1,,,,,8,,12490,B,,Expert,CHEMBL616402,BAO_0000019,1079
,,H,,,51,9823.0,Sus scrofa,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,1,,,,,8,,11828,B,,Expert,CHEMBL616403,BAO_0000019,1080
,,H,,,51,9823.0,Sus scrofa,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,1,Hippocampus,,,,8,,11866,B,10000000.0,Autocuration,CHEMBL616404,BAO_0000221,1081
,,H,,,51,9823.0,Sus scrofa,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,1,,,,,8,,12827,B,,Autocuration,CHEMBL616405,BAO_0000249,1082
,,H,,,51,9823.0,Sus scrofa,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,1,,,,,8,,12918,B,,Autocuration,CHEMBL616406,BAO_0000019,1083
,,H,,,51,9823.0,Sus scrofa,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,1,,,,,8,,12919,F,,Expert,CHEMBL616407,BAO_0000019,1084
,,H,,,51,9986.0,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,1,,,,,8,,13047,B,,Autocuration,CHEMBL616408,BAO_0000019,1085
,,D,,,10576,10116.0,Rattus norvegicus,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,1,,,,,9,,15796,B,,Expert,CHEMBL616409,BAO_0000249,1086
,,D,,,10576,10116.0,Rattus norvegicus,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",1,Hippocampus,,,,9,,3651,B,10000000.0,Expert,CHEMBL616410,BAO_0000221,1087
,,H,,,10576,,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,1,,,,,8,,188,B,,Autocuration,CHEMBL616411,BAO_0000357,1088
,Membranes,D,,,10576,10116.0,Rattus norvegicus,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",1,,,,,9,,16616,F,,Expert,CHEMBL616412,BAO_0000249,1089
,Membranes,D,,,10576,10116.0,Rattus norvegicus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",1,Hippocampus,,,,9,,16616,F,10000000.0,Expert,CHEMBL616413,BAO_0000249,1090
,,H,,,10576,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,1,Hippocampus,,,,8,,12306,B,10000000.0,Autocuration,CHEMBL616414,BAO_0000221,1091
,,D,,,10576,10116.0,Rattus norvegicus,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,1,Hippocampus,,,,9,,17167,B,10000000.0,Expert,CHEMBL616415,BAO_0000221,1092
,,H,,,10576,,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,1,,,,,8,,14776,B,,Autocuration,CHEMBL616416,BAO_0000019,1093
,,H,,,10576,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,1,,,,,8,,12158,B,,Expert,CHEMBL616417,BAO_0000357,1094
,,H,,,10576,,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,1,,,,,8,,13481,B,,Autocuration,CHEMBL616418,BAO_0000357,1095
,,H,,,10576,,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,1,,,,In vitro,8,,13427,B,,Autocuration,CHEMBL616419,BAO_0000219,1096
,,H,,,10576,,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,1,,,,,8,,10210,B,,Autocuration,CHEMBL616420,BAO_0000357,1097
,Membranes,H,,,10576,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,1,,,,,8,,10205,B,,Autocuration,CHEMBL616421,BAO_0000249,1098
,Membranes,H,,,10576,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,1,,,,,8,,10205,B,,Autocuration,CHEMBL616422,BAO_0000249,1099
,Membranes,H,,,10576,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,1,,,,,8,,10205,B,,Expert,CHEMBL616423,BAO_0000249,1100
,,D,,,10576,10116.0,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,1,,,,,9,,12280,B,,Expert,CHEMBL616424,BAO_0000357,1101
,,H,,,10576,,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,1,,,,,8,,17386,B,,Expert,CHEMBL616425,BAO_0000357,1102
,,H,,,10576,,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,1,,,,,8,,13654,B,,Expert,CHEMBL616426,BAO_0000357,1103
,,H,,,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,1,Hippocampus,,,,8,,14423,B,10000000.0,Autocuration,CHEMBL616427,BAO_0000221,1104
,,H,,,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,1,Hippocampus,,,,8,,15412,B,10000000.0,Autocuration,CHEMBL616428,BAO_0000221,1105
,,H,,,10576,,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,1,Hippocampus,,,,8,,12073,B,10000000.0,Autocuration,CHEMBL616290,BAO_0000221,1106
,,D,,,10576,10116.0,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,1,,,,,9,,4101,B,,Expert,CHEMBL616052,BAO_0000357,1107
,,H,,,10576,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,1,,,,,8,,10062,B,,Autocuration,CHEMBL616053,BAO_0000357,1108
,,H,,,10576,,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,1,,,,,8,,6238,B,,Autocuration,CHEMBL616054,BAO_0000249,1109
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,,,,,8,,16273,B,,Autocuration,CHEMBL616055,BAO_0000357,1110
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,1,,,,,8,,11139,B,,Autocuration,CHEMBL616056,BAO_0000357,1111
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,1,,,,,8,,16796,B,,Expert,CHEMBL616057,BAO_0000019,1112
,,D,,,10576,10116.0,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,1,Brain,,,,9,,9548,B,955.0,Expert,CHEMBL616058,BAO_0000221,1113
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,1,Brain,,,,8,,10381,B,955.0,Autocuration,CHEMBL616059,BAO_0000221,1114
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,1,,,,,8,,13408,B,,Autocuration,CHEMBL616060,BAO_0000249,1115
,,D,,,10576,10116.0,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,1,Hippocampus,,,,9,,13825,B,10000000.0,Expert,CHEMBL616061,BAO_0000221,1116
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,1,Hippocampus,,,,8,,11147,B,10000000.0,Expert,CHEMBL616062,BAO_0000221,1117
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,1,,,,,8,,10552,B,,Autocuration,CHEMBL616063,BAO_0000249,1118
,,H,,,10576,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",1,Striatum,,,,8,,10552,B,2435.0,Autocuration,CHEMBL616064,BAO_0000249,1119
,Membranes,D,,,10576,10116.0,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,1,,,,,9,,17136,B,,Expert,CHEMBL616065,BAO_0000249,1120
,Membranes,D,,,10576,10116.0,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,1,,,,,9,,5778,B,,Expert,CHEMBL616066,BAO_0000249,1121
,,H,,,10576,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,Hippocampus,,,,8,,13481,B,10000000.0,Autocuration,CHEMBL616067,BAO_0000221,1122
,,H,,,10576,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,1,Hippocampus,,,,8,,13481,B,10000000.0,Autocuration,CHEMBL616068,BAO_0000221,1123
,,H,,,10576,,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,1,Hippocampus,,,,8,,13630,B,10000000.0,Intermediate,CHEMBL616069,BAO_0000221,1124
,,H,,,10576,,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,1,,,,,8,,16245,B,,Expert,CHEMBL616070,BAO_0000249,1125
,,H,,,10576,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,1,Hippocampus,,,,8,,14509,B,10000000.0,Autocuration,CHEMBL616071,BAO_0000221,1126
,,H,,,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,1,Hippocampus,,,,8,,14509,B,10000000.0,Expert,CHEMBL616072,BAO_0000221,1127
,,H,,,10576,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,1,Hippocampus,,,,8,,14509,B,10000000.0,Autocuration,CHEMBL616073,BAO_0000221,1128
,,H,,,10576,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,1,Hippocampus,,,,8,,14509,B,10000000.0,Autocuration,CHEMBL616074,BAO_0000221,1129
,,H,,,10576,,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,1,,,,,8,,14256,B,,Expert,CHEMBL616075,BAO_0000019,1130
,,H,,,10576,,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,1,,,,,8,,11139,B,,Autocuration,CHEMBL616076,BAO_0000357,1131
,,D,,,10576,10116.0,Rattus norvegicus,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,1,,,,,9,,11047,B,,Expert,CHEMBL616077,BAO_0000019,1132
,,D,,,10576,10116.0,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,1,,,,,9,,11047,B,,Expert,CHEMBL616078,BAO_0000019,1133
,,D,,,10576,10116.0,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,1,,,,,9,,11047,B,,Expert,CHEMBL616079,BAO_0000019,1134
,,D,485.0,,10576,10116.0,Rattus norvegicus,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,1,,CHO-K1,,,9,,2395,B,,Expert,CHEMBL616080,BAO_0000219,1135
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,,,,,8,,9699,B,,Autocuration,CHEMBL616081,BAO_0000357,1136
,,D,,,10576,10116.0,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,1,Hippocampus,,,,9,,12028,B,10000000.0,Expert,CHEMBL616082,BAO_0000221,1137
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,1,Hippocampus,,,,8,,12028,B,10000000.0,Autocuration,CHEMBL616083,BAO_0000221,1138
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,1,,,,,8,,5815,B,,Autocuration,CHEMBL616084,BAO_0000019,1139
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,1,,,,,8,,16616,B,,Expert,CHEMBL616085,BAO_0000019,1140
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,1,,,,,8,,5815,B,,Autocuration,CHEMBL616086,BAO_0000019,1141
,,H,,,10576,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",1,Hippocampus,,,,8,,2761,B,10000000.0,Autocuration,CHEMBL616087,BAO_0000221,1142
,,H,,,10576,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,1,,,,,8,,13133,B,,Expert,CHEMBL616088,BAO_0000357,1143
,,H,,,10576,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,1,,,,,8,,10444,B,,Autocuration,CHEMBL616089,BAO_0000019,1144
,,D,,,10576,10116.0,Rattus norvegicus,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,1,,,,,9,,13278,B,,Expert,CHEMBL616090,BAO_0000357,1145
,,H,,,10576,,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,1,,,,,8,,15874,B,,Autocuration,CHEMBL616091,BAO_0000357,1146
,Membranes,H,,,10576,,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",1,Striatum,,,,8,,10552,B,2435.0,Autocuration,CHEMBL616092,BAO_0000249,1147
,,H,,,10576,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),1,,,,,8,,11130,B,,Autocuration,CHEMBL616093,BAO_0000357,1148
,,H,,,10576,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),1,,,,In vivo,8,,11130,B,,Autocuration,CHEMBL616094,BAO_0000218,1149
,,H,,,10576,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,1,Brain,,,,8,,14542,B,955.0,Autocuration,CHEMBL616095,BAO_0000221,1150
,,D,,,10576,10116.0,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,1,,,,,9,,13670,B,,Expert,CHEMBL616096,BAO_0000357,1151
,,H,,,10576,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,1,,,,,8,,9888,B,,Expert,CHEMBL616097,BAO_0000249,1152
,Membranes,D,,,10576,10116.0,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,1,,,,,9,,3678,B,,Expert,CHEMBL616098,BAO_0000249,1153
,,H,,,10576,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,1,Hippocampus,,,,8,,11332,B,10000000.0,Autocuration,CHEMBL616099,BAO_0000221,1154
,,H,,,10576,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,1,Hippocampus,,,,8,,11332,B,10000000.0,Autocuration,CHEMBL616100,BAO_0000221,1155
,,H,,,10576,,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,1,,,,,8,,1185,B,,Expert,CHEMBL616101,BAO_0000357,1156
,,H,,,10576,,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,1,,,,,8,,2014,B,,Expert,CHEMBL616102,BAO_0000249,1157
,,H,,,10576,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,1,,,,,8,,1185,B,,Autocuration,CHEMBL616103,BAO_0000357,1158
,,H,,,10576,,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,1,,,,,8,,14429,B,,Expert,CHEMBL616104,BAO_0000019,1159
,,H,,,10576,,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",1,,,,,8,,16288,B,,Expert,CHEMBL616105,BAO_0000019,1160
,,D,,,10576,10116.0,Rattus norvegicus,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,1,,,,,9,,5432,B,,Expert,CHEMBL616106,BAO_0000019,1161
,,H,,,10576,,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,1,,,,,8,,14429,B,,Autocuration,CHEMBL616107,BAO_0000019,1162
,,H,,,10576,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,1,,,,,8,,13672,B,,Expert,CHEMBL616108,BAO_0000357,1163
,,H,,,10576,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,1,Hippocampus,,,,8,,11296,B,10000000.0,Expert,CHEMBL616109,BAO_0000221,1164
,,H,,,10576,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,1,,,,,8,,11296,B,,Autocuration,CHEMBL616110,BAO_0000357,1165
,,H,449.0,,10576,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,1,,CHO,,,8,,14749,B,,Expert,CHEMBL616111,BAO_0000219,1166
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,1,,,,,8,,15086,B,,Expert,CHEMBL616112,BAO_0000019,1167
,,H,,,10576,,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,1,Hippocampus,,,,8,,13462,B,10000000.0,Autocuration,CHEMBL616113,BAO_0000221,1168
,,H,,,10576,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,1,,,,,8,,15363,B,,Autocuration,CHEMBL616114,BAO_0000019,1169
,,H,,,10576,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,1,,,,,8,,15363,B,,Autocuration,CHEMBL616115,BAO_0000019,1170
,,H,,,10576,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,1,,,,,8,,10796,B,,Autocuration,CHEMBL616116,BAO_0000357,1171
,,H,,,10576,,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,1,Brain,,,,8,,12816,B,955.0,Expert,CHEMBL615844,BAO_0000221,1172
,,H,,,10576,,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,1,Hippocampus,,,,8,,13542,B,10000000.0,Expert,CHEMBL615939,BAO_0000221,1173
,,H,,,10576,,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,1,,,,,8,,13308,B,,Expert,CHEMBL615940,BAO_0000019,1174
,,H,,,10576,,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,1,Hippocampus,,,,8,,13541,B,10000000.0,Expert,CHEMBL615941,BAO_0000221,1175
,,H,,,10576,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,1,Hippocampus,,,,8,,10058,B,10000000.0,Autocuration,CHEMBL615942,BAO_0000221,1176
,,H,,,10576,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,1,Hippocampus,,,,8,,10058,B,10000000.0,Autocuration,CHEMBL615943,BAO_0000221,1177
,,H,,,10576,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,1,Hippocampus,,,,8,,10058,B,10000000.0,Autocuration,CHEMBL615944,BAO_0000221,1178
,,H,,,10576,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,1,Hippocampus,,,,8,,10058,B,10000000.0,Autocuration,CHEMBL615945,BAO_0000221,1179
,,H,,,10576,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,1,Hippocampus,,,,8,,10058,B,10000000.0,Autocuration,CHEMBL615946,BAO_0000221,1180
,,H,,,10576,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,1,Hippocampus,,,,8,,10058,B,10000000.0,Autocuration,CHEMBL615947,BAO_0000221,1181
,,H,,,10576,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,1,Hippocampus,,,,8,,10058,B,10000000.0,Autocuration,CHEMBL615948,BAO_0000221,1182
,,H,,,10576,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,1,Hippocampus,,,,8,,10058,B,10000000.0,Autocuration,CHEMBL615949,BAO_0000221,1183
,,H,,,10576,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,1,Hippocampus,,,,8,,10058,B,10000000.0,Autocuration,CHEMBL615950,BAO_0000221,1184
,,H,,,10576,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,1,Hippocampus,,,,8,,10058,B,10000000.0,Autocuration,CHEMBL615951,BAO_0000221,1185
,,H,,,10576,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,1,Hippocampus,,,,8,,10058,B,10000000.0,Autocuration,CHEMBL615952,BAO_0000221,1186
,,H,,,10576,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,1,Hippocampus,,,,8,,10058,B,10000000.0,Autocuration,CHEMBL615953,BAO_0000221,1187
,,H,,,10576,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,1,Hippocampus,,,,8,,10058,B,10000000.0,Autocuration,CHEMBL615954,BAO_0000221,1188
,,D,,,10576,10116.0,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,1,Hippocampus,,,,9,,10058,B,10000000.0,Expert,CHEMBL615955,BAO_0000221,1189
,,H,,,10576,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,1,Hippocampus,,,,8,,10058,B,10000000.0,Autocuration,CHEMBL615956,BAO_0000221,1190
,,H,,,10576,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,1,Hippocampus,,,,8,,10058,B,10000000.0,Autocuration,CHEMBL615957,BAO_0000221,1191
,,H,,,10576,,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,1,,,,,8,,12879,B,,Expert,CHEMBL615958,BAO_0000019,1192
,,H,,,10576,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,1,,,,,8,,11964,B,,Expert,CHEMBL615959,BAO_0000019,1193
,,H,,,10576,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),1,,,,,8,,11964,B,,Autocuration,CHEMBL615960,BAO_0000019,1194
,,H,,,10576,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),1,,,,,8,,11964,B,,Autocuration,CHEMBL615961,BAO_0000019,1195
,,H,,,10576,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,1,Brain,,,,8,,9548,B,955.0,Expert,CHEMBL615962,BAO_0000221,1196
,,H,,,10576,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,1,,,,,8,,9098,B,,Expert,CHEMBL615963,BAO_0000019,1197
,,H,,,10576,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,1,,,,,8,,9098,B,,Autocuration,CHEMBL615964,BAO_0000019,1198
,,H,,,10576,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,1,,,,,8,,9098,B,,Autocuration,CHEMBL615965,BAO_0000019,1199
,,H,449.0,,10576,,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,1,,CHO,,,8,,13248,B,,Expert,CHEMBL615966,BAO_0000219,1200
,,H,,,10576,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,1,,,,,8,,3147,B,,Expert,CHEMBL615967,BAO_0000249,1201
,,H,,,10576,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,1,,,,,8,,13949,B,,Expert,CHEMBL615968,BAO_0000019,1202
,,H,449.0,,10576,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),1,,CHO,,,8,,11883,B,,Autocuration,CHEMBL615969,BAO_0000218,1203
,,H,,,10576,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),1,,,,,8,,11883,B,,Autocuration,CHEMBL615970,BAO_0000218,1204
,,D,,,10576,10116.0,Rattus norvegicus,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,1,,,,,9,,11883,B,,Expert,CHEMBL615971,BAO_0000357,1205
,Membranes,H,,,10576,,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,1,,,,,8,,15535,B,,Expert,CHEMBL615972,BAO_0000249,1206
,,H,,,10576,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,1,,,,,8,,15535,B,,Autocuration,CHEMBL615973,BAO_0000249,1207
,,H,,,10576,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,1,,,,,8,,15535,B,,Autocuration,CHEMBL615974,BAO_0000249,1208
,,D,449.0,,51,9606.0,Homo sapiens,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,1,,CHO,,,9,,16372,B,,Expert,CHEMBL615975,BAO_0000219,1209
,,H,,,10576,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,1,,,,,8,,14608,B,,Expert,CHEMBL615976,BAO_0000249,1210
,,D,,,10576,10116.0,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,1,Hippocampus,,,,9,,4795,B,10000000.0,Expert,CHEMBL872106,BAO_0000221,1211
,,H,,,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,1,,,,,8,,13863,B,,Autocuration,CHEMBL615977,BAO_0000357,1212
,,H,,,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,1,,,,,8,,13863,B,,Autocuration,CHEMBL615978,BAO_0000357,1213
,,H,,,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,1,,,,,8,,13863,B,,Autocuration,CHEMBL616166,BAO_0000357,1214
,,H,,,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,1,,,,,8,,13863,B,,Autocuration,CHEMBL616167,BAO_0000357,1215
,,H,,,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,1,,,,,8,,13863,B,,Autocuration,CHEMBL616168,BAO_0000357,1216
,,H,,,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,1,,,,,8,,13863,B,,Autocuration,CHEMBL616169,BAO_0000357,1217
,,H,,,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,1,,,,,8,,13863,B,,Autocuration,CHEMBL616170,BAO_0000357,1218
,,H,,,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,1,,,,,8,,13863,B,,Autocuration,CHEMBL616171,BAO_0000357,1219
,,H,,,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,1,,,,,8,,13863,B,,Autocuration,CHEMBL616172,BAO_0000357,1220
,,H,,,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,1,,,,,8,,13863,B,,Autocuration,CHEMBL616173,BAO_0000357,1221
,,H,,,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,1,,,,,8,,13863,B,,Autocuration,CHEMBL616174,BAO_0000357,1222
,,H,,,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,1,,,,,8,,13863,B,,Autocuration,CHEMBL616175,BAO_0000357,1223
,,H,,,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,1,,,,,8,,13863,B,,Autocuration,CHEMBL616176,BAO_0000357,1224
,,H,,,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,1,,,,,8,,13863,B,,Autocuration,CHEMBL616177,BAO_0000357,1225
,,H,,,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,1,,,,,8,,13863,B,,Autocuration,CHEMBL616178,BAO_0000357,1226
,,H,,,10576,,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,1,,,,,8,,9742,B,,Autocuration,CHEMBL616179,BAO_0000019,1227
,,H,,,10576,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,1,,,,,8,,12073,B,,Autocuration,CHEMBL616180,BAO_0000357,1228
,,H,,,10576,,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,1,,,,,8,,4101,B,,Autocuration,CHEMBL616181,BAO_0000357,1229
,,H,,,10576,,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,1,,,,,8,,15360,B,,Autocuration,CHEMBL616182,BAO_0000019,1230
,,H,,,10576,,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,1,Hippocampus,,,,8,,11576,B,10000000.0,Autocuration,CHEMBL616183,BAO_0000221,1231
,,H,,,10576,,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,1,,,,,8,,5834,B,,Expert,CHEMBL615874,BAO_0000019,1232
,,D,485.0,,10576,10116.0,Rattus norvegicus,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,1,,CHO-K1,,,9,,2395,B,,Expert,CHEMBL615875,BAO_0000219,1233
,,H,,,10576,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,1,,,,,8,,1375,B,,Autocuration,CHEMBL615876,BAO_0000019,1234
,,H,,,10576,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,1,,,,,8,,1375,B,,Autocuration,CHEMBL615877,BAO_0000019,1235
,,H,,,10576,,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),1,,,,,8,,3967,B,,Autocuration,CHEMBL615878,BAO_0000357,1236
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,1,,,,,8,,12884,B,,Expert,CHEMBL615879,BAO_0000357,1237
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,1,,,,,8,,2343,B,,Expert,CHEMBL615880,BAO_0000357,1238
,,H,,,10576,,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",1,,,,,8,,11511,B,,Autocuration,CHEMBL615881,BAO_0000019,1239
,,D,,,10576,10116.0,Rattus norvegicus,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",1,,,,,9,,11511,B,,Expert,CHEMBL615882,BAO_0000019,1240
,,H,,,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,1,,,,In vivo,8,,16394,F,,Autocuration,CHEMBL615883,BAO_0000218,1241
,,H,,,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),1,,,,In vivo,8,,16394,F,,Autocuration,CHEMBL615884,BAO_0000218,1242
,,H,,,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),1,,,,In vivo,8,,16394,F,,Autocuration,CHEMBL615885,BAO_0000218,1243
,,H,,,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),1,,,,In vivo,8,,16394,F,,Autocuration,CHEMBL615886,BAO_0000218,1244
,,H,,,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),1,,,,In vivo,8,,16394,F,,Autocuration,CHEMBL615887,BAO_0000218,1245
,,H,,,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),1,,,,In vivo,8,,16394,F,,Autocuration,CHEMBL615888,BAO_0000218,1246
,,H,,,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),1,,,,In vivo,8,,16394,F,,Autocuration,CHEMBL615889,BAO_0000218,1247
,,H,,,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),1,,,,In vivo,8,,16394,F,,Autocuration,CHEMBL615890,BAO_0000218,1248
,,H,,,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),1,,,,In vivo,8,,16394,F,,Autocuration,CHEMBL615891,BAO_0000218,1249
,,H,,,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),1,,,,In vivo,8,,16394,F,,Autocuration,CHEMBL615892,BAO_0000218,1250
,,H,,,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),1,,,,In vivo,8,,16394,F,,Autocuration,CHEMBL615893,BAO_0000218,1251
,,H,,,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),1,,,,In vivo,8,,16394,F,,Autocuration,CHEMBL615894,BAO_0000218,1252
,,H,,,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),1,,,,In vivo,8,,16394,F,,Autocuration,CHEMBL615895,BAO_0000218,1253
,,H,,,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),1,,,,In vivo,8,,16394,F,,Autocuration,CHEMBL615896,BAO_0000218,1254
,,H,,,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,1,,,,In vivo,8,,16394,F,,Autocuration,CHEMBL615897,BAO_0000218,1255
,Membranes,D,,,10576,10116.0,Rattus norvegicus,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",1,,,,,9,,16616,F,,Expert,CHEMBL615898,BAO_0000249,1256
,,H,,,10576,,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,1,,,,,8,,16796,B,,Autocuration,CHEMBL615899,BAO_0000019,1257
,,H,,,10576,,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,1,,,,,8,,16796,B,,Autocuration,CHEMBL616291,BAO_0000019,1258
,,H,,,10576,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,1,,,,,8,,15629,B,,Autocuration,CHEMBL616292,BAO_0000357,1259
,,H,,,10576,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",1,,,,,8,,13241,F,,Autocuration,CHEMBL616293,BAO_0000249,1260
,,H,,,10576,,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,1,Hippocampus,,,,8,,12073,B,10000000.0,Expert,CHEMBL616294,BAO_0000221,1261
,,H,,,10576,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,1,Hippocampus,,,,8,,14286,B,10000000.0,Autocuration,CHEMBL616295,BAO_0000249,1262
,,H,,,10576,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,1,Brain,,,,8,,14542,B,955.0,Autocuration,CHEMBL616296,BAO_0000221,1263
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,1,,,,,8,,13630,F,,Autocuration,CHEMBL616297,BAO_0000019,1264
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,1,,,,,8,,13630,F,,Autocuration,CHEMBL616605,BAO_0000019,1265
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,1,,,,,8,,13630,F,,Autocuration,CHEMBL616606,BAO_0000019,1266
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,1,,,,,8,,13630,F,,Autocuration,CHEMBL616607,BAO_0000019,1267
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,1,,,,,8,,13630,F,,Expert,CHEMBL616608,BAO_0000019,1268
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,1,,,,,8,,13630,F,,Autocuration,CHEMBL616609,BAO_0000019,1269
,,D,,,10576,10116.0,Rattus norvegicus,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,1,,,,,9,,13630,F,,Expert,CHEMBL616610,BAO_0000019,1270
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,1,,,,,8,,13630,F,,Autocuration,CHEMBL616611,BAO_0000019,1271
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,1,,,,,8,,13630,F,,Expert,CHEMBL616612,BAO_0000019,1272
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,1,,,,,8,,13630,F,,Autocuration,CHEMBL616613,BAO_0000019,1273
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,1,,,,,8,,13630,F,,Expert,CHEMBL616614,BAO_0000019,1274
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,1,,,,,8,,13630,F,,Autocuration,CHEMBL616615,BAO_0000019,1275
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,1,,,,,8,,13630,F,,Expert,CHEMBL616616,BAO_0000019,1276
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,1,,,,,8,,13630,F,,Autocuration,CHEMBL616617,BAO_0000019,1277
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,1,,,,,8,,13630,F,,Autocuration,CHEMBL616618,BAO_0000019,1278
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,1,,,,,8,,13630,F,,Autocuration,CHEMBL616619,BAO_0000019,1279
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,1,,,,,8,,13630,F,,Expert,CHEMBL616620,BAO_0000019,1280
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,1,,,,,8,,13630,F,,Expert,CHEMBL616621,BAO_0000019,1281
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,1,,,,,8,,13630,F,,Autocuration,CHEMBL616622,BAO_0000019,1282
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,1,,,,,8,,13630,F,,Expert,CHEMBL616146,BAO_0000019,1283
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,1,,,,,8,,13630,F,,Autocuration,CHEMBL832873,BAO_0000019,1284
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,1,,,,,8,,13630,F,,Autocuration,CHEMBL616147,BAO_0000019,1285
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,1,,,,,8,,13630,F,,Autocuration,CHEMBL872872,BAO_0000019,1286
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,1,,,,,8,,13630,F,,Autocuration,CHEMBL616148,BAO_0000019,1287
,,H,,,10576,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,1,Hippocampus,,,,8,,9783,B,10000000.0,Autocuration,CHEMBL616149,BAO_0000221,1288
,,H,,,10576,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,1,Hippocampus,,,,8,,9783,B,10000000.0,Expert,CHEMBL616150,BAO_0000221,1289
,Membranes,D,,,10576,10116.0,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,1,,,,,9,,14331,B,,Expert,CHEMBL616151,BAO_0000249,1290
,,H,,,10576,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,1,Hippocampus,,,,8,,15260,B,10000000.0,Expert,CHEMBL872873,BAO_0000221,1291
,,H,,,10576,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,1,Hippocampus,,,,8,,15260,B,10000000.0,Autocuration,CHEMBL616670,BAO_0000221,1292
,,H,,,10576,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,1,Hippocampus,,,,8,,15260,B,10000000.0,Autocuration,CHEMBL616671,BAO_0000221,1293
,,D,,,10576,10116.0,Rattus norvegicus,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",1,,,,,9,,16616,F,,Expert,CHEMBL884861,BAO_0000249,1294
,,H,,,10576,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,1,,,,,8,,15629,B,,Autocuration,CHEMBL616672,BAO_0000357,1295
,,H,,,10576,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,1,,,,,8,,15086,B,,Autocuration,CHEMBL616673,BAO_0000019,1296
,,H,,,10576,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,1,,,,,8,,5717,F,,Expert,CHEMBL616674,BAO_0000019,1297
,,H,,,10576,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,1,,,,,8,,12652,B,,Autocuration,CHEMBL616675,BAO_0000357,1298
,,H,,,10576,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,1,Hippocampus,,,,8,,14608,B,10000000.0,Autocuration,CHEMBL616676,BAO_0000221,1299
,,H,,,10576,,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,1,Hippocampus,,,,8,,12306,B,10000000.0,Autocuration,CHEMBL616677,BAO_0000221,1300
,,H,,,10576,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,1,Hippocampus,,,,8,,12306,B,10000000.0,Autocuration,CHEMBL616678,BAO_0000221,1301
,,D,,,10576,10116.0,Rattus norvegicus,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,1,,,,,9,,15247,B,,Expert,CHEMBL616679,BAO_0000357,1302
,,H,,,10576,,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,1,Hippocampus,,,,8,,17529,B,10000000.0,Expert,CHEMBL616680,BAO_0000221,1303
,,H,,,10576,,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,1,Hippocampus,,,,8,,14826,B,10000000.0,Autocuration,CHEMBL616681,BAO_0000221,1304
,,H,,,10576,,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,1,Hippocampus,,,,8,,14826,B,10000000.0,Autocuration,CHEMBL616682,BAO_0000221,1305
,,H,,,10576,,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,1,Hippocampus,,,,8,,13241,B,10000000.0,Autocuration,CHEMBL616683,BAO_0000221,1306
,,H,,,10576,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,1,Hippocampus,,,,8,,14093,B,10000000.0,Autocuration,CHEMBL616684,BAO_0000221,1307
,,H,,,10576,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,1,Hippocampus,,,,8,,14093,B,10000000.0,Autocuration,CHEMBL616685,BAO_0000221,1308
,,H,,,10576,,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,1,Brain,,,,8,,14442,B,955.0,Autocuration,CHEMBL616686,BAO_0000221,1309
,,H,,,10576,,,Affinity for 5-hydroxytryptamine 1A receptor site,1,,,,,8,,9919,B,,Autocuration,CHEMBL616687,BAO_0000357,1310
,,H,,,10576,,,Affinity for 5-hydroxytryptamine 1A receptor site,1,,,,,8,,9919,B,,Autocuration,CHEMBL616688,BAO_0000357,1311
,,H,,,10576,,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,1,Hippocampus,,,,8,,11440,B,10000000.0,Autocuration,CHEMBL616689,BAO_0000221,1312
,,H,,,10576,,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,1,,,,,8,,11257,B,,Autocuration,CHEMBL616690,BAO_0000357,1313
,,H,,,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,1,,,,,8,,10330,B,,Expert,CHEMBL616691,BAO_0000357,1314
,,D,,,10576,10116.0,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,1,Hippocampus,,,,9,,17331,B,10000000.0,Expert,CHEMBL616692,BAO_0000221,1315
,,H,,,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,1,,,,,8,,16567,B,,Expert,CHEMBL616693,BAO_0000249,1316
,,D,,,10576,10116.0,Rattus norvegicus,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",1,,,,,9,,12058,B,,Expert,CHEMBL616694,BAO_0000019,1317
,,H,,,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,1,Hippocampus,,,,8,,9699,B,10000000.0,Autocuration,CHEMBL616695,BAO_0000221,1318
,,H,,,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,1,,,,,8,,9547,B,,Autocuration,CHEMBL616696,BAO_0000357,1319
,,H,,,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,1,,,,,8,,10330,B,,Autocuration,CHEMBL616697,BAO_0000357,1320
,,H,,,10576,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,1,,,,,8,,14331,B,,Autocuration,CHEMBL616698,BAO_0000357,1321
,,D,,,10576,10116.0,Rattus norvegicus,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,1,,,,,9,,14060,B,,Expert,CHEMBL616949,BAO_0000019,1322
,,H,,,10576,,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,1,Hippocampus,,,,8,,14744,B,10000000.0,Autocuration,CHEMBL616950,BAO_0000221,1323
,,H,,,10576,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,1,,,,,8,,13506,B,,Autocuration,CHEMBL832875,BAO_0000357,1324
,,H,,,10576,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,1,Brain,,,,8,,10862,B,955.0,Expert,CHEMBL616951,BAO_0000221,1325
,,H,,,10576,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,1,Brain,,,,8,,10862,B,955.0,Expert,CHEMBL616952,BAO_0000221,1326
,,H,,,10576,,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,1,,,,,8,,10062,B,,Expert,CHEMBL616953,BAO_0000357,1327
,,H,,,10576,,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,1,,,,,8,,12073,B,,Autocuration,CHEMBL616954,BAO_0000357,1328
,,H,,,106,,,GTPgammaS radioligand binding assay,1,,,,,8,,14875,B,,Autocuration,CHEMBL616955,BAO_0000357,1329
,,H,,,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,1,,,,,8,,2391,B,,Autocuration,CHEMBL616956,BAO_0000357,1330
,,H,,,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,1,,,,,8,,2391,F,,Autocuration,CHEMBL616957,BAO_0000019,1331
,,H,,,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,1,,,,,8,,2391,F,,Autocuration,CHEMBL616958,BAO_0000019,1332
,,H,,,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,1,,,,,8,,2391,B,,Autocuration,CHEMBL616959,BAO_0000357,1333
,,H,,,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,1,,,,,8,,2391,B,,Autocuration,CHEMBL616960,BAO_0000357,1334
,,H,,,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,1,,,,,8,,2391,F,,Autocuration,CHEMBL616961,BAO_0000019,1335
,,H,308.0,,106,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,1,,HeLa,,,8,,17211,B,,Expert,CHEMBL616962,BAO_0000219,1336
,,H,308.0,,106,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,1,,HeLa,,,8,,17211,B,,Autocuration,CHEMBL616963,BAO_0000219,1337
,,D,,,106,9606.0,Homo sapiens,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,1,,,,,9,,6491,B,,Expert,CHEMBL616524,BAO_0000357,1338
,,H,449.0,,106,,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,1,,CHO,,,8,,16190,B,,Autocuration,CHEMBL616525,BAO_0000219,1339
,,H,,,106,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,1,,,,,8,,14165,B,,Autocuration,CHEMBL872908,BAO_0000019,1340
,,H,,,106,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,1,,,,,8,,14165,B,,Autocuration,CHEMBL616526,BAO_0000019,1341
,,D,,,106,9606.0,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,1,,,,,9,,4234,B,,Expert,CHEMBL616527,BAO_0000357,1342
,,H,,,106,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,1,,,,,8,,6328,B,,Expert,CHEMBL616528,BAO_0000219,1343
,,H,,,106,,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,1,,,,,8,,14770,B,,Autocuration,CHEMBL616529,BAO_0000357,1344
,,H,,,106,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,1,,,,,8,,2598,B,,Autocuration,CHEMBL616530,BAO_0000357,1345
,,H,,,106,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,1,,,,,8,,6897,B,,Expert,CHEMBL616531,BAO_0000357,1346
,,H,,,106,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,1,,,,,8,,6897,B,,Autocuration,CHEMBL616532,BAO_0000357,1347
,,H,,,106,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,1,,,,,8,,6013,B,,Autocuration,CHEMBL616533,BAO_0000357,1348
,,H,,,106,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,1,,,,,8,,5843,B,,Expert,CHEMBL616534,BAO_0000357,1349
,,H,,,106,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,1,,,,,8,,14454,B,,Expert,CHEMBL616535,BAO_0000357,1350
,,H,,,106,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,1,,,,,8,,16209,B,,Autocuration,CHEMBL616536,BAO_0000357,1351
,,H,,,106,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,1,,,,,8,,3935,B,,Autocuration,CHEMBL616537,BAO_0000357,1352
,,H,485.0,,106,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,1,,CHO-K1,,,8,,13729,F,,Expert,CHEMBL616538,BAO_0000219,1353
,,H,,,106,,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,1,,,,,8,,14251,F,,Expert,CHEMBL616539,BAO_0000019,1354
,,H,,,106,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,1,,,,,8,,17085,B,,Expert,CHEMBL616540,BAO_0000019,1355
,,H,,,106,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,1,,,,,8,,3025,B,,Autocuration,CHEMBL616429,BAO_0000357,1356
,,H,,,106,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,1,,,,,8,,15315,B,,Expert,CHEMBL616430,BAO_0000357,1357
,,D,,,106,9606.0,Homo sapiens,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,1,,,,,9,,14214,B,,Expert,CHEMBL616431,BAO_0000219,1358
,,D,,,106,9606.0,Homo sapiens,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,1,,,,,9,,3804,B,,Expert,CHEMBL616432,BAO_0000357,1359
,,D,,,106,9606.0,Homo sapiens,Affinity for 5-hydroxytryptamine 1B receptor subtype,1,,,,,9,,2391,B,,Expert,CHEMBL616433,BAO_0000357,1360
,,D,,,106,9606.0,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1B receptor,1,,,,,9,,4175,B,,Expert,CHEMBL616434,BAO_0000357,1361
,,H,449.0,,106,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,1,,CHO,,,8,,17296,B,,Autocuration,CHEMBL616435,BAO_0000219,1362
,,H,,,106,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,1,,,,,8,,17085,B,,Expert,CHEMBL616436,BAO_0000019,1363
,,H,308.0,,106,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,1,,HeLa,,,8,,17211,B,,Autocuration,CHEMBL616437,BAO_0000219,1364
,,H,308.0,,106,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,1,,HeLa,,,8,,17211,B,,Autocuration,CHEMBL616438,BAO_0000219,1365
,,H,308.0,,106,,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,1,,HeLa,,,8,,17211,B,,Autocuration,CHEMBL616439,BAO_0000219,1366
,,D,,,106,9606.0,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,1,,,,,9,,15926,B,,Expert,CHEMBL616440,BAO_0000357,1367
,,H,485.0,,106,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,1,,CHO-K1,,,8,,16312,B,,Autocuration,CHEMBL616441,BAO_0000219,1368
,,H,,,106,,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,1,,,,,8,,5843,B,,Expert,CHEMBL616442,BAO_0000357,1369
,,H,,,106,,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,1,,,,,8,,5843,B,,Autocuration,CHEMBL616443,BAO_0000357,1370
,,H,485.0,,106,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,1,,CHO-K1,,,8,,16312,B,,Expert,CHEMBL616444,BAO_0000219,1371
,,D,,,106,9606.0,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1B receptor,1,,,,,9,,15926,B,,Expert,CHEMBL616445,BAO_0000357,1372
,,D,,,106,9606.0,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1B receptor,1,,,,,9,,15926,B,,Expert,CHEMBL616446,BAO_0000357,1373
,,D,449.0,,106,9606.0,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,1,,CHO,,,9,,4540,B,,Expert,CHEMBL616447,BAO_0000219,1374
,,H,,,106,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,1,,,,,8,,6166,B,,Autocuration,CHEMBL616448,BAO_0000357,1375
,,H,449.0,,106,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,1,,CHO,,,8,,17296,B,,Autocuration,CHEMBL616449,BAO_0000219,1376
,,H,449.0,,106,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,1,,CHO,,,8,,17296,B,,Autocuration,CHEMBL616450,BAO_0000219,1377
,,H,449.0,,106,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,1,,CHO,,,8,,17296,B,,Autocuration,CHEMBL857974,BAO_0000219,1378
,,H,449.0,,106,,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,1,,CHO,,,8,,15779,B,,Autocuration,CHEMBL616451,BAO_0000219,1379
,,H,449.0,,106,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,1,,CHO,,,8,,15779,B,,Autocuration,CHEMBL616452,BAO_0000219,1380
,,H,449.0,,106,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,1,,CHO,,,8,,15779,B,,Autocuration,CHEMBL616453,BAO_0000219,1381
,,H,449.0,,106,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,1,,CHO,,,8,,4199,B,,Autocuration,CHEMBL616454,BAO_0000219,1382
,,D,,,106,9606.0,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1B receptor,1,,,,,9,,14875,B,,Expert,CHEMBL616455,BAO_0000357,1383
,,H,449.0,,106,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,1,,CHO,,,8,,15146,B,,Autocuration,CHEMBL616456,BAO_0000219,1384
,,H,,,106,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,1,,,,,8,,5213,B,,Autocuration,CHEMBL616457,BAO_0000357,1385
,,H,449.0,,106,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,1,,CHO,,,8,,14818,B,,Autocuration,CHEMBL616458,BAO_0000219,1386
,,H,449.0,,106,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",1,,CHO,,,8,,4829,B,,Autocuration,CHEMBL616459,BAO_0000219,1387
,,H,,,106,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,1,,,,,8,,14454,F,,Expert,CHEMBL616460,BAO_0000019,1388
,,H,,,106,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,1,,,,,8,,14454,F,,Expert,CHEMBL616461,BAO_0000019,1389
,,H,449.0,,106,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",1,,CHO,,,8,,14875,F,,Autocuration,CHEMBL616462,BAO_0000219,1390
,,H,449.0,,106,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",1,,CHO,,,8,,14875,F,,Autocuration,CHEMBL616463,BAO_0000219,1391
,,H,,,105,,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",1,,,,,8,,15250,F,,Autocuration,CHEMBL616464,BAO_0000019,1392
,,H,449.0,,105,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,1,,CHO,,,8,,15250,B,,Autocuration,CHEMBL616465,BAO_0000219,1393
,,H,,,17105,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,1,,,,,8,,15086,B,,Autocuration,CHEMBL832874,BAO_0000357,1394
,,H,,,106,9986.0,Oryctolagus cuniculus,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,1,,,,,8,,3025,F,,Autocuration,CHEMBL616184,BAO_0000019,1395
,,H,,,106,9986.0,Oryctolagus cuniculus,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,1,,,,,8,,14998,B,,Autocuration,CHEMBL616185,BAO_0000019,1396
,,H,,,106,9986.0,Oryctolagus cuniculus,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",1,,,,,8,,14998,B,,Intermediate,CHEMBL616186,BAO_0000019,1397
,,H,,,106,9986.0,Oryctolagus cuniculus,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,1,,,,,8,,14998,B,,Autocuration,CHEMBL616187,BAO_0000019,1398
,,H,,,10577,,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,1,,,,,8,,13969,B,,Expert,CHEMBL616188,BAO_0000357,1399
,,D,,,10577,,,Binding affinity for 5-hydroxytryptamine 1B receptor,1,,,,,9,,13392,B,,Intermediate,CHEMBL873475,BAO_0000357,1400
,,D,,,10577,10116.0,Rattus norvegicus,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,1,Striatum,,,,9,,3651,B,2435.0,Expert,CHEMBL616189,BAO_0000019,1401
,,H,,,10577,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,1,,,,,8,,10025,B,,Expert,CHEMBL616190,BAO_0000357,1402
,,H,,,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,1,,,,,8,,13863,B,,Autocuration,CHEMBL616191,BAO_0000357,1403
,,H,,,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,1,,,,,8,,13863,B,,Autocuration,CHEMBL616192,BAO_0000357,1404
,,H,,,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,1,,,,,8,,13863,B,,Autocuration,CHEMBL616193,BAO_0000357,1405
,,H,,,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,1,,,,,8,,13863,B,,Autocuration,CHEMBL616194,BAO_0000357,1406
,,H,,,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,1,,,,,8,,13863,B,,Autocuration,CHEMBL616195,BAO_0000357,1407
,,H,,,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,1,,,,,8,,13863,B,,Autocuration,CHEMBL616196,BAO_0000357,1408
,,H,,,10576,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,1,Hippocampus,,,,8,,4622,B,10000000.0,Autocuration,CHEMBL616197,BAO_0000249,1409
,,H,,,10576,,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,1,,,,,8,,14911,B,,Intermediate,CHEMBL616198,BAO_0000019,1410
,,H,,,10576,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,1,Hippocampus,,,,8,,12678,B,10000000.0,Autocuration,CHEMBL616199,BAO_0000221,1411
,,H,,,10576,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,1,Hippocampus,,,,8,,12678,B,10000000.0,Expert,CHEMBL616200,BAO_0000221,1412
,,H,,,10576,,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,1,Hippocampus,,,,8,,14235,B,10000000.0,Expert,CHEMBL616201,BAO_0000221,1413
,,H,,,10576,,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,1,Hippocampus,,,,8,,14949,B,10000000.0,Expert,CHEMBL616202,BAO_0000221,1414
,,H,,,10576,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,1,Hippocampus,,,,8,,14949,B,10000000.0,Expert,CHEMBL616203,BAO_0000221,1415
,,H,,,10576,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,1,Hippocampus,,,,8,,14949,B,10000000.0,Expert,CHEMBL616204,BAO_0000221,1416
,,H,,,10576,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,1,Hippocampus,,,,8,,14949,B,10000000.0,Expert,CHEMBL616205,BAO_0000221,1417
,,H,,,10576,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,1,Hippocampus,,,,8,,14949,B,10000000.0,Expert,CHEMBL616206,BAO_0000221,1418
,,H,,,10576,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,1,,,,,8,,16118,B,,Expert,CHEMBL616207,BAO_0000249,1419
,,H,,,10576,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,1,,,,,8,,3268,B,,Autocuration,CHEMBL616208,BAO_0000249,1420
,,H,,,10576,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,1,,,,,8,,3268,B,,Autocuration,CHEMBL616209,BAO_0000249,1421
,,H,,,10576,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,1,,,,,8,,16117,B,,Expert,CHEMBL616210,BAO_0000357,1422
,,H,,,10576,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,1,Hippocampus,,,,8,,9783,B,10000000.0,Expert,CHEMBL616211,BAO_0000221,1423
,,H,,,10576,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,1,Hippocampus,,,,8,,9783,B,10000000.0,Autocuration,CHEMBL616504,BAO_0000221,1424
,,D,,,10576,10116.0,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,1,Hippocampus,,,,9,,14356,B,10000000.0,Expert,CHEMBL616505,BAO_0000221,1425
,,H,,,10576,,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,1,,,,,8,,15740,F,,Autocuration,CHEMBL616506,BAO_0000019,1426
,,H,,,10576,,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,1,Hippocampus,,,,8,,12306,B,10000000.0,Autocuration,CHEMBL872107,BAO_0000221,1427
,,D,,,10576,10116.0,Rattus norvegicus,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,1,Hippocampus,,,,9,,13348,B,10000000.0,Expert,CHEMBL616507,BAO_0000221,1428
,,H,,,10576,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,1,,,,,8,,10394,B,,Autocuration,CHEMBL616303,BAO_0000249,1429
,,H,,,10576,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,1,Hippocampus,,,,8,,15260,B,10000000.0,Autocuration,CHEMBL616304,BAO_0000221,1430
,,H,,,10576,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,1,Hippocampus,,,,8,,10046,B,10000000.0,Expert,CHEMBL616305,BAO_0000221,1431
,,H,,,10576,,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,1,Hippocampus,,,,8,,15260,F,10000000.0,Intermediate,CHEMBL616306,BAO_0000221,1432
,,H,,,10576,,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,1,,,,,8,,12851,B,,Autocuration,CHEMBL616307,BAO_0000357,1433
,,D,,,10576,10116.0,Rattus norvegicus,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,1,Hippocampus,,,,9,,2148,B,10000000.0,Expert,CHEMBL881829,BAO_0000221,1434
,,H,,,10576,,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,1,,,,,8,,13134,B,,Expert,CHEMBL616308,BAO_0000357,1435
,,H,,,10576,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,1,,,,,8,,12462,B,,Autocuration,CHEMBL616309,BAO_0000019,1436
,,H,,,10576,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,1,,,,,8,,12462,B,,Expert,CHEMBL616310,BAO_0000019,1437
,,H,449.0,,10576,,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,1,,CHO,,,8,,12462,B,,Autocuration,CHEMBL616311,BAO_0000219,1438
,,H,,,10576,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,1,,,,,8,,11933,B,,Expert,CHEMBL616312,BAO_0000357,1439
,,H,,,10576,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,1,,,,,8,,11933,B,,Autocuration,CHEMBL616313,BAO_0000357,1440
,,D,,,10576,10116.0,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,1,Hippocampus,,,,9,,403,B,10000000.0,Expert,CHEMBL616314,BAO_0000221,1441
,,H,,,10576,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,1,Hippocampus,,,,8,,15538,B,10000000.0,Autocuration,CHEMBL616315,BAO_0000221,1442
,,H,,,10576,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,1,Hippocampus,,,,8,,15538,B,10000000.0,Autocuration,CHEMBL616567,BAO_0000221,1443
,,H,,,10576,,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,1,Hippocampus,,,,8,,15538,B,10000000.0,Autocuration,CHEMBL616568,BAO_0000221,1444
,,H,,,10576,,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,1,,,,,8,,12464,B,,Intermediate,CHEMBL616569,BAO_0000019,1445
,,H,,,10576,,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,1,,,,,8,,1455,B,,Expert,CHEMBL616570,BAO_0000357,1446
,,H,,,10576,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,1,,,,,8,,12652,B,,Autocuration,CHEMBL616571,BAO_0000357,1447
,,H,,,10576,,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,1,Hippocampus,,,,8,,12639,B,10000000.0,Autocuration,CHEMBL616572,BAO_0000221,1448
,,H,,,10576,,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,1,,,,,8,,13949,B,,Expert,CHEMBL616573,BAO_0000249,1449
,,D,,,10576,10116.0,Rattus norvegicus,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,1,,,,,9,,12463,B,,Expert,CHEMBL616574,BAO_0000357,1450
,,H,,,10576,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,1,Hippocampus,,,,8,,14829,B,10000000.0,Expert,CHEMBL616575,BAO_0000221,1451
,,H,,,10576,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,1,Hippocampus,,,,8,,14829,B,10000000.0,Autocuration,CHEMBL872108,BAO_0000221,1452
,,H,,,10576,,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,1,,,,,8,,12092,B,,Autocuration,CHEMBL616576,BAO_0000357,1453
,,H,,,10576,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,1,,,,,8,,403,B,,Autocuration,CHEMBL616577,BAO_0000249,1454
,,H,,,10576,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,1,,,,,8,,403,B,,Autocuration,CHEMBL616578,BAO_0000249,1455
,,H,,,10576,,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,1,,,,,8,,3967,B,,Expert,CHEMBL616579,BAO_0000357,1456
,,D,,,10576,10116.0,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,1,,,,,9,,12771,B,,Expert,CHEMBL616580,BAO_0000019,1457
,,H,,,10576,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,1,,,,,8,,15086,B,,Autocuration,CHEMBL616581,BAO_0000019,1458
,,H,,,10576,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,1,Hippocampus,,,,8,,14909,B,10000000.0,Autocuration,CHEMBL616582,BAO_0000221,1459
,,H,,,10576,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,1,Hippocampus,,,,8,,14949,B,10000000.0,Expert,CHEMBL616583,BAO_0000221,1460
,,D,,,10576,10116.0,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,1,Hippocampus,,,,9,,2309,B,10000000.0,Expert,CHEMBL616584,BAO_0000221,1461
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,,,,,8,,4170,B,,Expert,CHEMBL616585,BAO_0000357,1462
,,D,,,10576,10116.0,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,1,Hippocampus,,,,9,,11642,B,10000000.0,Expert,CHEMBL616586,BAO_0000221,1463
,,H,,,10576,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,1,Hippocampus,,,,8,,11642,B,10000000.0,Autocuration,CHEMBL616587,BAO_0000221,1464
,,H,,,10576,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,1,Hippocampus,,,,8,,12953,B,10000000.0,Autocuration,CHEMBL616588,BAO_0000221,1465
,,H,,,10576,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,1,Hippocampus,,,,8,,12953,B,10000000.0,Autocuration,CHEMBL616589,BAO_0000221,1466
,,H,,,10576,,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,1,Hippocampus,,,,8,,12953,B,10000000.0,Expert,CHEMBL616590,BAO_0000221,1467
,,H,449.0,,10576,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",1,,CHO,,,8,,12903,B,,Expert,CHEMBL616591,BAO_0000219,1468
,,H,,,10576,,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,1,,,,,8,,12536,B,,Expert,CHEMBL616592,BAO_0000357,1469
,,H,,,10576,,,The inhibition activity of 5-HT1A at 1 uM,1,,,,,8,,10058,B,,Autocuration,CHEMBL616593,BAO_0000357,1470
,,H,485.0,,10576,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",1,,CHO-K1,,,8,,12902,B,,Expert,CHEMBL616594,BAO_0000219,1471
,,H,,,10576,,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,1,,,,,8,,14057,B,,Expert,CHEMBL616595,BAO_0000249,1472
,,H,,,10576,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,1,,,,,8,,11296,B,,Autocuration,CHEMBL616596,BAO_0000357,1473
,,H,,,10576,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,1,Hippocampus,,,,8,,11296,B,10000000.0,Autocuration,CHEMBL616597,BAO_0000221,1474
,,H,,,10576,,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,1,Hippocampus,,,,8,,11296,B,10000000.0,Expert,CHEMBL616598,BAO_0000221,1475
,Membranes,D,,,10576,10116.0,Rattus norvegicus,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,1,,,,,9,,16616,F,,Expert,CHEMBL616599,BAO_0000249,1476
,Membranes,D,,,10576,10116.0,Rattus norvegicus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",1,Hippocampus,,,,9,,16616,F,10000000.0,Expert,CHEMBL616600,BAO_0000249,1477
,,H,,,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,1,,,,,8,,16567,B,,Autocuration,CHEMBL616601,BAO_0000019,1478
,,H,,,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,1,,,,,8,,16567,B,,Autocuration,CHEMBL616602,BAO_0000019,1479
,,H,,,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,1,,,,,8,,16567,B,,Autocuration,CHEMBL616603,BAO_0000019,1480
,,H,,,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,1,,,,,8,,16567,B,,Autocuration,CHEMBL616604,BAO_0000019,1481
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,1,,,,,8,,17136,B,,Autocuration,CHEMBL616316,BAO_0000249,1482
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,1,,,,,8,,17136,B,,Autocuration,CHEMBL616317,BAO_0000249,1483
,,D,,,10576,10116.0,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,1,,,,,9,,16616,B,,Expert,CHEMBL616318,BAO_0000019,1484
,,H,,,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,1,Hippocampus,,,,8,,17331,B,10000000.0,Autocuration,CHEMBL616319,BAO_0000221,1485
,,H,,,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,1,Hippocampus,,,,8,,17331,B,10000000.0,Autocuration,CHEMBL616320,BAO_0000221,1486
,,D,,,10576,10116.0,Rattus norvegicus,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,1,Hippocampus,,,,9,,17167,B,10000000.0,Expert,CHEMBL616321,BAO_0000221,1487
,,H,,,10576,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,1,,,,,8,,15740,F,,Autocuration,CHEMBL616322,BAO_0000019,1488
,,H,,,10576,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,1,,,,,8,,15740,F,,Autocuration,CHEMBL616323,BAO_0000019,1489
,,H,,,10576,,,Ratio of binding affinity to 5-HT 1A and D2 receptor,1,,,,,8,,4671,B,,Autocuration,CHEMBL616324,BAO_0000357,1490
,,H,,,10576,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,1,Hippocampus,,,,8,,10058,B,10000000.0,Autocuration,CHEMBL616325,BAO_0000221,1491
,,H,,,10576,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,1,Hippocampus,,,,8,,10058,B,10000000.0,Autocuration,CHEMBL616326,BAO_0000221,1492
,,H,,,10576,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,1,Hippocampus,,,,8,,10058,B,10000000.0,Autocuration,CHEMBL616327,BAO_0000221,1493
,,H,,,10576,,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,1,,,,,8,,12073,B,,Autocuration,CHEMBL616328,BAO_0000357,1494
,,H,,,10576,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),1,,,,,8,,2759,B,,Autocuration,CHEMBL858110,BAO_0000249,1495
,,H,,,10576,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),1,,,,,8,,2759,F,,Autocuration,CHEMBL616329,BAO_0000249,1496
,,H,,,10576,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),1,,,,,8,,2759,B,,Autocuration,CHEMBL616330,BAO_0000249,1497
,,H,,,10576,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),1,,,,,8,,2759,F,,Autocuration,CHEMBL616331,BAO_0000249,1498
,,H,,,10576,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,1,,,,,8,,2759,F,,Autocuration,CHEMBL616332,BAO_0000249,1499
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,1,Brain,,,,8,,9737,B,955.0,Autocuration,CHEMBL857063,BAO_0000249,1500
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,1,,,,,8,,9737,B,,Autocuration,CHEMBL616333,BAO_0000019,1501
,,H,,,10576,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,1,,,,,8,,5717,F,,Expert,CHEMBL616334,BAO_0000019,1502
,,H,,,10576,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,1,Hippocampus,,,,8,,12253,B,10000000.0,Autocuration,CHEMBL616335,BAO_0000221,1503
,,H,,,10576,,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,1,,,,,8,,14025,B,,Autocuration,CHEMBL616336,BAO_0000019,1504
,,H,,,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,1,,,,,8,,10425,B,,Expert,CHEMBL616337,BAO_0000249,1505
,,H,,,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,1,,,,,8,,14998,B,,Autocuration,CHEMBL616338,BAO_0000019,1506
,,H,,,10576,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,1,Hippocampus,,,,8,,13694,B,10000000.0,Autocuration,CHEMBL616339,BAO_0000221,1507
,,H,,,10576,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,1,Hippocampus,,,,8,,13694,B,10000000.0,Autocuration,CHEMBL616340,BAO_0000221,1508
,,H,,,10576,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,1,,,,,8,,4342,B,,Autocuration,CHEMBL616341,BAO_0000357,1509
,,D,,,10576,10116.0,Rattus norvegicus,Binding affinity against rat 5-hydroxytryptamine 1A receptor,1,,,,,9,,12936,B,,Expert,CHEMBL616342,BAO_0000357,1510
,,D,,,10576,10116.0,Rattus norvegicus,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,1,,,,,9,,13144,B,,Expert,CHEMBL616343,BAO_0000019,1511
,,H,,,10576,,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,1,,,,,8,,13343,B,,Expert,CHEMBL616344,BAO_0000019,1512
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,1,,,,,8,,12132,B,,Expert,CHEMBL616345,BAO_0000357,1513
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,1,,,,,8,,15419,B,,Expert,CHEMBL616346,BAO_0000019,1514
,,H,,,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,1,Hippocampus,,,,8,,1479,B,10000000.0,Autocuration,CHEMBL616347,BAO_0000221,1515
,,H,,,10576,,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,1,,,,,8,,14287,B,,Expert,CHEMBL616348,BAO_0000019,1516
,,H,,,10576,,,Binding affinity at 5-hydroxytryptamine 1A receptor,1,,,,,8,,13116,B,,Expert,CHEMBL616349,BAO_0000357,1517
,Membranes,D,,,10576,10116.0,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,1,,,,,9,,2759,B,,Expert,CHEMBL616152,BAO_0000249,1518
,,H,,,10576,,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,1,,,,,8,,2759,B,,Autocuration,CHEMBL616153,BAO_0000249,1519
,,H,,,10576,,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",1,,,,,8,,14748,B,,Expert,CHEMBL616154,BAO_0000019,1520
,,H,,,10576,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,1,,,,,8,,12304,B,,Autocuration,CHEMBL616155,BAO_0000019,1521
,,D,,,10576,10116.0,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,1,Hippocampus,,,,9,,12409,B,10000000.0,Expert,CHEMBL616156,BAO_0000221,1522
,,D,,,10576,10116.0,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,1,Hippocampus,,,,9,,12409,B,10000000.0,Expert,CHEMBL616157,BAO_0000221,1523
,,H,,,10576,,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,1,Hippocampus,,,,8,,13267,B,10000000.0,Autocuration,CHEMBL616158,BAO_0000221,1524
,,H,,,10576,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,1,,,,,8,,15194,B,,Autocuration,CHEMBL616159,BAO_0000357,1525
,,H,,,10576,,,pKi value against rat 5-hydroxytryptamine 1A receptor.,1,,,,,8,,14256,B,,Expert,CHEMBL616160,BAO_0000357,1526
,,H,,,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,1,,,,,8,,16567,B,,Autocuration,CHEMBL616161,BAO_0000019,1527
,,H,,,10576,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,1,,,,,8,,15740,F,,Autocuration,CHEMBL616162,BAO_0000019,1528
,,D,,,12687,10116.0,Rattus norvegicus,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,1,,,,,9,,13278,B,,Expert,CHEMBL616163,BAO_0000357,1529
,Membranes,H,,,10626,,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,1,,,,,8,,1970,B,,Expert,CHEMBL616164,BAO_0000249,1530
,,H,,,10576,,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,1,Brain,,,,8,,10034,B,955.0,Autocuration,CHEMBL616165,BAO_0000221,1531
,,H,,,51,10116.0,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,1,,,,,8,,13348,B,,Autocuration,CHEMBL616355,BAO_0000019,1532
,,H,,,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,1,,,,,8,,13630,F,,Autocuration,CHEMBL616356,BAO_0000019,1533
,,H,,,10576,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,1,Brain,,,,8,,10862,B,955.0,Autocuration,CHEMBL616357,BAO_0000221,1534
,,H,,,10576,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",1,,,,,8,,12058,B,,Autocuration,CHEMBL616358,BAO_0000019,1535
,,H,,,51,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,1,,,,,8,,4639,B,,Autocuration,CHEMBL616359,BAO_0000357,1536
,,H,,,51,,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,1,,,,,8,,15453,B,,Expert,CHEMBL616360,BAO_0000357,1537
,,H,,,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,,,,,8,,4820,B,,Expert,CHEMBL616361,BAO_0000357,1538
,,H,,,51,,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,1,,,,,8,,1089,B,,Autocuration,CHEMBL616362,BAO_0000357,1539
,Brain membranes,H,,,51,,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,1,,,,,8,,386,B,,Autocuration,CHEMBL616363,BAO_0000249,1540
,,H,,,51,,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,1,,,,,8,,6011,B,,Autocuration,CHEMBL616364,BAO_0000357,1541
,,H,,,51,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,1,,,,,8,,5014,B,,Autocuration,CHEMBL616365,BAO_0000357,1542
,,H,,,51,,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,1,,,,,8,,4402,B,,Expert,CHEMBL616366,BAO_0000357,1543
,,H,,,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,,,,,8,,17066,B,,Expert,CHEMBL872906,BAO_0000357,1544
,,H,,,51,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,1,,,,,8,,17515,B,,Autocuration,CHEMBL616367,BAO_0000357,1545
,,H,,,51,,,Binding affinity against 5-hydroxytryptamine 1A receptor,1,,,,,8,,2474,B,,Autocuration,CHEMBL616368,BAO_0000357,1546
,,H,,,51,,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,1,,,,,8,,4775,B,,Autocuration,CHEMBL616369,BAO_0000357,1547
,,D,,,51,9606.0,Homo sapiens,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,1,,,,,9,,14294,B,,Expert,CHEMBL616370,BAO_0000357,1548
,,D,,,51,9606.0,Homo sapiens,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,1,,,,,9,,14294,B,,Expert,CHEMBL616371,BAO_0000357,1549
,,H,449.0,,51,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,1,,CHO,,,8,,12249,B,,Autocuration,CHEMBL616372,BAO_0000219,1550
,,H,,,51,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,1,,,,,8,,11376,B,,Expert,CHEMBL616373,BAO_0000219,1551
,,H,,,51,,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,,,In vivo,8,,2474,B,,Autocuration,CHEMBL616374,BAO_0000218,1552
,,H,,,51,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,Hippocampus,,,,8,,13311,B,10000000.0,Autocuration,CHEMBL616375,BAO_0000221,1553
,,H,,,51,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,1,,,,,8,,4373,B,,Autocuration,CHEMBL616376,BAO_0000357,1554
,,H,,,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,1,,,,,8,,1633,B,,Expert,CHEMBL857064,BAO_0000357,1555
,,H,,,51,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,1,,,,,8,,11866,B,,Autocuration,CHEMBL616377,BAO_0000357,1556
,,H,,,51,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,1,,,,,8,,4373,B,,Autocuration,CHEMBL616378,BAO_0000357,1557
,,H,,,51,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,1,,,,,8,,4687,B,,Autocuration,CHEMBL616379,BAO_0000357,1558
,,H,,,11863,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,1,,,,,8,,16946,B,,Autocuration,CHEMBL616380,BAO_0000357,1559
,,H,,,11863,,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,1,,,,,8,,13291,B,,Autocuration,CHEMBL616381,BAO_0000357,1560
,,H,,,11863,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,1,,,,,8,,14159,B,,Autocuration,CHEMBL616382,BAO_0000357,1561
,,H,,,11863,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,1,,,,,8,,10812,B,,Autocuration,CHEMBL616383,BAO_0000357,1562
,,D,449.0,,11863,10090.0,Mus musculus,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,1,,CHO,,,9,,3032,B,,Expert,CHEMBL616350,BAO_0000219,1563
,,H,,,11863,,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,1,,,,,8,,16655,B,,Autocuration,CHEMBL616351,BAO_0000357,1564
,,H,,,11863,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,1,,,,,8,,14532,B,,Autocuration,CHEMBL616352,BAO_0000357,1565
,,H,,,11863,,,Binding affinity against 5-hydroxytryptamine 1A receptor,1,,,,,8,,13944,B,,Autocuration,CHEMBL616353,BAO_0000357,1566
,,H,,,11863,,,Binding affinity against serotonergic 5-HT1a receptor,1,,,,,8,,13033,B,,Autocuration,CHEMBL616354,BAO_0000357,1567
,,H,,,11863,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,1,,,,,8,,10321,B,,Autocuration,CHEMBL616508,BAO_0000357,1568
,,D,,,11863,10090.0,Mus musculus,Binding affinity for 5-hydroxytryptamine 1A receptor,1,,,,,9,,2968,B,,Expert,CHEMBL616559,BAO_0000357,1569
,,H,,,11863,,,Binding affinity at 5-hydroxytryptamine 1A receptor,1,,,,,8,,13964,B,,Autocuration,CHEMBL616560,BAO_0000357,1570
,,H,,,11863,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",1,,,,,8,,15527,B,,Autocuration,CHEMBL616561,BAO_0000357,1571
,,H,449.0,,11863,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,1,,CHO,,,8,,12248,B,,Autocuration,CHEMBL616562,BAO_0000219,1572
,,H,449.0,,11863,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,1,,CHO,,,8,,12249,B,,Autocuration,CHEMBL616563,BAO_0000219,1573
,,H,,,11863,,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,1,,,,,8,,15120,B,,Autocuration,CHEMBL616564,BAO_0000357,1574
,,H,,,11863,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,1,,,,,8,,13313,B,,Autocuration,CHEMBL616565,BAO_0000357,1575
,,H,,,11863,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,1,,,,,8,,2613,B,,Autocuration,CHEMBL616566,BAO_0000218,1576
,,H,,,11863,,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,1,,,,,8,,16700,B,,Autocuration,CHEMBL616989,BAO_0000357,1577
,,H,,,11863,,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,1,,,,,8,,2201,B,,Autocuration,CHEMBL857975,BAO_0000357,1578
,,D,,,11863,10090.0,Mus musculus,Binding affinity against 5-hydroxytryptamine 1A receptor,1,,,,,9,,1274,B,,Expert,CHEMBL616990,BAO_0000357,1579
,,H,,,11863,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,1,,,,,8,,1317,B,,Autocuration,CHEMBL616991,BAO_0000357,1580
,,H,,,11863,,,Tested against 5-hydroxytryptamine 1A receptor,1,,,,,8,,12146,B,,Autocuration,CHEMBL616992,BAO_0000357,1581
,,H,,,11863,,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,1,,,,,8,,14059,B,,Autocuration,CHEMBL616993,BAO_0000357,1582
,,H,,,106,9986.0,Oryctolagus cuniculus,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,1,,,,,8,,14025,B,,Expert,CHEMBL616994,BAO_0000019,1583
,,H,,,106,9986.0,Oryctolagus cuniculus,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,1,,,,,8,,14025,B,,Autocuration,CHEMBL616995,BAO_0000019,1584
,,D,722.0,,105571,9593.0,Gorilla gorilla,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,1,,HEK293,,,9,,14447,B,,Intermediate,CHEMBL616996,BAO_0000219,1585
,,H,,,106,10141.0,Cavia porcellus,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,1,,,,In vivo,8,,3025,F,,Autocuration,CHEMBL616997,BAO_0000218,1586
,,H,,,106,10141.0,Cavia porcellus,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,1,,,,In vivo,8,,3025,F,,Autocuration,CHEMBL616998,BAO_0000218,1587
,,H,,,106,10141.0,Cavia porcellus,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,1,,,,,8,,15329,F,,Autocuration,CHEMBL616999,BAO_0000019,1588
,,H,,,106,10141.0,Cavia porcellus,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,1,,,,,8,,15329,F,,Autocuration,CHEMBL617000,BAO_0000019,1589
,,H,,,106,10141.0,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,1,,,,,8,,15847,F,,Autocuration,CHEMBL617001,BAO_0000019,1590
,,H,,,106,10141.0,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,1,,,,,8,,15847,F,,Autocuration,CHEMBL858111,BAO_0000019,1591
,,H,,,106,,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,1,,,,,8,,14165,F,,Autocuration,CHEMBL617002,BAO_0000019,1592
,,H,,,106,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),1,,,,,8,,14214,F,,Autocuration,CHEMBL617003,BAO_0000019,1593
,,H,,,106,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),1,,,,,8,,14214,F,,Autocuration,CHEMBL617004,BAO_0000019,1594
,,D,,,106,9606.0,Homo sapiens,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,1,,,,,9,,14214,F,,Expert,CHEMBL617005,BAO_0000019,1595
,,D,485.0,,106,9606.0,Homo sapiens,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,1,,CHO-K1,,,9,,13729,F,,Expert,CHEMBL616623,BAO_0000219,1596
,,H,449.0,,106,,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,1,,CHO,,,8,,3025,F,,Autocuration,CHEMBL616624,BAO_0000219,1597
,,H,,,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,1,,,,,8,,2391,B,,Autocuration,CHEMBL883243,BAO_0000357,1598
,,H,,,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,1,,,,,8,,2391,F,,Autocuration,CHEMBL616625,BAO_0000019,1599
,,H,449.0,,106,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",1,,CHO,,,8,,14956,F,,Expert,CHEMBL616626,BAO_0000219,1600
,,H,449.0,,106,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,1,,CHO,,,8,,2598,F,,Autocuration,CHEMBL616627,BAO_0000219,1601
,,H,449.0,,106,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,1,,CHO,,,8,,2598,F,,Autocuration,CHEMBL616628,BAO_0000219,1602
,,H,449.0,,106,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,1,,CHO,,,8,,2598,F,,Autocuration,CHEMBL616629,BAO_0000219,1603
,,H,449.0,,106,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,1,,CHO,,,8,,2598,F,,Autocuration,CHEMBL616630,BAO_0000219,1604
,,H,,,106,,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",1,,,,,8,,14956,F,,Expert,CHEMBL616631,BAO_0000019,1605
,,H,,,106,,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",1,,,,,8,,14956,F,,Autocuration,CHEMBL616632,BAO_0000019,1606
,,D,,,106,9606.0,Homo sapiens,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,1,,,,,9,,14214,B,,Expert,CHEMBL616633,BAO_0000357,1607
,,H,449.0,,106,,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,1,,CHO,,,8,,3463,B,,Expert,CHEMBL616634,BAO_0000219,1608
,,H,,,106,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,1,,,,,8,,15331,B,,Autocuration,CHEMBL616635,BAO_0000357,1609
,,D,,,106,9606.0,Homo sapiens,Binding affinity against 5-hydroxytryptamine 1B receptor,1,,,,,9,,16146,B,,Expert,CHEMBL885358,BAO_0000357,1610
,,D,449.0,,106,9606.0,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,1,,CHO,,,9,,14159,B,,Expert,CHEMBL616636,BAO_0000219,1611
,,H,449.0,,106,,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,1,,CHO,,,8,,14158,B,,Expert,CHEMBL616637,BAO_0000219,1612
,,H,,,106,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,1,,,,,8,,14159,B,,Autocuration,CHEMBL616638,BAO_0000357,1613
,,H,449.0,,106,,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,1,,CHO,,,8,,15250,B,,Expert,CHEMBL616639,BAO_0000219,1614
,,H,449.0,,106,,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,1,,CHO,,,8,,15250,B,,Expert,CHEMBL616640,BAO_0000219,1615
,,H,449.0,,106,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,1,,CHO,,,8,,15331,B,,Expert,CHEMBL616641,BAO_0000219,1616
,,H,449.0,,106,,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,1,,CHO,,,8,,15332,B,,Expert,CHEMBL616642,BAO_0000219,1617
,,H,449.0,,106,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,1,,CHO,,,8,,14956,B,,Expert,CHEMBL616643,BAO_0000219,1618
,,H,,,106,,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),1,,,,,8,,3805,B,,Autocuration,CHEMBL616644,BAO_0000357,1619
,,H,,,106,,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,1,,,,,8,,14875,B,,Autocuration,CHEMBL616645,BAO_0000357,1620
,,H,,,105,9986.0,Oryctolagus cuniculus,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),1,,,,,8,,14454,F,,Autocuration,CHEMBL616646,BAO_0000019,1621
,,H,,,105,9986.0,Oryctolagus cuniculus,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),1,,,,,8,,14454,F,,Expert,CHEMBL616647,BAO_0000019,1622
,,H,,,105,,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),1,,,,,8,,16288,B,,Autocuration,CHEMBL616509,BAO_0000357,1623
,,H,,,105,,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),1,,,,,8,,16288,B,,Autocuration,CHEMBL616510,BAO_0000357,1624
,,H,,,105,,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,1,,,,,8,,16312,B,,Autocuration,CHEMBL616511,BAO_0000357,1625
,,H,,,105,9913.0,Bos taurus,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,1,,,,,8,,1348,B,,Expert,CHEMBL616512,BAO_0000357,1626
,,H,,,105,9913.0,Bos taurus,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,1,,,,,8,,5834,B,,Autocuration,CHEMBL616513,BAO_0000357,1627
,,H,,,105,9913.0,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,1,Striatum,,,,8,,13366,B,2435.0,Autocuration,CHEMBL616514,BAO_0000019,1628
,,H,,,105,9913.0,Bos taurus,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,1,,,,,8,,1414,B,,Expert,CHEMBL616515,BAO_0000357,1629
,,H,,,105,9913.0,Bos taurus,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,1,,,,,8,,14998,B,,Autocuration,CHEMBL616516,BAO_0000019,1630
,,H,,,105,9913.0,Bos taurus,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,1,,,,,8,,11473,B,,Autocuration,CHEMBL616517,BAO_0000357,1631
,,H,,,105,9913.0,Bos taurus,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,1,,,,,8,,11473,B,,Autocuration,CHEMBL616518,BAO_0000357,1632
,,H,,,105,9913.0,Bos taurus,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,1,,,,,8,,10639,B,,Autocuration,CHEMBL616519,BAO_0000357,1633
,,H,,,105,9913.0,Bos taurus,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,1,,,,,8,,10639,B,,Autocuration,CHEMBL616520,BAO_0000357,1634
,,H,,,105,9913.0,Bos taurus,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,1,,,,,8,,1375,B,,Autocuration,CHEMBL616521,BAO_0000357,1635
,,H,,,105,9913.0,Bos taurus,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,1,,,,,8,,1375,B,,Autocuration,CHEMBL616522,BAO_0000357,1636
,,H,,,105,9913.0,Bos taurus,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,1,,,,,8,,16532,B,,Autocuration,CHEMBL884531,BAO_0000357,1637
,,H,,,105,9913.0,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,1,,,,,8,,11147,B,,Autocuration,CHEMBL616523,BAO_0000357,1638
,,H,,,105,9913.0,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,1,Striatum,,,,8,,13366,B,2435.0,Autocuration,CHEMBL616731,BAO_0000019,1639
,,H,,,105,9913.0,Bos taurus,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,1,,,,,8,,10444,B,,Autocuration,CHEMBL616732,BAO_0000019,1640
,,H,,,105,9913.0,Bos taurus,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,1,,,,,8,,16532,B,,Autocuration,CHEMBL616733,BAO_0000357,1641
,,H,,,105,9913.0,Bos taurus,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,1,,,,,8,,16532,B,,Autocuration,CHEMBL616734,BAO_0000357,1642
,,H,,,105,9913.0,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,1,,,,,8,,12827,B,,Autocuration,CHEMBL616735,BAO_0000249,1643
,,H,,,105,9913.0,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,1,,,,,8,,12827,B,,Autocuration,CHEMBL616736,BAO_0000249,1644
,,H,,,105,9913.0,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,1,,,,,8,,12919,F,,Expert,CHEMBL616737,BAO_0000019,1645
,,H,,,105,9913.0,Bos taurus,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,1,,,,,8,,14025,B,,Autocuration,CHEMBL616738,BAO_0000019,1646
,,H,,,105,9913.0,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,1,,,,,8,,12919,F,,Expert,CHEMBL616739,BAO_0000019,1647
,,H,,,105,9913.0,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,1,,,,,8,,12919,F,,Expert,CHEMBL616740,BAO_0000019,1648
,,H,,,105,9913.0,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,1,,,,,8,,12919,F,,Expert,CHEMBL616741,BAO_0000019,1649
,,H,722.0,,105,9593.0,Gorilla gorilla,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,1,,HEK293,,,8,,14447,B,,Autocuration,CHEMBL616742,BAO_0000219,1650
,,D,,,105570,10141.0,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,1,,,,,9,,1375,B,,Intermediate,CHEMBL616743,BAO_0000019,1651
,,D,,,105570,10141.0,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,1,,,,,9,,1375,B,,Intermediate,CHEMBL616744,BAO_0000019,1652
,,D,,,105570,10141.0,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,1,,,,,9,,12409,F,,Intermediate,CHEMBL616745,BAO_0000019,1653
,,D,,,105570,10141.0,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,1,,,,,9,,12409,F,,Intermediate,CHEMBL616746,BAO_0000019,1654
,,D,,,105570,10141.0,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,1,,,,,9,,12409,F,,Intermediate,CHEMBL616747,BAO_0000019,1655
,,D,,,105570,10141.0,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,1,,,,,9,,12409,F,,Intermediate,CHEMBL616748,BAO_0000019,1656
,,D,,,105570,10141.0,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,1,,,,,9,,12409,F,,Intermediate,CHEMBL616648,BAO_0000019,1657
,,D,,,105570,10141.0,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 1D receptor,1,,,,,9,,11574,B,,Intermediate,CHEMBL616649,BAO_0000357,1658
,,D,,,105570,10141.0,Cavia porcellus,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,1,,,,,9,,1558,B,,Intermediate,CHEMBL616650,BAO_0000357,1659
,,D,,,105570,10141.0,Cavia porcellus,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,1,,,,,9,,12409,F,,Intermediate,CHEMBL616651,BAO_0000218,1660
,,D,,,105570,10141.0,Cavia porcellus,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,1,,,,,9,,12409,F,,Intermediate,CHEMBL616652,BAO_0000218,1661
,,D,,,105570,10141.0,Cavia porcellus,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,1,,,,,9,,12409,F,,Intermediate,CHEMBL616653,BAO_0000218,1662
,,D,,,105570,10141.0,Cavia porcellus,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,1,,,,,9,,12409,F,,Intermediate,CHEMBL616654,BAO_0000218,1663
,,D,,,105570,10141.0,Cavia porcellus,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,1,,,,,9,,12253,B,,Intermediate,CHEMBL616655,BAO_0000019,1664
,,D,,,105570,10141.0,Cavia porcellus,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,1,,,,,9,,12936,B,,Intermediate,CHEMBL616656,BAO_0000357,1665
,,H,,,105,10141.0,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,1,,,,,8,,13181,B,,Autocuration,CHEMBL616657,BAO_0000019,1666
,,D,,,105570,10141.0,Cavia porcellus,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,1,Striatum,,,,9,,12409,B,2435.0,Intermediate,CHEMBL616658,BAO_0000357,1667
,,D,,,105570,10141.0,Cavia porcellus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,1,,,,,9,,10639,B,,Intermediate,CHEMBL616659,BAO_0000357,1668
,,H,,,51,,,Binding affinity against 5-hydroxytryptamine 1D receptor,1,,,,,8,,5254,B,,Autocuration,CHEMBL616660,BAO_0000357,1669
,,H,,,106,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,1,,,,,8,,13051,B,,Autocuration,CHEMBL616661,BAO_0000357,1670
,,H,,,105,,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,1,,,,,8,,3463,F,,Expert,CHEMBL616662,BAO_0000019,1671
,,H,,,105,,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,1,,,,,8,,15315,F,,Autocuration,CHEMBL616663,BAO_0000019,1672
,,H,,,105,,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,1,,,,,8,,6011,F,,Autocuration,CHEMBL616664,BAO_0000019,1673
,,D,449.0,,105,9606.0,Homo sapiens,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",1,,CHO,,,9,,14159,F,,Expert,CHEMBL881820,BAO_0000219,1674
,,H,449.0,,105,,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",1,,CHO,,,8,,14159,F,,Autocuration,CHEMBL616665,BAO_0000219,1675
,,H,449.0,,105,,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,1,,CHO,,,8,,15250,B,,Expert,CHEMBL616666,BAO_0000219,1676
,,H,449.0,,105,,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,1,,CHO,,,8,,15250,B,,Autocuration,CHEMBL616667,BAO_0000219,1677
,,H,449.0,,105,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",1,,CHO,,,8,,15331,F,,Expert,CHEMBL616668,BAO_0000219,1678
,,D,449.0,,105,9606.0,Homo sapiens,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",1,,CHO,,,9,,15332,F,,Expert,CHEMBL616669,BAO_0000219,1679
,,H,449.0,,105,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",1,,CHO,,,8,,15332,F,,Expert,CHEMBL617040,BAO_0000219,1680
,,H,449.0,,105,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",1,,CHO,,,8,,3294,F,,Autocuration,CHEMBL617041,BAO_0000219,1681
,,H,449.0,,105,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",1,,CHO,,,8,,14158,F,,Expert,CHEMBL617042,BAO_0000219,1682
,,H,449.0,,105,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",1,,CHO,,,8,,14956,F,,Expert,CHEMBL617043,BAO_0000219,1683
,,H,,,105,,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,1,,,,,8,,12469,F,,Autocuration,CHEMBL617044,BAO_0000019,1684
,,H,449.0,,105,,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,1,,CHO,,,8,,3463,F,,Expert,CHEMBL617045,BAO_0000219,1685
,,D,449.0,,105,9606.0,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",1,,CHO,,,9,,15250,F,,Expert,CHEMBL617046,BAO_0000219,1686
,,D,449.0,,105,9606.0,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",1,,CHO,,,9,,15250,F,,Expert,CHEMBL617047,BAO_0000219,1687
,,H,,,105,,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",1,,,,,8,,14956,F,,Expert,CHEMBL617048,BAO_0000019,1688
,,H,,,105,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",1,,,,,8,,14159,F,,Autocuration,CHEMBL616897,BAO_0000019,1689
,,D,,,105,9606.0,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",1,,,,,9,,14159,F,,Expert,CHEMBL616898,BAO_0000019,1690
,,D,449.0,,105,9606.0,Homo sapiens,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,1,,CHO,,,9,,14499,F,,Expert,CHEMBL858201,BAO_0000219,1691
,,H,,,105,,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,1,,,,,8,,15315,F,,Autocuration,CHEMBL616899,BAO_0000019,1692
,,H,,,105,,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),1,,,,In vitro,8,,3294,B,,Autocuration,CHEMBL616900,BAO_0000219,1693
,,H,449.0,,105,,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,1,,CHO,,,8,,3463,B,,Expert,CHEMBL616901,BAO_0000219,1694
,,H,,,105,,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,1,,,,,8,,15331,B,,Autocuration,CHEMBL616902,BAO_0000357,1695
,,D,449.0,,105,9606.0,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,1,,CHO,,,9,,14159,B,,Expert,CHEMBL616903,BAO_0000219,1696
,,H,449.0,,105,,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,1,,CHO,,,8,,14158,B,,Expert,CHEMBL616904,BAO_0000219,1697
,,H,,,105,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,1,,,,,8,,14159,B,,Autocuration,CHEMBL616905,BAO_0000357,1698
,,H,449.0,,105,,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,1,,CHO,,,8,,15250,B,,Expert,CHEMBL616906,BAO_0000219,1699
,,H,449.0,,105,,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,1,,CHO,,,8,,15250,B,,Expert,CHEMBL616907,BAO_0000219,1700
,,H,449.0,,105,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,1,,CHO,,,8,,15331,B,,Expert,CHEMBL616908,BAO_0000219,1701
,,D,449.0,,105,9606.0,Homo sapiens,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,1,,CHO,,,9,,15332,B,,Expert,CHEMBL616909,BAO_0000219,1702
,,D,449.0,,105,9606.0,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,1,,CHO,,,9,,14499,B,,Expert,CHEMBL616910,BAO_0000219,1703
,,H,449.0,,105,,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,1,,CHO,,,8,,15332,B,,Expert,CHEMBL616911,BAO_0000219,1704
,,H,449.0,,105,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,1,,CHO,,,8,,14956,B,,Expert,CHEMBL616912,BAO_0000219,1705
,,H,,,105,,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),1,,,,,8,,3805,B,,Autocuration,CHEMBL616913,BAO_0000357,1706
,,D,449.0,,105,9606.0,Homo sapiens,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,1,,CHO,,,9,,6011,B,,Expert,CHEMBL616914,BAO_0000219,1707
,,H,449.0,,105,,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,1,,CHO,,,8,,16190,B,,Autocuration,CHEMBL616915,BAO_0000219,1708
,,H,,,105,,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,1,,,,,8,,14165,B,,Autocuration,CHEMBL616916,BAO_0000019,1709
,,D,,,105,9606.0,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,1,,,,,9,,4234,B,,Expert,CHEMBL616917,BAO_0000357,1710
,,H,,,105,,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",1,,,,,8,,15527,B,,Autocuration,CHEMBL616918,BAO_0000357,1711
,,H,,,105,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,1,,,,,8,,6328,B,,Expert,CHEMBL616919,BAO_0000219,1712
,,H,,,105,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,1,,,,,8,,16209,B,,Autocuration,CHEMBL616920,BAO_0000357,1713
,,H,,,105,,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,1,,,,,8,,14770,B,,Autocuration,CHEMBL872914,BAO_0000357,1714
,,H,,,105,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,1,,,,,8,,2598,B,,Autocuration,CHEMBL616921,BAO_0000357,1715
,,H,,,105,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,1,,,,,8,,6897,B,,Expert,CHEMBL616922,BAO_0000357,1716
,,H,,,105,,,Binding affinity towards 5-hydroxytryptamine 1D receptor,1,,,,,8,,6013,B,,Autocuration,CHEMBL616923,BAO_0000357,1717
,,H,,,105,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,1,,,,,8,,5843,B,,Expert,CHEMBL616924,BAO_0000357,1718
,,H,,,105,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,1,,,,,8,,14454,B,,Expert,CHEMBL875909,BAO_0000357,1719
,,H,,,105,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,1,,,,,8,,14454,B,,Autocuration,CHEMBL616925,BAO_0000357,1720
,,H,,,105,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,1,,,,,8,,14454,B,,Autocuration,CHEMBL616926,BAO_0000357,1721
,,H,,,105,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,1,,,,,8,,15818,B,,Autocuration,CHEMBL616927,BAO_0000357,1722
,,H,485.0,,105,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,1,,CHO-K1,,,8,,13729,F,,Expert,CHEMBL616928,BAO_0000219,1723
,,D,,,105,9606.0,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),1,,,,In vitro,9,,6011,B,,Expert,CHEMBL616929,BAO_0000219,1724
,,D,,,105,9606.0,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,1,,,,,9,,4234,B,,Expert,CHEMBL616930,BAO_0000357,1725
,,H,,,105,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,1,,,,,8,,17085,B,,Expert,CHEMBL616931,BAO_0000019,1726
,,H,,,105,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,1,,,,,8,,3025,B,,Autocuration,CHEMBL616932,BAO_0000357,1727
,,H,,,105,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,1,,,,,8,,15315,B,,Expert,CHEMBL616933,BAO_0000357,1728
,,D,,,105,9606.0,Homo sapiens,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,1,,,,,9,,14214,B,,Expert,CHEMBL616934,BAO_0000219,1729
,,D,,,105,9606.0,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1D receptor,1,,,,,9,,3804,B,,Expert,CHEMBL616935,BAO_0000357,1730
,,H,,,105,,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,1,,,,,8,,16700,B,,Autocuration,CHEMBL616936,BAO_0000357,1731
,,D,,,105,9606.0,Homo sapiens,Affinity for 5-hydroxytryptamine 1D receptor subtype,1,,,,,9,,2391,B,,Expert,CHEMBL616937,BAO_0000357,1732
,,D,,,105,9606.0,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1D receptor,1,,,,,9,,4175,B,,Expert,CHEMBL616938,BAO_0000357,1733
,,H,,,105,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,1,,,,,8,,17085,B,,Autocuration,CHEMBL616939,BAO_0000019,1734
,,H,,,105,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,1,,,,,8,,17085,B,,Expert,CHEMBL616940,BAO_0000019,1735
,,D,,,105,9606.0,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,1,,,,,9,,15926,B,,Expert,CHEMBL616941,BAO_0000357,1736
,,H,485.0,,105,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,1,,CHO-K1,,,8,,16312,B,,Autocuration,CHEMBL616942,BAO_0000219,1737
,,H,485.0,,105,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,1,,CHO-K1,,,8,,16312,B,,Autocuration,CHEMBL616943,BAO_0000219,1738
,,H,449.0,,104802,,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,1,,CHO,,,4,,14956,B,,Autocuration,CHEMBL616944,BAO_0000219,1739
,,H,,,105,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",1,,,,,8,,3294,F,,Autocuration,CHEMBL616945,BAO_0000019,1740
,,H,,,105,,,Binding activity radioligand.,1,,,,,8,,12861,B,,Autocuration,CHEMBL616946,BAO_0000357,1741
,,H,,,105,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,1,,,,,8,,12861,B,,Autocuration,CHEMBL616947,BAO_0000019,1742
,,H,485.0,,105,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,1,,CHO-K1,,,8,,16312,B,,Expert,CHEMBL616948,BAO_0000219,1743
,,H,,,105,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,1,,,,,8,,5104,B,,Autocuration,CHEMBL616851,BAO_0000357,1744
,,H,,,105,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,1,,,,,8,,5105,B,,Autocuration,CHEMBL616852,BAO_0000357,1745
,,H,,,105,,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,1,,,,,8,,14499,B,,Autocuration,CHEMBL616853,BAO_0000357,1746
,,D,,,105,9606.0,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1D receptor,1,,,,,9,,15926,B,,Expert,CHEMBL616854,BAO_0000357,1747
,,D,449.0,,105,9606.0,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,1,,CHO,,,9,,4540,B,,Expert,CHEMBL616855,BAO_0000219,1748
,,H,449.0,,105,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,1,,CHO,,,8,,15779,B,,Autocuration,CHEMBL616856,BAO_0000219,1749
,,H,449.0,,105,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,1,,CHO,,,8,,15779,B,,Autocuration,CHEMBL616857,BAO_0000219,1750
,,H,,,105,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,1,,,,,8,,6166,B,,Autocuration,CHEMBL616858,BAO_0000357,1751
,,H,449.0,,105,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,1,,CHO,,,8,,15779,B,,Autocuration,CHEMBL616859,BAO_0000219,1752
,,H,449.0,,105,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,1,,CHO,,,8,,15779,B,,Autocuration,CHEMBL616860,BAO_0000219,1753
,,H,722.0,,105,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,1,,HEK293,,,8,,17451,B,,Autocuration,CHEMBL616861,BAO_0000219,1754
,,H,722.0,,105,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,1,,HEK293,,,8,,17451,B,,Autocuration,CHEMBL616541,BAO_0000219,1755
,,H,722.0,,105,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,1,,HEK293,,,8,,17451,B,,Autocuration,CHEMBL616542,BAO_0000219,1756
,,H,449.0,,105,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,1,,CHO,,,8,,4199,B,,Autocuration,CHEMBL616543,BAO_0000219,1757
,,D,,,105,9606.0,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1D receptor,1,,,,,9,,14875,B,,Expert,CHEMBL616544,BAO_0000357,1758
,,H,449.0,,105,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,1,,CHO,,,8,,15146,B,,Autocuration,CHEMBL616545,BAO_0000219,1759
,,H,,,105,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,1,,,,,8,,5213,B,,Autocuration,CHEMBL616546,BAO_0000357,1760
,,H,449.0,,105,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,1,,CHO,,,8,,14818,B,,Autocuration,CHEMBL616547,BAO_0000219,1761
,,H,449.0,,105,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",1,,CHO,,,8,,4829,B,,Autocuration,CHEMBL616548,BAO_0000219,1762
,,H,,,105,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,1,,,,,8,,14454,F,,Expert,CHEMBL616549,BAO_0000019,1763
,,H,,,105,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,1,,,,,8,,14454,F,,Expert,CHEMBL616550,BAO_0000019,1764
,,H,,,108,,,Binding affinity against 5-HT2C receptor,1,,,,,8,,5254,B,,Autocuration,CHEMBL857066,BAO_0000357,1765
,,H,,,108,,,Binding affinity against 5-hydroxytryptamine 1D receptor,1,,,,,8,,5254,B,,Autocuration,CHEMBL616551,BAO_0000357,1766
,,H,,,10577,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,1,,,,,8,,10639,B,,Autocuration,CHEMBL616552,BAO_0000357,1767
,,H,,,10577,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,1,,,,,8,,10639,F,,Autocuration,CHEMBL832876,BAO_0000019,1768
,,H,,,10577,,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",1,,,,,8,,12352,B,,Expert,CHEMBL616553,BAO_0000019,1769
,,H,,,10577,,,Binding affinity towards 5-HT1B was determined,1,,,,,8,,9098,B,,Autocuration,CHEMBL616554,BAO_0000357,1770
,,H,,,10577,,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,1,,,,,8,,14430,B,,Expert,CHEMBL616555,BAO_0000019,1771
,,H,,,10577,,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",1,,,,,8,,13657,B,,Expert,CHEMBL616556,BAO_0000019,1772
,,H,,,10577,,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",1,,,,,8,,13657,B,,Autocuration,CHEMBL616557,BAO_0000019,1773
,,H,,,10577,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,1,,,,,8,,15854,B,,Expert,CHEMBL616558,BAO_0000019,1774
,,D,,,10577,10116.0,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,1,,,,,9,,10639,B,,Expert,CHEMBL616749,BAO_0000019,1775
,,H,,,10577,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,1,,,,,8,,10025,B,,Autocuration,CHEMBL616750,BAO_0000357,1776
,,H,,,10577,,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",1,,,,,8,,10025,B,,Autocuration,CHEMBL616751,BAO_0000357,1777
,,H,,,10577,,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,1,,,,,8,,14286,B,,Autocuration,CHEMBL616752,BAO_0000249,1778
,,H,,,10577,,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,1,Striatum,,,,8,,3651,B,2435.0,Autocuration,CHEMBL616753,BAO_0000019,1779
,,D,,,10577,10116.0,Rattus norvegicus,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,1,,,,,9,,14178,B,,Expert,CHEMBL616754,BAO_0000357,1780
,,H,,,10577,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,1,,,,,8,,10639,B,,Autocuration,CHEMBL616755,BAO_0000019,1781
,,H,,,10577,,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,1,Striatum,,,,8,,13605,B,2435.0,Autocuration,CHEMBL616756,BAO_0000019,1782
,,H,,,10577,,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,1,Striatum,,,,8,,5834,B,2435.0,Autocuration,CHEMBL616757,BAO_0000019,1783
,,H,,,10577,,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,1,Striatum,,,,8,,10922,B,2435.0,Autocuration,CHEMBL616758,BAO_0000357,1784
,,H,,,10577,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,1,,,,,8,,14286,B,,Autocuration,CHEMBL616759,BAO_0000249,1785
,,H,,,10577,,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,1,,,,,8,,11825,B,,Autocuration,CHEMBL616760,BAO_0000357,1786
,,H,,,10577,,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,1,Striatum,,,,8,,14826,B,2435.0,Autocuration,CHEMBL616761,BAO_0000019,1787
,,H,,,10577,,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,1,Striatum,,,,8,,9699,B,2435.0,Autocuration,CHEMBL616762,BAO_0000019,1788
,,H,,,10577,,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,1,,,,,8,,14423,B,,Autocuration,CHEMBL616763,BAO_0000019,1789
,,H,,,10577,,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,1,,,,,8,,10062,B,,Expert,CHEMBL872909,BAO_0000357,1790
,,H,,,10577,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,1,,,,,8,,10062,B,,Autocuration,CHEMBL616764,BAO_0000357,1791
,,D,,,10577,10116.0,Rattus norvegicus,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,1,,,,,9,,12280,B,,Expert,CHEMBL616765,BAO_0000357,1792
,,H,,,10577,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,1,Striatum,,,,8,,15412,B,2435.0,Autocuration,CHEMBL616766,BAO_0000357,1793
,,H,,,10577,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,1,Striatum,,,,8,,15412,B,2435.0,Autocuration,CHEMBL616767,BAO_0000357,1794
,,H,,,10577,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,1,,,,,8,,10062,B,,Autocuration,CHEMBL616768,BAO_0000357,1795
,,H,,,10577,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,1,,,,,8,,11147,B,,Autocuration,CHEMBL616769,BAO_0000357,1796
,,H,,,10577,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,1,,,,,8,,9547,B,,Autocuration,CHEMBL616770,BAO_0000019,1797
,,H,,,10577,,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,1,,,,,8,,10444,B,,Autocuration,CHEMBL616771,BAO_0000019,1798
,,H,,,10577,,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,1,Striatum,,,,8,,12469,B,2435.0,Autocuration,CHEMBL616772,BAO_0000019,1799
,,H,,,10577,,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,1,,,,,8,,9098,B,,Expert,CHEMBL616773,BAO_0000019,1800
,,H,,,10577,,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,1,,,,,8,,9098,B,,Autocuration,CHEMBL616774,BAO_0000019,1801
,,H,,,10577,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,1,,,,,8,,9699,B,,Autocuration,CHEMBL616775,BAO_0000357,1802
,,H,,,10577,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,1,,,,,8,,10394,B,,Autocuration,CHEMBL616776,BAO_0000249,1803
,,H,,,10577,,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,1,,,,,8,,12092,B,,Autocuration,CHEMBL616777,BAO_0000357,1804
,,H,,,10577,,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,1,,,,,8,,16700,B,,Autocuration,CHEMBL616778,BAO_0000357,1805
,,D,,,10577,10116.0,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,1,,,,,9,,403,B,,Expert,CHEMBL616779,BAO_0000249,1806
,,D,,,10577,10116.0,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1B receptor,1,,,,,9,,12771,B,,Expert,CHEMBL616780,BAO_0000357,1807
,,H,,,10577,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,1,,,,,8,,11642,B,,Autocuration,CHEMBL616781,BAO_0000019,1808
,,H,,,10577,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,1,,,,,8,,12953,B,,Autocuration,CHEMBL616782,BAO_0000357,1809
,,H,,,10577,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,1,,,,,8,,12953,B,,Autocuration,CHEMBL616783,BAO_0000357,1810
,,H,,,10577,,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,1,Striatum,,,,8,,12953,B,2435.0,Expert,CHEMBL616784,BAO_0000019,1811
,,H,,,10577,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,1,,,,,8,,12953,B,,Autocuration,CHEMBL616785,BAO_0000357,1812
,,H,,,10577,,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,1,Brain,,,,8,,9737,B,955.0,Autocuration,CHEMBL857067,BAO_0000249,1813
,,H,,,10577,,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,1,,,,,8,,9737,B,,Autocuration,CHEMBL616786,BAO_0000019,1814
,,H,,,10577,,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,1,Brain,,,,8,,9737,B,955.0,Autocuration,CHEMBL616787,BAO_0000249,1815
,,H,,,10577,,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,1,,,,,8,,12827,B,,Autocuration,CHEMBL616788,BAO_0000357,1816
,,H,,,10577,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,1,,,,,8,,5033,B,,Autocuration,CHEMBL616789,BAO_0000357,1817
,,D,,,10577,10116.0,Rattus norvegicus,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,1,,,,,9,,9786,B,,Expert,CHEMBL616790,BAO_0000019,1818
,,H,,,10577,,,Binding affinity at 5-hydroxytryptamine 1B receptor,1,,,,,8,,13116,B,,Expert,CHEMBL616791,BAO_0000357,1819
,,H,,,10577,,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,1,,,,,8,,16429,B,,Autocuration,CHEMBL616792,BAO_0000019,1820
,,D,,,10577,10116.0,Rattus norvegicus,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,1,,,,,9,,12409,B,,Expert,CHEMBL616793,BAO_0000249,1821
,,H,,,10577,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,1,,,,,8,,15194,B,,Autocuration,CHEMBL616794,BAO_0000357,1822
,,H,,,10577,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,1,,,,,8,,15194,B,,Autocuration,CHEMBL616795,BAO_0000357,1823
,,H,,,104686,,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,1,,,,,4,,5486,B,,Autocuration,CHEMBL616796,BAO_0000019,1824
,,H,,,106,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,1,,,,,8,,4639,B,,Autocuration,CHEMBL616797,BAO_0000357,1825
,Brain membranes,H,,,106,,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,1,,,,,8,,386,B,,Autocuration,CHEMBL616798,BAO_0000249,1826
,,H,,,106,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,1,,,,,8,,2474,B,,Autocuration,CHEMBL616799,BAO_0000357,1827
,,H,,,106,,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,1,,,,,8,,6011,B,,Autocuration,CHEMBL616800,BAO_0000357,1828
,,H,,,106,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,1,,,,,8,,5014,B,,Autocuration,CHEMBL616801,BAO_0000357,1829
,,H,,,106,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,1,,,,,8,,17515,B,,Autocuration,CHEMBL616802,BAO_0000357,1830
,,H,,,106,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,1,,,,,8,,4373,B,,Autocuration,CHEMBL616803,BAO_0000357,1831
,,H,,,106,,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,1,,,,,8,,1633,B,,Expert,CHEMBL857068,BAO_0000357,1832
,,H,,,106,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,1,,,,,8,,1633,B,,Autocuration,CHEMBL616804,BAO_0000357,1833
,,H,,,106,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,1,,,,,8,,4373,B,,Autocuration,CHEMBL616805,BAO_0000357,1834
,,H,,,106,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,1,,,,,8,,4687,B,,Autocuration,CHEMBL616806,BAO_0000357,1835
,,H,,,106,,,Binding affinity against 5-hydroxytryptamine 1B receptor,1,,,,,8,,11574,B,,Autocuration,CHEMBL616807,BAO_0000357,1836
,,H,,,106,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,1,,,,,8,,10321,B,,Autocuration,CHEMBL616808,BAO_0000357,1837
,,H,,,106,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,1,,,,,8,,15527,B,,Autocuration,CHEMBL616809,BAO_0000357,1838
,,H,,,106,,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,1,,,,,8,,17200,B,,Autocuration,CHEMBL616810,BAO_0000357,1839
,,H,,,104802,,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,1,,,,,4,,14423,B,,Autocuration,CHEMBL616811,BAO_0000224,1840
,,H,,,108,9913.0,Bos taurus,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,1,,,,,8,,5834,B,,Autocuration,CHEMBL616812,BAO_0000357,1841
,,H,,,108,9823.0,Sus scrofa,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,1,,,,,8,,11473,B,,Autocuration,CHEMBL616813,BAO_0000357,1842
,,H,,,108,9823.0,Sus scrofa,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,1,,,,,8,,11473,B,,Autocuration,CHEMBL616814,BAO_0000357,1843
,,H,,,108,9823.0,Sus scrofa,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,1,,,,,8,,10639,B,,Autocuration,CHEMBL616815,BAO_0000357,1844
,,H,,,108,9823.0,Sus scrofa,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,1,,,,,8,,10639,B,,Autocuration,CHEMBL616816,BAO_0000357,1845
,,H,,,108,9823.0,Sus scrofa,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,1,,,,,8,,14331,B,,Autocuration,CHEMBL616817,BAO_0000357,1846
,,H,,,108,9823.0,Sus scrofa,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,1,,,,,8,,10796,B,,Autocuration,CHEMBL616818,BAO_0000357,1847
,,H,,,108,9823.0,Sus scrofa,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,1,,,,,8,,9098,B,,Expert,CHEMBL616819,BAO_0000357,1848
,,H,,,108,9823.0,Sus scrofa,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,1,,,,,8,,14331,B,,Expert,CHEMBL616820,BAO_0000357,1849
,,H,,,108,9823.0,Sus scrofa,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,1,,,,,8,,11828,B,,Expert,CHEMBL616821,BAO_0000019,1850
,,H,,,108,9823.0,Sus scrofa,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,1,,,,,8,,11866,B,,Autocuration,CHEMBL616822,BAO_0000357,1851
,,H,,,108,9986.0,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,1,,,,,8,,13047,B,,Autocuration,CHEMBL616823,BAO_0000019,1852
,,D,,,12689,10116.0,Rattus norvegicus,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,1,,,,,9,,188,B,,Autocuration,CHEMBL616824,BAO_0000357,1853
,,D,,,12689,10116.0,Rattus norvegicus,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,1,,,,,9,,11825,B,,Autocuration,CHEMBL616825,BAO_0000357,1854
,,D,,,12689,10116.0,Rattus norvegicus,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,1,,,,,9,,11825,B,,Autocuration,CHEMBL616826,BAO_0000357,1855
,,D,,,12689,10116.0,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,1,,,,,9,,11624,B,,Expert,CHEMBL616827,BAO_0000019,1856
,,D,,,12689,10116.0,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,1,,,,,9,,11139,B,,Autocuration,CHEMBL616828,BAO_0000357,1857
,,D,,,12689,10116.0,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,1,,,,,9,,11147,B,,Autocuration,CHEMBL616829,BAO_0000357,1858
,,D,,,12689,10116.0,Rattus norvegicus,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,1,,,,,9,,10444,B,,Autocuration,CHEMBL616830,BAO_0000019,1859
,,D,,,12689,10116.0,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1C receptor,1,,,,,9,,11624,B,,Expert,CHEMBL616831,BAO_0000357,1860
,,D,,,12689,10116.0,Rattus norvegicus,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",1,,,,,9,,11662,B,,Autocuration,CHEMBL616832,BAO_0000019,1861
,,D,,,12689,10116.0,Rattus norvegicus,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",1,,,,,9,,11662,B,,Autocuration,CHEMBL616833,BAO_0000019,1862
,,D,,,12689,10116.0,Rattus norvegicus,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",1,,,,,9,,11662,B,,Expert,CHEMBL616834,BAO_0000019,1863
,,D,,,12689,10116.0,Rattus norvegicus,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",1,,,,,9,,11662,B,,Autocuration,CHEMBL829595,BAO_0000019,1864
,,D,,,12689,10116.0,Rattus norvegicus,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,1,,,,,9,,9098,B,,Autocuration,CHEMBL616835,BAO_0000357,1865
,,D,,,12689,10116.0,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,1,,,,,9,,10394,B,,Autocuration,CHEMBL872910,BAO_0000249,1866
,,H,,,12689,,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,1,,,,,8,,11933,B,,Expert,CHEMBL616836,BAO_0000357,1867
,,D,,,12689,10116.0,Rattus norvegicus,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,1,,,,,9,,12092,B,,Autocuration,CHEMBL616837,BAO_0000357,1868
,,D,,,12689,10116.0,Rattus norvegicus,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,1,,,,,9,,12253,B,,Autocuration,CHEMBL616466,BAO_0000019,1869
,,D,722.0,,12689,10116.0,Rattus norvegicus,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,1,,HEK293,,,9,,12253,B,,Autocuration,CHEMBL616467,BAO_0000219,1870
,,H,,,108,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,1,,,,,8,,1558,B,,Autocuration,CHEMBL616468,BAO_0000357,1871
,,H,,,108,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,1,,,,,8,,2474,B,,Autocuration,CHEMBL616469,BAO_0000357,1872
,,H,,,108,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,1,,,,,8,,2474,B,,Autocuration,CHEMBL616470,BAO_0000357,1873
,,H,,,12689,,,Binding affinity against 5-hydroxytryptamine 1C receptor,1,,,,,8,,11574,B,,Autocuration,CHEMBL616471,BAO_0000357,1874
,,H,,,12689,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,1,,,,,8,,1558,B,,Autocuration,CHEMBL616472,BAO_0000357,1875
,,H,,,12689,,,Binding affinity against 5-hydroxytryptamine 1C receptor,1,,,,,8,,13944,B,,Autocuration,CHEMBL616473,BAO_0000357,1876
,,H,,,12689,,,Binding affinity against serotonergic 5-HT1c receptor,1,,,,,8,,13033,B,,Autocuration,CHEMBL616474,BAO_0000357,1877
,,H,,,12689,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,1,,,,,8,,10321,B,,Autocuration,CHEMBL616475,BAO_0000357,1878
,,H,,,12689,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,1,,,,,8,,11866,B,,Autocuration,CHEMBL616476,BAO_0000357,1879
,,H,,,105,9986.0,Oryctolagus cuniculus,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),1,,,,,8,,14454,B,,Autocuration,CHEMBL616477,BAO_0000019,1880
,,H,,,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,1,,,,,4,,11574,B,,Autocuration,CHEMBL616478,BAO_0000224,1881
,,H,,,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,1,,,,,4,,11574,B,,Autocuration,CHEMBL616479,BAO_0000224,1882
,,H,,,104686,,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,1,,,,,4,,13631,B,,Autocuration,CHEMBL616480,BAO_0000019,1883
,,D,,,104686,10116.0,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,1,,,,,5,,9630,B,,Autocuration,CHEMBL616481,BAO_0000019,1884
,,D,,,104686,10116.0,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,1,,,,,5,,8822,B,,Autocuration,CHEMBL616482,BAO_0000249,1885
,,D,,,104686,10116.0,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,1,Brain,,,,5,,9064,B,955.0,Autocuration,CHEMBL884713,BAO_0000221,1886
,,H,,,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,1,,,,,4,,8868,B,,Autocuration,CHEMBL616483,BAO_0000224,1887
,,H,,,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,1,,,,,4,,9064,B,,Autocuration,CHEMBL616484,BAO_0000224,1888
,,H,,,104686,,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,1,,,,,4,,9806,B,,Autocuration,CHEMBL616485,BAO_0000019,1889
,,H,,,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,1,,,,,4,,9098,B,,Autocuration,CHEMBL616486,BAO_0000224,1890
,,H,,,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,1,,,,,4,,8868,B,,Autocuration,CHEMBL616487,BAO_0000224,1891
,,H,,,104686,,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,1,,,,,4,,12765,B,,Autocuration,CHEMBL616488,BAO_0000224,1892
,,H,,,104686,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,1,,,,,4,,11049,B,,Autocuration,CHEMBL616489,BAO_0000019,1893
,,H,,,104686,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,1,,,,,4,,11049,B,,Autocuration,CHEMBL616490,BAO_0000019,1894
,,H,,,104686,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,1,,,,,4,,11049,B,,Autocuration,CHEMBL616491,BAO_0000019,1895
,,H,,,104686,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,1,,,,,4,,11049,B,,Autocuration,CHEMBL616492,BAO_0000019,1896
,,H,,,104686,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,1,,,,,4,,11049,B,,Autocuration,CHEMBL616493,BAO_0000019,1897
,,H,,,104686,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,1,,,,,4,,11473,B,,Autocuration,CHEMBL616494,BAO_0000019,1898
,,H,,,104686,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,1,,,,,4,,11473,B,,Autocuration,CHEMBL616495,BAO_0000019,1899
,,H,,,104686,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,1,,,,,4,,3086,B,,Autocuration,CHEMBL616496,BAO_0000019,1900
,,H,,,104686,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,1,,,,,4,,11049,B,,Autocuration,CHEMBL616497,BAO_0000019,1901
,,H,,,104686,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,1,,,,,4,,11049,B,,Autocuration,CHEMBL616498,BAO_0000019,1902
,,H,,,104686,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,1,,,,,4,,10639,B,,Autocuration,CHEMBL616499,BAO_0000019,1903
,,H,,,104686,,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,1,,,,,4,,10922,B,,Autocuration,CHEMBL616500,BAO_0000019,1904
,,D,,,104686,10116.0,Rattus norvegicus,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,1,Brain,,,,5,,9064,B,955.0,Autocuration,CHEMBL616501,BAO_0000221,1905
,,H,,,104686,,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,1,Brain,,,,4,,10748,B,955.0,Autocuration,CHEMBL616502,BAO_0000221,1906
,Membranes,H,,,104686,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,1,,,,,4,,11614,B,,Autocuration,CHEMBL884529,BAO_0000249,1907
,Membranes,H,,,104686,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,1,,,,,4,,11615,B,,Autocuration,CHEMBL616503,BAO_0000249,1908
,,H,,,104686,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,1,,,,,4,,11615,B,,Autocuration,CHEMBL616964,BAO_0000224,1909
,Membranes,H,,,104686,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,1,,,,,4,,11614,B,,Autocuration,CHEMBL616965,BAO_0000249,1910
,,H,,,104686,,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,1,,,,,4,,11702,B,,Autocuration,CHEMBL616966,BAO_0000224,1911
,,H,,,104686,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,1,,,,,4,,11702,B,,Autocuration,CHEMBL616967,BAO_0000224,1912
,,D,,,104686,10116.0,Rattus norvegicus,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,1,,,,,5,,11702,B,,Autocuration,CHEMBL616968,BAO_0000224,1913
,,H,,,104686,,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,1,,,,,4,,11702,B,,Autocuration,CHEMBL616969,BAO_0000224,1914
,,H,,,104686,,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,1,,,,,4,,13346,B,,Autocuration,CHEMBL884530,BAO_0000019,1915
,,H,,,104686,,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,1,,,,,4,,10025,B,,Autocuration,CHEMBL616970,BAO_0000224,1916
,,H,,,104686,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,1,,,,,4,,10025,B,,Autocuration,CHEMBL616971,BAO_0000224,1917
,,H,,,104686,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",1,,,,,4,,10025,B,,Autocuration,CHEMBL616972,BAO_0000224,1918
,,H,,,104686,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,1,,,,,4,,9036,B,,Autocuration,CHEMBL616973,BAO_0000224,1919
,,H,,,104686,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,1,,,,,4,,9036,B,,Autocuration,CHEMBL616974,BAO_0000224,1920
,,H,,,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,1,,,,,4,,9161,B,,Autocuration,CHEMBL616975,BAO_0000019,1921
,,H,,,104686,,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,1,,,,,4,,12304,B,,Autocuration,CHEMBL616976,BAO_0000019,1922
,,H,,,104686,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,1,,,,,4,,13276,B,,Autocuration,CHEMBL616977,BAO_0000224,1923
,,H,,,104686,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,1,,,,,4,,11825,B,,Autocuration,CHEMBL616978,BAO_0000224,1924
,,H,,,104686,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,1,,,,,4,,12443,B,,Autocuration,CHEMBL616979,BAO_0000224,1925
,,H,,,104686,,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,1,,,,,4,,13830,B,,Autocuration,CHEMBL616980,BAO_0000224,1926
,Membranes,H,,,104686,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,1,,,,,4,,9592,B,,Autocuration,CHEMBL616981,BAO_0000249,1927
,Membranes,H,,,104686,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,1,,,,,4,,9592,B,,Autocuration,CHEMBL616982,BAO_0000249,1928
,,H,,,104686,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,1,,,,,4,,10881,B,,Autocuration,CHEMBL616983,BAO_0000224,1929
,,H,,,104686,,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,1,,,,,4,,13605,B,,Autocuration,CHEMBL616984,BAO_0000019,1930
,,D,,,104686,10116.0,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 2 receptor,1,,,,,5,,11624,B,,Autocuration,CHEMBL616985,BAO_0000224,1931
,,H,,,104686,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,1,,,,,4,,4101,B,,Autocuration,CHEMBL616986,BAO_0000224,1932
,,H,,,104686,,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,1,,,,,4,,4101,B,,Autocuration,CHEMBL616987,BAO_0000224,1933
,,H,,,104686,,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,1,,,,,4,,15360,B,,Autocuration,CHEMBL616988,BAO_0000019,1934
,,H,,,104686,,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,1,,,,,4,,11576,B,,Autocuration,CHEMBL617243,BAO_0000019,1935
,,H,,,104686,,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,1,,,,,4,,5834,B,,Autocuration,CHEMBL617244,BAO_0000019,1936
,,D,485.0,,104686,10116.0,Rattus norvegicus,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,1,,CHO-K1,,,5,,2395,B,,Autocuration,CHEMBL617245,BAO_0000219,1937
,Membranes,H,,,104686,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,1,,,,,4,,11965,B,,Autocuration,CHEMBL617246,BAO_0000249,1938
,,H,,,104686,,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),1,,,,,4,,3967,B,,Autocuration,CHEMBL617546,BAO_0000224,1939
,Brain membranes,H,,,104686,,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),1,,,,,4,,11130,B,,Autocuration,CHEMBL617547,BAO_0000249,1940
,,H,,,104686,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,1,,,,In vitro,4,,13427,B,,Autocuration,CHEMBL617548,BAO_0000219,1941
,,H,,,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,1,,,,,4,,9443,B,,Autocuration,CHEMBL617549,BAO_0000224,1942
,,H,,,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,1,,,,,4,,9443,B,,Autocuration,CHEMBL617550,BAO_0000224,1943
,,H,,,104686,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,1,,,,,4,,11825,B,,Autocuration,CHEMBL617551,BAO_0000224,1944
,Membranes,H,,,104686,,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,1,,,,,4,,12120,B,,Autocuration,CHEMBL617552,BAO_0000249,1945
,Membranes,H,,,104686,,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,1,,,,,4,,12120,B,,Autocuration,CHEMBL617553,BAO_0000249,1946
,,H,,,104686,,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,1,Thoracic aorta,,,,4,,11963,F,1515.0,Autocuration,CHEMBL617554,BAO_0000019,1947
,,H,,,104686,,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,1,,,,,4,,9069,B,,Autocuration,CHEMBL617555,BAO_0000019,1948
,,H,,,104686,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,1,,,,,4,,8868,B,,Autocuration,CHEMBL617556,BAO_0000224,1949
,,H,,,10624,,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,1,,,,,8,,17200,B,,Autocuration,CHEMBL617557,BAO_0000357,1950
,,H,,,10624,,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,1,,,,,8,,17200,B,,Autocuration,CHEMBL617558,BAO_0000357,1951
,,H,,,17106,,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,1,,,,,8,,13969,B,,Expert,CHEMBL617559,BAO_0000357,1952
,,D,,,17106,,,Binding affinity for 5-hydroxytryptamine 1D receptor,1,,,,,9,,13392,B,,Expert,CHEMBL617560,BAO_0000357,1953
,,H,,,17106,,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,1,,,,,8,,1742,B,,Autocuration,CHEMBL617561,BAO_0000249,1954
,,H,,,17106,,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,1,,,,,8,,1742,B,,Autocuration,CHEMBL617562,BAO_0000249,1955
,,H,,,17106,,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,1,Striatum,,,,8,,14331,B,2435.0,Autocuration,CHEMBL617563,BAO_0000357,1956
,,H,,,17106,,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,1,,,,,8,,12861,F,,Autocuration,CHEMBL617564,BAO_0000019,1957
,,H,,,17106,,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,1,,,,,8,,12861,B,,Expert,CHEMBL617565,BAO_0000019,1958
,,H,,,17106,,,Binding activity radioligand.,1,,,,,8,,12861,B,,Autocuration,CHEMBL856076,BAO_0000357,1959
,,H,,,17106,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,1,,,,,8,,12861,B,,Autocuration,CHEMBL617566,BAO_0000019,1960
,,H,,,17106,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,1,,,,,8,,12861,B,,Expert,CHEMBL875911,BAO_0000019,1961
,,H,,,17106,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,1,,,,,8,,12861,B,,Autocuration,CHEMBL617567,BAO_0000019,1962
,,H,,,17106,,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,1,,,,,8,,675,B,,Autocuration,CHEMBL617568,BAO_0000249,1963
,,H,,,17106,,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,1,,,,,8,,12490,B,,Expert,CHEMBL617569,BAO_0000019,1964
,,H,,,17106,,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,1,,,,,8,,11828,B,,Expert,CHEMBL617570,BAO_0000249,1965
,,H,,,17106,,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,1,,,,,8,,11866,B,,Autocuration,CHEMBL617571,BAO_0000357,1966
,,H,,,105,9823.0,Sus scrofa,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,1,,,,,8,,773,B,,Autocuration,CHEMBL617572,BAO_0000357,1967
,,H,,,105,9986.0,Oryctolagus cuniculus,The compound was tested for intrinsic activity against 5-HT1D receptor,1,,,,,8,,13047,B,,Expert,CHEMBL617573,BAO_0000357,1968
,,H,,,105,9986.0,Oryctolagus cuniculus,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,1,,,,,8,,13047,B,,Autocuration,CHEMBL617574,BAO_0000019,1969
,,H,,,105,9986.0,Oryctolagus cuniculus,The compound was tested for binding affinity against 5-HT1D receptor,1,,,,,8,,13047,B,,Expert,CHEMBL617575,BAO_0000357,1970
,,H,,,10578,,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,1,,,,,8,,188,B,,Autocuration,CHEMBL617576,BAO_0000357,1971
,,H,,,10578,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,1,,,,,8,,10639,F,,Autocuration,CHEMBL617577,BAO_0000019,1972
,,H,,,10578,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,1,,,,,8,,12438,F,,Autocuration,CHEMBL617578,BAO_0000019,1973
,,H,,,10578,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,1,,,,,8,,12438,B,,Autocuration,CHEMBL617579,BAO_0000357,1974
,,H,,,10578,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,1,,,,,8,,15854,B,,Expert,CHEMBL617580,BAO_0000019,1975
,,H,,,10578,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,1,,,,,8,,10394,B,,Autocuration,CHEMBL617581,BAO_0000249,1976
,,H,,,10578,,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,1,,,,,8,,12092,B,,Autocuration,CHEMBL617582,BAO_0000357,1977
,,H,,,10578,,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,1,,,,,8,,3389,B,,Expert,CHEMBL617583,BAO_0000019,1978
,,H,,,105,,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,1,,,,,8,,6011,B,,Autocuration,CHEMBL617584,BAO_0000357,1979
,,H,,,105,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,1,,,,,8,,4639,B,,Autocuration,CHEMBL617585,BAO_0000357,1980
,,H,,,105,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,1,,,,,8,,2474,B,,Autocuration,CHEMBL875912,BAO_0000357,1981
,,H,,,105,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,1,,,,,8,,5014,B,,Autocuration,CHEMBL617586,BAO_0000357,1982
,,H,,,105,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,1,,,,,8,,17515,B,,Autocuration,CHEMBL617587,BAO_0000357,1983
,,H,,,105,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,1,,,,,8,,11866,B,,Autocuration,CHEMBL617588,BAO_0000357,1984
,,H,,,105,,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,1,,,,,8,,4687,B,,Autocuration,CHEMBL857980,BAO_0000357,1985
,,H,,,105,,,Tested against 5-hydroxytryptamine 1D receptor,1,,,,,8,,12146,B,,Autocuration,CHEMBL617589,BAO_0000357,1986
,,H,,,105,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,1,,,,,8,,10321,B,,Autocuration,CHEMBL617590,BAO_0000357,1987
,,H,722.0,,105,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,1,,HEK293,,,8,,13267,B,,Autocuration,CHEMBL617591,BAO_0000219,1988
,,D,,,105,9606.0,Homo sapiens,Binding affinity against 5-Hydroxytryptamine 1D receptor,1,,,,,9,,1274,B,,Expert,CHEMBL617592,BAO_0000357,1989
,,H,,,105,,,,1,,,,,8,,15250,B,,Autocuration,CHEMBL617593,BAO_0000357,1990
,,H,485.0,,106,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,1,,CHO-K1,,,8,,13706,B,,Autocuration,CHEMBL617594,BAO_0000219,1991
,,H,485.0,,105,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,1,,CHO-K1,,,8,,13706,B,,Autocuration,CHEMBL617595,BAO_0000219,1992
,,H,722.0,,105,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,1,,HEK293,,,8,,13706,B,,Autocuration,CHEMBL617596,BAO_0000219,1993
,,H,722.0,,105,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,1,,HEK293,,,8,,13706,B,,Autocuration,CHEMBL617597,BAO_0000219,1994
,,H,,,105,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,1,,,,,8,,13047,B,,Autocuration,CHEMBL617598,BAO_0000019,1995
,,H,,,105,,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,1,,,,,8,,13366,B,,Autocuration,CHEMBL872916,BAO_0000357,1996
,,H,,,105,,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,1,,,,,8,,13366,B,,Expert,CHEMBL617599,BAO_0000357,1997
,,H,,,105,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,1,,,,,8,,1558,B,,Autocuration,CHEMBL617091,BAO_0000357,1998
,,H,485.0,,105,,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",1,,CHO-K1,,,8,,12902,B,,Expert,CHEMBL617092,BAO_0000219,1999
,,H,485.0,,105,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,1,,CHO-K1,,,8,,13706,B,,Autocuration,CHEMBL617093,BAO_0000219,2000
,,H,,,105,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,1,,,,,8,,13706,F,,Autocuration,CHEMBL617094,BAO_0000019,2001
,,H,,,105,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,1,,,,,8,,13706,F,,Autocuration,CHEMBL617095,BAO_0000019,2002
,,H,,,105,,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,1,,,,,8,,14251,F,,Autocuration,CHEMBL617096,BAO_0000019,2003
,,H,,,105,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,1,,,,,8,,14251,F,,Autocuration,CHEMBL617097,BAO_0000019,2004
,,H,,,105,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,1,,,,,8,,14251,F,,Autocuration,CHEMBL617098,BAO_0000019,2005
,,H,,,105,,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,1,,,,,8,,13313,B,,Autocuration,CHEMBL617301,BAO_0000357,2006
,,H,,,105,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,1,,,,,8,,13313,B,,Autocuration,CHEMBL617302,BAO_0000357,2007
,,H,,,105,,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,1,,,,,8,,13366,B,,Autocuration,CHEMBL617303,BAO_0000357,2008
,,H,,,105,,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,1,,,,,8,,13051,B,,Expert,CHEMBL617304,BAO_0000357,2009
,,H,449.0,,105,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",1,,CHO,,,8,,12903,B,,Expert,CHEMBL617305,BAO_0000219,2010
,,D,,,105,9606.0,Homo sapiens,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,1,,,,,9,,12469,B,,Autocuration,CHEMBL617306,BAO_0000219,2011
,,H,,,17106,,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,1,,,,,8,,5619,B,,Autocuration,CHEMBL617307,BAO_0000357,2012
,,H,,,105,9986.0,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,1,,,,,8,,13047,B,,Autocuration,CHEMBL617308,BAO_0000019,2013
,,H,,,105,,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,1,,,,,8,,16633,B,,Autocuration,CHEMBL617309,BAO_0000357,2014
,,H,,,105,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,1,,,,,8,,16633,B,,Autocuration,CHEMBL617310,BAO_0000357,2015
,,H,,,105,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,1,,,,,8,,16633,B,,Autocuration,CHEMBL617311,BAO_0000357,2016
,,H,,,105,,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,1,,,,,8,,16633,B,,Autocuration,CHEMBL617312,BAO_0000357,2017
,,H,,,105,,,Affinity against 5-hydroxytryptamine 1D receptor alpha,1,,,,,8,,3269,B,,Autocuration,CHEMBL617313,BAO_0000357,2018
,,H,,,105,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,1,,,,,8,,12409,B,,Expert,CHEMBL617314,BAO_0000357,2019
,,H,,,106,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,1,,,,,8,,13706,F,,Autocuration,CHEMBL617315,BAO_0000019,2020
,,H,722.0,,106,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,1,,HEK293,,,8,,13706,B,,Autocuration,CHEMBL617316,BAO_0000219,2021
,,H,722.0,,106,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,1,,HEK293,,,8,,13706,B,,Autocuration,CHEMBL617317,BAO_0000219,2022
,,H,449.0,,106,,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",1,,CHO,,,8,,12903,B,,Autocuration,CHEMBL617318,BAO_0000219,2023
,,H,,,106,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,1,,,,,8,,13047,B,,Autocuration,CHEMBL617319,BAO_0000019,2024
,,D,,,106,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,1,,,,,9,,13366,B,,Expert,CHEMBL617320,BAO_0000357,2025
,,D,,,106,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,1,,,,,9,,13366,B,,Expert,CHEMBL617321,BAO_0000357,2026
,,D,,,106,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,1,,,,,9,,13366,B,,Expert,CHEMBL617322,BAO_0000357,2027
,,H,,,106,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,1,,,,,8,,13366,B,,Autocuration,CHEMBL616862,BAO_0000357,2028
,,H,,,106,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,1,,,,,8,,13366,B,,Autocuration,CHEMBL616863,BAO_0000357,2029
,,H,449.0,,106,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,1,,CHO,,,8,,12469,B,,Autocuration,CHEMBL616864,BAO_0000219,2030
,,H,485.0,,106,,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,1,,CHO-K1,,,8,,13706,B,,Autocuration,CHEMBL616865,BAO_0000219,2031
,,H,485.0,,106,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,1,,CHO-K1,,,8,,13706,B,,Autocuration,CHEMBL616866,BAO_0000219,2032
,,H,,,106,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,1,,,,,8,,13706,F,,Autocuration,CHEMBL616867,BAO_0000019,2033
,,H,485.0,,106,,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",1,,CHO-K1,,,8,,12902,B,,Expert,CHEMBL616868,BAO_0000219,2034
,,H,,,105,,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,1,,,,,8,,13051,B,,Expert,CHEMBL616869,BAO_0000357,2035
,,H,449.0,,106,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",1,,CHO,,,8,,12903,B,,Expert,CHEMBL616870,BAO_0000219,2036
,,H,485.0,,105,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,1,,CHO-K1,,,8,,1558,F,,Autocuration,CHEMBL616871,BAO_0000219,2037
,,H,485.0,,105,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,1,,CHO-K1,,,8,,1558,F,,Autocuration,CHEMBL616872,BAO_0000219,2038
,,H,485.0,,105,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,1,,CHO-K1,,,8,,1558,F,,Autocuration,CHEMBL616873,BAO_0000219,2039
,,H,485.0,,105,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,1,,CHO-K1,,,8,,1558,F,,Autocuration,CHEMBL616838,BAO_0000219,2040
,,H,,,105,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,1,,,,,8,,1558,B,,Autocuration,CHEMBL616839,BAO_0000357,2041
,,H,,,106,9986.0,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,1,,,,,8,,13047,B,,Autocuration,CHEMBL616840,BAO_0000019,2042
,,H,,,105,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,1,,,,,8,,13313,B,,Autocuration,CHEMBL616841,BAO_0000357,2043
,,H,,,105,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,1,,,,,8,,13313,B,,Autocuration,CHEMBL616842,BAO_0000357,2044
,,H,,,105,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,1,,,,,8,,12409,B,,Expert,CHEMBL857976,BAO_0000357,2045
,,H,449.0,,10618,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,1,,CHO,,,8,,15250,B,,Autocuration,CHEMBL616843,BAO_0000219,2046
,,D,,,10618,9606.0,Homo sapiens,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,1,,,,,9,,1348,B,,Expert,CHEMBL616844,BAO_0000357,2047
,,H,,,10618,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,1,,,,,8,,1348,B,,Autocuration,CHEMBL616845,BAO_0000357,2048
,,D,,,10618,9606.0,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,1,,,,,9,,4234,B,,Expert,CHEMBL616846,BAO_0000357,2049
,,H,,,10618,,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,1,,,,,8,,16209,B,,Autocuration,CHEMBL616847,BAO_0000357,2050
,,H,,,10618,,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,1,,,,,8,,10444,B,,Autocuration,CHEMBL616848,BAO_0000019,2051
,,H,,,10618,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,1,,,,,8,,3935,B,,Autocuration,CHEMBL616849,BAO_0000357,2052
,,H,,,10618,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,1,,,,,8,,15818,B,,Autocuration,CHEMBL872911,BAO_0000357,2053
,,H,,,10618,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,1,,,,,8,,17085,B,,Autocuration,CHEMBL616850,BAO_0000019,2054
,,D,449.0,,10618,9606.0,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,1,,CHO,,,9,,12936,B,,Expert,CHEMBL616699,BAO_0000219,2055
,,H,,,10618,,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,1,,,,,8,,6166,B,,Autocuration,CHEMBL616700,BAO_0000357,2056
,,H,449.0,,10618,,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,1,,CHO,,,8,,15779,B,,Autocuration,CHEMBL616701,BAO_0000219,2057
,,H,449.0,,10618,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,1,,CHO,,,8,,15779,B,,Autocuration,CHEMBL616702,BAO_0000219,2058
,,H,449.0,,10618,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,1,,CHO,,,8,,15779,B,,Autocuration,CHEMBL616703,BAO_0000219,2059
,,H,,,10618,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,1,,,,,8,,13181,B,,Autocuration,CHEMBL616704,BAO_0000357,2060
,,H,449.0,,10618,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,1,,CHO,,,8,,4199,B,,Autocuration,CHEMBL616705,BAO_0000219,2061
,,H,,,10618,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,1,,,,,8,,14875,B,,Autocuration,CHEMBL616706,BAO_0000357,2062
,,H,449.0,,10618,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,1,,CHO,,,8,,15146,B,,Autocuration,CHEMBL616707,BAO_0000219,2063
,,H,,,10618,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,1,,,,,8,,5213,B,,Autocuration,CHEMBL616708,BAO_0000357,2064
,,H,,,10618,,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,1,,,,,8,,12146,B,,Autocuration,CHEMBL616709,BAO_0000357,2065
,,H,449.0,,10618,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,1,,CHO,,,8,,13267,B,,Autocuration,CHEMBL616710,BAO_0000219,2066
,,H,449.0,,10618,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,1,,CHO,,,8,,14818,B,,Autocuration,CHEMBL616711,BAO_0000219,2067
,,H,449.0,,10618,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",1,,CHO,,,8,,4829,B,,Autocuration,CHEMBL616712,BAO_0000219,2068
,,H,,,10618,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,1,,,,,8,,4373,B,,Autocuration,CHEMBL616713,BAO_0000357,2069
,,H,,,10618,,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,1,,,,,8,,4373,B,,Autocuration,CHEMBL616714,BAO_0000357,2070
,,H,,,10618,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,1,,,,,8,,14159,B,,Autocuration,CHEMBL616715,BAO_0000357,2071
,,H,,,10618,,,Binding affinity towards 5-hydroxytryptamine 1E receptor,1,,,,,8,,16633,B,,Autocuration,CHEMBL616716,BAO_0000357,2072
,,H,,,279,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",1,,,,,8,,17085,F,,Autocuration,CHEMBL616717,BAO_0000019,2073
,,H,,,279,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",1,,,,,8,,17085,F,,Expert,CHEMBL616718,BAO_0000019,2074
,,H,,,279,,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,1,,,,,8,,16209,F,,Autocuration,CHEMBL875905,BAO_0000019,2075
,,H,,,279,,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,1,,,,,8,,16209,F,,Autocuration,CHEMBL616719,BAO_0000019,2076
,,H,,,279,,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",1,,,,,8,,17085,F,,Expert,CHEMBL616720,BAO_0000019,2077
,,H,,,279,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,1,,,,,8,,14159,B,,Autocuration,CHEMBL616721,BAO_0000357,2078
,,H,449.0,,279,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,1,,CHO,,,8,,15250,B,,Autocuration,CHEMBL616722,BAO_0000219,2079
,,H,,,279,,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),1,,,,,8,,3805,B,,Autocuration,CHEMBL616723,BAO_0000357,2080
,,H,449.0,,279,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,1,,CHO,,,8,,16190,B,,Autocuration,CHEMBL616724,BAO_0000219,2081
,,H,,,279,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,1,,,,,8,,16190,B,,Autocuration,CHEMBL616725,BAO_0000357,2082
,,H,,,279,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,1,,,,,8,,16209,B,,Autocuration,CHEMBL616726,BAO_0000357,2083
,,H,,,279,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,1,,,,,8,,16209,B,,Autocuration,CHEMBL616727,BAO_0000357,2084
,,H,,,279,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,1,,,,,8,,16209,B,,Autocuration,CHEMBL616728,BAO_0000357,2085
,,H,,,279,,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,1,,,,,8,,6866,B,,Autocuration,CHEMBL616729,BAO_0000357,2086
,,H,,,279,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,1,,,,,8,,17085,B,,Expert,CHEMBL616730,BAO_0000019,2087
,,H,,,279,,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,1,,,,,8,,16312,B,,Autocuration,CHEMBL617125,BAO_0000357,2088
,,H,,,279,,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,1,,,,,8,,6166,B,,Autocuration,CHEMBL857977,BAO_0000357,2089
,,H,449.0,,279,,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,1,,CHO,,,8,,15779,B,,Autocuration,CHEMBL617126,BAO_0000219,2090
,,H,449.0,,279,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,1,,CHO,,,8,,4199,B,,Autocuration,CHEMBL617127,BAO_0000219,2091
,,H,,,279,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,1,,,,,8,,14875,B,,Autocuration,CHEMBL617128,BAO_0000357,2092
,,H,449.0,,279,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,1,,CHO,,,8,,15146,B,,Autocuration,CHEMBL617129,BAO_0000219,2093
,,H,,,279,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,1,,,,,8,,5213,B,,Autocuration,CHEMBL617130,BAO_0000357,2094
,,H,449.0,,279,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,1,,CHO,,,8,,14818,B,,Autocuration,CHEMBL617131,BAO_0000219,2095
,,H,449.0,,279,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",1,,CHO,,,8,,4829,B,,Autocuration,CHEMBL617132,BAO_0000219,2096
,,H,449.0,,279,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",1,,CHO,,,8,,4829,B,,Autocuration,CHEMBL617133,BAO_0000219,2097
,,H,,,279,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,1,,,,,8,,4373,B,,Autocuration,CHEMBL617134,BAO_0000357,2098
,,H,,,279,,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,1,,,,,8,,4373,B,,Autocuration,CHEMBL617135,BAO_0000357,2099
,,H,,,279,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,1,,,,,8,,5014,B,,Autocuration,CHEMBL617136,BAO_0000357,2100
,,H,,,104686,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",1,,,,,4,,11662,B,,Autocuration,CHEMBL617137,BAO_0000019,2101
,,H,,,104686,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",1,,,,,4,,11662,B,,Autocuration,CHEMBL617138,BAO_0000019,2102
,,H,,,104686,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",1,,,,,4,,11662,B,,Autocuration,CHEMBL617139,BAO_0000019,2103
,,H,,,12687,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,1,,,,,8,,14093,B,,Autocuration,CHEMBL617140,BAO_0000019,2104
,,H,,,104686,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",1,,,,In vivo,4,,11200,F,,Autocuration,CHEMBL617141,BAO_0000218,2105
,,H,,,104686,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,1,,,,,4,,11200,F,,Autocuration,CHEMBL858112,BAO_0000019,2106
,,H,,,17005,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,1,,,,,8,,12352,B,,Intermediate,CHEMBL617142,BAO_0000019,2107
,,U,,,22226,9913.0,Bos taurus,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",1,,,,,0,,13657,B,,Autocuration,CHEMBL617143,BAO_0000019,2108
,,U,,,22226,9913.0,Bos taurus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,1,,,,,0,,14331,B,,Autocuration,CHEMBL617144,BAO_0000019,2109
,,U,,,22226,9913.0,Bos taurus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,1,,,,,0,,14331,B,,Autocuration,CHEMBL617145,BAO_0000019,2110
,,U,,,22226,,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,1,,,,,0,,14331,B,,Autocuration,CHEMBL617146,BAO_0000019,2111
,,H,,,104784,10141.0,Cavia porcellus,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,1,,,,,4,,12685,B,,Autocuration,CHEMBL617147,BAO_0000019,2112
,,H,,,104784,10141.0,Cavia porcellus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,1,,,,,4,,14389,B,,Autocuration,CHEMBL617148,BAO_0000019,2113
,,H,,,104784,10141.0,Cavia porcellus,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,1,,,,,4,,14386,B,,Autocuration,CHEMBL617149,BAO_0000019,2114
,,H,,,104784,,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,1,,,,,4,,5732,B,,Autocuration,CHEMBL617150,BAO_0000224,2115
,,H,,,104784,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,1,,,,,4,,16293,B,,Autocuration,CHEMBL617151,BAO_0000224,2116
,,H,,,104784,,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,1,,,,,4,,2078,B,,Autocuration,CHEMBL617201,BAO_0000224,2117
,,H,,,10209,,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,1,,,,,8,,5486,B,,Autocuration,CHEMBL617202,BAO_0000357,2118
,,H,,,104826,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,1,,,,In vivo,4,,11820,B,,Autocuration,CHEMBL617203,BAO_0000218,2119
,,H,,,104826,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,1,,,,,4,,10297,B,,Autocuration,CHEMBL617204,BAO_0000019,2120
,,H,,,104826,,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,1,,,,,4,,13704,B,,Autocuration,CHEMBL617205,BAO_0000224,2121
,,D,,,104826,10090.0,Mus musculus,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,1,,,,,5,,10297,B,,Autocuration,CHEMBL617206,BAO_0000019,2122
,,H,,,104826,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,1,,,,In vivo,4,,11820,B,,Autocuration,CHEMBL617207,BAO_0000218,2123
,,D,,,104826,10090.0,Mus musculus,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,1,,,,,5,,10297,B,,Autocuration,CHEMBL617208,BAO_0000019,2124
,,H,,,104826,,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,1,,,,,4,,11555,B,,Autocuration,CHEMBL617209,BAO_0000224,2125
,,H,,,104826,,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,1,,,,,4,,11555,B,,Autocuration,CHEMBL617210,BAO_0000224,2126
,,H,,,104826,,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,1,,,,,4,,11555,B,,Autocuration,CHEMBL617211,BAO_0000224,2127
,,D,,,104826,10090.0,Mus musculus,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,1,,,,,5,,10297,B,,Autocuration,CHEMBL617212,BAO_0000019,2128
,,H,,,104784,9823.0,Sus scrofa,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,1,,,,,4,,16688,B,,Autocuration,CHEMBL617213,BAO_0000224,2129
,,H,,,104784,9823.0,Sus scrofa,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,1,,,,,4,,16688,B,,Autocuration,CHEMBL617214,BAO_0000224,2130
,,U,,,22226,,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,1,,,,,0,,5333,B,,Autocuration,CHEMBL617215,BAO_0000221,2131
,,U,,,22226,,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,1,,,,,0,,4437,B,,Autocuration,CHEMBL617216,BAO_0000221,2132
,,H,,,17005,9823.0,Sus scrofa,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,1,,,,,8,,5033,B,,Autocuration,CHEMBL617217,BAO_0000357,2133
,,H,,,104686,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,1,,,,,4,,15267,B,,Autocuration,CHEMBL617218,BAO_0000019,2134
,,H,,,104686,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,1,,,,,4,,15267,B,,Autocuration,CHEMBL872913,BAO_0000019,2135
,,H,,,104826,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,1,,,,,4,,11820,B,,Autocuration,CHEMBL617219,BAO_0000019,2136
,,H,,,104686,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,1,,,,,4,,9069,B,,Autocuration,CHEMBL873482,BAO_0000224,2137
,,D,,,104686,10116.0,Rattus norvegicus,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,1,,,,,5,,9162,B,,Autocuration,CHEMBL617220,BAO_0000019,2138
,,H,,,104686,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,1,,,,,4,,9162,B,,Autocuration,CHEMBL617221,BAO_0000019,2139
,,H,,,104686,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,1,,,,,4,,9162,B,,Autocuration,CHEMBL617222,BAO_0000019,2140
,,H,,,104686,,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,1,,,,,4,,10428,F,,Autocuration,CHEMBL875906,BAO_0000019,2141
,,H,,,104686,,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,1,,,,,4,,9628,B,,Autocuration,CHEMBL617223,BAO_0000019,2142
,,H,,,104686,,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,1,,,,,4,,12704,B,,Autocuration,CHEMBL617224,BAO_0000224,2143
,,D,,,104686,10116.0,Rattus norvegicus,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,1,,,,,5,,15453,B,,Autocuration,CHEMBL617225,BAO_0000224,2144
,,H,,,104686,,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,1,,,,,4,,188,B,,Autocuration,CHEMBL617226,BAO_0000224,2145
,,H,,,104686,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,1,,,,,4,,10349,B,,Autocuration,CHEMBL617227,BAO_0000224,2146
,,H,,,104686,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,1,,,,,4,,10349,B,,Autocuration,CHEMBL617228,BAO_0000224,2147
,,H,,,104686,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,1,,,,,4,,8868,B,,Autocuration,CHEMBL617229,BAO_0000224,2148
,,H,,,104686,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,1,,,,,4,,10025,B,,Autocuration,CHEMBL617230,BAO_0000224,2149
,,H,,,104686,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",1,,,,,4,,10025,B,,Autocuration,CHEMBL617231,BAO_0000224,2150
,,H,,,104686,,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,1,,,,,4,,11702,B,,Autocuration,CHEMBL617232,BAO_0000224,2151
,,H,,,104686,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,1,,,,,4,,11702,B,,Autocuration,CHEMBL617233,BAO_0000224,2152
,,H,,,104686,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,1,,,,,4,,11702,B,,Autocuration,CHEMBL617234,BAO_0000224,2153
,,H,,,104686,,,Compound was tested for the inhibition of quipazine induced head twitches in rats,1,,,,,4,,11702,F,,Autocuration,CHEMBL617235,BAO_0000019,2154
,,H,,,104686,,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,1,,,,,4,,11702,F,,Autocuration,CHEMBL617236,BAO_0000019,2155
,,H,,,104686,,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,1,Hippocampus,,,,4,,10085,B,10000000.0,Autocuration,CHEMBL617237,BAO_0000221,2156
,,H,,,104686,,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,1,Hippocampus,,,,4,,10085,B,10000000.0,Autocuration,CHEMBL617238,BAO_0000221,2157
,,D,,,104686,10116.0,Rattus norvegicus,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,1,Brain,,,,5,,9630,B,955.0,Autocuration,CHEMBL617239,BAO_0000221,2158
,,H,,,104686,,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,1,,,,,4,,11070,B,,Autocuration,CHEMBL617240,BAO_0000019,2159
,Membranes,H,,,104686,,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,1,,,,,4,,9841,B,,Autocuration,CHEMBL617241,BAO_0000249,2160
,Membranes,H,,,104686,,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,1,,,,,4,,9841,B,,Autocuration,CHEMBL875907,BAO_0000249,2161
,,H,,,104686,,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,1,,,,,4,,13291,B,,Autocuration,CHEMBL617242,BAO_0000019,2162
,,H,,,104686,,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,1,,,,,4,,10590,F,,Autocuration,CHEMBL617152,BAO_0000019,2163
,,D,,,104686,10116.0,Rattus norvegicus,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,1,Brain,,,,5,,9064,B,955.0,Autocuration,CHEMBL617153,BAO_0000221,2164
,Membranes,D,,,104686,10116.0,Rattus norvegicus,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,1,,,,,5,,12268,B,,Autocuration,CHEMBL617154,BAO_0000249,2165
,,H,,,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,1,Brain,,,,4,,13508,B,955.0,Autocuration,CHEMBL617155,BAO_0000221,2166
,,H,,,104686,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,1,,,,,4,,11279,F,,Autocuration,CHEMBL617156,BAO_0000019,2167
,,H,,,104686,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,1,,,,,4,,11200,F,,Autocuration,CHEMBL617157,BAO_0000019,2168
,,H,,,104686,,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,1,,,,,4,,11200,F,,Autocuration,CHEMBL617158,BAO_0000019,2169
,,H,,,104686,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,1,,,,,4,,11200,F,,Autocuration,CHEMBL617159,BAO_0000019,2170
,,H,,,104686,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,1,,,,,4,,11200,F,,Autocuration,CHEMBL617160,BAO_0000019,2171
,,H,,,104686,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,1,,,,,4,,11200,F,,Autocuration,CHEMBL858113,BAO_0000019,2172
,,H,,,104686,,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,1,Brain,,,,4,,9231,B,955.0,Autocuration,CHEMBL617247,BAO_0000220,2173
,,H,,,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,1,,,,,4,,9737,B,,Autocuration,CHEMBL617248,BAO_0000019,2174
,,H,,,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,1,Brain,,,,4,,9737,B,955.0,Autocuration,CHEMBL617249,BAO_0000249,2175
,,H,,,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,1,,,,,4,,9737,B,,Autocuration,CHEMBL617250,BAO_0000019,2176
,,H,,,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,1,,,,,4,,9737,B,,Autocuration,CHEMBL617251,BAO_0000019,2177
,,D,,,104686,10116.0,Rattus norvegicus,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,1,,,,,5,,11828,B,,Autocuration,CHEMBL617252,BAO_0000019,2178
,,H,,,104686,,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,1,,,,,4,,12253,B,,Autocuration,CHEMBL617006,BAO_0000019,2179
,,H,,,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,1,,,,,4,,12253,B,,Autocuration,CHEMBL617007,BAO_0000019,2180
,,H,,,104686,,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",1,,,,,4,,11279,F,,Autocuration,CHEMBL617008,BAO_0000019,2181
,,H,,,104686,,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,1,,,,,4,,11866,B,,Autocuration,CHEMBL617009,BAO_0000019,2182
,,D,,,104686,10116.0,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,1,,,,,5,,14424,B,,Autocuration,CHEMBL617010,BAO_0000224,2183
,,D,,,104686,10116.0,Rattus norvegicus,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,1,,,,,5,,15180,B,,Autocuration,CHEMBL857978,BAO_0000019,2184
,,D,,,104686,10116.0,Rattus norvegicus,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,1,,,,,5,,15180,B,,Autocuration,CHEMBL617011,BAO_0000019,2185
,,D,,,104686,10116.0,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,1,,,,,5,,9786,B,,Autocuration,CHEMBL617012,BAO_0000019,2186
,,H,,,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,1,,,,,4,,12132,B,,Autocuration,CHEMBL617013,BAO_0000224,2187
,,H,,,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,1,,,,,4,,5486,B,,Autocuration,CHEMBL617014,BAO_0000249,2188
,,H,,,104686,,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,1,,,,,4,,15316,B,,Autocuration,CHEMBL617015,BAO_0000019,2189
,,H,,,104686,,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,1,,,,,4,,16429,B,,Autocuration,CHEMBL617016,BAO_0000019,2190
,,H,,,104686,,,pKi value for 5-hydroxytryptamine 2 receptor binding site,1,,,,,4,,14617,B,,Autocuration,CHEMBL617017,BAO_0000224,2191
,,H,,,104686,,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,1,Brain,,,,4,,11351,B,955.0,Autocuration,CHEMBL617018,BAO_0000221,2192
,,H,,,104686,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,1,,,,,4,,11279,F,,Autocuration,CHEMBL617019,BAO_0000019,2193
,,H,,,105075,,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,1,,,,,4,,9523,B,,Autocuration,CHEMBL617020,BAO_0000019,2194
,,H,,,105075,,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,1,,,,,4,,9523,B,,Autocuration,CHEMBL617021,BAO_0000019,2195
,,H,,,105075,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,1,,,,,4,,9523,B,,Autocuration,CHEMBL617022,BAO_0000019,2196
,,H,,,105075,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,1,,,,,4,,9523,B,,Autocuration,CHEMBL617023,BAO_0000019,2197
,,H,,,105075,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,1,,,,,4,,9523,B,,Autocuration,CHEMBL617024,BAO_0000019,2198
,,H,,,105075,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,1,,,,,4,,9523,B,,Autocuration,CHEMBL617025,BAO_0000019,2199
,,H,,,105075,,,Hill coefficient of compound was determined,1,,,,,4,,9523,B,,Autocuration,CHEMBL617026,BAO_0000224,2200
,,U,,,22226,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,1,,,,,0,,4771,B,,Autocuration,CHEMBL617027,BAO_0000019,2201
,,D,,,104686,10116.0,Rattus norvegicus,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,1,,,,,5,,5033,B,,Autocuration,CHEMBL617028,BAO_0000019,2202
,,H,,,12687,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,1,,,,,8,,10845,B,,Expert,CHEMBL617029,BAO_0000019,2203
,,H,,,12687,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,1,,,,,8,,10845,B,,Expert,CHEMBL875908,BAO_0000019,2204
,,H,,,12687,,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),1,,,,,8,,16288,B,,Autocuration,CHEMBL617030,BAO_0000357,2205
,,H,,,12687,,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),1,,,,,8,,16288,B,,Autocuration,CHEMBL617031,BAO_0000019,2206
,,H,,,12687,,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,1,,,,,8,,16190,B,,Autocuration,CHEMBL617032,BAO_0000019,2207
,,D,,,104686,10116.0,Rattus norvegicus,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,1,,,,,5,,12463,B,,Autocuration,CHEMBL617033,BAO_0000224,2208
,,H,,,104686,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",1,,,,,4,,9699,B,,Autocuration,CHEMBL617034,BAO_0000224,2209
,,H,,,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,1,,,,,4,,9699,B,,Autocuration,CHEMBL617035,BAO_0000224,2210
,,H,,,104686,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",1,,,,,4,,11662,B,,Autocuration,CHEMBL617036,BAO_0000019,2211
,,H,,,104784,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,1,,,,,4,,1205,B,,Autocuration,CHEMBL617037,BAO_0000224,2212
,,U,,,22226,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,1,,,,,0,,11376,B,,Autocuration,CHEMBL617038,BAO_0000219,2213
,,H,,,104784,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",1,,,,,4,,11376,B,,Autocuration,CHEMBL617039,BAO_0000219,2214
,,H,,,104784,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,1,,,,,4,,4639,B,,Autocuration,CHEMBL617161,BAO_0000224,2215
,,H,,,104784,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,1,,,,,4,,2222,B,,Autocuration,CHEMBL617162,BAO_0000224,2216
,,H,,,104784,,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,1,,,,,4,,1558,B,,Autocuration,CHEMBL617163,BAO_0000224,2217
,,H,,,104784,,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,1,,,,,4,,1089,B,,Autocuration,CHEMBL617164,BAO_0000224,2218
,Brain membranes,H,,,104784,,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,1,,,,,4,,386,B,,Autocuration,CHEMBL617165,BAO_0000249,2219
,,H,,,104784,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,1,,,,,4,,2474,B,,Autocuration,CHEMBL617166,BAO_0000224,2220
,,H,,,104784,,,Binding affinity towards 5-HT2 receptor,1,,,,,4,,17066,B,,Autocuration,CHEMBL617167,BAO_0000224,2221
,,H,,,104784,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,1,,,,,4,,959,B,,Autocuration,CHEMBL872912,BAO_0000224,2222
,,H,,,104784,,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,1,,,,,4,,6398,B,,Autocuration,CHEMBL617168,BAO_0000224,2223
,,H,,,104686,,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,1,,,,,4,,11889,B,,Autocuration,CHEMBL617169,BAO_0000224,2224
,,H,,,104784,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,1,,,,,4,,4221,B,,Autocuration,CHEMBL617170,BAO_0000224,2225
,,H,,,104784,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,1,,,,,4,,11026,B,,Autocuration,CHEMBL617171,BAO_0000224,2226
,,H,,,104784,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,1,,,,,4,,11866,B,,Autocuration,CHEMBL617172,BAO_0000224,2227
,,H,,,104784,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,1,,,,,4,,4221,B,,Autocuration,CHEMBL617173,BAO_0000224,2228
,,U,,,22226,,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,1,,,,,0,,13950,B,,Autocuration,CHEMBL617174,BAO_0000019,2229
,,H,,,104784,,,5-hydroxytryptamine 2 receptor binding affinity,1,,,,,4,,1263,B,,Autocuration,CHEMBL617175,BAO_0000224,2230
,,H,,,17005,,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,1,,,,,8,,13291,B,,Autocuration,CHEMBL617176,BAO_0000357,2231
,,H,,,17005,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,1,,,,,8,,10812,B,,Autocuration,CHEMBL617177,BAO_0000357,2232
,,H,,,104784,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,1,,,,,4,,13020,B,,Autocuration,CHEMBL617178,BAO_0000224,2233
,,H,,,104784,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,1,,,,,4,,13021,B,,Autocuration,CHEMBL617179,BAO_0000224,2234
,,H,,,104784,,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,1,,,,,4,,13020,B,,Autocuration,CHEMBL617180,BAO_0000224,2235
,,H,,,17005,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,1,,,,,8,,14532,B,,Autocuration,CHEMBL617181,BAO_0000357,2236
,,H,,,17005,,,Binding affinity against 5-hydroxytryptamine 2 receptor,1,,,,,8,,13944,B,,Autocuration,CHEMBL617182,BAO_0000357,2237
,,H,,,17005,,,Binding affinity against 5-hydroxytryptamine 2 receptor,1,,,,,8,,14331,B,,Autocuration,CHEMBL617183,BAO_0000357,2238
,,H,,,17005,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,1,,,,,8,,14118,B,,Autocuration,CHEMBL617184,BAO_0000357,2239
,,H,,,17005,,,Binding affinity against serotonergic 5-HT2 receptor,1,,,,,8,,13033,B,,Autocuration,CHEMBL617185,BAO_0000357,2240
,,H,,,17005,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,1,,,,,8,,10321,B,,Autocuration,CHEMBL617186,BAO_0000357,2241
,,H,,,17005,,,Compound was evaluated for the binding affinity at 5- HT2 receptor,1,,,,,8,,12918,B,,Autocuration,CHEMBL617187,BAO_0000357,2242
,,H,,,17005,,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,1,,,,,8,,15120,B,,Autocuration,CHEMBL617188,BAO_0000357,2243
,,H,,,17005,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,1,,,,,8,,2613,B,,Autocuration,CHEMBL617189,BAO_0000218,2244
,,D,,,104784,9606.0,Homo sapiens,Inhibitory activity against cloned human 5-HT2 receptor,1,,,,,5,,13378,B,,Autocuration,CHEMBL617190,BAO_0000224,2245
,,D,449.0,,104784,9606.0,Homo sapiens,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",1,,CHO,,,5,,2331,B,,Autocuration,CHEMBL617191,BAO_0000219,2246
,,D,449.0,,104784,9606.0,Homo sapiens,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",1,,CHO,,,5,,2331,B,,Autocuration,CHEMBL617192,BAO_0000219,2247
,,D,449.0,,104784,9606.0,Homo sapiens,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",1,,CHO,,,5,,2331,B,,Autocuration,CHEMBL617193,BAO_0000219,2248
,,D,449.0,,104784,9606.0,Homo sapiens,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",1,,CHO,,,5,,2331,B,,Autocuration,CHEMBL617194,BAO_0000219,2249
,,H,,,104784,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,1,,,,,4,,4170,B,,Autocuration,CHEMBL617195,BAO_0000224,2250
,,H,,,104784,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,1,,,,,4,,15453,B,,Autocuration,CHEMBL881830,BAO_0000224,2251
,,H,,,17005,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,1,,,,,8,,1479,B,,Autocuration,CHEMBL617196,BAO_0000357,2252
,,H,,,104686,,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,1,,,,,4,,11139,B,,Autocuration,CHEMBL617197,BAO_0000224,2253
,,H,,,17005,,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,1,,,,,8,,13969,B,,Expert,CHEMBL617198,BAO_0000357,2254
,,H,,,17005,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,1,,,,,8,,13392,B,,Expert,CHEMBL873476,BAO_0000357,2255
,,H,,,17005,,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,1,,,,,8,,14430,B,,Expert,CHEMBL617199,BAO_0000019,2256
,,H,,,107,10141.0,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,1,,,,,8,,13181,B,,Autocuration,CHEMBL617200,BAO_0000357,2257
,,H,,,51,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,1,,,,,8,,17200,B,,Autocuration,CHEMBL617484,BAO_0000357,2258
,,H,,,107,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,1,,,,,8,,17200,B,,Autocuration,CHEMBL617485,BAO_0000357,2259
,,H,,,51,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,1,,,,,8,,17200,B,,Autocuration,CHEMBL617486,BAO_0000357,2260
,,H,,,107,,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,1,,,,,8,,13463,B,,Autocuration,CHEMBL858022,BAO_0000357,2261
,,H,449.0,,107,,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,1,,CHO,,,8,,6347,B,,Autocuration,CHEMBL617049,BAO_0000219,2262
,,D,449.0,,107,9606.0,Homo sapiens,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,1,,CHO,,,9,,6857,F,,Expert,CHEMBL617050,BAO_0000219,2263
,,H,,,107,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,1,,,,,8,,4176,F,,Autocuration,CHEMBL617051,BAO_0000219,2264
,,H,,,107,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,1,,,,,8,,4176,F,,Autocuration,CHEMBL617052,BAO_0000219,2265
,,H,,,107,,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,1,,,,,8,,4176,F,,Autocuration,CHEMBL617053,BAO_0000219,2266
,,H,449.0,,107,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",1,,CHO,,,8,,6347,B,,Autocuration,CHEMBL617054,BAO_0000219,2267
,,H,449.0,,107,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",1,,CHO,,,8,,6347,B,,Autocuration,CHEMBL617055,BAO_0000219,2268
,,H,,,107,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,1,,,,,8,,15331,B,,Autocuration,CHEMBL882924,BAO_0000357,2269
,,D,,,107,9606.0,Homo sapiens,Inhibition of human 5-hydroxytryptamine 2A receptor,1,,,,,9,,16146,B,,Expert,CHEMBL617056,BAO_0000357,2270
,,H,449.0,,107,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,1,,CHO,,,8,,15250,B,,Autocuration,CHEMBL617057,BAO_0000219,2271
,,H,,,107,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,1,,,,,8,,13631,B,,Expert,CHEMBL617058,BAO_0000219,2272
,,H,,,107,,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),1,,,,,8,,3805,B,,Autocuration,CHEMBL617059,BAO_0000357,2273
,,H,449.0,,107,,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,1,,CHO,,,8,,4011,B,,Autocuration,CHEMBL617060,BAO_0000219,2274
,,H,449.0,,107,,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,1,,CHO,,,8,,4012,B,,Expert,CHEMBL617061,BAO_0000219,2275
,,H,307.0,,107,,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,1,,L929,,,8,,6366,B,,Expert,CHEMBL617062,BAO_0000219,2276
,,H,449.0,,107,,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,1,,CHO,,,8,,15949,B,,Expert,CHEMBL617063,BAO_0000219,2277
,,H,,,107,,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,1,,,,,8,,14093,F,,Autocuration,CHEMBL617064,BAO_0000019,2278
,,H,,,107,,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,1,,,,,8,,13481,F,,Autocuration,CHEMBL617065,BAO_0000019,2279
,,H,449.0,,107,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,1,,CHO,,,8,,6347,B,,Autocuration,CHEMBL617066,BAO_0000219,2280
,,H,449.0,,107,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,1,,CHO,,,8,,6347,B,,Autocuration,CHEMBL617067,BAO_0000219,2281
,,H,,,107,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,1,,,,,8,,14093,F,,Autocuration,CHEMBL617068,BAO_0000019,2282
,,H,,,107,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,1,,,,,8,,14093,F,,Autocuration,CHEMBL617069,BAO_0000019,2283
,,H,,,107,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,,,,,8,,13481,F,,Autocuration,CHEMBL617070,BAO_0000019,2284
,,H,,,107,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,1,,,,,8,,14442,B,,Autocuration,CHEMBL617071,BAO_0000357,2285
,,H,,,107,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,,,,,8,,14442,B,,Autocuration,CHEMBL872915,BAO_0000357,2286
,,H,,,107,,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,1,,,,,8,,14755,B,,Autocuration,CHEMBL617072,BAO_0000357,2287
,,H,,,107,,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,1,,,,,8,,16441,B,,Autocuration,CHEMBL617073,BAO_0000357,2288
,,H,,,107,,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,1,,,,,8,,14744,B,,Autocuration,CHEMBL617074,BAO_0000357,2289
,,H,449.0,,107,,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,1,,CHO,,,8,,16659,B,,Expert,CHEMBL617075,BAO_0000219,2290
,,H,,,107,,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,1,,,,,8,,3307,B,,Autocuration,CHEMBL617076,BAO_0000357,2291
,,D,,,107,9606.0,Homo sapiens,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,1,,,,,9,,6857,B,,Expert,CHEMBL617077,BAO_0000019,2292
,,H,,,107,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,1,,,,,8,,5635,B,,Expert,CHEMBL617078,BAO_0000357,2293
,,D,,,107,9606.0,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,1,,,,,9,,4234,B,,Expert,CHEMBL617079,BAO_0000357,2294
,,H,,,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,1,,,,,8,,15527,B,,Autocuration,CHEMBL617080,BAO_0000357,2295
,,H,449.0,,107,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,1,,CHO,,,8,,6588,B,,Expert,CHEMBL617081,BAO_0000219,2296
,,H,,,107,,,Binding affinity towards human 5-HT2A receptor in BEK cells,1,,,,,8,,13631,B,,Expert,CHEMBL617082,BAO_0000219,2297
,,H,,,107,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,1,,,,,8,,17723,B,,Autocuration,CHEMBL617083,BAO_0000357,2298
,,H,,,107,,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,1,,,,,8,,14770,B,,Autocuration,CHEMBL617084,BAO_0000357,2299
,,D,,,107,9606.0,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 2A receptor,1,,,,,9,,16293,B,,Expert,CHEMBL617085,BAO_0000357,2300
,,H,,,107,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,1,,,,,8,,16209,B,,Autocuration,CHEMBL617086,BAO_0000357,2301
,,H,,,107,,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,1,,,,,8,,12469,B,,Autocuration,CHEMBL617087,BAO_0000219,2302
,,H,,,107,,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,1,,,,,8,,15363,B,,Autocuration,CHEMBL617088,BAO_0000357,2303
,,H,,,107,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,1,,,,,8,,15363,B,,Autocuration,CHEMBL617089,BAO_0000357,2304
,,H,,,107,,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",1,,,,,8,,16441,B,,Expert,CHEMBL617090,BAO_0000019,2305
,,H,,,107,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,1,,,,,8,,8,B,,Autocuration,CHEMBL617513,BAO_0000357,2306
,,H,722.0,,107,,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,1,,HEK293,,,8,,4176,B,,Autocuration,CHEMBL617514,BAO_0000219,2307
,,H,,,107,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,1,,,,,8,,17085,B,,Autocuration,CHEMBL617515,BAO_0000019,2308
,,H,,,107,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,1,,,,,8,,17200,B,,Autocuration,CHEMBL617516,BAO_0000357,2309
,,D,,,107,9606.0,Homo sapiens,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,1,,,,,9,,17200,B,,Expert,CHEMBL617517,BAO_0000357,2310
,,D,449.0,,107,9606.0,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,1,,CHO,,,9,,4013,B,,Expert,CHEMBL617518,BAO_0000219,2311
,,H,,,107,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,1,,,,,8,,5088,B,,Autocuration,CHEMBL617519,BAO_0000357,2312
,,D,,,107,9606.0,Homo sapiens,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,1,,,,,9,,5088,B,,Expert,CHEMBL617520,BAO_0000357,2313
,,H,,,107,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,1,,,,,8,,5088,B,,Autocuration,CHEMBL617521,BAO_0000357,2314
,,D,,,107,9606.0,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,1,,,,,9,,5088,B,,Expert,CHEMBL617522,BAO_0000357,2315
,,H,,,107,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,1,,,,,8,,5088,B,,Autocuration,CHEMBL617523,BAO_0000357,2316
,,H,,,107,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,1,,,,,8,,5088,B,,Autocuration,CHEMBL617524,BAO_0000357,2317
,,H,,,104686,,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,1,,,,,4,,9786,B,,Autocuration,CHEMBL617525,BAO_0000019,2318
,,D,,,104686,10116.0,Rattus norvegicus,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,1,,,,,5,,9205,B,,Autocuration,CHEMBL617526,BAO_0000019,2319
,,H,,,104686,,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,1,,,,,4,,11257,B,,Autocuration,CHEMBL617527,BAO_0000224,2320
,,H,,,104686,,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,1,,,,,4,,9362,B,,Autocuration,CHEMBL617528,BAO_0000019,2321
,,H,,,104686,,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,1,,,,,4,,9362,B,,Autocuration,CHEMBL617529,BAO_0000019,2322
,,H,,,104686,,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,1,,,,,4,,10590,B,,Autocuration,CHEMBL617530,BAO_0000224,2323
,,H,,,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,1,,,,,4,,10468,B,,Autocuration,CHEMBL617531,BAO_0000019,2324
,,H,,,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,1,,,,,4,,13050,B,,Autocuration,CHEMBL617532,BAO_0000019,2325
,,H,,,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,1,,,,,4,,11624,B,,Autocuration,CHEMBL617533,BAO_0000019,2326
,,H,,,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,1,,,,,4,,10468,B,,Autocuration,CHEMBL617534,BAO_0000019,2327
,,H,,,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,1,,,,,4,,10330,B,,Autocuration,CHEMBL617535,BAO_0000224,2328
,,H,,,104686,,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,1,,,,,4,,10062,B,,Autocuration,CHEMBL617536,BAO_0000224,2329
,,H,,,104686,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,1,,,,,4,,11642,B,,Autocuration,CHEMBL617537,BAO_0000224,2330
,,H,,,104686,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,1,,,,,4,,10062,B,,Autocuration,CHEMBL617538,BAO_0000224,2331
,,H,,,104686,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,1,,,,In vitro,4,,13427,B,,Autocuration,CHEMBL617539,BAO_0000219,2332
,,D,,,104686,10116.0,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,1,,,,,5,,12280,B,,Autocuration,CHEMBL617540,BAO_0000224,2333
,,D,,,104686,10116.0,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,1,,,,,5,,4101,B,,Autocuration,CHEMBL617541,BAO_0000224,2334
,,H,,,104686,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,1,,,,,4,,10062,B,,Autocuration,CHEMBL617542,BAO_0000224,2335
,,H,,,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,1,,,,,4,,11147,B,,Autocuration,CHEMBL617543,BAO_0000224,2336
,,D,485.0,,104686,10116.0,Rattus norvegicus,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,1,,CHO-K1,,,5,,2395,B,,Autocuration,CHEMBL617544,BAO_0000219,2337
,,D,485.0,,104686,10116.0,Rattus norvegicus,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,1,,CHO-K1,,,5,,2395,B,,Autocuration,CHEMBL617545,BAO_0000219,2338
,,D,,,104686,10116.0,Rattus norvegicus,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,1,,,,,5,,9098,B,,Autocuration,CHEMBL617413,BAO_0000019,2339
,,H,,,104686,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,1,,,,,4,,9098,B,,Autocuration,CHEMBL617414,BAO_0000019,2340
,,D,,,104686,10116.0,Rattus norvegicus,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,1,,,,,5,,9098,B,,Autocuration,CHEMBL617415,BAO_0000019,2341
,,H,,,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,1,,,,,4,,9443,B,,Autocuration,CHEMBL617416,BAO_0000224,2342
,,H,,,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,1,,,,,4,,9443,B,,Autocuration,CHEMBL617417,BAO_0000224,2343
,,H,,,104686,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",1,,,,,4,,9699,B,,Autocuration,CHEMBL617418,BAO_0000019,2344
,,H,,,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,1,,,,,4,,9699,B,,Autocuration,CHEMBL617419,BAO_0000019,2345
,,H,,,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,1,,,,,4,,9098,B,,Autocuration,CHEMBL617420,BAO_0000224,2346
,,D,,,104686,10116.0,Rattus norvegicus,Affinity for 5-hydroxytryptamine 2 receptor,1,,,,,5,,3070,B,,Autocuration,CHEMBL617421,BAO_0000224,2347
,,H,,,104686,,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,1,,,,,4,,9547,B,,Autocuration,CHEMBL617422,BAO_0000224,2348
,,H,,,104686,,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,1,,,,,4,,10444,B,,Autocuration,CHEMBL617423,BAO_0000019,2349
,,H,,,104686,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,1,,,,,4,,14617,B,,Autocuration,CHEMBL617424,BAO_0000019,2350
,,H,,,104686,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,1,,,,,4,,14617,B,,Autocuration,CHEMBL617425,BAO_0000019,2351
,,H,,,104686,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),1,,,,,4,,11130,B,,Autocuration,CHEMBL617426,BAO_0000224,2352
,,H,,,104686,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),1,,,,In vivo,4,,11130,B,,Autocuration,CHEMBL617427,BAO_0000218,2353
,,H,,,104686,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,1,Brain,,,,4,,14542,B,955.0,Autocuration,CHEMBL617428,BAO_0000221,2354
,,H,,,104686,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,1,,,,,4,,2797,B,,Autocuration,CHEMBL617429,BAO_0000224,2355
,,H,,,104686,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,1,,,,,4,,11332,B,,Autocuration,CHEMBL617430,BAO_0000019,2356
,,H,,,104686,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,1,,,,,4,,11332,B,,Autocuration,CHEMBL617431,BAO_0000019,2357
,,H,,,104686,,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,1,Frontal cortex,,,,4,,10752,B,1870.0,Autocuration,CHEMBL617432,BAO_0000019,2358
,,H,,,104686,,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,1,,,,,4,,1185,B,,Autocuration,CHEMBL617433,BAO_0000224,2359
,,H,,,104686,,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,1,,,,,4,,1185,B,,Autocuration,CHEMBL617434,BAO_0000224,2360
,,D,,,104686,10116.0,Rattus norvegicus,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,1,,,,,5,,11624,B,,Autocuration,CHEMBL617435,BAO_0000224,2361
,,H,,,104686,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,1,,,,,4,,1344,B,,Autocuration,CHEMBL617436,BAO_0000019,2362
,,D,,,104686,10116.0,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,1,Striatum,,,,5,,15453,B,2435.0,Autocuration,CHEMBL617437,BAO_0000019,2363
,,H,,,104686,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",1,,,,,4,,11662,B,,Autocuration,CHEMBL617438,BAO_0000019,2364
,,H,,,104686,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",1,,,,,4,,11662,B,,Autocuration,CHEMBL617439,BAO_0000019,2365
,,H,,,104686,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,1,,,,,4,,10796,B,,Autocuration,CHEMBL617440,BAO_0000224,2366
,,H,,,104686,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,1,,,,,4,,9069,B,,Autocuration,CHEMBL617441,BAO_0000224,2367
,,D,,,104686,10116.0,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,1,,,,,5,,8814,B,,Autocuration,CHEMBL872918,BAO_0000019,2368
,,D,,,104686,10116.0,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,1,,,,,5,,8908,B,,Autocuration,CHEMBL617442,BAO_0000019,2369
,,H,,,104686,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,1,,,,,4,,9098,B,,Autocuration,CHEMBL617443,BAO_0000019,2370
,,H,,,104686,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,1,,,,,4,,9098,B,,Autocuration,CHEMBL617444,BAO_0000019,2371
,,H,,,104686,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,1,,,,,4,,9098,B,,Autocuration,CHEMBL617445,BAO_0000019,2372
,,H,,,104686,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,1,,,,,4,,9098,B,,Autocuration,CHEMBL617446,BAO_0000019,2373
,,H,,,104686,,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,1,,,,,4,,9098,B,,Autocuration,CHEMBL617447,BAO_0000249,2374
,,H,,,104686,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,1,,,,,4,,9098,B,,Autocuration,CHEMBL617448,BAO_0000019,2375
,,H,,,104686,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,1,,,,,4,,9098,B,,Autocuration,CHEMBL617449,BAO_0000019,2376
,,H,,,104686,,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,1,,,,,4,,9161,B,,Autocuration,CHEMBL617450,BAO_0000019,2377
,,H,,,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,1,,,,,4,,9161,B,,Autocuration,CHEMBL617451,BAO_0000019,2378
,,H,,,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,1,,,,,4,,9161,B,,Autocuration,CHEMBL617452,BAO_0000019,2379
,,H,,,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,1,,,,,4,,9161,B,,Autocuration,CHEMBL617453,BAO_0000019,2380
,,H,,,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,1,,,,,4,,9161,B,,Autocuration,CHEMBL617660,BAO_0000019,2381
,,H,,,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,1,,,,,4,,9161,B,,Autocuration,CHEMBL617661,BAO_0000019,2382
,,H,,,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,1,,,,,4,,9161,B,,Autocuration,CHEMBL617662,BAO_0000019,2383
,,H,,,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,1,,,,,4,,9161,B,,Autocuration,CHEMBL872919,BAO_0000019,2384
,,H,,,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,1,,,,,4,,9161,B,,Autocuration,CHEMBL617663,BAO_0000019,2385
,,H,,,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,1,,,,,4,,9161,B,,Autocuration,CHEMBL617664,BAO_0000019,2386
,,H,,,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,1,,,,,4,,9161,B,,Autocuration,CHEMBL617665,BAO_0000019,2387
,,H,,,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,1,,,,,4,,9161,B,,Autocuration,CHEMBL617666,BAO_0000019,2388
,,H,,,104686,,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,1,,,,,4,,12094,B,,Autocuration,CHEMBL617667,BAO_0000019,2389
,,H,,,104686,,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,1,,,,,4,,12018,B,,Autocuration,CHEMBL617668,BAO_0000249,2390
,,H,,,104686,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,1,,,,,4,,10394,B,,Autocuration,CHEMBL617669,BAO_0000249,2391
,,H,,,104686,,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,1,,,,,4,,15260,B,,Autocuration,CHEMBL617670,BAO_0000224,2392
,,D,,,104686,10116.0,Rattus norvegicus,Inhibitory constant against 5-hydroxytryptamine 2 receptor,1,,,,,5,,11624,B,,Autocuration,CHEMBL617671,BAO_0000224,2393
,,H,,,104686,,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,1,,,,,4,,13654,B,,Autocuration,CHEMBL617672,BAO_0000224,2394
,,H,,,104686,,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,1,,,,,4,,9541,B,,Autocuration,CHEMBL617673,BAO_0000019,2395
,,H,,,104686,,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,1,,,,,4,,11933,B,,Autocuration,CHEMBL617674,BAO_0000224,2396
,,H,,,104686,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,1,,,,,4,,15538,B,,Autocuration,CHEMBL617675,BAO_0000019,2397
,,H,,,104686,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,1,,,,,4,,15538,B,,Autocuration,CHEMBL617676,BAO_0000019,2398
,,H,,,104686,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,1,,,,,4,,15538,B,,Autocuration,CHEMBL617677,BAO_0000019,2399
,,D,,,104686,,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,1,,,,,5,,8841,B,,Autocuration,CHEMBL617678,BAO_0000019,2400
,,H,,,104686,,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,1,,,,,4,,1455,B,,Autocuration,CHEMBL617679,BAO_0000224,2401
,,H,,,104686,,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,1,,,,,4,,1455,B,,Autocuration,CHEMBL617680,BAO_0000224,2402
,,H,,,104686,,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,1,,,,,4,,11752,B,,Autocuration,CHEMBL617681,BAO_0000019,2403
,,H,,,104686,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,1,Brain,,,,4,,11642,B,955.0,Autocuration,CHEMBL617682,BAO_0000221,2404
,,H,,,104686,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,1,,,,,4,,12092,B,,Autocuration,CHEMBL617683,BAO_0000224,2405
,,H,,,104686,,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,1,,,,,4,,3967,B,,Autocuration,CHEMBL617684,BAO_0000224,2406
,,D,,,104686,10116.0,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor,1,,,,,5,,12771,B,,Autocuration,CHEMBL617685,BAO_0000224,2407
,,H,,,104686,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,1,,,,,4,,11642,B,,Autocuration,CHEMBL617686,BAO_0000019,2408
,,H,,,104686,,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,1,,,,,4,,11628,B,,Autocuration,CHEMBL617687,BAO_0000224,2409
,,H,,,104686,,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,1,,,,,4,,13654,B,,Autocuration,CHEMBL617688,BAO_0000224,2410
,,H,,,104686,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,1,,,,,4,,11200,F,,Autocuration,CHEMBL617689,BAO_0000019,2411
,,H,,,104686,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,1,,,,,4,,11200,F,,Autocuration,CHEMBL617690,BAO_0000019,2412
,,H,,,104686,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",1,,,,In vivo,4,,11200,F,,Autocuration,CHEMBL617691,BAO_0000218,2413
,,H,,,104686,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",1,,,,In vivo,4,,11200,F,,Autocuration,CHEMBL617692,BAO_0000218,2414
,,H,,,104686,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",1,,,,In vivo,4,,11200,F,,Autocuration,CHEMBL617693,BAO_0000218,2415
,,H,,,104686,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",1,,,,In vivo,4,,11200,F,,Autocuration,CHEMBL617694,BAO_0000218,2416
,,H,,,12687,,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,1,Brain,,,,8,,15436,B,955.0,Expert,CHEMBL857985,BAO_0000221,2417
,,D,,,12687,10116.0,Rattus norvegicus,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,1,,,,,9,,15436,B,,Expert,CHEMBL617695,BAO_0000019,2418
,,H,,,12687,,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,1,,,,,8,,14025,B,,Autocuration,CHEMBL617696,BAO_0000019,2419
,,H,,,12687,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,1,,,,,8,,4342,B,,Autocuration,CHEMBL617697,BAO_0000357,2420
,,D,,,12687,10116.0,Rattus norvegicus,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,1,,,,,9,,13735,B,,Expert,CHEMBL617257,BAO_0000019,2421
,,D,,,12687,10116.0,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,1,,,,,9,,5816,B,,Expert,CHEMBL617258,BAO_0000357,2422
,,H,,,12687,,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,1,,,,,8,,14287,B,,Expert,CHEMBL617259,BAO_0000019,2423
,,H,,,12687,,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,1,,,,,8,,15738,B,,Autocuration,CHEMBL617260,BAO_0000357,2424
,,D,,,12687,10116.0,Rattus norvegicus,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,1,,,,,9,,15738,B,,Expert,CHEMBL617261,BAO_0000357,2425
,,H,,,12687,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,1,,,,,8,,15026,B,,Autocuration,CHEMBL617262,BAO_0000019,2426
,,H,,,12687,,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,1,,,,,8,,16647,B,,Expert,CHEMBL617263,BAO_0000019,2427
,,H,,,12687,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,1,,,,,8,,16647,B,,Autocuration,CHEMBL617264,BAO_0000019,2428
,,D,,,12687,10116.0,Rattus norvegicus,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,1,,,,,9,,13345,B,,Expert,CHEMBL617265,BAO_0000019,2429
,Membranes,H,,,12687,,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,1,,,,,8,,1543,B,,Autocuration,CHEMBL617266,BAO_0000249,2430
,,H,,,12687,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,1,,,,,8,,12444,B,,Autocuration,CHEMBL617267,BAO_0000019,2431
,,H,,,12687,,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,1,,,,,8,,16404,B,,Expert,CHEMBL617268,BAO_0000019,2432
,,H,449.0,,12687,,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,1,,CHO,,,8,,16404,B,,Autocuration,CHEMBL617269,BAO_0000219,2433
,,H,,,12687,,,Kinetic inhibition constant evaluated by measuring serotonergic activity,1,,,,,8,,15577,B,,Expert,CHEMBL617323,BAO_0000357,2434
,,H,,,12687,,,Serotonergic activity of the compound.,1,,,,,8,,15577,B,,Autocuration,CHEMBL617324,BAO_0000357,2435
,,H,,,12687,,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,1,,,,,8,,2495,B,,Autocuration,CHEMBL617325,BAO_0000249,2436
,,D,,,12687,10116.0,Rattus norvegicus,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,1,,,,,9,,15042,B,,Expert,CHEMBL617326,BAO_0000019,2437
,,H,,,12687,,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,1,,,,,8,,15026,B,,Expert,CHEMBL617327,BAO_0000249,2438
,,D,,,12687,10116.0,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,1,,,,,9,,12919,F,,Expert,CHEMBL617328,BAO_0000019,2439
,,D,,,12687,10116.0,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,1,,,,,9,,12919,F,,Expert,CHEMBL617329,BAO_0000019,2440
,,D,,,12687,10116.0,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,1,,,,,9,,12919,F,,Expert,CHEMBL617330,BAO_0000019,2441
,,H,,,12687,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,,,,,8,,15194,B,,Autocuration,CHEMBL617331,BAO_0000357,2442
,,H,,,12687,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,1,,,,,8,,15194,B,,Autocuration,CHEMBL617332,BAO_0000357,2443
,,H,,,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,1,,,,,8,,4820,B,,Expert,CHEMBL617333,BAO_0000357,2444
,,H,,,107,,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,1,,,,,8,,6736,B,,Autocuration,CHEMBL617334,BAO_0000357,2445
,,H,,,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,1,,,,,8,,5163,B,,Autocuration,CHEMBL617335,BAO_0000357,2446
,,H,,,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,1,,,,,8,,5163,B,,Autocuration,CHEMBL617336,BAO_0000357,2447
,,H,,,107,,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,1,,,,,8,,6011,B,,Autocuration,CHEMBL617337,BAO_0000357,2448
,,D,,,107,9606.0,Homo sapiens,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,1,,,,,9,,14294,B,,Expert,CHEMBL617338,BAO_0000357,2449
,,H,,,107,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,1,,,,,8,,5014,B,,Autocuration,CHEMBL617339,BAO_0000357,2450
,,H,,,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,1,,,,,8,,17066,B,,Expert,CHEMBL617340,BAO_0000357,2451
,,H,,,107,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,1,,,,,8,,17515,B,,Autocuration,CHEMBL617341,BAO_0000357,2452
,,H,,,107,,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,1,,,,,8,,6736,B,,Expert,CHEMBL617342,BAO_0000357,2453
,,H,,,107,,,Affinity for 5-hydroxytryptamine 2A receptor,1,,,,,8,,5163,B,,Expert,CHEMBL617343,BAO_0000357,2454
,,H,723.0,,107,,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,1,,NIH3T3,,,8,,16911,B,,Expert,CHEMBL617344,BAO_0000219,2455
,,H,,,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,1,,,,,8,,6841,B,,Expert,CHEMBL617345,BAO_0000357,2456
,,H,,,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,1,,,,,8,,6119,B,,Expert,CHEMBL617346,BAO_0000357,2457
,,H,,,107,,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,1,,,,,8,,3962,B,,Autocuration,CHEMBL617347,BAO_0000357,2458
,,H,,,107,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,1,,,,,8,,4373,B,,Autocuration,CHEMBL617348,BAO_0000357,2459
,,H,,,107,,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,1,,,,,8,,4373,B,,Autocuration,CHEMBL617349,BAO_0000357,2460
,,H,,,107,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,1,,,,,8,,3962,F,,Autocuration,CHEMBL617350,BAO_0000019,2461
,,H,,,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,1,,,,,8,,1633,B,,Expert,CHEMBL872339,BAO_0000357,2462
,,H,,,107,,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,1,,,,,8,,4373,B,,Autocuration,CHEMBL617351,BAO_0000357,2463
,,H,,,107,,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,1,,,,,8,,6576,B,,Expert,CHEMBL617352,BAO_0000357,2464
,,H,,,107,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,1,,,,,8,,4687,B,,Autocuration,CHEMBL617353,BAO_0000357,2465
,,H,,,107,,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,1,,,,,8,,16946,B,,Autocuration,CHEMBL617354,BAO_0000357,2466
,,H,,,107,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,1,,,,,8,,14159,B,,Autocuration,CHEMBL617355,BAO_0000357,2467
,,H,449.0,,107,10090.0,Mus musculus,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,1,,CHO,,,8,,3032,B,,Expert,CHEMBL617356,BAO_0000219,2468
,,H,,,107,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,1,,,,,8,,16655,B,,Autocuration,CHEMBL617357,BAO_0000357,2469
,,H,,,107,,,Binding affinity at 5-hydroxytryptamine 2A receptor,1,,,,,8,,13964,B,,Autocuration,CHEMBL617358,BAO_0000357,2470
,,H,,,107,,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,1,,,,,8,,16989,B,,Expert,CHEMBL617359,BAO_0000357,2471
,,H,,,107,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,1,,,,,8,,16117,B,,Autocuration,CHEMBL617360,BAO_0000357,2472
,,H,,,107,,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,1,,,,,8,,16700,B,,Autocuration,CHEMBL875913,BAO_0000357,2473
,,H,,,107,,,Affinity against 5-hydroxytryptamine 2A receptor,1,,,,,8,,3269,B,,Autocuration,CHEMBL617361,BAO_0000357,2474
,,D,,,107,9606.0,Homo sapiens,Binding affinity against 5-Hydroxytryptamine 2A receptor,1,,,,,9,,1274,B,,Expert,CHEMBL617362,BAO_0000357,2475
,,H,,,107,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,1,,,,,8,,1317,B,,Autocuration,CHEMBL617363,BAO_0000357,2476
,,H,,,107,,,Tested against 5-hydroxytryptamine 2A receptor,1,,,,,8,,12146,B,,Autocuration,CHEMBL617364,BAO_0000357,2477
,,H,,,105075,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,1,,,,,4,,12652,B,,Autocuration,CHEMBL617365,BAO_0000224,2478
,,H,,,105075,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,1,,,,,4,,12652,B,,Autocuration,CHEMBL617366,BAO_0000224,2479
,,H,,,105075,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,1,,,,,4,,12652,B,,Autocuration,CHEMBL617367,BAO_0000224,2480
,,H,,,105075,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,1,,,,,4,,12652,B,,Autocuration,CHEMBL617368,BAO_0000224,2481
,,H,,,107,,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),1,,,,,8,,16647,B,,Autocuration,CHEMBL617369,BAO_0000357,2482
,,D,722.0,,227,9606.0,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,1,,HEK293,,,9,,15851,B,,Expert,CHEMBL617370,BAO_0000219,2483
,,D,449.0,,227,9606.0,Homo sapiens,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,1,,CHO,,,9,,6857,F,,Expert,CHEMBL617371,BAO_0000219,2484
,,H,,,227,,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),1,,,,,8,,3805,B,,Autocuration,CHEMBL617372,BAO_0000357,2485
,,D,,,227,9606.0,Homo sapiens,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,1,,,,,9,,6491,B,,Expert,CHEMBL617373,BAO_0000357,2486
,,H,,,227,,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,1,,,,,8,,14093,F,,Autocuration,CHEMBL617374,BAO_0000019,2487
,,H,,,227,,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,1,,,,,8,,13481,F,,Autocuration,CHEMBL617375,BAO_0000019,2488
,,H,,,227,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,1,,,,,8,,14093,F,,Autocuration,CHEMBL617376,BAO_0000019,2489
,,H,,,227,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,1,,,,,8,,14093,F,,Autocuration,CHEMBL617377,BAO_0000019,2490
,,H,,,227,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,1,,,,,8,,14093,F,,Autocuration,CHEMBL617378,BAO_0000019,2491
,,H,,,227,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,1,,,,,8,,13481,F,,Autocuration,CHEMBL617379,BAO_0000019,2492
,,H,,,227,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,1,,,,,8,,14442,B,,Autocuration,CHEMBL617380,BAO_0000357,2493
,,H,,,227,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,1,,,,,8,,14442,B,,Autocuration,CHEMBL617381,BAO_0000357,2494
,,H,,,227,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,1,,,,,8,,14442,B,,Autocuration,CHEMBL617382,BAO_0000357,2495
,,H,,,107,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,1,,,,,8,,12369,B,,Autocuration,CHEMBL617383,BAO_0000357,2496
,,H,,,107,,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,1,,,,,8,,12369,B,,Expert,CHEMBL617384,BAO_0000357,2497
,,H,,,107,,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,1,,,,,8,,12369,B,,Expert,CHEMBL617385,BAO_0000357,2498
,,H,,,107,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,1,,,,,8,,14447,B,,Autocuration,CHEMBL617386,BAO_0000019,2499
,,H,,,107,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,1,,,,,8,,14447,B,,Autocuration,CHEMBL617387,BAO_0000019,2500
,,H,723.0,,107,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,1,,NIH3T3,,,8,,17451,B,,Autocuration,CHEMBL617388,BAO_0000219,2501
,,H,449.0,,107,,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,1,,CHO,,,8,,6857,F,,Autocuration,CHEMBL617389,BAO_0000219,2502
,,D,449.0,,107,9606.0,Homo sapiens,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,1,,CHO,,,9,,6857,F,,Expert,CHEMBL617390,BAO_0000219,2503
,,H,,,104817,,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,1,,,,,4,,5635,B,,Autocuration,CHEMBL617391,BAO_0000224,2504
,,H,,,107,,,Binding activity radioligand.,1,,,,,8,,12861,B,,Autocuration,CHEMBL617392,BAO_0000357,2505
,,H,,,107,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,1,,,,,8,,12861,B,,Autocuration,CHEMBL617393,BAO_0000019,2506
,,H,307.0,,107,,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,1,,L929,,,8,,5105,B,,Autocuration,CHEMBL617394,BAO_0000219,2507
,,H,307.0,,107,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,1,,L929,,,8,,5104,B,,Expert,CHEMBL617395,BAO_0000219,2508
,,H,307.0,,107,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,1,,L929,,,8,,5105,B,,Expert,CHEMBL617396,BAO_0000219,2509
,,H,307.0,,107,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,1,,L929,,,8,,5105,B,,Autocuration,CHEMBL617397,BAO_0000219,2510
,,H,,,107,,,Binding affinity against 5-HT2A receptor,1,,,,,8,,5254,B,,Autocuration,CHEMBL617398,BAO_0000357,2511
,,H,,,107,,,Binding affinity against 5-hydroxytryptamine 2A receptor,1,,,,,8,,5254,B,,Autocuration,CHEMBL617399,BAO_0000357,2512
,,H,722.0,,107,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,1,,HEK293,,,8,,13267,B,,Autocuration,CHEMBL617400,BAO_0000219,2513
,,H,722.0,,107,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,1,,HEK293,,,8,,13267,B,,Autocuration,CHEMBL617401,BAO_0000219,2514
,,D,722.0,,107,9606.0,Homo sapiens,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,1,,HEK293,,,9,,14157,B,,Expert,CHEMBL617402,BAO_0000219,2515
,,D,722.0,,107,9606.0,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,1,,HEK293,,,9,,12936,B,,Expert,CHEMBL617403,BAO_0000219,2516
,,H,,,107,,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,1,,,,,8,,14068,B,,Expert,CHEMBL617404,BAO_0000357,2517
,,D,722.0,,107,9606.0,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,1,,HEK293,,,9,,12936,B,,Expert,CHEMBL857981,BAO_0000219,2518
,,D,722.0,,107,9606.0,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,1,,HEK293,,,9,,12936,B,,Expert,CHEMBL617405,BAO_0000219,2519
,,D,722.0,,107,9606.0,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,1,,HEK293,,,9,,4540,B,,Expert,CHEMBL617253,BAO_0000219,2520
,,H,,,107,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,1,,,,,8,,6166,B,,Expert,CHEMBL617254,BAO_0000357,2521
,,H,722.0,,107,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,1,,HEK293,,,8,,17296,B,,Autocuration,CHEMBL617255,BAO_0000219,2522
,,H,722.0,,107,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,1,,HEK293,,,8,,17296,B,,Autocuration,CHEMBL617256,BAO_0000219,2523
,,H,722.0,,107,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,1,,HEK293,,,8,,17296,B,,Autocuration,CHEMBL616874,BAO_0000219,2524
,,D,722.0,,107,9606.0,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,1,,HEK293,,,9,,15779,B,,Expert,CHEMBL616875,BAO_0000219,2525
,,H,722.0,,107,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,1,,HEK293,,,8,,14391,B,,Expert,CHEMBL616876,BAO_0000219,2526
,,H,722.0,,107,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",1,,HEK293,,,8,,15851,B,,Expert,CHEMBL616877,BAO_0000219,2527
,,D,722.0,,107,9606.0,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,1,,HEK293,,,9,,15851,B,,Expert,CHEMBL616878,BAO_0000219,2528
,,H,722.0,,107,,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,1,,HEK293,,,8,,3832,B,,Expert,CHEMBL616879,BAO_0000219,2529
,,H,722.0,,107,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,1,,HEK293,,,8,,3833,B,,Expert,CHEMBL616880,BAO_0000219,2530
,,D,722.0,,107,9606.0,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,1,,HEK293,,,9,,12936,B,,Expert,CHEMBL616881,BAO_0000219,2531
,,H,723.0,,107,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,1,,NIH3T3,,,8,,17451,B,,Autocuration,CHEMBL616882,BAO_0000219,2532
,,H,723.0,,107,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,1,,NIH3T3,,,8,,17451,B,,Autocuration,CHEMBL616883,BAO_0000219,2533
,,H,723.0,,107,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,1,,NIH3T3,,,8,,17451,B,,Autocuration,CHEMBL616884,BAO_0000219,2534
,,H,722.0,,107,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,1,,HEK293,,,8,,4199,B,,Autocuration,CHEMBL616885,BAO_0000219,2535
,,H,485.0,,107,,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,1,,CHO-K1,,,8,,1883,B,,Autocuration,CHEMBL616886,BAO_0000219,2536
,,H,485.0,,107,,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,1,,CHO-K1,,,8,,1883,B,,Expert,CHEMBL616887,BAO_0000219,2537
,,D,,,107,9606.0,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 2A receptor,1,,,,,9,,14875,B,,Expert,CHEMBL616888,BAO_0000357,2538
,,H,722.0,,107,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,1,,HEK293,,,8,,15146,B,,Autocuration,CHEMBL616889,BAO_0000219,2539
,,H,722.0,,107,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,1,,HEK293,,,8,,5213,B,,Autocuration,CHEMBL616890,BAO_0000219,2540
,,D,449.0,,107,9606.0,Homo sapiens,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,1,,CHO,,,9,,16404,B,,Expert,CHEMBL616891,BAO_0000219,2541
,,H,722.0,,107,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,1,,HEK293,,,8,,14818,B,,Autocuration,CHEMBL616892,BAO_0000219,2542
,,H,722.0,,107,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",1,,HEK293,,,8,,4829,B,,Autocuration,CHEMBL616893,BAO_0000219,2543
,,H,723.0,,10620,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,1,,NIH3T3,,,8,,12652,F,,Autocuration,CHEMBL616894,BAO_0000219,2544
,,H,723.0,,107,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,1,,NIH3T3,,,8,,4682,B,,Expert,CHEMBL616895,BAO_0000219,2545
,,H,,,10620,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,1,,,,,8,,12652,F,,Autocuration,CHEMBL616896,BAO_0000019,2546
,,H,,,10621,,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,1,,,,,8,,4921,B,,Autocuration,CHEMBL617099,BAO_0000357,2547
,,H,,,10621,,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,1,,,,,8,,4921,B,,Autocuration,CHEMBL617100,BAO_0000357,2548
,,H,,,107,9986.0,Oryctolagus cuniculus,Binding affinity against rabbit aorta 5-HT2A receptor,1,,,,,8,,16312,B,,Autocuration,CHEMBL884532,BAO_0000357,2549
,,H,,,107,9986.0,Oryctolagus cuniculus,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,1,,,,,8,,14998,B,,Expert,CHEMBL617101,BAO_0000357,2550
,,H,,,107,9986.0,Oryctolagus cuniculus,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,1,,,,,8,,14025,B,,Expert,CHEMBL617102,BAO_0000357,2551
,,H,,,107,9986.0,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,1,,,,,8,,13047,B,,Autocuration,CHEMBL617103,BAO_0000019,2552
,,H,,,107,9986.0,Oryctolagus cuniculus,The compound was tested for binding affinity against 5-HT2A receptor,1,,,,,8,,13047,B,,Expert,CHEMBL617104,BAO_0000357,2553
,,H,485.0,,10576,,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,1,,CHO-K1,,,8,,1883,B,,Autocuration,CHEMBL857979,BAO_0000219,2554
,,H,,,12687,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,1,,,,,8,,13463,B,,Autocuration,CHEMBL857502,BAO_0000019,2555
,,H,,,12687,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,1,,,,,8,,13463,B,,Autocuration,CHEMBL617105,BAO_0000019,2556
,,H,,,12687,,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,1,Stomach,,,,8,,13463,B,945.0,Autocuration,CHEMBL858021,BAO_0000019,2557
,,D,,,12687,10116.0,Rattus norvegicus,Binding affinity for 5-HT 2A in rat stomach fundus,1,Stomach,,,,9,,13463,B,945.0,Expert,CHEMBL875910,BAO_0000019,2558
,,H,,,12687,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,1,,,,,8,,13463,B,,Autocuration,CHEMBL617106,BAO_0000019,2559
,,H,723.0,,12687,,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,1,,NIH3T3,,,8,,16326,B,,Expert,CHEMBL617107,BAO_0000219,2560
,,H,,,12687,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,1,,,,,8,,14093,F,,Autocuration,CHEMBL617108,BAO_0000019,2561
,,H,,,12687,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,1,,,,,8,,14093,F,,Autocuration,CHEMBL617109,BAO_0000019,2562
,,H,,,12687,,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,1,,,,,8,,15740,B,,Autocuration,CHEMBL617110,BAO_0000357,2563
,,H,,,12687,,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,1,,,,,8,,16633,B,,Autocuration,CHEMBL617111,BAO_0000357,2564
,,D,,,12687,10116.0,Rattus norvegicus,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,1,,,,,9,,17200,F,,Expert,CHEMBL617112,BAO_0000019,2565
,,H,,,12687,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,1,,,,,8,,17133,B,,Autocuration,CHEMBL617113,BAO_0000357,2566
,,H,,,12687,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,1,,,,,8,,17133,B,,Autocuration,CHEMBL617114,BAO_0000357,2567
,,H,,,12687,,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,1,,,,,8,,17133,B,,Autocuration,CHEMBL617115,BAO_0000357,2568
,,H,,,12687,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,1,,,,,8,,17200,F,,Autocuration,CHEMBL617116,BAO_0000219,2569
,,H,,,12687,,,Efficacy at 5-hydroxytryptamine 2A receptor,1,,,,,8,,15363,F,,Autocuration,CHEMBL617117,BAO_0000019,2570
,,H,,,12687,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),1,,,,,8,,17200,B,,Autocuration,CHEMBL617118,BAO_0000357,2571
,,D,,,12687,10116.0,Rattus norvegicus,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),1,,,,,9,,17200,B,,Expert,CHEMBL617119,BAO_0000357,2572
,,D,,,12687,10116.0,Rattus norvegicus,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),1,,,,,9,,17200,B,,Expert,CHEMBL617120,BAO_0000357,2573
,,D,,,12687,10116.0,Rattus norvegicus,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,1,,,,,9,,17200,F,,Expert,CHEMBL617121,BAO_0000219,2574
,,H,,,12687,,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,1,,,,,8,,17200,F,,Autocuration,CHEMBL617122,BAO_0000219,2575
,,H,,,12687,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,1,,,,,8,,17211,B,,Autocuration,CHEMBL617123,BAO_0000019,2576
,,H,,,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,1,,,,,8,,17331,B,,Expert,CHEMBL617124,BAO_0000019,2577
,,H,,,12687,,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,1,,,,,8,,13565,B,,Expert,CHEMBL617600,BAO_0000249,2578
,,H,,,12687,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,1,,,,,8,,13730,B,,Expert,CHEMBL617601,BAO_0000357,2579
,,H,,,12687,,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,1,,,,,8,,12416,B,,Expert,CHEMBL882923,BAO_0000019,2580
,,H,,,12687,,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,1,,,,,8,,15295,B,,Autocuration,CHEMBL617602,BAO_0000357,2581
,,H,,,12687,,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,1,,,,,8,,1742,B,,Autocuration,CHEMBL617603,BAO_0000019,2582
,,H,,,12687,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,1,,,,,8,,15295,B,,Autocuration,CHEMBL617604,BAO_0000357,2583
,,H,,,12687,,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,1,,,,,8,,14970,B,,Expert,CHEMBL617605,BAO_0000019,2584
,,H,,,12687,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,1,,,,,8,,16693,B,,Expert,CHEMBL617606,BAO_0000019,2585
,,D,,,12687,10116.0,Rattus norvegicus,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,1,,,,,9,,14776,B,,Expert,CHEMBL617607,BAO_0000019,2586
,,H,,,12687,,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,,,,,8,,14286,B,,Autocuration,CHEMBL617455,BAO_0000249,2587
,,D,,,12687,10116.0,Rattus norvegicus,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,1,,,,,9,,17200,B,,Expert,CHEMBL617456,BAO_0000019,2588
,,H,,,12687,,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),1,,,,,8,,15306,B,,Expert,CHEMBL617457,BAO_0000357,2589
,,D,,,12687,10116.0,Rattus norvegicus,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,1,,,,,9,,14178,B,,Expert,CHEMBL617458,BAO_0000357,2590
,,D,,,12687,10116.0,Rattus norvegicus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,1,,,,,9,,14229,B,,Expert,CHEMBL617459,BAO_0000019,2591
,,H,,,12687,,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,1,,,,,8,,12884,B,,Expert,CHEMBL617460,BAO_0000357,2592
,,H,,,12687,,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",1,,,,,8,,13149,B,,Expert,CHEMBL617461,BAO_0000357,2593
,,D,,,12687,10116.0,Rattus norvegicus,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,1,,,,,9,,15295,B,,Expert,CHEMBL617462,BAO_0000019,2594
,,H,,,12687,,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,1,,,,,8,,15740,B,,Autocuration,CHEMBL617463,BAO_0000357,2595
,,H,,,12687,,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",1,,,,,8,,15185,B,,Autocuration,CHEMBL617464,BAO_0000019,2596
,,H,,,12687,,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",1,,,,,8,,15185,B,,Autocuration,CHEMBL617465,BAO_0000019,2597
,,H,,,12687,,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,1,,,,,8,,17529,B,,Expert,CHEMBL617466,BAO_0000019,2598
,,H,,,12687,,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,1,,,,,8,,14826,B,,Autocuration,CHEMBL617467,BAO_0000019,2599
,,H,,,12687,,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,1,,,,,8,,17211,B,,Expert,CHEMBL617468,BAO_0000019,2600
,,H,,,12687,,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,1,,,,,8,,14826,B,,Autocuration,CHEMBL617469,BAO_0000019,2601
,,H,,,12687,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,1,,,,,8,,14093,B,,Autocuration,CHEMBL617470,BAO_0000019,2602
,,H,,,12687,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,1,,,,,8,,14093,B,,Autocuration,CHEMBL617471,BAO_0000019,2603
,,H,723.0,,12687,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,1,,NIH3T3,,,8,,13246,B,,Expert,CHEMBL617472,BAO_0000219,2604
,,H,,,12687,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,1,,,,,8,,13246,B,,Expert,CHEMBL617473,BAO_0000357,2605
,,D,,,12687,10116.0,Rattus norvegicus,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,1,,,,,9,,15436,B,,Expert,CHEMBL617474,BAO_0000019,2606
,,D,,,12687,10116.0,Rattus norvegicus,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,1,,,,,9,,15436,B,,Expert,CHEMBL617475,BAO_0000019,2607
,,H,,,12687,,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,1,Brain,,,,8,,14442,B,955.0,Autocuration,CHEMBL617476,BAO_0000221,2608
,,H,,,12687,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,1,,,,,8,,12457,B,,Expert,CHEMBL617477,BAO_0000357,2609
,,H,723.0,,12687,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,1,,NIH3T3,,,8,,12457,B,,Expert,CHEMBL617478,BAO_0000219,2610
,,H,,,12687,,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",1,,,,,8,,14755,F,,Autocuration,CHEMBL617479,BAO_0000221,2611
,,H,,,12687,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,1,,,,,8,,4707,B,,Autocuration,CHEMBL617480,BAO_0000357,2612
,,H,,,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor,1,,,,,8,,13297,B,,Expert,CHEMBL617481,BAO_0000357,2613
,,H,,,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,1,,,,,8,,17331,B,,Expert,CHEMBL617482,BAO_0000019,2614
,,H,,,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,1,,,,,8,,4664,B,,Autocuration,CHEMBL617483,BAO_0000019,2615
,,H,,,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,1,,,,,8,,16633,B,,Autocuration,CHEMBL621528,BAO_0000357,2616
,,D,723.0,,12687,10116.0,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,1,,NIH3T3,,,9,,4664,B,,Expert,CHEMBL621529,BAO_0000219,2617
,,H,,,12687,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,1,,,,,8,,16133,B,,Expert,CHEMBL621530,BAO_0000357,2618
,,H,,,12687,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,,,,,8,,16133,B,,Expert,CHEMBL621531,BAO_0000357,2619
,,D,,,12687,10116.0,Rattus norvegicus,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,1,,,,,9,,14060,B,,Expert,CHEMBL621532,BAO_0000019,2620
,,H,,,12687,,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,1,,,,,8,,16326,B,,Expert,CHEMBL621533,BAO_0000357,2621
,,H,449.0,,12687,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,1,,CHO,,,8,,16659,B,,Expert,CHEMBL621534,BAO_0000219,2622
,,H,,,12687,,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,1,,,,,8,,14776,B,,Autocuration,CHEMBL621535,BAO_0000019,2623
,,H,,,12687,,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,1,,,,,8,,13481,B,,Autocuration,CHEMBL621536,BAO_0000357,2624
,,H,,,12687,,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,1,,,,,8,,17386,B,,Autocuration,CHEMBL621537,BAO_0000357,2625
,,D,,,12687,10116.0,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2A receptor,1,,,,,9,,6611,B,,Expert,CHEMBL621538,BAO_0000357,2626
,,H,,,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,1,,,,,8,,14423,B,,Autocuration,CHEMBL621539,BAO_0000019,2627
,,H,,,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,1,,,,,8,,15412,B,,Autocuration,CHEMBL621540,BAO_0000019,2628
,,H,,,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,1,,,,,8,,15412,B,,Autocuration,CHEMBL621541,BAO_0000019,2629
,,H,,,12687,,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,1,,,,,8,,6238,B,,Autocuration,CHEMBL621542,BAO_0000019,2630
,,H,,,12687,,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,1,,,,,8,,6648,B,,Expert,CHEMBL621543,BAO_0000357,2631
,,H,,,12687,,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,1,,,,,8,,5667,B,,Expert,CHEMBL621544,BAO_0000357,2632
,,D,,,12687,10116.0,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,1,,,,,9,,6611,B,,Expert,CHEMBL621545,BAO_0000357,2633
,,H,,,12687,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,,,,,8,,13481,B,,Autocuration,CHEMBL621546,BAO_0000357,2634
,,H,,,12687,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,1,,,,,8,,13481,B,,Autocuration,CHEMBL621547,BAO_0000357,2635
,,H,723.0,,12687,,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,1,,NIH3T3,,,8,,15558,B,,Expert,CHEMBL618692,BAO_0000219,2636
,,H,,,12687,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,1,,,,,8,,6013,B,,Autocuration,CHEMBL618693,BAO_0000357,2637
,,H,,,12687,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,1,,,,,8,,16633,B,,Autocuration,CHEMBL872922,BAO_0000357,2638
,,H,,,12687,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,1,,,,,8,,6013,B,,Autocuration,CHEMBL618694,BAO_0000357,2639
,,D,,,12687,10116.0,Rattus norvegicus,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,1,,,,,9,,6013,B,,Expert,CHEMBL618695,BAO_0000357,2640
,,H,,,12687,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,1,,,,,8,,6013,B,,Autocuration,CHEMBL618696,BAO_0000357,2641
,,H,,,12687,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,1,,,,,8,,6013,B,,Expert,CHEMBL618697,BAO_0000357,2642
,,H,,,12687,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,1,,,,,8,,6013,B,,Autocuration,CHEMBL618892,BAO_0000357,2643
,,H,,,12687,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,1,,,,,8,,6013,B,,Autocuration,CHEMBL618893,BAO_0000357,2644
,,H,,,12687,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,1,,,,,8,,16293,B,,Autocuration,CHEMBL618894,BAO_0000357,2645
,,H,723.0,,12687,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,1,,NIH3T3,,,8,,17175,B,,Expert,CHEMBL618895,BAO_0000219,2646
,,D,,,12687,10116.0,Rattus norvegicus,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,1,,,,,9,,13278,B,,Expert,CHEMBL618896,BAO_0000357,2647
,,H,,,12687,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,1,Caudate-putamen,,,,8,,3682,B,5383.0,Autocuration,CHEMBL618897,BAO_0000019,2648
,,H,,,12687,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,1,,,,,8,,2014,B,,Autocuration,CHEMBL618898,BAO_0000357,2649
,,H,,,12687,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,1,,,,,8,,2014,B,,Autocuration,CHEMBL618899,BAO_0000357,2650
,,H,,,12687,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,1,,,,,8,,4932,B,,Autocuration,CHEMBL618900,BAO_0000357,2651
,,H,,,12687,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,1,,,,,8,,4932,B,,Autocuration,CHEMBL618901,BAO_0000019,2652
,,H,,,12687,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,1,,,,,8,,3935,B,,Autocuration,CHEMBL618902,BAO_0000357,2653
,,D,,,12687,10116.0,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,1,Hippocampus,,,,9,,5432,B,10000000.0,Expert,CHEMBL618903,BAO_0000221,2654
,,H,,,12687,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,1,,,,,8,,15818,B,,Autocuration,CHEMBL618904,BAO_0000357,2655
,,H,,,12687,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,1,,,,,8,,13672,B,,Autocuration,CHEMBL618905,BAO_0000357,2656
,,H,,,12687,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,1,,,,,8,,13672,B,,Autocuration,CHEMBL618906,BAO_0000357,2657
,,H,723.0,,12687,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,1,,NIH3T3,,,8,,14749,B,,Expert,CHEMBL618907,BAO_0000219,2658
,,H,,,12687,,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,1,,,,,8,,13462,B,,Autocuration,CHEMBL618908,BAO_0000019,2659
,,H,,,12687,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,1,,,,,8,,15740,B,,Autocuration,CHEMBL617909,BAO_0000357,2660
,,H,,,12687,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,1,,,,,8,,16647,B,,Expert,CHEMBL617910,BAO_0000019,2661
,,H,,,12687,,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,1,Brain,,,,8,,13345,B,955.0,Autocuration,CHEMBL617911,BAO_0000221,2662
,,H,,,12687,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,,,,,8,,16740,B,,Autocuration,CHEMBL872923,BAO_0000249,2663
,,H,,,12687,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,,,,,8,,16740,B,,Autocuration,CHEMBL617912,BAO_0000249,2664
,,D,,,12687,10116.0,Rattus norvegicus,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,1,,,,,9,,15535,B,,Expert,CHEMBL617913,BAO_0000019,2665
,,H,,,12687,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,,,,,8,,16740,B,,Expert,CHEMBL617914,BAO_0000249,2666
,,H,,,12687,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,,,,,8,,16740,B,,Autocuration,CHEMBL617915,BAO_0000249,2667
,,H,,,12687,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,,,,,8,,16740,B,,Autocuration,CHEMBL617916,BAO_0000249,2668
,,D,,,12687,10116.0,Rattus norvegicus,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,1,,,,,9,,4795,B,,Expert,CHEMBL617917,BAO_0000019,2669
,,H,,,12687,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,1,,,,,8,,8,B,,Expert,CHEMBL617918,BAO_0000019,2670
,,H,,,12687,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,1,,,,,8,,8,B,,Autocuration,CHEMBL617919,BAO_0000019,2671
,,D,,,12687,10116.0,Rattus norvegicus,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,1,,,,,9,,17200,B,,Expert,CHEMBL617920,BAO_0000019,2672
,,D,,,12687,10116.0,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,1,,,,,9,,2148,B,,Expert,CHEMBL617921,BAO_0000019,2673
,,D,,,105102,10116.0,Rattus norvegicus,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",1,,,,,5,,13345,B,,Expert,CHEMBL617922,BAO_0000224,2674
,,H,,,12687,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,1,,,,,8,,5088,B,,Autocuration,CHEMBL617923,BAO_0000357,2675
,,H,,,12687,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,,,,,8,,5088,B,,Autocuration,CHEMBL617924,BAO_0000357,2676
,,H,,,12687,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,1,,,,,8,,17133,B,,Autocuration,CHEMBL617925,BAO_0000357,2677
,,D,,,12687,10116.0,Rattus norvegicus,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,1,,,,,9,,17133,B,,Expert,CHEMBL617926,BAO_0000357,2678
,,H,,,12687,,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,1,,,,,8,,16532,B,,Autocuration,CHEMBL617927,BAO_0000357,2679
,,H,,,12687,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,1,,,,,8,,15086,B,,Autocuration,CHEMBL617928,BAO_0000357,2680
,,D,,,12687,10116.0,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,1,,,,,9,,2309,B,,Expert,CHEMBL617929,BAO_0000019,2681
,,H,,,12687,,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,1,,,,,8,,12953,B,,Expert,CHEMBL617930,BAO_0000019,2682
,,H,,,12687,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,1,,,,,8,,12953,B,,Autocuration,CHEMBL617931,BAO_0000019,2683
,,H,,,12687,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,1,,,,,8,,12953,B,,Autocuration,CHEMBL617932,BAO_0000019,2684
,,H,449.0,,12687,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,1,,CHO,,,8,,16659,B,,Autocuration,CHEMBL617933,BAO_0000219,2685
,,H,,,12687,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,1,,,,,8,,16740,B,,Autocuration,CHEMBL617934,BAO_0000019,2686
,,H,,,12687,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,1,,,,,8,,16740,B,,Autocuration,CHEMBL617935,BAO_0000019,2687
,,H,,,12687,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,1,,,,,8,,17133,B,,Autocuration,CHEMBL617936,BAO_0000357,2688
,,H,,,12687,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,1,,,,,8,,17211,B,,Autocuration,CHEMBL617937,BAO_0000019,2689
,,H,,,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,1,,,,,8,,17331,B,,Autocuration,CHEMBL617938,BAO_0000019,2690
,,H,,,12687,,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,1,,,,,8,,16633,B,,Autocuration,CHEMBL617939,BAO_0000218,2691
,,H,,,12687,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,1,,,,,8,,16633,B,,Autocuration,CHEMBL617940,BAO_0000218,2692
,,H,,,12687,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,1,,,,,8,,16633,B,,Autocuration,CHEMBL617941,BAO_0000218,2693
,,H,,,12687,,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,1,,,,,8,,15026,B,,Expert,CHEMBL617942,BAO_0000357,2694
,,H,,,12687,,,Ratio of pKi of 5-HT2A to that of D2 receptor,1,,,,,8,,15026,B,,Expert,CHEMBL617943,BAO_0000357,2695
,,H,,,105093,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,1,,,,,4,,16404,B,,Expert,CHEMBL617944,BAO_0000224,2696
,,H,,,105093,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,1,,,,,4,,16404,B,,Expert,CHEMBL617945,BAO_0000224,2697
,,H,,,105075,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,1,,,,,4,,16404,B,,Expert,CHEMBL617946,BAO_0000224,2698
,,H,,,12687,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,1,,,,,8,,16404,B,,Autocuration,CHEMBL617947,BAO_0000357,2699
,,H,,,12687,,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,1,,,,,8,,16326,B,,Expert,CHEMBL617948,BAO_0000357,2700
,,H,,,12687,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,1,,,,,8,,15847,F,,Autocuration,CHEMBL858116,BAO_0000019,2701
,,H,,,12687,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,1,,,,,8,,15847,F,,Autocuration,CHEMBL617949,BAO_0000019,2702
,,H,,,12687,,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,1,,,,,8,,15329,F,,Autocuration,CHEMBL617950,BAO_0000019,2703
,,H,,,12687,,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,1,Thoracic aorta,,,,8,,16404,F,1515.0,Expert,CHEMBL617951,BAO_0000019,2704
,,H,,,12687,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,1,Thoracic aorta,,,,8,,16404,F,1515.0,Expert,CHEMBL617952,BAO_0000019,2705
,,H,,,12687,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,1,Thoracic aorta,,,,8,,16404,F,1515.0,Autocuration,CHEMBL617953,BAO_0000019,2706
,,H,,,12687,,,Binding activity radioligand.,1,,,,,8,,12861,B,,Autocuration,CHEMBL617954,BAO_0000357,2707
,,H,,,12687,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,1,,,,,8,,12861,B,,Expert,CHEMBL617955,BAO_0000019,2708
,,H,,,12687,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,1,,,,,8,,12861,B,,Autocuration,CHEMBL857071,BAO_0000019,2709
,,H,,,12687,,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,1,,,,,8,,12490,B,,Expert,CHEMBL617270,BAO_0000019,2710
,,H,339.0,,12687,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,1,,N1E-115,,,8,,12827,B,,Autocuration,CHEMBL617271,BAO_0000219,2711
,,H,339.0,,12687,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,1,,N1E-115,,,8,,12827,B,,Autocuration,CHEMBL617272,BAO_0000219,2712
,,H,,,12687,,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,1,,,,,8,,12918,B,,Autocuration,CHEMBL617273,BAO_0000019,2713
,,D,,,12687,10116.0,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,1,,,,,9,,12919,F,,Expert,CHEMBL617274,BAO_0000019,2714
,,H,,,108,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,1,,,,,8,,17723,B,,Autocuration,CHEMBL617275,BAO_0000357,2715
,,H,,,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,1,,,,,8,,6013,B,,Autocuration,CHEMBL617276,BAO_0000357,2716
,,H,,,108,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,1,,,,,8,,16293,B,,Autocuration,CHEMBL617277,BAO_0000357,2717
,,H,,,108,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,1,,,,,8,,3857,B,,Expert,CHEMBL617278,BAO_0000019,2718
,,H,,,108,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,1,,,,,8,,3857,B,,Expert,CHEMBL617279,BAO_0000019,2719
,,H,,,108,,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,1,,,,,8,,3857,B,,Expert,CHEMBL617280,BAO_0000019,2720
,,H,,,108,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,1,,,,,8,,15363,B,,Autocuration,CHEMBL617281,BAO_0000357,2721
,,H,,,108,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,1,,,,,8,,15363,B,,Autocuration,CHEMBL617282,BAO_0000357,2722
,,H,,,108,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,1,,,,,8,,16441,B,,Expert,CHEMBL617283,BAO_0000019,2723
,,H,,,108,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,1,,,,,8,,16441,B,,Expert,CHEMBL617284,BAO_0000019,2724
,,H,722.0,,108,,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,1,,HEK293,,,8,,4176,B,,Autocuration,CHEMBL617285,BAO_0000219,2725
,,H,,,108,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,1,,,,,8,,17085,B,,Autocuration,CHEMBL617286,BAO_0000019,2726
,,D,,,108,9606.0,Homo sapiens,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,1,,,,,9,,17200,B,,Expert,CHEMBL617287,BAO_0000357,2727
,,H,,,108,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,1,,,,,8,,5088,B,,Expert,CHEMBL617288,BAO_0000357,2728
,,H,,,108,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,1,,,,,8,,5088,B,,Autocuration,CHEMBL617289,BAO_0000357,2729
,,H,,,108,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,1,,,,,8,,5088,B,,Autocuration,CHEMBL872917,BAO_0000357,2730
,,H,,,108,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,1,,,,,8,,5088,B,,Autocuration,CHEMBL617290,BAO_0000357,2731
,,H,449.0,,108,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,1,,CHO,,,8,,16659,B,,Autocuration,CHEMBL617291,BAO_0000219,2732
,,H,449.0,,108,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,1,,CHO,,,8,,16659,B,,Autocuration,CHEMBL617292,BAO_0000219,2733
,,H,723.0,,108,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,1,,NIH3T3,,,8,,17451,B,,Autocuration,CHEMBL617293,BAO_0000219,2734
,,D,449.0,,108,9606.0,Homo sapiens,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,1,,CHO,,,9,,6857,F,,Expert,CHEMBL617294,BAO_0000219,2735
,,H,,,108,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,1,,,,,8,,3857,B,,Expert,CHEMBL617295,BAO_0000019,2736
,,H,,,108,,,Binding activity radioligand.,1,,,,,8,,12861,B,,Autocuration,CHEMBL617296,BAO_0000357,2737
,,H,,,108,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,1,,,,,8,,12861,B,,Autocuration,CHEMBL617297,BAO_0000019,2738
,,H,449.0,,108,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,1,,CHO,,,8,,5104,B,,Expert,CHEMBL617298,BAO_0000219,2739
,,H,449.0,,108,,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,1,,CHO,,,8,,5105,B,,Expert,CHEMBL617299,BAO_0000219,2740
,,H,449.0,,108,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,1,,CHO,,,8,,5105,B,,Autocuration,CHEMBL617300,BAO_0000219,2741
,,H,,,108,,,Binding affinity against 5-HT2C receptor,1,,,,,8,,5254,B,,Autocuration,CHEMBL617454,BAO_0000357,2742
,,H,722.0,,108,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,1,,HEK293,,,8,,13267,B,,Autocuration,CHEMBL617505,BAO_0000219,2743
,,D,722.0,,108,9606.0,Homo sapiens,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,1,,HEK293,,,9,,14157,B,,Expert,CHEMBL617506,BAO_0000219,2744
,,D,722.0,,108,9606.0,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,1,,HEK293,,,9,,12936,B,,Expert,CHEMBL617507,BAO_0000219,2745
,,H,,,108,,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,1,,,,,8,,14068,B,,Expert,CHEMBL617508,BAO_0000357,2746
,,D,722.0,,108,9606.0,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,1,,HEK293,,,9,,12936,B,,Expert,CHEMBL857982,BAO_0000219,2747
,,D,722.0,,108,9606.0,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,1,,HEK293,,,9,,4540,B,,Expert,CHEMBL617509,BAO_0000219,2748
,,D,722.0,,108,9606.0,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,1,,HEK293,,,9,,4540,B,,Expert,CHEMBL617510,BAO_0000219,2749
,,H,,,108,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,1,,,,,8,,6166,B,,Autocuration,CHEMBL617511,BAO_0000357,2750
,,H,722.0,,108,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,1,,HEK293,,,8,,17296,B,,Autocuration,CHEMBL617512,BAO_0000219,2751
,,H,722.0,,108,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,1,,HEK293,,,8,,17296,B,,Autocuration,CHEMBL617749,BAO_0000219,2752
,,H,722.0,,108,,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,1,,HEK293,,,8,,15779,B,,Autocuration,CHEMBL617750,BAO_0000219,2753
,,H,722.0,,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,1,,HEK293,,,8,,15779,B,,Autocuration,CHEMBL617751,BAO_0000219,2754
,,H,722.0,,108,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,1,,HEK293,,,8,,14391,B,,Expert,CHEMBL617752,BAO_0000219,2755
,,H,722.0,,108,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",1,,HEK293,,,8,,15779,B,,Autocuration,CHEMBL617753,BAO_0000219,2756
,,H,722.0,,108,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",1,,HEK293,,,8,,15851,B,,Expert,CHEMBL617754,BAO_0000219,2757
,,D,722.0,,108,9606.0,Homo sapiens,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,1,,HEK293,,,9,,15851,B,,Expert,CHEMBL617755,BAO_0000219,2758
,,H,722.0,,108,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",1,,HEK293,,,8,,15779,B,,Autocuration,CHEMBL617756,BAO_0000219,2759
,,H,722.0,,108,,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,1,,HEK293,,,8,,3832,B,,Expert,CHEMBL617757,BAO_0000219,2760
,,H,722.0,,108,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,1,,HEK293,,,8,,3833,B,,Expert,CHEMBL617758,BAO_0000219,2761
,,H,723.0,,108,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,1,,NIH3T3,,,8,,17451,B,,Autocuration,CHEMBL617759,BAO_0000219,2762
,,H,722.0,,108,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,1,,HEK293,,,8,,4199,B,,Autocuration,CHEMBL617760,BAO_0000219,2763
,,H,485.0,,108,,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,1,,CHO-K1,,,8,,1883,B,,Expert,CHEMBL617761,BAO_0000219,2764
,,D,,,108,9606.0,Homo sapiens,Binding affinity against 5-hydroxytryptamine 2C receptor,1,,,,,9,,4321,B,,Expert,CHEMBL617762,BAO_0000357,2765
,,H,,,108,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,1,,,,,8,,14875,B,,Autocuration,CHEMBL617763,BAO_0000357,2766
,,H,722.0,,108,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,1,,HEK293,,,8,,15146,B,,Autocuration,CHEMBL857983,BAO_0000219,2767
,,H,722.0,,108,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,1,,HEK293,,,8,,5213,B,,Autocuration,CHEMBL617764,BAO_0000219,2768
,,H,308.0,,108,,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,1,,HeLa,,,8,,16404,B,,Autocuration,CHEMBL617765,BAO_0000219,2769
,,H,,,108,,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,1,,,,,8,,13267,F,,Autocuration,CHEMBL617766,BAO_0000019,2770
,,H,,,108,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,1,Hippocampus,,,,8,,13267,F,10000000.0,Autocuration,CHEMBL617767,BAO_0000221,2771
,,H,722.0,,108,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,1,,HEK293,,,8,,14818,B,,Autocuration,CHEMBL617768,BAO_0000219,2772
,,H,722.0,,108,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",1,,HEK293,,,8,,4829,B,,Autocuration,CHEMBL617769,BAO_0000219,2773
,,H,,,11864,,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,1,,,,,8,,13463,B,,Autocuration,CHEMBL858023,BAO_0000357,2774
,,H,,,11864,,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,1,Stomach,,,,8,,13463,B,945.0,Autocuration,CHEMBL617770,BAO_0000019,2775
,,H,,,11864,,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,1,Stomach,,,,8,,13463,B,945.0,Autocuration,CHEMBL617771,BAO_0000019,2776
,,H,625.0,,11864,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,1,,A9,,,8,,12652,F,,Autocuration,CHEMBL617772,BAO_0000219,2777
,,H,723.0,,11864,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,1,,NIH3T3,,,8,,4682,B,,Autocuration,CHEMBL617773,BAO_0000219,2778
,,H,723.0,,11864,,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,1,,NIH3T3,,,8,,4682,B,,Autocuration,CHEMBL617850,BAO_0000219,2779
,,H,723.0,,11864,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,1,,NIH3T3,,,8,,4682,B,,Autocuration,CHEMBL617851,BAO_0000219,2780
,,H,,,11864,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,1,,,,,8,,12652,F,,Autocuration,CHEMBL617852,BAO_0000019,2781
,,H,,,12689,10090.0,Mus musculus,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,1,Stomach,,,,8,,13463,B,945.0,Autocuration,CHEMBL858024,BAO_0000019,2782
,,D,,,12689,10116.0,Rattus norvegicus,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,1,Stomach,,,,9,,13463,B,945.0,Expert,CHEMBL617853,BAO_0000019,2783
,,H,,,108,,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,1,,,,,8,,13969,B,,Expert,CHEMBL617854,BAO_0000357,2784
,,H,,,108,9823.0,Sus scrofa,Binding affinity for 5-hydroxytryptamine 2C receptor,1,,,,,8,,13392,B,,Expert,CHEMBL873477,BAO_0000357,2785
,,H,,,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,1,,,,,8,,13392,B,,Expert,CHEMBL617855,BAO_0000357,2786
,,H,,,108,,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,1,,,,,8,,14430,B,,Expert,CHEMBL617856,BAO_0000019,2787
,,H,,,108,,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,1,,,,,8,,1742,B,,Autocuration,CHEMBL617857,BAO_0000019,2788
,,H,,,108,,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,1,,,,,8,,14286,B,,Autocuration,CHEMBL617858,BAO_0000249,2789
,,H,,,108,,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,1,,,,,8,,5619,B,,Autocuration,CHEMBL617859,BAO_0000357,2790
,,H,,,108,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,1,,,,,8,,15086,B,,Autocuration,CHEMBL617860,BAO_0000357,2791
,,H,,,108,,,Binding activity radioligand.,1,,,,,8,,12861,B,,Autocuration,CHEMBL617861,BAO_0000357,2792
,,H,,,108,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,1,,,,,8,,12861,B,,Expert,CHEMBL617862,BAO_0000019,2793
,,H,,,108,,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,1,,,,,8,,12861,B,,Autocuration,CHEMBL617863,BAO_0000019,2794
,,H,,,108,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,1,,,,,8,,12827,B,,Autocuration,CHEMBL617864,BAO_0000249,2795
,,H,,,108,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,1,,,,,8,,12827,B,,Autocuration,CHEMBL617649,BAO_0000249,2796
,,H,,,108,9823.0,Sus scrofa,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,1,,,,,8,,12919,F,,Expert,CHEMBL617650,BAO_0000019,2797
,,H,,,108,9823.0,Sus scrofa,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,1,,,,,8,,12919,F,,Expert,CHEMBL617651,BAO_0000019,2798
,,H,,,108,9823.0,Sus scrofa,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,1,,,,,8,,16429,B,,Autocuration,CHEMBL617652,BAO_0000357,2799
,,H,,,108,9823.0,Sus scrofa,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,1,,,,,8,,773,B,,Autocuration,CHEMBL857072,BAO_0000019,2800
,,H,,,108,9823.0,Sus scrofa,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,1,,,,,8,,5033,B,,Autocuration,CHEMBL617653,BAO_0000357,2801
,,H,,,12687,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,1,,,,,8,,12861,B,,Autocuration,CHEMBL617654,BAO_0000019,2802
,,H,,,12689,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,1,,,,,8,,14093,F,,Autocuration,CHEMBL617655,BAO_0000019,2803
,,H,,,12689,,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,1,,,,,8,,14970,B,,Expert,CHEMBL617656,BAO_0000357,2804
,,H,,,12689,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,1,,,,,8,,14970,B,,Autocuration,CHEMBL617657,BAO_0000357,2805
,,H,,,12689,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,1,,,,,8,,14970,B,,Autocuration,CHEMBL617658,BAO_0000357,2806
,,D,,,12689,10116.0,Rattus norvegicus,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,1,,,,,9,,14178,B,,Expert,CHEMBL617659,BAO_0000357,2807
,,D,,,12689,10116.0,Rattus norvegicus,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,1,,,,,9,,14178,B,,Expert,CHEMBL617838,BAO_0000357,2808
,Brain membranes,D,,,12689,10116.0,Rattus norvegicus,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,1,,,,,9,,14229,B,,Expert,CHEMBL617839,BAO_0000249,2809
,,H,,,12689,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,1,,,,,8,,16532,B,,Autocuration,CHEMBL617840,BAO_0000357,2810
,,H,,,12689,,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,1,,,,,8,,14826,B,,Autocuration,CHEMBL617841,BAO_0000019,2811
,,H,,,12689,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,1,,,,,8,,17211,B,,Autocuration,CHEMBL875915,BAO_0000019,2812
,,H,,,12689,,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,1,,,,In vitro,8,,17211,B,,Expert,CHEMBL617842,BAO_0000219,2813
,,H,723.0,,12689,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,1,,NIH3T3,,,8,,13246,B,,Expert,CHEMBL617843,BAO_0000219,2814
,,H,,,12689,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,1,,,,,8,,13246,B,,Expert,CHEMBL617844,BAO_0000357,2815
,,H,,,12689,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,1,,,,,8,,12457,B,,Expert,CHEMBL617845,BAO_0000357,2816
,,H,723.0,,12689,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,1,,NIH3T3,,,8,,12457,B,,Expert,CHEMBL617846,BAO_0000219,2817
,,H,,,12689,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,1,,,,,8,,4707,B,,Autocuration,CHEMBL617847,BAO_0000357,2818
,,H,,,12689,,,Binding affinity against 5-hydroxytryptamine 2C receptor,1,,,,,8,,13297,B,,Expert,CHEMBL617848,BAO_0000357,2819
,,H,,,12689,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,1,,,,,8,,16633,B,,Autocuration,CHEMBL617849,BAO_0000357,2820
,,H,,,12689,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,1,,,,,8,,16133,B,,Expert,CHEMBL621507,BAO_0000357,2821
,,H,,,12689,,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,1,,,,,8,,16326,B,,Expert,CHEMBL621508,BAO_0000357,2822
,,H,,,12689,,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,1,,,,,8,,14423,B,,Autocuration,CHEMBL621509,BAO_0000019,2823
,,H,,,12689,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,1,,,,,8,,15412,B,,Autocuration,CHEMBL621510,BAO_0000019,2824
,,H,,,12689,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,1,,,,,8,,15412,B,,Autocuration,CHEMBL621511,BAO_0000019,2825
,,H,625.0,,12689,,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,1,,A9,,,8,,15558,B,,Expert,CHEMBL621512,BAO_0000219,2826
,,H,,,12689,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,1,,,,,8,,16633,B,,Autocuration,CHEMBL621513,BAO_0000357,2827
,,H,,,12689,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,1,,,,,8,,6013,B,,Expert,CHEMBL621514,BAO_0000357,2828
,,H,,,12689,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,1,,,,In vitro,8,,17175,B,,Expert,CHEMBL621515,BAO_0000219,2829
,,H,,,12689,,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,1,,,,,8,,12469,B,,Autocuration,CHEMBL621516,BAO_0000219,2830
,,H,,,12689,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,1,Caudate-putamen,,,,8,,3682,B,5383.0,Autocuration,CHEMBL621517,BAO_0000019,2831
,,H,,,12689,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,1,,,,,8,,4932,B,,Autocuration,CHEMBL621518,BAO_0000357,2832
,,H,,,12689,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,1,,,,,8,,4932,B,,Autocuration,CHEMBL621519,BAO_0000019,2833
,,H,,,12689,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,1,,,,,8,,3935,B,,Autocuration,CHEMBL621520,BAO_0000357,2834
,,H,,,12689,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,1,,,,,8,,15818,B,,Autocuration,CHEMBL621521,BAO_0000357,2835
,,H,,,12689,,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,1,,,,,8,,15818,B,,Autocuration,CHEMBL621522,BAO_0000357,2836
,,H,,,12689,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,1,,,,,8,,14749,B,,Expert,CHEMBL621523,BAO_0000219,2837
,,H,,,12689,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,1,,,,,8,,15740,B,,Autocuration,CHEMBL621524,BAO_0000357,2838
,,D,,,12689,10116.0,Rattus norvegicus,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,1,,,,,9,,17133,B,,Expert,CHEMBL621525,BAO_0000357,2839
,,H,,,12689,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,1,,,,,8,,16532,B,,Autocuration,CHEMBL872921,BAO_0000357,2840
,,H,,,12689,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,1,,,,,8,,12369,B,,Autocuration,CHEMBL621526,BAO_0000357,2841
,,H,,,12689,,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,1,,,,,8,,12369,B,,Expert,CHEMBL621527,BAO_0000219,2842
,,D,,,12689,10116.0,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,1,,,,,9,,2309,B,,Expert,CHEMBL617865,BAO_0000019,2843
,,H,,,12689,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,1,,,,,8,,12953,B,,Autocuration,CHEMBL617866,BAO_0000357,2844
,,H,,,12689,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,1,,,,,8,,12953,B,,Autocuration,CHEMBL617867,BAO_0000019,2845
,,H,,,12689,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,1,,,,,8,,12953,B,,Autocuration,CHEMBL617487,BAO_0000357,2846
,,H,,,12689,,,Binding affinity for 5-hydroxytryptamine 2C receptor,1,,,,,8,,12953,B,,Expert,CHEMBL617488,BAO_0000357,2847
,,H,,,12689,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,1,,,,,8,,17133,B,,Autocuration,CHEMBL617489,BAO_0000357,2848
,,H,,,12689,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,1,,,,,8,,17211,B,,Autocuration,CHEMBL617490,BAO_0000019,2849
,,H,,,12689,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,1,,,,,8,,17211,B,,Autocuration,CHEMBL617491,BAO_0000019,2850
,,H,,,12689,,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,1,,,,,8,,14025,B,,Autocuration,CHEMBL617492,BAO_0000019,2851
,,H,,,12689,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,1,,,,,8,,14998,B,,Autocuration,CHEMBL617493,BAO_0000019,2852
,,H,,,12689,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,1,,,,,8,,4342,B,,Autocuration,CHEMBL617494,BAO_0000357,2853
,,D,,,12689,10116.0,Rattus norvegicus,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,1,,,,,9,,13735,B,,Expert,CHEMBL617495,BAO_0000019,2854
,,H,,,12689,,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,1,,,,,8,,13181,B,,Autocuration,CHEMBL617496,BAO_0000357,2855
,,H,485.0,,12689,,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,1,,CHO-K1,,,8,,1883,B,,Autocuration,CHEMBL617497,BAO_0000219,2856
,,H,,,12689,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,1,,,,,8,,15194,B,,Autocuration,CHEMBL617498,BAO_0000357,2857
,,H,,,12689,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,1,,,,,8,,15194,B,,Autocuration,CHEMBL617499,BAO_0000357,2858
,,H,,,12689,,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,1,,,,,8,,14579,F,,Autocuration,CHEMBL617500,BAO_0000019,2859
,,H,,,108,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,1,,,,,8,,4639,B,,Autocuration,CHEMBL617501,BAO_0000357,2860
,,H,,,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,1,,,,,8,,4820,B,,Expert,CHEMBL617502,BAO_0000357,2861
,,H,,,227,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,1,,,,,8,,14442,B,,Autocuration,CHEMBL617503,BAO_0000357,2862
,,H,,,227,,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,1,,,,,8,,14755,B,,Autocuration,CHEMBL617504,BAO_0000357,2863
,,H,,,227,,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,1,,,,,8,,14744,B,,Autocuration,CHEMBL617406,BAO_0000357,2864
,,D,,,227,9606.0,Homo sapiens,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,1,,,,,9,,6857,B,,Expert,CHEMBL617407,BAO_0000019,2865
,,H,,,227,,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,1,,,,,8,,16209,B,,Autocuration,CHEMBL617408,BAO_0000357,2866
,,H,,,227,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,1,,,,,8,,15363,B,,Autocuration,CHEMBL617409,BAO_0000357,2867
,,H,,,227,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,1,,,,,8,,15363,B,,Autocuration,CHEMBL617410,BAO_0000357,2868
,,H,,,227,,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,1,,,,,8,,15363,B,,Autocuration,CHEMBL617411,BAO_0000357,2869
,,H,,,227,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,1,,,,,8,,17085,B,,Autocuration,CHEMBL617412,BAO_0000019,2870
,,D,,,227,9606.0,Homo sapiens,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,1,,,,,9,,17200,B,,Expert,CHEMBL617774,BAO_0000357,2871
,,D,722.0,,227,9606.0,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,1,,HEK293,,,9,,15851,B,,Expert,CHEMBL617775,BAO_0000219,2872
,,D,722.0,,227,9606.0,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,1,,HEK293,,,9,,15851,B,,Expert,CHEMBL617776,BAO_0000219,2873
,,D,449.0,,227,9606.0,Homo sapiens,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,1,,CHO,,,9,,6857,F,,Expert,CHEMBL617777,BAO_0000219,2874
,,D,449.0,,227,9606.0,Homo sapiens,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,1,,CHO,,,9,,6857,F,,Expert,CHEMBL617778,BAO_0000219,2875
,,H,722.0,,227,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",1,,HEK293,,,8,,15779,B,,Autocuration,CHEMBL617779,BAO_0000219,2876
,,H,722.0,,227,,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,1,,HEK293,,,8,,15851,B,,Expert,CHEMBL617780,BAO_0000219,2877
,,H,722.0,,227,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",1,,HEK293,,,8,,15779,B,,Autocuration,CHEMBL617781,BAO_0000219,2878
,,D,722.0,,227,9606.0,Homo sapiens,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,1,,HEK293,,,9,,14157,B,,Expert,CHEMBL617782,BAO_0000219,2879
,,D,722.0,,227,9606.0,Homo sapiens,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,1,,HEK293,,,9,,4540,B,,Expert,CHEMBL617783,BAO_0000219,2880
,,H,,,227,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,1,,,,,8,,6166,B,,Autocuration,CHEMBL617784,BAO_0000357,2881
,,H,722.0,,227,,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,1,,HEK293,,,8,,15779,B,,Autocuration,CHEMBL617785,BAO_0000219,2882
,,H,722.0,,227,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,1,,HEK293,,,8,,14391,B,,Expert,CHEMBL857984,BAO_0000219,2883
,,H,722.0,,227,,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,1,,HEK293,,,8,,3832,B,,Expert,CHEMBL617786,BAO_0000219,2884
,,H,722.0,,227,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,1,,HEK293,,,8,,3833,B,,Expert,CHEMBL617787,BAO_0000219,2885
,,D,722.0,,227,9606.0,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,1,,HEK293,,,9,,15851,B,,Expert,CHEMBL617788,BAO_0000219,2886
,,D,722.0,,227,9606.0,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,1,,HEK293,,,9,,15851,B,,Expert,CHEMBL617789,BAO_0000219,2887
,,H,722.0,,227,,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,1,,HEK293,,,8,,4199,B,,Autocuration,CHEMBL617790,BAO_0000219,2888
,,H,485.0,,227,,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,1,,CHO-K1,,,8,,1883,B,,Expert,CHEMBL617791,BAO_0000219,2889
,,H,,,227,,,Binding affinity against 5-hydroxytryptamine 2B receptor,1,,,,,8,,4321,B,,Expert,CHEMBL617608,BAO_0000357,2890
,,H,722.0,,227,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,1,,HEK293,,,8,,15146,B,,Autocuration,CHEMBL617609,BAO_0000219,2891
,,H,722.0,,227,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,1,,HEK293,,,8,,5213,B,,Autocuration,CHEMBL617610,BAO_0000219,2892
,,H,722.0,,227,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,1,,HEK293,,,8,,14818,B,,Autocuration,CHEMBL617611,BAO_0000219,2893
,,H,722.0,,227,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",1,,HEK293,,,8,,4829,B,,Autocuration,CHEMBL617612,BAO_0000219,2894
,,H,722.0,,227,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",1,,HEK293,,,8,,4829,B,,Autocuration,CHEMBL617613,BAO_0000219,2895
,,H,,,227,9986.0,Oryctolagus cuniculus,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,1,,,,,8,,14025,B,,Autocuration,CHEMBL617614,BAO_0000019,2896
,,H,,,12688,,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,1,Stomach,,,,8,,13463,B,945.0,Expert,CHEMBL617615,BAO_0000019,2897
,,H,,,12688,,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,1,Stomach,,,,8,,7259,B,945.0,Expert,CHEMBL858114,BAO_0000357,2898
,,H,,,12688,,,Affinity against serotonergic receptor in the isolated rat stomach fundus,1,Stomach,,,,8,,7259,B,945.0,Autocuration,CHEMBL617616,BAO_0000357,2899
,,D,,,12688,10116.0,Rattus norvegicus,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,1,Stomach,,,,9,,7185,F,945.0,Expert,CHEMBL617617,BAO_0000019,2900
,,D,,,12688,10116.0,Rattus norvegicus,Antagonistic against 5-hydroxytryptamine 2B receptor,1,,,,,9,,7185,F,,Expert,CHEMBL875914,BAO_0000019,2901
,,H,,,12688,,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,1,Stomach,,,,8,,13267,F,945.0,Autocuration,CHEMBL617618,BAO_0000019,2902
,,D,,,12688,10116.0,Rattus norvegicus,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,1,Stomach,,,,9,,13735,B,945.0,Expert,CHEMBL617619,BAO_0000357,2903
,,H,,,12688,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,1,,,,,8,,15738,F,,Autocuration,CHEMBL617620,BAO_0000019,2904
,,H,,,12688,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,1,,,,,8,,15738,F,,Autocuration,CHEMBL617621,BAO_0000019,2905
,,H,,,12688,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,1,,,,,8,,15738,F,,Autocuration,CHEMBL617622,BAO_0000019,2906
,,D,,,12688,10116.0,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,1,Stomach,,,,9,,12936,B,945.0,Expert,CHEMBL617623,BAO_0000357,2907
,,D,,,12688,10116.0,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,1,Stomach,,,,9,,12936,B,945.0,Expert,CHEMBL617624,BAO_0000357,2908
,,D,,,12688,10116.0,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,1,Stomach,,,,9,,12936,B,945.0,Expert,CHEMBL617625,BAO_0000357,2909
,,D,,,12688,10116.0,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,1,Stomach,,,,9,,12936,B,945.0,Expert,CHEMBL617626,BAO_0000357,2910
,,H,,,12688,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,1,Stomach,,,,8,,16404,F,945.0,Autocuration,CHEMBL617627,BAO_0000019,2911
,,H,,,12688,,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,1,Stomach,,,,8,,16404,F,945.0,Expert,CHEMBL617628,BAO_0000019,2912
,,H,,,12688,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,1,Stomach,,,,8,,16404,F,945.0,Autocuration,CHEMBL617629,BAO_0000019,2913
,,H,,,12688,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,1,Stomach,,,,8,,16404,F,945.0,Autocuration,CHEMBL858115,BAO_0000019,2914
,,D,,,12688,10116.0,Rattus norvegicus,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,1,Stomach,,,,9,,16404,F,945.0,Expert,CHEMBL617630,BAO_0000019,2915
,,H,,,12688,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,1,Thoracic aorta,,,,8,,16404,F,1515.0,Autocuration,CHEMBL617631,BAO_0000019,2916
,,H,,,12688,,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,1,,,,,8,,7483,B,,Autocuration,CHEMBL617632,BAO_0000357,2917
,,H,,,12688,,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,1,,,,,8,,7483,B,,Expert,CHEMBL617633,BAO_0000357,2918
,,H,,,12688,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,1,,,,,8,,7483,B,,Autocuration,CHEMBL617634,BAO_0000357,2919
,,H,,,12688,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,1,,,,,8,,7483,B,,Autocuration,CHEMBL617635,BAO_0000357,2920
,,D,,,12688,10116.0,Rattus norvegicus,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,1,Stomach,,,,9,,16404,F,945.0,Autocuration,CHEMBL617637,BAO_0000019,2922
,,H,,,227,,,Binding affinity against 5-hydroxytryptamine 1A receptor,1,,,,,8,,6347,B,,Autocuration,CHEMBL617638,BAO_0000357,2923
,,H,,,227,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,1,,,,,8,,4373,B,,Autocuration,CHEMBL617639,BAO_0000357,2924
,,H,,,227,,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,1,,,,,8,,4373,B,,Autocuration,CHEMBL617640,BAO_0000357,2925
,,H,,,227,,,Evaluated for the binding affinity to 5-HT 2B receptor,1,,,,,8,,4687,B,,Autocuration,CHEMBL617641,BAO_0000357,2926
,,H,,,227,,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,1,,,,,8,,16946,B,,Autocuration,CHEMBL617642,BAO_0000357,2927
,,H,,,227,,,Binding affinities against 5-hydroxytryptamine 2B receptor,1,,,,,8,,16633,B,,Autocuration,CHEMBL617643,BAO_0000357,2928
,,H,,,227,,,Binding affinities towards 5-hydroxytryptamine 2B receptor,1,,,,,8,,16633,B,,Autocuration,CHEMBL617644,BAO_0000357,2929
,,H,,,227,,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,1,,,,,8,,16633,B,,Autocuration,CHEMBL617645,BAO_0000357,2930
,,H,,,108,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,1,,,,,8,,15026,B,,Expert,CHEMBL617646,BAO_0000357,2931
,,H,,,108,9913.0,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,1,,,,,8,,15738,B,,Autocuration,CHEMBL617647,BAO_0000357,2932
,,H,,,108,9913.0,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,1,,,,,8,,15738,B,,Autocuration,CHEMBL617648,BAO_0000357,2933
,,H,,,108,9913.0,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,1,,,,,8,,15738,B,,Autocuration,CHEMBL617875,BAO_0000357,2934
,,H,,,108,9913.0,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,1,,,,,8,,15738,B,,Autocuration,CHEMBL617876,BAO_0000357,2935
,,H,,,108,9913.0,Bos taurus,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,1,,,,,8,,16404,B,,Expert,CHEMBL617877,BAO_0000357,2936
,,H,,,108,9913.0,Bos taurus,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,1,,,,,8,,15026,B,,Expert,CHEMBL617878,BAO_0000357,2937
,,H,,,108,9913.0,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,1,,,,,8,,15738,B,,Autocuration,CHEMBL617879,BAO_0000357,2938
,,H,,,108,10141.0,Cavia porcellus,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,1,,,,,8,,16312,B,,Autocuration,CHEMBL617880,BAO_0000019,2939
,,D,,,20033,10141.0,Cavia porcellus,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,1,Striatum,,,,9,,5486,B,2435.0,Intermediate,CHEMBL617881,BAO_0000357,2940
,,H,,,51,,,Binding affinity against 5-HT1A receptor,1,,,,,8,,5254,B,,Autocuration,CHEMBL857073,BAO_0000357,2941
,,H,449.0,,108,,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,1,,CHO,,,8,,3857,F,,Expert,CHEMBL617882,BAO_0000219,2942
,,D,449.0,,108,9606.0,Homo sapiens,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,1,,CHO,,,9,,6857,F,,Expert,CHEMBL617883,BAO_0000219,2943
,,H,,,108,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,1,,,,,8,,4176,F,,Autocuration,CHEMBL617884,BAO_0000219,2944
,,H,449.0,,108,,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,1,,CHO,,,8,,6347,B,,Autocuration,CHEMBL617885,BAO_0000219,2945
,,H,449.0,,108,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",1,,CHO,,,8,,6347,B,,Autocuration,CHEMBL617886,BAO_0000219,2946
,,D,,,108,9606.0,Homo sapiens,Inhibition of human 5-hydroxytryptamine 2C receptor,1,,,,,9,,16146,B,,Expert,CHEMBL617887,BAO_0000357,2947
,,H,,,108,,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),1,,,,,8,,3805,B,,Autocuration,CHEMBL617888,BAO_0000357,2948
,,H,,,108,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,1,,,,,8,,3857,B,,Autocuration,CHEMBL617889,BAO_0000019,2949
,,H,,,108,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,1,,,,,8,,5635,B,,Autocuration,CHEMBL617890,BAO_0000357,2950
,,H,,,108,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,1,,,,,8,,5635,B,,Autocuration,CHEMBL617891,BAO_0000357,2951
,,H,,,108,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,1,,,,,8,,5635,B,,Autocuration,CHEMBL617892,BAO_0000357,2952
,,H,449.0,,108,,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,1,,CHO,,,8,,4012,B,,Expert,CHEMBL617893,BAO_0000219,2953
,,H,449.0,,108,,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,1,,CHO,,,8,,6366,B,,Expert,CHEMBL617894,BAO_0000219,2954
,,H,449.0,,108,,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,1,,CHO,,,8,,15949,B,,Expert,CHEMBL617895,BAO_0000219,2955
,,H,449.0,,108,,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,1,,CHO,,,8,,17211,B,,Autocuration,CHEMBL617896,BAO_0000219,2956
,,D,,,108,9606.0,Homo sapiens,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,1,,,,,9,,6491,B,,Expert,CHEMBL617897,BAO_0000357,2957
,,H,,,108,,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,1,,,,,8,,14093,F,,Autocuration,CHEMBL617898,BAO_0000019,2958
,,H,,,108,,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,1,,,,,8,,13481,F,,Autocuration,CHEMBL617899,BAO_0000019,2959
,,H,449.0,,108,10116.0,Rattus norvegicus,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,1,,CHO,,,8,,6347,B,,Expert,CHEMBL617900,BAO_0000219,2960
,,H,,,108,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,1,,,,,8,,14093,F,,Autocuration,CHEMBL617901,BAO_0000019,2961
,,H,,,108,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,1,,,,,8,,14093,F,,Autocuration,CHEMBL617902,BAO_0000019,2962
,,H,,,108,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,1,,,,,8,,13481,F,,Autocuration,CHEMBL617903,BAO_0000019,2963
,,H,,,108,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,1,,,,,8,,14442,B,,Autocuration,CHEMBL617904,BAO_0000357,2964
,,H,,,108,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,1,,,,,8,,14442,B,,Autocuration,CHEMBL617905,BAO_0000357,2965
,,H,,,108,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,1,,,,,8,,14442,B,,Autocuration,CHEMBL617906,BAO_0000357,2966
,,H,,,108,,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,1,,,,,8,,14755,B,,Autocuration,CHEMBL617907,BAO_0000357,2967
,,H,,,108,,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,1,,,,,8,,14744,B,,Autocuration,CHEMBL617908,BAO_0000357,2968
,,H,449.0,,108,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,1,,CHO,,,8,,16659,B,,Expert,CHEMBL620617,BAO_0000219,2969
,,D,,,108,9606.0,Homo sapiens,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,1,,,,,9,,6857,B,,Expert,CHEMBL620618,BAO_0000019,2970
,,H,,,108,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,1,,,,,8,,5635,B,,Expert,CHEMBL620619,BAO_0000357,2971
,,D,,,108,9606.0,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,1,,,,,9,,4234,B,,Expert,CHEMBL620620,BAO_0000357,2972
,,H,,,108,,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,1,,,,,8,,16209,B,,Autocuration,CHEMBL620621,BAO_0000357,2973
,Membranes,D,,,104698,10116.0,Rattus norvegicus,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,1,,,,,7,,5778,B,,Autocuration,CHEMBL872920,BAO_0000249,2974
,,H,,,104698,,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,1,,,,,6,,5094,B,,Autocuration,CHEMBL620622,BAO_0000223,2975
,,D,,,104698,10116.0,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,1,,,,,7,,809,B,,Autocuration,CHEMBL620623,BAO_0000019,2976
,,H,,,104698,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,1,,,,,6,,1578,B,,Autocuration,CHEMBL620624,BAO_0000019,2977
,,H,,,104698,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,1,,,,,6,,809,B,,Autocuration,CHEMBL620625,BAO_0000019,2978
,,H,,,104698,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,1,,,,,6,,12469,B,,Autocuration,CHEMBL620626,BAO_0000219,2979
,,H,,,104698,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,1,,,,,6,,14290,B,,Autocuration,CHEMBL621307,BAO_0000019,2980
,,H,,,104698,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,1,,,,,6,,14290,B,,Autocuration,CHEMBL621308,BAO_0000019,2981
,,H,,,104698,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,1,,,,,6,,10609,B,,Autocuration,CHEMBL621309,BAO_0000223,2982
,,H,,,104698,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,1,,,,,6,,10609,B,,Autocuration,CHEMBL621310,BAO_0000223,2983
,,H,,,104698,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,1,,,,,6,,10609,B,,Autocuration,CHEMBL621311,BAO_0000223,2984
,,H,,,104698,,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",1,,,,,6,,15253,B,,Autocuration,CHEMBL621502,BAO_0000249,2985
,,H,,,104698,,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",1,,,,,6,,15253,B,,Autocuration,CHEMBL621503,BAO_0000249,2986
,Membranes,H,,,104698,,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,1,,,,,6,,11683,B,,Autocuration,CHEMBL621504,BAO_0000249,2987
,,H,,,104698,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,1,,,,,6,,12092,B,,Autocuration,CHEMBL621505,BAO_0000223,2988
,,H,,,104698,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,1,,,,,6,,1946,B,,Autocuration,CHEMBL621506,BAO_0000019,2989
,,H,,,104698,,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,1,,,,,6,,11623,B,,Autocuration,CHEMBL619781,BAO_0000223,2990
,,H,,,104698,,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,1,,,,,6,,11623,B,,Autocuration,CHEMBL619782,BAO_0000223,2991
,,H,,,104698,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,1,,,,,6,,14788,B,,Autocuration,CHEMBL619783,BAO_0000019,2992
,,D,,,104698,10116.0,Rattus norvegicus,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,1,,,,,7,,5432,B,,Autocuration,CHEMBL619784,BAO_0000019,2993
,,H,,,104698,,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,1,,,,,6,,14826,B,,Autocuration,CHEMBL619785,BAO_0000249,2994
,,H,,,104698,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,1,,,,,6,,2222,B,,Autocuration,CHEMBL619786,BAO_0000223,2995
,,H,,,104698,,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,1,,,,,6,,11963,B,,Autocuration,CHEMBL619787,BAO_0000019,2996
,,H,,,104698,,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,1,,,,,6,,14145,B,,Autocuration,CHEMBL872925,BAO_0000019,2997
,,H,,,104698,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,1,,,,,6,,17819,B,,Autocuration,CHEMBL619788,BAO_0000019,2998
,,H,,,104698,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,1,,,,,6,,10394,B,,Autocuration,CHEMBL619789,BAO_0000249,2999
,,H,,,104698,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,1,,,,,6,,10394,B,,Autocuration,CHEMBL619790,BAO_0000249,3000
,,H,,,104698,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,1,,,,,6,,15034,B,,Autocuration,CHEMBL619791,BAO_0000019,3001
,,H,,,104698,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,1,,,,,6,,691,B,,Autocuration,CHEMBL619792,BAO_0000019,3002
,Membranes,H,,,104698,,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,1,,,,,6,,12092,B,,Autocuration,CHEMBL619793,BAO_0000249,3003
,,D,,,104698,10116.0,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,1,,,,,7,,11752,B,,Autocuration,CHEMBL619794,BAO_0000223,3004
,,H,,,104698,,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,1,Brain,,,,6,,11752,B,955.0,Autocuration,CHEMBL619795,BAO_0000221,3005
,,H,,,104698,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,1,,,,,6,,301,B,,Autocuration,CHEMBL619796,BAO_0000019,3006
,,H,,,104698,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,1,,,,,6,,16532,B,,Autocuration,CHEMBL620448,BAO_0000223,3007
,,H,,,104698,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,1,,,,,6,,16532,B,,Autocuration,CHEMBL620449,BAO_0000223,3008
,,H,,,104698,,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,1,,,,,6,,12092,B,,Autocuration,CHEMBL620450,BAO_0000223,3009
,,H,,,104698,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,1,,,,,6,,11684,B,,Autocuration,CHEMBL620451,BAO_0000223,3010
,,H,,,104698,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,1,,,,,6,,11684,B,,Autocuration,CHEMBL620631,BAO_0000223,3011
,,H,,,104698,,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,1,,,,,6,,12953,B,,Autocuration,CHEMBL620632,BAO_0000019,3012
,,H,,,104698,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,1,,,,,6,,12953,B,,Autocuration,CHEMBL620633,BAO_0000019,3013
,,H,,,104698,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,1,,,,,6,,12953,B,,Autocuration,CHEMBL620634,BAO_0000223,3014
,,H,,,104698,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,1,,,,,6,,12861,B,,Autocuration,CHEMBL620635,BAO_0000019,3015
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL620636,BAO_0000218,3016
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL620637,BAO_0000218,3017
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL620638,BAO_0000218,3018
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL620639,BAO_0000218,3019
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL620640,BAO_0000218,3020
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL620641,BAO_0000218,3021
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL620642,BAO_0000218,3022
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL620643,BAO_0000218,3023
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL620644,BAO_0000218,3024
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL620645,BAO_0000218,3025
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL620646,BAO_0000218,3026
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL620647,BAO_0000218,3027
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL620648,BAO_0000218,3028
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL620649,BAO_0000218,3029
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL620650,BAO_0000218,3030
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL620651,BAO_0000218,3031
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL872875,BAO_0000218,3032
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL620652,BAO_0000218,3033
,,H,,,104698,,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,1,,,,,6,,10609,F,,Autocuration,CHEMBL620653,BAO_0000019,3034
,,H,,,104698,,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,1,,,,,6,,12861,B,,Autocuration,CHEMBL857076,BAO_0000019,3035
,,D,,,104698,10116.0,Rattus norvegicus,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,1,,,,,7,,12861,B,,Autocuration,CHEMBL620654,BAO_0000019,3036
,,H,,,104698,,,Binding activity radioligand.,1,,,,,6,,12861,B,,Autocuration,CHEMBL620655,BAO_0000223,3037
,Brain membranes,H,,,104698,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,1,,,,,6,,10728,B,,Autocuration,CHEMBL620656,BAO_0000249,3038
,Brain membranes,H,,,104698,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,1,,,,,6,,10728,B,,Autocuration,CHEMBL620657,BAO_0000249,3039
,,H,,,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,1,,,,,8,,5163,B,,Autocuration,CHEMBL620658,BAO_0000357,3040
,,H,,,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,1,,,,,8,,5163,B,,Autocuration,CHEMBL620659,BAO_0000357,3041
,,H,,,108,,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,1,,,,,8,,6011,B,,Autocuration,CHEMBL620660,BAO_0000357,3042
,,H,,,108,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,1,,,,,8,,5014,B,,Autocuration,CHEMBL620661,BAO_0000357,3043
,,H,,,108,,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,1,,,,,8,,5635,B,,Autocuration,CHEMBL620662,BAO_0000357,3044
,,H,,,108,,,Affinity for 5-hydroxytryptamine 2C receptor,1,,,,,8,,5163,B,,Expert,CHEMBL620663,BAO_0000357,3045
,,H,,,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,1,,,,,8,,6841,B,,Autocuration,CHEMBL620664,BAO_0000357,3046
,,H,,,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,1,,,,,8,,6119,B,,Expert,CHEMBL620665,BAO_0000357,3047
,,H,,,108,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,1,,,,,8,,4373,B,,Autocuration,CHEMBL620666,BAO_0000357,3048
,,H,,,108,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,1,,,,,8,,1633,B,,Autocuration,CHEMBL620667,BAO_0000357,3049
,,H,,,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,1,,,,,8,,1633,B,,Expert,CHEMBL620668,BAO_0000357,3050
,,H,,,108,,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,1,,,,,8,,4373,B,,Autocuration,CHEMBL620669,BAO_0000357,3051
,,H,,,108,,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,1,,,,,8,,6576,B,,Expert,CHEMBL620670,BAO_0000357,3052
,,H,,,108,,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,1,,,,,8,,4687,B,,Autocuration,CHEMBL620671,BAO_0000357,3053
,,H,,,108,,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,1,,,,,8,,12146,B,,Autocuration,CHEMBL620672,BAO_0000357,3054
,,H,,,108,,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,1,,,,,8,,12146,B,,Autocuration,CHEMBL620673,BAO_0000357,3055
,,H,,,108,,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,1,,,,,8,,16946,B,,Autocuration,CHEMBL620674,BAO_0000357,3056
,,H,,,108,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,1,,,,,8,,14159,B,,Autocuration,CHEMBL620675,BAO_0000357,3057
,,H,,,108,,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,1,,,,,8,,16700,B,,Autocuration,CHEMBL620676,BAO_0000357,3058
,,H,,,108,,,Affinity against 5-hydroxytryptamine 2C receptor,1,,,,,8,,3269,B,,Autocuration,CHEMBL621382,BAO_0000357,3059
,,D,,,108,9606.0,Homo sapiens,Binding affinity against 5-hydroxytryptamine 2C receptor,1,,,,,9,,1274,B,,Expert,CHEMBL621383,BAO_0000357,3060
,,H,,,108,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,1,,,,,8,,1317,B,,Autocuration,CHEMBL621384,BAO_0000357,3061
,,H,,,144,9913.0,Bos taurus,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,1,,,,,8,,5834,B,,Autocuration,CHEMBL621385,BAO_0000357,3062
,,H,,,144,9913.0,Bos taurus,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,1,,,,,8,,11147,B,,Autocuration,CHEMBL617989,BAO_0000357,3063
,,H,,,104714,10141.0,Cavia porcellus,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,1,,,,,4,,14145,F,,Expert,CHEMBL617990,BAO_0000019,3064
,,H,,,104714,10141.0,Cavia porcellus,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,1,Ileum,,,,4,,10561,B,2116.0,Autocuration,CHEMBL875085,BAO_0000221,3065
,,H,,,104714,10141.0,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,1,,,,,4,,15847,F,,Autocuration,CHEMBL617991,BAO_0000019,3066
,,H,,,104714,10141.0,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,1,,,,,4,,15847,F,,Autocuration,CHEMBL617992,BAO_0000019,3067
,,H,,,104714,10141.0,Cavia porcellus,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,1,Ileum,,,,4,,10561,B,2116.0,Autocuration,CHEMBL617993,BAO_0000221,3068
,,H,,,104714,10141.0,Cavia porcellus,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,1,Ileum,,,,4,,11454,B,2116.0,Autocuration,CHEMBL617994,BAO_0000221,3069
,,H,,,104714,10141.0,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,1,,,,,4,,4639,F,,Autocuration,CHEMBL617995,BAO_0000019,3070
,,H,,,104714,10141.0,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,1,,,,,4,,4639,F,,Autocuration,CHEMBL617996,BAO_0000019,3071
,,H,,,104714,10141.0,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,1,,,,,4,,4639,F,,Autocuration,CHEMBL617997,BAO_0000019,3072
,,H,,,104714,10141.0,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,1,,,,,4,,4639,F,,Autocuration,CHEMBL617998,BAO_0000019,3073
,,H,,,104714,10141.0,Cavia porcellus,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,1,,,,,4,,4639,F,,Autocuration,CHEMBL617999,BAO_0000019,3074
,,H,,,104714,10141.0,Cavia porcellus,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,1,,,,,4,,4639,F,,Autocuration,CHEMBL618000,BAO_0000019,3075
,,H,,,104714,10141.0,Cavia porcellus,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",1,Ileum,,,,4,,15253,F,2116.0,Autocuration,CHEMBL617815,BAO_0000221,3076
,,H,,,104714,10141.0,Cavia porcellus,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",1,Ileum,,,,4,,15253,F,2116.0,Autocuration,CHEMBL617816,BAO_0000221,3077
,,H,,,104714,10141.0,Cavia porcellus,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,1,Ileum,,,,4,,11963,F,2116.0,Autocuration,CHEMBL617817,BAO_0000221,3078
,,H,,,104714,10141.0,Cavia porcellus,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,1,Ileum,,,,4,,1946,B,2116.0,Autocuration,CHEMBL617818,BAO_0000221,3079
,,H,,,104714,10141.0,Cavia porcellus,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,1,Ileum,,,,4,,1946,B,2116.0,Autocuration,CHEMBL617819,BAO_0000221,3080
,,H,,,104714,10141.0,Cavia porcellus,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,1,,,,,4,,12045,B,,Autocuration,CHEMBL617820,BAO_0000223,3081
,,H,,,104714,10141.0,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,1,Ileum,,,,4,,1559,B,2116.0,Autocuration,CHEMBL617821,BAO_0000221,3082
,,H,,,104714,10141.0,Cavia porcellus,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),1,Ileum,,,,4,,273,F,2116.0,Autocuration,CHEMBL617822,BAO_0000221,3083
,,H,,,104714,10141.0,Cavia porcellus,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),1,Ileum,,,,4,,273,F,2116.0,Autocuration,CHEMBL617823,BAO_0000221,3084
,,H,,,104714,10141.0,Cavia porcellus,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,1,Ileum,,,,4,,188,F,2116.0,Autocuration,CHEMBL617824,BAO_0000221,3085
,,H,,,104714,10141.0,Cavia porcellus,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,1,Ileum,,,,4,,12919,F,2116.0,Autocuration,CHEMBL617825,BAO_0000221,3086
,,H,,,104714,10141.0,Cavia porcellus,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,1,Ileum,,,,4,,12918,F,2116.0,Autocuration,CHEMBL617826,BAO_0000221,3087
,,H,,,104714,10141.0,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,1,Ileum,,,,4,,1559,B,2116.0,Autocuration,CHEMBL617827,BAO_0000221,3088
,,H,,,104714,10141.0,Cavia porcellus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),1,Ileum,,,,4,,273,F,2116.0,Autocuration,CHEMBL617828,BAO_0000221,3089
,,H,,,104714,10141.0,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,1,Ileum,,,,4,,1559,B,2116.0,Autocuration,CHEMBL617829,BAO_0000221,3090
,,H,,,104714,10141.0,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,1,Ileum,,,,4,,1559,B,2116.0,Autocuration,CHEMBL617830,BAO_0000221,3091
,,H,,,104714,10141.0,Cavia porcellus,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,1,Ileum,,,,4,,1559,B,2116.0,Autocuration,CHEMBL617831,BAO_0000221,3092
,,H,,,104714,10141.0,Cavia porcellus,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,1,Ileum,,,,4,,14424,B,2116.0,Autocuration,CHEMBL617832,BAO_0000221,3093
,,U,,,22226,10141.0,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,1,,,,,0,,13181,B,,Autocuration,CHEMBL617833,BAO_0000019,3094
,,H,,,51,,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,1,,,,,8,,5486,B,,Autocuration,CHEMBL617834,BAO_0000357,3095
,,D,,,104714,9606.0,Homo sapiens,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,1,,,,,5,,6491,B,,Expert,CHEMBL617835,BAO_0000223,3096
,,H,,,104714,,,Binding affinity towards 5-HT3 receptor,1,,,,,4,,6013,B,,Autocuration,CHEMBL617836,BAO_0000223,3097
,,H,,,104714,,,Binding activity radioligand.,1,,,,,4,,12861,B,,Autocuration,CHEMBL617837,BAO_0000223,3098
,,H,,,104714,,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,1,,,,,4,,12861,B,,Autocuration,CHEMBL620392,BAO_0000019,3099
,,H,,,104714,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,1,,,,,4,,5104,B,,Autocuration,CHEMBL620393,BAO_0000223,3100
,,H,,,104714,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,1,,,,,4,,5105,B,,Autocuration,CHEMBL620394,BAO_0000223,3101
,,H,,,104714,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,1,,,,,4,,5104,B,,Autocuration,CHEMBL620395,BAO_0000223,3102
,,U,,,22226,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,1,,,,,0,,3935,B,,Autocuration,CHEMBL620396,BAO_0000019,3103
,,H,433.0,,105030,,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,1,,NG108-15,,,4,,13657,B,,Expert,CHEMBL620582,BAO_0000219,3104
,,H,,,105030,,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",1,,,,In vivo,4,,10369,B,,Autocuration,CHEMBL620583,BAO_0000218,3105
,,H,,,105030,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),1,,,,,4,,10369,B,,Autocuration,CHEMBL620584,BAO_0000019,3106
,,H,,,105030,,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,1,,,,,4,,12918,B,,Autocuration,CHEMBL620585,BAO_0000224,3107
,,H,,,105030,,,Compound was evaluated for the binding affinity at 5- HT3 receptor,1,,,,,4,,12918,B,,Autocuration,CHEMBL620586,BAO_0000224,3108
,,H,,,105030,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),1,,,,,4,,10369,B,,Autocuration,CHEMBL620587,BAO_0000019,3109
,,H,,,105030,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,1,,,,,4,,773,B,,Autocuration,CHEMBL620588,BAO_0000019,3110
,,H,,,105030,,,5-hydroxytryptamine 3 receptor agonism in mouse,1,,,,,4,,12918,F,,Autocuration,CHEMBL620589,BAO_0000218,3111
,,H,,,105030,,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,1,,,,,4,,10561,B,,Autocuration,CHEMBL620590,BAO_0000219,3112
,,H,,,105030,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,1,,,,,4,,12827,B,,Autocuration,CHEMBL617956,BAO_0000019,3113
,,H,,,105030,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,1,,,,,4,,12827,B,,Autocuration,CHEMBL617957,BAO_0000019,3114
,,H,,,105030,,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,1,,,,,4,,12918,B,,Autocuration,CHEMBL617958,BAO_0000224,3115
,,H,,,105030,,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,1,,,,,4,,273,B,,Autocuration,CHEMBL617959,BAO_0000219,3116
,,H,,,105030,,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,1,,,,,4,,273,B,,Autocuration,CHEMBL617960,BAO_0000219,3117
,,H,,,105030,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,1,,,,,4,,10561,B,,Autocuration,CHEMBL617961,BAO_0000224,3118
,,H,,,105030,,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,1,,,,In vitro,4,,5033,B,,Autocuration,CHEMBL617962,BAO_0000219,3119
,,H,339.0,,105030,,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,1,,N1E-115,,,4,,16429,B,,Autocuration,CHEMBL617963,BAO_0000219,3120
,,H,,,11765,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,1,,,,,8,,10322,B,,Autocuration,CHEMBL617964,BAO_0000019,3121
,,H,,,11765,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,1,,,,,8,,14331,B,,Autocuration,CHEMBL617965,BAO_0000219,3122
,,D,,,10630,10090.0,Mus musculus,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,1,,,,,9,,13462,B,,Autocuration,CHEMBL617966,BAO_0000357,3123
,,H,,,17106,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,1,,,,,8,,12861,B,,Autocuration,CHEMBL857074,BAO_0000019,3124
,,H,,,144,9823.0,Sus scrofa,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,1,,,,,8,,15086,B,,Autocuration,CHEMBL617967,BAO_0000357,3125
,,H,,,144,9823.0,Sus scrofa,Binding activity radioligand.,1,,,,,8,,12861,B,,Autocuration,CHEMBL617968,BAO_0000357,3126
,,H,,,104714,9986.0,Oryctolagus cuniculus,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,1,,,,,4,,10561,B,,Autocuration,CHEMBL617969,BAO_0000223,3127
,,H,,,104714,9986.0,Oryctolagus cuniculus,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,1,,,,,4,,10561,B,,Autocuration,CHEMBL617970,BAO_0000223,3128
,,H,,,104714,9986.0,Oryctolagus cuniculus,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,1,,,,,4,,10561,B,,Autocuration,CHEMBL617971,BAO_0000223,3129
,,H,,,104714,9986.0,Oryctolagus cuniculus,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,1,,,,,4,,10561,B,,Autocuration,CHEMBL617972,BAO_0000019,3130
,,H,,,104714,9986.0,Oryctolagus cuniculus,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),1,,,,,4,,273,F,,Autocuration,CHEMBL617973,BAO_0000019,3131
,,H,,,104714,9986.0,Oryctolagus cuniculus,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),1,,,,,4,,273,F,,Autocuration,CHEMBL617974,BAO_0000019,3132
,,H,,,104714,9986.0,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),1,Ileum,,,,4,,273,F,2116.0,Autocuration,CHEMBL617975,BAO_0000221,3133
,,H,,,104714,9986.0,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),1,,,,,4,,273,F,,Autocuration,CHEMBL617976,BAO_0000019,3134
,,H,,,104714,9986.0,Oryctolagus cuniculus,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),1,,,,,4,,273,F,,Autocuration,CHEMBL617977,BAO_0000019,3135
,,H,,,104714,9986.0,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),1,,,,,4,,273,F,,Autocuration,CHEMBL617978,BAO_0000019,3136
,,H,,,104714,9986.0,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),1,,,,,4,,273,F,,Autocuration,CHEMBL617979,BAO_0000019,3137
,,H,449.0,,104714,9986.0,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,1,,CHO,,,4,,13047,B,,Autocuration,CHEMBL617980,BAO_0000219,3138
,,D,,,104698,10116.0,Rattus norvegicus,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,1,,,,,7,,1650,B,,Autocuration,CHEMBL617981,BAO_0000019,3139
,,H,,,12020,,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),1,,,,,8,,16288,B,,Autocuration,CHEMBL617982,BAO_0000019,3140
,,H,,,12020,,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),1,,,,,8,,16288,B,,Autocuration,CHEMBL617983,BAO_0000357,3141
,,D,,,104698,10116.0,Rattus norvegicus,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,1,,,,,7,,10254,B,,Autocuration,CHEMBL617984,BAO_0000019,3142
,,H,,,104698,,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",1,,,,,6,,14532,B,,Autocuration,CHEMBL617985,BAO_0000019,3143
,,H,,,104698,,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",1,Heart,,,In vivo,6,,13392,F,948.0,Autocuration,CHEMBL617986,BAO_0000218,3144
,,H,,,104698,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",1,Heart,,,,6,,13392,F,948.0,Autocuration,CHEMBL617987,BAO_0000019,3145
,,H,,,104698,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",1,Heart,,,,6,,13392,F,948.0,Autocuration,CHEMBL617988,BAO_0000019,3146
,,H,,,104698,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",1,Heart,,,,6,,13392,F,948.0,Autocuration,CHEMBL617792,BAO_0000019,3147
,,H,,,104698,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",1,Heart,,,,6,,13392,F,948.0,Autocuration,CHEMBL617793,BAO_0000019,3148
,,H,,,104698,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",1,,,,,6,,13392,F,,Autocuration,CHEMBL617794,BAO_0000019,3149
,,H,,,104698,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",1,,,,,6,,13392,F,,Autocuration,CHEMBL617795,BAO_0000019,3150
,,H,,,104698,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",1,,,,,6,,13392,F,,Autocuration,CHEMBL617796,BAO_0000019,3151
,,H,,,104698,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",1,,,,,6,,13392,F,,Autocuration,CHEMBL617797,BAO_0000019,3152
,,D,,,104698,10116.0,Rattus norvegicus,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),1,,,,In vivo,7,,1089,F,,Autocuration,CHEMBL617798,BAO_0000218,3153
,,H,,,104698,,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),1,,,,In vivo,6,,1089,F,,Autocuration,CHEMBL617799,BAO_0000218,3154
,,D,,,104698,10116.0,Rattus norvegicus,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,1,,,,In vivo,7,,11454,F,,Autocuration,CHEMBL617800,BAO_0000218,3155
,,D,,,104698,10116.0,Rattus norvegicus,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,1,,,,,7,,11454,F,,Autocuration,CHEMBL617801,BAO_0000019,3156
,,D,,,104698,10116.0,Rattus norvegicus,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,1,,,,In vivo,7,,12205,F,,Autocuration,CHEMBL617802,BAO_0000218,3157
,,D,,,104698,10116.0,Rattus norvegicus,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),1,,,,,7,,1089,F,,Autocuration,CHEMBL617803,BAO_0000019,3158
,,H,,,104698,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,1,,,,,6,,5094,B,,Autocuration,CHEMBL617804,BAO_0000019,3159
,,D,,,104698,10116.0,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,1,,,,,7,,2622,B,,Autocuration,CHEMBL617805,BAO_0000019,3160
,,H,,,104698,,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,1,,,,,6,,245,B,,Autocuration,CHEMBL617806,BAO_0000223,3161
,,H,,,104698,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,1,,,,,6,,14788,B,,Autocuration,CHEMBL617807,BAO_0000019,3162
,,H,,,104698,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,1,,,,,6,,14788,B,,Autocuration,CHEMBL617808,BAO_0000019,3163
,,H,,,104698,,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,1,,,,,6,,3020,B,,Autocuration,CHEMBL617809,BAO_0000249,3164
,,H,,,104698,,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,1,,,,,6,,1742,B,,Autocuration,CHEMBL617810,BAO_0000019,3165
,,H,,,104698,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,1,Brain,,,,6,,17394,B,955.0,Autocuration,CHEMBL617811,BAO_0000249,3166
,,H,,,104698,,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,1,Brain,,,,6,,17394,B,955.0,Autocuration,CHEMBL617812,BAO_0000221,3167
,,H,,,104698,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,1,,,,,6,,17394,B,,Autocuration,CHEMBL617813,BAO_0000249,3168
,,H,,,104698,,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,1,,,,,6,,14286,B,,Autocuration,CHEMBL617814,BAO_0000249,3169
,,H,,,104698,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,1,,,,,6,,14178,B,,Autocuration,CHEMBL617698,BAO_0000019,3170
,,D,,,104698,10116.0,Rattus norvegicus,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,1,,,,,7,,14178,B,,Autocuration,CHEMBL617699,BAO_0000019,3171
,,D,,,104698,10116.0,Rattus norvegicus,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,1,,,,,7,,14178,B,,Autocuration,CHEMBL617700,BAO_0000019,3172
,,D,,,104698,10116.0,Rattus norvegicus,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,1,,,,,7,,14178,B,,Autocuration,CHEMBL617701,BAO_0000223,3173
,,H,,,104698,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,1,,,,,6,,15034,B,,Autocuration,CHEMBL617702,BAO_0000019,3174
,Membranes,H,,,104698,,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",1,,,,,6,,1089,B,,Autocuration,CHEMBL617703,BAO_0000249,3175
,,D,,,104698,10116.0,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,1,,,,,7,,1089,B,,Autocuration,CHEMBL617704,BAO_0000019,3176
,,H,,,104698,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,1,,,,,6,,16532,B,,Autocuration,CHEMBL617705,BAO_0000223,3177
,,D,,,104698,10116.0,Rattus norvegicus,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,1,,,,,7,,12801,B,,Autocuration,CHEMBL617706,BAO_0000223,3178
,,H,433.0,,104698,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),1,,NG108-15,,,6,,15194,B,,Autocuration,CHEMBL617707,BAO_0000219,3179
,,H,433.0,,104698,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,1,,NG108-15,,,6,,15194,B,,Autocuration,CHEMBL617708,BAO_0000219,3180
,,H,,,104698,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,1,,,,,6,,15194,B,,Autocuration,CHEMBL617709,BAO_0000019,3181
,,H,,,104698,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,1,,,,,6,,15194,B,,Autocuration,CHEMBL617710,BAO_0000019,3182
,,H,,,104698,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,1,,,,,6,,15194,B,,Autocuration,CHEMBL882925,BAO_0000019,3183
,,H,,,104698,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,1,,,,,6,,15194,B,,Autocuration,CHEMBL617711,BAO_0000019,3184
,,H,,,104698,,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,1,,,,,6,,10610,F,,Autocuration,CHEMBL617712,BAO_0000019,3185
,,D,,,104698,10116.0,Rattus norvegicus,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,1,,,,,7,,10355,F,,Autocuration,CHEMBL617713,BAO_0000019,3186
,,H,,,104698,,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",1,,,,,6,,691,F,,Autocuration,CHEMBL617714,BAO_0000019,3187
,,H,,,104698,,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,1,,,,,6,,10611,F,,Autocuration,CHEMBL617715,BAO_0000218,3188
,,H,,,104698,,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,1,,,,In vivo,6,,12801,F,,Autocuration,CHEMBL617716,BAO_0000218,3189
,,H,,,104698,,,Inhibition of 5-HT evoked reflex bradycardia in rat.,1,,,,,6,,10609,F,,Autocuration,CHEMBL617717,BAO_0000218,3190
,,H,,,104698,,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617718,BAO_0000218,3191
,,H,,,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617719,BAO_0000218,3192
,,H,,,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617720,BAO_0000218,3193
,,D,,,104698,10116.0,Rattus norvegicus,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,1,,,,In vivo,7,,11454,F,,Autocuration,CHEMBL617721,BAO_0000218,3194
,,H,,,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617722,BAO_0000218,3195
,,H,,,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617723,BAO_0000218,3196
,,H,,,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617724,BAO_0000218,3197
,,H,,,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617725,BAO_0000218,3198
,,H,,,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617726,BAO_0000218,3199
,,H,,,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617727,BAO_0000218,3200
,,H,,,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617728,BAO_0000218,3201
,,H,,,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617729,BAO_0000218,3202
,,H,,,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617730,BAO_0000218,3203
,,H,,,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617731,BAO_0000218,3204
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617732,BAO_0000218,3205
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617733,BAO_0000218,3206
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617734,BAO_0000218,3207
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL872874,BAO_0000218,3208
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617735,BAO_0000218,3209
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617736,BAO_0000218,3210
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617737,BAO_0000218,3211
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617738,BAO_0000218,3212
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617739,BAO_0000218,3213
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617740,BAO_0000218,3214
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617741,BAO_0000218,3215
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617742,BAO_0000218,3216
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617743,BAO_0000218,3217
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617744,BAO_0000218,3218
,,H,,,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,1,,,,In vivo,6,,11454,F,,Autocuration,CHEMBL617745,BAO_0000218,3219
,,H,,,104698,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",1,,,,,6,,670,F,,Autocuration,CHEMBL617746,BAO_0000218,3220
,,H,,,104698,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",1,,,,,6,,670,F,,Autocuration,CHEMBL617747,BAO_0000218,3221
,,H,,,104698,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,1,,,,In vivo,6,,10321,F,,Autocuration,CHEMBL617748,BAO_0000218,3222
,,H,,,104698,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,1,,,,In vivo,6,,10321,F,,Autocuration,CHEMBL618909,BAO_0000218,3223
,,H,,,104698,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,1,,,,In vivo,6,,10321,F,,Autocuration,CHEMBL618910,BAO_0000218,3224
,,H,,,104698,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,1,,,,In vivo,6,,10321,F,,Autocuration,CHEMBL618911,BAO_0000218,3225
,,H,,,104698,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,1,,,,In vivo,6,,10321,F,,Autocuration,CHEMBL618912,BAO_0000218,3226
,,H,,,104698,,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),1,,,,In vivo,6,,10322,F,,Autocuration,CHEMBL618913,BAO_0000218,3227
,,H,,,104698,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,1,,,,,6,,15412,F,,Autocuration,CHEMBL618914,BAO_0000019,3228
,,H,,,104698,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,1,,,,,6,,15412,F,,Autocuration,CHEMBL618915,BAO_0000019,3229
,,D,,,104698,10116.0,Rattus norvegicus,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,1,,,,,7,,15412,B,,Autocuration,CHEMBL618916,BAO_0000223,3230
,,H,,,104698,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,1,,,,,6,,15412,F,,Autocuration,CHEMBL618917,BAO_0000019,3231
,,D,,,104698,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,1,Hippocampus,,,,7,,15412,B,10000000.0,Intermediate,CHEMBL618918,BAO_0000221,3232
,,D,,,104698,10116.0,Rattus norvegicus,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,1,,,,,7,,15412,B,,Autocuration,CHEMBL618919,BAO_0000019,3233
,,D,,,104698,10116.0,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,1,,,,,7,,17394,B,,Autocuration,CHEMBL618920,BAO_0000019,3234
,,H,,,104698,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,1,,,,,6,,12457,B,,Autocuration,CHEMBL618921,BAO_0000223,3235
,,H,,,104698,,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,1,,,,,6,,12457,B,,Autocuration,CHEMBL618922,BAO_0000019,3236
,,H,,,104698,,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,1,,,,,6,,12205,B,,Autocuration,CHEMBL618923,BAO_0000019,3237
,,H,,,104698,,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,1,,,,,6,,14532,B,,Autocuration,CHEMBL618924,BAO_0000019,3238
,,H,,,104698,,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,1,,,,,6,,1122,B,,Autocuration,CHEMBL618925,BAO_0000019,3239
,,H,,,104698,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,1,,,,,6,,5094,B,,Autocuration,CHEMBL618926,BAO_0000019,3240
,,D,,,20033,10141.0,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,1,Ileum,,,,9,,809,F,2116.0,Intermediate,CHEMBL618927,BAO_0000221,3241
,,D,,,20033,10141.0,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,1,Ileum,,,,9,,809,F,2116.0,Intermediate,CHEMBL618928,BAO_0000221,3242
,,D,,,20033,10141.0,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",1,Ileum,,,,9,,14290,F,2116.0,Intermediate,CHEMBL618929,BAO_0000221,3243
,,D,,,20033,10141.0,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",1,Ileum,,,,9,,14290,F,2116.0,Intermediate,CHEMBL618930,BAO_0000221,3244
,,D,,,20033,10141.0,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",1,Ileum,,,,9,,14290,F,2116.0,Intermediate,CHEMBL618931,BAO_0000221,3245
,,D,,,20033,10141.0,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",1,Ileum,,,,9,,14290,F,2116.0,Intermediate,CHEMBL619594,BAO_0000221,3246
,,D,,,20033,10141.0,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",1,Ileum,,,,9,,14290,F,2116.0,Intermediate,CHEMBL619595,BAO_0000221,3247
,,D,,,20033,10141.0,Cavia porcellus,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,1,Ileum,,,,9,,13961,F,2116.0,Intermediate,CHEMBL619596,BAO_0000221,3248
,,D,,,20033,10141.0,Cavia porcellus,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,1,Ileum,,,,9,,13961,F,2116.0,Intermediate,CHEMBL619755,BAO_0000221,3249
,,D,,,20033,10141.0,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,1,Ileum,,,,9,,809,F,2116.0,Intermediate,CHEMBL619756,BAO_0000221,3250
,,D,,,20033,10141.0,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,1,Ileum,,,,9,,809,F,2116.0,Intermediate,CHEMBL619757,BAO_0000221,3251
,,D,,,20033,10141.0,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,1,Ileum,,,,9,,809,F,2116.0,Intermediate,CHEMBL619758,BAO_0000221,3252
,,D,,,20033,10141.0,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",1,Ileum,,,,9,,14290,F,2116.0,Intermediate,CHEMBL619759,BAO_0000221,3253
,,D,,,20033,10141.0,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",1,Ileum,,,,9,,14290,F,2116.0,Intermediate,CHEMBL619760,BAO_0000221,3254
,,D,,,20033,10141.0,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",1,Ileum,,,,9,,14290,F,2116.0,Intermediate,CHEMBL619761,BAO_0000221,3255
,,D,,,20033,10141.0,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,1,Ileum,,,,9,,14290,F,2116.0,Intermediate,CHEMBL619762,BAO_0000221,3256
,,D,,,20033,10141.0,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",1,Ileum,,,,9,,14290,F,2116.0,Intermediate,CHEMBL619763,BAO_0000221,3257
,,D,,,20033,10141.0,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",1,Ileum,,,,9,,14290,F,2116.0,Intermediate,CHEMBL617868,BAO_0000221,3258
,,D,,,20033,10141.0,Cavia porcellus,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,1,,,,,9,,15034,B,,Intermediate,CHEMBL617869,BAO_0000357,3259
,,D,,,20033,10141.0,Cavia porcellus,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,1,Striatum,,,,9,,5094,B,2435.0,Intermediate,CHEMBL882926,BAO_0000249,3260
,,D,,,20033,10141.0,Cavia porcellus,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,1,Striatum,,,,9,,5094,B,2435.0,Intermediate,CHEMBL617870,BAO_0000249,3261
,,D,,,20033,10141.0,Cavia porcellus,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,1,Striatum,,,,9,,5399,B,2435.0,Intermediate,CHEMBL617871,BAO_0000357,3262
,,D,,,20033,10141.0,Cavia porcellus,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,1,Striatum,,,,9,,17394,B,2435.0,Intermediate,CHEMBL617872,BAO_0000357,3263
,,D,,,20033,10141.0,Cavia porcellus,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,1,Striatum,,,,9,,17394,B,2435.0,Intermediate,CHEMBL617873,BAO_0000357,3264
,,D,,,20033,10141.0,Cavia porcellus,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,1,Striatum,,,,9,,17394,B,2435.0,Intermediate,CHEMBL617874,BAO_0000357,3265
,,D,,,20033,10141.0,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,1,Ileum,,,,9,,13961,F,2116.0,Intermediate,CHEMBL619067,BAO_0000221,3266
,,D,,,20033,10141.0,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,1,Ileum,,,,9,,13961,F,2116.0,Intermediate,CHEMBL619068,BAO_0000221,3267
,,D,,,20033,10141.0,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,1,Ileum,,,,9,,13961,F,2116.0,Intermediate,CHEMBL619069,BAO_0000221,3268
,,D,,,20033,10141.0,Cavia porcellus,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,1,,,,,9,,16946,B,,Intermediate,CHEMBL619070,BAO_0000357,3269
,,D,,,20033,10141.0,Cavia porcellus,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,1,,,,,9,,16946,B,,Intermediate,CHEMBL619071,BAO_0000357,3270
,,D,,,20033,10141.0,Cavia porcellus,Agonistic activity against 5-hydroxytryptamine 4 receptor,1,,,,,9,,15034,F,,Intermediate,CHEMBL619072,BAO_0000019,3271
,,D,,,20033,10141.0,Cavia porcellus,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,1,,,,,9,,15034,F,,Intermediate,CHEMBL619073,BAO_0000019,3272
,,D,,,20033,10141.0,Cavia porcellus,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,1,,,,,9,,12918,F,,Intermediate,CHEMBL619074,BAO_0000019,3273
,,D,,,20033,10141.0,Cavia porcellus,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,1,,,,,9,,16946,B,,Intermediate,CHEMBL619075,BAO_0000357,3274
,,D,,,20033,10141.0,Cavia porcellus,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,1,Striatum,,,,9,,17394,B,2435.0,Intermediate,CHEMBL619076,BAO_0000357,3275
,,D,,,20033,10141.0,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,1,Striatum,,,,9,,15034,B,2435.0,Intermediate,CHEMBL619077,BAO_0000357,3276
,,D,,,20033,10141.0,Cavia porcellus,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,1,Striatum,,,,9,,5094,B,2435.0,Intermediate,CHEMBL619078,BAO_0000249,3277
,,D,,,20033,10141.0,Cavia porcellus,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,1,Striatum,,,,9,,5094,B,2435.0,Intermediate,CHEMBL619079,BAO_0000249,3278
,,D,,,20033,10141.0,Cavia porcellus,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,1,Ileum,,,,9,,17358,B,2116.0,Intermediate,CHEMBL619080,BAO_0000221,3279
,,D,,,20033,10141.0,Cavia porcellus,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,1,,,,,9,,12953,B,,Expert,CHEMBL619081,BAO_0000357,3280
,,D,,,20033,10141.0,Cavia porcellus,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,1,,,,,9,,12953,B,,Intermediate,CHEMBL619082,BAO_0000357,3281
,,D,,,20033,10141.0,Cavia porcellus,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,1,,,,,9,,12953,B,,Intermediate,CHEMBL619083,BAO_0000357,3282
,,D,,,20033,10141.0,Cavia porcellus,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,1,,,,,9,,12953,B,,Intermediate,CHEMBL619084,BAO_0000357,3283
,,D,,,20033,10141.0,Cavia porcellus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,1,Ileum,,,,9,,273,F,2116.0,Intermediate,CHEMBL859397,BAO_0000221,3284
,,D,,,20033,10141.0,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,1,Ileum,,,,9,,12918,F,2116.0,Intermediate,CHEMBL619085,BAO_0000221,3285
,,D,,,20033,10141.0,Cavia porcellus,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,1,Ileum,,,,9,,12919,F,2116.0,Intermediate,CHEMBL619086,BAO_0000221,3286
,,D,,,20033,10141.0,Cavia porcellus,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,1,Ileum,,,,9,,273,F,2116.0,Intermediate,CHEMBL619087,BAO_0000221,3287
,,D,,,20033,10141.0,Cavia porcellus,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,1,Ileum,,,,9,,273,F,2116.0,Intermediate,CHEMBL619088,BAO_0000221,3288
,,D,,,20033,10141.0,Cavia porcellus,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,1,,,,,9,,13181,B,,Intermediate,CHEMBL619089,BAO_0000357,3289
,,H,,,168,10141.0,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,1,,,,,8,,13181,B,,Autocuration,CHEMBL619090,BAO_0000357,3290
,,D,,,20033,10141.0,Cavia porcellus,Antagonistic activity against 5-hydroxytryptamine 4 receptor,1,,,,,9,,15034,F,,Intermediate,CHEMBL619091,BAO_0000019,3291
,,D,,,20033,10141.0,Cavia porcellus,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,1,,,,,9,,5033,B,,Intermediate,CHEMBL619092,BAO_0000357,3292
,,D,,,20033,10141.0,Cavia porcellus,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,1,,,,,9,,1980,B,,Intermediate,CHEMBL619093,BAO_0000019,3293
,,H,722.0,,168,10141.0,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,1,,HEK293,,,8,,13181,B,,Autocuration,CHEMBL619094,BAO_0000219,3294
,,D,,,20033,10141.0,Cavia porcellus,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,1,,,,,9,,14287,B,,Intermediate,CHEMBL619095,BAO_0000019,3295
,,D,,,20033,10141.0,Cavia porcellus,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,1,,,,,9,,1317,B,,Intermediate,CHEMBL857988,BAO_0000357,3296
,,D,,,20033,10141.0,Cavia porcellus,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,1,,,,,9,,15316,B,,Intermediate,CHEMBL619096,BAO_0000357,3297
,,D,,,20033,10141.0,Cavia porcellus,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,1,Striatum,,,,9,,16429,B,2435.0,Intermediate,CHEMBL619097,BAO_0000357,3298
,,D,,,20033,10141.0,Cavia porcellus,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,1,Hippocampus,,,,9,,14818,B,10000000.0,Intermediate,CHEMBL619098,BAO_0000221,3299
,,D,,,20033,10141.0,Cavia porcellus,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,1,,,,,9,,15194,B,,Intermediate,CHEMBL619751,BAO_0000357,3300
,,D,,,20033,10141.0,Cavia porcellus,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,1,,,,,9,,15194,B,,Intermediate,CHEMBL619752,BAO_0000357,3301
,,D,,,20033,10141.0,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,1,Ileum,,,,9,,13961,F,2116.0,Intermediate,CHEMBL875096,BAO_0000221,3302
,,H,,,108,,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,1,,,,,8,,5486,B,,Autocuration,CHEMBL619004,BAO_0000357,3303
,,H,,,168,,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,1,,,,,8,,16209,B,,Autocuration,CHEMBL619005,BAO_0000357,3304
,,H,,,168,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,1,,,,,8,,17085,B,,Autocuration,CHEMBL619006,BAO_0000019,3305
,,H,308.0,,168,,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,1,,HeLa,,,8,,4199,B,,Autocuration,CHEMBL619007,BAO_0000219,3306
,,H,,,168,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,1,,,,,8,,15146,B,,Autocuration,CHEMBL619008,BAO_0000357,3307
,,H,,,168,,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,1,,,,,8,,5213,B,,Autocuration,CHEMBL619009,BAO_0000357,3308
,,H,308.0,,168,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",1,,HeLa,,,8,,4829,B,,Autocuration,CHEMBL619010,BAO_0000219,3309
,,H,,,10622,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,1,,,,,8,,17358,B,,Autocuration,CHEMBL619011,BAO_0000357,3310
,,H,,,10622,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,1,,,,,8,,17358,B,,Autocuration,CHEMBL619012,BAO_0000357,3311
,,H,,,10622,,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,1,,,,,8,,16946,B,,Autocuration,CHEMBL619013,BAO_0000219,3312
,,H,,,10622,,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,1,,,,,8,,17358,B,,Autocuration,CHEMBL619014,BAO_0000357,3313
,,H,,,11249,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,1,Cardiac atrium,,,,8,,268,F,2081.0,Autocuration,CHEMBL857503,BAO_0000019,3314
,,H,,,11249,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,1,Cardiac atrium,,,,8,,268,F,2081.0,Autocuration,CHEMBL619015,BAO_0000019,3315
,,H,,,11249,,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,1,,,,,8,,15086,B,,Autocuration,CHEMBL619016,BAO_0000357,3316
,,H,,,11249,,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,1,Hippocampus,,,,8,,14875,B,10000000.0,Autocuration,CHEMBL619017,BAO_0000221,3317
,,H,,,168,9823.0,Sus scrofa,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,1,Hippocampus,,,,8,,13267,B,10000000.0,Autocuration,CHEMBL619018,BAO_0000221,3318
,,H,,,168,9986.0,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,1,,,,,8,,13047,B,,Autocuration,CHEMBL619019,BAO_0000019,3319
,,D,,,10623,10116.0,Rattus norvegicus,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,1,,,,,9,,1650,B,,Expert,CHEMBL619020,BAO_0000357,3320
,,H,,,10623,,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,1,,,,,8,,567,F,,Autocuration,CHEMBL619021,BAO_0000019,3321
,,H,,,10623,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,1,,,,,8,,17358,B,,Autocuration,CHEMBL619022,BAO_0000357,3322
,,H,,,10623,,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,1,,,,,8,,188,B,,Autocuration,CHEMBL619023,BAO_0000357,3323
,,H,,,10623,,,lntrinsic activity relative to 5-HT receptor,1,,,,,8,,670,F,,Autocuration,CHEMBL619024,BAO_0000019,3324
,,H,,,10623,,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,1,,,,,8,,204,F,,Autocuration,CHEMBL619025,BAO_0000019,3325
,,H,,,10623,,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,1,,,,,8,,1946,F,,Expert,CHEMBL619026,BAO_0000019,3326
,,H,,,10623,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,1,,,,,8,,6398,F,,Autocuration,CHEMBL619027,BAO_0000019,3327
,,H,,,10623,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,1,,,,,8,,6398,F,,Autocuration,CHEMBL619028,BAO_0000019,3328
,,H,,,10623,,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,1,,,,,8,,17358,F,,Autocuration,CHEMBL619029,BAO_0000019,3329
,,H,,,10623,,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,1,,,,,8,,6398,F,,Autocuration,CHEMBL619030,BAO_0000019,3330
,,H,,,10623,,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,1,,,,,8,,11752,B,,Expert,CHEMBL619031,BAO_0000357,3331
,,H,,,10623,,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,1,,,,,8,,809,F,,Autocuration,CHEMBL619032,BAO_0000019,3332
,,D,,,10623,10116.0,Rattus norvegicus,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,1,,,,,9,,14178,B,,Expert,CHEMBL619033,BAO_0000357,3333
,,H,,,10623,,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,1,,,,,8,,567,B,,Autocuration,CHEMBL619034,BAO_0000357,3334
,,H,,,10623,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,1,,,,,8,,1946,B,,Autocuration,CHEMBL619035,BAO_0000357,3335
,,H,,,10623,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,1,,,,,8,,1946,B,,Autocuration,CHEMBL619036,BAO_0000357,3336
,,D,,,10623,10116.0,Rattus norvegicus,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,1,,,,,9,,13961,B,,Expert,CHEMBL619037,BAO_0000019,3337
,,H,,,10623,,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,1,Striatum,,,,8,,6238,B,2435.0,Autocuration,CHEMBL619038,BAO_0000249,3338
,,H,,,10623,,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,1,,,,,8,,14290,B,,Autocuration,CHEMBL619039,BAO_0000249,3339
,,H,,,10623,,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,1,,,,,8,,14290,B,,Expert,CHEMBL619040,BAO_0000249,3340
,,D,,,10623,10116.0,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,1,Striatum,,,,9,,809,B,2435.0,Expert,CHEMBL619041,BAO_0000019,3341
,,H,,,10623,,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,1,Striatum,,,,8,,1578,B,2435.0,Autocuration,CHEMBL619042,BAO_0000019,3342
,,H,,,10623,,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,1,Striatum,,,,8,,16709,B,2435.0,Expert,CHEMBL619043,BAO_0000249,3343
,,H,,,10623,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,1,Striatum,,,,8,,1946,B,2435.0,Expert,CHEMBL619044,BAO_0000019,3344
,,H,,,10623,,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,1,Striatum,,,,8,,15253,B,2435.0,Expert,CHEMBL619045,BAO_0000249,3345
,,H,,,10623,,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,1,Striatum,,,,8,,4535,B,2435.0,Expert,CHEMBL619046,BAO_0000249,3346
,,H,,,10623,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,1,,,,,8,,13961,B,,Expert,CHEMBL619047,BAO_0000249,3347
,,H,,,10623,,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,1,Brain,,,,8,,17358,F,955.0,Autocuration,CHEMBL619048,BAO_0000221,3348
,,H,,,10623,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,1,,,,,8,,15847,F,,Autocuration,CHEMBL859398,BAO_0000019,3349
,,H,,,10623,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,1,,,,,8,,15847,F,,Autocuration,CHEMBL619049,BAO_0000019,3350
,,H,,,10623,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,1,,,,,8,,670,F,,Autocuration,CHEMBL857886,BAO_0000019,3351
,,H,,,10623,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,1,,,,,8,,670,F,,Autocuration,CHEMBL619050,BAO_0000019,3352
,,H,,,10623,,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,1,,,,,8,,1317,F,,Autocuration,CHEMBL620591,BAO_0000019,3353
,,D,,,10623,10116.0,Rattus norvegicus,Binding affinity against rat 5-hydroxytryptamine 4 receptor,1,,,,,9,,12936,B,,Expert,CHEMBL620592,BAO_0000357,3354
,,H,,,10623,,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,1,Striatum,,,,8,,4535,B,2435.0,Expert,CHEMBL620593,BAO_0000249,3355
,,D,,,10623,10116.0,Rattus norvegicus,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,1,,,,,9,,14424,F,,Expert,CHEMBL620594,BAO_0000019,3356
,,H,,,10623,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,1,,,,,8,,14424,F,,Expert,CHEMBL875079,BAO_0000019,3357
,,H,,,10623,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,1,,,,,8,,14424,F,,Expert,CHEMBL620595,BAO_0000019,3358
,,D,,,10623,10116.0,Rattus norvegicus,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,1,,,,,9,,14424,F,,Expert,CHEMBL620596,BAO_0000019,3359
,,H,,,10623,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,1,,,,,8,,14424,F,,Autocuration,CHEMBL620597,BAO_0000019,3360
,,H,,,10623,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,1,,,,,8,,14424,F,,Expert,CHEMBL620598,BAO_0000019,3361
,,H,,,10623,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),1,,,,,8,,14424,F,,Expert,CHEMBL620599,BAO_0000218,3362
,,H,,,10623,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,1,,,,,8,,14424,F,,Autocuration,CHEMBL620600,BAO_0000019,3363
,,H,,,168,10116.0,Rattus norvegicus,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,1,,,,,8,,1980,F,,Autocuration,CHEMBL620601,BAO_0000019,3364
,,H,,,168,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,1,,,,,8,,4639,F,,Autocuration,CHEMBL620602,BAO_0000019,3365
,,H,,,168,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,1,,,,,8,,17358,B,,Autocuration,CHEMBL620603,BAO_0000357,3366
,,H,,,168,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,1,,,,,8,,17358,B,,Autocuration,CHEMBL620604,BAO_0000357,3367
,,H,,,168,,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,1,,,,,8,,17358,B,,Autocuration,CHEMBL620605,BAO_0000357,3368
,,H,,,168,,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,1,,,,,8,,1558,B,,Autocuration,CHEMBL620606,BAO_0000357,3369
,,H,,,168,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,1,,,,,8,,17358,F,,Autocuration,CHEMBL620607,BAO_0000019,3370
,,H,,,168,,,In vitro binding affinity towards 5-HT4 receptor was determined,1,,,,,8,,16117,B,,Autocuration,CHEMBL620608,BAO_0000357,3371
,,H,,,168,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,1,,,,,8,,17358,F,,Autocuration,CHEMBL620609,BAO_0000019,3372
,,H,,,168,,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,1,,,,,8,,17358,F,,Autocuration,CHEMBL620610,BAO_0000019,3373
,,H,,,168,,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,1,,,,,8,,17358,B,,Autocuration,CHEMBL620611,BAO_0000357,3374
,,H,,,168,,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,1,,,,,8,,17358,B,,Autocuration,CHEMBL620612,BAO_0000357,3375
,,H,,,168,,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,1,,,,,8,,17358,B,,Autocuration,CHEMBL620613,BAO_0000357,3376
,,H,,,168,,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,1,,,,,8,,17358,B,,Autocuration,CHEMBL620614,BAO_0000357,3377
,,H,,,168,,,Binding affinity against 5-Hydroxytryptamine 4 receptor,1,,,,,8,,1274,B,,Expert,CHEMBL620615,BAO_0000357,3378
,Brain membranes,H,,,104698,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,1,,,,,6,,10728,B,,Autocuration,CHEMBL857075,BAO_0000249,3379
,Brain membranes,H,,,104698,,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,1,,,,,6,,11695,B,,Autocuration,CHEMBL620616,BAO_0000249,3380
,Brain membranes,H,,,104698,,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,1,,,,,6,,11695,B,,Autocuration,CHEMBL619411,BAO_0000249,3381
,,H,,,104698,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,1,,,,,6,,12490,B,,Autocuration,CHEMBL619412,BAO_0000019,3382
,,D,,,104698,10116.0,Rattus norvegicus,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,1,,,,,7,,11828,B,,Autocuration,CHEMBL619413,BAO_0000019,3383
,,H,,,104698,,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,1,Hippocampus,,,,6,,12253,B,10000000.0,Autocuration,CHEMBL619414,BAO_0000221,3384
,,H,,,104698,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,1,,,,,6,,10561,B,,Autocuration,CHEMBL619415,BAO_0000019,3385
,,H,,,104698,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,1,,,,,6,,10561,B,,Autocuration,CHEMBL619416,BAO_0000019,3386
,,H,,,104698,,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,1,,,,,6,,14432,F,,Autocuration,CHEMBL619417,BAO_0000019,3387
,,D,,,104698,10116.0,Rattus norvegicus,Binding affinity against rat 5-hydroxytryptamine 3 receptor,1,,,,,7,,12936,B,,Autocuration,CHEMBL619418,BAO_0000223,3388
,,D,,,104698,10116.0,Rattus norvegicus,Binding affinity against 5-Hydroxytryptamine 3 receptor,1,,,,,7,,1274,B,,Autocuration,CHEMBL619419,BAO_0000223,3389
,,H,,,104698,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,1,,,,,6,,1980,B,,Autocuration,CHEMBL619420,BAO_0000019,3390
,,H,,,104698,,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,1,,,,,6,,670,B,,Autocuration,CHEMBL619421,BAO_0000249,3391
,,D,,,104698,10116.0,Rattus norvegicus,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,1,,,,,7,,968,B,,Autocuration,CHEMBL619422,BAO_0000019,3392
,,H,,,104698,,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,1,,,,,6,,14287,B,,Autocuration,CHEMBL619423,BAO_0000019,3393
,,H,,,104698,,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,1,,,,,6,,567,B,,Autocuration,CHEMBL875080,BAO_0000019,3394
,,H,,,104698,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,1,,,,,6,,13267,B,,Autocuration,CHEMBL619424,BAO_0000019,3395
,,H,,,104698,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,1,,,,,6,,14826,B,,Autocuration,CHEMBL619425,BAO_0000249,3396
,,H,,,104698,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,1,,,,,6,,15194,B,,Autocuration,CHEMBL619426,BAO_0000223,3397
,,H,,,104698,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,1,,,,,6,,15194,B,,Autocuration,CHEMBL619427,BAO_0000223,3398
,,D,,,104698,10116.0,Rattus norvegicus,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,1,,,,,7,,10394,B,,Autocuration,CHEMBL619645,BAO_0000223,3399
,,D,,,10576,,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",1,,,,,9,,13657,B,,Expert,CHEMBL619646,BAO_0000249,3400
,,H,,,12020,,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,1,Brain,,,,8,,1879,F,955.0,Autocuration,CHEMBL619647,BAO_0000221,3401
,,H,,,12020,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,1,,,,,8,,1879,F,,Autocuration,CHEMBL619648,BAO_0000019,3402
,,H,,,12020,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,1,,,,,8,,1879,F,,Autocuration,CHEMBL619165,BAO_0000019,3403
,,H,,,12020,,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,1,,,,In vivo,8,,204,F,,Autocuration,CHEMBL620719,BAO_0000218,3404
,,H,,,12020,,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,1,,,,,8,,1879,B,,Autocuration,CHEMBL872924,BAO_0000019,3405
,,H,,,12020,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,1,,,,,8,,1879,B,,Autocuration,CHEMBL620720,BAO_0000357,3406
,,H,,,12020,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,1,,,,,8,,1879,B,,Autocuration,CHEMBL620721,BAO_0000019,3407
,,H,,,12020,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,1,,,,,8,,1879,B,,Autocuration,CHEMBL620722,BAO_0000019,3408
,,H,,,104698,,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",1,,,,,6,,10641,B,,Autocuration,CHEMBL620723,BAO_0000019,3409
,,H,,,12020,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,1,,,,,8,,773,B,,Autocuration,CHEMBL620724,BAO_0000019,3410
,,H,,,104698,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,1,,,,,6,,11952,B,,Autocuration,CHEMBL620725,BAO_0000249,3411
,,D,,,12020,10116.0,Rattus norvegicus,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,1,,,,,9,,14145,F,,Autocuration,CHEMBL620726,BAO_0000019,3412
,,H,,,144,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,1,,,,,8,,17066,B,,Expert,CHEMBL620727,BAO_0000357,3413
,,H,,,104714,,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,1,,,,,4,,6398,B,,Autocuration,CHEMBL620728,BAO_0000223,3414
,,U,,,22226,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,1,,,,,0,,10321,B,,Autocuration,CHEMBL620729,BAO_0000019,3415
,,H,,,104714,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,1,,,,,4,,511,F,,Autocuration,CHEMBL858288,BAO_0000019,3416
,,H,,,104714,,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,1,,,,,4,,4639,B,,Autocuration,CHEMBL620730,BAO_0000223,3417
,,H,,,104714,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,1,,,,,4,,4639,B,,Autocuration,CHEMBL620731,BAO_0000223,3418
,,H,,,104714,10141.0,Cavia porcellus,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,1,,,,,4,,4639,F,,Autocuration,CHEMBL620732,BAO_0000019,3419
,,H,,,104714,10141.0,Cavia porcellus,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,1,,,,,4,,4639,F,,Autocuration,CHEMBL618042,BAO_0000019,3420
,,H,,,104714,10141.0,Cavia porcellus,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,1,,,,,4,,4639,F,,Autocuration,CHEMBL618043,BAO_0000019,3421
,,H,,,104714,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,1,,,,,4,,1558,B,,Autocuration,CHEMBL618044,BAO_0000223,3422
,,H,,,104714,,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,1,,,,,4,,268,F,,Autocuration,CHEMBL618045,BAO_0000019,3423
,,H,,,104714,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,1,,,,,4,,2474,B,,Autocuration,CHEMBL618046,BAO_0000223,3424
,,H,,,104714,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,1,,,,,4,,5067,F,,Autocuration,CHEMBL618047,BAO_0000019,3425
,,H,,,104714,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,1,,,,,4,,5067,F,,Autocuration,CHEMBL875084,BAO_0000019,3426
,,H,,,104714,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,1,,,,,4,,5067,F,,Autocuration,CHEMBL618048,BAO_0000019,3427
,,H,,,104714,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,1,,,,,4,,5067,B,,Autocuration,CHEMBL618049,BAO_0000223,3428
,,H,,,104714,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,1,,,,,4,,5067,F,,Autocuration,CHEMBL619764,BAO_0000019,3429
,,H,,,104714,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,1,,,,,4,,5067,F,,Autocuration,CHEMBL619765,BAO_0000019,3430
,,H,,,104714,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,1,,,,,4,,5067,F,,Autocuration,CHEMBL619766,BAO_0000019,3431
,,H,,,104714,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,1,,,,,4,,5067,B,,Autocuration,CHEMBL619767,BAO_0000223,3432
,,H,,,104714,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,1,,,,,4,,5067,B,,Autocuration,CHEMBL619768,BAO_0000223,3433
,,H,,,104714,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,1,,,,,4,,5067,F,,Autocuration,CHEMBL619769,BAO_0000019,3434
,,H,,,104714,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,1,,,,,4,,5067,B,,Autocuration,CHEMBL619770,BAO_0000223,3435
,,H,,,104714,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,1,,,,,4,,5067,B,,Autocuration,CHEMBL619771,BAO_0000223,3436
,,H,,,104714,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,1,,,,,4,,14331,B,,Autocuration,CHEMBL619772,BAO_0000219,3437
,,H,,,104714,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,1,,,,,4,,5067,B,,Autocuration,CHEMBL619773,BAO_0000223,3438
,,H,433.0,,104714,,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,1,,NG108-15,,,4,,6179,B,,Autocuration,CHEMBL619774,BAO_0000219,3439
,,H,,,104714,,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,1,,,,,4,,4265,B,,Autocuration,CHEMBL875083,BAO_0000019,3440
,,H,433.0,,104714,,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,1,,NG108-15,,,4,,4265,B,,Autocuration,CHEMBL620718,BAO_0000219,3441
,,H,,,104714,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,1,,,,,4,,17358,B,,Autocuration,CHEMBL618127,BAO_0000223,3442
,,H,,,104714,,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,1,,,,,4,,17358,B,,Autocuration,CHEMBL618128,BAO_0000223,3443
,,H,,,104714,,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,1,,,,In vitro,4,,13628,B,,Autocuration,CHEMBL618129,BAO_0000219,3444
,,H,,,104714,,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,1,,,,,4,,4612,B,,Autocuration,CHEMBL618130,BAO_0000223,3445
,,H,,,104714,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,1,,,,,4,,17358,F,,Autocuration,CHEMBL618131,BAO_0000019,3446
,,H,,,104714,10141.0,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,1,,,,,4,,4639,F,,Autocuration,CHEMBL618132,BAO_0000019,3447
,,H,,,104714,10141.0,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,1,,,,,4,,4639,F,,Autocuration,CHEMBL618133,BAO_0000019,3448
,,H,,,104714,10141.0,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,1,,,,,4,,4639,F,,Autocuration,CHEMBL618134,BAO_0000019,3449
,,H,,,104714,10141.0,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,1,,,,,4,,4639,F,,Autocuration,CHEMBL618135,BAO_0000019,3450
,,H,,,104714,,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,1,,,,,4,,511,B,,Autocuration,CHEMBL618136,BAO_0000223,3451
,,H,,,104714,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,1,,,,,4,,1479,B,,Autocuration,CHEMBL618137,BAO_0000223,3452
,,H,,,104714,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,1,,,,,4,,1317,B,,Autocuration,CHEMBL618138,BAO_0000223,3453
,,H,,,104714,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,1,,,,,4,,12146,B,,Autocuration,CHEMBL618139,BAO_0000223,3454
,,H,,,104714,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,1,,,,,4,,12146,B,,Autocuration,CHEMBL618140,BAO_0000223,3455
,,H,,,104714,,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,1,,,,,4,,13969,B,,Autocuration,CHEMBL618141,BAO_0000223,3456
,,H,,,108,,,Binding affinity for 5-hydroxytryptamine 2C receptor,1,,,,,8,,13392,B,,Expert,CHEMBL873478,BAO_0000357,3457
,,H,,,104698,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,1,,,,,6,,13392,B,,Autocuration,CHEMBL618142,BAO_0000223,3458
,,H,,,144,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,1,,,,,8,,14159,B,,Autocuration,CHEMBL618143,BAO_0000357,3459
,,H,,,144,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,1,,,,,8,,1558,B,,Autocuration,CHEMBL618144,BAO_0000357,3460
,,H,,,144,,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,1,,,,,8,,16655,B,,Autocuration,CHEMBL618145,BAO_0000357,3461
,,H,,,104714,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,1,,,,,4,,13020,B,,Autocuration,CHEMBL618146,BAO_0000223,3462
,,H,,,104714,,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,1,,,,,4,,13021,B,,Autocuration,CHEMBL618147,BAO_0000223,3463
,,H,,,104714,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,1,,,,,4,,13020,B,,Autocuration,CHEMBL618148,BAO_0000223,3464
,,H,,,144,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,1,,,,,8,,10321,B,,Autocuration,CHEMBL618149,BAO_0000019,3465
,,H,,,144,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,1,,,,,8,,15818,B,,Autocuration,CHEMBL872927,BAO_0000357,3466
,,H,,,144,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,1,,,,,8,,15818,B,,Autocuration,CHEMBL618150,BAO_0000357,3467
,,H,,,144,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,1,,,,,8,,17358,B,,Autocuration,CHEMBL618151,BAO_0000357,3468
,,H,,,144,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,1,,,,,8,,2222,B,,Autocuration,CHEMBL875094,BAO_0000357,3469
,,H,,,144,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,1,,,,,8,,10322,B,,Autocuration,CHEMBL618152,BAO_0000019,3470
,,H,,,144,,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,1,,,,,8,,16117,B,,Autocuration,CHEMBL618153,BAO_0000357,3471
,,H,,,144,,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,1,,,,,8,,17200,B,,Autocuration,CHEMBL618888,BAO_0000357,3472
,,H,,,144,,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,1,,,,,8,,17358,F,,Autocuration,CHEMBL618889,BAO_0000019,3473
,,H,,,144,,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,1,,,,,8,,16700,B,,Autocuration,CHEMBL618890,BAO_0000357,3474
,,H,,,144,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,1,,,,,8,,1980,B,,Autocuration,CHEMBL618891,BAO_0000019,3475
,,H,,,144,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,1,,,,,8,,1980,B,,Autocuration,CHEMBL619054,BAO_0000019,3476
,,H,,,104714,,,Binding affinity against the 5-hydroxytryptamine 3 receptor,1,,,,,4,,12409,B,,Autocuration,CHEMBL619055,BAO_0000223,3477
,,H,,,144,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,1,,,,,8,,4365,B,,Autocuration,CHEMBL619056,BAO_0000357,3478
,,H,,,144,,,Percent efficacy against 5-hydroxytryptamine 3A receptor,1,,,,,8,,4365,F,,Autocuration,CHEMBL619057,BAO_0000019,3479
,,H,,,144,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,1,,,,,8,,4365,B,,Autocuration,CHEMBL619058,BAO_0000357,3480
,,D,,,12020,10116.0,Rattus norvegicus,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,1,,Oocytes,,,9,,6769,F,,Expert,CHEMBL619059,BAO_0000219,3481
,,D,,,12020,10116.0,Rattus norvegicus,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,1,,Oocytes,,,9,,6769,F,,Expert,CHEMBL619060,BAO_0000219,3482
,,D,,,12020,10116.0,Rattus norvegicus,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,1,,Oocytes,,,9,,6769,F,,Expert,CHEMBL875095,BAO_0000219,3483
,,D,,,20033,10141.0,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,1,Ileum,,,,9,,809,F,2116.0,Intermediate,CHEMBL619061,BAO_0000221,3484
,,D,,,20033,10141.0,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,1,Ileum,,,,9,,809,F,2116.0,Intermediate,CHEMBL619062,BAO_0000221,3485
,,D,,,20033,10141.0,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,1,,,,,9,,14290,F,,Intermediate,CHEMBL619063,BAO_0000019,3486
,,D,,,20033,10141.0,Cavia porcellus,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,1,Ileum,,,,9,,17358,B,2116.0,Intermediate,CHEMBL619064,BAO_0000221,3487
,,D,,,20033,10141.0,Cavia porcellus,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,1,,,,,9,,17358,B,,Intermediate,CHEMBL619065,BAO_0000357,3488
,,D,,,20033,10141.0,Cavia porcellus,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,1,Ileum,,,,9,,17358,B,2116.0,Intermediate,CHEMBL619066,BAO_0000221,3489
,,H,,,10209,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,1,Ileum,,,,8,,17386,B,2116.0,Autocuration,CHEMBL619775,BAO_0000221,3490
,,H,,,10209,,,Affinity against 5-hydroxytryptamine 7 receptor,1,,,,,8,,3269,B,,Autocuration,CHEMBL619776,BAO_0000357,3491
,,H,,,104841,10141.0,Cavia porcellus,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,1,,,,,4,,7721,B,,Autocuration,CHEMBL619777,BAO_0000224,3492
,,H,,,104841,10141.0,Cavia porcellus,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,1,,,,,4,,7721,B,,Autocuration,CHEMBL619778,BAO_0000224,3493
,,H,,,104841,10141.0,Cavia porcellus,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,1,Ileum,,,,4,,9117,B,2116.0,Autocuration,CHEMBL619779,BAO_0000221,3494
,,H,,,104841,10141.0,Cavia porcellus,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",1,,,,,4,,7721,B,,Autocuration,CHEMBL619780,BAO_0000224,3495
,,H,,,104841,10141.0,Cavia porcellus,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",1,,,,,4,,7721,B,,Autocuration,CHEMBL619166,BAO_0000224,3496
,,H,,,104841,10141.0,Cavia porcellus,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,1,,,,,4,,15796,F,,Autocuration,CHEMBL619167,BAO_0000019,3497
,,H,,,104841,10141.0,Cavia porcellus,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,1,,,,,4,,15796,F,,Autocuration,CHEMBL619168,BAO_0000019,3498
,,D,,,168,9606.0,Homo sapiens,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,1,Cardiac atrium,,,,9,,15650,B,2081.0,Expert,CHEMBL619169,BAO_0000219,3499
,,D,,,168,9606.0,Homo sapiens,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,1,Cardiac atrium,,,,9,,15650,B,2081.0,Expert,CHEMBL619170,BAO_0000219,3500
,,D,,,104841,9606.0,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",1,,,,,5,,6866,F,,Autocuration,CHEMBL619171,BAO_0000019,3501
,,D,,,168,9606.0,Homo sapiens,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",1,Cardiac atrium,,,,9,,15650,F,2081.0,Expert,CHEMBL619172,BAO_0000219,3502
,,U,,,22226,10090.0,Mus musculus,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,1,,,,,0,,10063,B,,Autocuration,CHEMBL619173,BAO_0000019,3503
,,U,,,22226,10090.0,Mus musculus,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,1,,,,,0,,12665,B,,Autocuration,CHEMBL619174,BAO_0000019,3504
,,H,,,104705,,,5-hydroxytryptamine receptor binding affinity was determined in rats,1,,,,,4,,7504,B,,Autocuration,CHEMBL619175,BAO_0000019,3505
,,H,,,104705,,,Binding affinity at rat 5-hydroxytryptamine receptor.,1,,,,,4,,7504,B,,Autocuration,CHEMBL619176,BAO_0000224,3506
,,H,,,104705,,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,1,,,,,4,,7038,B,,Autocuration,CHEMBL619177,BAO_0000019,3507
,,H,,,104705,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,1,,,,,4,,7626,B,,Autocuration,CHEMBL619178,BAO_0000224,3508
,,H,,,104705,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,1,,,,,4,,7626,B,,Autocuration,CHEMBL619179,BAO_0000224,3509
,,H,,,104705,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,1,Stomach,,,,4,,7185,F,945.0,Autocuration,CHEMBL619180,BAO_0000019,3510
,,H,,,104705,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,1,Stomach,,,,4,,7185,F,945.0,Autocuration,CHEMBL619181,BAO_0000019,3511
,,H,,,104705,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,1,,,,,4,,7185,F,,Autocuration,CHEMBL619182,BAO_0000019,3512
,,H,,,104705,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,1,,,,,4,,6960,B,,Autocuration,CHEMBL619183,BAO_0000224,3513
,,H,,,104705,,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",1,,,,,4,,6960,B,,Autocuration,CHEMBL619184,BAO_0000224,3514
,,H,,,10576,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,1,Hippocampus,,,,8,,12416,B,10000000.0,Autocuration,CHEMBL619185,BAO_0000221,3515
,,H,,,12198,,,Binding affinity for rat 5-hydroxytryptamine transporter.,1,,,,,8,,15753,B,,Expert,CHEMBL619186,BAO_0000357,3516
,,H,,,104705,,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,1,,,,,4,,8062,B,,Autocuration,CHEMBL619187,BAO_0000019,3517
,,D,,,104705,10116.0,Rattus norvegicus,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,1,,,,,5,,9036,B,,Autocuration,CHEMBL619188,BAO_0000019,3518
,,D,,,104705,10116.0,Rattus norvegicus,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,1,,,,,5,,15067,B,,Autocuration,CHEMBL619189,BAO_0000224,3519
,,D,,,12198,10116.0,Rattus norvegicus,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,1,Brain,,,,9,,15753,F,955.0,Expert,CHEMBL619190,BAO_0000019,3520
,,D,,,12198,10116.0,Rattus norvegicus,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,1,Cerebellum,,,,9,,15753,F,2037.0,Expert,CHEMBL619191,BAO_0000221,3521
,,D,,,104705,10116.0,Rattus norvegicus,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,1,,,,,5,,15295,B,,Autocuration,CHEMBL619192,BAO_0000019,3522
,,D,,,104705,10116.0,Rattus norvegicus,Percent binding affinity against 5-hydroxytryptamine receptor,1,,,,,5,,6347,B,,Autocuration,CHEMBL619193,BAO_0000224,3523
,,U,,,22226,,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,1,,,,,0,,6763,B,,Autocuration,CHEMBL619194,BAO_0000019,3524
,,D,,,104705,10116.0,Rattus norvegicus,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,1,,,,,5,,12092,B,,Autocuration,CHEMBL619195,BAO_0000224,3525
,,D,,,104705,10116.0,Rattus norvegicus,Affinity against 5-hydroxytryptamine receptor was determined,1,,,,,5,,1579,B,,Autocuration,CHEMBL619196,BAO_0000224,3526
,,D,,,104705,10116.0,Rattus norvegicus,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,1,Stomach,,,,5,,1579,B,945.0,Autocuration,CHEMBL619197,BAO_0000019,3527
,,D,,,121,9606.0,Homo sapiens,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,1,,,,In vitro,9,,5963,B,,Expert,CHEMBL619198,BAO_0000219,3528
,,D,,,121,9606.0,Homo sapiens,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,1,,,,In vitro,9,,5963,B,,Expert,CHEMBL875081,BAO_0000219,3529
,,H,,,18065,,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,1,,,,,8,,5030,B,,Autocuration,CHEMBL884712,BAO_0000357,3530
,,H,,,121,,,Inhibition of 5-hydroxytryptamine reuptake,1,,,,,8,,15796,B,,Expert,CHEMBL884710,BAO_0000357,3531
,,H,,,18065,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",1,,,,,8,,15413,F,,Autocuration,CHEMBL619199,BAO_0000019,3532
,,H,,,18065,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",1,,,,,8,,15413,F,,Autocuration,CHEMBL619200,BAO_0000019,3533
,,H,,,18065,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",1,,,,,8,,15413,F,,Autocuration,CHEMBL619201,BAO_0000019,3534
,,H,,,18065,,,Tested for 5-hydroxytryptamine receptor uptake,1,,,,,8,,12409,F,,Autocuration,CHEMBL619202,BAO_0000019,3535
,,D,449.0,,51,9606.0,Homo sapiens,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,1,,CHO,,,9,,16909,B,,Expert,CHEMBL619203,BAO_0000219,3536
,,D,,,51,9606.0,Homo sapiens,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,1,,,,,9,,16909,F,,Expert,CHEMBL619204,BAO_0000019,3537
,,H,,,10576,9606.0,Homo sapiens,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,1,,,,,8,,15629,B,,Autocuration,CHEMBL619205,BAO_0000249,3538
,,H,,,10576,,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,1,,,,,8,,15629,B,,Autocuration,CHEMBL619206,BAO_0000357,3539
,,H,,,10576,,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,1,,,,,8,,15629,B,,Expert,CHEMBL619207,BAO_0000249,3540
,,H,,,10825,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,1,Striatum,,,,8,,10034,F,2435.0,Autocuration,CHEMBL619208,BAO_0000019,3541
,,H,,,10825,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,1,Striatum,,,,8,,10034,F,2435.0,Autocuration,CHEMBL619209,BAO_0000019,3542
,,H,,,10825,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,1,Striatum,,,,8,,10034,F,2435.0,Autocuration,CHEMBL619210,BAO_0000019,3543
,,H,,,10825,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,1,Striatum,,,,8,,10034,F,2435.0,Autocuration,CHEMBL619211,BAO_0000019,3544
,,H,,,10825,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,1,Striatum,,,,8,,10034,F,2435.0,Autocuration,CHEMBL619212,BAO_0000019,3545
,,H,,,10825,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,1,Striatum,,,,8,,10034,F,2435.0,Autocuration,CHEMBL620681,BAO_0000019,3546
,,H,,,10825,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,1,Striatum,,,,8,,10034,F,2435.0,Autocuration,CHEMBL620682,BAO_0000019,3547
,,H,,,10825,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,1,Striatum,,,,8,,10034,F,2435.0,Autocuration,CHEMBL620683,BAO_0000019,3548
,,H,,,10825,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,1,Striatum,,,,8,,10034,F,2435.0,Autocuration,CHEMBL620684,BAO_0000019,3549
,,H,,,10825,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,1,Striatum,,,,8,,10034,F,2435.0,Autocuration,CHEMBL620685,BAO_0000019,3550
,,H,,,10825,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,1,Striatum,,,,8,,10034,F,2435.0,Autocuration,CHEMBL620686,BAO_0000019,3551
,,H,,,10825,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,1,Limbic system,,,,8,,10034,F,349.0,Autocuration,CHEMBL620687,BAO_0000019,3552
,,H,,,10825,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,1,Limbic system,,,,8,,10034,F,349.0,Autocuration,CHEMBL620688,BAO_0000019,3553
,,H,,,10825,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,1,Limbic system,,,,8,,10034,F,349.0,Autocuration,CHEMBL620689,BAO_0000019,3554
,,H,,,10825,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,1,Limbic system,,,,8,,10034,F,349.0,Autocuration,CHEMBL620690,BAO_0000019,3555
,,H,,,10825,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,1,Limbic system,,,,8,,10034,F,349.0,Autocuration,CHEMBL620691,BAO_0000019,3556
,,H,,,10825,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,1,Limbic system,,,,8,,10034,F,349.0,Autocuration,CHEMBL620692,BAO_0000019,3557
,,H,,,10825,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,1,Limbic system,,,,8,,10034,F,349.0,Autocuration,CHEMBL620693,BAO_0000019,3558
,,H,,,168,,,Binding affinity against 5-hydroxytryptamine 4 receptor,1,,,,,8,,1274,B,,Expert,CHEMBL620694,BAO_0000357,3559
,,H,,,168,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,1,,,,,8,,17358,F,,Autocuration,CHEMBL857986,BAO_0000019,3560
,,H,,,168,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,1,,,,,8,,14532,B,,Autocuration,CHEMBL620695,BAO_0000357,3561
,,H,,,168,,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,1,,,,,8,,16989,B,,Expert,CHEMBL620696,BAO_0000357,3562
,,H,,,168,,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,1,,,,,8,,17200,B,,Autocuration,CHEMBL620697,BAO_0000357,3563
,,H,,,168,,,Binding affinity towards 5-hydroxytryptamine 4 receptor,1,,,,,8,,15779,B,,Autocuration,CHEMBL620698,BAO_0000357,3564
,,H,,,168,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,1,,,,,8,,15779,B,,Autocuration,CHEMBL620699,BAO_0000357,3565
,,H,,,168,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,1,,,,,8,,15779,B,,Autocuration,CHEMBL620700,BAO_0000357,3566
,,H,643.0,,168,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,1,,COS-7,,,8,,15650,B,,Autocuration,CHEMBL620701,BAO_0000219,3567
,,H,643.0,,168,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,1,,COS-7,,,8,,15650,B,,Autocuration,CHEMBL875082,BAO_0000219,3568
,,H,643.0,,168,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,1,,COS-7,,,8,,15650,B,,Autocuration,CHEMBL620702,BAO_0000219,3569
,,H,643.0,,168,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,1,,COS-7,,,8,,15650,B,,Autocuration,CHEMBL620703,BAO_0000219,3570
,,H,673.0,,168,,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,1,,C6,,,8,,17046,B,,Autocuration,CHEMBL620704,BAO_0000219,3571
,,H,673.0,,168,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,1,,C6,,,8,,17046,B,,Expert,CHEMBL620705,BAO_0000219,3572
,,H,673.0,,168,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,1,,C6,,,8,,15650,B,,Expert,CHEMBL620706,BAO_0000219,3573
,,H,673.0,,168,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,1,,C6,,,8,,17046,B,,Expert,CHEMBL620707,BAO_0000219,3574
,,H,,,10624,,,Binding affinity towards 5-hydroxytryptamine 5 receptor,1,,,,,8,,17066,B,,Expert,CHEMBL620708,BAO_0000357,3575
,,H,,,105,,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,1,,,,,8,,17200,B,,Autocuration,CHEMBL620709,BAO_0000357,3576
,,D,,,10624,9606.0,Homo sapiens,Binding affinity against 5-hydroxytryptamine 5A receptor,1,,,,,9,,16146,B,,Expert,CHEMBL620710,BAO_0000357,3577
,,H,449.0,,10624,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,1,,CHO,,,8,,15250,B,,Autocuration,CHEMBL620711,BAO_0000219,3578
,,D,,,10624,9606.0,Homo sapiens,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,1,,,,,9,,6491,B,,Expert,CHEMBL620712,BAO_0000357,3579
,,D,,,10624,9606.0,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 5A receptor,1,,,,,9,,17066,B,,Expert,CHEMBL620713,BAO_0000357,3580
,,D,,,10624,9606.0,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,1,,,,,9,,17066,B,,Expert,CHEMBL620714,BAO_0000357,3581
,,D,,,10624,9606.0,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,1,,,,,9,,4234,B,,Expert,CHEMBL620715,BAO_0000357,3582
,,H,,,10624,,,Binding affinity towards 5-HT5A receptor,1,,,,,8,,6013,B,,Autocuration,CHEMBL620716,BAO_0000357,3583
,,H,,,10624,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,1,,,,,8,,17175,B,,Expert,CHEMBL620717,BAO_0000357,3584
,,H,,,10624,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,1,,,,,8,,15818,B,,Autocuration,CHEMBL618072,BAO_0000357,3585
,,H,,,10624,,,Binding affinity towards cloned human 5-HT5A receptor was determined,1,,,,,8,,6166,B,,Autocuration,CHEMBL857987,BAO_0000357,3586
,,H,722.0,,10624,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,1,,HEK293,,,8,,15779,B,,Autocuration,CHEMBL618073,BAO_0000219,3587
,,H,722.0,,10624,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,1,,HEK293,,,8,,15779,B,,Autocuration,CHEMBL618074,BAO_0000219,3588
,,H,722.0,,10624,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),1,,HEK293,,,8,,5213,B,,Autocuration,CHEMBL618075,BAO_0000219,3589
,,D,,,10625,10090.0,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,1,,,,,9,,17066,B,,Expert,CHEMBL618076,BAO_0000357,3590
,,D,,,10625,10090.0,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,1,,,,,9,,17066,B,,Expert,CHEMBL618077,BAO_0000357,3591
,,D,,,10625,10090.0,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,1,,,,,9,,17066,B,,Expert,CHEMBL618078,BAO_0000357,3592
,,D,,,10625,10090.0,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,1,,,,,9,,17066,B,,Expert,CHEMBL881821,BAO_0000357,3593
,,D,,,10625,10090.0,Mus musculus,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,1,,,,,9,,17066,B,,Expert,CHEMBL618079,BAO_0000357,3594
,,H,,,10625,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,1,,,,,8,,17175,B,,Expert,CHEMBL618080,BAO_0000357,3595
,,H,722.0,,10576,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,1,,HEK293,,,8,,16190,B,,Autocuration,CHEMBL618081,BAO_0000219,3596
,,H,722.0,,10626,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,1,,HEK293,,,8,,16190,B,,Autocuration,CHEMBL618082,BAO_0000219,3597
,,H,,,10624,,,Binding affinity towards 5-HT5a receptor,1,,,,,8,,4820,B,,Expert,CHEMBL618083,BAO_0000357,3598
,,D,,,10624,9606.0,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 5A receptor,1,,,,,9,,17066,B,,Expert,CHEMBL618084,BAO_0000357,3599
,,H,,,10624,,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,1,,,,,8,,17066,B,,Expert,CHEMBL618085,BAO_0000357,3600
,,H,,,10624,,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,1,,,,,8,,17175,B,,Expert,CHEMBL618086,BAO_0000357,3601
,,H,,,10624,,,Binding affinities against 5-hydroxytryptamine 5A receptor,1,,,,,8,,16633,B,,Autocuration,CHEMBL875092,BAO_0000357,3602
,,H,,,10624,,,Binding affinities towards 5-hydroxytryptamine 5A receptor,1,,,,,8,,16633,B,,Autocuration,CHEMBL618087,BAO_0000357,3603
,,H,,,10624,,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,1,,,,,8,,16700,B,,Autocuration,CHEMBL872926,BAO_0000357,3604
,,H,,,104714,10141.0,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,1,,,,,4,,4639,F,,Autocuration,CHEMBL618088,BAO_0000019,3605
,,H,,,104714,,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,1,,,,,4,,5486,B,,Autocuration,CHEMBL618089,BAO_0000223,3606
,,D,,,10627,9606.0,Homo sapiens,Inhibition of human 5-hydroxytryptamine 6 receptor,1,,,,,9,,16146,B,,Expert,CHEMBL618090,BAO_0000357,3607
,,D,,,10627,9606.0,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,1,,,,,9,,17273,B,,Expert,CHEMBL618091,BAO_0000357,3608
,,H,,,10627,,,Inhibition against human 5-hydroxytryptamine 6 receptor,1,,,,,8,,17687,B,,Autocuration,CHEMBL618092,BAO_0000357,3609
,,D,,,10627,9606.0,Homo sapiens,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,1,,,,,9,,6491,B,,Expert,CHEMBL618093,BAO_0000357,3610
,,H,308.0,,10627,,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,1,,HeLa,,,8,,16190,B,,Expert,CHEMBL618094,BAO_0000219,3611
,,D,,,10627,9606.0,Homo sapiens,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,1,,,,,9,,17066,B,,Expert,CHEMBL618095,BAO_0000357,3612
,,D,,,10627,9606.0,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,,,,,9,,17066,B,,Expert,CHEMBL875093,BAO_0000357,3613
,,D,,,10627,9606.0,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,1,,,,,9,,17066,B,,Expert,CHEMBL618096,BAO_0000357,3614
,,D,,,10627,9606.0,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,1,,,,,9,,17066,B,,Expert,CHEMBL618118,BAO_0000357,3615
,,D,,,10627,9606.0,Homo sapiens,Binding affinity against 5-hydroxytryptamine 6 receptor,1,,,,,9,,3555,B,,Expert,CHEMBL618119,BAO_0000357,3616
,,H,,,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,,,,,8,,5808,B,,Expert,CHEMBL618120,BAO_0000357,3617
,,H,,,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,,,,,8,,6013,B,,Autocuration,CHEMBL618121,BAO_0000357,3618
,,H,722.0,,10627,,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",1,,HEK293,,,8,,15818,B,,Expert,CHEMBL618122,BAO_0000219,3619
,,H,,,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,1,,,,,8,,16209,B,,Autocuration,CHEMBL618123,BAO_0000357,3620
,,H,722.0,,10627,,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,1,,HEK293,,,8,,3935,B,,Expert,CHEMBL618124,BAO_0000219,3621
,,H,,,10627,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,1,,,,,8,,15818,B,,Autocuration,CHEMBL618125,BAO_0000357,3622
,,D,722.0,,10627,9606.0,Homo sapiens,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,1,,HEK293,,,9,,3805,B,,Expert,CHEMBL618126,BAO_0000219,3623
,,H,,,10627,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,1,,,,,8,,16441,B,,Expert,CHEMBL618236,BAO_0000019,3624
,,H,,,10627,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,1,,,,,8,,16441,B,,Expert,CHEMBL618237,BAO_0000019,3625
,,H,643.0,,10627,,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,1,,COS-7,,,8,,6786,B,,Expert,CHEMBL618238,BAO_0000219,3626
,,D,,,10627,9606.0,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,1,,,,,9,,4234,B,,Expert,CHEMBL618239,BAO_0000357,3627
,,H,,,10627,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,1,,,,,8,,17085,B,,Autocuration,CHEMBL618240,BAO_0000019,3628
,,H,,,10627,,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,1,,,,,8,,17200,B,,Autocuration,CHEMBL618241,BAO_0000357,3629
,,H,722.0,,10627,,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,1,,HEK293,,,8,,17451,B,,Autocuration,CHEMBL859399,BAO_0000219,3630
,,H,,,10627,,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,1,,,,,8,,3935,F,,Autocuration,CHEMBL618242,BAO_0000019,3631
,,H,,,10627,,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,1,,,,,8,,5033,B,,Autocuration,CHEMBL857991,BAO_0000357,3632
,,H,,,10627,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,1,,,,,8,,4540,B,,Expert,CHEMBL619951,BAO_0000357,3633
,,D,308.0,,10627,9606.0,Homo sapiens,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,1,,HeLa,,,9,,4540,B,,Expert,CHEMBL619952,BAO_0000219,3634
,,D,308.0,,10627,9606.0,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,1,,HeLa,,,9,,4540,B,,Expert,CHEMBL619953,BAO_0000219,3635
,,H,308.0,,10627,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,1,,HeLa,,,8,,17296,B,,Autocuration,CHEMBL619954,BAO_0000219,3636
,,H,308.0,,10627,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,1,,HeLa,,,8,,17296,B,,Autocuration,CHEMBL619955,BAO_0000219,3637
,,H,308.0,,10627,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,1,,HeLa,,,8,,17296,B,,Autocuration,CHEMBL619956,BAO_0000219,3638
,,H,449.0,,10627,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,1,,CHO,,,8,,15779,B,,Autocuration,CHEMBL619957,BAO_0000219,3639
,,H,722.0,,10627,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,1,,HEK293,,,8,,15779,B,,Autocuration,CHEMBL619958,BAO_0000219,3640
,,H,722.0,,10627,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,1,,HEK293,,,8,,15779,B,,Autocuration,CHEMBL620627,BAO_0000219,3641
,,H,722.0,,10627,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,1,,HEK293,,,8,,15779,B,,Autocuration,CHEMBL620628,BAO_0000219,3642
,,H,308.0,,10627,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,1,,HeLa,,,8,,15779,B,,Autocuration,CHEMBL620629,BAO_0000219,3643
,,H,,,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,,,,,8,,6166,B,,Autocuration,CHEMBL620630,BAO_0000357,3644
,,H,308.0,,10627,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,1,,HeLa,,,8,,17451,B,,Autocuration,CHEMBL620782,BAO_0000219,3645
,,H,,,10627,,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,1,,,,,8,,15316,B,,Autocuration,CHEMBL620783,BAO_0000357,3646
,,H,,,10627,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,1,,,,,8,,4199,B,,Expert,CHEMBL620784,BAO_0000357,3647
,,H,308.0,,10627,,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,1,,HeLa,,,8,,15146,B,,Expert,CHEMBL620785,BAO_0000219,3648
,,H,,,10627,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),1,,,,,8,,5213,B,,Autocuration,CHEMBL857992,BAO_0000357,3649
,,H,,,10627,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,1,,,,,8,,16429,B,,Autocuration,CHEMBL620786,BAO_0000219,3650
,,H,308.0,,10627,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,1,,HeLa,,,8,,14818,B,,Autocuration,CHEMBL620787,BAO_0000219,3651
,,H,308.0,,10627,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",1,,HeLa,,,8,,4829,B,,Autocuration,CHEMBL620788,BAO_0000219,3652
,,H,308.0,,10627,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",1,,HeLa,,,8,,4829,B,,Autocuration,CHEMBL620789,BAO_0000219,3653
,,H,308.0,,10627,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",1,,HeLa,,,8,,4829,B,,Autocuration,CHEMBL620790,BAO_0000219,3654
,,H,449.0,,10628,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,1,,CHO,,,8,,15250,B,,Autocuration,CHEMBL620791,BAO_0000219,3655
,,H,,,10628,,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,1,,,,,8,,14423,B,,Autocuration,CHEMBL620792,BAO_0000019,3656
,,H,,,10628,,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,1,,,,,8,,15086,B,,Autocuration,CHEMBL620793,BAO_0000357,3657
,,H,,,10628,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,1,,,,,8,,4342,B,,Autocuration,CHEMBL620794,BAO_0000357,3658
,,D,308.0,,10627,9606.0,Homo sapiens,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,1,,HeLa,,,9,,16190,B,,Autocuration,CHEMBL620795,BAO_0000219,3659
,,H,,,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,,,,,8,,4820,B,,Expert,CHEMBL620796,BAO_0000357,3660
,,H,,,10627,,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,1,,,,,8,,4639,B,,Autocuration,CHEMBL620797,BAO_0000357,3661
,,D,,,10627,9606.0,Homo sapiens,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,1,,,,,9,,17066,F,,Expert,CHEMBL620798,BAO_0000019,3662
,,H,,,10627,,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,1,,,,,8,,6011,B,,Autocuration,CHEMBL620799,BAO_0000357,3663
,,H,,,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,,,,,8,,17066,B,,Expert,CHEMBL620800,BAO_0000357,3664
,,H,,,10627,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,1,,,,,8,,17515,B,,Autocuration,CHEMBL620801,BAO_0000357,3665
,,H,,,10627,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,1,,,,,8,,5014,B,,Autocuration,CHEMBL875100,BAO_0000357,3666
,,H,,,10627,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,1,,,,,8,,4373,B,,Autocuration,CHEMBL620802,BAO_0000357,3667
,,H,,,10627,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,1,,,,,8,,17066,F,,Expert,CHEMBL620803,BAO_0000019,3668
,,H,,,10627,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,1,,,,,8,,17066,F,,Expert,CHEMBL620804,BAO_0000019,3669
,,H,,,10627,,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,1,,,,,8,,4373,B,,Autocuration,CHEMBL620805,BAO_0000357,3670
,,H,,,10627,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,1,,,,,8,,4687,B,,Autocuration,CHEMBL620806,BAO_0000357,3671
,,H,,,10627,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,1,,,,,8,,16946,B,,Autocuration,CHEMBL620807,BAO_0000357,3672
,,H,,,10627,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,1,,,,,8,,16946,B,,Autocuration,CHEMBL620808,BAO_0000357,3673
,,H,,,10627,,,Binding affinities against 5-hydroxytryptamine 6 receptor,1,,,,,8,,16633,B,,Autocuration,CHEMBL620809,BAO_0000357,3674
,,H,,,10627,,,Binding affinities towards 5-hydroxytryptamine 6 receptor,1,,,,,8,,16633,B,,Autocuration,CHEMBL620810,BAO_0000357,3675
,,D,,,10627,9606.0,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 6 receptor,1,,,,,9,,17066,B,,Expert,CHEMBL620811,BAO_0000357,3676
,,H,,,10627,,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,1,,,,,8,,16700,B,,Autocuration,CHEMBL620812,BAO_0000357,3677
,,H,,,10627,,,Affinity against 5-hydroxytryptamine 6 receptor,1,,,,,8,,3269,B,,Autocuration,CHEMBL620813,BAO_0000357,3678
,,H,,,10627,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],1,,,,,8,,5486,B,,Autocuration,CHEMBL620814,BAO_0000357,3679
,,D,,,10209,9606.0,Homo sapiens,Inhibition of human 5-hydroxytryptamine 7 receptor,1,,,,,9,,16146,B,,Expert,CHEMBL620815,BAO_0000357,3680
,,H,722.0,,10209,,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,1,,HEK293,,,8,,5014,B,,Autocuration,CHEMBL620816,BAO_0000219,3681
,,H,,,10209,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,1,,,,,8,,15463,B,,Autocuration,CHEMBL620817,BAO_0000357,3682
,,H,,,10209,,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),1,,,,,8,,3805,B,,Autocuration,CHEMBL620818,BAO_0000357,3683
,,H,722.0,,10209,,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,1,,HEK293,,,8,,5014,B,,Expert,CHEMBL620819,BAO_0000219,3684
,,D,,,10209,9606.0,Homo sapiens,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,1,,,,,9,,6491,B,,Expert,CHEMBL620820,BAO_0000357,3685
,,H,449.0,,10209,,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,1,,CHO,,,8,,16190,B,,Autocuration,CHEMBL620821,BAO_0000219,3686
,,D,,,10209,9606.0,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 7 receptor,1,,,,,9,,17066,B,,Expert,CHEMBL620822,BAO_0000357,3687
,,D,,,10209,9606.0,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,1,,,,,9,,17066,B,,Expert,CHEMBL620823,BAO_0000357,3688
,,D,,,10209,9606.0,Homo sapiens,Binding affinity against 5-hydroxytryptamine 7 receptor,1,,,,,9,,3555,B,,Expert,CHEMBL620824,BAO_0000357,3689
,,H,449.0,,10209,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,1,,CHO,,,8,,6588,B,,Expert,CHEMBL620825,BAO_0000219,3690
,,H,,,10209,,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,1,,,,,8,,15463,B,,Autocuration,CHEMBL872930,BAO_0000357,3691
,,H,,,10209,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,1,,,,,8,,6013,B,,Autocuration,CHEMBL620826,BAO_0000357,3692
,,H,,,10209,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,1,,,,,8,,16209,B,,Autocuration,CHEMBL620827,BAO_0000357,3693
,,H,,,10209,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,1,,,,,8,,3935,B,,Autocuration,CHEMBL620828,BAO_0000357,3694
,,H,,,10209,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,1,,,,,8,,15818,B,,Autocuration,CHEMBL620829,BAO_0000357,3695
,,H,722.0,,10209,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,1,,HEK293,,,8,,5014,B,,Expert,CHEMBL620830,BAO_0000219,3696
,,H,,,10209,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,1,,,,,8,,16441,B,,Expert,CHEMBL620831,BAO_0000019,3697
,,H,,,10209,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,1,,,,,8,,16441,B,,Expert,CHEMBL620832,BAO_0000019,3698
,,D,,,10209,9606.0,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,1,,,,,9,,4234,B,,Expert,CHEMBL621548,BAO_0000357,3699
,,H,,,10209,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,1,,,,,8,,17085,B,,Autocuration,CHEMBL621549,BAO_0000019,3700
,,H,,,10209,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,1,,,,,8,,17200,B,,Autocuration,CHEMBL621550,BAO_0000357,3701
,,H,449.0,,10209,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,1,,CHO,,,8,,17451,B,,Autocuration,CHEMBL621551,BAO_0000219,3702
,,H,,,10209,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,1,,,,,8,,17085,B,,Autocuration,CHEMBL621552,BAO_0000019,3703
,,H,,,10209,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,1,,,,,8,,5104,B,,Autocuration,CHEMBL857077,BAO_0000357,3704
,,H,,,10209,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,1,,,,,8,,5104,B,,Autocuration,CHEMBL618158,BAO_0000357,3705
,,D,643.0,,10209,9606.0,Homo sapiens,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,1,,COS-7,,,9,,5033,B,,Expert,CHEMBL618159,BAO_0000219,3706
,,H,643.0,,10209,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,1,,COS-7,,,8,,5486,B,,Autocuration,CHEMBL875101,BAO_0000219,3707
,,D,722.0,,10209,9606.0,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,1,,HEK293,,,9,,4540,B,,Expert,CHEMBL618160,BAO_0000219,3708
,,H,,,10209,,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,1,,,,,8,,6166,B,,Expert,CHEMBL618161,BAO_0000357,3709
,,H,722.0,,10209,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,1,,HEK293,,,8,,17342,B,,Expert,CHEMBL618162,BAO_0000219,3710
,,H,,,10209,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,1,,,,,8,,17342,B,,Expert,CHEMBL618163,BAO_0000357,3711
,,H,,,10209,,,Binding affinity against 5-hydroxytryptamine 7 human receptors,1,,,,,8,,17296,B,,Autocuration,CHEMBL618164,BAO_0000357,3712
,,H,,,10209,,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,1,,,,,8,,16429,B,,Expert,CHEMBL618165,BAO_0000219,3713
,,H,722.0,,10209,,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,1,,HEK293,,,8,,15779,B,,Autocuration,CHEMBL618166,BAO_0000219,3714
,,H,722.0,,10209,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,1,,HEK293,,,8,,15779,B,,Autocuration,CHEMBL857989,BAO_0000219,3715
,,H,722.0,,10209,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,1,,HEK293,,,8,,15779,B,,Autocuration,CHEMBL619888,BAO_0000219,3716
,,H,722.0,,10209,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,1,,HEK293,,,8,,15779,B,,Autocuration,CHEMBL619889,BAO_0000219,3717
,,H,722.0,,10209,,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,1,,HEK293,,,8,,15779,B,,Autocuration,CHEMBL619890,BAO_0000219,3718
,,H,449.0,,10209,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,1,,CHO,,,8,,17451,B,,Autocuration,CHEMBL619891,BAO_0000219,3719
,,H,722.0,,10209,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),1,,HEK293,,,8,,4199,B,,Autocuration,CHEMBL619892,BAO_0000219,3720
,,D,722.0,,10209,,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,1,,HEK293,,,9,,4199,B,,Expert,CHEMBL619893,BAO_0000219,3721
,,H,722.0,,10209,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),1,,HEK293,,,8,,4199,B,,Autocuration,CHEMBL619894,BAO_0000219,3722
,,D,722.0,,10209,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,1,,HEK293,,,9,,3680,B,,Intermediate,CHEMBL619895,BAO_0000219,3723
,,D,,,10209,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,1,,,,,9,,3680,B,,Intermediate,CHEMBL619896,BAO_0000357,3724
,,H,643.0,,10209,,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,1,,COS-7,,,8,,15316,B,,Autocuration,CHEMBL619897,BAO_0000219,3725
,,H,722.0,,10209,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,1,,HEK293,,,8,,15146,B,,Autocuration,CHEMBL619898,BAO_0000219,3726
,,H,722.0,,10209,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,1,,HEK293,,,8,,5213,B,,Expert,CHEMBL619899,BAO_0000219,3727
,,H,722.0,,10209,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),1,,HEK293,,,8,,5213,B,,Autocuration,CHEMBL619900,BAO_0000219,3728
,,D,722.0,,10209,9606.0,Homo sapiens,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,1,,HEK293,,,9,,14818,B,,Expert,CHEMBL619901,BAO_0000219,3729
,,H,722.0,,10209,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,1,,HEK293,,,8,,14818,B,,Autocuration,CHEMBL620580,BAO_0000219,3730
,,H,722.0,,10209,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,1,,HEK293,,,8,,14818,B,,Autocuration,CHEMBL620581,BAO_0000219,3731
,,H,722.0,,10209,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",1,,HEK293,,,8,,4829,B,,Autocuration,CHEMBL620733,BAO_0000219,3732
,,D,,,10209,9606.0,Homo sapiens,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,1,,,,,9,,17200,B,,Autocuration,CHEMBL620734,BAO_0000357,3733
,,D,,,10022,10090.0,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,1,,,,,9,,17066,B,,Expert,CHEMBL620735,BAO_0000357,3734
,,H,,,10209,9986.0,Oryctolagus cuniculus,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,1,,,,,8,,14025,B,,Autocuration,CHEMBL620736,BAO_0000019,3735
,,H,449.0,,11923,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,1,,CHO,,,8,,15250,B,,Autocuration,CHEMBL620737,BAO_0000219,3736
,,H,449.0,,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,1,,CHO,,,8,,16372,B,,Autocuration,CHEMBL620738,BAO_0000219,3737
,,H,449.0,,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,1,,CHO,,,8,,16372,B,,Autocuration,CHEMBL620739,BAO_0000219,3738
,,H,449.0,,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,1,,CHO,,,8,,16372,B,,Autocuration,CHEMBL620740,BAO_0000219,3739
,,H,449.0,,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,1,,CHO,,,8,,16372,B,,Autocuration,CHEMBL620741,BAO_0000219,3740
,,H,449.0,,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,1,,CHO,,,8,,16372,B,,Autocuration,CHEMBL620742,BAO_0000219,3741
,,H,449.0,,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,1,,CHO,,,8,,16372,B,,Autocuration,CHEMBL620743,BAO_0000219,3742
,,H,449.0,,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,1,,CHO,,,8,,16372,B,,Autocuration,CHEMBL620744,BAO_0000219,3743
,,H,449.0,,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,1,,CHO,,,8,,16372,B,,Autocuration,CHEMBL620745,BAO_0000219,3744
,,H,449.0,,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,1,,CHO,,,8,,16372,B,,Autocuration,CHEMBL620746,BAO_0000219,3745
,,H,449.0,,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,1,,CHO,,,8,,16372,B,,Autocuration,CHEMBL620747,BAO_0000219,3746
,,H,449.0,,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,1,,CHO,,,8,,16372,B,,Autocuration,CHEMBL620748,BAO_0000219,3747
,,H,449.0,,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,1,,CHO,,,8,,16372,B,,Autocuration,CHEMBL620749,BAO_0000219,3748
,,H,,,11923,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,1,,,,,8,,17066,B,,Expert,CHEMBL620750,BAO_0000357,3749
,,D,,,11923,10116.0,Rattus norvegicus,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,1,,,,,9,,17066,B,,Expert,CHEMBL620751,BAO_0000357,3750
,,H,,,11923,,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,1,,,,,8,,17386,B,,Expert,CHEMBL620752,BAO_0000357,3751
,,H,,,11923,,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,1,,,,,8,,14423,B,,Autocuration,CHEMBL872929,BAO_0000019,3752
,,D,,,11923,10116.0,Rattus norvegicus,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,1,,,,,9,,15874,B,,Expert,CHEMBL620753,BAO_0000357,3753
,,D,,,11923,10116.0,Rattus norvegicus,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,1,,,,,9,,15874,B,,Expert,CHEMBL620754,BAO_0000357,3754
,,D,449.0,,11923,10116.0,Rattus norvegicus,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,1,,CHO,,,9,,16372,B,,Expert,CHEMBL620755,BAO_0000219,3755
,,H,,,11923,,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,1,,,,,8,,4622,B,,Autocuration,CHEMBL620756,BAO_0000357,3756
,,H,,,11923,,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,1,,,,,8,,15086,B,,Autocuration,CHEMBL620757,BAO_0000357,3757
,,H,449.0,,11923,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",1,,CHO,,,8,,16372,B,,Autocuration,CHEMBL620758,BAO_0000219,3758
,,H,449.0,,11923,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",1,,CHO,,,8,,16372,B,,Autocuration,CHEMBL620759,BAO_0000219,3759
,,H,449.0,,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,1,,CHO,,,8,,16372,B,,Autocuration,CHEMBL620760,BAO_0000219,3760
,,H,449.0,,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,1,,CHO,,,8,,16372,B,,Autocuration,CHEMBL620761,BAO_0000219,3761
,,H,,,11923,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,1,Ileum,,,,8,,17386,F,2116.0,Autocuration,CHEMBL620762,BAO_0000221,3762
,,H,,,11923,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,1,Ileum,,,,8,,17386,F,2116.0,Autocuration,CHEMBL620763,BAO_0000221,3763
,,H,,,11923,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,1,Ileum,,,,8,,17386,F,2116.0,Autocuration,CHEMBL620764,BAO_0000221,3764
,Membranes,D,,,11923,10116.0,Rattus norvegicus,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,1,,,,,9,,5831,B,,Expert,CHEMBL857990,BAO_0000249,3765
,,H,,,11923,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,1,,,,,8,,4342,B,,Autocuration,CHEMBL620765,BAO_0000357,3766
,,H,,,11923,,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,1,,,,,8,,17319,B,,Expert,CHEMBL620766,BAO_0000357,3767
,,H,,,11923,,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,1,Hypothalamus,,,,8,,17342,B,1898.0,Expert,CHEMBL620767,BAO_0000019,3768
,,H,,,11923,,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,1,,,,,8,,17342,B,,Autocuration,CHEMBL620768,BAO_0000357,3769
,,H,,,11923,,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,1,Hypothalamus,,,,8,,3680,B,1898.0,Expert,CHEMBL619051,BAO_0000249,3770
,,H,,,11923,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,1,,,,,8,,3680,B,,Expert,CHEMBL619052,BAO_0000357,3771
,,D,722.0,,11923,10116.0,Rattus norvegicus,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,1,,HEK293,,,9,,17319,F,,Expert,CHEMBL619053,BAO_0000219,3772
,,D,722.0,,11923,10116.0,Rattus norvegicus,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,1,,HEK293,,,9,,17319,F,,Expert,CHEMBL619703,BAO_0000219,3773
,,D,722.0,,11923,10116.0,Rattus norvegicus,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,1,,HEK293,,,9,,17319,F,,Autocuration,CHEMBL619704,BAO_0000219,3774
,,H,,,10209,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,1,,,,,8,,4820,B,,Expert,CHEMBL619851,BAO_0000357,3775
,,H,,,10209,,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,1,,,,,8,,4639,B,,Autocuration,CHEMBL619852,BAO_0000357,3776
,,H,,,10209,,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,1,,,,,8,,6011,B,,Autocuration,CHEMBL619853,BAO_0000357,3777
,,D,,,10209,9606.0,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 7 receptor,1,,,,,9,,17066,B,,Expert,CHEMBL619854,BAO_0000357,3778
,,H,,,10209,,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,1,,,,,8,,17066,B,,Expert,CHEMBL619855,BAO_0000357,3779
,,H,,,10209,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,1,,,,,8,,17515,B,,Autocuration,CHEMBL619856,BAO_0000357,3780
,,H,,,10209,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,1,,,,,8,,4373,B,,Autocuration,CHEMBL619857,BAO_0000357,3781
,,H,,,10209,,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,1,,,,,8,,17066,F,,Expert,CHEMBL619858,BAO_0000019,3782
,,H,,,10209,,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,1,,,,,8,,4373,B,,Autocuration,CHEMBL619859,BAO_0000357,3783
,,H,,,10209,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,1,,,,,8,,4373,B,,Autocuration,CHEMBL619860,BAO_0000357,3784
,,H,,,10209,,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,1,,,,,8,,4687,B,,Autocuration,CHEMBL619861,BAO_0000357,3785
,,H,,,10209,,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,1,,,,,8,,17342,B,,Expert,CHEMBL619862,BAO_0000357,3786
,,H,,,10209,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,1,,,,,8,,16946,B,,Autocuration,CHEMBL619863,BAO_0000357,3787
,,H,,,10209,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,1,,,,,8,,16946,B,,Autocuration,CHEMBL619864,BAO_0000357,3788
,,H,,,10209,,,Binding affinities against 5-hydroxytryptamine 7 receptor,1,,,,,8,,16633,B,,Autocuration,CHEMBL872928,BAO_0000357,3789
,,H,,,10209,,,Binding affinities towards 5-hydroxytryptamine 7 receptor,1,,,,,8,,16633,B,,Autocuration,CHEMBL619865,BAO_0000357,3790
,,H,,,10209,,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,1,,,,,8,,17066,B,,Expert,CHEMBL619866,BAO_0000357,3791
,,H,,,10209,,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,1,,,,,8,,16700,B,,Autocuration,CHEMBL619867,BAO_0000357,3792
,,H,,,10209,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,1,Ileum,,,,8,,17386,B,2116.0,Autocuration,CHEMBL619868,BAO_0000221,3793
,,H,,,55,,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,1,,,,,8,,14080,F,,Autocuration,CHEMBL619869,BAO_0000019,3794
,,D,,,55,9606.0,Homo sapiens,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,1,,,,,9,,14080,F,,Expert,CHEMBL619870,BAO_0000019,3795
,,H,,,55,,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,1,,,,,8,,409,B,,Autocuration,CHEMBL619871,BAO_0000357,3796
,,H,,,55,,,In vitro inhibition of human recombinant lipoxygenase enzyme,1,,,,,8,,409,B,,Autocuration,CHEMBL619872,BAO_0000357,3797
,,H,,,55,,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,1,,,,,8,,409,B,,Autocuration,CHEMBL619873,BAO_0000357,3798
,,H,,,55,,,Inhibition of 5-lipoxygenase in human whole blood.,1,Blood,,,,8,,11090,B,178.0,Expert,CHEMBL619874,BAO_0000357,3799
,,H,,,55,,,Inhibition of 5-lipoxygenase in human whole blood.,1,Blood,,,,8,,11090,B,178.0,Expert,CHEMBL619875,BAO_0000357,3800
,,H,,,55,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,1,,,,,8,,948,B,,Autocuration,CHEMBL619876,BAO_0000357,3801
,,H,,,55,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),1,,,,,8,,948,B,,Autocuration,CHEMBL619877,BAO_0000357,3802
,,H,,,55,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,1,,,,,8,,13622,F,,Expert,CHEMBL619878,BAO_0000219,3803
,,H,,,55,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,1,Blood,,,,8,,13622,F,178.0,Autocuration,CHEMBL619879,BAO_0000019,3804
,,H,,,55,,,In vitro inhibition of 5-lipoxygenase from human polymorphs,1,,,,,8,,9637,B,,Autocuration,CHEMBL619880,BAO_0000357,3805
,,H,,,55,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),1,,,,,8,,11320,B,,Autocuration,CHEMBL619881,BAO_0000357,3806
,,H,,,55,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,1,,,,,8,,11320,B,,Expert,CHEMBL619882,BAO_0000357,3807
,,H,,,55,,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,1,,,,,8,,6838,B,,Autocuration,CHEMBL619883,BAO_0000357,3808
,,D,,,55,9606.0,Homo sapiens,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),1,Blood,,,,9,,17667,B,178.0,Expert,CHEMBL619884,BAO_0000357,3809
,,H,,,55,,,In vitro potency against human 5-Lipoxygenase,1,,,,,8,,12703,B,,Autocuration,CHEMBL619885,BAO_0000357,3810
,,D,,,55,9606.0,Homo sapiens,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,1,,,,,9,,14312,F,,Expert,CHEMBL619886,BAO_0000019,3811
,,H,,,55,,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,1,Blood,,,,8,,14312,F,178.0,Autocuration,CHEMBL619887,BAO_0000019,3812
,,H,,,55,,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,1,,,,,8,,5364,F,,Autocuration,CHEMBL875097,BAO_0000019,3813
,,H,,,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,1,,,,,8,,951,B,,Autocuration,CHEMBL618001,BAO_0000219,3814
,,H,,,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,1,,,,,8,,951,B,,Autocuration,CHEMBL618002,BAO_0000219,3815
,,H,,,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,1,,,,,8,,951,B,,Autocuration,CHEMBL618003,BAO_0000219,3816
,,H,,,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,1,,,,,8,,951,B,,Autocuration,CHEMBL618004,BAO_0000219,3817
,,H,,,55,,,Inhibition of human 5-lipoxygenase in human cells,1,,,,,8,,12365,B,,Autocuration,CHEMBL618005,BAO_0000219,3818
,,H,,,55,,,Inhibition of human neutrophil 5-lipoxygenase,1,,,,,8,,10603,B,,Expert,CHEMBL618006,BAO_0000357,3819
,,H,,,55,,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,1,,,,,8,,10501,B,,Autocuration,CHEMBL875086,BAO_0000019,3820
,,H,,,55,,,Inhibition of 5-lipoxygenase from human whole blood,1,Blood,,,,8,,12281,B,178.0,Expert,CHEMBL618007,BAO_0000357,3821
,,H,,,55,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,1,,,,,8,,2567,B,,Autocuration,CHEMBL618008,BAO_0000357,3822
,,H,,,55,,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,1,,,,,8,,2567,B,,Autocuration,CHEMBL618009,BAO_0000219,3823
,,H,,,55,,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,1,,,,,8,,10193,B,,Expert,CHEMBL618010,BAO_0000357,3824
,,H,,,55,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,1,,,,,8,,10193,B,,Autocuration,CHEMBL618011,BAO_0000357,3825
,,H,,,55,,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,1,,,,,8,,13623,B,,Expert,CHEMBL618012,BAO_0000357,3826
,,H,,,55,,,Tested against 5-lipoxygenase,1,,,,,8,,12780,B,,Autocuration,CHEMBL882927,BAO_0000357,3827
,,H,,,55,,,Tested for activity against 5-Lipoxygenase (5-LO),1,,,,,8,,12780,B,,Autocuration,CHEMBL618013,BAO_0000357,3828
,,H,,,55,,,Tested for activity against 5-lipoxygenase,1,,,,,8,,12780,B,,Autocuration,CHEMBL618014,BAO_0000357,3829
,,H,,,55,,,Tested for inhibition of 5-HPETE production by human 5-LO,1,,,,,8,,11966,B,,Autocuration,CHEMBL618015,BAO_0000357,3830
,,H,,,55,,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,1,,,,,8,,5364,F,,Autocuration,CHEMBL618016,BAO_0000019,3831
,,H,,,55,,,Inhibition of Human 5-lipoxygenase,1,,,,,8,,13165,B,,Expert,CHEMBL618017,BAO_0000357,3832
,,H,,,55,,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,1,,,,,8,,5364,B,,Autocuration,CHEMBL618018,BAO_0000019,3833
,,H,,,55,,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],1,,,,,8,,11311,B,,Autocuration,CHEMBL875087,BAO_0000219,3834
,,H,,,55,,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],1,,,,,8,,11311,B,,Autocuration,CHEMBL618019,BAO_0000219,3835
,,H,,,55,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,1,,,,,8,,14863,B,,Autocuration,CHEMBL618020,BAO_0000019,3836
,,H,,,55,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,1,,,,,8,,14863,B,,Autocuration,CHEMBL618021,BAO_0000019,3837
,,H,,,55,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),1,Blood,,,,8,,11087,B,178.0,Autocuration,CHEMBL618022,BAO_0000357,3838
,,H,,,55,,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,1,,,,,8,,455,B,,Autocuration,CHEMBL618023,BAO_0000357,3839
,,H,,,55,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),1,,,,,8,,13183,B,,Autocuration,CHEMBL618024,BAO_0000357,3840
,,H,,,55,,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,1,,,,,8,,10319,B,,Expert,CHEMBL873950,BAO_0000019,3841
,,H,,,55,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,1,,,,,8,,10193,B,,Autocuration,CHEMBL618025,BAO_0000357,3842
,,H,,,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,1,,,,,8,,951,B,,Autocuration,CHEMBL618026,BAO_0000219,3843
,,H,,,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,1,,,,,8,,951,B,,Autocuration,CHEMBL618027,BAO_0000219,3844
,,H,,,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,1,,,,,8,,951,B,,Autocuration,CHEMBL618028,BAO_0000219,3845
,,H,,,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,1,,,,,8,,951,B,,Autocuration,CHEMBL618029,BAO_0000219,3846
,,H,,,55,,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,1,,,,,8,,9859,B,,Expert,CHEMBL618030,BAO_0000357,3847
,,H,,,55,,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,1,,,,,8,,9859,B,,Expert,CHEMBL618031,BAO_0000357,3848
,,H,,,55,,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,1,,,,,8,,9859,B,,Autocuration,CHEMBL618032,BAO_0000357,3849
,,H,,,55,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,1,,,,,8,,2567,B,,Autocuration,CHEMBL618033,BAO_0000357,3850
,,H,,,55,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,1,,,,,8,,10193,B,,Autocuration,CHEMBL618034,BAO_0000357,3851
,,H,,,55,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,1,,,,,8,,10193,B,,Autocuration,CHEMBL875088,BAO_0000357,3852
,,H,,,55,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,1,,,,,8,,949,B,,Autocuration,CHEMBL618035,BAO_0000019,3853
,,H,,,55,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,1,,,,,8,,949,B,,Autocuration,CHEMBL618036,BAO_0000019,3854
,,H,,,55,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,1,,,,,8,,10603,B,,Expert,CHEMBL618037,BAO_0000357,3855
,,H,,,55,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,1,,,,,8,,10603,B,,Expert,CHEMBL618038,BAO_0000357,3856
,,H,,,55,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,1,,,,,8,,10603,F,,Autocuration,CHEMBL618761,BAO_0000019,3857
,,H,,,55,,,Inhibition of lipoxygenase at the concentration of 0.1 uM,1,,,,,8,,10603,B,,Expert,CHEMBL618762,BAO_0000357,3858
,,H,,,55,,,Inhibition of lipoxygenase at the concentration of 1 uM,1,,,,,8,,10603,B,,Expert,CHEMBL618763,BAO_0000357,3859
,,H,,,55,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,1,,,,,8,,10193,B,,Autocuration,CHEMBL618764,BAO_0000357,3860
,,D,,,55,9606.0,Homo sapiens,Inhibition of 5-Lipoxygenase (5-LOX),1,,,,,9,,14580,B,,Expert,CHEMBL618765,BAO_0000357,3861
,,H,,,17087,,,Inhibition of 5-lipoxygenase in mouse macrophages.,1,,,,,8,,11090,B,,Expert,CHEMBL618766,BAO_0000357,3862
,,H,,,17087,,,Inhibition of 5-lipoxygenase in mouse macrophages.,1,,,,,8,,11090,B,,Expert,CHEMBL618767,BAO_0000357,3863
,,H,,,17087,,,Inhibitory activity against lipoxygenase-2 in mice,1,,,,,8,,6339,B,,Autocuration,CHEMBL619380,BAO_0000357,3864
,,H,,,17087,,,Inhibitory activity against murine lipoxygenase-2.,1,,,,,8,,6339,B,,Expert,CHEMBL619381,BAO_0000357,3865
,,D,,,17087,10090.0,Mus musculus,Inhibition of 5-lipoxygenase from mouse macrophage,1,,,,,9,,12281,B,,Expert,CHEMBL619382,BAO_0000357,3866
,,H,,,17087,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,1,,,,,8,,11311,B,,Autocuration,CHEMBL619383,BAO_0000357,3867
,,H,,,55,9823.0,Sus scrofa,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,1,,,,,8,,11089,B,,Autocuration,CHEMBL619384,BAO_0000019,3868
,,H,,,55,9823.0,Sus scrofa,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,1,,,,,8,,10091,B,,Autocuration,CHEMBL619385,BAO_0000019,3869
,,H,,,55,9986.0,Oryctolagus cuniculus,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,1,,,,,8,,14352,B,,Autocuration,CHEMBL882928,BAO_0000019,3870
,,D,,,12166,10116.0,Rattus norvegicus,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,1,,,,,9,,13329,B,,Expert,CHEMBL619386,BAO_0000019,3871
,,H,,,12166,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",1,,,,,8,,13329,B,,Autocuration,CHEMBL619387,BAO_0000019,3872
,,H,,,12166,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",1,,,,,8,,13329,B,,Autocuration,CHEMBL619388,BAO_0000019,3873
,,H,,,12166,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",1,,,,,8,,13329,B,,Autocuration,CHEMBL619389,BAO_0000019,3874
,,H,,,12166,,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),1,,,,,8,,13329,B,,Expert,CHEMBL619390,BAO_0000019,3875
,,H,,,12166,,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",1,,,,,8,,13329,B,,Expert,CHEMBL619391,BAO_0000019,3876
,,H,,,12166,,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,1,,,,,8,,13329,B,,Autocuration,CHEMBL619392,BAO_0000019,3877
,,H,,,12166,,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),1,,,,,8,,11311,B,,Autocuration,CHEMBL619393,BAO_0000019,3878
,,H,,,12166,,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,1,,,,,8,,11311,B,,Autocuration,CHEMBL619394,BAO_0000019,3879
,,H,702.0,,12166,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",1,,RBL-1,,,8,,105,B,,Autocuration,CHEMBL619395,BAO_0000219,3880
,,H,702.0,,12166,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",1,,RBL-1,,,8,,105,B,,Autocuration,CHEMBL619396,BAO_0000219,3881
,,H,,,12166,,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),1,,,,,8,,9138,B,,Autocuration,CHEMBL619397,BAO_0000357,3882
,,H,,,12166,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",1,,,,,8,,9138,B,,Autocuration,CHEMBL619398,BAO_0000357,3883
,,H,,,12166,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",1,,,,,8,,9138,B,,Autocuration,CHEMBL619399,BAO_0000357,3884
,,H,,,12166,,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,1,,,,,8,,14427,B,,Autocuration,CHEMBL619400,BAO_0000357,3885
,,H,,,12166,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",1,,,,,8,,13329,B,,Autocuration,CHEMBL619401,BAO_0000019,3886
,,H,,,12166,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",1,,,,,8,,13329,B,,Autocuration,CHEMBL619402,BAO_0000019,3887
,,D,663.0,,12166,10116.0,Rattus norvegicus,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,1,,RBL-2H3,,,9,,14427,B,,Expert,CHEMBL619403,BAO_0000219,3888
,,H,,,12166,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,1,,,,,8,,14427,B,,Autocuration,CHEMBL619404,BAO_0000357,3889
,,H,,,12166,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,1,,,,,8,,14427,B,,Autocuration,CHEMBL619405,BAO_0000357,3890
,,H,702.0,,12166,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,1,,RBL-1,,,8,,10293,B,,Expert,CHEMBL619406,BAO_0000219,3891
,,D,702.0,,12166,10116.0,Rattus norvegicus,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,1,,RBL-1,,,9,,338,B,,Expert,CHEMBL619407,BAO_0000219,3892
,,H,,,12166,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),1,,,,,8,,303,B,,Autocuration,CHEMBL619408,BAO_0000357,3893
,,H,702.0,,12166,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,1,,RBL-1,,,8,,303,B,,Autocuration,CHEMBL619409,BAO_0000219,3894
,,H,702.0,,12166,,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,1,,RBL-1,,,8,,9247,B,,Expert,CHEMBL619410,BAO_0000219,3895
,,H,702.0,,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,1,,RBL-1,,,8,,9247,B,,Autocuration,CHEMBL619753,BAO_0000219,3896
,,H,702.0,,12166,,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,1,,RBL-1,,,8,,137,B,,Autocuration,CHEMBL619754,BAO_0000219,3897
,,H,,,12166,,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,1,,,,,8,,11481,B,,Expert,CHEMBL619903,BAO_0000357,3898
,,H,,,12166,,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",1,,,,,8,,11481,B,,Expert,CHEMBL619904,BAO_0000357,3899
,,H,,,12166,,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,1,,,,,8,,9029,B,,Expert,CHEMBL619905,BAO_0000357,3900
,,H,,,12166,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,1,,,,,8,,1701,B,,Autocuration,CHEMBL619906,BAO_0000019,3901
,,H,,,12166,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,1,,,,,8,,1701,B,,Autocuration,CHEMBL619907,BAO_0000019,3902
,,H,,,12166,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,1,,,,,8,,1701,B,,Autocuration,CHEMBL619908,BAO_0000019,3903
,,H,,,12166,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,1,,,,,8,,1701,B,,Autocuration,CHEMBL619909,BAO_0000019,3904
,,H,702.0,,12166,,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,1,,RBL-1,,,8,,13358,F,,Expert,CHEMBL619910,BAO_0000219,3905
,,H,702.0,,12166,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,1,,RBL-1,,,8,,1175,B,,Expert,CHEMBL882929,BAO_0000219,3906
,,H,702.0,,12166,,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,1,,RBL-1,,,8,,8797,B,,Expert,CHEMBL619911,BAO_0000219,3907
,,H,,,12166,,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,1,,,,,8,,8797,B,,Autocuration,CHEMBL619912,BAO_0000019,3908
,,D,,,12166,10116.0,Rattus norvegicus,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,1,,,,,9,,577,B,,Expert,CHEMBL619913,BAO_0000357,3909
,,H,702.0,,12166,,,In vitro inhibitory activity against RBL-1 5-LO,1,,RBL-1,,,8,,9295,B,,Expert,CHEMBL619914,BAO_0000219,3910
,,H,702.0,,12166,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),1,,RBL-1,,,8,,9295,B,,Autocuration,CHEMBL619915,BAO_0000219,3911
,,H,702.0,,12166,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),1,,RBL-1,,,8,,9295,B,,Autocuration,CHEMBL619916,BAO_0000219,3912
,,H,,,12166,,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,1,,,,,8,,9295,B,,Autocuration,CHEMBL619917,BAO_0000218,3913
,,H,,,12166,,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,1,,,,,8,,9295,B,,Autocuration,CHEMBL619918,BAO_0000357,3914
,,H,,,12166,,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,1,,,,,8,,216,B,,Autocuration,CHEMBL619919,BAO_0000218,3915
,,H,702.0,,12166,,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,1,,RBL-1,,,8,,11090,B,,Autocuration,CHEMBL883710,BAO_0000219,3916
,,H,,,12166,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,1,Blood,,,,8,,11090,B,178.0,Autocuration,CHEMBL619920,BAO_0000019,3917
,,H,,,12166,,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,1,,,,,8,,10091,B,,Expert,CHEMBL619921,BAO_0000357,3918
,,H,,,12166,,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,1,,,,,8,,10274,F,,Autocuration,CHEMBL619922,BAO_0000019,3919
,,H,,,12166,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,1,,,,,8,,13622,F,,Autocuration,CHEMBL619923,BAO_0000219,3920
,,H,702.0,,12166,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,1,,RBL-1,,,8,,12118,B,,Expert,CHEMBL619924,BAO_0000219,3921
,,H,,,12166,,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,1,,,,,8,,12576,B,,Expert,CHEMBL619925,BAO_0000357,3922
,,H,702.0,,12166,,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,1,,RBL-1,,,8,,9546,B,,Expert,CHEMBL619926,BAO_0000219,3923
,,H,702.0,,12166,,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,1,,RBL-1,,,8,,9521,B,,Autocuration,CHEMBL619927,BAO_0000219,3924
,,H,702.0,,12166,,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,1,,RBL-1,,,8,,10626,B,,Expert,CHEMBL619928,BAO_0000219,3925
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL619929,BAO_0000219,3926
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL875089,BAO_0000219,3927
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL619930,BAO_0000219,3928
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL619931,BAO_0000219,3929
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL619932,BAO_0000219,3930
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL619933,BAO_0000219,3931
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL619934,BAO_0000219,3932
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL619935,BAO_0000219,3933
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL619936,BAO_0000219,3934
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL619937,BAO_0000219,3935
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL619938,BAO_0000219,3936
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL619939,BAO_0000219,3937
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL619940,BAO_0000219,3938
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL875090,BAO_0000219,3939
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL619941,BAO_0000219,3940
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL619942,BAO_0000219,3941
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL883711,BAO_0000219,3942
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL619943,BAO_0000219,3943
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL619944,BAO_0000219,3944
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL619945,BAO_0000219,3945
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL619946,BAO_0000219,3946
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL619947,BAO_0000219,3947
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL619948,BAO_0000219,3948
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL619949,BAO_0000219,3949
,,H,,,12166,,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,1,,,,,8,,9401,B,,Expert,CHEMBL619950,BAO_0000019,3950
,,H,,,12166,,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,1,,,,,8,,10325,B,,Autocuration,CHEMBL618050,BAO_0000019,3951
,,H,663.0,,12166,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,1,,RBL-2H3,,,8,,1556,F,,Expert,CHEMBL875091,BAO_0000219,3952
,,H,663.0,,12166,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,1,,RBL-2H3,,,8,,1556,F,,Expert,CHEMBL618051,BAO_0000219,3953
,,D,702.0,,12166,10116.0,Rattus norvegicus,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,1,,RBL-1,,,9,,961,B,,Expert,CHEMBL618052,BAO_0000219,3954
,,H,,,12166,,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,1,,,,,8,,6838,B,,Autocuration,CHEMBL618053,BAO_0000019,3955
,,H,,,12166,,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),1,,,,,8,,10325,B,,Expert,CHEMBL618054,BAO_0000019,3956
,,D,702.0,,12166,10116.0,Rattus norvegicus,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,1,,RBL-1,,,9,,9209,B,,Expert,CHEMBL618055,BAO_0000219,3957
,,H,702.0,,12166,,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,1,,RBL-1,,,8,,11520,B,,Expert,CHEMBL618056,BAO_0000219,3958
,,H,,,12166,,,In vitro inhibitory activity against 5-lipoxygenase was determined,1,,,,,8,,137,B,,Autocuration,CHEMBL618057,BAO_0000357,3959
,,H,702.0,,12166,,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,1,,RBL-1,,,8,,4717,B,,Autocuration,CHEMBL618058,BAO_0000219,3960
,,H,702.0,,12166,,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,1,,RBL-1,,,8,,10636,B,,Expert,CHEMBL618059,BAO_0000219,3961
,,D,,,12166,10116.0,Rattus norvegicus,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,1,,,,,9,,14312,F,,Expert,CHEMBL618060,BAO_0000019,3962
,,H,702.0,,12166,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,1,,RBL-1,,,8,,1203,B,,Autocuration,CHEMBL618061,BAO_0000219,3963
,,H,,,12166,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,1,,,,,8,,1203,B,,Autocuration,CHEMBL618062,BAO_0000019,3964
,,H,702.0,,12166,,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,1,,RBL-1,,,8,,13622,B,,Expert,CHEMBL618063,BAO_0000219,3965
,,H,,,12166,,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,1,,,,,8,,9793,B,,Autocuration,CHEMBL618064,BAO_0000357,3966
,,D,702.0,,12166,10116.0,Rattus norvegicus,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,1,,RBL-1,,,9,,1143,B,,Expert,CHEMBL618065,BAO_0000219,3967
,,D,702.0,,12166,10116.0,Rattus norvegicus,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,1,,RBL-1,,,9,,11854,B,,Expert,CHEMBL618066,BAO_0000219,3968
,,H,702.0,,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),1,,RBL-1,,,8,,3595,B,,Autocuration,CHEMBL618067,BAO_0000219,3969
,,H,702.0,,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),1,,RBL-1,,,8,,3595,B,,Autocuration,CHEMBL618068,BAO_0000219,3970
,,D,702.0,,12166,10116.0,Rattus norvegicus,Inhibition of 5-lipoxygenase in rat RBL-1 cells,1,,RBL-1,,,9,,10501,B,,Expert,CHEMBL618069,BAO_0000219,3971
,,H,702.0,,12166,,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,1,,RBL-1,,,8,,12526,B,,Expert,CHEMBL618070,BAO_0000219,3972
,,H,,,10825,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,1,Limbic system,,,,8,,10034,F,349.0,Autocuration,CHEMBL618071,BAO_0000019,3973
,,H,,,10825,,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,1,Limbic system,,,,8,,10034,F,349.0,Autocuration,CHEMBL619247,BAO_0000019,3974
,,H,,,10825,,,Approximate dose levels for a half maximal reduction of 5-HTP levels,1,,,,,8,,10034,F,,Autocuration,CHEMBL619248,BAO_0000019,3975
,,H,,,10576,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,1,Hippocampus,,,,8,,10046,B,10000000.0,Autocuration,CHEMBL619249,BAO_0000221,3976
,,H,,,10576,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,1,Hippocampus,,,,8,,10046,B,10000000.0,Autocuration,CHEMBL619250,BAO_0000221,3977
,,H,,,10577,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,1,,,,,8,,10046,B,,Autocuration,CHEMBL619251,BAO_0000019,3978
,,H,,,55,9615.0,Canis lupus familiaris,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,1,Blood,,,,8,,12079,F,178.0,Autocuration,CHEMBL619252,BAO_0000019,3979
,,H,,,55,,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,1,Blood,,,,8,,12079,F,178.0,Autocuration,CHEMBL619253,BAO_0000019,3980
,,H,,,12166,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],1,,,,,8,,11311,B,,Autocuration,CHEMBL619254,BAO_0000219,3981
,,H,,,17140,,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,1,,,,,8,,12338,B,,Expert,CHEMBL619255,BAO_0000219,3982
,,H,,,17140,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,1,,,,,8,,12143,B,,Expert,CHEMBL619256,BAO_0000219,3983
,,H,,,17140,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),1,,,,,8,,12143,B,,Autocuration,CHEMBL875418,BAO_0000219,3984
,,H,,,17140,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,1,,,,,8,,12143,B,,Expert,CHEMBL619257,BAO_0000219,3985
,,H,,,17140,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,1,,,,,8,,12143,B,,Autocuration,CHEMBL619258,BAO_0000219,3986
,,H,,,17140,,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,1,,,,,8,,12365,B,,Expert,CHEMBL619259,BAO_0000357,3987
,,H,,,17140,,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,1,,,,,8,,13500,B,,Expert,CHEMBL619260,BAO_0000357,3988
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL619261,BAO_0000218,3989
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL619263,BAO_0000218,3990
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL619264,BAO_0000218,3991
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL619265,BAO_0000218,3992
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL619266,BAO_0000218,3993
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL619902,BAO_0000218,3994
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620058,BAO_0000218,3995
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620059,BAO_0000218,3996
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620060,BAO_0000218,3997
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620061,BAO_0000218,3998
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620062,BAO_0000218,3999
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620063,BAO_0000218,4000
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620064,BAO_0000218,4001
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620065,BAO_0000218,4002
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620066,BAO_0000218,4003
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620067,BAO_0000218,4004
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620068,BAO_0000218,4005
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620069,BAO_0000218,4006
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620070,BAO_0000218,4007
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620071,BAO_0000218,4008
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620072,BAO_0000218,4009
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620036,BAO_0000218,4010
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL857702,BAO_0000218,4011
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620037,BAO_0000218,4012
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620038,BAO_0000218,4013
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620039,BAO_0000218,4014
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620040,BAO_0000218,4015
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620041,BAO_0000218,4016
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620042,BAO_0000218,4017
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620043,BAO_0000218,4018
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620044,BAO_0000218,4019
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620045,BAO_0000218,4020
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620046,BAO_0000218,4021
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620047,BAO_0000218,4022
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620048,BAO_0000218,4023
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL857703,BAO_0000218,4024
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620049,BAO_0000218,4025
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620050,BAO_0000218,4026
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL620051,BAO_0000218,4027
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL619213,BAO_0000218,4028
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL619214,BAO_0000218,4029
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL619804,BAO_0000218,4030
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL619805,BAO_0000218,4031
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL619806,BAO_0000218,4032
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL619807,BAO_0000218,4033
,,H,,,55,9615.0,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,In vivo,8,,12832,F,178.0,Autocuration,CHEMBL619808,BAO_0000218,4034
,,H,,,55,9615.0,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,1,,,,,8,,3595,B,,Autocuration,CHEMBL619809,BAO_0000218,4035
,,H,,,55,9615.0,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,1,,,,,8,,3595,B,,Autocuration,CHEMBL619810,BAO_0000218,4036
,,H,,,55,9615.0,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,1,,,,,8,,3595,B,,Autocuration,CHEMBL619811,BAO_0000218,4037
,,H,,,55,9615.0,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,1,,,,,8,,3595,B,,Autocuration,CHEMBL620769,BAO_0000218,4038
,,H,,,55,9615.0,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,1,,,,,8,,3595,B,,Autocuration,CHEMBL620770,BAO_0000218,4039
,,H,,,55,9615.0,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,1,,,,,8,,3595,B,,Autocuration,CHEMBL620771,BAO_0000218,4040
,,H,,,55,9615.0,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,1,,,,,8,,3595,B,,Autocuration,CHEMBL620772,BAO_0000218,4041
,,H,,,55,9615.0,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,1,,,,,8,,3595,B,,Autocuration,CHEMBL620773,BAO_0000218,4042
,,H,,,55,10141.0,Cavia porcellus,Ability to inhibit 5-lipoxygenase in guinea pig,1,,,,,8,,9203,B,,Autocuration,CHEMBL620774,BAO_0000357,4043
,,H,,,55,10141.0,Cavia porcellus,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),1,,,,,8,,82,B,,Expert,CHEMBL620775,BAO_0000357,4044
,,H,,,55,10141.0,Cavia porcellus,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,1,,,,,8,,11090,B,,Autocuration,CHEMBL620776,BAO_0000357,4045
,,H,,,55,10141.0,Cavia porcellus,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",1,Blood,,,,8,,12832,B,178.0,Autocuration,CHEMBL620777,BAO_0000218,4046
,,H,,,55,10141.0,Cavia porcellus,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,1,,,,,8,,1065,B,,Autocuration,CHEMBL620778,BAO_0000357,4047
,,H,,,55,10141.0,Cavia porcellus,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,1,,,,,8,,1065,B,,Autocuration,CHEMBL620779,BAO_0000357,4048
,,H,,,55,10141.0,Cavia porcellus,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,1,,,,,8,,12832,B,,Expert,CHEMBL621500,BAO_0000019,4049
,,H,,,55,10141.0,Cavia porcellus,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,1,,,,,8,,12832,B,,Expert,CHEMBL621501,BAO_0000019,4050
,,H,,,55,10141.0,Cavia porcellus,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,1,,,,,8,,12832,B,,Autocuration,CHEMBL618098,BAO_0000019,4051
,,H,,,55,10141.0,Cavia porcellus,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,1,,,,,8,,10504,B,,Autocuration,CHEMBL618099,BAO_0000019,4052
,,H,,,55,10141.0,Cavia porcellus,Inhibitory activity against 5-lipoxygenase,1,,,,,8,,7788,B,,Autocuration,CHEMBL618100,BAO_0000357,4053
,,H,,,55,10141.0,Cavia porcellus,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,1,,,,,8,,10001,B,,Autocuration,CHEMBL618101,BAO_0000357,4054
,,H,,,55,10141.0,Cavia porcellus,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,1,,,,,8,,10193,B,,Autocuration,CHEMBL618102,BAO_0000357,4055
,,H,,,55,10141.0,Cavia porcellus,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,1,,,,,8,,13243,B,,Autocuration,CHEMBL618103,BAO_0000357,4056
,,H,,,55,10141.0,Cavia porcellus,Inhibitory activity uM,1,,,,,8,,13243,B,,Autocuration,CHEMBL618104,BAO_0000357,4057
,,H,,,55,10141.0,Cavia porcellus,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,1,,,,,8,,969,B,,Autocuration,CHEMBL883712,BAO_0000219,4058
,,H,,,55,10141.0,Cavia porcellus,Inhibitory activity against 5-lipoxygenase at 10 uM,1,,,,,8,,10001,B,,Autocuration,CHEMBL618105,BAO_0000357,4059
,,H,,,55,10141.0,Cavia porcellus,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,1,,,,,8,,7788,B,,Autocuration,CHEMBL618106,BAO_0000357,4060
,,H,,,55,10141.0,Cavia porcellus,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,1,,,,,8,,10001,B,,Autocuration,CHEMBL618107,BAO_0000357,4061
,,H,,,55,10141.0,Cavia porcellus,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,1,,,,,8,,10193,B,,Autocuration,CHEMBL618108,BAO_0000357,4062
,,H,,,55,10141.0,Cavia porcellus,Inhibitory activity uM,1,,,,,8,,13243,B,,Autocuration,CHEMBL618109,BAO_0000357,4063
,,H,,,55,10141.0,Cavia porcellus,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,1,,,,,8,,13243,B,,Autocuration,CHEMBL618110,BAO_0000357,4064
,,H,,,55,10141.0,Cavia porcellus,Inhibitory activity uM,1,,,,,8,,13243,B,,Expert,CHEMBL618111,BAO_0000357,4065
,,H,,,55,10141.0,Cavia porcellus,Inhibitory activity uM,1,,,,,8,,13243,F,,Autocuration,CHEMBL618112,BAO_0000019,4066
,,H,,,55,10141.0,Cavia porcellus,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,1,,,,,8,,10504,B,,Autocuration,CHEMBL618113,BAO_0000019,4067
,,H,,,55,10141.0,Cavia porcellus,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,1,,,,,8,,7788,B,,Autocuration,CHEMBL618114,BAO_0000357,4068
,,H,,,55,10141.0,Cavia porcellus,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,1,Ileum,,,,8,,10546,F,2116.0,Expert,CHEMBL620871,BAO_0000221,4069
,,H,,,55,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),1,,,,,8,,13183,B,,Autocuration,CHEMBL620872,BAO_0000357,4070
,,H,,,55,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),1,,,,,8,,13183,B,,Autocuration,CHEMBL620873,BAO_0000357,4071
,,H,,,55,,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),1,,,,,8,,2578,B,,Autocuration,CHEMBL620874,BAO_0000357,4072
,,H,,,55,,,In vitro inhibition of human 5-Lipoxygenase.,1,,,,,8,,12780,B,,Expert,CHEMBL620875,BAO_0000357,4073
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL620876,BAO_0000251,4074
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL620877,BAO_0000251,4075
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL857854,BAO_0000251,4076
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL620878,BAO_0000251,4077
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL620879,BAO_0000251,4078
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL620880,BAO_0000251,4079
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL620881,BAO_0000251,4080
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL620882,BAO_0000251,4081
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL620883,BAO_0000251,4082
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL620884,BAO_0000251,4083
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL620885,BAO_0000251,4084
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL620886,BAO_0000251,4085
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL620887,BAO_0000251,4086
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618039,BAO_0000251,4087
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618040,BAO_0000251,4088
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618041,BAO_0000251,4089
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618216,BAO_0000251,4090
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618217,BAO_0000251,4091
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618218,BAO_0000251,4092
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618219,BAO_0000251,4093
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618220,BAO_0000251,4094
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618221,BAO_0000251,4095
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618222,BAO_0000251,4096
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618223,BAO_0000251,4097
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618224,BAO_0000251,4098
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618225,BAO_0000251,4099
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618226,BAO_0000251,4100
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618227,BAO_0000251,4101
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618228,BAO_0000251,4102
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618229,BAO_0000251,4103
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618230,BAO_0000251,4104
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618231,BAO_0000251,4105
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618232,BAO_0000251,4106
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618233,BAO_0000251,4107
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618234,BAO_0000251,4108
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618235,BAO_0000251,4109
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618115,BAO_0000251,4110
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618116,BAO_0000251,4111
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL618117,BAO_0000251,4112
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL619968,BAO_0000251,4113
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL619969,BAO_0000251,4114
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL619970,BAO_0000251,4115
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL619971,BAO_0000251,4116
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL619972,BAO_0000251,4117
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL619973,BAO_0000251,4118
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL619974,BAO_0000251,4119
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL619975,BAO_0000251,4120
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,1,,,,,0,,7411,B,,Autocuration,CHEMBL619976,BAO_0000251,4121
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL619977,BAO_0000251,4122
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL619978,BAO_0000251,4123
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL619979,BAO_0000251,4124
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL619980,BAO_0000251,4125
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL619981,BAO_0000251,4126
,,N,741.0,,80433,9606.0,Homo sapiens,In vitro inhibition of 7226/S myeloma cancer cell line,1,,RPMI-8226,,,1,,10797,F,,Intermediate,CHEMBL619982,BAO_0000219,4127
,,N,993.0,,80698,9606.0,Homo sapiens,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),1,,BEL-7404 tumor cell line,,,1,,6881,F,,Intermediate,CHEMBL619983,BAO_0000219,4128
,,N,391.0,,80640,9606.0,Homo sapiens,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,1,,786-0,,,1,,3838,F,,Intermediate,CHEMBL620031,BAO_0000219,4129
,,N,391.0,,80640,9606.0,Homo sapiens,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,1,,786-0,,,1,,3838,F,,Intermediate,CHEMBL620032,BAO_0000219,4130
,,N,505.0,,81264,10029.0,Cricetulus griseus,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,1,,V79,,,1,,12981,F,,Expert,CHEMBL620033,BAO_0000219,4131
,,N,505.0,,81264,10029.0,Cricetulus griseus,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,1,,V79,,,1,,12981,F,,Expert,CHEMBL620034,BAO_0000219,4132
,,N,1119.0,,80635,10116.0,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,1,,7800C1 cell line,,,1,,7653,F,,Intermediate,CHEMBL620035,BAO_0000219,4133
,,N,1119.0,,80635,10116.0,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,1,,7800C1 cell line,,,1,,7653,F,,Intermediate,CHEMBL618318,BAO_0000219,4134
,,N,1119.0,,80635,10116.0,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,1,,7800C1 cell line,,,1,,7653,F,,Intermediate,CHEMBL618319,BAO_0000219,4135
,,N,1119.0,,80635,10116.0,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,1,,7800C1 cell line,,,1,,7653,F,,Intermediate,CHEMBL618320,BAO_0000219,4136
,,N,1119.0,,80635,10116.0,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,1,,7800C1 cell line,,,1,,7653,F,,Intermediate,CHEMBL618321,BAO_0000219,4137
,,N,1119.0,,80635,10116.0,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,1,,7800C1 cell line,,,1,,7653,F,,Intermediate,CHEMBL883118,BAO_0000219,4138
,,N,391.0,,80640,9606.0,Homo sapiens,In vitro antitumor activity against renal 786-0 tumor cell lines,1,,786-0,,,1,,17229,F,,Intermediate,CHEMBL883795,BAO_0000219,4139
,,N,391.0,,80640,9606.0,Homo sapiens,Cytotoxic activity against 786-0 Renal cancer cell line,1,,786-0,,,1,,12858,F,,Intermediate,CHEMBL618322,BAO_0000219,4140
,,N,391.0,,80640,9606.0,Homo sapiens,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,1,,786-0,,,1,,16325,F,,Intermediate,CHEMBL618323,BAO_0000219,4141
,,N,391.0,,80640,9606.0,Homo sapiens,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,1,,786-0,,,1,,16325,F,,Intermediate,CHEMBL618324,BAO_0000219,4142
,,N,391.0,,80640,9606.0,Homo sapiens,In vitro antitumor activity against human renal 786-0 cell line,1,,786-0,,,1,,5858,F,,Intermediate,CHEMBL618325,BAO_0000219,4143
,,N,391.0,,80640,9606.0,Homo sapiens,Inhibition of Renal cancer in 786-0 cancer cell lines,1,,786-0,,,1,,16325,F,,Intermediate,CHEMBL875416,BAO_0000219,4144
,,N,391.0,,80640,9606.0,Homo sapiens,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,1,,786-0,,,1,,14696,F,,Intermediate,CHEMBL618326,BAO_0000219,4145
,,N,391.0,,80640,9606.0,Homo sapiens,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,1,,786-0,,,1,,3786,F,,Intermediate,CHEMBL618327,BAO_0000219,4146
,,N,391.0,,80640,9606.0,Homo sapiens,inhibition of the growth of renal cancer(786-0) cell line,1,,786-0,,,1,,14696,F,,Intermediate,CHEMBL619215,BAO_0000219,4147
,,N,391.0,,80640,9606.0,Homo sapiens,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),1,,786-0,,,1,,14769,F,,Intermediate,CHEMBL619216,BAO_0000219,4148
,,N,391.0,,80640,9606.0,Homo sapiens,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,1,,786-0,,,1,,15354,F,,Intermediate,CHEMBL619217,BAO_0000219,4149
,,N,391.0,,80640,9606.0,Homo sapiens,The IC50 value was measured on 786-0 cell line in ovarian tumor,1,,786-0,,,1,,14255,F,,Intermediate,CHEMBL619218,BAO_0000219,4150
,,N,391.0,,80640,9606.0,Homo sapiens,The IC50 value was measured on 786-0 cell line in ovarian tumor t,1,,786-0,,,1,,14255,F,,Intermediate,CHEMBL619219,BAO_0000219,4151
,,N,391.0,,80640,9606.0,Homo sapiens,The IC50 value was measured on 786-0 cell line in renal tumor type.,1,,786-0,,,1,,14255,F,,Intermediate,CHEMBL619220,BAO_0000219,4152
,,N,391.0,,80640,9606.0,Homo sapiens,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,1,,786-0,,,1,,14696,F,,Intermediate,CHEMBL619221,BAO_0000219,4153
,,N,391.0,,80640,9606.0,Homo sapiens,Tested for cytotoxic activity against renal cancer 786-0 cell line,1,,786-0,,,1,,12016,F,,Intermediate,CHEMBL619222,BAO_0000219,4154
,,N,391.0,,80640,9606.0,Homo sapiens,Compound was tested for growth inhibitory activity against 786-0 cell line,1,,786-0,,,1,,2597,F,,Intermediate,CHEMBL857454,BAO_0000219,4155
,,H,702.0,,12166,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,1,,RBL-1,,,8,,12526,B,,Autocuration,CHEMBL619223,BAO_0000219,4156
,,H,702.0,,12166,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,1,,RBL-1,,,8,,12526,B,,Autocuration,CHEMBL619224,BAO_0000219,4157
,,H,,,12166,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,1,,,,,8,,14799,B,,Autocuration,CHEMBL619225,BAO_0000019,4158
,,H,702.0,,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),1,,RBL-1,,,8,,3595,B,,Expert,CHEMBL619226,BAO_0000219,4159
,,H,702.0,,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),1,,RBL-1,,,8,,3595,B,,Expert,CHEMBL619227,BAO_0000219,4160
,,H,,,12166,,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,1,,,,,8,,12767,B,,Autocuration,CHEMBL619228,BAO_0000357,4161
,,H,,,12166,,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,1,,,,,8,,10997,B,,Autocuration,CHEMBL619229,BAO_0000219,4162
,,H,702.0,,12166,,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,1,,RBL-1,,,8,,11388,B,,Autocuration,CHEMBL619230,BAO_0000219,4163
,,H,,,12166,,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,1,,,,,8,,167,B,,Autocuration,CHEMBL619231,BAO_0000357,4164
,,H,,,12166,,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",1,,,,,8,,167,B,,Autocuration,CHEMBL619232,BAO_0000357,4165
,,H,,,12166,,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,1,,,,,8,,13744,B,,Expert,CHEMBL619233,BAO_0000357,4166
,,H,,,12166,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,1,,,,,8,,1630,B,,Autocuration,CHEMBL619234,BAO_0000357,4167
,,H,,,12166,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),1,,,,,8,,1630,B,,Autocuration,CHEMBL619235,BAO_0000357,4168
,,D,,,12166,10116.0,Rattus norvegicus,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",1,,,,,9,,969,B,,Expert,CHEMBL619236,BAO_0000019,4169
,,H,702.0,,12166,,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,1,,RBL-1,,,8,,13621,B,,Autocuration,CHEMBL619237,BAO_0000219,4170
,,H,,,12166,,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,1,,,,,8,,10089,B,,Autocuration,CHEMBL619238,BAO_0000357,4171
,,H,,,12166,,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,1,,,,,8,,10193,B,,Expert,CHEMBL619239,BAO_0000357,4172
,,H,,,12166,,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,1,,,,,8,,11966,B,,Autocuration,CHEMBL619240,BAO_0000357,4173
,,H,,,12166,,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,1,,,,,8,,12251,B,,Autocuration,CHEMBL875417,BAO_0000019,4174
,,H,702.0,,12166,,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),1,,RBL-1,,,8,,211,B,,Autocuration,CHEMBL619241,BAO_0000219,4175
,,H,,,12166,,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,1,,,,,8,,12251,F,,Expert,CHEMBL619242,BAO_0000019,4176
,,H,702.0,,12166,,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,1,,RBL-1,,,8,,12495,B,,Autocuration,CHEMBL883796,BAO_0000219,4177
,,H,,,12166,,,Tested for its inhibitory activity against 5-lipoxygenase,1,,,,,8,,414,B,,Autocuration,CHEMBL619243,BAO_0000357,4178
,,H,,,12166,,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,1,,,,,8,,414,B,,Autocuration,CHEMBL619244,BAO_0000357,4179
,,H,,,12166,,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",1,,,,,8,,10325,B,,Expert,CHEMBL619245,BAO_0000019,4180
,,H,,,12166,,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,1,,,,,8,,11966,B,,Expert,CHEMBL619246,BAO_0000019,4181
,,H,702.0,,12166,,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,1,,RBL-1,,,8,,165,B,,Expert,CHEMBL619984,BAO_0000219,4182
,,H,702.0,,12166,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,1,,RBL-1,,,8,,165,B,,Autocuration,CHEMBL619985,BAO_0000219,4183
,,H,702.0,,12166,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,1,,RBL-1,,,8,,165,B,,Autocuration,CHEMBL619986,BAO_0000219,4184
,,H,702.0,,12166,,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,1,,RBL-1,,,8,,165,B,,Expert,CHEMBL619987,BAO_0000219,4185
,,H,,,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,1,,,,,8,,11311,B,,Autocuration,CHEMBL619988,BAO_0000218,4186
,,H,702.0,,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,1,,RBL-1,,,8,,11311,B,,Autocuration,CHEMBL619989,BAO_0000219,4187
,,H,702.0,,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,1,,RBL-1,,,8,,11311,B,,Autocuration,CHEMBL619990,BAO_0000219,4188
,,H,,,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],1,,,,,8,,11311,B,,Autocuration,CHEMBL619991,BAO_0000219,4189
,,H,,,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),1,,,,,8,,11311,B,,Autocuration,CHEMBL619992,BAO_0000219,4190
,,H,,,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),1,,,,In vivo,8,,11311,B,,Autocuration,CHEMBL619993,BAO_0000218,4191
,,H,663.0,,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,1,,RBL-2H3,,,8,,11311,F,,Autocuration,CHEMBL619994,BAO_0000219,4192
,,H,663.0,,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,1,,RBL-2H3,,,8,,11311,F,,Autocuration,CHEMBL619995,BAO_0000219,4193
,,H,,,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],1,,,,,8,,11311,B,,Autocuration,CHEMBL619996,BAO_0000019,4194
,,H,,,12166,,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,1,,,,,8,,11732,B,,Autocuration,CHEMBL619997,BAO_0000019,4195
,,H,,,12166,,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,1,,,,,8,,11732,B,,Expert,CHEMBL619998,BAO_0000019,4196
,,H,,,12166,,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,1,,,,,8,,11087,B,,Expert,CHEMBL619999,BAO_0000019,4197
,,H,,,12166,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,1,,,,,8,,11087,B,,Autocuration,CHEMBL620000,BAO_0000019,4198
,,H,702.0,,12166,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,1,,RBL-1,,,8,,11087,B,,Autocuration,CHEMBL620001,BAO_0000219,4199
,,D,,,12166,10116.0,Rattus norvegicus,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,1,,,,,9,,11087,B,,Expert,CHEMBL620002,BAO_0000357,4200
,,H,702.0,,12166,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,1,,RBL-1,,,8,,496,B,,Autocuration,CHEMBL620003,BAO_0000219,4201
,,H,702.0,,12166,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,1,,RBL-1,,,8,,13986,F,,Expert,CHEMBL620004,BAO_0000219,4202
,,H,,,12166,,,Compound was evaluated for the inhibition of 5-lipoxygenase,1,,,,,8,,11520,B,,Autocuration,CHEMBL874063,BAO_0000357,4203
,,H,702.0,,12166,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,1,,RBL-1,,,8,,10293,B,,Autocuration,CHEMBL620005,BAO_0000219,4204
,,H,702.0,,12166,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,1,,RBL-1,,,8,,303,B,,Autocuration,CHEMBL620006,BAO_0000219,4205
,,H,702.0,,12166,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,1,,RBL-1,,,8,,303,B,,Autocuration,CHEMBL620007,BAO_0000219,4206
,,H,702.0,,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,1,,RBL-1,,,8,,9247,B,,Autocuration,CHEMBL620008,BAO_0000219,4207
,,D,702.0,,12166,10116.0,Rattus norvegicus,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,1,,RBL-1,,,9,,9247,B,,Expert,CHEMBL620009,BAO_0000219,4208
,,H,702.0,,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,1,,RBL-1,,,8,,9247,B,,Autocuration,CHEMBL620010,BAO_0000219,4209
,,H,702.0,,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,1,,RBL-1,,,8,,9247,B,,Autocuration,CHEMBL620011,BAO_0000219,4210
,,H,702.0,,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,1,,RBL-1,,,8,,9247,B,,Autocuration,CHEMBL620677,BAO_0000219,4211
,,H,702.0,,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,1,,RBL-1,,,8,,9247,B,,Autocuration,CHEMBL620678,BAO_0000219,4212
,,H,702.0,,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,1,,RBL-1,,,8,,9247,B,,Autocuration,CHEMBL620679,BAO_0000219,4213
,,H,702.0,,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,1,,RBL-1,,,8,,9247,B,,Autocuration,CHEMBL620680,BAO_0000219,4214
,,D,,,12166,10116.0,Rattus norvegicus,Inhibitory activity against 5-lipoxygenase at 10 uM,1,,,,,9,,11481,B,,Expert,CHEMBL620838,BAO_0000357,4215
,,H,,,12166,,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,1,,,,,8,,105,B,,Autocuration,CHEMBL620839,BAO_0000357,4216
,,H,,,12166,,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,1,,,,,8,,9029,B,,Expert,CHEMBL620840,BAO_0000357,4217
,,H,702.0,,12166,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,1,,RBL-1,,,8,,1175,B,,Expert,CHEMBL620841,BAO_0000219,4218
,,H,702.0,,12166,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,1,,RBL-1,,,8,,12118,B,,Autocuration,CHEMBL620842,BAO_0000219,4219
,,H,702.0,,12166,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,1,,RBL-1,,,8,,12118,B,,Autocuration,CHEMBL620843,BAO_0000219,4220
,,H,702.0,,12166,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,1,,RBL-1,,,8,,12118,B,,Autocuration,CHEMBL620844,BAO_0000219,4221
,,H,702.0,,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,1,,RBL-1,,,8,,9225,B,,Autocuration,CHEMBL620845,BAO_0000219,4222
,,H,,,12166,,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,1,,,,,8,,9401,B,,Autocuration,CHEMBL620846,BAO_0000019,4223
,,H,,,12166,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,1,,,,,8,,137,B,,Autocuration,CHEMBL873951,BAO_0000357,4224
,,H,,,12166,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,1,,,,,8,,137,B,,Autocuration,CHEMBL620847,BAO_0000357,4225
,,H,702.0,,12166,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,1,,RBL-1,,,8,,4717,B,,Autocuration,CHEMBL620848,BAO_0000219,4226
,,H,702.0,,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,1,,RBL-1,,,8,,3595,B,,Autocuration,CHEMBL620849,BAO_0000219,4227
,,H,702.0,,12166,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,1,,RBL-1,,,8,,10501,B,,Autocuration,CHEMBL620850,BAO_0000219,4228
,,H,702.0,,12166,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,1,,RBL-1,,,8,,10501,B,,Autocuration,CHEMBL620851,BAO_0000219,4229
,,H,702.0,,12166,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,1,,RBL-1,,,8,,10501,B,,Autocuration,CHEMBL620852,BAO_0000219,4230
,,H,702.0,,12166,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,1,,RBL-1,,,8,,12526,B,,Autocuration,CHEMBL875098,BAO_0000219,4231
,,D,702.0,,12166,10116.0,Rattus norvegicus,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,1,,RBL-1,,,9,,14799,B,,Expert,CHEMBL620853,BAO_0000219,4232
,,H,,,12166,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,1,,,,,8,,14799,B,,Autocuration,CHEMBL620854,BAO_0000019,4233
,,H,702.0,,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,1,,RBL-1,,,8,,3595,B,,Autocuration,CHEMBL620855,BAO_0000219,4234
,,H,702.0,,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,1,,RBL-1,,,8,,3595,B,,Expert,CHEMBL839884,BAO_0000219,4235
,,H,702.0,,12166,,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,1,,RBL-1,,,8,,12526,B,,Autocuration,CHEMBL620856,BAO_0000219,4236
,,H,702.0,,12166,,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,1,,RBL-1,,,8,,12526,B,,Autocuration,CHEMBL620857,BAO_0000219,4237
,,H,,,12166,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,1,,,,,8,,10193,B,,Autocuration,CHEMBL620858,BAO_0000019,4238
,,H,,,12166,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,1,,,,,8,,10193,B,,Autocuration,CHEMBL620859,BAO_0000019,4239
,,H,,,12166,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,1,,,,,8,,10193,B,,Autocuration,CHEMBL620860,BAO_0000019,4240
,,H,,,12166,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,1,,,,,8,,10193,B,,Autocuration,CHEMBL620861,BAO_0000019,4241
,,H,,,12166,,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),1,,,,,8,,9138,B,,Expert,CHEMBL620862,BAO_0000357,4242
,,H,,,12166,,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,1,,,,,8,,9138,B,,Autocuration,CHEMBL620863,BAO_0000357,4243
,,H,,,12166,,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,1,,,,,8,,11966,B,,Autocuration,CHEMBL620864,BAO_0000019,4244
,,H,702.0,,12166,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,1,,RBL-1,,,8,,165,B,,Autocuration,CHEMBL620865,BAO_0000219,4245
,,H,702.0,,12166,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,1,,RBL-1,,,8,,165,B,,Autocuration,CHEMBL620866,BAO_0000219,4246
,,H,663.0,,12166,,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,1,,RBL-2H3,,,8,,11311,B,,Autocuration,CHEMBL620867,BAO_0000219,4247
,,H,663.0,,12166,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,1,,RBL-2H3,,,8,,11311,B,,Autocuration,CHEMBL620868,BAO_0000219,4248
,,H,663.0,,12166,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,1,,RBL-2H3,,,8,,11311,F,,Autocuration,CHEMBL620869,BAO_0000219,4249
,,H,,,12166,,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,1,,,,,8,,11311,F,,Autocuration,CHEMBL873952,BAO_0000019,4250
,,H,,,12166,,,The compound was tested for inhibition of isolated 5-lipoxygenase,1,,,,,8,,11311,B,,Autocuration,CHEMBL875099,BAO_0000357,4251
,,H,663.0,,12166,,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,1,,RBL-2H3,,,8,,11311,F,,Autocuration,CHEMBL620870,BAO_0000219,4252
,,H,,,12166,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,1,,,,,8,,11087,B,,Autocuration,CHEMBL618261,BAO_0000019,4253
,,H,,,12166,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,1,,,,,8,,11087,B,,Autocuration,CHEMBL618262,BAO_0000019,4254
,,H,,,12166,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,1,,,,,8,,11087,B,,Autocuration,CHEMBL619428,BAO_0000019,4255
,,H,,,12166,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,1,,,,,8,,11087,B,,Autocuration,CHEMBL619429,BAO_0000019,4256
,,H,,,12166,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,1,,,,,8,,11087,B,,Autocuration,CHEMBL619430,BAO_0000019,4257
,,H,702.0,,12166,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,1,,RBL-1,,,8,,496,B,,Autocuration,CHEMBL620017,BAO_0000219,4258
,,H,702.0,,12166,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,1,,RBL-1,,,8,,496,B,,Autocuration,CHEMBL620018,BAO_0000219,4259
,,H,702.0,,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,1,,RBL-1,,,8,,13986,F,,Autocuration,CHEMBL620019,BAO_0000219,4260
,,H,702.0,,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,1,,RBL-1,,,8,,13986,F,,Autocuration,CHEMBL620020,BAO_0000219,4261
,,H,702.0,,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,1,,RBL-1,,,8,,13986,F,,Autocuration,CHEMBL620021,BAO_0000219,4262
,,H,702.0,,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,1,,RBL-1,,,8,,13986,F,,Autocuration,CHEMBL620022,BAO_0000219,4263
,,H,702.0,,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,1,,RBL-1,,,8,,13986,F,,Autocuration,CHEMBL620023,BAO_0000219,4264
,,H,702.0,,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,1,,RBL-1,,,8,,13986,F,,Autocuration,CHEMBL620024,BAO_0000219,4265
,,H,702.0,,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,1,,RBL-1,,,8,,13986,F,,Autocuration,CHEMBL620025,BAO_0000219,4266
,,H,702.0,,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,1,,RBL-1,,,8,,13986,F,,Autocuration,CHEMBL620026,BAO_0000219,4267
,,H,702.0,,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,1,,RBL-1,,,8,,13986,F,,Autocuration,CHEMBL620027,BAO_0000219,4268
,,D,,,12166,10116.0,Rattus norvegicus,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,1,,,,,9,,13986,F,,Expert,CHEMBL620028,BAO_0000019,4269
,,H,,,12166,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,1,,,,,8,,10193,B,,Autocuration,CHEMBL620029,BAO_0000357,4270
,,H,,,12166,,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,1,,,,,8,,9295,B,,Autocuration,CHEMBL620030,BAO_0000357,4271
,,H,702.0,,12166,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,1,,RBL-1,,,8,,4717,B,,Autocuration,CHEMBL875415,BAO_0000219,4272
,,H,702.0,,12166,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,1,,RBL-1,,,8,,4717,B,,Autocuration,CHEMBL618256,BAO_0000219,4273
,,H,702.0,,12166,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,1,,RBL-1,,,8,,11854,B,,Autocuration,CHEMBL618257,BAO_0000219,4274
,,H,702.0,,12166,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,1,,RBL-1,,,8,,11854,B,,Autocuration,CHEMBL618258,BAO_0000219,4275
,,H,702.0,,12166,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,1,,RBL-1,,,8,,11854,B,,Autocuration,CHEMBL618259,BAO_0000219,4276
,,H,,,12166,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,1,,,,,8,,10193,B,,Autocuration,CHEMBL618260,BAO_0000019,4277
,,H,702.0,,12166,,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,1,,RBL-1,,,8,,9295,B,,Autocuration,CHEMBL618215,BAO_0000219,4278
,,H,702.0,,12166,,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,1,,RBL-1,,,8,,9295,B,,Autocuration,CHEMBL618390,BAO_0000219,4279
,,H,702.0,,12166,,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,1,,RBL-1,,,8,,9295,B,,Autocuration,CHEMBL618391,BAO_0000219,4280
,,H,702.0,,12166,,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,1,,RBL-1,,,8,,9295,B,,Autocuration,CHEMBL618392,BAO_0000219,4281
,,H,702.0,,12166,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,1,,RBL-1,,,8,,165,B,,Autocuration,CHEMBL618393,BAO_0000219,4282
,,H,,,12166,,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,1,,,,,8,,11311,B,,Autocuration,CHEMBL618394,BAO_0000219,4283
,,H,702.0,,12166,9606.0,Homo sapiens,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),1,,RBL-1,,,8,,10489,B,,Expert,CHEMBL618395,BAO_0000219,4284
,,D,702.0,,12166,10116.0,Rattus norvegicus,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),1,,RBL-1,,,9,,10489,B,,Expert,CHEMBL618396,BAO_0000219,4285
,,D,702.0,,12166,10116.0,Rattus norvegicus,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),1,,RBL-1,,,9,,10489,B,,Expert,CHEMBL858253,BAO_0000219,4286
,,D,,,12166,10116.0,Rattus norvegicus,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,1,,,,,9,,14799,B,,Autocuration,CHEMBL618397,BAO_0000019,4287
,,H,,,12054,3847.0,Glycine max,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),1,,,,,8,,9295,B,,Autocuration,CHEMBL618398,BAO_0000357,4288
,,U,,,22226,,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",1,,,,,0,,16811,B,,Autocuration,CHEMBL618399,BAO_0000019,4289
,,H,,,55,,,In vitro inhibition of 5-Lipoxygenase; Inactive.,1,,,,,8,,168,B,,Expert,CHEMBL618400,BAO_0000357,4290
,,H,,,55,,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,1,,,,,8,,6309,B,,Autocuration,CHEMBL618401,BAO_0000357,4291
,,H,,,55,,,Inhibitory concentration against 5-lipoxygenase; No inhibition,1,,,,,8,,6309,B,,Autocuration,CHEMBL618402,BAO_0000357,4292
,,H,702.0,,55,,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,1,,RBL-1,,,8,,3092,B,,Autocuration,CHEMBL876400,BAO_0000219,4293
,,H,,,55,,,Inhibitory activity against 5-lipoxygenase.,1,,,,,8,,168,B,,Expert,CHEMBL618403,BAO_0000357,4294
,,H,,,55,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,1,,,,,8,,168,B,,Autocuration,CHEMBL618404,BAO_0000357,4295
,,H,,,55,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,1,,,,,8,,168,B,,Autocuration,CHEMBL618405,BAO_0000357,4296
,,H,,,55,,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,1,,,,,8,,168,B,,Autocuration,CHEMBL618406,BAO_0000357,4297
,,H,,,55,,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,1,,,,,8,,12338,F,,Expert,CHEMBL618407,BAO_0000019,4298
,,H,,,55,,,Tested for the inhibitory activity against 5-lipoxygenase,1,,,,,8,,4501,B,,Autocuration,CHEMBL618408,BAO_0000357,4299
,,H,,,55,,,Compound was tested for its inhibitory activity against 5-lipoxygenase,1,,,,,8,,1132,B,,Autocuration,CHEMBL618409,BAO_0000357,4300
,,H,,,55,,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,1,,,,,8,,2117,B,,Autocuration,CHEMBL618410,BAO_0000357,4301
,,H,,,55,,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,1,,,,,8,,168,B,,Autocuration,CHEMBL618411,BAO_0000357,4302
,,H,,,55,,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,1,,,,,8,,168,B,,Autocuration,CHEMBL618412,BAO_0000357,4303
,,H,702.0,,12166,,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,1,,RBL-1,,,8,,13575,B,,Autocuration,CHEMBL618413,BAO_0000219,4304
,,H,,,12166,,,,1,,,,,8,,11089,B,,Autocuration,CHEMBL618414,BAO_0000357,4305
,,H,,,10102,,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),1,,,,,8,,216,B,,Autocuration,CHEMBL618415,BAO_0000357,4306
,,H,,,10102,,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,1,,,,,8,,13165,B,,Autocuration,CHEMBL618416,BAO_0000019,4307
,,H,,,10102,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,1,,,,,8,,3278,B,,Autocuration,CHEMBL876401,BAO_0000357,4308
,,H,,,10102,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,1,,,,,8,,3278,B,,Expert,CHEMBL618417,BAO_0000357,4309
,,H,,,10102,,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,1,,,,,8,,11966,B,,Autocuration,CHEMBL618418,BAO_0000357,4310
,,H,,,10102,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",1,,,,,8,,175,B,,Autocuration,CHEMBL618419,BAO_0000357,4311
,,H,,,10102,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",1,,,,,8,,175,B,,Autocuration,CHEMBL618420,BAO_0000357,4312
,,H,,,10102,,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,1,,,,,8,,13449,B,,Autocuration,CHEMBL618421,BAO_0000357,4313
,,H,,,11238,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,1,,,,,8,,12014,B,,Autocuration,CHEMBL618422,BAO_0000019,4314
,,H,,,11238,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),1,,,,,8,,12014,B,,Autocuration,CHEMBL618423,BAO_0000019,4315
,,H,,,11238,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),1,,,,,8,,12014,B,,Autocuration,CHEMBL618424,BAO_0000019,4316
,,S,,,100284,,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,1,,,,,2,,99,B,,Intermediate,CHEMBL618425,BAO_0000220,4317
,,U,,,22226,9606.0,Homo sapiens,The dark toxicity against 543 human galactophore carcinoma cells,1,,,,,0,,4349,F,,Autocuration,CHEMBL618426,BAO_0000019,4318
,,N,390.0,,80623,9606.0,Homo sapiens,Tested in vitro for cytotoxicity against 56 human tumor cell lines,1,,Panel (56 tumour cell lines),,,1,,4071,F,,Expert,CHEMBL618427,BAO_0000219,4319
,,N,345.0,,80008,9606.0,Homo sapiens,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,1,,5637,,,1,,17589,F,,Expert,CHEMBL618428,BAO_0000219,4320
,,N,345.0,,80008,9606.0,Homo sapiens,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,1,,5637,,,1,,15002,F,,Intermediate,CHEMBL618429,BAO_0000219,4321
,,N,345.0,,80008,9606.0,Homo sapiens,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",1,,5637,,,1,,13958,F,,Intermediate,CHEMBL618430,BAO_0000219,4322
,,N,345.0,,80008,9606.0,Homo sapiens,Growth inhibition against human 5637 cell lines,1,,5637,,,1,,17589,F,,Expert,CHEMBL618431,BAO_0000219,4323
,,N,345.0,,80008,9606.0,Homo sapiens,Antitumor activity against human bladder carcinoma 5637 cells.,1,,5637,,,1,,16748,F,,Expert,CHEMBL883799,BAO_0000219,4324
,,N,345.0,,80008,9606.0,Homo sapiens,Antitumor activity against human bladder carcinoma 5637 cells,1,,5637,,,1,,16747,F,,Intermediate,CHEMBL618432,BAO_0000219,4325
,,N,345.0,,80008,9606.0,Homo sapiens,Antitumor activity against human bladder carcinoma 5637 cells,1,,5637,,,1,,16747,F,,Intermediate,CHEMBL618433,BAO_0000219,4326
,,D,,,10443,9913.0,Bos taurus,In vitro inhibition of bovine trypsin(Trp).,1,,,,,9,,15285,B,,Expert,CHEMBL618434,BAO_0000357,4327
,,H,407.0,,240,9527.0,Cercopithecidae,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,1,,CV-1,,,8,,3726,B,,Expert,CHEMBL618435,BAO_0000219,4328
,,H,,,10577,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,1,,,,,8,,5033,B,,Autocuration,CHEMBL876402,BAO_0000357,4329
,,H,,,104698,,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,1,,,,,6,,11756,F,,Autocuration,CHEMBL618436,BAO_0000019,4330
,,U,,,22226,,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,1,,,,In vivo,0,,11953,F,,Autocuration,CHEMBL618437,BAO_0000218,4331
,,D,,,20033,10141.0,Cavia porcellus,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,1,,,,,9,,5033,B,,Intermediate,CHEMBL618438,BAO_0000357,4332
,Microsomes,H,,,17045,10116.0,Rattus norvegicus,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,1,,,,,8,,11347,A,,Expert,CHEMBL883800,BAO_0000251,4333
,Microsomes,H,,,17045,10116.0,Rattus norvegicus,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,1,,,,,8,,11347,A,,Expert,CHEMBL618439,BAO_0000251,4334
,,U,,,22226,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,1,,,,,0,,1229,F,,Intermediate,CHEMBL618440,BAO_0000019,4335
,,U,,,22226,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,1,,,,,0,,1229,F,,Intermediate,CHEMBL618441,BAO_0000019,4336
,,H,,,11938,5691.0,Trypanosoma brucei,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,1,,,,,8,,17588,B,,Expert,CHEMBL618442,BAO_0000019,4337
,,H,,,11938,5691.0,Trypanosoma brucei,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,1,,,,,8,,17588,B,,Autocuration,CHEMBL618443,BAO_0000019,4338
,,H,,,11938,9940.0,Ovis aries,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,1,,,,,8,,17588,B,,Expert,CHEMBL619158,BAO_0000019,4339
,,H,,,11938,9940.0,Ovis aries,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,1,,,,,8,,17588,B,,Autocuration,CHEMBL620974,BAO_0000019,4340
,,H,,,11938,,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,1,,,,,8,,16485,B,,Autocuration,CHEMBL620975,BAO_0000357,4341
,,U,,,22226,9606.0,Homo sapiens,Average inhibitory concentration against 60 human cell lines was reported,1,,,,,0,,4337,F,,Intermediate,CHEMBL620976,BAO_0000019,4342
,,U,,,22226,9606.0,Homo sapiens,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,1,,,,,0,,4112,F,,Expert,CHEMBL620977,BAO_0000019,4343
,,N,542.0,,80315,9606.0,Homo sapiens,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,1,,Panel NCI-60 (60 carcinoma cell lines),,,1,,16160,F,,Intermediate,CHEMBL620978,BAO_0000219,4344
,,N,542.0,,80315,9606.0,Homo sapiens,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,1,,Panel NCI-60 (60 carcinoma cell lines),,,1,,16160,F,,Intermediate,CHEMBL620979,BAO_0000219,4345
,,N,542.0,,80315,,,In vitro mean growth inhibitory activity against 60-cell panel,1,,Panel NCI-60 (60 carcinoma cell lines),,,1,,17376,F,,Expert,CHEMBL620980,BAO_0000219,4346
,,N,542.0,,80315,,,In vitro mean growth lethal concentration against 60-cell panel,1,,Panel NCI-60 (60 carcinoma cell lines),,,1,,17376,F,,Expert,CHEMBL620981,BAO_0000219,4347
,,N,542.0,,80315,,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,1,,Panel NCI-60 (60 carcinoma cell lines),,,1,,17376,F,,Expert,CHEMBL620982,BAO_0000219,4348
,,N,542.0,,80315,,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,1,,Panel NCI-60 (60 carcinoma cell lines),,,1,,17376,F,,Expert,CHEMBL620983,BAO_0000219,4349
,,H,,,104775,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,1,,,,,4,,3241,F,,Autocuration,CHEMBL620984,BAO_0000019,4350
,,H,,,104775,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,1,,,,,4,,3241,F,,Autocuration,CHEMBL620985,BAO_0000019,4351
,,H,,,275,,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,1,,,,,8,,3725,B,,Expert,CHEMBL620986,BAO_0000357,4352
,,N,,,50425,5833.0,Plasmodium falciparum,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,1,,,,,1,,10805,F,,Expert,CHEMBL620987,BAO_0000218,4353
,,N,,,50425,5833.0,Plasmodium falciparum,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,1,,,,,1,,10805,F,,Expert,CHEMBL620988,BAO_0000218,4354
,,N,,,50425,5833.0,Plasmodium falciparum,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,1,,,,,1,,10805,F,,Expert,CHEMBL620989,BAO_0000218,4355
,,N,,,50425,5833.0,Plasmodium falciparum,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,1,,,,,1,,10805,F,,Expert,CHEMBL620990,BAO_0000218,4356
,,N,,,50425,5833.0,Plasmodium falciparum,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,1,,,,,1,,10805,F,,Intermediate,CHEMBL620991,BAO_0000218,4357
,,N,850.0,,80628,10090.0,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,1,,6C3HED,,,1,,10144,F,,Intermediate,CHEMBL620992,BAO_0000218,4358
,,N,850.0,,80628,10090.0,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,1,,6C3HED,,,1,,10144,F,,Intermediate,CHEMBL620993,BAO_0000218,4359
,,N,850.0,,80628,10090.0,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,1,,6C3HED,,,1,,10144,F,,Intermediate,CHEMBL620994,BAO_0000218,4360
,,N,850.0,,80628,10090.0,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,1,,6C3HED,,,1,,10144,F,,Intermediate,CHEMBL620995,BAO_0000218,4361
,,N,850.0,,80628,10090.0,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,1,,6C3HED,,,1,,10144,F,,Intermediate,CHEMBL620996,BAO_0000218,4362
,,N,850.0,,80628,10090.0,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,1,,6C3HED,,,1,,10144,F,,Intermediate,CHEMBL875581,BAO_0000218,4363
,,U,,,22224,10090.0,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,1,,,,In vivo,0,,10685,F,,Autocuration,CHEMBL620997,BAO_0000218,4364
,,U,,,22224,10090.0,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,1,,,,In vivo,0,,10685,F,,Autocuration,CHEMBL620998,BAO_0000218,4365
,,U,,,22224,10090.0,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),1,,,,In vivo,0,,10685,F,,Autocuration,CHEMBL620999,BAO_0000218,4366
,,U,,,22224,10090.0,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,1,,,,In vivo,0,,10685,F,,Autocuration,CHEMBL621000,BAO_0000218,4367
,,U,,,22224,10090.0,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,1,,,,In vivo,0,,10685,F,,Autocuration,CHEMBL621001,BAO_0000218,4368
,,U,,,22224,10090.0,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,1,,,,In vivo,0,,10685,F,,Autocuration,CHEMBL621002,BAO_0000218,4369
,,U,,,22224,10090.0,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,1,,,,In vivo,0,,10685,F,,Autocuration,CHEMBL621003,BAO_0000218,4370
,,U,,,22224,10090.0,Mus musculus,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",1,,,,In vivo,0,,10685,F,,Autocuration,CHEMBL621004,BAO_0000218,4371
,,U,,,22224,10090.0,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),1,,,,In vivo,0,,10685,F,,Autocuration,CHEMBL621005,BAO_0000218,4372
,,U,,,22224,10090.0,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),1,,,,In vivo,0,,10685,F,,Autocuration,CHEMBL621006,BAO_0000218,4373
,,U,,,22224,10090.0,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,1,,,,In vivo,0,,10685,F,,Autocuration,CHEMBL621007,BAO_0000218,4374
,,U,,,22224,10090.0,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,1,,,,,0,,10144,F,,Autocuration,CHEMBL621008,BAO_0000218,4375
,,U,,,22224,10090.0,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,1,,,,,0,,10144,F,,Autocuration,CHEMBL621009,BAO_0000218,4376
,,U,,,22224,10090.0,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,1,,,,,0,,10144,F,,Autocuration,CHEMBL857705,BAO_0000218,4377
,,U,,,22224,10090.0,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,1,,,,,0,,10144,F,,Autocuration,CHEMBL619828,BAO_0000218,4378
,,U,,,22224,10090.0,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,1,,,,,0,,10685,F,,Autocuration,CHEMBL619829,BAO_0000218,4379
,,U,,,22224,10090.0,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,1,,,,,0,,10685,F,,Autocuration,CHEMBL619830,BAO_0000218,4380
,,U,,,22224,10090.0,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,1,,,,,0,,10685,F,,Autocuration,CHEMBL619831,BAO_0000218,4381
,,U,,,22224,10090.0,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,1,,,,,0,,10685,F,,Autocuration,CHEMBL619832,BAO_0000218,4382
,,U,,,22224,10090.0,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,1,,,,,0,,10685,A,,Autocuration,CHEMBL619833,BAO_0000218,4383
,,U,,,22224,10090.0,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,1,,,,,0,,10685,A,,Autocuration,CHEMBL619834,BAO_0000218,4384
,,U,,,22224,10090.0,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,1,,,,,0,,10685,A,,Autocuration,CHEMBL619835,BAO_0000218,4385
,,U,,,22224,10090.0,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,1,,,,,0,,10685,A,,Autocuration,CHEMBL619836,BAO_0000218,4386
,,N,850.0,,80628,10090.0,Mus musculus,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",1,,6C3HED,,,1,,8831,F,,Intermediate,CHEMBL619837,BAO_0000218,4387
,,U,,,22224,,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,1,,,,In vivo,0,,11704,F,,Autocuration,CHEMBL619838,BAO_0000218,4388
,,N,,,50594,10090.0,Mus musculus,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,1,,,,,1,,11704,A,,Intermediate,CHEMBL619839,BAO_0000218,4389
,,N,850.0,,80628,10090.0,Mus musculus,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,1,,6C3HED,,In vivo,1,,10685,F,,Intermediate,CHEMBL619840,BAO_0000218,4390
,,N,850.0,,80628,10090.0,Mus musculus,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,1,,6C3HED,,In vivo,1,,10685,F,,Intermediate,CHEMBL619841,BAO_0000218,4391
,,N,850.0,,80628,10090.0,Mus musculus,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),1,,6C3HED,,,1,,11368,F,,Expert,CHEMBL857704,BAO_0000218,4392
,,N,850.0,,80628,10090.0,Mus musculus,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),1,,6C3HED,,,1,,11368,F,,Intermediate,CHEMBL619842,BAO_0000218,4393
,,N,850.0,,80628,10090.0,Mus musculus,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),1,,6C3HED,,,1,,11368,F,,Expert,CHEMBL619843,BAO_0000218,4394
,,U,,,22226,1280.0,Staphylococcus aureus,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",1,,,,,0,,17763,B,,Autocuration,CHEMBL619844,BAO_0000019,4395
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL857855,BAO_0000251,4396
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL619845,BAO_0000251,4397
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL619846,BAO_0000251,4398
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL619847,BAO_0000251,4399
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL619848,BAO_0000251,4400
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL620893,BAO_0000251,4401
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL620894,BAO_0000251,4402
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL620895,BAO_0000251,4403
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL620896,BAO_0000251,4404
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL620897,BAO_0000251,4405
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL620898,BAO_0000251,4406
,Microsomes,U,,,22226,10116.0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,1,Liver,,,,0,,7411,B,2107.0,Autocuration,CHEMBL620899,BAO_0000251,4407
,,U,,,22224,9527.0,Cercopithecidae,The apparent total plasma clearance in monkey,1,Plasma,,,In vivo,0,,347,A,1969.0,Autocuration,CHEMBL620900,BAO_0000218,4408
,,U,,,22224,9527.0,Cercopithecidae,Compound was evaluated for Hepatic clearance in monkey,1,,,,In vivo,0,,3341,A,,Autocuration,CHEMBL620901,BAO_0000218,4409
,,U,,,22224,9527.0,Cercopithecidae,Lower clearance in monkey (i.v.) at 0.5 mpk,1,,,,In vivo,0,,17853,A,,Autocuration,CHEMBL620902,BAO_0000218,4410
,,U,,,22224,9527.0,Cercopithecidae,Plasma clearance in rhesus monkey,1,,,,In vivo,0,,4514,A,,Autocuration,CHEMBL620903,BAO_0000218,4411
,,U,,,22224,9527.0,Cercopithecidae,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,1,,,,In vivo,0,,6062,A,,Autocuration,CHEMBL620904,BAO_0000218,4412
,,U,,,22224,9527.0,Cercopithecidae,Plasma clearance of compound was determined in monkey,1,,,,In vivo,0,,6821,A,,Autocuration,CHEMBL620905,BAO_0000218,4413
,,U,,,22224,9527.0,Cercopithecidae,Plasma clearance was calculated in rhesus monkey,1,,,,In vivo,0,,6057,A,,Autocuration,CHEMBL620906,BAO_0000218,4414
,,U,,,22224,9527.0,Cercopithecidae,Plasma clearance in rhesus monkey,1,,,,In vivo,0,,5145,A,,Autocuration,CHEMBL875420,BAO_0000218,4415
,,U,,,22224,9527.0,Cercopithecidae,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,,,In vivo,0,,6641,A,,Autocuration,CHEMBL620907,BAO_0000218,4416
,,U,,,22224,9527.0,Cercopithecidae,Plasma clearance was evaluated in rhesus,1,,,,In vivo,0,,5472,A,,Autocuration,CHEMBL620908,BAO_0000218,4417
,,U,,,22224,9527.0,Cercopithecidae,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,1,,,,In vivo,0,,4257,A,,Autocuration,CHEMBL620909,BAO_0000218,4418
,,U,,,22224,9527.0,Cercopithecidae,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,1,,,,In vivo,0,,5546,A,,Autocuration,CHEMBL620910,BAO_0000218,4419
,,U,,,22224,9527.0,Cercopithecidae,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),1,,,,In vivo,0,,5334,A,,Autocuration,CHEMBL620911,BAO_0000218,4420
,,U,,,22224,9527.0,Cercopithecidae,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),1,,,,In vivo,0,,5334,A,,Autocuration,CHEMBL620912,BAO_0000218,4421
,,U,,,22224,9527.0,Cercopithecidae,Cmax 24 hr after 2 mg/kg oral administration in monkeys,1,,,,In vivo,0,,17509,A,,Autocuration,CHEMBL620913,BAO_0000218,4422
,,U,,,22224,9527.0,Cercopithecidae,Cmax in monkey after administration of 1 mg/kg iv,1,,,,In vivo,0,,6535,A,,Autocuration,CHEMBL620914,BAO_0000218,4423
,,U,,,22224,9527.0,Cercopithecidae,Cmax was determine after peroral administration at 10 mpk in Rhesus,1,,,,In vivo,0,,5668,A,,Autocuration,CHEMBL620915,BAO_0000218,4424
,,U,,,22224,9527.0,Cercopithecidae,Cmax in cynomolgus monkey by iv administration,1,,,,In vivo,0,,5922,A,,Autocuration,CHEMBL620916,BAO_0000218,4425
,,U,,,22224,9527.0,Cercopithecidae,Cmax in cynomolgus monkey by po administration,1,,,,In vivo,0,,5922,A,,Autocuration,CHEMBL620917,BAO_0000218,4426
,,U,,,22224,9527.0,Cercopithecidae,Cmax value evaluated in monkey,1,,,,In vivo,0,,6078,A,,Autocuration,CHEMBL620918,BAO_0000218,4427
,,U,,,22224,9527.0,Cercopithecidae,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,1,,,,In vivo,0,,2661,A,,Autocuration,CHEMBL620919,BAO_0000218,4428
,,U,,,22224,9527.0,Cercopithecidae,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,1,Plasma,,,In vivo,0,,3249,A,1969.0,Autocuration,CHEMBL620920,BAO_0000218,4429
,,U,,,22224,9527.0,Cercopithecidae,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,1,Plasma,,,In vivo,0,,3249,A,1969.0,Autocuration,CHEMBL620921,BAO_0000218,4430
,,U,,,22224,9527.0,Cercopithecidae,Maximal plasma concentration in squirrel monkeys,1,Plasma,,,In vivo,0,,5553,A,1969.0,Autocuration,CHEMBL620922,BAO_0000218,4431
,,U,,,22224,9527.0,Cercopithecidae,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1,,,,In vivo,0,,1916,A,,Autocuration,CHEMBL620923,BAO_0000218,4432
,,U,,,22224,9527.0,Cercopithecidae,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,1,Plasma,,,In vivo,0,,6227,A,1969.0,Autocuration,CHEMBL620924,BAO_0000218,4433
,,U,,,22224,9527.0,Cercopithecidae,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),1,,,,In vivo,0,,4809,A,,Autocuration,CHEMBL620925,BAO_0000218,4434
,,U,,,22224,9527.0,Cercopithecidae,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,1,,,,In vivo,0,,5355,A,,Autocuration,CHEMBL620926,BAO_0000218,4435
,,U,,,22224,9527.0,Cercopithecidae,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,1,,,,In vivo,0,,5355,A,,Autocuration,CHEMBL620927,BAO_0000218,4436
,,U,,,22224,9527.0,Cercopithecidae,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,1,,,,In vivo,0,,5355,A,,Autocuration,CHEMBL620928,BAO_0000218,4437
,,U,,,22224,9527.0,Cercopithecidae,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,1,,,,In vivo,0,,5355,A,,Autocuration,CHEMBL620929,BAO_0000218,4438
,,U,,,22224,9527.0,Cercopithecidae,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,1,Plasma,,,In vivo,0,,6221,A,1969.0,Autocuration,CHEMBL620930,BAO_0000218,4439
,,U,,,22224,9527.0,Cercopithecidae,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,1,,,,,0,,167,A,,Autocuration,CHEMBL620931,BAO_0000218,4440
,,U,,,22224,9527.0,Cercopithecidae,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,1,,,,,0,,167,A,,Autocuration,CHEMBL620932,BAO_0000218,4441
,,U,,,22224,9443.0,monkey,Absolute bioavailability was evaluated in monkey,1,,,,In vivo,0,,4257,A,,Autocuration,CHEMBL620933,BAO_0000218,4442
,,U,,,22224,9443.0,monkey,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,1,,,,In vivo,0,,6221,A,,Autocuration,CHEMBL620934,BAO_0000218,4443
,,U,,,22224,9443.0,monkey,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,1,,,,In vivo,0,,17667,A,,Autocuration,CHEMBL620935,BAO_0000218,4444
,,U,,,22224,9544.0,Macaca mulatta,Bioavailability of compound was determined in rhesus monkey,1,,,,In vivo,0,,17267,A,,Autocuration,CHEMBL620936,BAO_0000218,4445
,,U,,,22224,38020.0,marmosets,Bioavailability determined after oral administration in marmoset,1,,,,In vivo,0,,4256,A,,Autocuration,CHEMBL620937,BAO_0000218,4446
,,U,,,22224,9541.0,Macaca fascicularis,Oral bioavailability in cynomolgus monkey,1,,,,In vivo,0,,4256,A,,Autocuration,CHEMBL620938,BAO_0000218,4447
,,U,,,22224,9443.0,monkey,Bioavailability in monkey (p.o.) at 2.0 mpk,1,,,,In vivo,0,,17853,A,,Autocuration,CHEMBL620939,BAO_0000218,4448
,,U,,,22224,9443.0,monkey,Bioavailability was evaluated after oral administration in monkey,1,,,,In vivo,0,,16365,A,,Autocuration,CHEMBL620940,BAO_0000218,4449
,,U,,,22224,9541.0,Macaca fascicularis,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1,,,,In vivo,0,,1916,A,,Autocuration,CHEMBL620941,BAO_0000218,4450
,,U,,,22224,9544.0,Macaca mulatta,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),1,,,,In vivo,0,,5334,A,,Autocuration,CHEMBL620942,BAO_0000218,4451
,,U,,,22224,9544.0,Macaca mulatta,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),1,,,,In vivo,0,,5334,A,,Autocuration,CHEMBL620943,BAO_0000218,4452
,,U,,,22224,9443.0,monkey,Bioavailability of the compound was determined in monkey,1,,,,In vivo,0,,17592,A,,Autocuration,CHEMBL620944,BAO_0000218,4453
,,U,,,22224,9521.0,Saimiri sciureus,Bioavailability in squirrel monkey (dose 5 mg/kg),1,,,,In vivo,0,,1399,A,,Autocuration,CHEMBL620945,BAO_0000218,4454
,,U,,,22224,9443.0,monkey,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),1,,,,In vivo,0,,4809,A,,Autocuration,CHEMBL620946,BAO_0000218,4455
,,U,,,22224,9443.0,monkey,Oral bioavailability in monkey,1,,,,In vivo,0,,3341,A,,Autocuration,CHEMBL620947,BAO_0000218,4456
,,U,,,22224,9521.0,Saimiri sciureus,Compound was tested for bioavailability in squirrel monkey,1,,,,In vivo,0,,64,A,,Autocuration,CHEMBL620948,BAO_0000218,4457
,,U,,,22224,9544.0,Macaca mulatta,Oral bioavailability in Rhesus monkey,1,,,,In vivo,0,,5005,A,,Autocuration,CHEMBL620949,BAO_0000218,4458
,,U,,,22224,9544.0,Macaca mulatta,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),1,,,,In vivo,0,,5005,A,,Autocuration,CHEMBL620950,BAO_0000218,4459
,,U,,,22224,9541.0,Macaca fascicularis,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,1,,,,In vivo,0,,5237,A,,Autocuration,CHEMBL620951,BAO_0000218,4460
,,U,,,22224,9541.0,Macaca fascicularis,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,1,,,,In vivo,0,,5237,A,,Autocuration,CHEMBL620952,BAO_0000218,4461
,,U,,,22224,9443.0,monkey,Oral bioavailability in monkey (dose 5 mg/kg),1,,,,In vivo,0,,5302,A,,Autocuration,CHEMBL875421,BAO_0000218,4462
,,U,,,22224,9443.0,monkey,Oral bioavailability of compound at 5 mg/kg in monkey,1,,,,In vivo,0,,17667,A,,Autocuration,CHEMBL620953,BAO_0000218,4463
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,1,,,,In vivo,1,,6161,A,,Intermediate,CHEMBL873491,BAO_0000218,4464
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,1,,,,In vivo,1,,6161,A,,Intermediate,CHEMBL620954,BAO_0000218,4465
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma half life determined,1,Plasma,,,,1,,3854,A,1969.0,Intermediate,CHEMBL620955,BAO_0000218,4466
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma half life in dog,1,Plasma,,,,1,,993,A,1969.0,Intermediate,CHEMBL618097,BAO_0000218,4467
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma half-life in Beagle dogs,1,Plasma,,,,1,,4514,A,1969.0,Intermediate,CHEMBL618268,BAO_0000218,4468
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),1,Plasma,,,In vivo,1,,5334,A,1969.0,Intermediate,CHEMBL618269,BAO_0000218,4469
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),1,Plasma,,,In vivo,1,,5334,A,1969.0,Intermediate,CHEMBL618270,BAO_0000218,4470
,,N,,,50588,9615.0,Canis lupus familiaris,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,1,,,,In vivo,1,,1466,A,,Intermediate,CHEMBL618271,BAO_0000218,4471
,,N,,,50588,9615.0,Canis lupus familiaris,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,1,,,,In vivo,1,,1466,A,,Intermediate,CHEMBL873493,BAO_0000218,4472
,,N,,,50588,9615.0,Canis lupus familiaris,Tested for the half life period in dog,1,,,,,1,,5313,A,,Intermediate,CHEMBL621031,BAO_0000218,4473
,,N,,,50588,9615.0,Canis lupus familiaris,Tested for the half life period in dog at dosage of 10 mpk,1,,,,In vivo,1,,5313,A,,Intermediate,CHEMBL621032,BAO_0000218,4474
,,N,,,50588,9615.0,Canis lupus familiaris,The compound was tested for half life in dog,1,,,,,1,,3880,A,,Intermediate,CHEMBL621033,BAO_0000218,4475
,,N,,,50588,9615.0,Canis lupus familiaris,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",1,Plasma,,,,1,,3639,A,1969.0,Intermediate,CHEMBL621034,BAO_0000218,4476
,,N,,,50588,9615.0,Canis lupus familiaris,The half life was determined,1,,,,,1,,3880,A,,Intermediate,CHEMBL621035,BAO_0000218,4477
,,N,,,50588,9615.0,Canis lupus familiaris,The plasma half-life in dogs,1,Plasma,,,,1,,3918,A,1969.0,Intermediate,CHEMBL621036,BAO_0000218,4478
,,N,,,50588,9615.0,Canis lupus familiaris,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,1,Plasma,,,,1,,16452,A,1969.0,Intermediate,CHEMBL621037,BAO_0000218,4479
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in dog,1,,,,,1,,17796,A,,Intermediate,CHEMBL619812,BAO_0000218,4480
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,1,,,,In vivo,1,,5983,A,,Intermediate,CHEMBL619813,BAO_0000218,4481
,,N,,,50588,9615.0,Canis lupus familiaris,tmax upon peroral administration of 10.0 mg/Kg dose in dog,1,,,,In vivo,1,,1466,A,,Intermediate,CHEMBL873335,BAO_0000218,4482
,,N,,,50588,9615.0,Canis lupus familiaris,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,1,,,,In vivo,1,,16456,A,,Intermediate,CHEMBL619814,BAO_0000218,4483
,,N,,,50506,9669.0,Mustela putorius furo,Cmax in ferrets after 30 mg/kg oral dose,1,,,,In vivo,1,,6113,A,,Expert,CHEMBL619815,BAO_0000218,4484
,,N,,,50506,9669.0,Mustela putorius furo,Emesis in ferrets at 30 mg/kg oral dose,1,,,,In vivo,1,,6113,F,,Expert,CHEMBL619816,BAO_0000218,4485
,,U,,,22224,9541.0,Macaca fascicularis,Bioavailability in cynomolgus monkey,1,,,,In vivo,0,,17796,A,,Autocuration,CHEMBL619817,BAO_0000218,4486
,,N,,,100710,9541.0,Macaca fascicularis,Volume of distribution in cynomolgus,1,,,,In vivo,1,,17796,A,,Intermediate,CHEMBL619818,BAO_0000218,4487
,,U,,,22224,10141.0,Cavia porcellus,AUC tested in guinea pig when 3 mg/kg dose was given perorally,1,Plasma,,,,0,,5308,A,1969.0,Autocuration,CHEMBL619819,BAO_0000218,4488
,,U,,,22224,10141.0,Cavia porcellus,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,1,,,,,0,,4877,A,,Autocuration,CHEMBL619820,BAO_0000218,4489
,,U,,,22224,10141.0,Cavia porcellus,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",1,,,,,0,,4876,A,,Autocuration,CHEMBL875419,BAO_0000218,4490
,,U,,,22224,10141.0,Cavia porcellus,AUC in guinea pig after 3mg/kg oral dose,1,Plasma,,,In vivo,0,,4878,A,1969.0,Autocuration,CHEMBL619821,BAO_0000218,4491
,,U,,,22224,10141.0,Cavia porcellus,Bioavailability in guinea pig was tested,1,,,,In vivo,0,,5308,A,,Autocuration,CHEMBL619822,BAO_0000218,4492
,,U,,,22224,10141.0,Cavia porcellus,Tested for oral bioavailability in guinea pig at 5 mg/kg,1,,,,In vivo,0,,4877,A,,Autocuration,CHEMBL619823,BAO_0000218,4493
,,U,,,22224,10141.0,Cavia porcellus,Tested for the oral bioavailability of the compound,1,,,,In vivo,0,,4876,A,,Autocuration,CHEMBL619824,BAO_0000218,4494
,,U,,,22224,10141.0,Cavia porcellus,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,1,,,,In vivo,0,,4876,A,,Autocuration,CHEMBL619825,BAO_0000218,4495
,,U,,,22224,10141.0,Cavia porcellus,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,1,,,,In vivo,0,,5308,A,,Autocuration,CHEMBL619826,BAO_0000218,4496
,,U,,,22224,10141.0,Cavia porcellus,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,1,Lung,,,In vivo,0,,4877,A,2048.0,Autocuration,CHEMBL619827,BAO_0000218,4497
,,U,,,22224,10141.0,Cavia porcellus,Cmax in guinea pig after 3mg/kg oral dose,1,,,,In vivo,0,,4878,A,,Autocuration,CHEMBL618167,BAO_0000218,4498
,,U,,,22224,10141.0,Cavia porcellus,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,1,Blood,,,,0,,5689,A,178.0,Autocuration,CHEMBL618168,BAO_0000019,4499
,,U,,,22224,10141.0,Cavia porcellus,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,1,Brain,,,,0,,5689,A,955.0,Autocuration,CHEMBL618169,BAO_0000019,4500
,,U,,,22224,10141.0,Cavia porcellus,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,1,,,,,0,,5689,A,,Autocuration,CHEMBL618170,BAO_0000019,4501
,,U,,,22224,10141.0,Cavia porcellus,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,1,Intestine,,,,0,,5689,A,160.0,Autocuration,CHEMBL618171,BAO_0000019,4502
,,U,,,22224,10141.0,Cavia porcellus,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,1,Kidney,,,,0,,5689,A,2113.0,Autocuration,CHEMBL618172,BAO_0000019,4503
,,U,,,22224,10141.0,Cavia porcellus,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,1,Liver,,,,0,,5689,A,2107.0,Autocuration,CHEMBL618173,BAO_0000019,4504
,,U,,,22224,10141.0,Cavia porcellus,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,1,,,,,0,,5689,A,,Autocuration,CHEMBL618174,BAO_0000019,4505
,,U,,,22224,10141.0,Cavia porcellus,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,1,Spleen,,,,0,,5689,A,2106.0,Autocuration,CHEMBL875408,BAO_0000019,4506
,,U,,,22224,10141.0,Cavia porcellus,Elimination T1/2 in Guinea pig (PO dose),1,,,,In vivo,0,,14465,A,,Autocuration,CHEMBL839827,BAO_0000218,4507
,,U,,,22224,10141.0,Cavia porcellus,Partition coefficient was measured as -log (counts per min ),1,,,,,0,,5689,A,,Autocuration,CHEMBL618175,BAO_0000019,4508
,,U,,,22224,10141.0,Cavia porcellus,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,1,,,,In vivo,0,,611,A,,Autocuration,CHEMBL618176,BAO_0000218,4509
,,U,,,22224,10141.0,Cavia porcellus,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,1,,,,In vivo,0,,611,A,,Autocuration,CHEMBL618177,BAO_0000218,4510
,,U,,,22224,10141.0,Cavia porcellus,Elimination T1/2 in Guinea pig (PO dose),1,,,,In vivo,0,,14465,A,,Autocuration,CHEMBL618178,BAO_0000218,4511
,,U,,,22224,10141.0,Cavia porcellus,"Tested for the half life period of the compound, intravenously",1,,,,In vivo,0,,4876,A,,Autocuration,CHEMBL618179,BAO_0000218,4512
,,U,,,22224,10141.0,Cavia porcellus,Half-life was measured,1,,,,,0,,5689,A,,Autocuration,CHEMBL873489,BAO_0000019,4513
,,U,,,22224,10141.0,Cavia porcellus,The time required for onset of inotropy after addition of a single dose of delta F75,1,,,,,0,,7515,A,,Autocuration,CHEMBL618180,BAO_0000019,4514
,,U,,,22224,10141.0,Cavia porcellus,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,1,,,,In vivo,0,,17667,A,,Autocuration,CHEMBL618181,BAO_0000218,4515
,,U,,,22224,10141.0,Cavia porcellus,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,1,,,,In vivo,0,,17667,A,,Autocuration,CHEMBL618182,BAO_0000218,4516
,,U,,,22224,10029.0,Cricetulus griseus,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,1,,,,In vivo,0,,4727,A,,Autocuration,CHEMBL618183,BAO_0000218,4517
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,,,In vivo,1,,10107,A,,Intermediate,CHEMBL618184,BAO_0000218,4518
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,,,,In vivo,1,,10107,A,,Intermediate,CHEMBL618185,BAO_0000218,4519
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,,,In vivo,1,,10107,A,,Intermediate,CHEMBL618186,BAO_0000218,4520
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,,,In vivo,1,,10107,A,,Intermediate,CHEMBL618187,BAO_0000218,4521
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,1,,,,In vivo,1,,10107,A,,Intermediate,CHEMBL618188,BAO_0000218,4522
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,,,In vivo,1,,10107,A,,Intermediate,CHEMBL875409,BAO_0000218,4523
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,,,In vivo,1,,10107,A,,Intermediate,CHEMBL618189,BAO_0000218,4524
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,1,Blood,,,In vivo,1,,3655,A,178.0,Intermediate,CHEMBL618190,BAO_0000218,4525
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,1,Blood,,,In vivo,1,,3655,A,178.0,Intermediate,CHEMBL618191,BAO_0000218,4526
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,1,Blood,,,In vivo,1,,3655,A,178.0,Intermediate,CHEMBL618192,BAO_0000218,4527
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,1,Bone,,,In vivo,1,,3655,A,10000001.0,Intermediate,CHEMBL618193,BAO_0000218,4528
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,1,Bone,,,In vivo,1,,3655,A,10000001.0,Intermediate,CHEMBL618194,BAO_0000218,4529
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,1,Bone,,,In vivo,1,,3655,A,10000001.0,Intermediate,CHEMBL618195,BAO_0000218,4530
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,1,Brain,,,In vivo,1,,3655,A,955.0,Intermediate,CHEMBL618196,BAO_0000218,4531
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,1,Brain,,,In vivo,1,,3655,A,955.0,Intermediate,CHEMBL618197,BAO_0000218,4532
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,1,Brain,,,In vivo,1,,3655,A,955.0,Intermediate,CHEMBL618198,BAO_0000218,4533
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,1,Heart,,,In vivo,1,,3655,A,948.0,Intermediate,CHEMBL618199,BAO_0000218,4534
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,1,Heart,,,In vivo,1,,3655,A,948.0,Intermediate,CHEMBL618200,BAO_0000218,4535
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,1,Heart,,,In vivo,1,,3655,A,948.0,Intermediate,CHEMBL618201,BAO_0000218,4536
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,1,Intestine,,,In vivo,1,,3655,A,160.0,Intermediate,CHEMBL618202,BAO_0000218,4537
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,1,Intestine,,,In vivo,1,,3655,A,160.0,Intermediate,CHEMBL618203,BAO_0000218,4538
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,1,Intestine,,,In vivo,1,,3655,A,160.0,Intermediate,CHEMBL618204,BAO_0000218,4539
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,1,Kidney,,,In vivo,1,,3655,A,2113.0,Intermediate,CHEMBL618205,BAO_0000218,4540
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,1,Kidney,,,In vivo,1,,3655,A,2113.0,Intermediate,CHEMBL618206,BAO_0000218,4541
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,1,Kidney,,,In vivo,1,,3655,A,2113.0,Intermediate,CHEMBL618207,BAO_0000218,4542
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,1,Liver,,,In vivo,1,,3655,A,2107.0,Intermediate,CHEMBL618208,BAO_0000218,4543
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,1,Liver,,,In vivo,1,,3655,A,2107.0,Intermediate,CHEMBL618932,BAO_0000218,4544
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,1,Liver,,,In vivo,1,,3655,A,2107.0,Intermediate,CHEMBL618933,BAO_0000218,4545
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,1,Lung,,,In vivo,1,,3655,A,2048.0,Intermediate,CHEMBL618934,BAO_0000218,4546
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,1,Lung,,,In vivo,1,,3655,A,2048.0,Intermediate,CHEMBL618935,BAO_0000218,4547
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,1,Lung,,,In vivo,1,,3655,A,2048.0,Intermediate,CHEMBL618936,BAO_0000218,4548
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,1,Muscle tissue,,,In vivo,1,,3655,A,2385.0,Intermediate,CHEMBL618937,BAO_0000218,4549
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,1,Muscle tissue,,,In vivo,1,,3655,A,2385.0,Intermediate,CHEMBL618938,BAO_0000218,4550
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,1,Muscle tissue,,,In vivo,1,,3655,A,2385.0,Intermediate,CHEMBL619104,BAO_0000218,4551
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,1,Spleen,,,In vivo,1,,3655,A,2106.0,Intermediate,CHEMBL619105,BAO_0000218,4552
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,1,Spleen,,,In vivo,1,,3655,A,2106.0,Intermediate,CHEMBL619106,BAO_0000218,4553
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,1,Spleen,,,In vivo,1,,3655,A,2106.0,Intermediate,CHEMBL619107,BAO_0000218,4554
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,1,Stomach,,,In vivo,1,,3655,A,945.0,Intermediate,CHEMBL875410,BAO_0000218,4555
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,1,Stomach,,,In vivo,1,,3655,A,945.0,Intermediate,CHEMBL619108,BAO_0000218,4556
,,N,,,50594,10090.0,Mus musculus,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,1,Stomach,,,In vivo,1,,3655,A,945.0,Intermediate,CHEMBL619109,BAO_0000218,4557
,,N,,,50594,10090.0,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,1,,,,In vivo,1,,16597,A,,Intermediate,CHEMBL619110,BAO_0000218,4558
,,N,,,50594,10090.0,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,1,,,,In vivo,1,,16597,F,,Intermediate,CHEMBL619111,BAO_0000218,4559
,,N,,,50594,10090.0,Mus musculus,MRT value at a dose of 10 mg/kg intravenous administration in mice.,1,,,,In vivo,1,,16597,A,,Intermediate,CHEMBL619112,BAO_0000218,4560
,,N,,,50594,10090.0,Mus musculus,MRT value at a dose of 10 mg/kg peroral administration in mice.,1,,,,In vivo,1,,16597,A,,Intermediate,CHEMBL619113,BAO_0000218,4561
,,N,,,50594,10090.0,Mus musculus,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,1,,,,In vivo,1,,17764,A,,Intermediate,CHEMBL619114,BAO_0000218,4562
,,N,,,50594,10090.0,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,1,,,,In vivo,1,,17764,F,,Intermediate,CHEMBL619115,BAO_0000218,4563
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,1,,A2780,,,1,,3830,F,,Intermediate,CHEMBL619116,BAO_0000219,4564
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,1,,A2780,,,1,,3829,F,,Intermediate,CHEMBL619117,BAO_0000219,4565
,,N,478.0,,81034,9606.0,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cell lines.,1,,A2780,,,1,,2040,F,,Intermediate,CHEMBL619118,BAO_0000219,4566
,,N,478.0,,81034,9606.0,Homo sapiens,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,1,,A2780,,,1,,15684,F,,Intermediate,CHEMBL619119,BAO_0000219,4567
,,N,478.0,,81034,9606.0,Homo sapiens,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,1,,A2780,,,1,,15684,F,,Intermediate,CHEMBL619120,BAO_0000219,4568
,,N,478.0,,81034,9606.0,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,1,,A2780,,,1,,15684,F,,Intermediate,CHEMBL619121,BAO_0000219,4569
,,N,478.0,,81034,9606.0,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,1,,A2780,,,1,,15684,F,,Intermediate,CHEMBL619122,BAO_0000219,4570
,,N,478.0,,81034,9606.0,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,1,,A2780,,,1,,15684,F,,Intermediate,CHEMBL619123,BAO_0000219,4571
,,N,478.0,,81034,9606.0,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,1,,A2780,,,1,,15684,F,,Intermediate,CHEMBL619124,BAO_0000219,4572
,,N,478.0,,81034,9606.0,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cell line,1,,A2780,,,1,,2859,F,,Intermediate,CHEMBL619125,BAO_0000219,4573
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro inhibitory activity against human tumor cell line A2780,1,,A2780,,,1,,5618,F,,Intermediate,CHEMBL875411,BAO_0000219,4574
,,N,478.0,,81034,9606.0,Homo sapiens,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,1,,A2780,,,1,,15684,F,,Intermediate,CHEMBL619126,BAO_0000219,4575
,,N,478.0,,81034,9606.0,Homo sapiens,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,1,,A2780,,,1,,15684,F,,Intermediate,CHEMBL619127,BAO_0000219,4576
,,N,478.0,,81034,9606.0,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,1,,A2780,,,1,,15684,F,,Intermediate,CHEMBL619128,BAO_0000219,4577
,,N,478.0,,81034,9606.0,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,1,,A2780,,,1,,15684,F,,Intermediate,CHEMBL619129,BAO_0000219,4578
,,N,478.0,,81034,9606.0,Homo sapiens,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,1,,A2780,,,1,,2113,F,,Intermediate,CHEMBL619130,BAO_0000219,4579
,,N,478.0,,81034,9606.0,Homo sapiens,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,1,,A2780,,,1,,2113,F,,Intermediate,CHEMBL619131,BAO_0000219,4580
,,N,478.0,,81034,9606.0,Homo sapiens,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,1,,A2780,,,1,,16745,F,,Intermediate,CHEMBL619132,BAO_0000219,4581
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,1,,A2780,,,1,,16597,F,,Expert,CHEMBL619133,BAO_0000218,4582
,,N,478.0,,81034,9606.0,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,1,,A2780,,,1,,15684,F,,Intermediate,CHEMBL619134,BAO_0000219,4583
,,N,478.0,,81034,9606.0,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,1,,A2780,,,1,,15684,F,,Intermediate,CHEMBL619135,BAO_0000219,4584
,,N,478.0,,81034,9606.0,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,1,,A2780,,,1,,2040,F,,Intermediate,CHEMBL619136,BAO_0000219,4585
,,N,478.0,,81034,9606.0,Homo sapiens,Relative resistance factor in A2780 cisplatin-resistant line,1,,A2780,,,1,,2040,F,,Intermediate,CHEMBL619137,BAO_0000219,4586
,,N,478.0,,81034,9606.0,Homo sapiens,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,1,,A2780,,,1,,16165,F,,Intermediate,CHEMBL883713,BAO_0000219,4587
,,N,478.0,,81034,9606.0,Homo sapiens,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,1,,A2780,,,1,,16165,F,,Intermediate,CHEMBL875412,BAO_0000219,4588
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,1,,A2780,,,1,,16597,F,,Expert,CHEMBL619138,BAO_0000218,4589
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,1,,A2780,,,1,,16597,F,,Expert,CHEMBL619262,BAO_0000218,4590
,,N,478.0,,81034,9606.0,Homo sapiens,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,1,,A2780,,,1,,3992,F,,Intermediate,CHEMBL619139,BAO_0000219,4591
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,1,,A2780,,,1,,10553,F,,Intermediate,CHEMBL619140,BAO_0000219,4592
,,N,478.0,,81034,9606.0,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,1,,A2780,,,1,,15608,F,,Intermediate,CHEMBL619141,BAO_0000219,4593
,,N,478.0,,81034,9606.0,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,1,,A2780,,,1,,15608,F,,Intermediate,CHEMBL619142,BAO_0000219,4594
,,N,478.0,,81034,9606.0,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,1,,A2780,,,1,,15608,F,,Intermediate,CHEMBL619143,BAO_0000219,4595
,,N,478.0,,81034,9606.0,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,1,,A2780,,,1,,15608,F,,Intermediate,CHEMBL619144,BAO_0000219,4596
,,N,478.0,,81034,9606.0,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,1,,A2780,,,1,,15608,F,,Intermediate,CHEMBL619145,BAO_0000219,4597
,,N,478.0,,81034,9606.0,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,1,,A2780,,,1,,15608,F,,Intermediate,CHEMBL619146,BAO_0000219,4598
,,N,478.0,,81034,9606.0,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,1,,A2780,,,1,,15569,F,,Intermediate,CHEMBL619147,BAO_0000219,4599
,,N,478.0,,81034,9606.0,Homo sapiens,Antiproliferative effect of compound on A2780/DX cell line,1,,A2780,,,1,,17420,F,,Intermediate,CHEMBL619148,BAO_0000219,4600
,,N,478.0,,81034,9606.0,Homo sapiens,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,1,,A2780,,,1,,17420,F,,Intermediate,CHEMBL619149,BAO_0000219,4601
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),1,,A2780,,,1,,15099,F,,Intermediate,CHEMBL619150,BAO_0000219,4602
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),1,,A2780,,,1,,15099,F,,Intermediate,CHEMBL619151,BAO_0000219,4603
,,N,478.0,,81034,9606.0,Homo sapiens,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,1,,A2780,,,1,,17672,F,,Intermediate,CHEMBL883794,BAO_0000219,4604
,,N,478.0,,81034,9606.0,Homo sapiens,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,1,,A2780,,,1,,17672,F,,Intermediate,CHEMBL619152,BAO_0000219,4605
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro cytotoxicity against A2780ADR cell line,1,,A2780,,,1,,17270,F,,Intermediate,CHEMBL619153,BAO_0000219,4606
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro cytotoxicity against A2780CIS cell line,1,,A2780,,,1,,17270,F,,Intermediate,CHEMBL619154,BAO_0000219,4607
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,1,,A2780,,,1,,5574,F,,Intermediate,CHEMBL619155,BAO_0000219,4608
,,N,478.0,,81034,9606.0,Homo sapiens,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,1,,A2780,,,1,,2113,F,,Intermediate,CHEMBL619156,BAO_0000219,4609
,,N,478.0,,81034,9606.0,Homo sapiens,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",1,,A2780,,,1,,16913,F,,Intermediate,CHEMBL619157,BAO_0000219,4610
,,N,478.0,,81034,9606.0,Homo sapiens,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",1,,A2780,,,1,,16913,F,,Intermediate,CHEMBL619797,BAO_0000219,4611
,,U,,,22224,9544.0,Macaca mulatta,Oral bioavailability of compound in rhesus macaques,1,,,,In vivo,0,,17839,A,,Autocuration,CHEMBL619798,BAO_0000218,4612
,,U,,,22224,9443.0,monkey,Oral bioavailability in monkey,1,,,,In vivo,0,,6821,A,,Autocuration,CHEMBL619799,BAO_0000218,4613
,,U,,,22224,9443.0,monkey,Oral bioavailability evaluated in monkey,1,,,,In vivo,0,,6078,A,,Autocuration,CHEMBL619800,BAO_0000218,4614
,,U,,,22224,9443.0,monkey,Oral bioavailability in monkey (dose 1 mg/kg p.o.),1,,,,In vivo,0,,6535,A,,Autocuration,CHEMBL619801,BAO_0000218,4615
,,U,,,22224,9544.0,Macaca mulatta,Oral bioavailability in Rhesus monkey,1,,,,In vivo,0,,4449,A,,Autocuration,CHEMBL619802,BAO_0000218,4616
,,U,,,22224,9544.0,Macaca mulatta,Oral bioavailability was calculated in rhesus monkey,1,,,,In vivo,0,,6057,A,,Autocuration,CHEMBL619803,BAO_0000218,4617
,,U,,,22224,9541.0,Macaca fascicularis,Oral bioavailability in cynomolgus monkey,1,,,,In vivo,0,,5922,A,,Autocuration,CHEMBL619965,BAO_0000218,4618
,,U,,,22224,9443.0,monkey,Oral bioavailability in monkey,1,,,,In vivo,0,,5940,A,,Autocuration,CHEMBL619966,BAO_0000218,4619
,,U,,,22224,9443.0,monkey,Oral bioavailability in monkey,1,,,,In vivo,0,,6265,A,,Autocuration,CHEMBL619967,BAO_0000218,4620
,,U,,,22224,9443.0,monkey,Oral bioavailability in monkey (dose 1 mg/kg),1,,,,In vivo,0,,6265,A,,Autocuration,CHEMBL620073,BAO_0000218,4621
,,U,,,22224,9443.0,monkey,Oral bioavailability in monkey (dose 5 mg/kg),1,,,,In vivo,0,,6265,A,,Autocuration,CHEMBL620074,BAO_0000218,4622
,,U,,,22224,9443.0,monkey,Oral bioavailability in monkey,1,,,,In vivo,0,,5940,A,,Autocuration,CHEMBL620075,BAO_0000218,4623
,,U,,,22224,9443.0,monkey,Oral bioavailability in monkey,1,,,,In vivo,0,,5940,A,,Autocuration,CHEMBL620076,BAO_0000218,4624
,,U,,,22224,9544.0,Macaca mulatta,Oral bioavailability in rhesus monkey,1,,,,In vivo,0,,4514,A,,Autocuration,CHEMBL620077,BAO_0000218,4625
,,U,,,22224,9544.0,Macaca mulatta,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,1,,,,In vivo,0,,5546,A,,Autocuration,CHEMBL620078,BAO_0000218,4626
,,U,,,22224,9521.0,Saimiri sciureus,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,1,,,,In vivo,0,,5553,A,,Autocuration,CHEMBL620079,BAO_0000218,4627
,,U,,,22224,9443.0,monkey,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,,,In vivo,0,,6641,A,,Autocuration,CHEMBL620080,BAO_0000218,4628
,,U,,,22224,9544.0,Macaca mulatta,Oral bioavailability in Rhesus monkey,1,,,,In vivo,0,,5472,A,,Autocuration,CHEMBL620081,BAO_0000218,4629
,,U,,,22224,9544.0,Macaca mulatta,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),1,,,,In vivo,0,,5668,A,,Autocuration,CHEMBL620082,BAO_0000218,4630
,,U,,,22224,9443.0,monkey,Oral bioavailability in monkey at 10 mg/kg of the compound,1,,,,In vivo,0,,5711,A,,Autocuration,CHEMBL620083,BAO_0000218,4631
,,U,,,22224,9544.0,Macaca mulatta,Bioavailability in Rhesus monkey,1,,,,In vivo,0,,5145,A,,Autocuration,CHEMBL620084,BAO_0000218,4632
,,U,,,22224,9527.0,Cercopithecidae,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,,,,,0,,3443,A,,Autocuration,CHEMBL620085,BAO_0000218,4633
,,U,,,22224,9527.0,Cercopithecidae,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,,,,,0,,3443,A,,Autocuration,CHEMBL874595,BAO_0000218,4634
,,U,,,22224,9527.0,Cercopithecidae,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,1,,,,In vivo,0,,3249,A,,Autocuration,CHEMBL873352,BAO_0000218,4635
,,U,,,22224,9527.0,Cercopithecidae,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,1,,,,In vivo,0,,3249,A,,Autocuration,CHEMBL620086,BAO_0000218,4636
,,U,,,22224,9527.0,Cercopithecidae,Mean residence time was determined after intravenous administration in cynomolgus monkeys,1,,,,In vivo,0,,5355,A,,Autocuration,CHEMBL620087,BAO_0000218,4637
,,U,,,22224,9527.0,Cercopithecidae,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,1,,,,In vivo,0,,5355,A,,Autocuration,CHEMBL620088,BAO_0000218,4638
,,U,,,22224,9527.0,Cercopithecidae,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,1,,,,In vivo,0,,5355,A,,Autocuration,CHEMBL620089,BAO_0000218,4639
,,U,,,22224,9527.0,Cercopithecidae,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),1,,,,In vivo,0,,4809,A,,Autocuration,CHEMBL620090,BAO_0000218,4640
,,U,,,22224,9527.0,Cercopithecidae,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),1,,,,In vivo,0,,4809,A,,Autocuration,CHEMBL620091,BAO_0000218,4641
,Microsomes,U,,,22224,9527.0,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),1,,,,,0,,14294,A,,Autocuration,CHEMBL620092,BAO_0000251,4642
,Microsomes,U,,,22224,9527.0,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),1,,,,,0,,14294,A,,Autocuration,CHEMBL620093,BAO_0000251,4643
,Microsomes,U,,,22224,9527.0,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),1,,,,,0,,14294,A,,Autocuration,CHEMBL620094,BAO_0000251,4644
,Microsomes,U,,,22224,9527.0,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),1,,,,,0,,14294,A,,Autocuration,CHEMBL620095,BAO_0000251,4645
,,U,,,22224,9527.0,Cercopithecidae,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,,,,In vivo,0,,3443,A,,Autocuration,CHEMBL620096,BAO_0000218,4646
,,U,,,22224,9527.0,Cercopithecidae,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,,,,In vivo,0,,3443,A,,Autocuration,CHEMBL620097,BAO_0000218,4647
,,U,,,22224,9527.0,Cercopithecidae,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,1,,,,,0,,11271,A,,Autocuration,CHEMBL620098,BAO_0000019,4648
,,U,,,22224,9527.0,Cercopithecidae,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,,,,,0,,3443,A,,Autocuration,CHEMBL620099,BAO_0000218,4649
,,U,,,22224,9527.0,Cercopithecidae,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,,,,,0,,3443,A,,Autocuration,CHEMBL620100,BAO_0000218,4650
,,U,,,22224,9527.0,Cercopithecidae,Elimination Half-life of compound was determined in monkey,1,,,,,0,,6821,A,,Autocuration,CHEMBL620101,BAO_0000019,4651
,,U,,,22224,9527.0,Cercopithecidae,Half life of compound was determined in rhesus monkey,1,,,,,0,,17267,A,,Autocuration,CHEMBL620102,BAO_0000019,4652
,,U,,,22224,9527.0,Cercopithecidae,Half life in monkey plasma,1,Plasma,,,,0,,5819,A,1969.0,Autocuration,CHEMBL620103,BAO_0000366,4653
,,U,,,22224,9527.0,Cercopithecidae,Half life in monkey plasma; Not detected,1,Plasma,,,,0,,5819,A,1969.0,Autocuration,CHEMBL620104,BAO_0000366,4654
,,U,,,22224,9527.0,Cercopithecidae,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1,,,,In vivo,0,,1916,A,,Autocuration,CHEMBL874596,BAO_0000218,4655
,,U,,,22224,9527.0,Cercopithecidae,Half-life 24 hr after 2 mg/kg iv administration in monkeys,1,,,,In vivo,0,,17509,A,,Autocuration,CHEMBL873490,BAO_0000218,4656
,,U,,,22224,9527.0,Cercopithecidae,Terminal half life of the compound.,1,,,,,0,,1399,A,,Autocuration,CHEMBL620105,BAO_0000019,4657
,,U,,,22224,9527.0,Cercopithecidae,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1,,,,In vivo,0,,1916,A,,Autocuration,CHEMBL620780,BAO_0000218,4658
,,U,,,22224,9527.0,Cercopithecidae,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),1,,,,In vivo,0,,4809,A,,Autocuration,CHEMBL620781,BAO_0000218,4659
,,U,,,22224,9527.0,Cercopithecidae,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,1,,,,,0,,5546,A,,Autocuration,CHEMBL620956,BAO_0000218,4660
,,U,,,22224,9527.0,Cercopithecidae,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,Urine,,,,0,,3443,A,1088.0,Autocuration,CHEMBL620957,BAO_0000218,4661
,,U,,,22224,9527.0,Cercopithecidae,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,Urine,,,,0,,3443,A,1088.0,Autocuration,CHEMBL620958,BAO_0000218,4662
,,U,,,22224,9527.0,Cercopithecidae,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,1,,,,In vivo,0,,4257,A,,Autocuration,CHEMBL620959,BAO_0000218,4663
,,U,,,22224,9527.0,Cercopithecidae,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,1,,,,In vivo,0,,6221,A,,Autocuration,CHEMBL620960,BAO_0000218,4664
,,U,,,22224,9527.0,Cercopithecidae,Volume of distribution was evaluated in rhesus,1,,,,In vivo,0,,5472,A,,Autocuration,CHEMBL620961,BAO_0000218,4665
,,U,,,22224,10029.0,Cricetulus griseus,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,1,,,,In vivo,0,,4727,A,,Autocuration,CHEMBL620962,BAO_0000218,4666
,,U,,,22224,10029.0,Cricetulus griseus,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,1,,,,In vivo,0,,4727,A,,Autocuration,CHEMBL620963,BAO_0000218,4667
,,U,,,22224,10029.0,Cricetulus griseus,Bioavailability in hamster was determined,1,,,,In vivo,0,,4727,A,,Autocuration,CHEMBL620964,BAO_0000218,4668
,,U,,,22224,10029.0,Cricetulus griseus,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,1,,,,In vivo,0,,4727,A,,Autocuration,CHEMBL620965,BAO_0000218,4669
,,U,,,22224,10029.0,Cricetulus griseus,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,1,,,,In vivo,0,,4727,A,,Autocuration,CHEMBL620966,BAO_0000218,4670
,,U,,,22224,10029.0,Cricetulus griseus,Half life of compound was determined in hamster blood,1,Blood,,,,0,,4727,A,178.0,Autocuration,CHEMBL620967,BAO_0000221,4671
,,U,,,22224,9823.0,Sus scrofa,Michaelis-Menten constant of the compound.,1,,,,,0,,1452,A,,Autocuration,CHEMBL620968,BAO_0000019,4672
,,U,,,22224,9823.0,Sus scrofa,Vmax value was measured at 0 uM concentration of silyl ether.,1,,,,,0,,1452,A,,Autocuration,CHEMBL874597,BAO_0000019,4673
,,U,,,22224,9823.0,Sus scrofa,Vmax value was measured at 10 uM concentration of silyl ether.,1,,,,,0,,1452,A,,Autocuration,CHEMBL620969,BAO_0000019,4674
,,U,,,22224,9823.0,Sus scrofa,Vmax value was measured at 5 uM concentration of silyl ether.,1,,,,,0,,1452,A,,Autocuration,CHEMBL620970,BAO_0000019,4675
,,D,,,235,9606.0,Homo sapiens,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,1,,,,,9,,11706,B,,Expert,CHEMBL620971,BAO_0000357,4676
,,U,,,22224,9606.0,Homo sapiens,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,1,,,,,0,,1916,A,,Autocuration,CHEMBL620972,BAO_0000218,4677
,,U,,,22224,9606.0,Homo sapiens,Compound was evaluated for area under the curve expressed as (h*ug/ml),1,,,,,0,,17791,A,,Autocuration,CHEMBL620973,BAO_0000019,4678
,,U,,,22224,9606.0,Homo sapiens,Active metabolite of ifosfamide determined in humans; A-Active,1,,,,,0,,7766,A,,Autocuration,CHEMBL618243,BAO_0000019,4679
,,U,,,22224,9606.0,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,1,,,,,0,,6567,A,,Autocuration,CHEMBL618244,BAO_0000019,4680
,,U,,,22224,9606.0,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,1,,,,,0,,6567,A,,Autocuration,CHEMBL618245,BAO_0000019,4681
,,U,,,22224,9606.0,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,1,,,,,0,,6567,A,,Autocuration,CHEMBL618246,BAO_0000019,4682
,,U,,,22224,9606.0,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,1,,,,,0,,6567,A,,Autocuration,CHEMBL618247,BAO_0000019,4683
,,U,,,22224,9606.0,Homo sapiens,Compound was evaluated for oral bioavailability in human,1,,,,,0,,17791,A,,Autocuration,CHEMBL618248,BAO_0000218,4684
,,U,,,22224,9606.0,Homo sapiens,Metabolite of ifosfamide determined in urine; NF-Not found,1,Urine,,,,0,,7766,A,1088.0,Autocuration,CHEMBL618249,BAO_0000019,4685
,,U,,,22224,9606.0,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),1,,,,,0,,6852,A,,Autocuration,CHEMBL618250,BAO_0000019,4686
,,U,,,22224,9606.0,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,1,,,,,0,,6852,A,,Autocuration,CHEMBL874598,BAO_0000019,4687
,,U,,,22224,9606.0,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,1,,,,,0,,6852,A,,Autocuration,CHEMBL618251,BAO_0000019,4688
,,U,,,22224,9606.0,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,1,,,,,0,,6852,A,,Autocuration,CHEMBL618252,BAO_0000019,4689
,,U,,,22224,9606.0,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,1,,,,,0,,6852,A,,Autocuration,CHEMBL618253,BAO_0000019,4690
,,U,,,22224,9606.0,Homo sapiens,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),1,,,,,0,,6852,A,,Autocuration,CHEMBL618254,BAO_0000019,4691
,,U,,,22224,9606.0,Homo sapiens,Percent of compound in healthy individuals (Group D),1,,,,,0,,6852,A,,Autocuration,CHEMBL618255,BAO_0000019,4692
,Microsomes,U,,,22224,9606.0,Homo sapiens,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,1,Liver,,,,0,,4397,A,2107.0,Autocuration,CHEMBL618983,BAO_0000251,4693
,,U,,,22224,9606.0,Homo sapiens,Binding towards human plasma protein at 10 uM,1,,,,,0,,17409,A,,Autocuration,CHEMBL618984,BAO_0000019,4694
,,U,,,22224,9606.0,Homo sapiens,Binding towards human plasma protein at 100 uM,1,,,,,0,,17409,A,,Autocuration,CHEMBL618985,BAO_0000019,4695
,,U,,,22224,9606.0,Homo sapiens,Human plasma protein binding activity was determined,1,,,,,0,,17176,A,,Autocuration,CHEMBL618986,BAO_0000019,4696
,,U,,,22224,9606.0,Homo sapiens,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),1,,,,,0,,15444,A,,Autocuration,CHEMBL618987,BAO_0000019,4697
,,U,,,22224,9606.0,Homo sapiens,Percent binding of compound towards human plasma protein was determined,1,,,,,0,,17267,A,,Autocuration,CHEMBL618988,BAO_0000019,4698
,Microsomes,U,,,22224,9606.0,Homo sapiens,Plasma clearance in human liver microsomes,1,Liver,,,In vitro,0,,5944,A,2107.0,Autocuration,CHEMBL618989,BAO_0000251,4699
,Microsomes,U,,,22224,9606.0,Homo sapiens,In vitro intrinsic clearance in human liver microsome,1,Liver,,,In vitro,0,,5668,A,2107.0,Autocuration,CHEMBL618990,BAO_0000251,4700
,Microsomes,U,,,22224,9606.0,Homo sapiens,In vitro intrinsic clearance in human liver microsome,1,Liver,,,In vitro,0,,5669,A,2107.0,Autocuration,CHEMBL618991,BAO_0000251,4701
,Microsomes,U,,,22224,9606.0,Homo sapiens,In vitro microsome metabolism clearance in human was determined,1,,,,In vitro,0,,5041,A,,Autocuration,CHEMBL876725,BAO_0000251,4702
,Microsomes,U,,,22224,9606.0,Homo sapiens,In vitro microsome metabolism clearance in human was determined; High,1,,,,In vitro,0,,5041,A,,Autocuration,CHEMBL618992,BAO_0000251,4703
,Microsomes,U,,,22224,9606.0,Homo sapiens,In vitro microsome metabolism clearance in human was determined; ND denotes no data,1,,,,In vitro,0,,5041,A,,Autocuration,CHEMBL618993,BAO_0000251,4704
,Microsomes,U,,,22224,9606.0,Homo sapiens,Pharmacokinetic property (clearance) in human liver microsome,1,Liver,,,In vitro,0,,5676,A,2107.0,Autocuration,CHEMBL618994,BAO_0000251,4705
,Microsomes,U,,,22224,9606.0,Homo sapiens,Plasma clearance in human liver microsomes,1,Liver,,,In vitro,0,,5944,A,2107.0,Autocuration,CHEMBL618995,BAO_0000251,4706
,Microsomes,U,,,22224,9606.0,Homo sapiens,In vitro clearance in human liver microsomes,1,Liver,,,In vitro,0,,17538,A,2107.0,Autocuration,CHEMBL618996,BAO_0000251,4707
,Microsomes,U,,,22224,9606.0,Homo sapiens,Intrinsic clearance in human liver microsomes was determined,1,Liver,,,In vitro,0,,6331,A,2107.0,Autocuration,CHEMBL618997,BAO_0000251,4708
,Microsomes,U,,,22224,9606.0,Homo sapiens,Intrinsic clearance in human liver microsomes was determined,1,Liver,,,In vitro,0,,5948,A,2107.0,Autocuration,CHEMBL618998,BAO_0000251,4709
,,U,,,22224,9606.0,Homo sapiens,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,1,,,,In vivo,0,,5965,A,,Autocuration,CHEMBL618999,BAO_0000218,4710
,,U,,,22224,9606.0,Homo sapiens,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,1,,,,In vivo,0,,1916,A,,Autocuration,CHEMBL620223,BAO_0000218,4711
,,U,,,22224,9606.0,Homo sapiens,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,1,,,,,0,,5965,A,,Autocuration,CHEMBL620224,BAO_0000218,4712
,,U,,,22224,9606.0,Homo sapiens,Stability in human plasma 2 hr after incubation expressed as percent concentration,1,,,,,0,,1299,A,,Autocuration,CHEMBL620225,BAO_0000019,4713
,,U,,,22224,9606.0,Homo sapiens,Stability in human plasma 4 hr after incubation expressed as percent concentration,1,,,,,0,,1299,A,,Autocuration,CHEMBL620226,BAO_0000019,4714
,,U,,,22224,9606.0,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,Urine,,,,0,,7766,A,1088.0,Autocuration,CHEMBL620227,BAO_0000019,4715
,,U,,,22224,9606.0,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,Urine,,,,0,,7766,A,1088.0,Autocuration,CHEMBL876726,BAO_0000019,4716
,,U,,,22224,9606.0,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,Urine,,,,0,,7766,A,1088.0,Autocuration,CHEMBL620228,BAO_0000019,4717
,,U,,,22224,9606.0,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,Urine,,,,0,,7766,A,1088.0,Autocuration,CHEMBL620229,BAO_0000019,4718
,,N,,,50594,10090.0,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,1,,,,In vivo,1,,17764,F,,Intermediate,CHEMBL620230,BAO_0000218,4719
,,N,,,50594,10090.0,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,1,,,,In vivo,1,,17764,F,,Intermediate,CHEMBL620231,BAO_0000218,4720
,,N,,,50594,10090.0,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,1,,,,In vivo,1,,17764,F,,Intermediate,CHEMBL620232,BAO_0000218,4721
,,N,,,50594,10090.0,Mus musculus,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,1,,,,In vivo,1,,17764,F,,Intermediate,CHEMBL620233,BAO_0000218,4722
,,N,,,50594,10090.0,Mus musculus,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),1,,,,,1,,14294,A,,Intermediate,CHEMBL620234,BAO_0000218,4723
,,N,,,50594,10090.0,Mus musculus,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),1,,,,,1,,14294,A,,Intermediate,CHEMBL620235,BAO_0000218,4724
,,N,,,50594,10090.0,Mus musculus,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),1,,,,,1,,14294,A,,Intermediate,CHEMBL620236,BAO_0000218,4725
,,N,,,50594,10090.0,Mus musculus,In vitro metabolic potential in mouse liver microsomes,1,Liver,,,,1,,6251,A,2107.0,Intermediate,CHEMBL620237,BAO_0000218,4726
,,N,,,50594,10090.0,Mus musculus,Ability of compound to bind to plasma protein was evaluated in HSA cells,1,,,,,1,,17582,A,,Intermediate,CHEMBL620238,BAO_0000218,4727
,,N,,,50594,10090.0,Mus musculus,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),1,Adrenal gland,,,,1,,17811,A,2369.0,Intermediate,CHEMBL620239,BAO_0000218,4728
,,N,,,50594,10090.0,Mus musculus,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,1,Brain,,,,1,,17811,A,955.0,Intermediate,CHEMBL620240,BAO_0000218,4729
,,N,,,50594,10090.0,Mus musculus,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,1,Brain,,,,1,,17811,A,955.0,Intermediate,CHEMBL620241,BAO_0000218,4730
,,N,,,50594,10090.0,Mus musculus,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),1,,,,,1,,17811,A,,Intermediate,CHEMBL876727,BAO_0000218,4731
,,N,,,50594,10090.0,Mus musculus,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),1,Kidney,,,,1,,17811,A,2113.0,Intermediate,CHEMBL620242,BAO_0000218,4732
,,N,,,50594,10090.0,Mus musculus,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),1,,,,,1,,17811,A,,Intermediate,CHEMBL620243,BAO_0000218,4733
,,N,,,50594,10090.0,Mus musculus,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,1,,,,,1,,5288,A,,Intermediate,CHEMBL620244,BAO_0000218,4734
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,1,Serum,,,,1,,2717,A,1977.0,Intermediate,CHEMBL620245,BAO_0000218,4735
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,1,Serum,,,,1,,2717,A,1977.0,Intermediate,CHEMBL620246,BAO_0000218,4736
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,1,Serum,,,,1,,2717,A,1977.0,Intermediate,CHEMBL620247,BAO_0000218,4737
,,N,,,50594,10090.0,Mus musculus,Half life of compound was determined in plasma of mice at 24 mg/Kg,1,Plasma,,,In vivo,1,,17753,A,1969.0,Intermediate,CHEMBL620248,BAO_0000218,4738
,,N,,,50594,10090.0,Mus musculus,Half life of compound was determined in plasma of mice at 40 mg/Kg,1,Plasma,,,In vivo,1,,17753,A,1969.0,Intermediate,CHEMBL873497,BAO_0000218,4739
,,N,,,50594,10090.0,Mus musculus,Half life of compound was determined in plasma of mice at 5 mg/Kg,1,Plasma,,,In vivo,1,,17753,A,1969.0,Intermediate,CHEMBL620249,BAO_0000218,4740
,,N,,,50594,10090.0,Mus musculus,Half life after intraperitoneal administration in mice at 18 uM/kg,1,,,,In vivo,1,,17764,F,,Intermediate,CHEMBL620250,BAO_0000218,4741
,,N,,,50594,10090.0,Mus musculus,Half life after intraperitoneal administration in mice at 23 uM/kg,1,,,,In vivo,1,,17764,F,,Intermediate,CHEMBL620251,BAO_0000218,4742
,,N,,,50594,10090.0,Mus musculus,Half life after intraperitoneal administration in mice at 25 uM/kg,1,,,,In vivo,1,,17764,F,,Intermediate,CHEMBL620252,BAO_0000218,4743
,,N,,,50594,10090.0,Mus musculus,Half life after intraperitoneal administration in mice at 26 uM/kg,1,,,,In vivo,1,,17764,F,,Intermediate,CHEMBL620253,BAO_0000218,4744
,,N,,,50594,10090.0,Mus musculus,Half life after intravenous administration in mice at 23 uM/kg,1,,,,In vivo,1,,17764,F,,Intermediate,CHEMBL620254,BAO_0000218,4745
,,N,,,50594,10090.0,Mus musculus,Half life after intravenous administration in mice at 24 uM/kg,1,,,,In vivo,1,,17764,A,,Intermediate,CHEMBL620255,BAO_0000218,4746
,,N,,,50594,10090.0,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,1,,,,In vivo,1,,16597,A,,Intermediate,CHEMBL620256,BAO_0000218,4747
,,N,,,50594,10090.0,Mus musculus,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,1,,,,In vivo,1,,2675,A,,Intermediate,CHEMBL876728,BAO_0000218,4748
,,N,,,50594,10090.0,Mus musculus,Maximum time required to reach Cp max was evaluated in mice after oral administration,1,,,,In vivo,1,,2675,A,,Intermediate,CHEMBL620257,BAO_0000218,4749
,,N,,,50594,10090.0,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),1,,,,In vivo,1,,16597,A,,Intermediate,CHEMBL620258,BAO_0000218,4750
,,N,,,50594,10090.0,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",1,,,,In vivo,1,,4890,A,,Intermediate,CHEMBL620259,BAO_0000218,4751
,,N,,,50594,10090.0,Mus musculus,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,1,,,,In vivo,1,,429,A,,Intermediate,CHEMBL620260,BAO_0000218,4752
,,N,,,50594,10090.0,Mus musculus,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,1,Blood,,,In vivo,1,,17837,A,178.0,Intermediate,CHEMBL620261,BAO_0000218,4753
,,N,,,50594,10090.0,Mus musculus,Half life at a dose of 10 mg/kg intravenous administration in mice.,1,,,,In vivo,1,,16597,A,,Intermediate,CHEMBL620262,BAO_0000218,4754
,,N,,,50594,10090.0,Mus musculus,Half life at a dose of 10 mg/kg peroral administration in mice.,1,,,,In vivo,1,,16597,A,,Intermediate,CHEMBL620263,BAO_0000218,4755
,,N,,,50594,10090.0,Mus musculus,Half life in ob/ob mice,1,,,,,1,,6619,A,,Intermediate,CHEMBL620264,BAO_0000218,4756
,,N,,,50594,10090.0,Mus musculus,Half-life at a single subcutaneous administration of 40 mg/kg in mice,1,,,,In vivo,1,,4066,A,,Intermediate,CHEMBL620265,BAO_0000218,4757
,,N,,,50594,10090.0,Mus musculus,Half-life was measured in mouse,1,,,,,1,,4239,A,,Intermediate,CHEMBL620266,BAO_0000218,4758
,,N,,,50594,10090.0,Mus musculus,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,1,,,,In vivo,1,,5969,A,,Intermediate,CHEMBL620267,BAO_0000218,4759
,,N,,,50594,10090.0,Mus musculus,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,1,,,,,1,,8999,A,,Intermediate,CHEMBL619364,BAO_0000218,4760
,,N,,,50594,10090.0,Mus musculus,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,1,,,,,1,,8999,A,,Intermediate,CHEMBL619365,BAO_0000218,4761
,,N,,,50594,10090.0,Mus musculus,T2 in brain of mice at the oral dose of 50 mg/kg,1,Brain,,,,1,,17641,A,955.0,Intermediate,CHEMBL619366,BAO_0000218,4762
,,N,,,50594,10090.0,Mus musculus,T2 in kidney of mice at the oral dose of 50 mg/kg,1,Kidney,,,,1,,17641,A,2113.0,Intermediate,CHEMBL619367,BAO_0000218,4763
,,N,,,50594,10090.0,Mus musculus,T2 in liver of mice at the oral dose of 50 mg/kg,1,Liver,,,,1,,17641,A,2107.0,Intermediate,CHEMBL619368,BAO_0000218,4764
,,N,,,50594,10090.0,Mus musculus,T2 in lungs of mice at the oral dose of 50 mg/kg,1,Lung,,,,1,,17641,A,2048.0,Intermediate,CHEMBL619369,BAO_0000218,4765
,,N,,,50594,10090.0,Mus musculus,T2 in spleen of mice at the oral dose of 50 mg/kg,1,Spleen,,,,1,,17641,A,2106.0,Intermediate,CHEMBL876729,BAO_0000218,4766
,,N,,,50594,10090.0,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,1,,,,In vivo,1,,16597,A,,Intermediate,CHEMBL619370,BAO_0000218,4767
,,N,,,50594,10090.0,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",1,,,,In vivo,1,,4890,A,,Intermediate,CHEMBL619371,BAO_0000218,4768
,,N,,,50594,10090.0,Mus musculus,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,1,,,,In vivo,1,,429,A,,Intermediate,CHEMBL619372,BAO_0000218,4769
,,N,,,50594,10090.0,Mus musculus,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,1,,,,In vivo,1,,429,A,,Intermediate,CHEMBL620012,BAO_0000218,4770
,,N,,,50594,10090.0,Mus musculus,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,1,,,,In vivo,1,,5969,A,,Intermediate,CHEMBL620013,BAO_0000218,4771
,,N,478.0,,81034,9606.0,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",1,,A2780,,,1,,16913,F,,Intermediate,CHEMBL620014,BAO_0000219,4772
,,N,478.0,,81034,9606.0,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",1,,A2780,,,1,,16913,F,,Intermediate,CHEMBL620015,BAO_0000219,4773
,,N,478.0,,81034,9606.0,Homo sapiens,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",1,,A2780,,,1,,16913,F,,Intermediate,CHEMBL621010,BAO_0000219,4774
,,N,478.0,,81034,9606.0,Homo sapiens,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",1,,A2780,,,1,,16913,F,,Intermediate,CHEMBL621011,BAO_0000219,4775
,,N,478.0,,81034,9606.0,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",1,,A2780,,,1,,16913,F,,Intermediate,CHEMBL621012,BAO_0000219,4776
,,N,478.0,,81034,9606.0,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",1,,A2780,,,1,,16913,F,,Intermediate,CHEMBL621013,BAO_0000219,4777
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro cytotoxicity against A2780TAX cell line,1,,A2780,,,1,,17270,F,,Intermediate,CHEMBL621014,BAO_0000219,4778
,,N,481.0,,80017,9606.0,Homo sapiens,In vitro inhibitory activity against human tumor cell line A2780cis,1,,A2780cisR,,,1,,5618,F,,Intermediate,CHEMBL618154,BAO_0000219,4779
,,N,478.0,,81034,9606.0,Homo sapiens,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,1,,A2780,,,1,,17777,F,,Expert,CHEMBL618155,BAO_0000219,4780
,,N,481.0,,80017,9606.0,Homo sapiens,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,1,,A2780cisR,,,1,,16112,F,,Intermediate,CHEMBL618156,BAO_0000219,4781
,,N,481.0,,80017,9606.0,Homo sapiens,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),1,,A2780cisR,,,1,,15748,F,,Intermediate,CHEMBL618157,BAO_0000219,4782
,,N,478.0,,81034,9606.0,Homo sapiens,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,1,,A2780,,,1,,6633,F,,Intermediate,CHEMBL618328,BAO_0000219,4783
,,N,478.0,,81034,9606.0,Homo sapiens,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,1,,A2780,,,1,,16930,F,,Intermediate,CHEMBL618329,BAO_0000219,4784
,,N,478.0,,81034,9606.0,Homo sapiens,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,1,,A2780,,,1,,17496,F,,Intermediate,CHEMBL618330,BAO_0000219,4785
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro antitumor activity against A2780cisR cell line.,1,,A2780,,,1,,12989,F,,Expert,CHEMBL618331,BAO_0000219,4786
,,N,478.0,,81034,9606.0,Homo sapiens,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),1,,A2780,,,1,,4840,F,,Intermediate,CHEMBL618332,BAO_0000219,4787
,,N,478.0,,81034,9606.0,Homo sapiens,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,1,,A2780,,,1,,12989,F,,Expert,CHEMBL618333,BAO_0000219,4788
,,N,481.0,,80017,9606.0,Homo sapiens,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,1,,A2780cisR,,,1,,16745,F,,Intermediate,CHEMBL618334,BAO_0000219,4789
,,N,478.0,,81034,9606.0,Homo sapiens,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,1,,A2780,,,1,,16597,F,,Expert,CHEMBL618335,BAO_0000219,4790
,,D,,,11736,10116.0,Rattus norvegicus,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,1,,,,,9,,16547,B,,Expert,CHEMBL618336,BAO_0000019,4791
,,H,,,11736,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),1,,,,,8,,16547,F,,Expert,CHEMBL618337,BAO_0000019,4792
,,D,,,11736,10116.0,Rattus norvegicus,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),1,,,,,9,,16547,F,,Expert,CHEMBL618338,BAO_0000019,4793
,,D,722.0,,278,9606.0,Homo sapiens,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,1,,HEK293,,,9,,15856,F,,Expert,CHEMBL618339,BAO_0000219,4794
,,D,722.0,,278,9606.0,Homo sapiens,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,1,,HEK293,,,9,,15856,F,,Expert,CHEMBL618340,BAO_0000219,4795
,,D,,,11831,10090.0,Mus musculus,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,1,,,,,9,,16547,B,,Expert,CHEMBL618341,BAO_0000019,4796
,,H,,,11831,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),1,,,,,8,,16547,F,,Expert,CHEMBL618342,BAO_0000019,4797
,,D,,,11831,10090.0,Mus musculus,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),1,,,,,9,,16547,F,,Expert,CHEMBL618343,BAO_0000019,4798
,,H,,,280,,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,1,,,,,8,,17402,B,,Expert,CHEMBL621038,BAO_0000357,4799
,,U,574.0,,22226,9606.0,Homo sapiens,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),1,,T-cells,,,0,,11746,F,,Autocuration,CHEMBL621039,BAO_0000219,4800
,,U,574.0,,22226,9606.0,Homo sapiens,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,1,,T-cells,,,0,,11746,F,,Autocuration,CHEMBL621040,BAO_0000219,4801
,,N,455.0,,80018,9606.0,Homo sapiens,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,1,,A-375,,,1,,5455,F,,Intermediate,CHEMBL621041,BAO_0000219,4802
,,N,455.0,,80018,9606.0,Homo sapiens,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,1,,A-375,,,1,,2068,F,,Intermediate,CHEMBL621042,BAO_0000219,4803
,,N,455.0,,80018,9606.0,Homo sapiens,In vitro antitumor activity against A375cell line extracted form melanoma,1,,A-375,,,1,,2683,F,,Intermediate,CHEMBL621043,BAO_0000219,4804
,,N,455.0,,80018,9606.0,Homo sapiens,Inhibition of cell growth in (A375) melan cell line,1,,A-375,,,1,,15313,F,,Expert,CHEMBL621044,BAO_0000219,4805
,,N,455.0,,80018,9606.0,Homo sapiens,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,1,,A-375,,,1,,13739,F,,Intermediate,CHEMBL621045,BAO_0000219,4806
,,N,455.0,,80018,9606.0,Homo sapiens,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,1,,A-375,,,1,,13739,F,,Intermediate,CHEMBL621046,BAO_0000219,4807
,,N,455.0,,80018,9606.0,Homo sapiens,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,1,,A-375,,,1,,14750,F,,Intermediate,CHEMBL621047,BAO_0000219,4808
,,N,797.0,,80019,9606.0,Homo sapiens,Antiproliferative activity measured against A427 human lung carcinoma,1,,A-427,,,1,,14777,F,,Intermediate,CHEMBL621048,BAO_0000219,4809
,,N,797.0,,80019,9606.0,Homo sapiens,Antiproliferative activity measured against A427 human lung carcinoma,1,,A-427,,,1,,14777,F,,Intermediate,CHEMBL883798,BAO_0000219,4810
,,N,797.0,,80019,9606.0,Homo sapiens,Cytotoxicity against lung carcinoma A427 tumor cell lines,1,,A-427,,,1,,17672,F,,Intermediate,CHEMBL621049,BAO_0000219,4811
,,N,797.0,,80019,9606.0,Homo sapiens,Inhibition of large cell lung carcinoma (A427),1,,A-427,,,1,,14368,F,,Intermediate,CHEMBL621050,BAO_0000219,4812
,,N,797.0,,80019,9606.0,Homo sapiens,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,1,,A-427,,,1,,14368,F,,Intermediate,CHEMBL621051,BAO_0000219,4813
,,N,797.0,,80019,9606.0,Homo sapiens,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,1,,A-427,,,1,,13866,F,,Intermediate,CHEMBL621052,BAO_0000219,4814
,,N,797.0,,80019,9606.0,Homo sapiens,Inhibitory concentration in human lung carcinoma A427 cell line,1,,A-427,,,1,,2545,F,,Intermediate,CHEMBL621053,BAO_0000219,4815
,,N,797.0,,80019,9606.0,Homo sapiens,Inhibitory concentration in human lung carcinoma A427/VCR cell line,1,,A-427,,,1,,2545,F,,Intermediate,CHEMBL621054,BAO_0000219,4816
,,U,,,22224,9527.0,Cercopithecidae,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,1,,,,In vivo,0,,6062,A,,Autocuration,CHEMBL621055,BAO_0000218,4817
,,U,,,22224,9527.0,Cercopithecidae,Tested for volume of distribution upon iv administration to african green monkey,1,,,,In vivo,0,,4578,A,,Autocuration,CHEMBL876398,BAO_0000218,4818
,,U,,,22224,9527.0,Cercopithecidae,Volume of distribution in monkey,1,,,,In vivo,0,,17592,A,,Autocuration,CHEMBL621056,BAO_0000218,4819
,,U,,,22224,9544.0,Macaca mulatta,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1,,,,In vivo,0,,5005,A,,Autocuration,CHEMBL621057,BAO_0000218,4820
,,U,,,22224,9544.0,Macaca mulatta,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,1,,,,In vivo,0,,5005,A,,Autocuration,CHEMBL621058,BAO_0000218,4821
,,U,,,22224,9527.0,Cercopithecidae,Pharmacokinetic property(Vdss) in cynomolgus monkey,1,,,,In vivo,0,,5922,A,,Autocuration,CHEMBL621059,BAO_0000218,4822
,,U,,,22224,9527.0,Cercopithecidae,The distribution volume after intravenous administration in cynomolgus monkeys,1,,,,In vivo,0,,5355,A,,Autocuration,CHEMBL621060,BAO_0000218,4823
,,U,,,22224,9527.0,Cercopithecidae,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,1,,,,In vivo,0,,5355,A,,Autocuration,CHEMBL621061,BAO_0000218,4824
,,U,,,22224,9527.0,Cercopithecidae,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,1,,,,In vivo,0,,5355,A,,Autocuration,CHEMBL621062,BAO_0000218,4825
,,U,,,22224,9527.0,Cercopithecidae,Volume displacement was calculated in rhesus monkey,1,,,,In vivo,0,,6057,A,,Autocuration,CHEMBL621063,BAO_0000218,4826
,,U,,,22224,9527.0,Cercopithecidae,Volume of distribution in steady state was determined in rhesus monkey,1,,,,In vivo,0,,5145,A,,Autocuration,CHEMBL621064,BAO_0000218,4827
,,U,,,22224,9527.0,Cercopithecidae,Volume of distribution of compound was determined in monkey,1,,,,In vivo,0,,6821,A,,Autocuration,CHEMBL621065,BAO_0000218,4828
,,U,,,22224,9527.0,Cercopithecidae,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),1,,,,In vivo,0,,5334,A,,Autocuration,CHEMBL621066,BAO_0000218,4829
,,U,,,22224,9527.0,Cercopithecidae,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),1,,,,In vivo,0,,5334,A,,Autocuration,CHEMBL621067,BAO_0000218,4830
,,U,,,22224,9527.0,Cercopithecidae,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,,,In vivo,0,,6641,A,,Autocuration,CHEMBL621068,BAO_0000218,4831
,,U,,,22224,9527.0,Cercopithecidae,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,1,,,,In vivo,0,,2661,A,,Autocuration,CHEMBL876399,BAO_0000218,4832
,,U,,,22224,9527.0,Cercopithecidae,Volume distribution in monkey after administration of 1 mg/kg iv,1,,,,In vivo,0,,6535,A,,Autocuration,CHEMBL621069,BAO_0000218,4833
,,U,,,22224,9527.0,Cercopithecidae,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),1,,,,In vivo,0,,4809,A,,Autocuration,CHEMBL621070,BAO_0000218,4834
,,U,,,22224,9527.0,Cercopithecidae,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,1,,,,In vivo,0,,6062,A,,Autocuration,CHEMBL621071,BAO_0000218,4835
,,U,,,22224,9527.0,Cercopithecidae,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,,,,In vivo,0,,3443,A,,Autocuration,CHEMBL621072,BAO_0000218,4836
,,U,,,22224,9527.0,Cercopithecidae,Oral systemic bioavailability upon iv administration to african green monkey,1,,,,In vivo,0,,4578,A,,Autocuration,CHEMBL618209,BAO_0000218,4837
,,U,,,22224,9527.0,Cercopithecidae,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),1,,,,In vivo,0,,4809,A,,Autocuration,CHEMBL618210,BAO_0000218,4838
,,U,,,22224,9527.0,Cercopithecidae,Baboon plasma free fraction. ,1,,,,,0,,11271,A,,Autocuration,CHEMBL618211,BAO_0000019,4839
,,U,,,22224,9527.0,Cercopithecidae,Area under the curve was calculated in rhesus monkey after iv administration,1,,,,,0,,6057,A,,Autocuration,CHEMBL618212,BAO_0000218,4840
,,U,,,22224,9527.0,Cercopithecidae,Area under the curve was calculated in rhesus monkey after peroral administration,1,,,,,0,,6057,A,,Autocuration,CHEMBL618213,BAO_0000019,4841
,,U,,,22224,9527.0,Cercopithecidae,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,1,,,,,0,,17853,A,,Autocuration,CHEMBL618214,BAO_0000019,4842
,,U,,,22224,9527.0,Cercopithecidae,Half life period in monkey after 5 mg/kg dose,1,,,,In vivo,0,,5302,A,,Autocuration,CHEMBL873492,BAO_0000218,4843
,,U,,,22224,9527.0,Cercopithecidae,Half-life was determined in monkey after 3 mg/kg of i.v. dose,1,,,,In vivo,0,,4257,A,,Autocuration,CHEMBL618272,BAO_0000218,4844
,,U,,,22224,9527.0,Cercopithecidae,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,1,,,,In vivo,0,,4257,A,,Autocuration,CHEMBL618273,BAO_0000218,4845
,,U,,,22224,9527.0,Cercopithecidae,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,1,Plasma,,,In vivo,0,,13501,A,1969.0,Autocuration,CHEMBL618274,BAO_0000218,4846
,,U,,,22224,9527.0,Cercopithecidae,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,1,,,,In vivo,0,,5394,A,,Autocuration,CHEMBL618275,BAO_0000218,4847
,,U,,,22224,9527.0,Cercopithecidae,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,1,,,,In vivo,0,,2661,A,,Autocuration,CHEMBL618276,BAO_0000218,4848
,,U,,,22224,9527.0,Cercopithecidae,Compound was evaluated for terminal half life in monkey,1,,,,,0,,3341,A,,Autocuration,CHEMBL618277,BAO_0000019,4849
,,U,,,22224,9527.0,Cercopithecidae,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,1,,,,In vivo,0,,3045,A,,Autocuration,CHEMBL618278,BAO_0000218,4850
,,U,,,22224,9544.0,Macaca mulatta,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1,Plasma,,,In vivo,0,,5005,A,1969.0,Autocuration,CHEMBL618279,BAO_0000218,4851
,,U,,,22224,9527.0,Cercopithecidae,Half life of compound was determined in squirrel monkey,1,,,,,0,,4847,A,,Autocuration,CHEMBL618280,BAO_0000019,4852
,,U,,,22224,9541.0,Macaca fascicularis,Half life after iv administration in cynomolgus monkey,1,,,,In vivo,0,,4256,A,,Autocuration,CHEMBL618281,BAO_0000218,4853
,,U,,,22224,9527.0,Cercopithecidae,Half life in monkey plasma after administration of 1 mg/kg iv,1,Plasma,,,In vivo,0,,6535,A,1969.0,Autocuration,CHEMBL618282,BAO_0000218,4854
,,U,,,22224,9527.0,Cercopithecidae,Half life was calculated in rhesus monkey,1,,,,,0,,6057,A,,Autocuration,CHEMBL618283,BAO_0000019,4855
,,U,,,22224,9527.0,Cercopithecidae,Half life in monkey,1,,,,,0,,17592,A,,Autocuration,CHEMBL618284,BAO_0000019,4856
,,U,,,22224,9527.0,Cercopithecidae,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,,,In vivo,0,,6641,A,,Autocuration,CHEMBL618285,BAO_0000218,4857
,,U,,,22224,9527.0,Cercopithecidae,Half life was evaluated in rhesus,1,,,,,0,,5472,A,,Autocuration,CHEMBL618286,BAO_0000019,4858
,,U,,,22224,9527.0,Cercopithecidae,Half life period after oral administration (2.5 mg/kg) in monkey was determined,1,,,,In vivo,0,,6221,A,,Autocuration,CHEMBL618287,BAO_0000218,4859
,,U,,,22224,9527.0,Cercopithecidae,Half life period was determine after peroral administration at 10 mpk in Rhesus,1,,,,In vivo,0,,5668,A,,Autocuration,CHEMBL618288,BAO_0000218,4860
,,U,,,22224,9527.0,Cercopithecidae,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),1,,,,In vivo,0,,4809,A,,Autocuration,CHEMBL876393,BAO_0000218,4861
,,U,,,22224,9527.0,Cercopithecidae,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,1,,,,In vivo,0,,5546,A,,Autocuration,CHEMBL618289,BAO_0000218,4862
,,U,,,22224,9527.0,Cercopithecidae,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,1,,,,In vivo,0,,5553,A,,Autocuration,CHEMBL618290,BAO_0000218,4863
,,U,,,22224,9527.0,Cercopithecidae,Half-life was calculated in monkey,1,,,,,0,,6078,A,,Autocuration,CHEMBL618291,BAO_0000019,4864
,,U,,,22224,9527.0,Cercopithecidae,Half-life in Squirrel monkey,1,,,,,0,,5147,A,,Autocuration,CHEMBL618292,BAO_0000019,4865
,,U,,,22224,9527.0,Cercopithecidae,Half-life in rhesus monkey,1,,,,,0,,5145,A,,Autocuration,CHEMBL618293,BAO_0000019,4866
,,U,,,22224,9527.0,Cercopithecidae,Half-life was measured in monkey after an iv dose of 1 mg/kg,1,,,,In vivo,0,,6062,A,,Autocuration,CHEMBL618294,BAO_0000218,4867
,,U,,,22224,9527.0,Cercopithecidae,Half-life period after intravenous administration in cynomolgus monkeys,1,,,,In vivo,0,,5355,A,,Autocuration,CHEMBL618295,BAO_0000218,4868
,,U,,,22224,9527.0,Cercopithecidae,Half-life period after oral administration in cynomolgus monkeys,1,,,,In vivo,0,,5355,A,,Autocuration,CHEMBL618296,BAO_0000218,4869
,,U,,,22224,9527.0,Cercopithecidae,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,1,,,,In vivo,0,,5355,A,,Autocuration,CHEMBL618297,BAO_0000218,4870
,,U,,,22224,9606.0,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,Urine,,,,0,,7766,A,1088.0,Autocuration,CHEMBL618298,BAO_0000019,4871
,,U,,,22224,9606.0,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,Urine,,,,0,,7766,A,1088.0,Autocuration,CHEMBL618299,BAO_0000019,4872
,,U,,,22224,9606.0,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,Urine,,,,0,,7766,A,1088.0,Autocuration,CHEMBL618300,BAO_0000019,4873
,,U,,,22224,9606.0,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,Urine,,,,0,,7766,A,1088.0,Autocuration,CHEMBL618301,BAO_0000019,4874
,,U,,,22224,9606.0,Homo sapiens,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,1,Urine,,,,0,,7766,A,1088.0,Autocuration,CHEMBL618302,BAO_0000019,4875
,,U,,,22224,9606.0,Homo sapiens,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,1,Urine,,,,0,,7766,A,1088.0,Autocuration,CHEMBL876394,BAO_0000019,4876
,,U,,,22224,9606.0,Homo sapiens,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,1,Urine,,,,0,,7766,A,1088.0,Autocuration,CHEMBL618303,BAO_0000019,4877
,,U,,,22224,9606.0,Homo sapiens,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,1,Urine,,,,0,,7766,A,1088.0,Autocuration,CHEMBL618304,BAO_0000019,4878
,,U,,,22224,9606.0,Homo sapiens,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,1,,,,In vivo,0,,1916,A,,Autocuration,CHEMBL618305,BAO_0000218,4879
,,U,,,22224,9606.0,Homo sapiens,Oral bioavailability in human,1,,,,In vivo,0,,16643,A,,Autocuration,CHEMBL618306,BAO_0000218,4880
,,U,,,22224,9606.0,Homo sapiens,Compound was tested for human plasma protein binding,1,,,,,0,,17248,A,,Autocuration,CHEMBL618307,BAO_0000019,4881
,,U,,,22224,9606.0,Homo sapiens,Compound was tested for human plasma protein binding; Not determined,1,,,,,0,,17248,A,,Autocuration,CHEMBL618308,BAO_0000019,4882
,,U,,,22224,9606.0,Homo sapiens,Protein binding activity of compound in human plasma; % Free,1,,,,,0,,6241,A,,Autocuration,CHEMBL618309,BAO_0000019,4883
,,U,,,22224,9606.0,Homo sapiens,Unbound fraction (plasma),1,,,,,0,,17716,A,,Autocuration,CHEMBL618310,BAO_0000019,4884
,,U,,,22224,9606.0,Homo sapiens,Half life for the hydrolysis of compound in human blood serum,1,Plasma,,,,0,,17605,A,1969.0,Autocuration,CHEMBL873353,BAO_0000366,4885
,,U,,,22224,9606.0,Homo sapiens,Half life period in human plasma using phosphate buffer (0.08 M),1,Plasma,,,,0,,17625,A,1969.0,Autocuration,CHEMBL618311,BAO_0000366,4886
,,U,,,22224,9606.0,Homo sapiens,Half life period in human plasma using phosphate buffer (0.1 M),1,Plasma,,,,0,,17625,A,1969.0,Autocuration,CHEMBL618312,BAO_0000366,4887
,,U,,,22224,9606.0,Homo sapiens,Half-life in human plasma was determined,1,Plasma,,,,0,,17747,A,1969.0,Autocuration,CHEMBL618313,BAO_0000366,4888
,,U,,,22224,9606.0,Homo sapiens,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,1,,,,,0,,15613,A,,Autocuration,CHEMBL618314,BAO_0000019,4889
,,U,,,22224,9606.0,Homo sapiens,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),1,,,,,0,,354,A,,Autocuration,CHEMBL618315,BAO_0000019,4890
,,U,,,22224,9606.0,Homo sapiens,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",1,,,,,0,,3741,A,,Autocuration,CHEMBL618316,BAO_0000019,4891
,,U,,,22224,9606.0,Homo sapiens,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",1,,,,,0,,3741,A,,Autocuration,CHEMBL618317,BAO_0000019,4892
,,U,,,22224,9606.0,Homo sapiens,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",1,,,,,0,,3741,A,,Autocuration,CHEMBL620138,BAO_0000019,4893
,,U,,,22224,9606.0,Homo sapiens,Partition coefficient (logP),1,,,,,0,,17599,A,,Autocuration,CHEMBL858280,BAO_0000019,4894
,,U,,,22224,9606.0,Homo sapiens,In vitro metabolic stability in human was measured as pmol/min/mg/protein,1,,,,,0,,5486,A,,Autocuration,CHEMBL620139,BAO_0000019,4895
,Microsomes,U,,,22224,9606.0,Homo sapiens,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,1,,,,,0,,5600,A,,Autocuration,CHEMBL620140,BAO_0000251,4896
,,U,,,22224,9606.0,Homo sapiens,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),1,,,,,0,,14294,A,,Autocuration,CHEMBL620141,BAO_0000019,4897
,,U,,,22224,9606.0,Homo sapiens,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),1,,,,,0,,14294,A,,Autocuration,CHEMBL620142,BAO_0000019,4898
,,U,,,22224,9606.0,Homo sapiens,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),1,,,,,0,,14294,A,,Autocuration,CHEMBL620143,BAO_0000019,4899
,Microsomes,U,,,22224,9606.0,Homo sapiens,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),1,,,,,0,,14294,A,,Autocuration,CHEMBL620144,BAO_0000251,4900
,Microsomes,U,,,22224,9606.0,Homo sapiens,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),1,,,,,0,,14294,A,,Autocuration,CHEMBL620145,BAO_0000251,4901
,Microsomes,U,,,22224,9606.0,Homo sapiens,Metabolism of compound in human microsomes; Trace,1,,,,,0,,14294,A,,Autocuration,CHEMBL620146,BAO_0000251,4902
,Microsomes,U,,,22224,9606.0,Homo sapiens,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,1,Liver,,,,0,,6260,A,2107.0,Autocuration,CHEMBL620147,BAO_0000251,4903
,Microsomes,U,,,22224,9606.0,Homo sapiens,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,1,,,,,0,,6187,A,,Autocuration,CHEMBL620148,BAO_0000251,4904
,Microsomes,U,,,22224,9606.0,Homo sapiens,In vitro metabolic potential in human liver microsomes,1,Liver,,,,0,,6251,A,2107.0,Autocuration,CHEMBL620149,BAO_0000251,4905
,,U,,,22224,9606.0,Homo sapiens,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,1,,,,,0,,3246,A,,Autocuration,CHEMBL876412,BAO_0000019,4906
,,U,,,22224,9606.0,Homo sapiens,Tested for human plasma protein binding of the compound; Not tested,1,,,,,0,,17313,A,,Autocuration,CHEMBL619352,BAO_0000019,4907
,,U,,,22224,9606.0,Homo sapiens,Compound was tested for percent protein binding (PB) in human,1,,,,,0,,6227,A,,Autocuration,CHEMBL619353,BAO_0000019,4908
,,U,,,22224,9606.0,Homo sapiens,Protein binding in human plasma,1,Plasma,,,,0,,5530,A,1969.0,Autocuration,CHEMBL619354,BAO_0000019,4909
,,U,,,22224,9606.0,Homo sapiens,Permeability coefficient (B to A) in Caco-2 cell,1,,,,,0,,6108,A,,Autocuration,CHEMBL619355,BAO_0000019,4910
,,U,,,22224,9606.0,Homo sapiens,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,1,,,,,0,,6108,A,,Autocuration,CHEMBL619356,BAO_0000019,4911
,,U,,,22224,9606.0,Homo sapiens,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),1,,,,,0,,2774,A,,Autocuration,CHEMBL619357,BAO_0000019,4912
,,U,,,22224,9606.0,Homo sapiens,In vitro rate of absorption observed as Caco-2 permeability in humans,1,,,,,0,,16643,A,,Autocuration,CHEMBL619358,BAO_0000019,4913
,,U,495.0,,22224,9606.0,Homo sapiens,Cellular permeability of compound was determined in Caco-2 cells; High,1,,Caco-2,,,0,,17582,A,,Autocuration,CHEMBL619359,BAO_0000219,4914
,,U,495.0,,22224,9606.0,Homo sapiens,Permeability in Caco-2 cells of compound,1,,Caco-2,,,0,,6838,A,,Autocuration,CHEMBL619360,BAO_0000219,4915
,,U,,,22224,9606.0,Homo sapiens,Permeability coefficient (A to B) in Caco-2 cell,1,,,,,0,,6108,A,,Autocuration,CHEMBL619361,BAO_0000019,4916
,,U,,,22224,9606.0,Homo sapiens,Permeability coefficient (B to A) in Caco-2 cell,1,,,,,0,,6108,A,,Autocuration,CHEMBL619362,BAO_0000019,4917
,,U,,,22224,9606.0,Homo sapiens,Permeability coefficient (Papp) (Caco-2 cell monolayer),1,,,,,0,,6108,A,,Autocuration,CHEMBL619363,BAO_0000019,4918
,,U,,,22224,9606.0,Homo sapiens,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,1,,,,,0,,2146,A,,Autocuration,CHEMBL618942,BAO_0000019,4919
,,U,,,22224,9606.0,Homo sapiens,Compound was tested for protein binding in human plasma,1,,,,,0,,4514,A,,Autocuration,CHEMBL618943,BAO_0000019,4920
,,U,,,22224,9606.0,Homo sapiens,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,1,,,,,0,,6108,A,,Autocuration,CHEMBL618944,BAO_0000019,4921
,,U,,,22224,9606.0,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,1,Urine,,,,0,,7766,A,1088.0,Autocuration,CHEMBL618945,BAO_0000019,4922
,,N,,,50594,10090.0,Mus musculus,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,1,,,,In vivo,1,,5969,A,,Intermediate,CHEMBL618946,BAO_0000218,4923
,,N,,,50594,10090.0,Mus musculus,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),1,,,,In vivo,1,,3277,A,,Intermediate,CHEMBL876413,BAO_0000218,4924
,,N,,,50594,10090.0,Mus musculus,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,1,,,,In vivo,1,,3802,A,,Intermediate,CHEMBL618947,BAO_0000218,4925
,,N,,,50594,10090.0,Mus musculus,Time taken to reach maximum concentration in plasma upon oral administration in mouse,1,Plasma,,,In vivo,1,,2862,A,1969.0,Intermediate,CHEMBL618948,BAO_0000218,4926
,,N,,,50594,10090.0,Mus musculus,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,Plasma,,,In vivo,1,,6348,A,1969.0,Intermediate,CHEMBL618949,BAO_0000218,4927
,,N,,,50594,10090.0,Mus musculus,Tmax after intraperitoneal administration in mice at 23 uM/kg,1,,,,In vivo,1,,17764,F,,Intermediate,CHEMBL618950,BAO_0000218,4928
,,N,,,50594,10090.0,Mus musculus,Tmax after oral administration at 30 mg/kg in ICR mouse,1,,,,In vivo,1,,5781,A,,Intermediate,CHEMBL618951,BAO_0000218,4929
,,N,,,50594,10090.0,Mus musculus,Tmax after peroral administration in mice at 2.4 uM/kg,1,,,,In vivo,1,,17764,A,,Intermediate,CHEMBL618952,BAO_0000218,4930
,,N,,,50594,10090.0,Mus musculus,Tmax at a single subcutaneous administration of 40 mg/kg in mice,1,,,,In vivo,1,,4066,A,,Intermediate,CHEMBL618953,BAO_0000218,4931
,,N,,,50594,10090.0,Mus musculus,Tmax in brain of mice at the oral dose of 50 mg/kg,1,Brain,,,In vivo,1,,17641,A,955.0,Intermediate,CHEMBL618954,BAO_0000218,4932
,,N,,,50594,10090.0,Mus musculus,Tmax in kidney of mice at the oral dose of 50 mg/kg,1,Kidney,,,In vivo,1,,17641,A,2113.0,Intermediate,CHEMBL618955,BAO_0000218,4933
,,N,,,50594,10090.0,Mus musculus,Tmax in liver of mice at the oral dose of 50 mg/kg,1,Liver,,,In vivo,1,,17641,A,2107.0,Intermediate,CHEMBL618956,BAO_0000218,4934
,,N,,,50594,10090.0,Mus musculus,Tmax in lungs of mice at the oral dose of 50 mg/kg,1,Lung,,,In vivo,1,,17641,A,2048.0,Intermediate,CHEMBL618957,BAO_0000218,4935
,,N,,,50594,10090.0,Mus musculus,Tmax in mice at 18 uM/kg i.p. administration,1,,,,In vivo,1,,17764,F,,Intermediate,CHEMBL618958,BAO_0000218,4936
,,N,,,50594,10090.0,Mus musculus,Tmax in mice at 23 uM/kg i.v. administration,1,,,,In vivo,1,,17764,F,,Intermediate,CHEMBL618959,BAO_0000218,4937
,,N,,,50594,10090.0,Mus musculus,Tmax in mice at 25 uM/kg i.p. administration,1,,,,In vivo,1,,17764,F,,Intermediate,CHEMBL618960,BAO_0000218,4938
,,N,,,50594,10090.0,Mus musculus,Tmax in mice at 26 uM/kg i.p. administration,1,,,,In vivo,1,,17764,F,,Intermediate,CHEMBL876723,BAO_0000218,4939
,,N,,,50594,10090.0,Mus musculus,Tmax in spleen of mice at the oral dose of 50 mg/kg,1,Spleen,,,In vivo,1,,17641,A,2106.0,Intermediate,CHEMBL618961,BAO_0000218,4940
,,N,,,50594,10090.0,Mus musculus,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,1,,,,In vivo,1,,16597,A,,Intermediate,CHEMBL618962,BAO_0000218,4941
,,N,,,50594,10090.0,Mus musculus,Tmax value at a dose of 10 mg/kg peroral administration in mice.,1,,,,In vivo,1,,16597,A,,Intermediate,CHEMBL618963,BAO_0000218,4942
,,N,,,50594,10090.0,Mus musculus,Tmax value in IRC mice,1,,,,,1,,5951,A,,Intermediate,CHEMBL618964,BAO_0000218,4943
,,N,,,50594,10090.0,Mus musculus,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,1,,,,In vivo,1,,5506,A,,Intermediate,CHEMBL618965,BAO_0000218,4944
,,N,,,50594,10090.0,Mus musculus,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,1,,,,In vivo,1,,5506,A,,Intermediate,CHEMBL618966,BAO_0000218,4945
,,N,,,50594,10090.0,Mus musculus,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),1,Urine,,,,1,,429,A,1088.0,Intermediate,CHEMBL618967,BAO_0000218,4946
,,N,,,50594,10090.0,Mus musculus,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),1,Urine,,,,1,,429,A,1088.0,Intermediate,CHEMBL618968,BAO_0000218,4947
,,N,,,50594,10090.0,Mus musculus,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),1,Urine,,,,1,,4066,A,1088.0,Intermediate,CHEMBL618969,BAO_0000218,4948
,,N,,,50594,10090.0,Mus musculus,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,1,,,,,1,,17734,A,,Intermediate,CHEMBL618970,BAO_0000218,4949
,,N,,,50594,10090.0,Mus musculus,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,1,,,,,1,,17734,A,,Intermediate,CHEMBL618971,BAO_0000218,4950
,,N,,,50594,10090.0,Mus musculus,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,1,,,,In vivo,1,,6062,A,,Intermediate,CHEMBL618972,BAO_0000218,4951
,,N,,,50594,10090.0,Mus musculus,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,1,,,,In vivo,1,,5969,A,,Intermediate,CHEMBL618973,BAO_0000218,4952
,,N,,,50594,10090.0,Mus musculus,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,1,,,,In vivo,1,,5969,A,,Intermediate,CHEMBL618974,BAO_0000218,4953
,,N,,,50594,10090.0,Mus musculus,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,1,,,,In vivo,1,,5969,A,,Intermediate,CHEMBL618975,BAO_0000218,4954
,,N,,,50594,10090.0,Mus musculus,Vd in mice,1,,,,In vivo,1,,5980,A,,Intermediate,CHEMBL618976,BAO_0000218,4955
,,N,,,50594,10090.0,Mus musculus,Volume of distribution in mouse,1,,,,In vivo,1,,17592,A,,Intermediate,CHEMBL618977,BAO_0000218,4956
,,N,,,50594,10090.0,Mus musculus,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,,,,In vivo,1,,6348,A,,Intermediate,CHEMBL876724,BAO_0000218,4957
,,N,,,50594,10090.0,Mus musculus,Volume of distribution of compound in plasma was determined at 24 mg/Kg,1,,,,In vivo,1,,17753,A,,Intermediate,CHEMBL618978,BAO_0000218,4958
,,N,,,50594,10090.0,Mus musculus,Volume of distribution of compound in plasma was determined at 40 mg/Kg,1,,,,In vivo,1,,17753,A,,Intermediate,CHEMBL618979,BAO_0000218,4959
,,N,,,50594,10090.0,Mus musculus,Volume of distribution of compound in plasma was determined at 5 mg/Kg,1,,,,In vivo,1,,17753,A,,Intermediate,CHEMBL618980,BAO_0000218,4960
,,N,,,50594,10090.0,Mus musculus,Pharmacokinetic property (vdss) was measured in mouse,1,,,,In vivo,1,,4239,A,,Intermediate,CHEMBL618981,BAO_0000218,4961
,,N,,,50594,10090.0,Mus musculus,Value distribution upon iv administration in mouse,1,,,,In vivo,1,,2862,A,,Intermediate,CHEMBL618982,BAO_0000218,4962
,,N,,,50594,10090.0,Mus musculus,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,1,,,,In vivo,1,,17734,A,,Intermediate,CHEMBL620150,BAO_0000218,4963
,,N,,,50594,10090.0,Mus musculus,Volume of distribution was evaluated in mice after intravenous administration,1,,,,In vivo,1,,2675,A,,Intermediate,CHEMBL620151,BAO_0000218,4964
,,N,,,50594,10090.0,Mus musculus,Volume of distribution was evaluated in mice after oral administration,1,,,,In vivo,1,,2675,A,,Intermediate,CHEMBL620152,BAO_0000218,4965
,,N,,,50594,10090.0,Mus musculus,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,1,,,,In vivo,1,,17837,A,,Intermediate,CHEMBL620153,BAO_0000218,4966
,,N,,,50594,10090.0,Mus musculus,Steady state volume of distribution was determined in mice,1,,,,In vivo,1,,5727,A,,Intermediate,CHEMBL876395,BAO_0000218,4967
,,N,,,50594,10090.0,Mus musculus,Volume distribution (steady state) of compound was determined in mouse,1,,,,In vivo,1,,17852,A,,Intermediate,CHEMBL620154,BAO_0000218,4968
,,N,,,50594,10090.0,Mus musculus,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,1,,,,In vivo,1,,17764,A,,Intermediate,CHEMBL620155,BAO_0000218,4969
,,N,,,50594,10090.0,Mus musculus,Vss value at a dose of 10 mg/kg intravenous administration in mice.,1,,,,In vivo,1,,16597,A,,Intermediate,CHEMBL620156,BAO_0000218,4970
,,N,,,50594,10090.0,Mus musculus,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,1,,,,In vivo,1,,6062,A,,Intermediate,CHEMBL620157,BAO_0000218,4971
,,N,,,50594,10090.0,Mus musculus,Biodistribution of compound (oxidized form) in in kidney tissue,1,Kidney,,,In vivo,1,,16438,A,2113.0,Intermediate,CHEMBL620158,BAO_0000218,4972
,,N,,,50594,10090.0,Mus musculus,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,1,Blood,,,In vivo,1,,16438,A,178.0,Intermediate,CHEMBL620159,BAO_0000218,4973
,,N,,,50594,10090.0,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",1,Blood,,,In vivo,1,,16438,A,178.0,Intermediate,CHEMBL620160,BAO_0000218,4974
,,N,,,50594,10090.0,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Blood,,,In vivo,1,,16438,A,178.0,Intermediate,CHEMBL620161,BAO_0000218,4975
,,N,797.0,,80019,9606.0,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,1,,A-427,,,1,,10708,F,,Intermediate,CHEMBL620162,BAO_0000219,4976
,,N,500.0,,80852,9606.0,Homo sapiens,Inhibition of A431 human squamous cell carcinoma cell proliferation,1,,A-431,,,1,,16597,F,,Expert,CHEMBL620163,BAO_0000219,4977
,,N,500.0,,80852,9606.0,Homo sapiens,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,1,,A-431,,,1,,16062,F,,Expert,CHEMBL620833,BAO_0000219,4978
,,N,500.0,,80852,9606.0,Homo sapiens,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,1,,A-431,,,1,,16062,F,,Expert,CHEMBL876396,BAO_0000219,4979
,,N,500.0,,80852,9606.0,Homo sapiens,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,1,,A-431,,,1,,16958,F,,Expert,CHEMBL620834,BAO_0000219,4980
,,N,500.0,,80852,9606.0,Homo sapiens,Inhibition of A431 human carcinoma cell proliferation,1,,A-431,,,1,,6700,F,,Expert,CHEMBL620835,BAO_0000219,4981
,,N,500.0,,80852,9606.0,Homo sapiens,In vitro inhibition of A431 (human carcinoma) cell basal growth.,1,,A-431,,,1,,17226,F,,Expert,CHEMBL620836,BAO_0000219,4982
,,N,500.0,,80852,9606.0,Homo sapiens,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,1,,A-431,,,1,,6828,F,,Intermediate,CHEMBL620837,BAO_0000219,4983
,,N,500.0,,80852,9606.0,Homo sapiens,In vitro cytotoxicity against epidermoid carcinoma cell line,1,,A-431,,,1,,12314,F,,Intermediate,CHEMBL621017,BAO_0000219,4984
,,D,500.0,,9,9606.0,Homo sapiens,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",1,,A-431,,,9,,13412,F,,Expert,CHEMBL621018,BAO_0000218,4985
,,N,500.0,,80852,9606.0,Homo sapiens,Antiproliferative activity of compound was measured on human tumor cell line A431.,1,,A-431,,,1,,13299,F,,Intermediate,CHEMBL621019,BAO_0000219,4986
,,N,500.0,,80852,9606.0,Homo sapiens,Antiproliferative effect of compound on A431 cell line expressing mutant p53,1,,A-431,,,1,,17420,F,,Intermediate,CHEMBL621020,BAO_0000219,4987
,,N,500.0,,80852,9606.0,Homo sapiens,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,1,,A-431,,,1,,13678,F,,Intermediate,CHEMBL621021,BAO_0000219,4988
,,H,500.0,,9,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,1,,A-431,,,8,,14171,F,,Expert,CHEMBL621022,BAO_0000219,4989
,,N,500.0,,80852,9606.0,Homo sapiens,Tested for antiproliferative activity against human A431 cells,1,,A-431,,,1,,6333,F,,Expert,CHEMBL621023,BAO_0000219,4990
,,D,500.0,,9,9606.0,Homo sapiens,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,1,,A-431,,,9,,2356,F,,Expert,CHEMBL621024,BAO_0000219,4991
,,N,500.0,,80852,9606.0,Homo sapiens,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,1,,A-431,,,1,,15578,F,,Expert,CHEMBL621025,BAO_0000219,4992
,,N,500.0,,80852,9606.0,Homo sapiens,Inhibition of A431 cell proliferation,1,,A-431,,,1,,5126,F,,Expert,CHEMBL621026,BAO_0000219,4993
,,N,500.0,,80852,9606.0,Homo sapiens,Cytotoxic effect on A431 human epidermoid carcinoma cells,1,,A-431,,,1,,6844,F,,Expert,CHEMBL621027,BAO_0000219,4994
,,N,500.0,,80852,9606.0,Homo sapiens,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),1,,A-431,,,1,,6844,F,,Expert,CHEMBL876397,BAO_0000219,4995
,,N,500.0,,80852,9606.0,Homo sapiens,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,1,,A-431,,,1,,4925,F,,Intermediate,CHEMBL883797,BAO_0000219,4996
,,N,500.0,,80852,9606.0,Homo sapiens,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,1,,A-431,,,1,,4925,F,,Intermediate,CHEMBL621028,BAO_0000219,4997
,,N,500.0,,80852,9606.0,Homo sapiens,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,1,,A-431,,,1,,13978,F,,Intermediate,CHEMBL621029,BAO_0000219,4998
,,N,500.0,,80852,9606.0,Homo sapiens,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,1,,A-431,,,1,,16786,F,,Intermediate,CHEMBL621030,BAO_0000219,4999
,,H,500.0,,9,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,1,,A-431,,,8,,13412,F,,Expert,CHEMBL621147,BAO_0000219,5000
,,N,500.0,,80852,9606.0,Homo sapiens,In vivo antiproliferative activity against A431 cell line,1,,A-431,,,1,,17824,F,,Intermediate,CHEMBL621148,BAO_0000218,5001
,,D,500.0,,9,9606.0,Homo sapiens,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,1,,A-431,,,9,,12751,F,,Expert,CHEMBL621149,BAO_0000219,5002
,,N,500.0,,80852,9606.0,Homo sapiens,Inhibition of A431 human epidermoid carcinoma cell proliferation,1,,A-431,,,1,,12380,F,,Expert,CHEMBL621150,BAO_0000219,5003
,,D,500.0,,9,9606.0,Homo sapiens,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,1,,A-431,,,9,,4959,F,,Expert,CHEMBL621151,BAO_0000219,5004
,,N,500.0,,80852,9606.0,Homo sapiens,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),1,,A-431,,,1,,6333,F,,Intermediate,CHEMBL621152,BAO_0000219,5005
,,N,500.0,,80852,9606.0,Homo sapiens,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),1,,A-431,,,1,,6333,F,,Intermediate,CHEMBL621153,BAO_0000219,5006
,,N,500.0,,80852,9606.0,Homo sapiens,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),1,,A-431,,,1,,6333,F,,Intermediate,CHEMBL884000,BAO_0000219,5007
,,D,,,9,9606.0,Homo sapiens,Inhibition of EGFR overexpressing A431 cell proliferation,1,,,,,9,,5296,F,,Expert,CHEMBL621154,BAO_0000019,5008
,,N,500.0,,80852,9606.0,Homo sapiens,Inhibition of A431 cell proliferation,1,,A-431,,,1,,12624,F,,Expert,CHEMBL621155,BAO_0000219,5009
,,D,500.0,,9,9606.0,Homo sapiens,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,1,,A-431,,,9,,14926,F,,Expert,CHEMBL621156,BAO_0000219,5010
,,D,500.0,,9,9606.0,Homo sapiens,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",1,,A-431,,,9,,14926,F,,Expert,CHEMBL621157,BAO_0000219,5011
,,H,500.0,,9,,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),1,,A-431,,,8,,14926,F,,Expert,CHEMBL621158,BAO_0000219,5012
,,N,500.0,,80852,9606.0,Homo sapiens,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,1,,A-431,,,1,,15144,F,,Intermediate,CHEMBL621159,BAO_0000219,5013
,,N,500.0,,80852,9606.0,Homo sapiens,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,1,,A-431,,,1,,15144,F,,Intermediate,CHEMBL621160,BAO_0000219,5014
,,N,500.0,,80852,9606.0,Homo sapiens,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,1,,A-431,,,1,,5245,F,,Intermediate,CHEMBL621161,BAO_0000219,5015
,,N,500.0,,80852,9606.0,Homo sapiens,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,1,,A-431,,,1,,5245,F,,Intermediate,CHEMBL621162,BAO_0000219,5016
,,N,500.0,,80852,9606.0,Homo sapiens,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,1,,A-431,,,1,,5245,F,,Intermediate,CHEMBL621163,BAO_0000219,5017
,,N,500.0,,80852,9606.0,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,1,,A-431,,,1,,5245,F,,Intermediate,CHEMBL621164,BAO_0000219,5018
,,N,500.0,,80852,9606.0,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,1,,A-431,,,1,,5245,F,,Intermediate,CHEMBL621165,BAO_0000219,5019
,,U,,,22224,9527.0,Cercopithecidae,Half-life period in cynomolgus monkey,1,,,,,0,,5922,A,,Autocuration,CHEMBL619159,BAO_0000019,5020
,,U,,,22224,9527.0,Cercopithecidae,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",1,Plasma,,,In vitro,0,,1116,A,1969.0,Autocuration,CHEMBL619160,BAO_0000366,5021
,,U,,,22224,9527.0,Cercopithecidae,Longer half-life in monkey (i.v.) at 0.5 mpk,1,,,,In vivo,0,,17853,A,,Autocuration,CHEMBL619161,BAO_0000218,5022
,,U,,,22224,9527.0,Cercopithecidae,Plasma half life in monkey,1,Plasma,,,,0,,993,A,1969.0,Autocuration,CHEMBL619162,BAO_0000366,5023
,,U,,,22224,9527.0,Cercopithecidae,Plasma half-life in rhesus monkey,1,Plasma,,,,0,,4514,A,1969.0,Autocuration,CHEMBL619163,BAO_0000366,5024
,,U,,,22224,9527.0,Cercopithecidae,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),1,Plasma,,,In vivo,0,,5334,A,1969.0,Autocuration,CHEMBL619164,BAO_0000218,5025
,,U,,,22224,9527.0,Cercopithecidae,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),1,Plasma,,,In vivo,0,,5334,A,1969.0,Autocuration,CHEMBL619320,BAO_0000218,5026
,,U,,,22224,9527.0,Cercopithecidae,Tested for half life upon iv administration to african green monkey,1,,,,In vivo,0,,4578,A,,Autocuration,CHEMBL619321,BAO_0000218,5027
,,U,,,22224,9527.0,Cercopithecidae,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,1,,,,In vivo,0,,2661,A,,Autocuration,CHEMBL873336,BAO_0000218,5028
,,U,,,22224,9527.0,Cercopithecidae,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,1,,,,In vivo,0,,5355,A,,Autocuration,CHEMBL619322,BAO_0000218,5029
,,U,,,22224,9527.0,Cercopithecidae,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,1,,,,In vivo,0,,5355,A,,Autocuration,CHEMBL619323,BAO_0000218,5030
,,U,,,22224,9527.0,Cercopithecidae,The time for peak concentration value after oral administration in cynomolgus monkeys,1,,,,In vivo,0,,5355,A,,Autocuration,CHEMBL619324,BAO_0000218,5031
,,U,,,22224,9527.0,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,1,,,,,0,,11271,A,,Autocuration,CHEMBL619325,BAO_0000019,5032
,,U,,,22224,9527.0,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,1,,,,,0,,11271,A,,Autocuration,CHEMBL876411,BAO_0000019,5033
,,U,,,22224,9527.0,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,1,,,,,0,,11271,A,,Autocuration,CHEMBL619326,BAO_0000019,5034
,,U,,,22224,9527.0,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,1,,,,,0,,11271,A,,Autocuration,CHEMBL619327,BAO_0000019,5035
,,U,,,22224,9527.0,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,1,,,,,0,,11271,A,,Autocuration,CHEMBL619328,BAO_0000019,5036
,,U,,,22224,9527.0,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,1,,,,,0,,11271,A,,Autocuration,CHEMBL619329,BAO_0000019,5037
,,U,,,22224,9527.0,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,1,,,,,0,,11271,A,,Autocuration,CHEMBL619330,BAO_0000019,5038
,,U,,,22224,9527.0,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,1,,,,,0,,11271,A,,Autocuration,CHEMBL619331,BAO_0000019,5039
,,U,,,22224,9527.0,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,1,,,,,0,,11271,A,,Autocuration,CHEMBL619332,BAO_0000019,5040
,,U,,,22224,9527.0,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,1,,,,,0,,11271,A,,Autocuration,CHEMBL619333,BAO_0000019,5041
,,U,,,22224,9527.0,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,1,,,,,0,,11271,A,,Autocuration,CHEMBL619334,BAO_0000019,5042
,,U,,,22224,9527.0,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,1,,,,,0,,11271,A,,Autocuration,CHEMBL619335,BAO_0000019,5043
,,U,,,22224,9527.0,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,1,,,,,0,,11271,A,,Autocuration,CHEMBL619336,BAO_0000019,5044
,,U,,,22224,9527.0,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,1,,,,,0,,11271,A,,Autocuration,CHEMBL619337,BAO_0000019,5045
,,U,,,22224,9527.0,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,1,,,,,0,,11271,A,,Autocuration,CHEMBL619338,BAO_0000019,5046
,,U,,,22224,9527.0,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,1,,,,,0,,11271,A,,Autocuration,CHEMBL619339,BAO_0000019,5047
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (cannulated) (dose 2 mg/kg),1,,,,In vivo,1,,5809,A,,Intermediate,CHEMBL619340,BAO_0000218,5048
,,N,,,50597,10116.0,Rattus norvegicus,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,1,Plasma,,,In vivo,1,,17720,A,1969.0,Intermediate,CHEMBL873496,BAO_0000218,5049
,,N,,,50597,10116.0,Rattus norvegicus,AUC value in rat after IV administration at a dose of 10 mg/kg,1,Plasma,,,,1,,3546,A,1969.0,Intermediate,CHEMBL619341,BAO_0000218,5050
,,N,,,50597,10116.0,Rattus norvegicus,AUC value in rat after oral administration at a dose of 10 mg/kg,1,Plasma,,,,1,,3546,A,1969.0,Intermediate,CHEMBL619342,BAO_0000218,5051
,,N,,,50597,10116.0,Rattus norvegicus,Cmax value in rat after oral administration at a dose of 10 mg/kg,1,,,,In vivo,1,,3546,A,,Intermediate,CHEMBL619343,BAO_0000218,5052
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat after oral administration at a dose of 10 mg/kg,1,,,,In vivo,1,,3546,A,,Intermediate,CHEMBL619344,BAO_0000218,5053
,,N,,,50597,10116.0,Rattus norvegicus,Tmax value in rat after oral administration at a dose of 10 mg/kg,1,,,,In vivo,1,,3546,A,,Intermediate,CHEMBL619345,BAO_0000218,5054
,,N,,,50597,10116.0,Rattus norvegicus,Vc value in rat after IV administration at a dose of 10 mg/kg,1,,,,,1,,3546,A,,Intermediate,CHEMBL619346,BAO_0000218,5055
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in rat after IV administration at a dose of 10 mg/kg,1,,,,In vivo,1,,3546,A,,Intermediate,CHEMBL619347,BAO_0000218,5056
,,U,,,22224,9557.0,Papio hamadryas,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,1,,,,,0,,10625,A,,Autocuration,CHEMBL619348,BAO_0000019,5057
,,U,,,22224,9557.0,Papio hamadryas,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),1,,,,,0,,10625,A,,Autocuration,CHEMBL619349,BAO_0000019,5058
,,U,,,22224,9557.0,Papio hamadryas,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),1,,,,,0,,10625,A,,Autocuration,CHEMBL619350,BAO_0000019,5059
,,U,,,22224,9557.0,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,1,,,,,0,,10625,A,,Autocuration,CHEMBL619351,BAO_0000019,5060
,,U,,,22224,9557.0,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,1,,,,,0,,10625,A,,Autocuration,CHEMBL875953,BAO_0000019,5061
,,U,,,22224,9557.0,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,1,,,,,0,,10625,A,,Autocuration,CHEMBL621716,BAO_0000019,5062
,,U,,,22224,9557.0,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,1,,,,,0,,10625,A,,Autocuration,CHEMBL621717,BAO_0000019,5063
,,U,,,22224,9557.0,Papio hamadryas,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,1,,,,,0,,10625,A,,Autocuration,CHEMBL621718,BAO_0000019,5064
,,U,,,22224,9615.0,beagle,Area under curve after 1 mpk peroral administration to beagles,1,,,,,0,,3510,A,,Autocuration,CHEMBL621719,BAO_0000019,5065
,,U,,,22224,9615.0,beagle,Area under curve after 2 mpk peroral administration to beagles,1,,,,,0,,3510,A,,Autocuration,CHEMBL621720,BAO_0000019,5066
,,U,,,22224,9615.0,beagle,Cmax value after 1 mpk peroral administration to beagles,1,,,,In vivo,0,,3510,A,,Autocuration,CHEMBL621721,BAO_0000218,5067
,,U,,,22224,9606.0,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,1,Urine,,,,0,,7766,A,1088.0,Autocuration,CHEMBL621722,BAO_0000019,5068
,,U,,,22224,9606.0,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,1,Urine,,,,0,,7766,A,1088.0,Autocuration,CHEMBL621723,BAO_0000019,5069
,,U,,,22224,9606.0,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,1,Urine,,,,0,,7766,A,1088.0,Autocuration,CHEMBL621724,BAO_0000019,5070
,,U,,,22224,9606.0,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,1,Urine,,,,0,,7766,A,1088.0,Autocuration,CHEMBL623443,BAO_0000019,5071
,,U,,,22224,9606.0,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,1,Urine,,,,0,,7766,A,1088.0,Autocuration,CHEMBL623444,BAO_0000019,5072
,,U,,,22224,9606.0,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,1,Urine,,,,0,,7766,A,1088.0,Autocuration,CHEMBL623445,BAO_0000019,5073
,,U,,,22224,9606.0,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,1,Urine,,,,0,,7766,A,1088.0,Autocuration,CHEMBL623446,BAO_0000019,5074
,Microsomes,U,,,22224,9606.0,Homo sapiens,Metabolic stability observed at 30 min after administration in human liver microsomes,1,Liver,,,,0,,16643,A,2107.0,Autocuration,CHEMBL623447,BAO_0000251,5075
,,U,,,22224,9606.0,Homo sapiens,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,1,,,,,0,,6852,A,,Autocuration,CHEMBL623448,BAO_0000019,5076
,,U,,,22224,9606.0,Homo sapiens,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,1,,,,,0,,6852,A,,Autocuration,CHEMBL623449,BAO_0000019,5077
,,U,,,22224,9606.0,Homo sapiens,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,1,,,,,0,,6852,A,,Autocuration,CHEMBL623450,BAO_0000019,5078
,Microsomes,U,,,22224,9606.0,Homo sapiens,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",1,Liver,,,,0,,6567,A,2107.0,Autocuration,CHEMBL623451,BAO_0000251,5079
,,U,,,22224,9606.0,Homo sapiens,Metabolic stability (% remaining at 30 mins) in human S9.,1,,,,,0,,6570,A,,Autocuration,CHEMBL623452,BAO_0000019,5080
,,U,,,22224,9606.0,Homo sapiens,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,1,,,,,0,,6570,A,,Autocuration,CHEMBL623453,BAO_0000019,5081
,Microsomes,U,,,22224,9606.0,Homo sapiens,Percent parent compound remaining after 20 min incubation with human liver microsomes,1,Liver,,,,0,,5237,A,2107.0,Autocuration,CHEMBL623454,BAO_0000251,5082
,Microsomes,U,,,22224,9606.0,Homo sapiens,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,1,Liver,,,,0,,5237,A,2107.0,Autocuration,CHEMBL623455,BAO_0000251,5083
,Microsomes,U,,,22224,9606.0,Homo sapiens,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,1,Liver,,,,0,,5237,A,2107.0,Autocuration,CHEMBL624371,BAO_0000251,5084
,,U,,,22224,9606.0,Homo sapiens,First pass metabolism and metabolic bioavailability using human hepatic microsomes,1,,,,,0,,5202,A,,Autocuration,CHEMBL624372,BAO_0000218,5085
,,U,,,22224,9606.0,Homo sapiens,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,1,,,,,0,,5481,A,,Autocuration,CHEMBL624373,BAO_0000019,5086
,,U,,,22224,9606.0,Homo sapiens,Percent remaining in human plasma after incubation for 60 min at 37 C.,1,,,,,0,,5481,A,,Autocuration,CHEMBL624374,BAO_0000019,5087
,,U,,,22224,9606.0,Homo sapiens,The percent remaining in human plasma after 30 min was determined,1,,,,,0,,3956,A,,Autocuration,CHEMBL624556,BAO_0000019,5088
,,U,,,22224,9606.0,Homo sapiens,Conversion rate of the prodrug in human plasma,1,Plasma,,,,0,,5074,A,1969.0,Autocuration,CHEMBL624557,BAO_0000366,5089
,,U,,,22224,9606.0,Homo sapiens,Conversion rate of the prodrug in human plasma; ND means no data,1,Plasma,,,,0,,5074,A,1969.0,Autocuration,CHEMBL624558,BAO_0000366,5090
,,U,,,22224,9606.0,Homo sapiens,Half life of compound was determined in human blood,1,Blood,,,,0,,4727,A,178.0,Autocuration,CHEMBL624559,BAO_0000221,5091
,,U,,,22224,9606.0,Homo sapiens,Half life of compound was determined in man with once daily dosing,1,,,,,0,,5965,A,,Autocuration,CHEMBL624560,BAO_0000019,5092
,Microsomes,U,,,22224,9606.0,Homo sapiens,Half life in human microsomes,1,,,,In vitro,0,,5732,A,,Autocuration,CHEMBL624561,BAO_0000251,5093
,,U,,,22224,9606.0,Homo sapiens,Half life in human plasma,1,Plasma,,,,0,,5819,A,1969.0,Autocuration,CHEMBL624562,BAO_0000366,5094
,,U,,,22224,9606.0,Homo sapiens,Half life in human plasma; Not detected,1,Plasma,,,,0,,5819,A,1969.0,Autocuration,CHEMBL624563,BAO_0000366,5095
,,U,,,22224,9606.0,Homo sapiens,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,1,,,,In vivo,0,,1916,A,,Autocuration,CHEMBL624564,BAO_0000218,5096
,Microsomes,U,,,22224,9606.0,Homo sapiens,Half-life for oxidative metabolic stability was determined using rat liver microsomes,1,Liver,,,In vitro,0,,6597,A,2107.0,Autocuration,CHEMBL624565,BAO_0000251,5097
,,U,,,22224,9606.0,Homo sapiens,Half-life in human plasma,1,Plasma,,,,0,,5229,A,1969.0,Autocuration,CHEMBL875152,BAO_0000366,5098
,,U,,,22224,9606.0,Homo sapiens,Half-life of the parent prodrug in plasma,1,Plasma,,,,0,,5229,A,1969.0,Autocuration,CHEMBL624566,BAO_0000366,5099
,,U,,,22224,9606.0,Homo sapiens,In vitro half life in human plasma was determined,1,Plasma,,,In vitro,0,,2192,A,1969.0,Autocuration,CHEMBL873805,BAO_0000366,5100
,Microsomes,U,,,22224,9606.0,Homo sapiens,The compound was tested In Vitro for half life in human liver microsomes.,1,Liver,,,In vitro,0,,3032,A,2107.0,Autocuration,CHEMBL624567,BAO_0000251,5101
,,U,,,22224,9606.0,Homo sapiens,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,1,,,,In vivo,0,,1916,A,,Autocuration,CHEMBL624568,BAO_0000218,5102
,,U,,,22224,9606.0,Homo sapiens,Observed volume of distribution,1,,,,In vivo,0,,17716,A,,Autocuration,CHEMBL624569,BAO_0000218,5103
,,U,,,22224,9606.0,Homo sapiens,Oral bioavailability in human,1,,,,In vivo,0,,15778,A,,Autocuration,CHEMBL624570,BAO_0000218,5104
,,U,,,22224,9606.0,Homo sapiens,Tested for human plasma protein binding of the compound,1,,,,,0,,17313,A,,Autocuration,CHEMBL624571,BAO_0000019,5105
,,U,,,22224,9606.0,Homo sapiens,"First order rate constant, k was determined in human plasma",1,,,,,0,,4231,A,,Autocuration,CHEMBL624572,BAO_0000019,5106
,,U,,,22224,9606.0,Homo sapiens,Observed rate constant in 80% human plasma at 37 degree Centigrade,1,,,,,0,,4755,A,,Autocuration,CHEMBL624573,BAO_0000019,5107
,,U,,,22224,9606.0,Homo sapiens,Observed rate constant in 80% human plasma at 37 degree Centigrade,1,,,,,0,,4755,A,,Autocuration,CHEMBL875153,BAO_0000019,5108
,Microsomes,U,,,22224,9606.0,Homo sapiens,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,1,Liver,,,,0,,16907,A,2107.0,Autocuration,CHEMBL624574,BAO_0000251,5109
,,U,,,22224,9606.0,Homo sapiens,The compound was tested for the plasma binding in human,1,,,,,0,,10839,A,,Autocuration,CHEMBL624575,BAO_0000019,5110
,,U,,,22224,9606.0,Homo sapiens,Plasma protein binding (human),1,,,,,0,,10839,A,,Autocuration,CHEMBL624576,BAO_0000019,5111
,Microsomes,U,,,22224,9606.0,Homo sapiens,Compound was evaluated for half-life in human liver microsomes,1,Liver,,,In vitro,0,,3199,A,2107.0,Autocuration,CHEMBL624577,BAO_0000251,5112
,,U,,,22224,9606.0,Homo sapiens,Half life measured in vitro for its stability in human blood,1,Blood,,,In vitro,0,,1345,A,178.0,Autocuration,CHEMBL624578,BAO_0000221,5113
,,U,,,22224,9606.0,Homo sapiens,Half life in human serum,1,Serum,,,,0,,4297,A,1977.0,Autocuration,CHEMBL622796,BAO_0000019,5114
,,U,,,22224,9606.0,Homo sapiens,Half life in human serum; ND=not determined,1,Serum,,,,0,,4297,A,1977.0,Autocuration,CHEMBL622797,BAO_0000019,5115
,,U,,,22224,9606.0,Homo sapiens,Half life were determined in CEM-SS cell extract in decomposition step 1,1,,,,,0,,4297,A,,Autocuration,CHEMBL622798,BAO_0000019,5116
,,U,,,22224,9606.0,Homo sapiens,Half life were determined in CEM-SS cell extract in decomposition step 2,1,,,,,0,,4297,A,,Autocuration,CHEMBL622799,BAO_0000019,5117
,,U,,,22224,9606.0,Homo sapiens,Half life of the in human plasma,1,Plasma,,,,0,,4231,A,1969.0,Autocuration,CHEMBL622800,BAO_0000366,5118
,S9,U,,,22224,9606.0,Homo sapiens,Half life period in human hepatic S9 fraction was determined,1,,,,In vitro,0,,5633,A,,Autocuration,CHEMBL622801,BAO_0000220,5119
,Microsomes,U,,,22224,9606.0,Homo sapiens,Half life period in human liver microsome was determined,1,Liver,,,In vitro,0,,5633,A,2107.0,Autocuration,CHEMBL622802,BAO_0000251,5120
,,U,,,22224,9606.0,Homo sapiens,Half life period was determined; 6-7,1,,,,,0,,17791,A,,Autocuration,CHEMBL622803,BAO_0000019,5121
,,U,,,22224,9606.0,Homo sapiens,Half life period was evaluated in human,1,,,,,0,,17791,A,,Autocuration,CHEMBL875154,BAO_0000019,5122
,,U,,,22224,9606.0,Homo sapiens,Half life time in human plasma,1,Plasma,,,,0,,3160,A,1969.0,Autocuration,CHEMBL622804,BAO_0000366,5123
,,N,,,50594,10090.0,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Brain,,,In vivo,1,,16438,A,955.0,Intermediate,CHEMBL622805,BAO_0000218,5124
,,N,,,50594,10090.0,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,Heart,,,In vivo,1,,16438,A,948.0,Intermediate,CHEMBL622611,BAO_0000218,5125
,,N,,,50594,10090.0,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Heart,,,In vivo,1,,16438,A,948.0,Intermediate,CHEMBL622612,BAO_0000218,5126
,,N,,,50594,10090.0,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,Kidney,,,In vivo,1,,16438,A,2113.0,Intermediate,CHEMBL875160,BAO_0000218,5127
,,N,,,50594,10090.0,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",1,Kidney,,,In vivo,1,,16438,A,2113.0,Intermediate,CHEMBL622613,BAO_0000218,5128
,,N,,,50594,10090.0,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Kidney,,,In vivo,1,,16438,A,2113.0,Intermediate,CHEMBL622614,BAO_0000218,5129
,,N,,,50594,10090.0,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,Liver,,,In vivo,1,,16438,A,2107.0,Intermediate,CHEMBL622615,BAO_0000218,5130
,,N,,,50594,10090.0,Mus musculus,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,1,Liver,,,In vivo,1,,16438,A,2107.0,Intermediate,CHEMBL622616,BAO_0000218,5131
,,N,,,50594,10090.0,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Liver,,,In vivo,1,,16438,A,2107.0,Intermediate,CHEMBL622617,BAO_0000218,5132
,,N,,,50594,10090.0,Mus musculus,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,1,Spleen,,,In vivo,1,,16438,A,2106.0,Intermediate,CHEMBL622618,BAO_0000218,5133
,,N,,,50594,10090.0,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",1,Spleen,,,In vivo,1,,16438,A,2106.0,Intermediate,CHEMBL622619,BAO_0000218,5134
,,N,,,50594,10090.0,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Spleen,,,In vivo,1,,16438,A,2106.0,Intermediate,CHEMBL622620,BAO_0000218,5135
,,N,,,50594,10090.0,Mus musculus,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,Brain,,,In vivo,1,,16438,A,955.0,Intermediate,CHEMBL622621,BAO_0000218,5136
,,N,,,50594,10090.0,Mus musculus,Biodistribution of compound (oxidized form) in blood tissue,1,Blood,,,In vivo,1,,16438,A,178.0,Intermediate,CHEMBL622622,BAO_0000218,5137
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,Blood,,,In vivo,1,,16438,A,178.0,Intermediate,CHEMBL622623,BAO_0000218,5138
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",1,Blood,,,In vivo,1,,16438,A,178.0,Intermediate,CHEMBL622624,BAO_0000218,5139
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,Blood,,,In vivo,1,,16438,A,178.0,Intermediate,CHEMBL622625,BAO_0000218,5140
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Blood,,,In vivo,1,,16438,A,178.0,Intermediate,CHEMBL622626,BAO_0000218,5141
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,Blood,,,In vivo,1,,16438,A,178.0,Intermediate,CHEMBL622627,BAO_0000218,5142
,,N,,,50594,10090.0,Mus musculus,Biodistribution of compound (oxidized form) in brain tissue of mice,1,Brain,,,In vivo,1,,16438,A,955.0,Intermediate,CHEMBL622628,BAO_0000218,5143
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,Brain,,,In vivo,1,,16438,A,955.0,Intermediate,CHEMBL622629,BAO_0000218,5144
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",1,Brain,,,In vivo,1,,16438,A,955.0,Intermediate,CHEMBL622630,BAO_0000218,5145
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Brain,,,In vivo,1,,16438,A,955.0,Intermediate,CHEMBL622631,BAO_0000218,5146
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,Brain,,,In vivo,1,,16438,A,955.0,Intermediate,CHEMBL622632,BAO_0000218,5147
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",1,Brain,,,In vivo,1,,16438,A,955.0,Intermediate,CHEMBL622633,BAO_0000218,5148
,,N,,,50594,10090.0,Mus musculus,Biodistribution of compound (oxidized form) in heart tissue of mice,1,Heart,,,In vivo,1,,16438,A,948.0,Intermediate,CHEMBL622634,BAO_0000218,5149
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,Heart,,,In vivo,1,,16438,A,948.0,Intermediate,CHEMBL622635,BAO_0000218,5150
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,Heart,,,In vivo,1,,16438,A,948.0,Intermediate,CHEMBL875161,BAO_0000218,5151
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",1,Heart,,,In vivo,1,,16438,A,948.0,Intermediate,CHEMBL622636,BAO_0000218,5152
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Heart,,,In vivo,1,,16438,A,948.0,Intermediate,CHEMBL623335,BAO_0000218,5153
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,Heart,,,In vivo,1,,16438,A,948.0,Intermediate,CHEMBL623336,BAO_0000218,5154
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,Kidney,,,In vivo,1,,16438,A,2113.0,Intermediate,CHEMBL623337,BAO_0000218,5155
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",1,Kidney,,,In vivo,1,,16438,A,2113.0,Intermediate,CHEMBL623338,BAO_0000218,5156
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",1,Kidney,,,In vivo,1,,16438,A,2113.0,Intermediate,CHEMBL623339,BAO_0000218,5157
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Kidney,,,In vivo,1,,16438,A,2113.0,Intermediate,CHEMBL623524,BAO_0000218,5158
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,Kidney,,,In vivo,1,,16438,A,2113.0,Intermediate,CHEMBL623525,BAO_0000218,5159
,,N,,,50594,10090.0,Mus musculus,Biodistribution of compound (oxidized form) in liver tissue,1,Liver,,,In vivo,1,,16438,A,2107.0,Intermediate,CHEMBL623526,BAO_0000218,5160
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,Liver,,,In vivo,1,,16438,A,2107.0,Intermediate,CHEMBL623527,BAO_0000218,5161
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,Liver,,,In vivo,1,,16438,A,2107.0,Intermediate,CHEMBL623528,BAO_0000218,5162
,,N,500.0,,80852,9606.0,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,1,,A-431,,,1,,5245,F,,Intermediate,CHEMBL624615,BAO_0000219,5163
,,N,500.0,,80852,9606.0,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,1,,A-431,,,1,,5245,F,,Intermediate,CHEMBL621672,BAO_0000219,5164
,,N,500.0,,80852,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",1,,A-431,,,1,,16289,F,,Expert,CHEMBL621673,BAO_0000218,5165
,,N,500.0,,80852,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",1,,A-431,,,1,,16289,F,,Expert,CHEMBL621674,BAO_0000218,5166
,,D,500.0,,9,9606.0,Homo sapiens,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,1,,A-431,,,9,,16093,F,,Expert,CHEMBL884002,BAO_0000219,5167
,,N,500.0,,80852,9606.0,Homo sapiens,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",1,,A-431,,,1,,16825,F,,Intermediate,CHEMBL621850,BAO_0000219,5168
,,N,500.0,,80852,9606.0,Homo sapiens,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,1,,A-431,,,1,,4848,F,,Intermediate,CHEMBL621851,BAO_0000219,5169
,,D,500.0,,9,9606.0,Homo sapiens,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,1,,A-431,,,9,,14827,F,,Expert,CHEMBL621852,BAO_0000219,5170
,,D,500.0,,9,9606.0,Homo sapiens,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,1,,A-431,,,9,,14827,F,,Expert,CHEMBL621853,BAO_0000219,5171
,,N,500.0,,80852,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",1,,A-431,,,1,,16289,F,,Expert,CHEMBL621854,BAO_0000218,5172
,,N,500.0,,80852,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",1,,A-431,,,1,,16289,F,,Expert,CHEMBL621855,BAO_0000218,5173
,,N,500.0,,80852,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",1,,A-431,,,1,,16289,F,,Expert,CHEMBL623724,BAO_0000218,5174
,,N,500.0,,80852,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",1,,A-431,,,1,,16289,F,,Expert,CHEMBL623725,BAO_0000218,5175
,,N,500.0,,80852,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",1,,A-431,,,1,,16289,F,,Expert,CHEMBL623726,BAO_0000218,5176
,,D,500.0,,9,9606.0,Homo sapiens,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",1,,A-431,,,9,,16289,F,,Expert,CHEMBL623727,BAO_0000219,5177
,,H,500.0,,9,,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,1,,A-431,,,8,,16289,F,,Expert,CHEMBL623728,BAO_0000219,5178
,,N,500.0,,80852,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",1,,A-431,,,1,,16289,F,,Expert,CHEMBL623729,BAO_0000218,5179
,,N,500.0,,80852,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",1,,A-431,,,1,,16289,F,,Expert,CHEMBL623730,BAO_0000218,5180
,,N,500.0,,80852,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",1,,A-431,,,1,,16289,F,,Expert,CHEMBL623731,BAO_0000218,5181
,,N,500.0,,80852,10090.0,Mus musculus,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",1,,A-431,,,1,,14555,F,,Expert,CHEMBL623732,BAO_0000218,5182
,,N,500.0,,80852,10090.0,Mus musculus,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",1,,A-431,,,1,,14555,F,,Expert,CHEMBL623733,BAO_0000218,5183
,,N,500.0,,80852,10090.0,Mus musculus,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",1,,A-431,,,1,,14555,F,,Expert,CHEMBL623734,BAO_0000218,5184
,,N,500.0,,80852,10090.0,Mus musculus,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",1,,A-431,,,1,,14555,F,,Expert,CHEMBL623735,BAO_0000218,5185
,,N,500.0,,80852,9606.0,Homo sapiens,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,1,,A-431,,,1,,1937,F,,Expert,CHEMBL623736,BAO_0000219,5186
,,N,500.0,,80852,9606.0,Homo sapiens,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,1,,A-431,,,1,,13739,F,,Intermediate,CHEMBL623737,BAO_0000219,5187
,,N,500.0,,80852,9606.0,Homo sapiens,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,1,,A-431,,,1,,3558,F,,Intermediate,CHEMBL623738,BAO_0000219,5188
,,N,500.0,,80852,9606.0,Homo sapiens,Dose giving a 50% decrease in the living cell number (A437 cells),1,,A-431,,,1,,3558,F,,Intermediate,CHEMBL875168,BAO_0000219,5189
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro inhibitory concentration against proliferation of A459 cell line.,1,,A549,,,1,,17686,F,,Expert,CHEMBL623739,BAO_0000219,5190
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,1,,A549,,,1,,5305,F,,Intermediate,CHEMBL623740,BAO_0000219,5191
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,1,,A549,,,1,,3614,F,,Intermediate,CHEMBL624424,BAO_0000219,5192
,,N,624.0,,80021,9606.0,Homo sapiens,In vitro antitumor activity against renal A498 tumor cell lines,1,,A498,,,1,,17229,F,,Intermediate,CHEMBL624425,BAO_0000219,5193
,,N,624.0,,80021,9606.0,Homo sapiens,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",1,,A498,,,1,,15935,F,,Intermediate,CHEMBL624426,BAO_0000219,5194
,,N,624.0,,80021,9606.0,Homo sapiens,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",1,,A498,,,1,,15935,F,,Intermediate,CHEMBL624427,BAO_0000219,5195
,,N,624.0,,80021,9606.0,Homo sapiens,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,1,,A498,,,1,,15560,F,,Intermediate,CHEMBL624428,BAO_0000219,5196
,,N,624.0,,80021,9606.0,Homo sapiens,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,1,,A498,,,1,,13891,F,,Intermediate,CHEMBL624429,BAO_0000219,5197
,,N,624.0,,80021,9606.0,Homo sapiens,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,1,,A498,,,1,,13891,F,,Intermediate,CHEMBL624620,BAO_0000219,5198
,,N,624.0,,80021,9606.0,Homo sapiens,Cytotoxicity on kidney carcinoma (A-498) cell line,1,,A498,,,1,,13788,F,,Intermediate,CHEMBL624621,BAO_0000219,5199
,,N,624.0,,80021,9606.0,Homo sapiens,Compound was evaluated against Human cell line renal A498,1,,A498,,,1,,15403,F,,Intermediate,CHEMBL624622,BAO_0000219,5200
,,N,624.0,,80021,9606.0,Homo sapiens,Compound was tested for inhibition of A498 human renal cancer cell line,1,,A498,,,1,,1009,F,,Intermediate,CHEMBL624623,BAO_0000219,5201
,,N,624.0,,80021,9606.0,Homo sapiens,Growth inhibitory activity against A498 human cancer cell line,1,,A498,,,1,,1043,F,,Intermediate,CHEMBL874365,BAO_0000219,5202
,,N,624.0,,80021,9606.0,Homo sapiens,In vitro antitumor activity against human renal A498 cell line,1,,A498,,,1,,5858,F,,Intermediate,CHEMBL624624,BAO_0000219,5203
,,N,624.0,,80021,9606.0,Homo sapiens,In vitro cytotoxic activity against renal (A498) cell line,1,,A498,,,1,,5958,F,,Intermediate,CHEMBL624625,BAO_0000219,5204
,,N,624.0,,80021,9606.0,Homo sapiens,In vitro cytotoxic activity against human renal cancer (A498) cell line,1,,A498,,,1,,5506,F,,Intermediate,CHEMBL624626,BAO_0000219,5205
,,N,624.0,,80021,9606.0,Homo sapiens,Tested for cytostatic activity against renal A498 cell line,1,,A498,,,1,,12781,F,,Intermediate,CHEMBL624627,BAO_0000219,5206
,,N,624.0,,80021,9606.0,Homo sapiens,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,1,,A498,,,1,,14399,F,,Intermediate,CHEMBL883157,BAO_0000219,5207
,,N,624.0,,80021,9606.0,Homo sapiens,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,1,,A498,,,1,,5958,F,,Expert,CHEMBL624628,BAO_0000219,5208
,,U,,,22224,9615.0,beagle,Cmax value after 2 mpk peroral administration to beagles,1,,,,In vivo,0,,3510,A,,Autocuration,CHEMBL624629,BAO_0000218,5209
beagle,,U,,,22224,9615.0,Canis lupus familiaris,Bioavailability,1,,,,In vivo,0,,3510,A,,Autocuration,CHEMBL623551,BAO_0000218,5210
beagle,,U,,,22224,9615.0,Canis lupus familiaris,Bioavailability after 1 mpk peroral administration to beagles,1,,,,In vivo,0,,3510,A,,Autocuration,CHEMBL623552,BAO_0000218,5211
beagle,,U,,,22224,9615.0,Canis lupus familiaris,Bioavailability after 2 mpk peroral administration to beagles,1,,,,In vivo,0,,3510,A,,Autocuration,CHEMBL623553,BAO_0000218,5212
,,U,,,22224,9913.0,Bos taurus,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,1,,,,,0,,3085,A,,Autocuration,CHEMBL623554,BAO_0000019,5213
,,U,,,22224,9913.0,Bos taurus,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,1,,,,,0,,3085,A,,Autocuration,CHEMBL623555,BAO_0000019,5214
,,U,,,22224,9913.0,Bos taurus,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,1,,,,,0,,3085,A,,Autocuration,CHEMBL623556,BAO_0000019,5215
,,U,,,22224,9913.0,Bos taurus,Solubility against bovine alpha-chymotrypsin,1,,,,,0,,9372,A,,Autocuration,CHEMBL623557,BAO_0000019,5216
,,U,,,22224,9913.0,Bos taurus,Rate constant of the bovine serum albumin catalyzed reaction of the compound,1,,,,,0,,3085,A,,Autocuration,CHEMBL623558,BAO_0000019,5217
,,U,,,22224,9913.0,Bos taurus,Rate constant of the bovine serum albumin catalyzed reaction of the compound,1,,,,,0,,3085,A,,Autocuration,CHEMBL623559,BAO_0000019,5218
,,U,,,22224,9913.0,Bos taurus,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,1,Spleen,,,,0,,1469,A,2106.0,Autocuration,CHEMBL623560,BAO_0000221,5219
,,U,,,22224,9913.0,Bos taurus,Half life in culture medium containing 10% of heat inactivated foetal calf serum,1,,,,,0,,4297,A,,Autocuration,CHEMBL623561,BAO_0000019,5220
,,U,,,22224,9913.0,Bos taurus,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,1,,,,,0,,4297,A,,Autocuration,CHEMBL623562,BAO_0000019,5221
,,U,,,22224,9913.0,Bos taurus,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,1,,,,,0,,17585,A,,Autocuration,CHEMBL623563,BAO_0000019,5222
,,U,,,22224,9913.0,Bos taurus,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,1,Spleen,,,,0,,1336,A,2106.0,Autocuration,CHEMBL623564,BAO_0000221,5223
,,U,,,22224,9913.0,Bos taurus,Half life in presence of 2 mg/mL BSA at pH 8.8,1,,,,,0,,3085,A,,Autocuration,CHEMBL873806,BAO_0000019,5224
,,U,,,22224,9913.0,Bos taurus,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,1,,,,,0,,2857,A,,Autocuration,CHEMBL623565,BAO_0000019,5225
,,U,,,22224,9913.0,Bos taurus,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,1,,,,,0,,2857,A,,Autocuration,CHEMBL623566,BAO_0000019,5226
,,U,,,22224,9913.0,Bos taurus,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,1,,,,,0,,2857,A,,Autocuration,CHEMBL623567,BAO_0000019,5227
,,U,,,22224,9913.0,Bos taurus,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),1,,,,,0,,1540,A,,Autocuration,CHEMBL623568,BAO_0000019,5228
,,N,,,50588,9615.0,Canis lupus familiaris,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,1,Plasma,,,,1,,6316,A,1969.0,Intermediate,CHEMBL623569,BAO_0000218,5229
,,N,,,50588,9615.0,Canis lupus familiaris,AUC after administration at 100 mg/kg/day in dogs,1,Plasma,,,,1,,17594,A,1969.0,Intermediate,CHEMBL623570,BAO_0000218,5230
,,N,,,50588,9615.0,Canis lupus familiaris,AUC in dog at 0-24 hr by peroral administration at 3 mpk,1,Plasma,,,,1,,4953,A,1969.0,Intermediate,CHEMBL624254,BAO_0000218,5231
,,N,,,50588,9615.0,Canis lupus familiaris,AUC value after 15 mg/kg iv dose in Dogs,1,Plasma,,,,1,,16907,A,1969.0,Intermediate,CHEMBL624255,BAO_0000218,5232
,,N,,,50588,9615.0,Canis lupus familiaris,AUC value after 30 mg/kg po dose in Dogs,1,Plasma,,,,1,,16907,A,1969.0,Intermediate,CHEMBL624256,BAO_0000218,5233
,,N,,,50588,9615.0,Canis lupus familiaris,AUC value after administration of 4 mg/Kg oral dose in dog,1,Plasma,,,,1,,2959,A,1969.0,Intermediate,CHEMBL624257,BAO_0000218,5234
,,N,,,50588,9615.0,Canis lupus familiaris,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,1,Plasma,,,,1,,17594,A,1969.0,Intermediate,CHEMBL624258,BAO_0000218,5235
,,N,,,50588,9615.0,Canis lupus familiaris,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,1,,,,,1,,5356,A,,Intermediate,CHEMBL875277,BAO_0000218,5236
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,1,,,,,1,,16807,A,,Intermediate,CHEMBL622667,BAO_0000218,5237
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,1,,,,,1,,4527,A,,Intermediate,CHEMBL622668,BAO_0000218,5238
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,1,,,,,1,,4527,A,,Intermediate,CHEMBL622669,BAO_0000218,5239
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve determined in dogs after intravenous administration of 3 mg/kg,1,,,,,1,,15660,A,,Intermediate,CHEMBL622670,BAO_0000218,5240
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve determined in dogs after oral administration of 10 mg/kg,1,,,,,1,,15660,A,,Intermediate,CHEMBL622671,BAO_0000218,5241
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,1,,,,,1,,5802,A,,Intermediate,CHEMBL622672,BAO_0000218,5242
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,1,,,,,1,,3598,A,,Expert,CHEMBL622673,BAO_0000218,5243
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,1,,,,,1,,3598,A,,Expert,CHEMBL622674,BAO_0000218,5244
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),1,,,,,1,,5944,A,,Intermediate,CHEMBL622675,BAO_0000218,5245
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,1,,,,,1,,5944,A,,Intermediate,CHEMBL622676,BAO_0000218,5246
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),1,,,,,1,,5944,A,,Intermediate,CHEMBL622677,BAO_0000218,5247
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,1,,,,,1,,5944,A,,Intermediate,CHEMBL622678,BAO_0000218,5248
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve in dog after administration of 20 mg/kg dose through peroral route,1,,,,,1,,4186,A,,Intermediate,CHEMBL622679,BAO_0000218,5249
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),1,,,,,1,,5007,A,,Intermediate,CHEMBL622680,BAO_0000218,5250
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve was determine after peroral administration at 10 mpk in dog,1,,,,,1,,5668,A,,Intermediate,CHEMBL622681,BAO_0000218,5251
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve was determine after peroral administration at 5 mpk in dog,1,,,,,1,,5668,A,,Intermediate,CHEMBL875278,BAO_0000218,5252
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve was determined,1,,,,,1,,5006,A,,Intermediate,CHEMBL622682,BAO_0000218,5253
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve in dogs,1,,,,,1,,5006,A,,Intermediate,CHEMBL622683,BAO_0000218,5254
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve in dogs at 10 mg/kg dose fo oral administration,1,,,,,1,,3771,A,,Intermediate,CHEMBL622684,BAO_0000218,5255
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),1,,,,,1,,3771,A,,Intermediate,CHEMBL622685,BAO_0000218,5256
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,1,,,,,1,,3771,A,,Intermediate,CHEMBL622686,BAO_0000218,5257
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,,,,,1,,1916,A,,Intermediate,CHEMBL618344,BAO_0000218,5258
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve value in dog at a dose of 5 mg/kg,1,,,,,1,,5302,A,,Intermediate,CHEMBL875582,BAO_0000218,5259
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve was determined after 0.1 mg/kg iv administration in dog,1,,,,,1,,5600,A,,Intermediate,CHEMBL618345,BAO_0000218,5260
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve was determined after 0.3 mg/kg po administration in dog,1,,,,,1,,5600,A,,Intermediate,CHEMBL618346,BAO_0000218,5261
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,1,,,,,1,,17764,A,,Intermediate,CHEMBL618347,BAO_0000218,5262
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,1,,,,,1,,4368,A,,Intermediate,CHEMBL618348,BAO_0000218,5263
,,U,,,22224,9606.0,Homo sapiens,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,1,,,,,0,,5318,A,,Autocuration,CHEMBL618349,BAO_0000019,5264
,,U,,,22224,9606.0,Homo sapiens,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,1,,,,,0,,5318,A,,Autocuration,CHEMBL618350,BAO_0000019,5265
,,U,,,22224,9606.0,Homo sapiens,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,1,,,,,0,,5318,A,,Autocuration,CHEMBL618351,BAO_0000019,5266
,,U,,,22224,9606.0,Homo sapiens,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,1,,,,,0,,5318,A,,Autocuration,CHEMBL618352,BAO_0000019,5267
,,U,,,22224,9606.0,Homo sapiens,Time taken to reduce 50% of the concentration of compound in blood plasma,1,Blood,,,,0,,14518,A,178.0,Autocuration,CHEMBL873494,BAO_0000221,5268
,,U,,,22224,9606.0,Homo sapiens,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",1,Plasma,,,,0,,2209,A,1969.0,Autocuration,CHEMBL618353,BAO_0000366,5269
,,U,,,22224,9606.0,Homo sapiens,Half life in human plasma,1,Plasma,,,,0,,6787,A,1969.0,Autocuration,CHEMBL618354,BAO_0000366,5270
,,U,,,22224,9606.0,Homo sapiens,Half life in human plasma was reported,1,Plasma,,,,0,,4898,A,1969.0,Autocuration,CHEMBL875583,BAO_0000366,5271
,,U,,,22224,9606.0,Homo sapiens,Half life in human serum,1,Serum,,,,0,,6072,A,1977.0,Autocuration,CHEMBL618355,BAO_0000019,5272
,,U,,,22224,9606.0,Homo sapiens,Half life upon exposure to human plasma,1,Plasma,,,,0,,16907,A,1969.0,Autocuration,CHEMBL618356,BAO_0000366,5273
,Microsomes,U,,,22224,9606.0,Homo sapiens,t1/2 in human microsomes,1,,,,In vitro,0,,5656,A,,Autocuration,CHEMBL618357,BAO_0000251,5274
,,U,,,22224,9606.0,Homo sapiens,Half life period in 80% human plasma at 37 degree Centigrade,1,Plasma,,,,0,,4755,A,1969.0,Autocuration,CHEMBL618358,BAO_0000366,5275
,,U,,,22224,9606.0,Homo sapiens,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),1,Zone of skin,,,,0,,17503,A,14.0,Autocuration,CHEMBL618359,BAO_0000221,5276
,,U,,,22224,9606.0,Homo sapiens,Half-life measured in in vitro Cathepsin B assay in human plasma,1,Plasma,,,In vitro,0,,12357,A,1969.0,Autocuration,CHEMBL618360,BAO_0000366,5277
,,U,,,22224,9606.0,Homo sapiens,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,1,,,,,0,,3076,A,,Autocuration,CHEMBL618361,BAO_0000019,5278
,Microsomes,U,,,22224,9606.0,Homo sapiens,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,1,Liver,,,In vitro,0,,6410,A,2107.0,Autocuration,CHEMBL618362,BAO_0000251,5279
,,U,,,22224,9606.0,Homo sapiens,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",1,Plasma,,,,0,,3741,A,1969.0,Autocuration,CHEMBL618363,BAO_0000366,5280
,,U,,,22224,9606.0,Homo sapiens,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",1,Plasma,,,,0,,3741,A,1969.0,Autocuration,CHEMBL618364,BAO_0000366,5281
,,U,,,22224,9606.0,Homo sapiens,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",1,Plasma,,,,0,,3741,A,1969.0,Autocuration,CHEMBL875584,BAO_0000366,5282
,,U,,,22224,9606.0,Homo sapiens,Half-life in the CEM cell extracts,1,,,,,0,,1540,A,,Autocuration,CHEMBL618365,BAO_0000019,5283
,,U,,,22224,9606.0,Homo sapiens,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,1,Plasma,,,,0,,2905,A,1969.0,Autocuration,CHEMBL873495,BAO_0000366,5284
,,U,,,22224,9606.0,Homo sapiens,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,1,Plasma,,,,0,,2905,A,1969.0,Autocuration,CHEMBL618366,BAO_0000366,5285
,,U,,,22224,9606.0,Homo sapiens,Half-life was determined,1,,,,,0,,5523,A,,Autocuration,CHEMBL618367,BAO_0000019,5286
,,U,,,22224,9606.0,Homo sapiens,Half-life (human blood stability),1,Blood,,,,0,,1499,A,178.0,Autocuration,CHEMBL618368,BAO_0000221,5287
,,U,,,22224,9606.0,Homo sapiens,Half-life (human blood stability); no data,1,Blood,,,,0,,1499,A,178.0,Autocuration,CHEMBL618369,BAO_0000221,5288
,,U,,,22224,9606.0,Homo sapiens,Half-life in human plasma,1,Plasma,,,,0,,17065,A,1969.0,Autocuration,CHEMBL618370,BAO_0000366,5289
,,U,,,22224,9606.0,Homo sapiens,CYP3A4 metabolism half-life (t1/2),1,,,,,0,,6861,A,,Autocuration,CHEMBL618371,BAO_0000019,5290
,,U,,,22224,9606.0,Homo sapiens,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),1,Blood,,,,0,,1499,A,178.0,Autocuration,CHEMBL618372,BAO_0000221,5291
,,U,,,22224,9606.0,Homo sapiens,In vitro half life in human plasma,1,Plasma,,,In vitro,0,,530,A,1969.0,Autocuration,CHEMBL618373,BAO_0000366,5292
,,U,,,22224,9606.0,Homo sapiens,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",1,Plasma,,,In vitro,0,,1116,A,1969.0,Autocuration,CHEMBL618374,BAO_0000366,5293
,,U,,,22224,9606.0,Homo sapiens,In vitro hydrolysis in human plasma,1,Plasma,,,In vitro,0,,6695,A,1969.0,Autocuration,CHEMBL618375,BAO_0000366,5294
,,U,,,22224,9606.0,Homo sapiens,In vitro hydrolysis in human plasma; no data,1,Plasma,,,In vitro,0,,6695,A,1969.0,Autocuration,CHEMBL618376,BAO_0000366,5295
,Microsomes,U,,,22224,9606.0,Homo sapiens,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,1,Liver,,,In vitro,0,,10,A,2107.0,Autocuration,CHEMBL618377,BAO_0000251,5296
,,U,,,22224,9606.0,Homo sapiens,Plasma half life in human,1,Plasma,,,,0,,993,A,1969.0,Autocuration,CHEMBL618378,BAO_0000366,5297
,,U,,,22224,9606.0,Homo sapiens,Stability after incubation with human plasma (at 37 degree C),1,Plasma,,,,0,,15429,A,1969.0,Autocuration,CHEMBL618379,BAO_0000366,5298
,,U,,,22224,9606.0,Homo sapiens,T1/2 was evaluated in human plasma,1,Plasma,,,,0,,1675,A,1969.0,Autocuration,CHEMBL618380,BAO_0000366,5299
,,U,,,22224,9606.0,Homo sapiens,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",1,Plasma,,,,0,,2209,A,1969.0,Autocuration,CHEMBL618381,BAO_0000366,5300
,,U,,,22224,9606.0,Homo sapiens,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",1,Plasma,,,,0,,2209,A,1969.0,Autocuration,CHEMBL618382,BAO_0000366,5301
,,U,,,22224,9606.0,Homo sapiens,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,1,,,,,0,,5318,A,,Autocuration,CHEMBL618383,BAO_0000019,5302
,,U,,,22224,9606.0,Homo sapiens,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,1,,,,In vitro,0,,2412,A,,Autocuration,CHEMBL618384,BAO_0000019,5303
,,U,,,22224,9606.0,Homo sapiens,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,1,,,,In vitro,0,,2412,A,,Autocuration,CHEMBL618385,BAO_0000019,5304
,,U,,,22224,9606.0,Homo sapiens,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,1,Plasma,,,,0,,2906,A,1969.0,Autocuration,CHEMBL619099,BAO_0000366,5305
,,U,,,22224,9606.0,Homo sapiens,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,1,Plasma,,,,0,,2906,A,1969.0,Autocuration,CHEMBL619100,BAO_0000366,5306
,,U,,,22224,9606.0,Homo sapiens,Time taken for 50% to be consumed by serum PON1 was determined,1,,,,,0,,5495,A,,Autocuration,CHEMBL619101,BAO_0000019,5307
,,U,,,22224,9606.0,Homo sapiens,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,1,,,,,0,,5495,A,,Autocuration,CHEMBL619102,BAO_0000019,5308
,Microsomes,U,,,22224,9606.0,Homo sapiens,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,1,Liver,,,,0,,4397,A,2107.0,Autocuration,CHEMBL619103,BAO_0000251,5309
,,U,,,22224,10095.0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,,,,,0,,2413,A,,Autocuration,CHEMBL619268,BAO_0000218,5310
,,U,,,22224,10095.0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,,,,,0,,2413,A,,Autocuration,CHEMBL619269,BAO_0000218,5311
,,U,,,22224,10095.0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,,,,,0,,2413,A,,Autocuration,CHEMBL619270,BAO_0000218,5312
,,U,,,22224,10095.0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,,,,,0,,2413,A,,Autocuration,CHEMBL619271,BAO_0000218,5313
,,U,,,22224,10095.0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,,,,,0,,2413,A,,Autocuration,CHEMBL875585,BAO_0000218,5314
,,U,,,22224,10095.0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,1,,,,,0,,2413,A,,Autocuration,CHEMBL619272,BAO_0000218,5315
,,N,391.0,,80640,9606.0,Homo sapiens,Compound tested for growth inhibition of renal cancer cell line 786-0,1,,786-0,,,1,,6058,F,,Intermediate,CHEMBL619273,BAO_0000219,5316
,,N,391.0,,80640,9606.0,Homo sapiens,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,1,,786-0,,,1,,17708,F,,Intermediate,CHEMBL619274,BAO_0000219,5317
,,N,391.0,,80640,9606.0,Homo sapiens,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,1,,786-0,,,1,,14017,F,,Expert,CHEMBL619275,BAO_0000219,5318
,,N,391.0,,80640,9606.0,Homo sapiens,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",1,,786-0,,,1,,16818,F,,Intermediate,CHEMBL619276,BAO_0000219,5319
,,N,391.0,,80640,9606.0,Homo sapiens,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",1,,786-0,,,1,,16818,F,,Intermediate,CHEMBL619277,BAO_0000219,5320
,,N,391.0,,80640,9606.0,Homo sapiens,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",1,,786-0,,,1,,16818,F,,Intermediate,CHEMBL619278,BAO_0000219,5321
,,N,391.0,,80640,9606.0,Homo sapiens,Tested for cytotoxicity against 786-0 cell lines in renal cancer,1,,786-0,,,1,,11970,F,,Intermediate,CHEMBL619279,BAO_0000219,5322
,,N,391.0,,80640,9606.0,Homo sapiens,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,1,,786-0,,,1,,12400,F,,Intermediate,CHEMBL858458,BAO_0000219,5323
,,N,391.0,,80640,9606.0,Homo sapiens,Cytotoxic effect on renal cancer line 786-0,1,,786-0,,,1,,12888,F,,Expert,CHEMBL619280,BAO_0000219,5324
,,N,391.0,,80640,9606.0,Homo sapiens,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,1,,786-0,,,1,,15300,F,,Intermediate,CHEMBL619281,BAO_0000219,5325
,,N,391.0,,80640,9606.0,Homo sapiens,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),1,,786-0,,,1,,14769,F,,Intermediate,CHEMBL619282,BAO_0000219,5326
,,N,391.0,,80640,9606.0,Homo sapiens,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",1,,786-0,,,1,,15895,F,,Intermediate,CHEMBL619283,BAO_0000219,5327
,,N,391.0,,80640,9606.0,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,1,,786-0,,,1,,17376,F,,Intermediate,CHEMBL619284,BAO_0000219,5328
,,N,391.0,,80640,9606.0,Homo sapiens,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,1,,786-0,,,1,,14882,F,,Intermediate,CHEMBL619285,BAO_0000219,5329
,,N,391.0,,80640,9606.0,Homo sapiens,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),1,,786-0,,,1,,14882,F,,Intermediate,CHEMBL619286,BAO_0000219,5330
,,N,391.0,,80640,9606.0,Homo sapiens,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,1,,786-0,,,1,,15176,F,,Intermediate,CHEMBL619287,BAO_0000219,5331
,,N,391.0,,80640,9606.0,Homo sapiens,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,1,,786-0,,,1,,12696,F,,Intermediate,CHEMBL857455,BAO_0000219,5332
,,N,391.0,,80640,9606.0,Homo sapiens,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),1,,786-0,,,1,,2496,F,,Intermediate,CHEMBL883801,BAO_0000219,5333
,,N,972.0,,80641,9606.0,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,1,,791T cell line,,,1,,11831,F,,Intermediate,CHEMBL619288,BAO_0000219,5334
,,N,972.0,,80641,9606.0,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),1,,791T cell line,,,1,,11831,F,,Intermediate,CHEMBL619289,BAO_0000219,5335
,,N,972.0,,80641,9606.0,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,1,,791T cell line,,,1,,11831,F,,Intermediate,CHEMBL619290,BAO_0000219,5336
,,N,972.0,,80641,9606.0,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),1,,791T cell line,,,1,,11831,F,,Intermediate,CHEMBL619291,BAO_0000219,5337
,,N,972.0,,80641,9606.0,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),1,,791T cell line,,,1,,11831,F,,Intermediate,CHEMBL619292,BAO_0000219,5338
,,N,972.0,,80641,9606.0,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,1,,791T cell line,,,1,,11831,F,,Intermediate,CHEMBL619293,BAO_0000219,5339
,,N,972.0,,80641,9606.0,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),1,,791T cell line,,,1,,11831,F,,Intermediate,CHEMBL619294,BAO_0000219,5340
,,N,972.0,,80641,9606.0,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),1,,791T cell line,,,1,,11831,F,,Intermediate,CHEMBL619295,BAO_0000219,5341
,,N,972.0,,80641,9606.0,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),1,,791T cell line,,,1,,11831,F,,Intermediate,CHEMBL619296,BAO_0000219,5342
,,N,972.0,,80641,9606.0,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,1,,791T cell line,,,1,,11831,F,,Intermediate,CHEMBL619297,BAO_0000219,5343
,,N,391.0,,80640,9606.0,Homo sapiens,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,1,,786-0,,,1,,12782,F,,Intermediate,CHEMBL619298,BAO_0000219,5344
,,U,,,22226,,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,1,,,,,0,,1229,F,,Intermediate,CHEMBL619299,BAO_0000019,5345
,,N,741.0,,80433,9606.0,Homo sapiens,Inhibition of cell growth in drug resistant 8226 myeloma cell line,1,,RPMI-8226,,,1,,15313,F,,Expert,CHEMBL619300,BAO_0000219,5346
,,N,741.0,,80433,9606.0,Homo sapiens,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,1,,RPMI-8226,,,1,,15313,F,,Expert,CHEMBL619301,BAO_0000219,5347
,,N,741.0,,80433,9606.0,Homo sapiens,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,1,,RPMI-8226,,,1,,11544,F,,Intermediate,CHEMBL619302,BAO_0000219,5348
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL619303,BAO_0000219,5349
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL619304,BAO_0000219,5350
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL857706,BAO_0000219,5351
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL619305,BAO_0000219,5352
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL619306,BAO_0000219,5353
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL619307,BAO_0000219,5354
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL619308,BAO_0000219,5355
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL619309,BAO_0000219,5356
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL619310,BAO_0000219,5357
,,N,624.0,,80021,9606.0,Homo sapiens,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),1,,A498,,,1,,14769,F,,Intermediate,CHEMBL619311,BAO_0000219,5358
,,N,624.0,,80021,9606.0,Homo sapiens,Compound was tested for the growth inhibition of A498 renal tumor cell line,1,,A498,,,1,,15354,F,,Intermediate,CHEMBL619312,BAO_0000219,5359
,,N,624.0,,80021,9606.0,Homo sapiens,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),1,,A498,,,1,,17445,F,,Intermediate,CHEMBL619313,BAO_0000219,5360
,,N,624.0,,80021,9606.0,Homo sapiens,In vitro inhibitory concentration against renal cancer cell line A498,1,,A498,,,1,,4337,F,,Intermediate,CHEMBL619314,BAO_0000219,5361
,,N,624.0,,80021,9606.0,Homo sapiens,Cytotoxicity against A 498 tumor cell line,1,,A498,,,1,,15277,F,,Intermediate,CHEMBL619959,BAO_0000219,5362
,,N,624.0,,80021,9606.0,Homo sapiens,In vitro antitumor activity against A498 human cancer cell line,1,,A498,,,1,,4812,F,,Intermediate,CHEMBL619960,BAO_0000219,5363
,,N,624.0,,80021,9606.0,Homo sapiens,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),1,,A498,,,1,,4812,F,,Intermediate,CHEMBL619961,BAO_0000219,5364
,,N,624.0,,80021,9606.0,Homo sapiens,Inhibitory dose required against A498 human tumor cell lines,1,,A498,,,1,,4995,F,,Intermediate,CHEMBL619962,BAO_0000219,5365
,,N,624.0,,80021,9606.0,Homo sapiens,Anticancer activity against one renal cancer (A498 cell line),1,,A498,,,1,,5847,F,,Intermediate,CHEMBL875586,BAO_0000219,5366
,,N,624.0,,80021,9606.0,Homo sapiens,In vitro cytotoxicity against melanoma A498 cell line,1,,A498,,,1,,6557,F,,Intermediate,CHEMBL619963,BAO_0000219,5367
,,N,624.0,,80021,9606.0,Homo sapiens,Compound was tested for growth inhibitory activity against A498 cell line,1,,A498,,,1,,2597,F,,Intermediate,CHEMBL619964,BAO_0000219,5368
,,N,624.0,,80021,9606.0,Homo sapiens,Compound tested for growth inhibition of renal cancer cell line A498,1,,A498,,,1,,6058,F,,Intermediate,CHEMBL620108,BAO_0000219,5369
,,N,624.0,,80021,9606.0,Homo sapiens,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,1,,A498,,,1,,17708,F,,Intermediate,CHEMBL620109,BAO_0000219,5370
,,N,624.0,,80021,9606.0,Homo sapiens,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,1,,A498,,,1,,15176,F,,Intermediate,CHEMBL620110,BAO_0000219,5371
,,N,624.0,,80021,9606.0,Homo sapiens,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,1,,A498,,,1,,15300,F,,Intermediate,CHEMBL620111,BAO_0000219,5372
,,N,624.0,,80021,9606.0,Homo sapiens,Tested for cytotoxicity against A498 cell lines in renal cancer,1,,A498,,,1,,11970,F,,Intermediate,CHEMBL620112,BAO_0000219,5373
,,N,624.0,,80021,9606.0,Homo sapiens,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,1,,A498,,,1,,12400,F,,Intermediate,CHEMBL620113,BAO_0000219,5374
,,N,624.0,,80021,9606.0,Homo sapiens,Cytotoxic effect on renal cancer lines A498,1,,A498,,,1,,12888,F,,Expert,CHEMBL620114,BAO_0000219,5375
,,N,624.0,,80021,9606.0,Homo sapiens,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,1,,A498,,,1,,3030,F,,Intermediate,CHEMBL620115,BAO_0000219,5376
,,N,624.0,,80021,9606.0,Homo sapiens,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),1,,A498,,,1,,14769,F,,Intermediate,CHEMBL620116,BAO_0000219,5377
,,N,624.0,,80021,9606.0,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,1,,A498,,,1,,17376,F,,Intermediate,CHEMBL620117,BAO_0000219,5378
,,N,624.0,,80021,9606.0,Homo sapiens,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,1,,A498,,,1,,16558,F,,Intermediate,CHEMBL620118,BAO_0000219,5379
,,N,624.0,,80021,9606.0,Homo sapiens,Cytotoxicity against human kidney carcinoma cell lines A4982LM,1,,A498,,,1,,5194,F,,Intermediate,CHEMBL620119,BAO_0000219,5380
,,N,624.0,,80021,9606.0,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,1,,A498,,,1,,10708,F,,Intermediate,CHEMBL620120,BAO_0000219,5381
,,N,646.0,,80682,9606.0,Homo sapiens,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,1,,A549,,,1,,16880,F,,Expert,CHEMBL620121,BAO_0000219,5382
,,N,646.0,,80682,9606.0,Homo sapiens,Antitumor activity against A549 human lung carcinoma cell line,1,,A549,,,1,,10196,F,,Intermediate,CHEMBL620122,BAO_0000219,5383
,,N,646.0,,80682,9606.0,Homo sapiens,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,1,,A549,,,1,,10196,F,,Intermediate,CHEMBL620123,BAO_0000219,5384
,,N,646.0,,80682,9606.0,Homo sapiens,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,1,,A549,,,1,,10196,F,,Intermediate,CHEMBL620124,BAO_0000219,5385
,,N,646.0,,80682,9606.0,Homo sapiens,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",1,,A549,,,1,,12083,F,,Intermediate,CHEMBL620125,BAO_0000219,5386
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,1,,A549,,,1,,16464,F,,Expert,CHEMBL620126,BAO_0000219,5387
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,,A549,,,1,,16464,F,,Intermediate,CHEMBL883027,BAO_0000219,5388
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line,1,,A549,,,1,,16470,F,,Expert,CHEMBL620127,BAO_0000219,5389
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),1,,A549,,,1,,16470,F,,Intermediate,CHEMBL620128,BAO_0000219,5390
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line),1,,A549,,,1,,16470,F,,Intermediate,CHEMBL620129,BAO_0000219,5391
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,1,,A549,,,1,,16470,F,,Intermediate,CHEMBL620130,BAO_0000219,5392
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against human non small-cell-lung cell line A549.,1,,A549,,,1,,16582,F,,Expert,CHEMBL620131,BAO_0000219,5393
,,N,646.0,,80682,9606.0,Homo sapiens,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",1,,A549,,,1,,15935,F,,Intermediate,CHEMBL620132,BAO_0000219,5394
,,N,646.0,,80682,9606.0,Homo sapiens,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",1,,A549,,,1,,15935,F,,Intermediate,CHEMBL620133,BAO_0000219,5395
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition of A549 human lung carcinoma cell proliferation,1,,A549,,,1,,16597,F,,Expert,CHEMBL620134,BAO_0000219,5396
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibitory activity against A549 lung adenocarcinoma cell line,1,,A549,,,1,,17376,F,,Intermediate,CHEMBL620135,BAO_0000219,5397
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,1,,A549,,,1,,16496,F,,Intermediate,CHEMBL620136,BAO_0000219,5398
,,N,646.0,,80682,9606.0,Homo sapiens,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,1,,A549,,,1,,16152,F,,Intermediate,CHEMBL620137,BAO_0000219,5399
,,N,646.0,,80682,9606.0,Homo sapiens,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,1,,A549,,,1,,16152,F,,Intermediate,CHEMBL620268,BAO_0000219,5400
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,,A549,,,1,,16464,F,,Intermediate,CHEMBL620269,BAO_0000219,5401
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,1,,A549,,,1,,2288,F,,Intermediate,CHEMBL620270,BAO_0000219,5402
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,1,,A549,,,1,,17350,F,,Intermediate,CHEMBL620271,BAO_0000219,5403
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition of A549 cancer cell proliferation,1,,A549,,,1,,4090,F,,Expert,CHEMBL620272,BAO_0000219,5404
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition of A549 cancer cell proliferation (Not tested),1,,A549,,,1,,4090,F,,Expert,CHEMBL620273,BAO_0000219,5405
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,1,,A549,,,1,,17350,F,,Intermediate,CHEMBL620274,BAO_0000219,5406
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,1,,A549,,,1,,4197,F,,Intermediate,CHEMBL620275,BAO_0000219,5407
,,N,646.0,,80682,9606.0,Homo sapiens,Antiproliferative potency determined as inhibitory concentration against A549 cells,1,,A549,,,1,,17072,F,,Intermediate,CHEMBL620276,BAO_0000219,5408
,,N,646.0,,80682,9606.0,Homo sapiens,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,1,,A549,,,1,,17072,F,,Intermediate,CHEMBL620277,BAO_0000219,5409
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity against Renal cell lines A549 was determined,1,,A549,,,1,,5194,F,,Intermediate,CHEMBL620278,BAO_0000219,5410
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve was determined in dog after a 3 mg/kg of oral dose,1,,,,,1,,4257,A,,Intermediate,CHEMBL620279,BAO_0000218,5411
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve was determined in dog after oral administration at 1 mg/kg,1,,,,,1,,6123,A,,Intermediate,CHEMBL620280,BAO_0000218,5412
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1,,,,,1,,1337,A,,Intermediate,CHEMBL620281,BAO_0000218,5413
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1,,,,,1,,1337,A,,Intermediate,CHEMBL620282,BAO_0000218,5414
,,N,,,50588,9615.0,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),1,,,,,1,,8833,A,,Intermediate,CHEMBL621134,BAO_0000218,5415
,,N,,,50588,9615.0,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),1,,,,,1,,8833,A,,Intermediate,CHEMBL621135,BAO_0000218,5416
,,N,,,50588,9615.0,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),1,,,,,1,,8833,A,,Intermediate,CHEMBL621136,BAO_0000218,5417
,,N,,,50588,9615.0,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),1,,,,,1,,8833,A,,Intermediate,CHEMBL621137,BAO_0000218,5418
,,N,,,50588,9615.0,Canis lupus familiaris,Area under plasma concentration time curve in dog upon oral administration,1,Plasma,,,,1,,17657,A,1969.0,Intermediate,CHEMBL621138,BAO_0000218,5419
,,N,,,50588,9615.0,Canis lupus familiaris,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,1,Plasma,,,,1,,17650,A,1969.0,Intermediate,CHEMBL875587,BAO_0000218,5420
,,N,,,50588,9615.0,Canis lupus familiaris,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,1,,,,,1,,1977,A,,Intermediate,CHEMBL621139,BAO_0000218,5421
,,N,,,50588,9615.0,Canis lupus familiaris,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,1,,,,,1,,1977,A,,Intermediate,CHEMBL621140,BAO_0000218,5422
,,N,,,50588,9615.0,Canis lupus familiaris,Area under the curve for the compound was obtained when tested in dog,1,,,,,1,,3132,A,,Intermediate,CHEMBL621141,BAO_0000218,5423
,,N,,,50588,9615.0,Canis lupus familiaris,Area under the curve at a dose of 1 mg/kg,1,,,,,1,,5473,A,,Intermediate,CHEMBL621142,BAO_0000218,5424
,,N,,,50588,9615.0,Canis lupus familiaris,Area under the curve at a dose of 1 mg/kg (oral),1,,,,,1,,5474,A,,Intermediate,CHEMBL621143,BAO_0000218,5425
,,N,,,50588,9615.0,Canis lupus familiaris,Area under the curve at i.v. dose of 0.2 mg/kg,1,,,,,1,,5474,A,,Intermediate,CHEMBL621144,BAO_0000218,5426
,,N,,,50588,9615.0,Canis lupus familiaris,Area under the curve was measured in dog after an iv dose of 1 mg/kg,1,,,,,1,,6062,A,,Intermediate,CHEMBL621145,BAO_0000218,5427
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,1,,,,,1,,4709,A,,Intermediate,CHEMBL621146,BAO_0000218,5428
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,1,,,,,1,,2652,A,,Intermediate,CHEMBL622567,BAO_0000218,5429
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,1,,,,,1,,2652,A,,Intermediate,CHEMBL622568,BAO_0000218,5430
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for area under the curve in dog blood.,1,,,,,1,,2877,A,,Intermediate,CHEMBL622569,BAO_0000218,5431
,,N,,,50588,9615.0,Canis lupus familiaris,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,1,,,,,1,,5444,A,,Intermediate,CHEMBL622570,BAO_0000218,5432
,,N,,,50588,9615.0,Canis lupus familiaris,AUC in dog after oral dose (1 mg/kg),1,Plasma,,,,1,,5130,A,1969.0,Intermediate,CHEMBL622571,BAO_0000218,5433
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,1,,,,,1,,6265,A,,Intermediate,CHEMBL622572,BAO_0000218,5434
,,N,,,50588,9615.0,Canis lupus familiaris,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",1,,,,,1,,4657,A,,Intermediate,CHEMBL622573,BAO_0000218,5435
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic parameter AUC after intravenous administration to dogs,1,,,,,1,,16367,A,,Intermediate,CHEMBL622574,BAO_0000218,5436
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic parameter AUC after oral administration to dogs,1,,,,,1,,16367,A,,Intermediate,CHEMBL622575,BAO_0000218,5437
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,1,,,,,1,,9579,A,,Intermediate,CHEMBL622576,BAO_0000218,5438
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,1,,,,,1,,9579,A,,Intermediate,CHEMBL622577,BAO_0000218,5439
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,1,,,,,1,,5983,A,,Intermediate,CHEMBL622578,BAO_0000218,5440
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,1,,,,,1,,6241,A,,Intermediate,CHEMBL622579,BAO_0000218,5441
,,N,,,50588,9615.0,Canis lupus familiaris,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",1,,,,,1,,5313,A,,Intermediate,CHEMBL622580,BAO_0000218,5442
,,N,,,50588,9615.0,Canis lupus familiaris,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",1,,,,,1,,5313,A,,Intermediate,CHEMBL622581,BAO_0000218,5443
,,N,,,50588,9615.0,Canis lupus familiaris,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,,,,,1,,6642,A,,Intermediate,CHEMBL622582,BAO_0000218,5444
,,N,,,50588,9615.0,Canis lupus familiaris,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,,,,,1,,6642,A,,Intermediate,CHEMBL622583,BAO_0000218,5445
,,N,,,50588,9615.0,Canis lupus familiaris,Oral AUCN in dog (dosed at 0.5 mpk iv ),1,,,,,1,,6641,A,,Intermediate,CHEMBL622584,BAO_0000218,5446
,,N,,,50588,9615.0,Canis lupus familiaris,Oral AUCN in dog (dosed at 0.5 mpk iv ),1,,,,,1,,6642,A,,Intermediate,CHEMBL622585,BAO_0000218,5447
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for oral bioavailability in dog; 90-100,1,,,,,1,,17791,A,,Intermediate,CHEMBL622586,BAO_0000218,5448
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,1,,,,,1,,17655,A,,Intermediate,CHEMBL623281,BAO_0000218,5449
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,1,,,,,1,,17655,A,,Intermediate,CHEMBL623282,BAO_0000218,5450
,,N,,,50588,9615.0,Canis lupus familiaris,PAPP (membrane permeability) in dog kidney cell monolayer assay,1,,,,,1,,6596,A,,Intermediate,CHEMBL623283,BAO_0000218,5451
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,,1,,3880,A,,Intermediate,CHEMBL623284,BAO_0000218,5452
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability administered orally at a dose of 10 mg/kg to dogs,1,,,,,1,,16367,A,,Intermediate,CHEMBL623285,BAO_0000218,5453
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma protein binding towards dog plasma at 10 uM,1,Plasma,,,,1,,17409,A,1969.0,Intermediate,CHEMBL623463,BAO_0000218,5454
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma protein binding towards dog plasma at 100 uM,1,Plasma,,,,1,,17409,A,1969.0,Intermediate,CHEMBL875952,BAO_0000218,5455
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog (dose 4 mg/kg p.o.),1,,,,In vivo,1,,2959,A,,Intermediate,CHEMBL621705,BAO_0000218,5456
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,1,,,,In vivo,1,,13501,A,,Intermediate,CHEMBL621706,BAO_0000218,5457
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,1,,,,In vivo,1,,4527,A,,Intermediate,CHEMBL621707,BAO_0000218,5458
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dogs,1,,,,In vivo,1,,15145,A,,Intermediate,CHEMBL621708,BAO_0000218,5459
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability,1,,,,In vivo,1,,4219,A,,Intermediate,CHEMBL621709,BAO_0000218,5460
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),1,,,,In vivo,1,,17538,A,,Intermediate,CHEMBL621710,BAO_0000218,5461
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,1,,,,In vivo,1,,17538,A,,Intermediate,CHEMBL621711,BAO_0000218,5462
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog (dose 10.0 mg/kg p.o.),1,,,,In vivo,1,,1466,A,,Intermediate,CHEMBL621712,BAO_0000218,5463
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,1,,,,In vivo,1,,17650,A,,Intermediate,CHEMBL621713,BAO_0000218,5464
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,1,,,,In vivo,1,,3132,A,,Intermediate,CHEMBL621714,BAO_0000218,5465
,,U,,,22224,10095.0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,,,,,0,,2413,A,,Autocuration,CHEMBL621715,BAO_0000218,5466
,,U,,,22224,10095.0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,Liver,,,,0,,2413,A,2107.0,Autocuration,CHEMBL623717,BAO_0000218,5467
,,U,,,22224,10095.0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,1,Liver,,,,0,,2413,A,2107.0,Autocuration,CHEMBL623718,BAO_0000218,5468
,,U,,,22224,10095.0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,Liver,,,,0,,2413,A,2107.0,Autocuration,CHEMBL623719,BAO_0000218,5469
,,U,,,22224,10095.0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,,,,,0,,2413,A,,Autocuration,CHEMBL623720,BAO_0000218,5470
,,U,,,22224,10095.0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,,,,,0,,2413,A,,Autocuration,CHEMBL623721,BAO_0000218,5471
,,U,,,22224,10095.0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,Muscle tissue,,,,0,,2413,A,2385.0,Autocuration,CHEMBL623722,BAO_0000218,5472
,,U,,,22224,10095.0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,1,Muscle tissue,,,,0,,2413,A,2385.0,Autocuration,CHEMBL623723,BAO_0000218,5473
,,U,,,22224,10095.0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,Muscle tissue,,,,0,,2413,A,2385.0,Autocuration,CHEMBL618543,BAO_0000218,5474
,,U,,,22224,10095.0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,Spleen,,,,0,,2413,A,2106.0,Autocuration,CHEMBL618544,BAO_0000218,5475
,,U,,,22224,10095.0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,Spleen,,,,0,,2413,A,2106.0,Autocuration,CHEMBL875155,BAO_0000218,5476
,,U,,,22224,10095.0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,,,,,0,,2413,A,,Autocuration,CHEMBL618545,BAO_0000218,5477
,,U,,,22224,10095.0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,1,,,,,0,,2413,A,,Autocuration,CHEMBL618546,BAO_0000218,5478
,,U,,,22224,10095.0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,,,,,0,,2413,A,,Autocuration,CHEMBL623529,BAO_0000218,5479
,,U,,,22224,10095.0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,1,,,,,0,,2413,A,,Autocuration,CHEMBL623530,BAO_0000218,5480
,,U,,,22224,10095.0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,,,,,0,,2413,A,,Autocuration,CHEMBL621764,BAO_0000218,5481
,,U,,,22224,9527.0,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),1,,,,,0,,17827,A,,Autocuration,CHEMBL621765,BAO_0000019,5482
,,U,,,22224,9527.0,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),1,Cerebellum,,,,0,,17827,A,2037.0,Autocuration,CHEMBL621766,BAO_0000019,5483
,,U,,,22224,9527.0,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),1,Frontal cortex,,,,0,,17827,A,1870.0,Autocuration,CHEMBL621767,BAO_0000019,5484
,,U,,,22224,9527.0,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),1,,,,,0,,17827,A,,Autocuration,CHEMBL621768,BAO_0000019,5485
,,U,,,22224,9527.0,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),1,Striatum,,,,0,,17827,A,2435.0,Autocuration,CHEMBL621769,BAO_0000019,5486
,,U,,,22224,9527.0,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),1,,,,,0,,17827,A,,Autocuration,CHEMBL621770,BAO_0000019,5487
,,U,,,22224,9527.0,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),1,Cerebellum,,,,0,,17827,A,2037.0,Autocuration,CHEMBL621771,BAO_0000019,5488
,,U,,,22224,9527.0,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),1,Frontal cortex,,,,0,,17827,A,1870.0,Autocuration,CHEMBL621772,BAO_0000019,5489
,,U,,,22224,9527.0,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),1,,,,,0,,17827,A,,Autocuration,CHEMBL621773,BAO_0000019,5490
,,U,,,22224,9527.0,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),1,Striatum,,,,0,,17827,A,2435.0,Autocuration,CHEMBL621774,BAO_0000019,5491
,,U,,,22224,9527.0,Cercopithecidae,Compound was evaluated for oral bioavailability in rats,1,,,,,0,,17791,A,,Autocuration,CHEMBL621775,BAO_0000218,5492
,,U,,,22224,9527.0,Cercopithecidae,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,1,Plasma,,,In vivo,0,,17667,A,1969.0,Autocuration,CHEMBL621776,BAO_0000218,5493
,,U,,,22224,9527.0,Cercopithecidae,Half life period was evaluated in monkey,1,,,,,0,,17791,A,,Autocuration,CHEMBL621777,BAO_0000019,5494
,,U,,,22224,9527.0,Cercopithecidae,Half-life in rhesus monkeys by intravenous administration of dose,1,,,,In vivo,0,,110,A,,Autocuration,CHEMBL875162,BAO_0000218,5495
,,N,,,50594,10090.0,Mus musculus,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,1,Plasma,,,,1,,5781,A,1969.0,Intermediate,CHEMBL621778,BAO_0000218,5496
,,N,,,50594,10090.0,Mus musculus,AUC after intraperitoneal administration of 100 mg/kg in mice,1,Plasma,,,,1,,17734,A,1969.0,Intermediate,CHEMBL621779,BAO_0000218,5497
,,N,,,50594,10090.0,Mus musculus,AUC value was determined after oral administration,1,Plasma,,,,1,,17718,A,1969.0,Intermediate,CHEMBL622479,BAO_0000218,5498
,,N,,,50594,10090.0,Mus musculus,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,1,,,,,1,,4573,A,,Intermediate,CHEMBL622480,BAO_0000218,5499
,,N,,,50594,10090.0,Mus musculus,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),1,,,,,1,,3277,A,,Intermediate,CHEMBL622481,BAO_0000218,5500
,,N,,,50594,10090.0,Mus musculus,Area under curve by ioral administration in mouse,1,,,,,1,,2862,A,,Intermediate,CHEMBL622482,BAO_0000218,5501
,,N,,,50594,10090.0,Mus musculus,Area under curve by iv administration in mouse,1,,,,,1,,2862,A,,Intermediate,CHEMBL622483,BAO_0000218,5502
,,N,,,50594,10090.0,Mus musculus,Area under curve at 0-8 hr in IRC mice after peroral administration,1,,,,,1,,5951,A,,Intermediate,CHEMBL622484,BAO_0000218,5503
,,N,,,50594,10090.0,Mus musculus,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,1,,,,,1,,17729,A,,Intermediate,CHEMBL622641,BAO_0000218,5504
,,N,,,50594,10090.0,Mus musculus,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,1,,,,,1,,17728,A,,Intermediate,CHEMBL622642,BAO_0000218,5505
,,N,,,50594,10090.0,Mus musculus,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,1,,,,,1,,17728,A,,Intermediate,CHEMBL622643,BAO_0000218,5506
,,N,,,50594,10090.0,Mus musculus,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,1,,,,,1,,17729,A,,Intermediate,CHEMBL622644,BAO_0000218,5507
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL622645,BAO_0000219,5508
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL622646,BAO_0000219,5509
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL621238,BAO_0000219,5510
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL621239,BAO_0000219,5511
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL621240,BAO_0000219,5512
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL621241,BAO_0000219,5513
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL621242,BAO_0000219,5514
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL620350,BAO_0000219,5515
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL620351,BAO_0000219,5516
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL620352,BAO_0000219,5517
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL620353,BAO_0000219,5518
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL620354,BAO_0000219,5519
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL620355,BAO_0000219,5520
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL620356,BAO_0000219,5521
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL620357,BAO_0000219,5522
,,N,741.0,,80433,9606.0,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),1,,RPMI-8226,,,1,,9424,F,,Intermediate,CHEMBL620358,BAO_0000219,5523
,,N,741.0,,80433,9606.0,Homo sapiens,In vitro inhibition of human 8226 myeloma tumor cell line growth.,1,,RPMI-8226,,,1,,9424,F,,Expert,CHEMBL620359,BAO_0000219,5524
,,N,741.0,,80433,9606.0,Homo sapiens,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,1,,RPMI-8226,,,1,,11544,F,,Intermediate,CHEMBL620360,BAO_0000219,5525
,,N,741.0,,80433,9606.0,Homo sapiens,Cytotoxicity of compound against 8226/DOX1V cells,1,,RPMI-8226,,,1,,17378,F,,Intermediate,CHEMBL620361,BAO_0000219,5526
,,N,741.0,,80433,9606.0,Homo sapiens,Cytotoxicity of compound against 8226/S cells,1,,RPMI-8226,,,1,,17378,F,,Intermediate,CHEMBL620362,BAO_0000219,5527
,,N,741.0,,80433,9606.0,Homo sapiens,Inhibitory concentration against 8226 myeloma cancer cell line,1,,RPMI-8226,,,1,,17079,F,,Intermediate,CHEMBL620363,BAO_0000219,5528
,,N,741.0,,80433,9606.0,Homo sapiens,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,1,,RPMI-8226,,,1,,17079,F,,Intermediate,CHEMBL620364,BAO_0000219,5529
,,N,854.0,,80647,9606.0,Homo sapiens,Inhibition of cell growth was studied in human teratocarcinoma (833K).,1,,833K,,,1,,13466,F,,Intermediate,CHEMBL620365,BAO_0000219,5530
,,N,854.0,,80647,9606.0,Homo sapiens,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',1,,833K,,,1,,13466,F,,Intermediate,CHEMBL620366,BAO_0000219,5531
,,N,854.0,,80647,9606.0,Homo sapiens,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,1,,833K,,,1,,2392,F,,Expert,CHEMBL620367,BAO_0000219,5532
,,N,854.0,,80647,9606.0,Homo sapiens,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,1,,833K,,,1,,2392,F,,Intermediate,CHEMBL620368,BAO_0000219,5533
,,U,,,22226,,,Inhibitory activity against caspase-1,1,,,,,0,,6608,B,,Autocuration,CHEMBL620369,BAO_0000019,5534
,,H,,,45,1351.0,Enterococcus faecalis,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,1,,,,,8,,10199,B,,Autocuration,CHEMBL620370,BAO_0000357,5535
,,N,705.0,,80648,9606.0,Homo sapiens,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,1,,8701-BC,,,1,,17749,F,,Intermediate,CHEMBL620371,BAO_0000219,5536
,,N,705.0,,80648,9606.0,Homo sapiens,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,1,,8701-BC,,,1,,17749,F,,Intermediate,CHEMBL620372,BAO_0000219,5537
,,U,,,22226,,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,1,,,,,0,,1229,F,,Intermediate,CHEMBL876492,BAO_0000019,5538
,,U,,,22226,,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,1,,,,,0,,1229,F,,Intermediate,CHEMBL620373,BAO_0000019,5539
,,U,,,22226,,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,1,,,,,0,,1229,F,,Intermediate,CHEMBL620374,BAO_0000019,5540
,,U,,,22226,,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,1,,,,,0,,6390,B,,Autocuration,CHEMBL620375,BAO_0000019,5541
,,U,,,22226,1314.0,Streptococcus pyogenes,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,1,,,,,0,,16219,F,,Autocuration,CHEMBL857902,BAO_0000019,5542
,,U,,,22226,1314.0,Streptococcus pyogenes,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,1,,,,,0,,16219,F,,Autocuration,CHEMBL620376,BAO_0000019,5543
,,H,,,11922,,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,1,,,,,8,,17043,B,,Autocuration,CHEMBL620377,BAO_0000357,5544
,,N,324.0,,81115,9606.0,Homo sapiens,Tested for in vitro cytotoxic potency of compound in 9KB assay,1,,KB ,,,1,,6929,F,,Intermediate,CHEMBL620378,BAO_0000219,5545
,,N,324.0,,81115,9606.0,Homo sapiens,Tested for in vitro cytotoxic potency of compound in 9KB assay,1,,KB ,,,1,,6929,A,,Intermediate,CHEMBL620379,BAO_0000219,5546
,,U,,,22226,9606.0,Homo sapiens,In vitro cytotoxicity of compound was tested against 9KB cells.,1,,,,,0,,7083,F,,Autocuration,CHEMBL620380,BAO_0000219,5547
,,N,392.0,,80653,10116.0,Rattus norvegicus,Cytotoxic concentration against 9L cells was determined on day 3,1,,9L,,,1,,12446,F,,Intermediate,CHEMBL884006,BAO_0000219,5548
,,N,392.0,,80653,10116.0,Rattus norvegicus,Tested in vitro for anticancer activity against 9L cells,1,,9L,,,1,,15345,F,,Expert,CHEMBL620381,BAO_0000219,5549
,,N,392.0,,80653,10116.0,Rattus norvegicus,Tested in vitro for anticancer activity against 9L cells; Not determined,1,,9L,,,1,,15345,F,,Expert,CHEMBL620382,BAO_0000219,5550
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,1,,A549,,,1,,6301,F,,Intermediate,CHEMBL620383,BAO_0000219,5551
,,N,646.0,,80682,9606.0,Homo sapiens,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,1,,A549,,,1,,4833,F,,Intermediate,CHEMBL876493,BAO_0000219,5552
,,N,646.0,,80682,9606.0,Homo sapiens,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,1,,A549,,,1,,4833,F,,Intermediate,CHEMBL620384,BAO_0000219,5553
,,N,646.0,,80682,9606.0,Homo sapiens,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,1,,A549,,,1,,4833,F,,Intermediate,CHEMBL620385,BAO_0000219,5554
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity against human lung carcinoma A549 cell line,1,,A549,,,1,,13330,F,,Expert,CHEMBL620386,BAO_0000219,5555
,,D,646.0,,25,9606.0,Homo sapiens,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,1,,A549,,,9,,17517,F,,Expert,CHEMBL620387,BAO_0000219,5556
,,D,646.0,,25,9606.0,Homo sapiens,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",1,,A549,,,9,,17517,F,,Expert,CHEMBL621404,BAO_0000219,5557
,,N,646.0,,80682,9606.0,Homo sapiens,"In vitro growth inhibition of A549, lung carcinoma",1,,A549,,,1,,14425,F,,Intermediate,CHEMBL621405,BAO_0000219,5558
,,N,646.0,,80682,9606.0,Homo sapiens,"In vitro growth inhibition of A549, lung carcinoma.",1,,A549,,,1,,14425,F,,Intermediate,CHEMBL621406,BAO_0000219,5559
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,1,,A549,,,1,,5228,F,,Expert,CHEMBL621407,BAO_0000219,5560
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic activity against human lung cancer A549 cell line was determined,1,,A549,,,1,,5351,F,,Intermediate,CHEMBL621408,BAO_0000219,5561
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,1,,A549,,,1,,12198,F,,Expert,CHEMBL885345,BAO_0000219,5562
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity concentration against human lung carcinoma A-549 cell line,1,,A549,,,1,,13891,F,,Intermediate,CHEMBL621409,BAO_0000219,5563
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity in A549 (human carcinoma) cell line.,1,,A549,,,1,,5677,F,,Expert,CHEMBL876034,BAO_0000219,5564
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity on lung carcinoma (A-549) cell line,1,,A549,,,1,,13788,F,,Intermediate,CHEMBL621410,BAO_0000219,5565
,,N,646.0,,80682,9606.0,Homo sapiens,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,1,,A549,,,1,,13384,F,,Expert,CHEMBL621411,BAO_0000219,5566
,,N,646.0,,80682,9606.0,Homo sapiens,Effective dose of compound against replication of A549 cell line was evaluated,1,,A549,,,1,,6726,F,,Intermediate,CHEMBL621412,BAO_0000219,5567
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,1,,A549,,,1,,3455,F,,Expert,CHEMBL621413,BAO_0000219,5568
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),1,,A549,,,1,,5726,F,,Intermediate,CHEMBL621414,BAO_0000219,5569
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,1,,A549,,,1,,5726,F,,Intermediate,CHEMBL621415,BAO_0000219,5570
,,N,646.0,,80682,9606.0,Homo sapiens,The compound was evaluated for antiproliferative activity against A549 cell line,1,,A549,,,1,,3936,F,,Intermediate,CHEMBL621416,BAO_0000219,5571
,,N,646.0,,80682,9606.0,Homo sapiens,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,1,,A549,,,1,,14991,F,,Intermediate,CHEMBL621417,BAO_0000219,5572
,,N,646.0,,80682,9606.0,Homo sapiens,Concentration required for growth inhibition of human lung carcinoma cell line A549,1,,A549,,,1,,5243,F,,Intermediate,CHEMBL621418,BAO_0000219,5573
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,1,,A549,,,1,,12858,F,,Intermediate,CHEMBL621419,BAO_0000219,5574
,,N,646.0,,80682,9606.0,Homo sapiens,Growth inhibition against A549 cell line was evaluated,1,,A549,,,1,,6776,F,,Intermediate,CHEMBL621420,BAO_0000219,5575
,,N,646.0,,80682,9606.0,Homo sapiens,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,1,,A549,,,1,,16558,F,,Intermediate,CHEMBL875823,BAO_0000219,5576
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,1,,A549,,,1,,4583,F,,Expert,CHEMBL621421,BAO_0000219,5577
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,1,,A549,,,1,,13514,F,,Intermediate,CHEMBL621422,BAO_0000219,5578
,,N,646.0,,80682,9606.0,Homo sapiens,Chemosensitivity against DT-diaphorase rich A549 cell lines,1,,A549,,,1,,15166,F,,Expert,CHEMBL884014,BAO_0000219,5579
,,N,646.0,,80682,9606.0,Homo sapiens,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,1,,A549,,,1,,13873,F,,Intermediate,CHEMBL621423,BAO_0000219,5580
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against human A549 (lung cancer) cell line.,1,,A549,,,1,,6447,F,,Expert,CHEMBL621424,BAO_0000219,5581
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro antitumor activity against A549 (lung) human tumor cell lines.,1,,A549,,,1,,2068,F,,Intermediate,CHEMBL621425,BAO_0000219,5582
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxic activity against human lung carcinoma A549 cell line,1,,A549,,,1,,1863,F,,Expert,CHEMBL621426,BAO_0000219,5583
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,1,,A549,,,1,,13873,F,,Intermediate,CHEMBL621427,BAO_0000219,5584
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,1,,A549,,,1,,13873,F,,Intermediate,CHEMBL621428,BAO_0000219,5585
,,N,646.0,,80682,9606.0,Homo sapiens,Tested against A549 lung carcinoma in the sulforhodamine B assay.,1,,A549,,,1,,13873,F,,Expert,CHEMBL621429,BAO_0000219,5586
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),1,,A549,,,1,,579,F,,Intermediate,CHEMBL621430,BAO_0000219,5587
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,1,,A549,,,1,,579,F,,Intermediate,CHEMBL621431,BAO_0000219,5588
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,1,,A549,,,1,,4584,F,,Intermediate,CHEMBL621432,BAO_0000219,5589
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,1,,A549,,,1,,5421,F,,Expert,CHEMBL621433,BAO_0000219,5590
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,1,,A549,,,1,,5421,F,,Intermediate,CHEMBL875824,BAO_0000219,5591
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,1,,A549,,,1,,5421,F,,Intermediate,CHEMBL621434,BAO_0000219,5592
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,1,,A549,,,1,,5421,F,,Intermediate,CHEMBL621435,BAO_0000219,5593
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,1,,A549,,,1,,14188,F,,Intermediate,CHEMBL621436,BAO_0000219,5594
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,1,,A549,,,1,,14188,F,,Intermediate,CHEMBL621437,BAO_0000219,5595
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested for the growth inhibition of A549 lung tumor cell line,1,,A549,,,1,,15354,F,,Intermediate,CHEMBL621438,BAO_0000219,5596
,,N,646.0,,80682,9606.0,Homo sapiens,Growth inhibition of human non-small-lung carcinoma (A549) cell line,1,,A549,,,1,,14253,F,,Expert,CHEMBL621439,BAO_0000219,5597
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,1,,A549,,,1,,13873,F,,Intermediate,CHEMBL621440,BAO_0000219,5598
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (conscious),1,,,,In vivo,1,,3043,A,,Intermediate,CHEMBL621441,BAO_0000218,5599
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for the oral bioavailability after oral administration in dog.,1,,,,In vivo,1,,3045,A,,Intermediate,CHEMBL621442,BAO_0000218,5600
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,1,,,,In vivo,1,,3022,A,,Intermediate,CHEMBL621443,BAO_0000218,5601
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,4453,A,,Intermediate,CHEMBL621444,BAO_0000218,5602
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,1696,A,,Intermediate,CHEMBL625133,BAO_0000218,5603
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,5045,A,,Intermediate,CHEMBL625134,BAO_0000218,5604
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (fasted),1,,,,In vivo,1,,5356,A,,Intermediate,CHEMBL625135,BAO_0000218,5605
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,1,,,,In vivo,1,,17764,A,,Intermediate,CHEMBL625136,BAO_0000218,5606
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,6448,A,,Intermediate,CHEMBL625137,BAO_0000218,5607
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,1475,A,,Intermediate,CHEMBL625138,BAO_0000218,5608
,,N,,,50588,9615.0,Canis lupus familiaris,Percent bioavailability in dog,1,,,,In vivo,1,,3788,A,,Intermediate,CHEMBL625139,BAO_0000218,5609
,,N,,,50588,9615.0,Canis lupus familiaris,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,1,,,,In vivo,1,,3639,A,,Intermediate,CHEMBL872264,BAO_0000218,5610
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,13397,A,,Intermediate,CHEMBL625140,BAO_0000218,5611
,,N,,,50588,9615.0,Canis lupus familiaris,The compound was evaluated for bioavailability in dogs; 34-44,1,,,,In vivo,1,,2137,A,,Intermediate,CHEMBL624436,BAO_0000218,5612
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog (dose 4 mg/kg p.o.),1,,,,In vivo,1,,2959,A,,Intermediate,CHEMBL624437,BAO_0000218,5613
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,6448,A,,Intermediate,CHEMBL872261,BAO_0000218,5614
,,N,,,50588,9615.0,Canis lupus familiaris,8 hour trough Blood level in dog was measured after administration of compound,1,,,,,1,,6084,A,,Intermediate,CHEMBL624438,BAO_0000218,5615
,,N,,,50588,9615.0,Canis lupus familiaris,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,1,Plasma,,,In vivo,1,,3639,A,1969.0,Intermediate,CHEMBL624439,BAO_0000218,5616
,,N,,,50588,9615.0,Canis lupus familiaris,C24 after oral administration at 5 mg/kg,1,,,,,1,,6316,A,,Intermediate,CHEMBL624440,BAO_0000218,5617
,,N,,,50588,9615.0,Canis lupus familiaris,Clearance after oral and iv dosing in dogs,1,,,,,1,,5238,A,,Intermediate,CHEMBL624441,BAO_0000218,5618
,,N,,,50588,9615.0,Canis lupus familiaris,Clearance of the drug was measured in the plasma of dog,1,Plasma,,,,1,,17796,A,1969.0,Intermediate,CHEMBL624442,BAO_0000218,5619
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,1,,,,,1,,2652,A,,Intermediate,CHEMBL624443,BAO_0000218,5620
,,N,,,50588,9615.0,Canis lupus familiaris,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,1,,,,In vivo,1,,5654,A,,Intermediate,CHEMBL624444,BAO_0000218,5621
,,N,,,50588,9615.0,Canis lupus familiaris,Clearance of compound was determined in dogs,1,,,,In vivo,1,,6621,A,,Intermediate,CHEMBL624445,BAO_0000218,5622
,,N,,,50588,9615.0,Canis lupus familiaris,Clearance on i.v. administration of 2 mg/kg was measured in dog,1,,,,In vivo,1,,6505,A,,Intermediate,CHEMBL624446,BAO_0000218,5623
,,N,,,50588,9615.0,Canis lupus familiaris,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,1,,,,In vivo,1,,5802,A,,Intermediate,CHEMBL624447,BAO_0000218,5624
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance in dog was determined,1,,,,In vivo,1,,17267,A,,Intermediate,CHEMBL624448,BAO_0000218,5625
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,1,,,,In vivo,1,,4521,A,,Intermediate,CHEMBL624449,BAO_0000218,5626
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance in dog after administration of 0.25 mg/kg iv,1,,,,In vivo,1,,6535,A,,Intermediate,CHEMBL624450,BAO_0000218,5627
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance in dog after administration of 1 mg/kg iv,1,,,,In vivo,1,,6535,A,,Intermediate,CHEMBL875942,BAO_0000218,5628
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance in dogs,1,,,,In vivo,1,,6535,A,,Intermediate,CHEMBL624451,BAO_0000218,5629
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,1,,,,In vivo,1,,5542,A,,Intermediate,CHEMBL624452,BAO_0000218,5630
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,1,,,,In vivo,1,,5199,A,,Intermediate,CHEMBL624453,BAO_0000218,5631
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance after 15 mg/kg iv dose in Dogs,1,,,,In vivo,1,,16907,A,,Intermediate,CHEMBL624454,BAO_0000218,5632
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance after 30 mg/kg po dose in Dogs,1,,,,In vivo,1,,16907,A,,Intermediate,CHEMBL624455,BAO_0000218,5633
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma administration to dogs,1,,,,In vivo,1,,16367,A,,Intermediate,CHEMBL624456,BAO_0000218,5634
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance was determined,1,,,,In vivo,1,,5505,A,,Intermediate,CHEMBL624457,BAO_0000218,5635
,,N,,,50588,9615.0,Canis lupus familiaris,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,1,,,,In vivo,1,,6215,A,,Intermediate,CHEMBL624458,BAO_0000218,5636
,,N,,,50588,9615.0,Canis lupus familiaris,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,1,,,,In vivo,1,,1466,A,,Intermediate,CHEMBL624459,BAO_0000218,5637
,Microsomes,S,,,102164,9606.0,Homo sapiens,Intrinsic clearance in human liver microsomes,1,Liver,,,In vitro,2,,5007,A,2107.0,Intermediate,CHEMBL624460,BAO_0000251,5638
,Microsomes,S,,,102164,9606.0,Homo sapiens,Intrinsic clearance in human liver microsomes,1,Liver,,,In vitro,2,,5007,A,2107.0,Intermediate,CHEMBL624461,BAO_0000251,5639
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,1,,,,In vivo,1,,16452,A,,Intermediate,CHEMBL875943,BAO_0000218,5640
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,1,,,,In vivo,1,,16452,A,,Intermediate,CHEMBL624462,BAO_0000218,5641
,,N,,,50588,9615.0,Canis lupus familiaris,Clearance in dog (dose 1 mg/kg i.v.),1,,,,In vivo,1,,16452,A,,Intermediate,CHEMBL624463,BAO_0000218,5642
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,1,,,,In vivo,1,,6221,A,,Intermediate,CHEMBL624464,BAO_0000218,5643
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),1,,,,In vivo,1,,5007,A,,Intermediate,CHEMBL624465,BAO_0000218,5644
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance after peroral administration at 10 mpk in dog,1,,,,In vivo,1,,5668,A,,Intermediate,CHEMBL624466,BAO_0000218,5645
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance after peroral administration at 5 mpk in dog,1,,,,In vivo,1,,5668,A,,Intermediate,CHEMBL624467,BAO_0000218,5646
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance after peroral administration at 5 mg/kg in dog,1,,,,In vivo,1,,5668,A,,Intermediate,CHEMBL624468,BAO_0000218,5647
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance was measured in dog,1,,,,In vivo,1,,15660,A,,Intermediate,CHEMBL624469,BAO_0000218,5648
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance was measured in dog,1,,,,In vivo,1,,15660,A,,Intermediate,CHEMBL624470,BAO_0000218,5649
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,1,,,,In vivo,1,,5983,A,,Intermediate,CHEMBL624471,BAO_0000218,5650
,,N,,,50588,9615.0,Canis lupus familiaris,Total clearance was determined after 0.1 mg/kg iv administration in dog,1,,,,In vivo,1,,5600,A,,Intermediate,CHEMBL624472,BAO_0000218,5651
,,N,,,50588,9615.0,Canis lupus familiaris,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,1,,,,In vivo,1,,17764,A,,Intermediate,CHEMBL622775,BAO_0000218,5652
,,N,,,50588,9615.0,Canis lupus familiaris,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,1,,,,In vivo,1,,6039,A,,Intermediate,CHEMBL622776,BAO_0000218,5653
,,N,,,50588,9615.0,Canis lupus familiaris,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,1,,,,In vivo,1,,6039,A,,Intermediate,CHEMBL622777,BAO_0000218,5654
,,N,,,50588,9615.0,Canis lupus familiaris,Clearance after peroral administration of 0.2 mg/kg in dog was determined,1,,,,In vivo,1,,6039,A,,Intermediate,CHEMBL622778,BAO_0000218,5655
,,N,,,50588,9615.0,Canis lupus familiaris,Clearance by intravenous administration of 1.2 mg/kg in dog,1,,,,In vivo,1,,4368,A,,Intermediate,CHEMBL622779,BAO_0000218,5656
,,N,,,50588,9615.0,Canis lupus familiaris,Clearance by iv administration in dogs at a dose of 1 mg/kg,1,,,,In vivo,1,,4305,A,,Intermediate,CHEMBL622780,BAO_0000218,5657
,,N,,,50588,9615.0,Canis lupus familiaris,Clearance value was evaluated in dog plasma,1,Plasma,,,In vivo,1,,1918,A,1969.0,Intermediate,CHEMBL622781,BAO_0000218,5658
,,N,,,50588,9615.0,Canis lupus familiaris,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,1,,,,In vivo,1,,6005,A,,Intermediate,CHEMBL622782,BAO_0000218,5659
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested for plasma clearance in dog,1,Plasma,,,In vivo,1,,4839,A,1969.0,Intermediate,CHEMBL622783,BAO_0000218,5660
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic property (Plasma clearance) was measured in dog,1,,,,In vivo,1,,4239,A,,Intermediate,CHEMBL622784,BAO_0000218,5661
,,N,,,50594,10090.0,Mus musculus,Area under curve when injected perorally in mice at a dose of 50 mg/kg,1,,,,,1,,17729,A,,Intermediate,CHEMBL622785,BAO_0000218,5662
,,N,,,50594,10090.0,Mus musculus,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,1,,,,,1,,17728,A,,Intermediate,CHEMBL622786,BAO_0000218,5663
,,N,,,50594,10090.0,Mus musculus,Area under curve value in mouse at a dose of 10 mg/kg,1,,,,,1,,5302,A,,Intermediate,CHEMBL622787,BAO_0000218,5664
,,N,,,50594,10090.0,Mus musculus,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,1,,,,,1,,5506,A,,Intermediate,CHEMBL875949,BAO_0000218,5665
,,N,,,50594,10090.0,Mus musculus,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,1,,,,,1,,5506,A,,Intermediate,CHEMBL622788,BAO_0000218,5666
,,N,,,50594,10090.0,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,1,,,,,1,,17764,F,,Intermediate,CHEMBL622789,BAO_0000218,5667
,,N,,,50594,10090.0,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,1,,,,,1,,17764,F,,Intermediate,CHEMBL622790,BAO_0000218,5668
,,N,,,50594,10090.0,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,1,,,,,1,,17764,F,,Intermediate,CHEMBL622791,BAO_0000218,5669
,,N,,,50594,10090.0,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,1,,,,,1,,17764,F,,Intermediate,CHEMBL622792,BAO_0000218,5670
,,N,,,50594,10090.0,Mus musculus,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,1,,,,,1,,17764,A,,Intermediate,CHEMBL622793,BAO_0000218,5671
,,N,,,50594,10090.0,Mus musculus,Area under curve was determined for the compound at 24 mg/Kg,1,,,,,1,,17753,A,,Intermediate,CHEMBL622794,BAO_0000218,5672
,,N,,,50594,10090.0,Mus musculus,Area under curve was determined for the compound at 40 mg/Kg,1,,,,,1,,17753,A,,Intermediate,CHEMBL622795,BAO_0000218,5673
,,N,,,50594,10090.0,Mus musculus,Area under curve was determined for the compound at 5 mg/Kg,1,,,,,1,,17753,A,,Intermediate,CHEMBL621803,BAO_0000218,5674
,,N,,,50594,10090.0,Mus musculus,Area under the curve for the compound is obtained at dose 25 mg/kg,1,,,,,1,,3132,A,,Intermediate,CHEMBL621804,BAO_0000218,5675
,,N,,,50594,10090.0,Mus musculus,Area under the curve for the compound was obtained when tested in mouse,1,,,,,1,,3132,A,,Intermediate,CHEMBL621805,BAO_0000218,5676
,,N,,,50594,10090.0,Mus musculus,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,1,,,,,1,,17837,A,,Intermediate,CHEMBL621806,BAO_0000218,5677
,,N,,,50594,10090.0,Mus musculus,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,1,,,,,1,,17837,A,,Intermediate,CHEMBL621807,BAO_0000218,5678
,,N,,,50594,10090.0,Mus musculus,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,1,,,,,1,,6062,A,,Intermediate,CHEMBL621808,BAO_0000218,5679
,,N,,,50594,10090.0,Mus musculus,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,1,,,,,1,,4066,A,,Intermediate,CHEMBL621809,BAO_0000218,5680
,,N,,,50594,10090.0,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),1,,,,,1,,16597,A,,Intermediate,CHEMBL621810,BAO_0000218,5681
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,1,,,,,1,,14239,A,,Intermediate,CHEMBL875164,BAO_0000218,5682
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,1,,,,,1,,14239,A,,Intermediate,CHEMBL621811,BAO_0000218,5683
,,N,,,50594,10090.0,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, area under curve",1,,,,,1,,4890,A,,Intermediate,CHEMBL621812,BAO_0000218,5684
,,N,,,50594,10090.0,Mus musculus,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),1,,,,,1,,429,A,,Intermediate,CHEMBL621813,BAO_0000218,5685
,,N,,,50594,10090.0,Mus musculus,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),1,,,,,1,,429,A,,Intermediate,CHEMBL621814,BAO_0000218,5686
,,N,,,50594,10090.0,Mus musculus,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,1,,,,,1,,5969,A,,Intermediate,CHEMBL621815,BAO_0000218,5687
,,N,,,50594,10090.0,Mus musculus,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,1,,,,,1,,5969,A,,Intermediate,CHEMBL621816,BAO_0000218,5688
,,N,,,50594,10090.0,Mus musculus,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,1,,,,,1,,5969,A,,Intermediate,CHEMBL621817,BAO_0000218,5689
,,N,,,50594,10090.0,Mus musculus,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,1,,,,,1,,6091,A,,Intermediate,CHEMBL621818,BAO_0000218,5690
,,N,,,50594,10090.0,Mus musculus,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,1,,,,,1,,6091,A,,Intermediate,CHEMBL621819,BAO_0000218,5691
,,N,,,50594,10090.0,Mus musculus,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,1,,,,,1,,6091,A,,Intermediate,CHEMBL621820,BAO_0000218,5692
,,N,,,50594,10090.0,Mus musculus,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,1,,,,,1,,6091,A,,Intermediate,CHEMBL621821,BAO_0000218,5693
,,N,,,50594,10090.0,Mus musculus,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,1,,,,,1,,6178,A,,Intermediate,CHEMBL621822,BAO_0000218,5694
,,N,,,50594,10090.0,Mus musculus,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,1,,,,,1,,6178,A,,Intermediate,CHEMBL619474,BAO_0000218,5695
,,N,,,50594,10090.0,Mus musculus,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",1,,,,,1,,6619,A,,Intermediate,CHEMBL619475,BAO_0000218,5696
,,N,,,50594,10090.0,Mus musculus,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",1,,,,,1,,6619,A,,Intermediate,CHEMBL619476,BAO_0000218,5697
,,N,,,50594,10090.0,Mus musculus,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",1,,,,,1,,3760,A,,Intermediate,CHEMBL619477,BAO_0000218,5698
,,N,,,50594,10090.0,Mus musculus,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",1,,,,,1,,3760,A,,Intermediate,CHEMBL619478,BAO_0000218,5699
,,N,,,50594,10090.0,Mus musculus,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",1,,,,,1,,3760,A,,Intermediate,CHEMBL619479,BAO_0000218,5700
,,N,,,50594,10090.0,Mus musculus,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",1,,,,,1,,3760,A,,Intermediate,CHEMBL619480,BAO_0000218,5701
,,N,,,50594,10090.0,Mus musculus,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,1,,,,,1,,3192,A,,Intermediate,CHEMBL619481,BAO_0000218,5702
,,N,,,50594,10090.0,Mus musculus,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,1,,,,,1,,3192,A,,Intermediate,CHEMBL619482,BAO_0000218,5703
,,N,,,50594,10090.0,Mus musculus,Area under the curve was evaluated in mice after intravenous administration,1,,,,,1,,2675,A,,Intermediate,CHEMBL619483,BAO_0000218,5704
,,N,,,50594,10090.0,Mus musculus,Area under the curve was evaluated in mice after oral administration,1,,,,,1,,2675,A,,Intermediate,CHEMBL619484,BAO_0000218,5705
,,N,,,50594,10090.0,Mus musculus,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,1,Plasma,,,,1,,16597,A,1969.0,Intermediate,CHEMBL619485,BAO_0000218,5706
,,N,,,50594,10090.0,Mus musculus,AUC total value at a dose of 10 mg/kg peroral administration in mice.,1,Plasma,,,,1,,16597,A,1969.0,Intermediate,CHEMBL619486,BAO_0000218,5707
,,N,,,50594,10090.0,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),1,,,,,1,,16597,A,,Intermediate,CHEMBL619487,BAO_0000218,5708
,,N,,,50594,10090.0,Mus musculus,AUMC after intraperitoneal administration of 100 mg/kg in mice,1,,,,,1,,17734,A,,Intermediate,CHEMBL619488,BAO_0000218,5709
,,N,,,50594,10090.0,Mus musculus,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,1,Blood,,,In vivo,1,,7767,A,178.0,Intermediate,CHEMBL620106,BAO_0000218,5710
,,N,392.0,,80653,,,The compound was tested in vitro for anticancer activity against 9L cells,1,,9L,,,1,,15345,F,,Intermediate,CHEMBL620107,BAO_0000219,5711
,,U,,,22226,10116.0,Rattus norvegicus,Anti proliferation activity determined; Weak effect,1,,,,,0,,2181,F,,Autocuration,CHEMBL620283,BAO_0000019,5712
,,U,,,22226,10116.0,Rattus norvegicus,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,1,,,,,0,,2181,F,,Autocuration,CHEMBL875176,BAO_0000219,5713
,,U,,,22226,10116.0,Rattus norvegicus,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,1,,,,,0,,2181,F,,Autocuration,CHEMBL620284,BAO_0000219,5714
,,U,,,22226,10116.0,Rattus norvegicus,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,1,,,,,0,,2181,F,,Autocuration,CHEMBL623515,BAO_0000219,5715
,,U,,,22226,10090.0,Mus musculus,The cytotoxic activity was in vitro tested by 9PS assay method,1,,,,,0,,10486,F,,Autocuration,CHEMBL623516,BAO_0000019,5716
,,U,,,22226,10090.0,Mus musculus,The cytotoxic activity was in vitro tested by 9PS assay method.,1,,,,,0,,10486,F,,Autocuration,CHEMBL623517,BAO_0000019,5717
,,U,,,22224,,,Partition coefficient (logD6.5),1,,,,,0,,15508,A,,Autocuration,CHEMBL857878,BAO_0000019,5718
,,N,478.0,,81034,9606.0,Homo sapiens,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,1,,A2780,,,1,,5242,F,,Expert,CHEMBL623518,BAO_0000219,5719
,,N,455.0,,80018,9606.0,Homo sapiens,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),1,,A-375,,,1,,16167,F,,Intermediate,CHEMBL624195,BAO_0000219,5720
,,N,500.0,,80852,9606.0,Homo sapiens,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,1,,A-431,,,1,,4782,F,,Expert,CHEMBL624196,BAO_0000219,5721
,,D,500.0,,9,9606.0,Homo sapiens,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,1,,A-431,,,9,,16093,F,,Expert,CHEMBL624197,BAO_0000219,5722
,,N,624.0,,80021,9606.0,Homo sapiens,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,1,,A498,,,1,,2596,F,,Intermediate,CHEMBL624198,BAO_0000219,5723
,,N,624.0,,80021,9606.0,Homo sapiens,in vitro cytotoxicity against A 498 cancer cell line,1,,A498,,,1,,2596,F,,Intermediate,CHEMBL621287,BAO_0000219,5724
,,N,624.0,,80021,9606.0,Homo sapiens,In vitro cytotoxic activity against renal (A 498) cancer cell line.,1,,A498,,,1,,3239,F,,Intermediate,CHEMBL621288,BAO_0000219,5725
,,N,624.0,,80021,9606.0,Homo sapiens,Cytotoxic activity against A 498 renal cancer cell lines.,1,,A498,,,1,,1847,F,,Intermediate,CHEMBL876496,BAO_0000219,5726
,,N,624.0,,80021,9606.0,Homo sapiens,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,1,,A498,,,1,,10553,F,,Intermediate,CHEMBL621289,BAO_0000219,5727
,,U,,,22226,1280.0,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,1,,,,,0,,16219,F,,Autocuration,CHEMBL621290,BAO_0000019,5728
,,U,,,22226,1280.0,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,1,,,,,0,,16219,F,,Autocuration,CHEMBL621291,BAO_0000019,5729
,,U,,,22226,1280.0,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,1,,,,,0,,16219,F,,Autocuration,CHEMBL621292,BAO_0000019,5730
,,U,,,22226,1280.0,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,1,,,,,0,,16219,F,,Autocuration,CHEMBL621293,BAO_0000019,5731
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibitory concentration required against A 549 lung cancer cell line,1,,A549,,,1,,4782,F,,Intermediate,CHEMBL621294,BAO_0000219,5732
,,N,646.0,,80682,9606.0,Homo sapiens,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,1,,A549,,,1,,11805,F,,Intermediate,CHEMBL621295,BAO_0000219,5733
,,N,646.0,,80682,9606.0,Homo sapiens,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,1,,A549,,,1,,11805,F,,Intermediate,CHEMBL884007,BAO_0000219,5734
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against lung cancer A 549 cell lines,1,,A549,,,1,,2007,F,,Intermediate,CHEMBL621296,BAO_0000219,5735
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested for its cytotoxicity against A 549 cell line,1,,A549,,,1,,4594,F,,Intermediate,CHEMBL621297,BAO_0000219,5736
,,N,646.0,,80682,9606.0,Homo sapiens,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",1,,A549,,,1,,6018,F,,Expert,CHEMBL839828,BAO_0000219,5737
,,N,646.0,,80682,9606.0,Homo sapiens,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",1,,A549,,,1,,6018,F,,Intermediate,CHEMBL620397,BAO_0000219,5738
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,1,,A549,,,1,,3599,F,,Expert,CHEMBL620398,BAO_0000219,5739
,,N,646.0,,80682,9606.0,Homo sapiens,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,1,,A549,,,1,,2551,F,,Intermediate,CHEMBL620399,BAO_0000219,5740
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro inhibition of A549 (human lung cancer) cell growth.,1,,A549,,,1,,16132,F,,Expert,CHEMBL620400,BAO_0000219,5741
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,1,,A549,,,1,,16132,F,,Intermediate,CHEMBL620401,BAO_0000219,5742
,,N,646.0,,80682,9606.0,Homo sapiens,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,1,,A549,,,1,,2551,F,,Expert,CHEMBL620402,BAO_0000219,5743
,,N,646.0,,80682,9606.0,Homo sapiens,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),1,,A549,,,1,,2551,F,,Expert,CHEMBL620403,BAO_0000219,5744
,,U,,,22226,,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,1,,,,,0,,11913,F,,Autocuration,CHEMBL620404,BAO_0000218,5745
,,H,,,104694,,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,1,,,,In vivo,4,,12621,F,,Autocuration,CHEMBL620405,BAO_0000218,5746
,,H,,,104694,,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,1,,,,In vivo,4,,12621,F,,Autocuration,CHEMBL620406,BAO_0000218,5747
,,H,,,104694,,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,1,,,,In vivo,4,,12621,F,,Autocuration,CHEMBL620407,BAO_0000218,5748
,,H,,,104694,,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,1,,,,In vivo,4,,12621,F,,Autocuration,CHEMBL620408,BAO_0000218,5749
,,H,,,104694,,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,1,,,,In vivo,4,,12621,F,,Autocuration,CHEMBL620409,BAO_0000218,5750
,,N,624.0,,80021,9606.0,Homo sapiens,Inhibition of A-498 human Renal cell proliferation,1,,A498,,,1,,3600,F,,Expert,CHEMBL620410,BAO_0000219,5751
,,U,,,22226,10116.0,Rattus norvegicus,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",1,,,,,0,,1796,F,,Autocuration,CHEMBL620411,BAO_0000019,5752
,,U,,,22226,10116.0,Rattus norvegicus,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",1,,,,,0,,1796,F,,Autocuration,CHEMBL620412,BAO_0000019,5753
,,U,,,22226,10116.0,Rattus norvegicus,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",1,,,,,0,,1796,F,,Autocuration,CHEMBL876596,BAO_0000019,5754
,,N,622.0,,80012,9606.0,Homo sapiens,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,1,,A 172,,,1,,16464,F,,Expert,CHEMBL620413,BAO_0000219,5755
,,N,622.0,,80012,9606.0,Homo sapiens,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,,A 172,,,1,,16464,F,,Intermediate,CHEMBL620414,BAO_0000219,5756
,,N,622.0,,80012,9606.0,Homo sapiens,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,,A 172,,,1,,16464,F,,Intermediate,CHEMBL620415,BAO_0000219,5757
,,N,646.0,,80682,9606.0,Homo sapiens,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,1,,A549,,,1,,13617,F,,Expert,CHEMBL620416,BAO_0000219,5758
,,N,646.0,,80682,9606.0,Homo sapiens,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,1,,A549,,,1,,4584,F,,Intermediate,CHEMBL620417,BAO_0000219,5759
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic activity evaluated against A549 tumor cells,1,,A549,,,1,,13799,F,,Expert,CHEMBL620418,BAO_0000219,5760
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,1,,A549,,,1,,16726,F,,Intermediate,CHEMBL620419,BAO_0000219,5761
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,1,,A549,,,1,,16109,F,,Intermediate,CHEMBL620420,BAO_0000219,5762
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,1,,A549,,,1,,16109,F,,Intermediate,CHEMBL620421,BAO_0000219,5763
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,1,,A549,,,1,,15474,F,,Intermediate,CHEMBL620422,BAO_0000219,5764
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity of compound against A549 cell line,1,,A549,,,1,,6851,F,,Intermediate,CHEMBL620423,BAO_0000219,5765
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity against human lung cell carcinoma A549 cell line,1,,A549,,,1,,17534,F,,Expert,CHEMBL620424,BAO_0000219,5766
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,1,,A549,,,1,,2621,F,,Intermediate,CHEMBL620425,BAO_0000219,5767
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,1,,A549,,,1,,830,F,,Intermediate,CHEMBL620426,BAO_0000219,5768
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,1,,A549,,,1,,14255,F,,Intermediate,CHEMBL620427,BAO_0000219,5769
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,1,,A549,,,1,,14255,F,,Intermediate,CHEMBL620428,BAO_0000219,5770
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,1,,A549,,,1,,1590,F,,Intermediate,CHEMBL620429,BAO_0000219,5771
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,1,,A549,,,1,,6146,F,,Expert,CHEMBL620430,BAO_0000219,5772
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,1,,A549,,,1,,17427,F,,Expert,CHEMBL839887,BAO_0000219,5773
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,1,,A549,,,1,,5280,F,,Intermediate,CHEMBL620431,BAO_0000219,5774
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,1,,A549,,,1,,16786,F,,Intermediate,CHEMBL884010,BAO_0000219,5775
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against A549 (human lung cancer),1,,A549,,,1,,5895,F,,Intermediate,CHEMBL620538,BAO_0000219,5776
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,1,,A549,,,1,,14297,F,,Expert,CHEMBL620539,BAO_0000219,5777
,,N,646.0,,80682,9606.0,Homo sapiens,In vivo antiproliferative activity against A549 cell line,1,,A549,,,1,,17824,F,,Intermediate,CHEMBL623373,BAO_0000218,5778
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition of non-small-cell lung adenocarcinoma (A549),1,,A549,,,1,,14368,F,,Intermediate,CHEMBL623374,BAO_0000219,5779
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,1,,A549,,,1,,14368,F,,Intermediate,CHEMBL623375,BAO_0000219,5780
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,1,,A549,,,1,,14254,F,,Intermediate,CHEMBL623376,BAO_0000219,5781
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),1,,A549,,,1,,15897,F,,Intermediate,CHEMBL623377,BAO_0000219,5782
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,1,,A549,,,1,,13866,F,,Intermediate,CHEMBL623378,BAO_0000219,5783
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibitory activity of compound against human A549 lung carcinoma cell line.,1,,A549,,,1,,13370,F,,Intermediate,CHEMBL623379,BAO_0000219,5784
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibitory activity against A549 lung cancer cell line,1,,A549,,,1,,4862,F,,Intermediate,CHEMBL623380,BAO_0000219,5785
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,1,,A549,,,1,,4862,F,,Intermediate,CHEMBL623381,BAO_0000219,5786
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,1,,A549,,,1,,4862,F,,Intermediate,CHEMBL623382,BAO_0000219,5787
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibitory concentration against A549 (lung cancer) cell line,1,,A549,,,1,,15970,F,,Intermediate,CHEMBL623383,BAO_0000219,5788
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,1,,A549,,,1,,17713,F,,Expert,CHEMBL623384,BAO_0000219,5789
,,N,646.0,,80682,9606.0,Homo sapiens,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,1,,A549,,,1,,4833,F,,Intermediate,CHEMBL623385,BAO_0000219,5790
,,N,646.0,,80682,9606.0,Homo sapiens,Activity against A549 cancer cell line.,1,,A549,,,1,,13736,F,,Expert,CHEMBL623386,BAO_0000219,5791
,,N,646.0,,80682,9606.0,Homo sapiens,The compound was evaluated for cytotoxicity against A549 cell line,1,,A549,,,1,,4312,F,,Intermediate,CHEMBL884105,BAO_0000219,5792
,,N,646.0,,80682,9606.0,Homo sapiens,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,1,,A549,,,1,,5421,F,,Intermediate,CHEMBL623387,BAO_0000219,5793
,,N,646.0,,80682,9606.0,Homo sapiens,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,1,,A549,,,1,,5421,F,,Intermediate,CHEMBL621568,BAO_0000219,5794
,,N,646.0,,80682,9606.0,Homo sapiens,Growth inhibitory activity was measured for human A549 tumor cell line.,1,,A549,,,1,,14717,F,,Intermediate,CHEMBL621569,BAO_0000219,5795
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibitory activity against A549 lung cancer cell line,1,,A549,,,1,,4634,F,,Intermediate,CHEMBL621570,BAO_0000219,5796
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibitory activity against A549 cell line; inactive,1,,A549,,,1,,1149,F,,Intermediate,CHEMBL621571,BAO_0000219,5797
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,1,,A549,,,1,,5421,F,,Expert,CHEMBL621572,BAO_0000219,5798
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,1,,A549,,,1,,5421,F,,Expert,CHEMBL621573,BAO_0000219,5799
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,1,,A549,,,1,,5421,F,,Intermediate,CHEMBL621574,BAO_0000219,5800
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),1,,A549,,,1,,3320,F,,Intermediate,CHEMBL621575,BAO_0000219,5801
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),1,,A549,,,1,,3320,F,,Intermediate,CHEMBL621576,BAO_0000219,5802
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),1,,A549,,,1,,3320,F,,Intermediate,CHEMBL621577,BAO_0000219,5803
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),1,,A549,,,1,,3320,F,,Intermediate,CHEMBL621578,BAO_0000219,5804
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),1,,A549,,,1,,3320,F,,Intermediate,CHEMBL621579,BAO_0000219,5805
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,1,,A549,,,1,,5726,F,,Intermediate,CHEMBL621580,BAO_0000219,5806
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance (in vivo) in mongrel dogs was determined,1,,,,In vivo,1,,17800,A,,Intermediate,CHEMBL621581,BAO_0000218,5807
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance was measured in dog,1,,,,In vivo,1,,5985,A,,Intermediate,CHEMBL621582,BAO_0000218,5808
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,1,,,,In vivo,1,,5530,A,,Intermediate,CHEMBL621583,BAO_0000218,5809
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,1,,,,In vivo,1,,5530,A,,Intermediate,CHEMBL621584,BAO_0000218,5810
,,N,,,50588,9615.0,Canis lupus familiaris,Tested for plasma clearance in dog,1,Plasma,,,In vivo,1,,4839,A,1969.0,Intermediate,CHEMBL621585,BAO_0000218,5811
,,N,,,50588,9615.0,Canis lupus familiaris,The compound was tested for clearance in dog plasma.,1,,,,In vivo,1,,3639,A,,Intermediate,CHEMBL621586,BAO_0000218,5812
,,N,,,50588,9615.0,Canis lupus familiaris,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",1,,,,In vivo,1,,4838,A,,Intermediate,CHEMBL875835,BAO_0000218,5813
,,N,,,50588,9615.0,Canis lupus familiaris,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,1,,,,In vivo,1,,4137,A,,Intermediate,CHEMBL621587,BAO_0000218,5814
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),1,Plasma,,,In vivo,1,,5017,A,1969.0,Intermediate,CHEMBL621588,BAO_0000218,5815
,Microsomes,N,,,50588,9615.0,Canis lupus familiaris,In vitro clearance in dog liver microsomes,1,Liver,,,In vitro,1,,17538,A,2107.0,Intermediate,CHEMBL621589,BAO_0000218,5816
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,1,,,,In vivo,1,,6161,A,,Intermediate,CHEMBL621590,BAO_0000218,5817
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,1,,,,In vivo,1,,6161,A,,Intermediate,CHEMBL621591,BAO_0000218,5818
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance in dog,1,,,,In vivo,1,,1696,A,,Intermediate,CHEMBL621592,BAO_0000218,5819
,,N,,,50588,9615.0,Canis lupus familiaris,Clearance rate in dog,1,,,,In vivo,1,,6762,A,,Intermediate,CHEMBL621593,BAO_0000218,5820
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,1,Plasma,,,In vivo,1,,5932,A,1969.0,Intermediate,CHEMBL621594,BAO_0000218,5821
,,N,,,50588,9615.0,Canis lupus familiaris,Clearance in dogs,1,,,,In vivo,1,,6305,A,,Intermediate,CHEMBL621595,BAO_0000218,5822
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance in dogs,1,,,,In vivo,1,,4942,A,,Intermediate,CHEMBL621596,BAO_0000218,5823
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance was determined,1,,,,In vivo,1,,4219,A,,Intermediate,CHEMBL621597,BAO_0000218,5824
,,N,,,50588,9615.0,Canis lupus familiaris,Lower clearance in dog (i.v.) at 0.5 mpk,1,,,,In vivo,1,,17853,A,,Intermediate,CHEMBL621598,BAO_0000218,5825
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance in Beagle dogs,1,,,,In vivo,1,,4514,A,,Intermediate,CHEMBL621599,BAO_0000218,5826
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance (Clp) in dog,1,,,,In vivo,1,,6448,A,,Intermediate,CHEMBL875836,BAO_0000218,5827
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,1,,,,In vivo,1,,6227,A,,Intermediate,CHEMBL621600,BAO_0000218,5828
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance (pharmacokinetic parameter) in dog was determined,1,,,,In vivo,1,,6227,A,,Intermediate,CHEMBL621601,BAO_0000218,5829
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,1,,,,In vivo,1,,6062,A,,Intermediate,CHEMBL618474,BAO_0000218,5830
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance of compound was determined in dog,1,,,,In vivo,1,,6821,A,,Intermediate,CHEMBL618475,BAO_0000218,5831
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance after intravenous administration of 1 mg/kg in dog,1,,,,In vivo,1,,4709,A,,Intermediate,CHEMBL624524,BAO_0000218,5832
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,1,,,,In vivo,1,,4521,A,,Intermediate,CHEMBL624525,BAO_0000218,5833
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance in dog was determined,1,,,,In vivo,1,,5374,A,,Intermediate,CHEMBL624526,BAO_0000218,5834
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance was calculated in dog,1,,,,In vivo,1,,6057,A,,Intermediate,CHEMBL624527,BAO_0000218,5835
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance at the dose of 2 mg/kg in dog,1,,,,In vivo,1,,4727,A,,Intermediate,CHEMBL624528,BAO_0000218,5836
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance in dog,1,,,,In vivo,1,,5145,A,,Intermediate,CHEMBL624529,BAO_0000218,5837
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance in dog,1,,,,In vivo,1,,17657,A,,Intermediate,CHEMBL624530,BAO_0000218,5838
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance in dog; Unable to calculate,1,,,,In vivo,1,,17657,A,,Intermediate,CHEMBL624531,BAO_0000218,5839
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance in rhesus monkey,1,,,,In vivo,1,,5145,A,,Intermediate,CHEMBL624532,BAO_0000218,5840
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,,,,In vivo,1,,6642,A,,Intermediate,CHEMBL624533,BAO_0000218,5841
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,,,In vivo,1,,6641,A,,Intermediate,CHEMBL624534,BAO_0000218,5842
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,,,In vivo,1,,6642,A,,Intermediate,CHEMBL624535,BAO_0000218,5843
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance was evaluated in dog,1,,,,In vivo,1,,5472,A,,Intermediate,CHEMBL624536,BAO_0000218,5844
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance was evaluated in dog; Not tested,1,,,,In vivo,1,,5472,A,,Intermediate,CHEMBL624537,BAO_0000218,5845
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance was evaluated in rhesus,1,,,,In vivo,1,,5472,A,,Intermediate,CHEMBL624538,BAO_0000218,5846
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance was evaluated in rhesus; Not tested,1,,,,In vivo,1,,5472,A,,Intermediate,CHEMBL624539,BAO_0000218,5847
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,1,,,,In vivo,1,,4257,A,,Intermediate,CHEMBL624540,BAO_0000218,5848
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,,,In vivo,1,,6679,A,,Intermediate,CHEMBL624541,BAO_0000218,5849
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,1,,,,In vivo,1,,5546,A,,Intermediate,CHEMBL624542,BAO_0000218,5850
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,,,,In vivo,1,,6348,A,,Intermediate,CHEMBL624543,BAO_0000218,5851
,,N,,,50588,9615.0,Canis lupus familiaris,Clearance value at a dose of 0.2 mg/kg i.v.,1,,,,In vivo,1,,5474,A,,Intermediate,CHEMBL624544,BAO_0000218,5852
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,1,Plasma,,,In vivo,1,,6316,A,1969.0,Intermediate,CHEMBL624545,BAO_0000218,5853
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax after oral dose of compound at 3 mg/kg in dogs,1,,,,In vivo,1,,17594,A,,Intermediate,CHEMBL624546,BAO_0000218,5854
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax after single intravenous bolus of 1 mg/kg in dogs,1,,,,In vivo,1,,17594,A,,Intermediate,CHEMBL875957,BAO_0000218,5855
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,1,,,,In vivo,1,,5802,A,,Intermediate,CHEMBL624547,BAO_0000218,5856
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,1,,,,In vivo,1,,6535,A,,Intermediate,CHEMBL624548,BAO_0000218,5857
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax in dog after administration of 1 mg/kg iv,1,,,,In vivo,1,,6535,A,,Intermediate,CHEMBL624549,BAO_0000218,5858
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,1,Plasma,,,In vivo,1,,1466,A,1969.0,Intermediate,CHEMBL624550,BAO_0000218,5859
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax on p.o. administration of 10 mg/kg was measured in dog,1,,,,In vivo,1,,6505,A,,Intermediate,CHEMBL621613,BAO_0000218,5860
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax was determine after peroral administration at 10 mpk in dog,1,,,,In vivo,1,,5668,A,,Intermediate,CHEMBL621614,BAO_0000218,5861
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax was determine after peroral administration at 5 mpk in dog,1,,,,In vivo,1,,5668,A,,Intermediate,CHEMBL623431,BAO_0000218,5862
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax was determine after peroral administration at 5 mg/kg in dog,1,,,,In vivo,1,,5668,A,,Intermediate,CHEMBL623432,BAO_0000218,5863
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax after 0.3 mg/kg po administration in dog,1,,,,In vivo,1,,5600,A,,Intermediate,CHEMBL623433,BAO_0000218,5864
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax after peroral administration in dogs at 2.4 uM/kg,1,,,,In vivo,1,,17764,A,,Intermediate,CHEMBL623434,BAO_0000218,5865
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax in dog after oral administration at 1 mg/kg,1,,,,In vivo,1,,6123,A,,Intermediate,CHEMBL623435,BAO_0000218,5866
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,1,,,,In vivo,1,,6123,A,,Intermediate,CHEMBL623436,BAO_0000218,5867
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax upon oral administration in male Beagle dog at 10 mg/kg,1,,,,In vivo,1,,6757,A,,Intermediate,CHEMBL875958,BAO_0000218,5868
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax value after 15 mg/kg iv dose in Dogs,1,,,,In vivo,1,,16907,A,,Intermediate,CHEMBL623437,BAO_0000218,5869
,,N,,,50594,10090.0,Mus musculus,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Blood,,,In vivo,1,,7767,A,178.0,Intermediate,CHEMBL623438,BAO_0000218,5870
,,N,,,50594,10090.0,Mus musculus,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Blood,,,In vivo,1,,7767,A,178.0,Intermediate,CHEMBL623439,BAO_0000218,5871
,,N,,,50594,10090.0,Mus musculus,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Bone,,,In vivo,1,,7767,A,10000001.0,Intermediate,CHEMBL623440,BAO_0000218,5872
,,N,,,50594,10090.0,Mus musculus,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Bone,,,In vivo,1,,7767,A,10000001.0,Intermediate,CHEMBL623441,BAO_0000218,5873
,,N,,,50594,10090.0,Mus musculus,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Bone,,,In vivo,1,,7767,A,10000001.0,Intermediate,CHEMBL623442,BAO_0000218,5874
,,N,,,50594,10090.0,Mus musculus,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,,,In vivo,1,,7767,A,,Intermediate,CHEMBL623469,BAO_0000218,5875
,,N,,,50594,10090.0,Mus musculus,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,,,In vivo,1,,7767,A,,Intermediate,CHEMBL623470,BAO_0000218,5876
,,N,,,50594,10090.0,Mus musculus,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,,,In vivo,1,,7767,A,,Intermediate,CHEMBL623471,BAO_0000218,5877
,,N,,,50594,10090.0,Mus musculus,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Heart,,,In vivo,1,,7767,A,948.0,Intermediate,CHEMBL623472,BAO_0000218,5878
,,N,,,50594,10090.0,Mus musculus,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Heart,,,In vivo,1,,7767,A,948.0,Intermediate,CHEMBL623473,BAO_0000218,5879
,,N,,,50594,10090.0,Mus musculus,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Heart,,,In vivo,1,,7767,A,948.0,Intermediate,CHEMBL623474,BAO_0000218,5880
,,N,,,50594,10090.0,Mus musculus,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Kidney,,,In vivo,1,,7767,A,2113.0,Intermediate,CHEMBL623475,BAO_0000218,5881
,,N,,,50594,10090.0,Mus musculus,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Kidney,,,In vivo,1,,7767,A,2113.0,Intermediate,CHEMBL623476,BAO_0000218,5882
,,N,,,50594,10090.0,Mus musculus,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Kidney,,,In vivo,1,,7767,A,2113.0,Intermediate,CHEMBL623477,BAO_0000218,5883
,,N,,,50594,10090.0,Mus musculus,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Intestine,,,In vivo,1,,7767,A,160.0,Intermediate,CHEMBL621896,BAO_0000218,5884
,,N,,,50594,10090.0,Mus musculus,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Intestine,,,In vivo,1,,7767,A,160.0,Intermediate,CHEMBL621897,BAO_0000218,5885
,,N,,,50594,10090.0,Mus musculus,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Intestine,,,In vivo,1,,7767,A,160.0,Intermediate,CHEMBL621898,BAO_0000218,5886
,,N,,,50594,10090.0,Mus musculus,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Liver,,,In vivo,1,,7767,A,2107.0,Intermediate,CHEMBL621899,BAO_0000218,5887
,,N,,,50594,10090.0,Mus musculus,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Liver,,,In vivo,1,,7767,A,2107.0,Intermediate,CHEMBL621900,BAO_0000218,5888
,,N,,,50594,10090.0,Mus musculus,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Liver,,,In vivo,1,,7767,A,2107.0,Intermediate,CHEMBL621901,BAO_0000218,5889
,,N,,,50594,10090.0,Mus musculus,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Lung,,,In vivo,1,,7767,A,2048.0,Intermediate,CHEMBL621902,BAO_0000218,5890
,,N,,,50594,10090.0,Mus musculus,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Lung,,,In vivo,1,,7767,A,2048.0,Intermediate,CHEMBL621903,BAO_0000218,5891
,,N,,,50594,10090.0,Mus musculus,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Lung,,,In vivo,1,,7767,A,2048.0,Intermediate,CHEMBL622587,BAO_0000218,5892
,,N,,,50594,10090.0,Mus musculus,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Muscle tissue,,,In vivo,1,,7767,A,2385.0,Intermediate,CHEMBL620285,BAO_0000218,5893
,,N,,,50594,10090.0,Mus musculus,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Muscle tissue,,,In vivo,1,,7767,A,2385.0,Intermediate,CHEMBL875285,BAO_0000218,5894
,,N,,,50594,10090.0,Mus musculus,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Muscle tissue,,,In vivo,1,,7767,A,2385.0,Intermediate,CHEMBL620286,BAO_0000218,5895
,,N,,,50594,10090.0,Mus musculus,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,,,In vivo,1,,7767,A,,Intermediate,CHEMBL620287,BAO_0000218,5896
,,N,,,50594,10090.0,Mus musculus,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,,,In vivo,1,,7767,A,,Intermediate,CHEMBL620288,BAO_0000218,5897
,,N,,,50594,10090.0,Mus musculus,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,,,In vivo,1,,7767,A,,Intermediate,CHEMBL620289,BAO_0000218,5898
,,N,,,50594,10090.0,Mus musculus,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Intestine,,,In vivo,1,,7767,A,160.0,Intermediate,CHEMBL620290,BAO_0000218,5899
,,N,,,50594,10090.0,Mus musculus,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Intestine,,,In vivo,1,,7767,A,160.0,Intermediate,CHEMBL620291,BAO_0000218,5900
,,N,,,50594,10090.0,Mus musculus,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Intestine,,,In vivo,1,,7767,A,160.0,Intermediate,CHEMBL620292,BAO_0000218,5901
,,N,,,50594,10090.0,Mus musculus,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Spleen,,,In vivo,1,,7767,A,2106.0,Intermediate,CHEMBL620293,BAO_0000218,5902
,,N,,,50594,10090.0,Mus musculus,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Spleen,,,In vivo,1,,7767,A,2106.0,Intermediate,CHEMBL620294,BAO_0000218,5903
,,N,,,50594,10090.0,Mus musculus,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Spleen,,,In vivo,1,,7767,A,2106.0,Intermediate,CHEMBL618614,BAO_0000218,5904
,,N,,,50594,10090.0,Mus musculus,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Stomach,,,In vivo,1,,7767,A,945.0,Intermediate,CHEMBL618615,BAO_0000218,5905
,,N,,,50594,10090.0,Mus musculus,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Stomach,,,In vivo,1,,7767,A,945.0,Intermediate,CHEMBL618616,BAO_0000218,5906
,,N,622.0,,80012,9606.0,Homo sapiens,Cytotoxicity against A-172 human tumor cell lines,1,,A 172,,,1,,2036,F,,Expert,CHEMBL618617,BAO_0000219,5907
,,N,622.0,,80012,9606.0,Homo sapiens,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,1,,A 172,,,1,,2357,F,,Intermediate,CHEMBL618618,BAO_0000219,5908
,,N,623.0,,80014,9606.0,Homo sapiens,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,1,,A204,,,1,,1457,F,,Intermediate,CHEMBL618619,BAO_0000219,5909
,,N,478.0,,81034,9606.0,Homo sapiens,Tested for antiproliferative activity against A-2780 tumoral cell line,1,,A2780,,,1,,4379,F,,Intermediate,CHEMBL618620,BAO_0000219,5910
,,N,455.0,,80018,9606.0,Homo sapiens,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,1,,A-375,,,1,,1093,F,,Intermediate,CHEMBL618621,BAO_0000219,5911
,,N,455.0,,80018,9606.0,Homo sapiens,Tested in vitro against A-375 cell line human melanoma,1,,A-375,,,1,,12152,F,,Intermediate,CHEMBL618622,BAO_0000219,5912
,,N,797.0,,80019,9606.0,Homo sapiens,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,1,,A-427,,,1,,16464,F,,Expert,CHEMBL618623,BAO_0000219,5913
,,N,797.0,,80019,9606.0,Homo sapiens,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,,A-427,,,1,,16464,F,,Intermediate,CHEMBL618624,BAO_0000219,5914
,,N,797.0,,80019,9606.0,Homo sapiens,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,1,,A-427,,,1,,16582,F,,Expert,CHEMBL618625,BAO_0000219,5915
,,N,797.0,,80019,9606.0,Homo sapiens,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,,A-427,,,1,,16464,F,,Intermediate,CHEMBL618626,BAO_0000219,5916
,,N,797.0,,80019,9606.0,Homo sapiens,Antitumor activity on A-427 lung carcinoma cell lines,1,,A-427,,,1,,10413,F,,Intermediate,CHEMBL618627,BAO_0000219,5917
,,N,797.0,,80019,9606.0,Homo sapiens,Cytotoxic activity against human A-427 lung tumor cell line,1,,A-427,,,1,,6418,F,,Intermediate,CHEMBL618628,BAO_0000219,5918
,,N,797.0,,80019,9606.0,Homo sapiens,In vitro antitumor effects against human A-427 cell lines.,1,,A-427,,,1,,17134,F,,Expert,CHEMBL618629,BAO_0000219,5919
,,N,797.0,,80019,9606.0,Homo sapiens,In vitro inhibition of A-427 (human lung cancer) cell growth.,1,,A-427,,,1,,16132,F,,Expert,CHEMBL618630,BAO_0000219,5920
,,N,797.0,,80019,9606.0,Homo sapiens,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,1,,A-427,,,1,,16132,F,,Intermediate,CHEMBL618631,BAO_0000219,5921
,,N,797.0,,80019,9606.0,Homo sapiens,Cytotoxic activity of compound against A-427 lung human tumor cell line,1,,A-427,,,1,,16780,F,,Intermediate,CHEMBL618632,BAO_0000219,5922
,,N,500.0,,80852,9606.0,Homo sapiens,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,1,,A-431,,,1,,4085,F,,Expert,CHEMBL618633,BAO_0000219,5923
,,N,624.0,,80021,9606.0,Homo sapiens,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,1,,A498,,,1,,1276,F,,Intermediate,CHEMBL619315,BAO_0000219,5924
,,N,624.0,,80021,9606.0,Homo sapiens,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,1,,A498,,,1,,3498,F,,Expert,CHEMBL619316,BAO_0000219,5925
,,N,624.0,,80021,9606.0,Homo sapiens,Cytotoxicity against human kidney carcinoma A-498cell lines,1,,A498,,,1,,1169,F,,Intermediate,CHEMBL619317,BAO_0000219,5926
,,N,624.0,,80021,9606.0,Homo sapiens,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,1,,A498,,,1,,4450,F,,Intermediate,CHEMBL619318,BAO_0000219,5927
,,N,624.0,,80021,9606.0,Homo sapiens,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,1,,A498,,,1,,3311,F,,Intermediate,CHEMBL619319,BAO_0000219,5928
,,N,624.0,,80021,9606.0,Homo sapiens,Antitumor cytotoxic activity against A-498 cell line was determined,1,,A498,,,1,,4461,F,,Intermediate,CHEMBL619739,BAO_0000219,5929
,,N,624.0,,80021,9606.0,Homo sapiens,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,1,,A498,,,1,,3311,F,,Intermediate,CHEMBL619740,BAO_0000219,5930
,,N,624.0,,80021,9606.0,Homo sapiens,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,1,,A498,,,1,,3311,F,,Intermediate,CHEMBL883158,BAO_0000219,5931
,,N,624.0,,80021,9606.0,Homo sapiens,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,1,,A498,,,1,,1457,F,,Intermediate,CHEMBL884012,BAO_0000219,5932
,,N,624.0,,80021,9606.0,Homo sapiens,In vitro inhibitory activity against A-498 ovarian cancer cell lines,1,,A498,,,1,,3664,F,,Intermediate,CHEMBL619741,BAO_0000219,5933
,,N,624.0,,80021,9606.0,Homo sapiens,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",1,,A498,,,1,,15895,F,,Intermediate,CHEMBL619742,BAO_0000219,5934
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition of growth lung non-small cell carcinoma A-549 cell line,1,,A549,,,1,,11843,F,,Intermediate,CHEMBL876610,BAO_0000219,5935
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,1,,A549,,,1,,11843,F,,Intermediate,CHEMBL619743,BAO_0000219,5936
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro antiproliferative activity against human A-549 NSCL cell line,1,,A549,,,1,,17705,F,,Intermediate,CHEMBL619744,BAO_0000219,5937
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,1,,A549,,,1,,17705,F,,Intermediate,CHEMBL619745,BAO_0000219,5938
,,N,646.0,,80682,9606.0,Homo sapiens,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,1,,A549,,,1,,4369,F,,Intermediate,CHEMBL619746,BAO_0000219,5939
,,N,646.0,,80682,9606.0,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,1,,A549,,,1,,4369,F,,Intermediate,CHEMBL619747,BAO_0000219,5940
,,N,646.0,,80682,9606.0,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,1,,A549,,,1,,4369,F,,Intermediate,CHEMBL619748,BAO_0000219,5941
,,N,646.0,,80682,9606.0,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,1,,A549,,,1,,4369,F,,Intermediate,CHEMBL619749,BAO_0000219,5942
,,N,646.0,,80682,9606.0,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,1,,A549,,,1,,4369,F,,Intermediate,CHEMBL619750,BAO_0000219,5943
,,N,646.0,,80682,9606.0,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,1,,A549,,,1,,4369,F,,Intermediate,CHEMBL624014,BAO_0000219,5944
,,N,646.0,,80682,9606.0,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,1,,A549,,,1,,4369,F,,Intermediate,CHEMBL624015,BAO_0000219,5945
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,1,,A549,,,1,,4787,F,,Expert,CHEMBL885344,BAO_0000219,5946
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,1,,A549,,,1,,4787,F,,Intermediate,CHEMBL623224,BAO_0000219,5947
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic activity against A-549 cell line,1,,A549,,,1,,6513,F,,Intermediate,CHEMBL623225,BAO_0000219,5948
,,N,646.0,,80682,9606.0,Homo sapiens,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,1,,A549,,,1,,6690,F,,Intermediate,CHEMBL622698,BAO_0000219,5949
,,N,646.0,,80682,9606.0,Homo sapiens,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,1,,A549,,,1,,6690,F,,Intermediate,CHEMBL622699,BAO_0000219,5950
,,N,646.0,,80682,9606.0,Homo sapiens,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",1,,A549,,,1,,12263,F,,Expert,CHEMBL622700,BAO_0000219,5951
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),1,,A549,,,1,,1054,F,,Intermediate,CHEMBL622701,BAO_0000219,5952
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),1,,A549,,,1,,1359,F,,Intermediate,CHEMBL622702,BAO_0000219,5953
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic activity against human lung carcinoma (A-549) cell line,1,,A549,,,1,,3547,F,,Intermediate,CHEMBL622703,BAO_0000219,5954
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic activity towards A-549 cells,1,,A549,,,1,,5771,F,,Expert,CHEMBL622704,BAO_0000219,5955
,,N,646.0,,80682,9606.0,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma.",1,,A549,,,1,,14425,F,,Intermediate,CHEMBL622705,BAO_0000219,5956
,,N,646.0,,80682,9606.0,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma",1,,A549,,,1,,14425,F,,Intermediate,CHEMBL622706,BAO_0000219,5957
,,N,646.0,,80682,9606.0,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma.",1,,A549,,,1,,14425,F,,Intermediate,CHEMBL622707,BAO_0000219,5958
,,N,646.0,,80682,9606.0,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",1,,A549,,,1,,14425,F,,Intermediate,CHEMBL622708,BAO_0000219,5959
,,N,646.0,,80682,9606.0,Homo sapiens,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,1,,A549,,,1,,5280,F,,Intermediate,CHEMBL622709,BAO_0000219,5960
,,N,646.0,,80682,9606.0,Homo sapiens,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,1,,A549,,,1,,15176,F,,Intermediate,CHEMBL622710,BAO_0000219,5961
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,1,,A549,,,1,,15300,F,,Intermediate,CHEMBL622711,BAO_0000219,5962
,,N,646.0,,80682,9606.0,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,,A549,,,1,,17824,F,,Intermediate,CHEMBL622712,BAO_0000218,5963
,,N,646.0,,80682,9606.0,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,,A549,,,1,,17824,F,,Intermediate,CHEMBL622713,BAO_0000218,5964
,,N,646.0,,80682,9606.0,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,,A549,,,1,,17824,F,,Intermediate,CHEMBL622714,BAO_0000218,5965
,,N,646.0,,80682,9606.0,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,,A549,,,1,,17824,F,,Intermediate,CHEMBL622715,BAO_0000218,5966
,,N,646.0,,80682,9606.0,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,,A549,,,1,,17824,F,,Intermediate,CHEMBL622716,BAO_0000218,5967
,,N,646.0,,80682,9606.0,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",1,,A549,,,1,,17824,F,,Intermediate,CHEMBL622717,BAO_0000219,5968
,,N,646.0,,80682,9606.0,Homo sapiens,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),1,,A549,,,1,,17528,F,,Intermediate,CHEMBL622718,BAO_0000218,5969
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,1,,A549,,,1,,6870,F,,Expert,CHEMBL622719,BAO_0000219,5970
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,1,,A549,,,1,,6870,F,,Intermediate,CHEMBL622720,BAO_0000219,5971
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,1,,A549,,,1,,6870,F,,Intermediate,CHEMBL622721,BAO_0000219,5972
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,1,,A549,,,1,,6870,F,,Intermediate,CHEMBL622722,BAO_0000219,5973
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,1,,A549,,,1,,16726,F,,Intermediate,CHEMBL876030,BAO_0000219,5974
,,N,646.0,,80682,9606.0,Homo sapiens,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",1,,A549,,,1,,6170,F,,Intermediate,CHEMBL620206,BAO_0000219,5975
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,1,,A549,,,1,,6583,F,,Expert,CHEMBL620207,BAO_0000219,5976
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,1,,A549,,,1,,6583,F,,Expert,CHEMBL620208,BAO_0000219,5977
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,1,,A549,,,1,,6583,F,,Expert,CHEMBL620209,BAO_0000219,5978
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,1,,A549,,,1,,6583,F,,Expert,CHEMBL620210,BAO_0000219,5979
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,1,,A549,,,1,,6583,F,,Expert,CHEMBL621639,BAO_0000219,5980
,,N,646.0,,80682,9606.0,Homo sapiens,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,1,,A549,,,1,,17321,F,,Intermediate,CHEMBL621640,BAO_0000219,5981
,,N,646.0,,80682,9606.0,Homo sapiens,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,1,,A549,,,1,,17528,F,,Expert,CHEMBL621641,BAO_0000219,5982
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,1,,A549,,,1,,12888,F,,Expert,CHEMBL621642,BAO_0000219,5983
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,1,,A549,,,1,,4312,F,,Intermediate,CHEMBL621643,BAO_0000219,5984
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,1,,A549,,,1,,4312,F,,Intermediate,CHEMBL621644,BAO_0000219,5985
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,1,,A549,,,1,,4312,F,,Intermediate,CHEMBL621645,BAO_0000219,5986
,,N,646.0,,80682,10090.0,Mus musculus,In vitro antiproliferative activity against A549 cell line,1,,A549,,,1,,17737,F,,Intermediate,CHEMBL621646,BAO_0000219,5987
,,N,646.0,,80682,,,Synergism with indomethacin in A549 cells,1,,A549,,,1,,6630,F,,Intermediate,CHEMBL621647,BAO_0000219,5988
,,N,646.0,,80682,,,Synergism with tolmetin in A549 cells,1,,A549,,,1,,6630,F,,Intermediate,CHEMBL621648,BAO_0000219,5989
,,N,646.0,,80682,,,Synergism with sulindac in A549 cells,1,,A549,,,1,,6630,F,,Intermediate,CHEMBL621649,BAO_0000219,5990
,,N,646.0,,80682,,,Antagonism of indomethacin in A549 cells,1,,A549,,,1,,6630,F,,Intermediate,CHEMBL621650,BAO_0000219,5991
,,N,646.0,,80682,,,Antagonism of sulindac in A549 cells,1,,A549,,,1,,6630,F,,Intermediate,CHEMBL621651,BAO_0000219,5992
,,N,646.0,,80682,,,Antagonism of tolmetin in A549 cells,1,,A549,,,1,,6630,F,,Intermediate,CHEMBL621652,BAO_0000219,5993
,,N,646.0,,80682,,,Synergism with indomethacin in A549 cells,1,,A549,,,1,,6630,F,,Intermediate,CHEMBL621653,BAO_0000219,5994
,,N,646.0,,80682,,,Synergism with sulindac in A549 cells,1,,A549,,,1,,6630,F,,Intermediate,CHEMBL621654,BAO_0000219,5995
,,N,646.0,,80682,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,1,,A549,,,1,,6630,F,,Intermediate,CHEMBL621655,BAO_0000219,5996
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax value after 30 mg/kg po dose in Dogs,1,,,,In vivo,1,,16907,A,,Intermediate,CHEMBL621656,BAO_0000218,5997
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),1,,,,In vivo,1,,5944,A,,Intermediate,CHEMBL621657,BAO_0000218,5998
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,1,,,,In vivo,1,,5944,A,,Intermediate,CHEMBL621658,BAO_0000218,5999
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),1,,,,In vivo,1,,5944,A,,Intermediate,CHEMBL621659,BAO_0000218,6000
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,1,,,,In vivo,1,,5944,A,,Intermediate,CHEMBL621660,BAO_0000218,6001
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax value after administration of 4 mg/Kg oral dose in dog,1,,,,In vivo,1,,2959,A,,Intermediate,CHEMBL621661,BAO_0000218,6002
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax value in dog,1,,,,In vivo,1,,6241,A,,Intermediate,CHEMBL621662,BAO_0000218,6003
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax value in dogs after oral administration at 1 mg/kg,1,,,,In vivo,1,,6241,A,,Intermediate,CHEMBL621663,BAO_0000218,6004
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,1,,,,In vivo,1,,2652,A,,Intermediate,CHEMBL621664,BAO_0000218,6005
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,1,Plasma,,,In vivo,1,,1806,A,1969.0,Intermediate,CHEMBL621665,BAO_0000218,6006
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,1,Plasma,,,In vivo,1,,1806,A,1969.0,Intermediate,CHEMBL621666,BAO_0000218,6007
,,N,,,50588,9615.0,Canis lupus familiaris,Concentration maxima after oral dosing in dogs,1,,,,In vivo,1,,1021,A,,Intermediate,CHEMBL621667,BAO_0000218,6008
,,N,,,50588,9615.0,Canis lupus familiaris,Concentration maxima after oral dosing in dogs; not available,1,,,,In vivo,1,,1021,A,,Intermediate,CHEMBL876738,BAO_0000218,6009
,,N,,,50588,9615.0,Canis lupus familiaris,Concentration maxima after oral dosing in dogs; not available,1,,,,In vivo,1,,1021,A,,Intermediate,CHEMBL621668,BAO_0000218,6010
,,N,,,50588,9615.0,Canis lupus familiaris,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,1,,,,In vivo,1,,5444,A,,Intermediate,CHEMBL621669,BAO_0000218,6011
,,N,,,50588,9615.0,Canis lupus familiaris,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,1,,,,In vivo,1,,5444,A,,Intermediate,CHEMBL621670,BAO_0000218,6012
,,N,,,50588,9615.0,Canis lupus familiaris,In vivo maximal concentration was calculated at 1 mg/kg in dog,1,,,,In vivo,1,,5444,A,,Intermediate,CHEMBL621671,BAO_0000218,6013
,,N,,,50588,9615.0,Canis lupus familiaris,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,1,,,,In vivo,1,,5444,A,,Intermediate,CHEMBL622360,BAO_0000218,6014
,,N,,,50588,9615.0,Canis lupus familiaris,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,1,,,,In vivo,1,,5444,A,,Intermediate,CHEMBL622361,BAO_0000218,6015
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax in dog plasma after oral dose (1 mg/kg),1,Plasma,,,In vivo,1,,5130,A,1969.0,Intermediate,CHEMBL622362,BAO_0000218,6016
,,N,,,50588,9615.0,Canis lupus familiaris,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,1,Plasma,,,In vivo,1,,3249,A,1969.0,Intermediate,CHEMBL622363,BAO_0000218,6017
,,N,,,50588,9615.0,Canis lupus familiaris,Maximal plasma concentration at a dose of 1 mg/kg,1,Plasma,,,In vivo,1,,5473,A,1969.0,Intermediate,CHEMBL622364,BAO_0000218,6018
,,N,,,50588,9615.0,Canis lupus familiaris,Maximal plasma concentration at a dose of 1 mg/kg (oral),1,Plasma,,,In vivo,1,,5474,A,1969.0,Intermediate,CHEMBL622365,BAO_0000218,6019
,,N,,,50588,9615.0,Canis lupus familiaris,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,1,Plasma,,,In vivo,1,,4657,A,1969.0,Intermediate,CHEMBL622533,BAO_0000218,6020
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum concentration of compound in dog was evaluated.,1,,,,In vivo,1,,3031,A,,Intermediate,CHEMBL622534,BAO_0000218,6021
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,1,,,,In vivo,1,,4527,A,,Intermediate,CHEMBL622535,BAO_0000218,6022
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,1,,,,In vivo,1,,4186,A,,Intermediate,CHEMBL876739,BAO_0000218,6023
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),1,,,,In vivo,1,,5007,A,,Intermediate,CHEMBL622536,BAO_0000218,6024
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum concentration obtained in dog plasma was determined,1,Plasma,,,In vivo,1,,3132,A,1969.0,Intermediate,CHEMBL622537,BAO_0000218,6025
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum concentration was determined,1,,,,In vivo,1,,5006,A,,Intermediate,CHEMBL622538,BAO_0000218,6026
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum concentration at the dose of 2 mg/kg in dog,1,,,,In vivo,1,,4727,A,,Intermediate,CHEMBL627867,BAO_0000218,6027
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,,,,In vivo,1,,1916,A,,Intermediate,CHEMBL627868,BAO_0000218,6028
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum concentration was evaluated in dog plasma,1,Plasma,,,In vivo,1,,1918,A,1969.0,Intermediate,CHEMBL627869,BAO_0000218,6029
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum concentration was evaluated after 75 min after administration in dog,1,,,,In vivo,1,,3045,A,,Intermediate,CHEMBL627870,BAO_0000218,6030
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum plasma concentration determined in dog after oral administration of 17b,1,Plasma,,,In vivo,1,,9579,A,1969.0,Intermediate,CHEMBL627871,BAO_0000218,6031
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum plasma concentration determined in dog after oral administration of 2b,1,Plasma,,,In vivo,1,,9579,A,1969.0,Intermediate,CHEMBL627872,BAO_0000218,6032
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum plasma concentration in dog,1,Plasma,,,In vivo,1,,933,A,1969.0,Intermediate,CHEMBL627873,BAO_0000218,6033
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,1,Plasma,,,In vivo,1,,17839,A,1969.0,Intermediate,CHEMBL627874,BAO_0000218,6034
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,1,Plasma,,,In vivo,1,,17839,A,1969.0,Intermediate,CHEMBL627875,BAO_0000218,6035
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,1,Plasma,,,In vivo,1,,17839,A,1969.0,Intermediate,CHEMBL627876,BAO_0000218,6036
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,1,Plasma,,,In vivo,1,,17839,A,1969.0,Intermediate,CHEMBL627877,BAO_0000218,6037
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,Plasma,,,In vivo,1,,6348,A,1969.0,Intermediate,CHEMBL627878,BAO_0000218,6038
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,1,Plasma,,,In vivo,1,,16367,A,1969.0,Intermediate,CHEMBL627879,BAO_0000218,6039
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1,Plasma,,,In vivo,1,,1337,A,1969.0,Intermediate,CHEMBL875355,BAO_0000218,6040
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1,Plasma,,,In vivo,1,,1337,A,1969.0,Intermediate,CHEMBL627880,BAO_0000218,6041
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,1,Plasma,,,In vivo,1,,5199,A,1969.0,Intermediate,CHEMBL627881,BAO_0000218,6042
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,1,Plasma,,,In vivo,1,,17650,A,1969.0,Intermediate,CHEMBL627882,BAO_0000218,6043
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,1,Plasma,,,In vivo,1,,6679,A,1969.0,Intermediate,CHEMBL627883,BAO_0000218,6044
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,1,Plasma,,,In vivo,1,,5356,A,1969.0,Intermediate,CHEMBL628526,BAO_0000218,6045
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,1,Plasma,,,In vivo,1,,5356,A,1969.0,Intermediate,CHEMBL628527,BAO_0000218,6046
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,1,Plasma,,,In vivo,1,,6227,A,1969.0,Intermediate,CHEMBL628528,BAO_0000218,6047
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,1,Plasma,,,In vivo,1,,6227,A,1969.0,Intermediate,CHEMBL628529,BAO_0000218,6048
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,1,Plasma,,,In vivo,1,,6227,A,1969.0,Intermediate,CHEMBL628530,BAO_0000218,6049
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,1,Plasma,,,In vivo,1,,6227,A,1969.0,Intermediate,CHEMBL625243,BAO_0000218,6050
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,1,Plasma,,,In vivo,1,,3598,A,1969.0,Expert,CHEMBL625244,BAO_0000218,6051
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,1,,,,In vivo,1,,4368,A,,Intermediate,CHEMBL625245,BAO_0000218,6052
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,1,,,,In vivo,1,,6265,A,,Intermediate,CHEMBL625246,BAO_0000218,6053
,,N,,,50594,10090.0,Mus musculus,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Stomach,,,In vivo,1,,7767,A,945.0,Intermediate,CHEMBL625247,BAO_0000218,6054
,,N,,,50594,10090.0,Mus musculus,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Urine,,,In vivo,1,,7767,A,1088.0,Intermediate,CHEMBL625248,BAO_0000218,6055
,,N,,,50594,10090.0,Mus musculus,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,1,Urine,,,In vivo,1,,7767,A,1088.0,Intermediate,CHEMBL625249,BAO_0000218,6056
,,N,,,50594,10090.0,Mus musculus,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,1,Urine,,,In vivo,1,,7767,A,1088.0,Intermediate,CHEMBL625250,BAO_0000218,6057
,,N,,,50594,10090.0,Mus musculus,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,1,,,,,1,,17811,A,,Intermediate,CHEMBL625251,BAO_0000218,6058
,,N,,,50594,10090.0,Mus musculus,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,1,,,,,1,,17811,A,,Intermediate,CHEMBL875356,BAO_0000218,6059
,,N,,,50594,10090.0,Mus musculus,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),1,,,,,1,,17827,A,,Intermediate,CHEMBL625252,BAO_0000218,6060
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),1,Blood,,,,1,,17827,A,178.0,Intermediate,CHEMBL625253,BAO_0000218,6061
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),1,,,,,1,,17827,A,,Intermediate,CHEMBL625254,BAO_0000218,6062
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),1,,,,,1,,17827,A,,Intermediate,CHEMBL625255,BAO_0000218,6063
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),1,,,,,1,,17827,A,,Intermediate,CHEMBL625256,BAO_0000218,6064
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),1,Blood,,,,1,,17827,A,178.0,Intermediate,CHEMBL625257,BAO_0000218,6065
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),1,Blood,,,,1,,17827,A,178.0,Intermediate,CHEMBL625258,BAO_0000218,6066
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated for washout rate in mice (Radiolabeled compound),1,,,,,1,,17827,A,,Intermediate,CHEMBL625259,BAO_0000218,6067
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,1,,,,,1,,17827,A,,Intermediate,CHEMBL625260,BAO_0000218,6068
,,N,,,50594,10090.0,Mus musculus,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",1,,,,,1,,17827,A,,Intermediate,CHEMBL625261,BAO_0000218,6069
,,N,,,50594,10090.0,Mus musculus,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",1,,,,,1,,17827,A,,Intermediate,CHEMBL625262,BAO_0000218,6070
,,N,,,50594,10090.0,Mus musculus,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",1,,,,,1,,17827,A,,Intermediate,CHEMBL622639,BAO_0000218,6071
,,N,,,50594,10090.0,Mus musculus,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,1,,,,,1,,17257,A,,Intermediate,CHEMBL622640,BAO_0000218,6072
,,N,,,50594,10090.0,Mus musculus,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,1,,,,,1,,17257,A,,Intermediate,CHEMBL622812,BAO_0000218,6073
,,N,,,50594,10090.0,Mus musculus,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,1,,,,,1,,17257,A,,Intermediate,CHEMBL622813,BAO_0000218,6074
,,N,,,50594,10090.0,Mus musculus,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,1,,,,,1,,17257,A,,Intermediate,CHEMBL622814,BAO_0000218,6075
,,N,,,50594,10090.0,Mus musculus,Time at maximum activity in mice (Radiolabeled compound),1,,,,,1,,17827,A,,Intermediate,CHEMBL622815,BAO_0000218,6076
,,N,,,50594,10090.0,Mus musculus,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,1,,,,,1,,3760,A,,Intermediate,CHEMBL625342,BAO_0000218,6077
,,N,,,50594,10090.0,Mus musculus,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,1,,,,,1,,3760,A,,Intermediate,CHEMBL625343,BAO_0000218,6078
,,N,,,50594,10090.0,Mus musculus,Binding towards mouse plasma protein at 10 uM,1,,,,,1,,17409,A,,Intermediate,CHEMBL877591,BAO_0000218,6079
,,N,,,50594,10090.0,Mus musculus,Binding towards mouse plasma protein at 100 uM,1,,,,,1,,17409,A,,Intermediate,CHEMBL625344,BAO_0000218,6080
,,N,,,50594,10090.0,Mus musculus,Bioavailability was evaluated in mice after intravenous administration,1,,,,In vivo,1,,2675,A,,Intermediate,CHEMBL625345,BAO_0000218,6081
,,N,,,50594,10090.0,Mus musculus,Bioavailability was evaluated in mice after oral administration,1,,,,In vivo,1,,2675,A,,Intermediate,CHEMBL625346,BAO_0000218,6082
,,N,,,50594,10090.0,Mus musculus,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,1,,,,In vivo,1,,3132,A,,Intermediate,CHEMBL625347,BAO_0000218,6083
,,N,,,50594,10090.0,Mus musculus,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,1,,,,In vivo,1,,3132,A,,Intermediate,CHEMBL625348,BAO_0000218,6084
,,N,,,50594,10090.0,Mus musculus,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,1,,,,In vivo,1,,16597,A,,Intermediate,CHEMBL625349,BAO_0000218,6085
,,N,,,50594,10090.0,Mus musculus,Oral bioavailability in mouse,1,,,,In vivo,1,,2862,A,,Intermediate,CHEMBL625350,BAO_0000218,6086
,,N,,,50594,10090.0,Mus musculus,Oral bioavailability after intravenous administration in mice at 24 uM/kg,1,,,,In vivo,1,,17764,A,,Intermediate,CHEMBL882952,BAO_0000218,6087
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,Brain,,,In vivo,1,,846,A,955.0,Intermediate,CHEMBL625351,BAO_0000218,6088
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,Brain,,,In vivo,1,,846,A,955.0,Intermediate,CHEMBL625352,BAO_0000218,6089
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,Brain,,,In vivo,1,,846,A,955.0,Intermediate,CHEMBL877592,BAO_0000218,6090
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,Brain,,,In vivo,1,,846,A,955.0,Intermediate,CHEMBL625353,BAO_0000218,6091
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,Brain,,,In vivo,1,,846,A,955.0,Intermediate,CHEMBL625354,BAO_0000218,6092
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,Brain,,,In vivo,1,,846,A,955.0,Intermediate,CHEMBL626019,BAO_0000218,6093
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,Heart,,,In vivo,1,,846,A,948.0,Intermediate,CHEMBL626020,BAO_0000218,6094
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,Heart,,,In vivo,1,,846,A,948.0,Intermediate,CHEMBL626021,BAO_0000218,6095
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,Heart,,,In vivo,1,,846,A,948.0,Intermediate,CHEMBL626022,BAO_0000218,6096
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,Heart,,,In vivo,1,,846,A,948.0,Intermediate,CHEMBL626192,BAO_0000218,6097
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),1,,A549,,,1,,1276,F,,Intermediate,CHEMBL626193,BAO_0000219,6098
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,1,,A549,,,1,,3498,F,,Expert,CHEMBL626194,BAO_0000219,6099
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity against human lung carcinoma A-549 cell lines,1,,A549,,,1,,1169,F,,Intermediate,CHEMBL626195,BAO_0000219,6100
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,1,,A549,,,1,,4450,F,,Intermediate,CHEMBL626196,BAO_0000219,6101
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549,1,,A549,,,1,,358,F,,Intermediate,CHEMBL626197,BAO_0000219,6102
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,1,,A549,,,1,,358,F,,Intermediate,CHEMBL626198,BAO_0000219,6103
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,1,,A549,,,1,,358,F,,Intermediate,CHEMBL626199,BAO_0000219,6104
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,1,,A549,,,1,,358,F,,Intermediate,CHEMBL626200,BAO_0000219,6105
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,1,,A549,,,1,,358,F,,Intermediate,CHEMBL626201,BAO_0000219,6106
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,1,,A549,,,1,,358,F,,Intermediate,CHEMBL626202,BAO_0000219,6107
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,1,,A549,,,1,,358,F,,Intermediate,CHEMBL626203,BAO_0000219,6108
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against A-549 human lung cancer cells,1,,A549,,,1,,15167,F,,Intermediate,CHEMBL626204,BAO_0000219,6109
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,1,,A549,,,1,,4139,F,,Intermediate,CHEMBL624701,BAO_0000219,6110
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,1,,A549,,,1,,833,F,,Intermediate,CHEMBL624702,BAO_0000219,6111
,,N,646.0,,80682,9606.0,Homo sapiens,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,1,,A549,,,1,,15718,F,,Expert,CHEMBL624703,BAO_0000219,6112
,,N,646.0,,80682,9606.0,Homo sapiens,Tested in vitro for cytotoxicity against A-549 lung cancer cells,1,,A549,,,1,,12373,F,,Intermediate,CHEMBL624704,BAO_0000219,6113
,,N,646.0,,80682,9606.0,Homo sapiens,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,1,,A549,,,1,,637,F,,Intermediate,CHEMBL624705,BAO_0000219,6114
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,1,,A549,,,1,,14867,F,,Expert,CHEMBL624706,BAO_0000219,6115
,,N,646.0,,80682,9606.0,Homo sapiens,Antitumor cytotoxic activity against A-549 cell line was determined,1,,A549,,,1,,4461,F,,Intermediate,CHEMBL624707,BAO_0000219,6116
,,N,646.0,,80682,9606.0,Homo sapiens,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",1,,A549,,,1,,5406,F,,Intermediate,CHEMBL624708,BAO_0000219,6117
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,1,,A549,,,1,,4457,F,,Intermediate,CHEMBL624709,BAO_0000219,6118
,,N,646.0,,80682,9606.0,Homo sapiens,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,1,,A549,,,1,,1386,F,,Expert,CHEMBL884107,BAO_0000219,6119
,,N,646.0,,80682,9606.0,Homo sapiens,Antitumoral activity was assayed against A-549 cell line,1,,A549,,,1,,3265,F,,Intermediate,CHEMBL624710,BAO_0000219,6120
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,1,,A549,,,1,,2359,F,,Intermediate,CHEMBL624711,BAO_0000219,6121
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,1,,A549,,,1,,4457,F,,Intermediate,CHEMBL624712,BAO_0000219,6122
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,1,,A549,,,1,,12454,F,,Expert,CHEMBL624713,BAO_0000219,6123
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested for inhibition of cell growth of A-549 cells,1,,A549,,,1,,1481,F,,Intermediate,CHEMBL624714,BAO_0000219,6124
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,1,,A549,,,1,,1750,F,,Intermediate,CHEMBL624715,BAO_0000219,6125
,,N,646.0,,80682,9606.0,Homo sapiens,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,1,,A549,,,1,,5065,F,,Intermediate,CHEMBL624716,BAO_0000219,6126
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against A549-human lung carcinoma cells.,1,,A549,,,1,,808,F,,Expert,CHEMBL619505,BAO_0000219,6127
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,1,,A549,,,1,,16364,F,,Expert,CHEMBL619506,BAO_0000219,6128
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic activity against A-549 cell lines.,1,,A549,,,1,,1847,F,,Intermediate,CHEMBL619507,BAO_0000219,6129
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,1,,A549,,,1,,1747,F,,Expert,CHEMBL619508,BAO_0000219,6130
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity against human A549 non small cell lung cell lines,1,,A549,,,1,,1003,F,,Intermediate,CHEMBL619509,BAO_0000219,6131
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition of cell growth in (A-549) lung cell line,1,,A549,,,1,,15313,F,,Expert,CHEMBL619510,BAO_0000219,6132
,,N,646.0,,80682,9606.0,Homo sapiens,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,1,,A549,,,1,,3122,F,,Intermediate,CHEMBL619511,BAO_0000219,6133
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro antitumor activity against A-549 tumor cells.,1,,A549,,,1,,16049,F,,Intermediate,CHEMBL619512,BAO_0000219,6134
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro antitumor effects against human A-549 cell lines.,1,,A549,,,1,,17134,F,,Expert,CHEMBL619513,BAO_0000219,6135
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxic activity of compound against A-549 cell line,1,,A549,,,1,,6406,F,,Intermediate,CHEMBL619514,BAO_0000219,6136
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against human lung carcinoma A-549 cell line,1,,A549,,,1,,627,F,,Intermediate,CHEMBL619515,BAO_0000219,6137
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against human non-small cell lung carcinoma A549,1,,A549,,,1,,12307,F,,Intermediate,CHEMBL619516,BAO_0000219,6138
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,1,,A549,,,1,,17861,F,,Intermediate,CHEMBL884005,BAO_0000219,6139
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,1,,A549,,,1,,6682,F,,Expert,CHEMBL619517,BAO_0000219,6140
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibitory concentration of compound against A-549 cell line,1,,A549,,,1,,6663,F,,Intermediate,CHEMBL619518,BAO_0000219,6141
,,N,646.0,,80682,9606.0,Homo sapiens,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,1,,A549,,,1,,2454,F,,Intermediate,CHEMBL619519,BAO_0000219,6142
,,N,646.0,,80682,9606.0,Homo sapiens,cytotoxic activity against leukemia (A-549) cancer cell line,1,,A549,,,1,,14709,F,,Intermediate,CHEMBL876489,BAO_0000219,6143
,,N,646.0,,80682,9606.0,Homo sapiens,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,1,,A549,,,1,,15718,F,,Expert,CHEMBL619520,BAO_0000219,6144
,,N,646.0,,80682,9606.0,Homo sapiens,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,1,,A549,,,1,,15718,F,,Intermediate,CHEMBL619521,BAO_0000219,6145
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),1,,A549,,,1,,17130,F,,Intermediate,CHEMBL619522,BAO_0000219,6146
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),1,,A549,,,1,,17130,F,,Intermediate,CHEMBL619523,BAO_0000219,6147
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),1,,A549,,,1,,17130,F,,Intermediate,CHEMBL619524,BAO_0000219,6148
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),1,,A549,,,1,,17130,F,,Intermediate,CHEMBL619525,BAO_0000219,6149
,,N,646.0,,80682,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,1,,A549,,,1,,6630,F,,Intermediate,CHEMBL619526,BAO_0000219,6150
,,N,646.0,,80682,9606.0,Homo sapiens,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,1,,A549,,,1,,16726,F,,Intermediate,CHEMBL619527,BAO_0000219,6151
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity against A549 cells; No cytotoxicity,1,,A549,,,1,,17846,F,,Intermediate,CHEMBL619528,BAO_0000219,6152
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity against human lung carcinoma (A549) cell lines,1,,A549,,,1,,3415,F,,Expert,CHEMBL619529,BAO_0000219,6153
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,1,,A549,,,1,,3415,F,,Expert,CHEMBL619530,BAO_0000219,6154
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro anticancer activity against human lung (A549) cell line,1,,A549,,,1,,5609,F,,Intermediate,CHEMBL876490,BAO_0000219,6155
,,N,646.0,,80682,9606.0,Homo sapiens,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,1,,A549,,,1,,17206,F,,Intermediate,CHEMBL619531,BAO_0000219,6156
,,N,646.0,,80682,9606.0,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,1,,A549,,,1,,17206,F,,Intermediate,CHEMBL619532,BAO_0000219,6157
,,N,646.0,,80682,9606.0,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,1,,A549,,,1,,17206,F,,Intermediate,CHEMBL619533,BAO_0000219,6158
,,N,646.0,,80682,9606.0,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,1,,A549,,,1,,17206,F,,Intermediate,CHEMBL619534,BAO_0000219,6159
,,N,646.0,,80682,9606.0,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,1,,A549,,,1,,17206,F,,Intermediate,CHEMBL620164,BAO_0000219,6160
,,N,646.0,,80682,9606.0,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,1,,A549,,,1,,17206,F,,Intermediate,CHEMBL620165,BAO_0000219,6161
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition of A549 human lung tumor cell proliferation,1,,A549,,,1,,16295,F,,Expert,CHEMBL620166,BAO_0000219,6162
,,N,646.0,,80682,9606.0,Homo sapiens,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",1,,A549,,,1,,16825,F,,Intermediate,CHEMBL620167,BAO_0000219,6163
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against human tumor cell line A549,1,,A549,,,1,,3439,F,,Expert,CHEMBL620168,BAO_0000219,6164
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,1,,A549,,,1,,10870,F,,Intermediate,CHEMBL620338,BAO_0000219,6165
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,1,,A549,,,1,,4845,F,,Intermediate,CHEMBL620339,BAO_0000219,6166
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,1,,A549,,,1,,5822,F,,Intermediate,CHEMBL620340,BAO_0000219,6167
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,1,,A549,,,1,,5822,F,,Intermediate,CHEMBL620341,BAO_0000219,6168
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,1,,A549,,,1,,5822,F,,Intermediate,CHEMBL876491,BAO_0000219,6169
,,N,646.0,,80682,9606.0,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,1,,A549,,,1,,16381,F,,Intermediate,CHEMBL620342,BAO_0000219,6170
,,N,646.0,,80682,9606.0,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,1,,A549,,,1,,16381,F,,Intermediate,CHEMBL620343,BAO_0000219,6171
,,N,646.0,,80682,9606.0,Homo sapiens,% inhibition against A549 cells (lung cancer) at 4 ug/mL,1,,A549,,,1,,16381,F,,Intermediate,CHEMBL620344,BAO_0000219,6172
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro anticancer activity against human lung (A549) cell line,1,,A549,,,1,,5609,F,,Intermediate,CHEMBL620345,BAO_0000219,6173
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,1,,A549,,,1,,4644,F,,Intermediate,CHEMBL620346,BAO_0000219,6174
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,1,,A549,,,1,,4644,F,,Intermediate,CHEMBL620347,BAO_0000219,6175
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,1,,A549,,,1,,4644,F,,Intermediate,CHEMBL620348,BAO_0000219,6176
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,1,,A549,,,1,,4644,F,,Intermediate,CHEMBL620349,BAO_0000219,6177
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,1,,A549,,,1,,5822,F,,Intermediate,CHEMBL618667,BAO_0000219,6178
,,N,646.0,,80682,9606.0,Homo sapiens,Percentage inhibition of human lung carcinoma (A549) cell lines,1,,A549,,,1,,3415,F,,Expert,CHEMBL618668,BAO_0000219,6179
,,N,646.0,,80682,9606.0,Homo sapiens,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,1,,A549,,,1,,16726,F,,Intermediate,CHEMBL876031,BAO_0000219,6180
,,N,646.0,,80682,9606.0,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",1,,A549,,,1,,17206,F,,Intermediate,CHEMBL618759,BAO_0000219,6181
,,N,646.0,,80682,9606.0,Homo sapiens,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,1,,A549,,,1,,17206,F,,Intermediate,CHEMBL618760,BAO_0000219,6182
,,N,646.0,,80682,9606.0,Homo sapiens,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,1,,A549,,,1,,17206,F,,Intermediate,CHEMBL619000,BAO_0000219,6183
,,N,646.0,,80682,9606.0,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",1,,A549,,,1,,17206,F,,Intermediate,CHEMBL619001,BAO_0000219,6184
,,N,646.0,,80682,9606.0,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",1,,A549,,,1,,17206,F,,Intermediate,CHEMBL619002,BAO_0000219,6185
,,N,646.0,,80682,9606.0,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",1,,A549,,,1,,17206,F,,Intermediate,CHEMBL619003,BAO_0000219,6186
,,N,646.0,,80682,9606.0,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",1,,A549,,,1,,17206,F,,Intermediate,CHEMBL619597,BAO_0000219,6187
,,N,646.0,,80682,9606.0,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",1,,A549,,,1,,17206,F,,Intermediate,CHEMBL619598,BAO_0000219,6188
,,N,646.0,,80682,9606.0,Homo sapiens,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,1,,A549,,,1,,17206,F,,Intermediate,CHEMBL619599,BAO_0000219,6189
,,N,646.0,,80682,9606.0,Homo sapiens,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,1,,A549,,,1,,17206,F,,Intermediate,CHEMBL619600,BAO_0000219,6190
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,1,,A549,,,1,,16726,F,,Intermediate,CHEMBL619601,BAO_0000219,6191
,,N,646.0,,80682,9606.0,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,1,,A549,,,1,,17206,F,,Intermediate,CHEMBL619602,BAO_0000219,6192
,,N,646.0,,80682,9606.0,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,1,,A549,,,1,,17206,F,,Intermediate,CHEMBL619603,BAO_0000219,6193
,,N,646.0,,80682,9606.0,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,1,,A549,,,1,,17206,F,,Intermediate,CHEMBL619604,BAO_0000219,6194
,,N,646.0,,80682,9606.0,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,1,,A549,,,1,,17206,F,,Intermediate,CHEMBL619605,BAO_0000219,6195
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,1,,,,In vivo,1,,6084,A,,Intermediate,CHEMBL619606,BAO_0000218,6196
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic activity (Cmax) in dog,1,,,,In vivo,1,,6084,A,,Intermediate,CHEMBL876032,BAO_0000218,6197
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),1,,,,In vivo,1,,4809,A,,Intermediate,CHEMBL619607,BAO_0000218,6198
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,1,,,,In vivo,1,,5983,A,,Intermediate,CHEMBL619608,BAO_0000218,6199
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,1,,,,In vivo,1,,6251,A,,Intermediate,CHEMBL619609,BAO_0000218,6200
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax in dog plasma after 30mg/kg oral dose,1,Plasma,,,In vivo,1,,5932,A,1969.0,Intermediate,CHEMBL619610,BAO_0000218,6201
,,N,,,50588,9615.0,Canis lupus familiaris,Tested for the peak blood level in dog,1,Blood,,,In vivo,1,,4273,A,178.0,Intermediate,CHEMBL619611,BAO_0000218,6202
,,N,,,50588,9615.0,Canis lupus familiaris,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",1,,,,In vivo,1,,5313,A,,Intermediate,CHEMBL619612,BAO_0000218,6203
,,N,,,50588,9615.0,Canis lupus familiaris,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",1,,,,In vivo,1,,5313,A,,Intermediate,CHEMBL619613,BAO_0000218,6204
,,N,,,50588,9615.0,Canis lupus familiaris,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,1,Blood,,,In vivo,1,,6221,A,178.0,Intermediate,CHEMBL619614,BAO_0000218,6205
,,N,,,50588,9615.0,Canis lupus familiaris,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,1,,,,,1,,4709,A,,Intermediate,CHEMBL619615,BAO_0000218,6206
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,1,,,,,1,,167,A,,Intermediate,CHEMBL619616,BAO_0000218,6207
,,N,,,50588,9615.0,Canis lupus familiaris,Final plasma concentration in dogs after oral administration at 1 mg/kg,1,Plasma,,,,1,,6241,A,1969.0,Intermediate,CHEMBL619617,BAO_0000218,6208
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,1,,,,,1,,344,A,,Intermediate,CHEMBL619618,BAO_0000218,6209
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,1,,,,,1,,344,A,,Intermediate,CHEMBL876033,BAO_0000218,6210
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,1,,,,,1,,344,A,,Intermediate,CHEMBL619619,BAO_0000218,6211
,,N,,,50588,9615.0,Canis lupus familiaris,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,1,,,,,1,,2189,A,,Intermediate,CHEMBL619620,BAO_0000218,6212
,,N,,,50588,9615.0,Canis lupus familiaris,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,1,Urine,,,,1,,2189,A,1088.0,Intermediate,CHEMBL619621,BAO_0000218,6213
,,N,,,50588,9615.0,Canis lupus familiaris,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,1,Urine,,,,1,,2189,A,1088.0,Intermediate,CHEMBL619622,BAO_0000218,6214
,,N,,,50588,9615.0,Canis lupus familiaris,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,1,Urine,,,,1,,2189,A,1088.0,Intermediate,CHEMBL618874,BAO_0000218,6215
,,N,,,50588,9615.0,Canis lupus familiaris,Absolute bioavailability was evaluated in dog,1,,,,In vivo,1,,4257,A,,Intermediate,CHEMBL618875,BAO_0000218,6216
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,1,,,,In vivo,1,,6221,A,,Intermediate,CHEMBL618876,BAO_0000218,6217
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability after peroral administration (1 mg/kg) was determined in dog,1,,,,In vivo,1,,6215,A,,Intermediate,CHEMBL618877,BAO_0000218,6218
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog,1,,,,In vivo,1,,17267,A,,Intermediate,CHEMBL618878,BAO_0000218,6219
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog,1,,,,In vivo,1,,6621,A,,Intermediate,CHEMBL618879,BAO_0000218,6220
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability after intravenous administration in dogs,1,,,,In vivo,1,,3854,A,,Intermediate,CHEMBL618880,BAO_0000218,6221
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability after peroral administration in dogs,1,,,,In vivo,1,,3854,A,,Intermediate,CHEMBL618881,BAO_0000218,6222
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),1,,,,In vivo,1,,5007,A,,Intermediate,CHEMBL618882,BAO_0000218,6223
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,1,,,,In vivo,1,,4333,A,,Intermediate,CHEMBL624226,BAO_0000218,6224
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,1,Plasma,,,In vivo,1,,4333,A,1969.0,Intermediate,CHEMBL624227,BAO_0000218,6225
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability,1,,,,In vivo,1,,5006,A,,Intermediate,CHEMBL624228,BAO_0000218,6226
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability,1,,,,In vivo,1,,5199,A,,Intermediate,CHEMBL624229,BAO_0000218,6227
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability by intravenous administration of 1.2 mg/kg in dog,1,,,,In vivo,1,,4368,A,,Intermediate,CHEMBL624230,BAO_0000218,6228
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog,1,,,,In vivo,1,,3771,A,,Intermediate,CHEMBL624231,BAO_0000218,6229
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog,1,,,,In vivo,1,,4953,A,,Intermediate,CHEMBL624232,BAO_0000218,6230
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog,1,,,,In vivo,1,,5064,A,,Intermediate,CHEMBL625127,BAO_0000218,6231
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog,1,,,,In vivo,1,,17657,A,,Intermediate,CHEMBL625128,BAO_0000218,6232
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog,1,,,,In vivo,1,,17796,A,,Intermediate,CHEMBL621675,BAO_0000218,6233
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog (p.o.) at 2.0 mpk,1,,,,In vivo,1,,17853,A,,Intermediate,CHEMBL621676,BAO_0000218,6234
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),1,,,,In vivo,1,,4521,A,,Intermediate,CHEMBL621677,BAO_0000218,6235
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,1,,,,In vivo,1,,4521,A,,Intermediate,CHEMBL621678,BAO_0000218,6236
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog,1,,,,In vivo,1,,5006,A,,Intermediate,CHEMBL621679,BAO_0000218,6237
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability was evaluated after oral administration in dog,1,,,,In vivo,1,,16365,A,,Intermediate,CHEMBL621680,BAO_0000218,6238
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,,,,In vivo,1,,1916,A,,Intermediate,CHEMBL621681,BAO_0000218,6239
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability was evaluated in dog,1,,,,In vivo,1,,1918,A,,Intermediate,CHEMBL876740,BAO_0000218,6240
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog,1,,,,In vivo,1,,4239,A,,Intermediate,CHEMBL621682,BAO_0000218,6241
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog,1,,,,In vivo,1,,6505,A,,Intermediate,CHEMBL621683,BAO_0000218,6242
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),1,,,,In vivo,1,,5334,A,,Intermediate,CHEMBL621684,BAO_0000218,6243
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),1,,,,In vivo,1,,5334,A,,Intermediate,CHEMBL621685,BAO_0000218,6244
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),1,,,,In vivo,1,,4809,A,,Intermediate,CHEMBL621686,BAO_0000218,6245
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,,,,In vivo,1,,6348,A,,Intermediate,CHEMBL621687,BAO_0000218,6246
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,1,,,,In vivo,1,,6005,A,,Intermediate,CHEMBL621688,BAO_0000218,6247
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability of compound in dog was determined after peroral administration,1,,,,In vivo,1,,17804,A,,Intermediate,CHEMBL621689,BAO_0000218,6248
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,3184,A,,Intermediate,CHEMBL621690,BAO_0000218,6249
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,1,,,,In vivo,1,,1806,A,,Intermediate,CHEMBL621691,BAO_0000218,6250
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,1,,,,In vivo,1,,1806,A,,Intermediate,CHEMBL875941,BAO_0000218,6251
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for oral bioavailability in dogs; 37-38 %,1,,,,In vivo,1,,1806,A,,Intermediate,CHEMBL621692,BAO_0000218,6252
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog,1,,,,In vivo,1,,4839,A,,Intermediate,CHEMBL621693,BAO_0000218,6253
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),1,,,,In vivo,1,,5017,A,,Intermediate,CHEMBL621694,BAO_0000218,6254
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,Heart,,,In vivo,1,,846,A,948.0,Intermediate,CHEMBL621695,BAO_0000218,6255
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,Heart,,,In vivo,1,,846,A,948.0,Intermediate,CHEMBL621696,BAO_0000218,6256
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,Kidney,,,In vivo,1,,846,A,2113.0,Intermediate,CHEMBL621697,BAO_0000218,6257
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,Kidney,,,In vivo,1,,846,A,2113.0,Intermediate,CHEMBL621698,BAO_0000218,6258
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,Kidney,,,In vivo,1,,846,A,2113.0,Intermediate,CHEMBL623420,BAO_0000218,6259
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,Kidney,,,In vivo,1,,846,A,2113.0,Intermediate,CHEMBL623421,BAO_0000218,6260
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,Kidney,,,In vivo,1,,846,A,2113.0,Intermediate,CHEMBL623422,BAO_0000218,6261
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,Kidney,,,In vivo,1,,846,A,2113.0,Intermediate,CHEMBL623423,BAO_0000218,6262
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,Liver,,,In vivo,1,,846,A,2107.0,Intermediate,CHEMBL623424,BAO_0000218,6263
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,Liver,,,In vivo,1,,846,A,2107.0,Intermediate,CHEMBL623425,BAO_0000218,6264
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,Liver,,,In vivo,1,,846,A,2107.0,Intermediate,CHEMBL623426,BAO_0000218,6265
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,Liver,,,In vivo,1,,846,A,2107.0,Intermediate,CHEMBL623427,BAO_0000218,6266
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,Liver,,,In vivo,1,,846,A,2107.0,Intermediate,CHEMBL623428,BAO_0000218,6267
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,Liver,,,In vivo,1,,846,A,2107.0,Intermediate,CHEMBL875947,BAO_0000218,6268
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,Lung,,,In vivo,1,,846,A,2048.0,Intermediate,CHEMBL623429,BAO_0000218,6269
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,Lung,,,In vivo,1,,846,A,2048.0,Intermediate,CHEMBL623430,BAO_0000218,6270
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,Lung,,,In vivo,1,,846,A,2048.0,Intermediate,CHEMBL622588,BAO_0000218,6271
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,Lung,,,In vivo,1,,846,A,2048.0,Intermediate,CHEMBL622589,BAO_0000218,6272
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,Lung,,,In vivo,1,,846,A,2048.0,Intermediate,CHEMBL622751,BAO_0000218,6273
,,N,,,50594,10090.0,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,Lung,,,In vivo,1,,846,A,2048.0,Intermediate,CHEMBL622752,BAO_0000218,6274
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL622753,BAO_0000218,6275
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL622647,BAO_0000218,6276
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL875163,BAO_0000218,6277
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL622648,BAO_0000218,6278
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL622649,BAO_0000218,6279
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,1,Brain,CCRF S-180,,,1,,6599,A,955.0,Intermediate,CHEMBL622650,BAO_0000218,6280
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,1,Brain,CCRF S-180,,,1,,6599,A,955.0,Intermediate,CHEMBL622651,BAO_0000218,6281
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,1,Brain,CCRF S-180,,,1,,6599,A,955.0,Intermediate,CHEMBL622652,BAO_0000218,6282
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,1,Brain,CCRF S-180,,,1,,6599,A,955.0,Intermediate,CHEMBL622653,BAO_0000218,6283
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,1,Brain,CCRF S-180,,,1,,6599,A,955.0,Intermediate,CHEMBL622654,BAO_0000218,6284
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,1,Heart,CCRF S-180,,,1,,6599,A,948.0,Intermediate,CHEMBL622655,BAO_0000218,6285
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,1,Heart,CCRF S-180,,,1,,6599,A,948.0,Intermediate,CHEMBL622656,BAO_0000218,6286
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,1,Heart,CCRF S-180,,,1,,6599,A,948.0,Intermediate,CHEMBL622657,BAO_0000218,6287
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,1,Heart,CCRF S-180,,,1,,6599,A,948.0,Intermediate,CHEMBL622658,BAO_0000218,6288
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,1,Heart,CCRF S-180,,,1,,6599,A,948.0,Intermediate,CHEMBL622659,BAO_0000218,6289
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,1,Kidney,CCRF S-180,,,1,,6599,A,2113.0,Intermediate,CHEMBL624630,BAO_0000218,6290
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,1,Kidney,CCRF S-180,,,1,,6599,A,2113.0,Intermediate,CHEMBL624631,BAO_0000218,6291
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,1,Kidney,CCRF S-180,,,1,,6599,A,2113.0,Intermediate,CHEMBL624632,BAO_0000218,6292
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,1,,A549,,,1,,17130,F,,Intermediate,CHEMBL624633,BAO_0000219,6293
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,1,,A549,,,1,,17130,F,,Intermediate,CHEMBL624634,BAO_0000219,6294
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),1,,A549,,,1,,17130,F,,Intermediate,CHEMBL624635,BAO_0000219,6295
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),1,,A549,,,1,,17130,F,,Intermediate,CHEMBL624636,BAO_0000219,6296
,,N,646.0,,80682,9606.0,Homo sapiens,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,1,,A549,,,1,,3263,F,,Expert,CHEMBL857055,BAO_0000219,6297
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,1,,A549,,,1,,6663,F,,Expert,CHEMBL624637,BAO_0000219,6298
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,1,,A549,,,1,,6663,F,,Expert,CHEMBL624638,BAO_0000219,6299
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,1,,A549,,,1,,6663,F,,Expert,CHEMBL874366,BAO_0000219,6300
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,1,,A549,,,1,,6663,F,,Expert,CHEMBL624639,BAO_0000219,6301
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,1,,A549,,,1,,6663,F,,Expert,CHEMBL624640,BAO_0000219,6302
,,N,646.0,,80682,9606.0,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,1,,A549,,,1,,6663,F,,Intermediate,CHEMBL624641,BAO_0000219,6303
,,N,646.0,,80682,9606.0,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,1,,A549,,,1,,6663,F,,Intermediate,CHEMBL624642,BAO_0000219,6304
,,N,646.0,,80682,9606.0,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,1,,A549,,,1,,6663,F,,Intermediate,CHEMBL624643,BAO_0000219,6305
,,N,646.0,,80682,9606.0,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,1,,A549,,,1,,6663,F,,Intermediate,CHEMBL624644,BAO_0000219,6306
,,N,646.0,,80682,9606.0,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,1,,A549,,,1,,6663,F,,Intermediate,CHEMBL624645,BAO_0000219,6307
,,N,646.0,,80682,9606.0,Homo sapiens,The compound was evaluated for its cytotoxic potency against A-549 cell line,1,,A549,,,1,,3983,F,,Intermediate,CHEMBL619445,BAO_0000219,6308
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,1,,A549,,,1,,11141,F,,Expert,CHEMBL839886,BAO_0000219,6309
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic activity of compound against A-549 tumor cell line.,1,,A549,,,1,,5076,F,,Intermediate,CHEMBL619446,BAO_0000219,6310
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,1,,A549,,,1,,3311,F,,Intermediate,CHEMBL619447,BAO_0000219,6311
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,1,,A549,,,1,,3311,F,,Intermediate,CHEMBL619448,BAO_0000219,6312
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,1,,A549,,,1,,3311,F,,Intermediate,CHEMBL619449,BAO_0000219,6313
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,1,,A549,,,1,,5076,F,,Intermediate,CHEMBL619450,BAO_0000219,6314
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),1,,A549,,,1,,4150,F,,Intermediate,CHEMBL619451,BAO_0000219,6315
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,1,,A549,,,1,,2150,F,,Expert,CHEMBL619452,BAO_0000219,6316
,,N,646.0,,80682,9606.0,Homo sapiens,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,1,,A549,,,1,,4644,F,,Intermediate,CHEMBL619453,BAO_0000219,6317
,,N,646.0,,80682,9606.0,Homo sapiens,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,1,,A549,,,1,,263,F,,Intermediate,CHEMBL874367,BAO_0000219,6318
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic concentration against A-549 tumor cells.,1,,A549,,,1,,11333,F,,Intermediate,CHEMBL619454,BAO_0000219,6319
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,1,,A549,,,1,,11333,F,,Intermediate,CHEMBL619455,BAO_0000219,6320
,,N,646.0,,80682,9606.0,Homo sapiens,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",1,,A549,,,1,,15895,F,,Intermediate,CHEMBL619456,BAO_0000219,6321
,,N,,,50191,470.0,Acinetobacter baumannii,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,1,,,,,1,,16677,F,,Expert,CHEMBL619457,BAO_0000218,6322
,,N,,,50192,471.0,Acinetobacter calcoaceticus,Activity against Acinetobacter calcoaceticus (AC54),1,,,,,1,,10624,F,,Intermediate,CHEMBL619458,BAO_0000218,6323
,,N,,,50274,5059.0,Aspergillus flavus,In vitro antifungal activity against Aspergillus flavus CM74,1,,,,,1,,16717,F,,Expert,CHEMBL619459,BAO_0000218,6324
,,N,,,50274,5059.0,Aspergillus flavus,In vitro antifungal activity against Aspergillus flavus CM74,1,,,,,1,,16717,F,,Expert,CHEMBL619460,BAO_0000218,6325
,,N,,,50416,746128.0,Aspergillus fumigatus,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,1,,,,,1,,5513,F,,Intermediate,CHEMBL619461,BAO_0000218,6326
,,N,,,50416,746128.0,Aspergillus fumigatus,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),1,,,,,1,,15962,F,,Intermediate,CHEMBL619462,BAO_0000218,6327
,,N,,,50416,746128.0,Aspergillus fumigatus,Antimicrobial activity against Aspergillus fumigatus (MIC),1,,,,,1,,15962,F,,Intermediate,CHEMBL620388,BAO_0000218,6328
,,N,,,50416,746128.0,Aspergillus fumigatus,Antimicrobial activity against Aspergillus fumigatus (MIC),1,,,,,1,,15962,F,,Intermediate,CHEMBL620389,BAO_0000218,6329
,,N,,,50416,746128.0,Aspergillus fumigatus,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),1,,,,,1,,15962,F,,Intermediate,CHEMBL620390,BAO_0000218,6330
,,N,,,50416,746128.0,Aspergillus fumigatus,In vitro antifungal activity against Aspergillus fumigatus 48238E,1,,,,,1,,16717,F,,Expert,CHEMBL620391,BAO_0000218,6331
,,N,,,50416,746128.0,Aspergillus fumigatus,In vitro antifungal activity against Aspergillus fumigatus 48238E,1,,,,,1,,16717,F,,Expert,CHEMBL621073,BAO_0000218,6332
,,N,,,50296,1655.0,Actinomyces naeslundii,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,1,,,,,1,,8117,F,,Intermediate,CHEMBL621074,BAO_0000218,6333
,,N,,,50366,1656.0,Actinomyces viscosus,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,1,,,,,1,,8117,F,,Intermediate,CHEMBL621075,BAO_0000218,6334
,,N,,,50535,6277.0,Acanthocheilonema viteae,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),1,,,,,1,,15472,F,,Intermediate,CHEMBL619554,BAO_0000218,6335
,,N,,,50535,6277.0,Acanthocheilonema viteae,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),1,,,,,1,,15472,F,,Intermediate,CHEMBL619555,BAO_0000218,6336
,,N,,,50169,714.0,Aggregatibacter actinomycetemcomitans,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,1,,,,,1,,16443,F,,Intermediate,CHEMBL619556,BAO_0000218,6337
,,N,,,50169,714.0,Aggregatibacter actinomycetemcomitans,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,1,,,,,1,,16443,F,,Intermediate,CHEMBL619557,BAO_0000218,6338
,,N,,,50169,714.0,Aggregatibacter actinomycetemcomitans,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,1,,,,,1,,16443,F,,Intermediate,CHEMBL619558,BAO_0000218,6339
,,N,646.0,,80682,9606.0,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,1,,A549,,,1,,17206,F,,Intermediate,CHEMBL619559,BAO_0000219,6340
,,N,646.0,,80682,9606.0,Homo sapiens,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,1,,A549,,,1,,17206,F,,Intermediate,CHEMBL619560,BAO_0000219,6341
,,N,646.0,,80682,9606.0,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,1,,A549,,,1,,16381,F,,Intermediate,CHEMBL619561,BAO_0000219,6342
,,N,646.0,,80682,9606.0,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,1,,A549,,,1,,16381,F,,Intermediate,CHEMBL619562,BAO_0000219,6343
,,N,646.0,,80682,9606.0,Homo sapiens,% inhibition against A549 cells (lung cancer) at 4 ug/mL,1,,A549,,,1,,16381,F,,Intermediate,CHEMBL619563,BAO_0000219,6344
,,N,646.0,,80682,9606.0,Homo sapiens,GI values against A549 cells (lung cancer),1,,A549,,,1,,16381,F,,Intermediate,CHEMBL857457,BAO_0000219,6345
,,N,646.0,,80682,9606.0,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,1,,A549,,,1,,17206,F,,Intermediate,CHEMBL619564,BAO_0000219,6346
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibitory activity against A549 human adenocarcinoma,1,,A549,,,1,,16325,F,,Intermediate,CHEMBL619565,BAO_0000219,6347
,,N,646.0,,80682,9606.0,Homo sapiens,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,1,,A549,,,1,,10708,F,,Intermediate,CHEMBL619566,BAO_0000218,6348
,,N,646.0,,80682,9606.0,Homo sapiens,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,1,,A549,,,1,,10708,F,,Intermediate,CHEMBL619567,BAO_0000218,6349
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibitory activity against A549 lung adenocarcinoma cell line,1,,A549,,,1,,17376,F,,Intermediate,CHEMBL619568,BAO_0000219,6350
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,1,,A549,,,1,,17376,F,,Intermediate,CHEMBL619569,BAO_0000219,6351
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity against human A549 lung cells,1,,A549,,,1,,17488,F,,Intermediate,CHEMBL619570,BAO_0000219,6352
,,N,646.0,,80682,9606.0,Homo sapiens,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,1,,A549,,,1,,17404,F,,Intermediate,CHEMBL619571,BAO_0000218,6353
,,N,646.0,,80682,9606.0,Homo sapiens,Growth inhibition of A549 (human lung carcinoma) cell line.,1,,A549,,,1,,10958,F,,Expert,CHEMBL619572,BAO_0000219,6354
,,N,646.0,,80682,9606.0,Homo sapiens,Effective dose required for inhibitory activity against A549 human tumor cell line.,1,,A549,,,1,,17099,F,,Expert,CHEMBL619573,BAO_0000219,6355
,,N,646.0,,80682,9606.0,Homo sapiens,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,1,,A549,,,1,,17099,F,,Intermediate,CHEMBL619574,BAO_0000219,6356
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,1,,A549,,,1,,4096,F,,Intermediate,CHEMBL619575,BAO_0000219,6357
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,1,,A549,,,1,,4096,F,,Expert,CHEMBL619576,BAO_0000219,6358
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,1,,A549,,,1,,4096,F,,Intermediate,CHEMBL619577,BAO_0000219,6359
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro inhibitory activity against A549 tumor cell culture,1,,A549,,,1,,2525,F,,Intermediate,CHEMBL619578,BAO_0000219,6360
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,1,,A549,,,1,,2525,F,,Intermediate,CHEMBL884009,BAO_0000219,6361
,,N,646.0,,80682,9606.0,Homo sapiens,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),1,,A549,,,1,,5302,F,,Intermediate,CHEMBL619579,BAO_0000219,6362
,,N,646.0,,80682,9606.0,Homo sapiens,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,1,,A549,,,1,,16325,F,,Intermediate,CHEMBL619580,BAO_0000219,6363
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,1,,A549,,,1,,16939,F,,Intermediate,CHEMBL619581,BAO_0000219,6364
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,1,,A549,,,1,,17229,F,,Intermediate,CHEMBL619582,BAO_0000219,6365
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,1,,A549,,,1,,17380,F,,Intermediate,CHEMBL619583,BAO_0000219,6366
,,N,646.0,,80682,9606.0,Homo sapiens,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,1,,A549,,,1,,17380,F,,Intermediate,CHEMBL876502,BAO_0000219,6367
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,1,,A549,,,1,,1903,F,,Intermediate,CHEMBL619584,BAO_0000219,6368
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,1,,A549,,,1,,3838,F,,Intermediate,CHEMBL619585,BAO_0000219,6369
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,1,,A549,,,1,,14696,F,,Intermediate,CHEMBL619586,BAO_0000219,6370
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,1,,A549,,,1,,3838,F,,Intermediate,CHEMBL619587,BAO_0000219,6371
,,N,646.0,,80682,9606.0,Homo sapiens,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,1,,A549,,,1,,1522,F,,Intermediate,CHEMBL619588,BAO_0000219,6372
,,N,646.0,,80682,9606.0,Homo sapiens,Tested in vitro for cytotoxicity in A549/ATCC cell lines,1,,A549,,,1,,12400,F,,Intermediate,CHEMBL619589,BAO_0000219,6373
,,N,646.0,,80682,9606.0,Homo sapiens,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,1,,A549,,,1,,14696,F,,Intermediate,CHEMBL619590,BAO_0000219,6374
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),1,,A549,,,1,,14769,F,,Intermediate,CHEMBL619591,BAO_0000219,6375
,,N,646.0,,80682,9606.0,Homo sapiens,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,1,,A549,,,1,,14696,F,,Intermediate,CHEMBL619592,BAO_0000219,6376
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,1,,A549,,,1,,1888,F,,Intermediate,CHEMBL619593,BAO_0000219,6377
,,N,646.0,,80682,9606.0,Homo sapiens,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,1,,A549,,,1,,12016,F,,Intermediate,CHEMBL620217,BAO_0000219,6378
,,N,646.0,,80682,9606.0,Homo sapiens,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,1,,A549,,,1,,6058,F,,Intermediate,CHEMBL620218,BAO_0000219,6379
,,N,646.0,,80682,9606.0,Homo sapiens,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,1,,A549,,,1,,17708,F,,Intermediate,CHEMBL620219,BAO_0000219,6380
,,N,646.0,,80682,9606.0,Homo sapiens,Antitumor activity against A549/ATCC cell line,1,,A549,,,1,,12301,F,,Intermediate,CHEMBL620220,BAO_0000219,6381
,,N,646.0,,80682,9606.0,Homo sapiens,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,1,,A549,,,1,,11970,F,,Intermediate,CHEMBL625141,BAO_0000219,6382
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro cytotoxicity against A549/ATCC cell line.,1,,A549,,,1,,11818,F,,Expert,CHEMBL625142,BAO_0000219,6383
,,N,646.0,,80682,9606.0,Homo sapiens,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,1,,A549,,,1,,12400,F,,Intermediate,CHEMBL625143,BAO_0000219,6384
,,N,646.0,,80682,9606.0,Homo sapiens,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,1,,A549,,,1,,3381,F,,Intermediate,CHEMBL625144,BAO_0000219,6385
,,N,646.0,,80682,9606.0,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,1,,A549,,,1,,17376,F,,Intermediate,CHEMBL622474,BAO_0000219,6386
,,N,646.0,,80682,9606.0,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,1,,A549,,,1,,10708,F,,Intermediate,CHEMBL884104,BAO_0000219,6387
,,U,,,22226,9606.0,Homo sapiens,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,1,,,,,0,,2964,F,,Autocuration,CHEMBL622475,BAO_0000219,6388
,,U,,,22224,9615.0,Canis lupus familiaris,Compound was tested for oral bioavailability in dogs,1,,,,In vivo,0,,5005,A,,Intermediate,CHEMBL622476,BAO_0000218,6389
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,1,,,,In vivo,1,,6229,A,,Intermediate,CHEMBL875831,BAO_0000218,6390
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,1,,,,In vivo,1,,6229,A,,Intermediate,CHEMBL622477,BAO_0000218,6391
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,5374,A,,Intermediate,CHEMBL622478,BAO_0000218,6392
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested for the oral bioavailability in dog; No availability,1,,,,In vivo,1,,5374,A,,Intermediate,CHEMBL623172,BAO_0000218,6393
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg),1,,,,In vivo,1,,6265,A,,Intermediate,CHEMBL623173,BAO_0000218,6394
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,1,,,,In vivo,1,,5654,A,,Intermediate,CHEMBL623174,BAO_0000218,6395
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,1,,,,In vivo,1,,5654,A,,Intermediate,CHEMBL623175,BAO_0000218,6396
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),1,,,,In vivo,1,,16456,A,,Intermediate,CHEMBL623340,BAO_0000218,6397
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg),1,,,,In vivo,1,,5302,A,,Intermediate,CHEMBL623341,BAO_0000218,6398
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),1,,,,In vivo,1,,3624,A,,Intermediate,CHEMBL623342,BAO_0000218,6399
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability of active FTIs in dogs,1,,,,In vivo,1,,16452,A,,Intermediate,CHEMBL623343,BAO_0000218,6400
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),1,,,,In vivo,1,,5802,A,,Intermediate,CHEMBL623344,BAO_0000218,6401
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,1,,,,In vivo,1,,3598,A,,Expert,CHEMBL623345,BAO_0000218,6402
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,17839,A,,Intermediate,CHEMBL875832,BAO_0000218,6403
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,6762,A,,Intermediate,CHEMBL623346,BAO_0000218,6404
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,6821,A,,Intermediate,CHEMBL623347,BAO_0000218,6405
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability of compound was determined in dog; Not tested,1,,,,In vivo,1,,6821,A,,Intermediate,CHEMBL623348,BAO_0000218,6406
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,5210,A,,Intermediate,CHEMBL623349,BAO_0000218,6407
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability (10 mg/kg) was determined in dog,1,,,,In vivo,1,,6227,A,,Intermediate,CHEMBL623350,BAO_0000218,6408
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability,1,,,,In vivo,1,,761,A,,Intermediate,CHEMBL623351,BAO_0000218,6409
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),1,,,,In vivo,1,,761,A,,Intermediate,CHEMBL623352,BAO_0000218,6410
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability administered in solution in rats,1,,,,In vivo,1,,761,A,,Intermediate,CHEMBL623353,BAO_0000218,6411
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability after 30 mg/kg po dose in Dogs,1,,,,In vivo,1,,16907,A,,Intermediate,CHEMBL875833,BAO_0000218,6412
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability at a dose of 1 mg/kg in dogs,1,,,,In vivo,1,,5474,A,,Intermediate,CHEMBL623354,BAO_0000218,6413
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (dose 1 mg/kg p.o.),1,,,,In vivo,1,,6535,A,,Intermediate,CHEMBL623355,BAO_0000218,6414
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in Dog; ND = not determined,1,,,,In vivo,1,,6535,A,,Intermediate,CHEMBL623356,BAO_0000218,6415
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,3352,A,,Intermediate,CHEMBL623357,BAO_0000218,6416
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,6168,A,,Intermediate,CHEMBL623358,BAO_0000218,6417
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,5988,A,,Intermediate,CHEMBL623359,BAO_0000218,6418
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,4942,A,,Intermediate,CHEMBL623360,BAO_0000218,6419
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dogs; No data,1,,,,In vivo,1,,4942,A,,Intermediate,CHEMBL623361,BAO_0000218,6420
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability measured in dogs,1,,,,In vivo,1,,14541,A,,Intermediate,CHEMBL623362,BAO_0000218,6421
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,4449,A,,Intermediate,CHEMBL623363,BAO_0000218,6422
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability was calculated in dog,1,,,,In vivo,1,,6057,A,,Intermediate,CHEMBL623364,BAO_0000218,6423
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability after 0.3 mg/kg po administration in dog,1,,,,In vivo,1,,5600,A,,Intermediate,CHEMBL875834,BAO_0000218,6424
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (i.v. dosing),1,,,,In vivo,1,,5542,A,,Intermediate,CHEMBL623365,BAO_0000218,6425
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,5542,A,,Intermediate,CHEMBL623366,BAO_0000218,6426
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,1,,,,In vivo,1,,5546,A,,Intermediate,CHEMBL623367,BAO_0000218,6427
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in Beagle dogs,1,,,,In vivo,1,,4514,A,,Intermediate,CHEMBL623368,BAO_0000218,6428
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,3624,A,,Intermediate,CHEMBL623369,BAO_0000218,6429
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,3854,A,,Intermediate,CHEMBL623370,BAO_0000218,6430
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,5836,A,,Intermediate,CHEMBL623371,BAO_0000218,6431
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,5940,A,,Intermediate,CHEMBL623372,BAO_0000218,6432
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,6168,A,,Intermediate,CHEMBL621351,BAO_0000218,6433
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,6227,A,,Intermediate,CHEMBL621352,BAO_0000218,6434
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,6251,A,,Intermediate,CHEMBL621353,BAO_0000218,6435
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,6448,A,,Intermediate,CHEMBL621354,BAO_0000218,6436
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,6647,A,,Intermediate,CHEMBL621355,BAO_0000218,6437
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,5940,A,,Intermediate,CHEMBL621356,BAO_0000218,6438
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,933,A,,Intermediate,CHEMBL621357,BAO_0000218,6439
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,5210,A,,Intermediate,CHEMBL621358,BAO_0000218,6440
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),1,,,,In vivo,1,,6642,A,,Intermediate,CHEMBL621359,BAO_0000218,6441
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),1,,,,In vivo,1,,6641,A,,Intermediate,CHEMBL621360,BAO_0000218,6442
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),1,,,,In vivo,1,,6642,A,,Intermediate,CHEMBL621361,BAO_0000218,6443
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,5472,A,,Intermediate,CHEMBL621362,BAO_0000218,6444
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,5985,A,,Intermediate,CHEMBL621363,BAO_0000218,6445
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,15660,A,,Intermediate,CHEMBL621364,BAO_0000218,6446
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),1,,,,In vivo,1,,5530,A,,Intermediate,CHEMBL621166,BAO_0000218,6447
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (dose 1 mg/kg i.v.),1,,,,In vivo,1,,5530,A,,Intermediate,CHEMBL621167,BAO_0000218,6448
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability (F) in dogs,1,,,,In vivo,1,,6305,A,,Intermediate,CHEMBL621168,BAO_0000218,6449
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,5210,A,,Intermediate,CHEMBL621169,BAO_0000218,6450
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog,1,,,,In vivo,1,,5238,A,,Intermediate,CHEMBL875950,BAO_0000218,6451
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),1,,,,In vivo,1,,5668,A,,Intermediate,CHEMBL621170,BAO_0000218,6452
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability after peroral administration at 5 mpk in Dog,1,,,,In vivo,1,,5668,A,,Intermediate,CHEMBL621171,BAO_0000218,6453
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg),1,,,,In vivo,1,,5668,A,,Intermediate,CHEMBL621172,BAO_0000218,6454
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),1,,,,In vivo,1,,6084,A,,Intermediate,CHEMBL621173,BAO_0000218,6455
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,1,Kidney,CCRF S-180,,,1,,6599,A,2113.0,Intermediate,CHEMBL621174,BAO_0000218,6456
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,1,Kidney,CCRF S-180,,,1,,6599,A,2113.0,Intermediate,CHEMBL621175,BAO_0000218,6457
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,1,Liver,CCRF S-180,,,1,,6599,A,2107.0,Intermediate,CHEMBL621176,BAO_0000218,6458
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,1,Liver,CCRF S-180,,,1,,6599,A,2107.0,Intermediate,CHEMBL621177,BAO_0000218,6459
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,1,Liver,CCRF S-180,,,1,,6599,A,2107.0,Intermediate,CHEMBL621178,BAO_0000218,6460
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,1,Liver,CCRF S-180,,,1,,6599,A,2107.0,Intermediate,CHEMBL621179,BAO_0000218,6461
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,1,Liver,CCRF S-180,,,1,,6599,A,2107.0,Intermediate,CHEMBL621180,BAO_0000218,6462
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,1,Lung,CCRF S-180,,,1,,6599,A,2048.0,Intermediate,CHEMBL875951,BAO_0000218,6463
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,1,Lung,CCRF S-180,,,1,,6599,A,2048.0,Intermediate,CHEMBL621181,BAO_0000218,6464
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,1,Lung,CCRF S-180,,,1,,6599,A,2048.0,Intermediate,CHEMBL621182,BAO_0000218,6465
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,1,Lung,CCRF S-180,,,1,,6599,A,2048.0,Intermediate,CHEMBL621183,BAO_0000218,6466
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,1,Lung,CCRF S-180,,,1,,6599,A,2048.0,Intermediate,CHEMBL621184,BAO_0000218,6467
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL621185,BAO_0000218,6468
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL621186,BAO_0000218,6469
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL621187,BAO_0000218,6470
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL621188,BAO_0000218,6471
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL621189,BAO_0000218,6472
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,1,Spleen,CCRF S-180,,,1,,6599,A,2106.0,Intermediate,CHEMBL621190,BAO_0000218,6473
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,1,Spleen,CCRF S-180,,,1,,6599,A,2106.0,Intermediate,CHEMBL618520,BAO_0000218,6474
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,1,Spleen,CCRF S-180,,,1,,6599,A,2106.0,Intermediate,CHEMBL621739,BAO_0000218,6475
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,1,Spleen,CCRF S-180,,,1,,6599,A,2106.0,Intermediate,CHEMBL621740,BAO_0000218,6476
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,1,Spleen,CCRF S-180,,,1,,6599,A,2106.0,Intermediate,CHEMBL621741,BAO_0000218,6477
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL621742,BAO_0000218,6478
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL621743,BAO_0000218,6479
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL621744,BAO_0000218,6480
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL621745,BAO_0000218,6481
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL621746,BAO_0000218,6482
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL621747,BAO_0000218,6483
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL621748,BAO_0000218,6484
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL621749,BAO_0000218,6485
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL621750,BAO_0000218,6486
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL621751,BAO_0000218,6487
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,1,Heart,CCRF S-180,,,1,,6599,A,948.0,Intermediate,CHEMBL621752,BAO_0000218,6488
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,1,Heart,CCRF S-180,,,1,,6599,A,948.0,Intermediate,CHEMBL621753,BAO_0000218,6489
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,1,Heart,CCRF S-180,,,1,,6599,A,948.0,Intermediate,CHEMBL875955,BAO_0000218,6490
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,1,Heart,CCRF S-180,,,1,,6599,A,948.0,Intermediate,CHEMBL621754,BAO_0000218,6491
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,1,Heart,CCRF S-180,,,1,,6599,A,948.0,Intermediate,CHEMBL621755,BAO_0000218,6492
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,1,Liver,CCRF S-180,,,1,,6599,A,2107.0,Intermediate,CHEMBL621756,BAO_0000218,6493
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,1,Liver,CCRF S-180,,,1,,6599,A,2107.0,Intermediate,CHEMBL624199,BAO_0000218,6494
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,1,Liver,CCRF S-180,,,1,,6599,A,2107.0,Intermediate,CHEMBL624200,BAO_0000218,6495
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,1,Liver,CCRF S-180,,,1,,6599,A,2107.0,Intermediate,CHEMBL624375,BAO_0000218,6496
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,1,Liver,CCRF S-180,,,1,,6599,A,2107.0,Intermediate,CHEMBL624376,BAO_0000218,6497
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,1,Lung,CCRF S-180,,,1,,6599,A,2048.0,Intermediate,CHEMBL624377,BAO_0000218,6498
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,1,Lung,CCRF S-180,,,1,,6599,A,2048.0,Intermediate,CHEMBL624378,BAO_0000218,6499
,,N,,,50067,107673.0,aeinetobacter anitrotap,Compound tested for the antimicrobial activity against Acinetobacter anitratus,1,,,,,1,,12269,F,,Intermediate,CHEMBL857901,BAO_0000218,6500
,,N,,,50067,107673.0,Acinetobacter calcoaceticus subsp. anitratus,Compound tested for the antimicrobial activity against Acinetobacter anitratus,1,,,,,1,,12269,F,,Intermediate,CHEMBL875274,BAO_0000218,6501
,,N,,,50067,107673.0,Acinetobacter calcoaceticus subsp. anitratus,Compound tested for the antimicrobial activity against Acinetobacter anitratus,1,,,,,1,,12269,F,,Intermediate,CHEMBL624379,BAO_0000218,6502
,,N,,,50067,107673.0,aeinetobacter anitrotap,Compound tested for the antimicrobial activity against Acinetobacter anitratus,1,,,,,1,,12269,F,,Intermediate,CHEMBL624380,BAO_0000218,6503
,,N,,,50192,471.0,Acinetobacter calcoaceticus,Activity against Acinetobacter calcoaceticus (AC54),1,,,,,1,,10624,F,,Intermediate,CHEMBL624381,BAO_0000218,6504
,,N,,,50714,28377.0,Anolis carolinensis,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,1,,,,,1,,17216,F,,Intermediate,CHEMBL624382,BAO_0000218,6505
,,N,,,50714,28377.0,Anolis carolinensis,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,1,,,,,1,,17216,F,,Intermediate,CHEMBL624383,BAO_0000218,6506
,,N,,,50296,1655.0,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii 631,1,,,,,1,,9560,F,,Intermediate,CHEMBL624384,BAO_0000218,6507
,,N,,,50296,1655.0,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii B74,1,,,,,1,,9560,F,,Intermediate,CHEMBL624385,BAO_0000218,6508
,,N,,,50296,1655.0,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii N/3,1,,,,,1,,9560,F,,Intermediate,CHEMBL624386,BAO_0000218,6509
,,N,,,50296,1655.0,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii N/9,1,,,,,1,,9560,F,,Intermediate,CHEMBL624387,BAO_0000218,6510
,,N,,,50296,1655.0,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii 631,1,,,,,1,,9560,F,,Intermediate,CHEMBL624388,BAO_0000218,6511
,,N,,,50296,1655.0,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii N/9,1,,,,,1,,9560,F,,Intermediate,CHEMBL624389,BAO_0000218,6512
,,N,,,50296,1655.0,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii B74,1,,,,,1,,9560,F,,Intermediate,CHEMBL624390,BAO_0000218,6513
,,N,,,50296,1655.0,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii N/3,1,,,,,1,,9560,F,,Intermediate,CHEMBL875275,BAO_0000218,6514
,,N,,,50056,85549.0,Artemia salina,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,1,,,,,1,,114,F,,Intermediate,CHEMBL624391,BAO_0000218,6515
,,N,,,50056,85549.0,Artemia salina,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",1,,,,,1,,114,F,,Intermediate,CHEMBL623636,BAO_0000218,6516
,,N,,,50532,6253.0,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,1,,,,,1,,10841,F,,Intermediate,CHEMBL623637,BAO_0000218,6517
,,N,,,50532,6253.0,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,1,,,,,1,,10841,F,,Intermediate,CHEMBL623638,BAO_0000218,6518
,,N,,,50532,6253.0,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,1,,,,,1,,10841,F,,Intermediate,CHEMBL623639,BAO_0000218,6519
,,N,,,50532,6253.0,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,1,,,,,1,,10841,F,,Intermediate,CHEMBL623640,BAO_0000218,6520
,,N,,,50532,6253.0,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,1,,,,,1,,10841,F,,Intermediate,CHEMBL623641,BAO_0000218,6521
,,N,,,50532,6253.0,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,1,,,,,1,,10841,F,,Intermediate,CHEMBL623642,BAO_0000218,6522
,,N,,,50532,6253.0,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,1,,,,,1,,10841,F,,Intermediate,CHEMBL623643,BAO_0000218,6523
,,N,,,50532,6253.0,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,1,,,,,1,,10841,F,,Intermediate,CHEMBL623644,BAO_0000218,6524
,,N,,,50532,6253.0,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,1,,,,,1,,10841,F,,Intermediate,CHEMBL623645,BAO_0000218,6525
,,N,,,50532,6253.0,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,1,,,,,1,,10841,F,,Intermediate,CHEMBL623646,BAO_0000218,6526
,,N,,,50532,6253.0,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,1,,,,,1,,10841,F,,Intermediate,CHEMBL623647,BAO_0000218,6527
,,N,,,50532,6253.0,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,1,,,,,1,,10841,F,,Intermediate,CHEMBL623648,BAO_0000218,6528
,,N,,,50366,1656.0,Actinomyces viscosus,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,1,,,,,1,,8117,F,,Intermediate,CHEMBL623649,BAO_0000218,6529
,,N,,,50366,1656.0,Actinomyces viscosus,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,1,,,,,1,,8117,F,,Intermediate,CHEMBL623650,BAO_0000218,6530
,,N,,,50366,1656.0,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus 8A06,1,,,,,1,,9560,F,,Intermediate,CHEMBL623651,BAO_0000218,6531
,,N,,,50366,1656.0,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus M-100,1,,,,,1,,9560,F,,Expert,CHEMBL623652,BAO_0000218,6532
,,N,,,50366,1656.0,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus M-626,1,,,,,1,,9560,F,,Intermediate,CHEMBL623653,BAO_0000218,6533
,,N,,,50366,1656.0,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus T14V,1,,,,,1,,9560,F,,Intermediate,CHEMBL623654,BAO_0000218,6534
,,N,,,50366,1656.0,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus 8A06,1,,,,,1,,9560,F,,Intermediate,CHEMBL623655,BAO_0000218,6535
,,N,,,50366,1656.0,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus M-100,1,,,,,1,,9560,F,,Intermediate,CHEMBL623656,BAO_0000218,6536
,,N,,,50366,1656.0,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,1,,,,,1,,9560,F,,Expert,CHEMBL623657,BAO_0000218,6537
,,N,,,50366,1656.0,Actinomyces viscosus,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",1,,,,,1,,9560,F,,Intermediate,CHEMBL623658,BAO_0000218,6538
,,N,,,50366,1656.0,Actinomyces viscosus,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",1,,,,,1,,9560,F,,Intermediate,CHEMBL623659,BAO_0000218,6539
,,N,,,50366,1656.0,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus 626,1,,,,,1,,9560,F,,Intermediate,CHEMBL623660,BAO_0000218,6540
,,N,,,50366,1656.0,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus T14V,1,,,,,1,,9560,F,,Intermediate,CHEMBL623661,BAO_0000218,6541
,,N,,,50535,6277.0,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,1,,,,,1,,10986,F,,Intermediate,CHEMBL875281,BAO_0000218,6542
,,N,,,50535,6277.0,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,1,,,,,1,,10986,F,,Intermediate,CHEMBL623662,BAO_0000218,6543
,,N,,,50535,6277.0,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,1,,,,,1,,10986,F,,Intermediate,CHEMBL623663,BAO_0000218,6544
,,N,,,50535,6277.0,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,1,,,,,1,,10986,F,,Intermediate,CHEMBL623664,BAO_0000218,6545
,,N,,,50535,6277.0,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,1,,,,,1,,10986,F,,Intermediate,CHEMBL623665,BAO_0000218,6546
,,N,165.0,,80023,9606.0,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,1,,A673,,,1,,10708,F,,Intermediate,CHEMBL621856,BAO_0000219,6547
,,N,645.0,,80661,9606.0,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,1,,A704,,,1,,10708,F,,Intermediate,CHEMBL620432,BAO_0000219,6548
,,U,,,22226,10116.0,Rattus norvegicus,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,1,,,,,0,,416,F,,Autocuration,CHEMBL620433,BAO_0000219,6549
,,N,625.0,,80024,10090.0,Mus musculus,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,1,,A9,,,1,,14354,F,,Intermediate,CHEMBL620434,BAO_0000219,6550
,,N,625.0,,80024,10090.0,Mus musculus,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,1,,A9,,,1,,14354,F,,Intermediate,CHEMBL620435,BAO_0000219,6551
,,N,625.0,,80024,9606.0,Homo sapiens,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,1,,A9,,,1,,5116,F,,Intermediate,CHEMBL620436,BAO_0000219,6552
,,N,625.0,,80024,9606.0,Homo sapiens,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,1,,A9,,,1,,5116,F,,Intermediate,CHEMBL876597,BAO_0000219,6553
,,N,874.0,,81037,9606.0,Homo sapiens,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,1,,Human ovarian carcinoma cell line,,,1,,15694,F,,Expert,CHEMBL620437,BAO_0000219,6554
,,N,625.0,,80024,10090.0,Mus musculus,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",1,,A9,,,1,,13038,F,,Expert,CHEMBL620438,BAO_0000219,6555
,,N,625.0,,80024,10090.0,Mus musculus,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,1,,A9,,,1,,13038,F,,Expert,CHEMBL620439,BAO_0000219,6556
,,N,625.0,,80024,10090.0,Mus musculus,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,1,,A9,,,1,,10923,F,,Expert,CHEMBL619657,BAO_0000219,6557
,,N,625.0,,80024,10090.0,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,1,,A9,,,1,,10923,F,,Intermediate,CHEMBL619658,BAO_0000219,6558
,,N,625.0,,80024,10090.0,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,1,,A9,,,1,,10923,F,,Intermediate,CHEMBL619659,BAO_0000219,6559
,,H,,,10649,,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",1,,,,,8,,10923,F,,Expert,CHEMBL619660,BAO_0000019,6560
,,N,625.0,,80024,10090.0,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,1,,A9,,,1,,10923,F,,Intermediate,CHEMBL619661,BAO_0000219,6561
,,N,625.0,,80024,10090.0,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,1,,A9,,,1,,10923,F,,Intermediate,CHEMBL619662,BAO_0000219,6562
,,N,975.0,,80663,10029.0,Cricetulus griseus,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,1,,AA6,,,1,,8158,F,,Intermediate,CHEMBL619663,BAO_0000219,6563
,,U,,,22226,9606.0,Homo sapiens,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,1,,,,,0,,15494,F,,Autocuration,CHEMBL619664,BAO_0000219,6564
,,U,,,22226,9606.0,Homo sapiens,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",1,,,,,0,,15494,F,,Autocuration,CHEMBL619665,BAO_0000219,6565
,,N,974.0,,80662,9606.0,Homo sapiens,Anti -HIV activity was measured against AA5/HIV-1(IIIB),1,,AA5,,,1,,12348,F,,Intermediate,CHEMBL883244,BAO_0000219,6566
,,N,974.0,,80662,9606.0,Homo sapiens,Cytotoxicity was measured against AA5/HIV-1(IIIB),1,,AA5,,,1,,12348,F,,Intermediate,CHEMBL884011,BAO_0000219,6567
,,N,974.0,,80662,9606.0,Homo sapiens,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,1,,AA5,,,1,,2726,F,,Intermediate,CHEMBL619666,BAO_0000219,6568
,,N,379.0,,80566,9606.0,Homo sapiens,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,1,,U-937,,,1,,2726,F,,Intermediate,CHEMBL619667,BAO_0000219,6569
,,N,274.0,,80578,10029.0,Cricetulus griseus,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,1,,UV4,,,1,,10747,F,,Intermediate,CHEMBL619668,BAO_0000219,6570
,,N,185.0,,80089,10029.0,Cricetulus griseus,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",1,,CHO-AA8,,,1,,11005,F,,Expert,CHEMBL619669,BAO_0000219,6571
,,N,185.0,,80089,10029.0,Cricetulus griseus,Average intracellular compound concentration when the hypoxic SER=1.6,1,,CHO-AA8,,,1,,12687,F,,Intermediate,CHEMBL876608,BAO_0000219,6572
,,N,185.0,,80089,10029.0,Cricetulus griseus,Average intracellular compound concentration when the hypoxic SER=1.6.,1,,CHO-AA8,,,1,,12687,F,,Intermediate,CHEMBL619670,BAO_0000219,6573
,,N,185.0,,80089,10029.0,Cricetulus griseus,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,1,,CHO-AA8,,,1,,12687,F,,Intermediate,CHEMBL619671,BAO_0000219,6574
,,N,185.0,,80089,10029.0,Cricetulus griseus,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,1,,CHO-AA8,,,1,,12687,F,,Intermediate,CHEMBL619672,BAO_0000219,6575
,,N,185.0,,80089,10029.0,Cricetulus griseus,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,1,,CHO-AA8,,,1,,12687,F,,Intermediate,CHEMBL619673,BAO_0000219,6576
,,N,185.0,,80089,10029.0,Cricetulus griseus,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",1,,CHO-AA8,,,1,,13436,F,,Intermediate,CHEMBL619674,BAO_0000219,6577
,,N,185.0,,80089,10029.0,Cricetulus griseus,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",1,,CHO-AA8,,,1,,13435,F,,Intermediate,CHEMBL619675,BAO_0000219,6578
,,N,185.0,,80089,10029.0,Cricetulus griseus,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,1,,CHO-AA8,,,1,,13302,F,,Intermediate,CHEMBL619676,BAO_0000219,6579
,,N,185.0,,80089,10029.0,Cricetulus griseus,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,1,,CHO-AA8,,,1,,12687,F,,Intermediate,CHEMBL619677,BAO_0000219,6580
,,N,185.0,,80089,10029.0,Cricetulus griseus,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,1,,CHO-AA8,,,1,,12687,A,,Intermediate,CHEMBL619678,BAO_0000219,6581
,,N,185.0,,80089,10029.0,Cricetulus griseus,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,1,,CHO-AA8,,,1,,12687,A,,Intermediate,CHEMBL619679,BAO_0000219,6582
,,N,185.0,,80089,10029.0,Cricetulus griseus,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,1,,CHO-AA8,,,1,,12878,A,,Expert,CHEMBL619680,BAO_0000219,6583
,,N,185.0,,80089,10029.0,Cricetulus griseus,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,1,,CHO-AA8,,,1,,12878,A,,Intermediate,CHEMBL621457,BAO_0000219,6584
,,N,185.0,,80089,10029.0,Cricetulus griseus,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,1,,CHO-AA8,,,1,,14367,F,,Expert,CHEMBL876609,BAO_0000219,6585
,,N,185.0,,80089,10029.0,Cricetulus griseus,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,1,,CHO-AA8,,,1,,14367,F,,Intermediate,CHEMBL621458,BAO_0000219,6586
,,N,185.0,,80089,36483.0,hampster,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,1,,CHO-AA8,,,1,,12398,F,,Expert,CHEMBL621459,BAO_0000219,6587
,,N,185.0,,80089,10029.0,Cricetulus griseus,Aerobic growth inhibition in Chinese hamster cell line AA8,1,,CHO-AA8,,,1,,12878,F,,Expert,CHEMBL621460,BAO_0000219,6588
,,N,185.0,,80089,10029.0,Cricetulus griseus,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,1,,CHO-AA8,,,1,,13820,F,,Expert,CHEMBL621461,BAO_0000219,6589
,,N,185.0,,80089,10029.0,Cricetulus griseus,Inhibition of growth under aerobic conditions in AA8 cells,1,,CHO-AA8,,,1,,13436,F,,Expert,CHEMBL621462,BAO_0000219,6590
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),1,,,,In vivo,1,,6084,A,,Intermediate,CHEMBL621463,BAO_0000218,6591
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog at 10 mg/kg of the compound,1,,,,In vivo,1,,5711,A,,Intermediate,CHEMBL621464,BAO_0000218,6592
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (dose 5 uM/kg),1,,,,In vivo,1,,4353,A,,Intermediate,CHEMBL621465,BAO_0000218,6593
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (dose 5 uM/kg),1,,,,In vivo,1,,4353,A,,Intermediate,CHEMBL621466,BAO_0000218,6594
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (mongrel),1,,,,In vivo,1,,17800,A,,Intermediate,CHEMBL621467,BAO_0000218,6595
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),1,,,,In vivo,1,,3994,A,,Intermediate,CHEMBL621468,BAO_0000218,6596
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),1,,,,In vivo,1,,3994,F,,Intermediate,CHEMBL876734,BAO_0000218,6597
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog,1,,,,In vivo,1,,5145,A,,Intermediate,CHEMBL618476,BAO_0000218,6598
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog (dose 1 mg/kg i.v.),1,,,,In vivo,1,,16452,A,,Intermediate,CHEMBL618477,BAO_0000218,6599
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),1,,,,In vivo,1,,16452,A,,Intermediate,CHEMBL618478,BAO_0000218,6600
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,1,,,,In vivo,1,,5983,A,,Intermediate,CHEMBL618479,BAO_0000218,6601
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog,1,,,,In vivo,1,,4273,A,,Intermediate,CHEMBL618480,BAO_0000218,6602
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog (dose 3-10 mg/kg),1,,,,In vivo,1,,12500,A,,Intermediate,CHEMBL618481,BAO_0000218,6603
,,N,,,50588,9615.0,Canis lupus familiaris,The compound was tested for bioavailability of compound in plasma of dog; Complete,1,Plasma,,,In vivo,1,,12500,A,1969.0,Intermediate,CHEMBL618482,BAO_0000218,6604
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,3639,A,,Intermediate,CHEMBL618483,BAO_0000218,6605
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,3880,A,,Intermediate,CHEMBL618484,BAO_0000218,6606
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog,1,,,,In vivo,1,,4838,A,,Intermediate,CHEMBL618485,BAO_0000218,6607
,,N,,,50588,9615.0,Canis lupus familiaris,oral bioavailability was measured in dogs,1,,,,In vivo,1,,15600,A,,Intermediate,CHEMBL618486,BAO_0000218,6608
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested for plasma protein binding in dog; Not determined,1,,,,,1,,17248,A,,Intermediate,CHEMBL618487,BAO_0000218,6609
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested for plasma protein binding of dog,1,,,,,1,,17248,A,,Intermediate,CHEMBL618488,BAO_0000218,6610
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested for plasma protein binding of dog; Not determined,1,,,,,1,,17248,A,,Intermediate,CHEMBL876735,BAO_0000218,6611
,,N,,,50588,9615.0,Canis lupus familiaris,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,1,,,,,1,,17443,A,,Intermediate,CHEMBL618489,BAO_0000218,6612
,,N,,,50588,9615.0,Canis lupus familiaris,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,1,,,,In vivo,1,,4186,A,,Intermediate,CHEMBL618490,BAO_0000218,6613
,,N,,,50588,9615.0,Canis lupus familiaris,Half life was determined,1,,,,,1,,3749,A,,Intermediate,CHEMBL618491,BAO_0000218,6614
,,N,,,50588,9615.0,Canis lupus familiaris,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,1,,,,In vivo,1,,3249,A,,Intermediate,CHEMBL618492,BAO_0000218,6615
,,N,,,50588,9615.0,Canis lupus familiaris,Half life was evaluated in dog,1,,,,,1,,3022,A,,Intermediate,CHEMBL873354,BAO_0000218,6616
,,N,,,50588,9615.0,Canis lupus familiaris,Half life was determined,1,,,,,1,,3749,A,,Intermediate,CHEMBL618493,BAO_0000218,6617
,,N,,,50588,9615.0,Canis lupus familiaris,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,,,,In vivo,1,,2517,A,,Intermediate,CHEMBL618494,BAO_0000218,6618
,,N,,,50588,9615.0,Canis lupus familiaris,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,Heart,,,In vivo,1,,2517,A,948.0,Intermediate,CHEMBL618495,BAO_0000218,6619
,,N,,,50588,9615.0,Canis lupus familiaris,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,Kidney,,,In vivo,1,,2517,A,2113.0,Intermediate,CHEMBL618496,BAO_0000218,6620
,,N,,,50588,9615.0,Canis lupus familiaris,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,Liver,,,In vivo,1,,2517,A,2107.0,Intermediate,CHEMBL618497,BAO_0000218,6621
,,N,,,50588,9615.0,Canis lupus familiaris,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,Lung,,,In vivo,1,,2517,A,2048.0,Intermediate,CHEMBL618498,BAO_0000218,6622
,,N,,,50588,9615.0,Canis lupus familiaris,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,Spleen,,,In vivo,1,,2517,A,2106.0,Intermediate,CHEMBL618499,BAO_0000218,6623
,,N,,,50588,9615.0,Canis lupus familiaris,LogP in dog,1,,,,,1,,3639,A,,Intermediate,CHEMBL876736,BAO_0000218,6624
,,N,,,50588,9615.0,Canis lupus familiaris,Partition coefficient (logP),1,,,,,1,,6227,A,,Intermediate,CHEMBL618500,BAO_0000218,6625
,,N,,,50588,9615.0,Canis lupus familiaris,Partition coefficient in dog,1,,,,,1,,6227,A,,Intermediate,CHEMBL857831,BAO_0000218,6626
,,N,,,50588,9615.0,Canis lupus familiaris,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,1,,,,In vivo,1,,17764,A,,Intermediate,CHEMBL618501,BAO_0000218,6627
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),1,,,,In vivo,1,,4809,A,,Intermediate,CHEMBL618502,BAO_0000218,6628
,,N,,,50588,9615.0,Canis lupus familiaris,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,1,,,,,1,,5600,A,,Intermediate,CHEMBL618503,BAO_0000218,6629
,,N,,,50588,9615.0,Canis lupus familiaris,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),1,,,,,1,,14294,A,,Intermediate,CHEMBL618504,BAO_0000218,6630
,,N,,,50588,9615.0,Canis lupus familiaris,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),1,,,,,1,,14294,A,,Intermediate,CHEMBL618505,BAO_0000218,6631
,,N,,,50588,9615.0,Canis lupus familiaris,Metabolism of compound in dog S9 microsomes; Trace,1,,,,,1,,14294,A,,Intermediate,CHEMBL618506,BAO_0000218,6632
,,N,,,50588,9615.0,Canis lupus familiaris,In vitro metabolic potential in dog liver microsomes,1,Liver,,,,1,,6251,A,2107.0,Intermediate,CHEMBL618507,BAO_0000218,6633
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,1,,,,In vivo,1,,3748,A,,Intermediate,CHEMBL876737,BAO_0000218,6634
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,2713,A,,Intermediate,CHEMBL618508,BAO_0000218,6635
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,6512,A,,Intermediate,CHEMBL618509,BAO_0000218,6636
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,,,In vivo,1,,6679,A,,Intermediate,CHEMBL618510,BAO_0000218,6637
,,N,,,50588,9615.0,Canis lupus familiaris,The compound was tested for bioavailability in dogs,1,,,,In vivo,1,,3749,A,,Intermediate,CHEMBL618511,BAO_0000218,6638
,,N,,,50588,9615.0,Canis lupus familiaris,The compound was tested for oral bioavailability in dogs,1,,,,In vivo,1,,3749,A,,Intermediate,CHEMBL618512,BAO_0000218,6639
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,1,,6742,A,,Intermediate,CHEMBL618513,BAO_0000218,6640
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested for percent protein binding (PB) in dog,1,,,,,1,,6227,A,,Intermediate,CHEMBL618514,BAO_0000218,6641
,,N,,,50588,9615.0,Canis lupus familiaris,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,1,,,,,1,,6874,A,,Intermediate,CHEMBL620052,BAO_0000218,6642
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for plasma clearance.,1,Plasma,,,In vivo,1,,2877,A,1969.0,Intermediate,CHEMBL620053,BAO_0000218,6643
,,N,,,50588,9615.0,Canis lupus familiaris,The compound was tested for plasma clearance in dog,1,Plasma,,,In vivo,1,,12500,A,1969.0,Intermediate,CHEMBL620054,BAO_0000218,6644
,,N,,,50588,9615.0,Canis lupus familiaris,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,1,Plasma,,,In vivo,1,,12500,A,1969.0,Intermediate,CHEMBL620055,BAO_0000218,6645
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,1,,,,,1,,4709,A,,Intermediate,CHEMBL620056,BAO_0000218,6646
,,N,,,50588,9615.0,Canis lupus familiaris,In vitro relative rate of metabolism was determined in dog liver microsomes,1,Liver,,,,1,,5542,A,2107.0,Intermediate,CHEMBL620057,BAO_0000218,6647
,,N,,,50588,9615.0,Canis lupus familiaris,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,1,,,,In vivo,1,,17594,A,,Intermediate,CHEMBL618939,BAO_0000218,6648
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,1,,,,In vivo,1,,2652,A,,Intermediate,CHEMBL618940,BAO_0000218,6649
,,N,,,50588,9615.0,Canis lupus familiaris,Half life after intravenous administration in dogs at 1.2 uM/kg,1,,,,In vivo,1,,17764,A,,Intermediate,CHEMBL618941,BAO_0000218,6650
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,1,Lung,CCRF S-180,,,1,,6599,A,2048.0,Intermediate,CHEMBL624473,BAO_0000218,6651
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,1,Lung,CCRF S-180,,,1,,6599,A,2048.0,Intermediate,CHEMBL624474,BAO_0000218,6652
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,1,Lung,CCRF S-180,,,1,,6599,A,2048.0,Intermediate,CHEMBL624475,BAO_0000218,6653
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL624476,BAO_0000218,6654
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL623478,BAO_0000218,6655
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL623479,BAO_0000218,6656
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL623480,BAO_0000218,6657
,,N,42.0,,50594,10090.0,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,1,,CCRF S-180,,,1,,6599,A,,Intermediate,CHEMBL623481,BAO_0000218,6658
,,N,,,50594,10090.0,Mus musculus,C2 in brain of mice at the oral dose of 50 mg/kg,1,Brain,,,,1,,17641,A,955.0,Intermediate,CHEMBL623482,BAO_0000218,6659
,,N,,,50594,10090.0,Mus musculus,C2 in kidney of mice at the oral dose of 50 mg/kg,1,Kidney,,,,1,,17641,A,2113.0,Intermediate,CHEMBL623483,BAO_0000218,6660
,,N,,,50594,10090.0,Mus musculus,C2 in liver of mice at the oral dose of 50 mg/kg,1,Liver,,,,1,,17641,A,2107.0,Intermediate,CHEMBL623484,BAO_0000218,6661
,,N,,,50594,10090.0,Mus musculus,C2 in lungs of mice at the oral dose of 50 mg/kg,1,Lung,,,,1,,17641,A,2048.0,Intermediate,CHEMBL623485,BAO_0000218,6662
,,N,,,50594,10090.0,Mus musculus,C2 in spleen of mice at the oral dose of 50 mg/kg,1,Spleen,,,,1,,17641,A,2106.0,Intermediate,CHEMBL623486,BAO_0000218,6663
,,N,,,50594,10090.0,Mus musculus,Plasma clearance in mouse,1,,,,In vivo,1,,17852,A,,Intermediate,CHEMBL623487,BAO_0000218,6664
,,N,,,50594,10090.0,Mus musculus,Clearance of compound after intravenous administration in mice at 24 uM/kg,1,,,,In vivo,1,,17764,A,,Intermediate,CHEMBL623488,BAO_0000218,6665
,,N,,,50594,10090.0,Mus musculus,Clearance from mouse blood following i.v. administration of 10 mg/kg,1,,,,In vivo,1,,17837,A,,Intermediate,CHEMBL623489,BAO_0000218,6666
,,N,,,50594,10090.0,Mus musculus,Clearance was evaluated in mice after intravenous administration,1,,,,In vivo,1,,2675,A,,Intermediate,CHEMBL875157,BAO_0000218,6667
,,N,,,50594,10090.0,Mus musculus,Clearance was evaluated in mice after oral administration,1,,,,In vivo,1,,2675,A,,Intermediate,CHEMBL623490,BAO_0000218,6668
,,N,,,50594,10090.0,Mus musculus,Pharmacokinetic property (Plasma clearance) was measured in mouse,1,,,,In vivo,1,,4239,A,,Intermediate,CHEMBL623491,BAO_0000218,6669
,,N,,,50594,10090.0,Mus musculus,Plasma clearance of compound was determined at 40 mg/Kg,1,,,,In vivo,1,,17753,A,,Intermediate,CHEMBL623492,BAO_0000218,6670
,,N,,,50594,10090.0,Mus musculus,Plasma clearance of at 24 mg/Kg,1,,,,In vivo,1,,17753,A,,Intermediate,CHEMBL623493,BAO_0000218,6671
,,N,,,50594,10090.0,Mus musculus,Plasma clearance at 24 mg/Kg,1,,,,In vivo,1,,17753,A,,Intermediate,CHEMBL623494,BAO_0000218,6672
,,N,,,50594,10090.0,Mus musculus,Plasma clearance at 5 mg/Kg,1,,,,In vivo,1,,17753,A,,Intermediate,CHEMBL623495,BAO_0000218,6673
,,N,,,50594,10090.0,Mus musculus,Plasma clearance in mice,1,,,,In vivo,1,,5727,A,,Intermediate,CHEMBL623496,BAO_0000218,6674
,,N,,,50594,10090.0,Mus musculus,Plasma clearance value upon iv administration in mouse,1,,,,In vivo,1,,2862,A,,Intermediate,CHEMBL623497,BAO_0000218,6675
,,N,,,50594,10090.0,Mus musculus,Total plasma clearance in mice,1,Plasma,,,In vivo,1,,5980,A,1969.0,Intermediate,CHEMBL623498,BAO_0000218,6676
,,N,,,50594,10090.0,Mus musculus,Clearance in mouse,1,,,,In vivo,1,,17592,A,,Intermediate,CHEMBL623499,BAO_0000218,6677
,,N,,,50594,10090.0,Mus musculus,Clearance value was determined,1,,,,In vivo,1,,17718,A,,Intermediate,CHEMBL623500,BAO_0000218,6678
,,N,,,50594,10090.0,Mus musculus,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,1,,,,In vivo,1,,16597,A,,Intermediate,CHEMBL623501,BAO_0000218,6679
,,U,,,22229,,,Calculated partition coefficient (clogP),1,,,,,0,,17384,P,,Intermediate,CHEMBL875158,BAO_0000100,6680
,,N,,,50594,10090.0,Mus musculus,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,1,,,,In vivo,1,,6062,A,,Intermediate,CHEMBL623502,BAO_0000218,6681
,,N,,,50594,10090.0,Mus musculus,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,1,,,,In vivo,1,,17734,A,,Intermediate,CHEMBL623503,BAO_0000218,6682
,,N,,,50594,10090.0,Mus musculus,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,,,,In vivo,1,,6348,A,,Intermediate,CHEMBL623504,BAO_0000218,6683
,,N,,,50594,10090.0,Mus musculus,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,1,,,,In vivo,1,,5969,A,,Intermediate,CHEMBL623505,BAO_0000218,6684
,,N,,,50594,10090.0,Mus musculus,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,1,,,,In vivo,1,,5969,A,,Intermediate,CHEMBL623506,BAO_0000218,6685
,,N,,,50594,10090.0,Mus musculus,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,1,,,,In vivo,1,,5969,A,,Intermediate,CHEMBL623507,BAO_0000218,6686
,,N,,,50594,10090.0,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,1,,,,In vivo,1,,16597,A,,Intermediate,CHEMBL623508,BAO_0000218,6687
,,N,,,50594,10090.0,Mus musculus,Cmax after oral administration at 30 mg/kg in ICR mouse,1,,,,In vivo,1,,5781,A,,Intermediate,CHEMBL623509,BAO_0000218,6688
,,N,,,50594,10090.0,Mus musculus,Cmax after peroral administration in mice at 2.4 uM/kg,1,,,,In vivo,1,,17764,A,,Intermediate,CHEMBL875159,BAO_0000218,6689
,,N,,,50594,10090.0,Mus musculus,Cmax in brain of mice at the oral dose of 50 mg/kg,1,Brain,,,In vivo,1,,17641,A,955.0,Intermediate,CHEMBL623510,BAO_0000218,6690
,,N,,,50594,10090.0,Mus musculus,Cmax in kidney of mice at the oral dose of 50 mg/kg,1,Kidney,,,In vivo,1,,17641,A,2113.0,Intermediate,CHEMBL623511,BAO_0000218,6691
,,N,,,50594,10090.0,Mus musculus,Cmax in liver of mice at the oral dose of 50 mg/kg,1,Liver,,,In vivo,1,,17641,A,2107.0,Intermediate,CHEMBL623512,BAO_0000218,6692
,,N,,,50594,10090.0,Mus musculus,Cmax in lungs of mice at the oral dose of 50 mg/kg,1,Lung,,,In vivo,1,,17641,A,2048.0,Intermediate,CHEMBL623513,BAO_0000218,6693
,,N,,,50594,10090.0,Mus musculus,Cmax in mice at 18 uM/kg i.p. administration,1,,,,In vivo,1,,17764,F,,Intermediate,CHEMBL623514,BAO_0000218,6694
,,N,,,50594,10090.0,Mus musculus,Cmax in mice at 23 uM/kg i.v. administration,1,,,,In vivo,1,,17764,F,,Intermediate,CHEMBL622609,BAO_0000218,6695
,,N,,,50594,10090.0,Mus musculus,Cmax in mice at 24 uM/kg i.p. administration,1,,,,In vivo,1,,17764,F,,Intermediate,CHEMBL622610,BAO_0000218,6696
,,N,,,50594,10090.0,Mus musculus,Cmax in mice at 25 uM/kg i.p. administration,1,,,,In vivo,1,,17764,F,,Intermediate,CHEMBL621823,BAO_0000218,6697
,,N,,,50594,10090.0,Mus musculus,Cmax in mice at 26 uM/kg i.p. administration,1,,,,In vivo,1,,17764,F,,Intermediate,CHEMBL621824,BAO_0000218,6698
,,N,,,50594,10090.0,Mus musculus,Cmax in spleen of mice at the oral dose of 50 mg/kg,1,Spleen,,,In vivo,1,,17641,A,2106.0,Intermediate,CHEMBL621825,BAO_0000218,6699
,,N,,,50594,10090.0,Mus musculus,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,1,,,,In vivo,1,,16597,A,,Intermediate,CHEMBL621826,BAO_0000218,6700
,,N,,,50594,10090.0,Mus musculus,Cmax value at a dose of 10 mg/kg peroral administration in mice.,1,,,,In vivo,1,,16597,A,,Intermediate,CHEMBL621827,BAO_0000218,6701
,,N,,,50594,10090.0,Mus musculus,Cmax value was determined,1,,,,In vivo,1,,5727,A,,Intermediate,CHEMBL621828,BAO_0000218,6702
,,N,,,50594,10090.0,Mus musculus,Cmax value in IRC mice,1,,,,In vivo,1,,5951,A,,Intermediate,CHEMBL621829,BAO_0000218,6703
,,N,,,50594,10090.0,Mus musculus,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,1,,,,In vivo,1,,5506,A,,Intermediate,CHEMBL621830,BAO_0000218,6704
,,N,,,50594,10090.0,Mus musculus,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,1,,,,In vivo,1,,5506,A,,Intermediate,CHEMBL621831,BAO_0000218,6705
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,1,Plasma,,,In vivo,1,,14239,A,1969.0,Intermediate,CHEMBL621832,BAO_0000218,6706
,,N,,,50594,10090.0,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",1,Plasma,,,In vivo,1,,4890,A,1969.0,Intermediate,CHEMBL624579,BAO_0000218,6707
,,N,,,50594,10090.0,Mus musculus,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,1,,,,In vivo,1,,429,A,,Intermediate,CHEMBL624580,BAO_0000218,6708
,,N,,,50535,6277.0,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,1,,,,,1,,10986,F,,Intermediate,CHEMBL624581,BAO_0000218,6709
,,N,,,50535,6277.0,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,1,,,,,1,,10986,F,,Intermediate,CHEMBL624582,BAO_0000218,6710
,,N,,,50535,6277.0,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,1,,,,,1,,10986,F,,Intermediate,CHEMBL624583,BAO_0000218,6711
,,N,455.0,,80018,9606.0,Homo sapiens,Inhibitory activity against human tumor cell line A0375 melanoma.,1,,A-375,,,1,,13227,F,,Intermediate,CHEMBL624584,BAO_0000219,6712
,Brain membranes,D,,,12512,10116.0,Rattus norvegicus,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,1,,,,,9,,4481,B,,Expert,CHEMBL624585,BAO_0000249,6713
,,D,,,114,9606.0,Homo sapiens,Forskolin-induced cAMP production at human A1 adenosine receptor,1,,,,,9,,16931,F,,Expert,CHEMBL875165,BAO_0000019,6714
,,H,449.0,,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,1,,CHO,,,8,,3850,F,,Autocuration,CHEMBL619490,BAO_0000219,6715
,,H,449.0,,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,1,,CHO,,,8,,3850,F,,Autocuration,CHEMBL619491,BAO_0000219,6716
,,H,449.0,,114,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,1,,CHO,,,8,,3850,F,,Expert,CHEMBL619492,BAO_0000219,6717
,,H,449.0,,114,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,1,,CHO,,,8,,3850,F,,Expert,CHEMBL619493,BAO_0000219,6718
,,H,449.0,,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,1,,CHO,,,8,,3850,F,,Autocuration,CHEMBL619494,BAO_0000219,6719
,,H,449.0,,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,1,,CHO,,,8,,3850,F,,Autocuration,CHEMBL619495,BAO_0000219,6720
,,H,449.0,,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,1,,CHO,,,8,,3850,F,,Autocuration,CHEMBL619496,BAO_0000219,6721
,,D,449.0,,114,9606.0,Homo sapiens,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,1,,CHO,,,9,,3850,F,,Expert,CHEMBL619497,BAO_0000219,6722
,,H,449.0,,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,1,,CHO,,,8,,3850,F,,Autocuration,CHEMBL619498,BAO_0000219,6723
,,H,449.0,,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,1,,CHO,,,8,,3850,F,,Autocuration,CHEMBL619499,BAO_0000219,6724
,,H,449.0,,114,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,1,,CHO,,,8,,3850,F,,Expert,CHEMBL619500,BAO_0000219,6725
,,H,449.0,,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,1,,CHO,,,8,,3850,F,,Autocuration,CHEMBL619501,BAO_0000219,6726
,,H,449.0,,114,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,1,,CHO,,,8,,3850,F,,Expert,CHEMBL619502,BAO_0000219,6727
,,H,449.0,,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,1,,CHO,,,8,,3850,F,,Autocuration,CHEMBL619503,BAO_0000219,6728
,,H,449.0,,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,1,,CHO,,,8,,3850,F,,Autocuration,CHEMBL619504,BAO_0000219,6729
,,H,449.0,,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,1,,CHO,,,8,,3850,F,,Autocuration,CHEMBL621298,BAO_0000219,6730
,,H,449.0,,114,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,1,,CHO,,,8,,3850,F,,Expert,CHEMBL621299,BAO_0000219,6731
,,H,449.0,,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,1,,CHO,,,8,,3850,F,,Autocuration,CHEMBL621300,BAO_0000219,6732
,,H,449.0,,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,1,,CHO,,,8,,3850,F,,Autocuration,CHEMBL621301,BAO_0000219,6733
,,H,449.0,,114,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,1,,CHO,,,8,,3850,F,,Expert,CHEMBL621302,BAO_0000219,6734
,,N,164.0,,80013,9986.0,Oryctolagus cuniculus,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,1,,A10,,,1,,12680,F,,Intermediate,CHEMBL621303,BAO_0000219,6735
,,U,164.0,,22226,10116.0,Rattus norvegicus,In vitro potassium channel opening activity in A10 (smooth muscle) cells,1,,A10,,,0,,1313,F,,Autocuration,CHEMBL621304,BAO_0000219,6736
,,U,164.0,,22226,10116.0,Rattus norvegicus,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,1,,A10,,,0,,1313,F,,Autocuration,CHEMBL621305,BAO_0000219,6737
,,N,164.0,,80013,10116.0,Rattus norvegicus,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,1,,A10,,,1,,17567,F,,Intermediate,CHEMBL621306,BAO_0000219,6738
,,N,164.0,,80013,10116.0,Rattus norvegicus,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,1,,A10,,,1,,17567,F,,Intermediate,CHEMBL618444,BAO_0000219,6739
,,N,164.0,,80013,10116.0,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,1,,A10,,,1,,11819,F,,Intermediate,CHEMBL618445,BAO_0000219,6740
,,N,185.0,,80089,10029.0,Cricetulus griseus,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,1,,CHO-AA8,,,1,,13436,F,,Intermediate,CHEMBL618446,BAO_0000219,6741
,,N,185.0,,80089,10029.0,Cricetulus griseus,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,1,,CHO-AA8,,,1,,12687,F,,Intermediate,CHEMBL618447,BAO_0000219,6742
,,N,185.0,,80089,10029.0,Cricetulus griseus,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,1,,CHO-AA8,,,1,,12651,F,,Intermediate,CHEMBL618448,BAO_0000219,6743
,,N,185.0,,80089,10029.0,Cricetulus griseus,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,1,,CHO-AA8,,,1,,13300,F,,Intermediate,CHEMBL618449,BAO_0000219,6744
,,N,185.0,,80089,10029.0,Cricetulus griseus,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,1,,CHO-AA8,,,1,,15296,F,,Intermediate,CHEMBL618637,BAO_0000219,6745
,,N,185.0,,80089,10029.0,Cricetulus griseus,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",1,,CHO-AA8,,,1,,15328,F,,Intermediate,CHEMBL618638,BAO_0000219,6746
,,N,185.0,,80089,10029.0,Cricetulus griseus,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),1,,CHO-AA8,,,1,,13302,F,,Intermediate,CHEMBL618639,BAO_0000219,6747
,,N,185.0,,80089,10029.0,Cricetulus griseus,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",1,,CHO-AA8,,,1,,14367,F,,Expert,CHEMBL618640,BAO_0000219,6748
,,N,185.0,,80089,10029.0,Cricetulus griseus,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,1,,CHO-AA8,,,1,,17002,F,,Expert,CHEMBL618641,BAO_0000219,6749
,,N,185.0,,80089,10029.0,Cricetulus griseus,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,1,,CHO-AA8,,,1,,13436,F,,Intermediate,CHEMBL618642,BAO_0000219,6750
,,N,185.0,,80089,10029.0,Cricetulus griseus,Inhibitory activity against aerobic growth of AA8 cells.,1,,CHO-AA8,,,1,,13435,F,,Intermediate,CHEMBL618643,BAO_0000219,6751
,,N,185.0,,80089,10029.0,Cricetulus griseus,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,1,,CHO-AA8,,,1,,10503,A,,Intermediate,CHEMBL884013,BAO_0000219,6752
,,N,185.0,,80089,10029.0,Cricetulus griseus,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,1,,CHO-AA8,,,1,,10503,F,,Expert,CHEMBL622723,BAO_0000219,6753
,,N,185.0,,80089,10029.0,Cricetulus griseus,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,1,,CHO-AA8,,,1,,10503,F,,Intermediate,CHEMBL622724,BAO_0000219,6754
,,N,185.0,,80089,10029.0,Cricetulus griseus,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,1,,CHO-AA8,,,1,,15090,F,,Expert,CHEMBL622725,BAO_0000219,6755
,,N,185.0,,80089,10029.0,Cricetulus griseus,Cytotoxicity against AA8 cell line,1,,CHO-AA8,,,1,,10368,F,,Expert,CHEMBL622726,BAO_0000219,6756
,,N,185.0,,80089,10029.0,Cricetulus griseus,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),1,,CHO-AA8,,,1,,12651,F,,Intermediate,CHEMBL622727,BAO_0000219,6757
,,N,185.0,,80089,10029.0,Cricetulus griseus,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),1,,CHO-AA8,,,1,,12687,A,,Intermediate,CHEMBL622728,BAO_0000219,6758
,,N,185.0,,80089,10029.0,Cricetulus griseus,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),1,,CHO-AA8,,,1,,12687,F,,Intermediate,CHEMBL622729,BAO_0000219,6759
,,N,185.0,,80089,10029.0,Cricetulus griseus,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),1,,CHO-AA8,,,1,,12687,A,,Intermediate,CHEMBL622730,BAO_0000219,6760
,,N,185.0,,80089,10029.0,Cricetulus griseus,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,1,,CHO-AA8,,,1,,1890,F,,Intermediate,CHEMBL622731,BAO_0000219,6761
,,N,185.0,,80089,10029.0,Cricetulus griseus,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,1,,CHO-AA8,,,1,,10747,F,,Intermediate,CHEMBL622732,BAO_0000219,6762
,,N,185.0,,80089,10029.0,Cricetulus griseus,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,1,,CHO-AA8,,,1,,10747,F,,Intermediate,CHEMBL622733,BAO_0000219,6763
,,U,,,22224,10029.0,Cricetulus griseus,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),1,,,,,0,,11616,F,,Autocuration,CHEMBL622734,BAO_0000218,6764
,,N,185.0,,80089,10029.0,Cricetulus griseus,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,1,,CHO-AA8,,,1,,11616,F,,Expert,CHEMBL622735,BAO_0000219,6765
,,U,185.0,,22224,10029.0,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,1,,CHO-AA8,,,0,,3471,F,,Autocuration,CHEMBL618746,BAO_0000219,6766
,,U,185.0,,22224,10029.0,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,1,,CHO-AA8,,,0,,3471,F,,Autocuration,CHEMBL618747,BAO_0000219,6767
,,U,185.0,,22224,10029.0,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,1,,CHO-AA8,,,0,,3471,F,,Autocuration,CHEMBL620540,BAO_0000219,6768
,,U,185.0,,22224,10029.0,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,1,,CHO-AA8,,,0,,3471,F,,Autocuration,CHEMBL620541,BAO_0000219,6769
,,U,185.0,,22224,10029.0,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,1,,CHO-AA8,,,0,,3471,F,,Autocuration,CHEMBL620542,BAO_0000219,6770
,,U,185.0,,22224,10029.0,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,1,,CHO-AA8,,,0,,3471,F,,Autocuration,CHEMBL620543,BAO_0000219,6771
,,U,185.0,,22224,10029.0,Cricetulus griseus,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,1,,CHO-AA8,,,0,,3471,F,,Autocuration,CHEMBL618832,BAO_0000219,6772
,,N,185.0,,80089,10029.0,Cricetulus griseus,Concentration required to reduce AA8 cell survival by 10%,1,,CHO-AA8,,,1,,11616,F,,Expert,CHEMBL618833,BAO_0000219,6773
,,U,185.0,,22224,10029.0,Cricetulus griseus,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",1,,CHO-AA8,,,0,,2656,F,,Autocuration,CHEMBL618834,BAO_0000219,6774
,,U,185.0,,22224,10029.0,Cricetulus griseus,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,1,,CHO-AA8,,,0,,10518,F,,Autocuration,CHEMBL618835,BAO_0000219,6775
,,U,185.0,,22224,10029.0,Cricetulus griseus,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,1,,CHO-AA8,,,0,,10518,F,,Autocuration,CHEMBL618836,BAO_0000219,6776
,,U,185.0,,22224,10029.0,Cricetulus griseus,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,1,,CHO-AA8,,,0,,10518,F,,Autocuration,CHEMBL618837,BAO_0000219,6777
,,U,185.0,,22224,10029.0,Cricetulus griseus,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,1,,CHO-AA8,,,0,,10518,F,,Autocuration,CHEMBL618838,BAO_0000219,6778
,,U,185.0,,22224,10029.0,Cricetulus griseus,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,1,,CHO-AA8,,,0,,16156,F,,Autocuration,CHEMBL618839,BAO_0000219,6779
,,U,185.0,,22224,10029.0,Cricetulus griseus,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,1,,CHO-AA8,,,0,,2656,F,,Autocuration,CHEMBL618840,BAO_0000219,6780
,,U,,,22224,10029.0,Cricetulus griseus,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",1,,,,,0,,11005,F,,Autocuration,CHEMBL618841,BAO_0000019,6781
,,U,185.0,,22224,10029.0,Cricetulus griseus,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,1,,CHO-AA8,,,0,,11942,F,,Autocuration,CHEMBL618842,BAO_0000219,6782
,,U,185.0,,22224,10029.0,Cricetulus griseus,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,1,,CHO-AA8,,,0,,2128,F,,Autocuration,CHEMBL618843,BAO_0000219,6783
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period after 15 mg/kg iv dose in Dogs,1,,,,In vivo,1,,16907,A,,Intermediate,CHEMBL618844,BAO_0000218,6784
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period after 30 mg/kg po dose in Dogs,1,,,,In vivo,1,,16907,A,,Intermediate,CHEMBL618845,BAO_0000218,6785
,,N,,,50588,9615.0,Canis lupus familiaris,Half life was measured after oral 2b administration (tested in 6 dogs),1,,,,In vivo,1,,9579,A,,Intermediate,CHEMBL618846,BAO_0000218,6786
,,N,,,50588,9615.0,Canis lupus familiaris,Half life was measured in dog after oral 17b administration,1,,,,In vivo,1,,9579,A,,Intermediate,CHEMBL618847,BAO_0000218,6787
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,1,,,,In vivo,1,,9579,A,,Intermediate,CHEMBL618848,BAO_0000218,6788
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,1,,,,In vivo,1,,9579,A,,Intermediate,CHEMBL618849,BAO_0000218,6789
,,N,,,50588,9615.0,Canis lupus familiaris,Tmax value after 15 mg/kg iv dose in Dogs,1,,,,In vivo,1,,16907,A,,Intermediate,CHEMBL618850,BAO_0000218,6790
,,N,,,50588,9615.0,Canis lupus familiaris,Tmax value after 30 mg/kg po dose in Dogs,1,,,,In vivo,1,,16907,A,,Intermediate,CHEMBL618851,BAO_0000218,6791
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for its half life when administered intravenously in dog,1,,,,In vivo,1,,3184,A,,Intermediate,CHEMBL873815,BAO_0000218,6792
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),1,Plasma,,,In vivo,1,,5017,A,1969.0,Intermediate,CHEMBL618852,BAO_0000218,6793
,,N,,,50588,9615.0,Canis lupus familiaris,Elimination Half-life of compound was determined in dog,1,,,,,1,,6821,A,,Intermediate,CHEMBL618853,BAO_0000218,6794
,,N,,,50588,9615.0,Canis lupus familiaris,Half life of compound in dog following oral administration,1,,,,In vivo,1,,17839,A,,Intermediate,CHEMBL618854,BAO_0000218,6795
,,N,,,50588,9615.0,Canis lupus familiaris,Half life of compound was determined in dog,1,,,,,1,,17267,A,,Intermediate,CHEMBL618855,BAO_0000218,6796
,,N,,,50588,9615.0,Canis lupus familiaris,Half life of compound was determined in dog blood,1,Blood,,,,1,,4727,A,178.0,Intermediate,CHEMBL618856,BAO_0000218,6797
,,N,,,50588,9615.0,Canis lupus familiaris,Half life after oral and iv dosing in dogs,1,,,,In vivo,1,,5238,A,,Intermediate,CHEMBL875827,BAO_0000218,6798
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in dogs in hours,1,,,,,1,,4942,A,,Intermediate,CHEMBL618857,BAO_0000218,6799
,,N,,,50588,9615.0,Canis lupus familiaris,Half life on i.v. administration of 2 mg/kg was measured in dog,1,,,,In vivo,1,,6505,A,,Intermediate,CHEMBL618858,BAO_0000218,6800
,,N,,,50588,9615.0,Canis lupus familiaris,t1/2 in dog after oral dose (1 mg/kg),1,,,,In vivo,1,,5130,A,,Intermediate,CHEMBL618859,BAO_0000218,6801
,,N,,,50588,9615.0,Canis lupus familiaris,Half life was evaluated in dog,1,,,,,1,,1475,A,,Intermediate,CHEMBL618860,BAO_0000218,6802
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period of compound was determined after intravenous administration at 2 mg/kg,1,,,,In vivo,1,,17804,A,,Intermediate,CHEMBL618861,BAO_0000218,6803
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period of compound was determined after peroral administration at 2 mg/kg,1,,,,In vivo,1,,17804,A,,Intermediate,CHEMBL622539,BAO_0000218,6804
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period (10 mg/kg) was determined in dog,1,,,,In vivo,1,,6084,A,,Intermediate,CHEMBL622540,BAO_0000218,6805
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period (10 mg/kg) was determined in dog,1,,,,In vivo,1,,6084,A,,Intermediate,CHEMBL873803,BAO_0000218,6806
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period by iv administration in dog at a dose of 0.3 mg/kg,1,,,,In vivo,1,,5542,A,,Intermediate,CHEMBL873804,BAO_0000218,6807
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period by po administration in dog at a dose of 0.3 mg/kg,1,,,,In vivo,1,,5542,A,,Intermediate,CHEMBL624311,BAO_0000218,6808
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period in dog,1,,,,,1,,6084,A,,Intermediate,CHEMBL624312,BAO_0000218,6809
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period in dogs after oral administration at 1 mg/kg,1,,,,In vivo,1,,6241,A,,Intermediate,CHEMBL624313,BAO_0000218,6810
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,,,,In vivo,1,,1916,A,,Intermediate,CHEMBL624314,BAO_0000218,6811
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life of compound was determined in dogs,1,,,,,1,,6621,A,,Intermediate,CHEMBL624315,BAO_0000218,6812
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life in dog plasma,1,Plasma,,,,1,,1696,A,1969.0,Intermediate,CHEMBL624316,BAO_0000218,6813
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life in mongrel dogs was determined,1,,,,,1,,17800,A,,Intermediate,CHEMBL624317,BAO_0000218,6814
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life in dog upon oral administration,1,,,,In vivo,1,,17657,A,,Intermediate,CHEMBL624318,BAO_0000218,6815
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life in dog upon oral administration; Unable to calculate,1,,,,In vivo,1,,17657,A,,Intermediate,CHEMBL624319,BAO_0000218,6816
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life was measured in dog,1,,,,,1,,4239,A,,Intermediate,CHEMBL624496,BAO_0000218,6817
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life was measured in dog,1,,,,,1,,5985,A,,Intermediate,CHEMBL624497,BAO_0000218,6818
,,N,,,50588,9615.0,Canis lupus familiaris,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,1,,,,,1,,9932,A,,Intermediate,CHEMBL624498,BAO_0000218,6819
,,N,,,50588,9615.0,Canis lupus familiaris,Oral half life was determined,1,,,,In vivo,1,,5199,A,,Intermediate,CHEMBL624499,BAO_0000218,6820
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,1,Plasma,,,In vivo,1,,5199,A,1969.0,Intermediate,CHEMBL624500,BAO_0000218,6821
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma half life was evaluated,1,Plasma,,,,1,,1475,A,1969.0,Intermediate,CHEMBL624501,BAO_0000218,6822
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma half life was evaluated in Dog,1,Plasma,,,,1,,1475,A,1969.0,Intermediate,CHEMBL623666,BAO_0000218,6823
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma half life was evaluated in dog,1,Plasma,,,,1,,1475,A,1969.0,Intermediate,CHEMBL623667,BAO_0000218,6824
,,N,,,50588,9615.0,Canis lupus familiaris,T1/2 (Half-life) was after oral administration at 5 mg/kg,1,,,,In vivo,1,,6316,A,,Intermediate,CHEMBL623668,BAO_0000218,6825
,,N,,,50588,9615.0,Canis lupus familiaris,Tested for the half life value in dog,1,,,,,1,,4883,A,,Intermediate,CHEMBL623669,BAO_0000218,6826
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum time at the dose of 2 mg/kg in dog,1,,,,In vivo,1,,4727,A,,Intermediate,CHEMBL623670,BAO_0000218,6827
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,,,,In vivo,1,,1916,A,,Intermediate,CHEMBL623671,BAO_0000218,6828
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1,Blood,,,In vivo,1,,1337,A,178.0,Intermediate,CHEMBL875945,BAO_0000218,6829
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1,Blood,,,In vivo,1,,1337,A,178.0,Intermediate,CHEMBL623672,BAO_0000218,6830
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,1,,,,In vivo,1,,6265,A,,Intermediate,CHEMBL623673,BAO_0000218,6831
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),1,,,,In vivo,1,,4809,A,,Intermediate,CHEMBL623674,BAO_0000218,6832
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,1,,,,In vivo,1,,5983,A,,Intermediate,CHEMBL623675,BAO_0000218,6833
,,N,,,50588,9615.0,Canis lupus familiaris,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",1,,,,,1,,5313,A,,Intermediate,CHEMBL872526,BAO_0000218,6834
,,N,,,50588,9615.0,Canis lupus familiaris,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",1,,,,In vivo,1,,5313,A,,Intermediate,CHEMBL623676,BAO_0000218,6835
,,N,,,50588,9615.0,Canis lupus familiaris,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,1,Plasma,,,In vivo,1,,17650,A,1969.0,Intermediate,CHEMBL623677,BAO_0000218,6836
,,N,,,50588,9615.0,Canis lupus familiaris,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,1,Plasma,,,In vivo,1,,5199,A,1969.0,Intermediate,CHEMBL623678,BAO_0000218,6837
,,N,,,50588,9615.0,Canis lupus familiaris,Time taken for maximum plasma concentration in dog,1,Plasma,,,,1,,933,A,1969.0,Intermediate,CHEMBL623679,BAO_0000218,6838
,,N,,,50588,9615.0,Canis lupus familiaris,Time to reach Cmax after oral administration to dogs,1,,,,In vivo,1,,16367,A,,Intermediate,CHEMBL623680,BAO_0000218,6839
,,N,,,50588,9615.0,Canis lupus familiaris,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,Plasma,,,In vivo,1,,6348,A,1969.0,Intermediate,CHEMBL623681,BAO_0000218,6840
,,N,,,50588,9615.0,Canis lupus familiaris,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,1,,,,In vivo,1,,6316,A,,Intermediate,CHEMBL623682,BAO_0000218,6841
,,N,,,50588,9615.0,Canis lupus familiaris,Tmax after peroral administration (1 mg/kg) was determined in dog,1,,,,In vivo,1,,6215,A,,Intermediate,CHEMBL623683,BAO_0000218,6842
,,N,,,50588,9615.0,Canis lupus familiaris,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,1,,,,In vivo,1,,3598,A,,Expert,CHEMBL623684,BAO_0000218,6843
,,N,,,50588,9615.0,Canis lupus familiaris,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,1,,,,In vivo,1,,4527,A,,Intermediate,CHEMBL622745,BAO_0000218,6844
,,N,,,50588,9615.0,Canis lupus familiaris,Tmax after peroral administration in dogs at 2.4 uM/kg,1,,,,In vivo,1,,17764,A,,Intermediate,CHEMBL622746,BAO_0000218,6845
,,N,,,50594,10090.0,Mus musculus,In vivo Cmax in mice at dose of 100 mg/kg,1,,,,In vivo,1,,5969,A,,Intermediate,CHEMBL622747,BAO_0000218,6846
,,N,,,50594,10090.0,Mus musculus,In vivo Cmax in mice at dose of 50 mg/kg,1,,,,In vivo,1,,5969,A,,Intermediate,CHEMBL622748,BAO_0000218,6847
,,N,,,50594,10090.0,Mus musculus,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,1,,,,In vivo,1,,4573,A,,Intermediate,CHEMBL622749,BAO_0000218,6848
,,N,,,50594,10090.0,Mus musculus,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),1,Plasma,,,In vivo,1,,3277,A,1969.0,Intermediate,CHEMBL622750,BAO_0000218,6849
,,N,,,50594,10090.0,Mus musculus,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,1,Plasma,,,In vivo,1,,17734,A,1969.0,Intermediate,CHEMBL623411,BAO_0000218,6850
,,N,,,50594,10090.0,Mus musculus,Maximum concentration obtained in mouse plasma was determined,1,Plasma,,,In vivo,1,,3132,A,1969.0,Intermediate,CHEMBL875946,BAO_0000218,6851
,,N,,,50594,10090.0,Mus musculus,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,1,Plasma,,,In vivo,1,,3132,A,1969.0,Intermediate,CHEMBL623412,BAO_0000218,6852
,,N,,,50594,10090.0,Mus musculus,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,Plasma,,,In vivo,1,,6348,A,1969.0,Intermediate,CHEMBL623413,BAO_0000218,6853
,,N,,,50594,10090.0,Mus musculus,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,1,Plasma,,,In vivo,1,,17729,A,1969.0,Intermediate,CHEMBL623414,BAO_0000218,6854
,,N,,,50594,10090.0,Mus musculus,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,1,Plasma,,,In vivo,1,,17729,A,1969.0,Intermediate,CHEMBL623415,BAO_0000218,6855
,,N,,,50594,10090.0,Mus musculus,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,1,Plasma,,,In vivo,1,,17729,A,1969.0,Intermediate,CHEMBL623416,BAO_0000218,6856
,,N,,,50594,10090.0,Mus musculus,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,1,Plasma,,,In vivo,1,,17728,A,1969.0,Intermediate,CHEMBL623417,BAO_0000218,6857
,,N,,,50594,10090.0,Mus musculus,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,1,Plasma,,,In vivo,1,,17728,A,1969.0,Intermediate,CHEMBL623418,BAO_0000218,6858
,,N,,,50594,10090.0,Mus musculus,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,1,Plasma,,,In vivo,1,,17728,A,1969.0,Intermediate,CHEMBL623419,BAO_0000218,6859
,,N,,,50594,10090.0,Mus musculus,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,1,,,,In vivo,1,,4066,A,,Intermediate,CHEMBL622816,BAO_0000218,6860
,,N,,,50594,10090.0,Mus musculus,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,1,,,,In vivo,1,,6178,A,,Intermediate,CHEMBL623313,BAO_0000218,6861
,,N,,,50594,10090.0,Mus musculus,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,1,,,,In vivo,1,,6178,A,,Intermediate,CHEMBL623314,BAO_0000218,6862
,,N,,,50594,10090.0,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,1,,,,In vivo,1,,3760,A,,Intermediate,CHEMBL876788,BAO_0000218,6863
,,N,,,50594,10090.0,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,1,,,,In vivo,1,,3760,A,,Intermediate,CHEMBL623315,BAO_0000218,6864
,,N,,,50594,10090.0,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,1,,,,In vivo,1,,3760,A,,Intermediate,CHEMBL623316,BAO_0000218,6865
,,N,,,50594,10090.0,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,1,,,,In vivo,1,,3760,A,,Intermediate,CHEMBL623317,BAO_0000218,6866
,,N,,,50594,10090.0,Mus musculus,Cmax in male mice after 2 mg/kg oral dose,1,,,,In vivo,1,,5961,A,,Intermediate,CHEMBL623319,BAO_0000218,6868
,,N,,,50594,10090.0,Mus musculus,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,1,,,,In vivo,1,,6137,A,,Intermediate,CHEMBL623320,BAO_0000218,6869
,,N,,,50594,10090.0,Mus musculus,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,1,,,,In vivo,1,,3802,A,,Intermediate,CHEMBL623321,BAO_0000218,6870
,,N,,,50594,10090.0,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,1,,,,,1,,3535,A,,Intermediate,CHEMBL623322,BAO_0000218,6871
,,N,,,50594,10090.0,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,1,,,,,1,,3535,A,,Intermediate,CHEMBL623323,BAO_0000218,6872
,,N,,,50594,10090.0,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,1,,,,,1,,3535,A,,Intermediate,CHEMBL623324,BAO_0000218,6873
,,N,,,50594,10090.0,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,1,,,,,1,,3535,A,,Intermediate,CHEMBL623325,BAO_0000218,6874
,,N,,,50594,10090.0,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,1,,,,,1,,3535,A,,Intermediate,CHEMBL623326,BAO_0000218,6875
,,N,,,50594,10090.0,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,1,,,,,1,,3535,A,,Intermediate,CHEMBL623327,BAO_0000218,6876
,,N,,,50594,10090.0,Mus musculus,Maximum concentration in plasma upon oral administration in mouse,1,Plasma,,,,1,,2862,A,1969.0,Intermediate,CHEMBL623328,BAO_0000218,6877
,,N,,,50594,10090.0,Mus musculus,Maximum plasma concentration was evaluated in mice after oral administration,1,Plasma,,,,1,,2675,A,1969.0,Intermediate,CHEMBL623329,BAO_0000218,6878
,,N,,,50594,10090.0,Mus musculus,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,1,Plasma,,,In vivo,1,,2675,A,1969.0,Intermediate,CHEMBL623330,BAO_0000218,6879
,,N,,,50594,10090.0,Mus musculus,Dose at which the compound induced fecal excretion in mice,1,,,,,1,,5399,A,,Intermediate,CHEMBL876789,BAO_0000218,6880
,,N,164.0,,80013,10116.0,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,1,,A10,,,1,,11819,F,,Expert,CHEMBL623333,BAO_0000219,6893
,,N,164.0,,80013,10116.0,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,1,,A10,,,1,,11819,F,,Expert,CHEMBL623334,BAO_0000219,6894
,,N,164.0,,80013,10116.0,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,1,,A10,,,1,,11819,F,,Expert,CHEMBL627536,BAO_0000219,6895
,,N,164.0,,80013,10116.0,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,1,,A10,,,1,,11819,F,,Expert,CHEMBL627537,BAO_0000219,6896
,,N,164.0,,80013,10116.0,Rattus norvegicus,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),1,,A10,,,1,,16361,F,,Intermediate,CHEMBL627538,BAO_0000219,6897
,,N,393.0,,80655,9606.0,Homo sapiens,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,1,,A121,,,1,,2288,F,,Intermediate,CHEMBL884106,BAO_0000219,6898
,,N,393.0,,80655,9606.0,Homo sapiens,Anticancer activity against human ovarian carcinoma A121 cells,1,,A121,,,1,,10404,F,,Intermediate,CHEMBL625294,BAO_0000219,6899
,,N,393.0,,80655,9606.0,Homo sapiens,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,1,,A121,,,1,,14790,F,,Intermediate,CHEMBL625295,BAO_0000219,6900
,,N,393.0,,80655,9606.0,Homo sapiens,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,1,,A121,,,1,,14790,F,,Intermediate,CHEMBL625296,BAO_0000219,6901
,,N,393.0,,80655,9606.0,Homo sapiens,Growth inhibition of human ovarian carcinoma (A121) cell line,1,,A121,,,1,,14253,F,,Expert,CHEMBL625297,BAO_0000219,6902
,,N,393.0,,80655,9606.0,Homo sapiens,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,1,,A121,,,1,,13617,F,,Expert,CHEMBL625298,BAO_0000219,6903
,,N,393.0,,80655,9606.0,Homo sapiens,Cytotoxicity against human A121 ovarian cells,1,,A121,,,1,,1003,F,,Intermediate,CHEMBL625960,BAO_0000219,6904
,,N,393.0,,80655,9606.0,Homo sapiens,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,1,,A121,,,1,,830,F,,Intermediate,CHEMBL625961,BAO_0000219,6905
,,N,393.0,,80655,9606.0,Homo sapiens,In vitro cytotoxicity against human ovarian carcinoma A21,1,,A121,,,1,,12307,F,,Intermediate,CHEMBL625962,BAO_0000219,6906
,,N,393.0,,80655,9606.0,Homo sapiens,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,1,,A121,,,1,,14254,F,,Intermediate,CHEMBL624717,BAO_0000219,6907
,,N,393.0,,80655,9606.0,Homo sapiens,Inhibitory activity of compound against human A121 ovarian cell line.,1,,A121,,,1,,13370,F,,Intermediate,CHEMBL624718,BAO_0000219,6908
,,N,393.0,,80655,9606.0,Homo sapiens,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,1,,A121,,,1,,14790,F,,Intermediate,CHEMBL624719,BAO_0000219,6909
,,N,393.0,,80655,9606.0,Homo sapiens,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,1,,A121,,,1,,3614,F,,Intermediate,CHEMBL624720,BAO_0000219,6910
,,N,622.0,,80012,9606.0,Homo sapiens,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,1,,A 172,,,1,,2664,F,,Intermediate,CHEMBL624721,BAO_0000219,6911
,,N,622.0,,80012,9606.0,Homo sapiens,In vitro cytotoxicity against A172 human tumor cell lines.,1,,A 172,,,1,,2037,F,,Expert,CHEMBL624722,BAO_0000219,6912
,,N,622.0,,80012,9606.0,Homo sapiens,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,1,,A 172,,,1,,14539,F,,Intermediate,CHEMBL877597,BAO_0000219,6913
,,N,622.0,,80012,9606.0,Homo sapiens,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,1,,A 172,,,1,,2836,F,,Intermediate,CHEMBL624723,BAO_0000219,6914
,,N,622.0,,80012,9606.0,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,1,,A 172,,,1,,10708,F,,Intermediate,CHEMBL624724,BAO_0000219,6915
,,H,,,104729,9615.0,Canis lupus familiaris,Association constant against A2 adenosine receptor,1,,,,,4,,8975,B,,Autocuration,CHEMBL624725,BAO_0000224,6916
,,N,1085.0,,80656,,fish,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,1,,A2,,,1,,7645,F,,Intermediate,CHEMBL624726,BAO_0000219,6917
,,D,,,104713,10116.0,Rattus norvegicus,Ratio of Ki for adenosine A2 and A1 receptor binding,1,,,,,5,,11377,B,,Autocuration,CHEMBL857535,BAO_0000224,6918
,,N,623.0,,80014,9606.0,Homo sapiens,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,1,,A204,,,1,,13528,F,,Expert,CHEMBL624727,BAO_0000219,6919
,,N,623.0,,80014,9606.0,Homo sapiens,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,1,,A204,,,1,,10160,F,,Expert,CHEMBL624728,BAO_0000219,6920
,,N,404.0,,80015,9606.0,Homo sapiens,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,1,,A2058,,,1,,15144,F,,Intermediate,CHEMBL624729,BAO_0000219,6921
,,N,973.0,,80657,9606.0,Homo sapiens,Growth inhibition against Human squamous cell line(A 253),1,,A253 cell line,,,1,,13160,F,,Intermediate,CHEMBL624730,BAO_0000219,6922
,,N,973.0,,80657,9606.0,Homo sapiens,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,1,,A253 cell line,,,1,,12898,F,,Intermediate,CHEMBL624731,BAO_0000219,6923
,,N,973.0,,80657,9606.0,Homo sapiens,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,1,,A253 cell line,,,1,,13069,F,,Intermediate,CHEMBL624732,BAO_0000219,6924
,,N,973.0,,80657,9606.0,Homo sapiens,Growth inhibition of A253 cell lines.,1,,A253 cell line,,,1,,15984,F,,Intermediate,CHEMBL883245,BAO_0000219,6925
,,N,973.0,,80657,9606.0,Homo sapiens,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),1,,A253 cell line,,,1,,15564,F,,Intermediate,CHEMBL624733,BAO_0000219,6926
,,N,973.0,,80657,9606.0,Homo sapiens,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,1,,A253 cell line,,,1,,15564,F,,Intermediate,CHEMBL624734,BAO_0000219,6927
,,N,973.0,,80657,9606.0,Homo sapiens,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,1,,A253 cell line,,,1,,15564,F,,Intermediate,CHEMBL624735,BAO_0000219,6928
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,1,,A2780,,,1,,4720,F,,Intermediate,CHEMBL621780,BAO_0000219,6929
,,N,478.0,,81034,9606.0,Homo sapiens,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,1,,A2780,,,1,,16112,F,,Intermediate,CHEMBL877598,BAO_0000219,6930
,,N,478.0,,81034,9606.0,Homo sapiens,Cytotoxic activity against A2780 human ovarian carcinoma cell line,1,,A2780,,,1,,16597,F,,Expert,CHEMBL621781,BAO_0000219,6931
,,N,478.0,,81034,9606.0,Homo sapiens,Cytotoxicity against human cancer cell lines A2780 (ovarian),1,,A2780,,,1,,16378,F,,Intermediate,CHEMBL621782,BAO_0000219,6932
,,N,478.0,,81034,9606.0,Homo sapiens,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,1,,A2780,,,1,,16085,F,,Expert,CHEMBL621783,BAO_0000219,6933
,,N,478.0,,81034,9606.0,Homo sapiens,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,1,,A2780,,,1,,16317,F,,Intermediate,CHEMBL621784,BAO_0000219,6934
,,N,478.0,,81034,9606.0,Homo sapiens,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),1,,A2780,,,1,,15748,F,,Intermediate,CHEMBL621785,BAO_0000219,6935
,,N,478.0,,81034,9606.0,Homo sapiens,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,1,,A2780,,,1,,16597,F,,Expert,CHEMBL621968,BAO_0000219,6936
,,N,478.0,,81034,9606.0,Homo sapiens,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,1,,A2780,,,1,,16597,F,,Expert,CHEMBL621969,BAO_0000219,6937
,,N,478.0,,81034,9606.0,Homo sapiens,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,1,,A2780,,,1,,16597,F,,Expert,CHEMBL621970,BAO_0000219,6938
,,N,478.0,,81034,9606.0,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,1,,A2780,,,1,,15608,F,,Intermediate,CHEMBL621971,BAO_0000219,6939
,,N,478.0,,81034,9606.0,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,1,,A2780,,,1,,15608,F,,Intermediate,CHEMBL621972,BAO_0000219,6940
,,N,478.0,,81034,9606.0,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,1,,A2780,,,1,,15608,F,,Intermediate,CHEMBL884108,BAO_0000219,6941
,,U,,,22224,10029.0,Cricetulus griseus,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,1,,,,,0,,15296,F,,Autocuration,CHEMBL623826,BAO_0000019,6942
,,U,185.0,,22224,10029.0,Cricetulus griseus,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,1,,CHO-AA8,,,0,,10251,A,,Autocuration,CHEMBL623827,BAO_0000219,6943
,,U,185.0,,22224,10029.0,Cricetulus griseus,Evaluated for growth inhibition of AA8 cells under aerobic conditions,1,,CHO-AA8,,,0,,10251,F,,Autocuration,CHEMBL623828,BAO_0000219,6944
,,U,185.0,,22224,10029.0,Cricetulus griseus,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,1,,CHO-AA8,,,0,,10251,F,,Autocuration,CHEMBL623829,BAO_0000219,6945
,,U,185.0,,22224,10029.0,Cricetulus griseus,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),1,,CHO-AA8,,,0,,10251,F,,Autocuration,CHEMBL623830,BAO_0000219,6946
,,U,,,22224,10029.0,Cricetulus griseus,Growth inhibition against CHO-derived cell line AA8,1,,,,,0,,11858,F,,Autocuration,CHEMBL623831,BAO_0000019,6947
,,U,185.0,,22224,10029.0,Cricetulus griseus,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],1,,CHO-AA8,,,0,,11858,F,,Autocuration,CHEMBL623832,BAO_0000219,6948
,,N,185.0,,80089,36483.0,hampster,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,1,,CHO-AA8,,,1,,11616,F,,Expert,CHEMBL623833,BAO_0000219,6949
,,N,185.0,,80089,10029.0,Cricetulus griseus,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,1,,CHO-AA8,,,1,,11616,F,,Expert,CHEMBL623834,BAO_0000219,6950
,,U,185.0,,22224,10029.0,Cricetulus griseus,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,1,,CHO-AA8,,,0,,10518,F,,Autocuration,CHEMBL623835,BAO_0000219,6951
,,U,185.0,,22224,10029.0,Cricetulus griseus,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,1,,CHO-AA8,,,0,,11396,F,,Autocuration,CHEMBL623836,BAO_0000219,6952
,,U,185.0,,22224,10029.0,Cricetulus griseus,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,1,,CHO-AA8,,,0,,10518,F,,Autocuration,CHEMBL623837,BAO_0000219,6953
,,N,185.0,,80089,10029.0,Cricetulus griseus,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,1,,CHO-AA8,,,1,,11616,F,,Expert,CHEMBL623838,BAO_0000219,6954
,,H,,,12675,,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,1,,,,,8,,14837,F,,Autocuration,CHEMBL623839,BAO_0000019,6955
,,H,,,12675,,,Number of binding sites (n) of isolated serum protein AAG,1,,,,,8,,14837,F,,Autocuration,CHEMBL623840,BAO_0000019,6956
,,M,,,22222,,,Association constant for binding to AATT duplex,1,,,,,3,,16037,B,,Intermediate,CHEMBL623841,BAO_0000225,6957
,,N,416.0,,100090,9606.0,Homo sapiens,Inhibition of ABAE human fibroblast cell proliferation,1,,ABAE,,,1,,16597,F,,Expert,CHEMBL623842,BAO_0000219,6958
,,N,1064.0,,80668,10090.0,Mus musculus,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",1,,AC755,,,1,,8831,F,,Intermediate,CHEMBL623843,BAO_0000218,6959
,,D,,,102444,9986.0,Oryctolagus cuniculus,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,1,,,,,9,,13419,F,,Expert,CHEMBL618669,BAO_0000218,6960
,,D,,,102444,9986.0,Oryctolagus cuniculus,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,1,,,,In vivo,9,,13419,F,,Expert,CHEMBL618670,BAO_0000218,6961
,,H,,,69,,,Inhibitory activity against angiotensin-converting enzyme (ACE).,1,,,,,8,,15778,B,,Autocuration,CHEMBL618671,BAO_0000357,6962
,,H,,,69,,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,1,,,,,8,,15778,B,,Autocuration,CHEMBL618672,BAO_0000357,6963
,,N,978.0,,80669,9606.0,Homo sapiens,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,1,,ACH-2 cell line,,,1,,12988,F,,Intermediate,CHEMBL618673,BAO_0000219,6964
,,N,978.0,,80669,9606.0,Homo sapiens,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),1,,ACH-2 cell line,,,1,,12988,F,,Intermediate,CHEMBL618674,BAO_0000219,6965
,,U,998.0,,22224,11676.0,Human immunodeficiency virus 1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,1,,T cell line,,,0,,12988,F,,Autocuration,CHEMBL618675,BAO_0000219,6966
,,U,998.0,,22224,11676.0,Human immunodeficiency virus 1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),1,,T cell line,,,0,,12988,F,,Autocuration,CHEMBL618676,BAO_0000219,6967
,,U,998.0,,22224,11676.0,Human immunodeficiency virus 1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),1,,T cell line,,,0,,12988,F,,Autocuration,CHEMBL618677,BAO_0000219,6968
,,N,626.0,,80025,9606.0,Homo sapiens,Inhibition of growth of renal cancer ACHN cell line,1,,ACHN,,,1,,11843,F,,Intermediate,CHEMBL618678,BAO_0000219,6969
,,N,626.0,,80025,9606.0,Homo sapiens,Inhibition of growth of ACHN renal cancer cell line,1,,ACHN,,,1,,16939,F,,Intermediate,CHEMBL618679,BAO_0000219,6970
,,N,626.0,,80025,9606.0,Homo sapiens,Inhibitory concentration required against ACHN renal cancer cell line,1,,ACHN,,,1,,4782,F,,Intermediate,CHEMBL618680,BAO_0000219,6971
,,N,626.0,,80025,9606.0,Homo sapiens,Concentration required to inhibit growth of human renal (ACHN) cell line,1,,ACHN,,,1,,6310,F,,Expert,CHEMBL618681,BAO_0000219,6972
,,N,626.0,,80025,9606.0,Homo sapiens,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,1,,ACHN,,,1,,6310,F,,Intermediate,CHEMBL618682,BAO_0000219,6973
,,N,626.0,,80025,9606.0,Homo sapiens,Cytotoxic activity against ACHN Renal cancer cell line,1,,ACHN,,,1,,12858,F,,Intermediate,CHEMBL618683,BAO_0000219,6974
,,N,626.0,,80025,9606.0,Homo sapiens,Cytotoxicity evaluation against ACHN renal cancer cells,1,,ACHN,,,1,,17380,F,,Intermediate,CHEMBL618684,BAO_0000219,6975
,,N,626.0,,80025,9606.0,Homo sapiens,In vitro antitumor activity against human renal ACHN cell line,1,,ACHN,,,1,,5858,F,,Intermediate,CHEMBL618685,BAO_0000219,6976
,,N,626.0,,80025,9606.0,Homo sapiens,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,1,,ACHN,,,1,,3838,F,,Intermediate,CHEMBL876499,BAO_0000219,6977
,,N,626.0,,80025,9606.0,Homo sapiens,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,1,,ACHN,,,1,,3838,F,,Intermediate,CHEMBL618686,BAO_0000219,6978
,,N,626.0,,80025,9606.0,Homo sapiens,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",1,,ACHN,,,1,,5406,F,,Intermediate,CHEMBL618687,BAO_0000219,6979
,,N,626.0,,80025,9606.0,Homo sapiens,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,1,,ACHN,,,1,,4071,F,,Intermediate,CHEMBL618688,BAO_0000219,6980
,,N,626.0,,80025,9606.0,Homo sapiens,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,1,,ACHN,,,1,,4071,F,,Expert,CHEMBL618689,BAO_0000219,6981
,,N,626.0,,80025,9606.0,Homo sapiens,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,1,,ACHN,,,1,,4071,F,,Intermediate,CHEMBL618690,BAO_0000219,6982
,,N,626.0,,80025,9606.0,Homo sapiens,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,1,,ACHN,,,1,,15002,F,,Intermediate,CHEMBL618691,BAO_0000219,6983
,,N,626.0,,80025,9606.0,Homo sapiens,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),1,,ACHN,,,1,,14769,F,,Intermediate,CHEMBL619373,BAO_0000219,6984
,,N,626.0,,80025,9606.0,Homo sapiens,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",1,,ACHN,,,1,,13958,F,,Intermediate,CHEMBL884008,BAO_0000219,6985
,,N,626.0,,80025,9606.0,Homo sapiens,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,1,,ACHN,,,1,,1665,F,,Intermediate,CHEMBL619374,BAO_0000219,6986
,,N,626.0,,80025,9606.0,Homo sapiens,Compound was tested for the growth inhibition of ACHN renal tumor cell line,1,,ACHN,,,1,,15354,F,,Intermediate,CHEMBL619375,BAO_0000219,6987
,,N,626.0,,80025,9606.0,Homo sapiens,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,1,,ACHN,,,1,,15354,F,,Intermediate,CHEMBL619376,BAO_0000219,6988
,,N,626.0,,80025,9606.0,Homo sapiens,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,1,,ACHN,,,1,,13978,F,,Intermediate,CHEMBL619377,BAO_0000219,6989
,,N,626.0,,80025,9606.0,Homo sapiens,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,1,,ACHN,,,1,,6798,F,,Intermediate,CHEMBL619378,BAO_0000219,6990
,,N,,,50588,9615.0,Canis lupus familiaris,Tmax value after administration of 4 mg/Kg oral dose in dog,1,,,,In vivo,1,,2959,A,,Intermediate,CHEMBL872527,BAO_0000218,6991
,,N,,,50588,9615.0,Canis lupus familiaris,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",1,,,,,1,,9932,A,,Intermediate,CHEMBL876500,BAO_0000218,6992
,,N,,,50588,9615.0,Canis lupus familiaris,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,1,,,,,1,,5546,A,,Intermediate,CHEMBL619379,BAO_0000218,6993
,,N,,,50588,9615.0,Canis lupus familiaris,Volume distribution after 15 mg/kg iv dose in Dogs,1,,,,In vivo,1,,16907,A,,Intermediate,CHEMBL619538,BAO_0000218,6994
,,N,,,50588,9615.0,Canis lupus familiaris,Volume distribution after 30 mg/kg po dose in Dogs,1,,,,In vivo,1,,16907,A,,Intermediate,CHEMBL619539,BAO_0000218,6995
,,N,,,50588,9615.0,Canis lupus familiaris,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,1,,,,In vivo,1,,4257,A,,Intermediate,CHEMBL619540,BAO_0000218,6996
,,N,,,50588,9615.0,Canis lupus familiaris,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,1,,,,In vivo,1,,4305,A,,Intermediate,CHEMBL619541,BAO_0000218,6997
,,N,,,50588,9615.0,Canis lupus familiaris,Volume of distribution was evaluated in dog,1,,,,In vivo,1,,5472,A,,Intermediate,CHEMBL619542,BAO_0000218,6998
,,N,,,50588,9615.0,Canis lupus familiaris,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,1,,,,In vivo,1,,6062,A,,Intermediate,CHEMBL619543,BAO_0000218,6999
,,N,,,50588,9615.0,Canis lupus familiaris,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,1,,,,,1,,3598,A,,Expert,CHEMBL619544,BAO_0000218,7000
,,N,,,50588,9615.0,Canis lupus familiaris,The compound was tested for volume of distribution in dog,1,,,,In vivo,1,,12500,A,,Intermediate,CHEMBL619545,BAO_0000218,7001
,,N,,,50588,9615.0,Canis lupus familiaris,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,1,,,,In vivo,1,,12500,A,,Intermediate,CHEMBL619546,BAO_0000218,7002
,,N,,,50588,9615.0,Canis lupus familiaris,Vd (1 mg/kg) was determined in dog (in vivo),1,,,,In vivo,1,,6227,A,,Intermediate,CHEMBL619547,BAO_0000218,7003
,,N,,,50588,9615.0,Canis lupus familiaris,Vd in dog,1,,,,In vivo,1,,6227,A,,Intermediate,CHEMBL619548,BAO_0000218,7004
,,N,,,50588,9615.0,Canis lupus familiaris,Volume distribution was determined,1,,,,In vivo,1,,4219,A,,Intermediate,CHEMBL619549,BAO_0000218,7005
,,N,,,50588,9615.0,Canis lupus familiaris,Volume of distribution in dog,1,,,,In vivo,1,,1696,A,,Intermediate,CHEMBL619550,BAO_0000218,7006
,,N,,,50588,9615.0,Canis lupus familiaris,Volume of distribution by as 4 fold increase by iv administration in dogs,1,,,,In vivo,1,,5542,A,,Intermediate,CHEMBL876501,BAO_0000218,7007
,,N,,,50588,9615.0,Canis lupus familiaris,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,1,,,,In vivo,1,,5199,A,,Intermediate,CHEMBL619551,BAO_0000218,7008
,,N,,,50588,9615.0,Canis lupus familiaris,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,,,,In vivo,1,,6348,A,,Intermediate,CHEMBL619552,BAO_0000218,7009
,,N,,,50588,9615.0,Canis lupus familiaris,Volume distribution at the dose of 2 mg/kg in dog,1,,,,In vivo,1,,4727,A,,Intermediate,CHEMBL619553,BAO_0000218,7010
,,N,,,50588,9615.0,Canis lupus familiaris,Steady state volume of distribution was determined,1,,,,In vivo,1,,16367,A,,Intermediate,CHEMBL618722,BAO_0000218,7011
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,1,,,,In vivo,1,,2652,A,,Intermediate,CHEMBL618723,BAO_0000218,7012
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,1,,,,In vivo,1,,16452,A,,Intermediate,CHEMBL618724,BAO_0000218,7013
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,1,,,,In vivo,1,,16452,A,,Intermediate,CHEMBL618725,BAO_0000218,7014
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog (dose 1 mg/kg i.v.),1,,,,In vivo,1,,16452,A,,Intermediate,CHEMBL618726,BAO_0000218,7015
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),1,,,,In vivo,1,,5334,A,,Intermediate,CHEMBL618727,BAO_0000218,7016
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic property (vdss) was measured in dog,1,,,,In vivo,1,,4239,A,,Intermediate,CHEMBL624233,BAO_0000218,7017
,,N,,,50588,9615.0,Canis lupus familiaris,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,1,,,,In vivo,1,,4709,A,,Intermediate,CHEMBL624234,BAO_0000218,7018
,,N,,,50588,9615.0,Canis lupus familiaris,Vdss was determined after iv 0.1 mg/kg administration in dog,1,,,,In vivo,1,,5600,A,,Intermediate,CHEMBL624235,BAO_0000218,7019
,,N,,,50588,9615.0,Canis lupus familiaris,Volume displacement was calculated in dog,1,,,,In vivo,1,,6057,A,,Intermediate,CHEMBL624236,BAO_0000218,7020
,,N,,,50588,9615.0,Canis lupus familiaris,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,1,,,,In vivo,1,,5654,A,,Intermediate,CHEMBL624237,BAO_0000218,7021
,,N,,,50588,9615.0,Canis lupus familiaris,Volume distribution constant was determined,1,,,,In vivo,1,,5505,A,,Intermediate,CHEMBL624238,BAO_0000218,7022
,,N,,,50588,9615.0,Canis lupus familiaris,Volume distribution at a dose of 1 uM/kg in dog was determined,1,,,,In vivo,1,,4527,A,,Intermediate,CHEMBL624239,BAO_0000218,7023
,,N,,,50588,9615.0,Canis lupus familiaris,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,1,,,,In vivo,1,,4521,A,,Intermediate,CHEMBL875829,BAO_0000218,7024
,,N,,,50588,9615.0,Canis lupus familiaris,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,1,,,,In vivo,1,,4521,A,,Intermediate,CHEMBL624240,BAO_0000218,7025
,,N,,,50588,9615.0,Canis lupus familiaris,Volume distribution (Vdss) was measured in dog,1,,,,In vivo,1,,15660,A,,Intermediate,CHEMBL624241,BAO_0000218,7026
,,N,,,50588,9615.0,Canis lupus familiaris,Volume distribution (Vdss) was measured in dog,1,,,,In vivo,1,,15660,A,,Intermediate,CHEMBL624242,BAO_0000218,7027
,,N,,,50588,9615.0,Canis lupus familiaris,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,,,In vivo,1,,6679,A,,Intermediate,CHEMBL624243,BAO_0000218,7028
,,N,,,50588,9615.0,Canis lupus familiaris,Volume of distribution in steady state was determined in dog,1,,,,In vivo,1,,5145,A,,Intermediate,CHEMBL624244,BAO_0000218,7029
,,N,,,50588,9615.0,Canis lupus familiaris,Volume of distribution of compound was determined in dog,1,,,,In vivo,1,,6821,A,,Intermediate,CHEMBL624245,BAO_0000218,7030
,,N,,,50588,9615.0,Canis lupus familiaris,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,1,,,,In vivo,1,,4137,A,,Intermediate,CHEMBL624246,BAO_0000218,7031
,,N,,,50588,9615.0,Canis lupus familiaris,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),1,,,,In vivo,1,,5334,A,,Intermediate,CHEMBL624247,BAO_0000218,7032
,,N,,,50588,9615.0,Canis lupus familiaris,Volume of distribution (Vdss) was measured in dog,1,,,,In vivo,1,,15660,A,,Intermediate,CHEMBL624248,BAO_0000218,7033
,,N,,,50588,9615.0,Canis lupus familiaris,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,,,,In vivo,1,,6642,A,,Intermediate,CHEMBL624249,BAO_0000218,7034
,,N,,,50588,9615.0,Canis lupus familiaris,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,,,In vivo,1,,6641,A,,Intermediate,CHEMBL624250,BAO_0000218,7035
,,N,,,50588,9615.0,Canis lupus familiaris,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,,,In vivo,1,,6642,A,,Intermediate,CHEMBL624251,BAO_0000218,7036
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum rate of depolarization of the upstroke of the action potential,1,,,,,1,,11659,A,,Intermediate,CHEMBL624252,BAO_0000218,7037
,,N,,,50588,9615.0,Canis lupus familiaris,Steady state volume distribution in dog,1,,,,In vivo,1,,6448,A,,Intermediate,CHEMBL624253,BAO_0000218,7038
,,N,,,50588,9615.0,Canis lupus familiaris,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,1,,,,In vivo,1,,5474,A,,Intermediate,CHEMBL624950,BAO_0000218,7039
,,N,,,50588,9615.0,Canis lupus familiaris,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,1,,,,In vivo,1,,1466,A,,Intermediate,CHEMBL624951,BAO_0000218,7040
,,N,,,50588,9615.0,Canis lupus familiaris,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,1,,,,In vivo,1,,6535,A,,Intermediate,CHEMBL875830,BAO_0000218,7041
,,N,,,50588,9615.0,Canis lupus familiaris,Volume distribution in dog after administration of 1 mg/kg iv,1,,,,In vivo,1,,6535,A,,Intermediate,CHEMBL624952,BAO_0000218,7042
,,N,,,50588,9615.0,Canis lupus familiaris,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,1,,,,In vivo,1,,17764,A,,Intermediate,CHEMBL624953,BAO_0000218,7043
,,N,,,50588,9615.0,Canis lupus familiaris,Vss after intravenous administration (0.5 mg/kg) was determined in dog,1,,,,In vivo,1,,6215,A,,Intermediate,CHEMBL624954,BAO_0000218,7044
,,N,,,50588,9615.0,Canis lupus familiaris,Vss on i.v. administration of 2 mg/kg was measured in dog,1,,,,In vivo,1,,6505,A,,Intermediate,CHEMBL624955,BAO_0000218,7045
,,N,,,50588,9615.0,Canis lupus familiaris,Vss was determined,1,,,,,1,,3639,A,,Intermediate,CHEMBL624956,BAO_0000218,7046
,,N,,,50588,9615.0,Canis lupus familiaris,Vss in dog,1,,,,,1,,3639,A,,Intermediate,CHEMBL625129,BAO_0000218,7047
,,N,,,50588,9615.0,Canis lupus familiaris,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,1,,,,In vivo,1,,6062,A,,Intermediate,CHEMBL625130,BAO_0000218,7048
,,N,,,50588,9615.0,Canis lupus familiaris,Volume distribution in dogs,1,,,,In vivo,1,,4942,A,,Intermediate,CHEMBL625131,BAO_0000218,7049
,,N,,,50588,9615.0,Canis lupus familiaris,Volume of distribution in dog,1,,,,In vivo,1,,17796,A,,Intermediate,CHEMBL625132,BAO_0000218,7050
,,N,,,50588,9615.0,Canis lupus familiaris,Tested for the oral bioavailability in dog,1,,,,In vivo,1,,4883,A,,Intermediate,CHEMBL872263,BAO_0000218,7051
,,N,,,50594,10090.0,Mus musculus,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,1,,,,In vivo,1,,17837,A,,Intermediate,CHEMBL624336,BAO_0000218,7060
,,N,,,50594,10090.0,Mus musculus,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,1,,,,In vivo,1,,17729,A,,Intermediate,CHEMBL624337,BAO_0000218,7061
,,N,,,50594,10090.0,Mus musculus,Bioavailability after peroral administration of 50 mg/kg of dose in mice,1,,,,In vivo,1,,17729,A,,Intermediate,CHEMBL624338,BAO_0000218,7062
,,N,,,50594,10090.0,Mus musculus,Bioavailability was measured in mouse,1,,,,In vivo,1,,4239,A,,Intermediate,CHEMBL624339,BAO_0000218,7063
,,N,,,50594,10090.0,Mus musculus,Bioavailability in mouse,1,,,,In vivo,1,,17592,A,,Intermediate,CHEMBL624340,BAO_0000218,7064
,,N,,,50594,10090.0,Mus musculus,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,,,,In vivo,1,,6348,A,,Intermediate,CHEMBL624341,BAO_0000218,7065
,,N,,,50594,10090.0,Mus musculus,Bioavailability in mouse,1,,,,In vivo,1,,2801,A,,Intermediate,CHEMBL624342,BAO_0000218,7066
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,1,,,,In vivo,1,,2801,A,,Intermediate,CHEMBL624343,BAO_0000218,7067
,,N,,,50594,10090.0,Mus musculus,Oral bioavailability in mouse,1,,,,In vivo,1,,17718,A,,Intermediate,CHEMBL624344,BAO_0000218,7068
,,N,,,50594,10090.0,Mus musculus,Oral availability at 50 mg/kg po in male mice,1,,,,In vivo,1,,5727,A,,Intermediate,CHEMBL624345,BAO_0000218,7069
,,N,,,50594,10090.0,Mus musculus,Oral bioavailability in mouse (dose 10 mg/kg),1,,,,In vivo,1,,5302,A,,Intermediate,CHEMBL624346,BAO_0000218,7070
,,N,,,50594,10090.0,Mus musculus,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,1,,,,In vivo,1,,3598,A,,Expert,CHEMBL624347,BAO_0000218,7071
,,N,,,50594,10090.0,Mus musculus,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",1,,,,In vivo,1,,5961,A,,Intermediate,CHEMBL624348,BAO_0000218,7072
,,N,,,50594,10090.0,Mus musculus,Oral bioavailability in mouse,1,,,,In vivo,1,,6091,A,,Intermediate,CHEMBL622754,BAO_0000218,7074
,,N,,,50594,10090.0,Mus musculus,Oral bioavailability in vivo in mice;ND=Not determined,1,,,,In vivo,1,,6091,A,,Intermediate,CHEMBL622755,BAO_0000218,7075
,,N,,,50594,10090.0,Mus musculus,Oral bioavailability in mouse at 10 mg/kg of the compound,1,,,,In vivo,1,,5711,A,,Intermediate,CHEMBL622756,BAO_0000218,7076
,,N,,,50594,10090.0,Mus musculus,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),1,,,,In vivo,1,,17728,A,,Intermediate,CHEMBL622757,BAO_0000218,7077
,,N,,,50594,10090.0,Mus musculus,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),1,,,,In vivo,1,,17728,A,,Intermediate,CHEMBL622758,BAO_0000218,7078
,,N,,,50594,10090.0,Mus musculus,Tested for bioavailability of the compound,1,,,,In vivo,1,,3802,A,,Intermediate,CHEMBL622759,BAO_0000218,7079
,,N,,,50594,10090.0,Mus musculus,Tested for half life at the dose of 10 mg/kg when administered intravenously,1,,,,In vivo,1,,3802,A,,Intermediate,CHEMBL622760,BAO_0000218,7080
,,N,,,50594,10090.0,Mus musculus,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,1,Plasma,,,,1,,14029,A,1969.0,Intermediate,CHEMBL622761,BAO_0000218,7081
,,N,,,50594,10090.0,Mus musculus,The plasma half life of compound was determined on heparin prepared by human plasma. ,1,Plasma,,,,1,,14029,A,1969.0,Intermediate,CHEMBL622762,BAO_0000218,7082
,,N,,,50594,10090.0,Mus musculus,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,1,Plasma,,,,1,,14029,A,1969.0,Intermediate,CHEMBL622763,BAO_0000218,7083
,,N,,,50594,10090.0,Mus musculus,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,1,Plasma,,,,1,,14029,A,1969.0,Intermediate,CHEMBL622764,BAO_0000218,7084
,,N,,,50594,10090.0,Mus musculus,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,1,Plasma,,,,1,,14029,A,1969.0,Intermediate,CHEMBL622765,BAO_0000218,7085
,,N,,,50594,10090.0,Mus musculus,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,1,,,,,1,,17753,F,,Intermediate,CHEMBL622766,BAO_0000218,7086
,,N,,,50594,10090.0,Mus musculus,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,1,,,,,1,,17753,A,,Intermediate,CHEMBL622767,BAO_0000218,7087
,,N,,,50594,10090.0,Mus musculus,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,1,,,,,1,,17753,A,,Intermediate,CHEMBL622768,BAO_0000218,7088
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,Blood,,,In vivo,1,,10107,A,178.0,Intermediate,CHEMBL875948,BAO_0000218,7089
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,Blood,,,In vivo,1,,10107,A,178.0,Intermediate,CHEMBL622769,BAO_0000218,7090
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,Blood,,,In vivo,1,,10107,A,178.0,Intermediate,CHEMBL622770,BAO_0000218,7091
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,Blood,,,In vivo,1,,10107,A,178.0,Intermediate,CHEMBL622771,BAO_0000218,7092
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,Blood,,,In vivo,1,,10107,A,178.0,Intermediate,CHEMBL622772,BAO_0000218,7093
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,Blood,,,In vivo,1,,10107,A,178.0,Intermediate,CHEMBL622773,BAO_0000218,7094
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,Blood,,,In vivo,1,,10107,A,178.0,Intermediate,CHEMBL622774,BAO_0000218,7095
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,Bone,,,In vivo,1,,10107,A,10000001.0,Intermediate,CHEMBL621725,BAO_0000218,7096
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,1,Bone,,,In vivo,1,,10107,A,10000001.0,Intermediate,CHEMBL621726,BAO_0000218,7097
,,N,478.0,,81034,9606.0,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,1,,A2780,,,1,,15608,F,,Intermediate,CHEMBL621727,BAO_0000219,7098
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,1,,A2780,,,1,,3290,F,,Expert,CHEMBL622413,BAO_0000219,7099
,,N,478.0,,81034,9606.0,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cell line,1,,A2780,,,1,,2859,F,,Intermediate,CHEMBL622414,BAO_0000219,7100
,,N,478.0,,81034,9606.0,Homo sapiens,Inhibition of A2780 cell clonogenic assay,1,,A2780,,,1,,15688,F,,Expert,CHEMBL622415,BAO_0000219,7101
,,N,478.0,,81034,9606.0,Homo sapiens,Cytotoxic effect on ovarian cancer cell line (A2780),1,,A2780,,,1,,5642,F,,Expert,CHEMBL884001,BAO_0000219,7102
,,N,478.0,,81034,9606.0,Homo sapiens,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,1,,A2780,,,1,,6633,F,,Intermediate,CHEMBL622416,BAO_0000219,7103
,,N,478.0,,81034,9606.0,Homo sapiens,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",1,,A2780,,,1,,3906,F,,Intermediate,CHEMBL622417,BAO_0000219,7104
,,N,478.0,,81034,9606.0,Homo sapiens,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,1,,A2780,,,1,,6788,F,,Expert,CHEMBL622590,BAO_0000219,7105
,,N,478.0,,81034,9606.0,Homo sapiens,Antiproliferative activity against human A2780 cells,1,,A2780,,,1,,17582,F,,Expert,CHEMBL622591,BAO_0000219,7106
,,N,478.0,,81034,9606.0,Homo sapiens,Inhibition of human A2780 cell proliferation,1,,A2780,,,1,,17764,F,,Expert,CHEMBL622592,BAO_0000219,7107
,,N,478.0,,81034,9606.0,Homo sapiens,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,1,,A2780,,,1,,17764,F,,Expert,CHEMBL622593,BAO_0000219,7108
,,N,478.0,,81034,9606.0,Homo sapiens,Inhibition of human A2780 cell proliferation (No data),1,,A2780,,,1,,17764,F,,Expert,CHEMBL622594,BAO_0000219,7109
,,N,478.0,,81034,9606.0,Homo sapiens,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,1,,A2780,,,1,,2815,F,,Intermediate,CHEMBL622595,BAO_0000219,7110
,,N,478.0,,81034,9606.0,Homo sapiens,Compound was evaluated against human Ovarian carcinoma cell line A2780,1,,A2780,,,1,,16930,F,,Intermediate,CHEMBL622596,BAO_0000219,7111
,,N,478.0,,81034,9606.0,Homo sapiens,Growth inhibition against A2780 wild-type ovarian cell lines,1,,A2780,,,1,,17777,F,,Expert,CHEMBL622597,BAO_0000219,7112
,,N,478.0,,81034,9606.0,Homo sapiens,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,1,,A2780,,,1,,17777,F,,Intermediate,CHEMBL622598,BAO_0000219,7113
,,D,,,104766,9606.0,Homo sapiens,Inhibition of tubulin polymerization in human ovarian cancer cell lines,1,,,,,5,,16936,F,,Autocuration,CHEMBL622599,BAO_0000019,7114
,,N,478.0,,81034,9606.0,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,1,,A2780,,,1,,13759,F,,Intermediate,CHEMBL622600,BAO_0000219,7115
,,N,478.0,,81034,9606.0,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,1,,A2780,,,1,,13759,F,,Intermediate,CHEMBL622601,BAO_0000219,7116
,,N,478.0,,81034,9606.0,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,1,,A2780,,,1,,13759,F,,Intermediate,CHEMBL622602,BAO_0000219,7117
,,N,478.0,,81034,9606.0,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,1,,A2780,,,1,,13759,F,,Intermediate,CHEMBL622603,BAO_0000219,7118
,,N,478.0,,81034,9606.0,Homo sapiens,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,1,,A2780,,,1,,15292,F,,Intermediate,CHEMBL622604,BAO_0000219,7119
,,N,478.0,,81034,9606.0,Homo sapiens,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,1,,A2780,,,1,,15292,F,,Intermediate,CHEMBL622605,BAO_0000219,7120
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro inhibition of human ovarian cell line A2780,1,,A2780,,,1,,15069,F,,Expert,CHEMBL622606,BAO_0000219,7121
,,N,478.0,,81034,9606.0,Homo sapiens,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",1,,A2780,,,1,,15069,F,,Expert,CHEMBL619463,BAO_0000219,7122
,,N,478.0,,81034,9606.0,Homo sapiens,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),1,,A2780,,,1,,14073,F,,Intermediate,CHEMBL619464,BAO_0000219,7123
,,N,478.0,,81034,9606.0,Homo sapiens,Concentration required to inhibit A2780-cell growth by 50%,1,,A2780,,,1,,14553,F,,Expert,CHEMBL619465,BAO_0000219,7124
,,N,478.0,,81034,9606.0,Homo sapiens,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,1,,A2780,,,1,,13040,F,,Expert,CHEMBL619466,BAO_0000219,7125
,,N,478.0,,81034,9606.0,Homo sapiens,Cytotoxic effect on human ovarian (A2780) cancer cell line,1,,A2780,,,1,,6891,F,,Expert,CHEMBL619467,BAO_0000219,7126
,,N,478.0,,81034,9606.0,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,1,,A2780,,,1,,15569,F,,Intermediate,CHEMBL619468,BAO_0000219,7127
,,N,478.0,,81034,9606.0,Homo sapiens,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,1,,A2780,,,1,,14190,F,,Expert,CHEMBL619469,BAO_0000219,7128
,,N,478.0,,81034,9606.0,Homo sapiens,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,1,,A2780,,,1,,15014,F,,Expert,CHEMBL619470,BAO_0000219,7129
,,N,478.0,,81034,9606.0,Homo sapiens,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,1,,A2780,,,1,,15014,F,,Intermediate,CHEMBL619471,BAO_0000219,7130
,,N,478.0,,81034,9606.0,Homo sapiens,Cytotoxicity against human ovarian carcinoma A2780 cell line,1,,A2780,,,1,,17496,F,,Intermediate,CHEMBL619472,BAO_0000219,7131
,,N,478.0,,81034,9606.0,Homo sapiens,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",1,,A2780,,,1,,13617,F,,Intermediate,CHEMBL619473,BAO_0000219,7132
,,N,478.0,,81034,9606.0,Homo sapiens,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",1,,A2780,,,1,,13617,F,,Intermediate,CHEMBL874368,BAO_0000219,7133
,,N,478.0,,81034,9606.0,Homo sapiens,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",1,,A2780,,,1,,13617,F,,Intermediate,CHEMBL884003,BAO_0000219,7134
,,N,478.0,,81034,9606.0,Homo sapiens,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",1,,A2780,,,1,,13617,F,,Intermediate,CHEMBL622690,BAO_0000219,7135
,,N,478.0,,81034,9606.0,Homo sapiens,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,1,,A2780,,,1,,17672,F,,Intermediate,CHEMBL622691,BAO_0000219,7136
,,N,478.0,,81034,9606.0,Homo sapiens,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,1,,A2780,,,1,,4544,F,,Intermediate,CHEMBL622692,BAO_0000219,7137
,,N,478.0,,81034,9606.0,Homo sapiens,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,1,,A2780,,,1,,4544,F,,Intermediate,CHEMBL623406,BAO_0000219,7138
,,N,478.0,,81034,9606.0,Homo sapiens,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",1,,A2780,,,1,,16317,F,,Intermediate,CHEMBL884004,BAO_0000219,7139
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,1,,A2780,,,1,,15099,F,,Intermediate,CHEMBL623407,BAO_0000219,7140
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,1,,A2780,,,1,,13978,F,,Intermediate,CHEMBL623408,BAO_0000219,7141
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro antitumor activity against A2780 cell line.,1,,A2780,,,1,,12989,F,,Expert,CHEMBL623409,BAO_0000219,7142
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,1,,A2780,,,1,,5574,F,,Intermediate,CHEMBL623410,BAO_0000219,7143
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro cytotoxicity against A2780 human ovarian cancer cell line,1,,A2780,,,1,,13528,F,,Expert,CHEMBL623576,BAO_0000219,7144
,,N,626.0,,80025,9606.0,Homo sapiens,Inhibitory activity against kidney A-CHN tumor cell growth in culture,1,,ACHN,,,1,,12782,F,,Intermediate,CHEMBL623577,BAO_0000219,7145
,,N,626.0,,80025,9606.0,Homo sapiens,The IC50 value was measured on ACHN cell line in renal tumor type.,1,,ACHN,,,1,,14255,F,,Intermediate,CHEMBL623578,BAO_0000219,7146
,,N,626.0,,80025,9606.0,Homo sapiens,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,1,,ACHN,,,1,,16364,F,,Intermediate,CHEMBL623579,BAO_0000219,7147
,,N,626.0,,80025,9606.0,Homo sapiens,In vitro lethal concentration against most sensitive ACHN cell line,1,,ACHN,,,1,,17376,F,,Expert,CHEMBL623580,BAO_0000219,7148
,,N,626.0,,80025,9606.0,Homo sapiens,Tested for cytotoxic activity against renal cancer ACHN cell line,1,,ACHN,,,1,,12016,F,,Intermediate,CHEMBL623581,BAO_0000219,7149
,,N,626.0,,80025,9606.0,Homo sapiens,Compound tested for growth inhibition of renal cancer cell line ACHN,1,,ACHN,,,1,,6058,F,,Intermediate,CHEMBL857456,BAO_0000219,7150
,,N,626.0,,80025,9606.0,Homo sapiens,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,1,,ACHN,,,1,,17708,F,,Intermediate,CHEMBL623582,BAO_0000219,7151
,,N,626.0,,80025,9606.0,Homo sapiens,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,1,,ACHN,,,1,,15176,F,,Intermediate,CHEMBL623583,BAO_0000219,7152
,,N,626.0,,80025,9606.0,Homo sapiens,In vitro anticancer activity against ACHN renal cancer cell line,1,,ACHN,,,1,,2806,F,,Intermediate,CHEMBL623584,BAO_0000219,7153
,,N,626.0,,80025,9606.0,Homo sapiens,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,1,,ACHN,,,1,,15300,F,,Intermediate,CHEMBL623585,BAO_0000219,7154
,,N,626.0,,80025,9606.0,Homo sapiens,Percent selectivity was evaluated in renal ACHN cell lines,1,,ACHN,,,1,,16364,F,,Intermediate,CHEMBL623586,BAO_0000219,7155
,,N,626.0,,80025,9606.0,Homo sapiens,In vitro inhibitory activity against renal ACHN cancer cell line,1,,ACHN,,,1,,13859,F,,Intermediate,CHEMBL623587,BAO_0000219,7156
,,N,626.0,,80025,9606.0,Homo sapiens,Tested for cytotoxicity against ACHN cell lines in renal cancer,1,,ACHN,,,1,,11970,F,,Intermediate,CHEMBL875279,BAO_0000219,7157
,,N,626.0,,80025,9606.0,Homo sapiens,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,1,,ACHN,,,1,,2450,F,,Intermediate,CHEMBL623588,BAO_0000219,7158
,,N,626.0,,80025,9606.0,Homo sapiens,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,1,,ACHN,,,1,,12696,F,,Intermediate,CHEMBL623589,BAO_0000219,7159
,,N,626.0,,80025,9606.0,Homo sapiens,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,1,,ACHN,,,1,,12400,F,,Intermediate,CHEMBL623590,BAO_0000219,7160
,,N,626.0,,80025,9606.0,Homo sapiens,Cytotoxic effect on renal cancer line ACHN,1,,ACHN,,,1,,12888,F,,Expert,CHEMBL623591,BAO_0000219,7161
,,N,626.0,,80025,9606.0,Homo sapiens,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,1,,ACHN,,,1,,3156,F,,Intermediate,CHEMBL623592,BAO_0000219,7162
,,N,626.0,,80025,9606.0,Homo sapiens,In vitro inhibition of Renal Cancer ACHN cell lines,1,,ACHN,,,1,,3381,F,,Intermediate,CHEMBL623593,BAO_0000219,7163
,,N,626.0,,80025,9606.0,Homo sapiens,Antitumor activity against human renal adenocarcinoma ACHN cells,1,,ACHN,,,1,,16747,F,,Intermediate,CHEMBL623594,BAO_0000219,7164
,,N,626.0,,80025,9606.0,Homo sapiens,Antitumor activity against human renal adenocarcinoma ACHN cells.,1,,ACHN,,,1,,16748,F,,Expert,CHEMBL621833,BAO_0000219,7165
,,N,626.0,,80025,9606.0,Homo sapiens,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,1,,ACHN,,,1,,12062,F,,Intermediate,CHEMBL621834,BAO_0000219,7166
,,N,626.0,,80025,9606.0,Homo sapiens,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),1,,ACHN,,,1,,14769,F,,Intermediate,CHEMBL621835,BAO_0000219,7167
,,N,626.0,,80025,9606.0,Homo sapiens,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",1,,ACHN,,,1,,15895,F,,Intermediate,CHEMBL621836,BAO_0000219,7168
,,N,626.0,,80025,9606.0,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,1,,ACHN,,,1,,17376,F,,Intermediate,CHEMBL621837,BAO_0000219,7169
,,N,626.0,,80025,9606.0,Homo sapiens,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,1,,ACHN,,,1,,14882,F,,Intermediate,CHEMBL875280,BAO_0000219,7170
,,N,626.0,,80025,9606.0,Homo sapiens,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,1,,ACHN,,,1,,14882,F,,Intermediate,CHEMBL621838,BAO_0000219,7171
,,N,626.0,,80025,9606.0,Homo sapiens,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,1,,ACHN,,,1,,15661,F,,Intermediate,CHEMBL621839,BAO_0000219,7172
,,U,,,22224,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,1,,,,,0,,9680,A,,Autocuration,CHEMBL621840,BAO_0000019,7173
,,H,,,10647,,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,1,,,,,8,,14579,F,,Autocuration,CHEMBL621841,BAO_0000019,7174
,,N,468.0,,50529,10358.0,Cytomegalovirus,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,1,,HEL,,,1,,17290,F,,Expert,CHEMBL622979,BAO_0000218,7175
,,N,,,50529,10358.0,Cytomegalovirus,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,1,,,,,1,,17290,F,,Intermediate,CHEMBL876595,BAO_0000218,7176
,,H,,,12159,,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),1,,,,,8,,15891,B,,Autocuration,CHEMBL620221,BAO_0000357,7177
,,H,,,12159,,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),1,,,,,8,,15890,B,,Autocuration,CHEMBL620222,BAO_0000357,7178
,,N,979.0,,80670,9913.0,Bos taurus,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,1,,ADDP cell line,,,1,,3801,F,,Intermediate,CHEMBL620506,BAO_0000219,7179
,,N,980.0,,80671,10090.0,Mus musculus,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,1,,ADJ/PC6,,,1,,9222,F,,Intermediate,CHEMBL620507,BAO_0000219,7180
,,N,980.0,,80671,10090.0,Mus musculus,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,1,,ADJ/PC6,,,1,,9222,F,,Intermediate,CHEMBL620508,BAO_0000219,7181
,,N,980.0,,80671,10090.0,Mus musculus,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",1,,ADJ/PC6,,,1,,7257,F,,Intermediate,CHEMBL620509,BAO_0000219,7182
,,N,980.0,,80671,10090.0,Mus musculus,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,1,,ADJ/PC6,,,1,,7257,F,,Intermediate,CHEMBL620510,BAO_0000219,7183
,,N,980.0,,80671,10090.0,Mus musculus,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,1,,ADJ/PC6,,,1,,7257,A,,Intermediate,CHEMBL620511,BAO_0000219,7184
,,N,980.0,,80671,10090.0,Mus musculus,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,1,,ADJ/PC6,,,1,,8084,F,,Intermediate,CHEMBL620512,BAO_0000219,7185
,,U,,,22224,10090.0,Mus musculus,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,1,,,,,0,,14943,F,,Autocuration,CHEMBL620513,BAO_0000019,7186
,,U,,,22224,10090.0,Mus musculus,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,1,,,,,0,,14943,F,,Autocuration,CHEMBL620514,BAO_0000019,7187
,,U,,,22224,10090.0,Mus musculus,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,1,,,,,0,,14943,F,,Autocuration,CHEMBL620515,BAO_0000019,7188
,,U,,,22224,1423.0,Bacillus subtilis,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),1,,,,In vivo,0,,10524,A,,Autocuration,CHEMBL620516,BAO_0000218,7189
,,N,,,50588,9615.0,Canis lupus familiaris,AUC value in dog after IV administration at a dose of 5 mg/kg,1,Plasma,,,,1,,3546,A,1969.0,Intermediate,CHEMBL620517,BAO_0000218,7190
,,N,,,50588,9615.0,Canis lupus familiaris,AUC value in dog after oral administration at a dose of 5 mg/kg,1,Plasma,,,,1,,3546,A,1969.0,Intermediate,CHEMBL620518,BAO_0000218,7191
,,N,,,50588,9615.0,Canis lupus familiaris,Cmax value in dog after oral administration at a dose of 5 mg/kg,1,,,,In vivo,1,,3546,A,,Intermediate,CHEMBL620519,BAO_0000218,7192
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog after oral administration at a dose of 5 mg/kg,1,,,,In vivo,1,,3546,A,,Intermediate,CHEMBL621386,BAO_0000218,7193
,,N,,,50588,9615.0,Canis lupus familiaris,Tmax value in dog after oral administration at a dose of 5 mg/kg,1,,,,In vivo,1,,3546,A,,Intermediate,CHEMBL621387,BAO_0000218,7194
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for its clearance when administered intravenously in dog,1,,,,In vivo,1,,3184,A,,Intermediate,CHEMBL621388,BAO_0000218,7195
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,1,,,,In vivo,1,,16456,A,,Intermediate,CHEMBL621389,BAO_0000218,7196
,,N,,,50588,9615.0,Canis lupus familiaris,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),1,,,,In vivo,1,,4809,A,,Intermediate,CHEMBL621390,BAO_0000218,7197
,,U,,,22229,,,Calculated partition coefficient (clogP),1,,,,,0,,4219,P,,Intermediate,CHEMBL621391,BAO_0000100,7198
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in dog,1,,,,,1,,3748,A,,Intermediate,CHEMBL621392,BAO_0000218,7199
,,N,,,50588,9615.0,Canis lupus familiaris,Time taken for EC90 was determined when tested in dog,1,,,,,1,,3132,A,,Intermediate,CHEMBL621393,BAO_0000218,7200
,,N,,,50588,9615.0,Canis lupus familiaris,Half life (iv) was determined,1,,,,,1,,4219,A,,Intermediate,CHEMBL621394,BAO_0000218,7201
,,N,,,50588,9615.0,Canis lupus familiaris,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,1,Liver,,,,1,,16907,A,2107.0,Intermediate,CHEMBL621395,BAO_0000218,7202
,,N,,,50588,9615.0,Canis lupus familiaris,Area under the curve was calculated in dog after iv administration,1,,,,,1,,6057,A,,Intermediate,CHEMBL621396,BAO_0000218,7203
,,N,,,50588,9615.0,Canis lupus familiaris,Area under the curve was calculated in dog after peroral administration,1,,,,,1,,6057,A,,Intermediate,CHEMBL621397,BAO_0000218,7204
,,N,,,50588,9615.0,Canis lupus familiaris,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,1,,,,,1,,17853,A,,Intermediate,CHEMBL621398,BAO_0000218,7205
,,N,,,50588,9615.0,Canis lupus familiaris,pKa was evaluated in dog,1,,,,,1,,3639,A,,Intermediate,CHEMBL618818,BAO_0000218,7206
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,1,,,,,1,,14541,A,,Intermediate,CHEMBL618819,BAO_0000218,7207
,,N,,,50588,9615.0,Canis lupus familiaris,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,1,,,,In vivo,1,,16456,A,,Intermediate,CHEMBL618820,BAO_0000218,7208
,,N,,,50588,9615.0,Canis lupus familiaris,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,1,,,,In vivo,1,,16456,A,,Intermediate,CHEMBL873810,BAO_0000218,7209
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,1,,,,In vivo,1,,2652,A,,Intermediate,CHEMBL876606,BAO_0000218,7210
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for the half-life (t 1/2) in hours,1,,,,,1,,3624,A,,Intermediate,CHEMBL618821,BAO_0000218,7211
,,N,,,50588,9615.0,Canis lupus familiaris,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1,Blood,,,In vivo,1,,1337,A,178.0,Intermediate,CHEMBL618822,BAO_0000218,7212
,,N,,,50588,9615.0,Canis lupus familiaris,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1,Blood,,,In vivo,1,,1337,A,178.0,Intermediate,CHEMBL618823,BAO_0000218,7213
,,N,,,50588,9615.0,Canis lupus familiaris,Half life after intravenous administration of 1 mg/kg in dog,1,,,,In vivo,1,,4709,A,,Intermediate,CHEMBL618824,BAO_0000218,7214
,,N,,,50588,9615.0,Canis lupus familiaris,Half life was measured in dog,1,,,,,1,,15660,A,,Intermediate,CHEMBL618825,BAO_0000218,7215
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period in dog after 5 mg/kg dose,1,,,,In vivo,1,,5302,A,,Intermediate,CHEMBL618826,BAO_0000218,7216
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period was evaluated in dog; 4-4.8,1,,,,,1,,17791,A,,Intermediate,CHEMBL618827,BAO_0000218,7217
,,N,,,50588,9615.0,Canis lupus familiaris,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,,,,In vivo,1,,6348,A,,Intermediate,CHEMBL618828,BAO_0000218,7218
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life was determined in dog after a3 mg/kg of iv dose,1,,,,In vivo,1,,4257,A,,Intermediate,CHEMBL618829,BAO_0000218,7219
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life was determined,1,,,,,1,,3771,A,,Intermediate,CHEMBL618830,BAO_0000218,7220
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in dogs,1,,,,,1,,6305,A,,Intermediate,CHEMBL618831,BAO_0000218,7221
,,N,,,50588,9615.0,Canis lupus familiaris,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,1,Plasma,,,In vivo,1,,13501,A,1969.0,Intermediate,CHEMBL619489,BAO_0000218,7222
,,N,,,50588,9615.0,Canis lupus familiaris,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,1,,,,In vivo,1,,17594,A,,Intermediate,CHEMBL619649,BAO_0000218,7223
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for the half life period after iv administration in Beagle dog.,1,,,,In vivo,1,,3045,A,,Intermediate,CHEMBL876607,BAO_0000218,7224
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for the half life period after oral administration in conscious dog.,1,,,,In vivo,1,,3043,A,,Intermediate,CHEMBL619650,BAO_0000218,7225
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested for half life in dog,1,,,,,1,,4839,A,,Intermediate,CHEMBL619651,BAO_0000218,7226
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested for its half life in dog,1,,,,,1,,4839,A,,Intermediate,CHEMBL619652,BAO_0000218,7227
,,N,,,50588,9615.0,Canis lupus familiaris,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,1,,,,In vivo,1,,5802,A,,Intermediate,CHEMBL619653,BAO_0000218,7228
,,N,,,50588,9615.0,Canis lupus familiaris,Half life of compound in dog was determined,1,,,,,1,,17839,A,,Intermediate,CHEMBL619654,BAO_0000218,7229
,,N,,,50588,9615.0,Canis lupus familiaris,Half life (iv) was determined,1,,,,In vivo,1,,4219,A,,Intermediate,CHEMBL619655,BAO_0000218,7230
,,N,,,50588,9615.0,Canis lupus familiaris,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),1,Blood,,,,1,,13966,A,178.0,Intermediate,CHEMBL619656,BAO_0000218,7231
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,1,Plasma,,,In vivo,1,,3994,A,1969.0,Intermediate,CHEMBL873812,BAO_0000218,7232
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,1,Plasma,,,In vivo,1,,3994,F,1969.0,Intermediate,CHEMBL621365,BAO_0000218,7233
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in dog,1,,,,,1,,4453,A,,Intermediate,CHEMBL621366,BAO_0000218,7234
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in dog plasma,1,Plasma,,,,1,,6535,A,1969.0,Intermediate,CHEMBL621367,BAO_0000218,7235
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in dog plasma after administration of 0.25 mg/kg iv,1,Plasma,,,In vivo,1,,6535,A,1969.0,Intermediate,CHEMBL621368,BAO_0000218,7236
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in dog plasma after administration of 1 mg/kg iv,1,Plasma,,,In vivo,1,,6535,A,1969.0,Intermediate,CHEMBL621369,BAO_0000218,7237
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in dog plasma was determined at dose 10 mg/kg,1,Plasma,,,In vivo,1,,3132,A,1969.0,Intermediate,CHEMBL621370,BAO_0000218,7238
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in dog was determined,1,,,,,1,,5374,A,,Intermediate,CHEMBL621371,BAO_0000218,7239
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),1,,,,In vivo,1,,5007,A,,Intermediate,CHEMBL621372,BAO_0000218,7240
,,N,,,50588,9615.0,Canis lupus familiaris,Half life upon exposure to human plasma,1,Plasma,,,,1,,16907,A,1969.0,Intermediate,CHEMBL621373,BAO_0000218,7241
,,N,,,50588,9615.0,Canis lupus familiaris,Half life was calculated in dog,1,,,,,1,,6057,A,,Intermediate,CHEMBL621374,BAO_0000218,7242
,,N,,,50588,9615.0,Canis lupus familiaris,Half life was determined,1,,,,,1,,5006,A,,Intermediate,CHEMBL621375,BAO_0000218,7243
,,N,,,50588,9615.0,Canis lupus familiaris,Half life was determined,1,,,,,1,,5473,A,,Intermediate,CHEMBL621376,BAO_0000218,7244
,,N,,,50588,9615.0,Canis lupus familiaris,Half life by intravenous administration of 1.2 mg/kg in dog,1,,,,In vivo,1,,4368,A,,Intermediate,CHEMBL619624,BAO_0000218,7245
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in dog,1,,,,,1,,6448,A,,Intermediate,CHEMBL875840,BAO_0000218,7246
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in dog after intra venous administration of the compound,1,,,,,1,,4353,A,,Intermediate,CHEMBL619625,BAO_0000218,7247
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in dog after intra venous administration of the compound; ND means Not determined,1,,,,,1,,4353,A,,Intermediate,CHEMBL619626,BAO_0000218,7248
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in dog after po administration of the compound,1,,,,In vivo,1,,4353,A,,Intermediate,CHEMBL619627,BAO_0000218,7249
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in dog after po administration of the compound; ND means Not determined,1,,,,In vivo,1,,4353,A,,Intermediate,CHEMBL873817,BAO_0000218,7250
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in dog at the single oral dose of 1 mg/kg,1,,,,In vivo,1,,6265,A,,Intermediate,CHEMBL619628,BAO_0000218,7251
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in dogs,1,,,,,1,,5006,A,,Intermediate,CHEMBL619629,BAO_0000218,7252
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,1,,,,In vivo,1,,5356,A,,Intermediate,CHEMBL619630,BAO_0000218,7253
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in rat,1,,,,,1,,405,A,,Intermediate,CHEMBL619631,BAO_0000218,7254
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,,,,In vivo,1,,6642,A,,Intermediate,CHEMBL619632,BAO_0000218,7255
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,Bone,,,In vivo,1,,10107,A,10000001.0,Intermediate,CHEMBL619633,BAO_0000218,7256
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,Bone,,,In vivo,1,,10107,A,10000001.0,Intermediate,CHEMBL875841,BAO_0000218,7257
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,Bone,,,In vivo,1,,10107,A,10000001.0,Intermediate,CHEMBL619634,BAO_0000218,7258
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,Bone,,,In vivo,1,,10107,A,10000001.0,Intermediate,CHEMBL619635,BAO_0000218,7259
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,Bone,,,In vivo,1,,10107,A,10000001.0,Intermediate,CHEMBL619636,BAO_0000218,7260
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,Gut,,,In vivo,1,,10107,A,10000004.0,Intermediate,CHEMBL619637,BAO_0000218,7261
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,Gut,,,In vivo,1,,10107,A,10000004.0,Intermediate,CHEMBL619638,BAO_0000218,7262
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,Gut,,,In vivo,1,,10107,A,10000004.0,Intermediate,CHEMBL619639,BAO_0000218,7263
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,Gut,,,In vivo,1,,10107,A,10000004.0,Intermediate,CHEMBL619640,BAO_0000218,7264
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,Gut,,,In vivo,1,,10107,A,10000004.0,Intermediate,CHEMBL619641,BAO_0000218,7265
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,Gut,,,In vivo,1,,10107,A,10000004.0,Intermediate,CHEMBL619642,BAO_0000218,7266
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,Gut,,,In vivo,1,,10107,A,10000004.0,Intermediate,CHEMBL619643,BAO_0000218,7267
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,Heart,,,In vivo,1,,10107,A,948.0,Intermediate,CHEMBL619644,BAO_0000218,7268
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,Heart,,,In vivo,1,,10107,A,948.0,Intermediate,CHEMBL621112,BAO_0000218,7269
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,Heart,,,In vivo,1,,10107,A,948.0,Intermediate,CHEMBL621113,BAO_0000218,7270
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,Heart,,,In vivo,1,,10107,A,948.0,Intermediate,CHEMBL621114,BAO_0000218,7271
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,Heart,,,In vivo,1,,10107,A,948.0,Intermediate,CHEMBL621115,BAO_0000218,7272
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,Heart,,,In vivo,1,,10107,A,948.0,Intermediate,CHEMBL621116,BAO_0000218,7273
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,Heart,,,In vivo,1,,10107,A,948.0,Intermediate,CHEMBL621117,BAO_0000218,7274
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,Kidney,,,In vivo,1,,10107,A,2113.0,Intermediate,CHEMBL621118,BAO_0000218,7275
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,1,Kidney,,,In vivo,1,,10107,A,2113.0,Intermediate,CHEMBL621119,BAO_0000218,7276
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,Kidney,,,In vivo,1,,10107,A,2113.0,Intermediate,CHEMBL621120,BAO_0000218,7277
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,Kidney,,,In vivo,1,,10107,A,2113.0,Intermediate,CHEMBL621757,BAO_0000218,7278
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,Kidney,,,In vivo,1,,10107,A,2113.0,Intermediate,CHEMBL621758,BAO_0000218,7279
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,Kidney,,,In vivo,1,,10107,A,2113.0,Intermediate,CHEMBL621759,BAO_0000218,7280
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,Kidney,,,In vivo,1,,10107,A,2113.0,Intermediate,CHEMBL621760,BAO_0000218,7281
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,Liver,,,In vivo,1,,10107,A,2107.0,Intermediate,CHEMBL621761,BAO_0000218,7282
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,Liver,,,In vivo,1,,10107,A,2107.0,Intermediate,CHEMBL621762,BAO_0000218,7283
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,Liver,,,In vivo,1,,10107,A,2107.0,Intermediate,CHEMBL621763,BAO_0000218,7284
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,Liver,,,In vivo,1,,10107,A,2107.0,Intermediate,CHEMBL624502,BAO_0000218,7285
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,Liver,,,In vivo,1,,10107,A,2107.0,Intermediate,CHEMBL624503,BAO_0000218,7286
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,Liver,,,In vivo,1,,10107,A,2107.0,Intermediate,CHEMBL624504,BAO_0000218,7287
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,Liver,,,In vivo,1,,10107,A,2107.0,Intermediate,CHEMBL624505,BAO_0000218,7288
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,Lung,,,In vivo,1,,10107,A,2048.0,Intermediate,CHEMBL624506,BAO_0000218,7289
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro cytotoxicity against A2780 (human ovarian cancer),1,,A2780,,,1,,5895,F,,Intermediate,CHEMBL624507,BAO_0000219,7290
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,1,,A2780,,,1,,6338,F,,Intermediate,CHEMBL624508,BAO_0000219,7291
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,1,,A2780,,,1,,15163,F,,Intermediate,CHEMBL624509,BAO_0000219,7292
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,1,,A2780,,,1,,15163,F,,Intermediate,CHEMBL624510,BAO_0000219,7293
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,1,,A2780,,,1,,15000,F,,Expert,CHEMBL875956,BAO_0000219,7294
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,1,,A2780,,,1,,15000,F,,Expert,CHEMBL839885,BAO_0000219,7295
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,1,,A2780,,,1,,14729,F,,Expert,CHEMBL624511,BAO_0000219,7296
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro cytotoxicity against A2780 cell line,1,,A2780,,,1,,17270,F,,Intermediate,CHEMBL624512,BAO_0000219,7297
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,1,,A2780,,,1,,5685,F,,Intermediate,CHEMBL624513,BAO_0000219,7298
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro inhibitory activity against human ovarian cancer A2780 cell line,1,,A2780,,,1,,3563,F,,Intermediate,CHEMBL624514,BAO_0000219,7299
,,N,478.0,,81034,9606.0,Homo sapiens,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,1,,A2780,,,1,,17753,F,,Intermediate,CHEMBL618547,BAO_0000218,7300
,,N,478.0,,81034,9606.0,Homo sapiens,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",1,,A2780,,,1,,16317,F,,Intermediate,CHEMBL618548,BAO_0000219,7301
,,N,478.0,,81034,9606.0,Homo sapiens,Inhibition of tubulin polymerization in analogy of ca.,1,,A2780,,,1,,16936,F,,Intermediate,CHEMBL618549,BAO_0000219,7302
,,N,478.0,,81034,9606.0,Homo sapiens,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,1,,A2780,,,1,,3801,F,,Intermediate,CHEMBL618550,BAO_0000219,7303
,,N,478.0,,81034,9606.0,Homo sapiens,Cytotoxic effect in ovarian cancer cell line (A2780),1,,A2780,,,1,,6181,F,,Expert,CHEMBL618551,BAO_0000219,7304
,,N,478.0,,81034,9606.0,Homo sapiens,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,1,,A2780,,,1,,5318,F,,Intermediate,CHEMBL618552,BAO_0000219,7305
,,N,478.0,,81034,9606.0,Homo sapiens,Tested for the cytotoxicity in A2780 ovarian cell line,1,,A2780,,,1,,4840,F,,Intermediate,CHEMBL618553,BAO_0000219,7306
,,N,478.0,,81034,9606.0,Homo sapiens,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),1,,A2780,,,1,,15748,F,,Intermediate,CHEMBL618554,BAO_0000219,7307
,,N,478.0,,81034,9606.0,Homo sapiens,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,1,,A2780,,,1,,15748,F,,Intermediate,CHEMBL618555,BAO_0000219,7308
,,N,481.0,,80017,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,1,,A2780cisR,,,1,,15748,F,,Intermediate,CHEMBL618556,BAO_0000219,7309
,,N,481.0,,80017,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),1,,A2780cisR,,,1,,15748,F,,Intermediate,CHEMBL618557,BAO_0000219,7310
,,N,481.0,,80017,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,1,,A2780cisR,,,1,,15748,F,,Intermediate,CHEMBL618558,BAO_0000219,7311
,,N,481.0,,80017,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),1,,A2780cisR,,,1,,15748,F,,Intermediate,CHEMBL618559,BAO_0000219,7312
,,N,478.0,,81034,9606.0,Homo sapiens,In vivo log of cells killed after administration of compound in A2780 cell line,1,,A2780,,,1,,17753,F,,Intermediate,CHEMBL618560,BAO_0000218,7313
,,N,478.0,,81034,9606.0,Homo sapiens,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,1,,A2780,,In vivo,1,,17753,F,,Intermediate,CHEMBL618561,BAO_0000218,7314
,,N,478.0,,81034,9606.0,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,1,,A2780,,,1,,16936,F,,Intermediate,CHEMBL618562,BAO_0000219,7315
,,N,478.0,,81034,9606.0,Homo sapiens,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,1,,A2780,,,1,,16936,F,,Intermediate,CHEMBL618563,BAO_0000219,7316
,,N,478.0,,81034,9606.0,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,1,,A2780,,,1,,16936,F,,Intermediate,CHEMBL618564,BAO_0000219,7317
,,N,478.0,,81034,9606.0,Homo sapiens,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,1,,A2780,,,1,,16936,F,,Intermediate,CHEMBL618565,BAO_0000219,7318
,,N,478.0,,81034,9606.0,Homo sapiens,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),1,,A2780,,,1,,17528,F,,Intermediate,CHEMBL618566,BAO_0000218,7319
,,N,478.0,,81034,9606.0,Homo sapiens,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,1,,A2780,,,1,,6633,F,,Intermediate,CHEMBL618567,BAO_0000219,7320
,,N,478.0,,81034,9606.0,Homo sapiens,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,1,,A2780,,,1,,15000,F,,Expert,CHEMBL618568,BAO_0000219,7321
,,N,478.0,,81034,9606.0,Homo sapiens,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,1,,A2780,,,1,,17528,F,,Expert,CHEMBL618569,BAO_0000219,7322
,,N,478.0,,81034,9606.0,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,1,,A2780,,,1,,16936,F,,Intermediate,CHEMBL621857,BAO_0000219,7323
,,N,478.0,,81034,9606.0,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,1,,A2780,,,1,,16936,F,,Intermediate,CHEMBL621858,BAO_0000219,7324
,,N,478.0,,81034,9606.0,Homo sapiens,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,1,,A2780,,,1,,16936,F,,Intermediate,CHEMBL621859,BAO_0000219,7325
,,N,478.0,,81034,9606.0,Homo sapiens,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",1,,A2780,,,1,,16936,F,,Intermediate,CHEMBL621860,BAO_0000219,7326
,,N,478.0,,81034,9606.0,Homo sapiens,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),1,,A2780,,,1,,16936,F,,Intermediate,CHEMBL621861,BAO_0000219,7327
,,N,478.0,,81034,9606.0,Homo sapiens,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",1,,A2780,,,1,,16936,F,,Expert,CHEMBL621862,BAO_0000219,7328
,,N,478.0,,81034,9606.0,Homo sapiens,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),1,,A2780,,,1,,16936,F,,Intermediate,CHEMBL621863,BAO_0000219,7329
,,N,478.0,,81034,9606.0,Homo sapiens,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),1,,A2780,,,1,,16936,F,,Intermediate,CHEMBL621864,BAO_0000219,7330
,,N,478.0,,81034,9606.0,Homo sapiens,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),1,,A2780,,,1,,16936,F,,Intermediate,CHEMBL621865,BAO_0000219,7331
,,N,478.0,,81034,10090.0,Mus musculus,In vitro antiproliferative activity against A2780 cell line,1,,A2780,,,1,,17737,F,,Intermediate,CHEMBL621866,BAO_0000219,7332
,,N,478.0,,81034,10090.0,Mus musculus,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,1,,A2780,,,1,,17764,F,,Expert,CHEMBL621867,BAO_0000219,7333
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,1,,A2780,,,1,,3830,F,,Intermediate,CHEMBL621868,BAO_0000219,7334
,,N,478.0,,81034,9606.0,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,1,,A2780,,,1,,3829,F,,Intermediate,CHEMBL875282,BAO_0000219,7335
,,N,,,50588,9615.0,Canis lupus familiaris,Vc value in dog after IV administration at a dose of 5 mg/kg,1,,,,,1,,3546,A,,Intermediate,CHEMBL621869,BAO_0000218,7336
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period in dog after IV administration at a dose of 5 mg/kg,1,,,,In vivo,1,,3546,A,,Intermediate,CHEMBL621870,BAO_0000218,7337
,,U,,,22224,9527.0,Cercopithecidae,Area under curve was determine after peroral administration at 10 mpk in Rhesus,1,,,,,0,,5668,A,,Autocuration,CHEMBL621871,BAO_0000019,7338
,,U,,,22224,9527.0,Cercopithecidae,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,Plasma,,,,0,,3443,A,1969.0,Autocuration,CHEMBL621243,BAO_0000218,7339
,,U,,,22224,9527.0,Cercopithecidae,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,Plasma,,,,0,,3443,A,1969.0,Autocuration,CHEMBL621244,BAO_0000218,7340
,,U,,,22224,9541.0,Macaca fascicularis,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,1,,,,In vivo,0,,4256,A,,Autocuration,CHEMBL621245,BAO_0000218,7341
,,U,,,22224,9541.0,Macaca fascicularis,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,1,,,,In vivo,0,,4256,A,,Autocuration,CHEMBL621246,BAO_0000218,7342
,,U,,,22224,9541.0,Macaca fascicularis,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,1,,,,In vivo,0,,4256,A,,Autocuration,CHEMBL621247,BAO_0000218,7343
,,U,,,22224,10116.0,Rattus norvegicus,Oral Bioavailability in rat,1,,,,In vivo,0,,4256,A,,Autocuration,CHEMBL618386,BAO_0000218,7344
,,U,,,22224,9527.0,Cercopithecidae,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1,,,,,0,,1916,A,,Autocuration,CHEMBL618387,BAO_0000218,7345
,,U,,,22224,9527.0,Cercopithecidae,Area under curve value in monkey at a dose of 5 mg/kg,1,,,,,0,,5302,A,,Autocuration,CHEMBL618388,BAO_0000218,7346
,,U,,,22224,9527.0,Cercopithecidae,Area under curve was determined in monkey after a 3 mg/kg of oral dose,1,,,,,0,,4257,A,,Autocuration,CHEMBL618389,BAO_0000218,7347
,,U,,,22224,9527.0,Cercopithecidae,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,1,,,,,0,,5355,A,,Autocuration,CHEMBL618574,BAO_0000019,7348
,,U,,,22224,9527.0,Cercopithecidae,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,1,,,,,0,,5355,A,,Autocuration,CHEMBL618575,BAO_0000019,7349
,,U,,,22224,9527.0,Cercopithecidae,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,1,,,,,0,,5355,A,,Autocuration,CHEMBL618576,BAO_0000019,7350
,,U,,,22224,9527.0,Cercopithecidae,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,1,,,,,0,,6078,A,,Autocuration,CHEMBL618577,BAO_0000218,7351
,,U,,,22224,9527.0,Cercopithecidae,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,1,,,,,0,,6078,A,,Autocuration,CHEMBL876487,BAO_0000218,7352
,,U,,,22224,9527.0,Cercopithecidae,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,1,,,,,0,,6062,A,,Autocuration,CHEMBL618578,BAO_0000218,7353
,,U,,,22224,9527.0,Cercopithecidae,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,1,,,,,0,,2661,A,,Autocuration,CHEMBL618579,BAO_0000218,7354
,,U,,,22224,9527.0,Cercopithecidae,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,1,,,,,0,,2661,A,,Autocuration,CHEMBL618580,BAO_0000019,7355
,,U,,,22224,9527.0,Cercopithecidae,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,1,,,,,0,,5394,A,,Autocuration,CHEMBL618581,BAO_0000218,7356
,,U,,,22224,9527.0,Cercopithecidae,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,1,,,,,0,,4397,A,,Autocuration,CHEMBL618582,BAO_0000218,7357
,,U,,,22224,9527.0,Cercopithecidae,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,1,,,,,0,,17509,A,,Autocuration,CHEMBL618583,BAO_0000218,7358
,,U,,,22224,9527.0,Cercopithecidae,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,1,,,,,0,,17509,A,,Autocuration,CHEMBL618584,BAO_0000218,7359
,,U,,,22224,9527.0,Cercopithecidae,Oral AUCN in monkey (dosed at 0.5 mpk iv ),1,,,,In vivo,0,,6641,A,,Autocuration,CHEMBL618585,BAO_0000218,7360
,,U,,,22224,9527.0,Cercopithecidae,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),1,,,,,0,,5355,A,,Autocuration,CHEMBL618586,BAO_0000218,7361
,,U,,,22224,9527.0,Cercopithecidae,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,,,,In vivo,0,,3443,A,,Autocuration,CHEMBL618587,BAO_0000218,7362
,,U,,,22224,9527.0,Cercopithecidae,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,,,,In vivo,0,,3443,A,,Autocuration,CHEMBL618588,BAO_0000218,7363
,,U,,,22224,9527.0,Cercopithecidae,Binding towards monkey plasma protein at 10 uM,1,,,,,0,,17409,A,,Autocuration,CHEMBL618589,BAO_0000019,7364
,,U,,,22224,9527.0,Cercopithecidae,Binding towards monkey plasma protein at 100 uM,1,,,,,0,,17409,A,,Autocuration,CHEMBL618590,BAO_0000019,7365
,,U,,,22224,9527.0,Cercopithecidae,Apparent bioavailability in squirrel monkey was determined,1,,,,In vivo,0,,1052,A,,Autocuration,CHEMBL872262,BAO_0000218,7366
,,U,,,22224,9527.0,Cercopithecidae,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,1,,,,In vivo,0,,13501,A,,Autocuration,CHEMBL618591,BAO_0000218,7367
,,U,,,22224,9443.0,monkey,Bioavailability in monkey (dose 2 mg/kg),1,,,,In vivo,0,,17509,A,,Autocuration,CHEMBL618592,BAO_0000218,7368
,,U,,,22224,9527.0,Cercopithecidae,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,1,,,,In vivo,0,,5394,A,,Autocuration,CHEMBL876488,BAO_0000218,7369
,,U,,,22224,9527.0,Cercopithecidae,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,1,,,,In vivo,0,,2661,A,,Autocuration,CHEMBL618593,BAO_0000218,7370
,,U,,,22224,9443.0,monkey,Bioavailability in monkey (i.d. dosing),1,,,,In vivo,0,,11219,A,,Autocuration,CHEMBL618594,BAO_0000218,7371
,,U,,,22224,9527.0,Cercopithecidae,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,1,,,,In vivo,0,,3045,A,,Autocuration,CHEMBL618595,BAO_0000218,7372
,,U,,,22224,9527.0,Cercopithecidae,Clearance of the drug was measured in cynomolgus,1,,,,,0,,17796,A,,Autocuration,CHEMBL621469,BAO_0000019,7373
,,U,,,22224,9527.0,Cercopithecidae,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,1,,,,In vivo,0,,1399,A,,Autocuration,CHEMBL621470,BAO_0000218,7374
,,U,,,22224,9527.0,Cercopithecidae,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,1,,,,In vivo,0,,2661,A,,Autocuration,CHEMBL621471,BAO_0000218,7375
,,U,,,22224,9544.0,Macaca mulatta,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1,Plasma,,,In vivo,0,,5005,A,1969.0,Autocuration,CHEMBL621472,BAO_0000218,7376
,,U,,,22224,9527.0,Cercopithecidae,Plasma clearance in rhesus monkey was determined,1,,,,In vivo,0,,17267,A,,Autocuration,CHEMBL621473,BAO_0000218,7377
,,U,,,22224,9527.0,Cercopithecidae,Plasma clearance in monkey after administration of 1 mg/kg iv,1,,,,In vivo,0,,6535,A,,Autocuration,CHEMBL621474,BAO_0000218,7378
,,U,,,22224,9527.0,Cercopithecidae,Plasma clearance in cynomolgus monkey,1,,,,In vivo,0,,5922,A,,Autocuration,CHEMBL621475,BAO_0000218,7379
,,U,,,22224,9527.0,Cercopithecidae,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,1,,,,In vivo,0,,6221,A,,Autocuration,CHEMBL621476,BAO_0000218,7380
,,U,,,22224,9527.0,Cercopithecidae,Plasma clearance after peroral administration at 10 mpk in Rhesus,1,,,,In vivo,0,,5668,A,,Autocuration,CHEMBL624290,BAO_0000218,7381
,,U,,,22224,9527.0,Cercopithecidae,The total clearance was determined after intravenous administration in cynomolgus monkeys,1,,,,In vivo,0,,5355,A,,Autocuration,CHEMBL624291,BAO_0000218,7382
,,U,,,22224,9527.0,Cercopithecidae,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,1,,,,In vivo,0,,5355,A,,Autocuration,CHEMBL624292,BAO_0000218,7383
,,U,,,22224,9527.0,Cercopithecidae,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,1,,,,In vivo,0,,5355,A,,Autocuration,CHEMBL624293,BAO_0000218,7384
,,U,,,22224,9527.0,Cercopithecidae,Tested for Clearance upon iv administration to african green monkey,1,,,,In vivo,0,,4578,A,,Autocuration,CHEMBL624294,BAO_0000218,7385
,,U,,,22224,9527.0,Cercopithecidae,Clearance in monkey,1,,,,In vivo,0,,17592,A,,Autocuration,CHEMBL624295,BAO_0000218,7386
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,,,In vivo,1,,6641,A,,Intermediate,CHEMBL624296,BAO_0000218,7387
,,N,,,50588,9615.0,Canis lupus familiaris,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,,,In vivo,1,,6642,A,,Intermediate,CHEMBL624297,BAO_0000218,7388
,,N,,,50588,9615.0,Canis lupus familiaris,Half life was evaluated after intravenous administration to dogs,1,,,,In vivo,1,,16367,A,,Intermediate,CHEMBL624298,BAO_0000218,7389
,,N,,,50588,9615.0,Canis lupus familiaris,Half life was evaluated in dog,1,,,,,1,,5472,A,,Intermediate,CHEMBL624299,BAO_0000218,7390
,,N,,,50588,9615.0,Canis lupus familiaris,Half life was evaluated in dog,1,,,,,1,,5474,A,,Intermediate,CHEMBL624300,BAO_0000218,7391
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,1,,,,In vivo,1,,5654,A,,Intermediate,CHEMBL624301,BAO_0000218,7392
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),1,,,,In vivo,1,,6227,A,,Intermediate,CHEMBL624302,BAO_0000218,7393
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period after intravenous administration in dog,1,,,,In vivo,1,,6227,A,,Intermediate,CHEMBL876026,BAO_0000218,7394
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period after oral administration (2.5 mg/kg) in dog was determined,1,,,,In vivo,1,,6221,A,,Intermediate,CHEMBL624303,BAO_0000218,7395
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period at a dose of 1 uM/kg in dog was determined,1,,,,,1,,4527,A,,Intermediate,CHEMBL624304,BAO_0000218,7396
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period was determine after peroral administration at 10 mpk in dog,1,,,,In vivo,1,,5668,A,,Intermediate,CHEMBL624305,BAO_0000218,7397
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period was determine after peroral administration at 5 mpk in dog,1,,,,In vivo,1,,5668,A,,Intermediate,CHEMBL624306,BAO_0000218,7398
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period was determined,1,,,,,1,,3854,A,,Intermediate,CHEMBL624307,BAO_0000218,7399
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period was determined,1,,,,,1,,5505,A,,Intermediate,CHEMBL624308,BAO_0000218,7400
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period by iv administration in dog at a dose of 6 mg/kg,1,,,,In vivo,1,,6251,A,,Intermediate,CHEMBL624309,BAO_0000218,7401
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period was evaluated in dog,1,,,,,1,,1918,A,,Intermediate,CHEMBL624310,BAO_0000218,7402
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,1,,,,In vivo,1,,5546,A,,Intermediate,CHEMBL625003,BAO_0000218,7403
,,N,,,50588,9615.0,Canis lupus familiaris,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),1,,,,In vivo,1,,4809,A,,Intermediate,CHEMBL625004,BAO_0000218,7404
,,N,,,50588,9615.0,Canis lupus familiaris,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,1,,,,In vivo,1,,6215,A,,Intermediate,CHEMBL625005,BAO_0000218,7405
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,1,,,,In vivo,1,,4527,A,,Intermediate,CHEMBL873813,BAO_0000218,7406
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life after oral dose of compound at 3 mg/kg in dogs,1,,,,In vivo,1,,17594,A,,Intermediate,CHEMBL625006,BAO_0000218,7407
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,1,,,,In vivo,1,,17839,A,,Intermediate,CHEMBL625007,BAO_0000218,7408
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,1,,,,In vivo,1,,17839,A,,Intermediate,CHEMBL876027,BAO_0000218,7409
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,1,,,,In vivo,1,,17839,A,,Intermediate,CHEMBL625008,BAO_0000218,7410
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 1 mg/kg,1,,,,In vivo,1,,17839,A,,Intermediate,CHEMBL625009,BAO_0000218,7411
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life of compound in plasma of dog was determined,1,Plasma,,,,1,,5210,A,1969.0,Intermediate,CHEMBL625010,BAO_0000218,7412
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life of compound was determined in dogs,1,,,,,1,,5210,A,,Intermediate,CHEMBL625011,BAO_0000218,7413
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life after administration of 4 mg/Kg oral dose in dog,1,,,,In vivo,1,,2959,A,,Intermediate,CHEMBL621553,BAO_0000218,7414
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life after intravenous administration of 1 mg/kg/h in dog,1,,,,In vivo,1,,4137,A,,Intermediate,CHEMBL621554,BAO_0000218,7415
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life in Dog,1,,,,,1,,5064,A,,Intermediate,CHEMBL621555,BAO_0000218,7416
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life in Dog,1,,,,,1,,5147,A,,Intermediate,CHEMBL621556,BAO_0000218,7417
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life in dog,1,,,,,1,,5145,A,,Intermediate,CHEMBL621557,BAO_0000218,7418
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life in dog after oral administration at 1 mg/kg,1,,,,In vivo,1,,6123,A,,Intermediate,CHEMBL621558,BAO_0000218,7419
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,1,,,,In vivo,1,,6123,A,,Intermediate,CHEMBL621559,BAO_0000218,7420
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life in dogs,1,,,,,1,,4333,A,,Intermediate,CHEMBL621560,BAO_0000218,7421
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life in dogs; ND indicates not determined,1,,,,,1,,4333,A,,Intermediate,CHEMBL876028,BAO_0000218,7422
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life in plasma of dog,1,Plasma,,,,1,,12500,A,1969.0,Intermediate,CHEMBL621561,BAO_0000218,7423
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life in plasma of dog at dose of 3-10 mgkg,1,Plasma,,,,1,,12500,A,1969.0,Intermediate,CHEMBL621562,BAO_0000218,7424
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,1,,,,In vivo,1,,6005,A,,Intermediate,CHEMBL621563,BAO_0000218,7425
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life was measured in dog after an iv dose of 1 mg/kg,1,,,,In vivo,1,,6062,A,,Intermediate,CHEMBL621564,BAO_0000218,7426
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life was measured in dogs after an oral dose of 10 uM/kg,1,,,,In vivo,1,,17650,A,,Intermediate,CHEMBL621565,BAO_0000218,7427
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,1,,,,In vivo,1,,5530,A,,Intermediate,CHEMBL621566,BAO_0000218,7428
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,1,,,,In vivo,1,,5530,A,,Intermediate,CHEMBL621567,BAO_0000218,7429
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life of the compound after 0.3 mg/kg po administration in dog,1,,,,In vivo,1,,5600,A,,Intermediate,CHEMBL622978,BAO_0000218,7430
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,1,,,,In vivo,1,,6039,A,,Intermediate,CHEMBL873814,BAO_0000218,7431
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,1,,,,In vivo,1,,6039,A,,Intermediate,CHEMBL623219,BAO_0000218,7432
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,1,,,,In vivo,1,,6039,A,,Intermediate,CHEMBL624477,BAO_0000218,7433
,,N,,,50588,9615.0,Canis lupus familiaris,t1/2 in dog,1,,,,,1,,6227,A,,Intermediate,CHEMBL624478,BAO_0000218,7434
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life period measured in dogs,1,,,,,1,,14541,A,,Intermediate,CHEMBL624479,BAO_0000218,7435
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,1,,,,In vivo,1,,4521,A,,Intermediate,CHEMBL624480,BAO_0000218,7436
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,1,,,,In vivo,1,,4521,A,,Intermediate,CHEMBL623595,BAO_0000218,7437
,,N,,,50588,9615.0,Canis lupus familiaris,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,,,In vivo,1,,6679,A,,Intermediate,CHEMBL623596,BAO_0000218,7438
,,N,,,50588,9615.0,Canis lupus familiaris,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",1,Plasma,,,In vitro,1,,1116,A,1969.0,Intermediate,CHEMBL623597,BAO_0000218,7439
,,N,,,50588,9615.0,Canis lupus familiaris,In vivo half life period was calculated at 1 mg/kg in dog,1,,,,In vivo,1,,5444,A,,Intermediate,CHEMBL623598,BAO_0000218,7440
,,N,,,50588,9615.0,Canis lupus familiaris,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,1,,,,In vivo,1,,5444,A,,Intermediate,CHEMBL623599,BAO_0000218,7441
,,N,,,50588,9615.0,Canis lupus familiaris,Longer half-life in dog (i.v.) at 0.5 mpk,1,,,,In vivo,1,,17853,A,,Intermediate,CHEMBL623600,BAO_0000218,7442
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog (dose 5 uM/kg),1,,,,In vivo,1,,4353,A,,Intermediate,CHEMBL623601,BAO_0000218,7443
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,1,,,,In vivo,1,,16452,A,,Intermediate,CHEMBL623602,BAO_0000218,7444
,,N,,,50588,9615.0,Canis lupus familiaris,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,1,,,,In vivo,1,,16452,A,,Intermediate,CHEMBL623603,BAO_0000218,7445
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability in dog (dose 1 mg/kg i.v.),1,,,,In vivo,1,,16452,A,,Intermediate,CHEMBL623604,BAO_0000218,7446
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,1,Lung,,,In vivo,1,,10107,A,2048.0,Intermediate,CHEMBL623605,BAO_0000218,7447
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,Lung,,,In vivo,1,,10107,A,2048.0,Intermediate,CHEMBL623606,BAO_0000218,7448
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,Lung,,,In vivo,1,,10107,A,2048.0,Intermediate,CHEMBL623607,BAO_0000218,7449
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,Lung,,,In vivo,1,,10107,A,2048.0,Intermediate,CHEMBL623608,BAO_0000218,7450
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,Lung,,,In vivo,1,,10107,A,2048.0,Intermediate,CHEMBL623609,BAO_0000218,7451
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,Lung,,,In vivo,1,,10107,A,2048.0,Intermediate,CHEMBL623610,BAO_0000218,7452
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,Muscle tissue,,,In vivo,1,,10107,A,2385.0,Intermediate,CHEMBL623611,BAO_0000218,7453
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,1,Muscle tissue,,,In vivo,1,,10107,A,2385.0,Intermediate,CHEMBL623612,BAO_0000218,7454
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,Muscle tissue,,,In vivo,1,,10107,A,2385.0,Intermediate,CHEMBL623613,BAO_0000218,7455
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,Muscle tissue,,,In vivo,1,,10107,A,2385.0,Intermediate,CHEMBL623614,BAO_0000218,7456
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,Muscle tissue,,,In vivo,1,,10107,A,2385.0,Intermediate,CHEMBL623615,BAO_0000218,7457
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,Muscle tissue,,,In vivo,1,,10107,A,2385.0,Intermediate,CHEMBL623616,BAO_0000218,7458
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,Muscle tissue,,,In vivo,1,,10107,A,2385.0,Intermediate,CHEMBL623617,BAO_0000218,7459
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,Zone of skin,,,In vivo,1,,10107,A,14.0,Intermediate,CHEMBL875944,BAO_0000218,7460
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,Zone of skin,,,In vivo,1,,10107,A,14.0,Intermediate,CHEMBL623618,BAO_0000218,7461
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,Zone of skin,,,In vivo,1,,10107,A,14.0,Intermediate,CHEMBL623619,BAO_0000218,7462
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,Zone of skin,,,In vivo,1,,10107,A,14.0,Intermediate,CHEMBL623620,BAO_0000218,7463
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,Zone of skin,,,In vivo,1,,10107,A,14.0,Intermediate,CHEMBL623621,BAO_0000218,7464
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,Zone of skin,,,In vivo,1,,10107,A,14.0,Intermediate,CHEMBL623622,BAO_0000218,7465
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,Zone of skin,,,In vivo,1,,10107,A,14.0,Intermediate,CHEMBL623623,BAO_0000218,7466
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,Spleen,,,In vivo,1,,10107,A,2106.0,Intermediate,CHEMBL623624,BAO_0000218,7467
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,Spleen,,,In vivo,1,,10107,A,2106.0,Intermediate,CHEMBL618521,BAO_0000218,7468
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,Spleen,,,In vivo,1,,10107,A,2106.0,Intermediate,CHEMBL618522,BAO_0000218,7469
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,Spleen,,,In vivo,1,,10107,A,2106.0,Intermediate,CHEMBL618523,BAO_0000218,7470
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,Spleen,,,In vivo,1,,10107,A,2106.0,Intermediate,CHEMBL618524,BAO_0000218,7471
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,Spleen,,,In vivo,1,,10107,A,2106.0,Intermediate,CHEMBL618525,BAO_0000218,7472
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,Spleen,,,In vivo,1,,10107,A,2106.0,Intermediate,CHEMBL624586,BAO_0000218,7473
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,Stomach,,,In vivo,1,,10107,A,945.0,Intermediate,CHEMBL624587,BAO_0000218,7474
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,Stomach,,,In vivo,1,,10107,A,945.0,Intermediate,CHEMBL624588,BAO_0000218,7475
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,Stomach,,,In vivo,1,,10107,A,945.0,Intermediate,CHEMBL624589,BAO_0000218,7476
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,Stomach,,,In vivo,1,,10107,A,945.0,Intermediate,CHEMBL624590,BAO_0000218,7477
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,Stomach,,,In vivo,1,,10107,A,945.0,Intermediate,CHEMBL624591,BAO_0000218,7478
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,Stomach,,,In vivo,1,,10107,A,945.0,Intermediate,CHEMBL624592,BAO_0000218,7479
,,N,,,50594,10090.0,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,Stomach,,,In vivo,1,,10107,A,945.0,Intermediate,CHEMBL624593,BAO_0000218,7480
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,4689,A,,Intermediate,CHEMBL624594,BAO_0000218,7481
,,N,,,50597,10116.0,Rattus norvegicus,Tested for the bioavailability in rat,1,,,,In vivo,1,,4950,A,,Intermediate,CHEMBL624595,BAO_0000218,7482
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,,,,In vivo,1,,5328,A,,Intermediate,CHEMBL624596,BAO_0000218,7483
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,406,A,,Intermediate,CHEMBL624597,BAO_0000218,7484
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,12500,A,,Intermediate,CHEMBL624598,BAO_0000218,7485
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (dose 3-10 mg/kg),1,,,,In vivo,1,,12500,A,,Intermediate,CHEMBL624599,BAO_0000218,7486
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,5247,A,,Intermediate,CHEMBL875166,BAO_0000218,7487
,,N,,,50597,10116.0,Rattus norvegicus,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,Plasma,,,In vivo,1,,4186,A,1969.0,Intermediate,CHEMBL624600,BAO_0000218,7488
,,N,,,50597,10116.0,Rattus norvegicus,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,1,Plasma,,,In vivo,1,,4186,A,1969.0,Intermediate,CHEMBL624601,BAO_0000218,7489
,,N,,,50597,10116.0,Rattus norvegicus,Half life after oral administration was determined in rats at 6 mg/kg,1,,,,In vivo,1,,6647,A,,Intermediate,CHEMBL624602,BAO_0000218,7490
,,N,,,50597,10116.0,Rattus norvegicus,Half life was determined,1,,,,,1,,6484,A,,Intermediate,CHEMBL624603,BAO_0000218,7491
,,N,,,50597,10116.0,Rattus norvegicus,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,1,,,,In vivo,1,,3249,A,,Intermediate,CHEMBL624604,BAO_0000218,7492
,,N,,,50597,10116.0,Rattus norvegicus,Plasma half life in rat at oral dose 2.8 mg/mk body weight,1,Plasma,,,In vivo,1,,6281,A,1969.0,Intermediate,CHEMBL624605,BAO_0000218,7493
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rats,1,,,,,1,,3307,A,,Intermediate,CHEMBL624606,BAO_0000218,7494
,,N,,,50597,10116.0,Rattus norvegicus,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,1,Blood,,,In vivo,1,,12058,A,178.0,Intermediate,CHEMBL624607,BAO_0000218,7495
,,N,,,50597,10116.0,Rattus norvegicus,Hill coefficient of the compound,1,,,,,1,,8833,A,,Intermediate,CHEMBL624608,BAO_0000218,7496
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,1,Blood,,,,1,,3193,A,178.0,Intermediate,CHEMBL624609,BAO_0000218,7497
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,1,Blood,,,,1,,3193,A,178.0,Intermediate,CHEMBL624610,BAO_0000218,7498
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,1,Blood,,,,1,,3193,A,178.0,Intermediate,CHEMBL624611,BAO_0000218,7499
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,1,Blood,,,,1,,3193,A,178.0,Intermediate,CHEMBL624612,BAO_0000218,7500
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,1,Blood,,,,1,,3193,A,178.0,Intermediate,CHEMBL875167,BAO_0000218,7501
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,1,Blood,,,,1,,3193,A,178.0,Intermediate,CHEMBL624613,BAO_0000218,7502
,,N,,,50597,10116.0,Rattus norvegicus,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",1,Blood,,,,1,,3193,A,178.0,Intermediate,CHEMBL624614,BAO_0000218,7503
,,N,,,50597,10116.0,Rattus norvegicus,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,1,,,,,1,,5960,A,,Intermediate,CHEMBL624392,BAO_0000218,7504
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,1,Brain,,,In vivo,1,,13950,A,955.0,Intermediate,CHEMBL624393,BAO_0000218,7505
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,1,Brain,,,In vivo,1,,13950,A,955.0,Intermediate,CHEMBL624394,BAO_0000218,7506
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,1,Brain,,,In vivo,1,,13950,A,955.0,Intermediate,CHEMBL624395,BAO_0000218,7507
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,1,Brain,,,In vivo,1,,13950,A,955.0,Intermediate,CHEMBL624396,BAO_0000218,7508
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,1,Brain,,,In vivo,1,,13950,A,955.0,Intermediate,CHEMBL624397,BAO_0000218,7509
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,1,Thyroid gland,,,In vivo,1,,13950,A,2046.0,Intermediate,CHEMBL624398,BAO_0000218,7510
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,1,Thyroid gland,,,In vivo,1,,13950,A,2046.0,Intermediate,CHEMBL624399,BAO_0000218,7511
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,1,Thyroid gland,,,In vivo,1,,13950,A,2046.0,Intermediate,CHEMBL624400,BAO_0000218,7512
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,1,Thyroid gland,,,In vivo,1,,13950,A,2046.0,Intermediate,CHEMBL624401,BAO_0000218,7513
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,1,Thyroid gland,,,In vivo,1,,13950,A,2046.0,Intermediate,CHEMBL624402,BAO_0000218,7514
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL624403,BAO_0000218,7515
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL624404,BAO_0000218,7516
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL624405,BAO_0000218,7517
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL624406,BAO_0000218,7518
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL624407,BAO_0000218,7519
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL624408,BAO_0000218,7520
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL618644,BAO_0000218,7521
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL618645,BAO_0000218,7522
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL618646,BAO_0000218,7523
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,Kidney,,,In vivo,1,,9866,A,2113.0,Intermediate,CHEMBL618647,BAO_0000218,7524
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,1,Kidney,,,In vivo,1,,9866,A,2113.0,Intermediate,CHEMBL618648,BAO_0000218,7525
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,1,Kidney,,,In vivo,1,,9866,A,2113.0,Intermediate,CHEMBL618649,BAO_0000218,7526
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL618650,BAO_0000218,7527
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL618651,BAO_0000218,7528
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL876497,BAO_0000218,7529
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,Lung,,,In vivo,1,,9866,A,2048.0,Intermediate,CHEMBL618652,BAO_0000218,7530
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,1,Lung,,,In vivo,1,,9866,A,2048.0,Intermediate,CHEMBL618653,BAO_0000218,7531
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,1,Lung,,,In vivo,1,,9866,A,2048.0,Intermediate,CHEMBL618654,BAO_0000218,7532
,,N,,,50597,10116.0,Rattus norvegicus,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,1,,,,,1,,6351,A,,Intermediate,CHEMBL618655,BAO_0000218,7533
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for solubility in water,1,,,,,1,,1465,A,,Intermediate,CHEMBL618656,BAO_0000218,7534
,,U,,,22229,,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),1,,,,,0,,5182,P,,Intermediate,CHEMBL618657,BAO_0000100,7535
,,N,,,50597,10116.0,Rattus norvegicus,Solubility was determined,1,,,,,1,,17847,A,,Intermediate,CHEMBL618658,BAO_0000218,7536
,,N,,,50597,10116.0,Rattus norvegicus,solubility in water (ug/mL) at 37 degree C.,1,,,,,1,,15339,A,,Intermediate,CHEMBL618659,BAO_0000218,7537
,,N,,,50597,10116.0,Rattus norvegicus,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,1,,,,,1,,5202,A,,Intermediate,CHEMBL618660,BAO_0000218,7538
,,N,,,50597,10116.0,Rattus norvegicus,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,1,,,,,1,,1088,A,,Intermediate,CHEMBL618661,BAO_0000218,7539
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rats,1,,,,,1,,3169,A,,Intermediate,CHEMBL873807,BAO_0000218,7540
,,N,,,50597,10116.0,Rattus norvegicus,Half life in Dawley rat,1,,,,,1,,5353,A,,Intermediate,CHEMBL618662,BAO_0000218,7541
,,N,,,50597,10116.0,Rattus norvegicus,Half life period after 3 mg/kg iv administration,1,,,,In vivo,1,,2864,A,,Intermediate,CHEMBL618663,BAO_0000218,7542
,,N,,,50597,10116.0,Rattus norvegicus,Half life period after 3 mg/kg iv administration in rat,1,,,,In vivo,1,,2864,A,,Intermediate,CHEMBL618664,BAO_0000218,7543
,,N,,,50597,10116.0,Rattus norvegicus,Half life period after 3 mg/kg iv administration in the rat,1,,,,In vivo,1,,2864,A,,Intermediate,CHEMBL618665,BAO_0000218,7544
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in female Sprague-Dawley rats,1,,,,,1,,6362,A,,Intermediate,CHEMBL876498,BAO_0000218,7545
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in rat,1,,,,,1,,6249,A,,Intermediate,CHEMBL618666,BAO_0000218,7546
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rats was determined,1,,,,,1,,3169,A,,Intermediate,CHEMBL620440,BAO_0000218,7547
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rats with metabolic oxidation,1,,,,,1,,3169,A,,Intermediate,CHEMBL620441,BAO_0000218,7548
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rats,1,,,,,1,,3169,A,,Intermediate,CHEMBL620442,BAO_0000218,7549
,,N,,,50597,10116.0,Rattus norvegicus,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,,,,In vivo,1,,17260,A,,Intermediate,CHEMBL620443,BAO_0000218,7550
,,N,,,50597,10116.0,Rattus norvegicus,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,,,,In vivo,1,,17260,A,,Intermediate,CHEMBL620444,BAO_0000218,7551
,,N,,,50597,10116.0,Rattus norvegicus,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,,,,In vivo,1,,17260,A,,Intermediate,CHEMBL620445,BAO_0000218,7552
,,N,,,50597,10116.0,Rattus norvegicus,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,,,,In vivo,1,,17260,A,,Intermediate,CHEMBL620446,BAO_0000218,7553
,,N,,,50597,10116.0,Rattus norvegicus,Biological half-life measured in plasma of rat,1,Plasma,,,,1,,2879,A,1969.0,Intermediate,CHEMBL620447,BAO_0000218,7554
,,N,,,50597,10116.0,Rattus norvegicus,Biological half-life measured in plasma of rat; 22-25,1,Plasma,,,,1,,2879,A,1969.0,Intermediate,CHEMBL621129,BAO_0000218,7555
,,N,,,50597,10116.0,Rattus norvegicus,Biological half-life measured in plasma of rat; 9-16,1,Plasma,,,,1,,2879,A,1969.0,Intermediate,CHEMBL621130,BAO_0000218,7556
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for its half life when administered intravenously in rat,1,,,,In vivo,1,,3184,A,,Intermediate,CHEMBL873808,BAO_0000218,7557
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,1,,,,In vivo,1,,4891,A,,Intermediate,CHEMBL876598,BAO_0000218,7558
,,N,,,50597,10116.0,Rattus norvegicus,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,1,,,,In vivo,1,,429,A,,Intermediate,CHEMBL621131,BAO_0000218,7559
,,N,,,50597,10116.0,Rattus norvegicus,Half life (T1/2) after oral administration in rat,1,,,,In vivo,1,,5656,A,,Intermediate,CHEMBL621132,BAO_0000218,7560
,,N,,,50597,10116.0,Rattus norvegicus,Half life of compound after iv administration of 20 mg/kg dose in rat,1,,,,In vivo,1,,4413,A,,Intermediate,CHEMBL621133,BAO_0000218,7561
,,N,,,50597,10116.0,Rattus norvegicus,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,1,,,,In vivo,1,,3598,A,,Expert,CHEMBL621312,BAO_0000218,7562
,,N,,,50597,10116.0,Rattus norvegicus,Half life of compound was determined in rat,1,,,,,1,,17267,A,,Intermediate,CHEMBL621313,BAO_0000218,7563
,,N,,,50597,10116.0,Rattus norvegicus,Half life of compound was determined in rat blood,1,Blood,,,,1,,4727,A,178.0,Intermediate,CHEMBL621314,BAO_0000218,7564
,,N,,,50597,10116.0,Rattus norvegicus,Half life at 1 mg/kg was determined in rat,1,,,,In vivo,1,,17651,A,,Intermediate,CHEMBL621315,BAO_0000218,7565
,,N,,,50597,10116.0,Rattus norvegicus,Half life at 10 mg/kg was determined in rat,1,,,,In vivo,1,,17651,A,,Intermediate,CHEMBL621316,BAO_0000218,7566
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rats,1,,,,,1,,401,A,,Intermediate,CHEMBL621317,BAO_0000218,7567
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rats in hours,1,,,,,1,,4942,A,,Intermediate,CHEMBL621318,BAO_0000218,7568
,,N,,,50597,10116.0,Rattus norvegicus,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,1,,,,In vivo,1,,17735,A,,Intermediate,CHEMBL621319,BAO_0000218,7569
,,N,,,50597,10116.0,Rattus norvegicus,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,1,,,,In vivo,1,,6056,A,,Intermediate,CHEMBL621377,BAO_0000218,7570
,,N,,,50597,10116.0,Rattus norvegicus,Half life was determined,1,,,,,1,,5213,A,,Intermediate,CHEMBL621378,BAO_0000218,7571
,,N,,,50597,10116.0,Rattus norvegicus,Half life after i.v. administration,1,,,,In vivo,1,,6616,A,,Intermediate,CHEMBL876599,BAO_0000218,7572
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,1,,,,In vivo,1,,5937,A,,Intermediate,CHEMBL621379,BAO_0000218,7573
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rat plasma,1,Plasma,,,,1,,5819,A,1969.0,Intermediate,CHEMBL621380,BAO_0000218,7574
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rat plasma; Not detected,1,Plasma,,,,1,,5819,A,1969.0,Intermediate,CHEMBL621381,BAO_0000218,7575
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rats,1,,,,,1,,6803,A,,Intermediate,CHEMBL618515,BAO_0000218,7576
,,N,,,50597,10116.0,Rattus norvegicus,Half life period of compound was determined after peroral administration,1,,,,In vivo,1,,17804,A,,Intermediate,CHEMBL618516,BAO_0000218,7577
,,N,,,50597,10116.0,Rattus norvegicus,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,1,,,,In vivo,1,,17804,A,,Intermediate,CHEMBL618517,BAO_0000218,7578
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in rat,1,,,,,1,,5948,A,,Intermediate,CHEMBL618518,BAO_0000218,7579
,,N,,,50597,10116.0,Rattus norvegicus,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,1,,,,In vivo,1,,1916,A,,Intermediate,CHEMBL618519,BAO_0000218,7580
,,N,,,50597,10116.0,Rattus norvegicus,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1,,,,In vivo,1,,1916,A,,Intermediate,CHEMBL618698,BAO_0000218,7581
,,N,,,50597,10116.0,Rattus norvegicus,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,1,,,,In vivo,1,,1916,A,,Intermediate,CHEMBL618862,BAO_0000218,7582
,,N,,,50597,10116.0,Rattus norvegicus,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,,,,In vivo,1,,4890,A,,Intermediate,CHEMBL618863,BAO_0000218,7583
,,N,,,50597,10116.0,Rattus norvegicus,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,1,,,,In vivo,1,,17764,A,,Intermediate,CHEMBL618864,BAO_0000218,7584
,,N,,,50597,10116.0,Rattus norvegicus,Half life time in rat the dose of 2 mg/kg,1,,,,In vivo,1,,4727,A,,Intermediate,CHEMBL618865,BAO_0000218,7585
,,N,,,50597,10116.0,Rattus norvegicus,Half-life 24 hr after 10 mg/kg iv administration in rats,1,,,,In vivo,1,,17509,A,,Intermediate,CHEMBL618866,BAO_0000218,7586
,,N,,,50597,10116.0,Rattus norvegicus,Half-life 24 hr after 2 mg/kg iv administration in rats,1,,,,In vivo,1,,17509,A,,Intermediate,CHEMBL618867,BAO_0000218,7587
,,N,,,50597,10116.0,Rattus norvegicus,Half-life consistent with the observed metabolic steady state in rats,1,,,,,1,,6597,A,,Intermediate,CHEMBL875828,BAO_0000218,7588
,,N,,,50597,10116.0,Rattus norvegicus,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,1,,,,In vivo,1,,17735,A,,Intermediate,CHEMBL618868,BAO_0000218,7589
,,N,,,50597,10116.0,Rattus norvegicus,Half-life for oxidative metabolic stability was determined using male human,1,,,,,1,,6597,A,,Intermediate,CHEMBL618869,BAO_0000218,7590
,,N,,,50597,10116.0,Rattus norvegicus,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",1,,,,In vivo,1,,17670,A,,Intermediate,CHEMBL618870,BAO_0000218,7591
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat plasma,1,Plasma,,,,1,,1696,A,1969.0,Intermediate,CHEMBL618871,BAO_0000218,7592
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat plasma was determined,1,Plasma,,,,1,,1742,A,1969.0,Intermediate,CHEMBL618872,BAO_0000218,7593
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rats was determined,1,,,,,1,,17800,A,,Intermediate,CHEMBL873816,BAO_0000218,7594
,,U,,,22224,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,1,,,,,0,,12923,A,,Autocuration,CHEMBL618873,BAO_0000218,7595
,,U,,,22224,,,Area under curve after oral dose of 0.1 mg//kg,1,,,,,0,,11954,A,,Autocuration,CHEMBL621602,BAO_0000019,7596
,,U,,,22224,,,Area under curve after oral dose of 0.3 mg/kg,1,,,,,0,,11954,A,,Autocuration,CHEMBL621603,BAO_0000218,7597
,,U,,,22224,,,Area under curve after oral dose of 1 mg/kg,1,,,,,0,,11954,A,,Autocuration,CHEMBL621604,BAO_0000218,7598
,,U,,,22224,,,Area under curve after oral dose of 10 mg/kg,1,,,,,0,,11954,A,,Autocuration,CHEMBL621605,BAO_0000218,7599
,,U,,,22224,,,Area under curve after oral dose of 23.4 mg/kg,1,,,,,0,,11954,A,,Autocuration,CHEMBL621606,BAO_0000218,7600
,,U,,,22224,,,Area under curve after oral dose of 3 mg/kg,1,,,,,0,,11954,A,,Autocuration,CHEMBL621607,BAO_0000218,7601
,,U,,,22224,,,Area under curve after oral dose of 3.87 mg/kg,1,,,,,0,,11954,A,,Autocuration,CHEMBL621608,BAO_0000218,7602
,,U,,,22224,,,Area under curve was determined,1,,,,,0,,5237,A,,Autocuration,CHEMBL621609,BAO_0000019,7603
,,U,,,22224,,,Area under curve at a dose of 10 mg/kg,1,,,,,0,,4026,A,,Autocuration,CHEMBL621610,BAO_0000218,7604
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined; ND=No data,1,,,,,1,,5237,A,,Intermediate,CHEMBL621611,BAO_0000218,7605
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,1,,,,,1,,14793,A,,Intermediate,CHEMBL621612,BAO_0000218,7606
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,1,,,,,1,,14793,A,,Intermediate,CHEMBL622308,BAO_0000218,7607
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,1,,,,,1,,14793,A,,Intermediate,CHEMBL622309,BAO_0000218,7608
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,1,,,,,1,,14793,A,,Intermediate,CHEMBL622310,BAO_0000218,7609
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,1,,,,,1,,14793,A,,Intermediate,CHEMBL622311,BAO_0000218,7610
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,1,,,,,1,,14793,A,,Intermediate,CHEMBL622312,BAO_0000218,7611
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,1,,,,,1,,14793,A,,Intermediate,CHEMBL622931,BAO_0000218,7612
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,1,,,,,1,,14793,A,,Intermediate,CHEMBL622932,BAO_0000218,7613
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,1,Plasma,,,,1,,14793,A,1969.0,Intermediate,CHEMBL622736,BAO_0000218,7614
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,1,Plasma,,,,1,,14793,A,1969.0,Intermediate,CHEMBL622737,BAO_0000218,7615
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,1,Plasma,,,,1,,14793,A,1969.0,Intermediate,CHEMBL622738,BAO_0000218,7616
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,1,Plasma,,,,1,,14793,A,1969.0,Intermediate,CHEMBL622739,BAO_0000218,7617
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,1,Plasma,,,,1,,14793,A,1969.0,Intermediate,CHEMBL622740,BAO_0000218,7618
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,1,Plasma,,,,1,,14793,A,1969.0,Intermediate,CHEMBL622741,BAO_0000218,7619
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,1,Plasma,,,,1,,14793,A,1969.0,Intermediate,CHEMBL622742,BAO_0000218,7620
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,1,Plasma,,,,1,,14793,A,1969.0,Intermediate,CHEMBL622743,BAO_0000218,7621
,,N,,,50594,10090.0,Mus musculus,AUC in mice,1,Plasma,,,,1,,11637,A,1969.0,Intermediate,CHEMBL622744,BAO_0000218,7622
,,U,,,22224,,,Area under curve was measured from the graph obtained from concentration Vs time,1,,,,,0,,11149,A,,Autocuration,CHEMBL624134,BAO_0000019,7623
,,U,,,22224,,,Area under curve value of compound per hour after oral administration,1,,,,,0,,10016,A,,Autocuration,CHEMBL624135,BAO_0000019,7624
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined after oral administration in rats,1,,,,,1,,17796,A,,Intermediate,CHEMBL624136,BAO_0000218,7625
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined after oral administration in rats; No data,1,,,,,1,,17796,A,,Intermediate,CHEMBL624137,BAO_0000218,7626
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined after oral administration in rats;No data,1,,,,,1,,17796,A,,Intermediate,CHEMBL624320,BAO_0000218,7627
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,1,,,,,1,,12923,A,,Intermediate,CHEMBL624321,BAO_0000218,7628
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,1,,,,,1,,15372,A,,Intermediate,CHEMBL624322,BAO_0000218,7629
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined for the compound after iv dose of 5.06 in rats,1,,,,,1,,15372,A,,Intermediate,CHEMBL624323,BAO_0000218,7630
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,1,,,,,1,,15372,A,,Intermediate,CHEMBL624324,BAO_0000218,7631
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,1,,,,,1,,15372,A,,Intermediate,CHEMBL624325,BAO_0000218,7632
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,1,,,,,1,,15372,A,,Intermediate,CHEMBL624326,BAO_0000218,7633
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,1,,,,,1,,15372,A,,Intermediate,CHEMBL624327,BAO_0000218,7634
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,1,,,,,1,,15372,A,,Intermediate,CHEMBL624328,BAO_0000218,7635
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve was determined in Dogs after peroral administration,1,,,,,1,,14169,A,,Intermediate,CHEMBL627848,BAO_0000218,7636
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined in Rats after peroral administration,1,,,,,1,,14169,A,,Intermediate,CHEMBL627849,BAO_0000218,7637
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined in carotid blood of rat when administered intradermally,1,,,,,1,,14258,A,,Intermediate,CHEMBL627850,BAO_0000218,7638
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined in portal blood of rat when administered intradermally,1,,,,,1,,14258,A,,Intermediate,CHEMBL627851,BAO_0000218,7639
,,N,,,50594,10090.0,Mus musculus,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,,,,,1,,15011,A,,Intermediate,CHEMBL627852,BAO_0000218,7640
,,N,,,50594,10090.0,Mus musculus,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,1,,,,,1,,15011,A,,Intermediate,CHEMBL627853,BAO_0000218,7641
,,N,,,50594,10090.0,Mus musculus,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),1,,,,,1,,15011,A,,Intermediate,CHEMBL627854,BAO_0000218,7642
,,N,,,50594,10090.0,Mus musculus,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,,,,,1,,15011,A,,Intermediate,CHEMBL627855,BAO_0000218,7643
,,N,,,50594,10090.0,Mus musculus,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),1,,,,,1,,15011,A,,Intermediate,CHEMBL627856,BAO_0000218,7644
,,N,,,50594,10090.0,Mus musculus,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,1,,,,,1,,15011,A,,Intermediate,CHEMBL875339,BAO_0000218,7645
,,N,,,50594,10090.0,Mus musculus,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),1,,,,,1,,15011,A,,Intermediate,CHEMBL627857,BAO_0000218,7646
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,1,Spleen,,,In vivo,1,,11195,A,2106.0,Intermediate,CHEMBL627858,BAO_0000218,7647
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,1,Blood,,,,1,,10130,A,178.0,Intermediate,CHEMBL627859,BAO_0000218,7648
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,1,Brain,,,,1,,10130,A,955.0,Intermediate,CHEMBL627860,BAO_0000218,7649
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,1,Heart,,,,1,,10130,A,948.0,Intermediate,CHEMBL627019,BAO_0000218,7650
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,1,Liver,,,,1,,10130,A,2107.0,Intermediate,CHEMBL627020,BAO_0000218,7651
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,1,Lung,,,,1,,10130,A,2048.0,Intermediate,CHEMBL627021,BAO_0000218,7652
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,1,Muscle tissue,,,,1,,10130,A,2385.0,Intermediate,CHEMBL627022,BAO_0000218,7653
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,1,,,,,1,,10130,A,,Intermediate,CHEMBL627023,BAO_0000218,7654
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,1,Spleen,,,,1,,10130,A,2106.0,Intermediate,CHEMBL627024,BAO_0000218,7655
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,1,Thyroid gland,,,,1,,10130,A,2046.0,Intermediate,CHEMBL627025,BAO_0000218,7656
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,1,Kidney,,,,1,,10130,A,2113.0,Intermediate,CHEMBL627026,BAO_0000218,7657
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,1,Blood,,,,1,,10130,A,178.0,Intermediate,CHEMBL627027,BAO_0000218,7658
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,1,Brain,,,,1,,10130,A,955.0,Intermediate,CHEMBL627028,BAO_0000218,7659
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,1,Heart,,,,1,,10130,A,948.0,Intermediate,CHEMBL627029,BAO_0000218,7660
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,1,Kidney,,,,1,,10130,A,2113.0,Intermediate,CHEMBL627030,BAO_0000218,7661
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,1,Liver,,,,1,,10130,A,2107.0,Intermediate,CHEMBL627031,BAO_0000218,7662
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,1,Lung,,,,1,,10130,A,2048.0,Intermediate,CHEMBL627032,BAO_0000218,7663
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,1,Muscle tissue,,,,1,,10130,A,2385.0,Intermediate,CHEMBL627033,BAO_0000218,7664
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,1,,,,,1,,10130,A,,Intermediate,CHEMBL627034,BAO_0000218,7665
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,1,Spleen,,,,1,,10130,A,2106.0,Intermediate,CHEMBL627035,BAO_0000218,7666
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,1,Thyroid gland,,,,1,,10130,A,2046.0,Intermediate,CHEMBL627036,BAO_0000218,7667
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,1,Blood,,,,1,,10130,A,178.0,Intermediate,CHEMBL875340,BAO_0000218,7668
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,1,Heart,,,,1,,10130,A,948.0,Intermediate,CHEMBL627037,BAO_0000218,7669
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,1,Kidney,,,,1,,10130,A,2113.0,Intermediate,CHEMBL627038,BAO_0000218,7670
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,1,Liver,,,,1,,10130,A,2107.0,Intermediate,CHEMBL627039,BAO_0000218,7671
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,1,Muscle tissue,,,,1,,10130,A,2385.0,Intermediate,CHEMBL627040,BAO_0000218,7672
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,1,Spleen,,,,1,,10130,A,2106.0,Intermediate,CHEMBL624663,BAO_0000218,7673
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,1,Thyroid gland,,,,1,,10130,A,2046.0,Intermediate,CHEMBL625963,BAO_0000218,7674
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,1,Brain,,,,1,,10130,A,955.0,Intermediate,CHEMBL876799,BAO_0000218,7675
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,1,Lung,,,,1,,10130,A,2048.0,Intermediate,CHEMBL626133,BAO_0000218,7676
,,N,,,50597,10116.0,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,1,,,,,1,,10130,A,,Intermediate,CHEMBL626134,BAO_0000218,7677
,,N,,,50597,10116.0,Rattus norvegicus,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,1,,,,,1,,6295,A,,Intermediate,CHEMBL626135,BAO_0000218,7678
,,N,,,50597,10116.0,Rattus norvegicus,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,1,,,,,1,,6296,A,,Intermediate,CHEMBL626136,BAO_0000218,7679
,,N,,,50597,10116.0,Rattus norvegicus,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,1,,,,,1,,6296,A,,Intermediate,CHEMBL626137,BAO_0000218,7680
,,N,,,50597,10116.0,Rattus norvegicus,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,1,,,,,1,,6295,A,,Intermediate,CHEMBL626138,BAO_0000218,7681
,,N,,,50597,10116.0,Rattus norvegicus,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,1,,,,,1,,6296,A,,Intermediate,CHEMBL626139,BAO_0000218,7682
,,N,,,50597,10116.0,Rattus norvegicus,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,,,,In vivo,1,,17260,A,,Intermediate,CHEMBL626140,BAO_0000218,7683
,,N,,,50597,10116.0,Rattus norvegicus,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,,,,In vivo,1,,17260,A,,Intermediate,CHEMBL626141,BAO_0000218,7684
,,N,,,50597,10116.0,Rattus norvegicus,C24h in rat p.o. at 20 mg/kg concentration,1,,,,,1,,17686,A,,Intermediate,CHEMBL626142,BAO_0000218,7685
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,Muscle tissue,,,In vivo,1,,9866,A,2385.0,Intermediate,CHEMBL627930,BAO_0000218,7686
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,1,Muscle tissue,,,In vivo,1,,9866,A,2385.0,Intermediate,CHEMBL627931,BAO_0000218,7687
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,1,Muscle tissue,,,In vivo,1,,9866,A,2385.0,Intermediate,CHEMBL627932,BAO_0000218,7688
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,Spleen,,,In vivo,1,,9866,A,2106.0,Intermediate,CHEMBL627933,BAO_0000218,7689
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,1,Spleen,,,In vivo,1,,9866,A,2106.0,Intermediate,CHEMBL627934,BAO_0000218,7690
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,1,Spleen,,,In vivo,1,,9866,A,2106.0,Intermediate,CHEMBL627935,BAO_0000218,7691
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL627936,BAO_0000218,7692
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL627937,BAO_0000218,7693
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL627938,BAO_0000218,7694
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL627939,BAO_0000218,7695
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL627940,BAO_0000218,7696
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL627941,BAO_0000218,7697
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL876800,BAO_0000218,7698
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL627942,BAO_0000218,7699
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL627943,BAO_0000218,7700
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL627944,BAO_0000218,7701
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL627945,BAO_0000218,7702
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL628584,BAO_0000218,7703
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA at 15 min,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL628585,BAO_0000218,7704
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL628586,BAO_0000218,7705
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA at 30 min,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL628587,BAO_0000218,7706
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL628588,BAO_0000218,7707
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL628589,BAO_0000218,7708
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL625304,BAO_0000218,7709
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL625305,BAO_0000218,7710
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL625306,BAO_0000218,7711
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL625307,BAO_0000218,7712
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL625308,BAO_0000218,7713
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL627740,BAO_0000218,7714
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL627741,BAO_0000218,7715
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL627742,BAO_0000218,7716
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL627743,BAO_0000218,7717
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,1,Blood,,,In vivo,1,,9866,A,178.0,Intermediate,CHEMBL627744,BAO_0000218,7718
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL627745,BAO_0000218,7719
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL627746,BAO_0000218,7720
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL627747,BAO_0000218,7721
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL876810,BAO_0000218,7722
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL627748,BAO_0000218,7723
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL627749,BAO_0000218,7724
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL627750,BAO_0000218,7725
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL618728,BAO_0000218,7726
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL618729,BAO_0000218,7727
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA at 15 min,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL618730,BAO_0000218,7728
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL618731,BAO_0000218,7729
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA at 30 min,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL618732,BAO_0000218,7730
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL618733,BAO_0000218,7731
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL618734,BAO_0000218,7732
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL618735,BAO_0000218,7733
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL876602,BAO_0000218,7734
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL618736,BAO_0000218,7735
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL618737,BAO_0000218,7736
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL618738,BAO_0000218,7737
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL618739,BAO_0000218,7738
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL618740,BAO_0000218,7739
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL618741,BAO_0000218,7740
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL618742,BAO_0000218,7741
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,1,Bone,,,In vivo,1,,9866,A,10000001.0,Intermediate,CHEMBL618743,BAO_0000218,7742
,,N,,,50597,10116.0,Rattus norvegicus,Half-life from rat plasma at a single oral dose of 25 mg/kg,1,Plasma,,,In vivo,1,,17752,A,1969.0,Intermediate,CHEMBL618744,BAO_0000218,7743
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in male rat,1,,,,,1,,5610,A,,Intermediate,CHEMBL618745,BAO_0000218,7744
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat after peroral administration at 10 mg/kg concentration,1,,,,In vivo,1,,5939,A,,Intermediate,CHEMBL620479,BAO_0000218,7745
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat after peroral administration at 5 mg/kg concentration,1,,,,In vivo,1,,5939,A,,Intermediate,CHEMBL620480,BAO_0000218,7746
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat at a dose of 3 mg/kg,1,,,,In vivo,1,,17771,A,,Intermediate,CHEMBL620481,BAO_0000218,7747
,,N,,,50597,10116.0,Rattus norvegicus,Half-life was evaluated in rats,1,,,,,1,,1974,A,,Intermediate,CHEMBL620482,BAO_0000218,7748
,,N,,,50597,10116.0,Rattus norvegicus,Half-life was measured in rat,1,,,,,1,,4239,A,,Intermediate,CHEMBL876603,BAO_0000218,7749
,,N,,,50597,10116.0,Rattus norvegicus,Half-life period for the compound was determined in rats at 50 mg/kg dose,1,,,,In vivo,1,,6681,A,,Intermediate,CHEMBL620483,BAO_0000218,7750
,,N,,,50597,10116.0,Rattus norvegicus,Half-life period in rats after intravenous administration at 5 mg/kg,1,,,,In vivo,1,,17752,A,,Intermediate,CHEMBL620484,BAO_0000218,7751
,,N,,,50597,10116.0,Rattus norvegicus,Half-life period in rat at 10 mg/kg,1,,,,In vivo,1,,6046,A,,Intermediate,CHEMBL620485,BAO_0000218,7752
,,N,,,50597,10116.0,Rattus norvegicus,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",1,,,,In vivo,1,,6685,A,,Intermediate,CHEMBL620486,BAO_0000218,7753
,,N,,,50597,10116.0,Rattus norvegicus,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",1,,,,In vivo,1,,6685,A,,Intermediate,CHEMBL620487,BAO_0000218,7754
,,N,,,50597,10116.0,Rattus norvegicus,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",1,,,,In vivo,1,,6685,A,,Intermediate,CHEMBL620488,BAO_0000218,7755
,,N,,,50597,10116.0,Rattus norvegicus,Half-life time in rat the dose of 2 mg/kg,1,,,,In vivo,1,,4727,A,,Intermediate,CHEMBL620489,BAO_0000218,7756
,,N,,,50597,10116.0,Rattus norvegicus,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,1,,,,In vivo,1,,1088,A,,Intermediate,CHEMBL620490,BAO_0000218,7757
,,N,,,50597,10116.0,Rattus norvegicus,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,1,,,,In vivo,1,,5610,A,,Intermediate,CHEMBL620491,BAO_0000218,7758
,,N,,,50597,10116.0,Rattus norvegicus,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",1,Plasma,,,In vivo,1,,3032,A,1969.0,Intermediate,CHEMBL876604,BAO_0000218,7759
,,N,,,50597,10116.0,Rattus norvegicus,Oral half life was determined,1,,,,In vivo,1,,5199,A,,Intermediate,CHEMBL620492,BAO_0000218,7760
,,N,,,50597,10116.0,Rattus norvegicus,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",1,,,,In vivo,1,,14941,A,,Intermediate,CHEMBL620493,BAO_0000218,7761
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (t1/2) in rat,1,,,,In vivo,1,,4408,A,,Intermediate,CHEMBL620494,BAO_0000218,7762
,,N,,,50597,10116.0,Rattus norvegicus,Plasma elimination half-life was determined,1,Plasma,,,,1,,2552,A,1969.0,Intermediate,CHEMBL620495,BAO_0000218,7763
,,N,,,50597,10116.0,Rattus norvegicus,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,1,Plasma,,,In vivo,1,,5199,A,1969.0,Intermediate,CHEMBL620496,BAO_0000218,7764
,,N,,,50597,10116.0,Rattus norvegicus,Plasma half life was observed after intravenous administration in rat,1,Plasma,,,In vivo,1,,15662,A,1969.0,Intermediate,CHEMBL620497,BAO_0000218,7765
,,N,,,50597,10116.0,Rattus norvegicus,Plasma half-life was determined,1,Plasma,,,,1,,1465,A,1969.0,Intermediate,CHEMBL620498,BAO_0000218,7766
,,N,,,50597,10116.0,Rattus norvegicus,Plasma half-life following oral administration in Fisher rats,1,Plasma,,,In vivo,1,,1446,A,1969.0,Intermediate,CHEMBL620499,BAO_0000218,7767
,,N,,,50597,10116.0,Rattus norvegicus,Plasma half-life in rat,1,Plasma,,,,1,,6824,A,1969.0,Intermediate,CHEMBL620500,BAO_0000218,7768
,,N,,,50597,10116.0,Rattus norvegicus,Plasmatic Half-life after intravenous administration to rat,1,Plasma,,,In vivo,1,,17533,A,1969.0,Intermediate,CHEMBL873809,BAO_0000218,7769
,,N,,,50597,10116.0,Rattus norvegicus,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,1,,,,In vivo,1,,5979,A,,Intermediate,CHEMBL620501,BAO_0000218,7770
,,N,,,50597,10116.0,Rattus norvegicus,Terminal half life after intravenous administration (1 mg/kg) in rat,1,,,,In vivo,1,,4689,A,,Intermediate,CHEMBL620502,BAO_0000218,7771
,,N,,,50597,10116.0,Rattus norvegicus,Terminal half life in Rat at a oral dose of 5 mg/kg,1,,,,In vivo,1,,4689,A,,Intermediate,CHEMBL620503,BAO_0000218,7772
,,N,,,50597,10116.0,Rattus norvegicus,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,1,,,,In vivo,1,,2463,A,,Intermediate,CHEMBL620504,BAO_0000218,7773
,,N,,,50597,10116.0,Rattus norvegicus,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,1,,,,In vivo,1,,4883,A,,Intermediate,CHEMBL876605,BAO_0000218,7774
,,N,,,50597,10116.0,Rattus norvegicus,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,1,,,,In vivo,1,,4883,A,,Intermediate,CHEMBL620505,BAO_0000218,7775
,,N,,,50597,10116.0,Rattus norvegicus,plasma half life was observed after intravenous administration in rat,1,Plasma,,,In vivo,1,,15662,A,1969.0,Intermediate,CHEMBL873811,BAO_0000218,7776
,,N,,,50597,10116.0,Rattus norvegicus,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,1,,,,In vivo,1,,3598,A,,Expert,CHEMBL624016,BAO_0000218,7777
,,N,,,50597,10116.0,Rattus norvegicus,Half life of compound determined in rat,1,,,,,1,,4576,A,,Intermediate,CHEMBL624017,BAO_0000218,7778
,,N,,,50597,10116.0,Rattus norvegicus,Mean residence time determined in rat,1,,,,,1,,4576,A,,Intermediate,CHEMBL624018,BAO_0000218,7779
,,N,,,50597,10116.0,Rattus norvegicus,Plasma half life determined in rat,1,,,,,1,,4576,A,,Intermediate,CHEMBL624019,BAO_0000218,7780
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for Tmax in brain after intravenous administration in male rats,1,Brain,,,In vivo,1,,4910,A,955.0,Intermediate,CHEMBL624020,BAO_0000218,7781
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for pharmacokinetic parameter maximum time period,1,,,,In vivo,1,,4891,A,,Intermediate,CHEMBL624201,BAO_0000218,7782
,,N,,,50597,10116.0,Rattus norvegicus,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,1,,,,In vivo,1,,429,A,,Intermediate,CHEMBL872528,BAO_0000218,7783
,,N,,,50597,10116.0,Rattus norvegicus,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,,,,In vivo,1,,5974,A,,Intermediate,CHEMBL624202,BAO_0000218,7784
,,N,,,50597,10116.0,Rattus norvegicus,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,,,,In vivo,1,,5974,A,,Intermediate,CHEMBL624203,BAO_0000218,7785
,,N,,,50597,10116.0,Rattus norvegicus,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,,,,In vivo,1,,5974,A,,Intermediate,CHEMBL624350,BAO_0000218,7786
,,N,,,50597,10116.0,Rattus norvegicus,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,,,,In vivo,1,,5974,A,,Intermediate,CHEMBL621320,BAO_0000218,7787
,,N,,,50597,10116.0,Rattus norvegicus,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,1,,,,In vivo,1,,17582,A,,Intermediate,CHEMBL621321,BAO_0000218,7788
,,N,,,50597,10116.0,Rattus norvegicus,Maximum time (Tmax) required to reach Cmax in rats,1,,,,,1,,4026,A,,Intermediate,CHEMBL621322,BAO_0000218,7789
,,N,,,50597,10116.0,Rattus norvegicus,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,1,,,,In vivo,1,,4890,A,,Intermediate,CHEMBL621323,BAO_0000218,7790
,,N,,,50597,10116.0,Rattus norvegicus,Maximum time of clearance of compound in rats after peroral administration,1,,,,In vivo,1,,6571,A,,Intermediate,CHEMBL621324,BAO_0000218,7791
,,N,,,50597,10116.0,Rattus norvegicus,Maximum time at the dose of 2 mg/kg in rat,1,,,,,1,,4727,A,,Intermediate,CHEMBL621325,BAO_0000218,7792
,,N,,,50597,10116.0,Rattus norvegicus,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,1,Plasma,,,In vivo,1,,17651,A,1969.0,Intermediate,CHEMBL875837,BAO_0000218,7793
,,N,,,50597,10116.0,Rattus norvegicus,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,1,Plasma,,,In vivo,1,,17651,A,1969.0,Intermediate,CHEMBL621326,BAO_0000218,7794
,,N,,,50597,10116.0,Rattus norvegicus,Tmax in Guinea pig (PO dose),1,,,,In vivo,1,,14465,A,,Intermediate,CHEMBL621327,BAO_0000218,7795
,,N,,,50597,10116.0,Rattus norvegicus,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",1,,,,In vivo,1,,14941,A,,Intermediate,CHEMBL621328,BAO_0000218,7796
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter (Tmax) in rat,1,,,,In vivo,1,,5960,A,,Intermediate,CHEMBL621329,BAO_0000218,7797
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter (Tmax) was estimated,1,,,,In vivo,1,,5022,A,,Intermediate,CHEMBL621330,BAO_0000218,7798
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (Tmax) in rat,1,,,,In vivo,1,,4408,A,,Intermediate,CHEMBL621331,BAO_0000218,7799
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,1,,,,In vivo,1,,5983,A,,Intermediate,CHEMBL621332,BAO_0000218,7800
,,N,,,50597,10116.0,Rattus norvegicus,T max in Rat at a oral dose of 5 mg/kg,1,,,,In vivo,1,,4689,A,,Intermediate,CHEMBL621333,BAO_0000218,7801
,,N,,,50597,10116.0,Rattus norvegicus,T max was determined at 10 mg/kg po dose in rats,1,,,,In vivo,1,,2792,A,,Intermediate,CHEMBL621334,BAO_0000218,7802
,,N,,,50594,10090.0,Mus musculus,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),1,,,,,1,,15011,A,,Intermediate,CHEMBL621335,BAO_0000218,7803
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,1,,,,,1,,14180,A,,Intermediate,CHEMBL621336,BAO_0000218,7804
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,1,,,,,1,,14180,A,,Intermediate,CHEMBL621337,BAO_0000218,7805
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve was measured after i.v. administration into Beagle dog.,1,,,,,1,,14599,A,,Intermediate,CHEMBL621338,BAO_0000218,7806
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve was measured after iv administration into Beagle dog,1,,,,,1,,14599,A,,Intermediate,CHEMBL875838,BAO_0000218,7807
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve was measured after po administration into Beagle dog,1,,,,,1,,14599,A,,Intermediate,CHEMBL621339,BAO_0000218,7808
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve was measured after po administration into Beagle dog.,1,,,,,1,,14599,A,,Intermediate,CHEMBL621340,BAO_0000218,7809
,,U,,,22224,,,Area under curve was measured at peroral dose of 3 mg/kg,1,,,,,0,,15675,A,,Autocuration,CHEMBL621341,BAO_0000218,7810
,,U,,,22224,,,Area under curve was measured by using concentration Vs time,1,,,,,0,,12706,A,,Autocuration,CHEMBL621342,BAO_0000019,7811
,,U,,,22224,,,Area under curve was measured by using concentration Vs time; not tested,1,,,,,0,,12706,A,,Autocuration,CHEMBL621343,BAO_0000019,7812
,,N,,,50594,10090.0,Mus musculus,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),1,,,,,1,,9750,A,,Intermediate,CHEMBL621344,BAO_0000218,7813
,,N,,,50594,10090.0,Mus musculus,Area under curve(AUC) was measured in mice after oral administration.,1,,,,,1,,9750,A,,Intermediate,CHEMBL621345,BAO_0000218,7814
,,U,,,22224,,,Area under curve(AUC) value of the compound,1,,,,,0,,14691,A,,Autocuration,CHEMBL621346,BAO_0000019,7815
,,U,,,22224,,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,1,,,,,0,,14691,A,,Autocuration,CHEMBL621347,BAO_0000218,7816
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,1,,,,,1,,14691,A,,Intermediate,CHEMBL621348,BAO_0000218,7817
,,U,,,22224,,,Area under curve(carotid artery) was determined by the availability in blood,1,Blood,,,,0,,2939,A,178.0,Autocuration,CHEMBL621349,BAO_0000019,7818
,,U,,,22224,,,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,1,Blood,,,,0,,2939,A,178.0,Autocuration,CHEMBL621350,BAO_0000019,7819
,,U,,,22224,,,Area under curve(carotid artery) was determined by the availability in blood; No data,1,Blood,,,,0,,2939,A,178.0,Autocuration,CHEMBL875839,BAO_0000019,7820
,,U,,,22224,,,Area under curve(portal vein) was determined by the availability in blood,1,Blood,,,,0,,2939,A,178.0,Autocuration,CHEMBL620211,BAO_0000019,7821
,,U,,,22224,,,Area under curve(portal vein) was determined by the availability in blood; ND means no data,1,Blood,,,,0,,2939,A,178.0,Autocuration,CHEMBL620212,BAO_0000019,7822
,,U,,,22224,,,Area under curve(portal vein) was determined by the availability in blood; No data,1,Blood,,,,0,,2939,A,178.0,Autocuration,CHEMBL620213,BAO_0000019,7823
,,N,,,50797,9544.0,Macaca mulatta,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",1,Plasma,,,,1,,9552,A,1969.0,Intermediate,CHEMBL620214,BAO_0000218,7824
,,N,,,50797,9544.0,Macaca mulatta,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",1,Plasma,,,,1,,9552,A,1969.0,Intermediate,CHEMBL620215,BAO_0000218,7825
,,N,,,50797,9544.0,Macaca mulatta,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,1,Plasma,,,,1,,9552,A,1969.0,Intermediate,CHEMBL620216,BAO_0000218,7826
,,N,,,50588,9615.0,Canis lupus familiaris,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",1,Plasma,,,,1,,9552,A,1969.0,Intermediate,CHEMBL620888,BAO_0000218,7827
,,N,,,50588,9615.0,Canis lupus familiaris,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",1,Plasma,,,,1,,9552,A,1969.0,Intermediate,CHEMBL620889,BAO_0000218,7828
,,U,,,22224,,,Area under plasma concentration vs time curve observed in rats for 0-3 h,1,Plasma,,,,0,,9552,A,1969.0,Autocuration,CHEMBL620890,BAO_0000019,7829
,,N,,,50597,10116.0,Rattus norvegicus,Area under plasma time curve determined in male rat,1,Plasma,,,,1,,11911,A,1969.0,Intermediate,CHEMBL620891,BAO_0000218,7830
,,U,,,22224,,,Area under the MAP curve measured over 5 min.,1,,,,,0,,16618,A,,Autocuration,CHEMBL620892,BAO_0000019,7831
,,N,,,50594,10090.0,Mus musculus,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,1,,,,,1,,14387,A,,Intermediate,CHEMBL621079,BAO_0000218,7832
,,N,,,50594,10090.0,Mus musculus,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,1,,,,,1,,14387,A,,Intermediate,CHEMBL621080,BAO_0000218,7833
,,N,,,50588,9615.0,Canis lupus familiaris,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,1,,,,,1,,12836,A,,Intermediate,CHEMBL621081,BAO_0000218,7834
,,N,,,100712,10026.0,Cricetinae,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,1,,,,,1,,12836,A,,Intermediate,CHEMBL621082,BAO_0000218,7835
,,N,,,50597,10116.0,Rattus norvegicus,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,1,,,,,1,,12836,A,,Intermediate,CHEMBL621083,BAO_0000218,7836
,,N,,,50588,9615.0,Canis lupus familiaris,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,1,,,,,1,,14339,A,,Intermediate,CHEMBL621084,BAO_0000218,7837
,,N,,,50588,9615.0,Canis lupus familiaris,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,1,,,,,1,,14339,A,,Intermediate,CHEMBL621085,BAO_0000218,7838
,,N,,,50588,9615.0,Canis lupus familiaris,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,1,,,,,1,,14339,A,,Intermediate,CHEMBL621086,BAO_0000218,7839
,,N,,,50588,9615.0,Canis lupus familiaris,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),1,,,,,1,,10524,A,,Intermediate,CHEMBL621087,BAO_0000218,7840
,,N,,,50588,9615.0,Canis lupus familiaris,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),1,,,,,1,,9994,A,,Intermediate,CHEMBL622607,BAO_0000218,7841
,,N,,,50588,9615.0,Canis lupus familiaris,Serum AUC in marmosets (IV dose),1,,,,,1,,11325,A,,Intermediate,CHEMBL622608,BAO_0000218,7842
,,U,,,22224,,,Area under the curve after intravenous administration at a dose of 10 umol/kg,1,,,,,0,,12536,A,,Autocuration,CHEMBL624481,BAO_0000019,7843
,,U,,,22224,,,Area under the curve after intravenous administration at a dose of 2 umol/kg,1,,,,,0,,12536,A,,Autocuration,CHEMBL624482,BAO_0000019,7844
,,U,,,22224,,,Area under the curve after intravenous administration at a dose of 4 umol/kg,1,,,,,0,,12536,A,,Autocuration,CHEMBL624483,BAO_0000019,7845
,,U,,,22224,,,Area under the curve after intravenous administration at a dose of 40 umol/kg,1,,,,,0,,12536,A,,Autocuration,CHEMBL624484,BAO_0000019,7846
,,U,,,22224,,,Area under the curve after intravenous administration at a dose of 5 umol/kg,1,,,,,0,,12536,A,,Autocuration,CHEMBL624485,BAO_0000019,7847
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve for fumarate salt was evaluated in F344 Rats.,1,,,,,1,,15556,A,,Intermediate,CHEMBL624486,BAO_0000218,7848
,,U,,,22224,,,Area under the curve for the compound was calculated.,1,,,,,0,,2809,A,,Autocuration,CHEMBL624487,BAO_0000019,7849
,,U,,,22224,,,Area under the curve in concentration/ time,1,,,,,0,,9511,A,,Autocuration,CHEMBL624488,BAO_0000019,7850
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve administered intraintestinal in rats.,1,,,,,1,,12818,A,,Intermediate,CHEMBL624489,BAO_0000218,7851
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve administered intravenously in rats.,1,,,,,1,,12818,A,,Intermediate,CHEMBL625184,BAO_0000218,7852
,,U,,,22224,,,Area under the curve during intravenous administration,1,,,,,0,,15118,A,,Autocuration,CHEMBL625185,BAO_0000019,7853
,,U,,,22224,,,Area under the curve during intravenous administration; Not determined,1,,,,,0,,15118,A,,Autocuration,CHEMBL875954,BAO_0000019,7854
,,U,,,22224,,,Area under the curve during systemic administration,1,,,,,0,,15118,A,,Autocuration,CHEMBL625186,BAO_0000019,7855
,,U,,,22224,,,Area under the curve during systemic administration; Not determined,1,,,,,0,,15118,A,,Autocuration,CHEMBL625187,BAO_0000019,7856
,,U,,,22224,,,Area under the curve was calculated for the compound.,1,,,,,0,,2632,A,,Autocuration,CHEMBL625188,BAO_0000019,7857
,,N,,,50588,9615.0,Canis lupus familiaris,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,1,,,,,1,,14346,A,,Intermediate,CHEMBL625189,BAO_0000218,7858
,,N,,,50588,9615.0,Canis lupus familiaris,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,1,,,,,1,,14346,A,,Intermediate,CHEMBL625190,BAO_0000218,7859
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,1,,,,,1,,14346,A,,Intermediate,CHEMBL621733,BAO_0000218,7860
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,1,,,,,1,,14346,A,,Intermediate,CHEMBL621734,BAO_0000218,7861
,,N,,,50597,10116.0,Rattus norvegicus,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,1,,,,,1,,11149,A,,Intermediate,CHEMBL621735,BAO_0000218,7862
,,N,,,50597,10116.0,Rattus norvegicus,Clearance of the drug was measured in the plasma of rat; No data,1,Plasma,,,,1,,17796,A,1969.0,Intermediate,CHEMBL621736,BAO_0000218,7863
,,N,,,50597,10116.0,Rattus norvegicus,The pharmacokinetic parameter plasma clearance in vivo in rats,1,Plasma,,,,1,,5247,A,1969.0,Intermediate,CHEMBL621737,BAO_0000218,7864
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance at the dose of 2 mg/kg in rat,1,,,,,1,,4727,A,,Intermediate,CHEMBL621738,BAO_0000218,7865
,,N,,,50597,10116.0,Rattus norvegicus,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,,,,In vivo,1,,5654,A,,Intermediate,CHEMBL622806,BAO_0000218,7866
,,N,,,50597,10116.0,Rattus norvegicus,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,,,,In vivo,1,,5654,A,,Intermediate,CHEMBL623519,BAO_0000218,7867
,,N,,,50597,10116.0,Rattus norvegicus,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,,,,In vivo,1,,17260,A,,Intermediate,CHEMBL623520,BAO_0000218,7868
,,N,,,50597,10116.0,Rattus norvegicus,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,,,,In vivo,1,,17065,A,,Intermediate,CHEMBL623521,BAO_0000218,7869
,,N,,,50597,10116.0,Rattus norvegicus,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,,,,In vivo,1,,17671,A,,Intermediate,CHEMBL623522,BAO_0000218,7870
,,N,,,50597,10116.0,Rattus norvegicus,Clearance rate in rat,1,,,,In vivo,1,,6672,A,,Intermediate,CHEMBL623523,BAO_0000218,7871
,,N,,,50597,10116.0,Rattus norvegicus,Clearance rate in rat,1,,,,In vivo,1,,6673,A,,Intermediate,CHEMBL623690,BAO_0000218,7872
,,N,,,50597,10116.0,Rattus norvegicus,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL623691,BAO_0000218,7873
,,N,,,50597,10116.0,Rattus norvegicus,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL623692,BAO_0000218,7874
,,N,,,50597,10116.0,Rattus norvegicus,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL623693,BAO_0000218,7875
,,N,,,50597,10116.0,Rattus norvegicus,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL623694,BAO_0000218,7876
,,N,,,50597,10116.0,Rattus norvegicus,Clearance of compound after iv administration of 20 mg/kg dose in rat,1,,,,In vivo,1,,4413,A,,Intermediate,CHEMBL623695,BAO_0000218,7877
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,1,,,,In vivo,1,,2661,A,,Intermediate,CHEMBL623696,BAO_0000218,7878
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,1,,,,In vivo,1,,2661,A,,Intermediate,CHEMBL623697,BAO_0000218,7879
,,U,,,22224,9544.0,Macaca mulatta,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1,Plasma,,,In vivo,0,,5005,A,1969.0,Intermediate,CHEMBL623698,BAO_0000218,7880
,,U,,,22224,10116.0,Rattus norvegicus,Compound was tested for its plasma clearance rate in Sprague Dawley rats,1,Plasma,,,In vivo,0,,5005,A,1969.0,Intermediate,CHEMBL623699,BAO_0000218,7881
,,N,,,50597,10116.0,Rattus norvegicus,Mean (%CV) PK parameters for CL(mL/min/kg).,1,,,,In vivo,1,,15765,A,,Intermediate,CHEMBL623700,BAO_0000218,7882
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,1,,,,In vivo,1,,3747,A,,Intermediate,CHEMBL623701,BAO_0000218,7883
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,1,Plasma,,,In vivo,1,,16366,A,1969.0,Intermediate,CHEMBL623702,BAO_0000218,7884
,,N,,,50597,10116.0,Rattus norvegicus,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,1,,,,In vivo,1,,4199,A,,Intermediate,CHEMBL623703,BAO_0000218,7885
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rat was determined,1,,,,In vivo,1,,17267,A,,Intermediate,CHEMBL623704,BAO_0000218,7886
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rat after administration of 2 mg/kg iv,1,,,,In vivo,1,,6535,A,,Intermediate,CHEMBL623705,BAO_0000218,7887
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rat after administration of 2 mg/kg iv,1,,,,In vivo,1,,6535,A,,Intermediate,CHEMBL623706,BAO_0000218,7888
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance was determined,1,,,,In vivo,1,,5041,A,,Intermediate,CHEMBL623707,BAO_0000218,7889
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rat,1,,,,In vivo,1,,5960,A,,Intermediate,CHEMBL623708,BAO_0000218,7890
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,1,,,,In vivo,1,,5937,A,,Intermediate,CHEMBL623709,BAO_0000218,7891
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rat by iv administration,1,,,,In vivo,1,,5871,A,,Intermediate,CHEMBL623710,BAO_0000218,7892
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,1,,,,In vivo,1,,5874,A,,Intermediate,CHEMBL623711,BAO_0000218,7893
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rat p.o.,1,,,,In vivo,1,,6504,A,,Intermediate,CHEMBL623712,BAO_0000218,7894
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rats,1,,,,In vivo,1,,6803,A,,Intermediate,CHEMBL623713,BAO_0000218,7895
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance was determined; ND denotes no data,1,,,,In vivo,1,,5041,A,,Intermediate,CHEMBL623714,BAO_0000218,7896
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance was determined; ND denotes not determined,1,,,,In vivo,1,,5041,A,,Intermediate,CHEMBL623715,BAO_0000218,7897
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,1,,,,In vivo,1,,1916,A,,Intermediate,CHEMBL623716,BAO_0000218,7898
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,1,,,,In vivo,1,,5199,A,,Intermediate,CHEMBL622980,BAO_0000218,7899
,,N,,,50597,10116.0,Rattus norvegicus,Plasma administration to rats,1,,,,In vivo,1,,16367,A,,Intermediate,CHEMBL622981,BAO_0000218,7900
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance of the compound in female Sprague-Dawley rats,1,,,,In vivo,1,,6362,A,,Intermediate,CHEMBL622982,BAO_0000218,7901
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance was observed after intravenous administration in rat,1,,,,In vivo,1,,15662,A,,Intermediate,CHEMBL622983,BAO_0000218,7902
,,N,,,50597,10116.0,Rattus norvegicus,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,1,,,,In vivo,1,,6215,A,,Intermediate,CHEMBL622984,BAO_0000218,7903
,,N,,,50597,10116.0,Rattus norvegicus,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,1,,,,In vivo,1,,1466,A,,Intermediate,CHEMBL622985,BAO_0000218,7904
,,N,,,50597,10116.0,Rattus norvegicus,plasma clearance was observed after intravenous administration in rat,1,Plasma,,,In vivo,1,,15662,A,1969.0,Intermediate,CHEMBL623631,BAO_0000218,7905
,,N,,,50597,10116.0,Rattus norvegicus,In vivo CL/F determined,1,,,,In vivo,1,,4723,A,,Intermediate,CHEMBL623632,BAO_0000218,7906
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,1,Plasma,,,In vivo,1,,2792,A,1969.0,Intermediate,CHEMBL623633,BAO_0000218,7907
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,1,Plasma,,,In vivo,1,,2792,A,1969.0,Intermediate,CHEMBL623634,BAO_0000218,7908
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for the lower blood clearance in rat,1,,,,In vivo,1,,5213,A,,Intermediate,CHEMBL623635,BAO_0000218,7909
,,N,,,50597,10116.0,Rattus norvegicus,Evaluated for the low clearance in rat (in vivo),1,,,,In vivo,1,,4687,A,,Intermediate,CHEMBL621195,BAO_0000218,7910
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (CLb)of the compound was determined in rat,1,,,,In vivo,1,,3371,A,,Intermediate,CHEMBL621196,BAO_0000218,7911
,,N,,,50597,10116.0,Rattus norvegicus,Rapid clearance after intravenous administration in rat was determined,1,,,,In vivo,1,,4690,A,,Intermediate,CHEMBL875287,BAO_0000218,7912
,,N,,,50597,10116.0,Rattus norvegicus,Clearance measured in rat,1,,,,In vivo,1,,5702,A,,Intermediate,CHEMBL621197,BAO_0000218,7913
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for plasma clearance in rat,1,Plasma,,,In vivo,1,,740,A,1969.0,Intermediate,CHEMBL621198,BAO_0000218,7914
,,N,,,50597,10116.0,Rattus norvegicus,Low plasma clearance was calculated in rat,1,Plasma,,,In vivo,1,,4853,A,1969.0,Intermediate,CHEMBL621199,BAO_0000218,7915
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (Clp) in rat,1,,,,In vivo,1,,5789,A,,Intermediate,CHEMBL621200,BAO_0000218,7916
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,1,,,,In vivo,1,,4527,A,,Intermediate,CHEMBL621201,BAO_0000218,7917
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,1,,,,In vivo,1,,4527,A,,Intermediate,CHEMBL621202,BAO_0000218,7918
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance after IV dosing at 0.5 mg/kg in rat,1,,,,In vivo,1,,6518,A,,Intermediate,CHEMBL621203,BAO_0000218,7919
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance after IV dosing at 1 mg/kg in rat,1,,,,In vivo,1,,6518,A,,Intermediate,CHEMBL621204,BAO_0000218,7920
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL621205,BAO_0000218,7921
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL621206,BAO_0000218,7922
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL621207,BAO_0000218,7923
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL621208,BAO_0000218,7924
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL621209,BAO_0000218,7925
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL876484,BAO_0000218,7926
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL621210,BAO_0000218,7927
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL621211,BAO_0000218,7928
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL621212,BAO_0000218,7929
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA at 15 min,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL621213,BAO_0000218,7930
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL621214,BAO_0000218,7931
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA at 30 min,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL621215,BAO_0000218,7932
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL621216,BAO_0000218,7933
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL621217,BAO_0000218,7934
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL621218,BAO_0000218,7935
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL621219,BAO_0000218,7936
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL621220,BAO_0000218,7937
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL621221,BAO_0000218,7938
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL621222,BAO_0000218,7939
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL621223,BAO_0000218,7940
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL876485,BAO_0000218,7941
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL621224,BAO_0000218,7942
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL621225,BAO_0000218,7943
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,1,Heart,,,In vivo,1,,9866,A,948.0,Intermediate,CHEMBL621226,BAO_0000218,7944
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,1,Kidney,,,In vivo,1,,9866,A,2113.0,Intermediate,CHEMBL621227,BAO_0000218,7945
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,Kidney,,,In vivo,1,,9866,A,2113.0,Intermediate,CHEMBL621228,BAO_0000218,7946
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,1,Kidney,,,In vivo,1,,9866,A,2113.0,Intermediate,CHEMBL621229,BAO_0000218,7947
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,1,Kidney,,,In vivo,1,,9866,A,2113.0,Intermediate,CHEMBL621230,BAO_0000218,7948
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,1,Kidney,,,In vivo,1,,9866,A,2113.0,Intermediate,CHEMBL621231,BAO_0000218,7949
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,Kidney,,,In vivo,1,,9866,A,2113.0,Intermediate,CHEMBL621232,BAO_0000218,7950
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,Kidney,,,In vivo,1,,9866,A,2113.0,Intermediate,CHEMBL621233,BAO_0000218,7951
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,1,Kidney,,,In vivo,1,,9866,A,2113.0,Intermediate,CHEMBL621234,BAO_0000218,7952
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,1,Kidney,,,In vivo,1,,9866,A,2113.0,Intermediate,CHEMBL621235,BAO_0000218,7953
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,Kidney,,,In vivo,1,,9866,A,2113.0,Intermediate,CHEMBL621236,BAO_0000218,7954
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,1,Kidney,,,In vivo,1,,9866,A,2113.0,Intermediate,CHEMBL621237,BAO_0000218,7955
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,1,Kidney,,,In vivo,1,,9866,A,2113.0,Intermediate,CHEMBL876486,BAO_0000218,7956
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,1,Intestine,,,In vivo,1,,9866,A,160.0,Intermediate,CHEMBL622436,BAO_0000218,7957
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,1,Intestine,,,In vivo,1,,9866,A,160.0,Intermediate,CHEMBL622437,BAO_0000218,7958
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,1,Intestine,,,In vivo,1,,9866,A,160.0,Intermediate,CHEMBL622438,BAO_0000218,7959
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL622439,BAO_0000218,7960
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL622440,BAO_0000218,7961
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL622441,BAO_0000218,7962
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL622442,BAO_0000218,7963
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL622443,BAO_0000218,7964
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL622444,BAO_0000218,7965
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL622445,BAO_0000218,7966
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL622446,BAO_0000218,7967
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL622447,BAO_0000218,7968
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL622448,BAO_0000218,7969
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL622449,BAO_0000218,7970
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL622450,BAO_0000218,7971
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL622451,BAO_0000218,7972
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA at 15 min,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL622452,BAO_0000218,7973
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL622453,BAO_0000218,7974
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA at 30 min,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL622454,BAO_0000218,7975
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL622455,BAO_0000218,7976
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL876024,BAO_0000218,7977
,,N,,,50597,10116.0,Rattus norvegicus,T max was determined at 3 mg/kg po dose in rats,1,,,,In vivo,1,,2792,A,,Intermediate,CHEMBL622456,BAO_0000218,7978
,,N,,,50597,10116.0,Rattus norvegicus,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",1,,,,In vivo,1,,15078,A,,Intermediate,CHEMBL622457,BAO_0000218,7979
,,N,,,50597,10116.0,Rattus norvegicus,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",1,,,,In vivo,1,,15078,A,,Intermediate,CHEMBL622458,BAO_0000218,7980
,,N,,,50597,10116.0,Rattus norvegicus,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,1,,,,,1,,15022,A,,Intermediate,CHEMBL622459,BAO_0000218,7981
,,N,,,50597,10116.0,Rattus norvegicus,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,1,,,,,1,,15022,A,,Intermediate,CHEMBL873343,BAO_0000218,7982
,,N,,,50597,10116.0,Rattus norvegicus,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,1,,,,,1,,15022,A,,Intermediate,CHEMBL622460,BAO_0000218,7983
,,N,,,50597,10116.0,Rattus norvegicus,Time for maximum plasma concentration determined in rat,1,Plasma,,,,1,,4576,A,1969.0,Intermediate,CHEMBL622461,BAO_0000218,7984
,,N,,,50597,10116.0,Rattus norvegicus,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,1,Plasma,,,In vivo,1,,6681,A,1969.0,Intermediate,CHEMBL622462,BAO_0000218,7985
,,N,,,50597,10116.0,Rattus norvegicus,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,1,,,,In vivo,1,,16365,A,,Intermediate,CHEMBL622463,BAO_0000218,7986
,,N,,,50597,10116.0,Rattus norvegicus,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,1,,,,In vivo,1,,16365,A,,Intermediate,CHEMBL622464,BAO_0000218,7987
,,N,,,50597,10116.0,Rattus norvegicus,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,1,,,,In vivo,1,,16365,A,,Intermediate,CHEMBL622465,BAO_0000218,7988
,,N,,,50597,10116.0,Rattus norvegicus,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,1,,,,In vivo,1,,16365,A,,Intermediate,CHEMBL622466,BAO_0000218,7989
,,N,,,50597,10116.0,Rattus norvegicus,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,1,,,,In vivo,1,,16365,A,,Intermediate,CHEMBL622467,BAO_0000218,7990
,,N,,,50597,10116.0,Rattus norvegicus,Time of maximum plasma concentration in rat,1,Plasma,,,,1,,6824,A,1969.0,Intermediate,CHEMBL622468,BAO_0000218,7991
,,N,,,50597,10116.0,Rattus norvegicus,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",1,Plasma,,,,1,,6685,A,1969.0,Intermediate,CHEMBL876025,BAO_0000218,7992
,,N,,,50597,10116.0,Rattus norvegicus,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",1,Plasma,,,,1,,6685,A,1969.0,Intermediate,CHEMBL622469,BAO_0000218,7993
,,N,,,50597,10116.0,Rattus norvegicus,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1,Plasma,,,,1,,6685,A,1969.0,Intermediate,CHEMBL622470,BAO_0000218,7994
,,N,,,50597,10116.0,Rattus norvegicus,Time required to reach maximum concentration (Cmax) after oral administration in rat,1,,,,In vivo,1,,15662,A,,Intermediate,CHEMBL622471,BAO_0000218,7995
,,N,,,50597,10116.0,Rattus norvegicus,Time required to reach maximum concentration in rat plasma,1,Plasma,,,,1,,1742,A,1969.0,Intermediate,CHEMBL622472,BAO_0000218,7996
,,N,,,50597,10116.0,Rattus norvegicus,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,1,Plasma,,,In vivo,1,,2774,A,1969.0,Intermediate,CHEMBL622473,BAO_0000218,7997
,,N,,,50597,10116.0,Rattus norvegicus,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,1,Plasma,,,In vivo,1,,5199,A,1969.0,Intermediate,CHEMBL624282,BAO_0000218,7998
,,N,,,50597,10116.0,Rattus norvegicus,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,Plasma,,,In vivo,1,,12873,A,1969.0,Intermediate,CHEMBL624283,BAO_0000218,7999
,,N,,,50597,10116.0,Rattus norvegicus,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,Plasma,,,In vivo,1,,12873,A,1969.0,Intermediate,CHEMBL624284,BAO_0000218,8000
,,N,,,50597,10116.0,Rattus norvegicus,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1,Plasma,,,In vivo,1,,1916,A,1969.0,Intermediate,CHEMBL624285,BAO_0000218,8001
,,N,,,50597,10116.0,Rattus norvegicus,Time to reach Cmax after oral administration to rats,1,,,,In vivo,1,,16367,A,,Intermediate,CHEMBL624286,BAO_0000218,8002
,,N,,,50597,10116.0,Rattus norvegicus,Time to reach Cmax when a dose of 1 mg/kg is administered orally,1,,,,In vivo,1,,16366,A,,Intermediate,CHEMBL624287,BAO_0000218,8003
,,N,,,50597,10116.0,Rattus norvegicus,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,1,,,,,1,,216,A,,Intermediate,CHEMBL624288,BAO_0000218,8004
,,N,,,50597,10116.0,Rattus norvegicus,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,1,Plasma,,,In vivo,1,,6410,A,1969.0,Intermediate,CHEMBL624289,BAO_0000218,8005
,,N,,,50597,10116.0,Rattus norvegicus,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,1,Plasma,,,In vivo,1,,6410,A,1969.0,Intermediate,CHEMBL873344,BAO_0000218,8006
,,N,,,50597,10116.0,Rattus norvegicus,Tmax after peroral administration (10 mg/kg) was determined in rat,1,,,,In vivo,1,,6215,A,,Intermediate,CHEMBL619623,BAO_0000218,8007
,,N,,,50597,10116.0,Rattus norvegicus,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,1,,,,In vivo,1,,3598,A,,Expert,CHEMBL621399,BAO_0000218,8008
,,N,,,50597,10116.0,Rattus norvegicus,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,1,,,,In vivo,1,,4527,A,,Intermediate,CHEMBL621400,BAO_0000218,8009
,,N,,,50597,10116.0,Rattus norvegicus,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",1,,,,In vivo,1,,17670,A,,Intermediate,CHEMBL621401,BAO_0000218,8010
,,N,,,50597,10116.0,Rattus norvegicus,Tmax was determined,1,,,,,1,,1465,A,,Intermediate,CHEMBL621402,BAO_0000218,8011
,,N,,,50597,10116.0,Rattus norvegicus,Tmax was determined,1,,,,,1,,2552,A,,Intermediate,CHEMBL621403,BAO_0000218,8012
,,N,,,50597,10116.0,Rattus norvegicus,Tmax after oral administration in rat,1,,,,In vivo,1,,5656,A,,Intermediate,CHEMBL621121,BAO_0000218,8013
,,N,,,50597,10116.0,Rattus norvegicus,Tmax after peroral administration in rats at 2.4 uM/kg,1,,,,In vivo,1,,17764,A,,Intermediate,CHEMBL872525,BAO_0000218,8014
,,N,,,50597,10116.0,Rattus norvegicus,Tmax in male rat,1,,,,,1,,5610,A,,Intermediate,CHEMBL621122,BAO_0000218,8015
,,N,,,50597,10116.0,Rattus norvegicus,Tmax in rat at 10 mg/kg,1,,,,In vivo,1,,6046,A,,Intermediate,CHEMBL621123,BAO_0000218,8016
,,N,,,50597,10116.0,Rattus norvegicus,Tmax in rat by po administration at a dose of 40 mg/kg,1,,,,In vivo,1,,5874,A,,Intermediate,CHEMBL621124,BAO_0000218,8017
,,N,,,50597,10116.0,Rattus norvegicus,Tmax in rats,1,,,,,1,,17596,A,,Intermediate,CHEMBL621125,BAO_0000218,8018
,,N,,,50597,10116.0,Rattus norvegicus,Tmax was measured in rats after peroral administration at 5 mg/kg,1,,,,In vivo,1,,17804,A,,Intermediate,CHEMBL621126,BAO_0000218,8019
,,N,,,50597,10116.0,Rattus norvegicus,Tmax value after oral dose at a dose of 10 mg/kg in rats.,1,,,,In vivo,1,,1908,A,,Intermediate,CHEMBL621127,BAO_0000218,8020
,,N,,,50597,10116.0,Rattus norvegicus,Tmax value after administration of 20 mg/Kg oral dose in rat,1,,,,In vivo,1,,2959,A,,Intermediate,CHEMBL621128,BAO_0000218,8021
,,N,,,50597,10116.0,Rattus norvegicus,Tmax value at a dose of 10 mg/kg in male SD rats,1,,,,In vivo,1,,6757,A,,Intermediate,CHEMBL618263,BAO_0000218,8022
,,N,,,50597,10116.0,Rattus norvegicus,Tmax value at a dose of 100 mg/kg in male SD rats,1,,,,In vivo,1,,6757,A,,Intermediate,CHEMBL618264,BAO_0000218,8023
,,N,,,50597,10116.0,Rattus norvegicus,Tmax value at a dose of 50 mg/kg in male SD rats,1,,,,In vivo,1,,6757,A,,Intermediate,CHEMBL618265,BAO_0000218,8024
,,N,,,50597,10116.0,Rattus norvegicus,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,Plasma,,,In vivo,1,,4186,A,1969.0,Intermediate,CHEMBL618266,BAO_0000218,8025
,,N,,,50597,10116.0,Rattus norvegicus,time required to reach maximum concentration (Cmax) after oral administration in rat,1,,,,In vivo,1,,15662,A,,Intermediate,CHEMBL618267,BAO_0000218,8026
,,N,,,50597,10116.0,Rattus norvegicus,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),1,Urine,,,,1,,429,A,1088.0,Intermediate,CHEMBL618450,BAO_0000218,8027
,,N,,,50597,10116.0,Rattus norvegicus,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),1,Urine,,,,1,,429,A,1088.0,Intermediate,CHEMBL618451,BAO_0000218,8028
,,N,,,50597,10116.0,Rattus norvegicus,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,1,,,,,1,,5546,A,,Intermediate,CHEMBL618452,BAO_0000218,8029
,,N,,,50597,10116.0,Rattus norvegicus,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,1,Urine,,,,1,,3173,A,1088.0,Intermediate,CHEMBL618453,BAO_0000218,8030
,,N,,,50597,10116.0,Rattus norvegicus,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,1,Urine,,,,1,,3173,A,1088.0,Intermediate,CHEMBL618454,BAO_0000218,8031
,,N,,,50597,10116.0,Rattus norvegicus,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,1,Urine,,,,1,,3173,A,1088.0,Intermediate,CHEMBL618455,BAO_0000218,8032
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,1,,,,In vivo,1,,4257,A,,Intermediate,CHEMBL618456,BAO_0000218,8033
,,N,,,50597,10116.0,Rattus norvegicus,Compound distribution in rat tissues was determined,1,,,,In vivo,1,,6011,A,,Intermediate,CHEMBL618457,BAO_0000218,8034
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution was evaluated in rat,1,,,,In vivo,1,,5472,A,,Intermediate,CHEMBL618458,BAO_0000218,8035
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,1,,,,,1,,14346,A,,Intermediate,CHEMBL618459,BAO_0000218,8036
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,1,,,,,1,,14346,A,,Intermediate,CHEMBL876733,BAO_0000218,8037
,,N,,,50588,9615.0,Canis lupus familiaris,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,1,,,,,1,,14346,A,,Intermediate,CHEMBL618460,BAO_0000218,8038
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,1,,,,,1,,14346,A,,Intermediate,CHEMBL618461,BAO_0000218,8039
,,U,,,22224,,,Area under the curve was determined after oral administration (300 uM/Kg),1,,,,,0,,15469,A,,Autocuration,CHEMBL618462,BAO_0000019,8040
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,1,,,,,1,,14346,A,,Intermediate,CHEMBL618463,BAO_0000218,8041
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,1,,,,,1,,14346,A,,Intermediate,CHEMBL618464,BAO_0000218,8042
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,1,,,,,1,,14346,A,,Intermediate,CHEMBL618465,BAO_0000218,8043
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,1,,,,,1,,14346,A,,Intermediate,CHEMBL618466,BAO_0000218,8044
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,1,,,,,1,,14346,A,,Intermediate,CHEMBL618467,BAO_0000218,8045
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,1,,,,,1,,15372,A,,Intermediate,CHEMBL618468,BAO_0000218,8046
,,N,,,50588,9615.0,Canis lupus familiaris,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,1,Plasma,,,,1,,12935,A,1969.0,Intermediate,CHEMBL618469,BAO_0000218,8047
,,N,,,50588,9615.0,Canis lupus familiaris,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,1,Plasma,,,,1,,12935,A,1969.0,Intermediate,CHEMBL618470,BAO_0000218,8048
,,U,,,22224,,,Plasma drug AUC in rat (PO dose),1,,,,,0,,14813,A,,Autocuration,CHEMBL618471,BAO_0000218,8049
,,N,,,50594,10090.0,Mus musculus,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,1,,,,,1,,15792,A,,Intermediate,CHEMBL618472,BAO_0000218,8050
,,U,,,22224,,,Area under was determined at a dose of 30 mg/kg,1,,,,,0,,3579,A,,Autocuration,CHEMBL618473,BAO_0000218,8051
,,N,,,50506,9669.0,Mustela putorius furo,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,1,,,,,1,,12487,A,,Intermediate,CHEMBL621699,BAO_0000218,8052
,,N,,,50597,10116.0,Rattus norvegicus,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,1,,,,,1,,12487,A,,Intermediate,CHEMBL621700,BAO_0000218,8053
,,N,,,50597,10116.0,Rattus norvegicus,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,1,,,,,1,,12487,A,,Intermediate,CHEMBL621701,BAO_0000218,8054
,,N,,,50506,9669.0,Mustela putorius furo,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,1,,,,,1,,12487,A,,Intermediate,CHEMBL621702,BAO_0000218,8055
,,N,,,50588,9615.0,Canis lupus familiaris,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,1,,,,,1,,12487,A,,Intermediate,CHEMBL621703,BAO_0000218,8056
,,N,,,50588,9615.0,Canis lupus familiaris,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,1,,,,,1,,12487,A,,Intermediate,CHEMBL621704,BAO_0000218,8057
,,N,,,50597,10116.0,Rattus norvegicus,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",1,,,,,1,,12902,A,,Intermediate,CHEMBL624259,BAO_0000218,8058
,,N,,,50597,10116.0,Rattus norvegicus,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",1,,,,,1,,12902,A,,Intermediate,CHEMBL624260,BAO_0000218,8059
,,N,,,50597,10116.0,Rattus norvegicus,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",1,,,,,1,,12902,A,,Intermediate,CHEMBL624430,BAO_0000218,8060
,,N,,,50597,10116.0,Rattus norvegicus,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",1,,,,,1,,12902,A,,Intermediate,CHEMBL624431,BAO_0000218,8061
,,N,,,50597,10116.0,Rattus norvegicus,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",1,,,,,1,,12902,A,,Intermediate,CHEMBL624432,BAO_0000218,8062
,,N,,,50597,10116.0,Rattus norvegicus,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",1,,,,,1,,12902,A,,Intermediate,CHEMBL624433,BAO_0000218,8063
,,N,,,50597,10116.0,Rattus norvegicus,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",1,,,,,1,,12902,A,,Intermediate,CHEMBL624434,BAO_0000218,8064
,,N,,,50597,10116.0,Rattus norvegicus,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",1,,,,,1,,12902,A,,Intermediate,CHEMBL624435,BAO_0000218,8065
,,N,,,50594,10090.0,Mus musculus,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,1,,,,,1,,12745,A,,Intermediate,CHEMBL618570,BAO_0000218,8066
,,N,,,50594,10090.0,Mus musculus,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,,,,,1,,12745,A,,Intermediate,CHEMBL618571,BAO_0000218,8067
,,N,,,50594,10090.0,Mus musculus,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,1,,,,,1,,12745,A,,Intermediate,CHEMBL618572,BAO_0000218,8068
,,N,,,50594,10090.0,Mus musculus,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,,,,,1,,12745,A,,Intermediate,CHEMBL618573,BAO_0000218,8069
,,N,,,50594,10090.0,Mus musculus,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,1,,,,,1,,12745,A,,Intermediate,CHEMBL619267,BAO_0000218,8070
,,N,,,50594,10090.0,Mus musculus,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,,,,,1,,12745,A,,Intermediate,CHEMBL619431,BAO_0000218,8071
,,N,,,50594,10090.0,Mus musculus,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,1,,,,,1,,12745,A,,Intermediate,CHEMBL619432,BAO_0000218,8072
,,N,,,50594,10090.0,Mus musculus,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,,,,,1,,12745,A,,Intermediate,CHEMBL619433,BAO_0000218,8073
,,U,,,22224,,,AUC in mice after oral dose (50 mg/kg),1,Plasma,,,,0,,13298,A,1969.0,Autocuration,CHEMBL619434,BAO_0000218,8074
,,N,,,50594,10090.0,Mus musculus,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,1,Serum,,,,1,,12226,A,1977.0,Intermediate,CHEMBL619435,BAO_0000218,8075
,,U,,,22224,,,AUC (0-4 hr) ug/ml/h,1,Plasma,,,,0,,12634,A,1969.0,Autocuration,CHEMBL619436,BAO_0000019,8076
,,N,,,50597,10116.0,Rattus norvegicus,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,1,,,,,1,,14810,A,,Intermediate,CHEMBL619437,BAO_0000218,8077
,,U,,,22224,,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,1,,,,,0,,13889,A,,Autocuration,CHEMBL619438,BAO_0000218,8078
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated for Area under curve in mice,1,,,,,1,,10018,A,,Intermediate,CHEMBL619439,BAO_0000218,8079
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,1,,,,,1,,8758,A,,Intermediate,CHEMBL619440,BAO_0000218,8080
,,U,,,22224,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,1,,,,,0,,8758,F,,Autocuration,CHEMBL619441,BAO_0000218,8081
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,1,,,,,1,,8758,A,,Intermediate,CHEMBL619442,BAO_0000218,8082
,,U,,,22224,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,1,,,,,0,,2249,A,,Autocuration,CHEMBL875156,BAO_0000019,8083
,,U,,,22224,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,1,,,,,0,,2249,A,,Autocuration,CHEMBL619443,BAO_0000019,8084
,,U,,,22224,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,1,,,,,0,,2249,A,,Autocuration,CHEMBL619444,BAO_0000019,8085
,,U,,,22224,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,1,,,,,0,,2249,A,,Autocuration,CHEMBL623464,BAO_0000019,8086
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated for area under curve when administered through oral route in mouse,1,,,,,1,,15115,A,,Intermediate,CHEMBL623465,BAO_0000218,8087
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,1,,,,In vivo,1,,6518,A,,Intermediate,CHEMBL623466,BAO_0000218,8088
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,1,,,,In vivo,1,,6518,A,,Intermediate,CHEMBL623467,BAO_0000218,8089
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rat,1,,,,In vivo,1,,6249,A,,Intermediate,CHEMBL623468,BAO_0000218,8090
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,1,,,,In vivo,1,,2463,A,,Intermediate,CHEMBL622660,BAO_0000218,8091
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance rate in Sprague-Dawley rats,1,,,,In vivo,1,,4969,A,,Intermediate,CHEMBL622661,BAO_0000218,8092
,,N,,,50597,10116.0,Rattus norvegicus,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,1,,,,In vivo,1,,17720,F,,Intermediate,CHEMBL622662,BAO_0000218,8093
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (total body clearance) in rat,1,,,,In vivo,1,,3457,A,,Intermediate,CHEMBL622663,BAO_0000218,8094
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,1,,,,In vivo,1,,5983,A,,Intermediate,CHEMBL622664,BAO_0000218,8095
,,N,,,50597,10116.0,Rattus norvegicus,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,1,,,,,1,,6295,A,,Intermediate,CHEMBL622665,BAO_0000218,8096
,,N,,,50597,10116.0,Rattus norvegicus,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,1,,,,,1,,6296,A,,Intermediate,CHEMBL622666,BAO_0000218,8097
,,N,,,50597,10116.0,Rattus norvegicus,Cl in rat i.v. at 2 mg/kg concentration,1,,,,In vivo,1,,17686,A,,Intermediate,CHEMBL621615,BAO_0000218,8098
,,N,,,50597,10116.0,Rattus norvegicus,Clearance of compound after intravenous administration in rats at 24 uM/kg,1,,,,In vivo,1,,17764,A,,Intermediate,CHEMBL621616,BAO_0000218,8099
,,N,,,50597,10116.0,Rattus norvegicus,Clearance was determined,1,,,,In vivo,1,,5503,A,,Intermediate,CHEMBL621617,BAO_0000218,8100
,,N,,,50597,10116.0,Rattus norvegicus,Clearance by intravenous administration of 3.4 mg/kg in rat,1,,,,In vivo,1,,4368,A,,Intermediate,CHEMBL621618,BAO_0000218,8101
,,N,,,50597,10116.0,Rattus norvegicus,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,1,,,,In vivo,1,,6005,A,,Intermediate,CHEMBL621619,BAO_0000218,8102
,,N,,,50597,10116.0,Rattus norvegicus,Clearance rate after i.v. administration in rats,1,,,,In vivo,1,,5031,A,,Intermediate,CHEMBL621620,BAO_0000218,8103
,,N,,,50597,10116.0,Rattus norvegicus,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,,,,In vivo,1,,4890,A,,Intermediate,CHEMBL621786,BAO_0000218,8104
,,N,,,50597,10116.0,Rattus norvegicus,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,1,,,,In vivo,1,,5182,A,,Intermediate,CHEMBL621787,BAO_0000218,8105
,,N,,,50597,10116.0,Rattus norvegicus,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,1,,,,In vivo,1,,5979,A,,Intermediate,CHEMBL621788,BAO_0000218,8106
,,N,,,50597,10116.0,Rattus norvegicus,Clearance (Cl) after oral administration in rat,1,,,,In vivo,1,,5656,A,,Intermediate,CHEMBL621789,BAO_0000218,8107
,,N,,,50597,10116.0,Rattus norvegicus,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,1,,,,In vivo,1,,17804,A,,Intermediate,CHEMBL621790,BAO_0000218,8108
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for plasma clearance in rat,1,Plasma,,,In vivo,1,,4839,A,1969.0,Intermediate,CHEMBL621791,BAO_0000218,8109
,Microsomes,N,,,50597,10116.0,Rattus norvegicus,In vitro microsome metabolism clearance in rat was determined,1,,,,In vitro,1,,5041,A,,Intermediate,CHEMBL621792,BAO_0000218,8110
,Microsomes,N,,,50597,10116.0,Rattus norvegicus,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,1,,,,In vitro,1,,5041,A,,Intermediate,CHEMBL621793,BAO_0000218,8111
,,N,,,50597,10116.0,Rattus norvegicus,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,,,,In vivo,1,,5974,A,,Intermediate,CHEMBL621794,BAO_0000218,8112
,,N,,,50597,10116.0,Rattus norvegicus,In vivo plasma clearance was determined,1,Plasma,,,In vivo,1,,5496,A,1969.0,Intermediate,CHEMBL621795,BAO_0000218,8113
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,1,,,,In vivo,1,,5739,A,,Intermediate,CHEMBL621796,BAO_0000218,8114
,,N,401.0,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,1,Liver,Hepatocyte,,In vivo,1,,5676,A,2107.0,Intermediate,CHEMBL621797,BAO_0000218,8115
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (Plasma clearance) was measured in rat,1,,,,In vivo,1,,4239,A,,Intermediate,CHEMBL621798,BAO_0000218,8116
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (clearance) in rat i.v.,1,,,,In vivo,1,,5676,A,,Intermediate,CHEMBL621799,BAO_0000218,8117
,,N,,,50597,10116.0,Rattus norvegicus,"Plasma Clearance was evaluated in rats, iv",1,,,,In vivo,1,,1918,A,,Intermediate,CHEMBL621800,BAO_0000218,8118
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance (in vivo) in rats was determined,1,,,,In vivo,1,,17800,A,,Intermediate,CHEMBL621801,BAO_0000218,8119
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,1,,,,In vivo,1,,6056,A,,Intermediate,CHEMBL621802,BAO_0000218,8120
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance was determined,1,,,,In vivo,1,,5496,A,,Intermediate,CHEMBL618596,BAO_0000218,8121
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,1,,,,In vivo,1,,5939,A,,Intermediate,CHEMBL618597,BAO_0000218,8122
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,1,,,,In vivo,1,,5939,A,,Intermediate,CHEMBL618598,BAO_0000218,8123
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rats,1,,,,In vivo,1,,17752,A,,Intermediate,CHEMBL618599,BAO_0000218,8124
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance rate determined in rat,1,,,,In vivo,1,,4576,A,,Intermediate,CHEMBL618600,BAO_0000218,8125
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance was determined in rat,1,,,,In vivo,1,,6011,A,,Intermediate,CHEMBL618601,BAO_0000218,8126
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance was determined,1,,,,In vivo,1,,5510,A,,Intermediate,CHEMBL618602,BAO_0000218,8127
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance value in rat,1,,,,In vivo,1,,5948,A,,Intermediate,CHEMBL618603,BAO_0000218,8128
,,N,,,50597,10116.0,Rattus norvegicus,Clearance rate constant using isolated perfused rat liver (IPRL) assay,1,Liver,,,Ex vivo,1,,6125,A,2107.0,Intermediate,CHEMBL618604,BAO_0000218,8129
,,N,,,50597,10116.0,Rattus norvegicus,Clearance in rat,1,,,,In vivo,1,,4839,A,,Intermediate,CHEMBL618605,BAO_0000218,8130
,,N,,,50597,10116.0,Rattus norvegicus,Total body clearance in rat i.v. at 2 mg/kg concentration,1,,,,In vivo,1,,17686,A,,Intermediate,CHEMBL618606,BAO_0000218,8131
,,N,,,50597,10116.0,Rattus norvegicus,Clearance of compound in rats after intravenous administration,1,,,,In vivo,1,,6571,A,,Intermediate,CHEMBL618607,BAO_0000218,8132
,,N,,,50597,10116.0,Rattus norvegicus,Clearance after iv administration to rats,1,,,,In vivo,1,,3364,A,,Intermediate,CHEMBL618608,BAO_0000218,8133
,,N,,,50597,10116.0,Rattus norvegicus,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,1,,,,In vivo,1,,13569,A,,Intermediate,CHEMBL618609,BAO_0000218,8134
,,N,,,50597,10116.0,Rattus norvegicus,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,1,,,,In vivo,1,,13569,A,,Intermediate,CHEMBL618610,BAO_0000218,8135
,,N,,,50597,10116.0,Rattus norvegicus,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,1,,,,In vivo,1,,13569,A,,Intermediate,CHEMBL618611,BAO_0000218,8136
,,N,,,50597,10116.0,Rattus norvegicus,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,1,,,,In vivo,1,,13569,A,,Intermediate,CHEMBL618612,BAO_0000218,8137
,,N,,,50597,10116.0,Rattus norvegicus,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,1,,,,In vivo,1,,13569,A,,Intermediate,CHEMBL618613,BAO_0000218,8138
,,N,,,50597,10116.0,Rattus norvegicus,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,1,,,,In vivo,1,,13569,A,,Intermediate,CHEMBL621076,BAO_0000218,8139
,,N,,,50597,10116.0,Rattus norvegicus,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,1,,,,In vivo,1,,13569,A,,Intermediate,CHEMBL621077,BAO_0000218,8140
,,N,,,50597,10116.0,Rattus norvegicus,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",1,,,,In vivo,1,,17670,A,,Intermediate,CHEMBL621078,BAO_0000218,8141
,,N,,,50597,10116.0,Rattus norvegicus,Clearance in rat,1,,,,In vivo,1,,5970,A,,Intermediate,CHEMBL621251,BAO_0000218,8142
,,N,,,50597,10116.0,Rattus norvegicus,Clearance in rat after oral administration at 10 mg/kg,1,,,,In vivo,1,,6495,A,,Intermediate,CHEMBL621252,BAO_0000218,8143
,,N,,,50597,10116.0,Rattus norvegicus,Clearance in rat.,1,,,,In vivo,1,,4590,A,,Intermediate,CHEMBL621253,BAO_0000218,8144
,,N,,,50597,10116.0,Rattus norvegicus,Clearance rate following an oral dose of 20 mg/kg in rats,1,,,,In vivo,1,,6193,A,,Intermediate,CHEMBL621254,BAO_0000218,8145
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,1,,,,In vivo,1,,2832,A,,Intermediate,CHEMBL621255,BAO_0000218,8146
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,1,Plasma,,,In vivo,1,,1052,A,1969.0,Intermediate,CHEMBL621256,BAO_0000218,8147
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL621257,BAO_0000218,8148
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL621258,BAO_0000218,8149
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL621259,BAO_0000218,8150
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL621260,BAO_0000218,8151
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL876494,BAO_0000218,8152
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL621261,BAO_0000218,8153
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL621262,BAO_0000218,8154
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL621263,BAO_0000218,8155
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,1,Liver,,,In vivo,1,,9866,A,2107.0,Intermediate,CHEMBL621264,BAO_0000218,8156
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,1,Muscle tissue,,,In vivo,1,,9866,A,2385.0,Intermediate,CHEMBL621265,BAO_0000218,8157
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,1,Muscle tissue,,,In vivo,1,,9866,A,2385.0,Intermediate,CHEMBL621266,BAO_0000218,8158
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,1,Muscle tissue,,,In vivo,1,,9866,A,2385.0,Intermediate,CHEMBL621267,BAO_0000218,8159
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,1,Muscle tissue,,,In vivo,1,,9866,A,2385.0,Intermediate,CHEMBL621268,BAO_0000218,8160
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,1,Muscle tissue,,,In vivo,1,,9866,A,2385.0,Intermediate,CHEMBL621269,BAO_0000218,8161
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,1,Muscle tissue,,,In vivo,1,,9866,A,2385.0,Intermediate,CHEMBL621270,BAO_0000218,8162
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,1,Muscle tissue,,,In vivo,1,,9866,A,2385.0,Intermediate,CHEMBL621271,BAO_0000218,8163
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,1,Muscle tissue,,,In vivo,1,,9866,A,2385.0,Intermediate,CHEMBL621272,BAO_0000218,8164
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,1,Muscle tissue,,,In vivo,1,,9866,A,2385.0,Intermediate,CHEMBL621273,BAO_0000218,8165
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,1,Muscle tissue,,,In vivo,1,,9866,A,2385.0,Intermediate,CHEMBL621274,BAO_0000218,8166
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,1,Muscle tissue,,,In vivo,1,,9866,A,2385.0,Intermediate,CHEMBL876495,BAO_0000218,8167
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,1,Muscle tissue,,,In vivo,1,,9866,A,2385.0,Intermediate,CHEMBL621275,BAO_0000218,8168
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,1,Muscle tissue,,,In vivo,1,,9866,A,2385.0,Intermediate,CHEMBL621276,BAO_0000218,8169
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,1,Muscle tissue,,,In vivo,1,,9866,A,2385.0,Intermediate,CHEMBL621277,BAO_0000218,8170
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,1,Intestine,,,In vivo,1,,9866,A,160.0,Intermediate,CHEMBL621278,BAO_0000218,8171
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,1,Intestine,,,In vivo,1,,9866,A,160.0,Intermediate,CHEMBL621279,BAO_0000218,8172
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),1,Intestine,,,In vivo,1,,9866,A,160.0,Intermediate,CHEMBL621280,BAO_0000218,8173
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,1,Spleen,,,In vivo,1,,9866,A,2106.0,Intermediate,CHEMBL621281,BAO_0000218,8174
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,1,Spleen,,,In vivo,1,,9866,A,2106.0,Intermediate,CHEMBL621282,BAO_0000218,8175
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,1,Spleen,,,In vivo,1,,9866,A,2106.0,Intermediate,CHEMBL621283,BAO_0000218,8176
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,1,Spleen,,,In vivo,1,,9866,A,2106.0,Intermediate,CHEMBL621284,BAO_0000218,8177
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,1,Spleen,,,In vivo,1,,9866,A,2106.0,Intermediate,CHEMBL621285,BAO_0000218,8178
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,1,Spleen,,,In vivo,1,,9866,A,2106.0,Intermediate,CHEMBL621286,BAO_0000218,8179
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,1,Spleen,,,In vivo,1,,9866,A,2106.0,Intermediate,CHEMBL623220,BAO_0000218,8180
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,1,Spleen,,,In vivo,1,,9866,A,2106.0,Intermediate,CHEMBL623221,BAO_0000218,8181
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,1,Spleen,,,In vivo,1,,9866,A,2106.0,Intermediate,CHEMBL876029,BAO_0000218,8182
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,1,Stomach,,,In vivo,1,,9866,A,945.0,Intermediate,CHEMBL623222,BAO_0000218,8183
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,1,Stomach,,,In vivo,1,,9866,A,945.0,Intermediate,CHEMBL623223,BAO_0000218,8184
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,1,Stomach,,,In vivo,1,,9866,A,945.0,Intermediate,CHEMBL621445,BAO_0000218,8185
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,Blood,,,In vivo,1,,13950,A,178.0,Intermediate,CHEMBL621446,BAO_0000218,8186
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,Blood,,,In vivo,1,,13950,A,178.0,Intermediate,CHEMBL621447,BAO_0000218,8187
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,Blood,,,In vivo,1,,13950,A,178.0,Intermediate,CHEMBL619681,BAO_0000218,8188
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,Blood,,,In vivo,1,,13950,A,178.0,Intermediate,CHEMBL619682,BAO_0000218,8189
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,Blood,,,In vivo,1,,13950,A,178.0,Intermediate,CHEMBL619683,BAO_0000218,8190
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,Brain,,,In vivo,1,,13950,A,955.0,Intermediate,CHEMBL619684,BAO_0000218,8191
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,Brain,,,In vivo,1,,13950,A,955.0,Intermediate,CHEMBL619685,BAO_0000218,8192
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,Brain,,,In vivo,1,,13950,A,955.0,Intermediate,CHEMBL619686,BAO_0000218,8193
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,Brain,,,In vivo,1,,13950,A,955.0,Intermediate,CHEMBL619687,BAO_0000218,8194
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,Brain,,,In vivo,1,,13950,A,955.0,Intermediate,CHEMBL619688,BAO_0000218,8195
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,Heart,,,In vivo,1,,13950,A,948.0,Intermediate,CHEMBL619689,BAO_0000218,8196
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,Heart,,,In vivo,1,,13950,A,948.0,Intermediate,CHEMBL619690,BAO_0000218,8197
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,Heart,,,In vivo,1,,13950,A,948.0,Intermediate,CHEMBL619691,BAO_0000218,8198
,,N,,,50597,10116.0,Rattus norvegicus,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,1,,,,In vivo,1,,6062,A,,Intermediate,CHEMBL619692,BAO_0000218,8199
,,N,,,50597,10116.0,Rattus norvegicus,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,1,,,,,1,,3598,A,,Expert,CHEMBL619693,BAO_0000218,8200
,,N,,,50597,10116.0,Rattus norvegicus,Vc value after IV dose at a dose of 5 mg/kg in rats.,1,,,,In vivo,1,,1908,A,,Intermediate,CHEMBL619694,BAO_0000218,8201
,,N,,,50597,10116.0,Rattus norvegicus,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,1,,,,In vivo,1,,17596,A,,Intermediate,CHEMBL619695,BAO_0000218,8202
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for pharmacokinetic parameter volume of distribution,1,,,,In vivo,1,,4891,A,,Intermediate,CHEMBL619696,BAO_0000218,8203
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for volume of distribution in rat,1,,,,In vivo,1,,740,A,,Intermediate,CHEMBL619697,BAO_0000218,8204
,,N,,,50597,10116.0,Rattus norvegicus,Steady state volume distribution was determined; steady state(ss),1,,,,In vivo,1,,16366,A,,Intermediate,CHEMBL619698,BAO_0000218,8205
,,N,,,50597,10116.0,Rattus norvegicus,Steady state volume of distribution after iv administration to rats,1,,,,In vivo,1,,3364,A,,Intermediate,CHEMBL619699,BAO_0000218,8206
,,N,,,50597,10116.0,Rattus norvegicus,Steady state volume of distribution dosing at 3 mg/kg iv,1,,,,In vivo,1,,2552,A,,Intermediate,CHEMBL619700,BAO_0000218,8207
,,N,,,50597,10116.0,Rattus norvegicus,The compound was evaluated for volume of distribution in rat,1,,,,In vivo,1,,406,A,,Intermediate,CHEMBL619701,BAO_0000218,8208
,,N,,,50597,10116.0,Rattus norvegicus,The compound was tested for volume of distribution in rat,1,,,,In vivo,1,,12500,A,,Intermediate,CHEMBL619702,BAO_0000218,8209
,,N,,,50597,10116.0,Rattus norvegicus,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,1,,,,In vivo,1,,12500,A,,Intermediate,CHEMBL620335,BAO_0000218,8210
,,N,,,50597,10116.0,Rattus norvegicus,Volume distribution (VD) after oral administration in rat,1,,,,In vivo,1,,5656,A,,Intermediate,CHEMBL620336,BAO_0000218,8211
,,N,,,50597,10116.0,Rattus norvegicus,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,,,,In vivo,1,,17671,A,,Intermediate,CHEMBL620337,BAO_0000218,8212
,,N,,,50597,10116.0,Rattus norvegicus,Volume distribution in rat,1,,,,In vivo,1,,1094,A,,Intermediate,CHEMBL620520,BAO_0000218,8213
,,N,,,50597,10116.0,Rattus norvegicus,Volume distribution in rat,1,,,,In vivo,1,,5833,A,,Intermediate,CHEMBL620521,BAO_0000218,8214
,,N,,,50597,10116.0,Rattus norvegicus,Volume distribution in rat after peroral administration at 10 mg/kg,1,,,,In vivo,1,,5939,A,,Intermediate,CHEMBL875825,BAO_0000218,8215
,,N,,,50597,10116.0,Rattus norvegicus,Volume distribution in rat after peroral administration at 5 mg/kg,1,,,,In vivo,1,,5939,A,,Intermediate,CHEMBL620522,BAO_0000218,8216
,,N,,,50597,10116.0,Rattus norvegicus,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,1,,,,In vivo,1,,6005,A,,Intermediate,CHEMBL620523,BAO_0000218,8217
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution in rat.,1,,,,In vivo,1,,1696,A,,Intermediate,CHEMBL620524,BAO_0000218,8218
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution in rat,1,,,,In vivo,1,,6672,A,,Intermediate,CHEMBL620525,BAO_0000218,8219
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution in rat,1,,,,In vivo,1,,6673,A,,Intermediate,CHEMBL620526,BAO_0000218,8220
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution in rat by iv administration,1,,,,In vivo,1,,5871,A,,Intermediate,CHEMBL620527,BAO_0000218,8221
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution in rats,1,,,,In vivo,1,,6803,A,,Intermediate,CHEMBL620528,BAO_0000218,8222
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,1,,,,In vivo,1,,5199,A,,Intermediate,CHEMBL620529,BAO_0000218,8223
,,N,,,50597,10116.0,Rattus norvegicus,Volume distribution at the dose of 2 mg/kg in rat,1,,,,,1,,4727,A,,Intermediate,CHEMBL620530,BAO_0000218,8224
,,N,,,50597,10116.0,Rattus norvegicus,Steady state volume of distribution was determined,1,,,,In vivo,1,,16367,A,,Intermediate,CHEMBL620531,BAO_0000218,8225
,,U,,,22224,9544.0,Macaca mulatta,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1,,,,In vivo,0,,5005,A,,Intermediate,CHEMBL620532,BAO_0000218,8226
,,U,,,22224,10116.0,Rattus norvegicus,Compound was tested for its plasma volume distribution in Sprague Dawley rats,1,,,,In vivo,0,,5005,A,,Intermediate,CHEMBL620533,BAO_0000218,8227
,,U,,,22224,10116.0,Rattus norvegicus,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,1,,,,In vivo,0,,5005,A,,Intermediate,CHEMBL620534,BAO_0000218,8228
,,N,,,50597,10116.0,Rattus norvegicus,Mean (%CV) PK parameters for Vdss(mL/kg).,1,,,,In vivo,1,,15765,A,,Intermediate,CHEMBL620535,BAO_0000218,8229
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,1,,,,In vivo,1,,2792,A,,Intermediate,CHEMBL875826,BAO_0000218,8230
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,1,,,,In vivo,1,,2792,A,,Intermediate,CHEMBL620536,BAO_0000218,8231
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,1,,,,In vivo,1,,5334,A,,Intermediate,CHEMBL620537,BAO_0000218,8232
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,1,,,,In vivo,1,,5334,A,,Intermediate,CHEMBL618526,BAO_0000218,8233
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,1,,,,In vivo,1,,5739,A,,Intermediate,CHEMBL618527,BAO_0000218,8234
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (Vdss) in rat,1,,,,In vivo,1,,5789,A,,Intermediate,CHEMBL618528,BAO_0000218,8235
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (vdss) was measured in rat,1,,,,In vivo,1,,4239,A,,Intermediate,CHEMBL618529,BAO_0000218,8236
,,N,,,50597,10116.0,Rattus norvegicus,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,1,,,,In vivo,1,,4709,A,,Intermediate,CHEMBL618530,BAO_0000218,8237
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution in rat,1,,,,In vivo,1,,6642,A,,Intermediate,CHEMBL618531,BAO_0000218,8238
,,N,,,50597,10116.0,Rattus norvegicus,The pharmacokinetic parameter volume of distribution in vivo in rats,1,,,,In vivo,1,,5247,A,,Intermediate,CHEMBL618532,BAO_0000218,8239
,,N,,,50597,10116.0,Rattus norvegicus,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,1,,,,In vivo,1,,17720,F,,Intermediate,CHEMBL618533,BAO_0000218,8240
,,N,,,50597,10116.0,Rattus norvegicus,Vdss in rat i.v. at 2 mg/kg concentration,1,,,,In vivo,1,,17686,A,,Intermediate,CHEMBL618534,BAO_0000218,8241
,,N,,,50597,10116.0,Rattus norvegicus,Volume distribution after intravenous administration (1 mg/kg) in rat,1,,,,In vivo,1,,4689,A,,Intermediate,CHEMBL618535,BAO_0000218,8242
,,N,,,50597,10116.0,Rattus norvegicus,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,,,,In vivo,1,,5654,A,,Intermediate,CHEMBL618536,BAO_0000218,8243
,,N,,,50597,10116.0,Rattus norvegicus,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,,,,In vivo,1,,5654,A,,Intermediate,CHEMBL618537,BAO_0000218,8244
,,N,,,50597,10116.0,Rattus norvegicus,Volume distribution at a dose of 10 uM/kg in rat was determined,1,,,,In vivo,1,,4527,A,,Intermediate,CHEMBL618538,BAO_0000218,8245
,,N,,,50597,10116.0,Rattus norvegicus,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,,,,In vivo,1,,4521,A,,Intermediate,CHEMBL618539,BAO_0000218,8246
,,N,,,50597,10116.0,Rattus norvegicus,Volume distribution was calculated in rat,1,,,,In vivo,1,,6057,A,,Intermediate,CHEMBL618540,BAO_0000218,8247
,,N,,,50597,10116.0,Rattus norvegicus,Volume distribution was determined,1,,,,In vivo,1,,5510,A,,Intermediate,CHEMBL618541,BAO_0000218,8248
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution after intravenous administration was evaluated in rat,1,,,,In vivo,1,,2938,A,,Intermediate,CHEMBL618542,BAO_0000218,8249
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,,,In vivo,1,,6679,A,,Intermediate,CHEMBL622544,BAO_0000218,8250
,,N,,,50597,10116.0,Rattus norvegicus,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",1,,,,In vivo,1,,6685,A,,Intermediate,CHEMBL622545,BAO_0000218,8251
,,N,,,50597,10116.0,Rattus norvegicus,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",1,,,,In vivo,1,,6685,A,,Intermediate,CHEMBL622546,BAO_0000218,8252
,,N,,,50597,10116.0,Rattus norvegicus,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",1,,,,In vivo,1,,6685,A,,Intermediate,CHEMBL622547,BAO_0000218,8253
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution in steady state was determined in rat,1,,,,In vivo,1,,5145,A,,Intermediate,CHEMBL622548,BAO_0000218,8254
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,1,,,,In vivo,1,,6467,A,,Intermediate,CHEMBL622549,BAO_0000218,8255
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,1,,,,In vivo,1,,6467,A,,Intermediate,CHEMBL622550,BAO_0000218,8256
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated for area under curve when administered through oral route to mouse,1,,,,,1,,15115,A,,Intermediate,CHEMBL622551,BAO_0000218,8257
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,1,,,,,1,,8758,A,,Intermediate,CHEMBL622552,BAO_0000218,8258
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,1,,,,,1,,8758,A,,Intermediate,CHEMBL622553,BAO_0000218,8259
,,U,,,22224,,,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,1,,,,In vivo,0,,8267,F,,Autocuration,CHEMBL622554,BAO_0000218,8260
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,1,,,,,1,,8267,A,,Intermediate,CHEMBL622555,BAO_0000218,8261
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,1,,,,,1,,14239,A,,Intermediate,CHEMBL622556,BAO_0000218,8262
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,1,,,,,1,,14239,A,,Intermediate,CHEMBL622557,BAO_0000218,8263
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,1,Blood,,,,1,,10754,A,178.0,Intermediate,CHEMBL622558,BAO_0000218,8264
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,1,Blood,,,,1,,10754,A,178.0,Intermediate,CHEMBL622559,BAO_0000218,8265
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,1,,,,,1,,10754,A,,Intermediate,CHEMBL622560,BAO_0000218,8266
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,1,,,,,1,,14681,A,,Intermediate,CHEMBL622561,BAO_0000218,8267
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,1,,,,,1,,14681,A,,Intermediate,CHEMBL622562,BAO_0000218,8268
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,1,,,,,1,,14681,A,,Intermediate,CHEMBL622563,BAO_0000218,8269
,,U,,,22224,,,Concentration of compound in Central nervous system,1,,,,,0,,13118,A,,Autocuration,CHEMBL622564,BAO_0000019,8270
,,U,,,22224,,,Concentration of compound in Central nervous system; Not detectable,1,,,,,0,,13118,A,,Autocuration,CHEMBL622565,BAO_0000019,8271
,,N,,,50594,10090.0,Mus musculus,"Concentration of diester in the blood, following oral administration in mice",1,,,,,1,,13318,A,,Intermediate,CHEMBL622566,BAO_0000218,8272
,,N,,,50594,10090.0,Mus musculus,"Concentration of monoester in the blood, following oral administration in mice",1,,,,,1,,13318,A,,Intermediate,CHEMBL624515,BAO_0000218,8273
,,N,,,50594,10090.0,Mus musculus,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,1,,,,,1,,13318,A,,Intermediate,CHEMBL624516,BAO_0000218,8274
,,U,,,22224,,,Evaluated for Pharmacokinetic property: Area under the curve,1,,,,,0,,15692,A,,Autocuration,CHEMBL624517,BAO_0000019,8275
,,N,,,50594,10090.0,Mus musculus,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,1,,,,,1,,14839,A,,Intermediate,CHEMBL624518,BAO_0000218,8276
,,N,,,100710,9541.0,Macaca fascicularis,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,1,,,,,1,,14839,A,,Intermediate,CHEMBL624519,BAO_0000218,8277
,,N,,,100710,9541.0,Macaca fascicularis,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,1,,,,,1,,14839,A,,Intermediate,CHEMBL624520,BAO_0000218,8278
,,N,,,100710,9541.0,Macaca fascicularis,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,1,,,,,1,,14839,A,,Intermediate,CHEMBL624521,BAO_0000218,8279
,,N,,,100710,9541.0,Macaca fascicularis,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,1,,,,,1,,14839,A,,Intermediate,CHEMBL624522,BAO_0000218,8280
,,N,,,100710,9541.0,Macaca fascicularis,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,1,,,,,1,,14839,A,,Intermediate,CHEMBL624523,BAO_0000218,8281
,,N,,,100710,9541.0,Macaca fascicularis,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",1,,,,,1,,14839,A,,Intermediate,CHEMBL624409,BAO_0000218,8282
,,N,,,100710,9541.0,Macaca fascicularis,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",1,,,,,1,,14839,A,,Intermediate,CHEMBL624410,BAO_0000218,8283
,,N,,,100710,9541.0,Macaca fascicularis,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",1,,,,,1,,14839,A,,Intermediate,CHEMBL624411,BAO_0000218,8284
,,N,,,100710,9541.0,Macaca fascicularis,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",1,,,,,1,,14839,A,,Intermediate,CHEMBL623531,BAO_0000218,8285
,,N,,,100710,9541.0,Macaca fascicularis,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",1,,,,,1,,14839,A,,Intermediate,CHEMBL623532,BAO_0000218,8286
,,N,,,100710,9541.0,Macaca fascicularis,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",1,,,,,1,,14839,A,,Intermediate,CHEMBL623533,BAO_0000218,8287
,,N,,,100710,9541.0,Macaca fascicularis,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",1,,,,,1,,14839,A,,Intermediate,CHEMBL623534,BAO_0000218,8288
,,N,,,50594,10090.0,Mus musculus,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,1,,,,,1,,14839,A,,Intermediate,CHEMBL623535,BAO_0000218,8289
,,N,,,50594,10090.0,Mus musculus,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,1,,,,,1,,14839,A,,Intermediate,CHEMBL623536,BAO_0000218,8290
,,N,,,50594,10090.0,Mus musculus,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,1,,,,,1,,14839,A,,Intermediate,CHEMBL623537,BAO_0000218,8291
,,N,,,50594,10090.0,Mus musculus,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,1,,,,,1,,14839,A,,Intermediate,CHEMBL623538,BAO_0000218,8292
,,N,,,50594,10090.0,Mus musculus,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,1,,,,,1,,14839,A,,Intermediate,CHEMBL623539,BAO_0000218,8293
,,N,,,50594,10090.0,Mus musculus,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,1,,,,,1,,14839,A,,Intermediate,CHEMBL623540,BAO_0000218,8294
,,N,,,50594,10090.0,Mus musculus,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",1,,,,,1,,14839,A,,Intermediate,CHEMBL623541,BAO_0000218,8295
,,N,,,50594,10090.0,Mus musculus,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",1,,,,,1,,14839,A,,Intermediate,CHEMBL623542,BAO_0000218,8296
,,N,,,50594,10090.0,Mus musculus,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",1,,,,,1,,14839,A,,Intermediate,CHEMBL623543,BAO_0000218,8297
,,N,,,50594,10090.0,Mus musculus,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",1,,,,,1,,14839,A,,Intermediate,CHEMBL623544,BAO_0000218,8298
,,N,,,50594,10090.0,Mus musculus,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",1,,,,,1,,14839,A,,Intermediate,CHEMBL623545,BAO_0000218,8299
,,N,,,50594,10090.0,Mus musculus,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",1,,,,,1,,14839,A,,Intermediate,CHEMBL623546,BAO_0000218,8300
,,N,,,50597,10116.0,Rattus norvegicus,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,1,Plasma,,,In vivo,1,,5408,A,1969.0,Intermediate,CHEMBL623547,BAO_0000218,8301
,,N,,,50597,10116.0,Rattus norvegicus,High i.v. clearance in Dawley rats,1,,,,In vivo,1,,6827,A,,Intermediate,CHEMBL623548,BAO_0000218,8302
,Microsomes,N,,,50597,10116.0,Rattus norvegicus,In vitro clearance in rat liver microsomes,1,Liver,,,In vitro,1,,17538,A,2107.0,Intermediate,CHEMBL623549,BAO_0000218,8303
,Microsomes,N,,,50597,10116.0,Rattus norvegicus,Intrinsic clearance in rat liver microsomes was determined,1,Liver,,,In vitro,1,,6331,A,2107.0,Intermediate,CHEMBL623550,BAO_0000218,8304
,,N,401.0,,50597,10116.0,Rattus norvegicus,Intrinsic clearance in rat hepatocytes was determined,1,Liver,Hepatocyte,,In vitro,1,,5948,A,2107.0,Intermediate,CHEMBL875276,BAO_0000218,8305
,,N,,,50597,10116.0,Rattus norvegicus,Plasma Clearance was determined,1,,,,In vivo,1,,4026,A,,Intermediate,CHEMBL621872,BAO_0000218,8306
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,1,,,,In vivo,1,,6647,A,,Intermediate,CHEMBL621873,BAO_0000218,8307
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rat.,1,,,,In vivo,1,,1696,A,,Intermediate,CHEMBL621874,BAO_0000218,8308
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rats,1,,,,In vivo,1,,6597,A,,Intermediate,CHEMBL621875,BAO_0000218,8309
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,1,,,,In vivo,1,,347,A,,Intermediate,CHEMBL621876,BAO_0000218,8310
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,1,,,,In vivo,1,,16423,A,,Intermediate,CHEMBL621877,BAO_0000218,8311
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance was measured in rat,1,,,,In vivo,1,,2879,A,,Intermediate,CHEMBL621878,BAO_0000218,8312
,,N,,,50597,10116.0,Rattus norvegicus,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,1,,,,In vivo,1,,4883,A,,Intermediate,CHEMBL621879,BAO_0000218,8313
,,N,,,50597,10116.0,Rattus norvegicus,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",1,Plasma,,,In vivo,1,,5328,A,1969.0,Intermediate,CHEMBL621880,BAO_0000218,8314
,,N,,,50597,10116.0,Rattus norvegicus,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,1,,,,In vivo,1,,5160,A,,Intermediate,CHEMBL621881,BAO_0000218,8315
,,N,,,50597,10116.0,Rattus norvegicus,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,,,,In vivo,1,,17582,A,,Intermediate,CHEMBL621882,BAO_0000218,8316
,,N,,,50597,10116.0,Rattus norvegicus,Total clearance at 1 mg/kg was determined in rat,1,,,,In vivo,1,,17651,A,,Intermediate,CHEMBL875283,BAO_0000218,8317
,,N,,,50597,10116.0,Rattus norvegicus,Total clearance at 10 mg/kg was determined in rat,1,,,,In vivo,1,,17651,A,,Intermediate,CHEMBL621883,BAO_0000218,8318
,,N,,,50597,10116.0,Rattus norvegicus,Clearance in rat,1,,,,In vivo,1,,6596,A,,Intermediate,CHEMBL621884,BAO_0000218,8319
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance rate determined in rats,1,,,,In vivo,1,,4796,A,,Intermediate,CHEMBL621885,BAO_0000218,8320
,,N,,,50597,10116.0,Rattus norvegicus,Clearance of compound in rat was evaluated,1,,,,In vivo,1,,6850,A,,Intermediate,CHEMBL621886,BAO_0000218,8321
,,N,,,50597,10116.0,Rattus norvegicus,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,1,Plasma,,,In vivo,1,,5932,A,1969.0,Intermediate,CHEMBL621887,BAO_0000218,8322
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (blood clearance) in rat,1,,,,In vivo,1,,3371,A,,Intermediate,CHEMBL621888,BAO_0000218,8323
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rat,1,,,,In vivo,1,,2083,A,,Intermediate,CHEMBL621889,BAO_0000218,8324
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rats,1,,,,In vivo,1,,4942,A,,Intermediate,CHEMBL621890,BAO_0000218,8325
,Microsomes,N,,,50597,10116.0,Rattus norvegicus,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,1,Liver,,,In vitro,1,,6838,A,2107.0,Intermediate,CHEMBL621891,BAO_0000218,8326
,,N,,,50597,10116.0,Rattus norvegicus,Clearance in Dawley rat,1,,,,In vivo,1,,5353,A,,Intermediate,CHEMBL621892,BAO_0000218,8327
,,N,,,50597,10116.0,Rattus norvegicus,Clearance rat,1,,,,In vivo,1,,6641,A,,Intermediate,CHEMBL621893,BAO_0000218,8328
,,N,,,50597,10116.0,Rattus norvegicus,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),1,,,,In vivo,1,,6641,A,,Intermediate,CHEMBL621894,BAO_0000218,8329
,,N,,,50597,10116.0,Rattus norvegicus,Clearance rat; Not determined,1,,,,In vivo,1,,6641,A,,Intermediate,CHEMBL621895,BAO_0000218,8330
,,N,,,50597,10116.0,Rattus norvegicus,Clearance rate was determined in rat at a dose of 1 mpk i.v.,1,,,,In vivo,1,,6444,A,,Intermediate,CHEMBL875284,BAO_0000218,8331
,,N,,,50597,10116.0,Rattus norvegicus,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,1,,,,In vivo,1,,6444,A,,Intermediate,CHEMBL618699,BAO_0000218,8332
,,N,,,50597,10116.0,Rattus norvegicus,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,1,,,,In vivo,1,,6444,A,,Intermediate,CHEMBL618700,BAO_0000218,8333
,,N,,,50597,10116.0,Rattus norvegicus,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,1,,,,In vivo,1,,6211,A,,Intermediate,CHEMBL618701,BAO_0000218,8334
,,N,,,50597,10116.0,Rattus norvegicus,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",1,Plasma,,,In vivo,1,,12873,A,1969.0,Intermediate,CHEMBL876600,BAO_0000218,8335
,,N,,,50597,10116.0,Rattus norvegicus,Clearance of compound in rat after 1 mg/kg i.v. administration,1,,,,In vivo,1,,6570,A,,Intermediate,CHEMBL618702,BAO_0000218,8336
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for Hepatic clearance in rat,1,,,,In vivo,1,,3341,A,,Intermediate,CHEMBL618703,BAO_0000218,8337
,,N,,,50597,10116.0,Rattus norvegicus,In vivo clearance after 5 mg/kg dose,1,,,,In vivo,1,,4891,A,,Intermediate,CHEMBL618704,BAO_0000218,8338
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for plasma clearance in rats,1,Plasma,,,In vivo,1,,1094,A,1969.0,Intermediate,CHEMBL618705,BAO_0000218,8339
,,N,,,50597,10116.0,Rattus norvegicus,Hepatic clearance after intravenous administration was evaluated in rat,1,,,,In vivo,1,,2938,A,,Intermediate,CHEMBL618706,BAO_0000218,8340
,,N,,,50597,10116.0,Rattus norvegicus,Lower clearance in rat (i.v.) at 0.5 mpk,1,,,,In vivo,1,,17853,A,,Intermediate,CHEMBL618707,BAO_0000218,8341
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter expressed as plasma clearance in rat,1,Plasma,,,In vivo,1,,6049,A,1969.0,Intermediate,CHEMBL618708,BAO_0000218,8342
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (Clp) in rat,1,,,,In vivo,1,,5789,A,,Intermediate,CHEMBL618709,BAO_0000218,8343
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in Sprague-Dawley rats,1,,,,In vivo,1,,4514,A,,Intermediate,CHEMBL618710,BAO_0000218,8344
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance (Clp) in rat,1,,,,In vivo,1,,6448,A,,Intermediate,CHEMBL618711,BAO_0000218,8345
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,1,,,,In vivo,1,,6062,A,,Intermediate,CHEMBL618712,BAO_0000218,8346
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,1,,,,In vivo,1,,5710,A,,Intermediate,CHEMBL618713,BAO_0000218,8347
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance after intravenous administration of 1 mg/kg in rat,1,,,,In vivo,1,,4709,A,,Intermediate,CHEMBL618714,BAO_0000218,8348
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,,,,In vivo,1,,4521,A,,Intermediate,CHEMBL618715,BAO_0000218,8349
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rat was determined,1,,,,In vivo,1,,1742,A,,Intermediate,CHEMBL618716,BAO_0000218,8350
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance measured in rat,1,,,,In vivo,1,,6057,A,,Intermediate,CHEMBL876601,BAO_0000218,8351
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance was calculated in rat,1,,,,In vivo,1,,6057,A,,Intermediate,CHEMBL618717,BAO_0000218,8352
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rat,1,,,,In vivo,1,,5145,A,,Intermediate,CHEMBL618718,BAO_0000218,8353
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rat,1,,,,In vivo,1,,5833,A,,Intermediate,CHEMBL618719,BAO_0000218,8354
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rat,1,,,,In vivo,1,,6453,A,,Intermediate,CHEMBL618720,BAO_0000218,8355
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rat,1,,,,In vivo,1,,6640,A,,Intermediate,CHEMBL618721,BAO_0000218,8356
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rats,1,,,,In vivo,1,,6305,A,,Intermediate,CHEMBL621477,BAO_0000218,8357
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rat,1,,,,In vivo,1,,6642,A,,Intermediate,CHEMBL621478,BAO_0000218,8358
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance was evaluated in rat,1,,,,In vivo,1,,5472,A,,Intermediate,CHEMBL621479,BAO_0000218,8359
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance was evaluated in rat; Not tested,1,,,,In vivo,1,,5472,A,,Intermediate,CHEMBL621480,BAO_0000218,8360
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance rate was determined for the compound in rat,1,,,,In vivo,1,,5144,A,,Intermediate,CHEMBL621481,BAO_0000218,8361
,,N,,,50597,10116.0,Rattus norvegicus,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",1,,,,In vivo,1,,6685,A,,Intermediate,CHEMBL621482,BAO_0000218,8362
,,N,,,50597,10116.0,Rattus norvegicus,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",1,,,,In vivo,1,,6685,A,,Intermediate,CHEMBL621483,BAO_0000218,8363
,,N,,,50597,10116.0,Rattus norvegicus,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",1,,,,In vivo,1,,6685,A,,Intermediate,CHEMBL621484,BAO_0000218,8364
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,Heart,,,In vivo,1,,13950,A,948.0,Intermediate,CHEMBL621485,BAO_0000218,8365
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,Heart,,,In vivo,1,,13950,A,948.0,Intermediate,CHEMBL621486,BAO_0000218,8366
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,Intestine,,,In vivo,1,,13950,A,160.0,Intermediate,CHEMBL621487,BAO_0000218,8367
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,Intestine,,,In vivo,1,,13950,A,160.0,Intermediate,CHEMBL621488,BAO_0000218,8368
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,Intestine,,,In vivo,1,,13950,A,160.0,Intermediate,CHEMBL621489,BAO_0000218,8369
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,Intestine,,,In vivo,1,,13950,A,160.0,Intermediate,CHEMBL621490,BAO_0000218,8370
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,Intestine,,,In vivo,1,,13950,A,160.0,Intermediate,CHEMBL621491,BAO_0000218,8371
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,Kidney,,,In vivo,1,,13950,A,2113.0,Intermediate,CHEMBL621492,BAO_0000218,8372
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,1,Kidney,,,In vivo,1,,13950,A,2113.0,Intermediate,CHEMBL621493,BAO_0000218,8373
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,Kidney,,,In vivo,1,,13950,A,2113.0,Intermediate,CHEMBL621494,BAO_0000218,8374
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,Kidney,,,In vivo,1,,13950,A,2113.0,Intermediate,CHEMBL621495,BAO_0000218,8375
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,Kidney,,,In vivo,1,,13950,A,2113.0,Intermediate,CHEMBL621496,BAO_0000218,8376
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,Liver,,,In vivo,1,,13950,A,2107.0,Intermediate,CHEMBL621497,BAO_0000218,8377
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,Liver,,,In vivo,1,,13950,A,2107.0,Intermediate,CHEMBL621498,BAO_0000218,8378
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,Liver,,,In vivo,1,,13950,A,2107.0,Intermediate,CHEMBL621499,BAO_0000218,8379
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,1,Liver,,,In vivo,1,,13950,A,2107.0,Intermediate,CHEMBL618634,BAO_0000218,8380
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,Liver,,,In vivo,1,,13950,A,2107.0,Intermediate,CHEMBL618635,BAO_0000218,8381
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,Lung,,,In vivo,1,,13950,A,2048.0,Intermediate,CHEMBL618636,BAO_0000218,8382
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,Lung,,,In vivo,1,,13950,A,2048.0,Intermediate,CHEMBL619737,BAO_0000218,8383
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,Lung,,,In vivo,1,,13950,A,2048.0,Intermediate,CHEMBL619738,BAO_0000218,8384
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,Lung,,,In vivo,1,,13950,A,2048.0,Intermediate,CHEMBL624329,BAO_0000218,8385
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,Lung,,,In vivo,1,,13950,A,2048.0,Intermediate,CHEMBL624330,BAO_0000218,8386
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,Muscle tissue,,,In vivo,1,,13950,A,2385.0,Intermediate,CHEMBL624331,BAO_0000218,8387
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,Muscle tissue,,,In vivo,1,,13950,A,2385.0,Intermediate,CHEMBL624332,BAO_0000218,8388
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,Muscle tissue,,,In vivo,1,,13950,A,2385.0,Intermediate,CHEMBL624333,BAO_0000218,8389
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,Muscle tissue,,,In vivo,1,,13950,A,2385.0,Intermediate,CHEMBL624334,BAO_0000218,8390
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,Muscle tissue,,,In vivo,1,,13950,A,2385.0,Intermediate,CHEMBL624335,BAO_0000218,8391
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,Spleen,,,In vivo,1,,13950,A,2106.0,Intermediate,CHEMBL620016,BAO_0000218,8392
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,Spleen,,,In vivo,1,,13950,A,2106.0,Intermediate,CHEMBL620169,BAO_0000218,8393
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,Spleen,,,In vivo,1,,13950,A,2106.0,Intermediate,CHEMBL620170,BAO_0000218,8394
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,1,Spleen,,,In vivo,1,,13950,A,2106.0,Intermediate,CHEMBL620171,BAO_0000218,8395
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,Spleen,,,In vivo,1,,13950,A,2106.0,Intermediate,CHEMBL620172,BAO_0000218,8396
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,Stomach,,,In vivo,1,,13950,A,945.0,Intermediate,CHEMBL620173,BAO_0000218,8397
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,1,Stomach,,,In vivo,1,,13950,A,945.0,Intermediate,CHEMBL620174,BAO_0000218,8398
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,Stomach,,,In vivo,1,,13950,A,945.0,Intermediate,CHEMBL620175,BAO_0000218,8399
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,Stomach,,,In vivo,1,,13950,A,945.0,Intermediate,CHEMBL620176,BAO_0000218,8400
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,Stomach,,,In vivo,1,,13950,A,945.0,Intermediate,CHEMBL620177,BAO_0000218,8401
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,Cerebellum,,,,1,,13950,A,2037.0,Intermediate,CHEMBL620178,BAO_0000218,8402
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,Cerebellum,,,,1,,13950,A,2037.0,Intermediate,CHEMBL620179,BAO_0000218,8403
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,,,,,1,,13950,A,,Intermediate,CHEMBL620180,BAO_0000218,8404
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,1,,,,In vivo,1,,6570,A,,Intermediate,CHEMBL620181,BAO_0000218,8405
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution of compound in rats after intravenous administration,1,,,,In vivo,1,,6571,A,,Intermediate,CHEMBL620182,BAO_0000218,8406
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution in rat,1,,,,In vivo,1,,6453,A,,Intermediate,CHEMBL620183,BAO_0000218,8407
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,1,,,,In vivo,1,,6444,A,,Intermediate,CHEMBL620184,BAO_0000218,8408
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,1,,,,In vivo,1,,6444,A,,Intermediate,CHEMBL620185,BAO_0000218,8409
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,1,,,,In vivo,1,,6444,A,,Intermediate,CHEMBL620186,BAO_0000218,8410
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution was determined in Dawley rat,1,,,,In vivo,1,,5353,A,,Intermediate,CHEMBL620187,BAO_0000218,8411
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,1,,,,In vivo,1,,5334,A,,Intermediate,CHEMBL620188,BAO_0000218,8412
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution was reported in Sprague-Dawley rat,1,,,,In vivo,1,,5334,A,,Intermediate,CHEMBL620189,BAO_0000218,8413
,,N,,,50597,10116.0,Rattus norvegicus,Volumes of distribution in rat after peroral administration,1,,,,In vivo,1,,6641,A,,Intermediate,CHEMBL620190,BAO_0000218,8414
,,N,,,50597,10116.0,Rattus norvegicus,Volumes of distribution in rat after po administration,1,,,,In vivo,1,,6641,A,,Intermediate,CHEMBL620191,BAO_0000218,8415
,,N,,,50597,10116.0,Rattus norvegicus,Volumes of distribution in rat after po administration; Not determined,1,,,,In vivo,1,,6641,A,,Intermediate,CHEMBL620192,BAO_0000218,8416
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (Volume) in rat i.v.,1,,,,In vivo,1,,5676,A,,Intermediate,CHEMBL620193,BAO_0000218,8417
,,N,,,50597,10116.0,Rattus norvegicus,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,1,,,,In vivo,1,,6410,A,,Intermediate,CHEMBL620194,BAO_0000218,8418
,,N,,,50597,10116.0,Rattus norvegicus,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",1,,,,In vivo,1,,17670,A,,Intermediate,CHEMBL876730,BAO_0000218,8419
,,N,,,50597,10116.0,Rattus norvegicus,Volume distribution in rat after oral administration at 10 mg/kg,1,,,,In vivo,1,,6495,A,,Intermediate,CHEMBL620195,BAO_0000218,8420
,,N,,,50597,10116.0,Rattus norvegicus,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,1,,,,In vivo,1,,5408,A,,Intermediate,CHEMBL620196,BAO_0000218,8421
,,N,,,50597,10116.0,Rattus norvegicus,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,1,,,,In vivo,1,,4883,A,,Intermediate,CHEMBL620197,BAO_0000218,8422
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,1,,,,In vivo,1,,6647,A,,Intermediate,CHEMBL620198,BAO_0000218,8423
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution in rats,1,,,,In vivo,1,,6495,A,,Intermediate,CHEMBL620199,BAO_0000218,8424
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,1,,,,In vivo,1,,2661,A,,Intermediate,CHEMBL620200,BAO_0000218,8425
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,1,,,,In vivo,1,,2661,A,,Intermediate,CHEMBL620201,BAO_0000218,8426
,,N,,,50597,10116.0,Rattus norvegicus,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,,,,In vivo,1,,5974,A,,Intermediate,CHEMBL620202,BAO_0000218,8427
,,N,,,50597,10116.0,Rattus norvegicus,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,,,,In vivo,1,,5974,A,,Intermediate,CHEMBL620203,BAO_0000218,8428
,,N,,,50597,10116.0,Rattus norvegicus,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,1,,,,In vivo,1,,5974,A,,Intermediate,CHEMBL620204,BAO_0000218,8429
,,N,,,50597,10116.0,Rattus norvegicus,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,,,,In vivo,1,,5974,A,,Intermediate,CHEMBL620205,BAO_0000218,8430
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter (Vss) in rat,1,,,,In vivo,1,,5960,A,,Intermediate,CHEMBL624664,BAO_0000218,8431
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (Volume) in rat i.v.,1,,,,In vivo,1,,5676,A,,Intermediate,CHEMBL624665,BAO_0000218,8432
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (Vss) in rat,1,,,,,1,,5948,A,,Intermediate,CHEMBL624666,BAO_0000218,8433
,,N,,,50597,10116.0,Rattus norvegicus,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,1,,,,In vivo,1,,5979,A,,Intermediate,CHEMBL624667,BAO_0000218,8434
,,N,,,50597,10116.0,Rattus norvegicus,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL624668,BAO_0000218,8435
,,N,,,50597,10116.0,Rattus norvegicus,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL624669,BAO_0000218,8436
,,N,,,50597,10116.0,Rattus norvegicus,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL624670,BAO_0000218,8437
,,N,,,50597,10116.0,Rattus norvegicus,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL624671,BAO_0000218,8438
,,N,,,50597,10116.0,Rattus norvegicus,Steady state volume distribution in rat,1,,,,In vivo,1,,6448,A,,Intermediate,CHEMBL624672,BAO_0000218,8439
,,N,,,50597,10116.0,Rattus norvegicus,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",1,Plasma,,,In vivo,1,,12873,A,1969.0,Intermediate,CHEMBL624673,BAO_0000218,8440
,,N,,,50597,10116.0,Rattus norvegicus,Steady state volume of distribution determined in rat,1,,,,In vivo,1,,4576,A,,Intermediate,CHEMBL624674,BAO_0000218,8441
,,N,,,50597,10116.0,Rattus norvegicus,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,,,,In vivo,1,,17582,A,,Intermediate,CHEMBL624675,BAO_0000218,8442
,,N,,,50597,10116.0,Rattus norvegicus,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,1,,,,In vivo,1,,1466,A,,Intermediate,CHEMBL621728,BAO_0000218,8443
,,N,,,50597,10116.0,Rattus norvegicus,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,1,,,,,1,,5182,A,,Intermediate,CHEMBL621729,BAO_0000218,8444
,,N,,,50597,10116.0,Rattus norvegicus,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,1,,,,,1,,5182,A,,Intermediate,CHEMBL621730,BAO_0000218,8445
,,N,,,50597,10116.0,Rattus norvegicus,Volume distribution in rat after administration of 2 mg/kg iv,1,,,,In vivo,1,,6535,A,,Intermediate,CHEMBL621731,BAO_0000218,8446
,,N,,,50597,10116.0,Rattus norvegicus,Volume distribution in rat after administration of 2 mg/kg iv,1,,,,In vivo,1,,6535,A,,Intermediate,CHEMBL621732,BAO_0000218,8447
,,N,,,50597,10116.0,Rattus norvegicus,Volume in steady state distribution value was determined,1,,,,In vivo,1,,5041,A,,Intermediate,CHEMBL621908,BAO_0000218,8448
,,N,,,50597,10116.0,Rattus norvegicus,Volume in steady state distribution value was determined; ND denotes no data,1,,,,In vivo,1,,5041,A,,Intermediate,CHEMBL875347,BAO_0000218,8449
,,N,,,50597,10116.0,Rattus norvegicus,Volume in steady state distribution value was determined; ND denotes not determined,1,,,,In vivo,1,,5041,A,,Intermediate,CHEMBL621909,BAO_0000218,8450
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,,,,In vivo,1,,17065,A,,Intermediate,CHEMBL621910,BAO_0000218,8451
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution at steady state was evaluated in rats,1,,,,In vivo,1,,6597,A,,Intermediate,CHEMBL621911,BAO_0000218,8452
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution at steady state was observed after intravenous administration in rat,1,,,,In vivo,1,,15662,A,,Intermediate,CHEMBL621912,BAO_0000218,8453
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution in steady state was determined in rat,1,,,,In vivo,1,,6485,A,,Intermediate,CHEMBL621913,BAO_0000218,8454
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution in steady state was determined in rat,1,,,,In vivo,1,,17655,A,,Intermediate,CHEMBL621914,BAO_0000218,8455
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution after i.v. administration,1,,,,In vivo,1,,6616,A,,Intermediate,CHEMBL621915,BAO_0000218,8456
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,1,,,,In vivo,1,,1916,A,,Intermediate,CHEMBL621916,BAO_0000218,8457
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,Liver,,,In vivo,1,,16438,A,2107.0,Intermediate,CHEMBL621917,BAO_0000218,8458
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Liver,,,In vivo,1,,16438,A,2107.0,Intermediate,CHEMBL621918,BAO_0000218,8459
,,N,,,50594,10090.0,Mus musculus,Biodistribution of compound (oxidized form) in spleen tissue,1,Spleen,,,In vivo,1,,16438,A,2106.0,Intermediate,CHEMBL621919,BAO_0000218,8460
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,Spleen,,,In vivo,1,,16438,A,2106.0,Intermediate,CHEMBL621920,BAO_0000218,8461
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",1,Spleen,,,In vivo,1,,16438,A,2106.0,Intermediate,CHEMBL621921,BAO_0000218,8462
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,Spleen,,,In vivo,1,,16438,A,2106.0,Intermediate,CHEMBL622401,BAO_0000218,8463
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Spleen,,,In vivo,1,,16438,A,2106.0,Intermediate,CHEMBL875348,BAO_0000218,8464
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,Spleen,,,In vivo,1,,16438,A,2106.0,Intermediate,CHEMBL622402,BAO_0000218,8465
,,N,,,50594,10090.0,Mus musculus,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,1,Blood,,,In vivo,1,,16438,A,178.0,Intermediate,CHEMBL622403,BAO_0000218,8466
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,Blood,,,In vivo,1,,16438,A,178.0,Intermediate,CHEMBL622404,BAO_0000218,8467
,,N,,,50594,10090.0,Mus musculus,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,1,Brain,,,In vivo,1,,16438,A,955.0,Intermediate,CHEMBL622405,BAO_0000218,8468
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",1,Brain,,,In vivo,1,,16438,A,955.0,Intermediate,CHEMBL622406,BAO_0000218,8469
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,Brain,,,In vivo,1,,16438,A,955.0,Intermediate,CHEMBL622407,BAO_0000218,8470
,,N,,,50594,10090.0,Mus musculus,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,1,Heart,,,In vivo,1,,16438,A,948.0,Intermediate,CHEMBL622408,BAO_0000218,8471
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",1,Heart,,,In vivo,1,,16438,A,948.0,Intermediate,CHEMBL622409,BAO_0000218,8472
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,Heart,,,In vivo,1,,16438,A,948.0,Intermediate,CHEMBL622410,BAO_0000218,8473
,,N,,,50594,10090.0,Mus musculus,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,1,Kidney,,,In vivo,1,,16438,A,2113.0,Intermediate,CHEMBL622411,BAO_0000218,8474
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",1,Kidney,,,In vivo,1,,16438,A,2113.0,Intermediate,CHEMBL627864,BAO_0000218,8475
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,Kidney,,,In vivo,1,,16438,A,2113.0,Intermediate,CHEMBL627865,BAO_0000218,8476
,,N,,,50594,10090.0,Mus musculus,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,1,Liver,,,In vivo,1,,16438,A,2107.0,Intermediate,CHEMBL627866,BAO_0000218,8477
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,Liver,,,In vivo,1,,16438,A,2107.0,Intermediate,CHEMBL627751,BAO_0000218,8478
,,N,,,50594,10090.0,Mus musculus,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,1,Spleen,,,In vivo,1,,16438,A,2106.0,Intermediate,CHEMBL627752,BAO_0000218,8479
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",1,Spleen,,,In vivo,1,,16438,A,2106.0,Intermediate,CHEMBL627753,BAO_0000218,8480
,,N,,,50594,10090.0,Mus musculus,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,Spleen,,,In vivo,1,,16438,A,2106.0,Intermediate,CHEMBL627754,BAO_0000218,8481
,,N,,,50594,10090.0,Mus musculus,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,1,,,,,1,,12467,A,,Intermediate,CHEMBL627755,BAO_0000218,8482
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),1,Brain,,,In vivo,1,,17208,A,955.0,Intermediate,CHEMBL627756,BAO_0000218,8483
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),1,Brain,,,In vivo,1,,17208,A,955.0,Intermediate,CHEMBL627757,BAO_0000218,8484
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),1,Brain,,,In vivo,1,,17208,A,955.0,Intermediate,CHEMBL627758,BAO_0000218,8485
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),1,Brain,,,In vivo,1,,17208,A,955.0,Intermediate,CHEMBL627759,BAO_0000218,8486
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),1,Brain,,,In vivo,1,,17208,A,955.0,Intermediate,CHEMBL627760,BAO_0000218,8487
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),1,Brain,,,In vivo,1,,17208,A,955.0,Intermediate,CHEMBL627761,BAO_0000218,8488
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),1,Heart,,,In vivo,1,,17208,A,948.0,Intermediate,CHEMBL876811,BAO_0000218,8489
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),1,Heart,,,In vivo,1,,17208,A,948.0,Intermediate,CHEMBL627762,BAO_0000218,8490
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),1,Heart,,,In vivo,1,,17208,A,948.0,Intermediate,CHEMBL627763,BAO_0000218,8491
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),1,Heart,,,In vivo,1,,17208,A,948.0,Intermediate,CHEMBL627764,BAO_0000218,8492
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),1,Heart,,,In vivo,1,,17208,A,948.0,Intermediate,CHEMBL627765,BAO_0000218,8493
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),1,Heart,,,In vivo,1,,17208,A,948.0,Intermediate,CHEMBL627766,BAO_0000218,8494
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),1,Kidney,,,In vivo,1,,17208,A,2113.0,Intermediate,CHEMBL627767,BAO_0000218,8495
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),1,Kidney,,,In vivo,1,,17208,A,2113.0,Intermediate,CHEMBL627768,BAO_0000218,8496
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),1,Kidney,,,In vivo,1,,17208,A,2113.0,Intermediate,CHEMBL628422,BAO_0000218,8497
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),1,Kidney,,,In vivo,1,,17208,A,2113.0,Intermediate,CHEMBL628423,BAO_0000218,8498
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,1,,,,In vivo,1,,5089,A,,Intermediate,CHEMBL628424,BAO_0000218,8499
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,1,,,,In vivo,1,,5089,A,,Intermediate,CHEMBL628425,BAO_0000218,8500
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,1,,,,In vivo,1,,4257,A,,Intermediate,CHEMBL628426,BAO_0000218,8501
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,,,In vivo,1,,6679,A,,Intermediate,CHEMBL628427,BAO_0000218,8502
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,1,,,,In vivo,1,,5546,A,,Intermediate,CHEMBL626938,BAO_0000218,8503
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,1,,,,In vivo,1,,6141,A,,Intermediate,CHEMBL626939,BAO_0000218,8504
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,1,,,,In vivo,1,,5334,A,,Intermediate,CHEMBL626940,BAO_0000218,8505
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,1,,,,In vivo,1,,5334,A,,Intermediate,CHEMBL626941,BAO_0000218,8506
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance was reported in Sprague-Dawley rat,1,,,,In vivo,1,,5334,A,,Intermediate,CHEMBL626942,BAO_0000218,8507
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance after intravenous administration (1 mg/kg) in rat,1,,,,In vivo,1,,4689,A,,Intermediate,CHEMBL876812,BAO_0000218,8508
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance of compound in rats was evaluated,1,,,,In vivo,1,,6848,A,,Intermediate,CHEMBL626943,BAO_0000218,8509
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance of compound in rats was evaluated; ND indicates not determined,1,,,,In vivo,1,,6848,A,,Intermediate,CHEMBL626944,BAO_0000218,8510
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,1,,,,In vivo,1,,6467,A,,Intermediate,CHEMBL626945,BAO_0000218,8511
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,1,,,,In vivo,1,,6467,A,,Intermediate,CHEMBL626946,BAO_0000218,8512
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance rate in Sprague-Dawley rats,1,,,,In vivo,1,,4956,A,,Intermediate,CHEMBL626856,BAO_0000218,8513
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),1,,,,In vivo,1,,5529,A,,Intermediate,CHEMBL626857,BAO_0000218,8514
,,N,,,50597,10116.0,Rattus norvegicus,The compound was evaluated for plasma clearance in rat,1,Plasma,,,In vivo,1,,406,A,1969.0,Intermediate,CHEMBL626858,BAO_0000218,8515
,,N,,,50597,10116.0,Rattus norvegicus,Total plasma clearance in rat,1,Plasma,,,In vivo,1,,17655,A,1969.0,Intermediate,CHEMBL627018,BAO_0000218,8516
,,N,,,50597,10116.0,Rattus norvegicus,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,1,Blood,,,In vivo,1,,3293,A,178.0,Intermediate,CHEMBL625331,BAO_0000218,8517
,,N,,,50597,10116.0,Rattus norvegicus,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,1,Blood,,,In vivo,1,,4075,A,178.0,Intermediate,CHEMBL625332,BAO_0000218,8518
,,N,,,50597,10116.0,Rattus norvegicus,C max was determined at 10 mg/kg po dose in rats,1,,,,In vivo,1,,2792,A,,Intermediate,CHEMBL877590,BAO_0000218,8519
,,N,,,50597,10116.0,Rattus norvegicus,C max was determined at 3 mg/kg po dose in rats,1,,,,In vivo,1,,2792,A,,Intermediate,CHEMBL625333,BAO_0000218,8520
,,N,,,50597,10116.0,Rattus norvegicus,Cmax after repeated oral dose of compound at 1 mg/kg in rats,1,,,,In vivo,1,,17594,A,,Intermediate,CHEMBL625334,BAO_0000218,8521
,,N,,,50597,10116.0,Rattus norvegicus,Cmax after single intravenous bolus of 1 mg/kg in rats,1,,,,In vivo,1,,17594,A,,Intermediate,CHEMBL625335,BAO_0000218,8522
,,N,,,50597,10116.0,Rattus norvegicus,Cmax of compound at 5 mg/kg after po administration was determined in rat,1,,,,In vivo,1,,4762,A,,Intermediate,CHEMBL625336,BAO_0000218,8523
,,N,,,50597,10116.0,Rattus norvegicus,Cmax 24 hr after 10 mg/kg oral administration in rats,1,,,,In vivo,1,,17509,A,,Intermediate,CHEMBL625337,BAO_0000218,8524
,,N,,,50597,10116.0,Rattus norvegicus,Cmax 24 hr after 2 mg/kg oral administration in rats,1,,,,In vivo,1,,17509,A,,Intermediate,CHEMBL625338,BAO_0000218,8525
,,N,,,50597,10116.0,Rattus norvegicus,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,1,Plasma,,,In vivo,1,,1466,A,1969.0,Intermediate,CHEMBL625339,BAO_0000218,8526
,,N,,,50597,10116.0,Rattus norvegicus,Cmax in rat after administration of 2 mg/kg iv,1,,,,In vivo,1,,6535,A,,Intermediate,CHEMBL625340,BAO_0000218,8527
,,N,,,50597,10116.0,Rattus norvegicus,Cmax in rat after administration of 2 mg/kg iv,1,,,,In vivo,1,,6535,A,,Intermediate,CHEMBL625341,BAO_0000218,8528
,,N,,,50597,10116.0,Rattus norvegicus,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,1,,,,In vivo,1,,3169,A,,Intermediate,CHEMBL622687,BAO_0000218,8529
,,N,,,50597,10116.0,Rattus norvegicus,Cmax wa determined in rat plasma at 30 mg/kg after po administration,1,Plasma,,,In vivo,1,,6515,A,1969.0,Intermediate,CHEMBL622688,BAO_0000218,8530
,,N,,,50597,10116.0,Rattus norvegicus,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,1,Blood,,,In vivo,1,,11149,A,178.0,Intermediate,CHEMBL622689,BAO_0000218,8531
,,N,,,50597,10116.0,Rattus norvegicus,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,1,Blood,,,In vivo,1,,11149,A,178.0,Intermediate,CHEMBL620295,BAO_0000218,8532
,,N,,,50597,10116.0,Rattus norvegicus,Cmax after 10 mg/kg oral administration in rat,1,,,,In vivo,1,,17858,A,,Intermediate,CHEMBL620296,BAO_0000218,8533
,,N,,,50597,10116.0,Rattus norvegicus,Cmax after IV dosing at 0.5 mg/kg in rat; no data,1,,,,In vivo,1,,6518,A,,Intermediate,CHEMBL620297,BAO_0000218,8534
,,N,,,50597,10116.0,Rattus norvegicus,Cmax after IV dosing at 1 mg/kg in rat; no data,1,,,,In vivo,1,,6518,A,,Intermediate,CHEMBL620298,BAO_0000218,8535
,,N,,,50597,10116.0,Rattus norvegicus,Cmax after oral administration at 20 mpk in rats,1,,,,In vivo,1,,4426,A,,Intermediate,CHEMBL620299,BAO_0000218,8536
,,N,,,50597,10116.0,Rattus norvegicus,Cmax after oral administration at 20 mpk in rats; Not performed.,1,,,,In vivo,1,,4426,A,,Intermediate,CHEMBL620300,BAO_0000218,8537
,,N,,,50597,10116.0,Rattus norvegicus,Cmax after oral administration at 20 mpk in rats d; Not performed.,1,,,,In vivo,1,,4426,A,,Intermediate,CHEMBL620301,BAO_0000218,8538
,,N,,,50597,10116.0,Rattus norvegicus,Cmax after oral administration in rat,1,,,,In vivo,1,,5656,A,,Intermediate,CHEMBL620302,BAO_0000218,8539
,,N,,,50597,10116.0,Rattus norvegicus,Cmax after oral administration at a dose of 2 mg/kg in rat,1,,,,In vivo,1,,6518,A,,Intermediate,CHEMBL620303,BAO_0000218,8540
,,N,,,50597,10116.0,Rattus norvegicus,Cmax after oral administration at a dose of 4 mg/kg in rat,1,,,,In vivo,1,,6518,A,,Intermediate,CHEMBL620304,BAO_0000218,8541
,,N,,,50597,10116.0,Rattus norvegicus,Cmax in rats after 20 mg/kg oral dose,1,,,,In vivo,1,,6113,A,,Intermediate,CHEMBL620305,BAO_0000218,8542
,,N,,,50597,10116.0,Rattus norvegicus,Cmax after peroral administration in rats at 2.4 uM/kg,1,,,,In vivo,1,,17764,A,,Intermediate,CHEMBL620306,BAO_0000218,8543
,,N,,,50597,10116.0,Rattus norvegicus,Cmax at the dose of 2 mg/Kg administered perorally in rats,1,,,,In vivo,1,,4756,A,,Intermediate,CHEMBL620307,BAO_0000218,8544
,,N,,,50597,10116.0,Rattus norvegicus,Cmax at the dose of 5 mg/Kg administered perorally in rats,1,,,,In vivo,1,,4756,A,,Intermediate,CHEMBL620308,BAO_0000218,8545
,,N,,,50597,10116.0,Rattus norvegicus,Cmax by administering at 20 mg/kg p.o. in rats,1,,,,In vivo,1,,6402,A,,Intermediate,CHEMBL620309,BAO_0000218,8546
,,N,,,50597,10116.0,Rattus norvegicus,Cmax in male rat,1,,,,In vivo,1,,5610,A,,Intermediate,CHEMBL620310,BAO_0000218,8547
,,N,,,50597,10116.0,Rattus norvegicus,Cmax in rat,1,,,,In vivo,1,,5207,A,,Intermediate,CHEMBL620311,BAO_0000218,8548
,,N,,,50597,10116.0,Rattus norvegicus,Cmax in rat,1,,,,In vivo,1,,6011,A,,Intermediate,CHEMBL620312,BAO_0000218,8549
,,N,,,50597,10116.0,Rattus norvegicus,Cmax in rat,1,,,,In vivo,1,,6504,A,,Intermediate,CHEMBL620313,BAO_0000218,8550
,,N,,,50597,10116.0,Rattus norvegicus,Cmax in rat at 10 mg/kg,1,,,,In vivo,1,,6046,A,,Intermediate,CHEMBL620314,BAO_0000218,8551
,,N,,,50597,10116.0,Rattus norvegicus,Cmax in rat at the dose of 1 mg/kg i.v.,1,,,,In vivo,1,,6504,A,,Intermediate,CHEMBL620315,BAO_0000218,8552
,,N,,,50597,10116.0,Rattus norvegicus,Cmax in rat by po administration at a dose of 40 mg/kg,1,,,,In vivo,1,,5874,A,,Intermediate,CHEMBL620316,BAO_0000218,8553
,,N,,,50597,10116.0,Rattus norvegicus,Cmax in rat p.o. at 20 mg/kg concentration,1,,,,In vivo,1,,17686,A,,Intermediate,CHEMBL620317,BAO_0000218,8554
,,N,,,50597,10116.0,Rattus norvegicus,Cmax in rats,1,,,,In vivo,1,,5836,A,,Intermediate,CHEMBL620318,BAO_0000218,8555
,,N,,,50597,10116.0,Rattus norvegicus,Cmax in rats,1,,,,In vivo,1,,17596,A,,Intermediate,CHEMBL620319,BAO_0000218,8556
,,N,,,50597,10116.0,Rattus norvegicus,Cmax was evaluated after 20 uM/kg of peroral administration,1,,,,In vivo,1,,16423,A,,Intermediate,CHEMBL620320,BAO_0000218,8557
,,N,,,50597,10116.0,Rattus norvegicus,Cmax was measured in rats after peroral administration at 3 mg/kg,1,,,,In vivo,1,,17804,A,,Intermediate,CHEMBL620321,BAO_0000218,8558
,,N,,,50597,10116.0,Rattus norvegicus,Cmax value after oral dose at a dose of 10 mg/kg in rats.,1,,,,In vivo,1,,1908,A,,Intermediate,CHEMBL620322,BAO_0000218,8559
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,,,,,1,,13950,A,,Intermediate,CHEMBL620323,BAO_0000218,8560
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,Frontal cortex,,,,1,,13950,A,1870.0,Intermediate,CHEMBL620324,BAO_0000218,8561
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,Frontal cortex,,,,1,,13950,A,1870.0,Intermediate,CHEMBL620325,BAO_0000218,8562
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,Hippocampus,,,,1,,13950,A,10000000.0,Intermediate,CHEMBL620326,BAO_0000218,8563
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,Hippocampus,,,,1,,13950,A,10000000.0,Intermediate,CHEMBL620327,BAO_0000218,8564
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,,,,,1,,13950,A,,Intermediate,CHEMBL620328,BAO_0000218,8565
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,,,,,1,,13950,A,,Intermediate,CHEMBL620329,BAO_0000218,8566
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,Midbrain,,,,1,,13950,A,1891.0,Intermediate,CHEMBL620330,BAO_0000218,8567
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,Midbrain,,,,1,,13950,A,1891.0,Intermediate,CHEMBL875286,BAO_0000218,8568
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,,,,,1,,13950,A,,Intermediate,CHEMBL620331,BAO_0000218,8569
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,,,,,1,,13950,A,,Intermediate,CHEMBL620332,BAO_0000218,8570
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,Striatum,,,,1,,13950,A,2435.0,Intermediate,CHEMBL620333,BAO_0000218,8571
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,Striatum,,,,1,,13950,A,2435.0,Intermediate,CHEMBL620334,BAO_0000218,8572
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,Blood,,,,1,,16434,A,178.0,Intermediate,CHEMBL621015,BAO_0000218,8573
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,Blood,,,,1,,16434,A,178.0,Intermediate,CHEMBL621016,BAO_0000218,8574
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,Blood,,,,1,,16434,A,178.0,Intermediate,CHEMBL621191,BAO_0000218,8575
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,Blood,,,,1,,16434,A,178.0,Intermediate,CHEMBL621192,BAO_0000218,8576
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,Blood,,,,1,,16434,A,178.0,Intermediate,CHEMBL621193,BAO_0000218,8577
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,Blood,,,,1,,16434,A,178.0,Intermediate,CHEMBL621194,BAO_0000218,8578
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,Blood,,,,1,,16434,A,178.0,Intermediate,CHEMBL624204,BAO_0000218,8579
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,Blood,,,,1,,16434,A,178.0,Intermediate,CHEMBL624205,BAO_0000218,8580
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,Blood,,,,1,,16435,A,178.0,Intermediate,CHEMBL624206,BAO_0000218,8581
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,Blood,,,,1,,16435,A,178.0,Intermediate,CHEMBL624207,BAO_0000218,8582
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,Blood,,,,1,,16435,A,178.0,Intermediate,CHEMBL624208,BAO_0000218,8583
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,Blood,,,,1,,16435,A,178.0,Intermediate,CHEMBL624209,BAO_0000218,8584
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,Blood,,,,1,,16435,A,178.0,Intermediate,CHEMBL624210,BAO_0000218,8585
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,Blood,,,,1,,16435,A,178.0,Intermediate,CHEMBL624211,BAO_0000218,8586
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,Blood,,,,1,,16435,A,178.0,Intermediate,CHEMBL624212,BAO_0000218,8587
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,Blood,,,,1,,16435,A,178.0,Intermediate,CHEMBL624213,BAO_0000218,8588
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,Blood,,,,1,,16434,A,178.0,Intermediate,CHEMBL876611,BAO_0000218,8589
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,Blood,,,,1,,16434,A,178.0,Intermediate,CHEMBL624214,BAO_0000218,8590
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,Blood,,,,1,,16434,A,178.0,Intermediate,CHEMBL624215,BAO_0000218,8591
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,Blood,,,,1,,16435,A,178.0,Intermediate,CHEMBL624216,BAO_0000218,8592
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,Blood,,,,1,,16435,A,178.0,Intermediate,CHEMBL624217,BAO_0000218,8593
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,Blood,,,,1,,16435,A,178.0,Intermediate,CHEMBL624218,BAO_0000218,8594
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,Blood,,,,1,,16435,A,178.0,Intermediate,CHEMBL624219,BAO_0000218,8595
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,Blood,,,,1,,16435,A,178.0,Intermediate,CHEMBL624220,BAO_0000218,8596
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,Blood,,,,1,,16435,A,178.0,Intermediate,CHEMBL624221,BAO_0000218,8597
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL624222,BAO_0000218,8598
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL624223,BAO_0000218,8599
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL624224,BAO_0000218,8600
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL624225,BAO_0000218,8601
,,N,,,50597,10116.0,Rattus norvegicus,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,1,,,,In vivo,1,,17764,A,,Intermediate,CHEMBL622420,BAO_0000218,8602
,,N,,,50597,10116.0,Rattus norvegicus,Volume of steady state distribution after i.v. administration in rats,1,,,,In vivo,1,,5031,A,,Intermediate,CHEMBL622421,BAO_0000218,8603
,,N,,,50597,10116.0,Rattus norvegicus,Vss after intravenous administration (5.0 mg/kg) was determined in rat,1,,,,In vivo,1,,6215,A,,Intermediate,CHEMBL622422,BAO_0000218,8604
,,N,,,50597,10116.0,Rattus norvegicus,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,,,,In vivo,1,,17671,A,,Intermediate,CHEMBL622423,BAO_0000218,8605
,,N,,,50597,10116.0,Rattus norvegicus,Vss was determined,1,,,,In vivo,1,,17752,A,,Intermediate,CHEMBL622424,BAO_0000218,8606
,,N,,,50597,10116.0,Rattus norvegicus,Vss in rat,1,,,,In vivo,1,,6596,A,,Intermediate,CHEMBL622425,BAO_0000218,8607
,,N,,,50597,10116.0,Rattus norvegicus,Vss was evaluated after 10 uM/kg of intra arterial administration,1,,,,In vivo,1,,16423,A,,Intermediate,CHEMBL876612,BAO_0000218,8608
,,N,,,50597,10116.0,Rattus norvegicus,volume of distribution at steady state was observed after intravenous administration in rat,1,,,,In vivo,1,,15662,A,,Intermediate,CHEMBL622426,BAO_0000218,8609
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,1,,,,In vivo,1,,6062,A,,Intermediate,CHEMBL622427,BAO_0000218,8610
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic (PK) parameter Vz in rat,1,,,,In vivo,1,,5874,A,,Intermediate,CHEMBL622428,BAO_0000218,8611
,,N,,,50597,10116.0,Rattus norvegicus,Volume distribution in rats,1,,,,In vivo,1,,4942,A,,Intermediate,CHEMBL622429,BAO_0000218,8612
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution in rat; No data,1,,,,In vivo,1,,17796,A,,Intermediate,CHEMBL622430,BAO_0000218,8613
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,,,,In vivo,1,,4890,A,,Intermediate,CHEMBL622431,BAO_0000218,8614
,,N,,,50597,10116.0,Rattus norvegicus,% absorption predicted from in vitro rat ileum transport studies,1,Ileum,,,,1,,15765,A,2116.0,Intermediate,CHEMBL622432,BAO_0000218,8615
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,1,,,,In vivo,1,,13569,A,,Intermediate,CHEMBL622433,BAO_0000218,8616
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,1,,,,In vivo,1,,13569,A,,Intermediate,CHEMBL622434,BAO_0000218,8617
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,1,,,,In vivo,1,,13569,A,,Intermediate,CHEMBL622435,BAO_0000218,8618
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),1,,,,In vivo,1,,13569,A,,Intermediate,CHEMBL618748,BAO_0000218,8619
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,1,,,,In vivo,1,,13569,A,,Intermediate,CHEMBL618749,BAO_0000218,8620
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,1,,,,In vivo,1,,13569,A,,Intermediate,CHEMBL618750,BAO_0000218,8621
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,1,,,,In vivo,1,,13569,A,,Intermediate,CHEMBL618751,BAO_0000218,8622
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,1,,,,In vivo,1,,13569,A,,Intermediate,CHEMBL618752,BAO_0000218,8623
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,4576,A,,Intermediate,CHEMBL618753,BAO_0000218,8624
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,1,Plasma,,,In vivo,1,,750,A,1969.0,Intermediate,CHEMBL618754,BAO_0000218,8625
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,750,A,,Intermediate,CHEMBL618755,BAO_0000218,8626
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,4590,A,,Intermediate,CHEMBL618756,BAO_0000218,8627
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,1716,A,,Intermediate,CHEMBL618757,BAO_0000218,8628
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,1974,A,,Intermediate,CHEMBL618758,BAO_0000218,8629
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose 30 mg/kg),1,,,,In vivo,1,,4502,A,,Intermediate,CHEMBL621088,BAO_0000218,8630
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (cLogP) in rat,1,,,,,1,,3371,A,,Intermediate,CHEMBL621089,BAO_0000218,8631
,,N,,,50597,10116.0,Rattus norvegicus,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,1,Blood,,,,1,,9099,F,178.0,Intermediate,CHEMBL621090,BAO_0000218,8632
,,N,,,50597,10116.0,Rattus norvegicus,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,1,Blood,,,,1,,9099,F,178.0,Intermediate,CHEMBL621091,BAO_0000218,8633
,,N,,,50597,10116.0,Rattus norvegicus,Clearance in rat.,1,,,,In vivo,1,,4590,A,,Intermediate,CHEMBL876731,BAO_0000218,8634
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for its clearance when administered intravenously in rat,1,,,,In vivo,1,,3184,A,,Intermediate,CHEMBL621092,BAO_0000218,8635
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,,,,In vivo,1,,16456,A,,Intermediate,CHEMBL621093,BAO_0000218,8636
,,N,,,50597,10116.0,Rattus norvegicus,Blood: Brain distribution ratio is determined in rat,1,,,,,1,,4199,A,,Intermediate,CHEMBL621094,BAO_0000218,8637
,,N,,,50597,10116.0,Rattus norvegicus,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,1,,,,,1,,4199,A,,Intermediate,CHEMBL621095,BAO_0000218,8638
,,N,,,50597,10116.0,Rattus norvegicus,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,1,,,,,1,,4199,A,,Intermediate,CHEMBL621096,BAO_0000218,8639
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Kidney,,,In vivo,1,,8677,A,2113.0,Intermediate,CHEMBL621097,BAO_0000218,8640
,,N,,,50597,10116.0,Rattus norvegicus,Percent dose excreted in 0-48 hours administered ip to male rat,1,,,,,1,,7449,F,,Intermediate,CHEMBL621098,BAO_0000218,8641
,,N,,,50597,10116.0,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Cerebellum,,,,1,,11977,A,2037.0,Intermediate,CHEMBL621099,BAO_0000218,8642
,,N,,,50597,10116.0,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Cerebellum,,,,1,,11977,A,2037.0,Intermediate,CHEMBL621100,BAO_0000218,8643
,,N,,,50597,10116.0,Rattus norvegicus,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,Cerebellum,,,,1,,11977,A,2037.0,Intermediate,CHEMBL621101,BAO_0000218,8644
,,N,,,50597,10116.0,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Cerebellum,,,,1,,11977,A,2037.0,Intermediate,CHEMBL621102,BAO_0000218,8645
,,N,,,50597,10116.0,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Cerebellum,,,,1,,11977,A,2037.0,Intermediate,CHEMBL876732,BAO_0000218,8646
,,N,,,50597,10116.0,Rattus norvegicus,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,,,,1,,11977,A,,Intermediate,CHEMBL621103,BAO_0000218,8647
,,N,,,50597,10116.0,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,,,,1,,11977,A,,Intermediate,CHEMBL621104,BAO_0000218,8648
,,N,,,50597,10116.0,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,,,,1,,11977,A,,Intermediate,CHEMBL621105,BAO_0000218,8649
,,N,,,50597,10116.0,Rattus norvegicus,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,,,,1,,11977,A,,Intermediate,CHEMBL621106,BAO_0000218,8650
,,N,,,50597,10116.0,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,,,,1,,11977,A,,Intermediate,CHEMBL621107,BAO_0000218,8651
,,N,,,50597,10116.0,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,,,,1,,11977,A,,Intermediate,CHEMBL621108,BAO_0000218,8652
,,N,,,50597,10116.0,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,,,,1,,11977,A,,Intermediate,CHEMBL621109,BAO_0000218,8653
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),1,Kidney,,,In vivo,1,,17208,A,2113.0,Intermediate,CHEMBL621110,BAO_0000218,8654
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),1,Kidney,,,In vivo,1,,17208,A,2113.0,Intermediate,CHEMBL621111,BAO_0000218,8655
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),1,Liver,,,In vivo,1,,17208,A,2107.0,Intermediate,CHEMBL622541,BAO_0000218,8656
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),1,Liver,,,In vivo,1,,17208,A,2107.0,Intermediate,CHEMBL622542,BAO_0000218,8657
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),1,Liver,,,In vivo,1,,17208,A,2107.0,Intermediate,CHEMBL622543,BAO_0000218,8658
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),1,Liver,,,In vivo,1,,17208,A,2107.0,Intermediate,CHEMBL624412,BAO_0000218,8659
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),1,Liver,,,In vivo,1,,17208,A,2107.0,Intermediate,CHEMBL624413,BAO_0000218,8660
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),1,Liver,,,In vivo,1,,17208,A,2107.0,Intermediate,CHEMBL624414,BAO_0000218,8661
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),1,Lung,,,In vivo,1,,17208,A,2048.0,Intermediate,CHEMBL624415,BAO_0000218,8662
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),1,Lung,,,In vivo,1,,17208,A,2048.0,Intermediate,CHEMBL624416,BAO_0000218,8663
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),1,Lung,,,In vivo,1,,17208,A,2048.0,Intermediate,CHEMBL624417,BAO_0000218,8664
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),1,Lung,,,In vivo,1,,17208,A,2048.0,Intermediate,CHEMBL624418,BAO_0000218,8665
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),1,Lung,,,In vivo,1,,17208,A,2048.0,Intermediate,CHEMBL624419,BAO_0000218,8666
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),1,Lung,,,In vivo,1,,17208,A,2048.0,Intermediate,CHEMBL624420,BAO_0000218,8667
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),1,Muscle tissue,,,In vivo,1,,17208,A,2385.0,Intermediate,CHEMBL624421,BAO_0000218,8668
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),1,Muscle tissue,,,In vivo,1,,17208,A,2385.0,Intermediate,CHEMBL624422,BAO_0000218,8669
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),1,Muscle tissue,,,In vivo,1,,17208,A,2385.0,Intermediate,CHEMBL624423,BAO_0000218,8670
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),1,Muscle tissue,,,In vivo,1,,17208,A,2385.0,Intermediate,CHEMBL625123,BAO_0000218,8671
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),1,Muscle tissue,,,In vivo,1,,17208,A,2385.0,Intermediate,CHEMBL625124,BAO_0000218,8672
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),1,Muscle tissue,,,In vivo,1,,17208,A,2385.0,Intermediate,CHEMBL625125,BAO_0000218,8673
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),1,Zone of skin,,,In vivo,1,,17208,A,14.0,Intermediate,CHEMBL625126,BAO_0000218,8674
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),1,Zone of skin,,,In vivo,1,,17208,A,14.0,Intermediate,CHEMBL626947,BAO_0000218,8675
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),1,Zone of skin,,,In vivo,1,,17208,A,14.0,Intermediate,CHEMBL626948,BAO_0000218,8676
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),1,Zone of skin,,,In vivo,1,,17208,A,14.0,Intermediate,CHEMBL626949,BAO_0000218,8677
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),1,Zone of skin,,,In vivo,1,,17208,A,14.0,Intermediate,CHEMBL626950,BAO_0000218,8678
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),1,Zone of skin,,,In vivo,1,,17208,A,14.0,Intermediate,CHEMBL626951,BAO_0000218,8679
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),1,Spleen,,,In vivo,1,,17208,A,2106.0,Intermediate,CHEMBL626952,BAO_0000218,8680
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),1,Spleen,,,In vivo,1,,17208,A,2106.0,Intermediate,CHEMBL626953,BAO_0000218,8681
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),1,Spleen,,,In vivo,1,,17208,A,2106.0,Intermediate,CHEMBL626954,BAO_0000218,8682
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),1,Spleen,,,In vivo,1,,17208,A,2106.0,Intermediate,CHEMBL626955,BAO_0000218,8683
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),1,Spleen,,,In vivo,1,,17208,A,2106.0,Intermediate,CHEMBL626956,BAO_0000218,8684
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),1,Spleen,,,In vivo,1,,17208,A,2106.0,Intermediate,CHEMBL626957,BAO_0000218,8685
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),1,Blood,,,In vivo,1,,17208,A,178.0,Intermediate,CHEMBL626958,BAO_0000218,8686
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),1,Blood,,,In vivo,1,,17208,A,178.0,Intermediate,CHEMBL626959,BAO_0000218,8687
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),1,Blood,,,In vivo,1,,17208,A,178.0,Intermediate,CHEMBL626960,BAO_0000218,8688
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),1,Blood,,,In vivo,1,,17208,A,178.0,Intermediate,CHEMBL626961,BAO_0000218,8689
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),1,Blood,,,In vivo,1,,17208,A,178.0,Intermediate,CHEMBL627589,BAO_0000218,8690
,,N,,,50594,10090.0,Mus musculus,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),1,Blood,,,In vivo,1,,17208,A,178.0,Intermediate,CHEMBL627590,BAO_0000218,8691
,,N,,,50594,10090.0,Mus musculus,Time taken for EC90 was determined when tested in mouse,1,,,,,1,,3132,A,,Intermediate,CHEMBL627591,BAO_0000218,8692
,,N,,,50594,10090.0,Mus musculus,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,1,,,,,1,,3132,A,,Intermediate,CHEMBL627592,BAO_0000218,8693
,,N,,,50594,10090.0,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),1,,,,In vivo,1,,16597,A,,Intermediate,CHEMBL627593,BAO_0000218,8694
,,N,,,50594,10090.0,Mus musculus,Half life in mice,1,,,,,1,,5727,A,,Intermediate,CHEMBL627594,BAO_0000218,8695
,,N,,,50594,10090.0,Mus musculus,Half life period in mouse after 10 mg/Kg dose,1,,,,In vivo,1,,5302,A,,Intermediate,CHEMBL876813,BAO_0000218,8696
,,N,,,50594,10090.0,Mus musculus,Half life period in mouse after 10 mg/kg dose,1,,,,In vivo,1,,5302,A,,Intermediate,CHEMBL627595,BAO_0000218,8697
,,N,,,50594,10090.0,Mus musculus,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,,,,In vivo,1,,6348,A,,Intermediate,CHEMBL627596,BAO_0000218,8698
,,N,,,50597,10116.0,Rattus norvegicus,Cmax value at 5 mg/kg po was determined in rat,1,,,,In vivo,1,,5964,A,,Intermediate,CHEMBL627597,BAO_0000218,8699
,,N,,,50597,10116.0,Rattus norvegicus,Cmax value evaluated in rat,1,,,,In vivo,1,,6078,A,,Intermediate,CHEMBL627598,BAO_0000218,8700
,,N,,,50597,10116.0,Rattus norvegicus,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,1,Brain,,,In vivo,1,,5206,A,955.0,Intermediate,CHEMBL627599,BAO_0000218,8701
,,N,,,50597,10116.0,Rattus norvegicus,Cmax value after administration of 20 mg/Kg oral dose in rat,1,,,,In vivo,1,,2959,A,,Intermediate,CHEMBL627600,BAO_0000218,8702
,,N,,,50597,10116.0,Rattus norvegicus,Cmax value at 1 mg/kg po in rat,1,,,,In vivo,1,,5964,A,,Intermediate,CHEMBL627601,BAO_0000218,8703
,,N,,,50597,10116.0,Rattus norvegicus,Cmax value at 5 mg/kg po in rat,1,,,,In vivo,1,,5964,A,,Intermediate,CHEMBL627776,BAO_0000218,8704
,,N,,,50597,10116.0,Rattus norvegicus,Cmax value at a dose of 10 mg/kg in male SD rats,1,,,,In vivo,1,,6757,A,,Intermediate,CHEMBL627777,BAO_0000218,8705
,,N,,,50597,10116.0,Rattus norvegicus,Cmax value at a dose of 100 mg/kg in male SD rats,1,,,,In vivo,1,,6757,A,,Intermediate,CHEMBL627778,BAO_0000218,8706
,,N,,,50597,10116.0,Rattus norvegicus,Cmax value at a dose of 50 mg/kg in male SD rats,1,,,,In vivo,1,,6757,A,,Intermediate,CHEMBL627779,BAO_0000218,8707
,,N,,,50597,10116.0,Rattus norvegicus,Cmax value in rats at 10 mg/kg,1,,,,In vivo,1,,17617,A,,Intermediate,CHEMBL876814,BAO_0000218,8708
,,N,,,50597,10116.0,Rattus norvegicus,Cmax value was evaluated in rats at a dose of 20 mg/kg,1,,,,In vivo,1,,1445,A,,Intermediate,CHEMBL627780,BAO_0000218,8709
,,N,,,50597,10116.0,Rattus norvegicus,Cmax value was determined after peroral administration of 20 mg/kg in rat,1,,,,In vivo,1,,6082,A,,Intermediate,CHEMBL627781,BAO_0000218,8710
,,N,,,50597,10116.0,Rattus norvegicus,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,1,,,,In vivo,1,,1446,A,,Intermediate,CHEMBL627782,BAO_0000218,8711
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,1,Plasma,,,In vivo,1,,5407,A,1969.0,Intermediate,CHEMBL627783,BAO_0000218,8712
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,1,Plasma,,,In vivo,1,,2690,A,1969.0,Intermediate,CHEMBL627784,BAO_0000218,8713
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,1,,,,In vivo,1,,2661,A,,Intermediate,CHEMBL627785,BAO_0000218,8714
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,1,,,,In vivo,1,,2661,A,,Intermediate,CHEMBL627786,BAO_0000218,8715
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,1,Plasma,,,In vivo,1,,4891,A,1969.0,Intermediate,CHEMBL627787,BAO_0000218,8716
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,1,Plasma,,,In vivo,1,,2807,A,1969.0,Intermediate,CHEMBL627788,BAO_0000218,8717
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,1,Plasma,,,In vivo,1,,2807,A,1969.0,Intermediate,CHEMBL626579,BAO_0000218,8718
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,1,Plasma,,,In vivo,1,,2807,A,1969.0,Intermediate,CHEMBL626580,BAO_0000218,8719
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,1,,,,In vivo,1,,3634,A,,Intermediate,CHEMBL876815,BAO_0000218,8720
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,1,Plasma,,,In vivo,1,,1881,A,1969.0,Intermediate,CHEMBL626581,BAO_0000218,8721
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,1,Plasma,,,In vivo,1,,1881,A,1969.0,Intermediate,CHEMBL626582,BAO_0000218,8722
,,N,,,50597,10116.0,Rattus norvegicus,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,1,,,,In vivo,1,,429,A,,Intermediate,CHEMBL626583,BAO_0000218,8723
,,N,,,50597,10116.0,Rattus norvegicus,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,,,,In vivo,1,,5974,A,,Intermediate,CHEMBL626205,BAO_0000218,8724
,,N,,,50597,10116.0,Rattus norvegicus,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,,,,In vivo,1,,5974,A,,Intermediate,CHEMBL626206,BAO_0000218,8725
,,N,,,50597,10116.0,Rattus norvegicus,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,,,,In vivo,1,,5974,A,,Intermediate,CHEMBL626207,BAO_0000218,8726
,,N,,,50597,10116.0,Rattus norvegicus,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,,,,In vivo,1,,5974,A,,Intermediate,CHEMBL623882,BAO_0000218,8727
,,N,,,50597,10116.0,Rattus norvegicus,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,1,,,,In vivo,1,,17582,A,,Intermediate,CHEMBL623883,BAO_0000218,8728
,,N,,,50597,10116.0,Rattus norvegicus,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,1,,,,In vivo,1,,17582,A,,Intermediate,CHEMBL623884,BAO_0000218,8729
,,N,,,50597,10116.0,Rattus norvegicus,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",1,Plasma,,,In vivo,1,,3032,A,1969.0,Intermediate,CHEMBL623885,BAO_0000218,8730
,,N,,,50597,10116.0,Rattus norvegicus,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,1,Plasma,,,In vivo,1,,6295,A,1969.0,Intermediate,CHEMBL623886,BAO_0000218,8731
,,N,,,50597,10116.0,Rattus norvegicus,Maximal concentration in rat was determined,1,,,,In vivo,1,,6619,A,,Intermediate,CHEMBL623887,BAO_0000218,8732
,,N,,,50597,10116.0,Rattus norvegicus,Maximal concentration after i.v. administration,1,,,,In vivo,1,,6616,A,,Intermediate,CHEMBL623888,BAO_0000218,8733
,,N,,,50597,10116.0,Rattus norvegicus,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,1,Plasma,,,In vivo,1,,3249,A,1969.0,Intermediate,CHEMBL623889,BAO_0000218,8734
,,N,,,50597,10116.0,Rattus norvegicus,Maximal plasma concentration in rat after oral administration at 50 mg/kg,1,Plasma,,,In vivo,1,,17791,A,1969.0,Intermediate,CHEMBL623890,BAO_0000218,8735
,,N,,,50597,10116.0,Rattus norvegicus,Cmax in rat plasma after oral dose (50 mg/Kg),1,Plasma,,,In vivo,1,,17791,A,1969.0,Intermediate,CHEMBL623891,BAO_0000218,8736
,,N,,,50597,10116.0,Rattus norvegicus,Maximal plasma concentration was determined.,1,Plasma,,,In vivo,1,,1360,A,1969.0,Intermediate,CHEMBL623892,BAO_0000218,8737
,,N,,,50597,10116.0,Rattus norvegicus,Maximal plasma drug concentration was determined,1,Plasma,,,In vivo,1,,2552,A,1969.0,Intermediate,CHEMBL623893,BAO_0000218,8738
,,N,,,50597,10116.0,Rattus norvegicus,Maximal concentration in rats after peroral administration,1,,,,In vivo,1,,6571,A,,Intermediate,CHEMBL877616,BAO_0000218,8739
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration in rat after 2 mg/kg peroral administration,1,,,,In vivo,1,,6570,A,,Intermediate,CHEMBL623894,BAO_0000218,8740
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration in rat plasma after 5 mg/kg oral gavage,1,Plasma,,,In vivo,1,,6567,A,1969.0,Intermediate,CHEMBL623895,BAO_0000218,8741
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration of compound in rat was evaluated.,1,,,,In vivo,1,,3031,A,,Intermediate,CHEMBL623896,BAO_0000218,8742
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,1,,,,In vivo,1,,3436,A,,Intermediate,CHEMBL623897,BAO_0000218,8743
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,1,,,,In vivo,1,,3436,A,,Intermediate,CHEMBL623898,BAO_0000218,8744
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,1,,,,In vivo,1,,2083,A,,Intermediate,CHEMBL623899,BAO_0000218,8745
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,1,,,,In vivo,1,,3436,A,,Intermediate,CHEMBL623900,BAO_0000218,8746
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,1,,,,In vivo,1,,4527,A,,Intermediate,CHEMBL623901,BAO_0000218,8747
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration was evaluated in rats,1,,,,In vivo,1,,1974,A,,Intermediate,CHEMBL623902,BAO_0000218,8748
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,1,Cerebrospinal fluid,,,In vivo,1,,3307,A,1359.0,Intermediate,CHEMBL623903,BAO_0000218,8749
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,1,Plasma,,,In vivo,1,,3307,A,1969.0,Intermediate,CHEMBL623904,BAO_0000218,8750
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1,Plasma,,,In vivo,1,,1916,A,1969.0,Intermediate,CHEMBL877617,BAO_0000218,8751
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,1,,,,In vivo,1,,1500,A,,Intermediate,CHEMBL623905,BAO_0000218,8752
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,1,,,,In vivo,1,,1500,A,,Intermediate,CHEMBL623906,BAO_0000218,8753
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,Plasma,,,In vivo,1,,4186,A,1969.0,Intermediate,CHEMBL623907,BAO_0000218,8754
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL623908,BAO_0000218,8755
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL623909,BAO_0000218,8756
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL623910,BAO_0000218,8757
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL623911,BAO_0000218,8758
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL623912,BAO_0000218,8759
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL624616,BAO_0000218,8760
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL624617,BAO_0000218,8761
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL624618,BAO_0000218,8762
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL624619,BAO_0000218,8763
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL624794,BAO_0000218,8764
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL624795,BAO_0000218,8765
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL623921,BAO_0000218,8766
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,,,,1,,16434,A,,Intermediate,CHEMBL623922,BAO_0000218,8767
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,,,,,1,,16434,A,,Intermediate,CHEMBL623923,BAO_0000218,8768
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,,,,1,,16434,A,,Intermediate,CHEMBL623924,BAO_0000218,8769
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,,,,1,,16435,A,,Intermediate,CHEMBL623925,BAO_0000218,8770
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,,,,1,,16435,A,,Intermediate,CHEMBL623926,BAO_0000218,8771
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,,,,1,,16435,A,,Intermediate,CHEMBL623927,BAO_0000218,8772
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,,,,1,,16435,A,,Intermediate,CHEMBL623928,BAO_0000218,8773
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,,,,1,,16435,A,,Intermediate,CHEMBL623929,BAO_0000218,8774
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,,,,1,,16435,A,,Intermediate,CHEMBL623930,BAO_0000218,8775
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,Brain,,,,1,,16434,A,955.0,Intermediate,CHEMBL623931,BAO_0000218,8776
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,Brain,,,,1,,16434,A,955.0,Intermediate,CHEMBL622165,BAO_0000218,8777
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,Brain,,,,1,,16434,A,955.0,Intermediate,CHEMBL621249,BAO_0000218,8778
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,Brain,,,,1,,16434,A,955.0,Intermediate,CHEMBL621250,BAO_0000218,8779
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,Brain,,,,1,,16434,A,955.0,Intermediate,CHEMBL621448,BAO_0000218,8780
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,Brain,,,,1,,16434,A,955.0,Intermediate,CHEMBL621449,BAO_0000218,8781
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,Brain,,,,1,,16434,A,955.0,Intermediate,CHEMBL621450,BAO_0000218,8782
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,Brain,,,,1,,16434,A,955.0,Intermediate,CHEMBL621451,BAO_0000218,8783
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,Brain,,,,1,,16435,A,955.0,Intermediate,CHEMBL621452,BAO_0000218,8784
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,Brain,,,,1,,16435,A,955.0,Intermediate,CHEMBL621453,BAO_0000218,8785
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,Brain,,,,1,,16435,A,955.0,Intermediate,CHEMBL621454,BAO_0000218,8786
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,Brain,,,,1,,16435,A,955.0,Intermediate,CHEMBL621455,BAO_0000218,8787
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,Brain,,,,1,,16435,A,955.0,Intermediate,CHEMBL621456,BAO_0000218,8788
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,Brain,,,,1,,16435,A,955.0,Intermediate,CHEMBL625145,BAO_0000218,8789
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,Brain,,,,1,,16435,A,955.0,Intermediate,CHEMBL875847,BAO_0000218,8790
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,Brain,,,,1,,16435,A,955.0,Intermediate,CHEMBL625146,BAO_0000218,8791
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,Brain,,,,1,,16434,A,955.0,Intermediate,CHEMBL625147,BAO_0000218,8792
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,Brain,,,,1,,16434,A,955.0,Intermediate,CHEMBL625148,BAO_0000218,8793
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,Brain,,,,1,,16434,A,955.0,Intermediate,CHEMBL625149,BAO_0000218,8794
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,Brain,,,,1,,16435,A,955.0,Intermediate,CHEMBL625150,BAO_0000218,8795
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,Brain,,,,1,,16435,A,955.0,Intermediate,CHEMBL625151,BAO_0000218,8796
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,Brain,,,,1,,16435,A,955.0,Intermediate,CHEMBL625152,BAO_0000218,8797
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,Brain,,,,1,,16435,A,955.0,Intermediate,CHEMBL625153,BAO_0000218,8798
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,Brain,,,,1,,16435,A,955.0,Intermediate,CHEMBL625154,BAO_0000218,8799
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,Brain,,,,1,,16435,A,955.0,Intermediate,CHEMBL625155,BAO_0000218,8800
,,N,,,50597,10116.0,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,,,,1,,11977,A,,Intermediate,CHEMBL625156,BAO_0000218,8801
,,N,,,50597,10116.0,Rattus norvegicus,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,,,,1,,11977,A,,Intermediate,CHEMBL624354,BAO_0000218,8802
,,N,,,50597,10116.0,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Hippocampus,,,,1,,11977,A,10000000.0,Intermediate,CHEMBL624355,BAO_0000218,8803
,,N,,,50597,10116.0,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Hippocampus,,,,1,,11977,A,10000000.0,Intermediate,CHEMBL624356,BAO_0000218,8804
,,N,,,50597,10116.0,Rattus norvegicus,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Hippocampus,,,,1,,11977,A,10000000.0,Intermediate,CHEMBL624357,BAO_0000218,8805
,,N,,,50597,10116.0,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Hippocampus,,,,1,,11977,A,10000000.0,Intermediate,CHEMBL624358,BAO_0000218,8806
,,N,,,50597,10116.0,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Striatum,,,,1,,11977,A,2435.0,Intermediate,CHEMBL624359,BAO_0000218,8807
,,N,,,50597,10116.0,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Striatum,,,,1,,11977,A,2435.0,Intermediate,CHEMBL624360,BAO_0000218,8808
,,N,,,50597,10116.0,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,Striatum,,,,1,,11977,A,2435.0,Intermediate,CHEMBL624361,BAO_0000218,8809
,,N,,,50597,10116.0,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Striatum,,,,1,,11977,A,2435.0,Intermediate,CHEMBL624362,BAO_0000218,8810
,,N,,,50597,10116.0,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Striatum,,,,1,,11977,A,2435.0,Intermediate,CHEMBL624363,BAO_0000218,8811
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Blood,,,In vivo,1,,11977,A,178.0,Intermediate,CHEMBL624364,BAO_0000218,8812
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Blood,,,In vivo,1,,11977,A,178.0,Intermediate,CHEMBL624365,BAO_0000218,8813
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Blood,,,In vivo,1,,11977,A,178.0,Intermediate,CHEMBL624366,BAO_0000218,8814
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Blood,,,In vivo,1,,11977,A,178.0,Intermediate,CHEMBL624367,BAO_0000218,8815
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Brain,,,In vivo,1,,11977,A,955.0,Intermediate,CHEMBL624368,BAO_0000218,8816
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Brain,,,In vivo,1,,11977,A,955.0,Intermediate,CHEMBL624369,BAO_0000218,8817
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,Brain,,,In vivo,1,,11977,A,955.0,Intermediate,CHEMBL624370,BAO_0000218,8818
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Brain,,,In vivo,1,,11977,A,955.0,Intermediate,CHEMBL625069,BAO_0000218,8819
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Brain,,,In vivo,1,,11977,A,955.0,Intermediate,CHEMBL625070,BAO_0000218,8820
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Heart,,,In vivo,1,,11977,A,948.0,Intermediate,CHEMBL626051,BAO_0000218,8821
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Heart,,,In vivo,1,,11977,A,948.0,Intermediate,CHEMBL626052,BAO_0000218,8822
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,Heart,,,In vivo,1,,11977,A,948.0,Intermediate,CHEMBL626053,BAO_0000218,8823
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Heart,,,In vivo,1,,11977,A,948.0,Intermediate,CHEMBL626054,BAO_0000218,8824
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Heart,,,In vivo,1,,11977,A,948.0,Intermediate,CHEMBL626055,BAO_0000218,8825
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Kidney,,,In vivo,1,,11977,A,2113.0,Intermediate,CHEMBL626056,BAO_0000218,8826
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Kidney,,,In vivo,1,,11977,A,2113.0,Intermediate,CHEMBL626057,BAO_0000218,8827
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Kidney,,,In vivo,1,,11977,A,2113.0,Intermediate,CHEMBL625193,BAO_0000218,8828
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Kidney,,,In vivo,1,,11977,A,2113.0,Intermediate,CHEMBL625194,BAO_0000218,8829
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Liver,,,In vivo,1,,11977,A,2107.0,Intermediate,CHEMBL625195,BAO_0000218,8830
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Liver,,,In vivo,1,,11977,A,2107.0,Intermediate,CHEMBL625196,BAO_0000218,8831
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,Liver,,,In vivo,1,,11977,A,2107.0,Intermediate,CHEMBL625197,BAO_0000218,8832
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Liver,,,In vivo,1,,11977,A,2107.0,Intermediate,CHEMBL625198,BAO_0000218,8833
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Liver,,,In vivo,1,,11977,A,2107.0,Intermediate,CHEMBL627929,BAO_0000218,8834
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Lung,,,In vivo,1,,11977,A,2048.0,Intermediate,CHEMBL627074,BAO_0000218,8835
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Lung,,,In vivo,1,,11977,A,2048.0,Intermediate,CHEMBL627075,BAO_0000218,8836
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,Lung,,,In vivo,1,,11977,A,2048.0,Intermediate,CHEMBL627076,BAO_0000218,8837
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Lung,,,In vivo,1,,11977,A,2048.0,Intermediate,CHEMBL627077,BAO_0000218,8838
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Lung,,,In vivo,1,,11977,A,2048.0,Intermediate,CHEMBL627078,BAO_0000218,8839
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),1,Muscle tissue,,,In vivo,1,,11977,A,2385.0,Intermediate,CHEMBL627079,BAO_0000218,8840
,,N,,,50594,10090.0,Mus musculus,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,1,,,,In vivo,1,,4573,A,,Intermediate,CHEMBL873824,BAO_0000218,8841
,,N,,,50594,10090.0,Mus musculus,Half life in mouse plasma was determined at dose 25 mg/kg,1,Plasma,,,In vivo,1,,3132,A,1969.0,Intermediate,CHEMBL627080,BAO_0000218,8842
,,N,,,50594,10090.0,Mus musculus,Half life was determined,1,,,,,1,,17718,A,,Intermediate,CHEMBL627081,BAO_0000218,8843
,,N,,,50594,10090.0,Mus musculus,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,1,,,,In vivo,1,,17728,A,,Intermediate,CHEMBL627082,BAO_0000218,8844
,,N,,,50594,10090.0,Mus musculus,Half-life in male mice after 1 mg/kg intravenous dose,1,,,,In vivo,1,,5961,A,,Intermediate,CHEMBL627083,BAO_0000218,8845
,,N,,,50594,10090.0,Mus musculus,Half life in mice plasma,1,Plasma,,,,1,,17731,A,1969.0,Intermediate,CHEMBL627085,BAO_0000218,8847
,,N,,,50594,10090.0,Mus musculus,Half life in mouse,1,,,,,1,,17592,A,,Intermediate,CHEMBL627086,BAO_0000218,8848
,,N,,,50594,10090.0,Mus musculus,Half life in mouse plasma at dose 25 mg/kg,1,Plasma,,,In vivo,1,,3132,A,1969.0,Intermediate,CHEMBL627087,BAO_0000218,8849
,,N,,,50594,10090.0,Mus musculus,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,1,,,,In vivo,1,,17729,A,,Intermediate,CHEMBL627088,BAO_0000218,8850
,,N,,,50594,10090.0,Mus musculus,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,1,,,,In vivo,1,,17729,A,,Intermediate,CHEMBL627089,BAO_0000218,8851
,,N,,,50594,10090.0,Mus musculus,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,1,,,,In vivo,1,,17729,A,,Intermediate,CHEMBL627090,BAO_0000218,8852
,,N,,,50594,10090.0,Mus musculus,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),1,,,,In vivo,1,,3277,A,,Intermediate,CHEMBL627091,BAO_0000218,8853
,,N,,,50594,10090.0,Mus musculus,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",1,,,,In vivo,1,,3760,A,,Intermediate,CHEMBL627092,BAO_0000218,8854
,,N,,,50594,10090.0,Mus musculus,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",1,,,,In vivo,1,,3760,A,,Intermediate,CHEMBL876785,BAO_0000218,8855
,,N,,,50594,10090.0,Mus musculus,Half-life by iv administration in mouse,1,,,,In vivo,1,,2862,A,,Intermediate,CHEMBL627093,BAO_0000218,8856
,,N,,,50594,10090.0,Mus musculus,Half-life by oral administration in mouse,1,,,,In vivo,1,,2862,A,,Intermediate,CHEMBL627094,BAO_0000218,8857
,,N,,,50594,10090.0,Mus musculus,Half-life in mice,1,,,,,1,,5980,A,,Intermediate,CHEMBL627095,BAO_0000218,8858
,,N,,,50594,10090.0,Mus musculus,Half-life using mouse brain homogenate,1,Brain,,,,1,,6159,A,955.0,Intermediate,CHEMBL627096,BAO_0000218,8859
,,N,,,50594,10090.0,Mus musculus,Half-life was measured in mice,1,,,,,1,,6254,A,,Intermediate,CHEMBL627097,BAO_0000218,8860
,,N,,,50594,10090.0,Mus musculus,Half-life was measured in mouse after an iv dose of 1 mg/kg,1,,,,In vivo,1,,6062,A,,Intermediate,CHEMBL627098,BAO_0000218,8861
,,N,,,50594,10090.0,Mus musculus,Half-life period was determined in mouse blood,1,Blood,,,,1,,1574,A,178.0,Intermediate,CHEMBL627099,BAO_0000218,8862
,,N,,,50594,10090.0,Mus musculus,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",1,Brain,,,,1,,56,A,955.0,Intermediate,CHEMBL627100,BAO_0000218,8863
,,N,,,50594,10090.0,Mus musculus,Plasma half life in mouse,1,Plasma,,,,1,,993,A,1969.0,Intermediate,CHEMBL627101,BAO_0000218,8864
,,N,,,50594,10090.0,Mus musculus,Stability of the peptide in the presence of mouse serum,1,,,,,1,,6652,A,,Intermediate,CHEMBL627102,BAO_0000218,8865
,,N,,,50594,10090.0,Mus musculus,Terminal half life of compound was determined in mouse,1,,,,,1,,17852,A,,Intermediate,CHEMBL627103,BAO_0000218,8866
,,N,,,50594,10090.0,Mus musculus,Terminal half life was evaluated in mice after intravenous administration,1,,,,In vivo,1,,2675,A,,Intermediate,CHEMBL627104,BAO_0000218,8867
,,N,,,50594,10090.0,Mus musculus,Terminal half life was evaluated in mice after oral administration,1,,,,In vivo,1,,2675,A,,Intermediate,CHEMBL627105,BAO_0000218,8868
,,N,,,50594,10090.0,Mus musculus,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,1,,,,,1,,499,A,,Intermediate,CHEMBL876786,BAO_0000218,8869
,,N,,,50594,10090.0,Mus musculus,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,1,,,,,1,,499,A,,Intermediate,CHEMBL873825,BAO_0000218,8870
,,N,,,50594,10090.0,Mus musculus,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,1,,,,,1,,499,A,,Intermediate,CHEMBL627106,BAO_0000218,8871
,,N,,,50594,10090.0,Mus musculus,half life period is evaluated by administering intravenously at 25 mg/kg in mice,1,,,,In vivo,1,,14239,A,,Intermediate,CHEMBL626336,BAO_0000218,8872
,,N,,,50594,10090.0,Mus musculus,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",1,,,,In vivo,1,,5506,A,,Intermediate,CHEMBL877462,BAO_0000218,8873
,,N,,,50594,10090.0,Mus musculus,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",1,,,,In vivo,1,,5506,A,,Intermediate,CHEMBL626337,BAO_0000218,8874
,,N,,,50594,10090.0,Mus musculus,Half life after intraperitoneal administration of 100 mg/kg in mice,1,,,,,1,,17734,A,,Intermediate,CHEMBL626338,BAO_0000218,8875
,,N,,,50594,10090.0,Mus musculus,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,1,,,,In vivo,1,,17728,A,,Intermediate,CHEMBL626339,BAO_0000218,8876
,,N,,,50594,10090.0,Mus musculus,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,1,,,,In vivo,1,,17728,A,,Intermediate,CHEMBL626340,BAO_0000218,8877
,,N,,,50594,10090.0,Mus musculus,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,1,,,,In vivo,1,,17728,A,,Intermediate,CHEMBL625377,BAO_0000218,8878
,,N,,,50594,10090.0,Mus musculus,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,1,,,,In vivo,1,,17728,A,,Intermediate,CHEMBL625378,BAO_0000218,8879
,,N,,,50594,10090.0,Mus musculus,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,1,,,,In vivo,1,,17728,A,,Intermediate,CHEMBL625379,BAO_0000218,8880
,Microsomes,U,,,22224,9823.0,Sus scrofa,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),1,,,,,0,,14294,A,,Autocuration,CHEMBL625380,BAO_0000251,8881
,Microsomes,U,,,22224,9823.0,Sus scrofa,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),1,,,,,0,,14294,A,,Autocuration,CHEMBL625381,BAO_0000251,8882
,,U,,,22224,9823.0,Sus scrofa,Stability to porcine renal DHP-I,1,,,,,0,,6056,A,,Autocuration,CHEMBL625382,BAO_0000019,8883
,,U,,,22224,9823.0,Sus scrofa,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,1,,,,In vivo,0,,1317,A,,Autocuration,CHEMBL873828,BAO_0000218,8884
,,U,,,22224,9823.0,Sus scrofa,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,1,,,,In vivo,0,,1317,A,,Autocuration,CHEMBL625383,BAO_0000218,8885
,,U,,,22224,9823.0,Sus scrofa,Half-life of the parent prodrug in porcine esterase solution,1,,,,,0,,5229,A,,Autocuration,CHEMBL625384,BAO_0000019,8886
,,U,,,22224,9823.0,Sus scrofa,"First order rate constant, k was determined in in pig liver Esterase",1,,,,,0,,4231,A,,Autocuration,CHEMBL625385,BAO_0000019,8887
,,U,,,22224,9823.0,Sus scrofa,Half life of the in pig liver Esterase,1,Liver,,,,0,,4231,A,2107.0,Autocuration,CHEMBL625386,BAO_0000221,8888
,,U,,,22224,9823.0,Sus scrofa,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,1,Liver,,,,0,,5318,A,2107.0,Autocuration,CHEMBL623571,BAO_0000221,8889
,,U,,,22224,9823.0,Sus scrofa,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,1,Liver,,,,0,,5318,A,2107.0,Autocuration,CHEMBL623572,BAO_0000221,8890
,,U,,,22224,9823.0,Sus scrofa,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,1,Liver,,,,0,,5318,A,2107.0,Autocuration,CHEMBL623573,BAO_0000221,8891
,,U,,,22224,9823.0,Sus scrofa,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,1,Liver,,,,0,,3305,A,2107.0,Autocuration,CHEMBL623574,BAO_0000221,8892
,,U,,,22224,9823.0,Sus scrofa,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,1,Liver,,,,0,,3305,A,2107.0,Autocuration,CHEMBL623575,BAO_0000221,8893
,,U,,,22224,9823.0,Sus scrofa,Half-life in the presence of pig liver esterase(PLE) was evaluated.,1,Liver,,,,0,,2842,A,2107.0,Autocuration,CHEMBL623749,BAO_0000221,8894
,,U,,,22224,9823.0,Sus scrofa,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,1,Liver,,,,0,,2842,A,2107.0,Autocuration,CHEMBL623750,BAO_0000221,8895
,,U,,,22224,9823.0,Sus scrofa,Half-life in vitro in pig liver,1,Liver,,,In vitro,0,,889,A,2107.0,Autocuration,CHEMBL623751,BAO_0000221,8896
,,U,,,22224,9823.0,Sus scrofa,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,1,Liver,,,,0,,1904,A,2107.0,Autocuration,CHEMBL623752,BAO_0000221,8897
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,1,Plasma,,,In vivo,1,,4186,A,1969.0,Intermediate,CHEMBL623753,BAO_0000218,8898
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,1,Plasma,,,In vivo,1,,2774,A,1969.0,Intermediate,CHEMBL623754,BAO_0000218,8899
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration in rat plasma was determined,1,Plasma,,,In vivo,1,,1742,A,1969.0,Intermediate,CHEMBL623755,BAO_0000218,8900
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration in rats,1,,,,In vivo,1,,3169,A,,Intermediate,CHEMBL623756,BAO_0000218,8901
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration in rats at 1-2 hours,1,,,,In vivo,1,,3169,A,,Intermediate,CHEMBL623757,BAO_0000218,8902
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,1,,,,In vivo,1,,2081,A,,Intermediate,CHEMBL623758,BAO_0000218,8903
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,1,Brain,,,In vivo,1,,3307,A,955.0,Intermediate,CHEMBL623759,BAO_0000218,8904
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration at the dose of 2 mg/kg in rat,1,,,,In vivo,1,,4727,A,,Intermediate,CHEMBL623760,BAO_0000218,8905
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration was evaluated in rats,1,,,,In vivo,1,,6597,A,,Intermediate,CHEMBL623761,BAO_0000218,8906
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,1,Plasma,,,In vivo,1,,16365,A,1969.0,Intermediate,CHEMBL623762,BAO_0000218,8907
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,1,Plasma,,,In vivo,1,,16365,A,1969.0,Intermediate,CHEMBL877594,BAO_0000218,8908
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,1,Plasma,,,In vivo,1,,16365,A,1969.0,Intermediate,CHEMBL623763,BAO_0000218,8909
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,1,Plasma,,,In vivo,1,,16365,A,1969.0,Intermediate,CHEMBL623764,BAO_0000218,8910
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,1,Plasma,,,In vivo,1,,16365,A,1969.0,Intermediate,CHEMBL623765,BAO_0000218,8911
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,1,Blood,,,In vivo,1,,2591,A,178.0,Intermediate,CHEMBL623766,BAO_0000218,8912
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,1,Blood,,,In vivo,1,,2591,A,178.0,Intermediate,CHEMBL623767,BAO_0000218,8913
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,1,Blood,,,In vivo,1,,2591,A,178.0,Intermediate,CHEMBL623768,BAO_0000218,8914
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,1,Plasma,,,In vivo,1,,5978,A,1969.0,Intermediate,CHEMBL623769,BAO_0000218,8915
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,1,Plasma,,,In vivo,1,,5978,A,1969.0,Intermediate,CHEMBL623770,BAO_0000218,8916
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,1,Plasma,,,In vivo,1,,5978,A,1969.0,Intermediate,CHEMBL623771,BAO_0000218,8917
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,1,Plasma,,,In vivo,1,,5978,A,1969.0,Intermediate,CHEMBL623772,BAO_0000218,8918
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,1,Plasma,,,In vivo,1,,5978,A,1969.0,Intermediate,CHEMBL623773,BAO_0000218,8919
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,1,Plasma,,,In vivo,1,,5978,A,1969.0,Intermediate,CHEMBL623774,BAO_0000218,8920
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,1,Plasma,,,In vivo,1,,5978,A,1969.0,Intermediate,CHEMBL623775,BAO_0000218,8921
,,N,,,50597,10116.0,Rattus norvegicus,Cmax in rat (PO dose),1,,,,In vivo,1,,14465,A,,Intermediate,CHEMBL623776,BAO_0000218,8922
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,Plasma,,,In vivo,1,,4723,A,1969.0,Intermediate,CHEMBL622191,BAO_0000218,8923
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,Plasma,,,In vivo,1,,4723,A,1969.0,Intermediate,CHEMBL622192,BAO_0000218,8924
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration determined in rat,1,Plasma,,,In vivo,1,,4576,A,1969.0,Intermediate,CHEMBL622193,BAO_0000218,8925
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,Plasma,,,In vivo,1,,12873,A,1969.0,Intermediate,CHEMBL622194,BAO_0000218,8926
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,Plasma,,,In vivo,1,,12873,A,1969.0,Intermediate,CHEMBL622195,BAO_0000218,8927
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration in rat,1,Plasma,,,In vivo,1,,6824,A,1969.0,Intermediate,CHEMBL622196,BAO_0000218,8928
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,Plasma,,,In vivo,1,,17065,A,1969.0,Intermediate,CHEMBL622197,BAO_0000218,8929
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,1,Plasma,,,In vivo,1,,2932,A,1969.0,Intermediate,CHEMBL622198,BAO_0000218,8930
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,1,Plasma,,,In vivo,1,,2932,A,1969.0,Intermediate,CHEMBL622199,BAO_0000218,8931
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration of compound was measured in rat,1,Plasma,,,In vivo,1,,2879,A,1969.0,Intermediate,CHEMBL622200,BAO_0000218,8932
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration after 20 mg/kg oral administration in rat,1,Plasma,,,In vivo,1,,2864,A,1969.0,Intermediate,CHEMBL622201,BAO_0000218,8933
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration after oral administration to rats,1,Plasma,,,In vivo,1,,16367,A,1969.0,Intermediate,CHEMBL623990,BAO_0000218,8934
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,Plasma,,,In vivo,1,,17717,A,1969.0,Intermediate,CHEMBL623991,BAO_0000218,8935
,,N,,,50597,10116.0,Rattus norvegicus,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",1,Plasma,,,In vivo,1,,17717,A,1969.0,Intermediate,CHEMBL623992,BAO_0000218,8936
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,Plasma,,,In vivo,1,,17717,A,1969.0,Intermediate,CHEMBL623993,BAO_0000218,8937
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,1,Plasma,,,In vivo,1,,17717,A,1969.0,Intermediate,CHEMBL623994,BAO_0000218,8938
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,1,Plasma,,,In vivo,1,,17720,F,1969.0,Intermediate,CHEMBL623995,BAO_0000218,8939
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,1,Plasma,,,In vivo,1,,17720,F,1969.0,Intermediate,CHEMBL623996,BAO_0000218,8940
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,1,Plasma,,,In vivo,1,,17720,F,1969.0,Intermediate,CHEMBL623997,BAO_0000218,8941
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration dosed orally in rats,1,Plasma,,,In vivo,1,,4516,A,1969.0,Intermediate,CHEMBL623998,BAO_0000218,8942
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration dosed orally in rats after 6 hours,1,Plasma,,,In vivo,1,,4516,A,1969.0,Intermediate,CHEMBL623999,BAO_0000218,8943
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,1,Plasma,,,In vivo,1,,4516,A,1969.0,Intermediate,CHEMBL624000,BAO_0000218,8944
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,1,Plasma,,,In vivo,1,,5199,A,1969.0,Intermediate,CHEMBL624001,BAO_0000218,8945
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration in rat after po administration,1,Plasma,,,In vivo,1,,17538,A,1969.0,Intermediate,CHEMBL624002,BAO_0000218,8946
,,N,,,50597,10116.0,Rattus norvegicus,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",1,Plasma,,,In vivo,1,,6685,A,1969.0,Intermediate,CHEMBL624003,BAO_0000218,8947
,,N,,,50597,10116.0,Rattus norvegicus,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",1,Plasma,,,In vivo,1,,6685,A,1969.0,Intermediate,CHEMBL624004,BAO_0000218,8948
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,Heart,,,,1,,16434,A,948.0,Intermediate,CHEMBL624005,BAO_0000218,8949
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,Heart,,,,1,,16434,A,948.0,Intermediate,CHEMBL624006,BAO_0000218,8950
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,Heart,,,,1,,16434,A,948.0,Intermediate,CHEMBL624007,BAO_0000218,8951
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,Heart,,,,1,,16434,A,948.0,Intermediate,CHEMBL624008,BAO_0000218,8952
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,Heart,,,,1,,16434,A,948.0,Intermediate,CHEMBL624009,BAO_0000218,8953
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,Heart,,,,1,,16434,A,948.0,Intermediate,CHEMBL874387,BAO_0000218,8954
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,Heart,,,,1,,16434,A,948.0,Intermediate,CHEMBL624010,BAO_0000218,8955
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,1,Heart,,,,1,,16434,A,948.0,Intermediate,CHEMBL624011,BAO_0000218,8956
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,Heart,,,,1,,16435,A,948.0,Intermediate,CHEMBL624012,BAO_0000218,8957
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,Heart,,,,1,,16435,A,948.0,Intermediate,CHEMBL624013,BAO_0000218,8958
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,Heart,,,,1,,16435,A,948.0,Intermediate,CHEMBL624736,BAO_0000218,8959
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,Heart,,,,1,,16435,A,948.0,Intermediate,CHEMBL624737,BAO_0000218,8960
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,Heart,,,,1,,16434,A,948.0,Intermediate,CHEMBL624738,BAO_0000218,8961
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,Heart,,,,1,,16434,A,948.0,Intermediate,CHEMBL624739,BAO_0000218,8962
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,Heart,,,,1,,16434,A,948.0,Intermediate,CHEMBL624740,BAO_0000218,8963
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,Heart,,,,1,,16435,A,948.0,Intermediate,CHEMBL624896,BAO_0000218,8964
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,Heart,,,,1,,16435,A,948.0,Intermediate,CHEMBL624897,BAO_0000218,8965
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,Heart,,,,1,,16435,A,948.0,Intermediate,CHEMBL624108,BAO_0000218,8966
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,Heart,,,,1,,16435,A,948.0,Intermediate,CHEMBL624109,BAO_0000218,8967
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,Heart,,,,1,,16435,A,948.0,Intermediate,CHEMBL624110,BAO_0000218,8968
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,Heart,,,,1,,16435,A,948.0,Intermediate,CHEMBL624111,BAO_0000218,8969
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,Heart,,,,1,,16435,A,948.0,Intermediate,CHEMBL624112,BAO_0000218,8970
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,Heart,,,,1,,16435,A,948.0,Intermediate,CHEMBL624113,BAO_0000218,8971
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,Heart,,,,1,,16435,A,948.0,Intermediate,CHEMBL619709,BAO_0000218,8972
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,Heart,,,,1,,16435,A,948.0,Intermediate,CHEMBL619710,BAO_0000218,8973
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,Kidney,,,,1,,16434,A,2113.0,Intermediate,CHEMBL619711,BAO_0000218,8974
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,Kidney,,,,1,,16434,A,2113.0,Intermediate,CHEMBL619712,BAO_0000218,8975
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,Kidney,,,,1,,16434,A,2113.0,Intermediate,CHEMBL619713,BAO_0000218,8976
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,Kidney,,,,1,,16434,A,2113.0,Intermediate,CHEMBL619714,BAO_0000218,8977
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,Kidney,,,,1,,16434,A,2113.0,Intermediate,CHEMBL619715,BAO_0000218,8978
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,Kidney,,,,1,,16434,A,2113.0,Intermediate,CHEMBL619716,BAO_0000218,8979
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,Kidney,,,,1,,16434,A,2113.0,Intermediate,CHEMBL619717,BAO_0000218,8980
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,Kidney,,,,1,,16434,A,2113.0,Intermediate,CHEMBL619718,BAO_0000218,8981
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,Kidney,,,,1,,16435,A,2113.0,Intermediate,CHEMBL619719,BAO_0000218,8982
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,Kidney,,,,1,,16435,A,2113.0,Intermediate,CHEMBL875329,BAO_0000218,8983
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,Kidney,,,,1,,16435,A,2113.0,Intermediate,CHEMBL619720,BAO_0000218,8984
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,Kidney,,,,1,,16435,A,2113.0,Intermediate,CHEMBL619721,BAO_0000218,8985
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,Kidney,,,,1,,16435,A,2113.0,Intermediate,CHEMBL619722,BAO_0000218,8986
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,Kidney,,,,1,,16435,A,2113.0,Intermediate,CHEMBL619723,BAO_0000218,8987
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,Kidney,,,,1,,16435,A,2113.0,Intermediate,CHEMBL619724,BAO_0000218,8988
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,Kidney,,,,1,,16435,A,2113.0,Intermediate,CHEMBL619725,BAO_0000218,8989
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,Kidney,,,,1,,16434,A,2113.0,Intermediate,CHEMBL619726,BAO_0000218,8990
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,Kidney,,,,1,,16434,A,2113.0,Intermediate,CHEMBL619727,BAO_0000218,8991
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,Kidney,,,,1,,16434,A,2113.0,Intermediate,CHEMBL619728,BAO_0000218,8992
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,Kidney,,,,1,,16435,A,2113.0,Intermediate,CHEMBL619729,BAO_0000218,8993
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Muscle tissue,,,In vivo,1,,11977,A,2385.0,Intermediate,CHEMBL619730,BAO_0000218,8994
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Muscle tissue,,,In vivo,1,,11977,A,2385.0,Intermediate,CHEMBL619731,BAO_0000218,8995
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,Muscle tissue,,,In vivo,1,,11977,A,2385.0,Intermediate,CHEMBL619732,BAO_0000218,8996
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Muscle tissue,,,In vivo,1,,11977,A,2385.0,Intermediate,CHEMBL619733,BAO_0000218,8997
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Muscle tissue,,,In vivo,1,,11977,A,2385.0,Intermediate,CHEMBL619734,BAO_0000218,8998
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Zone of skin,,,In vivo,1,,11977,A,14.0,Intermediate,CHEMBL619735,BAO_0000218,8999
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Zone of skin,,,In vivo,1,,11977,A,14.0,Intermediate,CHEMBL875330,BAO_0000218,9000
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,Zone of skin,,,In vivo,1,,11977,A,14.0,Intermediate,CHEMBL628465,BAO_0000218,9001
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Zone of skin,,,In vivo,1,,11977,A,14.0,Intermediate,CHEMBL628466,BAO_0000218,9002
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Zone of skin,,,In vivo,1,,11977,A,14.0,Intermediate,CHEMBL628467,BAO_0000218,9003
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Spleen,,,In vivo,1,,11977,A,2106.0,Intermediate,CHEMBL628468,BAO_0000218,9004
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Spleen,,,In vivo,1,,11977,A,2106.0,Intermediate,CHEMBL628469,BAO_0000218,9005
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,Spleen,,,In vivo,1,,11977,A,2106.0,Intermediate,CHEMBL628470,BAO_0000218,9006
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Spleen,,,In vivo,1,,11977,A,2106.0,Intermediate,CHEMBL628471,BAO_0000218,9007
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Spleen,,,In vivo,1,,11977,A,2106.0,Intermediate,CHEMBL628472,BAO_0000218,9008
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Thyroid gland,,,In vivo,1,,11977,A,2046.0,Intermediate,CHEMBL625191,BAO_0000218,9009
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Thyroid gland,,,In vivo,1,,11977,A,2046.0,Intermediate,CHEMBL625192,BAO_0000218,9010
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,Thyroid gland,,,In vivo,1,,11977,A,2046.0,Intermediate,CHEMBL875337,BAO_0000218,9011
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Thyroid gland,,,In vivo,1,,11977,A,2046.0,Intermediate,CHEMBL626341,BAO_0000218,9012
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Thyroid gland,,,In vivo,1,,11977,A,2046.0,Intermediate,CHEMBL626342,BAO_0000218,9013
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Liver,,,In vivo,1,,11977,A,2107.0,Intermediate,CHEMBL621943,BAO_0000218,9014
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rats,1,,,,,1,,3748,A,,Intermediate,CHEMBL621944,BAO_0000218,9015
,,N,,,50597,10116.0,Rattus norvegicus,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,1,,,,,1,,15765,A,,Intermediate,CHEMBL621945,BAO_0000218,9016
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),1,,,,,1,,4871,A,,Intermediate,CHEMBL621946,BAO_0000218,9017
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,1,,,,,1,,4871,A,,Intermediate,CHEMBL621947,BAO_0000218,9018
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),1,,,,,1,,4872,A,,Intermediate,CHEMBL621948,BAO_0000218,9019
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,1,,,,,1,,4872,A,,Intermediate,CHEMBL621949,BAO_0000218,9020
,,N,,,50597,10116.0,Rattus norvegicus,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),1,,,,,1,,5413,A,,Intermediate,CHEMBL621950,BAO_0000218,9021
,,N,,,50597,10116.0,Rattus norvegicus,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,1,,,,,1,,5413,A,,Intermediate,CHEMBL621951,BAO_0000218,9022
,,N,,,50597,10116.0,Rattus norvegicus,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,1,Blood,,,In vivo,1,,15272,A,178.0,Intermediate,CHEMBL621952,BAO_0000218,9023
,,N,,,50597,10116.0,Rattus norvegicus,Stability (%) in rat liver microsomes,1,Liver,,,,1,,4689,A,2107.0,Intermediate,CHEMBL621953,BAO_0000218,9024
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was calculated after intravenous administration,1,,,,,1,,6057,A,,Intermediate,CHEMBL621954,BAO_0000218,9025
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve was calculated after iv administration in rat,1,,,,,1,,6057,A,,Intermediate,CHEMBL621955,BAO_0000218,9026
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve was calculated in rat after peroral administration,1,,,,,1,,6057,A,,Intermediate,CHEMBL621956,BAO_0000218,9027
,,N,,,50597,10116.0,Rattus norvegicus,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,1,,,,,1,,6211,A,,Intermediate,CHEMBL621957,BAO_0000218,9028
,,N,,,50597,10116.0,Rattus norvegicus,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,1,,,,,1,,5710,A,,Intermediate,CHEMBL621958,BAO_0000218,9029
,,N,,,50597,10116.0,Rattus norvegicus,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,1,,,,,1,,5710,A,,Intermediate,CHEMBL621959,BAO_0000218,9030
,,N,,,50597,10116.0,Rattus norvegicus,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,1,,,,,1,,17853,A,,Intermediate,CHEMBL621960,BAO_0000218,9031
,,N,,,50597,10116.0,Rattus norvegicus,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,1,,,,,1,,17853,A,,Intermediate,CHEMBL621961,BAO_0000218,9032
,,N,,,50597,10116.0,Rattus norvegicus,p value of the compound,1,,,,,1,,15765,A,,Intermediate,CHEMBL621962,BAO_0000218,9033
,,N,,,50597,10116.0,Rattus norvegicus,p value of the compound,1,,,,,1,,15765,F,,Intermediate,CHEMBL876787,BAO_0000218,9034
,,N,,,50597,10116.0,Rattus norvegicus,p value of the compound,1,,,,,1,,15765,A,,Intermediate,CHEMBL621963,BAO_0000218,9035
,,N,,,50597,10116.0,Rattus norvegicus,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,Stomach,,,,1,,6175,A,945.0,Intermediate,CHEMBL622637,BAO_0000218,9036
,,N,,,50597,10116.0,Rattus norvegicus,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,Stomach,,,,1,,6175,A,945.0,Intermediate,CHEMBL622638,BAO_0000218,9037
,,N,,,50597,10116.0,Rattus norvegicus,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,Stomach,,,,1,,6175,A,945.0,Intermediate,CHEMBL626561,BAO_0000218,9038
,,U,,,22224,9986.0,Oryctolagus cuniculus,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),1,,,,,0,,7991,F,,Autocuration,CHEMBL626562,BAO_0000019,9039
,,U,,,22224,9986.0,Oryctolagus cuniculus,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),1,,,,,0,,429,A,,Autocuration,CHEMBL626563,BAO_0000218,9040
,,U,,,22224,9986.0,Oryctolagus cuniculus,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),1,,,,,0,,429,A,,Autocuration,CHEMBL626564,BAO_0000218,9041
,,U,,,22224,9986.0,Oryctolagus cuniculus,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,1,,,,In vivo,0,,6253,A,,Autocuration,CHEMBL626565,BAO_0000218,9042
,,U,,,22224,9986.0,Oryctolagus cuniculus,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,1,,,,In vivo,0,,6253,A,,Autocuration,CHEMBL626566,BAO_0000218,9043
,,U,,,22224,9986.0,Oryctolagus cuniculus,Clearance rate in rabbits,1,,,,In vivo,0,,3615,A,,Autocuration,CHEMBL626567,BAO_0000218,9044
,,U,,,22224,9986.0,Oryctolagus cuniculus,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,1,,,,In vivo,0,,4059,A,,Autocuration,CHEMBL626568,BAO_0000218,9045
,,U,,,22224,9986.0,Oryctolagus cuniculus,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,1,,,,In vivo,0,,5124,A,,Autocuration,CHEMBL626569,BAO_0000218,9046
,,U,,,22224,9986.0,Oryctolagus cuniculus,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,1,,,,In vivo,0,,5124,A,,Autocuration,CHEMBL626570,BAO_0000218,9047
,,U,,,22224,9986.0,Oryctolagus cuniculus,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,1,,,,In vivo,0,,5124,A,,Autocuration,CHEMBL626571,BAO_0000218,9048
,,U,,,22224,9986.0,Oryctolagus cuniculus,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,1,,,,In vivo,0,,429,A,,Autocuration,CHEMBL626572,BAO_0000218,9049
,,U,,,22224,9986.0,Oryctolagus cuniculus,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,1,Plasma,,,In vivo,0,,4059,A,1969.0,Autocuration,CHEMBL626573,BAO_0000218,9050
,Microsomes,U,,,22224,9986.0,Oryctolagus cuniculus,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,1,Liver,,,,0,,9659,A,2107.0,Autocuration,CHEMBL626574,BAO_0000251,9051
,Microsomes,U,,,22224,9986.0,Oryctolagus cuniculus,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,1,Liver,,,,0,,9659,A,2107.0,Autocuration,CHEMBL626575,BAO_0000251,9052
,,U,,,22224,9986.0,Oryctolagus cuniculus,Dose at which bioavailability of intravenously administered compound was tested in rabbit,1,,,,,0,,3639,A,,Autocuration,CHEMBL626576,BAO_0000218,9053
,,U,,,22224,9986.0,Oryctolagus cuniculus,Dose at which bioavailability of perorally administered compound was tested in rabbit,1,,,,,0,,3639,A,,Autocuration,CHEMBL626577,BAO_0000218,9054
,,U,,,22224,9986.0,Oryctolagus cuniculus,The compound was tested for its bioavailability in rabbit (by oral dosage).,1,,,,In vivo,0,,3639,A,,Autocuration,CHEMBL626578,BAO_0000218,9055
,,U,,,22224,9986.0,Oryctolagus cuniculus,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,1,,,,In vivo,0,,5124,A,,Autocuration,CHEMBL625263,BAO_0000218,9056
,,U,,,22224,9986.0,Oryctolagus cuniculus,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,1,,,,In vivo,0,,5124,A,,Autocuration,CHEMBL625264,BAO_0000218,9057
,,U,,,22224,9986.0,Oryctolagus cuniculus,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,1,,,,In vivo,0,,5124,A,,Autocuration,CHEMBL625265,BAO_0000218,9058
,Microsomes,U,,,22224,9986.0,Oryctolagus cuniculus,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),1,,,,,0,,14294,A,,Autocuration,CHEMBL625266,BAO_0000251,9059
,Microsomes,U,,,22224,9986.0,Oryctolagus cuniculus,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),1,,,,,0,,14294,A,,Autocuration,CHEMBL876796,BAO_0000251,9060
,,U,,,22224,9986.0,Oryctolagus cuniculus,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,1,,,,In vivo,0,,429,A,,Autocuration,CHEMBL625267,BAO_0000218,9061
,,U,,,22224,9986.0,Oryctolagus cuniculus,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,1,Plasma,,,In vivo,0,,5124,A,1969.0,Autocuration,CHEMBL625268,BAO_0000218,9062
,,U,,,22224,9986.0,Oryctolagus cuniculus,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,1,Plasma,,,In vivo,0,,5124,A,1969.0,Autocuration,CHEMBL625269,BAO_0000218,9063
,,U,,,22224,9986.0,Oryctolagus cuniculus,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,1,Plasma,,,In vivo,0,,5124,A,1969.0,Autocuration,CHEMBL624689,BAO_0000218,9064
,,U,,,22224,9986.0,Oryctolagus cuniculus,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,1,,,,In vivo,0,,429,A,,Autocuration,CHEMBL624690,BAO_0000218,9065
,,U,,,22224,9986.0,Oryctolagus cuniculus,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),1,Urine,,,,0,,429,A,1088.0,Autocuration,CHEMBL624691,BAO_0000218,9066
,,U,,,22224,9986.0,Oryctolagus cuniculus,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),1,Urine,,,,0,,429,A,1088.0,Autocuration,CHEMBL624692,BAO_0000218,9067
,,U,,,22224,9986.0,Oryctolagus cuniculus,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,1,,,,In vivo,0,,4059,A,,Autocuration,CHEMBL624693,BAO_0000218,9068
,,U,,,22224,9986.0,Oryctolagus cuniculus,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,1,,,,In vivo,0,,4137,A,,Autocuration,CHEMBL624694,BAO_0000218,9069
,,U,,,22224,9986.0,Oryctolagus cuniculus,In vitro Biological half-life in crude homogenate of rabbit renal cortex,1,,,,In vitro,0,,11672,A,,Autocuration,CHEMBL877596,BAO_0000221,9070
,,U,,,22224,9986.0,Oryctolagus cuniculus,Time within which only 10% of the drug was degraded,1,,,,,0,,12886,A,,Autocuration,CHEMBL624695,BAO_0000019,9071
,,U,,,22224,9986.0,Oryctolagus cuniculus,Half life period in rabbit liver homogenate,1,Liver,,,,0,,3853,A,2107.0,Autocuration,CHEMBL624696,BAO_0000221,9072
,,U,,,22224,9986.0,Oryctolagus cuniculus,Half life value in rabbits,1,,,,,0,,3615,A,,Autocuration,CHEMBL624697,BAO_0000019,9073
,,U,,,22224,9986.0,Oryctolagus cuniculus,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,1,Blood,,,In vivo,0,,6253,A,178.0,Autocuration,CHEMBL624698,BAO_0000218,9074
,,U,,,22224,9986.0,Oryctolagus cuniculus,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,1,Blood,,,In vivo,0,,6253,A,178.0,Autocuration,CHEMBL624699,BAO_0000218,9075
,,U,,,22224,9986.0,Oryctolagus cuniculus,Half-life period in rabbits following intravenous administration at 2 mg/kg,1,,,,In vivo,0,,6077,A,,Autocuration,CHEMBL624700,BAO_0000218,9076
,,N,,,50597,10116.0,Rattus norvegicus,AUC 0-8 hr value in rats at 10 mg/kg,1,Plasma,,,,1,,17617,A,1969.0,Intermediate,CHEMBL622903,BAO_0000218,9077
,,N,,,50597,10116.0,Rattus norvegicus,AUC after administration at 2000 mg/kg/day in rats,1,Plasma,,,,1,,17594,A,1969.0,Intermediate,CHEMBL622904,BAO_0000218,9078
,,N,,,50597,10116.0,Rattus norvegicus,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,1,Plasma,,,,1,,6149,A,1969.0,Intermediate,CHEMBL622905,BAO_0000218,9079
,,N,,,50597,10116.0,Rattus norvegicus,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,Plasma,,,,1,,17260,A,1969.0,Intermediate,CHEMBL622906,BAO_0000218,9080
,,N,,,50597,10116.0,Rattus norvegicus,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,Plasma,,,,1,,17260,A,1969.0,Intermediate,CHEMBL622907,BAO_0000218,9081
,,N,,,50597,10116.0,Rattus norvegicus,AUC in rat after oral administration at 10.5 mg/kg dose,1,Plasma,,,,1,,6644,A,1969.0,Intermediate,CHEMBL622908,BAO_0000218,9082
,,N,,,50597,10116.0,Rattus norvegicus,AUC in rat after oral administration at 11.2 mg/kg dose,1,Plasma,,,,1,,6644,A,1969.0,Intermediate,CHEMBL622909,BAO_0000218,9083
,,N,,,50597,10116.0,Rattus norvegicus,AUC in rat after oral administration at 9.7 mg/kg dose,1,Plasma,,,,1,,6644,A,1969.0,Intermediate,CHEMBL622910,BAO_0000218,9084
,,N,,,50597,10116.0,Rattus norvegicus,AUC in rat brain after oral administration at 10 mg/kg,1,Brain,,,,1,,6495,A,955.0,Intermediate,CHEMBL622911,BAO_0000218,9085
,,N,,,50597,10116.0,Rattus norvegicus,AUC in rat p.o.,1,Plasma,,,,1,,6504,A,1969.0,Intermediate,CHEMBL622912,BAO_0000218,9086
,,N,,,50597,10116.0,Rattus norvegicus,AUC in rat p.o. at 20 mg/kg concentration,1,Plasma,,,,1,,17686,A,1969.0,Intermediate,CHEMBL622913,BAO_0000218,9087
,,N,,,50597,10116.0,Rattus norvegicus,AUC in rat plasma after oral administration at 10 mg/kg,1,Plasma,,,,1,,6495,A,1969.0,Intermediate,CHEMBL622914,BAO_0000218,9088
,,N,,,50597,10116.0,Rattus norvegicus,AUC in rats,1,Plasma,,,,1,,216,A,1969.0,Intermediate,CHEMBL622915,BAO_0000218,9089
,,N,,,50597,10116.0,Rattus norvegicus,AUC value after IV dose at a dose of 5 mg/kg in rats.,1,Plasma,,,,1,,1908,A,1969.0,Intermediate,CHEMBL622916,BAO_0000218,9090
,,N,,,50597,10116.0,Rattus norvegicus,AUC value after oral dose at a dose of 10 mg/kg in rats.,1,Plasma,,,,1,,1908,A,1969.0,Intermediate,CHEMBL622917,BAO_0000218,9091
,,N,,,50597,10116.0,Rattus norvegicus,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1,Plasma,,,In vivo,1,,6685,A,1969.0,Intermediate,CHEMBL622918,BAO_0000218,9092
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,1,Plasma,,,In vivo,1,,216,A,1969.0,Intermediate,CHEMBL622919,BAO_0000218,9093
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration was evaluated in rat,1,Plasma,,,In vivo,1,,6049,A,1969.0,Intermediate,CHEMBL622920,BAO_0000218,9094
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,1,Plasma,,,In vivo,1,,2463,A,1969.0,Intermediate,CHEMBL622921,BAO_0000218,9095
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,1,Plasma,,,In vivo,1,,6679,A,1969.0,Intermediate,CHEMBL622922,BAO_0000218,9096
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,1,Plasma,,,In vivo,1,,6681,A,1969.0,Intermediate,CHEMBL622923,BAO_0000218,9097
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,1,Plasma,,,In vivo,1,,4890,A,1969.0,Intermediate,CHEMBL877604,BAO_0000218,9098
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,1,Plasma,,,In vivo,1,,6410,A,1969.0,Intermediate,CHEMBL622924,BAO_0000218,9099
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,1,Plasma,,,In vivo,1,,6410,A,1969.0,Intermediate,CHEMBL622925,BAO_0000218,9100
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,1,Plasma,,,In vivo,1,,16366,A,1969.0,Intermediate,CHEMBL622926,BAO_0000218,9101
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,1,Plasma,,,In vivo,1,,6227,A,1969.0,Intermediate,CHEMBL623625,BAO_0000218,9102
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,1,Plasma,,,In vivo,1,,3598,A,1969.0,Expert,CHEMBL623626,BAO_0000218,9103
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma drug concentration was determined,1,Plasma,,,In vivo,1,,1465,A,1969.0,Intermediate,CHEMBL623627,BAO_0000218,9104
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,1,,,,In vivo,1,,4368,A,,Intermediate,CHEMBL623628,BAO_0000218,9105
,,N,,,50597,10116.0,Rattus norvegicus,Mean peak plasma concentration was observed after intravenous administration in rat,1,Plasma,,,In vivo,1,,15662,A,1969.0,Intermediate,CHEMBL623629,BAO_0000218,9106
,,N,,,50597,10116.0,Rattus norvegicus,Mean peak plasma concentration was observed after oral administration in rat,1,Plasma,,,In vivo,1,,15662,A,1969.0,Intermediate,CHEMBL623630,BAO_0000218,9107
,,N,,,50597,10116.0,Rattus norvegicus,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,1,,,,In vivo,1,,5355,A,,Intermediate,CHEMBL623804,BAO_0000218,9108
,,N,,,50597,10116.0,Rattus norvegicus,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,1,,,,In vivo,1,,5355,A,,Intermediate,CHEMBL623805,BAO_0000218,9109
,,N,,,50597,10116.0,Rattus norvegicus,Peak oral plasma concentration was determined in rats by oral administration,1,Plasma,,,In vivo,1,,1567,A,1969.0,Intermediate,CHEMBL623806,BAO_0000218,9110
,,N,,,50597,10116.0,Rattus norvegicus,Peak plasma concentration (Cmax) was determined,1,Plasma,,,In vivo,1,,4026,A,1969.0,Intermediate,CHEMBL623807,BAO_0000218,9111
,,N,,,50597,10116.0,Rattus norvegicus,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,1,Plasma,,,In vivo,1,,6193,A,1969.0,Intermediate,CHEMBL623808,BAO_0000218,9112
,,N,,,50597,10116.0,Rattus norvegicus,Peak plasma concentration (Cmax) in rats,1,Plasma,,,In vivo,1,,4026,A,1969.0,Intermediate,CHEMBL623809,BAO_0000218,9113
,,N,,,50597,10116.0,Rattus norvegicus,Peak plasma concentration at 1 mg/kg peroral administration,1,Plasma,,,In vivo,1,,6485,A,1969.0,Intermediate,CHEMBL623810,BAO_0000218,9114
,,N,,,50597,10116.0,Rattus norvegicus,Peak plasma concentration in rat,1,Plasma,,,In vivo,1,,17655,A,1969.0,Intermediate,CHEMBL623811,BAO_0000218,9115
,,N,,,50597,10116.0,Rattus norvegicus,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",1,Plasma,,,In vivo,1,,14941,A,1969.0,Intermediate,CHEMBL623812,BAO_0000218,9116
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,1,,,,In vivo,1,,5394,A,,Intermediate,CHEMBL877605,BAO_0000218,9117
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (Cmax) in rat,1,,,,In vivo,1,,4408,A,,Intermediate,CHEMBL623813,BAO_0000218,9118
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,1,,,,In vivo,1,,5983,A,,Intermediate,CHEMBL623814,BAO_0000218,9119
,,N,,,50597,10116.0,Rattus norvegicus,Cmax in rat after 3mg/kg oral dose,1,,,,In vivo,1,,4878,A,,Intermediate,CHEMBL623815,BAO_0000218,9120
Sprague-Dawley,,N,,,50597,10116.0,Rattus norvegicus,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,1,,,,In vivo,1,,5862,A,,Intermediate,CHEMBL623816,BAO_0000218,9121
,,N,,,50597,10116.0,Rattus norvegicus,Cmax in rats after 20 mg/kg oral dose,1,,,,In vivo,1,,4517,A,,Intermediate,CHEMBL623145,BAO_0000218,9122
,,N,,,50597,10116.0,Rattus norvegicus,Cmax in rat plasma after 30mg/kg oral dose,1,Plasma,,,In vivo,1,,5932,A,1969.0,Intermediate,CHEMBL623146,BAO_0000218,9123
,,N,,,50597,10116.0,Rattus norvegicus,Plasma concentration after oral administration of 100 mg/kg to rats,1,Plasma,,,In vivo,1,,5436,A,1969.0,Intermediate,CHEMBL623147,BAO_0000218,9124
,,N,,,50597,10116.0,Rattus norvegicus,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,1,Brain,,,In vivo,1,,4910,A,955.0,Intermediate,CHEMBL623042,BAO_0000218,9125
,,N,,,50597,10116.0,Rattus norvegicus,Tested for the Cmax in rat at 10 mg/kg per orally,1,,,,In vivo,1,,4950,A,,Intermediate,CHEMBL623043,BAO_0000218,9126
,,N,,,50597,10116.0,Rattus norvegicus,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",1,,,,In vivo,1,,15078,A,,Intermediate,CHEMBL623044,BAO_0000218,9127
,,N,,,50597,10116.0,Rattus norvegicus,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",1,,,,In vivo,1,,15078,A,,Intermediate,CHEMBL623045,BAO_0000218,9128
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability as oral Cmax in rats at 30 mins,1,,,,In vivo,1,,3360,A,,Intermediate,CHEMBL623046,BAO_0000218,9129
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability as oral Cmax in rats at 6hr,1,,,,In vivo,1,,3360,A,,Intermediate,CHEMBL623226,BAO_0000218,9130
,,N,,,50597,10116.0,Rattus norvegicus,The maximum concentration of compound was measured at the dose of 100 umol/kg,1,,,,In vivo,1,,15022,A,,Intermediate,CHEMBL623227,BAO_0000218,9131
,,N,,,50597,10116.0,Rattus norvegicus,The maximum concentration of compound was measured at the dose of 300 umol/kg,1,,,,In vivo,1,,15022,A,,Intermediate,CHEMBL623228,BAO_0000218,9132
,,N,,,50597,10116.0,Rattus norvegicus,The maximum concentration of compound was measured at the dose of 30 umol/kg,1,,,,In vivo,1,,15022,A,,Intermediate,CHEMBL623229,BAO_0000218,9133
,,N,,,50597,10116.0,Rattus norvegicus,The maximum plasma levels for the compounds were determined by LC-MS.,1,Plasma,,,In vivo,1,,5160,A,1969.0,Intermediate,CHEMBL623230,BAO_0000218,9134
,,N,,,50597,10116.0,Rattus norvegicus,mean peak plasma concentration was observed after intravenous administration in rat,1,Plasma,,,In vivo,1,,15662,A,1969.0,Intermediate,CHEMBL623231,BAO_0000218,9135
,,N,,,50597,10116.0,Rattus norvegicus,mean peak plasma concentration was observed after oral administration in rat,1,Plasma,,,In vivo,1,,15662,A,1969.0,Intermediate,CHEMBL623232,BAO_0000218,9136
,,N,,,50597,10116.0,Rattus norvegicus,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,1,,,,,1,,4709,A,,Intermediate,CHEMBL623233,BAO_0000218,9137
,,N,,,50597,10116.0,Rattus norvegicus,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,1,,,,,1,,3535,A,,Intermediate,CHEMBL623234,BAO_0000218,9138
,,N,,,50597,10116.0,Rattus norvegicus,Concentration in plasma (portal) following oral dose in rats at 1 hr,1,,,,,1,,3535,A,,Intermediate,CHEMBL623235,BAO_0000218,9139
,,N,,,50597,10116.0,Rattus norvegicus,Concentration in plasma (portal) following oral dose in rats at 2 hr,1,,,,,1,,3535,A,,Intermediate,CHEMBL623236,BAO_0000218,9140
,,N,,,50597,10116.0,Rattus norvegicus,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,1,,,,,1,,3535,A,,Intermediate,CHEMBL623237,BAO_0000218,9141
,,N,,,50597,10116.0,Rattus norvegicus,Concentration in plasma (systemic) following oral dose in rats at 1 hr,1,,,,,1,,3535,A,,Intermediate,CHEMBL623238,BAO_0000218,9142
,,N,,,50597,10116.0,Rattus norvegicus,Concentration in plasma (systemic) following oral dose in rats at 2 hr,1,,,,,1,,3535,A,,Intermediate,CHEMBL623239,BAO_0000218,9143
,,U,,,22224,10116.0,Rattus norvegicus,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,1,Plasma,,,In vivo,0,,5005,A,1969.0,Intermediate,CHEMBL623240,BAO_0000218,9144
,,N,,,50597,10116.0,Rattus norvegicus,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",1,Hypothalamus,,,,1,,6326,A,1898.0,Intermediate,CHEMBL623241,BAO_0000218,9145
,,N,,,50597,10116.0,Rattus norvegicus,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",1,Hypothalamus,,,,1,,6326,A,1898.0,Intermediate,CHEMBL623242,BAO_0000218,9146
,,N,,,50597,10116.0,Rattus norvegicus,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",1,,,,,1,,6326,A,,Intermediate,CHEMBL874394,BAO_0000218,9147
,,N,,,50597,10116.0,Rattus norvegicus,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",1,,,,,1,,6326,A,,Intermediate,CHEMBL623243,BAO_0000218,9148
,,N,,,50597,10116.0,Rattus norvegicus,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,,,,1,,17411,A,,Intermediate,CHEMBL623244,BAO_0000218,9149
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,Kidney,,,,1,,16435,A,2113.0,Intermediate,CHEMBL623245,BAO_0000218,9150
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,Kidney,,,,1,,16435,A,2113.0,Intermediate,CHEMBL623246,BAO_0000218,9151
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,Kidney,,,,1,,16435,A,2113.0,Intermediate,CHEMBL623247,BAO_0000218,9152
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,Kidney,,,,1,,16435,A,2113.0,Intermediate,CHEMBL623248,BAO_0000218,9153
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,Kidney,,,,1,,16435,A,2113.0,Intermediate,CHEMBL623249,BAO_0000218,9154
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,Liver,,,,1,,16434,A,2107.0,Intermediate,CHEMBL625072,BAO_0000218,9155
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,Liver,,,,1,,16434,A,2107.0,Intermediate,CHEMBL625073,BAO_0000218,9156
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,Liver,,,,1,,16434,A,2107.0,Intermediate,CHEMBL625074,BAO_0000218,9157
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,Liver,,,,1,,16434,A,2107.0,Intermediate,CHEMBL625075,BAO_0000218,9158
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,1,Liver,,,,1,,16434,A,2107.0,Intermediate,CHEMBL625076,BAO_0000218,9159
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,Liver,,,,1,,16434,A,2107.0,Intermediate,CHEMBL625077,BAO_0000218,9160
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,Liver,,,,1,,16434,A,2107.0,Intermediate,CHEMBL625078,BAO_0000218,9161
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,Liver,,,,1,,16434,A,2107.0,Intermediate,CHEMBL874395,BAO_0000218,9162
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,Liver,,,,1,,16435,A,2107.0,Intermediate,CHEMBL625079,BAO_0000218,9163
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,Liver,,,,1,,16435,A,2107.0,Intermediate,CHEMBL625080,BAO_0000218,9164
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,Liver,,,,1,,16435,A,2107.0,Intermediate,CHEMBL625081,BAO_0000218,9165
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,Liver,,,,1,,16435,A,2107.0,Intermediate,CHEMBL625082,BAO_0000218,9166
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,Liver,,,,1,,16435,A,2107.0,Intermediate,CHEMBL625083,BAO_0000218,9167
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,Liver,,,,1,,16435,A,2107.0,Intermediate,CHEMBL625084,BAO_0000218,9168
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,Liver,,,,1,,16435,A,2107.0,Intermediate,CHEMBL625085,BAO_0000218,9169
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,Liver,,,,1,,16435,A,2107.0,Intermediate,CHEMBL625086,BAO_0000218,9170
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,Liver,,,,1,,16434,A,2107.0,Intermediate,CHEMBL625087,BAO_0000218,9171
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,Liver,,,,1,,16434,A,2107.0,Intermediate,CHEMBL625088,BAO_0000218,9172
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,Liver,,,,1,,16434,A,2107.0,Intermediate,CHEMBL622205,BAO_0000218,9173
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,Liver,,,,1,,16435,A,2107.0,Intermediate,CHEMBL622206,BAO_0000218,9174
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,Liver,,,,1,,16435,A,2107.0,Intermediate,CHEMBL622207,BAO_0000218,9175
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,Liver,,,,1,,16435,A,2107.0,Intermediate,CHEMBL622366,BAO_0000218,9176
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,Liver,,,,1,,16435,A,2107.0,Intermediate,CHEMBL622367,BAO_0000218,9177
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,Liver,,,,1,,16435,A,2107.0,Intermediate,CHEMBL875331,BAO_0000218,9178
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,Liver,,,,1,,16435,A,2107.0,Intermediate,CHEMBL622368,BAO_0000218,9179
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,Lung,,,,1,,16434,A,2048.0,Intermediate,CHEMBL622369,BAO_0000218,9180
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,Lung,,,,1,,16434,A,2048.0,Intermediate,CHEMBL622370,BAO_0000218,9181
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,Lung,,,,1,,16434,A,2048.0,Intermediate,CHEMBL622371,BAO_0000218,9182
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,Lung,,,,1,,16434,A,2048.0,Intermediate,CHEMBL622372,BAO_0000218,9183
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,Lung,,,,1,,16434,A,2048.0,Intermediate,CHEMBL622373,BAO_0000218,9184
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,Lung,,,,1,,16434,A,2048.0,Intermediate,CHEMBL622374,BAO_0000218,9185
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,Lung,,,,1,,16434,A,2048.0,Intermediate,CHEMBL622375,BAO_0000218,9186
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,1,Lung,,,,1,,16434,A,2048.0,Intermediate,CHEMBL622376,BAO_0000218,9187
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,Lung,,,,1,,16435,A,2048.0,Intermediate,CHEMBL622377,BAO_0000218,9188
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,Lung,,,,1,,16435,A,2048.0,Intermediate,CHEMBL622378,BAO_0000218,9189
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,Lung,,,,1,,16435,A,2048.0,Intermediate,CHEMBL622379,BAO_0000218,9190
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,Lung,,,,1,,16435,A,2048.0,Intermediate,CHEMBL622380,BAO_0000218,9191
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,Lung,,,,1,,16435,A,2048.0,Intermediate,CHEMBL622381,BAO_0000218,9192
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,Lung,,,,1,,16435,A,2048.0,Intermediate,CHEMBL622382,BAO_0000218,9193
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,1,Lung,,,,1,,16434,A,2048.0,Intermediate,CHEMBL622383,BAO_0000218,9194
,,N,,,50597,10116.0,Rattus norvegicus,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,Stomach,,,,1,,6175,A,945.0,Intermediate,CHEMBL875332,BAO_0000218,9195
,,N,,,50597,10116.0,Rattus norvegicus,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,Stomach,,,,1,,6175,A,945.0,Intermediate,CHEMBL622384,BAO_0000218,9196
,,N,,,50597,10116.0,Rattus norvegicus,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,Stomach,,,,1,,6175,A,945.0,Intermediate,CHEMBL622385,BAO_0000218,9197
,,N,,,50597,10116.0,Rattus norvegicus,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,Stomach,,,,1,,6175,A,945.0,Intermediate,CHEMBL622386,BAO_0000218,9198
,,N,,,50597,10116.0,Rattus norvegicus,The compound was tested for the plasma binding in rat,1,,,,,1,,10839,A,,Intermediate,CHEMBL622387,BAO_0000218,9199
,,N,,,50597,10116.0,Rattus norvegicus,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",1,,,,,1,,16459,A,,Intermediate,CHEMBL622388,BAO_0000218,9200
,,N,,,50597,10116.0,Rattus norvegicus,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",1,,,,,1,,16459,A,,Intermediate,CHEMBL622389,BAO_0000218,9201
,,N,,,50597,10116.0,Rattus norvegicus,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",1,,,,,1,,16459,A,,Intermediate,CHEMBL622390,BAO_0000218,9202
,,N,,,50597,10116.0,Rattus norvegicus,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),1,,,,,1,,16459,A,,Intermediate,CHEMBL622391,BAO_0000218,9203
,,N,,,50597,10116.0,Rattus norvegicus,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),1,,,,,1,,16459,A,,Intermediate,CHEMBL622392,BAO_0000218,9204
,,N,,,50597,10116.0,Rattus norvegicus,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),1,,,,,1,,16459,A,,Intermediate,CHEMBL622393,BAO_0000218,9205
,,N,,,50597,10116.0,Rattus norvegicus,Plasma level at 2 hr after administration of the compound,1,,,,,1,,3278,A,,Intermediate,CHEMBL622394,BAO_0000218,9206
,,N,,,50597,10116.0,Rattus norvegicus,plasma level at 2 hr after administration of the compound,1,,,,,1,,3278,A,,Intermediate,CHEMBL622395,BAO_0000218,9207
,,N,,,50597,10116.0,Rattus norvegicus,Stability in rat serum measured as % recovery at 1 min,1,Serum,,,,1,,4684,A,1977.0,Intermediate,CHEMBL622396,BAO_0000218,9208
,,N,,,50597,10116.0,Rattus norvegicus,Stability in rat serum measured as % recovery at 10 min,1,Serum,,,,1,,4684,A,1977.0,Intermediate,CHEMBL624894,BAO_0000218,9209
,,N,,,50597,10116.0,Rattus norvegicus,Stability in rat serum measured as % recovery at 10 mins,1,Serum,,,,1,,4684,A,1977.0,Intermediate,CHEMBL624895,BAO_0000218,9210
,,N,,,50597,10116.0,Rattus norvegicus,Stability in rat serum measured as % recovery at 2 hr,1,Serum,,,,1,,4684,A,1977.0,Intermediate,CHEMBL624058,BAO_0000218,9211
,,N,,,50597,10116.0,Rattus norvegicus,Stability in rat serum measured as % recovery at 3 min,1,Serum,,,,1,,4684,A,1977.0,Intermediate,CHEMBL624059,BAO_0000218,9212
,,N,,,50597,10116.0,Rattus norvegicus,Stability in rat serum measured as % recovery at 3 mins,1,Serum,,,,1,,4684,A,1977.0,Intermediate,CHEMBL624060,BAO_0000218,9213
,,N,,,50597,10116.0,Rattus norvegicus,Stability in rat serum measured as % recovery at 5 min,1,Serum,,,,1,,4684,A,1977.0,Intermediate,CHEMBL624061,BAO_0000218,9214
,,N,,,50597,10116.0,Rattus norvegicus,Stability in rat serum measured as % recovery at 5 mins,1,Serum,,,,1,,4684,A,1977.0,Intermediate,CHEMBL624062,BAO_0000218,9215
,,N,,,50597,10116.0,Rattus norvegicus,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,,,,In vivo,1,,16456,A,,Intermediate,CHEMBL624063,BAO_0000218,9216
,,N,,,50597,10116.0,Rattus norvegicus,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,,,,In vivo,1,,16456,A,,Intermediate,CHEMBL624064,BAO_0000218,9217
,,N,,,50597,10116.0,Rattus norvegicus,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,1,Plasma,,,,1,,723,A,1969.0,Intermediate,CHEMBL624065,BAO_0000218,9218
,,N,,,50597,10116.0,Rattus norvegicus,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,1,Plasma,,,,1,,723,A,1969.0,Intermediate,CHEMBL624066,BAO_0000218,9219
,,N,,,50597,10116.0,Rattus norvegicus,Half life tested in mature male rat at a dose of 30 mg/kg,1,,,,In vivo,1,,5160,A,,Intermediate,CHEMBL877490,BAO_0000218,9220
,,N,,,50597,10116.0,Rattus norvegicus,Half life after intravenous administration of 1 mg/kg in rat,1,,,,In vivo,1,,4709,A,,Intermediate,CHEMBL874442,BAO_0000218,9221
,,N,,,50597,10116.0,Rattus norvegicus,Half life period after administration (30 mg/kg) in rat,1,,,,In vivo,1,,5633,A,,Intermediate,CHEMBL626890,BAO_0000218,9222
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in rat after 5 mg/Kg dose,1,,,,In vivo,1,,5302,A,,Intermediate,CHEMBL626891,BAO_0000218,9223
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in rat after 5 mg/kg dose,1,,,,In vivo,1,,5302,A,,Intermediate,CHEMBL626892,BAO_0000218,9224
,,N,,,50597,10116.0,Rattus norvegicus,Half life period was determined,1,,,,,1,,17791,A,,Intermediate,CHEMBL626893,BAO_0000218,9225
,,N,,,50597,10116.0,Rattus norvegicus,Half life period was evaluated in rat,1,,,,,1,,17791,A,,Intermediate,CHEMBL626894,BAO_0000218,9226
,,N,,,50597,10116.0,Rattus norvegicus,Half life period was evaluated in rat; 0.5-1.0,1,,,,,1,,17791,A,,Intermediate,CHEMBL626895,BAO_0000218,9227
,,N,,,50597,10116.0,Rattus norvegicus,Half life period was evaluated in rat; 5.9-7.5,1,,,,,1,,17791,A,,Intermediate,CHEMBL626896,BAO_0000218,9228
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat plasma,1,Plasma,,,,1,,14512,A,1969.0,Intermediate,CHEMBL626897,BAO_0000218,9229
,,N,,,50597,10116.0,Rattus norvegicus,Half-life time in rat was determined,1,,,,,1,,6230,A,,Intermediate,CHEMBL626898,BAO_0000218,9230
,,N,,,50597,10116.0,Rattus norvegicus,Terminal half-life after iv administration to rats,1,,,,In vivo,1,,3364,A,,Intermediate,CHEMBL626899,BAO_0000218,9231
,,N,,,50597,10116.0,Rattus norvegicus,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,1,,,,In vivo,1,,6874,A,,Intermediate,CHEMBL626900,BAO_0000218,9232
,,N,,,50597,10116.0,Rattus norvegicus,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,1,,,,,1,,857,A,,Intermediate,CHEMBL626901,BAO_0000218,9233
,,N,,,50597,10116.0,Rattus norvegicus,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),1,,,,In vivo,1,,858,A,,Intermediate,CHEMBL626902,BAO_0000218,9234
,,N,,,50597,10116.0,Rattus norvegicus,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),1,,,,In vivo,1,,858,A,,Intermediate,CHEMBL626903,BAO_0000218,9235
,,N,,,50597,10116.0,Rattus norvegicus,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,1,,,,In vivo,1,,5355,A,,Intermediate,CHEMBL874443,BAO_0000218,9236
,,N,,,50597,10116.0,Rattus norvegicus,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,1,,,,In vivo,1,,5355,A,,Intermediate,CHEMBL626904,BAO_0000218,9237
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rats,1,,,,,1,,6305,A,,Intermediate,CHEMBL626905,BAO_0000218,9238
,,N,,,50597,10116.0,Rattus norvegicus,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,1,Plasma,,,In vivo,1,,13501,A,1969.0,Intermediate,CHEMBL873830,BAO_0000218,9239
,,N,,,50597,10116.0,Rattus norvegicus,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,1,,,,In vivo,1,,17594,A,,Intermediate,CHEMBL626906,BAO_0000218,9240
,,N,,,50597,10116.0,Rattus norvegicus,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,Plasma,,,In vivo,1,,4186,A,1969.0,Intermediate,CHEMBL631076,BAO_0000218,9241
,,N,,,50597,10116.0,Rattus norvegicus,Biological half-life was measured in plasma of rats,1,Plasma,,,,1,,2932,A,1969.0,Intermediate,CHEMBL631077,BAO_0000218,9242
,,N,,,50597,10116.0,Rattus norvegicus,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,,,,In vivo,1,,17065,A,,Intermediate,CHEMBL631078,BAO_0000218,9243
,,N,,,50597,10116.0,Rattus norvegicus,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,1,,,,In vivo,1,,15765,A,,Intermediate,CHEMBL631079,BAO_0000218,9244
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,1,,,,In vivo,1,,2713,A,,Intermediate,CHEMBL631080,BAO_0000218,9245
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,1,,,,In vivo,1,,2661,A,,Intermediate,CHEMBL631081,BAO_0000218,9246
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,1,,,,In vivo,1,,2661,A,,Intermediate,CHEMBL631239,BAO_0000218,9247
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for plasma half life in rat,1,Plasma,,,,1,,740,A,1969.0,Intermediate,CHEMBL631240,BAO_0000218,9248
,,N,,,50597,10116.0,Rattus norvegicus,AUC value at a dose of 5 mg/kg (p.o.) in rats,1,Plasma,,,,1,,6597,A,1969.0,Intermediate,CHEMBL631241,BAO_0000218,9249
,,N,,,50597,10116.0,Rattus norvegicus,AUC value after administration of 20 mg/Kg oral dose in rat,1,Plasma,,,,1,,2959,A,1969.0,Intermediate,CHEMBL631242,BAO_0000218,9250
,,N,,,50597,10116.0,Rattus norvegicus,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,1,Plasma,,,,1,,17594,A,1969.0,Intermediate,CHEMBL631243,BAO_0000218,9251
,,N,,,50597,10116.0,Rattus norvegicus,AUC0-96 after administration at 50 mg/kg,1,Plasma,,,,1,,17596,A,1969.0,Intermediate,CHEMBL874444,BAO_0000218,9252
,,N,,,50597,10116.0,Rattus norvegicus,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,1,Plasma,,,,1,,17594,A,1969.0,Intermediate,CHEMBL631244,BAO_0000218,9253
,,N,,,50597,10116.0,Rattus norvegicus,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",1,,,,,1,,3293,A,,Intermediate,CHEMBL631245,BAO_0000218,9254
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,1,,,,,1,,6757,A,,Intermediate,CHEMBL627162,BAO_0000218,9255
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,1,,,,,1,,6757,A,,Intermediate,CHEMBL627163,BAO_0000218,9256
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,1,,,,,1,,6757,A,,Intermediate,CHEMBL627164,BAO_0000218,9257
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,1,Kidney,,,,1,,5979,A,2113.0,Intermediate,CHEMBL627165,BAO_0000218,9258
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,1,,,,,1,,5979,A,,Intermediate,CHEMBL627166,BAO_0000218,9259
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,1,,,,,1,,5979,A,,Intermediate,CHEMBL627167,BAO_0000218,9260
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve (AUC) at a dose of 30 mg/kg in rats,1,,,,,1,,4026,A,,Intermediate,CHEMBL627822,BAO_0000218,9261
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,1,,,,,1,,5355,A,,Intermediate,CHEMBL627823,BAO_0000218,9262
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,1,,,,,1,,5355,A,,Intermediate,CHEMBL627824,BAO_0000218,9263
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,1,,,,,1,,5355,A,,Intermediate,CHEMBL627825,BAO_0000218,9264
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,1,,,,,1,,5633,A,,Intermediate,CHEMBL627826,BAO_0000218,9265
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve (Pharmacokinetic property) was determined,1,,,,,1,,1716,A,,Intermediate,CHEMBL627827,BAO_0000218,9266
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve (Pharmacokinetic property) of the compound; Not determined,1,,,,,1,,1716,A,,Intermediate,CHEMBL627828,BAO_0000218,9267
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve after intravenous administration (1 mg/kg) in rat,1,,,,,1,,4689,A,,Intermediate,CHEMBL627829,BAO_0000218,9268
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,1,,,,,1,,4527,A,,Intermediate,CHEMBL627830,BAO_0000218,9269
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,1,,,,,1,,4527,A,,Intermediate,CHEMBL627831,BAO_0000218,9270
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve in male SD rats was observed after oral administration in rat,1,,,,,1,,15662,A,,Intermediate,CHEMBL627832,BAO_0000218,9271
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve of compound after iv administration of 20 mg/kg dose in rat,1,,,,,1,,4413,A,,Intermediate,CHEMBL627833,BAO_0000218,9272
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,1,,,,,1,,3598,A,,Expert,CHEMBL627834,BAO_0000218,9273
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,1,,,,,1,,3598,A,,Expert,CHEMBL628004,BAO_0000218,9274
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve at 5 mg/kg po was determined in rat,1,,,,,1,,5964,A,,Intermediate,CHEMBL628005,BAO_0000218,9275
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve in Rat at a oral dose of 5 mg/kg,1,,,,,1,,4689,A,,Intermediate,CHEMBL628006,BAO_0000218,9276
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,,,,,1,,4186,A,,Intermediate,CHEMBL628007,BAO_0000218,9277
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined,1,,,,,1,,5510,A,,Intermediate,CHEMBL625676,BAO_0000218,9278
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,1,,,,,1,,17858,A,,Intermediate,CHEMBL631309,BAO_0000218,9279
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve after intravenous administration at 3 mg/kg,1,,,,,1,,17804,A,,Intermediate,CHEMBL631310,BAO_0000218,9280
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,1,,,,,1,,6106,A,,Intermediate,CHEMBL631311,BAO_0000218,9281
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve at 4 hr in rat,1,,,,,1,,5964,A,,Intermediate,CHEMBL631312,BAO_0000218,9282
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve at a dose of 30 mg/kg,1,,,,,1,,4026,A,,Intermediate,CHEMBL631313,BAO_0000218,9283
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve at the dose of 2 mg/Kg administered perorally in rats,1,,,,,1,,4756,A,,Intermediate,CHEMBL631314,BAO_0000218,9284
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve at the dose of 5 mg/Kg administered perorally in rats,1,,,,,1,,4756,A,,Intermediate,CHEMBL631315,BAO_0000218,9285
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve for a 2-mpk po dose in SD rats,1,,,,,1,,5862,A,,Intermediate,CHEMBL631316,BAO_0000218,9286
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve in SD rats,1,,,,,1,,5862,A,,Intermediate,CHEMBL631317,BAO_0000218,9287
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve in rat after oral administration at 13 mg/kg dose,1,,,,,1,,6644,A,,Intermediate,CHEMBL874471,BAO_0000218,9288
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve in rat by po administration at 0-24 hr,1,,,,,1,,5871,A,,Intermediate,CHEMBL631318,BAO_0000218,9289
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve in rat plasma,1,Plasma,,,,1,,5919,A,1969.0,Intermediate,CHEMBL631319,BAO_0000218,9290
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,1,,,,,1,,5939,A,,Intermediate,CHEMBL631320,BAO_0000218,9291
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,1,,,,,1,,5939,A,,Intermediate,CHEMBL631321,BAO_0000218,9292
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,1,,,,,1,,10,A,,Intermediate,CHEMBL631322,BAO_0000218,9293
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,1,,,,,1,,11149,A,,Intermediate,CHEMBL631323,BAO_0000218,9294
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve value in rat at a dose of 5 mg/kg,1,,,,,1,,5302,A,,Intermediate,CHEMBL631324,BAO_0000218,9295
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined after oral administration in rats,1,,,,,1,,17796,A,,Intermediate,CHEMBL631325,BAO_0000218,9296
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,1,,,,,1,,4890,A,,Intermediate,CHEMBL631326,BAO_0000218,9297
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined after peroral administration in rat,1,,,,,1,,6011,A,,Intermediate,CHEMBL631327,BAO_0000218,9298
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined at a dose 30 mpk administered orally.,1,,,,,1,,5375,A,,Intermediate,CHEMBL631328,BAO_0000218,9299
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,1,,,,,1,,17764,A,,Intermediate,CHEMBL631329,BAO_0000218,9300
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,1,,,,,1,,4368,A,,Intermediate,CHEMBL627217,BAO_0000218,9301
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined in male rat,1,,,,,1,,5610,A,,Intermediate,CHEMBL626352,BAO_0000218,9302
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined in rat after PO administration,1,,,,,1,,5833,A,,Intermediate,CHEMBL626353,BAO_0000218,9303
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined in rat after a 3 mg/kg of oral dose,1,,,,,1,,4257,A,,Intermediate,CHEMBL626354,BAO_0000218,9304
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,1,,,,,1,,5937,A,,Intermediate,CHEMBL626355,BAO_0000218,9305
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,1,,,,,1,,5932,A,,Intermediate,CHEMBL626356,BAO_0000218,9306
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,1,,,,,1,,5932,A,,Intermediate,CHEMBL626357,BAO_0000218,9307
,,N,,,50597,10116.0,Rattus norvegicus,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,,,,1,,17411,A,,Intermediate,CHEMBL626358,BAO_0000218,9308
,,N,,,50597,10116.0,Rattus norvegicus,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,,,,1,,17411,A,,Intermediate,CHEMBL626359,BAO_0000218,9309
,,N,,,50597,10116.0,Rattus norvegicus,Peak plasma concentration in rat at a dose of 3 mg/kg,1,Plasma,,,,1,,17771,A,1969.0,Intermediate,CHEMBL626360,BAO_0000218,9310
,,N,,,50597,10116.0,Rattus norvegicus,Plasma concentration at 2 hr in rats was evaluated.,1,,,,,1,,1628,A,,Intermediate,CHEMBL626361,BAO_0000218,9311
,,N,,,50597,10116.0,Rattus norvegicus,Plasma concentration at 2 hr in rats was evaluated; Not available,1,,,,,1,,1628,A,,Intermediate,CHEMBL626362,BAO_0000218,9312
,,N,,,50597,10116.0,Rattus norvegicus,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,,,,1,,17411,A,,Intermediate,CHEMBL626363,BAO_0000218,9313
,,N,,,50597,10116.0,Rattus norvegicus,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,,,,,1,,4910,A,,Intermediate,CHEMBL626970,BAO_0000218,9314
,,N,,,50597,10116.0,Rattus norvegicus,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,,,,,1,,4910,A,,Intermediate,CHEMBL626971,BAO_0000218,9315
,,N,,,50597,10116.0,Rattus norvegicus,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,Plasma,,,,1,,4910,A,1969.0,Intermediate,CHEMBL626972,BAO_0000218,9316
,,N,,,50597,10116.0,Rattus norvegicus,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,Plasma,,,,1,,4910,A,1969.0,Intermediate,CHEMBL626973,BAO_0000218,9317
,,N,,,50597,10116.0,Rattus norvegicus,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,Plasma,,,,1,,4910,A,1969.0,Intermediate,CHEMBL626974,BAO_0000218,9318
,,N,,,50597,10116.0,Rattus norvegicus,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,Plasma,,,,1,,4910,A,1969.0,Intermediate,CHEMBL874592,BAO_0000218,9319
,,N,,,50597,10116.0,Rattus norvegicus,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,1,,,,,1,,5510,A,,Intermediate,CHEMBL626975,BAO_0000218,9320
,,N,,,50597,10116.0,Rattus norvegicus,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,1,,,,,1,,5510,A,,Intermediate,CHEMBL626976,BAO_0000218,9321
,,N,,,50597,10116.0,Rattus norvegicus,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,1,,,,,1,,5510,A,,Intermediate,CHEMBL626977,BAO_0000218,9322
,,N,,,50597,10116.0,Rattus norvegicus,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,1,,,,,1,,5510,A,,Intermediate,CHEMBL626978,BAO_0000218,9323
,,N,,,50597,10116.0,Rattus norvegicus,PK study was carried to determine the relative absorption ranking in rat.,1,,,,,1,,16427,A,,Intermediate,CHEMBL626979,BAO_0000218,9324
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,1,Plasma,,,In vivo,1,,4689,A,1969.0,Intermediate,CHEMBL626980,BAO_0000218,9325
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",1,Blood,,,,1,,11450,A,178.0,Intermediate,CHEMBL626981,BAO_0000218,9326
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",1,Blood,,,,1,,11450,A,178.0,Intermediate,CHEMBL626982,BAO_0000218,9327
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",1,Blood,,,,1,,11450,A,178.0,Intermediate,CHEMBL626983,BAO_0000218,9328
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",1,Blood,,,,1,,11450,A,178.0,Intermediate,CHEMBL622522,BAO_0000218,9329
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",1,Blood,,,,1,,11450,A,178.0,Intermediate,CHEMBL622523,BAO_0000218,9330
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",1,Blood,,,,1,,11450,A,178.0,Intermediate,CHEMBL622524,BAO_0000218,9331
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",1,Brain,,,,1,,11450,A,955.0,Intermediate,CHEMBL622525,BAO_0000218,9332
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",1,Brain,,,,1,,11450,A,955.0,Intermediate,CHEMBL622526,BAO_0000218,9333
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",1,Brain,,,,1,,11450,A,955.0,Intermediate,CHEMBL619849,BAO_0000218,9334
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",1,Brain,,,,1,,11450,A,955.0,Intermediate,CHEMBL619850,BAO_0000218,9335
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",1,Brain,,,,1,,11450,A,955.0,Intermediate,CHEMBL623864,BAO_0000218,9336
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",1,Brain,,,,1,,11450,A,955.0,Intermediate,CHEMBL623865,BAO_0000218,9337
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",1,Heart,,,,1,,11450,A,948.0,Intermediate,CHEMBL623866,BAO_0000218,9338
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",1,Heart,,,,1,,11450,A,948.0,Intermediate,CHEMBL623867,BAO_0000218,9339
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",1,Heart,,,,1,,11450,A,948.0,Intermediate,CHEMBL877615,BAO_0000218,9340
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",1,Heart,,,,1,,11450,A,948.0,Intermediate,CHEMBL623868,BAO_0000218,9341
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",1,Heart,,,,1,,11450,A,948.0,Intermediate,CHEMBL623869,BAO_0000218,9342
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",1,Heart,,,,1,,11450,A,948.0,Intermediate,CHEMBL623870,BAO_0000218,9343
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,1,Lung,,,,1,,16434,A,2048.0,Intermediate,CHEMBL623871,BAO_0000218,9344
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,Lung,,,,1,,16434,A,2048.0,Intermediate,CHEMBL623872,BAO_0000218,9345
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,Lung,,,,1,,16435,A,2048.0,Intermediate,CHEMBL622129,BAO_0000218,9346
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,Lung,,,,1,,16435,A,2048.0,Intermediate,CHEMBL622130,BAO_0000218,9347
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,Lung,,,,1,,16435,A,2048.0,Intermediate,CHEMBL622131,BAO_0000218,9348
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,Lung,,,,1,,16435,A,2048.0,Intermediate,CHEMBL622132,BAO_0000218,9349
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,Lung,,,,1,,16435,A,2048.0,Intermediate,CHEMBL622133,BAO_0000218,9350
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,Lung,,,,1,,16435,A,2048.0,Intermediate,CHEMBL622134,BAO_0000218,9351
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,Lung,,,,1,,16435,A,2048.0,Intermediate,CHEMBL622135,BAO_0000218,9352
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,Lung,,,,1,,16435,A,2048.0,Intermediate,CHEMBL622136,BAO_0000218,9353
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,Muscle tissue,,,,1,,16434,A,2385.0,Intermediate,CHEMBL622137,BAO_0000218,9354
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,Muscle tissue,,,,1,,16434,A,2385.0,Intermediate,CHEMBL622138,BAO_0000218,9355
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,Muscle tissue,,,,1,,16434,A,2385.0,Intermediate,CHEMBL623017,BAO_0000218,9356
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,Muscle tissue,,,,1,,16434,A,2385.0,Intermediate,CHEMBL623018,BAO_0000218,9357
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,Muscle tissue,,,,1,,16434,A,2385.0,Intermediate,CHEMBL623019,BAO_0000218,9358
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,Muscle tissue,,,,1,,16434,A,2385.0,Intermediate,CHEMBL623020,BAO_0000218,9359
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,1,Muscle tissue,,,,1,,16434,A,2385.0,Intermediate,CHEMBL623021,BAO_0000218,9360
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,1,Muscle tissue,,,,1,,16434,A,2385.0,Intermediate,CHEMBL623022,BAO_0000218,9361
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,Muscle tissue,,,,1,,16435,A,2385.0,Intermediate,CHEMBL623023,BAO_0000218,9362
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,Muscle tissue,,,,1,,16435,A,2385.0,Intermediate,CHEMBL623024,BAO_0000218,9363
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,Muscle tissue,,,,1,,16435,A,2385.0,Intermediate,CHEMBL623025,BAO_0000218,9364
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,Muscle tissue,,,,1,,16435,A,2385.0,Intermediate,CHEMBL620545,BAO_0000218,9365
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,Muscle tissue,,,,1,,16435,A,2385.0,Intermediate,CHEMBL620546,BAO_0000218,9366
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,Muscle tissue,,,,1,,16435,A,2385.0,Intermediate,CHEMBL620547,BAO_0000218,9367
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,Muscle tissue,,,,1,,16435,A,2385.0,Intermediate,CHEMBL620548,BAO_0000218,9368
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,Muscle tissue,,,,1,,16435,A,2385.0,Intermediate,CHEMBL620549,BAO_0000218,9369
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,Muscle tissue,,,,1,,16434,A,2385.0,Intermediate,CHEMBL620550,BAO_0000218,9370
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,1,Muscle tissue,,,,1,,16434,A,2385.0,Intermediate,CHEMBL620551,BAO_0000218,9371
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,Muscle tissue,,,,1,,16434,A,2385.0,Intermediate,CHEMBL620552,BAO_0000218,9372
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,Muscle tissue,,,,1,,16435,A,2385.0,Intermediate,CHEMBL620553,BAO_0000218,9373
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,Muscle tissue,,,,1,,16435,A,2385.0,Intermediate,CHEMBL620554,BAO_0000218,9374
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,Muscle tissue,,,,1,,16435,A,2385.0,Intermediate,CHEMBL875845,BAO_0000218,9375
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,Muscle tissue,,,,1,,16435,A,2385.0,Intermediate,CHEMBL620555,BAO_0000218,9376
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,Muscle tissue,,,,1,,16435,A,2385.0,Intermediate,CHEMBL620556,BAO_0000218,9377
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,Muscle tissue,,,,1,,16435,A,2385.0,Intermediate,CHEMBL620557,BAO_0000218,9378
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL620558,BAO_0000218,9379
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL620559,BAO_0000218,9380
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL622939,BAO_0000218,9381
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL622940,BAO_0000218,9382
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL622941,BAO_0000218,9383
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL622942,BAO_0000218,9384
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL622943,BAO_0000218,9385
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL622944,BAO_0000218,9386
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL622945,BAO_0000218,9387
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL622946,BAO_0000218,9388
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for terminal half life in rat,1,,,,,1,,3341,A,,Intermediate,CHEMBL622947,BAO_0000218,9389
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,1,Plasma,,,In vivo,1,,3634,A,1969.0,Intermediate,CHEMBL622948,BAO_0000218,9390
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,1,Plasma,,,In vivo,1,,3634,A,1969.0,Intermediate,CHEMBL622949,BAO_0000218,9391
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for its half life in rat,1,,,,,1,,4839,A,,Intermediate,CHEMBL622950,BAO_0000218,9392
,,U,,,22224,9544.0,Macaca mulatta,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,1,Plasma,,,In vivo,0,,5005,A,1969.0,Intermediate,CHEMBL622951,BAO_0000218,9393
,,U,,,22224,10116.0,Rattus norvegicus,Compound was tested for its plasma half life in Sprague Dawley rats,1,Plasma,,,,0,,5005,A,1969.0,Intermediate,CHEMBL622952,BAO_0000366,9394
,,U,,,22224,10116.0,Rattus norvegicus,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,1,Plasma,,,,0,,5005,A,1969.0,Intermediate,CHEMBL622953,BAO_0000366,9395
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for plasma half-life period in rat,1,Plasma,,,,1,,1094,A,1969.0,Intermediate,CHEMBL873818,BAO_0000218,9396
,,N,,,50597,10116.0,Rattus norvegicus,Elimination half life after i.v. administration of compound in rats,1,,,,In vivo,1,,5031,A,,Intermediate,CHEMBL622954,BAO_0000218,9397
,,N,,,50597,10116.0,Rattus norvegicus,Elimination half-life after IV dosing at 0.5 mg/kg in rat,1,,,,In vivo,1,,6518,A,,Intermediate,CHEMBL622955,BAO_0000218,9398
,,N,,,50597,10116.0,Rattus norvegicus,Elimination half-life after IV dosing at 1 mg/kg in rat,1,,,,In vivo,1,,6518,A,,Intermediate,CHEMBL875229,BAO_0000218,9399
,,N,,,50597,10116.0,Rattus norvegicus,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,1,,,,In vivo,1,,6518,A,,Intermediate,CHEMBL622956,BAO_0000218,9400
,,N,,,50597,10116.0,Rattus norvegicus,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,1,,,,In vivo,1,,6518,A,,Intermediate,CHEMBL622957,BAO_0000218,9401
,,N,,,50597,10116.0,Rattus norvegicus,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,1,Brain,,,In vivo,1,,5408,A,955.0,Intermediate,CHEMBL622958,BAO_0000218,9402
,,N,,,50597,10116.0,Rattus norvegicus,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,1,Plasma,,,In vivo,1,,5408,A,1969.0,Intermediate,CHEMBL622959,BAO_0000218,9403
,,N,,,50597,10116.0,Rattus norvegicus,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,1,Brain,,,In vivo,1,,5408,A,955.0,Intermediate,CHEMBL622960,BAO_0000218,9404
,,N,,,50597,10116.0,Rattus norvegicus,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,1,Plasma,,,In vivo,1,,5408,A,1969.0,Intermediate,CHEMBL622961,BAO_0000218,9405
,,N,,,50597,10116.0,Rattus norvegicus,Evaluated for the half life in rat (in vivo),1,,,,In vivo,1,,4687,A,,Intermediate,CHEMBL622962,BAO_0000218,9406
,,N,,,50597,10116.0,Rattus norvegicus,Hafl life in rat,1,,,,,1,,6640,A,,Intermediate,CHEMBL622963,BAO_0000218,9407
,,N,,,50597,10116.0,Rattus norvegicus,Hafl life rat,1,,,,,1,,6640,A,,Intermediate,CHEMBL622964,BAO_0000218,9408
,,N,,,50597,10116.0,Rattus norvegicus,Hafl life rat,1,,,,,1,,6641,A,,Intermediate,CHEMBL622965,BAO_0000218,9409
,,N,,,50597,10116.0,Rattus norvegicus,Hafl life rat; Not determined,1,,,,,1,,6640,A,,Intermediate,CHEMBL622966,BAO_0000218,9410
,,N,,,50597,10116.0,Rattus norvegicus,Hafl life rat; Not determined,1,,,,,1,,6641,A,,Intermediate,CHEMBL622967,BAO_0000218,9411
,,N,,,50597,10116.0,Rattus norvegicus,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,Kidney,,,In vivo,1,,17411,A,2113.0,Intermediate,CHEMBL622968,BAO_0000218,9412
,,N,,,50597,10116.0,Rattus norvegicus,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,Liver,,,In vivo,1,,17411,A,2107.0,Intermediate,CHEMBL622969,BAO_0000218,9413
,,N,,,50597,10116.0,Rattus norvegicus,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,Lung,,,In vivo,1,,17411,A,2048.0,Intermediate,CHEMBL875327,BAO_0000218,9414
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rat after 1 mg/kg i.v. administration,1,,,,In vivo,1,,6570,A,,Intermediate,CHEMBL628638,BAO_0000218,9415
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rat after 2 mg/kg peroral administration,1,,,,In vivo,1,,6570,A,,Intermediate,CHEMBL628639,BAO_0000218,9416
,,N,,,50597,10116.0,Rattus norvegicus,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,,,In vivo,1,,17411,A,,Intermediate,CHEMBL625840,BAO_0000218,9417
,,N,,,50597,10116.0,Rattus norvegicus,Half life of 10 mg/kg oral dose determined in rats,1,,,,In vivo,1,,4722,A,,Intermediate,CHEMBL625841,BAO_0000218,9418
,,N,,,50597,10116.0,Rattus norvegicus,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL625842,BAO_0000218,9419
,,N,,,50597,10116.0,Rattus norvegicus,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL625843,BAO_0000218,9420
,,N,,,50597,10116.0,Rattus norvegicus,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL625844,BAO_0000218,9421
,,N,,,50597,10116.0,Rattus norvegicus,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL873822,BAO_0000218,9422
,,N,,,50597,10116.0,Rattus norvegicus,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL625845,BAO_0000218,9423
,,N,,,50597,10116.0,Rattus norvegicus,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL627059,BAO_0000218,9424
,,N,,,50597,10116.0,Rattus norvegicus,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL627060,BAO_0000218,9425
,,N,,,50597,10116.0,Rattus norvegicus,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL627061,BAO_0000218,9426
,,N,,,50597,10116.0,Rattus norvegicus,Half life of compound at 5 mg/kg after po administration was determined in rat,1,,,,In vivo,1,,4762,A,,Intermediate,CHEMBL627709,BAO_0000218,9427
,,N,,,50597,10116.0,Rattus norvegicus,Half life of compound determined after intravenous administration to rat,1,,,,In vivo,1,,5327,A,,Intermediate,CHEMBL627710,BAO_0000218,9428
,,N,,,50597,10116.0,Rattus norvegicus,Half life of compound was determined in rat,1,,,,,1,,4847,A,,Intermediate,CHEMBL627711,BAO_0000218,9429
,,N,,,50597,10116.0,Rattus norvegicus,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,1,Plasma,,,In vivo,1,,17720,A,1969.0,Intermediate,CHEMBL627712,BAO_0000218,9430
,,N,,,50597,10116.0,Rattus norvegicus,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,,,,In vivo,1,,4723,A,,Intermediate,CHEMBL627713,BAO_0000218,9431
,,N,,,50597,10116.0,Rattus norvegicus,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,,,,In vivo,1,,4723,A,,Intermediate,CHEMBL627714,BAO_0000218,9432
,,U,,,22224,9541.0,Macaca fascicularis,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,1,,,,In vivo,0,,4256,A,,Intermediate,CHEMBL627889,BAO_0000218,9433
,,U,,,22224,10116.0,Rattus norvegicus,Half life determined in rat by intravenous administration,1,,,,In vivo,0,,4256,A,,Intermediate,CHEMBL627890,BAO_0000218,9434
,,N,,,50597,10116.0,Rattus norvegicus,Half life determined in rats after iv administration,1,,,,In vivo,1,,4722,A,,Intermediate,CHEMBL627891,BAO_0000218,9435
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rat plasma after administration of 2 mg/kg iv,1,Plasma,,,In vivo,1,,6535,A,1969.0,Intermediate,CHEMBL627892,BAO_0000218,9436
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rat plasma after administration of 2 mg/kg iv,1,Plasma,,,In vivo,1,,6535,A,1969.0,Intermediate,CHEMBL627893,BAO_0000218,9437
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rat plasma was determined,1,Plasma,,,,1,,1435,A,1969.0,Intermediate,CHEMBL627894,BAO_0000218,9438
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rat plasma was determined; NA means not applicable,1,Plasma,,,,1,,1435,A,1969.0,Intermediate,CHEMBL627895,BAO_0000218,9439
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rat was tested,1,,,,,1,,5206,A,,Intermediate,CHEMBL627896,BAO_0000218,9440
,,N,,,50597,10116.0,Rattus norvegicus,Half life measured in rat plasma,1,Plasma,,,,1,,6080,A,1969.0,Intermediate,CHEMBL627897,BAO_0000218,9441
,,N,,,50597,10116.0,Rattus norvegicus,Half life recorded in rats,1,,,,,1,,4449,A,,Intermediate,CHEMBL627898,BAO_0000218,9442
,,N,,,50597,10116.0,Rattus norvegicus,Half life was calculated,1,,,,,1,,6057,A,,Intermediate,CHEMBL627899,BAO_0000218,9443
,,N,,,50597,10116.0,Rattus norvegicus,Half life was calculated in rat,1,,,,,1,,6057,A,,Intermediate,CHEMBL873823,BAO_0000218,9444
,,N,,,50597,10116.0,Rattus norvegicus,Half life was determined,1,,,,,1,,3747,A,,Intermediate,CHEMBL627900,BAO_0000218,9445
,,N,,,50597,10116.0,Rattus norvegicus,Half life after 10 mg/kg oral administration in rat,1,,,,In vivo,1,,17858,A,,Intermediate,CHEMBL627901,BAO_0000218,9446
,,N,,,50597,10116.0,Rattus norvegicus,Half life after administering orally a dose of 10 mg/kg to a fasting rat,1,,,,In vivo,1,,16365,A,,Intermediate,CHEMBL627902,BAO_0000218,9447
,,N,,,50597,10116.0,Rattus norvegicus,Half life after administering orally a dose of 30 mg/kg,1,,,,In vivo,1,,16365,A,,Intermediate,CHEMBL627903,BAO_0000218,9448
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,1,,,,,1,,5031,A,,Intermediate,CHEMBL627904,BAO_0000218,9449
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,1,,,,,1,,4722,A,,Intermediate,CHEMBL627905,BAO_0000218,9450
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,1,,,,,1,,6078,A,,Intermediate,CHEMBL627906,BAO_0000218,9451
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,1,,,,,1,,6078,A,,Intermediate,CHEMBL627907,BAO_0000218,9452
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,1,,,,,1,,6078,A,,Intermediate,CHEMBL876783,BAO_0000218,9453
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,1,,,,,1,,6078,A,,Intermediate,CHEMBL627908,BAO_0000218,9454
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,,,,,1,,17065,A,,Intermediate,CHEMBL627909,BAO_0000218,9455
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,1,,,,,1,,1353,A,,Intermediate,CHEMBL627910,BAO_0000218,9456
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),1,,,,,1,,1353,A,,Intermediate,CHEMBL627911,BAO_0000218,9457
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),1,,,,,1,,1353,A,,Intermediate,CHEMBL627912,BAO_0000218,9458
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),1,,,,,1,,1353,A,,Intermediate,CHEMBL627913,BAO_0000218,9459
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),1,,,,,1,,1353,A,,Intermediate,CHEMBL627914,BAO_0000218,9460
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,1,,,,,1,,16423,A,,Intermediate,CHEMBL627915,BAO_0000218,9461
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve was evaluated after 20 uM/kg of peroral administration,1,,,,,1,,16423,A,,Intermediate,CHEMBL627916,BAO_0000218,9462
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve was measured in rat after an iv dose of 1 mg/kg,1,,,,,1,,6062,A,,Intermediate,CHEMBL627917,BAO_0000218,9463
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,1,,,,,1,,6056,A,,Intermediate,CHEMBL627918,BAO_0000218,9464
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,1,,,,,1,,5182,A,,Intermediate,CHEMBL627919,BAO_0000218,9465
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,1,,,,,1,,6410,A,,Intermediate,CHEMBL627920,BAO_0000218,9466
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve was evaluated at an oral dose of 30 mg/kg,1,,,,,1,,6410,A,,Intermediate,CHEMBL627921,BAO_0000218,9467
,,N,,,50597,10116.0,Rattus norvegicus,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,,,,,1,,4723,A,,Intermediate,CHEMBL627922,BAO_0000218,9468
,,N,,,50597,10116.0,Rattus norvegicus,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,,,,,1,,4723,A,,Intermediate,CHEMBL876784,BAO_0000218,9469
,,N,,,50597,10116.0,Rattus norvegicus,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,,,,,1,,4723,A,,Intermediate,CHEMBL627923,BAO_0000218,9470
,,N,,,50597,10116.0,Rattus norvegicus,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,,,,,1,,4723,A,,Intermediate,CHEMBL626208,BAO_0000218,9471
,,N,,,50597,10116.0,Rattus norvegicus,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,,,,,1,,4723,A,,Intermediate,CHEMBL626209,BAO_0000218,9472
,,N,,,50597,10116.0,Rattus norvegicus,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,,,,,1,,4723,A,,Intermediate,CHEMBL626210,BAO_0000218,9473
,,N,,,50597,10116.0,Rattus norvegicus,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,1,Plasma,,,,1,,2463,A,1969.0,Intermediate,CHEMBL627994,BAO_0000218,9474
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,1,,,,,1,,4709,A,,Intermediate,CHEMBL627995,BAO_0000218,9475
,,N,,,50597,10116.0,Rattus norvegicus,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,1,,,,,1,,4075,A,,Intermediate,CHEMBL627996,BAO_0000218,9476
,,N,,,50597,10116.0,Rattus norvegicus,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,1,,,,,1,,5394,A,,Intermediate,CHEMBL627997,BAO_0000218,9477
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,1,,,,,1,,2661,A,,Intermediate,CHEMBL627998,BAO_0000218,9478
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,1,,,,,1,,2661,A,,Intermediate,CHEMBL628640,BAO_0000218,9479
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,1,,,,,1,,2661,A,,Intermediate,CHEMBL628641,BAO_0000218,9480
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,1,,,,,1,,2661,A,,Intermediate,CHEMBL628642,BAO_0000218,9481
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for area under the curve expressed as (h*ug/ml),1,,,,,1,,17791,A,,Intermediate,CHEMBL628643,BAO_0000218,9482
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for area under curve in rat,1,,,,,1,,2591,A,,Intermediate,CHEMBL628644,BAO_0000218,9483
,,N,,,50597,10116.0,Rattus norvegicus,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,1,,,,,1,,6567,A,,Intermediate,CHEMBL628645,BAO_0000218,9484
,,N,,,50597,10116.0,Rattus norvegicus,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,1,,,,,1,,6211,A,,Intermediate,CHEMBL628646,BAO_0000218,9485
,,N,,,50597,10116.0,Rattus norvegicus,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),1,,,,,1,,5529,A,,Intermediate,CHEMBL628647,BAO_0000218,9486
,,N,,,50597,10116.0,Rattus norvegicus,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,1,,,,,1,,5408,A,,Intermediate,CHEMBL628648,BAO_0000218,9487
,,N,,,50597,10116.0,Rattus norvegicus,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,1,,,,,1,,5408,A,,Intermediate,CHEMBL625358,BAO_0000218,9488
,,N,,,50597,10116.0,Rattus norvegicus,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,1,,,,,1,,5408,A,,Intermediate,CHEMBL625359,BAO_0000218,9489
,,N,,,50597,10116.0,Rattus norvegicus,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,1,,,,,1,,5408,A,,Intermediate,CHEMBL625360,BAO_0000218,9490
,,N,,,50597,10116.0,Rattus norvegicus,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),1,,,,,1,,429,A,,Intermediate,CHEMBL625361,BAO_0000218,9491
,,N,,,50597,10116.0,Rattus norvegicus,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),1,,,,,1,,429,A,,Intermediate,CHEMBL625362,BAO_0000218,9492
,,N,,,50597,10116.0,Rattus norvegicus,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),1,,,,,1,,429,A,,Intermediate,CHEMBL625363,BAO_0000218,9493
,,N,,,50597,10116.0,Rattus norvegicus,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,1,,,,,1,,4796,A,,Intermediate,CHEMBL625364,BAO_0000218,9494
,,N,,,50597,10116.0,Rattus norvegicus,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,,,,,1,,5974,A,,Intermediate,CHEMBL625365,BAO_0000218,9495
,,N,,,50597,10116.0,Rattus norvegicus,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,,,,,1,,5974,A,,Intermediate,CHEMBL625366,BAO_0000218,9496
,,N,,,50597,10116.0,Rattus norvegicus,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,,,,,1,,5974,A,,Intermediate,CHEMBL625367,BAO_0000218,9497
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",1,Kidney,,,,1,,11450,A,2113.0,Intermediate,CHEMBL625368,BAO_0000218,9498
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",1,Kidney,,,,1,,11450,A,2113.0,Intermediate,CHEMBL625369,BAO_0000218,9499
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",1,Kidney,,,,1,,11450,A,2113.0,Intermediate,CHEMBL625370,BAO_0000218,9500
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",1,Kidney,,,,1,,11450,A,2113.0,Intermediate,CHEMBL625371,BAO_0000218,9501
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",1,Kidney,,,,1,,11450,A,2113.0,Intermediate,CHEMBL625372,BAO_0000218,9502
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",1,Kidney,,,,1,,11450,A,2113.0,Intermediate,CHEMBL625373,BAO_0000218,9503
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",1,Liver,,,,1,,11450,A,2107.0,Intermediate,CHEMBL625374,BAO_0000218,9504
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",1,Liver,,,,1,,11450,A,2107.0,Intermediate,CHEMBL877593,BAO_0000218,9505
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",1,Liver,,,,1,,11450,A,2107.0,Intermediate,CHEMBL625375,BAO_0000218,9506
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",1,Liver,,,,1,,11450,A,2107.0,Intermediate,CHEMBL625376,BAO_0000218,9507
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",1,Liver,,,,1,,11450,A,2107.0,Intermediate,CHEMBL621973,BAO_0000218,9508
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",1,Liver,,,,1,,11450,A,2107.0,Intermediate,CHEMBL621974,BAO_0000218,9509
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",1,Lung,,,,1,,11450,A,2048.0,Intermediate,CHEMBL621975,BAO_0000218,9510
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",1,Lung,,,,1,,11450,A,2048.0,Intermediate,CHEMBL622166,BAO_0000218,9511
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",1,Lung,,,,1,,11450,A,2048.0,Intermediate,CHEMBL622167,BAO_0000218,9512
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",1,Lung,,,,1,,11450,A,2048.0,Intermediate,CHEMBL622168,BAO_0000218,9513
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",1,Lung,,,,1,,11450,A,2048.0,Intermediate,CHEMBL622169,BAO_0000218,9514
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",1,Lung,,,,1,,11450,A,2048.0,Intermediate,CHEMBL622170,BAO_0000218,9515
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",1,Thyroid gland,,,,1,,11450,A,2046.0,Intermediate,CHEMBL622171,BAO_0000218,9516
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",1,Thyroid gland,,,,1,,11450,A,2046.0,Intermediate,CHEMBL622172,BAO_0000218,9517
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",1,Thyroid gland,,,,1,,11450,A,2046.0,Intermediate,CHEMBL622173,BAO_0000218,9518
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",1,Thyroid gland,,,,1,,11450,A,2046.0,Intermediate,CHEMBL622174,BAO_0000218,9519
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",1,Thyroid gland,,,,1,,11450,A,2046.0,Intermediate,CHEMBL622175,BAO_0000218,9520
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",1,Thyroid gland,,,,1,,11450,A,2046.0,Intermediate,CHEMBL622176,BAO_0000218,9521
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",1,Thyroid gland,,,,1,,11450,A,2046.0,Intermediate,CHEMBL622177,BAO_0000218,9522
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",1,Thyroid gland,,,,1,,11450,A,2046.0,Intermediate,CHEMBL622178,BAO_0000218,9523
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",1,Thyroid gland,,,,1,,11450,A,2046.0,Intermediate,CHEMBL622179,BAO_0000218,9524
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",1,Thyroid gland,,,,1,,11450,A,2046.0,Intermediate,CHEMBL622180,BAO_0000218,9525
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL622181,BAO_0000218,9526
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL622182,BAO_0000218,9527
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL622183,BAO_0000218,9528
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL622184,BAO_0000218,9529
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL622185,BAO_0000218,9530
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL622186,BAO_0000218,9531
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,,,,1,,16434,A,,Intermediate,CHEMBL622187,BAO_0000218,9532
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,1,,,,,1,,16434,A,,Intermediate,CHEMBL625002,BAO_0000218,9533
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,1,,,,,1,,16434,A,,Intermediate,CHEMBL622090,BAO_0000218,9534
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,,,,1,,16435,A,,Intermediate,CHEMBL622091,BAO_0000218,9535
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,,,,1,,16435,A,,Intermediate,CHEMBL622092,BAO_0000218,9536
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,,,,1,,16435,A,,Intermediate,CHEMBL622093,BAO_0000218,9537
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,,,,1,,16435,A,,Intermediate,CHEMBL622094,BAO_0000218,9538
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,,,,1,,16435,A,,Intermediate,CHEMBL622095,BAO_0000218,9539
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,,,,1,,16435,A,,Intermediate,CHEMBL622264,BAO_0000218,9540
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,Spleen,,,,1,,16434,A,2106.0,Intermediate,CHEMBL622265,BAO_0000218,9541
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,Spleen,,,,1,,16434,A,2106.0,Intermediate,CHEMBL622266,BAO_0000218,9542
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,Spleen,,,,1,,16434,A,2106.0,Intermediate,CHEMBL622267,BAO_0000218,9543
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,Spleen,,,,1,,16434,A,2106.0,Intermediate,CHEMBL622268,BAO_0000218,9544
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,Spleen,,,,1,,16434,A,2106.0,Intermediate,CHEMBL622269,BAO_0000218,9545
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,Spleen,,,,1,,16434,A,2106.0,Intermediate,CHEMBL625071,BAO_0000218,9546
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,Spleen,,,,1,,16434,A,2106.0,Intermediate,CHEMBL621621,BAO_0000218,9547
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,Spleen,,,,1,,16434,A,2106.0,Intermediate,CHEMBL621622,BAO_0000218,9548
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,Spleen,,,,1,,16435,A,2106.0,Intermediate,CHEMBL621623,BAO_0000218,9549
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,Spleen,,,,1,,16435,A,2106.0,Intermediate,CHEMBL621624,BAO_0000218,9550
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,Spleen,,,,1,,16435,A,2106.0,Intermediate,CHEMBL621625,BAO_0000218,9551
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,Spleen,,,,1,,16435,A,2106.0,Intermediate,CHEMBL621626,BAO_0000218,9552
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,Spleen,,,,1,,16435,A,2106.0,Intermediate,CHEMBL621627,BAO_0000218,9553
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,Spleen,,,,1,,16435,A,2106.0,Intermediate,CHEMBL621628,BAO_0000218,9554
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,Spleen,,,,1,,16435,A,2106.0,Intermediate,CHEMBL875328,BAO_0000218,9555
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,Spleen,,,,1,,16435,A,2106.0,Intermediate,CHEMBL621629,BAO_0000218,9556
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,Spleen,,,,1,,16434,A,2106.0,Intermediate,CHEMBL621630,BAO_0000218,9557
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,Spleen,,,,1,,16434,A,2106.0,Intermediate,CHEMBL621631,BAO_0000218,9558
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,Spleen,,,,1,,16434,A,2106.0,Intermediate,CHEMBL621632,BAO_0000218,9559
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,Spleen,,,,1,,16435,A,2106.0,Intermediate,CHEMBL621633,BAO_0000218,9560
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,Spleen,,,,1,,16435,A,2106.0,Intermediate,CHEMBL621634,BAO_0000218,9561
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,Spleen,,,,1,,16435,A,2106.0,Intermediate,CHEMBL621635,BAO_0000218,9562
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,Spleen,,,,1,,16435,A,2106.0,Intermediate,CHEMBL621636,BAO_0000218,9563
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,Spleen,,,,1,,16435,A,2106.0,Intermediate,CHEMBL621637,BAO_0000218,9564
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,Spleen,,,,1,,16435,A,2106.0,Intermediate,CHEMBL621638,BAO_0000218,9565
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL618883,BAO_0000218,9566
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL618884,BAO_0000218,9567
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL628627,BAO_0000218,9568
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL628628,BAO_0000218,9569
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL628629,BAO_0000218,9570
,,N,,,50597,10116.0,Rattus norvegicus,Half life after administering orally a dose of 3 mg/kg,1,,,,In vivo,1,,16365,A,,Intermediate,CHEMBL628630,BAO_0000218,9571
,,N,,,50597,10116.0,Rattus norvegicus,Half life after administering orally a dose of 3 mg/kg to a fasting rat,1,,,,In vivo,1,,16365,A,,Intermediate,CHEMBL628631,BAO_0000218,9572
,,N,,,50597,10116.0,Rattus norvegicus,Half life after administering intravenously a dose of 1 mg/kg,1,,,,In vivo,1,,16365,A,,Intermediate,CHEMBL628632,BAO_0000218,9573
,,N,,,50597,10116.0,Rattus norvegicus,Half life after oral dosing in rats,1,,,,In vivo,1,,526,A,,Intermediate,CHEMBL628633,BAO_0000218,9574
,,N,,,50597,10116.0,Rattus norvegicus,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,1,,,,In vivo,1,,16365,A,,Intermediate,CHEMBL628634,BAO_0000218,9575
,,N,,,50597,10116.0,Rattus norvegicus,Half life by intravenous administration of 3.4 mg/kg in rat,1,,,,In vivo,1,,4368,A,,Intermediate,CHEMBL627789,BAO_0000218,9576
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rat,1,,,,,1,,3371,A,,Intermediate,CHEMBL627790,BAO_0000218,9577
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rat,1,,,,,1,,6448,A,,Intermediate,CHEMBL627791,BAO_0000218,9578
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rat,1,,,,,1,,6453,A,,Intermediate,CHEMBL627792,BAO_0000218,9579
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rat after intravenous administration of the compound,1,,,,In vivo,1,,4353,A,,Intermediate,CHEMBL627793,BAO_0000218,9580
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,1,Plasma,,,In vivo,1,,4353,A,1969.0,Intermediate,CHEMBL627794,BAO_0000218,9581
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rat after po administration of the compound,1,,,,In vivo,1,,4353,A,,Intermediate,CHEMBL627795,BAO_0000218,9582
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rat after po administration of the compound; ND means Not determined,1,,,,In vivo,1,,4353,A,,Intermediate,CHEMBL627796,BAO_0000218,9583
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,1,Plasma,,,In vivo,1,,4353,A,1969.0,Intermediate,CHEMBL875335,BAO_0000218,9584
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,1,Plasma,,,In vivo,1,,4353,A,1969.0,Intermediate,CHEMBL627797,BAO_0000218,9585
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rat i.v.,1,,,,In vivo,1,,5789,A,,Intermediate,CHEMBL627798,BAO_0000218,9586
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rat i.v. at 2 mg/kg concentration,1,,,,In vivo,1,,17686,A,,Intermediate,CHEMBL627799,BAO_0000218,9587
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rats,1,,,,,1,,6495,A,,Intermediate,CHEMBL627800,BAO_0000218,9588
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rats after intravenous administration,1,,,,In vivo,1,,484,A,,Intermediate,CHEMBL627801,BAO_0000218,9589
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rats at the dose of 1.0 mpk by i.v. administration,1,,,,In vivo,1,,6467,A,,Intermediate,CHEMBL627802,BAO_0000218,9590
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rat,1,,,,,1,,6642,A,,Expert,CHEMBL627803,BAO_0000218,9591
,,N,,,50597,10116.0,Rattus norvegicus,Half life was evaluated after intravenous administration to rats,1,,,,In vivo,1,,16367,A,,Intermediate,CHEMBL873820,BAO_0000218,9592
,,N,,,50597,10116.0,Rattus norvegicus,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),1,,,,,1,,1369,A,,Intermediate,CHEMBL627804,BAO_0000218,9593
,,N,,,50597,10116.0,Rattus norvegicus,Half life was evaluated in rat,1,,,,,1,,5472,A,,Intermediate,CHEMBL627805,BAO_0000218,9594
,,N,,,50597,10116.0,Rattus norvegicus,Half life was evaluated in rat,1,,,,,1,,6049,A,,Intermediate,CHEMBL627806,BAO_0000218,9595
,,N,,,50597,10116.0,Rattus norvegicus,Half life was evaluated in rat; Not tested,1,,,,,1,,5472,A,,Intermediate,CHEMBL627107,BAO_0000218,9596
,,N,,,50597,10116.0,Rattus norvegicus,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,1,,,,In vivo,1,,16366,A,,Intermediate,CHEMBL627108,BAO_0000218,9597
,,N,,,50597,10116.0,Rattus norvegicus,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,1,,,,In vivo,1,,11149,A,,Intermediate,CHEMBL627109,BAO_0000218,9598
,,N,,,50597,10116.0,Rattus norvegicus,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,1,Blood,,,In vivo,1,,11149,A,178.0,Intermediate,CHEMBL627110,BAO_0000218,9599
,,U,,,22224,9443.0,Primates,Half life was measured in monkey at dose of 10 mg/kg by po administration,1,,,,In vivo,0,,2891,A,,Intermediate,CHEMBL627111,BAO_0000218,9600
,,U,,,22224,9443.0,Primates,Half life was measured in monkey at dose of 10 mg/kg by po administration,1,,,,In vivo,0,,2891,A,,Intermediate,CHEMBL627112,BAO_0000218,9601
,,U,,,22224,10116.0,Rattus norvegicus,Half life was measured in rat at dose of 30 mg/kg by iv administration,1,,,,In vivo,0,,2891,A,,Intermediate,CHEMBL627113,BAO_0000218,9602
,,U,,,22224,10116.0,Rattus norvegicus,Half life was measured in rat at dose of 30 mg/kg by po administration,1,,,,In vivo,0,,2891,A,,Intermediate,CHEMBL627114,BAO_0000218,9603
,,N,,,50597,10116.0,Rattus norvegicus,Half life (t1/2) was determined,1,,,,,1,,4026,A,,Intermediate,CHEMBL627115,BAO_0000218,9604
,,N,,,50597,10116.0,Rattus norvegicus,Half life period at a dose of 10 uM/kg in rat was determined,1,,,,,1,,4527,A,,Intermediate,CHEMBL627116,BAO_0000218,9605
,,N,,,50597,10116.0,Rattus norvegicus,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,1,,,,In vivo,1,,4527,A,,Intermediate,CHEMBL627117,BAO_0000218,9606
,,N,,,50597,10116.0,Rattus norvegicus,Half life period was determined,1,,,,,1,,5503,A,,Intermediate,CHEMBL627118,BAO_0000218,9607
,,N,,,50597,10116.0,Rattus norvegicus,Half life period after intravenous administration at 20 mpk in rats,1,,,,In vivo,1,,4426,A,,Intermediate,CHEMBL627119,BAO_0000218,9608
,,N,,,50597,10116.0,Rattus norvegicus,Half life period after intravenous administration at 20 mpk in rats; Not performed.,1,,,,In vivo,1,,4426,A,,Intermediate,CHEMBL627120,BAO_0000218,9609
,,N,,,50597,10116.0,Rattus norvegicus,Half life period after intravenous administration in rat,1,,,,In vivo,1,,6109,A,,Intermediate,CHEMBL626922,BAO_0000218,9610
,,N,,,50597,10116.0,Rattus norvegicus,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,,,,In vivo,1,,5654,A,,Intermediate,CHEMBL626923,BAO_0000218,9611
,,N,,,50597,10116.0,Rattus norvegicus,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,,,,In vivo,1,,5654,A,,Intermediate,CHEMBL626924,BAO_0000218,9612
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in 80% rat plasma at 37 degree Centigrade,1,Plasma,,,,1,,4755,A,1969.0,Intermediate,CHEMBL626925,BAO_0000218,9613
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in SD rats,1,,,,,1,,5862,A,,Intermediate,CHEMBL626926,BAO_0000218,9614
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),1,Plasma,,,,1,,1515,A,1969.0,Intermediate,CHEMBL626927,BAO_0000218,9615
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),1,Plasma,,,,1,,1515,A,1969.0,Intermediate,CHEMBL626928,BAO_0000218,9616
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,Plasma,,,,1,,1515,A,1969.0,Intermediate,CHEMBL626929,BAO_0000218,9617
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,Plasma,,,,1,,1515,A,1969.0,Intermediate,CHEMBL626930,BAO_0000218,9618
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in rat,1,,,,,1,,5960,A,,Intermediate,CHEMBL626931,BAO_0000218,9619
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in rat,1,,,,,1,,6103,A,,Intermediate,CHEMBL626932,BAO_0000218,9620
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in rat,1,,,,,1,,6317,A,,Intermediate,CHEMBL626933,BAO_0000218,9621
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in rat after oral administration at 10.5 mg/kg dose,1,,,,In vivo,1,,6644,A,,Intermediate,CHEMBL873826,BAO_0000218,9622
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in rat after oral administration at 11.2 mg/kg dose,1,,,,In vivo,1,,6644,A,,Intermediate,CHEMBL626934,BAO_0000218,9623
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in rat after oral administration at 13 mg/kg dose,1,,,,In vivo,1,,6644,A,,Intermediate,CHEMBL626935,BAO_0000218,9624
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in rat after oral administration at 9.7 mg/kg dose,1,,,,In vivo,1,,6644,A,,Intermediate,CHEMBL626936,BAO_0000218,9625
,,N,,,50597,10116.0,Rattus norvegicus,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,,,,,1,,5974,A,,Intermediate,CHEMBL626937,BAO_0000218,9626
,,N,,,50597,10116.0,Rattus norvegicus,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,1,,,,,1,,6295,A,,Intermediate,CHEMBL625906,BAO_0000218,9627
,,N,,,50597,10116.0,Rattus norvegicus,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,1,,,,,1,,6296,A,,Intermediate,CHEMBL625907,BAO_0000218,9628
,,N,,,50597,10116.0,Rattus norvegicus,PK study was carried to determine AUC (area under curve) value in rat,1,,,,,1,,16427,A,,Intermediate,CHEMBL625908,BAO_0000218,9629
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter AUC after intravenous administration to rats,1,,,,,1,,16367,A,,Intermediate,CHEMBL625909,BAO_0000218,9630
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter AUC after oral administration to rats,1,,,,,1,,16367,A,,Intermediate,CHEMBL625910,BAO_0000218,9631
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,1,,,,,1,,16365,A,,Intermediate,CHEMBL625911,BAO_0000218,9632
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,1,,,,,1,,16365,A,,Intermediate,CHEMBL625912,BAO_0000218,9633
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,1,,,,,1,,16365,A,,Intermediate,CHEMBL626538,BAO_0000218,9634
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,1,,,,,1,,16365,A,,Intermediate,CHEMBL876794,BAO_0000218,9635
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,1,,,,,1,,16365,A,,Intermediate,CHEMBL626539,BAO_0000218,9636
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,1,,,,,1,,16365,A,,Intermediate,CHEMBL626540,BAO_0000218,9637
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,1,,,,,1,,5394,A,,Intermediate,CHEMBL626541,BAO_0000218,9638
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,1,,,,,1,,5394,A,,Intermediate,CHEMBL626542,BAO_0000218,9639
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,1,,,,,1,,2792,A,,Intermediate,CHEMBL626543,BAO_0000218,9640
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,1,,,,,1,,2792,A,,Intermediate,CHEMBL626544,BAO_0000218,9641
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,1,,,,,1,,2792,A,,Intermediate,CHEMBL626545,BAO_0000218,9642
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,1,,,,,1,,2792,A,,Intermediate,CHEMBL626546,BAO_0000218,9643
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter area under curve was reported,1,,,,,1,,5334,A,,Intermediate,CHEMBL626547,BAO_0000218,9644
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (AUC) in rat,1,,,,,1,,4408,A,,Intermediate,CHEMBL626548,BAO_0000218,9645
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,1,,,,,1,,5983,A,,Intermediate,CHEMBL626549,BAO_0000218,9646
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,1,,,,,1,,4397,A,,Intermediate,CHEMBL626550,BAO_0000218,9647
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,1,,,,,1,,4397,A,,Intermediate,CHEMBL626551,BAO_0000218,9648
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property was determined,1,,,,,1,,5491,A,,Intermediate,CHEMBL623777,BAO_0000218,9649
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,1,,,,,1,,5491,A,,Intermediate,CHEMBL623778,BAO_0000218,9650
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,1,,,,,1,,5491,A,,Intermediate,CHEMBL623779,BAO_0000218,9651
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,1,Plasma,,,,1,,4199,A,1969.0,Intermediate,CHEMBL623780,BAO_0000218,9652
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,1,Plasma,,,,1,,4199,A,1969.0,Intermediate,CHEMBL622015,BAO_0000218,9653
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,1,Plasma,,,,1,,4199,A,1969.0,Intermediate,CHEMBL622016,BAO_0000218,9654
,,N,,,50597,10116.0,Rattus norvegicus,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",1,,,,,1,,5173,A,,Intermediate,CHEMBL622017,BAO_0000218,9655
,,N,,,50597,10116.0,Rattus norvegicus,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",1,,,,,1,,5173,A,,Intermediate,CHEMBL622018,BAO_0000218,9656
,,N,,,50597,10116.0,Rattus norvegicus,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",1,,,,,1,,5173,A,,Intermediate,CHEMBL622019,BAO_0000218,9657
,,N,,,50597,10116.0,Rattus norvegicus,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",1,,,,,1,,5173,A,,Intermediate,CHEMBL622020,BAO_0000218,9658
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,1,,,,,1,,16366,A,,Intermediate,CHEMBL622021,BAO_0000218,9659
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,1,,,,,1,,16366,A,,Intermediate,CHEMBL622022,BAO_0000218,9660
,,N,,,50597,10116.0,Rattus norvegicus,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,1,,,,,1,,5327,A,,Intermediate,CHEMBL622023,BAO_0000218,9661
,,N,,,50597,10116.0,Rattus norvegicus,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,1,,,,,1,,6681,A,,Intermediate,CHEMBL622024,BAO_0000218,9662
,,N,,,50597,10116.0,Rattus norvegicus,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),1,,,,,1,,12873,A,,Intermediate,CHEMBL622693,BAO_0000218,9663
,,N,,,50597,10116.0,Rattus norvegicus,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),1,,,,,1,,12873,A,,Intermediate,CHEMBL622694,BAO_0000218,9664
,,N,,,50597,10116.0,Rattus norvegicus,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",1,,,,,1,,6685,A,,Intermediate,CHEMBL622695,BAO_0000218,9665
,,N,,,50597,10116.0,Rattus norvegicus,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",1,,,,,1,,6685,A,,Intermediate,CHEMBL622696,BAO_0000218,9666
,,N,,,50597,10116.0,Rattus norvegicus,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",1,,,,,1,,6685,A,,Intermediate,CHEMBL622697,BAO_0000218,9667
,,N,,,50597,10116.0,Rattus norvegicus,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",1,,,,,1,,6619,A,,Intermediate,CHEMBL622874,BAO_0000218,9668
,,N,,,50597,10116.0,Rattus norvegicus,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",1,,,,,1,,6619,A,,Intermediate,CHEMBL622875,BAO_0000218,9669
,,N,,,50597,10116.0,Rattus norvegicus,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,1,,,,,1,,10363,A,,Intermediate,CHEMBL622876,BAO_0000218,9670
,,N,,,50597,10116.0,Rattus norvegicus,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,1,,,,,1,,4796,A,,Intermediate,CHEMBL622877,BAO_0000218,9671
,,N,,,50597,10116.0,Rattus norvegicus,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,1,,,,,1,,4910,A,,Intermediate,CHEMBL622878,BAO_0000218,9672
,,N,,,50597,10116.0,Rattus norvegicus,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,1,Plasma,,,,1,,4910,A,1969.0,Intermediate,CHEMBL622879,BAO_0000218,9673
,,N,,,50597,10116.0,Rattus norvegicus,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,1,,,,,1,,4839,A,,Intermediate,CHEMBL877602,BAO_0000218,9674
,,N,,,50597,10116.0,Rattus norvegicus,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",1,,,,,1,,15078,A,,Intermediate,CHEMBL622880,BAO_0000218,9675
,,N,,,50597,10116.0,Rattus norvegicus,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",1,,,,,1,,15078,A,,Intermediate,CHEMBL622881,BAO_0000218,9676
,,N,,,50597,10116.0,Rattus norvegicus,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",1,,,,,1,,15078,A,,Intermediate,CHEMBL622882,BAO_0000218,9677
,,N,,,50597,10116.0,Rattus norvegicus,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",1,,,,,1,,15078,A,,Intermediate,CHEMBL622883,BAO_0000218,9678
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",1,Thyroid gland,,,,1,,11450,A,2046.0,Intermediate,CHEMBL622884,BAO_0000218,9679
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",1,Thyroid gland,,,,1,,11450,A,2046.0,Intermediate,CHEMBL622885,BAO_0000218,9680
,,N,,,50597,10116.0,Rattus norvegicus,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,1,,,,,1,,8151,A,,Intermediate,CHEMBL622886,BAO_0000218,9681
,,N,,,50597,10116.0,Rattus norvegicus,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,1,,,,,1,,8151,A,,Intermediate,CHEMBL622887,BAO_0000218,9682
,,N,,,50597,10116.0,Rattus norvegicus,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,1,Urine,,,,1,,8151,A,1088.0,Intermediate,CHEMBL622888,BAO_0000218,9683
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Blood,,,In vivo,1,,8677,A,178.0,Intermediate,CHEMBL622889,BAO_0000218,9684
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Blood,,,In vivo,1,,8677,A,178.0,Intermediate,CHEMBL622890,BAO_0000218,9685
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Blood,,,In vivo,1,,8677,A,178.0,Intermediate,CHEMBL622891,BAO_0000218,9686
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Blood,,,In vivo,1,,8677,A,178.0,Intermediate,CHEMBL877603,BAO_0000218,9687
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Brain,,,In vivo,1,,8677,A,955.0,Intermediate,CHEMBL622892,BAO_0000218,9688
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Brain,,,In vivo,1,,8677,A,955.0,Intermediate,CHEMBL622893,BAO_0000218,9689
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Brain,,,In vivo,1,,8677,A,955.0,Intermediate,CHEMBL622894,BAO_0000218,9690
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Brain,,,In vivo,1,,8677,A,955.0,Intermediate,CHEMBL622895,BAO_0000218,9691
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,1,Brain,,,In vivo,1,,8677,A,955.0,Intermediate,CHEMBL622896,BAO_0000218,9692
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Heart,,,In vivo,1,,8677,A,948.0,Intermediate,CHEMBL622897,BAO_0000218,9693
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Heart,,,In vivo,1,,8677,A,948.0,Intermediate,CHEMBL622898,BAO_0000218,9694
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Heart,,,In vivo,1,,8677,A,948.0,Intermediate,CHEMBL622899,BAO_0000218,9695
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Kidney,,,In vivo,1,,8677,A,2113.0,Intermediate,CHEMBL622900,BAO_0000218,9696
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Kidney,,,In vivo,1,,8677,A,2113.0,Intermediate,CHEMBL624114,BAO_0000218,9697
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Kidney,,,In vivo,1,,8677,A,2113.0,Intermediate,CHEMBL624115,BAO_0000218,9698
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Kidney,,,In vivo,1,,8677,A,2113.0,Intermediate,CHEMBL624116,BAO_0000218,9699
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Liver,,,In vivo,1,,8677,A,2107.0,Intermediate,CHEMBL624117,BAO_0000218,9700
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Liver,,,In vivo,1,,8677,A,2107.0,Intermediate,CHEMBL624118,BAO_0000218,9701
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Liver,,,In vivo,1,,8677,A,2107.0,Intermediate,CHEMBL624119,BAO_0000218,9702
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Liver,,,In vivo,1,,8677,A,2107.0,Intermediate,CHEMBL624120,BAO_0000218,9703
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Lung,,,In vivo,1,,8677,A,2048.0,Intermediate,CHEMBL624121,BAO_0000218,9704
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Lung,,,In vivo,1,,8677,A,2048.0,Intermediate,CHEMBL624122,BAO_0000218,9705
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Lung,,,In vivo,1,,8677,A,2048.0,Intermediate,CHEMBL624123,BAO_0000218,9706
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Lung,,,In vivo,1,,8677,A,2048.0,Intermediate,CHEMBL624124,BAO_0000218,9707
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Muscle tissue,,,In vivo,1,,8677,A,2385.0,Intermediate,CHEMBL624125,BAO_0000218,9708
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Muscle tissue,,,In vivo,1,,8677,A,2385.0,Intermediate,CHEMBL624126,BAO_0000218,9709
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Muscle tissue,,,In vivo,1,,8677,A,2385.0,Intermediate,CHEMBL624127,BAO_0000218,9710
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Muscle tissue,,,In vivo,1,,8677,A,2385.0,Intermediate,CHEMBL624128,BAO_0000218,9711
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Zone of skin,,,In vivo,1,,8677,A,14.0,Intermediate,CHEMBL624129,BAO_0000218,9712
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Zone of skin,,,In vivo,1,,8677,A,14.0,Intermediate,CHEMBL624130,BAO_0000218,9713
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Zone of skin,,,In vivo,1,,8677,A,14.0,Intermediate,CHEMBL622340,BAO_0000218,9714
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Zone of skin,,,In vivo,1,,8677,A,14.0,Intermediate,CHEMBL622341,BAO_0000218,9715
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Intestine,,,In vivo,1,,8677,A,160.0,Intermediate,CHEMBL622342,BAO_0000218,9716
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Intestine,,,In vivo,1,,8677,A,160.0,Intermediate,CHEMBL622343,BAO_0000218,9717
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Intestine,,,In vivo,1,,8677,A,160.0,Intermediate,CHEMBL622344,BAO_0000218,9718
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Intestine,,,In vivo,1,,8677,A,160.0,Intermediate,CHEMBL622345,BAO_0000218,9719
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Spleen,,,In vivo,1,,8677,A,2106.0,Intermediate,CHEMBL622346,BAO_0000218,9720
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Spleen,,,In vivo,1,,8677,A,2106.0,Intermediate,CHEMBL622347,BAO_0000218,9721
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Spleen,,,In vivo,1,,8677,A,2106.0,Intermediate,CHEMBL622348,BAO_0000218,9722
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Spleen,,,In vivo,1,,8677,A,2106.0,Intermediate,CHEMBL622349,BAO_0000218,9723
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL622350,BAO_0000218,9724
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL622351,BAO_0000218,9725
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL622352,BAO_0000218,9726
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL622353,BAO_0000218,9727
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL622354,BAO_0000218,9728
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL622355,BAO_0000218,9729
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL622356,BAO_0000218,9730
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL622357,BAO_0000218,9731
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL622358,BAO_0000218,9732
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL622359,BAO_0000218,9733
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,,,,1,,16435,A,,Intermediate,CHEMBL874393,BAO_0000218,9734
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,,,,1,,16434,A,,Intermediate,CHEMBL622872,BAO_0000218,9735
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,,,,,1,,16434,A,,Intermediate,CHEMBL622873,BAO_0000218,9736
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,,,,1,,16434,A,,Intermediate,CHEMBL623047,BAO_0000218,9737
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,,,,1,,16435,A,,Intermediate,CHEMBL623048,BAO_0000218,9738
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,,,,1,,16435,A,,Intermediate,CHEMBL623049,BAO_0000218,9739
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,,,,1,,16435,A,,Intermediate,CHEMBL623050,BAO_0000218,9740
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,,,,1,,16435,A,,Intermediate,CHEMBL623051,BAO_0000218,9741
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,,,,1,,16435,A,,Intermediate,CHEMBL623052,BAO_0000218,9742
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,,,,1,,16435,A,,Intermediate,CHEMBL626343,BAO_0000218,9743
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL626344,BAO_0000218,9744
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL626345,BAO_0000218,9745
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,,,,1,,16434,A,,Intermediate,CHEMBL626346,BAO_0000218,9746
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,,,,1,,16434,A,,Intermediate,CHEMBL626347,BAO_0000218,9747
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,,,,,1,,16434,A,,Intermediate,CHEMBL626348,BAO_0000218,9748
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,,,,1,,16434,A,,Intermediate,CHEMBL626349,BAO_0000218,9749
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,,,,1,,16435,F,,Intermediate,CHEMBL626350,BAO_0000218,9750
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,,,,1,,16435,A,,Intermediate,CHEMBL626351,BAO_0000218,9751
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,,,,1,,16435,A,,Intermediate,CHEMBL627650,BAO_0000218,9752
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,,,,1,,16435,F,,Intermediate,CHEMBL627651,BAO_0000218,9753
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,,,,1,,16435,A,,Intermediate,CHEMBL627652,BAO_0000218,9754
,,N,,,50597,10116.0,Rattus norvegicus,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,,,,1,,16435,A,,Intermediate,CHEMBL627653,BAO_0000218,9755
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL627654,BAO_0000218,9756
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL627835,BAO_0000218,9757
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL627836,BAO_0000218,9758
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL627837,BAO_0000218,9759
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL627838,BAO_0000218,9760
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL875338,BAO_0000218,9761
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL627839,BAO_0000218,9762
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL627840,BAO_0000218,9763
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL627841,BAO_0000218,9764
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL627842,BAO_0000218,9765
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL627843,BAO_0000218,9766
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL627844,BAO_0000218,9767
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL627845,BAO_0000218,9768
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in rat by iv administration at a dose of 3 mg/kg,1,,,,In vivo,1,,5874,A,,Intermediate,CHEMBL627846,BAO_0000218,9769
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),1,Plasma,,,,1,,1515,A,1969.0,Intermediate,CHEMBL627847,BAO_0000218,9770
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),1,Plasma,,,,1,,1515,A,1969.0,Intermediate,CHEMBL873821,BAO_0000218,9771
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,Plasma,,,,1,,1515,A,1969.0,Intermediate,CHEMBL626079,BAO_0000218,9772
,,N,,,50597,10116.0,Rattus norvegicus,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,Plasma,,,,1,,1515,A,1969.0,Intermediate,CHEMBL626080,BAO_0000218,9773
,,N,,,50597,10116.0,Rattus norvegicus,Half life period was evaluated in rat plasma,1,Plasma,,,,1,,5491,A,1969.0,Intermediate,CHEMBL626081,BAO_0000218,9774
,,N,,,50597,10116.0,Rattus norvegicus,Half life period was evaluated in rat plasma; Not tested,1,Plasma,,,,1,,5491,A,1969.0,Intermediate,CHEMBL875344,BAO_0000218,9775
,,N,,,50597,10116.0,Rattus norvegicus,Half life period was evaluated in rats,1,,,,,1,,1918,A,,Intermediate,CHEMBL626082,BAO_0000218,9776
,,N,,,50597,10116.0,Rattus norvegicus,"Half life period was evaluated in rats, iv",1,,,,In vivo,1,,1918,A,,Intermediate,CHEMBL626250,BAO_0000218,9777
,,N,,,50597,10116.0,Rattus norvegicus,Half life period after intravenous administration at 5 mg/kg in rat,1,,,,In vivo,1,,6113,A,,Intermediate,CHEMBL626251,BAO_0000218,9778
,,N,,,50597,10116.0,Rattus norvegicus,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,1,,,,In vivo,1,,5546,A,,Intermediate,CHEMBL626252,BAO_0000218,9779
,,N,,,50597,10116.0,Rattus norvegicus,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,1,,,,In vivo,1,,5553,A,,Intermediate,CHEMBL626253,BAO_0000218,9780
,,N,,,50597,10116.0,Rattus norvegicus,Half life stability of compound was evaluated in rat plasma,1,Plasma,,,,1,,4188,A,1969.0,Intermediate,CHEMBL626254,BAO_0000218,9781
,,N,,,50597,10116.0,Rattus norvegicus,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,1,,,,In vivo,1,,6215,A,,Intermediate,CHEMBL626255,BAO_0000218,9782
,,N,,,50597,10116.0,Rattus norvegicus,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,1,,,,In vivo,1,,6141,A,,Intermediate,CHEMBL626256,BAO_0000218,9783
,,N,,,50597,10116.0,Rattus norvegicus,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,1,,,,In vivo,1,,5182,A,,Intermediate,CHEMBL626257,BAO_0000218,9784
,,N,,,50597,10116.0,Rattus norvegicus,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,1,,,,In vivo,1,,5182,A,,Intermediate,CHEMBL626258,BAO_0000218,9785
,,N,,,50597,10116.0,Rattus norvegicus,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,1,,,,In vivo,1,,5710,A,,Intermediate,CHEMBL626259,BAO_0000218,9786
,,N,,,50597,10116.0,Rattus norvegicus,Half in rat i.v.,1,,,,In vivo,1,,5789,A,,Intermediate,CHEMBL626260,BAO_0000218,9787
,,N,,,50597,10116.0,Rattus norvegicus,Half period in rat after intravenous administration,1,,,,In vivo,1,,6011,A,,Intermediate,CHEMBL875345,BAO_0000218,9788
,,N,,,50597,10116.0,Rattus norvegicus,Half-life after repeated oral dose of compound at 1 mg/kg in rats,1,,,,In vivo,1,,17594,A,,Intermediate,CHEMBL626261,BAO_0000218,9789
,,N,,,50597,10116.0,Rattus norvegicus,Half-life measured in in vitro Cathepsin B assay in rat liver,1,Liver,,,In vitro,1,,12357,A,2107.0,Intermediate,CHEMBL626262,BAO_0000218,9790
,,N,,,50597,10116.0,Rattus norvegicus,Half-life of compound was determined in rats,1,,,,,1,,5210,A,,Intermediate,CHEMBL626263,BAO_0000218,9791
,,N,,,50597,10116.0,Rattus norvegicus,Half-life at 10 mg/kg in rat upon intravenous administration,1,,,,In vivo,1,,17596,A,,Intermediate,CHEMBL625270,BAO_0000218,9792
,,N,,,50597,10116.0,Rattus norvegicus,Half-life determined in rat,1,,,,,1,,6672,A,,Intermediate,CHEMBL625271,BAO_0000218,9793
,,N,,,50597,10116.0,Rattus norvegicus,Half-life determined in rat,1,,,,,1,,6673,A,,Intermediate,CHEMBL625272,BAO_0000218,9794
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,1,Brain,,,In vivo,1,,4910,A,955.0,Intermediate,CHEMBL625273,BAO_0000218,9795
,,N,,,50597,10116.0,Rattus norvegicus,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",1,Plasma,,,,1,,3741,A,1969.0,Intermediate,CHEMBL625274,BAO_0000218,9796
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,,,,In vivo,1,,17671,A,,Intermediate,CHEMBL625275,BAO_0000218,9797
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,1,Plasma,,,In vivo,1,,4910,A,1969.0,Intermediate,CHEMBL625276,BAO_0000218,9798
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat plasma,1,Plasma,,,,1,,17537,A,1969.0,Intermediate,CHEMBL625277,BAO_0000218,9799
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat plasma was determined,1,Plasma,,,,1,,4965,A,1969.0,Intermediate,CHEMBL625278,BAO_0000218,9800
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat plasma; Not tested,1,Plasma,,,,1,,17537,A,1969.0,Intermediate,CHEMBL625279,BAO_0000218,9801
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat serum,1,Serum,,,,1,,6124,A,1977.0,Intermediate,CHEMBL625280,BAO_0000218,9802
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat serum; na is not available,1,Serum,,,,1,,6124,A,1977.0,Intermediate,CHEMBL876797,BAO_0000218,9803
,,N,,,50597,10116.0,Rattus norvegicus,Half-life was calculated in rat,1,,,,,1,,6078,A,,Intermediate,CHEMBL625281,BAO_0000218,9804
,,N,,,50597,10116.0,Rattus norvegicus,Half-life was calculated in rat plasma,1,Plasma,,,,1,,17668,A,1969.0,Intermediate,CHEMBL873827,BAO_0000218,9805
,,N,,,50597,10116.0,Rattus norvegicus,Half-life was determined,1,,,,,1,,3185,A,,Intermediate,CHEMBL625282,BAO_0000218,9806
,,N,,,50597,10116.0,Rattus norvegicus,Half-life was determined,1,,,,,1,,4883,A,,Intermediate,CHEMBL625283,BAO_0000218,9807
,,N,,,50597,10116.0,Rattus norvegicus,Half-life after administration of 20 mg/Kg oral dose in rat,1,,,,In vivo,1,,2959,A,,Intermediate,CHEMBL625284,BAO_0000218,9808
,,N,,,50597,10116.0,Rattus norvegicus,Half-life after administration of 3.2 mg/kg intravenously in male rat,1,,,,In vivo,1,,4029,A,,Intermediate,CHEMBL625285,BAO_0000218,9809
,,N,,,50597,10116.0,Rattus norvegicus,Half-life after intravenous administration in female rat,1,,,,In vivo,1,,4029,A,,Intermediate,CHEMBL625286,BAO_0000218,9810
,,N,,,50597,10116.0,Rattus norvegicus,Half-life after intravenous administration in male rat,1,,,,In vivo,1,,4029,A,,Intermediate,CHEMBL625287,BAO_0000218,9811
,,N,,,50597,10116.0,Rattus norvegicus,Half-life after intravenous dose in rat,1,,,,In vivo,1,,6180,A,,Intermediate,CHEMBL625288,BAO_0000218,9812
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in a rat liver homogenate preparation,1,Liver,,,,1,,1557,A,2107.0,Intermediate,CHEMBL625289,BAO_0000218,9813
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in plasma of rat,1,Plasma,,,,1,,12500,A,1969.0,Intermediate,CHEMBL625290,BAO_0000218,9814
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in plasma of rat at dose of 3-10 mgkg,1,Plasma,,,,1,,12500,A,1969.0,Intermediate,CHEMBL876798,BAO_0000218,9815
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat,1,,,,,1,,5064,A,,Intermediate,CHEMBL625291,BAO_0000218,9816
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat,1,,,,,1,,5145,A,,Intermediate,CHEMBL625292,BAO_0000218,9817
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat,1,,,,,1,,5147,A,,Intermediate,CHEMBL625293,BAO_0000218,9818
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat,1,,,,,1,,5833,A,,Intermediate,CHEMBL622832,BAO_0000218,9819
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat,1,,,,,1,,6596,A,,Intermediate,CHEMBL622833,BAO_0000218,9820
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat,1,,,,,1,,17655,A,,Intermediate,CHEMBL622834,BAO_0000218,9821
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat after oral administration at 10 mg/kg,1,,,,In vivo,1,,6495,A,,Intermediate,CHEMBL622835,BAO_0000218,9822
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat after po administration at a dose of 10 mg/kg,1,,,,In vivo,1,,17538,A,,Intermediate,CHEMBL622836,BAO_0000218,9823
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,1,,,,In vivo,1,,17538,A,,Intermediate,CHEMBL622837,BAO_0000218,9824
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat at 3 mg/kg dose administered intravenously,1,,,,In vivo,1,,10,A,,Intermediate,CHEMBL622838,BAO_0000218,9825
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat brain homogenate,1,Brain,,,,1,,17669,A,955.0,Intermediate,CHEMBL622839,BAO_0000218,9826
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat plasma,1,Plasma,,,,1,,17065,A,1969.0,Intermediate,CHEMBL622840,BAO_0000218,9827
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rats,1,,,,,1,,4333,A,,Intermediate,CHEMBL622841,BAO_0000218,9828
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in Dawley rats,1,,,,,1,,6827,A,,Intermediate,CHEMBL622842,BAO_0000218,9829
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in vitro in rat plasma,1,Plasma,,,In vitro,1,,889,A,1969.0,Intermediate,CHEMBL622843,BAO_0000218,9830
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,1,Plasma,,,In vitro,1,,889,A,1969.0,Intermediate,CHEMBL622844,BAO_0000218,9831
,,N,,,50597,10116.0,Rattus norvegicus,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",1,,,,,1,,3747,A,,Intermediate,CHEMBL622845,BAO_0000218,9832
,,N,,,50597,10116.0,Rattus norvegicus,The area under the curve of compound was measured at the dose of 100 umol/kg,1,,,,,1,,15022,A,,Intermediate,CHEMBL622846,BAO_0000218,9833
,,N,,,50597,10116.0,Rattus norvegicus,The area under the curve of compound was measured at the dose of 300 umol/kg,1,,,,,1,,15022,A,,Intermediate,CHEMBL622847,BAO_0000218,9834
,,N,,,50597,10116.0,Rattus norvegicus,The area under the curve of compound was measured at the dose of 30 umol/kg,1,,,,,1,,15022,A,,Intermediate,CHEMBL622848,BAO_0000218,9835
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability as oral AUC in rats,1,,,,In vivo,1,,3360,A,,Intermediate,CHEMBL622849,BAO_0000218,9836
,,N,,,50597,10116.0,Rattus norvegicus,The plasma concentration versus time curve (AUC) was determined,1,Plasma,,,,1,,5334,A,1969.0,Intermediate,CHEMBL622850,BAO_0000218,9837
,,N,,,50597,10116.0,Rattus norvegicus,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,,,,1,,17411,A,,Intermediate,CHEMBL876807,BAO_0000218,9838
,,N,,,50597,10116.0,Rattus norvegicus,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,,,,1,,17411,A,,Intermediate,CHEMBL622851,BAO_0000218,9839
,,N,,,50597,10116.0,Rattus norvegicus,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,,,,1,,17411,A,,Intermediate,CHEMBL622852,BAO_0000218,9840
,,N,,,50597,10116.0,Rattus norvegicus,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,1,,,,,1,,6570,A,,Intermediate,CHEMBL622853,BAO_0000218,9841
,,N,,,50597,10116.0,Rattus norvegicus,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,1,,,,,1,,6570,A,,Intermediate,CHEMBL622854,BAO_0000218,9842
,,N,,,50597,10116.0,Rattus norvegicus,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,,,,1,,17411,A,,Intermediate,CHEMBL622855,BAO_0000218,9843
,,N,,,50597,10116.0,Rattus norvegicus,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",1,Plasma,,,,1,,14941,A,1969.0,Intermediate,CHEMBL622856,BAO_0000218,9844
,,N,,,50597,10116.0,Rattus norvegicus,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",1,Plasma,,,,1,,14941,A,1969.0,Intermediate,CHEMBL622857,BAO_0000218,9845
,,N,,,50597,10116.0,Rattus norvegicus,AUC in rat after po administration at a dose of 10 mg/kg,1,Plasma,,,,1,,17538,A,1969.0,Intermediate,CHEMBL622858,BAO_0000218,9846
,,N,,,50597,10116.0,Rattus norvegicus,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,1,Plasma,,,,1,,17752,A,1969.0,Intermediate,CHEMBL622859,BAO_0000218,9847
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve value 24 hr after 10 mg/kg iv administration in rats,1,,,,,1,,17509,A,,Intermediate,CHEMBL622860,BAO_0000218,9848
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve value 24 hr after 10 mg/kg oral administration in rats,1,,,,,1,,17509,A,,Intermediate,CHEMBL622861,BAO_0000218,9849
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve value 24 hr after 2 mg/kg iv administration in rats,1,,,,,1,,17509,A,,Intermediate,CHEMBL622862,BAO_0000218,9850
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve value 24 hr after 2 mg/kg oral administration in rats,1,,,,,1,,17509,A,,Intermediate,CHEMBL622863,BAO_0000218,9851
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve value 6 hr after po administration in rat,1,,,,,1,,17509,A,,Intermediate,CHEMBL623817,BAO_0000218,9852
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,,,,,1,,17717,A,,Intermediate,CHEMBL623818,BAO_0000218,9853
,,N,,,50597,10116.0,Rattus norvegicus,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",1,,,,,1,,17717,A,,Intermediate,CHEMBL623819,BAO_0000218,9854
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,,,,,1,,17717,A,,Intermediate,CHEMBL623820,BAO_0000218,9855
,,N,,,50597,10116.0,Rattus norvegicus,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,1,,,,,1,,17717,A,,Intermediate,CHEMBL623821,BAO_0000218,9856
,,N,,,50597,10116.0,Rattus norvegicus,AUC normalized for dose (AUCN) in rat,1,Plasma,,,,1,,6642,A,1969.0,Intermediate,CHEMBL623822,BAO_0000218,9857
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve in rat after p.o. administration,1,,,,,1,,6640,A,,Intermediate,CHEMBL623823,BAO_0000218,9858
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve in rat after p.o. administration,1,,,,,1,,6641,A,,Intermediate,CHEMBL623824,BAO_0000218,9859
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve in rat after p.o. administration; Not determined,1,,,,,1,,6641,A,,Intermediate,CHEMBL623825,BAO_0000218,9860
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve in rat after peroral administration,1,,,,,1,,6641,A,,Intermediate,CHEMBL622070,BAO_0000218,9861
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve (carotid artery) value of the compound,1,,,,,1,,3603,A,,Intermediate,CHEMBL622071,BAO_0000218,9862
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability expressed as the area under curve of rat carotid artery,1,,,,,1,,3550,A,,Intermediate,CHEMBL622072,BAO_0000218,9863
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve in male SD rats was observed after intravenous administration in rat,1,,,,,1,,15662,A,,Intermediate,CHEMBL622073,BAO_0000218,9864
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve of the compound was determined,1,,,,,1,,17720,A,,Intermediate,CHEMBL622074,BAO_0000218,9865
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,1,,,,,1,,5407,A,,Intermediate,CHEMBL622075,BAO_0000218,9866
,,N,,,50597,10116.0,Rattus norvegicus,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,1,Plasma,,,,1,,17752,A,1969.0,Intermediate,CHEMBL622076,BAO_0000218,9867
,,N,,,50597,10116.0,Rattus norvegicus,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,1,Plasma,,,,1,,17752,A,1969.0,Intermediate,CHEMBL622077,BAO_0000218,9868
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve (portal vein) value of the compound,1,,,,,1,,3603,A,,Intermediate,CHEMBL622078,BAO_0000218,9869
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability expressed as the area under curve of rat portal vein,1,,,,,1,,3550,A,,Intermediate,CHEMBL622079,BAO_0000218,9870
,,N,,,50597,10116.0,Rattus norvegicus,Area Under plasma concentration time curve in rat upon peroral administration,1,Plasma,,,,1,,17655,A,1969.0,Intermediate,CHEMBL622080,BAO_0000218,9871
,,N,,,50597,10116.0,Rattus norvegicus,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,1,,,,,1,,17582,A,,Intermediate,CHEMBL877612,BAO_0000218,9872
,,N,,,50597,10116.0,Rattus norvegicus,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,1,,,,,1,,17582,A,,Intermediate,CHEMBL622081,BAO_0000218,9873
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for oral bioavailability in rats,1,,,,,1,,17791,A,,Intermediate,CHEMBL622082,BAO_0000218,9874
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for oral bioavailability in rats after iv administration,1,,,,,1,,17791,A,,Intermediate,CHEMBL622083,BAO_0000218,9875
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for oral bioavailability in rats; 30-80,1,,,,,1,,17791,A,,Intermediate,CHEMBL622084,BAO_0000218,9876
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for oral bioavailability in rats; 50-60,1,,,,,1,,17791,A,,Intermediate,CHEMBL622085,BAO_0000218,9877
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for oral bioavailability in rats; no data,1,,,,,1,,17791,A,,Intermediate,CHEMBL622086,BAO_0000218,9878
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for oral bioavailability in rats; peptide,1,,,,,1,,17791,A,,Intermediate,CHEMBL622087,BAO_0000218,9879
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",1,Blood,,,,1,,7768,A,178.0,Intermediate,CHEMBL622088,BAO_0000218,9880
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",1,Blood,,,,1,,7768,A,178.0,Intermediate,CHEMBL622089,BAO_0000218,9881
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",1,Blood,,,,1,,7768,A,178.0,Intermediate,CHEMBL623685,BAO_0000218,9882
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",1,Blood,,,,1,,7768,A,178.0,Intermediate,CHEMBL623686,BAO_0000218,9883
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Stomach,,,In vivo,1,,8677,A,945.0,Intermediate,CHEMBL623687,BAO_0000218,9884
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Stomach,,,In vivo,1,,8677,A,945.0,Intermediate,CHEMBL623688,BAO_0000218,9885
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Stomach,,,In vivo,1,,8677,A,945.0,Intermediate,CHEMBL623689,BAO_0000218,9886
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Stomach,,,In vivo,1,,8677,A,945.0,Intermediate,CHEMBL622485,BAO_0000218,9887
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Thyroid gland,,,In vivo,1,,8677,A,2046.0,Intermediate,CHEMBL622486,BAO_0000218,9888
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Thyroid gland,,,In vivo,1,,8677,A,2046.0,Intermediate,CHEMBL877613,BAO_0000218,9889
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Thyroid gland,,,In vivo,1,,8677,A,2046.0,Intermediate,CHEMBL622487,BAO_0000218,9890
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Thyroid gland,,,In vivo,1,,8677,A,2046.0,Intermediate,CHEMBL622488,BAO_0000218,9891
,,N,,,50597,10116.0,Rattus norvegicus,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Heart,,,In vivo,1,,8677,A,948.0,Intermediate,CHEMBL622489,BAO_0000218,9892
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1,Urine,,,,1,,6899,A,1088.0,Intermediate,CHEMBL622490,BAO_0000218,9893
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,1,Urine,,,,1,,6899,A,1088.0,Intermediate,CHEMBL622491,BAO_0000218,9894
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,1,Liver,,,,1,,6899,A,2107.0,Intermediate,CHEMBL622492,BAO_0000218,9895
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1,Urine,,,,1,,6899,A,1088.0,Intermediate,CHEMBL622493,BAO_0000218,9896
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,1,Urine,,,,1,,6899,A,1088.0,Intermediate,CHEMBL622494,BAO_0000218,9897
,,N,,,50597,10116.0,Rattus norvegicus,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Muscle tissue,,,,1,,8677,A,2385.0,Intermediate,CHEMBL622495,BAO_0000218,9898
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,1,,,,,1,,6899,A,,Intermediate,CHEMBL622496,BAO_0000218,9899
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1,Urine,,,,1,,6899,A,1088.0,Intermediate,CHEMBL622497,BAO_0000218,9900
,,N,,,50597,10116.0,Rattus norvegicus,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,1,,,,,1,,2189,A,,Intermediate,CHEMBL622498,BAO_0000218,9901
,,N,,,50597,10116.0,Rattus norvegicus,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,1,Urine,,,,1,,2189,A,1088.0,Intermediate,CHEMBL624918,BAO_0000218,9902
,,N,,,50597,10116.0,Rattus norvegicus,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,1,Urine,,,,1,,2189,A,1088.0,Intermediate,CHEMBL624919,BAO_0000218,9903
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of compound in rat blood after 5 min of administration,1,Blood,,,In vivo,1,,10839,A,178.0,Intermediate,CHEMBL624920,BAO_0000218,9904
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of compound in rat blood after 5 min of administration.,1,Blood,,,In vivo,1,,10839,A,178.0,Intermediate,CHEMBL624921,BAO_0000218,9905
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of compound in rat brain after 5 min of administration,1,Brain,,,In vivo,1,,10839,A,955.0,Intermediate,CHEMBL624922,BAO_0000218,9906
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of compound in rat heart after 5 min of administration,1,Heart,,,In vivo,1,,10839,A,948.0,Intermediate,CHEMBL624923,BAO_0000218,9907
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of compound in rat heart after 5 min of administration.,1,Heart,,,In vivo,1,,10839,A,948.0,Intermediate,CHEMBL624924,BAO_0000218,9908
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of compound in rat kidney after 5 min of administration,1,Kidney,,,In vivo,1,,10839,A,2113.0,Intermediate,CHEMBL624925,BAO_0000218,9909
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of compound in rat kidney after 5 min of administration.,1,Kidney,,,In vivo,1,,10839,A,2113.0,Intermediate,CHEMBL624926,BAO_0000218,9910
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of compound in rat liver after 5 min of administration,1,Liver,,,In vivo,1,,10839,A,2107.0,Intermediate,CHEMBL624927,BAO_0000218,9911
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of compound in rat liver after 5 min of administration.,1,Liver,,,In vivo,1,,10839,A,2107.0,Intermediate,CHEMBL874402,BAO_0000218,9912
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of compound in rat lung after 5 min of administration,1,Lung,,,In vivo,1,,10839,A,2048.0,Intermediate,CHEMBL624928,BAO_0000218,9913
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of compound in rat lung after 5 min of administration.,1,Lung,,,In vivo,1,,10839,A,2048.0,Intermediate,CHEMBL624929,BAO_0000218,9914
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of compound in rat muscle after 5 min of administration,1,Muscle tissue,,,In vivo,1,,10839,A,2385.0,Intermediate,CHEMBL624930,BAO_0000218,9915
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of compound in rat muscle after 5 min of administration.,1,Muscle tissue,,,In vivo,1,,10839,A,2385.0,Intermediate,CHEMBL624931,BAO_0000218,9916
,,N,,,50597,10116.0,Rattus norvegicus,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,Heart,,,,1,,4043,A,948.0,Intermediate,CHEMBL624932,BAO_0000218,9917
,,N,,,50597,10116.0,Rattus norvegicus,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,Heart,,,,1,,4043,A,948.0,Intermediate,CHEMBL624933,BAO_0000218,9918
,,N,,,50597,10116.0,Rattus norvegicus,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,Liver,,,,1,,4043,A,2107.0,Intermediate,CHEMBL624934,BAO_0000218,9919
,,N,,,50597,10116.0,Rattus norvegicus,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,Liver,,,,1,,4043,A,2107.0,Intermediate,CHEMBL624935,BAO_0000218,9920
,,N,,,50597,10116.0,Rattus norvegicus,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,,,,1,,4043,A,,Intermediate,CHEMBL624936,BAO_0000218,9921
,,N,,,50597,10116.0,Rattus norvegicus,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,,,,1,,4043,A,,Intermediate,CHEMBL624937,BAO_0000218,9922
,,N,,,50597,10116.0,Rattus norvegicus,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,Spleen,,,,1,,4043,A,2106.0,Intermediate,CHEMBL624938,BAO_0000218,9923
,,N,,,50597,10116.0,Rattus norvegicus,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,Spleen,,,,1,,4043,A,2106.0,Intermediate,CHEMBL624939,BAO_0000218,9924
,,N,,,50597,10116.0,Rattus norvegicus,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,,,,1,,4043,A,,Intermediate,CHEMBL624940,BAO_0000218,9925
,,N,,,50597,10116.0,Rattus norvegicus,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,,,,1,,4043,A,,Intermediate,CHEMBL874403,BAO_0000218,9926
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,1,,,,,1,,1446,A,,Intermediate,CHEMBL624941,BAO_0000218,9927
,,N,,,50597,10116.0,Rattus norvegicus,Dose required to lower urine osmolality to 300 mOsm/kg in rat,1,Urine,,,,1,,9971,A,1088.0,Intermediate,CHEMBL624942,BAO_0000218,9928
,,N,,,50597,10116.0,Rattus norvegicus,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,1,Urine,,,,1,,9971,A,1088.0,Intermediate,CHEMBL624943,BAO_0000218,9929
,,N,,,50597,10116.0,Rattus norvegicus,% Bioavailability after 1 day of the drug administration in rats,1,,,,In vivo,1,,5765,A,,Intermediate,CHEMBL624944,BAO_0000218,9930
,,N,,,50597,10116.0,Rattus norvegicus,% Bioavailability after 4 day of the drug administration in rats,1,,,,In vivo,1,,5765,A,,Intermediate,CHEMBL624945,BAO_0000218,9931
,,N,,,50597,10116.0,Rattus norvegicus,Absolute bioavailability was evaluated in rat,1,,,,In vivo,1,,4257,A,,Intermediate,CHEMBL624946,BAO_0000218,9932
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL624947,BAO_0000218,9933
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL624948,BAO_0000218,9934
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL624949,BAO_0000218,9935
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,1,Kidney,,,,1,,13091,A,2113.0,Intermediate,CHEMBL622025,BAO_0000218,9936
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,1,Kidney,,,,1,,13091,A,2113.0,Intermediate,CHEMBL622026,BAO_0000218,9937
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,1,Kidney,,,,1,,13091,A,2113.0,Intermediate,CHEMBL622027,BAO_0000218,9938
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,1,Kidney,,,,1,,13091,A,2113.0,Intermediate,CHEMBL622028,BAO_0000218,9939
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,1,Liver,,,,1,,13091,A,2107.0,Intermediate,CHEMBL622029,BAO_0000218,9940
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,1,Liver,,,,1,,13091,A,2107.0,Intermediate,CHEMBL622208,BAO_0000218,9941
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,1,Liver,,,,1,,13091,A,2107.0,Intermediate,CHEMBL622209,BAO_0000218,9942
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,1,Liver,,,,1,,13091,A,2107.0,Intermediate,CHEMBL622210,BAO_0000218,9943
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL622211,BAO_0000218,9944
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL622212,BAO_0000218,9945
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL622213,BAO_0000218,9946
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL874404,BAO_0000218,9947
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,1,Muscle tissue,,,,1,,13091,A,2385.0,Intermediate,CHEMBL620452,BAO_0000218,9948
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,1,Muscle tissue,,,,1,,13091,A,2385.0,Intermediate,CHEMBL620453,BAO_0000218,9949
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,1,Muscle tissue,,,,1,,13091,A,2385.0,Intermediate,CHEMBL620454,BAO_0000218,9950
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,1,Muscle tissue,,,,1,,13091,A,2385.0,Intermediate,CHEMBL624067,BAO_0000218,9951
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL624068,BAO_0000218,9952
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,1,Female gonad,,,,1,,13091,A,992.0,Intermediate,CHEMBL624069,BAO_0000218,9953
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,1,Female gonad,,,,1,,13091,A,992.0,Intermediate,CHEMBL624070,BAO_0000218,9954
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,1,Female gonad,,,,1,,13091,A,992.0,Intermediate,CHEMBL624071,BAO_0000218,9955
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,1,Uterus,,,,1,,13091,A,995.0,Intermediate,CHEMBL624072,BAO_0000218,9956
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,1,Uterus,,,,1,,13091,A,995.0,Intermediate,CHEMBL624073,BAO_0000218,9957
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,1,Uterus,,,,1,,13091,A,995.0,Intermediate,CHEMBL624788,BAO_0000218,9958
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,1,Uterus,,,,1,,13091,A,995.0,Intermediate,CHEMBL624789,BAO_0000218,9959
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL624790,BAO_0000218,9960
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL624791,BAO_0000218,9961
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL624792,BAO_0000218,9962
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,1,,,,,1,,13091,A,,Intermediate,CHEMBL624793,BAO_0000218,9963
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,1,Muscle tissue,,,,1,,13091,A,2385.0,Intermediate,CHEMBL877491,BAO_0000218,9964
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,1,Muscle tissue,,,,1,,13091,A,2385.0,Intermediate,CHEMBL624957,BAO_0000218,9965
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,1,Muscle tissue,,,,1,,13091,A,2385.0,Intermediate,CHEMBL624958,BAO_0000218,9966
,,N,,,50597,10116.0,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,1,Muscle tissue,,,,1,,13091,A,2385.0,Intermediate,CHEMBL624959,BAO_0000218,9967
,,N,,,50597,10116.0,Rattus norvegicus,Dissociation constant was determined,1,,,,,1,,11977,A,,Intermediate,CHEMBL624960,BAO_0000218,9968
,,N,,,50597,10116.0,Rattus norvegicus,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",1,,,,,1,,14941,A,,Intermediate,CHEMBL624961,BAO_0000218,9969
,,N,,,50597,10116.0,Rattus norvegicus,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",1,,,,,1,,15078,A,,Intermediate,CHEMBL624962,BAO_0000218,9970
,,N,,,50597,10116.0,Rattus norvegicus,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",1,,,,,1,,15078,A,,Intermediate,CHEMBL624963,BAO_0000218,9971
,,N,,,50597,10116.0,Rattus norvegicus,Observed rate constant in 80% rat plasma at 37 degree Centigrade,1,,,,,1,,4755,A,,Intermediate,CHEMBL624964,BAO_0000218,9972
,,N,,,50597,10116.0,Rattus norvegicus,LogP value was evaluated in the in situ rat gut perfusion assay,1,,,,,1,,589,A,,Intermediate,CHEMBL624965,BAO_0000218,9973
,,N,,,50597,10116.0,Rattus norvegicus,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,,,,In vivo,1,,17582,A,,Intermediate,CHEMBL624966,BAO_0000218,9974
,,N,,,50597,10116.0,Rattus norvegicus,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,1,,,,In vivo,1,,5031,A,,Intermediate,CHEMBL624967,BAO_0000218,9975
,,N,,,50597,10116.0,Rattus norvegicus,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,1,,,,In vivo,1,,17764,A,,Intermediate,CHEMBL624968,BAO_0000218,9976
,,N,,,50597,10116.0,Rattus norvegicus,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,1,,,,,1,,17720,A,,Intermediate,CHEMBL624969,BAO_0000218,9977
,,N,,,50597,10116.0,Rattus norvegicus,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,1,,,,,1,,2862,F,,Expert,CHEMBL624970,BAO_0000218,9978
,,N,,,50597,10116.0,Rattus norvegicus,Half-life was evaluated after 10 uM/kg of intra arterial administration,1,,,,,1,,16423,A,,Intermediate,CHEMBL624971,BAO_0000218,9979
,,N,,,50597,10116.0,Rattus norvegicus,Half-life was evaluated after 20 uM/kg of peroral administration,1,,,,In vivo,1,,16423,A,,Intermediate,CHEMBL624972,BAO_0000218,9980
,,N,,,50597,10116.0,Rattus norvegicus,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,1,,,,In vivo,1,,6005,A,,Intermediate,CHEMBL624973,BAO_0000218,9981
,,N,,,50597,10116.0,Rattus norvegicus,Half-life was evaluated in plasma of rat,1,Plasma,,,,1,,2938,A,1969.0,Intermediate,CHEMBL624974,BAO_0000218,9982
,,N,,,50597,10116.0,Rattus norvegicus,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,1,,,,In vivo,1,,6410,A,,Intermediate,CHEMBL624975,BAO_0000218,9983
,,N,,,50597,10116.0,Rattus norvegicus,Half-life was evaluated in rats at an oral dose of 30 mg/kg,1,,,,In vivo,1,,6410,A,,Intermediate,CHEMBL877492,BAO_0000218,9984
,,N,,,50597,10116.0,Rattus norvegicus,Half-life was measured in rat after an iv dose of 1 mg/kg,1,,,,In vivo,1,,6062,A,,Intermediate,CHEMBL624976,BAO_0000218,9985
,,N,,,50597,10116.0,Rattus norvegicus,Half-life period of compound in rats after peroral administration,1,,,,In vivo,1,,6571,A,,Intermediate,CHEMBL624977,BAO_0000218,9986
,,N,,,50597,10116.0,Rattus norvegicus,Half-life period of compound was measured in rat plasma.,1,Plasma,,,,1,,3136,A,1969.0,Intermediate,CHEMBL626848,BAO_0000218,9987
,,N,,,50597,10116.0,Rattus norvegicus,Half-life period of compound was measured in rat plasma; ND is not determined,1,Plasma,,,,1,,3136,A,1969.0,Intermediate,CHEMBL626849,BAO_0000218,9988
,,N,,,50597,10116.0,Rattus norvegicus,Half-life period of compound was measured in rat plasma; not determined,1,Plasma,,,,1,,3136,A,1969.0,Intermediate,CHEMBL626850,BAO_0000218,9989
,,N,,,50597,10116.0,Rattus norvegicus,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,,,,In vivo,1,,4521,A,,Intermediate,CHEMBL626851,BAO_0000218,9990
,,N,,,50597,10116.0,Rattus norvegicus,Half-life period in rat by iv administration,1,,,,In vivo,1,,5871,A,,Intermediate,CHEMBL626852,BAO_0000218,9991
,,N,,,50597,10116.0,Rattus norvegicus,Half-life period in rats following intravenous administration at 2 mg/kg,1,,,,In vivo,1,,6077,A,,Intermediate,CHEMBL626853,BAO_0000218,9992
,,N,,,50597,10116.0,Rattus norvegicus,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,,,In vivo,1,,6679,A,,Intermediate,CHEMBL626854,BAO_0000218,9993
,,N,,,50597,10116.0,Rattus norvegicus,Half-life period was determined for the compound in rat,1,,,,,1,,5144,A,,Intermediate,CHEMBL627486,BAO_0000218,9994
,,N,,,50597,10116.0,Rattus norvegicus,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",1,,,,In vivo,1,,4498,A,,Intermediate,CHEMBL627487,BAO_0000218,9995
,,N,,,50597,10116.0,Rattus norvegicus,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",1,,,,In vivo,1,,4498,A,,Intermediate,CHEMBL627488,BAO_0000218,9996
,,N,,,50597,10116.0,Rattus norvegicus,Half-life value after IV dose at a dose of 5 mg/kg in rats.,1,,,,In vivo,1,,1908,A,,Intermediate,CHEMBL627489,BAO_0000218,9997
,,N,,,50597,10116.0,Rattus norvegicus,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,1,,,,In vivo,1,,6211,A,,Intermediate,CHEMBL627490,BAO_0000218,9998
,,N,,,50597,10116.0,Rattus norvegicus,Half-life was determined in rat after intravenous administration (0.5 mg/kg),1,,,,In vivo,1,,5529,A,,Intermediate,CHEMBL873829,BAO_0000218,9999
,,N,,,50597,10116.0,Rattus norvegicus,Half-life was determined in rat at a dose of 1 mpk i.v.,1,,,,In vivo,1,,6444,A,,Intermediate,CHEMBL627655,BAO_0000218,10000
,,N,,,50597,10116.0,Rattus norvegicus,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,1,,,,In vivo,1,,6444,A,,Intermediate,CHEMBL625994,BAO_0000218,10001
,,N,,,50597,10116.0,Rattus norvegicus,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,1,,,,In vivo,1,,6444,A,,Intermediate,CHEMBL625995,BAO_0000218,10002
,,N,,,50597,10116.0,Rattus norvegicus,Half-life in rat,1,,,,,1,,5207,A,,Intermediate,CHEMBL625996,BAO_0000218,10003
,,N,,,50597,10116.0,Rattus norvegicus,In vitro half life in rat plasma,1,Plasma,,,In vitro,1,,530,A,1969.0,Intermediate,CHEMBL625850,BAO_0000218,10004
,,N,,,50597,10116.0,Rattus norvegicus,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",1,Plasma,,,In vitro,1,,1116,A,1969.0,Intermediate,CHEMBL625851,BAO_0000218,10005
,,N,,,50597,10116.0,Rattus norvegicus,In vitro half life in rat,1,,,,In vitro,1,,3219,A,,Intermediate,CHEMBL625852,BAO_0000218,10006
,,N,,,50597,10116.0,Rattus norvegicus,In vivo half life period after intravenous administration in rat,1,,,,In vivo,1,,6109,A,,Intermediate,CHEMBL625853,BAO_0000218,10007
,,N,,,50597,10116.0,Rattus norvegicus,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,,,,In vivo,1,,17582,A,,Intermediate,CHEMBL625854,BAO_0000218,10008
,,N,,,50597,10116.0,Rattus norvegicus,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,1,,,,In vivo,1,,17582,A,,Intermediate,CHEMBL874450,BAO_0000218,10009
,,N,,,50597,10116.0,Rattus norvegicus,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,,,,In vivo,1,,5974,A,,Intermediate,CHEMBL625855,BAO_0000218,10010
,,N,,,50597,10116.0,Rattus norvegicus,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,,,,In vivo,1,,5974,A,,Intermediate,CHEMBL625856,BAO_0000218,10011
,,N,,,50597,10116.0,Rattus norvegicus,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,,,,In vivo,1,,5974,A,,Intermediate,CHEMBL625857,BAO_0000218,10012
,,N,,,50597,10116.0,Rattus norvegicus,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,,,,In vivo,1,,5974,A,,Intermediate,CHEMBL873831,BAO_0000218,10013
,,N,,,50597,10116.0,Rattus norvegicus,Longer half-life in rat (i.v.) at 0.5 mpk,1,,,,In vivo,1,,17853,A,,Intermediate,CHEMBL625858,BAO_0000218,10014
,,N,,,50597,10116.0,Rattus norvegicus,Longer half-life in rat (p.o.) at 2.0 mpk,1,,,,In vivo,1,,17853,A,,Intermediate,CHEMBL625859,BAO_0000218,10015
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (half life) in rat,1,,,,,1,,3457,A,,Intermediate,CHEMBL625860,BAO_0000218,10016
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,1,,,,In vivo,1,,2792,A,,Intermediate,CHEMBL625861,BAO_0000218,10017
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,1,,,,In vivo,1,,2792,A,,Intermediate,CHEMBL625862,BAO_0000218,10018
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,1,,,,In vivo,1,,2792,A,,Intermediate,CHEMBL625863,BAO_0000218,10019
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,1,,,,In vivo,1,,2792,A,,Intermediate,CHEMBL625864,BAO_0000218,10020
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,1,,,,In vivo,1,,5739,A,,Intermediate,CHEMBL625865,BAO_0000218,10021
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic half time was determined intravenously in rats.,1,,,,In vivo,1,,15765,A,,Intermediate,CHEMBL625866,BAO_0000218,10022
,,N,,,50597,10116.0,Rattus norvegicus,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,1,Plasma,,,In vivo,1,,6567,A,1969.0,Intermediate,CHEMBL625867,BAO_0000218,10023
,,N,,,50597,10116.0,Rattus norvegicus,Plasma half life of hydrolysis of the compound,1,Plasma,,,,1,,2448,A,1969.0,Intermediate,CHEMBL625868,BAO_0000218,10024
,,N,,,50597,10116.0,Rattus norvegicus,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,1,Plasma,,,In vivo,1,,5423,A,1969.0,Intermediate,CHEMBL625869,BAO_0000218,10025
,,N,,,50597,10116.0,Rattus norvegicus,Plasma half life period was calculated in rat,1,Plasma,,,,1,,4853,A,1969.0,Intermediate,CHEMBL874451,BAO_0000218,10026
,,N,,,50597,10116.0,Rattus norvegicus,Plasma half-life in Sprague-Dawley rats,1,Plasma,,,,1,,4514,A,1969.0,Intermediate,CHEMBL625870,BAO_0000218,10027
,,N,,,50597,10116.0,Rattus norvegicus,Plasma half-life in Sprague-Dawley rats; Not determined,1,Plasma,,,,1,,4514,A,1969.0,Intermediate,CHEMBL625871,BAO_0000218,10028
,,N,,,50597,10116.0,Rattus norvegicus,Plasma half-life in rats,1,Plasma,,,,1,,1500,A,1969.0,Intermediate,CHEMBL625872,BAO_0000218,10029
,,N,,,50597,10116.0,Rattus norvegicus,Plasma half-life in rats; <MQL,1,Plasma,,,,1,,1500,A,1969.0,Intermediate,CHEMBL625873,BAO_0000218,10030
,,N,,,50597,10116.0,Rattus norvegicus,Plasma half-life period (0-8 h) was determined,1,Plasma,,,,1,,5334,A,1969.0,Intermediate,CHEMBL625874,BAO_0000218,10031
,,N,,,50597,10116.0,Rattus norvegicus,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,1,Plasma,,,,1,,5334,A,1969.0,Intermediate,CHEMBL625875,BAO_0000218,10032
,,N,,,50597,10116.0,Rattus norvegicus,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,1,Plasma,,,In vivo,1,,5334,A,1969.0,Intermediate,CHEMBL625876,BAO_0000218,10033
,,N,,,50597,10116.0,Rattus norvegicus,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,1,Plasma,,,In vivo,1,,5334,A,1969.0,Intermediate,CHEMBL631258,BAO_0000218,10034
,,N,,,50597,10116.0,Rattus norvegicus,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,1,Plasma,,,,1,,4956,A,1969.0,Intermediate,CHEMBL631259,BAO_0000218,10035
,,N,,,50597,10116.0,Rattus norvegicus,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,1,Plasma,,,,1,,4956,A,1969.0,Intermediate,CHEMBL631260,BAO_0000218,10036
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",1,Blood,,,,1,,7768,A,178.0,Intermediate,CHEMBL631261,BAO_0000218,10037
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",1,Blood,,,,1,,7768,A,178.0,Intermediate,CHEMBL631262,BAO_0000218,10038
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",1,Blood,,,,1,,7768,A,178.0,Intermediate,CHEMBL631263,BAO_0000218,10039
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",1,,,,,1,,7768,A,,Intermediate,CHEMBL631264,BAO_0000218,10040
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",1,,,,,1,,7768,A,,Intermediate,CHEMBL631265,BAO_0000218,10041
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",1,,,,,1,,7768,A,,Intermediate,CHEMBL631266,BAO_0000218,10042
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",1,,,,,1,,7768,A,,Intermediate,CHEMBL631267,BAO_0000218,10043
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",1,,,,,1,,7768,A,,Intermediate,CHEMBL631268,BAO_0000218,10044
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",1,,,,,1,,7768,A,,Intermediate,CHEMBL631269,BAO_0000218,10045
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",1,,,,,1,,7768,A,,Intermediate,CHEMBL631270,BAO_0000218,10046
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",1,Heart,,,,1,,7768,A,948.0,Intermediate,CHEMBL631271,BAO_0000218,10047
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",1,Heart,,,,1,,7768,A,948.0,Intermediate,CHEMBL631272,BAO_0000218,10048
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",1,Heart,,,,1,,7768,A,948.0,Intermediate,CHEMBL631273,BAO_0000218,10049
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",1,Heart,,,,1,,7768,A,948.0,Intermediate,CHEMBL631274,BAO_0000218,10050
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",1,Heart,,,,1,,7768,A,948.0,Intermediate,CHEMBL631275,BAO_0000218,10051
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",1,Heart,,,,1,,7768,A,948.0,Intermediate,CHEMBL626984,BAO_0000218,10052
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",1,Heart,,,,1,,7768,A,948.0,Intermediate,CHEMBL626985,BAO_0000218,10053
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",1,Liver,,,,1,,7768,A,2107.0,Intermediate,CHEMBL626986,BAO_0000218,10054
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",1,Liver,,,,1,,7768,A,2107.0,Intermediate,CHEMBL626987,BAO_0000218,10055
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",1,Liver,,,,1,,7768,A,2107.0,Intermediate,CHEMBL626988,BAO_0000218,10056
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",1,Liver,,,,1,,7768,A,2107.0,Intermediate,CHEMBL626989,BAO_0000218,10057
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",1,Liver,,,,1,,7768,A,2107.0,Intermediate,CHEMBL626990,BAO_0000218,10058
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",1,Liver,,,,1,,7768,A,2107.0,Intermediate,CHEMBL626991,BAO_0000218,10059
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",1,Liver,,,,1,,7768,A,2107.0,Intermediate,CHEMBL626992,BAO_0000218,10060
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",1,Lung,,,,1,,7768,A,2048.0,Intermediate,CHEMBL626993,BAO_0000218,10061
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",1,Lung,,,,1,,7768,A,2048.0,Intermediate,CHEMBL874593,BAO_0000218,10062
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",1,Lung,,,,1,,7768,A,2048.0,Intermediate,CHEMBL626994,BAO_0000218,10063
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",1,Lung,,,,1,,7768,A,2048.0,Intermediate,CHEMBL626995,BAO_0000218,10064
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",1,Lung,,,,1,,7768,A,2048.0,Intermediate,CHEMBL626190,BAO_0000218,10065
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",1,Lung,,,,1,,7768,A,2048.0,Intermediate,CHEMBL626191,BAO_0000218,10066
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",1,Lung,,,,1,,7768,A,2048.0,Intermediate,CHEMBL626364,BAO_0000218,10067
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",1,Thyroid gland,,,,1,,7768,A,2046.0,Intermediate,CHEMBL626365,BAO_0000218,10068
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",1,Thyroid gland,,,,1,,7768,A,2046.0,Intermediate,CHEMBL626366,BAO_0000218,10069
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",1,Thyroid gland,,,,1,,7768,A,2046.0,Intermediate,CHEMBL626367,BAO_0000218,10070
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",1,Thyroid gland,,,,1,,7768,A,2046.0,Intermediate,CHEMBL626368,BAO_0000218,10071
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",1,Thyroid gland,,,,1,,7768,A,2046.0,Intermediate,CHEMBL626369,BAO_0000218,10072
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",1,Thyroid gland,,,,1,,7768,A,2046.0,Intermediate,CHEMBL626370,BAO_0000218,10073
,,N,,,50597,10116.0,Rattus norvegicus,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",1,,,,In vivo,1,,4498,A,,Intermediate,CHEMBL626371,BAO_0000218,10074
,,N,,,50597,10116.0,Rattus norvegicus,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",1,,,,In vivo,1,,4498,A,,Intermediate,CHEMBL626372,BAO_0000218,10075
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability after a dose of 10 mg/kg p.o.,1,,,,In vivo,1,,3603,A,,Intermediate,CHEMBL626373,BAO_0000218,10076
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability after peroral administration (10 mg/kg) was determined in rat,1,,,,In vivo,1,,6215,A,,Intermediate,CHEMBL626374,BAO_0000218,10077
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,1,,,,In vivo,1,,5710,A,,Intermediate,CHEMBL626375,BAO_0000218,10078
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),1,,,,In vivo,1,,5710,A,,Intermediate,CHEMBL626376,BAO_0000218,10079
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat po was determined,1,,,,In vivo,1,,5676,A,,Intermediate,CHEMBL626377,BAO_0000218,10080
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability of compound at 10 mg/kg in rat after oral administration,1,,,,In vivo,1,,17667,A,,Intermediate,CHEMBL626378,BAO_0000218,10081
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,1,,,,In vivo,1,,17667,A,,Intermediate,CHEMBL626379,BAO_0000218,10082
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,,,,In vivo,1,,6848,A,,Intermediate,CHEMBL626380,BAO_0000218,10083
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,,,,In vivo,1,,6848,A,,Intermediate,CHEMBL626381,BAO_0000218,10084
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,17267,A,,Intermediate,CHEMBL626382,BAO_0000218,10085
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (Sprague-Dawley) (female),1,,,,In vivo,1,,6362,A,,Intermediate,CHEMBL626383,BAO_0000218,10086
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,,,,In vivo,1,,17671,A,,Intermediate,CHEMBL874652,BAO_0000218,10087
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),1,,,,In vivo,1,,17671,A,,Intermediate,CHEMBL626384,BAO_0000218,10088
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,1,,,,In vivo,1,,4333,A,,Intermediate,CHEMBL626385,BAO_0000218,10089
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat at an oral dose of 2 mg/kg,1,,,,In vivo,1,,6077,A,,Intermediate,CHEMBL626386,BAO_0000218,10090
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,3278,A,,Intermediate,CHEMBL626387,BAO_0000218,10091
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,5964,A,,Intermediate,CHEMBL626388,BAO_0000218,10092
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,4884,A,,Intermediate,CHEMBL626389,BAO_0000218,10093
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,4905,A,,Intermediate,CHEMBL626390,BAO_0000218,10094
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,1,,,,In vivo,1,,4884,A,,Intermediate,CHEMBL626391,BAO_0000218,10095
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,6850,A,,Intermediate,CHEMBL626392,BAO_0000218,10096
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,2864,A,,Intermediate,CHEMBL626393,BAO_0000218,10097
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability was determined in rat,1,,,,In vivo,1,,5780,A,,Intermediate,CHEMBL623026,BAO_0000218,10098
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability,1,,,,In vivo,1,,1465,A,,Intermediate,CHEMBL623027,BAO_0000218,10099
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability,1,,,,In vivo,1,,5199,A,,Intermediate,CHEMBL623028,BAO_0000218,10100
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat after 1 day dosing,1,,,,In vivo,1,,5765,A,,Intermediate,CHEMBL623029,BAO_0000218,10101
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat after 4 day dosing,1,,,,In vivo,1,,5765,A,,Intermediate,CHEMBL623030,BAO_0000218,10102
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,1,,,,In vivo,1,,6518,A,,Intermediate,CHEMBL623031,BAO_0000218,10103
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability after IV dosing at 1 mg/kg in rat; no data,1,,,,In vivo,1,,6518,A,,Intermediate,CHEMBL623032,BAO_0000218,10104
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability after oral administration at a dose of 2 mg/kg in rat,1,,,,In vivo,1,,6518,A,,Intermediate,CHEMBL623033,BAO_0000218,10105
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability after oral administration at a dose of 4 mg/kg in rat,1,,,,In vivo,1,,6518,A,,Intermediate,CHEMBL623034,BAO_0000218,10106
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,1,,,,In vivo,1,,2083,A,,Intermediate,CHEMBL623035,BAO_0000218,10107
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,,,,In vivo,1,,17260,A,,Intermediate,CHEMBL623036,BAO_0000218,10108
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,,,,In vivo,1,,4956,A,,Intermediate,CHEMBL623037,BAO_0000218,10109
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability by intravenous administration of 3.4 mg/kg in rat,1,,,,In vivo,1,,4368,A,,Intermediate,CHEMBL623038,BAO_0000218,10110
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,1,Plasma,,,In vivo,1,,17752,A,1969.0,Intermediate,CHEMBL874385,BAO_0000218,10111
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (Fisher) (fasted),1,,,,In vivo,1,,1446,A,,Intermediate,CHEMBL623039,BAO_0000218,10112
,,U,,,22224,9443.0,Primates,Bioavailability in monkey after po administration of 10 mg/kg dose,1,,,,In vivo,0,,2891,A,,Intermediate,CHEMBL623040,BAO_0000218,10113
,,U,,,22224,9443.0,Primates,Oral bioavailability in monkey (dose 10 mg/kg),1,,,,In vivo,0,,2891,A,,Intermediate,CHEMBL623041,BAO_0000218,10114
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,6672,A,,Intermediate,CHEMBL623741,BAO_0000218,10115
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,6673,A,,Intermediate,CHEMBL623742,BAO_0000218,10116
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,17655,A,,Intermediate,CHEMBL623743,BAO_0000218,10117
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,17796,A,,Intermediate,CHEMBL623744,BAO_0000218,10118
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (dose 2.0 mg/kg p.o.),1,,,,In vivo,1,,17853,A,,Intermediate,CHEMBL623745,BAO_0000218,10119
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),1,,,,In vivo,1,,4521,A,,Intermediate,CHEMBL623746,BAO_0000218,10120
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose 5 mg/kg p.o.),1,,,,In vivo,1,,4940,A,,Intermediate,CHEMBL623747,BAO_0000218,10121
,,U,,,22224,10116.0,Rattus norvegicus,Bioavailability in rat after po administration of 30 mg/kg dose,1,,,,In vivo,0,,2891,A,,Intermediate,CHEMBL623748,BAO_0000218,10122
,,U,,,22224,10116.0,Rattus norvegicus,Bioavailability in rat after po administration of 30 mg/kg dose,1,,,,In vivo,0,,2891,A,,Intermediate,CHEMBL623916,BAO_0000218,10123
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,,,,In vivo,1,,4521,A,,Intermediate,CHEMBL623917,BAO_0000218,10124
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (dose 2 mg/kg i.v.),1,,,,In vivo,1,,17686,A,,Intermediate,CHEMBL623918,BAO_0000218,10125
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,17796,A,,Intermediate,CHEMBL874386,BAO_0000218,10126
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat; Only traces detected in rat plasma,1,Plasma,,,In vivo,1,,17796,A,1969.0,Intermediate,CHEMBL623919,BAO_0000218,10127
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,5064,A,,Intermediate,CHEMBL623920,BAO_0000218,10128
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability upon oral administration of compound,1,,,,In vivo,1,,5147,A,,Intermediate,CHEMBL623148,BAO_0000218,10129
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),1,,,,In vivo,1,,1916,A,,Intermediate,CHEMBL623149,BAO_0000218,10130
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,6049,A,,Intermediate,CHEMBL623150,BAO_0000218,10131
,,N,,,50597,10116.0,Rattus norvegicus,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",1,,,,In vivo,1,,1445,A,,Intermediate,CHEMBL623151,BAO_0000218,10132
,,N,,,50597,10116.0,Rattus norvegicus,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",1,,,,In vivo,1,,1445,A,,Intermediate,CHEMBL623152,BAO_0000218,10133
,,N,,,50597,10116.0,Rattus norvegicus,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,1,,,,,1,,2862,F,,Expert,CHEMBL623153,BAO_0000218,10134
,,N,,,50597,10116.0,Rattus norvegicus,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,1,,,,,1,,2862,F,,Expert,CHEMBL623154,BAO_0000218,10135
,,N,,,50597,10116.0,Rattus norvegicus,In vitro and metabolic stability was determined,1,,,,,1,,4194,A,,Intermediate,CHEMBL623155,BAO_0000218,10136
,,N,,,50597,10116.0,Rattus norvegicus,In vitro metabolic stability in rat hepatocytes,1,,,,,1,,4194,A,,Intermediate,CHEMBL623156,BAO_0000218,10137
,,N,,,50597,10116.0,Rattus norvegicus,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,1,,,,,1,,5486,A,,Intermediate,CHEMBL623157,BAO_0000218,10138
,,N,401.0,,50597,10116.0,Rattus norvegicus,Metabolic rate for compound was observed in rat hepatocytes,1,Liver,Hepatocyte,,In vitro,1,,17582,A,2107.0,Intermediate,CHEMBL623158,BAO_0000218,10139
,,N,,,50597,10116.0,Rattus norvegicus,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,1,,,,,1,,5600,A,,Intermediate,CHEMBL623159,BAO_0000218,10140
,,N,,,50597,10116.0,Rattus norvegicus,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),1,,,,,1,,14294,A,,Intermediate,CHEMBL874390,BAO_0000218,10141
,,N,,,50597,10116.0,Rattus norvegicus,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),1,,,,,1,,14294,A,,Intermediate,CHEMBL623160,BAO_0000218,10142
,,N,,,50597,10116.0,Rattus norvegicus,Metabolism of compound in rat S9 microsomes; Trace,1,,,,,1,,14294,A,,Intermediate,CHEMBL623161,BAO_0000218,10143
,,N,,,50597,10116.0,Rattus norvegicus,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,1,,,,,1,,17847,A,,Intermediate,CHEMBL623162,BAO_0000218,10144
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,1,,,,,1,,11020,A,,Intermediate,CHEMBL623163,BAO_0000218,10145
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,1,,,,,1,,11020,A,,Intermediate,CHEMBL623164,BAO_0000218,10146
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,1,,,,,1,,11020,A,,Intermediate,CHEMBL623165,BAO_0000218,10147
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,1,,,,,1,,11020,A,,Intermediate,CHEMBL623166,BAO_0000218,10148
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,1,,,,,1,,11020,A,,Intermediate,CHEMBL624983,BAO_0000218,10149
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,1,,,,,1,,11020,A,,Intermediate,CHEMBL624984,BAO_0000218,10150
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,1,,,,,1,,11020,A,,Intermediate,CHEMBL624985,BAO_0000218,10151
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,1,,,,,1,,11020,A,,Intermediate,CHEMBL622970,BAO_0000218,10152
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,1,,,,,1,,11020,A,,Intermediate,CHEMBL622971,BAO_0000218,10153
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,1,,,,,1,,11020,A,,Intermediate,CHEMBL622972,BAO_0000218,10154
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,1,,,,,1,,11020,A,,Intermediate,CHEMBL622973,BAO_0000218,10155
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,1,,,,,1,,11020,A,,Intermediate,CHEMBL622974,BAO_0000218,10156
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,1,,,,,1,,11020,A,,Intermediate,CHEMBL622975,BAO_0000218,10157
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,1,,,,,1,,11020,A,,Intermediate,CHEMBL622976,BAO_0000218,10158
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,1,,,,,1,,11020,A,,Intermediate,CHEMBL622977,BAO_0000218,10159
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,1,,,,,1,,11020,A,,Intermediate,CHEMBL624351,BAO_0000218,10160
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,1,,,,,1,,11020,A,,Intermediate,CHEMBL624352,BAO_0000218,10161
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,1,,,,,1,,11020,A,,Intermediate,CHEMBL624353,BAO_0000218,10162
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,1,,,,,1,,11020,A,,Intermediate,CHEMBL622397,BAO_0000218,10163
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,1,,,,,1,,11020,A,,Intermediate,CHEMBL622398,BAO_0000218,10164
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,1,,,,,1,,11020,A,,Intermediate,CHEMBL622399,BAO_0000218,10165
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,1,,,,,1,,11020,A,,Intermediate,CHEMBL622400,BAO_0000218,10166
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,1,,,,,1,,11020,A,,Intermediate,CHEMBL628428,BAO_0000218,10167
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,1,,,,,1,,11020,A,,Intermediate,CHEMBL628590,BAO_0000218,10168
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,1,,,,,1,,11020,A,,Intermediate,CHEMBL628591,BAO_0000218,10169
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,1,,,,,1,,11020,A,,Intermediate,CHEMBL628592,BAO_0000218,10170
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,1,,,,,1,,11020,A,,Intermediate,CHEMBL628593,BAO_0000218,10171
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,1,,,,,1,,11020,A,,Intermediate,CHEMBL875333,BAO_0000218,10172
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,1,,,,,1,,11020,A,,Intermediate,CHEMBL628594,BAO_0000218,10173
,,N,,,50597,10116.0,Rattus norvegicus,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,1,Plasma,,,,1,,4969,A,1969.0,Intermediate,CHEMBL628595,BAO_0000218,10174
,,N,,,50597,10116.0,Rattus norvegicus,Stability in rat plasma was determined,1,Plasma,,,,1,,6737,A,1969.0,Intermediate,CHEMBL628596,BAO_0000218,10175
,,N,,,50597,10116.0,Rattus norvegicus,Stability in rat plasma was determined; ND= no data,1,Plasma,,,,1,,6737,A,1969.0,Intermediate,CHEMBL628597,BAO_0000218,10176
,,N,,,50597,10116.0,Rattus norvegicus,Tested for plasma half life period in rat (0-8 hr),1,Plasma,,,,1,,5089,A,1969.0,Intermediate,CHEMBL628598,BAO_0000218,10177
,,N,,,50597,10116.0,Rattus norvegicus,Tested for plasma half life period in rat (0-8 hr); Not determined,1,Plasma,,,,1,,5089,A,1969.0,Intermediate,CHEMBL628599,BAO_0000218,10178
,,N,,,50597,10116.0,Rattus norvegicus,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,1,,,,In vivo,1,,1466,A,,Intermediate,CHEMBL628600,BAO_0000218,10179
,,N,,,50597,10116.0,Rattus norvegicus,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,1,,,,In vivo,1,,1466,A,,Intermediate,CHEMBL628601,BAO_0000218,10180
,,N,,,50597,10116.0,Rattus norvegicus,Tested for the half life in rat,1,,,,,1,,4950,A,,Intermediate,CHEMBL628602,BAO_0000218,10181
,,N,,,50597,10116.0,Rattus norvegicus,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,1,,,,In vitro,1,,2412,A,,Intermediate,CHEMBL628603,BAO_0000218,10182
,,N,,,50597,10116.0,Rattus norvegicus,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,1,,,,In vitro,1,,2412,A,,Intermediate,CHEMBL628604,BAO_0000218,10183
,,N,,,50597,10116.0,Rattus norvegicus,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,1,,,,In vitro,1,,2412,A,,Intermediate,CHEMBL628605,BAO_0000218,10184
,,N,,,50597,10116.0,Rattus norvegicus,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,1,,,,In vitro,1,,2412,A,,Intermediate,CHEMBL628606,BAO_0000218,10185
,,N,,,50597,10116.0,Rattus norvegicus,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,1,,,,In vitro,1,,2412,A,,Intermediate,CHEMBL628607,BAO_0000218,10186
,,N,,,50597,10116.0,Rattus norvegicus,The biological half life the compound was measured at the dose of 100 umol/kg,1,,,,,1,,15022,A,,Intermediate,CHEMBL628608,BAO_0000218,10187
,,N,,,50597,10116.0,Rattus norvegicus,The biological half life the compound was measured at the dose of 30 umol/kg,1,,,,,1,,15022,A,,Intermediate,CHEMBL628609,BAO_0000218,10188
,,N,,,50597,10116.0,Rattus norvegicus,The compound was evaluated for plasma half life period in rat,1,Plasma,,,,1,,406,A,1969.0,Intermediate,CHEMBL628610,BAO_0000218,10189
,,N,,,50597,10116.0,Rattus norvegicus,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",1,,,,In vivo,1,,15078,A,,Intermediate,CHEMBL873819,BAO_0000218,10190
,,N,,,50597,10116.0,Rattus norvegicus,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",1,,,,In vivo,1,,15078,A,,Intermediate,CHEMBL628611,BAO_0000218,10191
,,N,,,50597,10116.0,Rattus norvegicus,The pharmacokinetic parameter half-life period in vivo in rats,1,,,,In vivo,1,,5247,A,,Intermediate,CHEMBL628612,BAO_0000218,10192
,,N,,,50597,10116.0,Rattus norvegicus,"The pharmacokinetic property, Half-life was determined",1,,,,In vivo,1,,5041,A,,Intermediate,CHEMBL628613,BAO_0000218,10193
,,N,,,50597,10116.0,Rattus norvegicus,"The pharmacokinetic property, Half-life in rat in vivo",1,,,,In vivo,1,,5041,A,,Intermediate,CHEMBL628614,BAO_0000218,10194
,,N,,,50597,10116.0,Rattus norvegicus,"The pharmacokinetic property, Half-life was determined; ND denotes no data",1,,,,In vivo,1,,5041,A,,Intermediate,CHEMBL628615,BAO_0000218,10195
,,N,,,50597,10116.0,Rattus norvegicus,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",1,,,,In vivo,1,,5041,A,,Intermediate,CHEMBL628616,BAO_0000218,10196
,,N,,,50597,10116.0,Rattus norvegicus,The plasma half life period in rats,1,Plasma,,,,1,,3918,A,1969.0,Intermediate,CHEMBL627924,BAO_0000218,10197
,,N,,,50597,10116.0,Rattus norvegicus,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,1,Liver,,,,1,,2906,A,2107.0,Intermediate,CHEMBL627925,BAO_0000218,10198
,,N,,,50597,10116.0,Rattus norvegicus,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,1,,,,In vivo,1,,6467,A,,Intermediate,CHEMBL627926,BAO_0000218,10199
,,N,,,50597,10116.0,Rattus norvegicus,t1/2 (apparent elimination)of the compound was determined,1,,,,,1,,5510,A,,Intermediate,CHEMBL627927,BAO_0000218,10200
,,N,,,50597,10116.0,Rattus norvegicus,t1/2 value in rat,1,,,,,1,,3788,A,,Intermediate,CHEMBL627928,BAO_0000218,10201
,,N,,,50597,10116.0,Rattus norvegicus,Half life in rat,1,,,,,1,,17796,A,,Intermediate,CHEMBL627539,BAO_0000218,10202
,,N,,,50597,10116.0,Rattus norvegicus,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",1,Plasma,,,In vivo,1,,12873,A,1969.0,Intermediate,CHEMBL876790,BAO_0000218,10203
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,1,,,,In vivo,1,,5983,A,,Intermediate,CHEMBL858186,BAO_0000218,10204
,,N,,,50597,10116.0,Rattus norvegicus,Half-life period in fasted rats,1,,,,,1,,15765,A,,Intermediate,CHEMBL627540,BAO_0000218,10205
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,1,,,,In vivo,1,,2661,A,,Intermediate,CHEMBL627541,BAO_0000218,10206
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,1,,,,In vivo,1,,2661,A,,Intermediate,CHEMBL627715,BAO_0000218,10207
,,N,,,50597,10116.0,Rattus norvegicus,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,1,,,,In vivo,1,,429,A,,Intermediate,CHEMBL627716,BAO_0000218,10208
,,N,,,50597,10116.0,Rattus norvegicus,Maximum time required to achieve Cmax was determined in rat,1,,,,,1,,17655,A,,Intermediate,CHEMBL627717,BAO_0000218,10209
,,N,,,50597,10116.0,Rattus norvegicus,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,,,,In vivo,1,,17717,A,,Intermediate,CHEMBL627718,BAO_0000218,10210
,,N,,,50597,10116.0,Rattus norvegicus,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,,,,In vivo,1,,17717,A,,Intermediate,CHEMBL627719,BAO_0000218,10211
,,N,,,50597,10116.0,Rattus norvegicus,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,1,,,,In vivo,1,,17717,A,,Intermediate,CHEMBL627720,BAO_0000218,10212
,,N,,,50597,10116.0,Rattus norvegicus,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,1,,,,In vivo,1,,6570,A,,Intermediate,CHEMBL627721,BAO_0000218,10213
,,N,,,50597,10116.0,Rattus norvegicus,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,1,,,,In vivo,1,,6570,A,,Intermediate,CHEMBL627722,BAO_0000218,10214
,,N,,,50597,10116.0,Rattus norvegicus,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL627723,BAO_0000218,10215
,,N,,,50597,10116.0,Rattus norvegicus,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL626058,BAO_0000218,10216
,,N,,,50597,10116.0,Rattus norvegicus,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL626059,BAO_0000218,10217
,,N,,,50597,10116.0,Rattus norvegicus,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL626060,BAO_0000218,10218
,,N,,,50597,10116.0,Rattus norvegicus,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,1,Plasma,,,In vivo,1,,17720,A,1969.0,Intermediate,CHEMBL626061,BAO_0000218,10219
,,N,,,50597,10116.0,Rattus norvegicus,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,,,,In vivo,1,,4723,A,,Intermediate,CHEMBL876791,BAO_0000218,10220
,,N,,,50597,10116.0,Rattus norvegicus,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,,,,In vivo,1,,4723,A,,Intermediate,CHEMBL626062,BAO_0000218,10221
,,N,,,50597,10116.0,Rattus norvegicus,Tmax at the dose of 2 mg/Kg administered perorally in rats,1,,,,In vivo,1,,4756,A,,Intermediate,CHEMBL626063,BAO_0000218,10222
,,N,,,50597,10116.0,Rattus norvegicus,Tmax at the dose of 5 mg/Kg administered perorally in rats,1,,,,In vivo,1,,4756,A,,Intermediate,CHEMBL626064,BAO_0000218,10223
,,N,,,50597,10116.0,Rattus norvegicus,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,1,Plasma,,,In vivo,1,,17720,A,1969.0,Intermediate,CHEMBL626065,BAO_0000218,10224
,,N,,,50597,10116.0,Rattus norvegicus,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,1,Plasma,,,In vivo,1,,17720,A,1969.0,Intermediate,CHEMBL626066,BAO_0000218,10225
,,N,,,50597,10116.0,Rattus norvegicus,tmax upon peroral administration of 10.0 mg/Kg dose in rat,1,,,,In vivo,1,,1466,A,,Intermediate,CHEMBL626067,BAO_0000218,10226
,,N,,,50597,10116.0,Rattus norvegicus,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,1,,,,,1,,7449,F,,Intermediate,CHEMBL626068,BAO_0000218,10227
,,N,,,50597,10116.0,Rattus norvegicus,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,1,,,,,1,,7449,F,,Intermediate,CHEMBL626069,BAO_0000218,10228
,,N,,,50597,10116.0,Rattus norvegicus,Percent total excretion of 3-methoxyacetaminophen glucuronide,1,,,,,1,,7449,F,,Intermediate,CHEMBL626070,BAO_0000218,10229
,,N,,,50597,10116.0,Rattus norvegicus,Percent total excretion of N-methoxyacetaminophen glucuronide,1,,,,,1,,7449,F,,Intermediate,CHEMBL626071,BAO_0000218,10230
,,N,,,50597,10116.0,Rattus norvegicus,Percent total excretion of N-methoxyacetaminophen sulfate,1,,,,,1,,7449,F,,Intermediate,CHEMBL626072,BAO_0000218,10231
,,N,,,50597,10116.0,Rattus norvegicus,Percent total excretion of acetaminophen,1,,,,,1,,7449,F,,Intermediate,CHEMBL626073,BAO_0000218,10232
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",1,Thyroid gland,,,,1,,7768,A,2046.0,Intermediate,CHEMBL626741,BAO_0000218,10233
,,N,,,50597,10116.0,Rattus norvegicus,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",1,,,,,1,,17655,A,,Intermediate,CHEMBL626742,BAO_0000218,10234
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,1,,,,,1,,17735,A,,Intermediate,CHEMBL626743,BAO_0000218,10235
,,N,,,50597,10116.0,Rattus norvegicus,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,1,,,,,1,,5960,A,,Intermediate,CHEMBL876792,BAO_0000218,10236
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,1,,,,,1,,17735,A,,Intermediate,CHEMBL626744,BAO_0000218,10237
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for antidiuretic activity in rats,1,,,,,1,,7116,A,,Intermediate,CHEMBL626745,BAO_0000218,10238
,,N,,,50597,10116.0,Rattus norvegicus,AUC in rat after 3mg/kg oral dose,1,Plasma,,,In vivo,1,,4878,A,1969.0,Intermediate,CHEMBL626746,BAO_0000218,10239
,,N,,,50597,10116.0,Rattus norvegicus,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,1,,,,,1,,5939,A,,Intermediate,CHEMBL626747,BAO_0000218,10240
,,N,,,50597,10116.0,Rattus norvegicus,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,1,,,,,1,,5939,A,,Intermediate,CHEMBL626748,BAO_0000218,10241
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability administered orally at a dose of 10 mg/kg to rats,1,,,,,1,,16367,A,,Intermediate,CHEMBL626749,BAO_0000218,10242
,,N,,,50597,10116.0,Rattus norvegicus,Oral Bioavailability was determined,1,,,,,1,,16366,A,,Intermediate,CHEMBL626750,BAO_0000218,10243
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,,1,,4426,A,,Intermediate,CHEMBL626751,BAO_0000218,10244
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat; Not performed.,1,,,,,1,,4426,A,,Intermediate,CHEMBL626913,BAO_0000218,10245
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability,1,,,,,1,,5041,A,,Intermediate,CHEMBL626914,BAO_0000218,10246
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability was determined; ND denotes no data,1,,,,,1,,5041,A,,Intermediate,CHEMBL626915,BAO_0000218,10247
,,N,,,50597,10116.0,Rattus norvegicus,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,1,,,,,1,,1500,A,,Intermediate,CHEMBL626916,BAO_0000218,10248
,,N,,,50597,10116.0,Rattus norvegicus,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,1,,,,,1,,1500,A,,Intermediate,CHEMBL626917,BAO_0000218,10249
,,N,,,50597,10116.0,Rattus norvegicus,Binding towards rat plasma protein at 10 uM,1,,,,,1,,17409,A,,Intermediate,CHEMBL626918,BAO_0000218,10250
,,N,,,50597,10116.0,Rattus norvegicus,Binding towards rat plasma protein at 100 uM,1,,,,,1,,17409,A,,Intermediate,CHEMBL626919,BAO_0000218,10251
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (dose 20 mg/kg p.o.),1,,,,In vivo,1,,2959,A,,Intermediate,CHEMBL626920,BAO_0000218,10252
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,1,,,,In vivo,1,,13501,A,,Intermediate,CHEMBL621976,BAO_0000218,10253
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat after 5 mg/kg oral gavage,1,,,,In vivo,1,,6567,A,,Intermediate,CHEMBL877599,BAO_0000218,10254
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,6571,A,,Intermediate,CHEMBL621977,BAO_0000218,10255
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (dose 1 mg/kg i.v.),1,,,,In vivo,1,,6715,A,,Intermediate,CHEMBL621978,BAO_0000218,10256
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (dose 3 mg/kg p.o.),1,,,,In vivo,1,,6715,A,,Intermediate,CHEMBL621979,BAO_0000218,10257
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,2932,A,,Intermediate,CHEMBL621980,BAO_0000218,10258
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability of the compound in rats after administration of 30 mg/kg,1,,,,In vivo,1,,4171,A,,Intermediate,CHEMBL621981,BAO_0000218,10259
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability after administration of 10 mg/kg in rats,1,,,,In vivo,1,,17509,A,,Intermediate,CHEMBL621982,BAO_0000218,10260
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability after administration of 2 mg/kg in rats,1,,,,In vivo,1,,17509,A,,Intermediate,CHEMBL882953,BAO_0000218,10261
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,1,,,,In vivo,1,,4527,A,,Intermediate,CHEMBL621983,BAO_0000218,10262
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in dogs was determined; high,1,,,,In vivo,1,,4026,A,,Intermediate,CHEMBL621984,BAO_0000218,10263
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in monkey after intravenous administration at 1 mpk,1,,,,In vivo,1,,6659,A,,Intermediate,CHEMBL621985,BAO_0000218,10264
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in monkey after peroral administration at 10 mpk,1,,,,In vivo,1,,6659,A,,Intermediate,CHEMBL621986,BAO_0000218,10265
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat after intravenous administration at 1 mpk,1,,,,In vivo,1,,6659,A,,Intermediate,CHEMBL621987,BAO_0000218,10266
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat after intravenous administration at 2 mpk,1,,,,In vivo,1,,6659,F,,Intermediate,CHEMBL877600,BAO_0000218,10267
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat after peroral administration at 30 mpk,1,,,,In vivo,1,,6659,A,,Intermediate,CHEMBL621988,BAO_0000218,10268
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat after peroral administration at at 100 mpk,1,,,,In vivo,1,,6659,F,,Intermediate,CHEMBL621989,BAO_0000218,10269
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rats was evaluated,1,,,,In vivo,1,,6597,A,,Intermediate,CHEMBL621990,BAO_0000218,10270
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,1,,,,In vivo,1,,1202,A,,Intermediate,CHEMBL621991,BAO_0000218,10271
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,1,,,,In vivo,1,,1202,A,,Intermediate,CHEMBL621992,BAO_0000218,10272
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,1,,,,In vivo,1,,1202,A,,Intermediate,CHEMBL621993,BAO_0000218,10273
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,1,,,,In vivo,1,,1202,A,,Intermediate,CHEMBL621994,BAO_0000218,10274
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,5207,A,,Intermediate,CHEMBL621995,BAO_0000218,10275
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,5970,A,,Intermediate,CHEMBL621996,BAO_0000218,10276
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose 10 mg/kg),1,,,,In vivo,1,,17538,A,,Intermediate,CHEMBL621997,BAO_0000218,10277
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,1,,,,In vivo,1,,17538,A,,Intermediate,CHEMBL621998,BAO_0000218,10278
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,1,,,,In vivo,1,,1466,A,,Intermediate,CHEMBL621999,BAO_0000218,10279
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,2879,A,,Intermediate,CHEMBL622000,BAO_0000218,10280
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability was measured in rat after oral administration; 2-4,1,,,,In vivo,1,,2879,A,,Intermediate,CHEMBL622001,BAO_0000218,10281
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability was measured in rat after oral administration; 3-7,1,,,,In vivo,1,,2879,A,,Intermediate,CHEMBL622002,BAO_0000218,10282
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (intraduodenal administration),1,,,,In vivo,1,,3777,A,,Intermediate,CHEMBL622003,BAO_0000218,10283
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (intraduodenal administration),1,,,,In vivo,1,,3777,A,,Intermediate,CHEMBL877601,BAO_0000218,10284
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,3777,A,,Intermediate,CHEMBL624871,BAO_0000218,10285
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,3777,A,,Intermediate,CHEMBL622004,BAO_0000218,10286
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),1,,,,In vivo,1,,5423,A,,Intermediate,CHEMBL882954,BAO_0000218,10287
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,1,,,,In vivo,1,,16365,A,,Intermediate,CHEMBL622005,BAO_0000218,10288
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,1,,,,In vivo,1,,16365,A,,Intermediate,CHEMBL622006,BAO_0000218,10289
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability was measured in rat,1,,,,In vivo,1,,4239,A,,Intermediate,CHEMBL622007,BAO_0000218,10290
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability was reported,1,,,,In vivo,1,,5438,A,,Intermediate,CHEMBL622008,BAO_0000218,10291
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,,,,In vivo,1,,5334,A,,Intermediate,CHEMBL622009,BAO_0000218,10292
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,,,,In vivo,1,,5334,A,,Intermediate,CHEMBL622010,BAO_0000218,10293
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,1,,,,In vivo,1,,4199,A,,Intermediate,CHEMBL622011,BAO_0000218,10294
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),1,,,,In vivo,1,,4199,A,,Intermediate,CHEMBL622012,BAO_0000218,10295
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),1,,,,In vivo,1,,4199,A,,Intermediate,CHEMBL622013,BAO_0000218,10296
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,,,,In vivo,1,,4890,A,,Intermediate,CHEMBL622014,BAO_0000218,10297
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability was determined at 3 mg/kg po dose in rats,1,,,,In vivo,1,,2792,A,,Intermediate,CHEMBL624749,BAO_0000218,10298
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose 2 mg/kg),1,,,,In vivo,1,,5529,A,,Intermediate,CHEMBL624750,BAO_0000218,10299
,,N,,,50597,10116.0,Rattus norvegicus,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",1,,,,In vivo,1,,6685,A,,Intermediate,CHEMBL624751,BAO_0000218,10300
,,N,,,50597,10116.0,Rattus norvegicus,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",1,,,,In vivo,1,,6685,A,,Intermediate,CHEMBL624752,BAO_0000218,10301
,,N,,,50597,10116.0,Rattus norvegicus,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1,,,,In vivo,1,,6685,A,,Intermediate,CHEMBL624753,BAO_0000218,10302
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,1,,,,In vivo,1,,6005,A,,Intermediate,CHEMBL624754,BAO_0000218,10303
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,1,,,,In vivo,1,,6410,A,,Intermediate,CHEMBL624755,BAO_0000218,10304
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,1,,,,In vivo,1,,6410,A,,Intermediate,CHEMBL624756,BAO_0000218,10305
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,6103,A,,Intermediate,CHEMBL624757,BAO_0000218,10306
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,1,,,,In vivo,1,,6410,A,,Intermediate,CHEMBL624758,BAO_0000218,10307
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,1,,,,In vivo,1,,6410,A,,Intermediate,CHEMBL622270,BAO_0000218,10308
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (Sprague-Dawley),1,,,,In vivo,1,,5353,A,,Intermediate,CHEMBL622271,BAO_0000218,10309
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat at the dose of 2 mg/kg,1,,,,In vivo,1,,4727,A,,Intermediate,CHEMBL622272,BAO_0000218,10310
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,17804,A,,Intermediate,CHEMBL622273,BAO_0000218,10311
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (cannulated) (dose 2 mg/kg),1,,,,In vivo,1,,5809,A,,Intermediate,CHEMBL622274,BAO_0000218,10312
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability value of compound in rats was determined after peroral administration,1,,,,In vivo,1,,17804,A,,Intermediate,CHEMBL622275,BAO_0000218,10313
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose 20 mg/kg),1,,,,In vivo,1,,3634,A,,Intermediate,CHEMBL622276,BAO_0000218,10314
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,3341,A,,Intermediate,CHEMBL622277,BAO_0000218,10315
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose 5 mg/kg),1,,,,In vivo,1,,2690,A,,Intermediate,CHEMBL622278,BAO_0000218,10316
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,3184,A,,Intermediate,CHEMBL622279,BAO_0000218,10317
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,740,A,,Intermediate,CHEMBL622280,BAO_0000218,10318
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for oral bioavailability in rats; 15-27 %,1,,,,In vivo,1,,1806,A,,Intermediate,CHEMBL624083,BAO_0000218,10319
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,1,,,,In vivo,1,,4891,A,,Intermediate,CHEMBL624084,BAO_0000218,10320
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),1,,,,In vivo,1,,3634,A,,Intermediate,CHEMBL624085,BAO_0000218,10321
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for bioavailability in rats,1,,,,In vivo,1,,64,A,,Intermediate,CHEMBL624086,BAO_0000218,10322
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,4839,A,,Intermediate,CHEMBL624087,BAO_0000218,10323
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,1094,A,,Intermediate,CHEMBL624088,BAO_0000218,10324
,,U,,,22224,9544.0,Macaca mulatta,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,1,,,,In vivo,0,,5005,A,,Intermediate,CHEMBL624089,BAO_0000218,10325
,,U,,,22224,10116.0,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,,,,In vivo,0,,5005,A,,Intermediate,CHEMBL624090,BAO_0000218,10326
,,N,,,50597,10116.0,Rattus norvegicus,Evaluated for the bioavailability in rat (in vivo),1,,,,In vivo,1,,4687,A,,Intermediate,CHEMBL624091,BAO_0000218,10327
,,N,,,50597,10116.0,Rattus norvegicus,F value of compound in rats was determined after peroral administration,1,,,,In vivo,1,,17804,A,,Intermediate,CHEMBL624092,BAO_0000218,10328
,,N,,,50597,10116.0,Rattus norvegicus,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,,,,In vivo,1,,5974,A,,Intermediate,CHEMBL624093,BAO_0000218,10329
,,N,,,50597,10116.0,Rattus norvegicus,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,,,,In vivo,1,,5974,A,,Intermediate,CHEMBL624094,BAO_0000218,10330
,,N,,,50597,10116.0,Rattus norvegicus,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,,,,In vivo,1,,5974,A,,Intermediate,CHEMBL624095,BAO_0000218,10331
,,N,,,50597,10116.0,Rattus norvegicus,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,,,,In vivo,1,,5974,A,,Intermediate,CHEMBL624096,BAO_0000218,10332
,,N,,,50597,10116.0,Rattus norvegicus,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",1,,,,In vivo,1,,1088,A,,Intermediate,CHEMBL624097,BAO_0000218,10333
,,N,,,50597,10116.0,Rattus norvegicus,Maximum fall in carotid flow in rat,1,,,,In vivo,1,,1742,A,,Intermediate,CHEMBL624098,BAO_0000218,10334
,,N,,,50597,10116.0,Rattus norvegicus,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,1,,,,In vivo,1,,4689,A,,Intermediate,CHEMBL874392,BAO_0000218,10335
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose 5 mg/kg),1,,,,In vivo,1,,2463,A,,Intermediate,CHEMBL624099,BAO_0000218,10336
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,,,,In vivo,1,,5654,A,,Intermediate,CHEMBL624100,BAO_0000218,10337
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,,,,In vivo,1,,5654,A,,Intermediate,CHEMBL624101,BAO_0000218,10338
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (male Wistar),1,,,,In vivo,1,,6874,A,,Intermediate,CHEMBL624102,BAO_0000218,10339
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability after administration (30 mg/kg) in rat; good,1,,,,In vivo,1,,5633,A,,Intermediate,CHEMBL624103,BAO_0000218,10340
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability at the dose of 2 mg/kg in rat,1,,,,In vivo,1,,5496,A,,Intermediate,CHEMBL624104,BAO_0000218,10341
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability determined in rats,1,,,,In vivo,1,,2358,A,,Intermediate,CHEMBL624105,BAO_0000218,10342
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),1,,,,In vivo,1,,16456,A,,Intermediate,CHEMBL624106,BAO_0000218,10343
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose single 10 mg/kg),1,,,,In vivo,1,,5302,A,,Intermediate,CHEMBL624107,BAO_0000218,10344
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose single 10 mg/kg),1,,,,In vivo,1,,5302,A,,Intermediate,CHEMBL623943,BAO_0000218,10345
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose 5 mg/kg,1,,,,In vivo,1,,5302,A,,Intermediate,CHEMBL623944,BAO_0000218,10346
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,1,,,,,1,,11020,A,,Intermediate,CHEMBL623945,BAO_0000218,10347
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,1,,,,,1,,11020,A,,Intermediate,CHEMBL623946,BAO_0000218,10348
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,1,,,,,1,,11020,A,,Intermediate,CHEMBL623947,BAO_0000218,10349
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,1,,,,,1,,11020,A,,Intermediate,CHEMBL623948,BAO_0000218,10350
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,1,,,,,1,,11020,A,,Intermediate,CHEMBL623949,BAO_0000218,10351
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,1,,,,,1,,11020,A,,Intermediate,CHEMBL623950,BAO_0000218,10352
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,1,,,,,1,,11020,A,,Intermediate,CHEMBL874398,BAO_0000218,10353
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,1,,,,,1,,11020,A,,Intermediate,CHEMBL623951,BAO_0000218,10354
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,1,,,,,1,,11020,A,,Intermediate,CHEMBL623952,BAO_0000218,10355
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,1,,,,,1,,11020,A,,Intermediate,CHEMBL623953,BAO_0000218,10356
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,1,,,,,1,,11020,A,,Intermediate,CHEMBL623954,BAO_0000218,10357
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,1,,,,,1,,11020,A,,Intermediate,CHEMBL623955,BAO_0000218,10358
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,1,,,,,1,,11020,A,,Intermediate,CHEMBL623956,BAO_0000218,10359
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,1,,,,,1,,11020,A,,Intermediate,CHEMBL627807,BAO_0000218,10360
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,1,,,,,1,,11020,A,,Intermediate,CHEMBL627808,BAO_0000218,10361
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,1,,,,,1,,11020,A,,Intermediate,CHEMBL627809,BAO_0000218,10362
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,1,,,,,1,,11020,A,,Intermediate,CHEMBL627810,BAO_0000218,10363
,,N,,,50597,10116.0,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",1,,,,,1,,11020,A,,Intermediate,CHEMBL627811,BAO_0000218,10364
,,N,,,50597,10116.0,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",1,,,,,1,,11020,A,,Intermediate,CHEMBL627812,BAO_0000218,10365
,,N,,,50597,10116.0,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",1,,,,,1,,11020,A,,Intermediate,CHEMBL627813,BAO_0000218,10366
,,N,,,50597,10116.0,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",1,,,,,1,,11020,A,,Intermediate,CHEMBL627814,BAO_0000218,10367
,,N,,,50597,10116.0,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",1,,,,,1,,11020,A,,Intermediate,CHEMBL875336,BAO_0000218,10368
,,N,,,50597,10116.0,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",1,,,,,1,,11020,A,,Intermediate,CHEMBL627815,BAO_0000218,10369
,,N,,,50597,10116.0,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",1,,,,,1,,11020,A,,Intermediate,CHEMBL627816,BAO_0000218,10370
,,N,,,50597,10116.0,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",1,,,,,1,,11020,A,,Intermediate,CHEMBL627817,BAO_0000218,10371
,,N,,,50597,10116.0,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",1,,,,,1,,11020,A,,Intermediate,CHEMBL627818,BAO_0000218,10372
,,N,,,50597,10116.0,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",1,,,,,1,,11020,A,,Intermediate,CHEMBL627819,BAO_0000218,10373
,,N,,,50597,10116.0,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",1,,,,,1,,11020,A,,Intermediate,CHEMBL627820,BAO_0000218,10374
,,N,,,50597,10116.0,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",1,,,,,1,,11020,A,,Intermediate,CHEMBL627821,BAO_0000218,10375
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,1,,,,,1,,11020,A,,Intermediate,CHEMBL628464,BAO_0000218,10376
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,1,,,,,1,,11020,A,,Intermediate,CHEMBL626239,BAO_0000218,10377
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,1,,,,,1,,11020,A,,Intermediate,CHEMBL626240,BAO_0000218,10378
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,1,,,,,1,,11020,A,,Intermediate,CHEMBL626241,BAO_0000218,10379
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,1,,,,,1,,11020,A,,Intermediate,CHEMBL626242,BAO_0000218,10380
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,1,,,,,1,,11020,A,,Intermediate,CHEMBL626243,BAO_0000218,10381
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,1,,,,,1,,11020,A,,Intermediate,CHEMBL626244,BAO_0000218,10382
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,1,,,,,1,,11020,A,,Intermediate,CHEMBL626907,BAO_0000218,10383
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,1,,,,,1,,11020,A,,Intermediate,CHEMBL626908,BAO_0000218,10384
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,1,,,,,1,,11020,A,,Intermediate,CHEMBL626909,BAO_0000218,10385
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,1,,,,,1,,11020,A,,Intermediate,CHEMBL626910,BAO_0000218,10386
,,N,,,50597,10116.0,Rattus norvegicus,Percent total excretion of acetaminophen cysteine conjugate,1,,,,,1,,7449,F,,Intermediate,CHEMBL875342,BAO_0000218,10387
,,N,,,50597,10116.0,Rattus norvegicus,Percent total excretion of acetaminophen glucuronide,1,,,,,1,,7449,F,,Intermediate,CHEMBL626911,BAO_0000218,10388
,,N,,,50597,10116.0,Rattus norvegicus,Percent total excretion of acetaminophen sulfate,1,,,,,1,,7449,F,,Intermediate,CHEMBL626912,BAO_0000218,10389
,,N,,,50597,10116.0,Rattus norvegicus,Percent total excretion of acetaminophen-mercapturic acid,1,,,,,1,,7449,F,,Intermediate,CHEMBL627065,BAO_0000218,10390
,,N,,,50597,10116.0,Rattus norvegicus,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,1,Urine,,,,1,,3172,A,1088.0,Intermediate,CHEMBL627066,BAO_0000218,10391
,,N,,,50597,10116.0,Rattus norvegicus,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,,,,In vivo,1,,16456,A,,Intermediate,CHEMBL627067,BAO_0000218,10392
,,U,,,22224,8656.0,ratrat,Biodistribution of compound in rat muscle after 5 min of administration,1,Muscle tissue,,,In vivo,0,,10839,A,2385.0,Autocuration,CHEMBL627068,BAO_0000218,10393
,,U,,,22224,8656.0,ratrat,Biodistribution of compound in rat muscle after 5 min of administration.,1,Muscle tissue,,,In vivo,0,,10839,A,2385.0,Autocuration,CHEMBL627069,BAO_0000218,10394
,,U,,,22224,9940.0,Ovis aries,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),1,,,,In vivo,0,,5334,A,,Autocuration,CHEMBL627070,BAO_0000218,10395
,,U,,,22224,9940.0,Ovis aries,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),1,,,,In vivo,0,,5334,A,,Autocuration,CHEMBL627071,BAO_0000218,10396
,,U,,,22224,9940.0,Ovis aries,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),1,,,,In vivo,0,,5334,A,,Autocuration,CHEMBL627072,BAO_0000218,10397
,,U,,,22224,9940.0,Ovis aries,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),1,,,,In vivo,0,,5334,A,,Autocuration,CHEMBL627073,BAO_0000218,10398
,,U,,,22224,9940.0,Ovis aries,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),1,,,,In vivo,0,,5334,A,,Autocuration,CHEMBL625387,BAO_0000218,10399
,,U,,,22224,9940.0,Ovis aries,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),1,,,,In vivo,0,,5334,A,,Autocuration,CHEMBL625388,BAO_0000218,10400
,,U,,,22224,9940.0,Ovis aries,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),1,Plasma,,,In vivo,0,,5334,A,1969.0,Autocuration,CHEMBL625389,BAO_0000218,10401
,,U,,,22224,9940.0,Ovis aries,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),1,Plasma,,,In vivo,0,,5334,A,1969.0,Autocuration,CHEMBL875343,BAO_0000218,10402
,,N,,,50497,8570.0,Serpentes,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),1,,,,,1,,1735,A,,Intermediate,CHEMBL876795,BAO_0000218,10403
,,N,,,50497,8570.0,Serpentes,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,1,,,,,1,,1469,A,,Intermediate,CHEMBL626552,BAO_0000218,10404
,,N,,,50497,8570.0,Serpentes,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,1,,,,,1,,1336,A,,Intermediate,CHEMBL626553,BAO_0000218,10405
,,U,,,22224,9606.0,Homo sapiens,The human biological plasma half life of the compound,1,Plasma,,,,0,,12403,A,1969.0,Autocuration,CHEMBL626554,BAO_0000366,10406
,,N,,,50597,10116.0,Rattus norvegicus,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,1,Urine,,,,1,,8151,A,1088.0,Intermediate,CHEMBL626555,BAO_0000218,10407
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,1,,,,,1,,8004,A,,Intermediate,CHEMBL626556,BAO_0000218,10408
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,1,,,,,1,,8004,A,,Intermediate,CHEMBL626557,BAO_0000218,10409
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,1,,,,,1,,8004,A,,Intermediate,CHEMBL626558,BAO_0000218,10410
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,1,,,,,1,,8004,A,,Intermediate,CHEMBL626559,BAO_0000218,10411
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,1,,,,,1,,8004,A,,Intermediate,CHEMBL626560,BAO_0000218,10412
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,1,,,,,1,,8004,A,,Intermediate,CHEMBL876803,BAO_0000218,10413
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,1,,,,,1,,8004,A,,Intermediate,CHEMBL627964,BAO_0000218,10414
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,1,,,,,1,,8004,A,,Intermediate,CHEMBL627965,BAO_0000218,10415
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,1,,,,,1,,8004,A,,Intermediate,CHEMBL627966,BAO_0000218,10416
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,1,,,,,1,,8004,A,,Intermediate,CHEMBL627967,BAO_0000218,10417
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,1,,,,,1,,8004,A,,Intermediate,CHEMBL627968,BAO_0000218,10418
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,1,,,,,1,,8004,A,,Intermediate,CHEMBL627969,BAO_0000218,10419
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,1,,,,,1,,8004,A,,Intermediate,CHEMBL627970,BAO_0000218,10420
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,1,Blood,,,,1,,8004,A,178.0,Intermediate,CHEMBL627971,BAO_0000218,10421
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,1,Blood,,,,1,,8004,A,178.0,Intermediate,CHEMBL627972,BAO_0000218,10422
,,D,,,180,9606.0,Homo sapiens,Dissociation constant against binding to human cyclophilin A,1,,,,,9,,15917,B,,Expert,CHEMBL856029,BAO_0000357,10423
,,H,,,11591,9913.0,Bos taurus,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,1,,,,,8,,12396,B,,Expert,CHEMBL627973,BAO_0000019,10424
,,U,,,22224,,,-Log C was determined by performing the electroshock minimum test,1,,,,,0,,7065,A,,Autocuration,CHEMBL627974,BAO_0000019,10425
,,U,,,22224,,,-Log C was determined by performing the foot shock test,1,,,,,0,,7065,A,,Autocuration,CHEMBL627975,BAO_0000019,10426
,,U,,,22224,,,-Log C was determined by performing the incl screen test,1,,,,,0,,7065,A,,Autocuration,CHEMBL627976,BAO_0000019,10427
,,U,,,22224,,,-Log C was determined by performing the maximum electroshock test,1,,,,,0,,7065,A,,Autocuration,CHEMBL627977,BAO_0000019,10428
,,U,,,22224,,,-Log C was determined by performing the pentylenetetrazole test,1,,,,,0,,7065,A,,Autocuration,CHEMBL627978,BAO_0000019,10429
,,U,,,22224,,,Tested for experimental arotinoid inhibitory dose,1,,,,,0,,12415,A,,Autocuration,CHEMBL627979,BAO_0000019,10430
,,U,,,22224,,,Negative log transformed activity,1,,,,,0,,10256,A,,Autocuration,CHEMBL876804,BAO_0000019,10431
,,U,,,22224,,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",1,,,,,0,,7991,A,,Autocuration,CHEMBL627980,BAO_0000019,10432
,,N,,,50512,10141.0,Cavia porcellus,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,1,,,,,1,,14342,A,,Intermediate,CHEMBL627981,BAO_0000218,10433
,,N,,,50512,10141.0,Cavia porcellus,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,1,,,,,1,,14342,A,,Intermediate,CHEMBL627982,BAO_0000218,10434
,,N,,,50512,10141.0,Cavia porcellus,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,1,,,,,1,,14342,A,,Intermediate,CHEMBL627983,BAO_0000218,10435
,,N,,,50512,10141.0,Cavia porcellus,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,1,Ileum,,,,1,,14342,A,2116.0,Intermediate,CHEMBL627984,BAO_0000218,10436
,,U,,,22229,,,Solubility in water was determined; values expressed as -log,1,,,,,0,,6047,P,,Autocuration,CHEMBL627985,BAO_0000100,10437
,,U,,,22224,,,Ratio of Kcat to that of Km was determined,1,,,,,0,,17269,A,,Autocuration,CHEMBL627986,BAO_0000019,10438
,,U,,,22224,,,Observed first order rate constant,1,,,,,0,,10026,A,,Autocuration,CHEMBL627987,BAO_0000019,10439
,,U,,,22224,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,1,,,,,0,,14583,A,,Autocuration,CHEMBL627988,BAO_0000019,10440
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,1,,,,In vivo,1,,2661,A,,Intermediate,CHEMBL627989,BAO_0000218,10441
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,1,,,,In vivo,1,,2661,A,,Intermediate,CHEMBL627990,BAO_0000218,10442
,,N,,,50597,10116.0,Rattus norvegicus,Oral Bioavailability after administration of 10 mg/kg in male rat,1,,,,In vivo,1,,4029,A,,Intermediate,CHEMBL876805,BAO_0000218,10443
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),1,,,,In vivo,1,,17735,A,,Intermediate,CHEMBL627991,BAO_0000218,10444
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,4576,A,,Intermediate,CHEMBL627992,BAO_0000218,10445
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,1,,,,In vivo,1,,17582,A,,Intermediate,CHEMBL627993,BAO_0000218,10446
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability at 1 mg/kg was determined in rat,1,,,,In vivo,1,,17651,A,,Intermediate,CHEMBL622817,BAO_0000218,10447
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability at 10 mg/kg was determined in rat,1,,,,In vivo,1,,17651,A,,Intermediate,CHEMBL622818,BAO_0000218,10448
,,N,,,50597,10116.0,Rattus norvegicus,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",1,,,,In vivo,1,,17670,A,,Intermediate,CHEMBL622819,BAO_0000218,10449
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,5045,A,,Intermediate,CHEMBL872267,BAO_0000218,10450
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,1696,A,,Intermediate,CHEMBL622820,BAO_0000218,10451
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability after intravenous administration in rats at 24 uM/kg,1,,,,In vivo,1,,17764,A,,Intermediate,CHEMBL622821,BAO_0000218,10452
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,6448,A,,Intermediate,CHEMBL622822,BAO_0000218,10453
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,6596,A,,Intermediate,CHEMBL622823,BAO_0000218,10454
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,17547,A,,Intermediate,CHEMBL622824,BAO_0000218,10455
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat at a dose of 3 mg/kg,1,,,,In vivo,1,,17771,A,,Intermediate,CHEMBL622825,BAO_0000218,10456
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat after oral administration at 10 mg/kg,1,,,,In vivo,1,,6495,A,,Intermediate,CHEMBL622901,BAO_0000218,10457
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,4558,A,,Intermediate,CHEMBL622902,BAO_0000218,10458
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,17596,A,,Intermediate,CHEMBL621844,BAO_0000218,10459
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in Dawley rats,1,,,,In vivo,1,,6827,A,,Intermediate,CHEMBL621845,BAO_0000218,10460
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability,1,,,,In vivo,1,,4026,A,,Intermediate,CHEMBL621846,BAO_0000218,10461
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose 30 mg/kg),1,,,,In vivo,1,,10,A,,Intermediate,CHEMBL621847,BAO_0000218,10462
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,1,,,,In vivo,1,,17717,A,,Intermediate,CHEMBL877609,BAO_0000218,10463
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (dose 3 mg/kg i.v.),1,,,,In vivo,1,,17717,A,,Intermediate,CHEMBL621848,BAO_0000218,10464
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,1,,,,In vivo,1,,17717,A,,Intermediate,CHEMBL621849,BAO_0000218,10465
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose 60 mg/kg p.o.),1,,,,In vivo,1,,17717,A,,Intermediate,CHEMBL622030,BAO_0000218,10466
,,N,,,50597,10116.0,Rattus norvegicus,Percent oral bioavailability determined in rats,1,,,,In vivo,1,,4796,A,,Intermediate,CHEMBL622031,BAO_0000218,10467
,,N,,,50597,10116.0,Rattus norvegicus,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,1,,,,In vivo,1,,4883,A,,Intermediate,CHEMBL622032,BAO_0000218,10468
,,N,,,50597,10116.0,Rattus norvegicus,The compound was evaluated for bioavailability in rats; 32-51,1,,,,In vivo,1,,2137,A,,Intermediate,CHEMBL622033,BAO_0000218,10469
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (dose 20 mg/kg p.o.),1,,,,In vivo,1,,2959,A,,Intermediate,CHEMBL622034,BAO_0000218,10470
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,1361,A,,Intermediate,CHEMBL622035,BAO_0000218,10471
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability percent in rat at the dose of 2 mg/kg,1,,,,In vivo,1,,4727,A,,Intermediate,CHEMBL882966,BAO_0000218,10472
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability was evaluated after 20 uM/kg of peroral administration,1,,,,In vivo,1,,16423,A,,Intermediate,CHEMBL622036,BAO_0000218,10473
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,5206,A,,Intermediate,CHEMBL622037,BAO_0000218,10474
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,6448,A,,Intermediate,CHEMBL622038,BAO_0000218,10475
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rats,1,,,,In vivo,1,,17723,A,,Intermediate,CHEMBL622039,BAO_0000218,10476
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,1,Blood,,,In vivo,1,,17738,A,178.0,Intermediate,CHEMBL622040,BAO_0000218,10477
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,1,Blood,,,In vivo,1,,17738,A,178.0,Intermediate,CHEMBL622041,BAO_0000218,10478
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,1,Blood,,,In vivo,1,,17738,A,178.0,Intermediate,CHEMBL622042,BAO_0000218,10479
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,1,Blood,,,In vivo,1,,17738,A,178.0,Intermediate,CHEMBL622043,BAO_0000218,10480
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,1,Blood,,,In vivo,1,,17738,A,178.0,Intermediate,CHEMBL622044,BAO_0000218,10481
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,1,Bone,,,In vivo,1,,17738,A,10000001.0,Intermediate,CHEMBL622045,BAO_0000218,10482
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,1,Bone,,,In vivo,1,,17738,A,10000001.0,Intermediate,CHEMBL622046,BAO_0000218,10483
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,1,Bone,,,In vivo,1,,17738,A,10000001.0,Intermediate,CHEMBL622047,BAO_0000218,10484
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,1,Bone,,,In vivo,1,,17738,A,10000001.0,Intermediate,CHEMBL877610,BAO_0000218,10485
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,1,Brain,,,In vivo,1,,17738,A,955.0,Intermediate,CHEMBL622048,BAO_0000218,10486
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,1,Brain,,,In vivo,1,,17738,A,955.0,Intermediate,CHEMBL622049,BAO_0000218,10487
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,1,Brain,,,In vivo,1,,17738,A,955.0,Intermediate,CHEMBL622050,BAO_0000218,10488
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,1,Brain,,,In vivo,1,,17738,A,955.0,Intermediate,CHEMBL622051,BAO_0000218,10489
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,1,,,,In vivo,1,,17738,A,,Intermediate,CHEMBL622052,BAO_0000218,10490
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,1,,,,In vivo,1,,17738,A,,Intermediate,CHEMBL622053,BAO_0000218,10491
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,1,,,,In vivo,1,,17738,A,,Intermediate,CHEMBL622054,BAO_0000218,10492
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,1,,,,In vivo,1,,17738,A,,Intermediate,CHEMBL622055,BAO_0000218,10493
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rats was determined; High,1,,,,In vivo,1,,5237,A,,Intermediate,CHEMBL622056,BAO_0000218,10494
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in the rat was determined,1,,,,In vivo,1,,5503,A,,Intermediate,CHEMBL622057,BAO_0000218,10495
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,1,,,,In vivo,1,,15765,A,,Intermediate,CHEMBL628008,BAO_0000218,10496
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),1,,,,In vivo,1,,15660,A,,Intermediate,CHEMBL622058,BAO_0000218,10497
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL622059,BAO_0000218,10498
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL622060,BAO_0000218,10499
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL622061,BAO_0000218,10500
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,,In vivo,1,,5978,A,,Intermediate,CHEMBL622062,BAO_0000218,10501
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,1,,,,In vivo,1,,5656,A,,Intermediate,CHEMBL622063,BAO_0000218,10502
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,1,,,,In vivo,1,,3598,A,,Expert,CHEMBL877611,BAO_0000218,10503
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability of compound in Sprague Dawley rats,1,,,,In vivo,1,,4216,A,,Intermediate,CHEMBL622064,BAO_0000218,10504
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability of compound in rat,1,,,,In vivo,1,,17839,A,,Intermediate,CHEMBL622065,BAO_0000218,10505
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose 2 mg/kg),1,,,,In vivo,1,,6570,A,,Intermediate,CHEMBL622066,BAO_0000218,10506
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability of compound in rat was determined,1,,,,In vivo,1,,5334,A,,Intermediate,CHEMBL622067,BAO_0000218,10507
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability of compound in rats,1,,,,In vivo,1,,6886,A,,Intermediate,CHEMBL622068,BAO_0000218,10508
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability of compound was determined in rats,1,,,,In vivo,1,,5210,A,,Intermediate,CHEMBL622069,BAO_0000218,10509
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability at a dose of 30 mg/kg in rats,1,,,,In vivo,1,,4170,A,,Intermediate,CHEMBL624796,BAO_0000218,10510
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose 10 mg/kg),1,,,,In vivo,1,,6028,A,,Intermediate,CHEMBL624797,BAO_0000218,10511
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose 10 mg/kg),1,,,,In vivo,1,,6028,A,,Intermediate,CHEMBL623053,BAO_0000218,10512
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability evaluated in rat,1,,,,In vivo,1,,6078,A,,Intermediate,CHEMBL623054,BAO_0000218,10513
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in fasted rat,1,,,,In vivo,1,,6168,A,,Intermediate,CHEMBL623055,BAO_0000218,10514
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in fed rat,1,,,,In vivo,1,,6168,A,,Intermediate,CHEMBL623056,BAO_0000218,10515
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (mature male) (dose 30 mg/kg),1,,,,In vivo,1,,5160,A,,Intermediate,CHEMBL623057,BAO_0000218,10516
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,6057,A,,Intermediate,CHEMBL623058,BAO_0000218,10517
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose 10 mg/kg p.o.),1,,,,In vivo,1,,6535,A,,Intermediate,CHEMBL623059,BAO_0000218,10518
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat after administration of 10 mg/kg po,1,,,,In vivo,1,,6535,A,,Intermediate,CHEMBL623060,BAO_0000218,10519
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,4194,A,,Intermediate,CHEMBL623061,BAO_0000218,10520
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,6230,A,,Intermediate,CHEMBL623062,BAO_0000218,10521
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,6619,A,,Intermediate,CHEMBL623063,BAO_0000218,10522
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,17607,A,,Intermediate,CHEMBL623064,BAO_0000218,10523
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in ratrs,1,,,,In vivo,1,,4942,A,,Intermediate,CHEMBL623065,BAO_0000218,10524
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,4942,A,,Intermediate,CHEMBL623066,BAO_0000218,10525
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,6646,A,,Intermediate,CHEMBL623067,BAO_0000218,10526
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rats was determined; High,1,,,,In vivo,1,,5237,A,,Intermediate,CHEMBL623068,BAO_0000218,10527
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,6646,A,,Intermediate,CHEMBL623069,BAO_0000218,10528
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,4449,A,,Intermediate,CHEMBL623070,BAO_0000218,10529
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability was calculated in rat,1,,,,In vivo,1,,6057,A,,Intermediate,CHEMBL623071,BAO_0000218,10530
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability,1,,,,In vivo,1,,2552,A,,Intermediate,CHEMBL623072,BAO_0000218,10531
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability,1,,,,In vivo,1,,5496,A,,Intermediate,CHEMBL623073,BAO_0000218,10532
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability,1,,,,In vivo,1,,6484,A,,Intermediate,CHEMBL623074,BAO_0000218,10533
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability,1,,,,In vivo,1,,6485,A,,Intermediate,CHEMBL623075,BAO_0000218,10534
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability after i.v. administration,1,,,,In vivo,1,,6616,A,,Intermediate,CHEMBL623076,BAO_0000218,10535
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,,,,In vivo,1,,4969,A,,Intermediate,CHEMBL623077,BAO_0000218,10536
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley),1,,,,In vivo,1,,5862,A,,Intermediate,CHEMBL623078,BAO_0000218,10537
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in Sprague-Dawley rats,1,,,,In vivo,1,,4514,A,,Intermediate,CHEMBL623079,BAO_0000218,10538
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,,,,In vivo,1,,4514,A,,Intermediate,CHEMBL623080,BAO_0000218,10539
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,,,,In vivo,1,,4514,A,,Intermediate,CHEMBL623081,BAO_0000218,10540
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,1,,,,In vivo,1,,5546,A,,Intermediate,CHEMBL623082,BAO_0000218,10541
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in fasted rat,1,,,,In vivo,1,,6168,A,,Intermediate,CHEMBL874400,BAO_0000218,10542
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in fed rat,1,,,,In vivo,1,,6168,A,,Intermediate,CHEMBL623083,BAO_0000218,10543
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,3624,A,,Intermediate,CHEMBL623084,BAO_0000218,10544
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,5213,A,,Intermediate,CHEMBL623085,BAO_0000218,10545
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,5496,A,,Intermediate,CHEMBL623086,BAO_0000218,10546
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,5553,A,,Intermediate,CHEMBL623087,BAO_0000218,10547
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,5833,A,,Intermediate,CHEMBL623088,BAO_0000218,10548
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,5836,A,,Intermediate,CHEMBL623089,BAO_0000218,10549
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,5865,A,,Intermediate,CHEMBL623090,BAO_0000218,10550
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,5960,A,,Intermediate,CHEMBL623091,BAO_0000218,10551
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,6249,A,,Intermediate,CHEMBL623092,BAO_0000218,10552
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,6448,A,,Intermediate,CHEMBL623093,BAO_0000218,10553
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,6453,A,,Intermediate,CHEMBL874401,BAO_0000218,10554
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,6640,A,,Intermediate,CHEMBL623094,BAO_0000218,10555
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,17607,A,,Intermediate,CHEMBL623095,BAO_0000218,10556
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat after peroral administration at 10 mg/kg,1,,,,In vivo,1,,5939,A,,Intermediate,CHEMBL623096,BAO_0000218,10557
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat after peroral administration at 5 mg/kg,1,,,,In vivo,1,,5939,A,,Intermediate,CHEMBL624913,BAO_0000218,10558
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),1,,,,In vivo,1,,6281,A,,Intermediate,CHEMBL624914,BAO_0000218,10559
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,1,,,,In vivo,1,,5874,A,,Intermediate,CHEMBL624915,BAO_0000218,10560
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat; Not measured,1,,,,In vivo,1,,5213,A,,Intermediate,CHEMBL624916,BAO_0000218,10561
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,4964,A,,Intermediate,CHEMBL624917,BAO_0000218,10562
,,N,,,50597,10116.0,Rattus norvegicus,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,1,,,,,1,,11020,A,,Intermediate,CHEMBL625157,BAO_0000218,10563
,,N,,,50597,10116.0,Rattus norvegicus,In vitro metabolic potential in rat liver microsomes,1,Liver,,,,1,,6251,A,2107.0,Intermediate,CHEMBL625158,BAO_0000218,10564
,,N,,,50597,10116.0,Rattus norvegicus,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",1,,,,In vivo,1,,1568,A,,Intermediate,CHEMBL625159,BAO_0000218,10565
,,N,,,50597,10116.0,Rattus norvegicus,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",1,,,,In vivo,1,,3032,A,,Intermediate,CHEMBL625160,BAO_0000218,10566
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,1,,,,In vivo,1,,3748,A,,Intermediate,CHEMBL625161,BAO_0000218,10567
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,401,A,,Intermediate,CHEMBL625162,BAO_0000218,10568
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,6512,A,,Intermediate,CHEMBL625163,BAO_0000218,10569
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rats at 10 mg/kg,1,,,,In vivo,1,,17617,A,,Intermediate,CHEMBL625164,BAO_0000218,10570
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,,,In vivo,1,,6679,A,,Intermediate,CHEMBL625165,BAO_0000218,10571
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,6742,A,,Intermediate,CHEMBL625166,BAO_0000218,10572
,,N,,,50597,10116.0,Rattus norvegicus,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,1,,,,,1,,589,A,,Intermediate,CHEMBL625167,BAO_0000218,10573
,,N,,,50597,10116.0,Rattus norvegicus,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,1,,,,,1,,589,A,,Intermediate,CHEMBL625168,BAO_0000218,10574
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance of the compound,1,,,,In vivo,1,,3185,A,,Intermediate,CHEMBL625169,BAO_0000218,10575
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance at 10 mg/kg in rat upon intravenous administration,1,,,,In vivo,1,,17596,A,,Intermediate,CHEMBL626264,BAO_0000218,10576
,,N,,,50597,10116.0,Rattus norvegicus,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,1,,,,In vivo,1,,2713,A,,Intermediate,CHEMBL626265,BAO_0000218,10577
,,N,,,50597,10116.0,Rattus norvegicus,The compound was tested for plasma clearance in rat,1,Plasma,,,In vivo,1,,12500,A,1969.0,Intermediate,CHEMBL626266,BAO_0000218,10578
,,N,,,50597,10116.0,Rattus norvegicus,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,1,Plasma,,,In vivo,1,,12500,A,1969.0,Intermediate,CHEMBL626267,BAO_0000218,10579
,,N,,,50597,10116.0,Rattus norvegicus,Plasma concentration upon oral administration of 1 mg/Kg in rats,1,,,,,1,,2713,A,,Intermediate,CHEMBL626268,BAO_0000218,10580
,,N,,,50597,10116.0,Rattus norvegicus,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,1,,,,,1,,1446,A,,Intermediate,CHEMBL626269,BAO_0000218,10581
,,N,,,50597,10116.0,Rattus norvegicus,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,1,,,,,1,,6227,A,,Intermediate,CHEMBL626270,BAO_0000218,10582
,,N,,,50597,10116.0,Rattus norvegicus,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,1,,,,,1,,4709,A,,Intermediate,CHEMBL626271,BAO_0000218,10583
,,N,,,50597,10116.0,Rattus norvegicus,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",1,,,,,1,,5510,A,,Intermediate,CHEMBL626272,BAO_0000218,10584
,,N,,,50597,10116.0,Rattus norvegicus,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",1,,,,,1,,5510,A,,Intermediate,CHEMBL626273,BAO_0000218,10585
,,N,,,50597,10116.0,Rattus norvegicus,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",1,,,,,1,,5510,A,,Intermediate,CHEMBL875346,BAO_0000218,10586
,,N,,,50597,10116.0,Rattus norvegicus,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",1,,,,,1,,5510,A,,Intermediate,CHEMBL626274,BAO_0000218,10587
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for protein binding in rat plasma,1,,,,,1,,4514,A,,Intermediate,CHEMBL626275,BAO_0000218,10588
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,1,,,,,1,,2713,A,,Intermediate,CHEMBL624646,BAO_0000218,10589
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,1,,,,,1,,2713,A,,Intermediate,CHEMBL624647,BAO_0000218,10590
,,N,,,50597,10116.0,Rattus norvegicus,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,1,Liver,,,,1,,5340,A,2107.0,Intermediate,CHEMBL624648,BAO_0000218,10591
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve ratio was determined (po/iv) in rat,1,,,,,1,,12058,A,,Intermediate,CHEMBL624649,BAO_0000218,10592
,,N,,,50597,10116.0,Rattus norvegicus,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,1,,,,,1,,11195,A,,Intermediate,CHEMBL624650,BAO_0000218,10593
,,N,,,50597,10116.0,Rattus norvegicus,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,1,,,,,1,,11195,A,,Intermediate,CHEMBL624651,BAO_0000218,10594
,,N,,,50597,10116.0,Rattus norvegicus,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,1,,,,,1,,11195,A,,Intermediate,CHEMBL624652,BAO_0000218,10595
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,1,,,,,1,,6495,A,,Intermediate,CHEMBL624653,BAO_0000218,10596
,,N,,,50597,10116.0,Rattus norvegicus,Ratio of AUCbrain to AUCplasma,1,,,,,1,,6078,A,,Intermediate,CHEMBL624654,BAO_0000218,10597
,,N,,,50597,10116.0,Rattus norvegicus,Ratio of brain to plasma,1,,,,,1,,5656,A,,Intermediate,CHEMBL624655,BAO_0000218,10598
,,N,,,50597,10116.0,Rattus norvegicus,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,1,,,,,1,,4910,A,,Intermediate,CHEMBL624656,BAO_0000218,10599
,,N,,,50597,10116.0,Rattus norvegicus,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,1,,,,,1,,4910,A,,Intermediate,CHEMBL624657,BAO_0000218,10600
,,N,,,50597,10116.0,Rattus norvegicus,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,1,,,,,1,,4910,A,,Intermediate,CHEMBL624658,BAO_0000218,10601
,,N,,,50597,10116.0,Rattus norvegicus,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,1,,,,,1,,10130,A,,Intermediate,CHEMBL624659,BAO_0000218,10602
,,N,,,50597,10116.0,Rattus norvegicus,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,1,,,,,1,,10130,A,,Intermediate,CHEMBL624660,BAO_0000218,10603
,,N,,,50597,10116.0,Rattus norvegicus,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,1,,,,,1,,10130,A,,Intermediate,CHEMBL624661,BAO_0000218,10604
,,N,,,50597,10116.0,Rattus norvegicus,Steady state brain :blood ratio was determined,1,,,,,1,,5213,A,,Intermediate,CHEMBL624662,BAO_0000218,10605
,,N,,,50597,10116.0,Rattus norvegicus,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,,,,,1,,4910,A,,Intermediate,CHEMBL625199,BAO_0000218,10606
,,N,,,50597,10116.0,Rattus norvegicus,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,1,,,,,1,,4910,A,,Intermediate,CHEMBL625200,BAO_0000218,10607
,,N,,,50597,10116.0,Rattus norvegicus,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,,,,,1,,4910,A,,Intermediate,CHEMBL625201,BAO_0000218,10608
,,N,,,50597,10116.0,Rattus norvegicus,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,1,,,,,1,,4910,A,,Intermediate,CHEMBL625202,BAO_0000218,10609
,,N,,,50597,10116.0,Rattus norvegicus,Percentage recovery after 3h incubation with rat hapatocytes was determined,1,,,,,1,,2083,A,,Intermediate,CHEMBL625203,BAO_0000218,10610
,,N,,,50597,10116.0,Rattus norvegicus,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,1,,,,,1,,2082,A,,Intermediate,CHEMBL625204,BAO_0000218,10611
,,N,,,50597,10116.0,Rattus norvegicus,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,1,,,,,1,,2082,A,,Intermediate,CHEMBL625205,BAO_0000218,10612
,,N,,,50597,10116.0,Rattus norvegicus,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,1,,,,,1,,6351,A,,Intermediate,CHEMBL625206,BAO_0000218,10613
,,U,,,22224,,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",1,,,,,0,,14583,A,,Autocuration,CHEMBL625207,BAO_0000019,10614
,,U,,,22224,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,1,,,,,0,,14583,A,,Autocuration,CHEMBL625208,BAO_0000019,10615
,,N,495.0,,50587,9606.0,Homo sapiens,In vivo absorption in Caco-2 cell line monolayers was determined,1,,Caco-2,,,1,,4608,A,,Intermediate,CHEMBL625209,BAO_0000218,10616
,,U,,,22229,,,Calculated partition coefficient (clogP),1,,,,,0,,13668,P,,Autocuration,CHEMBL625210,BAO_0000100,10617
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determine after peroral administration at 10 mpk in Rat,1,,,,,1,,5669,A,,Intermediate,CHEMBL625211,BAO_0000218,10618
,,N,,,50797,9544.0,Macaca mulatta,Area under curve was determine after peroral administration at 10 mpk in Rhesus,1,,,,,1,,5669,A,,Intermediate,CHEMBL625212,BAO_0000218,10619
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determine after peroral administration at 160 mpk in Rat,1,,,,,1,,5669,A,,Intermediate,CHEMBL625213,BAO_0000218,10620
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determine after peroral administration at 20 mpk in Rat,1,,,,,1,,5669,A,,Intermediate,CHEMBL625214,BAO_0000218,10621
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve was determine after peroral administration at 50 mpk in Rat,1,,,,,1,,5669,A,,Intermediate,CHEMBL874542,BAO_0000218,10622
,,U,,,22229,,,Calculated partition coefficient (clogP) (AlogP),1,,,,,0,,6472,P,,Autocuration,CHEMBL625215,BAO_0000100,10623
,,U,,,22224,,,Activated partial thromboplastin time measured,1,,,,,0,,15106,A,,Autocuration,CHEMBL625216,BAO_0000019,10624
,,U,,,22224,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),1,,,,,0,,15207,P,,Autocuration,CHEMBL625217,BAO_0000100,10625
,,U,,,22224,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),1,,,,,0,,15207,P,,Autocuration,CHEMBL625218,BAO_0000100,10626
,,N,,,50588,9615.0,Canis lupus familiaris,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,1,Plasma,,,,1,,13941,A,1969.0,Intermediate,CHEMBL622864,BAO_0000218,10627
,,N,,,50597,10116.0,Rattus norvegicus,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,1,Plasma,,,,1,,13941,A,1969.0,Intermediate,CHEMBL622865,BAO_0000218,10628
,,N,,,50597,10116.0,Rattus norvegicus,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,1,Plasma,,,,1,,13941,A,1969.0,Intermediate,CHEMBL622866,BAO_0000218,10629
,,N,,,50588,9615.0,Canis lupus familiaris,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,1,Plasma,,,,1,,13941,A,1969.0,Intermediate,CHEMBL622867,BAO_0000218,10630
,,N,,,50512,10141.0,Cavia porcellus,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,1,Plasma,,,,1,,15240,A,1969.0,Intermediate,CHEMBL876808,BAO_0000218,10631
,,U,,,22224,,,AUC in brain,1,Brain,,,,0,,10655,A,955.0,Autocuration,CHEMBL627725,BAO_0000019,10632
,,U,,,22224,,,AUC in serum,1,Serum,,,,0,,10655,A,1977.0,Autocuration,CHEMBL627726,BAO_0000019,10633
,,U,,,22224,,,AUC was determined,1,Plasma,,,,0,,6504,A,1969.0,Autocuration,CHEMBL627727,BAO_0000019,10634
,,U,,,22224,,,AUC of the compound.,1,Plasma,,,,0,,10615,A,1969.0,Autocuration,CHEMBL627728,BAO_0000019,10635
,,U,,,22224,,,AUC value (0-4 hr),1,Plasma,,,,0,,10353,A,1969.0,Autocuration,CHEMBL627729,BAO_0000019,10636
,,U,,,22224,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",1,Plasma,,,,0,,14907,A,1969.0,Autocuration,CHEMBL627730,BAO_0000019,10637
,,U,,,22224,,,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,1,Plasma,,,,0,,14907,A,1969.0,Autocuration,CHEMBL627731,BAO_0000019,10638
,,U,,,22224,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",1,Plasma,,,,0,,14907,A,1969.0,Autocuration,CHEMBL627732,BAO_0000019,10639
,,U,,,22224,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",1,Plasma,,,,0,,14907,A,1969.0,Autocuration,CHEMBL627733,BAO_0000019,10640
,,N,,,50597,10116.0,Rattus norvegicus,AUC(area under curve) was determined after intravenous administration in rats,1,Plasma,,,,1,,16359,A,1969.0,Intermediate,CHEMBL627734,BAO_0000218,10641
,,N,,,50597,10116.0,Rattus norvegicus,AUC(area under curve) was determined after oral administration in rats,1,Plasma,,,,1,,16359,A,1969.0,Intermediate,CHEMBL627735,BAO_0000218,10642
,,N,,,50512,10141.0,Cavia porcellus,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,1,Plasma,,,,1,,15240,A,1969.0,Intermediate,CHEMBL627736,BAO_0000218,10643
,,N,,,50597,10116.0,Rattus norvegicus,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,1,Plasma,,,,1,,15240,A,1969.0,Intermediate,CHEMBL876809,BAO_0000218,10644
,,U,,,22224,,,Area Under Curve after oral dosing of 100 uM/Kg,1,,,,,0,,15469,A,,Autocuration,CHEMBL627737,BAO_0000019,10645
,,U,,,22224,,,Area Under Curve after oral dosing of 30 uM/Kg,1,,,,,0,,15469,A,,Autocuration,CHEMBL627738,BAO_0000019,10646
,,U,,,22224,,,Area Under Curve was measured by ploting the graph between concentration verses time,1,,,,,0,,13520,A,,Autocuration,CHEMBL627739,BAO_0000019,10647
,,N,,,50588,9615.0,Canis lupus familiaris,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,1,,,,,1,,17025,A,,Intermediate,CHEMBL626143,BAO_0000218,10648
,,U,,,22224,314293.0,Simiiformes,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,1,,,,,0,,17025,A,,Autocuration,CHEMBL626144,BAO_0000218,10649
,,N,,,50592,9986.0,Oryctolagus cuniculus,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,1,,,,,1,,17025,A,,Intermediate,CHEMBL626145,BAO_0000218,10650
,,N,,,50597,10116.0,Rattus norvegicus,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,1,,,,,1,,17025,A,,Intermediate,CHEMBL626146,BAO_0000218,10651
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,1,Blood,,,,1,,12032,A,178.0,Intermediate,CHEMBL626147,BAO_0000218,10652
,,U,,,22224,,,Area under curve (AUC) was determined,1,,,,,0,,10291,A,,Autocuration,CHEMBL626148,BAO_0000019,10653
,,U,,,22224,,,Area under curve (AUC) following ip administration at 1 mg/kg,1,,,,,0,,5767,A,,Autocuration,CHEMBL626149,BAO_0000218,10654
,,U,,,22224,,,Area under curve (AUC) was determined; ND is Not determined,1,,,,,0,,1434,A,,Autocuration,CHEMBL626150,BAO_0000019,10655
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,1,,,,,1,,14925,A,,Intermediate,CHEMBL626151,BAO_0000218,10656
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,1,,,,,1,,14925,A,,Intermediate,CHEMBL626152,BAO_0000218,10657
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,1,,,,,1,,14925,A,,Intermediate,CHEMBL626153,BAO_0000218,10658
,,U,,,22224,,,Area under curve (AUR) was determined,1,,,,,0,,1434,A,,Autocuration,CHEMBL626154,BAO_0000019,10659
,,U,,,22224,,,Area under curve at 1 uM/dg administered intravenously,1,,,,,0,,11883,A,,Autocuration,CHEMBL626155,BAO_0000019,10660
,,U,,,22224,,,Area under curve at 10 uM/dg administered perorally,1,,,,,0,,11883,A,,Autocuration,CHEMBL626156,BAO_0000019,10661
,,U,,,22224,,,Area under curve at 2 uM/dg administered intravenously,1,,,,,0,,11883,A,,Autocuration,CHEMBL626157,BAO_0000019,10662
,,U,,,22224,,,Area under curve at 20 uM/dg administered perorally,1,,,,,0,,11883,A,,Autocuration,CHEMBL626158,BAO_0000019,10663
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve at a peroral dose of 3 mg/kg in dog,1,,,,,1,,15233,A,,Intermediate,CHEMBL626159,BAO_0000218,10664
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve at a peroral dose of 3 mg/kg in rat,1,,,,,1,,15233,A,,Intermediate,CHEMBL626160,BAO_0000218,10665
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve at an iv dose of 1 mg/kg in dog,1,,,,,1,,15233,A,,Intermediate,CHEMBL626161,BAO_0000218,10666
,,N,,,50597,10116.0,Rattus norvegicus,Area under curve at an iv dose of 1 mg/kg in rat,1,,,,,1,,15233,A,,Intermediate,CHEMBL626162,BAO_0000218,10667
,,U,,,22224,,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,1,,,,,0,,12978,A,,Autocuration,CHEMBL626163,BAO_0000019,10668
,,U,,,22224,,,Area under curve gives the effective duration for the angiotensin II antagonist effect.,1,,,,,0,,12978,A,,Autocuration,CHEMBL626164,BAO_0000019,10669
,,N,,,50594,10090.0,Mus musculus,Area under curve measured as conc vs time after intravenous administration to mice.,1,,,,,1,,11355,A,,Intermediate,CHEMBL626165,BAO_0000218,10670
,,N,,,50594,10090.0,Mus musculus,Area under curve measured as conc vs time after peroral administration to mice.,1,,,,,1,,11355,A,,Intermediate,CHEMBL626166,BAO_0000218,10671
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,1,,,,,1,,12923,A,,Intermediate,CHEMBL626167,BAO_0000218,10672
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,1,,,,,1,,12923,A,,Intermediate,CHEMBL626168,BAO_0000218,10673
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,1,,,,,1,,12923,A,,Intermediate,CHEMBL877463,BAO_0000218,10674
,,N,,,50588,9615.0,Canis lupus familiaris,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,1,,,,,1,,12923,A,,Intermediate,CHEMBL626169,BAO_0000218,10675
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,1,Heart,,,In vivo,1,,17738,A,948.0,Intermediate,CHEMBL626170,BAO_0000218,10676
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,1,Heart,,,In vivo,1,,17738,A,948.0,Intermediate,CHEMBL626171,BAO_0000218,10677
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,1,Heart,,,In vivo,1,,17738,A,948.0,Intermediate,CHEMBL626172,BAO_0000218,10678
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,1,Heart,,,In vivo,1,,17738,A,948.0,Intermediate,CHEMBL626173,BAO_0000218,10679
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,1,Kidney,,,In vivo,1,,17738,A,2113.0,Intermediate,CHEMBL626174,BAO_0000218,10680
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,1,Kidney,,,In vivo,1,,17738,A,2113.0,Intermediate,CHEMBL626175,BAO_0000218,10681
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,1,Kidney,,,In vivo,1,,17738,A,2113.0,Intermediate,CHEMBL626176,BAO_0000218,10682
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,1,Kidney,,,In vivo,1,,17738,A,2113.0,Intermediate,CHEMBL626177,BAO_0000218,10683
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,1,Kidney,,,In vivo,1,,17738,A,2113.0,Intermediate,CHEMBL622499,BAO_0000218,10684
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,1,Liver,,,In vivo,1,,17738,A,2107.0,Intermediate,CHEMBL622500,BAO_0000218,10685
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,1,Liver,,,In vivo,1,,17738,A,2107.0,Intermediate,CHEMBL622501,BAO_0000218,10686
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,1,Liver,,,In vivo,1,,17738,A,2107.0,Intermediate,CHEMBL622502,BAO_0000218,10687
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,1,Liver,,,In vivo,1,,17738,A,2107.0,Intermediate,CHEMBL622503,BAO_0000218,10688
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,1,Liver,,,In vivo,1,,17738,A,2107.0,Intermediate,CHEMBL877614,BAO_0000218,10689
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,1,Lung,,,In vivo,1,,17738,A,2048.0,Intermediate,CHEMBL624839,BAO_0000218,10690
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,1,Lung,,,In vivo,1,,17738,A,2048.0,Intermediate,CHEMBL624840,BAO_0000218,10691
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,1,Lung,,,In vivo,1,,17738,A,2048.0,Intermediate,CHEMBL624841,BAO_0000218,10692
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,1,Lung,,,In vivo,1,,17738,A,2048.0,Intermediate,CHEMBL624842,BAO_0000218,10693
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,1,Muscle tissue,,,In vivo,1,,17738,A,2385.0,Intermediate,CHEMBL624843,BAO_0000218,10694
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,1,Muscle tissue,,,In vivo,1,,17738,A,2385.0,Intermediate,CHEMBL624844,BAO_0000218,10695
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,1,Muscle tissue,,,In vivo,1,,17738,A,2385.0,Intermediate,CHEMBL624845,BAO_0000218,10696
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,1,Muscle tissue,,,In vivo,1,,17738,A,2385.0,Intermediate,CHEMBL621904,BAO_0000218,10697
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,1,Blood,,,In vivo,1,,11195,A,178.0,Intermediate,CHEMBL621905,BAO_0000218,10698
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,1,Blood,,,In vivo,1,,11195,A,178.0,Intermediate,CHEMBL874382,BAO_0000218,10699
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,1,Blood,,,In vivo,1,,11195,A,178.0,Intermediate,CHEMBL621906,BAO_0000218,10700
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,1,Brain,,,In vivo,1,,11195,A,955.0,Intermediate,CHEMBL621907,BAO_0000218,10701
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,1,Brain,,,In vivo,1,,11195,A,955.0,Intermediate,CHEMBL622096,BAO_0000218,10702
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,1,Brain,,,In vivo,1,,11195,A,955.0,Intermediate,CHEMBL622097,BAO_0000218,10703
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,1,Heart,,,In vivo,1,,11195,A,948.0,Intermediate,CHEMBL622098,BAO_0000218,10704
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,1,Heart,,,In vivo,1,,11195,A,948.0,Intermediate,CHEMBL622099,BAO_0000218,10705
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,1,Heart,,,In vivo,1,,11195,A,948.0,Intermediate,CHEMBL622100,BAO_0000218,10706
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,1,Kidney,,,In vivo,1,,11195,A,2113.0,Intermediate,CHEMBL622101,BAO_0000218,10707
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,1,Kidney,,,In vivo,1,,11195,A,2113.0,Intermediate,CHEMBL622102,BAO_0000218,10708
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,1,Kidney,,,In vivo,1,,11195,A,2113.0,Intermediate,CHEMBL622103,BAO_0000218,10709
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,1,Liver,,,In vivo,1,,11195,A,2107.0,Intermediate,CHEMBL622104,BAO_0000218,10710
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,1,Liver,,,In vivo,1,,11195,A,2107.0,Intermediate,CHEMBL622105,BAO_0000218,10711
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,1,Liver,,,In vivo,1,,11195,A,2107.0,Intermediate,CHEMBL622106,BAO_0000218,10712
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,1,Lung,,,In vivo,1,,11195,A,2048.0,Intermediate,CHEMBL622107,BAO_0000218,10713
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,1,Lung,,,In vivo,1,,11195,A,2048.0,Intermediate,CHEMBL622108,BAO_0000218,10714
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,1,Lung,,,In vivo,1,,11195,A,2048.0,Intermediate,CHEMBL622109,BAO_0000218,10715
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,1,Muscle tissue,,,In vivo,1,,11195,A,2385.0,Intermediate,CHEMBL622110,BAO_0000218,10716
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,1,Muscle tissue,,,In vivo,1,,11195,A,2385.0,Intermediate,CHEMBL622111,BAO_0000218,10717
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,1,Muscle tissue,,,In vivo,1,,11195,A,2385.0,Intermediate,CHEMBL874383,BAO_0000218,10718
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,1,Zone of skin,,,In vivo,1,,11195,A,14.0,Intermediate,CHEMBL622112,BAO_0000218,10719
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,1,Zone of skin,,,In vivo,1,,11195,A,14.0,Intermediate,CHEMBL622113,BAO_0000218,10720
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,1,Zone of skin,,,In vivo,1,,11195,A,14.0,Intermediate,CHEMBL622114,BAO_0000218,10721
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,1,Spleen,,,In vivo,1,,11195,A,2106.0,Intermediate,CHEMBL622115,BAO_0000218,10722
,,N,,,50597,10116.0,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,1,Spleen,,,In vivo,1,,11195,A,2106.0,Intermediate,CHEMBL622116,BAO_0000218,10723
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,6193,A,,Intermediate,CHEMBL622117,BAO_0000218,10724
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,6803,A,,Intermediate,CHEMBL622118,BAO_0000218,10725
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rats at 6 mg/kg,1,,,,In vivo,1,,6647,A,,Intermediate,CHEMBL622119,BAO_0000218,10726
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose 6 mg/kg),1,,,,In vivo,1,,6647,A,,Intermediate,CHEMBL622120,BAO_0000218,10727
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rats at 6 mg/kg dose; Not tested,1,,,,In vivo,1,,6647,A,,Intermediate,CHEMBL622121,BAO_0000218,10728
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,6640,A,,Intermediate,CHEMBL622122,BAO_0000218,10729
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,6641,A,,Intermediate,CHEMBL622123,BAO_0000218,10730
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,6641,A,,Intermediate,CHEMBL622124,BAO_0000218,10731
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,6642,A,,Intermediate,CHEMBL622125,BAO_0000218,10732
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability,1,,,,In vivo,1,,5472,A,,Intermediate,CHEMBL622126,BAO_0000218,10733
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,,,,In vivo,1,,6141,A,,Intermediate,CHEMBL620455,BAO_0000218,10734
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,4390,A,,Intermediate,CHEMBL620456,BAO_0000218,10735
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,5472,A,,Intermediate,CHEMBL620457,BAO_0000218,10736
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability was evaluated; Not tested,1,,,,In vivo,1,,5472,A,,Intermediate,CHEMBL620458,BAO_0000218,10737
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability,1,,,,In vivo,1,,5438,A,,Intermediate,CHEMBL620459,BAO_0000218,10738
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat by oral dosing,1,,,,In vivo,1,,4883,A,,Intermediate,CHEMBL620460,BAO_0000218,10739
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose 10 mg/kg p.o.),1,,,,In vivo,1,,1908,A,,Intermediate,CHEMBL620461,BAO_0000218,10740
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley),1,,,,In vivo,1,,4853,A,,Intermediate,CHEMBL620462,BAO_0000218,10741
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,,,,In vivo,1,,4853,A,,Intermediate,CHEMBL620463,BAO_0000218,10742
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,,,,In vivo,1,,4853,A,,Intermediate,CHEMBL620464,BAO_0000218,10743
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,,,,In vivo,1,,4853,A,,Intermediate,CHEMBL620465,BAO_0000218,10744
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),1,,,,In vivo,1,,4853,A,,Intermediate,CHEMBL620466,BAO_0000218,10745
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,1,,,,In vivo,1,,4853,A,,Intermediate,CHEMBL620467,BAO_0000218,10746
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,1,,,,In vivo,1,,4853,A,,Intermediate,CHEMBL620468,BAO_0000218,10747
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,1,,,,In vivo,1,,12873,A,,Intermediate,CHEMBL620469,BAO_0000218,10748
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,1,,,,In vivo,1,,12873,A,,Intermediate,CHEMBL620470,BAO_0000218,10749
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,3169,A,,Intermediate,CHEMBL620471,BAO_0000218,10750
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,6305,A,,Intermediate,CHEMBL620472,BAO_0000218,10751
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,1,,,,In vivo,1,,4762,A,,Intermediate,CHEMBL620473,BAO_0000218,10752
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,17847,A,,Intermediate,CHEMBL620474,BAO_0000218,10753
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),1,,,,In vivo,1,,6211,A,,Intermediate,CHEMBL620475,BAO_0000218,10754
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,6011,A,,Intermediate,CHEMBL620476,BAO_0000218,10755
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,6317,A,,Intermediate,CHEMBL620477,BAO_0000218,10756
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,1,,,,In vivo,1,,6644,A,,Intermediate,CHEMBL620478,BAO_0000218,10757
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,1,,,,In vivo,1,,6644,A,,Intermediate,CHEMBL618768,BAO_0000218,10758
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat after oral administration at 13 mg/kg dose,1,,,,In vivo,1,,6644,A,,Intermediate,CHEMBL618769,BAO_0000218,10759
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,1,,,,In vivo,1,,6644,A,,Intermediate,CHEMBL618770,BAO_0000218,10760
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability (dose 20 mg/kg p.o.),1,,,,In vivo,1,,6113,A,,Intermediate,CHEMBL618771,BAO_0000218,10761
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,1,,,,In vivo,1,,5937,A,,Intermediate,CHEMBL618772,BAO_0000218,10762
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat at 10 mg/kg of the compound,1,,,,In vivo,1,,5711,A,,Intermediate,CHEMBL618773,BAO_0000218,10763
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,1,,,,In vivo,1,,17717,A,,Intermediate,CHEMBL875842,BAO_0000218,10764
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (dose 3 mg/kg i.v.),1,,,,In vivo,1,,17717,A,,Intermediate,CHEMBL618774,BAO_0000218,10765
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,1,,,,In vivo,1,,17717,A,,Intermediate,CHEMBL618775,BAO_0000218,10766
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose 60 mg/kg p.o.),1,,,,In vivo,1,,17717,A,,Intermediate,CHEMBL618776,BAO_0000218,10767
,,N,,,50597,10116.0,Rattus norvegicus,Percent bioavailability (F) in rats after iv administration,1,,,,In vivo,1,,4722,A,,Intermediate,CHEMBL618777,BAO_0000218,10768
,,N,,,50597,10116.0,Rattus norvegicus,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,1,,,,In vivo,1,,4722,A,,Intermediate,CHEMBL618778,BAO_0000218,10769
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (dose 5 uM/kg p.o.),1,,,,In vivo,1,,4353,A,,Intermediate,CHEMBL618779,BAO_0000218,10770
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability,1,,,,In vivo,1,,15662,A,,Intermediate,CHEMBL618780,BAO_0000218,10771
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat (dose 2 mg/kg p.o.),1,,,,In vivo,1,,4756,A,,Intermediate,CHEMBL618781,BAO_0000218,10772
,,N,,,50597,10116.0,Rattus norvegicus,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,1,,,,In vivo,1,,4756,A,,Intermediate,CHEMBL618782,BAO_0000218,10773
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose 20 mg/kg),1,,,,In vivo,1,,3436,A,,Intermediate,CHEMBL618783,BAO_0000218,10774
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,17800,A,,Intermediate,CHEMBL618784,BAO_0000218,10775
,,N,,,50597,10116.0,Rattus norvegicus,Percent oral bioavailability evaluated in rat,1,,,,In vivo,1,,15762,A,,Intermediate,CHEMBL618785,BAO_0000218,10776
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,5089,A,,Intermediate,CHEMBL618786,BAO_0000218,10777
,,N,,,50597,10116.0,Rattus norvegicus,Percent oral bioavailability in rat; Not determined,1,,,,In vivo,1,,5089,A,,Intermediate,CHEMBL618787,BAO_0000218,10778
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,1,,3185,A,,Intermediate,CHEMBL618788,BAO_0000218,10779
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,1,,5145,A,,Intermediate,CHEMBL618789,BAO_0000218,10780
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),1,,,,In vivo,1,,3457,A,,Intermediate,CHEMBL618790,BAO_0000218,10781
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),1,,,,In vivo,1,,3457,A,,Intermediate,CHEMBL618791,BAO_0000218,10782
,,N,,,50597,10116.0,Rattus norvegicus,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,1,,,,In vivo,1,,5983,A,,Intermediate,CHEMBL875843,BAO_0000218,10783
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose 20 mg/kg p.o.),1,,,,In vivo,1,,5739,A,,Intermediate,CHEMBL618792,BAO_0000218,10784
,,N,,,50597,10116.0,Rattus norvegicus,Cmax at a dose of 30 mg/kg in rat,1,,,,In vivo,1,,3579,A,,Intermediate,CHEMBL623395,BAO_0000218,10785
,,U,,,22224,314293.0,Simiiformes,Cmax in monkeys at a dose of 1 mg/kg,1,,,,In vivo,0,,17788,A,,Autocuration,CHEMBL623396,BAO_0000218,10786
,,N,,,50597,10116.0,Rattus norvegicus,Cmax in rat,1,,,,In vivo,1,,14956,A,,Intermediate,CHEMBL623397,BAO_0000218,10787
,,N,,,50597,10116.0,Rattus norvegicus,Cmax in rats at a dose of 1 mg/kg,1,,,,In vivo,1,,17788,A,,Intermediate,CHEMBL623398,BAO_0000218,10788
,,N,,,50594,10090.0,Mus musculus,Cmax was measured in mice after an oral dose of 50 mg/kg.,1,,,,In vivo,1,,9750,A,,Intermediate,CHEMBL623399,BAO_0000218,10789
,,U,,,22224,,,"Cmax value at a dose of 12.7 uM/kg, po",1,,,,In vivo,0,,12767,A,,Autocuration,CHEMBL623400,BAO_0000218,10790
,,U,,,22224,,,"Cmax value at a dose of 6.3 uM/kg, iv",1,,,,In vivo,0,,12767,A,,Autocuration,CHEMBL623401,BAO_0000218,10791
,,U,,,22224,,,"Cmax value at a dose of 7.1 uM/kg, iv",1,,,,In vivo,0,,12767,A,,Autocuration,CHEMBL623402,BAO_0000218,10792
,,U,,,22224,,,Cmax value of compound was determined after 1 hr,1,,,,In vivo,0,,12703,A,,Autocuration,CHEMBL623403,BAO_0000218,10793
,,U,,,22224,,,Cmax value of the compound,1,,,,In vivo,0,,15778,A,,Autocuration,CHEMBL623404,BAO_0000218,10794
,,N,,,50597,10116.0,Rattus norvegicus,Cmax value administered intraintestinal in rats.,1,,,,In vivo,1,,12818,A,,Intermediate,CHEMBL625997,BAO_0000218,10795
,,N,,,50597,10116.0,Rattus norvegicus,Cmax value administered perorally was determined in rat; Not determined,1,,,,In vivo,1,,14964,A,,Intermediate,CHEMBL625998,BAO_0000218,10796
,,U,,,22224,,,Cmax value at the dose of 2.3 mg/kg,1,,,,In vivo,0,,15808,A,,Autocuration,CHEMBL625999,BAO_0000218,10797
,,U,,,22224,,,Cmax value at the dose of 5 mg/kg,1,,,,In vivo,0,,15808,A,,Autocuration,CHEMBL626000,BAO_0000218,10798
,,U,,,22224,,,Cmax value in the period of 8 hr after dosing. ,1,,,,In vivo,0,,15778,A,,Autocuration,CHEMBL626001,BAO_0000218,10799
,,U,,,22224,,,Cmax value at a oral dose of 20 mg/kg; Not tested,1,,,,In vivo,0,,3715,A,,Autocuration,CHEMBL626002,BAO_0000218,10800
,,U,,,22224,,,Cmax value at a oral dose of 20 mg/kg,1,,,,In vivo,0,,3715,A,,Autocuration,CHEMBL626003,BAO_0000218,10801
,,N,,,50597,10116.0,Rattus norvegicus,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,1,,,,In vivo,1,,1446,A,,Intermediate,CHEMBL626004,BAO_0000218,10802
,,N,,,50512,10141.0,Cavia porcellus,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,1,,,,In vivo,1,,15240,A,,Intermediate,CHEMBL626005,BAO_0000218,10803
,,N,,,50597,10116.0,Rattus norvegicus,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,1,,,,In vivo,1,,15240,A,,Intermediate,CHEMBL626006,BAO_0000218,10804
,,N,,,50597,10116.0,Rattus norvegicus,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,1,Plasma,,,In vivo,1,,14810,A,1969.0,Intermediate,CHEMBL626007,BAO_0000218,10805
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,1,Plasma,,,In vivo,1,,14239,A,1969.0,Intermediate,CHEMBL626008,BAO_0000218,10806
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,1,Liver,,,In vivo,1,,12555,A,2107.0,Intermediate,CHEMBL626009,BAO_0000218,10807
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,1,,,,In vivo,1,,10754,A,,Intermediate,CHEMBL626010,BAO_0000218,10808
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,1,Blood,,,In vivo,1,,10754,A,178.0,Intermediate,CHEMBL626011,BAO_0000218,10809
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,1,Blood,,,In vivo,1,,10754,A,178.0,Intermediate,CHEMBL626012,BAO_0000218,10810
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,1,Blood,,,In vivo,1,,10754,A,178.0,Intermediate,CHEMBL626013,BAO_0000218,10811
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,1,Blood,,,In vivo,1,,10754,A,178.0,Intermediate,CHEMBL626014,BAO_0000218,10812
,,N,,,50594,10090.0,Mus musculus,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,1,Blood,,,In vivo,1,,10754,A,178.0,Intermediate,CHEMBL877496,BAO_0000218,10813
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,1,,,,In vivo,1,,14600,F,,Intermediate,CHEMBL626015,BAO_0000218,10814
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,1,,,,In vivo,1,,14600,F,,Intermediate,CHEMBL626016,BAO_0000218,10815
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,1,,,,In vivo,1,,14600,F,,Intermediate,CHEMBL626017,BAO_0000218,10816
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability as maximal plasma concentration in dogs,1,Plasma,,,In vivo,1,,13543,A,1969.0,Intermediate,CHEMBL626018,BAO_0000218,10817
,,N,,,50588,9615.0,Canis lupus familiaris,Bioavailability as maximal plasma concentration in dogs,1,Plasma,,,In vivo,1,,13543,A,1969.0,Intermediate,CHEMBL626692,BAO_0000218,10818
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability as maximal plasma concentration in rats,1,Plasma,,,In vivo,1,,13543,A,1969.0,Intermediate,CHEMBL626693,BAO_0000218,10819
,,U,,,22224,10116.0,Rattus norvegicus,Bioavailability as maximal plasma concentration in rats,1,Plasma,,,In vivo,0,,13543,A,1969.0,Autocuration,CHEMBL626694,BAO_0000218,10820
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,Blood,,,In vivo,1,,14600,A,178.0,Intermediate,CHEMBL626695,BAO_0000218,10821
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,Blood,,,In vivo,1,,14600,A,178.0,Intermediate,CHEMBL626696,BAO_0000218,10822
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,Blood,,,In vivo,1,,14600,A,178.0,Intermediate,CHEMBL626697,BAO_0000218,10823
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,1,Blood,,,In vivo,1,,14600,A,178.0,Intermediate,CHEMBL626859,BAO_0000218,10824
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,Blood,,,In vivo,1,,14600,A,178.0,Intermediate,CHEMBL626860,BAO_0000218,10825
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,Blood,,,In vivo,1,,14600,A,178.0,Intermediate,CHEMBL626861,BAO_0000218,10826
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,1,,,,In vivo,1,,14681,A,,Intermediate,CHEMBL626296,BAO_0000218,10827
,,U,,,22224,,,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,1,,,,In vivo,0,,15905,A,,Autocuration,CHEMBL626297,BAO_0000218,10828
,,U,,,22224,,,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,1,Plasma,,,In vivo,0,,15905,A,1969.0,Autocuration,CHEMBL626298,BAO_0000218,10829
,,N,,,50597,10116.0,Rattus norvegicus,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",1,Plasma,,,In vivo,1,,13304,A,1969.0,Intermediate,CHEMBL626299,BAO_0000218,10830
,,N,,,50597,10116.0,Rattus norvegicus,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,1,Plasma,,,In vivo,1,,15137,A,1969.0,Intermediate,CHEMBL626300,BAO_0000218,10831
,,N,,,50597,10116.0,Rattus norvegicus,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,1,Plasma,,,In vivo,1,,15137,A,1969.0,Intermediate,CHEMBL626301,BAO_0000218,10832
,,N,,,50597,10116.0,Rattus norvegicus,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,1,Plasma,,,In vivo,1,,15137,A,1969.0,Intermediate,CHEMBL626962,BAO_0000218,10833
,,N,,,50597,10116.0,Rattus norvegicus,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,1,Plasma,,,In vivo,1,,15137,A,1969.0,Intermediate,CHEMBL626963,BAO_0000218,10834
,,N,,,50597,10116.0,Rattus norvegicus,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,1,Plasma,,,In vivo,1,,15137,A,1969.0,Intermediate,CHEMBL626964,BAO_0000218,10835
,,N,,,100710,9541.0,Macaca fascicularis,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,1,Plasma,,,In vivo,1,,14839,A,1969.0,Intermediate,CHEMBL626965,BAO_0000218,10836
,,N,,,50594,10090.0,Mus musculus,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,Plasma,,,In vivo,1,,14839,A,1969.0,Intermediate,CHEMBL626966,BAO_0000218,10837
,,N,,,50594,10090.0,Mus musculus,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,Plasma,,,In vivo,1,,14839,A,1969.0,Intermediate,CHEMBL626967,BAO_0000218,10838
,,N,,,100710,9541.0,Macaca fascicularis,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,1,Plasma,,,In vivo,1,,14839,A,1969.0,Intermediate,CHEMBL626968,BAO_0000218,10839
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,1,Heart,,,,1,,8418,A,948.0,Intermediate,CHEMBL626969,BAO_0000218,10840
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,1,Heart,,,,1,,8418,A,948.0,Intermediate,CHEMBL627126,BAO_0000218,10841
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,1,Heart,,,,1,,8418,A,948.0,Intermediate,CHEMBL631276,BAO_0000218,10842
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,1,Heart,,,,1,,8418,A,948.0,Intermediate,CHEMBL631277,BAO_0000218,10843
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,1,Heart,,,,1,,8418,A,948.0,Intermediate,CHEMBL631278,BAO_0000218,10844
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,1,Heart,,,,1,,8418,A,948.0,Intermediate,CHEMBL874457,BAO_0000218,10845
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,1,Heart,,,,1,,8418,A,948.0,Intermediate,CHEMBL631279,BAO_0000218,10846
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,1,Heart,,,,1,,8418,A,948.0,Intermediate,CHEMBL631280,BAO_0000218,10847
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,1,Heart,,,,1,,8418,A,948.0,Intermediate,CHEMBL631281,BAO_0000218,10848
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,1,Heart,,,,1,,8418,A,948.0,Intermediate,CHEMBL631968,BAO_0000218,10849
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,1,Heart,,,,1,,8418,A,948.0,Intermediate,CHEMBL631969,BAO_0000218,10850
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,1,Heart,,,,1,,8418,A,948.0,Intermediate,CHEMBL631970,BAO_0000218,10851
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,1,Heart,,,,1,,8418,A,948.0,Intermediate,CHEMBL631971,BAO_0000218,10852
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,1,Heart,,,,1,,8418,A,948.0,Intermediate,CHEMBL631972,BAO_0000218,10853
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,1,Heart,,,,1,,8418,A,948.0,Intermediate,CHEMBL630435,BAO_0000218,10854
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,1,Heart,,,,1,,8418,A,948.0,Intermediate,CHEMBL630436,BAO_0000218,10855
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,1,Heart,,,,1,,8418,A,948.0,Intermediate,CHEMBL630437,BAO_0000218,10856
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,1,Heart,,,,1,,8418,A,948.0,Intermediate,CHEMBL630438,BAO_0000218,10857
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,1,Heart,,,,1,,8418,A,948.0,Intermediate,CHEMBL630439,BAO_0000218,10858
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,1,Kidney,,,,1,,8418,A,2113.0,Intermediate,CHEMBL630440,BAO_0000218,10859
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,1,Kidney,,,,1,,8418,A,2113.0,Intermediate,CHEMBL630441,BAO_0000218,10860
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,1,Kidney,,,,1,,8418,A,2113.0,Intermediate,CHEMBL630442,BAO_0000218,10861
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,1,Kidney,,,,1,,8418,A,2113.0,Intermediate,CHEMBL625234,BAO_0000218,10862
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,1,Kidney,,,,1,,8418,A,2113.0,Intermediate,CHEMBL625235,BAO_0000218,10863
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,1,Kidney,,,,1,,8418,A,2113.0,Intermediate,CHEMBL625236,BAO_0000218,10864
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,1,Kidney,,,,1,,8418,A,2113.0,Intermediate,CHEMBL625237,BAO_0000218,10865
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,1,Kidney,,,,1,,8418,A,2113.0,Intermediate,CHEMBL626125,BAO_0000218,10866
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,1,Kidney,,,,1,,8418,A,2113.0,Intermediate,CHEMBL626126,BAO_0000218,10867
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,1,Kidney,,,,1,,8418,A,2113.0,Intermediate,CHEMBL626127,BAO_0000218,10868
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,1,Kidney,,,,1,,8418,A,2113.0,Intermediate,CHEMBL626128,BAO_0000218,10869
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,1,Kidney,,,,1,,8418,A,2113.0,Intermediate,CHEMBL626129,BAO_0000218,10870
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,1,Kidney,,,,1,,8418,A,2113.0,Intermediate,CHEMBL626130,BAO_0000218,10871
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,1,Kidney,,,,1,,8418,A,2113.0,Intermediate,CHEMBL626131,BAO_0000218,10872
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,1,Kidney,,,,1,,8418,A,2113.0,Intermediate,CHEMBL626132,BAO_0000218,10873
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,1,Kidney,,,,1,,8418,A,2113.0,Intermediate,CHEMBL626752,BAO_0000218,10874
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,1,Kidney,,,,1,,8418,A,2113.0,Intermediate,CHEMBL626753,BAO_0000218,10875
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,1,Kidney,,,,1,,8418,A,2113.0,Intermediate,CHEMBL626754,BAO_0000218,10876
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,1,Kidney,,,,1,,8418,A,2113.0,Intermediate,CHEMBL626755,BAO_0000218,10877
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,1,Liver,,,,1,,8418,A,2107.0,Intermediate,CHEMBL626756,BAO_0000218,10878
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,1,Liver,,,,1,,8418,A,2107.0,Intermediate,CHEMBL626757,BAO_0000218,10879
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,1,Liver,,,,1,,8418,A,2107.0,Intermediate,CHEMBL626758,BAO_0000218,10880
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,1,Liver,,,,1,,8418,A,2107.0,Intermediate,CHEMBL626759,BAO_0000218,10881
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,1,Liver,,,,1,,8418,A,2107.0,Intermediate,CHEMBL626760,BAO_0000218,10882
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL626394,BAO_0000218,10883
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,1,,,,,1,,6996,A,,Intermediate,CHEMBL626395,BAO_0000218,10884
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL626396,BAO_0000218,10885
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL626397,BAO_0000218,10886
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),1,,,,,1,,6996,A,,Intermediate,CHEMBL626398,BAO_0000218,10887
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL626399,BAO_0000218,10888
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,1,,,,,1,,6996,A,,Intermediate,CHEMBL874653,BAO_0000218,10889
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL626400,BAO_0000218,10890
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL626401,BAO_0000218,10891
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL626402,BAO_0000218,10892
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),1,,,,,1,,6996,A,,Intermediate,CHEMBL626403,BAO_0000218,10893
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL626404,BAO_0000218,10894
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,1,,,,,1,,6996,A,,Intermediate,CHEMBL626405,BAO_0000218,10895
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL625529,BAO_0000218,10896
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL625530,BAO_0000218,10897
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL625531,BAO_0000218,10898
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),1,,,,,1,,6996,A,,Intermediate,CHEMBL625532,BAO_0000218,10899
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL625533,BAO_0000218,10900
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,1,,,,,1,,6996,A,,Intermediate,CHEMBL875474,BAO_0000218,10901
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL625534,BAO_0000218,10902
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL625535,BAO_0000218,10903
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL625536,BAO_0000218,10904
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),1,,,,,1,,6996,A,,Intermediate,CHEMBL625537,BAO_0000218,10905
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL625538,BAO_0000218,10906
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,1,,,,,1,,6996,A,,Intermediate,CHEMBL625539,BAO_0000218,10907
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL625540,BAO_0000218,10908
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL625541,BAO_0000218,10909
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL625542,BAO_0000218,10910
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),1,,,,,1,,6996,A,,Intermediate,CHEMBL625543,BAO_0000218,10911
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL625544,BAO_0000218,10912
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,1,,,,,1,,6996,A,,Intermediate,CHEMBL625545,BAO_0000218,10913
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL625546,BAO_0000218,10914
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,1,,,,,1,,6996,A,,Intermediate,CHEMBL625547,BAO_0000218,10915
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL625548,BAO_0000218,10916
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL625549,BAO_0000218,10917
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL625550,BAO_0000218,10918
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL625551,BAO_0000218,10919
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL875475,BAO_0000218,10920
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL625552,BAO_0000218,10921
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL625553,BAO_0000218,10922
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL625554,BAO_0000218,10923
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),1,,,,,1,,6996,A,,Intermediate,CHEMBL625555,BAO_0000218,10924
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL625556,BAO_0000218,10925
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,1,,,,,1,,6996,A,,Intermediate,CHEMBL624986,BAO_0000218,10926
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL624987,BAO_0000218,10927
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL624988,BAO_0000218,10928
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,1,Artery,,,In vivo,1,,9025,A,1637.0,Intermediate,CHEMBL624989,BAO_0000218,10929
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,1,Artery,,,In vivo,1,,9025,A,1637.0,Intermediate,CHEMBL624990,BAO_0000218,10930
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,1,Artery,,,In vivo,1,,9025,A,1637.0,Intermediate,CHEMBL874391,BAO_0000218,10931
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,1,Artery,,,In vivo,1,,9025,A,1637.0,Intermediate,CHEMBL624991,BAO_0000218,10932
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,1,Artery,,,In vivo,1,,9025,A,1637.0,Intermediate,CHEMBL624992,BAO_0000218,10933
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,1,Artery,,,In vivo,1,,9025,A,1637.0,Intermediate,CHEMBL624993,BAO_0000218,10934
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,1,Artery,,,In vivo,1,,9025,A,1637.0,Intermediate,CHEMBL624994,BAO_0000218,10935
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,1,Artery,,,In vivo,1,,9025,A,1637.0,Intermediate,CHEMBL624995,BAO_0000218,10936
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,1,Artery,,,In vivo,1,,9025,A,1637.0,Intermediate,CHEMBL624996,BAO_0000218,10937
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,1,Artery,,,In vivo,1,,9025,A,1637.0,Intermediate,CHEMBL624997,BAO_0000218,10938
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,1,Artery,,,In vivo,1,,9025,A,1637.0,Intermediate,CHEMBL624998,BAO_0000218,10939
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,1,Artery,,,In vivo,1,,9025,A,1637.0,Intermediate,CHEMBL624999,BAO_0000218,10940
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,1,Artery,,,In vivo,1,,9025,A,1637.0,Intermediate,CHEMBL882955,BAO_0000218,10941
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,1,Artery,,,In vivo,1,,9025,A,1637.0,Intermediate,CHEMBL625000,BAO_0000218,10942
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,1,Artery,,,In vivo,1,,9025,A,1637.0,Intermediate,CHEMBL625001,BAO_0000218,10943
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,1,Artery,,,In vivo,1,,9025,A,1637.0,Intermediate,CHEMBL625089,BAO_0000218,10944
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,1,Artery,,,In vivo,1,,9025,A,1637.0,Intermediate,CHEMBL625090,BAO_0000218,10945
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,1,Artery,,,In vivo,1,,9025,A,1637.0,Intermediate,CHEMBL625091,BAO_0000218,10946
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,1,Artery,,,In vivo,1,,9025,A,1637.0,Intermediate,CHEMBL625092,BAO_0000218,10947
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,1,Artery,,,In vivo,1,,9025,A,1637.0,Intermediate,CHEMBL625093,BAO_0000218,10948
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,1,Artery,,,In vivo,1,,9025,A,1637.0,Intermediate,CHEMBL625094,BAO_0000218,10949
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,1,Artery,,,In vivo,1,,9025,A,1637.0,Intermediate,CHEMBL625095,BAO_0000218,10950
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for its bioavailability in the dogs,1,,,,In vivo,1,,2249,A,,Intermediate,CHEMBL625096,BAO_0000218,10951
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for its bioavailability in the rats,1,,,,In vivo,1,,2249,A,,Intermediate,CHEMBL625097,BAO_0000218,10952
,,U,,,22224,,,Compound was evaluated for oral bioavailability,1,,,,In vivo,0,,17515,A,,Autocuration,CHEMBL882956,BAO_0000218,10953
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for percentage of Oral bioavailability in rats,1,,,,In vivo,1,,14541,A,,Intermediate,CHEMBL625098,BAO_0000218,10954
,,U,,,22224,10141.0,Cavia porcellus,Bioavailability in guinea pig,1,,,,In vivo,0,,12797,A,,Autocuration,CHEMBL625099,BAO_0000218,10955
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for the oral bioavailability in rat,1,,,,In vivo,1,,12797,A,,Intermediate,CHEMBL625100,BAO_0000218,10956
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was evaluated for the oral bioavailability in dog,1,,,,In vivo,1,,12797,A,,Intermediate,CHEMBL625101,BAO_0000218,10957
,,N,,,50597,10116.0,Rattus norvegicus,Compound was evaluated for the oral bioavailability in rat,1,,,,In vivo,1,,12797,A,,Intermediate,CHEMBL874396,BAO_0000218,10958
,,U,,,22224,9615.0,Canis lupus familiaris,Bioavailability in dog (dosed i.v.),1,,,,In vivo,0,,11727,F,,Autocuration,CHEMBL625102,BAO_0000218,10959
,,N,,,50588,9615.0,Canis lupus familiaris,Compound was tested for in vivo bioavailability in dog,1,,,,In vivo,1,,13249,A,,Intermediate,CHEMBL625103,BAO_0000218,10960
,,N,,,100712,10026.0,Cricetinae,Compound was tested for in vivo bioavailability in hamsters,1,,,,In vivo,1,,13249,A,,Intermediate,CHEMBL625104,BAO_0000218,10961
,,U,,,22224,314293.0,Simiiformes,Compound was tested for in vivo bioavailability in monkey,1,,,,In vivo,0,,13249,A,,Autocuration,CHEMBL625105,BAO_0000218,10962
,,N,,,50597,10116.0,Rattus norvegicus,Compound was tested for in vivo bioavailability in rat,1,,,,In vivo,1,,13249,A,,Intermediate,CHEMBL625106,BAO_0000218,10963
,,U,,,22224,10090.0,Mus musculus,Oral bioavailability in mouse,1,,,,In vivo,0,,9552,A,,Autocuration,CHEMBL625107,BAO_0000218,10964
,,N,,,50594,10090.0,Mus musculus,Compound was tested for percent of oral bioavailability in mice; 56-74,1,,,,In vivo,1,,9552,A,,Intermediate,CHEMBL625108,BAO_0000218,10965
,,U,,,22224,10090.0,Mus musculus,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),1,,,,In vivo,0,,14839,A,,Autocuration,CHEMBL625109,BAO_0000218,10966
,,U,,,22224,9541.0,Macaca fascicularis,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),1,,,,In vivo,0,,14839,A,,Autocuration,CHEMBL625110,BAO_0000218,10967
,,U,,,22224,9541.0,Macaca fascicularis,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),1,,,,In vivo,0,,14839,A,,Autocuration,CHEMBL625111,BAO_0000218,10968
,,N,,,50594,10090.0,Mus musculus,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),1,,,,In vivo,1,,14839,A,,Intermediate,CHEMBL625112,BAO_0000218,10969
,,N,,,50594,10090.0,Mus musculus,Oral bioavailability in nude mice,1,,,,In vivo,1,,14839,A,,Intermediate,CHEMBL875334,BAO_0000218,10970
,,U,,,22224,9443.0,Primates,Bioavailability in monkey (i.d. dosing),1,,,,In vivo,0,,11219,A,,Autocuration,CHEMBL628617,BAO_0000218,10971
,,U,,,22224,10116.0,Rattus norvegicus,Bioavailability in rat,1,,,,In vivo,0,,9552,A,,Autocuration,CHEMBL628618,BAO_0000218,10972
,,U,,,22224,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,1,,,,In vivo,0,,11732,A,,Autocuration,CHEMBL628619,BAO_0000218,10973
,,U,,,22224,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,1,,,,In vivo,0,,11732,A,,Autocuration,CHEMBL628620,BAO_0000218,10974
,,N,,,100710,9541.0,Macaca fascicularis,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",1,,,,In vivo,1,,14839,A,,Intermediate,CHEMBL628621,BAO_0000218,10975
,,N,,,100710,9541.0,Macaca fascicularis,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",1,,,,In vivo,1,,14839,A,,Intermediate,CHEMBL628622,BAO_0000218,10976
,,N,,,100710,9541.0,Macaca fascicularis,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",1,,,,In vivo,1,,14839,A,,Intermediate,CHEMBL628623,BAO_0000218,10977
,,N,,,100710,9541.0,Macaca fascicularis,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,1,Plasma,,,In vivo,1,,14839,A,1969.0,Intermediate,CHEMBL628624,BAO_0000218,10978
,,N,,,50594,10090.0,Mus musculus,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,Plasma,,,In vivo,1,,14839,A,1969.0,Intermediate,CHEMBL628625,BAO_0000218,10979
,,N,,,100710,9541.0,Macaca fascicularis,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,1,Plasma,,,In vivo,1,,14839,A,1969.0,Intermediate,CHEMBL628626,BAO_0000218,10980
,,N,,,50594,10090.0,Mus musculus,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,Plasma,,,In vivo,1,,14839,A,1969.0,Intermediate,CHEMBL627041,BAO_0000218,10981
,,N,,,50594,10090.0,Mus musculus,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,Plasma,,,In vivo,1,,14839,A,1969.0,Intermediate,CHEMBL627042,BAO_0000218,10982
,,N,,,50594,10090.0,Mus musculus,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,Plasma,,,In vivo,1,,14839,A,1969.0,Intermediate,CHEMBL627043,BAO_0000218,10983
,,U,,,22224,,,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,1,Plasma,,,In vivo,0,,13932,A,1969.0,Autocuration,CHEMBL627044,BAO_0000218,10984
,,N,,,50594,10090.0,Mus musculus,Cmax in mouse plasma,1,Plasma,,,In vivo,1,,11637,A,1969.0,Intermediate,CHEMBL627045,BAO_0000218,10985
,,U,,,22224,,,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,1,Plasma,,,In vivo,0,,11637,A,1969.0,Autocuration,CHEMBL627046,BAO_0000218,10986
,,N,,,50597,10116.0,Rattus norvegicus,Maximal plasma concentration in rat,1,Plasma,,,In vivo,1,,13960,A,1969.0,Intermediate,CHEMBL627047,BAO_0000218,10987
,,N,,,50597,10116.0,Rattus norvegicus,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,1,Plasma,,,In vivo,1,,15905,A,1969.0,Intermediate,CHEMBL627048,BAO_0000218,10988
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,1,,,,In vivo,1,,14062,A,,Intermediate,CHEMBL627049,BAO_0000218,10989
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,1,,,,In vivo,1,,14062,A,,Intermediate,CHEMBL627050,BAO_0000218,10990
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,1,,,,In vivo,1,,14062,A,,Intermediate,CHEMBL627051,BAO_0000218,10991
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,1,,,,In vivo,1,,14062,A,,Intermediate,CHEMBL627052,BAO_0000218,10992
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,1,,,,In vivo,1,,14062,A,,Intermediate,CHEMBL627053,BAO_0000218,10993
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,1,,,,In vivo,1,,14062,A,,Intermediate,CHEMBL627054,BAO_0000218,10994
,,N,,,50594,10090.0,Mus musculus,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,,,,In vivo,1,,15011,A,,Intermediate,CHEMBL627055,BAO_0000218,10995
,,N,,,50594,10090.0,Mus musculus,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,1,,,,In vivo,1,,15011,A,,Intermediate,CHEMBL627056,BAO_0000218,10996
,,N,,,50594,10090.0,Mus musculus,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),1,,,,In vivo,1,,15011,A,,Intermediate,CHEMBL627057,BAO_0000218,10997
,,N,,,50594,10090.0,Mus musculus,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,,,,In vivo,1,,15011,A,,Intermediate,CHEMBL627058,BAO_0000218,10998
,,N,,,50594,10090.0,Mus musculus,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,1,,,,In vivo,1,,15011,A,,Intermediate,CHEMBL626211,BAO_0000218,10999
,,U,,,22224,,,Maximum Concentration of the compound.,1,,,,In vivo,0,,10291,A,,Autocuration,CHEMBL626212,BAO_0000218,11000
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum Concentration was measured after iv administration into Beagle dog,1,,,,In vivo,1,,14599,A,,Intermediate,CHEMBL626213,BAO_0000218,11001
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum Concentration was measured after iv administration into Beagle dog.,1,,,,In vivo,1,,14599,A,,Intermediate,CHEMBL626214,BAO_0000218,11002
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum Concentration was measured after po administration into Beagle dog,1,,,,In vivo,1,,14599,A,,Intermediate,CHEMBL626215,BAO_0000218,11003
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum Concentration was measured after po administration into Beagle dog.,1,,,,In vivo,1,,14599,A,,Intermediate,CHEMBL626216,BAO_0000218,11004
,,U,,,22224,,,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,1,Blood,,,In vivo,0,,12767,A,178.0,Autocuration,CHEMBL626217,BAO_0000218,11005
,,U,,,22224,,,Maximum blood level reached after an iv dose of 12.2 uM/kg,1,Blood,,,In vivo,0,,12767,A,178.0,Autocuration,CHEMBL626218,BAO_0000218,11006
,,U,,,22224,,,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,1,Blood,,,In vivo,0,,12767,A,178.0,Autocuration,CHEMBL626219,BAO_0000218,11007
,,U,,,22224,,,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,1,Blood,,,In vivo,0,,12767,A,178.0,Autocuration,CHEMBL626220,BAO_0000218,11008
,,U,,,22224,,,Maximum blood level reached after an oral dose of 5.0 mg/kg,1,Blood,,,In vivo,0,,12767,A,178.0,Autocuration,CHEMBL626221,BAO_0000218,11009
,,U,,,22224,,,Maximum blood level reached at dose of 10.6 uM/kg orally,1,Blood,,,In vivo,0,,12767,A,178.0,Autocuration,CHEMBL626222,BAO_0000218,11010
,,N,,,50512,10141.0,Cavia porcellus,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,1,,,,In vivo,1,,14706,A,,Intermediate,CHEMBL626223,BAO_0000218,11011
,,N,,,50512,10141.0,Cavia porcellus,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,1,,,,In vivo,1,,14706,A,,Intermediate,CHEMBL626224,BAO_0000218,11012
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,1,Brain,,,In vivo,1,,14793,A,955.0,Intermediate,CHEMBL626225,BAO_0000218,11013
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,1,Brain,,,In vivo,1,,14793,A,955.0,Intermediate,CHEMBL626226,BAO_0000218,11014
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,1,Brain,,,In vivo,1,,14793,A,955.0,Intermediate,CHEMBL626227,BAO_0000218,11015
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,1,Brain,,,In vivo,1,,14793,A,955.0,Intermediate,CHEMBL626228,BAO_0000218,11016
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,1,,,,In vivo,1,,14793,A,,Intermediate,CHEMBL626229,BAO_0000218,11017
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,1,,,,In vivo,1,,14793,A,,Intermediate,CHEMBL626921,BAO_0000218,11018
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,1,,,,In vivo,1,,14793,A,,Intermediate,CHEMBL876793,BAO_0000218,11019
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,1,,,,In vivo,1,,14793,A,,Intermediate,CHEMBL625309,BAO_0000218,11020
,,N,,,50278,1423.0,Bacillus subtilis,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),1,,,,In vivo,1,,10524,A,,Intermediate,CHEMBL625310,BAO_0000218,11021
,,U,,,22224,314293.0,Simiiformes,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,1,,,,In vivo,0,,11871,A,,Autocuration,CHEMBL625311,BAO_0000218,11022
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,1,,,,In vivo,1,,11871,A,,Intermediate,CHEMBL625312,BAO_0000218,11023
,,U,,,22224,,,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,1,,,,In vivo,0,,3437,A,,Autocuration,CHEMBL625313,BAO_0000218,11024
,,N,,,50594,10090.0,Mus musculus,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,1,,,,In vivo,1,,12038,A,,Intermediate,CHEMBL625314,BAO_0000218,11025
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration in male rats after iv administration of 20 mg/kg,1,,,,In vivo,1,,12038,A,,Intermediate,CHEMBL625315,BAO_0000218,11026
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,1,Liver,,,,1,,8418,A,2107.0,Intermediate,CHEMBL625316,BAO_0000218,11027
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,1,Liver,,,,1,,8418,A,2107.0,Intermediate,CHEMBL625317,BAO_0000218,11028
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,1,Liver,,,,1,,8418,A,2107.0,Intermediate,CHEMBL625318,BAO_0000218,11029
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,1,Liver,,,,1,,8418,A,2107.0,Intermediate,CHEMBL625319,BAO_0000218,11030
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,1,Liver,,,,1,,8418,A,2107.0,Intermediate,CHEMBL625320,BAO_0000218,11031
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,1,Liver,,,,1,,8418,A,2107.0,Intermediate,CHEMBL625321,BAO_0000218,11032
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,1,Liver,,,,1,,8418,A,2107.0,Intermediate,CHEMBL625322,BAO_0000218,11033
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,1,Liver,,,,1,,8418,A,2107.0,Intermediate,CHEMBL876801,BAO_0000218,11034
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,1,Liver,,,,1,,8418,A,2107.0,Intermediate,CHEMBL625323,BAO_0000218,11035
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,1,Liver,,,,1,,8418,A,2107.0,Intermediate,CHEMBL625324,BAO_0000218,11036
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,1,Liver,,,,1,,8418,A,2107.0,Intermediate,CHEMBL625325,BAO_0000218,11037
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,1,Liver,,,,1,,8418,A,2107.0,Intermediate,CHEMBL625326,BAO_0000218,11038
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,1,Liver,,,,1,,8418,A,2107.0,Intermediate,CHEMBL625327,BAO_0000218,11039
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,1,Liver,,,,1,,8418,A,2107.0,Intermediate,CHEMBL625328,BAO_0000218,11040
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,1,Lung,,,,1,,8418,A,2048.0,Intermediate,CHEMBL625329,BAO_0000218,11041
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,1,Lung,,,,1,,8418,A,2048.0,Intermediate,CHEMBL625330,BAO_0000218,11042
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,1,Lung,,,,1,,8418,A,2048.0,Intermediate,CHEMBL627774,BAO_0000218,11043
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,1,Lung,,,,1,,8418,A,2048.0,Intermediate,CHEMBL627775,BAO_0000218,11044
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,1,Lung,,,,1,,8418,A,2048.0,Intermediate,CHEMBL627949,BAO_0000218,11045
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,1,Lung,,,,1,,8418,A,2048.0,Intermediate,CHEMBL627950,BAO_0000218,11046
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,1,Lung,,,,1,,8418,A,2048.0,Intermediate,CHEMBL627951,BAO_0000218,11047
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,1,Lung,,,,1,,8418,A,2048.0,Intermediate,CHEMBL627952,BAO_0000218,11048
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,1,Lung,,,,1,,8418,A,2048.0,Intermediate,CHEMBL627953,BAO_0000218,11049
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,1,Lung,,,,1,,8418,A,2048.0,Intermediate,CHEMBL627954,BAO_0000218,11050
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,1,Lung,,,,1,,8418,A,2048.0,Intermediate,CHEMBL627955,BAO_0000218,11051
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,1,Lung,,,,1,,8418,A,2048.0,Intermediate,CHEMBL627956,BAO_0000218,11052
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,1,Lung,,,,1,,8418,A,2048.0,Intermediate,CHEMBL876802,BAO_0000218,11053
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,1,Lung,,,,1,,8418,A,2048.0,Intermediate,CHEMBL627957,BAO_0000218,11054
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,1,Lung,,,,1,,8418,A,2048.0,Intermediate,CHEMBL627958,BAO_0000218,11055
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,1,Lung,,,,1,,8418,A,2048.0,Intermediate,CHEMBL627959,BAO_0000218,11056
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,1,Lung,,,,1,,8418,A,2048.0,Intermediate,CHEMBL627960,BAO_0000218,11057
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,1,Lung,,,,1,,8418,A,2048.0,Intermediate,CHEMBL627961,BAO_0000218,11058
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,1,Lung,,,,1,,8418,A,2048.0,Intermediate,CHEMBL627962,BAO_0000218,11059
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,,,,,1,,9796,A,,Intermediate,CHEMBL627963,BAO_0000218,11060
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,1,,,,,1,,9796,A,,Intermediate,CHEMBL624759,BAO_0000218,11061
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,,,,,1,,9796,A,,Intermediate,CHEMBL624760,BAO_0000218,11062
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,,,,,1,,9796,A,,Intermediate,CHEMBL624761,BAO_0000218,11063
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,,,,,1,,9796,A,,Intermediate,CHEMBL877607,BAO_0000218,11064
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,Liver,,,,1,,9796,A,2107.0,Intermediate,CHEMBL624762,BAO_0000218,11065
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,1,Liver,,,,1,,9796,A,2107.0,Intermediate,CHEMBL624763,BAO_0000218,11066
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,Liver,,,,1,,9796,A,2107.0,Intermediate,CHEMBL624764,BAO_0000218,11067
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,Liver,,,,1,,9796,A,2107.0,Intermediate,CHEMBL624765,BAO_0000218,11068
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,Liver,,,,1,,9796,A,2107.0,Intermediate,CHEMBL624766,BAO_0000218,11069
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL624767,BAO_0000218,11070
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,1,,,,,1,,6996,A,,Intermediate,CHEMBL624768,BAO_0000218,11071
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL624769,BAO_0000218,11072
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL624770,BAO_0000218,11073
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),1,,,,,1,,6996,A,,Intermediate,CHEMBL624771,BAO_0000218,11074
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL624772,BAO_0000218,11075
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,1,,,,,1,,6996,A,,Intermediate,CHEMBL624773,BAO_0000218,11076
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL624774,BAO_0000218,11077
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL624775,BAO_0000218,11078
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL624776,BAO_0000218,11079
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),1,,,,,1,,6996,A,,Intermediate,CHEMBL624777,BAO_0000218,11080
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL624778,BAO_0000218,11081
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,1,,,,,1,,6996,A,,Intermediate,CHEMBL624779,BAO_0000218,11082
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL624780,BAO_0000218,11083
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),1,,,,,1,,6996,A,,Intermediate,CHEMBL624781,BAO_0000218,11084
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL877608,BAO_0000218,11085
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL624782,BAO_0000218,11086
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL624783,BAO_0000218,11087
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,1,,,,,1,,6996,A,,Intermediate,CHEMBL624784,BAO_0000218,11088
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL624785,BAO_0000218,11089
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL624786,BAO_0000218,11090
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),1,,,,,1,,6996,A,,Intermediate,CHEMBL624787,BAO_0000218,11091
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL628676,BAO_0000218,11092
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,1,,,,,1,,6996,A,,Intermediate,CHEMBL621842,BAO_0000218,11093
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL621843,BAO_0000218,11094
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL623873,BAO_0000218,11095
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL623874,BAO_0000218,11096
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),1,,,,,1,,6996,A,,Intermediate,CHEMBL623875,BAO_0000218,11097
,,N,,,50597,10116.0,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL623876,BAO_0000218,11098
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,1,,,,,1,,6996,A,,Intermediate,CHEMBL623877,BAO_0000218,11099
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL623878,BAO_0000218,11100
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,1,,,,,1,,6996,A,,Intermediate,CHEMBL623879,BAO_0000218,11101
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL623880,BAO_0000218,11102
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL623881,BAO_0000218,11103
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL623957,BAO_0000218,11104
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL623958,BAO_0000218,11105
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL623959,BAO_0000218,11106
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL623960,BAO_0000218,11107
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL623961,BAO_0000218,11108
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL623962,BAO_0000218,11109
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),1,,,,,1,,6996,A,,Intermediate,CHEMBL624676,BAO_0000218,11110
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL624677,BAO_0000218,11111
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,1,,,,,1,,6996,A,,Intermediate,CHEMBL624678,BAO_0000218,11112
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL624679,BAO_0000218,11113
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL624680,BAO_0000218,11114
,,U,,,22224,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,1,,,,In vivo,0,,11732,A,,Autocuration,CHEMBL624849,BAO_0000218,11115
,,U,,,22224,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,1,,,,In vivo,0,,11732,A,,Autocuration,CHEMBL624850,BAO_0000218,11116
,,U,,,22224,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,1,,,,In vivo,0,,11732,A,,Autocuration,CHEMBL874399,BAO_0000218,11117
,,U,,,22224,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,1,,,,In vivo,0,,11732,A,,Autocuration,CHEMBL624851,BAO_0000218,11118
,,U,,,22224,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,1,,,,In vivo,0,,11732,A,,Autocuration,CHEMBL624852,BAO_0000218,11119
,,U,,,22224,10116.0,Rattus norvegicus,Oral bioavailability in rat (dose 10 mg/kg),1,,,,In vivo,0,,13359,A,,Autocuration,CHEMBL624853,BAO_0000218,11120
,,U,,,22224,10116.0,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley),1,,,,In vivo,0,,16618,A,,Autocuration,CHEMBL624854,BAO_0000218,11121
,,U,,,22224,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,0,,13960,A,,Autocuration,CHEMBL624855,BAO_0000218,11122
,,U,,,22224,10116.0,Rattus norvegicus,Oral bioavailability in rats was determined in vivo,1,,,,In vivo,0,,13917,A,,Autocuration,CHEMBL624856,BAO_0000218,11123
,,U,,,22224,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,0,,14266,A,,Autocuration,CHEMBL882957,BAO_0000218,11124
,,U,,,22224,314293.0,Simiiformes,Oral bioavailability of compound in monkey,1,,,,In vivo,0,,12359,A,,Autocuration,CHEMBL624857,BAO_0000218,11125
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability of compound in rat,1,,,,In vivo,1,,12359,A,,Intermediate,CHEMBL622202,BAO_0000218,11126
,,U,,,22224,10116.0,Rattus norvegicus,Bioavailability in rat of PMEA prodrug,1,,,,In vivo,0,,12359,A,,Autocuration,CHEMBL622203,BAO_0000218,11127
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,1,,,,In vivo,1,,12359,A,,Intermediate,CHEMBL625522,BAO_0000218,11128
,,U,,,22224,9544.0,Macaca mulatta,Serum conc at 3 hours following 25 mg/kg dose,1,,,,In vivo,0,,10791,A,,Autocuration,CHEMBL622868,BAO_0000218,11129
,,U,,,22224,9544.0,Macaca mulatta,Urine conc 0-5 hours following 25 mg/kg dose,1,Urine,,,In vivo,0,,10791,A,1088.0,Autocuration,CHEMBL622869,BAO_0000218,11130
,,U,,,22224,9544.0,Macaca mulatta,Urine conc 0-24 hours following 25 mg/kg dose,1,Urine,,,In vivo,0,,10791,A,1088.0,Autocuration,CHEMBL622870,BAO_0000218,11131
,,U,,,22224,9534.0,Chlorocebus aethiops,Oral bioavailability in African green monkeys; 20-25,1,,,,In vivo,0,,138,A,,Autocuration,CHEMBL622871,BAO_0000218,11132
,,N,,,100710,9541.0,Macaca fascicularis,Oral bioavailability in cynomolgus monkey.,1,,,,In vivo,1,,14521,A,,Intermediate,CHEMBL620560,BAO_0000218,11133
,,U,,,22224,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,0,,13953,A,,Autocuration,CHEMBL620561,BAO_0000218,11134
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability in dog at 10 mg/kg oral dose,1,,,,In vivo,1,,12836,A,,Intermediate,CHEMBL620562,BAO_0000218,11135
,,N,,,100712,10026.0,Cricetinae,Oral bioavailability in hamster at 10 mg/kg oral dose,1,,,,In vivo,1,,12836,A,,Intermediate,CHEMBL620563,BAO_0000218,11136
,,N,,,50597,10116.0,Rattus norvegicus,Oral bioavailability in rat at 10 mg/kg oral dose,1,,,,In vivo,1,,12836,A,,Intermediate,CHEMBL620564,BAO_0000218,11137
,,U,,,22224,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,0,,14521,A,,Autocuration,CHEMBL872265,BAO_0000218,11138
,,U,,,22224,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,0,,13953,A,,Autocuration,CHEMBL620565,BAO_0000218,11139
,,U,,,22224,9347.0,Eutheria,Oral bioavailability,1,,,,In vivo,0,,6799,A,,Autocuration,CHEMBL620566,BAO_0000218,11140
,,U,,,22224,,,Oral bioavailability was determined; range 49-102%,1,,,,In vivo,0,,11311,A,,Autocuration,CHEMBL620567,BAO_0000218,11141
,,N,,,50588,9615.0,Canis lupus familiaris,Oral bioavailability was determined in dogs,1,,,,In vivo,1,,4013,A,,Intermediate,CHEMBL620568,BAO_0000218,11142
,,U,,,22224,10116.0,Rattus norvegicus,Oral bioavailability in rat,1,,,,In vivo,0,,4013,A,,Autocuration,CHEMBL620569,BAO_0000218,11143
,,U,,,22224,9347.0,Eutheria,Oral bioavailability,1,,,,In vivo,0,,17591,A,,Autocuration,CHEMBL620570,BAO_0000218,11144
,,U,,,22224,,,Oral bioavailability was determined; Not orally available,1,,,,In vivo,0,,17591,A,,Autocuration,CHEMBL620571,BAO_0000218,11145
,,N,,,50594,10090.0,Mus musculus,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),1,,,,In vivo,1,,15011,A,,Intermediate,CHEMBL620572,BAO_0000218,11146
,,U,,,22224,10090.0,Mus musculus,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),1,,,,In vivo,0,,15011,A,,Autocuration,CHEMBL620573,BAO_0000218,11147
,,U,,,22224,10090.0,Mus musculus,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,1,,,,In vivo,0,,15011,A,,Autocuration,CHEMBL620574,BAO_0000218,11148
,,U,,,22224,9544.0,Macaca mulatta,Oral bioavailability in Rhesus monkey,1,,,,In vivo,0,,9552,A,,Autocuration,CHEMBL620575,BAO_0000218,11149
,,U,,,22224,9615.0,Canis lupus familiaris,Oral bioavailability in dog (female mongrel),1,,,,In vivo,0,,9552,A,,Autocuration,CHEMBL620576,BAO_0000218,11150
,,U,,,22224,,,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,1,,,,In vivo,0,,3639,A,,Autocuration,CHEMBL875846,BAO_0000218,11151
,,U,,,22224,9615.0,Canis lupus familiaris,Oral bioavailability in dog,1,,,,In vivo,0,,13397,A,,Autocuration,CHEMBL620577,BAO_0000218,11152
,,U,,,22224,,,Percentage Bioavailability was evaluated.,1,,,,In vivo,0,,3031,A,,Autocuration,CHEMBL620578,BAO_0000218,11153
,,U,,,22224,10116.0,Rattus norvegicus,Bioavailability in rat administered i.d.,1,,,,In vivo,0,,12818,A,,Autocuration,CHEMBL620579,BAO_0000218,11154
,,U,,,22224,9347.0,Eutheria,Bioavailability,1,,,,In vivo,0,,4847,A,,Autocuration,CHEMBL621248,BAO_0000218,11155
,,U,,,22224,9615.0,Canis lupus familiaris,Bioavailability in dog (male Beagle) i.v. administration,1,,,,In vivo,0,,12421,A,,Autocuration,CHEMBL625390,BAO_0000218,11156
,,U,,,22224,10116.0,Rattus norvegicus,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",1,,,,In vivo,0,,11966,A,,Autocuration,CHEMBL625391,BAO_0000218,11157
,,U,,,22224,9443.0,Primates,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),1,,,,In vivo,0,,11218,A,,Autocuration,CHEMBL872266,BAO_0000218,11158
,,U,,,22224,10116.0,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (male),1,,,,In vivo,0,,13129,A,,Autocuration,CHEMBL625392,BAO_0000218,11159
,,N,,,50597,10116.0,Rattus norvegicus,The oral bioavailability was measured on rats after oral administration,1,,,,In vivo,1,,12350,A,,Intermediate,CHEMBL625393,BAO_0000218,11160
,,N,,,50597,10116.0,Rattus norvegicus,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,1,,,,In vivo,1,,2231,A,,Intermediate,CHEMBL625394,BAO_0000218,11161
,,N,,,50797,9544.0,Macaca mulatta,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,1,,,,In vivo,1,,2231,A,,Intermediate,CHEMBL625395,BAO_0000218,11162
,,U,,,22224,10116.0,Rattus norvegicus,Bioavailability in rat (dose 10 mg/kg i.d.),1,,,,In vivo,0,,12187,A,,Autocuration,CHEMBL625396,BAO_0000218,11163
,,U,,,22224,9615.0,Canis lupus familiaris,Bioavailability in dog (male Beagle) i.v. administration,1,,,,In vivo,0,,12421,A,,Autocuration,CHEMBL625397,BAO_0000218,11164
,,N,,,50594,10090.0,Mus musculus,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,,In vivo,1,,13256,A,,Intermediate,CHEMBL625398,BAO_0000218,11165
,,N,,,50594,10090.0,Mus musculus,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),1,Blood,,,In vivo,1,,13256,A,178.0,Intermediate,CHEMBL625399,BAO_0000218,11166
,,N,,,50594,10090.0,Mus musculus,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,Cerebellum,,,In vivo,1,,13256,A,2037.0,Intermediate,CHEMBL626074,BAO_0000218,11167
,,N,,,50594,10090.0,Mus musculus,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,,In vivo,1,,13256,A,,Intermediate,CHEMBL626075,BAO_0000218,11168
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,1,Plasma,,,In vivo,1,,2231,A,1969.0,Intermediate,CHEMBL626076,BAO_0000218,11169
,,N,,,50797,9544.0,Macaca mulatta,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,1,Plasma,,,In vivo,1,,2231,A,1969.0,Intermediate,CHEMBL626077,BAO_0000218,11170
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),1,Blood,,,In vivo,1,,12178,A,178.0,Intermediate,CHEMBL626078,BAO_0000218,11171
,,U,,,22224,,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),1,Blood,,,In vivo,0,,12178,A,178.0,Autocuration,CHEMBL625846,BAO_0000218,11172
,,U,,,22224,,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),1,Blood,,,In vivo,0,,12178,A,178.0,Autocuration,CHEMBL625847,BAO_0000218,11173
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration observed in rats at an oral dose of 50 mg/kg,1,,,,In vivo,1,,15633,A,,Expert,CHEMBL625848,BAO_0000218,11174
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration of compound in plasma administered orally to rats,1,Plasma,,,In vivo,1,,14258,A,1969.0,Intermediate,CHEMBL625849,BAO_0000218,11175
,,N,,,50588,9615.0,Canis lupus familiaris,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",1,Plasma,,,In vivo,1,,14224,A,1969.0,Intermediate,CHEMBL626023,BAO_0000218,11176
,,N,,,50588,9615.0,Canis lupus familiaris,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",1,Plasma,,,In vivo,1,,14224,A,1969.0,Intermediate,CHEMBL626024,BAO_0000218,11177
,,N,,,50588,9615.0,Canis lupus familiaris,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",1,Plasma,,,In vivo,1,,14224,A,1969.0,Intermediate,CHEMBL626025,BAO_0000218,11178
,,U,,,22224,,,Maximum concentration after 10 mg/kg by oral administration,1,,,,In vivo,0,,5566,A,,Autocuration,CHEMBL626026,BAO_0000218,11179
,,U,,,22224,,,Maximum concentration at a dose of 1.5 mg/kg,1,,,,In vivo,0,,16935,A,,Autocuration,CHEMBL626027,BAO_0000218,11180
,,U,,,22224,,,Maximum concentration at a dose of 2.0 mg/kg,1,,,,In vivo,0,,16935,A,,Autocuration,CHEMBL626028,BAO_0000218,11181
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum concentration in dog plasma,1,Plasma,,,In vivo,1,,14224,A,1969.0,Intermediate,CHEMBL626029,BAO_0000218,11182
,,U,,,22224,,,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,1,Plasma,,,In vivo,0,,12536,A,1969.0,Autocuration,CHEMBL626030,BAO_0000218,11183
,,U,,,22224,,,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,1,Plasma,,,In vivo,0,,12536,A,1969.0,Autocuration,CHEMBL626031,BAO_0000218,11184
,,U,,,22224,,,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,1,Plasma,,,In vivo,0,,12536,A,1969.0,Autocuration,CHEMBL626032,BAO_0000218,11185
,,U,,,22224,,,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,1,Plasma,,,In vivo,0,,12536,A,1969.0,Autocuration,CHEMBL626033,BAO_0000218,11186
,,U,,,22224,,,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,1,Plasma,,,In vivo,0,,12536,A,1969.0,Autocuration,CHEMBL626034,BAO_0000218,11187
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum concentration in plasma after oral administration in dog (25 mg/kg),1,Plasma,,,In vivo,1,,9994,A,1969.0,Intermediate,CHEMBL626035,BAO_0000218,11188
,,U,,,22224,,,Maximum concentration in plasma at Tmax,1,Plasma,,,In vivo,0,,1434,A,1969.0,Autocuration,CHEMBL626036,BAO_0000218,11189
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,1,Plasma,,,In vivo,1,,12836,A,1969.0,Expert,CHEMBL626037,BAO_0000218,11190
,,N,,,100712,10026.0,Cricetinae,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,1,Plasma,,,In vivo,1,,12836,A,1969.0,Intermediate,CHEMBL626038,BAO_0000218,11191
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,1,Plasma,,,In vivo,1,,12836,A,1969.0,Intermediate,CHEMBL626039,BAO_0000218,11192
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,1,Plasma,,,In vivo,1,,12545,A,1969.0,Intermediate,CHEMBL626040,BAO_0000218,11193
,,N,,,50592,9986.0,Oryctolagus cuniculus,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,1,Plasma,,,In vivo,1,,13856,A,1969.0,Intermediate,CHEMBL626041,BAO_0000218,11194
,,U,,,22224,,,Maximum concentration was calculated,1,,,,In vivo,0,,3550,A,,Autocuration,CHEMBL626042,BAO_0000218,11195
,,U,,,22224,,,Maximum concentration was calculated.,1,,,,In vivo,0,,2632,A,,Autocuration,CHEMBL626043,BAO_0000218,11196
,,U,,,22224,,,Maximum concentration at a peroral dose of 10 mg/kg,1,,,,In vivo,0,,5566,A,,Autocuration,CHEMBL626044,BAO_0000218,11197
,,U,,,22224,,,Maximum concentration of the drug at 10 uM/dg administered perorally,1,,,,In vivo,0,,11883,A,,Autocuration,CHEMBL626045,BAO_0000218,11198
,,U,,,22224,,,Maximum concentration of the drug at 2 uM/dg administered intravenously,1,,,,In vivo,0,,11883,A,,Autocuration,CHEMBL626046,BAO_0000218,11199
,,N,,,50588,9615.0,Canis lupus familiaris,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",1,Plasma,,,In vivo,1,,14122,A,1969.0,Intermediate,CHEMBL626047,BAO_0000218,11200
,,N,,,100712,10026.0,Cricetinae,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",1,Plasma,,,In vivo,1,,14122,A,1969.0,Intermediate,CHEMBL626048,BAO_0000218,11201
,,N,,,50597,10116.0,Rattus norvegicus,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",1,Plasma,,,In vivo,1,,14122,A,1969.0,Intermediate,CHEMBL626049,BAO_0000218,11202
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,1,Plasma,,,In vivo,1,,12542,A,1969.0,Intermediate,CHEMBL626050,BAO_0000218,11203
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,1,Plasma,,,In vivo,1,,12542,A,1969.0,Intermediate,CHEMBL874541,BAO_0000218,11204
,,N,,,100712,10026.0,Cricetinae,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,1,Plasma,,,In vivo,1,,12542,A,1969.0,Intermediate,CHEMBL622826,BAO_0000218,11205
,,N,,,100712,10026.0,Cricetinae,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,1,Plasma,,,In vivo,1,,12542,A,1969.0,Intermediate,CHEMBL622827,BAO_0000218,11206
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,1,Plasma,,,In vivo,1,,12542,A,1969.0,Intermediate,CHEMBL622828,BAO_0000218,11207
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,1,Plasma,,,In vivo,1,,14080,A,1969.0,Intermediate,CHEMBL622829,BAO_0000218,11208
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration reached following intravenous administration in male rat,1,,,,In vivo,1,,11911,A,,Intermediate,CHEMBL876806,BAO_0000218,11209
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,1,,,,In vivo,1,,13204,A,,Intermediate,CHEMBL622830,BAO_0000218,11210
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,1,,,,In vivo,1,,13204,A,,Intermediate,CHEMBL622831,BAO_0000218,11211
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,1,,,,In vivo,1,,14346,A,,Intermediate,CHEMBL626794,BAO_0000218,11212
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,1,,,,In vivo,1,,14346,A,,Intermediate,CHEMBL626795,BAO_0000218,11213
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,1,,,,In vivo,1,,14346,A,,Intermediate,CHEMBL626796,BAO_0000218,11214
,,N,,,50597,10116.0,Rattus norvegicus,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,1,,,,In vivo,1,,14346,A,,Intermediate,CHEMBL626797,BAO_0000218,11215
,,N,,,50597,10116.0,Rattus norvegicus,Maximum drug concentration is determined after oral dosing in rats.,1,,,,In vivo,1,,14127,A,,Intermediate,CHEMBL626798,BAO_0000218,11216
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum observed concentration in oral (5 mg/kg) fasted dogs,1,,,,In vivo,1,,14339,A,,Intermediate,CHEMBL626799,BAO_0000218,11217
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum observed concentration in oral (5 mg/kg) fed dogs,1,,,,In vivo,1,,14339,A,,Intermediate,CHEMBL626800,BAO_0000218,11218
,,U,,,22224,,,Maximum plasma concentration,1,Plasma,,,In vivo,0,,13494,A,1969.0,Autocuration,CHEMBL626801,BAO_0000218,11219
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,1,Plasma,,,In vivo,1,,14925,A,1969.0,Intermediate,CHEMBL876816,BAO_0000218,11220
,,N,,,50597,10116.0,Rattus norvegicus,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,1,Plasma,,,In vivo,1,,14474,A,1969.0,Intermediate,CHEMBL626802,BAO_0000218,11221
,,N,,,50588,9615.0,Canis lupus familiaris,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,1,Plasma,,,In vivo,1,,14474,A,1969.0,Intermediate,CHEMBL626803,BAO_0000218,11222
,,U,,,22224,,,Maximum plasma concentration following oral administration of 30 umol/kg,1,Plasma,,,In vivo,0,,13917,A,1969.0,Autocuration,CHEMBL626804,BAO_0000218,11223
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,1,Plasma,,,,1,,9796,A,1969.0,Intermediate,CHEMBL626805,BAO_0000218,11224
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,Plasma,,,,1,,9796,A,1969.0,Intermediate,CHEMBL626309,BAO_0000218,11225
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,Plasma,,,,1,,9796,A,1969.0,Intermediate,CHEMBL626310,BAO_0000218,11226
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,Plasma,,,,1,,9796,A,1969.0,Intermediate,CHEMBL626311,BAO_0000218,11227
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,Plasma,,,,1,,9796,A,1969.0,Intermediate,CHEMBL626312,BAO_0000218,11228
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,1,Uterus,,,,1,,9796,A,995.0,Intermediate,CHEMBL626313,BAO_0000218,11229
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,Uterus,,,,1,,9796,A,995.0,Intermediate,CHEMBL626314,BAO_0000218,11230
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,Uterus,,,,1,,9796,A,995.0,Intermediate,CHEMBL626315,BAO_0000218,11231
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,Uterus,,,,1,,9796,A,995.0,Intermediate,CHEMBL626316,BAO_0000218,11232
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,Uterus,,,,1,,9796,A,995.0,Intermediate,CHEMBL626317,BAO_0000218,11233
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),1,,,,,1,,8363,A,,Intermediate,CHEMBL626318,BAO_0000218,11234
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),1,,,,,1,,8363,A,,Intermediate,CHEMBL626319,BAO_0000218,11235
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),1,,,,,1,,8363,A,,Intermediate,CHEMBL626320,BAO_0000218,11236
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),1,,,,,1,,8363,A,,Intermediate,CHEMBL875053,BAO_0000218,11237
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),1,,,,,1,,8363,A,,Intermediate,CHEMBL626321,BAO_0000218,11238
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),1,,,,,1,,8363,A,,Intermediate,CHEMBL626322,BAO_0000218,11239
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),1,,,,,1,,8363,A,,Intermediate,CHEMBL626323,BAO_0000218,11240
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),1,,,,,1,,8363,A,,Intermediate,CHEMBL626324,BAO_0000218,11241
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),1,,,,,1,,8363,A,,Intermediate,CHEMBL626325,BAO_0000218,11242
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),1,,,,,1,,8363,A,,Intermediate,CHEMBL626326,BAO_0000218,11243
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),1,,,,,1,,8363,A,,Intermediate,CHEMBL626327,BAO_0000218,11244
,,N,,,50597,10116.0,Rattus norvegicus,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),1,,,,,1,,8363,A,,Intermediate,CHEMBL626328,BAO_0000218,11245
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",1,Blood,,,,1,,8684,A,178.0,Intermediate,CHEMBL626329,BAO_0000218,11246
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",1,Blood,,,,1,,8684,A,178.0,Intermediate,CHEMBL626330,BAO_0000218,11247
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",1,Blood,,,,1,,8684,A,178.0,Intermediate,CHEMBL626331,BAO_0000218,11248
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",1,Blood,,,,1,,8684,A,178.0,Intermediate,CHEMBL626332,BAO_0000218,11249
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",1,Blood,,,,1,,8684,A,178.0,Intermediate,CHEMBL626333,BAO_0000218,11250
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",1,Blood,,,,1,,8684,A,178.0,Intermediate,CHEMBL626334,BAO_0000218,11251
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",1,Blood,,,,1,,8684,A,178.0,Intermediate,CHEMBL626335,BAO_0000218,11252
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",1,Blood,,,,1,,8684,A,178.0,Intermediate,CHEMBL624798,BAO_0000218,11253
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",1,Brain,,,,1,,8684,A,955.0,Intermediate,CHEMBL624799,BAO_0000218,11254
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",1,Brain,,,,1,,8684,A,955.0,Intermediate,CHEMBL624800,BAO_0000218,11255
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",1,Brain,,,,1,,8684,A,955.0,Intermediate,CHEMBL624801,BAO_0000218,11256
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",1,Brain,,,,1,,8684,A,955.0,Intermediate,CHEMBL624802,BAO_0000218,11257
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",1,Brain,,,,1,,8684,A,955.0,Intermediate,CHEMBL624803,BAO_0000218,11258
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",1,Brain,,,,1,,8684,A,955.0,Intermediate,CHEMBL624804,BAO_0000218,11259
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",1,Brain,,,,1,,8684,A,955.0,Intermediate,CHEMBL624805,BAO_0000218,11260
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",1,Brain,,,,1,,8684,A,955.0,Intermediate,CHEMBL624806,BAO_0000218,11261
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",1,,,,,1,,8684,A,,Intermediate,CHEMBL624807,BAO_0000218,11262
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",1,,,,,1,,8684,A,,Intermediate,CHEMBL624808,BAO_0000218,11263
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",1,,,,,1,,8684,A,,Intermediate,CHEMBL624809,BAO_0000218,11264
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",1,,,,,1,,8684,A,,Intermediate,CHEMBL624810,BAO_0000218,11265
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",1,,,,,1,,8684,A,,Intermediate,CHEMBL877618,BAO_0000218,11266
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",1,,,,,1,,8684,A,,Intermediate,CHEMBL624811,BAO_0000218,11267
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",1,,,,,1,,8684,A,,Intermediate,CHEMBL624812,BAO_0000218,11268
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",1,,,,,1,,8684,A,,Intermediate,CHEMBL624813,BAO_0000218,11269
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",1,,,,,1,,8684,A,,Intermediate,CHEMBL624814,BAO_0000218,11270
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",1,,,,,1,,8684,A,,Intermediate,CHEMBL624815,BAO_0000218,11271
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",1,,,,,1,,8684,A,,Intermediate,CHEMBL624816,BAO_0000218,11272
,,N,,,50597,10116.0,Rattus norvegicus,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",1,,,,,1,,8684,A,,Intermediate,CHEMBL624817,BAO_0000218,11273
,,N,,,50588,9615.0,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),1,,,,,1,,6996,A,,Intermediate,CHEMBL624818,BAO_0000218,11274
